PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Khan, JA; Brint, EK; O'Neill, LAJ; Tong, L				Khan, JA; Brint, EK; O'Neill, LAJ; Tong, L			Crystal structure of the Toll/interleukin-1 receptor domain of human IL-1RAPL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED MENTAL-RETARDATION; NEURONAL CALCIUM SENSOR-1; ANOMALOUS DIFFRACTION; SIGNALING PATHWAYS; FAMILY; DENSITY; SYSTEM; MODELS	The Toll/interleukin-1 receptor (TIR) domain is conserved in the intracellular regions of Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs) as well as in several cytoplasmic adapter molecules. This domain has crucial roles in signal transduction by these receptors for host immune response. Here we report the crystal structure at 2.3-Angstrom resolution of the TIR domain of human IL-1RAPL, the first structure of a TIR domain of the IL-1R superfamily. There are large structural differences between this TIR domain and that of TLR1 and TLR2. Helix alphaD in IL-1RAPL is almost perpendicular to its equivalent in TLR1 or TLR2. The BB loop contains a hydrogen bond unique to IL-1RAPL between Thr residues at the 8th and 10th positions. The structural and sequence diversity among these domains may be important for specificity in the signal transduction by these receptors. A dimer of the TIR domain of IL-1RAPL is observed in the crystal, although this domain is monomeric in solution. Residues in the dimer interface are mostly unique to IL-1RAPL, which is consistent with the distinct functional roles of this receptor. Our functional studies show IL-1RAPL can activate JNK but not the ERK or the p38 MAP kinases, whereas its close homolog, TIGIRR, cannot activate JNK. Deletion mutagenesis studies show that the activation of JNK by IL-1RAPL does not depend on the integrity of its TIR domain, suggesting a distinct mechanism of signaling through this receptor.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Dublin Trinity Coll, Dept Biochem, Cytokine Res Grp, Dublin 2, Ireland	Columbia University; Trinity College Dublin	Tong, L (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	tong@como.bio.columbia.edu		O'Neill, Luke/0000-0002-4333-2748; Brint, Elizabeth/0000-0001-9214-149X; Tong, Liang/0000-0002-0563-6468	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049475] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49475] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; Bahi N, 2003, HUM MOL GENET, V12, P1415, DOI 10.1093/hmg/ddg147; Born TL, 2000, J BIOL CHEM, V275, P29946, DOI 10.1074/jbc.M004077200; Brint EK, 2002, J BIOL CHEM, V277, P49205, DOI 10.1074/jbc.M209685200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carrie A, 1999, NAT GENET, V23, P25, DOI 10.1038/12623; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; DUNNE A, 2003, SCI STKE; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koh PO, 2003, P NATL ACAD SCI USA, V100, P313, DOI 10.1073/pnas.232693499; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Sims JE, 2002, CURR OPIN IMMUNOL, V14, P117, DOI 10.1016/S0952-7915(01)00306-5; Tao X, 2002, BIOCHEM BIOPH RES CO, V299, P216, DOI 10.1016/S0006-291X(02)02581-0; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1872, DOI 10.1107/S090744499901029X; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600	20	111	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31664	31670		10.1074/jbc.M403434200	http://dx.doi.org/10.1074/jbc.M403434200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15123616	hybrid			2022-12-25	WOS:000222726800091
J	Gawenis, LR; Ledoussal, C; Judd, LM; Prasad, V; Alper, SL; Stuart-Tilley, A; Woo, AL; Grisham, C; Sanford, LP; Doetschman, T; Miller, ML; Shull, GE				Gawenis, LR; Ledoussal, C; Judd, LM; Prasad, V; Alper, SL; Stuart-Tilley, A; Woo, AL; Grisham, C; Sanford, LP; Doetschman, T; Miller, ML; Shull, GE			Mice with a targeted disruption of the AE2 Cl-/HCO3- exchanger are achlorhydric	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC PARIETAL-CELLS; H,K-ATPASE ALPHA-SUBUNIT; RABBIT PARIETAL; ACID-SECRETION; TRANSGENIC MICE; DIFFERENTIAL EXPRESSION; NA-K-2CL COTRANSPORTER; BASOLATERAL MEMBRANE; INTRACELLULAR PH; PLASMA-MEMBRANE	The AE2 Cl-/HCO3- exchanger is expressed in numerous cell types, including epithelial cells of the kidney, respiratory tract, and alimentary tract. In gastric epithelia, AE2 is particularly abundant in parietal cells, where it may be the predominant mechanism for HCO3- efflux and Cl- influx across the basolateral membrane that is needed for acid secretion. To investigate the hypothesis that AE2 is critical for parietal cell function and to assess its importance in other tissues, homozygous null mutant (AE2(-/-)) mice were prepared by targeted disruption of the AE2 (Slc4a2) gene. AE2(-/-) mice were emaciated, edentulous (toothless), and exhibited severe growth retardation, and most of them died around the time of weaning. AE2(-/-) mice exhibited achlorhydria, and histological studies revealed abnormalities of the gastric epithelium, including moderate dilation of the gastric gland lumens and a reduction in the number of parietal cells. There was little evidence, however, that parietal cell viability was impaired. Ultrastructural analysis of AE2(-/-) gastric mucosa revealed abnormal parietal cell structure, with severely impaired development of secretory canaliculi and few tubulovesicles but normal apical microvilli. These results demonstrate that AE2 is essential for gastric acid secretion and for normal development of secretory canalicular and tubulovesicular membranes in mouse parietal cells.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; Harvard Univ, Sch Med, Mol Med Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Renal Unit, Boston, MA 02215 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Shull, GE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way,ML524, Cincinnati, OH 45267 USA.	shullge@ucmail.uc.edu		Judd, Louise/0000-0003-3613-4839	NHLBI NIH HHS [HL61974, T32-HL7571] Funding Source: Medline; NIDDK NIH HHS [DK3495, DK50594, DK34854, DK67749] Funding Source: Medline; NIEHS NIH HHS [P30 ES06096] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061974, T32HL007571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK067749, R37DK050594, P30DK034854, R01DK050594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agnew BJ, 1999, J CELL SCI, V112, P2639; ALLEN A, 1993, PHYSIOL REV, V73, P823, DOI 10.1152/physrev.1993.73.4.823; Alper SL, 2002, J NEPHROL, V15, pS41; Bachmann O, 1998, AM J PHYSIOL-GASTR L, V275, pG1085, DOI 10.1152/ajpgi.1998.275.5.G1085; Cox KH, 1996, J BIOL CHEM, V271, P8895, DOI 10.1074/jbc.271.15.8895; Flagella M, 1999, J BIOL CHEM, V274, P26946, DOI 10.1074/jbc.274.38.26946; FLEMSTROM G, 1994, PHYSL GASTROINTESTIN; HORIE S, 1992, EUR J PHARMACOL, V229, P15; Jiang Z, 2002, J BIOL CHEM, V277, P33963, DOI 10.1074/jbc.M202660200; JONS T, 1994, HISTOCHEMISTRY, V102, P255, DOI 10.1007/BF00269161; Jons T, 1998, EUR J CELL BIOL, V75, P232; KAKEI N, 1993, BIOCHEM BIOPH RES CO, V195, P997, DOI 10.1006/bbrc.1993.2143; KARAM SM, 1993, ANAT REC, V236, P314, DOI 10.1002/ar.1092360205; LAMPRECHT G, 1993, AM J PHYSIOL, V265, pG903, DOI 10.1152/ajpgi.1993.265.5.G903; Langhans N, 1997, GASTROENTEROLOGY, V112, P280, DOI 10.1016/S0016-5085(97)90000-7; Li QT, 1996, J BIOL CHEM, V271, P3671, DOI 10.1074/jbc.271.7.3671; LI QT, 1995, J BIOL CHEM, V270, P15777, DOI 10.1074/jbc.270.26.15777; LORENZ RG, 1993, J BIOL CHEM, V268, P26559; MAEDA M, 1995, J BIOCHEM-TOKYO, V117, P1305, DOI 10.1093/oxfordjournals.jbchem.a124859; McDaniel N, 1999, AM J PHYSIOL-GASTR L, V276, pG1273, DOI 10.1152/ajpgi.1999.276.5.G1273; Medina JF, 2003, P NATL ACAD SCI USA, V100, P15847, DOI 10.1073/pnas.2536127100; Medina JF, 1997, GENOMICS, V39, P74, DOI 10.1006/geno.1996.4467; Medina JF, 2000, BIOCHEM BIOPH RES CO, V267, P228, DOI 10.1006/bbrc.1999.1951; Milller ML, 2002, CELL TISSUE RES, V309, P369, DOI 10.1007/s00441-002-0606-z; MUALLEM S, 1988, J BIOL CHEM, V263, P14703; MUALLEM S, 1985, J BIOL CHEM, V260, P6641; PARADISO AM, 1989, AM J PHYSIOL, V257, pC554, DOI 10.1152/ajpcell.1989.257.3.C554; Parkkila S, 1996, SCAND J GASTROENTERO, V31, P305, DOI 10.3109/00365529609006403; Petrovic S, 2003, AM J PHYSIOL-GASTR L, V284, pG1093, DOI 10.1152/ajpgi.00454.2002; PETROVIC S, 2002, AM J PHYSIOL, V283, pR1207; Romero MF, 2004, PFLUG ARCH EUR J PHY, V447, P495, DOI 10.1007/s00424-003-1180-2; Rossmann H, 2001, J PHYSIOL-LONDON, V534, P837, DOI 10.1111/j.1469-7793.2001.00837.x; Rossmann H, 2001, AM J PHYSIOL-GASTR L, V281, pG447, DOI 10.1152/ajpgi.2001.281.2.G447; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; Scarff KL, 1999, GASTROENTEROLOGY, V117, P605, DOI 10.1016/S0016-5085(99)70453-1; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; Smolka AJ, 2000, BIOCHEM BIOPH RES CO, V273, P942, DOI 10.1006/bbrc.2000.3031; Sonnentag T, 2000, AM J PHYSIOL-GASTR L, V279, pG40, DOI 10.1152/ajpgi.2000.279.1.G40; SOYBEL DI, 1995, AM J PHYSIOL-CELL PH, V269, pC242, DOI 10.1152/ajpcell.1995.269.1.C242; Spicer Z, 2000, J BIOL CHEM, V275, P21555, DOI 10.1074/jbc.M001558200; STUARTTILLEY A, 1994, AM J PHYSIOL, V266, pC559, DOI 10.1152/ajpcell.1994.266.2.C559; THOMAS HA, 1991, CELL REGUL, V2, P727, DOI 10.1091/mbc.2.9.727; Wang Z, 1996, J BIOL CHEM, V271, P7835, DOI 10.1074/jbc.271.13.7835; Yao XB, 2003, ANNU REV PHYSIOL, V65, P103, DOI 10.1146/annurev.physiol.65.072302.114200	44	110	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30531	30539		10.1074/jbc.M403779200	http://dx.doi.org/10.1074/jbc.M403779200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123620	hybrid			2022-12-25	WOS:000222531900082
J	Miranda, M; Sorkina, T; Grammatopoulos, TN; Zawada, WM; Sorkin, A				Miranda, M; Sorkina, T; Grammatopoulos, TN; Zawada, WM; Sorkin, A			Multiple molecular determinants in the carboxyl terminus regulate dopamine transporter export from endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY-TRANSFER MICROSCOPY; RAT GABA TRANSPORTER-1; SEROTONIN TRANSPORTER; CYSTIC-FIBROSIS; LIVING CELLS; G-PROTEIN; TRAFFICKING; ER; DOMAIN; SIGNAL	The plasma membrane dopamine transporter (DAT) has an essential role in terminating dopaminergic neurotransmission by reuptake of dopamine into the presynaptic neurons. Therefore, the amount of DAT at the cell surface is a critical determinant of DAT function. In this study, we examined the role of the carboxyl terminus of DAT in trafficking of the transporter through the biosynthetic pathway to the plasma membrane. Live cell fluorescence microscopy and cell surface biotinylation were used to study the effects of systematic deletions and alanine substitutions in the carboxyl terminus on DAT localization. It was found that alanine substitutions of Lys-590 and Asp-600 significantly delayed the delivery of DAT to the plasma membrane because of retention of DAT in the endoplasmic reticulum (ER). Most surprising, mutation of Gly-585 to alanine completely blocked the exit of DAT from the ER and surface expression of the transporter. The effect of these three mutations on ER export of DAT was demonstrated in porcine aortic endothelial cells and the immortalized neuronal cell line 1RB(3)AN(27). In primary cultures of rat embryonic midbrain neurons, DAT G585A, K590A, and D600A mutants were restricted to the cell soma and did not traffic to the dendrites or axonal processes. These data are consistent with the model whereby the local conformation and/or intramolecular interactions of the sequences of the DAT carboxyl terminus proximal to the last transmembrane domain are essential for the ER export of the transporter.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Div Clin Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Neurosci, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sorkin, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th Ave, Denver, CO 80262 USA.	alexander.sorkin@uchsc.edu		Grammatopoulos, Tom/0000-0001-7175-051X; Sorkin, Alexander/0000-0002-4446-1920	NIDA NIH HHS [DA14204] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014204] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Androutsellis-Theotokis A, 2002, J NEUROSCI, V22, P8370; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; Barlowe C, 2003, TRENDS CELL BIOL, V13, P295, DOI 10.1016/S0962-8924(03)00082-5; Bauman PA, 2002, ARCH BIOCHEM BIOPHYS, V404, P80, DOI 10.1016/S0003-9861(02)00232-1; Carneiro AM, 2002, J NEUROSCI, V22, P7045; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Carvelli L, 2002, J NEUROCHEM, V81, P859, DOI 10.1046/j.1471-4159.2002.00892.x; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Clarkson ED, 1998, P NATL ACAD SCI USA, V95, P1265, DOI 10.1073/pnas.95.3.1265; Cohen J, 2002, CURR OPIN NEUROBIOL, V12, P223, DOI 10.1016/S0959-4388(02)00314-8; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Giraudo CG, 2003, MOL BIOL CELL, V14, P3753, DOI 10.1091/mbc.E03-02-0101; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Horton AC, 2003, NEURON, V40, P277, DOI 10.1016/S0896-6273(03)00629-9; Lee FJS, 1996, J BIOL CHEM, V271, P20885, DOI 10.1074/jbc.271.34.20885; Lin ZC, 2000, MOL PHARMACOL, V58, P1581, DOI 10.1124/mol.58.6.1581; Lin ZC, 1999, MOL PHARMACOL, V56, P434, DOI 10.1124/mol.56.2.434; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; Nirenberg MJ, 1997, J NEUROSCI, V17, P5255; Nirenberg MJ, 1997, J NEUROSCI, V17, P6899; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Nufer O, 2002, J CELL SCI, V115, P619; Otte S, 2002, EMBO J, V21, P6095, DOI 10.1093/emboj/cdf598; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Sevier CS, 2000, MOL BIOL CELL, V11, P13, DOI 10.1091/mbc.11.1.13; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; Sorkina T, 2003, J BIOL CHEM, V278, P28274, DOI 10.1074/jbc.M210652200; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Votsmeier C, 2001, EMBO J, V20, P6742, DOI 10.1093/emboj/20.23.6742; Zawada WM, 2001, BRAIN RES, V891, P185; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	40	56	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30760	30770		10.1074/jbc.M312774200	http://dx.doi.org/10.1074/jbc.M312774200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15128747	hybrid			2022-12-25	WOS:000222531900107
J	Lin, H; Juang, JL; Wang, PS				Lin, H; Juang, JL; Wang, PS			Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; CARDIAC-GLYCOSIDES; GROWTH-FACTOR; DIGITALIS; P35; EXPRESSION; P25; EVENTS; LEYDIG; DEATH	Cardiac digitalis has been considered to be a treatment for breast cancer. Our previous study indicates that digoxin, one member in digitalis, decreases the proliferation of prostate cancer cells, but the mechanisms remain unclear. In the present study, Ca2+ proved to be an important factor in digoxin-triggered prostate cancer cell death. Because cyclin-dependent kinase (Cdk) 5 and p35 cleavage (p25 formation) have been reported to be targets of intracellular Ca2+, and subsequently correlated to apoptosis, we not only demonstrated first that Cdk5, p35, and p25 proteins were all expressed in prostate cancer cells (including lymph node carcinoma of the prostate (LNCaP) and DU-145 cells), but also showed where p25 formation and Cdk5 kinase activity were affected by treatment with digoxin. The inhibitor of p35 cleavage (calpeptin) was used to reduce p25 formation, and the result suggested that p25 accumulation might be the major cause of digoxin-triggered LNCaP cell death. Butyrolactone-I and roscovitine, two Cdk5 kinase inhibitors, were also found to prevent digoxin-triggered LNCaP cell death. In addition, treatment of siRNA-Cdk5 diminished digoxin-triggered cell death, as compared with the treatments of siRNA-Cdk1 or siRNA-Cdk2, which implies the specific involvement of Cdk5 in digoxin-triggered cell death. Caspase inhibitor set and terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling assay were used to demonstrate that digoxin-triggered LNCaP cell apoptosis through Cdk5 activation. These results suggest that Cdk5/p35 and p25 are novel players in digoxin-triggered prostate cancer cell apoptosis and, therefore, become potential therapeutic targets.	Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 115, Taiwan; Natl Yang Ming Univ, Sch Med, Dept Physiol, Taipei 112, Taiwan; Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 112, Taiwan	National Health Research Institutes - Taiwan; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital	Wang, PS (corresponding author), Natl Hlth Res Inst, Div Mol & Genom Med, 128 Yen Chiu Yuan Rd,Sec 2, Taipei 115, Taiwan.	pswang@ym.edu.tw	Juang, Jyh-Lyh/E-3944-2010	Lin, Ho/0000-0001-7849-9137				Alvarez A, 2001, EXP CELL RES, V264, P266, DOI 10.1006/excr.2001.5152; Chen JJ, 2002, J CELL BIOCHEM, V86, P107, DOI 10.1002/jcb.10154; Chen JJ, 2001, BRIT J PHARMACOL, V132, P1761, DOI 10.1038/sj.bjp.0703974; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; Demers C, 1999, CORONARY ARTERY DIS, V10, P353, DOI 10.1097/00019501-199909000-00002; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; Hauptman PJ, 1999, CIRCULATION, V99, P1265, DOI 10.1161/01.CIR.99.9.1265; Hsieh TC, 1997, PROSTATE, V33, P97; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lin H, 1998, BRIT J PHARMACOL, V125, P1635, DOI 10.1038/sj.bjp.0702229; Maccioni RB, 2001, EUR J BIOCHEM, V268, P1518, DOI 10.1046/j.1432-1327.2001.02024.x; McConkey DJ, 2000, CANCER RES, V60, P3807; Musa FRM, 1998, J ANDROL, V19, P657; Musa FRM, 2000, J ANDROL, V21, P392; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Patzke H, 2002, TRENDS NEUROSCI, V25, P8, DOI 10.1016/S0166-2236(00)02000-2; Rhim JS, 1997, CRIT REV ONCOGENESIS, V8, P305, DOI 10.1615/CritRevOncog.v8.i4.20; Rosales JL, 2004, J BIOL CHEM, V279, P1224, DOI 10.1074/jbc.M310867200; Steel R.G., 1980, PRINCIPLES PROCEDURE, P481; Stenkvist B, 1999, ONCOL REP, V6, P493; STENKVIST B, 1982, NEW ENGL J MED, V306, P484; Tang D, 1996, Prog Cell Cycle Res, V2, P205; Tang DM, 1996, BIOCHEM CELL BIOL, V74, P419, DOI 10.1139/o96-046; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Ubeda M, 2004, ENDOCRINOLOGY, V145, P3023, DOI 10.1210/en.2003-1522; Wei WL, 2002, J BIOL CHEM, V277, P17649, DOI 10.1074/jbc.M111704200; Weishaupt JH, 2003, CELL TISSUE RES, V312, P1, DOI 10.1007/s00441-003-0703-7; Yeh JY, 2003, PROSTATE, V54, P112, DOI 10.1002/pros.10172; Yeh JY, 2001, J UROLOGY, V166, P1937, DOI 10.1016/S0022-5347(05)65724-2; Zapata-Torres G, 2004, J NAT PROD, V67, P416, DOI 10.1021/np034011s; Zhang Q, 1997, DEV BIOL, V183, P222, DOI 10.1006/dbio.1996.8494	32	81	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29302	29307		10.1074/jbc.M403664200	http://dx.doi.org/10.1074/jbc.M403664200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123618	hybrid			2022-12-25	WOS:000222445300060
J	Nagata, R; Nishio, Y; Sekine, O; Nagai, Y; Maeno, Y; Ugi, S; Maegawa, H; Kashiwagi, A				Nagata, R; Nishio, Y; Sekine, O; Nagai, Y; Maeno, Y; Ugi, S; Maegawa, H; Kashiwagi, A			Single nucleotide polymorphism (-468 gly to ala) at the promoter region of sterol regulatory element-binding protein-1c associates with genetic defect of fructose-induced hepatic lipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; RAT HEPATOCYTES; TRANSGENIC MICE; CULTURED-CELLS; MESSENGER-RNA; EXPRESSION; TRANSCRIPTION; SREBP-1C; GLUCOSE; TISSUE	To evaluate the genetic susceptibility to metabolic disorders induced by high fructose diet, we investigated the metabolic characteristics in 10 strains of inbred mice and found that they were separated into CBA and DBA groups according to the response to high fructose diet. The hepatic mRNA expression of the sterol regulatory element-binding protein-1 (SREBP-1) in CBA/JN was remarkably enhanced by high fructose diet but not in DBA/2N. Similar results were observed in primary hepatocytes after exposure to fructose. The nucleotide sequence at - 468 bp from the putative starting point of the SREBP-1c gene was adenine in the DBA group while it was guanine in the CBA group. In hepatocytes from CBA/JN, the activity of CBA-SREBP-1c promoter was significantly increased by 2.4- and 2.2-fold, in response to 30 mM fructose or 10 nM insulin, respectively, whereas the activity of DBA-SREBP-1c promoter responded to insulin but not to fructose. In hepatocytes from DBA/2N, both types of SREBP-1c promoter activities in response to insulin were attenuated. Furthermore, electrophoretic mobility shift assay revealed an unidentified nuclear protein bound to the oligonucleotides made from the region between - 453 to - 480 bp of the SREBP-1c promoter of CBA/JN but not to the probe from DBA/2N. Thus, in DBA/2N, the reduced mRNA expression of SREBP-1 after fructose refeeding appeared to associate with two independent mechanisms, 1) loss of binding of unidentified proteins to the region between - 453 to - 480 bp of the SREBP-1c promoter and 2) impaired insulin stimulation of SREBP-1c promoter activity.	Shiga Univ Med Sci, Dept Med, Div Endocrinol & Metab, Shiga 5202192, Japan	Shiga University of Medical Science	Nishio, Y (corresponding author), Shiga Univ Med Sci, Dept Med, Div Endocrinol & Metab, Shiga 5202192, Japan.	nishio@belle.shiga-med.ac.jp	Kashiwagi, Atsunori/H-8712-2019	Maegawa, Hiroshi/0000-0002-4611-8149				Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Azzout-Marniche D, 2000, BIOCHEM J, V350, P389, DOI 10.1042/0264-6021:3500389; Deng X, 2002, BIOCHEM BIOPH RES CO, V290, P256, DOI 10.1006/bbrc.2001.6148; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Hasty AH, 2000, J BIOL CHEM, V275, P31069, DOI 10.1074/jbc.M003335200; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; Koya D, 1999, FASEB J, V13, P2329, DOI 10.1096/fasebj.13.15.2329; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; Nagai Y, 2002, AM J PHYSIOL-ENDOC M, V282, pE1180, DOI 10.1152/ajpendo.00471.2001; Nishio Y, 1998, DIABETES, V47, P1318, DOI 10.2337/diabetes.47.8.1318; NISHIO Y, 1995, J CLIN INVEST, V96, P1759, DOI 10.1172/JCI118221; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Sekine M, 1997, J BIOL CHEM, V272, P27246, DOI 10.1074/jbc.272.43.27246; Sekine M, 2002, J BIOCHEM, V132, P387, DOI 10.1093/oxfordjournals.jbchem.a003234; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Shinozaki K, 1999, DIABETES, V48, P2437, DOI 10.2337/diabetes.48.12.2437; Shinozaki K, 2000, CIRC RES, V87, P566, DOI 10.1161/01.RES.87.7.566; SLEDER J, 1980, METABOLISM, V29, P303, DOI 10.1016/0026-0495(80)90001-3; STEINEGER HH, 1994, EUR J BIOCHEM, V225, P967, DOI 10.1111/j.1432-1033.1994.0967b.x; Stoeckman AK, 2002, J BIOL CHEM, V277, P27029, DOI 10.1074/jbc.M202638200; TENENHOUSE HS, 1995, AM J PHYSIOL-RENAL, V268, pF1062, DOI 10.1152/ajprenal.1995.268.6.F1062; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Yoshikawa T, 2002, J BIOL CHEM, V277, P1705, DOI 10.1074/jbc.M105711200; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	29	53	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29031	29042		10.1074/jbc.M309449200	http://dx.doi.org/10.1074/jbc.M309449200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123654	hybrid			2022-12-25	WOS:000222445300026
J	Tempel, W; Karaveg, K; Liu, ZJ; Rose, J; Wang, BC; Moremen, KW				Tempel, W; Karaveg, K; Liu, ZJ; Rose, J; Wang, BC; Moremen, KW			Structure of mouse Golgi alpha-mannosidase IA reveals the molecular basis for substrate specificity among class 1 (family 47 glycosylhydrolase) alpha 1,2-mannosidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; RETICULUM-ASSOCIATED DEGRADATION; NON-DETERGENT SULFOBETAINES; SHORT-LIVED VARIANT; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; PROCESSING ALPHA-1,2-MANNOSIDASE; NONDETERGENT SULFOBETAINES; GLYCOPROTEIN DEGRADATION; MISFOLDED GLYCOPROTEINS	Three subfamilies of mammalian Class 1 processing alpha1,2-mannosidases ( family 47 glycosidases) play critical roles in the maturation of Asn-linked glycoproteins in the endoplasmic reticulum ( ER) and Golgi complex as well as influencing the timing and recognition for disposal of terminally unfolded proteins by ER-associated degradation. In an effort to define the structural basis for substrate recognition among Class 1 mannosidases, we have crystallized murine Golgi mannosidase IA ( space group P2(1)2(1)2(1)), and the structure was solved to 1.5-Angstrom resolution by molecular replacement. The enzyme assumes an (alphaalpha)(7) barrel structure with a Ca(2+) ion coordinated at the base of the barrel similar to other Class 1 mannosidases. Critical residues within the barrel structure that coordinate the Ca(2+) ion or presumably bind and catalyze the hydrolysis of the glycone are also highly conserved. A Man(6)GlcNAc(2) oligosaccharide attached to Asn(515) in the murine enzyme was found to extend into the active site of an adjoining protein unit in the crystal lattice in a presumed enzyme-product complex. In contrast to an analogous complex previously isolated for Saccharomyces cerevisiae ER mannosidase I, the oligosaccharide in the active site of the murine Golgi enzyme assumes a different conformation to present an alternate oligosaccharide branch into the active site pocket. A comparison of the observed protein-carbohydrate interactions for the murine Golgi enzyme with the binding cleft topologies of the other family 47 glycosidases provides a framework for understanding the structural basis for substrate recognition among this class of enzymes.	Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Moremen, KW (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, 220 Riverbend Rd, Athens, GA 30602 USA.	moremen@uga.edu	Moremen, Kelley/AAD-4661-2019; Liu, Zhi-Jie/A-3946-2012	Liu, Zhi-Jie/0000-0001-7279-2893	NCRR NIH HHS [RR05351] Funding Source: Medline; NIGMS NIH HHS [GM47533] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUSE E, 1992, EUR J BIOCHEM, V208, P451, DOI 10.1111/j.1432-1033.1992.tb17207.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabral CM, 2000, J BIOL CHEM, V275, P25015, DOI 10.1074/jbc.M910172199; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; DANIEL PF, 1994, GLYCOBIOLOGY, V4, P551, DOI 10.1093/glycob/4.5.551; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Ermonval M, 2001, GLYCOBIOLOGY, V11, P565, DOI 10.1093/glycob/11.7.565; Gemmill TR, 1999, BBA-GEN SUBJECTS, V1426, P227, DOI 10.1016/S0304-4165(98)00126-3; Goldberg, 1995, Fold Des, V1, P21; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; HERSCOVICS A, 1994, J BIOL CHEM, V269, P9864; Herscovics A, 2002, ROY SOC CH, P28, DOI 10.1039/9781847550323-00028; Herscovics A, 1999, BBA-GEN SUBJECTS, V1426, P275, DOI 10.1016/S0304-4165(98)00129-9; Herscovics A, 2002, GLYCOBIOLOGY, V12, p14G; HERSCOVICS A, 1999, COMPREHENSIVE NATURA, V3, P13; Hosokawa N, 2003, J BIOL CHEM, V278, P26287, DOI 10.1074/jbc.M303395200; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Ichishima E, 1999, BIOCHEM J, V339, P589, DOI 10.1042/0264-6021:3390589; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Jakob CA, 2001, EMBO REP, V2, P423; Kitzmuller C, 2003, BIOCHEM J, V376, P687, DOI 10.1042/BJ20030887; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAL A, 1994, J BIOL CHEM, V269, P9872; Lal A, 1998, GLYCOBIOLOGY, V8, P981, DOI 10.1093/glycob/8.10.981; LIPARI F, 1995, BIOCHEM BIOPH RES CO, V209, P322, DOI 10.1006/bbrc.1995.1506; LIPARI F, 1994, GLYCOBIOLOGY, V4, P697, DOI 10.1093/glycob/4.5.697; Lobsanov YD, 2002, J BIOL CHEM, V277, P5620, DOI 10.1074/jbc.M110243200; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; More TA, 2000, US FOR SERV RMRS-P, V2, P81; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Nakatsukasa K, 2001, J BIOL CHEM, V276, P8635, DOI 10.1074/jbc.C100023200; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PUCCIA R, 1993, BIOCHEM J, V290, P21, DOI 10.1042/bj2900021; RENKEL Z, 2003, J BIOL CHEM, V278, P34119; Romero PA, 2000, J BIOL CHEM, V275, P11071, DOI 10.1074/jbc.275.15.11071; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tremblay LO, 1998, GLYCOBIOLOGY, V8, P585, DOI 10.1093/glycob/8.6.585; TRIMBLE RB, 1991, J BIOL CHEM, V266, P22807; Vallee F, 1999, ACTA CRYSTALLOGR D, V55, P571, DOI 10.1107/S090744499801244X; Vallee F, 2000, EMBO J, V19, P581, DOI 10.1093/emboj/19.4.581; Vallee F, 2000, J BIOL CHEM, V275, P41287, DOI 10.1074/jbc.M006927200; Van Petegem F, 2001, J MOL BIOL, V312, P157, DOI 10.1006/jmbi.2001.4946; Vuillard L, 1998, EUR J BIOCHEM, V256, P128, DOI 10.1046/j.1432-1327.1998.2560128.x; VUILLARD L, 1995, ANAL BIOCHEM, V230, P290, DOI 10.1006/abio.1995.1476; VUILLARD L, 1995, BIOCHEM J, V305, P337, DOI 10.1042/bj3050337; VUILLARD L, 1994, FEBS LETT, V353, P294, DOI 10.1016/0014-5793(94)01060-9; VUILLARD L, 1995, ELECTROPHORESIS, V16, P295, DOI 10.1002/elps.1150160148; Wang T, 2003, NAT STRUCT BIOL, V10, P319, DOI 10.1038/nsb0503-319; Winn MD, 2002, ACTA CRYSTALLOGR D, V58, P1929, DOI 10.1107/S0907444902016116; Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100; Yoshida T, 1998, BIOSCI BIOTECH BIOCH, V62, P309, DOI 10.1271/bbb.62.309; ZIEGLER F D, 1991, Glycobiology, V1, P605, DOI 10.1093/glycob/1.6.605	59	42	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29774	29786		10.1074/jbc.M403065200	http://dx.doi.org/10.1074/jbc.M403065200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15102839	hybrid			2022-12-25	WOS:000222445300114
J	Wang, HB; Faucette, S; Moore, R; Sueyoshi, T; Negishi, M; LeCluyse, E				Wang, HB; Faucette, S; Moore, R; Sueyoshi, T; Negishi, M; LeCluyse, E			Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY HUMAN HEPATOCYTES; RESPONSIVE ENHANCER MODULE; DRUG-METABOLISM; NUCLEAR TRANSLOCATION; XENOBIOTIC INDUCTION; PRIMARY CULTURE; MOUSE-LIVER; CAR; CYTOCHROME-P450; ACTIVATION	Compared with its rodent orthologs, little is known about the chemical specificity of human constitutive androstane receptor (hCAR) and its regulation of hepatic enzyme expression. Phenytoin (PHY), a widely used antiepileptic drug, is a potent inducer of CYP2B6 in primary human hepatocytes, but does not activate human pregnane X receptor (PXR) significantly in cell-based transfection assays at the same concentrations associated with potent induction of CYP2B6. Based on this observation, we hypothesized that PHY may be a selective activator of hCAR. In primary human hepatocytes, expression of CYP2B6 reporter genes containing phenobarbital-responsive enhancer module (PBREM) or PBREM/xenobiotic- responsive enhancer module (XREM) response elements were activated up to 14- and 28-fold, respectively, by 50 muM PHY. By contrast, parallel experiments in HepG2 cell lines co-transfected with an hPXR expression vector did not show increased reporter activity. These results indicated that a PXR-independent pathway, which is retained in primary hepatocytes, is responsible for PHY induction of CYP2B6. Further experiments revealed that PHY effectively translocates hCAR from the cytoplasm into the nucleus in both primary human hepatocytes and CAR(-/-) mice. Compared with vehicle controls, PHY administration significantly increased CYP2B6 reporter gene expression, when this reporter construct was delivered together with hCAR expression vector into CAR(-/-) mice. However, PHY did not increase reporter gene expression in CAR(-/-) mice in the absence of hCAR vector, implying that CAR is essential for mediating PHY induction of CYP2B6 gene expression. Taken together, these observations demonstrate that, in contrast to most of the known CYP2B6 inducers, PHY is a selective activator of CAR in humans.	NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Sch Pharm, Div Drug Delivery & Disposit, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill	LeCluyse, E (corresponding author), NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	ed_lecluyse@unc.edu	Negishi, Masahiko/F-7805-2019	Negishi, Masahiko/0000-0002-2076-8928; LeCluyse, Edward/0000-0002-2149-8990	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071005, Z01ES080040] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK061652] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bajpai M, 1996, DRUG METAB DISPOS, V24, P1401; Chang TKH, 1997, CANCER RES, V57, P1946; Ducharme MP, 1997, CANCER CHEMOTH PHARM, V40, P531, DOI 10.1007/s002800050698; Faucette SR, 2004, DRUG METAB DISPOS, V32, P348, DOI 10.1124/dmd.32.3.348; Gerbal-Chaloin S, 2001, DRUG METAB DISPOS, V29, P242; Goodwin B, 2001, MOL PHARMACOL, V60, P427; Hamilton GA, 2001, CELL TISSUE RES, V306, P85; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Kakizaki S, 2003, BBA-GEN SUBJECTS, V1619, P239, DOI 10.1016/S0304-4165(02)00482-8; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Klaassen SL, 1998, ANN PHARMACOTHER, V32, P1295, DOI 10.1345/aph.17296; KOBAYASHI K, 2000, MOL PHARMACOL, V64, P1069; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Li AP, 1997, CHEM-BIOL INTERACT, V107, P5, DOI 10.1016/S0009-2797(97)00070-7; Maglich JM, 2003, J BIOL CHEM, V278, P17277, DOI 10.1074/jbc.M300138200; Makinen JM, 2002, MOL PHARMACOL, V62, P366, DOI 10.1124/mol.62.2.366; MANONESPAILLAT R, 1991, EPILEPSIA, V32, P96, DOI 10.1111/j.1528-1157.1991.tb05619.x; Maurel P, 1996, ADV DRUG DELIVER REV, V22, P105, DOI 10.1016/S0169-409X(96)00417-6; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; MOOTS PL, 1995, ARCH NEUROL-CHICAGO, V52, P717, DOI 10.1001/archneur.1995.00540310091021; Muangmoonchai R, 2001, BIOCHEM J, V355, P71, DOI 10.1042/0264-6021:3550071; Pascussi JM, 2000, MOL PHARMACOL, V58, P1441, DOI 10.1124/mol.58.6.1441; Patsalos PN, 2002, EPILEPSIA, V43, P365, DOI 10.1046/j.1528-1157.2002.13001.x; Raucy JL, 2003, DRUG METAB DISPOS, V31, P533, DOI 10.1124/dmd.31.5.533; Relling MV, 2000, LANCET, V356, P285, DOI 10.1016/S0140-6736(00)02503-4; Sahi J, 2000, XENOBIOTICA, V30, P273, DOI 10.1080/004982500237668; SPATZENEGGER M, 1995, DRUG METAB REV, V27, P397, DOI 10.3109/03602539508998329; Strom SC, 1996, METHOD ENZYMOL, V272, P388, DOI 10.1016/S0076-6879(96)72044-X; Sueyoshi T, 2002, METHOD ENZYMOL, V357, P205; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; Ueda A, 2002, MOL PHARMACOL, V61, P1284, DOI 10.1124/mol.61.6.1284; Vecht CJ, 2003, LANCET NEUROL, V2, P404, DOI 10.1016/S1474-4422(03)00435-6; Wang HB, 2003, DRUG METAB DISPOS, V31, P620, DOI 10.1124/dmd.31.5.620; Wang HB, 2003, J BIOL CHEM, V278, P14146, DOI 10.1074/jbc.M212482200; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Williams ML, 1999, CHIRALITY, V11, P569; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Yoshinari K, 2001, MOL PHARMACOL, V59, P278, DOI 10.1124/mol.59.2.278; Zelko I, 2001, MOL CELL BIOL, V21, P2838, DOI 10.1128/MCB.21.8.2838-2846.2001; Zelko I, 2000, BIOCHEM BIOPH RES CO, V277, P1, DOI 10.1006/bbrc.2000.3557	41	119	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29295	29301		10.1074/jbc.M400580200	http://dx.doi.org/10.1074/jbc.M400580200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123723	Green Published, hybrid			2022-12-25	WOS:000222445300059
J	Hibbs, RE; Talley, TT; Taylor, P				Hibbs, RE; Talley, TT; Taylor, P			Acrylodan-conjugated cysteine side chains reveal conformational state and ligand site locations of the acetylcholine-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-BUNGAROTOXIN; NICOTINIC RECEPTOR; SUBUNIT INTERFACES; CRYSTAL-STRUCTURE; COMPLEX; NEUROTOXINS; CYS(69)-CYS(96); ANTAGONISTS; INHIBITION; RESIDUES	We undertook cysteine substitution mutagenesis and fluorophore conjugation at selected residue positions to map sites of ligand binding and changes in solvent exposure of the acetylcholine-binding protein from Lymnaea stagnalis, a nicotinic receptor surrogate. Acrylodan fluorescence emission is highly sensitive to its local environment, and when bound to protein, exhibits changes in both intensity and emission wavelength that are reflected in the degree of solvent exclusion and the effective dielectric constant of the environment of the fluorophore. Hence, cysteine mutants were generated based on the acetylcholine- binding protein crystal structure and predicted ligand binding sites, and fluorescence parameters were assayed on the acrylodan-conjugated proteins. This approach allows one to analyze the environment around the conjugated fluorophore side chain and the changes induced by bound ligand. Introduction of an acrylodan-cysteine conjugate at position 178 yields a large blue shift with alpha-bungarotoxin association, whereas the agonists and alkaloid antagonists induce red shifts reflecting solvent exposure at this position. Such residue-selective changes in fluorescence parameters suggest that certain ligands can induce distinct conformational states of the binding protein, and that mutually exclusive binding results from disparate portals of entry to and orientations of the bound alpha-toxin and smaller acetylcholine congeners at the binding pocket. Labeling at other residue positions around the predicted binding pocket also reveals distinctive spectral changes for alpha-bungarotoxin, agonists, and alkaloid antagonists.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	pwtaylor@ucsd.edu	Talley, Todd/B-3630-2010	Talley, Todd/0000-0002-1077-1947	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, T32GM007752] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM 18360, GM/NS 043063, T32 GM 07752] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Bourne Y, 2004, P NATL ACAD SCI USA, V101, P1449, DOI 10.1073/pnas.0308206100; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CHANGEUX JP, 1970, P NATL ACAD SCI USA, V67, P1241, DOI 10.1073/pnas.67.3.1241; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; Fruchart-Gaillard C, 2002, P NATL ACAD SCI USA, V99, P3216, DOI 10.1073/pnas.042699899; Gao F, 2003, J BIOL CHEM, V278, P23020, DOI 10.1074/jbc.M301151200; Hansen SB, 2002, J BIOL CHEM, V277, P41299, DOI 10.1074/jbc.C200462200; Hansen SB, 2004, J BIOL CHEM, V279, P24197, DOI 10.1074/jbc.M402452200; Harel M, 2001, NEURON, V32, P265, DOI 10.1016/S0896-6273(01)00461-5; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lozzi L, 2003, CHEM BIOL, V10, P411, DOI 10.1016/S1074-5521(03)00094-2; Malany S, 2000, BIOCHEMISTRY-US, V39, P15388, DOI 10.1021/bi001825o; Martin M, 1996, J BIOL CHEM, V271, P13497, DOI 10.1074/jbc.271.23.13497; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Moise L, 2002, J BIOL CHEM, V277, P12406, DOI 10.1074/jbc.M110320200; Osaka H, 2000, J BIOL CHEM, V275, P5478, DOI 10.1074/jbc.275.8.5478; Quiram PA, 2000, J BIOL CHEM, V275, P4889, DOI 10.1074/jbc.275.7.4889; REITER MJ, 1972, P NATL ACAD SCI USA, V69, P1168, DOI 10.1073/pnas.69.5.1168; Samson AO, 2002, NEURON, V35, P319, DOI 10.1016/S0896-6273(02)00773-0; Shi JX, 2001, J BIOL CHEM, V276, P42196, DOI 10.1074/jbc.M106896200; Shi JX, 2003, J BIOL CHEM, V278, P30905, DOI 10.1074/jbc.M303730200; SILMAN I, 2000, CHOLINESTERASES CHOL, P9; Sine SM, 2002, J NEUROBIOL, V53, P431, DOI 10.1002/neu.10139; Sine SM, 2002, J BIOL CHEM, V277, P29210, DOI 10.1074/jbc.M203396200; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Sugiyama N, 1998, MOL PHARMACOL, V53, P787, DOI 10.1124/mol.53.4.787; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 2000, HANDB EXP PHARM, V144, P79; Teixeira-Clerc F, 2002, J BIOL CHEM, V277, P25741, DOI 10.1074/jbc.M200534200; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; WEBER M, 1974, MOL PHARMACOL, V10, P15; WEILAND G, 1977, J BIOL CHEM, V252, P7648; Zeng HY, 2001, J BIOL CHEM, V276, P22930, DOI 10.1074/jbc.M102300200	37	42	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28483	28491		10.1074/jbc.M403713200	http://dx.doi.org/10.1074/jbc.M403713200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117947	hybrid			2022-12-25	WOS:000222265400083
J	Cheng, Q; Jayaraman, V				Cheng, Q; Jayaraman, V			Chemistry and conformation of the ligand-binding domain of GluR2 subtype of glutamate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; CRYSTAL-STRUCTURES; STRUCTURAL BASIS; ACTIVATION; CORE; PROTEINS; CHANNELS	In the present report, using vibrational spectroscopy we have probed the ligand-protein interactions for full agonists (glutamate and alpha-amino-5-methyl-3-hydroxy-4-isoxazole propionate ( AMPA)) and a partial agonist ( kainate) in the isolated ligand-binding domain of the GluR2 subunit of the glutamate receptor. These studies indicate differences in the strength of the interactions of the alpha-carboxylates for the various agonists, with kainate having the strongest interactions and glutamate having the weakest. Additionally, the interactions at the alpha-amine group of the agonists have also been probed by studying the environment of the non-disulfide-bonded Cys-425, which is in close proximity to the alpha-amine group. These investigations suggest that the interactions at the alpha-amine group are stronger for full agonists such as glutamate and AMPA as evidenced by the increase in the hydrogen bond strength at Cys-425. Partial agonists such as kainate do not change the environment of Cys-425 relative to the apo form, suggesting weak interactions at the alpha-amine group of kainate. In addition to probing the ligand environment, we have also investigated the changes in the secondary structure of the protein. Results clearly indicate that full agonists such as glutamate and AMPA induce similar secondary structural changes that are different from those of the partial agonist kainate; thus, a spectroscopic signature is provided for identifying the functional consequences of a specific ligand binding to this protein.	Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Jayaraman, V (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA.	vasanthi.jayaraman@uth.tmc.edu						Armstrong N, 2003, P NATL ACAD SCI USA, V100, P5736, DOI 10.1073/pnas.1037393100; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CHAPMAN D, 1989, BIOCHEM SOC T, V17, P617, DOI 10.1042/bst0170617; Cheng Q, 2002, BIOCHEMISTRY-US, V41, P1602, DOI 10.1021/bi015729e; Hogner A, 2002, J MOL BIOL, V322, P93, DOI 10.1016/S0022-2836(02)00650-2; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Jayaraman V, 2000, BIOCHEMISTRY-US, V39, P8693, DOI 10.1021/bi000892f; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; Koening J. K., 1980, ANAL APPLICATIONS FT, P241; LI HM, 1991, J AM CHEM SOC, V113, P456, DOI 10.1021/ja00002a012; Madden DR, 2002, CURR OPIN DRUG DI DE, V5, P741; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Madden DR, 2001, J BIOL CHEM, V276, P37821; McFeeters RL, 2004, FASEB J, V18, P428, DOI 10.1096/fj.03-0873rev; McFeeters RL, 2002, J BIOMOL NMR, V22, P297, DOI 10.1023/A:1014954931635; McFeeters RL, 2002, BIOCHEMISTRY-US, V41, P10472, DOI 10.1021/bi026010p; SOMMER B, 1992, TRENDS PHARMACOL SCI, V13, P291, DOI 10.1016/0165-6147(92)90088-N; SPINNER E, 1967, J CHEM SOC B, P874, DOI 10.1039/j29670000874; Spiro T., 1987, BIOL APPL RAMAN SPEC; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a	21	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26346	26350		10.1074/jbc.M403111200	http://dx.doi.org/10.1074/jbc.M403111200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15100219	hybrid			2022-12-25	WOS:000222003000054
J	Menendez, JA; Oza, BP; Atlas, E; Verma, VA; Mehmi, I; Lupu, R				Menendez, JA; Oza, BP; Atlas, E; Verma, VA; Mehmi, I; Lupu, R			Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells	ONCOGENE			English	Article						fatty acid synthase; estradiol; tamoxifen; cerulenin; C75; RNA interference; small interfering RNA; estrogen receptor; apoptosis; endometrial cancer	BREAST-CANCER; FOOD-INTAKE; PROGESTERONE-RECEPTOR; ANTIBIOTIC CERULENIN; RIBONUCLEIC-ACID; RNA INTERFERENCE; LIPID-METABOLISM; GENE-EXPRESSION; IN-VITRO; ACTIVATION	Overexpression of the lipogenic enzyme fatty acid synthase (FAS) is a common molecular feature in subsets of sex-steroid-related tumors including endometrium and breast carcinomas that are associated with poor prognosis. Pharmacological inhibition of tumor-associated FAS hyperactivity is under investigation as a chemotherapeutic target. We examined the effects of the mycotoxin cerulenin (a covalent FAS inactivator), and the novel small compound C75 ( a slow-binding FAS inhibitor) on estradiol (E-2)- and tamoxifen (TAM)-stimulated ER-driven molecular responses in Ishikawa cells, an in vitro model of well-differentiated human endometrial carcinoma. We evaluated the effects of FAS inhibition on E-2- and TAM-induced estrogen receptor ( ER) transcriptional activity by using transient cotransfection assays with an estrogen-response element reporter construct (ERE-Luciferase). Antiestrogenic effects of cerulenin and C75 were observed by dose-dependent inhibition of E-2- stimulated ERE-dependent transcription, whereas FAS inhibitors did not significantly increase the levels of ERE transcriptional activity in the absence of E-2. Moreover, pharmacological blockade of FAS activity completely abolished TAM-stimulated ERE activity. To address the reliability of transient transfection assays, the effects of FAS inhibitors on E-2- inducible gene products were evaluated. FAS blockade induced a dose-dependent decrease in E-2- inducible alkaline phosphatase activity. E-2- stimulated accumulation of progesterone receptor (PR) and HER-2/neu oncogene was abolished in the presence of FAS blockers. FAS inhibition also resulted in a marked downregulation of E-2-stimulated ERalpha expression, and noticeably impaired E-2- induced ERalpha nuclear accumulation. A dose-dependent decrease in cell proliferation and cell viability was observed after FAS blockade. A Cell Death ELISA, detecting DNA fragmentation, demonstrated that FAS inhibitors stimulated apoptosis of Ishikawa cells. The analysis of critical E-2- and TAM-related cell cycle proteins revealed an increase of both the expression and the nuclear accumulation of cyclin-dependent kinase inhibitors p21(WAF1/CIP1) and p27(Kip1) following FAS inhibition. To rule out non-FAS cerulenin- and C75-related effects, we finally monitored ER signaling after silencing of FAS gene expression using the highly sequence-specific mechanism of RNA interference (RNAi). The concentrations of E-2 and TAM inducing half-maximal ERE activity (EC50) dramatically increased (4100 times) in FAS RNAi-transfected Ishikawa cells. Moreover, depletion of FAS by RNAi also caused loss of ERalpha expression, downregulation of PR, and accumulation of p21(WAF1/CIP1) and p27(Kip1) in E-2- stimulated Ishikawa cells. If chemically stable FAS inhibitors or cell-selective vector systems able to deliver RNAi targeting FAS gene demonstrate systemic anticancer effects in vivo, our results render FAS as a novel target for the prevention and treatment of endometrial carcinoma.	Evanston NW Healthcare Res Inst, Dept Med, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Lupu, R (corresponding author), Evanston NW Healthcare Res Inst, Dept Med, 1001 Univ Pl, Evanston, IL 60201 USA.	r-lupu@northwestern.edu	MENENDEZ, JAVIER A/C-6148-2016	MENENDEZ, JAVIER A/0000-0001-8733-4561; Verma, Vishal/0000-0001-7600-4372				ALBERT JL, 1990, CANCER RES, V50, P3306; Alo PL, 1999, TUMORI, V85, P35, DOI 10.1177/030089169908500108; Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Atanaskova N, 2002, ONCOGENE, V21, P4000, DOI 10.1038/sj.onc.1205506; Bamberger AM, 1999, VIRCHOWS ARCH, V434, P423, DOI 10.1007/s004280050361; Barsalou A, 1998, J BIOL CHEM, V273, P17138, DOI 10.1074/jbc.273.27.17138; Beato M, 1996, STEROIDS, V61, P240, DOI 10.1016/0039-128X(96)00030-X; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; CHALBOS D, 1992, J STEROID BIOCHEM, V43, P223, DOI 10.1016/0960-0760(92)90211-Z; CHRISTIE WW, 1981, BIOCHIM BIOPHYS ACTA, V666, P284, DOI 10.1016/0005-2760(81)90118-1; Colacurci N, 2000, PANMINERVA MED, V42, P45; Cosman F, 1999, ENDOCR REV, V20, P418, DOI 10.1210/er.20.3.418; De Schrijver E, 2003, CANCER RES, V63, P3799; Dils R, 1975, Methods Enzymol, V35, P74, DOI 10.1016/0076-6879(75)35140-9; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ESCOT C, 1990, J CLIN ENDOCR METAB, V70, P1319, DOI 10.1210/jcem-70-5-1319; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Favoni RE, 1998, TRENDS PHARMACOL SCI, V19, P406, DOI 10.1016/S0165-6147(98)01252-8; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Gallo MA, 1997, SEMIN ONCOL, V24, pS71; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; Goldstein SR, 2000, EUR J CANCER, V36, pS54; Harborth J, 2001, J CELL SCI, V114, P4557; Hata H, 1998, ONCOLOGY-BASEL, V55, P35, DOI 10.1159/000055257; Heemers H, 2001, MOL ENDOCRINOL, V15, P1817, DOI 10.1210/me.15.10.1817; HOLINKA CF, 1986, J STEROID BIOCHEM, V25, P781, DOI 10.1016/0022-4731(86)90308-0; JAMIL A, 1991, J MOL ENDOCRINOL, V6, P215, DOI 10.1677/jme.0.0060215; JENSEN V, 1993, BREAST CANC RES TREA, V27, P1; JOYEUX C, 1989, MOL ENDOCRINOL, V3, P681, DOI 10.1210/mend-3-4-681; KALKHOVEN E, 1994, MOL CELL ENDOCRINOL, V102, P45, DOI 10.1016/0303-7207(94)90096-5; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Kawata M, 2001, ARCH HISTOL CYTOL, V64, P353, DOI 10.1679/aohc.64.353; Kim EK, 2002, AM J PHYSIOL-ENDOC M, V283, pE867, DOI 10.1152/ajpendo.00178.2002; KRISHNA PLB, 2001, CANCER RES, V61, P6137; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Kumar MV, 2002, P NATL ACAD SCI USA, V99, P1921, DOI 10.1073/pnas.042683699; Kusakabe T, 2000, J HISTOCHEM CYTOCHEM, V48, P613, DOI 10.1177/002215540004800505; Lasset C, 2001, LANCET, V357, P66, DOI 10.1016/S0140-6736(05)71563-4; Lessey BA, 1996, J STEROID BIOCHEM, V59, P31, DOI 10.1016/S0960-0760(96)00103-3; Li JN, 2001, CANCER RES, V61, P1493; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Lupu R, 2003, INT J ONCOL, V23, P1407; Markogiannakis E, 1997, LIFE SCI, V61, P1083, DOI 10.1016/S0024-3205(97)00617-6; Menendez JA, 2004, INT J ONCOL, V24, P591; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Moche M, 1999, J BIOL CHEM, V274, P6031, DOI 10.1074/jbc.274.10.6031; MOELLING K, 1990, FEBS LETT, V261, P373, DOI 10.1016/0014-5793(90)80595-A; Nishida M, 1996, Hum Cell, V9, P109; Nishida Masato, 2002, Hum Cell, V15, P104, DOI 10.1111/j.1749-0774.2002.tb00105.x; OMURA S, 1976, BACTERIOL REV, V40, P681, DOI 10.1128/MMBR.40.3.681-697.1976; PEREZ L, 1991, FEBS LETT, V280, P129, DOI 10.1016/0014-5793(91)80220-W; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Persson I, 2000, J STEROID BIOCHEM, V74, P357, DOI 10.1016/S0960-0760(00)00113-8; Pisha Emily, 1997, Methods in Cell Science, V19, P37, DOI 10.1023/A:1009746605060; Pizer ES, 1997, INT J GYNECOL PATHOL, V16, P45, DOI 10.1097/00004347-199701000-00008; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 1998, CANCER-AM CANCER SOC, V83, P528, DOI 10.1002/(SICI)1097-0142(19980801)83:3<528::AID-CNCR22>3.0.CO;2-X; Pizer ES, 2000, CANCER RES, V60, P213; Pizer ES, 1996, CANCER RES, V56, P2745; Pizer ES, 1998, CANCER RES, V58, P4611; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; RONCARI DAK, 1974, CAN J BIOCHEM CELL B, V52, P221, DOI 10.1139/o74-035; Sakamoto T, 2002, MOL CELL ENDOCRINOL, V192, P93, DOI 10.1016/S0303-7207(02)00086-2; Schwartz LB, 1997, AM J OBSTET GYNECOL, V176, P129, DOI 10.1016/S0002-9378(97)80025-7; Shimokawa T, 2002, P NATL ACAD SCI USA, V99, P66, DOI 10.1073/pnas.012606199; Shiozawa T, 1998, MOL HUM REPROD, V4, P899, DOI 10.1093/molehr/4.9.899; Shurbaji MS, 1996, HUM PATHOL, V27, P917, DOI 10.1016/S0046-8177(96)90218-X; Simard J, 1997, CANCER RES, V57, P3494; SIMON SM, 1992, J BIOL CHEM, V267, P3922; Smith SMR, 2000, AM J SURG, V180, P249, DOI 10.1016/S0002-9610(00)00453-0; Swinnen JV, 2002, INT J CANCER, V98, P19, DOI 10.1002/ijc.10127; Swinnen JV, 1997, CANCER RES, V57, P1086; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; VANLEEUWEN FE, 1994, LANCET, V343, P448, DOI 10.1016/S0140-6736(94)92692-1; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WEISS L, 1986, BIOL CHEM H-S, V367, P905, DOI 10.1515/bchm3.1986.367.2.905; WITKOWSKI A, 1991, EUR J BIOCHEM, V198, P571, DOI 10.1111/j.1432-1033.1991.tb16052.x; Wortman MD, 2003, NAT MED, V9, P483, DOI 10.1038/nm0503-483; Ye QN, 2000, BBA-GENE STRUCT EXPR, V1493, P373, DOI 10.1016/S0167-4781(00)00202-5; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	89	39	40	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4945	4958		10.1038/sj.onc.1207476	http://dx.doi.org/10.1038/sj.onc.1207476			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15094777				2022-12-25	WOS:000222104200016
J	Mamane, Y; Petroulakis, E; Rong, LW; Yoshida, K; Ler, LW; Sonenberg, N				Mamane, Y; Petroulakis, E; Rong, LW; Yoshida, K; Ler, LW; Sonenberg, N			eIF4E - from translation to transformation	ONCOGENE			English	Review						translation initiation; eIF4E; transformation	INITIATION-FACTOR 4E; CAP-BINDING PROTEIN; MESSENGER-RNA TRANSLATION; MYC-DEPENDENT APOPTOSIS; CYCLIN D1 PROTEIN; EUKARYOTIC TRANSLATION; ORNITHINE-DECARBOXYLASE; C-MYC; CELL-CYCLE; ANTI-ANGIOGENESIS	Over the years, studies have focused on the transcriptional regulation of oncogenesis. More recently, a growing emphasis has been placed on translational control. The Ras and Akt signal transduction pathways play a critical role in regulating mRNA translation and cellular transformation. The question arises: How might the Ras and Akt signaling pathways affect translation and mediate transformation? These pathways converge on a crucial effector of translation, the initiation factor eIF4E, which binds the 5' cap of mRNAs. This review focuses on the role of eIF4E in oncogenesis. eIF4E controls the translation of various malignancy-associated mRNAs which are involved in polyamine synthesis, cell cycle progression, activation of proto-oncogenes, angiogenesis, autocrine growth stimulation, cell survival, invasion and communication with the extracellular environment. eIF4E-mediated translational modulation of these mRNAs plays a pivotal role in both tumor formation and metastasis. Interestingly, eIF4E activity is implicated in mitosis, embryogenesis and in apoptosis. Finally, the finding that eIF4E is overexpressed in several human cancers makes it a prime target for anticancer therapies.	McGill Univ, Dept Biochem, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University	Sonenberg, N (corresponding author), McGill Univ, Dept Biochem, McGill Canc Ctr, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	nahum.sonenberg@mcgill.ca						Amiri A, 2001, DEVELOPMENT, V128, P3899; Anthony B, 1996, INT J CANCER, V65, P858, DOI 10.1002/(SICI)1097-0215(19960315)65:6<858::AID-IJC25>3.0.CO;2-Z; Auvinen M, 1997, CANCER RES, V57, P3016; Bauer C, 2002, INT J CANCER, V98, P181, DOI 10.1002/ijc.10180; Bauer C, 2001, CANCER, V92, P822, DOI 10.1002/1097-0142(20010815)92:4<822::AID-CNCR1388>3.0.CO;2-A; Bisacchi D, 2003, CANCER DETECT PREV, V27, P229, DOI 10.1016/S0361-090X(03)00030-8; Boudreau N, 2003, BREAST CANCER RES, V5, P140, DOI 10.1186/bcr589; Brass N, 1997, HUM MOL GENET, V6, P33, DOI 10.1093/hmg/6.1.33; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Carter PS, 1999, ONCOGENE, V18, P4326, DOI 10.1038/sj.onc.1202890; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Clemens MJ, 2001, J CELL MOL MED, V5, P221, DOI 10.1111/j.1582-4934.2001.tb00157.x; Cormier P, 2001, DEV BIOL, V232, P275, DOI 10.1006/dbio.2001.0206; Cruz MC, 1999, MOL CELL BIOL, V19, P4101; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; Dai Y, 2003, CURR OPIN PHARMACOL, V3, P362, DOI 10.1016/S1471-4892(03)00079-1; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; Davidson NE, 1999, ENDOCR-RELAT CANCER, V6, P69, DOI 10.1677/erc.0.0060069; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DeFatta RJ, 2000, LARYNGOSCOPE, V110, P928, DOI 10.1097/00005537-200006000-00007; Detillieux KA, 2003, CARDIOVASC RES, V57, P8, DOI 10.1016/S0008-6363(02)00708-3; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Dobashi Y, 2003, CURR MED CHEM, V10, P2549, DOI 10.2174/0929867033456495; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; DUNCAN R, 1987, J BIOL CHEM, V262, P380; Duncan RF, 2003, BIOCHEM J, V369, P213, DOI 10.1042/BJ20020435; Eberle J, 1997, INT J CANCER, V71, P396, DOI 10.1002/(SICI)1097-0215(19970502)71:3<396::AID-IJC16>3.0.CO;2-E; Fahrenkrug SC, 1999, DIFFERENTIATION, V65, P191, DOI 10.1046/j.1432-0436.1999.6540191.x; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Gallego J, 2002, CURR OPIN DRUG DISC, V5, P777; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; GRAFF JR, 1995, INT J CANCER, V60, P255; Graff JR, 1997, BIOCHEM BIOPH RES CO, V240, P15, DOI 10.1006/bbrc.1997.7592; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; GRENS A, 1990, J BIOL CHEM, V265, P11810; Guo SS, 2003, J ENDOCRINOL, V179, P73, DOI 10.1677/joe.0.1790073; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; Hermeking H, 2003, CURR CANCER DRUG TAR, V3, P163, DOI 10.2174/1568009033481949; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hillary RA, 2003, BBA-PROTEINS PROTEOM, V1647, P161, DOI 10.1016/S1570-9639(03)00088-8; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Houghton PJ, 2003, CURR TOP MICROBIOL, V279, P339; Hui P, 2003, LEUKEMIA LYMPHOMA, V44, P1385, DOI 10.1080/1042819031000079168; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JEFFERIES HBJ, 1996, TRANSLATIONAL CONTRO, P389; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Keiper BD, 1999, INT J BIOCHEM CELL B, V31, P37, DOI 10.1016/S1357-2725(98)00130-7; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2003, CURR TOP MICROBIOL, V279, P259; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; KLEIN PS, 1994, SCIENCE, V265, P803, DOI 10.1126/science.8047887; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; Lai HK, 2000, ONCOGENE, V19, P1623, DOI 10.1038/sj.onc.1203473; Lasko P, 2003, DEV CELL, V5, P671, DOI 10.1016/S1534-5807(03)00333-2; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; Li BDL, 2002, ANN SURG, V235, P732, DOI 10.1097/00000658-200205000-00016; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; Li SN, 2002, MOL CELL BIOL, V22, P2853, DOI 10.1128/MCB.22.8.2853-2861.2002; LODISH HF, 1974, NATURE, V251, P385, DOI 10.1038/251385a0; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Long XM, 2002, CURR BIOL, V12, P1448, DOI 10.1016/S0960-9822(02)01091-6; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; Lynch M, 2004, J BIOL CHEM, V279, P3327, DOI 10.1074/jbc.M310872200; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Manni A, 2002, IN VIVO, V16, P493; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; Marygold SJ, 2002, CURR BIOL, V12, pR785, DOI 10.1016/S0960-9822(02)01294-0; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Menand B, 2002, P NATL ACAD SCI USA, V99, P6422, DOI 10.1073/pnas.092141899; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Meyuhas Oded, 1996, V30, P363; Mita Monica M, 2003, Clin Breast Cancer, V4, P126, DOI 10.3816/CBC.2003.n.018; Miyamoto R, 2003, ORAL ONCOL, V39, P610, DOI 10.1016/S1368-8375(03)00048-4; Morris MJ, 2002, SURG ONCOL, V11, P13, DOI 10.1016/S0960-7404(02)00006-3; Morrish F, 2003, GENE DEV, V17, P240, DOI 10.1101/gad.1032503; MOSHIER JA, 1993, CANCER RES, V53, P2618; Nathan CAO, 1999, LARYNGOSCOPE, V109, P1253, DOI 10.1097/00005537-199908000-00013; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; Park MT, 2003, J BIOCHEM MOL BIOL, V36, P60; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pegg AE, 2003, BIOCHEM SOC T, V31, P356, DOI 10.1042/BST0310356; Pelengaris S, 2003, ARCH BIOCHEM BIOPHYS, V416, P129, DOI 10.1016/S0003-9861(03)00294-7; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Polsky D, 2003, ONCOGENE, V22, P3087, DOI 10.1038/sj.onc.1206449; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; Prendergast GC, 2003, CANCER CELL, V4, P244, DOI 10.1016/S1535-6108(03)00247-2; Prevot D, 2003, BIOL CELL, V95, P141, DOI 10.1016/S0248-4900(03)00031-5; Proud CG, 2003, CURR TOP MICROBIOL, V279, P215; Proud CG, 2002, EUR J BIOCHEM, V269, P5337, DOI 10.1046/j.1432-1033.2002.03289.x; Pyronnet S, 2001, CURR OPIN GENET DEV, V11, P13, DOI 10.1016/S0959-437X(00)00150-7; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Pyronnet S, 2000, BIOCHEM PHARMACOL, V60, P1237, DOI 10.1016/S0006-2952(00)00429-9; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; Ribatti D, 2003, J HEMATOTH STEM CELL, V12, P11, DOI 10.1089/152581603321210091; Ribatti D, 2002, EUR J CANCER, V38, P750, DOI 10.1016/S0959-8049(01)00337-9; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; RINKERSCHAEFFER CW, 1993, INT J CANCER, V55, P841, DOI 10.1002/ijc.2910550525; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; Rosenwald IB, 2001, CANCER-AM CANCER SOC, V92, P2164, DOI 10.1002/1097-0142(20011015)92:8<2164::AID-CNCR1559>3.0.CO;2-A; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Ruegg C, 2003, CELL MOL LIFE SCI, V60, P1135, DOI 10.1007/s00018-003-2297-3; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; Salaun P, 2003, DEV BIOL, V255, P428, DOI 10.1016/S0012-1606(02)00099-4; Schipper RG, 2002, J HISTOCHEM CYTOCHEM, V50, P1143, DOI 10.1177/002215540205000901; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Seiler N, 2003, CURR DRUG TARGETS, V4, P565, DOI 10.2174/1389450033490876; SHANTZ LM, 1994, CANCER RES, V54, P2313; Shantz LM, 1999, INT J BIOCHEM CELL B, V31, P107, DOI 10.1016/S1357-2725(98)00135-6; Shantz LM, 2004, BIOCHEM J, V377, P257, DOI 10.1042/BJ20030778; Shepherd FA, 2001, LUNG CANCER, V34, pS81; Shinkaruk S., 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P95, DOI 10.2174/1568011033353452; Shuda M, 2000, ANTICANCER RES, V20, P2489; SMITH MR, 1991, NEW BIOL, V3, P601; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; Streit M, 2003, ONCOGENE, V22, P3172, DOI 10.1038/sj.onc.1206457; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Thomas T, 2003, J CELL MOL MED, V7, P113, DOI 10.1111/j.1582-4934.2003.tb00210.x; Thomas T, 2002, ONCOL RES, V13, P123; Thornton S, 2003, J MOL MED, V81, P536, DOI 10.1007/s00109-003-0461-8; Tonini T, 2003, ONCOGENE, V22, P6549, DOI 10.1038/sj.onc.1206816; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Wallace HM, 2001, EUR J GASTROEN HEPAT, V13, P1033, DOI 10.1097/00042737-200109000-00006; Wang ST, 1999, AM J PATHOL, V155, P247, DOI 10.1016/S0002-9440(10)65118-8; Wang ST, 2001, THYROID, V11, P1101, DOI 10.1089/10507250152740939; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Watkins SJ, 2002, BRIT J CANCER, V86, P1023, DOI 10.1038/sj/bjc/6600222; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zimmer SG, 2000, ANTICANCER RES, V20, P1343; Zogakis TG, 2001, EXPERT OPIN BIOL TH, V1, P253, DOI 10.1517/14712598.1.2.253	173	366	382	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3172	3179		10.1038/sj.onc.1207549	http://dx.doi.org/10.1038/sj.onc.1207549			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094766	Green Published			2022-12-25	WOS:000220879700005
J	Torregrossa, P; Buhl, L; Bancila, M; Durbec, P; Schafer, C; Schachner, M; Rougon, G				Torregrossa, P; Buhl, L; Bancila, M; Durbec, P; Schafer, C; Schachner, M; Rougon, G			Selection of poly-alpha 2,8-sialic acid mimotopes from a random phage peptide library and analysis of their bioactivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; POLYSIALIC ACID; CAPSULAR POLYSACCHARIDE; DISPLAYED PEPTIDES; CROSS-REACTIVITY; NERVOUS-SYSTEM; N-CAM; EXPRESSION; PLASTICITY; MIGRATION	Poly-alpha2-8 sialic acid (PSA), attached to the neural cell adhesion molecule, is a permissive determinant for numerous morphogenetic and neural plasticity processes, making it a potential therapeutic target. Here, using a monoclonal antibody specific for PSA, we screened a phage-display library and identified two cyclic nine-amino acid peptides (p1, p2) that are PSA epitope analogues. We evaluated their bioactivity in vitro and in vivo. In culture, micromolar concentrations of the peptides promoted axon growth, defasciculation, and migration of neural progenitors. When injected into developing chicken retina, the peptides modified the trajectory of retinal ganglion cell axons. Moreover, they enhanced migration of grafted neuroblasts in mouse brain. These effects were selective and dependent upon the presence of PSA on transplanted cells. Our results demonstrate the feasibility and therapeutic potential of enhancing PSA biological activity.	Univ Mediterranee, Inst Dev Biol, Lab Neurogenese & Morphogenese Dev & Chez Adulte, CNRS,Unite Mixte Rech 6156, F-13288 Marseille 9, France; Schafer N Fruebjergen, DK-2100 Copenhagen, Denmark; Univ Hamburg, Zentrum Mol Neurobiol, D-20251 Hamburg, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Hamburg; University Medical Center Hamburg-Eppendorf	Rougon, G (corresponding author), Univ Mediterranee, Inst Dev Biol, Lab Neurogenese & Morphogenese Dev & Chez Adulte, CNRS,Unite Mixte Rech 6156, Parc Sci Luminy, F-13288 Marseille 9, France.	rougon@ibdm.univ-mrs.fr		ROUGON, Genevieve/0000-0003-1316-8200				Aubert I, 1998, J COMP NEUROL, V399, P1; Beenhouwer DO, 2002, J IMMUNOL, V169, P6992, DOI 10.4049/jimmunol.169.12.6992; BRISSON JR, 1992, BIOCHEMISTRY-US, V31, P4996, DOI 10.1021/bi00136a012; Charter NW, 2002, J BIOL CHEM, V277, P9255, DOI 10.1074/jbc.M111619200; Chazal G, 2000, J NEUROSCI, V20, P1446; Coquillat D, 2001, INFECT IMMUN, V69, P7130, DOI 10.1128/IAI.69.11.7130-7139.2001; Decker L, 2000, MOL CELL NEUROSCI, V16, P422, DOI 10.1006/mcne.2000.0885; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; Felici F, 1996, METHOD ENZYMOL, V267, P116; FIGARELLABRANGER D, 1990, J NEUROL SCI, V98, P21, DOI 10.1016/0022-510X(90)90179-Q; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; HAYRINEN J, 1989, VACCINE, V7, P217, DOI 10.1016/0264-410X(89)90232-6; Hayrinen J, 2002, MOL IMMUNOL, V39, P399, DOI 10.1016/S0161-5890(02)00202-X; LANDMESSER L, 1990, NEURON, V4, P655, DOI 10.1016/0896-6273(90)90193-J; Le Belle JE, 2002, BIODRUGS, V16, P389, DOI 10.2165/00063030-200216060-00001; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; Mahal LK, 2001, SCIENCE, V294, P380, DOI 10.1126/science.1062192; Marx M, 2001, DEVELOPMENT, V128, P4949; Meloen RH, 2000, J MOL RECOGNIT, V13, P352, DOI 10.1002/1099-1352(200011/12)13:6<352::AID-JMR509>3.0.CO;2-C; Monnier PP, 2001, DEV BIOL, V229, P1, DOI 10.1006/dbio.2000.9970; Muller D, 2000, P NATL ACAD SCI USA, V97, P4315, DOI 10.1073/pnas.070022697; MULLER D, 1994, NEUROSCIENCE, V61, P441, DOI 10.1016/0306-4522(94)90424-3; ONO K, 1994, NEURON, V13, P395; Paratcha G, 2003, CELL, V113, P867, DOI 10.1016/S0092-8674(03)00435-5; Pincus SH, 1998, J IMMUNOL, V160, P293; ROUGON G, 1993, EUR J CELL BIOL, V61, P197; ROUGON G, 1986, J CELL BIOL, V103, P2429, DOI 10.1083/jcb.103.6.2429; ROUGON G, 1993, POLYSIALIC ACID MICR, P323; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; Seki T, 1998, J NEUROSCI, V18, P3757; Shin JS, 2002, J IMMUNOL, V168, P6273, DOI 10.4049/jimmunol.168.12.6273; Simon-Haldi M, 2002, J NEUROCHEM, V83, P1380, DOI 10.1046/j.1471-4159.2002.01247.x; Stuermer CAO, 2000, PROG NEUROBIOL, V62, P197, DOI 10.1016/S0301-0082(00)00012-5; TANG J, 1992, NEURON, V8, P1031, DOI 10.1016/0896-6273(92)90125-W; TANG JC, 1994, NEURON, V13, P405, DOI 10.1016/0896-6273(94)90356-5; Theodosis DT, 1999, J NEUROSCI, V19, P10228; Toikka J, 1998, J BIOL CHEM, V273, P28557, DOI 10.1074/jbc.273.44.28557; Vutskits L, 2001, EUR J NEUROSCI, V13, P1391, DOI 10.1046/j.0953-816x.2001.01516.x; Zhang H, 2004, J CELL SCI, V117, P93, DOI 10.1242/jcs.00827	40	54	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30707	30714		10.1074/jbc.M403935200	http://dx.doi.org/10.1074/jbc.M403935200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131117	hybrid			2022-12-25	WOS:000222531900101
J	Xing, Y; Liu, D; Zhang, RG; Joachimiak, A; Songyang, Z; Xu, WQ				Xing, Y; Liu, D; Zhang, RG; Joachimiak, A; Songyang, Z; Xu, WQ			Structural basis of membrane targeting by the phox homology domain of cytokine-independent survival kinase (CISK-PX)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; MEDIATED INTERACTION; CRYSTAL-STRUCTURE; FYVE DOMAIN; SH3 DOMAINS; BINDING; ACTIVATION; P40(PHOX)	The cytokine-independent survival kinase (CISK) in the serum and glucocorticoid-regulated kinase family plays an important role in mediating cell growth and survival. N-terminal to its catalytic kinase domain, CISK contains a phox homology (PX) domain, a phosphoinositide-binding motif that directs the membrane localization of CISK and regulates CISK activity. We have determined the crystal structures of the mouse CISK-PX domain to unravel the structural basis of membrane targeting of CISK. In addition to the specific interactions conferred by the phosphoinositide-binding pocket, the structure suggests that a hydrophobic loop region and a hydrophilic beta-turn contribute to the interactions with the membrane. Furthermore, biochemical studies reveal that CISK-PX dimerizes in the presence of the linker between the PX domain and kinase domain, suggesting a multivalent mechanism in membrane localization of CISK.	Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Argonne Natl Lab, Struct Biol Ctr, Biosci Div, Argonne, IL 60439 USA	University of Washington; University of Washington Seattle; Baylor College of Medicine; United States Department of Energy (DOE); Argonne National Laboratory	Xu, WQ (corresponding author), Univ Washington, Dept Biol Struct, 1959 NE Pacific St, Seattle, WA 98195 USA.	wxu@u.washington.edu		Xu, Wenqing/0000-0002-2884-3101	NCI NIH HHS [CA84208] Funding Source: Medline; NIGMS NIH HHS [GM69572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084208] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Ellson CD, 2002, J CELL SCI, V115, P1099; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Itoh T, 2002, CELL SIGNAL, V14, P733, DOI 10.1016/S0898-6568(02)00028-1; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; Lang F, 2001, SCI STKE, V2001; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; Lu J, 2002, BIOCHEMISTRY-US, V41, P5956, DOI 10.1021/bi020050b; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; Stahelin RV, 2003, J BIOL CHEM, V278, P14469, DOI 10.1074/jbc.M212579200; Virbasius JV, 2001, P NATL ACAD SCI USA, V98, P12908, DOI 10.1073/pnas.221352898; Xing Y, 2003, ACTA CRYSTALLOGR D, V59, P1816, DOI 10.1107/S0907444903015567; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhan Y, 2002, J BIOL CHEM, V277, P4512, DOI 10.1074/jbc.M109520200; Zhou CZ, 2003, J BIOL CHEM, V278, P50371, DOI 10.1074/jbc.M304392200	49	49	51	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30662	30669		10.1074/jbc.M404107200	http://dx.doi.org/10.1074/jbc.M404107200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15126499	hybrid			2022-12-25	WOS:000222531900096
J	Hawkins, LM; Prybylowski, K; Chang, K; Moussan, C; Stephenson, FA; Wenthold, RJ				Hawkins, LM; Prybylowski, K; Chang, K; Moussan, C; Stephenson, FA; Wenthold, RJ			Export from the endoplasmic reticulum of assembled N-methyl-D-aspartic acid receptors is controlled by a motif in the C terminus of the NR2 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER RETENTION SIGNAL; CELL-SURFACE EXPRESSION; NMDA RECEPTORS; GLUTAMATE RECEPTORS; PHARMACOLOGICAL CHAPERONES; MOLECULAR CHARACTERIZATION; TRAFFICKING; NEURONS; PROTEIN; PHOSPHORYLATION	Functional N-methyl-D-aspartic acid ( NMDA) receptors are formed from the assembly of NR1 and NR2 subunits. When expressed alone, the major NR1 splice variant and the NR2 subunits are retained in the endoplasmic reticulum ( ER), reflecting a quality control mechanism found in many complex multisubunit proteins to ensure that only fully assembled and properly folded complexes reach the cell surface. Recent studies have identified an RRR motif in the C terminus of the NR1 subunit, which controls the ER retention of the unassembled subunit. Here we investigated the mechanisms controlling the ER retention of the NR2 subunit and the export of the assembled complex from the ER. We found that Tac chimeras of the C terminus of the NR2B subunit show that an ER retention signal is also present in the NR2B subunit. In assembled complexes, ER retention signals on the individual subunits must be overcome to allow the complex to leave the ER. One common mechanism involves mutual masking of the signals on the individual subunits. Our data do not support such a mechanism for regulating the release of assembled NMDA receptors from the ER. We found that the motif, HLFY, immediately following transmembrane domain 4 of the NR2 subunit, is required for the assembled complex to exit from the ER. Mutation of this motif allowed the assembly of NR1 and NR2 subunits into a complex that was functional, based on MK-801 binding, but it is retained in the ER. These results are consistent with HLFY functioning as a signal that is necessary for the release of the assembled functional NMDA receptor complex from the ER.	NIDCD, Neurochem Lab, NIH, Bethesda, MD 20892 USA; Univ London, Sch Pharm, Dept Pharmaceut & Biol Chem, London WC1N 1AX, England	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); University of London; University College London; University of London School of Pharmacy	Wenthold, RJ (corresponding author), NIDCD, Neurochem Lab, NIH, Bldg 50,Rm 4140,50 South Dr, Bethesda, MD 20892 USA.	wenthold@nidcd.nih.gov			NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000003, ZIADC000003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Chatterton JE, 2002, NATURE, V415, P793, DOI 10.1038/nature715; CHAZOT PL, 1994, J BIOL CHEM, V269, P24403; Das S, 1998, NATURE, V393, P377, DOI 10.1038/30748; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fukaya M, 2003, P NATL ACAD SCI USA, V100, P4855, DOI 10.1073/PNAS.0830996100; Greger IH, 2003, NEURON, V40, P763, DOI 10.1016/S0896-6273(03)00668-8; Greger IH, 2002, NEURON, V34, P759, DOI 10.1016/S0896-6273(02)00693-1; Grunwald ME, 2003, NEUROPHARMACOLOGY, V45, P768, DOI 10.1016/S0028-3908(03)00274-0; Hawkins LM, 1999, J BIOL CHEM, V274, P27211, DOI 10.1074/jbc.274.38.27211; Huh KH, 1999, J BIOL CHEM, V274, P151, DOI 10.1074/jbc.274.1.151; ISHII T, 1993, J BIOL CHEM, V268, P2836; Kew JNC, 1998, J NEUROSCI, V18, P1935; LAURIE DJ, 1994, EUR J PHARM-MOLEC PH, V268, P335, DOI 10.1016/0922-4106(94)90058-2; Luo JH, 2002, NEUROPHARMACOLOGY, V42, P306, DOI 10.1016/S0028-3908(01)00188-5; LYNCH DR, 1994, MOL PHARMACOL, V45, P540; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; MAH SJ, 2003, SOC NEUR ABSTR, V360, P10; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14643, DOI 10.1073/pnas.251554798; Matsuda I, 2000, BIOCHEM BIOPH RES CO, V275, P565, DOI 10.1006/bbrc.2000.3351; McIlhinney RAJ, 1998, NEUROPHARMACOLOGY, V37, P1355, DOI 10.1016/S0028-3908(98)00121-X; Meddows E, 2001, J BIOL CHEM, V276, P18795, DOI 10.1074/jbc.M101382200; MONTERO VM, 1989, NEUROSCIENCE, V31, P639, DOI 10.1016/0306-4522(89)90429-6; Morello JP, 2000, TRENDS PHARMACOL SCI, V21, P466, DOI 10.1016/S0165-6147(00)01575-3; Mu YY, 2003, NEURON, V40, P581, DOI 10.1016/S0896-6273(03)00676-7; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Okabe S, 1999, J NEUROSCI, V19, P7781; Papadakis M, 2004, J BIOL CHEM, V279, P14703, DOI 10.1074/jbc.M313446200; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Prybylowski K, 2002, J NEUROSCI, V22, P8902; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Rubio ME, 1997, NEURON, V18, P939, DOI 10.1016/S0896-6273(00)80333-5; Rumbaugh G, 1999, J NEUROSCI, V19, P10603, DOI 10.1523/JNEUROSCI.19-24-10603.1999; Schorge S, 2003, J NEUROSCI, V23, P1151, DOI 10.1523/JNEUROSCI.23-04-01151.2003; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Tovar KR, 1999, J NEUROSCI, V19, P4180; Vissel B, 2001, NAT NEUROSCI, V4, P587, DOI 10.1038/88404; Wang JM, 2002, NAT NEUROSCI, V5, P963, DOI 10.1038/nn918; Wenthold RJ, 2003, ANNU REV PHARMACOL, V43, P335, DOI 10.1146/annurev.pharmtox.43.100901.135803; Xia H, 2001, NEUROPHARMACOLOGY, V41, P714, DOI 10.1016/S0028-3908(01)00103-4; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zheng X, 1999, P NATL ACAD SCI USA, V96, P15262, DOI 10.1073/pnas.96.26.15262	44	66	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28903	28910		10.1074/jbc.M402599200	http://dx.doi.org/10.1074/jbc.M402599200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15102836	hybrid			2022-12-25	WOS:000222445300011
J	Hong, SS; Morrow, TJ; Paulson, PE; Isom, LL; Wiley, JW				Hong, SS; Morrow, TJ; Paulson, PE; Isom, LL; Wiley, JW			Early painful diabetic neuropathy is associated with differential changes in tetrodotoxin-sensitive and -resistant sodium channels in dorsal root ganglion neurons in the rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SENSORY NEURONS; MECHANICAL HYPERALGESIA; ACTION-POTENTIALS; PURKINJE NEURONS; ALDOSE REDUCTASE; IONIC CURRENTS; GROWTH-FACTOR; DRG NEURONS; EXPRESSION	Diabetic neuropathy is a common form of peripheral neuropathy, yet the mechanisms responsible for pain in this disease are poorly understood. Alterations in the expression and function of voltage-gated tetrodotoxin-resistant (TTX-R) sodium channels have been implicated in animal models of neuropathic pain, including models of diabetic neuropathy. We investigated the expression and function of TTX-sensitive (TTX-S) and TTX-R sodium channels in dorsal root ganglion (DRG) neurons and the responses to thermal hyperalgesia and mechanical allodynia in streptozotocin-treated rats between 4-8 weeks after onset of diabetes. Diabetic rats demonstrated a significant reduction in the threshold for escape from innocuous mechanical pressure ( allodynia) and a reduction in the latency to withdrawal from a noxious thermal stimulus ( hyperalgesia). Both TTX-S and TTX-R sodium currents increased significantly in small DRG neurons isolated from diabetic rats. The voltage-dependent activation and steady-state inactivation curves for these currents were shifted negatively. TTX-S currents induced by fast or slow voltage ramps increased markedly in neurons from diabetic rats. Immunoblots and immunofluorescence staining demonstrated significant increases in the expression of Na(v)1.3 (TTX-S) and Na(v)1.7 (TTX-S) and decreases in the expression of Na(v)1.6 (TTX-S) and Na(v)1.8 (TTX-R) in diabetic rats. The level of serine/threonine phosphorylation of Na(v)1.6 and Na(v)1.8 increased in response to diabetes. In addition, increased tyrosine phosphorylation of Na(v)1.6 and Na(v)1.7 was observed in DRGs from diabetic rats. These results suggest that both TTX-S and TTX-R sodium channels play important roles and that differential phosphorylation of sodium channels involving both serine/threonine and tyrosine sites contributes to painful diabetic neuropathy.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Vet Affairs Med Ctr, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Wiley, JW (corresponding author), Univ Michigan Hosp, Dept Internal Med, A7007 UH,Box 0108,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	jwiley@med.umich.edu		Isom, Lori/0000-0002-9479-6729	NIDDK NIH HHS [R01 DK52387, DK 45820] Funding Source: Medline; NIMH NIH HHS [R01 MH059980] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052387, R29DK045820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059980] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ahlgren SC, 1997, NEUROSCIENCE, V76, P285; AHLGREN SC, 1993, NEUROSCIENCE, V52, P1049, DOI 10.1016/0306-4522(93)90551-P; AHLGREN SC, 1994, J NEUROPHYSIOL, V72, P684, DOI 10.1152/jn.1994.72.2.684; Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; Amaya F, 2000, MOL CELL NEUROSCI, V15, P331, DOI 10.1006/mcne.1999.0828; Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425; Black JA, 1999, J NEUROPHYSIOL, V82, P2776, DOI 10.1152/jn.1999.82.5.2776; Black JA, 2002, MOL BRAIN RES, V105, P19, DOI 10.1016/S0169-328X(02)00385-6; Blackburn-Munro G, 1999, NEUROSCIENCE, V90, P153, DOI 10.1016/S0306-4522(98)00415-1; Blair NT, 2002, J NEUROSCI, V22, P10277; CAFFREY JM, 1992, BRAIN RES, V592, P283, DOI 10.1016/0006-8993(92)91687-A; Calcutt NA, 1996, PAIN, V68, P293, DOI 10.1016/S0304-3959(96)03201-0; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Coward K, 2000, PAIN, V85, P41, DOI 10.1016/S0304-3959(99)00251-1; Craner MJ, 2002, ANN NEUROL, V52, P786, DOI 10.1002/ana.10364; Cummins TR, 1998, J NEUROSCI, V18, P9607; Dib-Hajj SD, 1998, P NATL ACAD SCI USA, V95, P8963, DOI 10.1073/pnas.95.15.8963; Djouhri L, 2003, J PHYSIOL-LONDON, V546, P565, DOI 10.1113/jphysiol.2002.026559; Djouhri L, 1998, J PHYSIOL-LONDON, V513, P857, DOI 10.1111/j.1469-7793.1998.857ba.x; Fitzgerald EM, 1999, J PHYSIOL-LONDON, V516, P433, DOI 10.1111/j.1469-7793.1999.0433v.x; Fox A, 1999, PAIN, V81, P307, DOI 10.1016/S0304-3959(99)00024-X; GALLEGO R, 1983, J PHYSIOL-LONDON, V342, P591, DOI 10.1113/jphysiol.1983.sp014870; Gold MS, 1998, J NEUROSCI, V18, P10345; Gould HJ, 2000, BRAIN RES, V854, P19, DOI 10.1016/S0006-8993(99)02216-7; Grieco TM, 2004, J NEUROSCI, V24, P35, DOI 10.1523/JNEUROSCI.3807-03.2004; Hall KE, 2001, J NEUROPHYSIOL, V86, P760, DOI 10.1152/jn.2001.86.2.760; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hilborn MD, 1998, J NEUROSCI, V18, P590; Hirade M, 1999, NEUROSCIENCE, V90, P933, DOI 10.1016/S0306-4522(98)00486-2; Isom LL, 2002, NOVART FDN SYMP, V241, P124; Kerr BJ, 2001, NEUROREPORT, V12, P3077, DOI 10.1097/00001756-200110080-00019; KOSTYUK PG, 1981, NEUROSCIENCE, V6, P2423, DOI 10.1016/0306-4522(81)90088-9; Kral MG, 1999, PAIN, V81, P15, DOI 10.1016/S0304-3959(98)00264-4; Lai J, 2004, ANNU REV PHARMACOL, V44, P371, DOI 10.1146/annurev.pharmtox.44.101802.121627; Lyu YS, 2000, BRAIN RES, V871, P98, DOI 10.1016/S0006-8993(00)02451-3; Malcangio M, 1998, PAIN, V76, P151, DOI 10.1016/S0304-3959(98)00037-2; Moller KA, 1998, J NEUROSCI METH, V84, P41, DOI 10.1016/S0165-0270(98)00083-1; Novakovic SD, 1998, J NEUROSCI, V18, P2174; Ogata N, 2002, JPN J PHARMACOL, V88, P365, DOI 10.1254/jjp.88.365; Porreca F, 1999, P NATL ACAD SCI USA, V96, P7640, DOI 10.1073/pnas.96.14.7640; Raman IM, 1997, NEURON, V19, P881, DOI 10.1016/S0896-6273(00)80969-1; Ratcliffe CF, 2000, NAT NEUROSCI, V3, P437, DOI 10.1038/74805; Renganathan M, 2001, J NEUROPHYSIOL, V86, P629, DOI 10.1152/jn.2001.86.2.629; ROY ML, 1992, J NEUROSCI, V12, P2104; Said G, 1996, J NEUROL, V243, P431, DOI 10.1007/BF00900495; Spruce MC, 2003, DIABETIC MED, V20, P88, DOI 10.1046/j.1464-5491.2003.00852.x; Srinivasan S, 2000, DIABETES, V49, P1932, DOI 10.2337/diabetes.49.11.1932; STEVENS MJ, 1994, J CLIN INVEST, V94, P853, DOI 10.1172/JCI117406; Tate S, 1998, NAT NEUROSCI, V1, P653, DOI 10.1038/3652; Vijayaragavan K, 2004, J NEUROPHYSIOL, V91, P1556, DOI 10.1152/jn.00676.2003; Wada A, 2004, FRONT BIOSCI-LANDMRK, V9, P1954, DOI 10.2741/1314; Wang YG, 2003, PFLUG ARCH EUR J PHY, V446, P485, DOI 10.1007/s00424-003-1061-8; Waxman SG, 1999, PAIN, pS133, DOI 10.1016/S0304-3959(99)00147-5; Waxman SG, 1999, P NATL ACAD SCI USA, V96, P7635, DOI 10.1073/pnas.96.14.7635; Yu FH, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-207	55	206	231	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29341	29350		10.1074/jbc.M404167200	http://dx.doi.org/10.1074/jbc.M404167200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123645	Green Submitted, hybrid, Green Accepted			2022-12-25	WOS:000222445300065
J	Woodruff, PJ; Carlson, BL; Siridechadilok, B; Pratt, MR; Senaratne, RH; Mougous, JD; Riley, LW; Williams, SJ; Bertozzi, CR				Woodruff, PJ; Carlson, BL; Siridechadilok, B; Pratt, MR; Senaratne, RH; Mougous, JD; Riley, LW; Williams, SJ; Bertozzi, CR			Trehalose is required for growth of Mycobacterium smegmatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTAINING LIPOOLIGOSACCHARIDES; CORYNEBACTERIUM-GLUTAMICUM; SACCHAROMYCES-CEREVISIAE; PYRUVYLATED GLYCOLIPIDS; BIOSYNTHESIS GENES; ESCHERICHIA-COLI; SYNTHASE GENE; 3 PATHWAYS; IN-VIVO; TUBERCULOSIS	Mycobacteria contain high levels of the disaccharide trehalose in free form as well as within various immunologically relevant glycolipids such as cord factor and sulfolipid-1. By contrast, most bacteria use trehalose solely as a general osmoprotectant or thermoprotectant. Mycobacterium tuberculosis and Mycobacterium smegmatis possess three pathways for the synthesis of trehalose. Most bacteria possess only one trehalose biosynthesis pathway and do not elaborate the disaccharide into more complex metabolites, suggesting a distinct role for trehalose in mycobacteria. We disabled key enzymes required for each of the three pathways in M. smegmatis by allelic replacement. The resulting trehalose biosynthesis mutant was unable to proliferate and enter stationary phase unless supplemented with trehalose. At elevated temperatures, however, the mutant was unable to proliferate even in the presence of trehalose. Genetic complementation experiments showed that each of the three pathways was able to recover the mutant in the absence of trehalose, even at elevated temperatures. From a panel of trehalose analogs, only those with the native alpha,alpha- (1,1) anomeric stereochemistry rescued the mutant, whereas alternate stereoisomers and general osmo- and thermoprotectants were inactive. These findings suggest a dual role for trehalose as both a thermoprotectant and a precursor of critical cell wall metabolites.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Williams, SJ (corresponding author), Univ Melbourne, Sch Chem, Parkville, Vic 3054, Australia.	sjwill@unimelb.edu.au; crb@berkeley.edu	Williams, Spencer/C-3545-2009	Williams, Spencer/0000-0001-6341-4364	NIAID NIH HHS [AI51622] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051622] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arguelles JC, 2000, ARCH MICROBIOL, V174, P217, DOI 10.1007/s002030000192; Armitige LY, 2000, INFECT IMMUN, V68, P767, DOI 10.1128/IAI.68.2.767-778.2000; Bell W, 1998, J BIOL CHEM, V273, P33311, DOI 10.1074/jbc.273.50.33311; BESRA GS, 1993, BIOCHEMISTRY-US, V32, P12705, DOI 10.1021/bi00210a020; BESRA GS, 1994, CARBOHYD RES, V251, P99, DOI 10.1016/0008-6215(94)84279-5; BESRA GS, 1992, BIOCHEMISTRY-US, V31, P9832, DOI 10.1021/bi00155a040; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12735, DOI 10.1073/pnas.91.26.12735; CROWE JH, 1992, ANNU REV PHYSIOL, V54, P579, DOI 10.1146/annurev.ph.54.030192.003051; De Smet KAL, 2000, MICROBIOL-UK, V146, P199, DOI 10.1099/00221287-146-1-199; DHARIWAL KR, 1987, J GEN MICROBIOL, V133, P201; Elbein AD, 2003, GLYCOBIOLOGY, V13, p17R, DOI 10.1093/glycob/cwg047; ELBEIN AD, 1973, J BACTERIOL, V113, P863, DOI 10.1128/JB.113.2.863-873.1973; GAUTIER N, 1992, FEMS MICROBIOL LETT, V98, P81; Gibson RP, 2002, ACTA CRYSTALLOGR D, V58, P349, DOI 10.1107/S090744490102056X; Gibson RP, 2002, CHEM BIOL, V9, P1337, DOI 10.1016/S1074-5521(02)00292-2; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; GOREN MB, 1970, BIOCHIM BIOPHYS ACTA, V210, P116, DOI 10.1016/0005-2760(70)90067-6; Hamasaki N, 2000, INFECT IMMUN, V68, P3704, DOI 10.1128/IAI.68.6.3704-3709.2000; HUNTER SW, 1983, J BIOL CHEM, V258, P481; Jackson M, 1999, MOL MICROBIOL, V31, P1573, DOI 10.1046/j.1365-2958.1999.01310.x; KAMISANGO K, 1985, J BIOL CHEM, V260, P4117; Kandror O, 2002, P NATL ACAD SCI USA, V99, P9727, DOI 10.1073/pnas.142314099; Maruta K, 1996, BBA-GEN SUBJECTS, V1291, P177, DOI 10.1016/S0304-4165(96)00082-7; Maruta K, 1996, BBA-GEN SUBJECTS, V1289, P10, DOI 10.1016/0304-4165(95)00139-5; Maruta K, 1996, BIOSCI BIOTECH BIOCH, V60, P717, DOI 10.1271/bbb.60.717; Mougous JD, 2002, P NATL ACAD SCI USA, V99, P17037, DOI 10.1073/pnas.252514899; MOUGOUS JD, IN PRESS NAT STRUCT; NARUMI K, 1967, J BIOL CHEM, V242, P2233; Ohta M, 2002, EUR J BIOCHEM, V269, P3142, DOI 10.1046/j.1432-1033.2002.02971.x; OrtaloMagne A, 1996, J BACTERIOL, V178, P456, DOI 10.1128/jb.178.2.456-461.1996; Pan YT, 2002, EUR J BIOCHEM, V269, P6091, DOI 10.1046/j.1432-1033.2002.03327.x; Parish T, 2000, MICROBIOL-SGM, V146, P1969, DOI 10.1099/00221287-146-8-1969; Pratt MR, 2003, ORG LETT, V5, P3185, DOI 10.1021/ol034836t; SAADAT S, 1983, J BIOL CHEM, V258, P1813; Singer MA, 1998, TRENDS BIOTECHNOL, V16, P460, DOI 10.1016/S0167-7799(98)01251-7; Singer MA, 1998, MOL CELL, V1, P639, DOI 10.1016/S1097-2765(00)80064-7; Smeulders MJ, 1999, J BACTERIOL, V181, P270, DOI 10.1128/JB.181.1.270-283.1999; Tsusaki K, 1996, BBA-GEN SUBJECTS, V1290, P1, DOI 10.1016/0304-4165(96)00023-2; Tsusaki K, 1997, BBA-GEN SUBJECTS, V1334, P28, DOI 10.1016/S0304-4165(96)00103-1; Tzvetkov M, 2003, MICROBIOL-SGM, V149, P1659, DOI 10.1099/mic.0.26205-0; Wolf A, 2003, MOL MICROBIOL, V49, P1119, DOI 10.1046/j.1365-2958.2003.03625.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	42	85	91	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28835	28843		10.1074/jbc.M313103200	http://dx.doi.org/10.1074/jbc.M313103200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15102847	hybrid			2022-12-25	WOS:000222445300003
J	Saleem, A; Dutta, J; Malegaonkar, D; Rasheed, F; Rasheed, Z; Rajendra, R; Marshall, H; Luo, MJ; Li, HH; Rubin, EH				Saleem, A; Dutta, J; Malegaonkar, D; Rasheed, F; Rasheed, Z; Rajendra, R; Marshall, H; Luo, MJ; Li, HH; Rubin, EH			The topoisomerase I- and p53-binding protein topors is differentially expressed in normal and malignant human tissues and may function as a tumor suppressor	ONCOGENE			English	Article						topors; tumor suppressor; topoisomerase I; p53; ubiquitin E3 ligase	CHROMOSOME 9P; HUMAN CANCERS; PROSTATE-CANCER; HIGH-FREQUENCY; GENE; DELETION; LUNG; IDENTIFICATION; METHYLATION; REGION	Topors was identified recently as a human protein that binds to topoisomerase I and p53. Topors contains a highly conserved RING domain and localizes in promyelocytic leukemia nuclear bodies. Relatively little is known regarding topors expression patterns or function. We now demonstrate that topors mRNA and protein are widely expressed in normal human tissues. By contrast, topors mRNA and protein levels are decreased or undetectable in colon adenocarcinomas relative to normal colon tissue, and expression of the topors protein is not detectable in several colon cancer cell lines. The human TOPORS gene is located on chromosome 9p21, with loss of heterozygosity in this region frequently observed in several different malignancies. While we were unable to detect loss of heterozygosity of the TOPORS gene in 16 sporadic colon cancer cases, increased methylation of a CpG island in the TOPORS promoter was evident in colon adenocarcinoma specimens relative to matched normal tissues. Additional studies indicate that forced expression of topors inhibits cellular proliferation and is associated with an accumulation of cells in the G(0)/G(1) phase of the cell cycle. This effect is independent of the topors RING domain and maps to a C-terminal region of the protein. These results suggest that topors functions as a negative regulator of cell growth, and possibly as a tumor suppressor.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Pharmacol, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Mol Genet & Microbiol, New Brunswick, NJ USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Med, New Brunswick, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Rubin, EH (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Pharmacol, New Brunswick, NJ 08903 USA.	ehrubin@umdnj.edu			NATIONAL CANCER INSTITUTE [R01CA039662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059170] Funding Source: NIH RePORTER; NCI NIH HHS [CA39662] Funding Source: Medline; NIGMS NIH HHS [GM59170] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boutell C, 2003, J BIOL CHEM, V278, P36596, DOI 10.1074/jbc.M300776200; Boutell C, 2002, J VIROL, V76, P841, DOI 10.1128/JVI.76.2.841-850.2002; CHANG JY, 1992, BIOCHEM PHARMACOL, V43, P2443, DOI 10.1016/0006-2952(92)90325-D; Chu D, 2001, J BIOL CHEM, V276, P14004, DOI 10.1074/jbc.M010262200; Cui XF, 2000, J MOL DIAGN, V2, P29, DOI 10.1016/S1525-1578(10)60612-5; Devlin J, 1996, BRIT J CANCER, V73, P420, DOI 10.1038/bjc.1996.75; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GIOVANELLA BC, 1989, SCIENCE, V246, P1046, DOI 10.1126/science.2555920; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; He DL, 2003, CHINESE MED J-PEKING, V116, P1394; HERMAN JG, 1995, CANCER RES, V55, P4525; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KAMB A, 1994, SCIENCE, V264, P440; Kim SK, 1997, CANCER RES, V57, P400; LI HH, 1995, GENOMICS, V26, P199, DOI 10.1016/0888-7543(95)80201-V; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Perinchery G, 1999, INT J CANCER, V83, P610, DOI 10.1002/(SICI)1097-0215(19991126)83:5<610::AID-IJC7>3.0.CO;2-2; Pollock PM, 2001, CANCER RES, V61, P1154; PUIG S, 1995, AM J HUM GENET, V57, P395; Rasheed ZA, 2002, EXP CELL RES, V277, P152, DOI 10.1006/excr.2002.5550; Schraml P, 2001, AM J PATHOL, V158, P593, DOI 10.1016/S0002-9440(10)64001-1; Waber P, 1997, ONCOGENE, V15, P1699, DOI 10.1038/sj.onc.1201336; Weger S, 2003, EXP CELL RES, V290, P13, DOI 10.1016/S0014-4827(03)00292-1; Wiest JS, 1997, CANCER RES, V57, P1; Zhou R, 1999, GENE, V235, P93, DOI 10.1016/S0378-1119(99)00203-6	30	37	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5293	5300		10.1038/sj.onc.1207700	http://dx.doi.org/10.1038/sj.onc.1207700			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15107820				2022-12-25	WOS:000222491600005
J	He, L; Simmen, FA; Ronis, MJJ; Badger, TM				He, L; Simmen, FA; Ronis, MJJ; Badger, TM			Post-transcriptional regulation of sterol regulatory element-binding protein-1 by ethanol induces class I alcohol dehydrogenase in rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHESIS; MESSENGER-RNA; TRANSCRIPTION; ACTIVATION; EXPRESSION; GENE; SREBP-1C; INSULIN; CHOLESTEROL; INDUCTION	Members of the sterol regulatory element-binding protein ( SREBP) family of transcription factors control the synthesis and uptake of cholesterol, fatty acids, triglycerides, and phospholipids. Continuous intragastric infusion of ethanol-containing diets as part of total enteral nutrition generates well defined 6-day cycles ( pulses) of urine ethanol concentrations (UECs) in rats. Pulsatile UECs are the result of cyclical expression and activity of the principal alcohol-metabolizing enzyme, hepatic Class I alcohol dehydrogenase (ADH), and this mechanism involves regulated CCAAT/enhancer-binding protein-beta expression and binding to the ADH promoter. In this study, we further explore the molecular mechanism for ethanol-induced ADH expression during the UEC pulse in adult male rats fed ethanol by total enteral nutrition for 21 - 30 days. In hypophysectomized rats, in which the ADH protein increased by similar to6-fold, the nuclear form of SREBP-1 decreased by similar to7-fold. Because the ADH promoter contains two canonical sterol response element (SRE) sites ( - 63 to - 53 and - 52 to - 40 relative to the transcription start site), electrophoretic mobility shift assays were conducted using an ADH- specific SRE site. Hepatic nuclear protein binding decreased by 2.4-fold on the ascending limbs and by 3.6-fold on the descending limbs of UEC pulses ( p < 0.05). The specificity of nuclear protein binding to the ADH- SRE site was confirmed using antibody and UV cross-link assays. The in vivo binding status of SREBP-1 to ADH- SRE sites, as measured by the chromatin immunoprecipitation assay, had a pattern very similar to the electrophoretic mobility shift assay results. Functional analysis of the ADH- SREs demonstrated these sites to be essential for ADH transcription. In vitro transcription assays demonstrated that depletion of the SREBP-1 protein from nuclear extracts increased transcription activity by similar to 5-fold and that the liver X receptor agonist T0901317 ( a known activator of SREBP-1c transcription) reduced in vitro expression of ADH mRNA by 2-fold. We conclude that SREBP-1 is a negative regulator of the ADH gene and may work in concert with the CCAAT/enhancer-binding proteins to mediate ethanol induction of ADH in vivo.	Univ Arkansas Med Sci, Arkansas Childrens Nutr Ctr, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72202 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Badger, TM (corresponding author), Univ Arkansas Med Sci, Arkansas Childrens Nutr Ctr, 1120 Marshall St, Little Rock, AR 72202 USA.	badgerthomasm@uams.edu	Simmen, Frank A/J-9464-2012	Simmen, Frank/0000-0001-6842-7754				BADGER TM, 1993, J PHARMACOL EXP THER, V264, P938; BADGER TM, 1993, J PHARMACOL EXP THER, V264, P438; Badger TM, 2000, BIOCHEM BIOPH RES CO, V274, P684, DOI 10.1006/bbrc.2000.3186; BOLEDA MD, 1992, BIOCHEM PHARMACOL, V43, P1555, DOI 10.1016/0006-2952(92)90214-4; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BUETLER TM, 1995, TOXICOL APPL PHARM, V135, P45, DOI 10.1006/taap.1995.1207; Chen GF, 1999, XENOBIOTICA, V29, P437, DOI 10.1080/004982599238461; Cheng JZ, 2003, GASTROENTEROLOGY, V124, pA14, DOI 10.1016/S0016-5085(03)80068-9; CORTESE JF, 1994, J BIOL CHEM, V269, P21898; CRABB DW, 1987, PHARMACOL THERAPEUT, V34, P59, DOI 10.1016/0163-7258(87)90092-1; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; Eliasson E, 1996, MOL PHARMACOL, V50, P573; FELDER MR, 1988, J BIOL CHEM, V263, P14531; GamaCarvalho M, 1997, J CELL BIOL, V137, P975, DOI 10.1083/jcb.137.5.975; He L, 2002, J BIOL CHEM, V277, P43572, DOI 10.1074/jbc.M204535200; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hirano Y, 2003, J BIOL CHEM, V278, P16809, DOI 10.1074/jbc.M212448200; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; KEEGAN A, 1995, J HEPATOL, V23, P591, DOI 10.1016/0168-8278(95)80067-0; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Kono H, 1999, AM J PHYSIOL-GASTR L, V277, pG1259, DOI 10.1152/ajpgi.1999.277.6.G1259; Korourian S, 1999, TOXICOL SCI, V47, P110, DOI 10.1093/toxsci/47.1.110; Le Lay S, 2002, J BIOL CHEM, V277, P35625, DOI 10.1074/jbc.M203913200; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; LIEBER CS, 1969, J LIPID RES, V10, P283; McGehee RE, 1997, DNA CELL BIOL, V16, P725, DOI 10.1089/dna.1997.16.725; MEZEY E, 1990, ARCH BIOCHEM BIOPHYS, V280, P390, DOI 10.1016/0003-9861(90)90347-2; MEZEY E, 1993, ARCH BIOCHEM BIOPHYS, V225, P787; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; POTTER JJ, 1993, BIOCHEM BIOPH RES CO, V191, P1040, DOI 10.1006/bbrc.1993.1322; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; POTTER JJ, 1991, ARCH BIOCHEM BIOPHYS, V285, P246, DOI 10.1016/0003-9861(91)90356-N; QULALI M, 1991, ARCH BIOCHEM BIOPHYS, V288, P406, DOI 10.1016/0003-9861(91)90213-3; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Ronis MJJ, 2004, J NUTR, V134, P904, DOI 10.1093/jn/134.4.904; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SATO R, 1994, J BIOL CHEM, V269, P17267; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Simon FR, 2002, AM J PHYSIOL-GASTR L, V283, pG646, DOI 10.1152/ajpgi.00438.2001; TSUKAMOTO H, 1985, ALCOHOL CLIN EXP RES, V9, P31, DOI 10.1111/j.1530-0277.1985.tb05046.x; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; You M, 2002, J BIOL CHEM, V277, P29342, DOI 10.1074/jbc.M202411200	47	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28113	28121		10.1074/jbc.M400906200	http://dx.doi.org/10.1074/jbc.M400906200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123720	hybrid			2022-12-25	WOS:000222265400037
J	Panicker, S; Cruz, H; Arrabit, C; Suen, KF; Slesinger, PA				Panicker, S; Cruz, H; Arrabit, C; Suen, KF; Slesinger, PA			Minimal structural rearrangement of the cytoplasmic pore during activation of the 5-HT3A receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; GATED ION-CHANNEL; FRONTAL-LOBE EPILEPSY; CHARGED AMINO-ACIDS; X-RAY STRUCTURES; GABA(A) RECEPTOR; AFFECTS DESENSITIZATION; NEUROBLASTOMA-CELLS; MUTATIONAL ANALYSIS; SELECTIVITY FILTER	Ligand-gated ion channel receptors mediate the response of fast neurotransmitters by opening in less than a millisecond. Here, we investigated the activation mechanism of a serotonin-gated receptor (5-HT3A) by systematically introducing cysteine substitutions throughout the pore-lining M1-M2 loop and M2 transmembrane domain. We hypothesized that multiple cysteines in the narrowest region of the pore, which together can form a high affinity binding site for metal cations, would reveal changes in pore structure during gating. Using cadmium (Cd2+) as a probe, two cysteine substitutions in the cytoplasmic selectivity filter, S2'C and, to a lesser extent, G-2'C, showed high affinity inhibition with Cd2+ when applied extracellularly in the open state. Cd2+ inhibition in S2'C was attenuated if applied in the presence of an open-channel inhibitor and showed voltage-dependent recovery, indicating a direct effect of Cd2+ in the pore. When applied intracellularly, Cd2+ appeared to bind S2'C receptors in the closed state. The ability of cysteine side chains at the 2' and -2' positions to coordinate Cd2+ in both the native open and closed states of the channel suggests that the cytoplasmic selectivity filter of 5-HT3A receptors maintains a narrow pore during channel gating.	Salk Inst Biol Studies, Peptide Biol Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Grad Program Neurosci, La Jolla, CA 92093 USA	Salk Institute; University of California System; University of California San Diego	Slesinger, PA (corresponding author), Salk Inst Biol Studies, Peptide Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	slesinger@salk.edu		Panicker, Sandip/0000-0001-7901-2730				ARNOLD FH, 1991, SCIENCE, V252, P1796, DOI 10.1126/science.1648261; Benning MM, 2001, BIOCHEMISTRY-US, V40, P2712, DOI 10.1021/bi002661e; BERTRAND D, 1993, P NATL ACAD SCI USA, V90, P6971, DOI 10.1073/pnas.90.15.6971; Brocke L, 2002, J BIOL CHEM, V277, P3985, DOI 10.1074/jbc.M107735200; Brown AM, 1998, J PHYSIOL-LONDON, V507, P653, DOI 10.1111/j.1469-7793.1998.653bs.x; CamposCaro A, 1996, P NATL ACAD SCI USA, V93, P6118, DOI 10.1073/pnas.93.12.6118; COHEN BN, 1992, J GEN PHYSIOL, V100, P373, DOI 10.1085/jgp.100.3.373; Corringer PJ, 1999, NEURON, V22, P831, DOI 10.1016/S0896-6273(00)80741-2; Cymes GD, 2002, BIOCHEMISTRY-US, V41, P5548, DOI 10.1021/bi011864f; Dudev T, 2002, J AM CHEM SOC, V124, P6759, DOI 10.1021/ja012620l; FILATOV GN, 1995, MOL PHARMACOL, V48, P379; FORSTER I, 1995, P ROY SOC B-BIOL SCI, V260, P139, DOI 10.1098/rspb.1995.0071; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Grosman C, 2000, J GEN PHYSIOL, V116, P327, DOI 10.1085/jgp.116.3.327; Grosman C, 2000, NATURE, V403, P773, DOI 10.1038/35001586; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; Gunthorpe MJ, 2000, J PHYSIOL-LONDON, V522, P187, DOI 10.1111/j.1469-7793.2000.00187.x; Gunthorpe MJ, 1999, J PHYSIOL-LONDON, V519, P713, DOI 10.1111/j.1469-7793.1999.0713n.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLE B, 2001, ION CHANNELS EXCITAB, P170; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; Hsiao B, 2001, J NEUROSCI, V21, P1848, DOI 10.1523/JNEUROSCI.21-06-01848.2001; Hubbard PC, 2000, EUR J PHARMACOL, V394, P189, DOI 10.1016/S0014-2999(00)00143-6; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; Jensen ML, 2002, J BIOL CHEM, V277, P41438, DOI 10.1074/jbc.M205645200; Kandel E., 2000, PRINCIPLES NEURAL SC; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Keramidas A, 2000, BIOPHYS J, V79, P247, DOI 10.1016/S0006-3495(00)76287-4; Krovetz HS, 1997, BIOPHYS J, V72, P117, DOI 10.1016/S0006-3495(97)78651-X; Kuryatov A, 1997, J NEUROSCI, V17, P9035; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; Laube B, 2000, J PHYSIOL-LONDON, V522, P215, DOI 10.1111/j.1469-7793.2000.t01-1-00215.x; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; Loussouarn G, 2000, J BIOL CHEM, V275, P1137, DOI 10.1074/jbc.275.2.1137; LOVINGER DM, 1991, J NEUROPHYSIOL, V66, P1329, DOI 10.1152/jn.1991.66.4.1329; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Palma E, 1998, P NATL ACAD SCI USA, V95, P10246, DOI 10.1073/pnas.95.17.10246; Panicker S, 2002, J NEUROSCI, V22, P1629, DOI 10.1523/JNEUROSCI.22-05-01629.2002; Phillips HA, 2001, AM J HUM GENET, V68, P225, DOI 10.1086/316946; Rauser WE, 1999, CELL BIOCHEM BIOPHYS, V31, P19, DOI 10.1007/BF02738153; Reeves DC, 2001, J BIOL CHEM, V276, P42035, DOI 10.1074/jbc.M106066200; Rothberg BS, 2003, J GEN PHYSIOL, V122, P501, DOI 10.1085/jgp.200308928; Shan Q, 2002, J BIOL CHEM, V277, P44845, DOI 10.1074/jbc.M208647200; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; Slesinger PA, 1996, NEURON, V16, P321, DOI 10.1016/S0896-6273(00)80050-1; Sobolevsky AI, 2004, NEURON, V41, P367, DOI 10.1016/S0896-6273(04)00008-X; Thompson AJ, 2003, BRIT J PHARMACOL, V140, P359, DOI 10.1038/sj.bjp.0705424; UEYAMA N, 1988, INORG CHEM, V27, P741, DOI 10.1021/ic00277a031; Uki M, 1996, ARCH TOXICOL, V70, P652, DOI 10.1007/s002040050325; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Unwin N, 2000, PHILOS T R SOC B, V355, P1813, DOI 10.1098/rstb.2000.0737; VILLARROEL A, 1992, BIOPHYS J, V62, P196, DOI 10.1016/S0006-3495(92)81805-2; Wilson GG, 2001, P NATL ACAD SCI USA, V98, P1241, DOI 10.1073/pnas.031567798; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; Wotring VE, 2003, J PHYSIOL-LONDON, V548, P527, DOI 10.1113/jphysiol.2002.032045; YAKEL JL, 1993, P NATL ACAD SCI USA, V90, P5030, DOI 10.1073/pnas.90.11.5030; YANG J, 1990, J GEN PHYSIOL, V96, P1177, DOI 10.1085/jgp.96.6.1177; ZHU ZW, 1994, BIOCHEMISTRY-US, V33, P8858, DOI 10.1021/bi00196a002	62	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28149	28158		10.1074/jbc.M403545200	http://dx.doi.org/10.1074/jbc.M403545200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15131114	hybrid			2022-12-25	WOS:000222265400042
J	Unkles, SE; Wang, RC; Wang, Y; Glass, ADM; Crawford, NM; Kinghorn, JR				Unkles, SE; Wang, RC; Wang, Y; Glass, ADM; Crawford, NM; Kinghorn, JR			Nitrate reductase activity is required for nitrate uptake into fungal but not plant cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-NIDULANS; IDENTIFICATION; TRANSPORTER; PROTEINS; CHLORATE; INVITRO; NITRITE; ROOTS; GENES	The ability to transport net nitrate was conferred upon transformant cells of the non-nitrate-assimilating yeast Pichia pastoris after the introduction of two genes, one encoding nitrate reductase and the other nitrate transport. It was observed that cells of this lower eukaryote transformed with the nitrate transporter gene alone failed to display net nitrate transport despite having the ability to produce the protein. In addition, loss-of-function nitrate reductase mutants isolated from several nitrate-assimilating fungi appeared to be unable to accumulate nitrate. Uptake assays using the tracer (NO3-)-N-13 showed that nitrate influx is negligible in cells of a nitrate reductase null mutant. In parallel studies using a higher eukaryotic plant, Arabidopsis thaliana, loss-of-function nitrate reductase strains homozygous for both NIA1 insertion and NIA2 deletion were found to have no detectable nitrate reductase mRNA or nitrate reductase activity but retained the ability to transport nitrate. The reasons for these fundamental differences in nitrate transport into the cells of representative members of these two eukaryotic kingdoms are discussed.	Univ St Andrews, Sch Biol, St Andrews KY16 9TH, Fife, Scotland; Univ Calif San Diego, Div Biol Sci, Sect Cell & Dev Biol, La Jolla, CA 92093 USA; Univ British Columbia, Dept Bot, Vancouver, BC V6T 1Z4, Canada	University of St Andrews; University of California System; University of California San Diego; University of British Columbia	Kinghorn, JR (corresponding author), Univ St Andrews, Sch Biol, St Andrews KY16 9TH, Fife, Scotland.	jrk@st-andrews.ac.uk			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040672, R01GM040672] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 40672] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWNLEE AG, 1983, J BACTERIOL, V155, P1138, DOI 10.1128/JB.155.3.1138-1146.1983; Clutterbuck A.J, 1974, HDB GENETICS, V1, P447; COVE DJ, 1976, HEREDITY, V36, P191, DOI 10.1038/hdy.1976.24; Crawford NM, 1998, TRENDS PLANT SCI, V3, P389, DOI 10.1016/S1360-1385(98)01311-9; Daniel-Vedele F, 1998, CURR OPIN PLANT BIOL, V1, P235, DOI 10.1016/S1369-5266(98)80110-6; Garcia-Mata C, 2003, TRENDS PLANT SCI, V8, P20, DOI 10.1016/S1360-1385(02)00009-2; GARRETT RH, 1976, MOL GEN GENET, V149, P179, DOI 10.1007/BF00332887; KAMPHAKE LJ, 1967, WATER RES, V1, P205, DOI 10.1016/0043-1354(67)90011-5; KING BJ, 1992, PLANT PHYSIOL, V99, P1582, DOI 10.1104/pp.99.4.1582; KRAMER S, 1984, ARCH BIOCHEM BIOPHYS, V233, P821, DOI 10.1016/0003-9861(84)90511-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Machin F, 2004, YEAST, V21, P265, DOI 10.1002/yea.1075; Parinov S, 1999, PLANT CELL, V11, P2263, DOI 10.1105/tpc.11.12.2263; Scheible WR, 1997, PLANT J, V11, P671, DOI 10.1046/j.1365-313X.1997.11040671.x; SCHLOEMER RH, 1974, J BACTERIOL, V118, P258; Siddiqi MY, 2002, PLANT CELL ENVIRON, V25, P1211, DOI 10.1046/j.1365-3040.2002.00927.x; SIDDIQI MY, 1992, PLANT PHYSIOL, V100, P644, DOI 10.1104/pp.100.2.644; Skipper L, 2001, J BIOL CHEM, V276, P26995, DOI 10.1074/jbc.M100356200; Su WP, 1997, PLANT PHYSIOL, V115, P1135, DOI 10.1104/pp.115.3.1135; Su WP, 1996, PLANT CELL, V8, P519, DOI 10.1105/tpc.8.3.519; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Unkles SE, 1999, J BIOL CHEM, V274, P19286, DOI 10.1074/jbc.274.27.19286; UNKLES SE, 1991, P NATL ACAD SCI USA, V88, P204, DOI 10.1073/pnas.88.1.204; Unkles SE, 2001, EMBO J, V20, P6246, DOI 10.1093/emboj/20.22.6246; Vidmar JJ, 2000, PLANT PHYSIOL, V123, P307, DOI 10.1104/pp.123.1.307; Wang RC, 2003, PLANT PHYSIOL, V132, P556, DOI 10.1104/pp.103.021253; WILKINSON JQ, 1991, PLANT CELL, V3, P461, DOI 10.1105/tpc.3.5.461; Williams LE, 2001, ANNU REV PLANT PHYS, V52, P659, DOI 10.1146/annurev.arplant.52.1.659; WRAY JL, 1989, MOL GENETICAL ASPECT; Zhang HM, 2000, J EXP BOT, V51, P51, DOI 10.1093/jexbot/51.342.51	30	37	38	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28182	28186		10.1074/jbc.M403974200	http://dx.doi.org/10.1074/jbc.M403974200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123642	hybrid			2022-12-25	WOS:000222265400046
J	Xu, H; Vavilin, D; Funk, C; Vermaas, W				Xu, H; Vavilin, D; Funk, C; Vermaas, W			Multiple deletions of small cab-like proteins in the cyanobacterium Synechocystis sp PCC 6803 - Consequences for pigment biosynthesis and accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A/B-BINDING-PROTEINS; LIGHT-INDUCIBLE POLYPEPTIDES; STRAIN PCC 6803; PHOTOSYSTEM-II; CHLOROPHYLL-B; GENE FAMILY; TETRAPYRROLE BIOSYNTHESIS; HIGHER-PLANTS; EVOLUTION; COMPLEXES	Deletion of the genes for four or five small Cab-like proteins (SCPs) in photosystem (PS) I-less and PS I-less/ PS II-less strains of Synechocystis sp. PCC 6803 caused a large decrease in the chlorophyll and carotenoid content of the cells without accumulation of early intermediates in the chlorophyll biosynthesis pathway, suggesting limited chlorophyll availability. The PS II/PS I ratio increased upon deletion of multiple SCPs in a wild type background, similar to what is observed in the presence of subsaturating concentrations of gabaculin, an inhibitor of an early step in the tetrapyrrole biosynthesis pathway. Upon deletion of multiple SCPs, neither 77 K fluorescence emission properties of phycobilisomeless thylakoids from the PS I- less/PS II-less strain nor the energy trapping efficiency of PS II were affected, indicating that under steady-state conditions SCPs do not bind much chlorophyll and do not serve as PS II antenna. Under conditions where protochlorophyllide reduction and thus chlorophyll synthesis were inhibited, chlorophyll disappeared quickly in a mutant lacking all five SCPs. This implies a role of SCPs in stabilization of chlorophyll-binding proteins and/or in reuse of chlorophylls. Under these conditions of inhibited reduction of protochlorophyllide, the accumulation kinetics of this intermediate were greatly altered in the absence of the five SCPs. This indicates an alteration of tetrapyrrole biosynthesis kinetics by SCPs. Based on this and other evidence, we propose that SCPs bind carotenoids and transiently bind chlorophyll, aiding in the supply of chlorophyll to nascent or reassembling photosynthetic complexes, and regulate the tetrapyrrole biosynthesis pathway as a function of the demand for chlorophyll.	Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA; Arizona State Univ, Ctr Study Early Events Photosynth, Tempe, AZ 85287 USA; Umea Univ, Umea Plant Sci Ctr, SE-90187 Umea, Sweden; Umea Univ, Dept Biochem, SE-90187 Umea, Sweden	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; Umea University; Umea University	Vermaas, W (corresponding author), Arizona State Univ, Sch Life Sci, Box 874501, Tempe, AZ 85287 USA.	wim@asu.edu	Funk, Christiane/AAO-6041-2021	Funk, Christiane/0000-0002-7897-4038				ANDERSON SL, 1991, J BACTERIOL, V173, P2761, DOI 10.1128/JB.173.9.2761-2767.1991; Bhaya D, 2002, FEMS MICROBIOL LETT, V215, P209, DOI 10.1111/j.1574-6968.2002.tb11393.x; BOUSSIBA S, 1992, RES PHOTOSYNTHESIS, V3, P429; CARPENTER SD, 1990, FEBS LETT, V260, P135, DOI 10.1016/0014-5793(90)80085-W; DOLGANOV NAM, 1995, P NATL ACAD SCI USA, V92, P636, DOI 10.1073/pnas.92.2.636; ERMAKOVAGERDES S, 1995, PHOTOSYNTHESIS LIGHT, V1, P483; Funk C, 1999, BIOCHEMISTRY-US, V38, P9397, DOI 10.1021/bi990545+; Green BR, 1996, ANNU REV PLANT PHYS, V47, P685, DOI 10.1146/annurev.arplant.47.1.685; HAO L, 2001, PS2001 P 12 INT C PH; Hartel H, 1998, J EXP BOT, V49, P535, DOI 10.1093/jexbot/49.320.535; Havaux M, 2003, BBA-BIOENERGETICS, V1557, P21, DOI 10.1016/S0005-2728(02)00391-2; He QF, 1999, PLANT MOL BIOL, V39, P1175, DOI 10.1023/A:1006177103225; He QF, 2001, J BIOL CHEM, V276, P306, DOI 10.1074/jbc.M008686200; Heddad M, 2000, P NATL ACAD SCI USA, V97, P3741, DOI 10.1073/pnas.050391397; Hirschberg J., 1994, MOL BIOL CYANOBACTER, DOI [10.1007/978-94-011-0227-8_18, DOI 10.1007/978-94-011-0227-8_18]; Howitt CA, 1999, J BACTERIOL, V181, P3994, DOI 10.1128/JB.181.13.3994-4003.1999; Howitt CA, 2001, PLANTA, V214, P46, DOI 10.1007/s004250100578; Jansson S, 2000, PLANT MOL BIOL, V42, P345, DOI 10.1023/A:1006365213954; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; Kashino Y, 2002, BIOCHEMISTRY-US, V41, P8004, DOI 10.1021/bi026012+; KIM S, 1992, FEBS LETT, V314, P67, DOI 10.1016/0014-5793(92)81463-V; Lagarde D, 2000, APPL ENVIRON MICROB, V66, P64, DOI 10.1128/AEM.66.1.64-72.2000; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; RICCHELLI F, 1995, J PHOTOCH PHOTOBIO B, V29, P109, DOI 10.1016/1011-1344(95)07155-U; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; SHEN GZ, 1993, PLANT CELL, V5, P1853, DOI 10.1105/tpc.5.12.1853; SHEN GZ, 1994, J BIOL CHEM, V269, P13904; STEINMETZ M, 1985, MOL GEN GENET, V200, P220, DOI 10.1007/BF00425427; TANG XS, 1994, BIOCHEMISTRY-US, V33, P4594, DOI 10.1021/bi00181a021; Vavilin D, 2003, BIOCHEMISTRY-US, V42, P1731, DOI 10.1021/bi026853g; VERMAAS WFJ, 1987, PLANT MOL BIOL, V8, P317, DOI 10.1007/BF00021311; Wu QG, 1995, PLANT MOL BIOL, V29, P933, DOI 10.1007/BF00014967; Xu H, 2002, PLANT MOL BIOL, V49, P149, DOI 10.1023/A:1014900806905; Xu H, 2002, J BIOL CHEM, V277, P42726, DOI 10.1074/jbc.M205237200; Xu H, 2001, P NATL ACAD SCI USA, V98, P14168, DOI 10.1073/pnas.251530298; YIN JCP, 1988, J MOL BIOL, V199, P35, DOI 10.1016/0022-2836(88)90377-4	38	82	85	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27971	27979		10.1074/jbc.M403307200	http://dx.doi.org/10.1074/jbc.M403307200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15107425	hybrid			2022-12-25	WOS:000222265400019
J	Di Stefano, V; Blandino, G; Sacchi, A; Soddu, S; D'Orazi, G				Di Stefano, V; Blandino, G; Sacchi, A; Soddu, S; D'Orazi, G			HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function	ONCOGENE			English	Article						HIPK2; p53; ubiquitination; MDM2; nuclear export; apoptosis	INTERACTING PROTEIN KINASE-2; AUTOREGULATORY FEEDBACK LOOP; TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; P53-INDUCED APOPTOSIS; GENE AMPLIFICATION; GROWTH-CONTROL; PHOSPHORYLATION; DEGRADATION; CANCER	The p53 oncosuppressor protein is subject to negative regulation by MDM2, which efficiently inhibits its activity through an autoregulatory loop. In response to stress, however, p53 undergoes post-translational modi. cations that allow the protein to escape MDM2 control, accumulate, and become active. Recent studies have shown that, following DNA damage, the HIPK2 serine/ threonine kinase binds and phosphorylates p53, inducing p53 transcriptional activity and apoptotic function. Here, we investigated the role of HIPK2 in the activation of p53 in the presence of MDM2. We found that HIPK2 rescues p53 transcriptional activity overcoming MDM2 inhibition, and that restoration of this p53 function induces apoptosis. Recovery of p53-dependent apoptosis is achieved by preventing p53 nuclear export and ubiquitination mediated by MDM2 in vitro and in vivo following genotoxic stress. These results shed new light on the mechanisms by which the HIPK2/p53 pathway promotes apoptosis and suppression of tumorigenesis.	Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, I-00158 Rome, Italy; Univ G DAnnunzio, Dept Oncol & Neurosci, I-66013 Chieti, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; G d'Annunzio University of Chieti-Pescara	D'Orazi, G (corresponding author), Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, Via Messi Oro 156, I-00158 Rome, Italy.	dorazi@ifo.it	Soddu, Silvia/ABH-6774-2020; Blandino, Giovanni/B-1137-2013; D'Orazi, Gabriella/T-2792-2019; Soddu, Silvia/K-2467-2018	Soddu, Silvia/0000-0001-8526-0044; Blandino, Giovanni/0000-0002-6970-2241; D'Orazi, Gabriella/0000-0001-6876-9105; Soddu, Silvia/0000-0001-8526-0044	Telethon [GP0234Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Di Stefano V, 2004, EXP CELL RES, V293, P311, DOI 10.1016/j.yexcr.2003.09.032; Eymin B, 2002, ONCOGENE, V21, P2750, DOI 10.1038/sj.onc.1205359; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Leite KRM, 2001, MODERN PATHOL, V14, P428, DOI 10.1038/modpathol.3880330; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUCA RMD, 1995, NATURE, V378, P203; MIYASHITA T, 1995, CELL, V80, P293; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; Polsky D, 2001, CANCER RES, V61, P7642; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Velculescu VE, 1996, CLIN CHEM, V42, P858; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang Y, 2001, BMC Mol Biol, V2, P8, DOI 10.1186/1471-2199-2-8; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	47	56	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5185	5192		10.1038/sj.onc.1207656	http://dx.doi.org/10.1038/sj.onc.1207656			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122315				2022-12-25	WOS:000222382500008
J	Reagan-Shaw, S; Afaq, F; Aziz, MH; Ahmad, N				Reagan-Shaw, S; Afaq, F; Aziz, MH; Ahmad, N			Modulations of critical cell cycle regulatory events during chemoprevention of ultraviolet B-mediated responses by resveratrol in SKH-1 hairless mouse skin	ONCOGENE			English	Article						resveratrol; cell cycle; ultraviolet (UV); skin cancer	GREEN TEA POLYPHENOL; GENE-EXPRESSION; KAPPA-B; PHOTOCARCINOGENESIS; CANCER; ACTIVATION; PREVENTION; CARCINOMA; LIGHT; MICE	Multiple exposures to solar ultraviolet (UV) radiation cause critical damages that may lead to the development of several cutaneous disorders including skin cancer, the most frequently diagnosed malignancy in the USA. Therefore, efforts are needed to: (i) study the mechanism(s) of UV-mediated cutaneous damages, and (ii) design novel approaches for the management of skin cancer. 'Chemoprevention' via plant-based agents may be a useful approach for the management of neoplasia. Here, we evaluated the involvement of cell cycle regulatory molecules during resveratrol-mediated protection from multiple exposures of UVB ( 180 mJ/cm(2); on alternate days x 7 exposures) radiations in the SKH-1 hairless mouse skin. Resveratrol was topically applied on the skin of SKH-1 hairless mice at a dose of 10 mumol/mouse ( in 0.2 ml acetone; 30 min prior to each UVB exposure). Studies were performed at 24 h following the last UVB exposure. Topical application of resveratrol resulted in significant decrease in UVB-induced bi-fold skin thickness, hyperplasia, and infiltration of leukocytes. The data from immunoblot and/or immunohistochemical analyses revealed that multiple exposure to UVB radiations causes significant upregulation in: ( i) proliferating cell nuclear antigen ( PCNA), a marker of cellular proliferation, and ( ii) cyclin-dependent kinase (cdk)- 2, - 4 and - 6, cyclin-D1, and cyclin-D2. Resveratrol treatment resulted in significant downregulation in UV-mediated increases in these critical cell cycle regulatory proteins. An interesting observation of this study was that resveratrol treatment resulted in a further stimulation of UVB-mediated increases in cyclin kinase inhibitor WAF1/p21 and tumor suppressor p53. Further, resveratrol was also found to cause significant decreases in UVB-mediated upregulation of: ( i) the mitogen-activated protein kinase kinase, and ( ii) the 42 kDa isotype of mitogen-activated protein kinase ( MAPK). Thus, our data suggested that the antiproliferative effects of resveratrol might be mediated via modulation in the expression and function of cell cycle regulatory proteins cyclin-D1 and -D2, cdk-2, -4 and -6, and WAF1/p21. Our data further suggest that the modulation of cki-cyclin-cdk network by resveratrol may be associated with inhibition of the MAPK pathway. We suggest that resveratrol may be useful for the prevention of UVB-mediated cutaneous damages including skin cancer.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA; Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA; Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ahmad, N (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, 1300 Univ Ave, Madison, WI 53706 USA.	nahmad@wisc.edu	Ahmad, Nihal/AAR-4249-2021	Ahmad, Nihal/0000-0002-4239-9887	NATIONAL CANCER INSTITUTE [R03CA099076, R03CA098368] Funding Source: NIH RePORTER; NCI NIH HHS [R03 CA 99076, R03 CA 98368] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; Adhami VM, 2003, NEOPLASIA, V5, P74, DOI 10.1016/S1476-5586(03)80019-2; Adhami VM, 2001, BIOCHEM BIOPH RES CO, V288, P579, DOI 10.1006/bbrc.2001.5819; Afaq F, 2003, ONCOGENE, V22, P9254, DOI 10.1038/sj.onc.1207035; Afaq F, 2003, TOXICOL APPL PHARM, V186, P28, DOI 10.1016/S0041-008X(02)00014-5; Afaq F, 2002, FRONT BIOSCI-LANDMRK, V7, pD784, DOI 10.2741/afaq; Ahmad N, 2001, CLIN CANCER RES, V7, P1466; Ahmad N, 2001, SKIN PHARMACOL APPL, V14, P69, DOI 10.1159/000056336; Ahmed NU, 1999, J DERMATOL SCI, V19, P175, DOI 10.1016/S0923-1811(98)00068-1; Bickers D R, 2000, J Dermatol, V27, P691; Black HS, 1997, J PHOTOCH PHOTOBIO B, V40, P29, DOI 10.1016/S1011-1344(97)00021-3; Bowden GT, 2004, NAT REV CANCER, V4, P23, DOI 10.1038/nrc1253; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen WX, 1999, ONCOGENE, V18, P7469, DOI 10.1038/sj.onc.1203210; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; de Gruijl FR, 2002, SKIN PHARMACOL APPL, V15, P316, DOI 10.1159/000064535; Dreher F, 2001, CURR PROBL DERMATOL, V29, P157; Eckert RL, 2002, J INVEST DERM SYMP P, V7, P36, DOI 10.1046/j.1523-1747.2002.19634.x; Einspahr JG, 2003, RECENT RESULTS CANC, V163, P151; F'guyer S, 2003, PHOTODERMATOL PHOTO, V19, P56, DOI 10.1034/j.1600-0781.2003.00019.x; Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513; Hatoko M, 2001, ANN PLAS SURG, V47, P425, DOI 10.1097/00000637-200110000-00011; Katiyar SK, 2001, TOXICOL APPL PHARM, V176, P110, DOI 10.1006/taap.2001.9276; Katiyar SK, 1999, CARCINOGENESIS, V20, P2117, DOI 10.1093/carcin/20.11.2117; Katiyar SK, 2001, J LEUKOCYTE BIOL, V69, P719; Katiyar SK, 1997, JNCI-J NATL CANCER I, V89, P556, DOI 10.1093/jnci/89.8.556; Kim AL, 2002, PHOTOCHEM PHOTOBIOL, V75, P58, DOI 10.1562/0031-8655(2002)075<0058:SSAOCE>2.0.CO;2; Kulms D, 2002, J DERMATOL, V29, P189, DOI 10.1111/j.1346-8138.2002.tb00248.x; Lu YP, 1999, CANCER RES, V59, P4591; Lu YP, 2000, CANCER RES, V60, P4785; Murphy M, 2002, J CLIN PATHOL, V55, P829, DOI 10.1136/jcp.55.11.829; Naylor MF, 1997, ARCH DERMATOL, V133, P373, DOI 10.1001/archderm.133.3.373; Petrocelli T, 2000, ONCOGENE, V19, P4480, DOI 10.1038/sj.onc.1203808; Petrocelli T, 1996, ONCOGENE, V12, P1387; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Sander CS, 2003, BRIT J DERMATOL, V148, P913, DOI 10.1046/j.1365-2133.2003.05303.x; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; Terada Y, 1999, KIDNEY INT, V56, P1258, DOI 10.1046/j.1523-1755.1999.00704.x; Terada Y, 1999, KIDNEY INT, V56, P1378, DOI 10.1046/j.1523-1755.1999.00665.x; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; Wang WG, 2003, CANCER BIOL THER, V2, pS55; Yamamoto H, 2002, CANCER RES, V62, P1641; Yano S, 2003, BIOCHEM BIOPH RES CO, V301, P841, DOI 10.1016/S0006-291X(03)00060-3	43	100	110	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5151	5160		10.1038/sj.onc.1207666	http://dx.doi.org/10.1038/sj.onc.1207666			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122319				2022-12-25	WOS:000222382500005
J	Bohren, KM; Nadkarni, V; Song, JH; Gabbay, KH; Owerbach, D				Bohren, KM; Nadkarni, V; Song, JH; Gabbay, KH; Owerbach, D			A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; UBIQUITIN; SENTRIN; LINKAGE; BINDING; STRESS; HSP60; CELLS	Three SUMO ( small ubiquitin-related modifier) genes have been identified in humans, which tag proteins to modulate subcellular localization and/or enhance protein stability and activity. We report the identification of a novel intronless SUMO gene, SUMO-4, that encodes a 95-amino acid protein having an 86% amino acid homology with SUMO-2. In contrast to SUMO-2, which is highly expressed in all of the tissues examined, SUMO-4 mRNA was detected mainly in the kidney. A single nucleotide polymorphism was detected in SUMO-4, substituting a highly conserved methionine with a valine residue (M55V). In HepG2 ( liver carcinoma) cells transiently transfected with SUMO-4 expression vectors, Met-55 was associated with the elevated levels of activated heat shock factor transcription factors as compared with Val-55, whereas the levels of NF-kappaB were suppressed to an identical degree. The SUMO-4M ( Met) variant is associated with type I diabetes mellitus susceptibility in families ( p = 4.0 x 10(-4)), suggesting that it may be involved in the pathogenesis of type I diabetes.	Baylor Coll Med, Mol Diabet & Metab Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Harry B & Aileen B Gordon Diabet Res Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Owerbach, D (corresponding author), Baylor Coll Med, Mol Diabet & Metab Sect, Houston, TX 77030 USA.	davido@bcm.tmc.edu	Owerbach, David/A-3144-2008	Bohren, Kurt/0000-0002-3183-4118				Barski OA, 1999, GENOMICS, V60, P188, DOI 10.1006/geno.1999.5915; Birk OS, 1996, J AUTOIMMUN, V9, P159, DOI 10.1006/jaut.1996.0019; Cohen IR, 2002, DIABETOLOGIA, V45, P1468, DOI 10.1007/s00125-002-0937-z; Cox NJ, 2001, AM J HUM GENET, V69, P820, DOI 10.1086/323501; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Devaney JM, 2001, ANAL CHEM, V73, P620, DOI 10.1021/ac000912j; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; He HY, 2003, J BIOL CHEM, V278, P35465, DOI 10.1074/jbc.M304663200; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; JONES DB, 1993, IMMUNOL TODAY, V14, P115, DOI 10.1016/0167-5699(93)90210-C; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Martin ER, 1997, AM J HUM GENET, V61, P439, DOI 10.1086/514860; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Okura T, 1996, J IMMUNOL, V157, P4277; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Su HL, 2002, GENE, V296, P65, DOI 10.1016/S0378-1119(02)00843-0; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192	23	273	299	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27233	27238		10.1074/jbc.M402273200	http://dx.doi.org/10.1074/jbc.M402273200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15123604	hybrid			2022-12-25	WOS:000222120400051
J	Camarota, LM; Chapman, JM; Hui, DY; Howles, PN				Camarota, LM; Chapman, JM; Hui, DY; Howles, PN			Carboxyl ester lipase cofractionates with scavenger receptor BI in hepatocyte lipid rafts and enhances selective uptake and hydrolysis of cholesteryl esters from HDL3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; SR-BI; TARGETED MUTATION; PARTICLE UPTAKE; HEART-DISEASE; SECRETION; TRANSPORT; HYDROLASE; PATHWAY	Cholesteryl esters are selectively removed from high density lipoproteins by hepatocytes and steroidogenic cells through a process mediated by scavenger receptor BI. In the liver this cholesterol is secreted into bile, primarily as free cholesterol. Previous work showed that carboxyl ester lipase enhanced selective uptake of cholesteryl ether from high density lipoprotein by an unknown mechanism. Experiments were performed to determine whether carboxyl ester lipase plays a role in scavenger receptor BI-mediated selective uptake. When added to cultures of HepG2 cells, carboxyl ester lipase cofractionated with scavenger receptor BI and [H-3]cholesteryl ether-labeled high density lipoprotein in lipid raft fractions of cell homogenates. Confocal microscopy of immunostained carboxyl ester lipase and scavenger receptor BI showed a close association of these proteins in HepG2 cells. The enzyme and receptor also cofractionated from homogenates of mouse liver using two different fractionation methods. Antibodies that block scavenger receptor BI function prevented carboxyl ester lipase stimulation of selective uptake in primary hepatocytes from carboxyl ester lipase knockout mice. Heparin blockage of cell-surface proteoglycans also prevented carboxyl ester lipase stimulation of cholesteryl ester uptake by HepG2 cells. Inhibition of carboxyl ester lipase activity in HepG2 cells reduced hydrolysis of high density lipoprotein-cholesteryl esters similar to40%. In vivo, hydrolysis was similarly reduced in lipid rafts from the livers of carboxyl ester lipase-null mice compared with control animals. Primary hepatocytes from these mice yielded similar results. The data suggest that carboxyl ester lipase plays a physiological role in hepatic selective uptake and metabolism of high density lipoprotein cholesteryl esters by direct and indirect interactions with the scavenger receptor BI pathway.	Univ Cincinnati, Coll Med, Dept Pathol N, GRI, Cincinnati, OH 45237 USA	University System of Ohio; University of Cincinnati	Howles, PN (corresponding author), Univ Cincinnati, Coll Med, Dept Pathol N, GRI, ML 0507,2120 E Galbraith Rd, Cincinnati, OH 45237 USA.	philip.howles@uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066246] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL66246] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; BRODTEPPLEY J, 1995, BBA-MOL BASIS DIS, V1272, P69, DOI 10.1016/0925-4439(95)00083-G; CAMULLI ED, 1989, BIOCHIM BIOPHYS ACTA, V1005, P177, DOI 10.1016/0005-2760(89)90184-7; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; Connelly MA, 2003, J LIPID RES, V44, P331, DOI 10.1194/jlr.M200186-JLR200; DELAMATRE JG, 1990, J LIPID RES, V31, P191; Fayard E, 2003, J BIOL CHEM, V278, P35725, DOI 10.1074/jbc.M302370200; Francis GA, 2003, ANNU REV PHYSIOL, V65, P261, DOI 10.1146/annurev.physiol.65.092101.142528; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; Fresnedo O, 2001, HEPATOLOGY, V33, P662, DOI 10.1053/jhep.2001.22763; Fuki IV, 2000, BIOCHEM J, V351, P607, DOI 10.1042/0264-6021:3510607; Fuki IV, 2003, J BIOL CHEM, V278, P34331, DOI 10.1074/jbc.M302181200; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Ghosh S, 1995, BBA-LIPID LIPID MET, V1259, P305, DOI 10.1016/0005-2760(95)00184-0; Ghosh S, 1998, AM J PHYSIOL-GASTR L, V274, pG662, DOI 10.1152/ajpgi.1998.274.4.G662; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLOMSET JA, 1968, J LIPID RES, V9, P155; GOLDSTEIN JL, 1976, CELL, V7, P85, DOI 10.1016/0092-8674(76)90258-0; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hornick CA, 1997, AM J PHYSIOL-CELL PH, V273, pC1075, DOI 10.1152/ajpcell.1997.273.3.C1075; Howles PN, 1999, AM J PHYSIOL-GASTR L, V277, pG653, DOI 10.1152/ajpgi.1999.277.3.G653; Howles PN, 1996, J BIOL CHEM, V271, P7196, DOI 10.1074/jbc.271.12.7196; Hui DY, 2002, J LIPID RES, V43, P2017, DOI 10.1194/jlr.R200013-JLR200; IVERSON SJ, 1991, BIOCHIM BIOPHYS ACTA, V1083, P109, DOI 10.1016/0005-2760(91)90131-Z; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Kirby RJ, 2002, J BIOL CHEM, V277, P4104, DOI 10.1074/jbc.M107549200; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Li F, 1998, BIOCHEM J, V329, P675, DOI 10.1042/bj3290675; Li F, 1997, J BIOL CHEM, V272, P28666, DOI 10.1074/jbc.272.45.28666; Li F, 1996, BIOCHEMISTRY-US, V35, P6657, DOI 10.1021/bi952313q; Li H, 2002, ENDOCRINOLOGY, V143, P3333, DOI 10.1210/en.2002-220341; Lombardo D, 2001, BBA-MOL CELL BIOL L, V1533, P1, DOI 10.1016/S1388-1981(01)00130-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; MYERSPAYNE SC, 1995, BIOCHEMISTRY-US, V34, P3942, DOI 10.1021/bi00012a011; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; Pol A, 1999, HEPATOLOGY, V29, P1848, DOI 10.1002/hep.510290602; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RINNINGER F, 1993, BIOCHIM BIOPHYS ACTA, V1166, P275, DOI 10.1016/0005-2760(93)90108-L; Robins SJ, 1997, J CLIN INVEST, V99, P380, DOI 10.1172/JCI119170; Sawle A, 2002, J LIPID RES, V43, P335; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shamir R, 1996, J CLIN INVEST, V97, P1696, DOI 10.1172/JCI118596; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; SPARROW CP, 1990, BIOCHIM BIOPHYS ACTA, V1043, P203, DOI 10.1016/0005-2760(90)90297-B; Tall AR, 1998, EUR HEART J, V19, pA31; Temel RE, 2002, J BIOL CHEM, V277, P26565, DOI 10.1074/jbc.M203014200; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; Weng W, 1999, BIOCHEMISTRY-US, V38, P4143, DOI 10.1021/bi981679a; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; WINKLER KE, 1992, BIOCHIM BIOPHYS ACTA, V1126, P151	57	24	27	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27599	27606		10.1074/jbc.M402946200	http://dx.doi.org/10.1074/jbc.M402946200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15105424	hybrid			2022-12-25	WOS:000222120400094
J	Howell, M; Borchers, C; Milgram, SL				Howell, M; Borchers, C; Milgram, SL			Heterogeneous nuclear ribonuclear protein U associates with YAP and regulates its co-activation of Bax transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YES-ASSOCIATED PROTEIN; RNA-POLYMERASE-II; KAPPA-B PROTEINS; HNRNP-U; HELA-CELLS; WW DOMAIN; SUBCELLULAR-LOCALIZATION; DEPENDENT TRANSCRIPTION; P53/P63/P73 FAMILY; BINDING-PROTEIN	Although initially described as a cytosolic scaffolding protein, YAP (Yes-associated protein of 65 kDa) is known to associate with multiple transcription factors in the nucleus. Using affinity chromatography and mass spectrometry, we show that YAP interacts with heterogeneous nuclear ribonuclear protein U (hnRNP U), an RNA- and DNA-binding protein enriched in the nuclear matrix that also plays a role in the regulation of gene expression. hnRNP U interacts specifically with the proline-rich amino terminus of YAP, a region of YAP that is not found in the related protein TAZ. Although hnRNP U and YAP localize to both the nucleus and the cytoplasm, YAP does not translocate to the nucleus in an hnRNP U-dependent manner. Furthermore, hnRNP U and YAP only interact in the nucleus, suggesting that the association between the two proteins is regulated. Co-expression of hnRNP U attenuates the ability of YAP to increase the activity of a p73-driven Bax-luciferase reporter plasmid. In contrast, hnRNP U has no effect when co-expressed with a truncated YAP protein lacking the hnRNP U-binding site. Because YAP is distinguished from the homologue TAZ by its proline-rich amino terminus, the YAP-hnRNP U interaction may uniquely regulate the nuclear function(s) of YAP. The YAP-hnRNP U interaction provides another mechanism of YAP transcriptional regulation.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Neurobiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Milgram, SL (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, CB 7090, Chapel Hill, NC 27599 USA.	milg@med.unc.edu	BORCHERS, Christoph/U-5964-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063755] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63755] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alvarez M, 2003, GENE, V313, P43, DOI 10.1016/S0378-1119(03)00627-9; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Berezney R, 1995, INT REV CYTOL, V162A, P1; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; Carpenter G, 2003, CURR OPIN CELL BIOL, V15, P143, DOI 10.1016/S0955-0674(03)00015-2; Carty SM, 2002, MOL CELL PROTEOMICS, V1, P598, DOI 10.1074/mcp.M200029-MCP200; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; De Laurenzi V, 2000, ANN NY ACAD SCI, V926, P90; Desterro JMP, 2000, CELL MOL LIFE SCI, V57, P1207, DOI 10.1007/PL00000760; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; Eggert H, 2001, J STEROID BIOCHEM, V78, P59, DOI 10.1016/S0960-0760(01)00074-7; Eggert M, 1997, J BIOL CHEM, V272, P28471, DOI 10.1074/jbc.272.45.28471; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Ferrigno O, 2002, ONCOGENE, V21, P4879, DOI 10.1038/sj.onc.1205623; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Goodman RH, 2000, GENE DEV, V14, P1553; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; HENDZEL MJ, 1994, J BIOL CHEM, V269, P22894; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; JACKSON DA, 1990, EMBO J, V9, P567, DOI 10.1002/j.1460-2075.1990.tb08144.x; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kang KH, 2002, FEBS LETT, V522, P161, DOI 10.1016/S0014-5793(02)02921-6; Kast J, 2003, RAPID COMMUN MASS SP, V17, P1825, DOI 10.1002/rcm.1114; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Kim MK, 1999, MOL CELL BIOL, V19, P6833; Kipp M, 2000, J BIOL CHEM, V275, P5031, DOI 10.1074/jbc.275.7.5031; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Levrero M, 2000, J CELL SCI, V113, P1661; Mattern KA, 1996, J CELL BIOCHEM, V62, P275, DOI 10.1002/(SICI)1097-4644(199608)62:2<275::AID-JCB15>3.0.CO;2-K; Mery L, 2002, J CELL SCI, V115, P3497; Mohler Peter J, 2002, Methods Mol Med, V70, P383; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Palancade B, 2003, EUR J BIOCHEM, V270, P3859, DOI 10.1046/j.1432-1033.2003.03794.x; Pile LA, 2000, EMBO J, V19, P6131, DOI 10.1093/emboj/19.22.6131; Reczek D, 2001, J CELL BIOL, V153, P191, DOI 10.1083/jcb.153.1.191; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; Rousseau G G, 1979, Monogr Endocrinol, V12, P49; Sasaki Y, 2003, CANCER RES, V63, P8145; Stiewe T, 2001, APOPTOSIS, V6, P447, DOI 10.1023/A:1012433522902; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; SUDOL M, 1994, ONCOGENE, V9, P2145; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Takahashi Y, 2003, NEUROCHEM RES, V28, P1265, DOI 10.1023/A:1024296932670; Taniura H, 2002, J CELL BIOCHEM, V84, P545, DOI 10.1002/jcb.10047.abs; Trotter KW, 1999, J CELL BIOL, V147, P1481, DOI 10.1083/jcb.147.7.1481; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; VONKRIES JP, 1994, NUCLEIC ACIDS RES, V22, P1215, DOI 10.1093/nar/22.7.1215; Whitmarsh AJ, 2000, CELL MOL LIFE SCI, V57, P1172, DOI 10.1007/PL00000757; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Zhu JH, 1998, CANCER RES, V58, P5061; Zurita M, 2003, TRENDS GENET, V19, P578, DOI 10.1016/j.tig.2003.08.005	66	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26300	26306		10.1074/jbc.M401070200	http://dx.doi.org/10.1074/jbc.M401070200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15096513	hybrid, Green Published			2022-12-25	WOS:000222003000048
J	Hong, YK; Lange-Asschenfeldt, B; Velasco, P; Hirakawa, S; Kunstfeld, R; Brown, LF; Bohlen, P; Senger, DR; Detmar, M				Hong, YK; Lange-Asschenfeldt, B; Velasco, P; Hirakawa, S; Kunstfeld, R; Brown, LF; Bohlen, P; Senger, DR; Detmar, M			VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha 1 beta 1 and alpha 2 beta 1 integrins	FASEB JOURNAL			English	Article						VEGF; lymphangiogenesis; wound healing; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; LYMPHANGIOGENESIS; ANGIOGENESIS; MECHANISMS; SKIN; KERATINOCYTES; EXPRESSION; DELIVERY; RECEPTOR; WOUNDS	Vascular endothelial growth factor-A (VEGF-A) is strongly up-regulated in wounded cutaneous tissue and promotes repair-associated angiogenesis. However, little is known about its role in lymphatic regeneration of the healing skin. We studied wound healing in transgenic mice that overexpress VEGF-A specifically in the epidermis and in wild-type mice in the absence or presence of inhibitors of VEGF-A signaling. Surprisingly, transgenic overexpression of VEGF-A in the skin promoted lymphangiogenesis at the wound healing site, whereas systemic blockade of VEGFR-2 prevented lymphatic vessel formation. Studies in cultured lymphatic endothelial cells revealed that VEGF-A induced expression of the alpha1 and alpha2 integrins, which promoted their in vitro tube formation and their haptotactic migration toward type I collagen. VEGF-A-induced lymphatic endothelial cord formation and haptotactic migration were suppressed by anti-alpha1 and anti-alpha2 integrin blocking antibodies, and systemic blockade of the alpha1 and alpha2 integrins inhibited VEGF-A-driven lymphangiogenesis in vivo. We propose that VEGF-A promotes lymphatic vasculature formation via activation of VEGFR-2 and that lineage-specific differences of integrin receptor expression contribute to the distinct dynamics of wound-associated angiogenesis and lymphangiogenesis.	Massachusetts Gen Hosp, Dept Dermatol, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA USA; ImClone Syst Inc, New York, NY USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Eli Lilly	Detmar, M (corresponding author), Massachusetts Gen Hosp, Dept Dermatol, Cutaneous Biol Res Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.	michael.detmar@cbrc2.mgh.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA069184, R01CA086410, P01CA092644, R01CA077357] Funding Source: NIH RePORTER; NCI NIH HHS [CA92644, CA86410, CA77357, CA69184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; ARNOLD F, 1991, PHARMACOL THERAPEUT, V52, P407, DOI 10.1016/0163-7258(91)90034-J; BELLMAN S, 1959, Acta Chir Scand, V116, P99; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Hawighorst T, 2002, ONCOGENE, V21, P7945, DOI 10.1038/sj.onc.1205956; Hirakawa S, 2003, AM J PATHOL, V162, P575, DOI 10.1016/S0002-9440(10)63851-5; Hong YK, 2002, DEV DYNAM, V225, P351, DOI 10.1002/dvdy.10163; Howdieshell TR, 2001, J SURG RES, V96, P173, DOI 10.1006/jsre.2001.6089; Inoue K, 2000, CLIN CANCER RES, V6, P2635; Jacobi J, 2004, GENE THER, V11, P302, DOI 10.1038/sj.gt.3302162; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Nagy JA, 2002, J EXP MED, V196, P1497, DOI 10.1084/jem.20021244; Nissen NN, 1998, AM J PATHOL, V152, P1445; Oliver G, 2002, GENE DEV, V16, P773, DOI 10.1101/gad.975002; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; Rissanen TT, 2003, CIRC RES, V92, P1098, DOI 10.1161/01.RES.0000073584.46059.E3; Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Streit M, 2000, EMBO J, V19, P3272, DOI 10.1093/emboj/19.13.3272; Tsou R, 2002, WOUND REPAIR REGEN, V10, P222, DOI 10.1046/j.1524-475X.2002.10405.x; Whelan MC, 2003, J BIOL CHEM, V278, P327, DOI 10.1074/jbc.M207554200; Witte MH, 2001, MICROSC RES TECHNIQ, V55, P122, DOI 10.1002/jemt.1163; Xia YP, 2003, BLOOD, V102, P161, DOI 10.1182/blood-2002-12-3793; Yano K, 2001, J CLIN INVEST, V107, P409, DOI 10.1172/JCI11317	31	230	253	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1111	+		10.1096/fj.03-1179fje	http://dx.doi.org/10.1096/fj.03-1179fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132990				2022-12-25	WOS:000221883200026
J	Zampetaki, A; Mitsialis, SA; Pfeilschifter, J; Kourembanas, S				Zampetaki, A; Mitsialis, SA; Pfeilschifter, J; Kourembanas, S			Hypoxia induces macrophage inflammatory protein-2 (MIP-2) gene expression in murine macrophages via NF-kappa B: the prominent role of p42/p44 and PI3 kinase pathways	FASEB JOURNAL			English	Article						chemokines; signaling pathways	NECROSIS-FACTOR-ALPHA; RNA POLYMERASE-II; DEPENDENT TRANSCRIPTION; BETA ENHANCEOSOME; RELA/P65 SUBUNIT; LUNG INJURY; IN-VIVO; ACTIVATION; PHOSPHORYLATION; CHEMOKINES	We have previously reported that hypoxia induces a pronounced inflammatory response in the mouse lung associated with elevated levels of specific chemokines. To further explore the mechanisms involved in lung inflammation, we exposed RAW 264.7 cells as well as mouse primary macrophages to hypoxia and analyzed chemokine gene expression. Among the genes examined, macrophage inflammatory protein-2 (MIP-2) expression was prominently induced by hypoxia both at the mRNA and the protein level. When RAW 264.7 cells were transfected with a panel of plasmids harboring a luciferase marker gene under the control of wild-type or mutant variants of the MIP-2 gene promoter, a strong hypoxic induction of expression (9- to 17-fold) was observed. This induction was abolished by a mutation targeted to an NF-kappaB binding site in the MIP-2 promoter. Concordantly, specific NF-kappaB binding to the cognate sequence was enriched in nuclear extracts from hypoxic but not normoxic RAW 264.7 cells. The mechanism of MIP-2 gene induction by hypoxia was further characterized using inhibitors of signaling kinases. Inhibition of the p42/p44 and PI3 kinases but not p38 MAPK abolished the NF-kappaB-driven upregulation of MIP-2 gene expression by hypoxia. This attenuation of the NF-kappaB response to hypoxia did not involve decreased nuclear NF-kappaB abundance but correlated with diminished transactivation potential of the p65 subunit. Our results indicate that the hypoxic signal for induction of MIP-2 gene expression is implemented through enhanced NF-kappaB activity and transmitted along the p42/44 and PI3 kinase pathways.	Childrens Hosp, Dept Med, Div Newborn Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, D-6000 Frankfurt, Germany	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Kourembanas, S (corresponding author), Childrens Hosp, Dept Med, Div Newborn Med, 300 Longwood Ave,Enders 9, Boston, MA 02115 USA.	stella.kourembanas@childrens.Harvard.edu		Zampetaki, Anna/0000-0002-7257-8624; Mitsialis, S. Alex/0000-0001-8315-7828	NHLBI NIH HHS [R01 HL55454, 5P50 HL67669] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL067669, R01HL055454] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cantrell DA, 2001, J CELL SCI, V114, P1439; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chandel NS, 2000, J IMMUNOL, V165, P1013, DOI 10.4049/jimmunol.165.2.1013; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Galindo M, 2001, CLIN EXP IMMUNOL, V123, P36, DOI 10.1046/j.1365-2249.2001.01412.x; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Kim TK, 1998, P NATL ACAD SCI USA, V95, P12191, DOI 10.1073/pnas.95.21.12191; KOONG AC, 1994, CANCER RES, V54, P5273; Kourembanas S, 1997, KIDNEY INT, V51, P438, DOI 10.1038/ki.1997.58; Leeper-Woodford SK, 1999, AM J PHYSIOL-LUNG C, V276, pL909, DOI 10.1152/ajplung.1999.276.6.L909; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Madjdpour C, 2003, AM J PHYSIOL-LUNG C, V284, pL360, DOI 10.1152/ajplung.00158.2002; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Matsui H, 1999, CARDIOVASC RES, V42, P104, DOI 10.1016/S0008-6363(98)00285-5; Matsushita H, 2000, CIRC RES, V86, P974, DOI 10.1161/01.RES.86.9.974; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Minamino T, 2001, P NATL ACAD SCI USA, V98, P8798, DOI 10.1073/pnas.161272598; Ozes ON, 1999, NATURE, V401, P82; Pearlstein DP, 2002, ARTERIOSCL THROM VAS, V22, P566, DOI 10.1161/01.ATV.0000012262.76205.6A; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmal H, 1996, J IMMUNOL, V156, P1963; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Shanley TP, 1997, J IMMUNOL, V158, P3439; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; STANDIFORD TJ, 1995, J IMMUNOL, V155, P2222; Strieter RM, 1999, CHEST, V116, p103S, DOI 10.1378/chest.116.suppl_1.103S; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Walpen S, 2001, FASEB J, V15, P571; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WIDMER U, 1993, J IMMUNOL, V150, P4996; WOLPE SD, 1989, P NATL ACAD SCI USA, V86, P612, DOI 10.1073/pnas.86.2.612; XING Z, 1994, AM J RESP CELL MOL, V10, P148, DOI 10.1165/ajrcmb.10.2.8110470; Xu L, 1999, CANCER RES, V59, P5822; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	54	67	72	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1090	+		10.1096/fj.03-0991fje	http://dx.doi.org/10.1096/fj.03-0991fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132979				2022-12-25	WOS:000221883200014
J	Boswell, EJ; Jeon, H; Blacklow, SC; Downing, AK				Boswell, EJ; Jeon, H; Blacklow, SC; Downing, AK			Global defects in the expression and function of the low density lipoprotein receptor (LDLR) associated with two familial hypercholesterolemia mutations resulting in misfolding of the LDLR epidermal growth factor-AB pair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-LIKE DOMAIN; CALCIUM-BINDING; MOLECULAR-GENETICS; FACTOR-IX; IN-VITRO; MODULES; GENES; 1ST	The low density lipoprotein (LDL) receptor is a modular protein involved in the endocytosis of cholesterol-rich lipoproteins from the circulation. Mutations to the receptor result in familial hypercholesterolemia, and over 60 of these occur in the calcium-binding epidermal growth factor-like domain pair. Two selected mutations in this region (G322S and R329P) were introduced into the domain pair and analyzed by in vitro refolding. Both exhibited differing levels of protein misfolding with R329P being the most pronounced. Solution NMR studies of the mutant domain pairs after purification established that a fraction of protein maintains a native-like fold and that this fraction contains two intact calcium-binding sites. An in vivo analysis of intact receptors containing these binding sites showed significantly reduced cell-surface expression compared with the native LDL receptor levels, again with R329P showing the most severe decrease. The sum of these results suggests that either local changes in structure or domain misfolding may be associated with the mutations. There is also the possibility that the misfolding of the calcium-binding epidermal growth factor-like pair region is propagated to other regions of the intact receptor, resulting in more global defects. Surprisingly, for both mutants, those full-length receptors that fold and reach the cell surface retain the ability to bind LDL and release the ligand upon exposure to low pH. This analysis provides significant insight into the protein defect resulting from each of the two mutations and allows their classification to be 2B (partially transport-defective). The results also highlight a range of misfolding defects that may be associated with familial hypercholesterolemia and may enable the prediction of the consequences of homologous disease-causing mutations to other proteins.	Univ Oxford, Dept Biochem, Div Struct Biol, Oxford OX1 3QU, England; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	University of Oxford; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Downing, AK (corresponding author), Univ Oxford, Dept Biochem, Div Struct Biol, S Parks Rd, Oxford OX1 3QU, England.	kristy.downing@bioch.ox.ac.uk			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061001] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-61001] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andre I, 2002, ANAL BIOCHEM, V305, P195, DOI 10.1006/abio.2002.5661; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bross P, 1999, HUM MUTAT, V14, P186, DOI 10.1002/(SICI)1098-1004(1999)14:3<186::AID-HUMU2>3.0.CO;2-J; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; Buxbaum JN, 2003, TRENDS BIOCHEM SCI, V28, P585, DOI 10.1016/j.tibs.2003.09.009; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; Day INM, 1997, HUM MUTAT, V10, P116; DENTON PH, 1988, BLOOD, V72, P1407; Dirlam KA, 1996, PROTEIN EXPRES PURIF, V8, P489, DOI 10.1016/S1046-5928(96)90129-1; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; Fouchier SW, 2001, HUM GENET, V109, P602, DOI 10.1007/s00439-001-0628-8; FRANCKE U, 1995, AM J HUM GENET, V56, P1287; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goldstein JL, 2001, METABOLIC MOL BASES, V8th, P2863; GUDNASON V, 1994, ARTERIOSCLER THROMB, V14, P1717, DOI 10.1161/01.ATV.14.11.1717; Herz J, 2003, CELL, V112, P289, DOI 10.1016/S0092-8674(03)00073-4; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jansens A, 2002, SCIENCE, V298, P2401, DOI 10.1126/science.1078376; JEENAH M, 1993, ATHEROSCLEROSIS, V98, P51, DOI 10.1016/0021-9150(93)90222-G; Jeon H, 2001, NAT STRUCT BIOL, V8, P499, DOI 10.1038/88556; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KITA T, 1981, P NATL ACAD SCI-BIOL, V78, P2268, DOI 10.1073/pnas.78.4.2268; Kurniawan ND, 2000, PROTEIN SCI, V9, P1282, DOI 10.1110/ps.9.7.1282; Li YH, 2002, BIOCHEMISTRY-US, V41, P4921, DOI 10.1021/bi011894i; LINSE S, 1991, BIOCHEMISTRY-US, V30, P154, DOI 10.1021/bi00215a023; Malby S, 2001, BIOCHEMISTRY-US, V40, P2555, DOI 10.1021/bi002322l; North CL, 2000, BIOCHEMISTRY-US, V39, P2564, DOI 10.1021/bi992087a; Rand MD, 1997, PROTEIN SCI, V6, P2059; Reshef A, 1996, HUM GENET, V98, P581, DOI 10.1007/s004390050263; Robinson PN, 2000, J MED GENET, V37, P9, DOI 10.1136/jmg.37.1.9; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; Saha S, 2001, STRUCTURE, V9, P451, DOI 10.1016/S0969-2126(01)00606-2; Salazar LA, 2000, BRAZ J MED BIOL RES, V33, P1301, DOI 10.1590/S0100-879X2000001100006; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Thiart R, 2000, MOL CELL PROBE, V14, P299, DOI 10.1006/mcpr.2000.0318; Villeger L, 2002, HUM MUTAT, V20, P81, DOI 10.1002/humu.10102; Webb JC, 1996, J LIPID RES, V37, P368; Whiteman P, 1998, J BIOL CHEM, V273, P7807, DOI 10.1074/jbc.273.14.7807	42	15	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30611	30621		10.1074/jbc.M401412200	http://dx.doi.org/10.1074/jbc.M401412200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15100232	hybrid			2022-12-25	WOS:000222531900091
J	Das, I; Craig, C; Funahashi, Y; Jung, KM; Kim, TW; Byers, R; Weng, AP; Kutok, JL; Aster, JC; Kitajewski, J				Das, I; Craig, C; Funahashi, Y; Jung, KM; Kim, TW; Byers, R; Weng, AP; Kutok, JL; Aster, JC; Kitajewski, J			Notch Oncoproteins depend on gamma-secretase/presenilin activity for processing and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR DOMAIN; ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION; MAMMALIAN NOTCH; NEOPLASTIC TRANSFORMATION; INTRAMEMBRANE PROTEOLYSIS; NUCLEAR TRANSLOCATION; SECRETASE INHIBITORS; ACTIVATED NOTCH4; PLASMA-MEMBRANE	During normal development Notch receptor signaling is important in regulating numerous cell fate decisions. Mutations that truncate the extracellular domain of Notch receptors can cause aberrant signaling and promote unregulated cell growth. We have examined two types of truncated Notch oncoproteins that arise from proviral insertion into the Notch4 gene (Notch4/int-3) or a chromosomal translocation involving the Notch1 gene (TAN-1). Both Notch4/int-3 and TAN-1 oncoproteins lack most or all of their ectodomain. Normal Notch signaling requires gamma-secretase/presenilin-mediated proteolytic processing, but whether Notch oncoproteins are also dependent on gamma-secretase/presenilin activity is not known. We demonstrate that Notch4/int-3-induced activation of the downstream transcription factor, CSL, is abrogated in cells deficient in presenilins or treated with a pharmacological inhibitor of gamma-secretase/presenilins. Furthermore, we find that both Notch4/int-3 and TAN-1 accumulate at the cell surface, where presenilin-dependent cleavage occurs, when gamma-secretase/presenilin activity is inhibited. gamma-Secretase/presenilin inhibition effectively blocks cellular responses to Notch4/int-3, but not TAN-1, apparently because some TAN-1 polypeptides lack transmembrane domains and do not require gamma-secretase/presenilin activity for nuclear access. These studies highlight potential uses and limitations of gamma-secretase/presenilin inhibitors in targeted therapy of Notch-related neoplasms.	Columbia Univ Coll Phys & Surg, Dept Pathol & Obstet Gynecol, New York, NY 10032 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Columbia University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Kitajewski, J (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol & Obstet Gynecol, 630 W 168th St, New York, NY 10032 USA.	jkk9@columbia.edu	Aster, Jon C/B-6857-2009; Weng, Andrew P/I-5015-2014; Jung, Kwang-Mook/F-1035-2018	Jung, Kwang-Mook/0000-0003-4096-6953; Byers, Richard/0000-0003-0796-0365; craig, colleen/0000-0003-1308-6440; Weng, Andrew/0000-0001-7394-5425	NHLBI NIH HHS [HL-32454] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; ASTER JC, 1995, COLD SPRING HARB SYM, V49, P125; Berechid BE, 2002, J BIOL CHEM, V277, P8154, DOI 10.1074/jbc.M108238200; Berechid BE, 1999, CURR BIOL, V9, P1493, DOI 10.1016/S0960-9822(00)80121-9; Berezovska O, 2000, J NEUROCHEM, V75, P583, DOI 10.1046/j.1471-4159.2000.0750583.x; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Cai DM, 2003, J BIOL CHEM, V278, P3446, DOI 10.1074/jbc.M209065200; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Chen FS, 2003, J BIOL CHEM, V278, P19974, DOI 10.1074/jbc.M210049200; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hasserjian RP, 1996, BLOOD, V88, P970, DOI 10.1182/blood.V88.3.970.bloodjournal883970; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Krebs LT, 2000, GENE DEV, V14, P1343; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lauring AS, 2000, MOL CELL, V6, P939, DOI 10.1016/S1097-2765(05)00084-5; Lawson ND, 2001, DEVELOPMENT, V128, P3675; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Leong KG, 2002, MOL CELL BIOL, V22, P2830, DOI 10.1128/MCB.22.8.2830-2841.2002; Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; Mizutani T, 2001, P NATL ACAD SCI USA, V98, P9026, DOI 10.1073/pnas.161269998; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Rohn JL, 1998, J VIROL, V72, P2686, DOI 10.1128/JVI.72.4.2686-2696.1998; Saxena MT, 2001, J BIOL CHEM, V276, P40268, DOI 10.1074/jbc.M107234200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Shirayoshi Y, 1997, GENES CELLS, V2, P213, DOI 10.1046/j.1365-2443.1997.d01-310.x; SMITH SD, 1989, BLOOD, V73, P2182; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Taylor KL, 2002, MICROVASC RES, V64, P372, DOI 10.1006/mvre.2002.2443; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Uyttendaele H, 2000, MICROVASC RES, V60, P91, DOI 10.1006/mvre.2000.2254; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	67	63	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30771	30780		10.1074/jbc.M309252200	http://dx.doi.org/10.1074/jbc.M309252200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123653	hybrid			2022-12-25	WOS:000222531900108
J	Becker, HM; Deitmer, JW				Becker, HM; Deitmer, JW			Voltage dependence of H+ buffering mediated by sodium bicarbonate cotransport expressed in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROGENIC NA+-HCO3-COTRANSPORTER; LEECH GLIAL-CELLS; INTRACELLULAR PH; LAEVIS OOCYTES; CLONING; STOICHIOMETRY; TRANSPORTERS; BRAIN; NBC	The electrogenic sodium bicarbonate cotransporter (NBCe1) is expressed in many epithelial cells and, in the brain, in glial cells. Little is known about the physiological significance of the NBCe1 for proton homeostasis and for other acid/base-coupled transporters in these cells. We have measured the voltage-dependent transport activity of an NBC from human kidney, type hkNBCe1, expressed in oocytes of the frog Xenopus laevis, by recording membrane current and the changes in intracellular pH and sodium at different membrane potentials between - 20 and - 100 mV. The apparent intracellular buffer capacity was increased and became dependent upon membrane voltage when the NBCe1 was expressed; the measured buffer capacity increased by up to 7 mM/10 mV of membrane depolarization. Lactate transport by the electroneutral monocarboxylate transporter became enhanced and dependent upon membrane potential, when the monocarboxylate transporter ( isoform 1) was co-expressed with NBCe1 in oocytes. Our results indicate that the electrogenic NBCe1 renders the cell membrane potential an effective regulator of intracellular H+ buffering and acid/base-coupled metabolite transport.	Tech Univ Kaiserslautern, Fachbereich Biol, Abt Allgemeine Zool, D-67653 Kaiserslautern, Germany	University of Kaiserslautern	Deitmer, JW (corresponding author), Tech Univ Kaiserslautern, Fachbereich Biol, Abt Allgemeine Zool, Postfach 3049, D-67653 Kaiserslautern, Germany.	deitmer@rhrk.uni-kl.de	Becker, Holger/AAB-4322-2020					Amara SG, 2002, NEUROCHEM INT, V41, P313, DOI 10.1016/S0197-0186(02)00018-9; Becker HM, 2004, BIOPHYS J, V86, P235, DOI 10.1016/S0006-3495(04)74099-0; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; Broer S, 1998, BIOCHEM J, V333, P167, DOI 10.1042/bj3330167; BROER S, 1997, J BIOL CHEM, V272, P3096; Chesler M, 2003, PHYSIOL REV, V83, P1183, DOI 10.1152/physrev.00010.2003; Choi I, 1999, AM J PHYSIOL-CELL PH, V276, pC576, DOI 10.1152/ajpcell.1999.276.3.C576; Deitmer JW, 2000, BIOESSAYS, V22, P747, DOI 10.1002/1521-1878(200008)22:8<747::AID-BIES8>3.3.CO;2-S; DEITMER JW, 1995, J PHYSIOL-LONDON, V485, P157, DOI 10.1113/jphysiol.1995.sp020720; Deitmer JW, 2002, J NEUROCHEM, V80, P721, DOI 10.1046/j.0022-3042.2002.00765.x; DEITMER JW, 1991, J GEN PHYSIOL, V98, P637, DOI 10.1085/jgp.98.3.637; Gross E, 2001, J PHYSIOL-LONDON, V531, P597, DOI 10.1111/j.1469-7793.2001.0597h.x; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Heyer M, 1999, PFLUG ARCH EUR J PHY, V438, P322, DOI 10.1007/s004240050916; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; MUNSCH T, 1994, J PHYSIOL-LONDON, V474, P43, DOI 10.1113/jphysiol.1994.sp020001; Romero MF, 1999, ANNU REV PHYSIOL, V61, P699, DOI 10.1146/annurev.physiol.61.1.699; Schousboe A, 2000, NEUROCHEM RES, V25, P1241, DOI 10.1023/A:1007692012048; Sciortino CM, 1999, AM J PHYSIOL-RENAL, V277, pF611, DOI 10.1152/ajprenal.1999.277.4.F611; Soleimani M, 2001, J MEMBRANE BIOL, V183, P71, DOI 10.1007/s00232-001-0055-8; THOMAS RC, 1991, NATURE, V350, P564, DOI 10.1038/350564b0	21	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28057	28062		10.1074/jbc.M402401200	http://dx.doi.org/10.1074/jbc.M402401200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123668	hybrid			2022-12-25	WOS:000222265400030
J	Kang, SK; Chung, TW; Lee, JY; Lee, YC; Morton, RE; Kim, CH				Kang, SK; Chung, TW; Lee, JY; Lee, YC; Morton, RE; Kim, CH			The hepatitis B virus x protein inhibits secretion of apolipoprotein B by enhancing the expression of N-acetylglucosaminyltransferase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; RAT-LIVER CARCINOGENESIS; HEPG2 CELLS; HEPATOCELLULAR-CARCINOMA; APO-B; CONTAINING LIPOPROTEINS; INTRACELLULAR DEGRADATION; TRANSGENIC MICE; SUGAR CHAINS; HUMAN-SERUM	The X protein of hepatitis B virus (HBx) plays a major role on hepatocellular carcinoma (HCC). Apolipoprotein B ( apoB) in the liver is an important glycoprotein for transportation of very low density lipoproteins and low density lipoproteins. Although lipid accumulation in the liver is known as one of the factors for the HCC, the relationship between HBx and apoB during the HCC development is poorly understood. To better understand the biological significance of HBx in HCC, liver Chang cells that specifically express HBx were established and characterized. In this study we demonstrate that overexpression of HBx significantly up-regulates the expression of UDP-N-acetylglucosamine: beta-D-mannoside-1,4- N-acetylglucosaminyltransferase- III (GnT-III), an enzyme that functions as a bisecting-N-acetylglucosamine ( GlcNAc) transferase in apoB, and increases GnT-III promoter activity in a chloramphenicol acetyltransferase assay. GnT-III expression levels of HBx-transfected cells appeared to be higher than that of hepatocarcinoma cells as well as GnT-III-transfected cells, indicating that HBx may has a strong GnT-III promotor-enhancing activity. Intracellular levels of apoBs, which contained the increased bisecting GlcNAc, were accumulated in HBx-transfected liver cells. These cells as well as GnT-III-transfected liver cells revealed the inhibition of apoB secretion and the increased accumulation of intracellular triglyceride and cholesterol compared with vector-transfected cells. Moreover, overexpression of GnT-III and HBx in liver cells was shown to down-regulate the transcriptional level of microsomal triglyceride transfer protein, which regulates the assembly and secretion of apoB. Therefore, our study strongly suggested that the HBx increase in intracellular accumulation of aberrantly glycosylated apoB resulted in inhibition of secretion of apoB as well as intracellular lipid accumulation by elevating the expression of GnT-III.	Dongguk Univ, Coll Oriental Med, NRLG, Kyungju 780714, Kyungbuk, South Korea; Dongguk Univ, Coll Oriental Med, Dept Biochem & Mol Biol, Kyungju 780714, Kyungbuk, South Korea; Dong A Univ, Fac Biotechnol, Pusan 604714, South Korea; Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Dongguk University; Dongguk University; Dong A University; Cleveland Clinic Foundation	Kim, CH (corresponding author), Dongguk Univ, Coll Oriental Med, NRLG, Sukjang Dong 707, Kyungju 780714, Kyungbuk, South Korea.	chkimbio@dongguk.ac.kr		Kim, Cheorl-Ho/0000-0002-6323-0714; Chung, Tae-Wook/0000-0001-5243-5020				Avramoglu RK, 1995, J LIPID RES, V36, P2513; Benoist F, 1996, ARTERIOSCL THROM VAS, V16, P1229, DOI 10.1161/01.ATV.16.10.1229; Bullock C, 2000, METHOD ENZYMOL, V326, P202; Caselmann WH, 1998, HEPATITIS B VIRUS, P161; Chung TW, 2003, CANCER RES, V63, P3453; Colombo M, 1998, HEPATO-GASTROENTEROL, V45, P1221; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; Davis RA, 2001, ARTERIOSCL THROM VAS, V21, P887, DOI 10.1161/01.ATV.21.6.887; DAVIS RA, 1999, BIOCHIM BIOPHYS ACTA, V1441, P1; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Ginsberg HN, 1997, CLIN EXP PHARMACOL P, V24, pA29, DOI 10.1111/j.1440-1681.1997.tb03051.x; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; Ihara Y, 1998, P NATL ACAD SCI USA, V95, P2526, DOI 10.1073/pnas.95.5.2526; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHIBASHI K, 1989, CLIN CHIM ACTA, V185, P325, DOI 10.1016/0009-8981(89)90223-4; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; Kang BS, 1998, J BIOCHEM MOL BIOL, V31, P578; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim YJ, 1996, GENE, V170, P281, DOI 10.1016/0378-1119(95)00818-7; Koyama N, 1996, EUR J BIOCHEM, V238, P853, DOI 10.1111/j.1432-1033.1996.0853w.x; Lee J, 2004, ARCH BIOCHEM BIOPHYS, V426, P18, DOI 10.1016/j.abb.2003.12.039; MIYOSHI E, 1993, CANCER RES, V53, P3899; Mori S, 1998, J GASTROEN HEPATOL, V13, P610, DOI 10.1111/j.1440-1746.1998.tb00699.x; NARASIMHAN S, 1988, J BIOL CHEM, V263, P1273; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NISHIKAWA A, 1988, BIOCHEM BIOPH RES CO, V152, P107, DOI 10.1016/S0006-291X(88)80686-7; OHNO M, 1992, INT J CANCER, V51, P315, DOI 10.1002/ijc.2910510223; Olofsson SO, 1999, CURR OPIN LIPIDOL, V10, P341, DOI 10.1097/00041433-199908000-00008; PASCALE R, 1989, CARCINOGENESIS, V10, P961, DOI 10.1093/carcin/10.5.961; PULLINGER CR, 1989, J LIPID RES, V30, P1065; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; SERAFINICESSI F, 1979, BIOCHEM J, V183, P381, DOI 10.1042/bj1830381; Song EY, 2000, BIOTECHNOL LETT, V22, P201, DOI 10.1023/A:1005641115696; Song EY, 2001, CANCER INVEST, V19, P799, DOI 10.1081/CNV-100107741; SONG EY, 2003, GLYCOCONJ J, V9, P1415; SWAMINATHAN N, 1976, BIOCHEMISTRY-US, V15, P1516, DOI 10.1021/bi00652a024; TANIGUCHI N, 1999, BIOCHIM BIOPHYS ACTA, V455, P287; TANIGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V273, P197, DOI 10.1016/0003-9861(89)90179-3; TIOLLAIS P, 1981, SCIENCE, V213, P406, DOI 10.1126/science.6264599; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Wilcox LJ, 1999, ARTERIOSCL THROM VAS, V19, P939, DOI 10.1161/01.ATV.19.4.939; Wilcox LJ, 1999, J LIPID RES, V40, P1078; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; YAMASHITA K, 1983, J BIOL CHEM, V258, P4753; YAMASHITA K, 1983, CANCER RES, V43, P5059; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; Yao ZM, 1997, J LIPID RES, V38, P1937; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754	56	57	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28106	28112		10.1074/jbc.M403176200	http://dx.doi.org/10.1074/jbc.M403176200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123606	hybrid			2022-12-25	WOS:000222265400036
J	Roy, AK; Korkaya, H; Oberoi, R; Lal, SK; Jameel, S				Roy, AK; Korkaya, H; Oberoi, R; Lal, SK; Jameel, S			The hepatitis E virus open reading frame 3 protein activates ERK through binding and inhibition of the MAPK phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; DUAL-SPECIFICITY PHOSPHATASE; ORF3 PROTEIN; CORE PROTEIN; KINASE-C; SIGNAL-TRANSDUCTION; FULMINANT-HEPATITIS; MOLECULAR-CLONING; VIRAL-HEPATITIS; EXPRESSION	The hepatitis E virus causes acute viral hepatitis endemic in much of the developing world and is a serious public health problem. However, due to the lack of an in vitro culture system or a small animal model, its biology and pathogenesis are poorly understood. We have shown earlier that the ORF3 protein (pORF3) of hepatitis E virus activates ERK, a member of the MAPK superfamily. Here we have explored the mechanism of pORF3-mediated ERK activation and demonstrated it to be independent of the Raf/MEK pathway. Using biochemical assays, yeast two-hybrid analysis, and intracellular fluorescence resonance energy transfer we showed that pORF3 binds Pyst1, a prototypic member of the ERK-specific MAPK phosphatase. The binding regions in the two proteins were mapped to the N terminus of pORF3 and a central portion of Pyst1. Expression of pORF3 protected ERK from the inhibitory effects of ectopically expressed Pyst1. This is the first example of a viral protein regulating ERK activation by inhibition of its cognate dual specificity phosphatase.	ICGEB, Virol Grp, New Delhi 110067, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Jameel, S (corresponding author), ICGEB, Virol Grp, Aruna Asaf Marg, New Delhi 110067, India.	shahid@icgeb.res.in	Korkaya, Hasan/C-2201-2009; Korkaya, Hasan/ABD-6282-2020; Korkaya, Hasan/GRY-1016-2022	Korkaya, Hasan/0000-0002-0719-5862; 	Wellcome Trust [063171] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Agrawal S, 2001, VIROLOGY, V282, P87, DOI 10.1006/viro.2000.0819; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALESSI DR, 1993, ONCOGENE, V8, P2015; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; DAVIS RJ, 2000, SIGNALING NETWORKS C, P3219; Farooq A, 2001, MOL CELL, V7, P387, DOI 10.1016/S1097-2765(01)00186-1; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fukuda K, 2001, HEPATOLOGY, V33, P159, DOI 10.1053/jhep.2001.20794; Giambartolomei S, 2001, ONCOGENE, V20, P2606, DOI 10.1038/sj.onc.1204372; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Hayashi J, 2000, HEPATOLOGY, V32, P958, DOI 10.1053/jhep.2000.19343; Hildt E, 2002, EMBO J, V21, P525, DOI 10.1093/emboj/21.4.525; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jameel S, 1996, J VIROL, V70, P207, DOI 10.1128/JVI.70.1.207-216.1996; Kabrane-Lazizi Y, 1999, J VIROL, V73, P8848, DOI 10.1128/JVI.73.10.8848-8850.1999; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KHUROO MS, 1981, AM J MED, V70, P252, DOI 10.1016/0002-9343(81)90758-0; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOONIN EV, 1992, P NATL ACAD SCI USA, V89, P8259, DOI 10.1073/pnas.89.17.8259; Korkaya H, 2001, J BIOL CHEM, V276, P42389, DOI 10.1074/jbc.M101546200; KRAWCZYNSKI K, 1993, HEPATOLOGY, V17, P932, DOI 10.1002/hep.1840170525; LAU JYN, 1995, J HEPATOL, V22, P605, DOI 10.1016/0168-8278(95)80215-0; Li TC, 1997, J VIROL, V71, P7207, DOI 10.1128/JVI.71.10.7207-7213.1997; Li TC, 2001, VACCINE, V19, P3476, DOI 10.1016/S0264-410X(01)00059-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MENZO S, 1993, VIROLOGY, V196, P878, DOI 10.1006/viro.1993.1550; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; NANDA SK, 1994, J MED VIROL, V42, P133, DOI 10.1002/jmv.1890420207; NAYAK NC, 1989, J GASTROEN HEPATOL, V4, P345, DOI 10.1111/j.1440-1746.1989.tb00846.x; NORTHOVER BJ, 1992, BIOCHEM PHARMACOL, V44, P425, DOI 10.1016/0006-2952(92)90432-I; O'Brien V, 1998, J GEN VIROL, V79, P1833, DOI 10.1099/0022-1317-79-8-1833; Purcell R.H., 2001, FIELDS VIROLOGY, P3051; PURCELL RH, 1988, VIRAL HEPATITIS LIVE, P131; RAMALINGASWAMI V, 1988, LANCET, V1, P571; Rescan C, 2001, MOL BIOL CELL, V12, P725, DOI 10.1091/mbc.12.3.725; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; ROSENBERG IM, 1996, PROTEIN ANAL PURIFIC, P343; Siegel R. M., 2000, SCI STKE, V2000, ppl1; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; TAM AW, 1991, VIROLOGY, V185, P120, DOI 10.1016/0042-6822(91)90760-9; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2002, J BIOL CHEM, V277, P22942, DOI 10.1074/jbc.M202096200; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Truong K, 2001, CURR OPIN STRUC BIOL, V11, P573, DOI 10.1016/S0959-440X(00)00249-9; Tyagi S, 2002, J BIOL CHEM, V277, P22759, DOI 10.1074/jbc.M200185200; Tyagi S, 2001, J VIROL, V75, P2493, DOI 10.1128/JVI.75.5.2493-2498.2001; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; ZACHARIAS DA, 2002, SCI STKE; Zafrullah M, 1997, J VIROL, V71, P9045, DOI 10.1128/JVI.71.12.9045-9053.1997; Zafrullah M, 1999, J VIROL, V73, P4074, DOI 10.1128/JVI.73.5.4074-4082.1999; Zhang MD, 2002, VACCINE, V20, P3285, DOI 10.1016/S0264-410X(02)00314-6; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; [No title captured]	73	65	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28345	28357		10.1074/jbc.M400457200	http://dx.doi.org/10.1074/jbc.M400457200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15096509	hybrid, Green Accepted			2022-12-25	WOS:000222265400067
J	Abbing, A; Blaschke, UK; Grein, S; Kretschmar, M; Stark, CMB; Thies, MJW; Walter, J; Weigand, M; Woith, DC; Hess, J; Reiser, COA				Abbing, A; Blaschke, UK; Grein, S; Kretschmar, M; Stark, CMB; Thies, MJW; Walter, J; Weigand, M; Woith, DC; Hess, J; Reiser, COA			Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR CAPSID PROTEIN; VIRUS-LIKE PARTICLES; MURINE POLYOMAVIRUS; ESCHERICHIA-COLI; GENE DELIVERY; IN-VITRO; METHOTREXATE; VP1; METABOLISM; RESOLUTION	Efficient encapsulation of foreign molecules like proteins and low molecular weight drugs into polyoma virus-like particles (capsoids) was achieved by the development of an anchoring technique based upon the specific interaction of the inner core protein VP2 with VP1 pentamers. A stretch of 49 amino acids of VP2 served as an anchor molecule, either expressed as a fusion protein with green fluorescent protein (GFP) or covalently linked to methotrexate (MTX). The loaded capsoids showed regular morphology and stability for several months. GFP and MTX were internalized into cells in vitro, as was demonstrated by the detection of GFP and VP1 fluorescence in mouse fibroblasts and the cytostatic effect of intracellularly released MTX on leukemia T cells.	Responsif GmbH, D-91056 Erlangen, Germany; November AG, D-91056 Erlangen, Germany		Hess, J (corresponding author), Responsif GmbH, Schallershofer Str 84, D-91056 Erlangen, Germany.	hess@responsif.de						An K, 2000, J VIROL METHODS, V84, P153, DOI 10.1016/S0166-0934(99)00137-8; BAROUCH DH, 1994, J VIROL, V68, P3982, DOI 10.1128/JVI.68.6.3982-3989.1994; Bertino JR, 1996, STEM CELLS, V14, P5, DOI 10.1002/stem.140005; BRADY JN, 1978, J VIROL, V27, P193, DOI 10.1128/JVI.27.1.193-204.1978; Braun H, 1999, BIOTECHNOL APPL BIOC, V29, P31; BRINKMAN M, 2004, LETT DRUG DES DISCOV, V1, P137; Calvert H, 1999, SEMIN ONCOL, V26, P3; Chen XJS, 1998, EMBO J, V17, P3233, DOI 10.1093/emboj/17.12.3233; Dawson PE, 2000, ANNU REV BIOCHEM, V69, P923, DOI 10.1146/annurev.biochem.69.1.923; Goldmann C, 2000, J VIROL METHODS, V90, P85, DOI 10.1016/S0166-0934(00)00226-3; GRIFFITH JP, 1992, NATURE, V355, P652, DOI 10.1038/355652a0; GUENTHER K, 2001, FASEB J         0509, DOI DOI 10.1096/FJ.00-0645FJE; Gunther C, 2001, FASEB J, V15, P1646, DOI 10.1096/fj.00-0645fje; Harris Jr, 1999, METH MOL B, V117, P13; Henke S, 2000, PHARMACEUT RES, V17, P1062, DOI 10.1023/A:1026497411053; Hong MS, 2002, J PHARM PHARMACOL, V54, P51, DOI 10.1211/0022357021771913; Konigsberg PJ, 1998, BBA-BIOMEMBRANES, V1370, P243, DOI 10.1016/S0005-2736(97)00269-1; Krauzewicz N, 2000, GENE THER, V7, P1094, DOI 10.1038/sj.gt.3301219; KUEFNER U, 1990, BIOCHEMISTRY-US, V29, P10540, DOI 10.1021/bi00498a017; LEAVITT AD, 1985, J BIOL CHEM, V260, P2803; MICHAEL SI, 1994, GENE THER, V1, P223; MONTROSS L, 1991, J VIROL, V65, P4991, DOI 10.1128/JVI.65.9.4991-4998.1991; NG KY, 1989, BIOCHIM BIOPHYS ACTA, V981, P261; RAYMENT I, 1982, NATURE, V295, P110, DOI 10.1038/295110a0; Richterova Z, 2001, J VIROL, V75, P10880, DOI 10.1128/JVI.75.22.10880-10891.2001; Riebeseel K, 2002, BIOCONJUGATE CHEM, V13, P773, DOI 10.1021/bc010098m; ROSOWSKY A, 1978, J MED CHEM, V21, P170, DOI 10.1021/jm00200a005; SALUNKE DM, 1986, CELL, V46, P895, DOI 10.1016/0092-8674(86)90071-1; Schmidt U, 2000, J VIROL, V74, P1658, DOI 10.1128/JVI.74.4.1658-1662.2000; Severinov K, 1998, J BIOL CHEM, V273, P16205, DOI 10.1074/jbc.273.26.16205; Stehle T, 1996, STRUCTURE, V4, P165, DOI 10.1016/S0969-2126(96)00020-2; Stehle T, 1996, STRUCTURE, V4, P183, DOI 10.1016/S0969-2126(96)00021-4; STEHLE T, 1994, NATURE, V369, P160, DOI 10.1038/369160a0; Weigand M, 2001, ANTI-CANCER DRUG DES, V16, P227; WRIGHT JE, 1987, BIOCHEM PHARMACOL, V36, P2209, DOI 10.1016/0006-2952(87)90152-3; Yang YW, 2000, BIOTECHNOL APPL BIOC, V32, P73, DOI 10.1042/BA20000024	36	77	93	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27410	27421		10.1074/jbc.M313612200	http://dx.doi.org/10.1074/jbc.M313612200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102846	hybrid			2022-12-25	WOS:000222120400072
J	Lee, HHC; Choi, RCY; Ting, AKL; Siow, NL; Jiang, JXS; Massoulie, J; Tsim, KWK				Lee, HHC; Choi, RCY; Ting, AKL; Siow, NL; Jiang, JXS; Massoulie, J; Tsim, KWK			Transcriptional regulation of acetylcholinesterase-associated collagen ColQ - Differential expression in fast and slow twitch muscle fibers is driven by distinct promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GENE-EXPRESSION; CHICK MUSCLE; TAILED FORMS; SUBUNIT; STABILITY; SEQUENCES; KINASE; DOMAIN; LEVEL; RAT	The presence of a collagenous protein ( ColQ) characterizes the collagen-tailed forms of acetylcholinesterase and butyrylcholinesterase at vertebrate neuromuscular junctions which is tethered in the synaptic basal lamina. ColQ subunits, differing mostly by their signal sequences, are encoded by transcripts ColQ-1 and ColQ-1a, which are differentially expressed in slow and fast twitch muscles in mammals. Two distinct promoters, pColQ-1 and pColQ-1a, were isolated from the upstream sequences of human COLQ gene; they showed muscle-specific expression and were activated by myogenic transcriptional elements in cultured myotubes. After in vivo DNA transfection, pColQ-1 showed strong activity in slow twitch muscle ( e. g. soleus), whereas pColQ-1a was preferably expressed in fast twitch muscle ( e. g. tibialis). Mutation analysis of the ColQ promoters suggested that the muscle fiber type-specific expression pattern of ColQ transcripts were regulated by a slow upsteam regulatory element ( SURE) and a fast intronic regulatory element ( FIRE). These regulatory elements were responsive to a calcium ionophore and to calcineurin inhibition by cyclosporine A. The slow fiber type-specific expression of ColQ-1 was abolished by the mutation of an NFAT element in pColQ-1. Moreover, both the ColQ promoters contained N-box element that was responsible for the synapse-specific expression of ColQ transcripts. These results explain the specific expression patterns of collagen-tailed acetylcholinesterase in slow and fast muscle fibers.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Kowloon, Hong Kong, Peoples R China; Ecole Normale Super, CNRS, UMR 8544, Neurobiol Cellulaire & Mol Lab, F-75005 Paris, France	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Tsim, KWK (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Clear Water Bay Rd, Kowloon, Hong Kong, Peoples R China.	botsim@ust.hk	Lee, Henry HC/S-6014-2016; Lee, Henry/GVS-2114-2022	Lee, Henry HC/0000-0003-4975-7330; Tsim, Karl/0000-0003-4808-1674				Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; Angus LM, 2001, J BIOL CHEM, V276, P17603, DOI 10.1074/jbc.M100916200; Bon S, 1997, J BIOL CHEM, V272, P3016, DOI 10.1074/jbc.272.5.3016; Boudreau-Lariviere C, 2000, AM J PHYSIOL-REG I, V278, pR140, DOI 10.1152/ajpregu.2000.278.1.R140; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calvo S, 2001, MOL CELL BIOL, V21, P8490, DOI 10.1128/MCB.21.24.8490-8503.2001; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Choi RCY, 2001, J NEUROSCI, V21, P9224, DOI 10.1523/JNEUROSCI.21-23-09224.2001; Choi RCY, 2003, J NEUROSCI, V23, P4445; CRESNAR B, 1994, J NEUROSCI RES, V38, P294, DOI 10.1002/jnr.490380307; Deprez P, 2003, J BIOL CHEM, V278, P23233, DOI 10.1074/jbc.M301384200; Donger C, 1998, AM J HUM GENET, V63, P967, DOI 10.1086/302059; DUCLERT A, 1995, PHYSIOL REV, V75, P339, DOI 10.1152/physrev.1995.75.2.339; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Feng GP, 1999, J CELL BIOL, V144, P1349, DOI 10.1083/jcb.144.6.1349; FERNANDEZ HL, 1984, NEUROSCI LETT, V44, P187, DOI 10.1016/0304-3940(84)90079-X; GISIGER V, 1988, J NEUROSCI RES, V19, P62, DOI 10.1002/jnr.490190110; GLANTZ SA, 1988, PRIMER BIOSTATISTICS; Gramolini AO, 2001, AM J PHYSIOL-CELL PH, V281, pC1300, DOI 10.1152/ajpcell.2001.281.4.C1300; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Jiang JXS, 2003, J BIOL CHEM, V278, P45435, DOI 10.1074/jbc.M306320200; Krejci E, 1997, J BIOL CHEM, V272, P22840, DOI 10.1074/jbc.272.36.22840; KREJCI E, 1991, EMBO J, V10, P1285, DOI 10.1002/j.1460-2075.1991.tb08070.x; Krejci E, 1999, J NEUROSCI, V19, P10672, DOI 10.1523/JNEUROSCI.19-24-10672.1999; LAI J, 1986, NATURE, V321, P72, DOI 10.1038/321072a0; Legay C, 1999, J NEUROSCI, V19, P8252; LEGAY C, 1995, EUR J NEUROSCI, V7, P1803, DOI 10.1111/j.1460-9568.1995.tb00699.x; Luo ZD, 1999, MOL PHARMACOL, V56, P886, DOI 10.1124/mol.56.5.886; Macpherson P, 2002, J BIOL CHEM, V277, P15638, DOI 10.1074/jbc.M109864200; Massoulie J, 2002, NEUROSIGNALS, V11, P130, DOI 10.1159/000065054; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MCMAHAN UJ, 1978, NATURE, V271, P172, DOI 10.1038/271172a0; Meissner JD, 2001, J PHYSIOL-LONDON, V533, P215, DOI 10.1111/j.1469-7793.2001.0215b.x; Mineo C, 1997, J BIOL CHEM, V272, P10345; Nakayama M, 1996, MOL CELL BIOL, V16, P2408; Ohno K, 1998, P NATL ACAD SCI USA, V95, P9654, DOI 10.1073/pnas.95.16.9654; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; PUN S, 1995, NEUROSCI LETT, V198, P107, DOI 10.1016/0304-3940(95)11974-2; Sambrook J, 2001, MOL CLONING LAB MANU; Schaeffer L, 2001, NEURON, V31, P15, DOI 10.1016/S0896-6273(01)00353-1; Serrano AL, 2001, P NATL ACAD SCI USA, V98, P13108, DOI 10.1073/pnas.231148598; SILMAN I, 1978, FEBS LETT, V94, P166, DOI 10.1016/0014-5793(78)80929-6; Siow NL, 2002, J BIOL CHEM, V277, P36129, DOI 10.1074/jbc.M206498200; SKETELJ J, 1985, J NEUROSCI RES, V14, P95, DOI 10.1002/jnr.490140109; Sketelj J, 1998, J NEUROSCI, V18, P1944; Swoap SJ, 2000, AM J PHYSIOL-CELL PH, V279, pC915, DOI 10.1152/ajpcell.2000.279.4.C915; TSIM KWK, 1988, P NATL ACAD SCI USA, V85, P1262, DOI 10.1073/pnas.85.4.1262; WALKE W, 1994, J BIOL CHEM, V269, P19447	50	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27098	27107		10.1074/jbc.M402596200	http://dx.doi.org/10.1074/jbc.M402596200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102835	hybrid			2022-12-25	WOS:000222120400036
J	Luo, BH; Strokovich, K; Walz, T; Springer, TA; Takagi, J				Luo, BH; Strokovich, K; Walz, T; Springer, TA; Takagi, J			Allosteric beta(1) integrin antibodies that stabilize the low affinity state by preventing the swing-out of the hybrid domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN MONOCLONAL-ANTIBODY; FIBRONECTIN RECEPTOR; CONFORMATIONAL-CHANGES; REGULATORY REGION; BINDING SITES; CELL-ADHESION; ACTIVATION; SUBUNIT; EPITOPE; IDENTIFICATION	The ligand binding function of integrins can be modulated by various monoclonal antibodies by both direct and indirect mechanisms. We have characterized an anti-beta(1) antibody, SG/19, that had been reported to inhibit the function of the beta(1) integrin on the cell surface. SG/19 recognized the wild type beta(1) subunit that exists in a conformational equilibrium between the high and low affinity states but bound poorly to a mutant beta(1) integrin that had been locked in a high affinity state. Epitope mapping of SG/19 revealed that Thr(82) in the beta(1) subunit, located at the outer face of the boundary between the I-like and hybrid domains, was the key binding determinant for this antibody. Direct visualization of the alpha(5)beta(1) headpiece fragment in complex with SG/19 Fab with electron microscopy confirmed the location of the binding surface and showed that the ligand binding site is not occluded by the bound Fab. Surface plasmon resonance showed that alpha(5)beta(1) integrin bound by SG/19 maintained a low affinity toward its physiological ligand fibronectin (Fn) whereas binding by function-blocking anti-alpha(5) antibodies resulted in a complete loss of fibronectin binding. Thus a class of the anti-beta antibodies represented by SG/19 attenuate the ligand binding function by restricting the conformational shift to the high affinity state involving the swing-out of the hybrid domain without directly interfering with ligand docking.	Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Osaka Univ, Inst Prot Res, Lab Prot Synth & Express, Osaka 5650871, Japan	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Osaka University	Takagi, J (corresponding author), Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA.	takagi@protein.osaka-u.ac.jp		Walz, Thomas/0000-0003-2606-2835	NHLBI NIH HHS [HL48675] Funding Source: Medline; NIGMS NIH HHS [GM62580] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM062580] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Billheimer JT, 2002, BLOOD, V99, P3540, DOI 10.1182/blood.V99.10.3540; CAIXIA S, 1991, CELL IMMUNOL, V138, P216, DOI 10.1016/0008-8749(91)90146-3; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; GROUX H, 1989, NATURE, V339, P152, DOI 10.1038/339152a0; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Luo BH, 2004, J BIOL CHEM, V279, P10215, DOI 10.1074/jbc.M312732200; Luo BH, 2003, P NATL ACAD SCI USA, V100, P2403, DOI 10.1073/pnas.0438060100; LUO BH, 2004, IN PRESS PLOS BIOL; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; MIYAKE K, 1992, J CELL BIOL, V119, P653, DOI 10.1083/jcb.119.3.653; MIYAKE K, 1994, INT IMMUNOL, V6, P1221, DOI 10.1093/intimm/6.8.1221; Mould AP, 2003, J BIOL CHEM, V278, P17028, DOI 10.1074/jbc.M213139200; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; Mould AP, 1996, J CELL SCI, V109, P2613; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PETRUZZELLI L, 1995, LEUCOCYTE TYPING, V5, P1581; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Tsuchida J, 1998, J CELL SCI, V111, P1759; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881	37	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27466	27471		10.1074/jbc.M404354200	http://dx.doi.org/10.1074/jbc.M404354200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15123676	Green Published, hybrid			2022-12-25	WOS:000222120400078
J	Yamashita, M; Ukai-Tadenuma, M; Miyamoto, T; Sugaya, K; Hosokawa, H; Hasegawa, A; Kimura, M; Taniguchi, M; DeGregori, J; Nakayama, T				Yamashita, M; Ukai-Tadenuma, M; Miyamoto, T; Sugaya, K; Hosokawa, H; Hasegawa, A; Kimura, M; Taniguchi, M; DeGregori, J; Nakayama, T			Essential role of GATA3 for the maintenance of type 2 helper T (Th2) cytokine production and chromatin remodeling at the Th2 cytokine gene loci	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-3; CELL-DIFFERENTIATION; HISTONE H3; CUTTING EDGE; DNA METHYLATION; IL-4 PRODUCTION; IN-VIVO; EXPRESSION; ACTIVATION; RECEPTOR	GATA3 expression is essential for type-2 helper T (Th2) cell differentiation. GATA3-mediated chromatin remodeling at the Th2 cytokine gene loci, including Th2-specific long range histone hyperacetylation of the interleukin (IL)-13/IL-4 gene loci, occurs in developing Th2 cells. However, little is known about the role of GATA3, if any, in the maintenance of established remodeled chromatin at the Th2 cytokine gene loci. Here, we established a Cre/LoxP-based site-specific recombination system in cultured CD4 T cells using a unique adenovirus-mediated gene transfer technique. This system allowed us to investigate the effect of loss of GATA3 expression in in vitro differentiated Th2 cells. After ablation of GATA3, we detected reduced production of all Th2 cytokines, increased DNA methylation at the IL- 4 gene locus, and decreased histone hyperacetylation at the IL- 5 gene locus but not significantly so at the IL-13/IL-4 gene loci. Thus, GATA3 plays important roles in the maintenance of the Th2 phenotype and continuous chromatin remodeling of the specific Th2 cytokine gene locus through cell division.	Chiba Univ, Grad Sch Med, Dept Immunol, Chuo Ku, Chiba 2608670, Japan; Japan Sci & Technol Corp, PRESTO Project, Chuo Ku, Chiba 2608670, Japan; RIKEN Res Ctr Allergy & Immunol, Lab Immune Regulat, Yokohama, Kanagawa 2300045, Japan; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	Chiba University; Japan Science & Technology Agency (JST); RIKEN; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Nakayama, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Immunol, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	tnakayama@faculty.chiba-u.jp	Taniguchi, Masaru/N-7932-2015; Nakayama, Toshinori/E-1067-2017	Taniguchi, Masaru/0000-0001-7821-7179; Nakayama, Toshinori/0000-0002-1434-2007; Hosokawa, Hiroyuki/0000-0002-9592-2889; DeGregori, James/0000-0002-1287-1976; Sugaya, Kiminobu/0000-0002-2788-5457	NCI NIH HHS [R01 CA077314, R01 CA077314-06, R01 CA77314] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077314] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Agarwal S, 1998, CURR OPIN IMMUNOL, V10, P345, DOI 10.1016/S0952-7915(98)80174-X; Asnagli H, 2002, J IMMUNOL, V168, P4268, DOI 10.4049/jimmunol.168.9.4268; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; Dent AL, 1998, P NATL ACAD SCI USA, V95, P13823, DOI 10.1073/pnas.95.23.13823; Farrar JD, 2001, J EXP MED, V193, P643, DOI 10.1084/jem.193.5.643; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Finkelman FD, 2000, J IMMUNOL, V164, P2303, DOI 10.4049/jimmunol.164.5.2303; Goll MG, 2002, GENE DEV, V16, P1739, DOI 10.1101/gad.1013902; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Guo LY, 2002, P NATL ACAD SCI USA, V99, P10623, DOI 10.1073/pnas.162360199; Hutchins AS, 2002, MOL CELL, V10, P81, DOI 10.1016/S1097-2765(02)00564-6; INAMI M, 2004, J BIOL CHEM; Jankovic D, 2000, J IMMUNOL, V164, P3047, DOI 10.4049/jimmunol.164.6.3047; Kanegae Y, 1996, GENE, V181, P207, DOI 10.1016/S0378-1119(96)00516-1; Kaplan MH, 1999, J IMMUNOL, V163, P6536; Kimura M, 2001, IMMUNITY, V15, P275, DOI 10.1016/S1074-7613(01)00182-0; Kishikawa H, 2001, J IMMUNOL, V167, P4414, DOI 10.4049/jimmunol.167.8.4414; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lavenu-Bombled C, 2002, J BIOL CHEM, V277, P18313, DOI 10.1074/jbc.M110013200; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; NAKAYAMA T, 1990, SCIENCE, V249, P1558, DOI 10.1126/science.2120773; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; O'Garra A, 2000, NATURE, V404, P719, DOI 10.1038/35008191; Omori M, 2003, IMMUNITY, V19, P281, DOI 10.1016/S1074-7613(03)00210-3; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takemoto N, 2000, J IMMUNOL, V165, P6687, DOI 10.4049/jimmunol.165.12.6687; Tamaru H, 2003, NAT GENET, V34, P75, DOI 10.1038/ng1143; Wan YY, 2000, P NATL ACAD SCI USA, V97, P13784, DOI 10.1073/pnas.250356297; Yamashita M, 1999, P NATL ACAD SCI USA, V96, P1024, DOI 10.1073/pnas.96.3.1024; Yamashita M, 2002, J BIOL CHEM, V277, P42399, DOI 10.1074/jbc.M205876200; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	47	122	127	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26983	26990		10.1074/jbc.M403688200	http://dx.doi.org/10.1074/jbc.M403688200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15087456	hybrid			2022-12-25	WOS:000222120400024
J	Serakinci, N; Guldberg, P; Burns, JS; Abdallah, B; Schrodder, H; Jensen, T; Kassem, M				Serakinci, N; Guldberg, P; Burns, JS; Abdallah, B; Schrodder, H; Jensen, T; Kassem, M			Adult human mesenchymal stem cell as a target for neoplastic transformation	ONCOGENE			English	Article						mesenchymal stem cells; transformation; telomerase	TELOMERASE EXPRESSION; EPITHELIAL-CELLS; BRAIN-TUMORS; CANCER; IMMORTALIZATION; MARROW; MECHANISMS; BMI-1	The neoplastic process may involve a cancer stem cell. This concept has emerged largely from the careful analysis of tumour biopsy systems from haematological, breast and brain tumours. However, the experimental systems necessary to provide the cellular and molecular evidence to support this important concept have been lacking. We have used adult mesenchymal stem cells (hMSC) transduced with the telomerase hTERT gene to investigate the neoplastic potential of adult stem cells. The hTERT-transduced line, hMSC-TERT20 at population doubling level (PDL) 256 showed loss of contact inhibition, anchorage independence and formed tumours in 10/10 mice. hMSC-TERT4 showed loss of contact inhibition at PDL 95, but did not exhibit anchorage independence and did not form tumours in mice. Both lines had a normal karyotype but showed deletion of the Ink4a/ARF locus. At later passage, hMSC-TERT4 also acquired an activating mutation in KRAS. In hMSC-TERT20, expression of the cell cycle-associated gene, DBCCR1 was lost due to promoter hypermethylation. This epigenetic event correlated with acquisition of tumorigenicity. These data suggest that the adult hMSCs can be targets for neoplastic transformation and have implications for the development of novel anticancer therapeutics and for the use of hMSC in tissue engineering and transplantation protocols.	Aarhus Univ, Dept Human Genet, DK-8000 Aarhus C, Denmark; Odense Univ Hosp, Dept Endocrinol, Odense, Denmark; Danish Canc Soc, Inst Canc Biol, Copenhagen, Denmark; Odense Univ Hosp, Inst Pathol, Odense, Denmark	Aarhus University; University of Southern Denmark; Odense University Hospital; Danish Cancer Society; University of Southern Denmark; Odense University Hospital	Serakinci, N (corresponding author), Aarhus Univ, Dept Human Genet, Bartholin Bldg,Univ Pk, DK-8000 Aarhus C, Denmark.	nedi@humgen.au.dk	Abdallah, Basem/G-5667-2017; Burns, Jorge S./J-3395-2012; Kassem, Moustapha/J-7688-2013; Kassem, Moustapha/O-3819-2019; Schrøder, Henrik Daa/E-2077-2013; Burns, Jorge/AAF-5291-2019	Abdallah, Basem/0000-0003-0324-8055; Burns, Jorge S./0000-0002-8602-1536; Kassem, Moustapha/0000-0003-1557-0869; Kassem, Moustapha/0000-0003-1557-0869; Schrøder, Henrik Daa/0000-0001-7588-235X; SERAKINCI, Nedime/0000-0002-1884-0839				AHAJJ M, 2003, P NATL ACAD SCI USA, V100, P3983; Collas P, 2003, TRENDS BIOTECHNOL, V21, P354, DOI 10.1016/S0167-7799(03)00147-1; Dick JE, 2003, P NATL ACAD SCI USA, V100, P3547, DOI 10.1073/pnas.0830967100; Gronbaek K, 2000, LEUKEMIA, V14, P1727, DOI 10.1038/sj.leu.2401901; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Hahn WC, 2001, ANN MED, V33, P123, DOI 10.3109/07853890109002067; Hamad NM, 2002, ONCOGENE, V21, P7121, DOI 10.1038/sj.onc.1205860; Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Korbling M, 2003, NEW ENGL J MED, V349, P570, DOI 10.1056/NEJMra022361; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lundberg AS, 2002, ONCOGENE, V21, P4577, DOI 10.1038/sj.onc.1205550; Mackall CL, 2002, CANCER CELL, V2, P175, DOI 10.1016/S1535-6108(02)00132-0; Milyavsky M, 2003, CANCER RES, V63, P7147; Nishiyama H, 2001, ONCOGENE, V20, P2956, DOI 10.1038/sj.onc.1204432; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Perez-Losada J, 2003, NAT REV CANCER, V3, P434, DOI 10.1038/nrc1095; Preston SL, 2003, J CLIN PATHOL-MOL PA, V56, P86, DOI 10.1136/mp.56.2.86; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Shi ST, 2002, NAT BIOTECHNOL, V20, P587, DOI 10.1038/nbt0602-587; Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602-592; Singh SK, 2003, CANCER RES, V63, P5821; Wang J, 2000, NATURE, V405, P755, DOI 10.1038/35015674	27	281	310	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5095	5098		10.1038/sj.onc.1207651	http://dx.doi.org/10.1038/sj.onc.1207651			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15107831				2022-12-25	WOS:000222237300017
J	Mammoto, A; Huang, S; Moore, K; Oh, P; Ingber, DE				Mammoto, A; Huang, S; Moore, K; Oh, P; Ingber, DE			Role of RhoA, mDia, and ROCK in cell shape-dependent control of the Skp2-p27(kip1) pathway and the G(1)/S transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR; CYCLIN D1; RETINOBLASTOMA PROTEIN; P27(KIP1) DEGRADATION; MYOSIN PHOSPHATASE; GEOMETRIC CONTROL; CDC42 GTPASES; FORMIN MDIA1	Cell shape-dependent control of cell-cycle progression underlies the spatial differentials of growth that drive tissue morphogenesis, yet little is known about how cell distortion impacts the biochemical signaling machinery that is responsible for growth control. Here we show that the Rho family GTPase, RhoA, conveys the "cell shape signal" to the cell-cycle machinery in human capillary endothelial cells. Cells accumulating p27(kip1) and arrested in mid G(1) phase when spreading were inhibited by restricted extracellular matrix adhesion, whereas constitutively active RhoA increased expression of the F-box protein Skp2 required for ubiquitination-dependent degradation of p27(kip1) and restored G1 progression in these cells. Studies with dominant-negative and constitutively active forms of mDia1, a downstream effector of RhoA, and with a pharmacological inhibitor of ROCK, another RhoA target, revealed that RhoA promoted G1 progression by altering the balance of activities between these two downstream effectors. These data indicate that signaling proteins such as mDia1 and ROCK, which are thought to be involved primarily in cytoskeletal remodeling, also mediate cell growth regulation by coupling cell shape to the cell-cycle machinery at the level of signal transduction.	Harvard Univ, Sch Med, Childrens Hosp, Dept Pathol,Vasc Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Surg,Vasc Biol Program, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Ingber, DE (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Dept Pathol,Vasc Biol Program, Room 11-127,Karp Family Res Labs,300 Londwood Ave, Boston, MA 02115 USA.	donald.ingber@childrens.harvard.edu	Ingber, Donald E/AAC-5894-2019		NATIONAL CANCER INSTITUTE [S15CA058833] Funding Source: NIH RePORTER; NCI NIH HHS [CA58833] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aktories K, 2000, BIOL CHEM, V381, P421, DOI 10.1515/BC.2000.054; Aplin AE, 1999, J BIOL CHEM, V274, P31223, DOI 10.1074/jbc.274.44.31223; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Bao WJ, 2002, MOL CELL BIOL, V22, P4587, DOI 10.1128/MCB.22.13.4587-4597.2002; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; Defilippi P, 1999, MICROSC RES TECHNIQ, V47, P67, DOI 10.1002/(SICI)1097-0029(19991001)47:1<67::AID-JEMT7>3.3.CO;2-G; Dike LE, 1999, IN VITRO CELL DEV-AN, V35, P441; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Ezzell RM, 1997, EXP CELL RES, V231, P14, DOI 10.1006/excr.1996.3451; Fiorentini C, 1997, J BIOL CHEM, V272, P19532, DOI 10.1074/jbc.272.31.19532; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Galbraith CG, 1998, CURR OPIN CELL BIOL, V10, P566, DOI 10.1016/S0955-0674(98)80030-6; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; HANSEN LK, 1994, MOL BIOL CELL, V5, P967, DOI 10.1091/mbc.5.9.967; Hirai A, 1997, J BIOL CHEM, V272, P13; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Huang S, 2002, EXP CELL RES, V275, P255, DOI 10.1006/excr.2002.5504; Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; Ingber DE, 2003, J CELL SCI, V116, P1157, DOI 10.1242/jcs.00359; Ingber DE, 1995, J BIOMECH, V28, P1471, DOI 10.1016/0021-9290(95)00095-X; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; IWIG M, 1995, EUR J CELL BIOL, V67, P145; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Laufs U, 1999, J BIOL CHEM, V274, P21926, DOI 10.1074/jbc.274.31.21926; LEE KM, 1998, AM J PHYSIOL, V274, pG76; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nishi K, 2002, EXP CELL RES, V280, P233, DOI 10.1006/excr.2002.5637; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Numaguchi Yasushi, 2003, Angiogenesis, V6, P55, DOI 10.1023/A:1025821517679; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Parker KK, 2002, FASEB J, V16, DOI 10.1096/fj.02-0038com; POLTE T, 2003, AM J PHYSIOL, V286, pC518; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reshetnikova G, 2000, EXP CELL RES, V259, P35, DOI 10.1006/excr.2000.4966; Resnitzky D, 1997, MOL CELL BIOL, V17, P5640, DOI 10.1128/MCB.17.9.5640; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Roovers K, 2003, MOL CELL BIOL, V23, P4283, DOI 10.1128/MCB.23.12.4283-4294.2003; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Schwartz MA, 2001, J CELL SCI, V114, P2553; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Welsh CF, 2000, BBA-REV CANCER, V1471, pM21, DOI 10.1016/S0304-419X(00)00016-0; Wilde C, 2001, TOXICON, V39, P1647, DOI 10.1016/S0041-0101(01)00152-0; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	82	172	181	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26323	26330		10.1074/jbc.M402725200	http://dx.doi.org/10.1074/jbc.M402725200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15096506	hybrid			2022-12-25	WOS:000222003000051
J	Tschope, C; Walther, T; Koniger, J; Spillmann, F; Westermann, D; Escher, F; Pauschinger, M; Pesquero, JB; Bader, M; Schultheiss, HP; Noutsias, M				Tschope, C; Walther, T; Koniger, J; Spillmann, F; Westermann, D; Escher, F; Pauschinger, M; Pesquero, JB; Bader, M; Schultheiss, HP; Noutsias, M			Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene	FASEB JOURNAL			English	Article						diabetes mellitus; diabetic cardiomyopathy; kallikrein; pathogenesis; therapy; transgenic animal	ANGIOTENSIN-CONVERTING ENZYME; DELIVERY ATTENUATES HYPERTENSION; ENDOGENOUS BRADYKININ; CONNECTIVE-TISSUE; BLOOD-PRESSURE; RENAL INJURY; COLLAGEN; RECEPTOR; INHIBITION; GLUCOSE	Diabetic cardiomyopathy includes fibrosis. Kallikrein (KLK) can inhibit collagen synthesis and promote collagen breakdown. We investigated cardiac fibrosis and left ventricular (LV) function in transgenic rats (TGR) expressing the human kallikrein 1 (hKLK1) gene in streptozotocin (STZ) - induced diabetic conditions. Six weeks after STZ injection, LV function was determined in male Sprague-Dawley (SD) rats and TGR(hKLK1) (n = 10/group) by a Millar tip catheter. Total collagen content ( Sirius Red staining) and expression of types I, III, and VI collagen were quantified by digital image analysis. SD-STZ hearts demonstrated significantly higher total collagen amounts than normoglycemic controls, reflected by the concomitant increment of collagen types I, III, and VI. This correlated with a significant reduction of LV function vs. normoglycemic controls. In contrast, surface-specific content of the extracellular matrix, including collagen types I, III, and VI expression, was significantly lower in TGR( hKLK1)- STZ, not exceeding the content of SD and TGR( hKLK1) controls. This was paralleled by a preserved LV function in TGR( hKLK1)- STZ animals. The kallikrein inhibitor aprotinin and the bradykinin (BK) B2 receptor antagonist icatibant reduced the beneficial effects on LV function and collagen content in TGR( hKLK1)- STZ animals. Transgenic expression of hKLK1 counteracts the progression of LV contractile dysfunction and extracellular matrix remodeling in STZ-induced diabetic cardiomyopathy via a BK B2 receptor-dependent pathway.	Free Univ Berlin, Charite Univ Med, Dept Cardiol & Pneumonol, D-12220 Berlin, Germany; Univ Fed Sao Paulo, Dept Biophys, Sao Paulo, Brazil; Max Delbruck Ctr Mol Med, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Universidade Federal de Sao Paulo (UNIFESP); Helmholtz Association; Max Delbruck Center for Molecular Medicine	Tschope, C (corresponding author), Free Univ Berlin, Charite Univ Med, Dept Cardiol & Pneumonol, Campus Benjamin Franklin,Hindenburgdamm 30, D-12220 Berlin, Germany.	ctschoepe@yahoo.com	Pesquero, Joao/C-1470-2012; Bader, Michael/K-2124-2013; Westermann, Dirk/D-1344-2011; Noutsias, Michel/AAM-4006-2021	Pesquero, Joao/0000-0002-4507-632X; Westermann, Dirk/0000-0002-7542-1956; Tschope, Carsten/0000-0001-5243-8985; Bader, Michael/0000-0003-4780-4164; Noutsias, Michel/0000-0002-9066-5262; Escher, Felicitas/0000-0003-0678-5681; Spillmann, Frank/0000-0003-0002-5745				Cellier E, 2002, CAN J PHYSIOL PHARM, V80, P341, DOI 10.1139/Y02-033; Chao J, 1998, HUM GENE THER, V9, P21, DOI 10.1089/hum.1998.9.1-21; Cheng CP, 1998, J AM COLL CARDIOL, V31, P1679, DOI 10.1016/S0735-1097(98)00159-4; Clements J, 2001, BIOL CHEM, V382, P5, DOI 10.1515/BC.2001.002; Dostal DE, 2001, HYPERTENSION, V37, P841, DOI 10.1161/01.HYP.37.3.841; Douillet CD, 2000, AM J PHYSIOL-HEART C, V279, pH2829, DOI 10.1152/ajpheart.2000.279.6.H2829; Emanueli C, 2000, ARTERIOSCL THROM VAS, V20, P2379, DOI 10.1161/01.ATV.20.11.2379; Emanueli C, 2002, CIRCULATION, V106, P993, DOI 10.1161/01.CIR.0000027104.33206.C8; Emanueli C, 2001, CIRCULATION, V103, P125; Gallagher AM, 1998, HYPERTENSION, V32, P84, DOI 10.1161/01.HYP.32.1.84; GROVES P, 1995, CIRCULATION, V92, P3424, DOI 10.1161/01.CIR.92.12.3424; Hu K, 1998, CARDIOVASC RES, V39, P401, DOI 10.1016/S0008-6363(98)00090-X; KANNEL WB, 1974, AM J CARDIOL, V34, P29, DOI 10.1016/0002-9149(74)90089-7; Kim NN, 1999, J MOL CELL CARDIOL, V31, P457, DOI 10.1006/jmcc.1998.0887; Kudoh A, 2000, HYPERTENSION, V36, P239, DOI 10.1161/01.HYP.36.2.239; Mayfield RK, 1996, DIABETES, V45, pS20, DOI 10.2337/diab.45.1.S20; Mizushige K, 2000, CIRCULATION, V101, P899, DOI 10.1161/01.CIR.101.8.899; MODRAK J, 1980, DIABETES, V29, P547, DOI 10.2337/diabetes.29.7.547; Noutsias M, 2002, MED SCI MONITOR, V8, pMT59; Pauschinger M, 1999, CIRCULATION, V99, P2750, DOI 10.1161/01.CIR.99.21.2750; Rittenhouse HG, 1998, CRIT REV CL LAB SCI, V35, P275, DOI 10.1080/10408369891234219; Schanstra JP, 2002, J CLIN INVEST, V110, P371, DOI 10.1172/JCI200215493; SHANAHAN MF, 1989, ENDOCRINOLOGY, V125, P1074, DOI 10.1210/endo-125-2-1074; Sharma JN, 1996, IMMUNOPHARMACOLOGY, V33, P341, DOI 10.1016/0162-3109(96)00104-X; Shimizu M, 1993, Nihon Rinsho, V51, P1362; SHIMIZU M, 1993, J CLIN PATHOL, V46, P32, DOI 10.1136/jcp.46.1.32; Silva JA, 2000, FASEB J, V14, P1858; Somasundaram R, 1996, J BIOL CHEM, V271, P26884, DOI 10.1074/jbc.271.43.26884; Spillmann F, 2002, INT IMMUNOPHARMACOL, V2, P1823, DOI 10.1016/S1567-5769(02)00174-1; Spinale FG, 2002, CIRC RES, V90, P520, DOI 10.1161/01.RES.0000013290.12884.A3; SPIRO MJ, 1993, DIABETOLOGIA, V36, P93, DOI 10.1007/BF00400687; Tschesche H, 1989, Adv Exp Med Biol, V247A, P545; Tschope C, 2002, J CARDIOVASC PHARM, V39, P478, DOI 10.1097/00005344-200204000-00003; Tschope C, 1999, IMMUNOPHARMACOLOGY, V44, P35, DOI 10.1016/S0162-3109(99)00109-5; Tschope C, 2000, J HYPERTENS, V18, P223, DOI 10.1097/00004872-200018020-00014; WANG C, 1995, J CLIN INVEST, V95, P1710, DOI 10.1172/JCI117847; WEBER KT, 1995, ANN NY ACAD SCI, V752, P286, DOI 10.1111/j.1749-6632.1995.tb17438.x; WEBER KT, 1995, J MOL CELL CARDIOL, V27, P107, DOI 10.1016/S0022-2828(08)80011-9; Wolf WC, 2000, KIDNEY INT, V58, P730, DOI 10.1046/j.1523-1755.2000.00219.x; Yang XP, 2001, CIRC RES, V88, P1072, DOI 10.1161/hh1001.090759; ZARICH SW, 1989, AM HEART J, V118, P1000, DOI 10.1016/0002-8703(89)90236-6	41	82	92	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					828	835		10.1096/fj.03-0736com	http://dx.doi.org/10.1096/fj.03-0736com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15117887				2022-12-25	WOS:000221883200031
J	Gonzales, PE; Solomon, A; Miller, AB; Leesnitzer, MA; Sagi, I; Milla, ME				Gonzales, PE; Solomon, A; Miller, AB; Leesnitzer, MA; Sagi, I; Milla, ME			Inhibition of the tumor necrosis factor-alpha-converting enzyme by its pro domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-ABSORPTION; PROTEIN-FOLDING REACTION; INTRACELLULAR MATURATION; MATRIX METALLOPROTEINASE-2; SUBTILISIN BPN; CELL-CELL; DISINTEGRIN; ACTIVATION; MECHANISM; LOCALIZATION	Tumor necrosis factor-alpha-converting enzyme ( TACE) is a disintegrin metalloproteinase that processes tumor necrosis factor and a host of other ectodomains. TACE is biosynthesized as a zymogen, and activation requires the removal of an inhibitory pro domain. Little is known about how the pro domain exerts inhibition for this class of enzymes. To study the inhibitory properties of the pro domain of TACE, we have expressed it in isolation from the rest of the protease. Here we show that the TACE pro domain ( TACE Pro) is a stably folded protein that is able to inhibit this enzyme. TACE Pro inhibited the catalytic domain of TACE with an IC50 of 70 nM. In contrast, this inhibitory potency decreased over 30-fold against a TACE form containing the catalytic plus disintegrin/ cysteine-rich domains (IC50 greater that 2 muM). The disintegrin/ cysteine-rich region in isolation also decreases the interaction of TACE Pro with the catalytic domain. Surprisingly, we found that the cysteine switch motif located in TACE Pro was not essential for inhibition of the enzymatic activity of TACE; the pro domain variant C184A showed the same inhibitory potency against both TACE forms as wild type TACE Pro. X-ray absorption spectroscopy experiments indicate that binding of TACE Pro to the catalytic domain does include ligation of the catalytic zinc ion via the sulfur atom of its conserved Cys(184) residue. Moreover, the binding of TACE Pro to the catalytic zinc ion partially oxidizes the catalytic zinc ion of the enzyme. Despite this, the nature of the interaction between the pro and catalytic domains of TACE is not consistent with a simple competitive model of inhibition based on cysteine switch ligation of the zinc ion within the active site of TACE.	Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Johnson Res Fdn, Philadelphia, PA 19104 USA; Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; GlaxoSmithKline Res & Dev Ltd, Res Triangle Pk, NC 27709 USA	University of Pennsylvania; University of Pennsylvania; Weizmann Institute of Science; GlaxoSmithKline	Milla, ME (corresponding author), 242 Anat Chem Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	mmilla@mail.med.upenn.edu			NIAMS NIH HHS [AR-45949] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045949] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anders A, 2001, FASEB J, V15, P1837, DOI 10.1096/fj.01-0007fje; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; CHEN LC, 1993, BIOCHEMISTRY-US, V32, P10289, DOI 10.1021/bi00090a003; Cunningham EL, 1999, P NATL ACAD SCI USA, V96, P11008, DOI 10.1073/pnas.96.20.11008; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; Endres K, 2003, EUR J BIOCHEM, V270, P2386, DOI 10.1046/j.1432-1033.2003.03606.x; FEIMARK BD, 1994, J BIOL CHEM, V269, P26982; Galazka G, 1999, BIOCHEMISTRY-US, V38, P1316, DOI 10.1021/bi982135b; Galazka G, 1996, BIOCHEMISTRY-US, V35, P11221, DOI 10.1021/bi960618e; Howard L, 2000, BIOCHEM J, V348, P21, DOI 10.1042/0264-6021:3480021; Kang TB, 2002, J BIOL CHEM, V277, P25583, DOI 10.1074/jbc.M203532200; Kleifeld O, 2003, NAT STRUCT BIOL, V10, P98, DOI 10.1038/nsb889; Kleifeld O, 2001, J BIOL CHEM, V276, P17125, DOI 10.1074/jbc.M011604200; Lee MH, 2003, BIOCHEM J, V371, P369, DOI 10.1042/BJ20021538; Lee MH, 2002, FEBS LETT, V520, P102, DOI 10.1016/S0014-5793(02)02776-X; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Schlomann U, 2002, J BIOL CHEM, V277, P48210, DOI 10.1074/jbc.M203355200; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schlondorff J, 1999, J CELL SCI, V112, P3603; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; Solomon A, 2004, J BIOL CHEM, V279, P31646, DOI 10.1074/jbc.M401310200; STERN EA, 1995, PHYSICA B, V208, P117, DOI 10.1016/0921-4526(94)00826-H; STRAUSBERG S, 1993, BIOCHEMISTRY-US, V32, P8112, DOI 10.1021/bi00083a009; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; ZABINSKY SI, 1995, PHYS REV B, V52, P2995, DOI 10.1103/PhysRevB.52.2995; Zou J, 2004, J BIOL CHEM, V279, P9818, DOI 10.1074/jbc.M309696200	36	88	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31638	31645		10.1074/jbc.M401311200	http://dx.doi.org/10.1074/jbc.M401311200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15100227	hybrid			2022-12-25	WOS:000222726800088
J	Mol, CD; Dougan, DR; Schneider, TR; Skene, RJ; Kraus, ML; Scheibe, DN; Snell, GP; Zou, H; Sang, BC; Wilson, KP				Mol, CD; Dougan, DR; Schneider, TR; Skene, RJ; Kraus, ML; Scheibe, DN; Snell, GP; Zou, H; Sang, BC; Wilson, KP			Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC DOMAIN MUTATIONS; WW-LIKE DOMAIN; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; PDGF RECEPTOR; CDNA CLONING; WILD-TYPE; JUXTAMEMBRANE; STI571; GENE	The activity of the c-Kit receptor protein-tyrosine kinase is tightly regulated in normal cells, whereas deregulated c-Kit kinase activity is implicated in the pathogenesis of human cancers. The c-Kit juxtamembrane region is known to have an autoinhibitory function; however the precise mechanism by which c-Kit is maintained in an autoinhibited state is not known. We report the 1.9-Angstrom resolution crystal structure of native c-Kit kinase in an autoinhibited conformation and compare it with active c-Kit kinase. Autoinhibited c-Kit is stabilized by the juxtamembrane domain, which inserts into the kinase-active site and disrupts formation of the activated structure. A 1.6-Angstrom crystal structure of c-Kit in complex with STI-571 ( Imatinib(R) or Gleevec(R)) demonstrates that inhibitor binding disrupts this natural mechanism for maintaining c-Kit in an autoinhibited state. Together, these results provide a structural basis for understanding c-Kit kinase autoinhibition and will facilitate the structure-guided design of specific inhibitors that target the activated and autoinhibited conformations of c-Kit kinase.	Syrrx Inc, San Diego, CA 92121 USA; Italian Fdn Canc Res, Inst Mol Oncol, I-20139 Milan, Italy	IFOM - FIRC Institute of Molecular Oncology	Mol, CD (corresponding author), Syrrx Inc, San Diego, CA 92121 USA.	clifford.mol@syrrx.com	Schneider, Thomas/B-7442-2011	Schneider, Thomas/0000-0001-6955-7374; Skene, Robert/0000-0002-1482-6546				BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Chang PM, 2003, MOL CELL BIOL, V23, P3067, DOI 10.1128/MCB.23.9.3067-3078.2003; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; Frost MJ, 2002, MOL CANCER THER, V1, P1115; Griffith J, 2004, MOL CELL, V13, P169, DOI 10.1016/S1097-2765(03)00505-7; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hosfield D, 2003, J STRUCT BIOL, V142, P207, DOI 10.1016/S1047-8477(03)00051-0; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 2002, CURR OPIN STRUC BIOL, V12, P735, DOI 10.1016/S0959-440X(02)00383-4; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Ilsley JL, 2002, CELL SIGNAL, V14, P183, DOI 10.1016/S0898-6568(01)00236-4; Irusta PM, 1998, EMBO J, V17, P6912, DOI 10.1093/emboj/17.23.6912; Irusta PM, 2002, J BIOL CHEM, V277, P38627, DOI 10.1074/jbc.M204890200; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; Kitamura Y, 2001, MUTAT RES-FUND MOL M, V477, P165, DOI 10.1016/S0027-5107(01)00117-8; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; Li SQ, 2003, J BIOL CHEM, V278, P26007, DOI 10.1074/jbc.M302425200; Linnekin D, 1999, INT J BIOCHEM CELL B, V31, P1053, DOI 10.1016/S1357-2725(99)00078-3; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; Ma YS, 1999, J BIOL CHEM, V274, P13399, DOI 10.1074/jbc.274.19.13399; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mol CD, 2003, J BIOL CHEM, V278, P31461, DOI 10.1074/jbc.C300186200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagar B, 2002, CANCER RES, V62, P4236; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; O'Dwyer ME, 2003, CANCER INVEST, V21, P429, DOI 10.1081/CNV-120018235; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; ROSNET O, 1993, BLOOD, V82, P1110, DOI 10.1182/blood.V82.4.1110.bloodjournal8241110; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P195, DOI 10.1107/S0907444901019291; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; Till JH, 2002, STRUCTURE, V10, P1187, DOI 10.1016/S0969-2126(02)00814-6; Ueda S, 2002, INT J HEMATOL, V76, P427, DOI 10.1007/BF02982808; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; Zermati Y, 2003, ONCOGENE, V22, P660, DOI 10.1038/sj.onc.1206120	52	475	509	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31655	31663		10.1074/jbc.M403319200	http://dx.doi.org/10.1074/jbc.M403319200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15123710	hybrid			2022-12-25	WOS:000222726800090
J	Chen, H; Hewison, M; Hu, B; Sharma, M; Sun, ZJ; Adams, JS				Chen, H; Hewison, M; Hu, B; Sharma, M; Sun, ZJ; Adams, JS			An Hsp27-related, dominant-negative-acting intracellular estradiol-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; HUMAN ESTROGEN-RECEPTOR; WORLD PRIMATE CELLS; ALPHA-B-CRYSTALLIN; VITAMIN-D; SQUIRREL-MONKEY; BREAST-CANCER; FUNCTIONAL-CHARACTERIZATION; HEAT-SHOCK-PROTEIN-27 GENE; GLUCOCORTICOID-RECEPTOR	New World primates (NWPs) exhibit a compensated form of resistance to gonadal steroid hormones. We demonstrated recently that estrogen resistance in NWP cells was associated with the overexpression of two proteins, a nonreceptor-related, dominant-negative-acting estrogen response element (ERE)-binding protein (ERE-BP) and an intracellular estradiol-binding protein (IEBP). Based on the N-terminal sequences of tryptic fragments of IEBP isolated from a 17beta-estradiol (E-2) affinity column we cloned a full-length cDNA for IEBP from the estrogen-resistant NWP cell line, B95-8. Subsequent sequence analysis revealed 87% sequence identity between the deduced peptide for IEBP and human Hsp27. When hormone-responsive, wild-type Old World primate (OWP) cells were transiently transfected with IEBP cDNA, E-2-directed ERE reporter luciferase activity was reduced by 50% compared with vector only-transfected OWP cells (p < 0.0018). When IEBP and ERE-BP were cotransfected, ERE promoter-reporter activity was reduced by a further 60% (p < 0.0001). Electrophoresis mobility shift analyses showed that IEBP neither bound to ERE nor competed with the estrogen receptor (ER) for binding to ERE. However, there was evidence of protein-protein interaction of IEBP and ERalpha; IEBP was coimmunoprecipitated with anti-ERalpha antibody in wildtype cells stably transfected with IEBP. A specific interaction between ERalpha and IEBP was confirmed in glutathione S-transferase pull-down and yeast two-hybrid assays. Data indicate that the Hsp27-related IEBP interacts with the ligand binding domain of the ERalpha. In summary, by inhibiting the ERalpha-E-2 interaction, IEBP acts to squelch ERalpha-directed ERE-regulated transactivation and promote estrogen resistance in NWP cells.	Univ Calif Los Angeles, Div Endocrinol Diabet & Metab, Cedars Sinai Med Ctr, Sch Med, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Dept Pathol, Cedars Sinai Med Ctr, Sch Med, Los Angeles, CA 90048 USA; Univ Birmingham, Queen Elizabeth Med Ctr, Div Med Sci, Birmingham B15 2TH, W Midlands, England; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Birmingham City University; University of Birmingham; Stanford University	Adams, JS (corresponding author), Univ Calif Los Angeles, Div Endocrinol Diabet & Metab, Cedars Sinai Med Ctr, Sch Med, 8700 Beverly Blvd,Rm B-131, Los Angeles, CA 90048 USA.	adamsj@cshs.org	Adams, John S/I-3365-2013	Adams, John S/0000-0001-9607-5020	NCI NIH HHS [R01 CA087767, R01 CA070297] Funding Source: Medline; NIDDK NIH HHS [R01 DK055843, R01 DK061002, R01DK55843, R01 DK055843-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055843] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JS, 1985, ENDOCRINOLOGY, V116, P2523, DOI 10.1210/endo-116-6-2523; Adams JS, 2003, J CELL BIOCHEM, V88, P308, DOI 10.1002/jcb.10333; BHATTACHARYYA T, 1995, J BIOL CHEM, V270, P1705, DOI 10.1074/jbc.270.4.1705; BONNEGARD M, 1995, TRENDS ENDOCRIN MET, V6, P160; BROWN GM, 1970, ENDOCRINOLOGY, V86, P519, DOI 10.1210/endo-86-3-519; Bullard B, 2004, J BIOL CHEM, V279, P7917, DOI 10.1074/jbc.M307473200; Chen H, 2003, J CLIN ENDOCR METAB, V88, P501, DOI 10.1210/jc.2002-021488; Chen H, 1997, J CLIN INVEST, V99, P669, DOI 10.1172/JCI119210; Chen H, 1998, J BIOL CHEM, V273, P31352, DOI 10.1074/jbc.273.47.31352; Chen H, 2003, P NATL ACAD SCI USA, V100, P6109, DOI 10.1073/pnas.1031395100; Chen H, 2000, J BIOL CHEM, V275, P35557, DOI 10.1074/jbc.M007117200; CHROUSOS GP, 1984, J CLIN ENDOCR METAB, V58, P516, DOI 10.1210/jcem-58-3-516; CHROUSOS GP, 1984, ENDOCRINOLOGY, V115, P25, DOI 10.1210/endo-115-1-25; CHROUSOS GP, 1982, P NATL ACAD SCI-BIOL, V79, P2036, DOI 10.1073/pnas.79.6.2036; CHROUSOS GP, 1982, J CLIN ENDOCR METAB, V55, P364, DOI 10.1210/jcem-55-2-364; CHROUSOS GP, 1984, ADV EXP MED BIOL, V196, P317; Chun RF, 2001, AM J PRIMATOL, V54, P107, DOI 10.1002/ajp.1016; CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558; CLEMMONS DR, 1990, ENDOCRINOLOGY, V127, P2679, DOI 10.1210/endo-127-6-2679; Concannon CG, 2003, APOPTOSIS, V8, P61, DOI 10.1023/A:1021601103096; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Denny WB, 2000, ENDOCRINOLOGY, V141, P4107, DOI 10.1210/en.141.11.4107; deToro MMM, 1997, J STEROID BIOCHEM, V60, P277, DOI 10.1016/S0960-0760(96)00221-X; Ferro P, 2003, INT J MOL MED, V12, P355; Fu L, 2003, BIOCHEM BIOPH RES CO, V302, P710, DOI 10.1016/S0006-291X(03)00257-2; Gacad MA, 1998, J CLIN ENDOCR METAB, V83, P1264, DOI 10.1210/jc.83.4.1264; Gacad MA, 1997, J BIOL CHEM, V272, P8433, DOI 10.1074/jbc.272.13.8433; GACAD MA, 1992, AM J PRIMATOL, V28, P263, DOI 10.1002/ajp.1350280404; Gerthoffer WT, 2001, J APPL PHYSIOL, V91, P963, DOI 10.1152/jappl.2001.91.2.963; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; Haslbeck M, 2002, CELL MOL LIFE SCI, V59, P1649, DOI 10.1007/PL00012492; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HUTCHISON KA, 1993, ANN NY ACAD SCI, V684, P35, DOI 10.1111/j.1749-6632.1993.tb32269.x; Jia YF, 2001, J BIOL CHEM, V276, P39911, DOI 10.1074/jbc.M103510200; Klein-Hitpass L, 1998, J MOL MED, V76, P490, DOI 10.1007/s001090050243; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Labrie F, 2000, J MOL ENDOCRINOL, V25, P1, DOI 10.1677/jme.0.0250001; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; Oesterreich S, 1996, CLIN CANCER RES, V2, P1199; Pasta SY, 2003, J BIOL CHEM, V278, P51159, DOI 10.1074/jbc.M307523200; Porter W, 2001, J MOL ENDOCRINOL, V26, P31, DOI 10.1677/jme.0.0260031; Porter W, 1996, MOL ENDOCRINOL, V10, P1371, DOI 10.1210/me.10.11.1371; Reynolds PD, 1997, J CLIN ENDOCR METAB, V82, P465, DOI 10.1210/jc.82.2.465; Reynolds PD, 1999, J CLIN ENDOCR METAB, V84, P663, DOI 10.1210/jc.84.2.663; Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219; Sabbah M, 1996, BIOCHEM J, V314, P205, DOI 10.1042/bj3140205; Sathish HA, 2003, J BIOL CHEM, V278, P44214, DOI 10.1074/jbc.M307578200; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; Siiteri P K, 1986, Adv Exp Med Biol, V196, P279; Simpson ER, 2001, ENDOCRINOLOGY, V142, P4589, DOI 10.1210/endo.142.11.8547; Smith LL, 2000, CRIT REV TOXICOL, V30, P571, DOI 10.1080/10408440008951120; Stock AD, 2003, AM J MED GENET A, V120A, P320, DOI 10.1002/ajmg.a.20055; TAKAHASHI N, 1985, BIOCHEM J, V227, P555, DOI 10.1042/bj2270555; TAKAHASHI S, 1995, ONCOLOGY, V52, P371; Tamrazi A, 2002, MOL ENDOCRINOL, V16, P2706, DOI 10.1210/me.2002-0250; Welsh MJ, 1998, ANN NY ACAD SCI, V851, P28, DOI 10.1111/j.1749-6632.1998.tb08973.x; Witek Andrzej, 2003, Ginekol Pol, V74, P246; Wood JR, 1998, MOL CELL BIOL, V18, P1927, DOI 10.1128/MCB.18.4.1927; Wu SX, 2000, MOL ENDOCRINOL, V14, P1387, DOI 10.1210/me.14.9.1387; Wu SX, 2002, ENDOCRINOLOGY, V143, P4135, DOI 10.1210/en.2002-220568; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3	64	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29944	29951		10.1074/jbc.M401317200	http://dx.doi.org/10.1074/jbc.M401317200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123601	hybrid			2022-12-25	WOS:000222531900011
J	Matyash, A; Chung, HR; Jackle, H				Matyash, A; Chung, HR; Jackle, H			Genome-wide mapping of in vivo targets of the Drosophila transcription factor Kruppel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; GAP GENES; POSTERIOR REGION; MODIFIER SCREEN; BINDING-SITES; PROTEIN; ACTIVATION; REPRESSION; KNIRPS; SEQUENCE	Kruppel (Kr), a member of the gap class of Drosophila segmentation genes, encodes a DNA binding zinc finger-type transcription factor. In addition to its segmentation function at the blastoderm stage, Kruppel also plays a critical role in organ formation during later stages of embryogenesis. To systematically identify in vivo target genes of Kruppel, we isolated DNA fragments from the Kruppel-associated portion of chromatin and used them to find and map Kruppel-dependent cis-acting regulatory sites in the Drosophila genome. We show that Kruppel binding sites are not enriched in Kruppel-associated chromatin and that the clustering of Kruppel binding sites, as found in the cis-acting elements of Kruppel-dependent segmentation genes used for in silico searches of Kruppel target genes, is not a prerequisite for the in vivo binding of Kruppel to its regulatory elements. Results obtained with the newly identified target gene ken and barbie (ken) indicate that Kruppel represses transcription and thereby restricts the spatial expression pattern of ken during blastoderm and gastrulation.	Max Planck Inst Biophys Chem, Abt Mol Entwicklungsbiol, D-37070 Gottingen, Germany	Max Planck Society	Jackle, H (corresponding author), Max Planck Inst Biophys Chem, Abt Mol Entwicklungsbiol, D-37070 Gottingen, Germany.	hjaeckl@gwdg.de						Abrell S, 2000, CHROMOSOMA, V109, P334, DOI 10.1007/s004120000092; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bashaw GJ, 2001, J CELL BIOL, V155, P1117, DOI 10.1083/jcb.200110077; Berman BP, 2002, P NATL ACAD SCI USA, V99, P757, DOI 10.1073/pnas.231608898; Carrera P, 1998, P NATL ACAD SCI USA, V95, P10779, DOI 10.1073/pnas.95.18.10779; CASARES F, 1995, DEVELOPMENT, V121, P1855; CASTRILLON DH, 1993, GENETICS, V135, P489; Cavalli G, 1999, PRACT APPROACH SER, P20; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; CHIANG CM, 1993, PEPTIDE RES, V6, P62; Fujioka M, 1999, DEVELOPMENT, V126, P2527; GAUL U, 1989, P NATL ACAD SCI USA, V86, P4599, DOI 10.1073/pnas.86.12.4599; Gaul U, 1990, Adv Genet, V27, P239; GUTJAHR T, 1993, DEVELOPMENT, V117, P609; Hader T, 1998, MECH DEVELOP, V71, P177, DOI 10.1016/S0925-4773(98)00014-8; Hartmann C, 1997, DEV GENES EVOL, V207, P186, DOI 10.1007/s004270050106; Hartmann C, 1997, EMBO J, V16, P5299, DOI 10.1093/emboj/16.17.5299; Henegariu O, 1997, BIOTECHNIQUES, V23, P504, DOI 10.2144/97233rr01; Hertz GZ, 1999, BIOINFORMATICS, V15, P563, DOI 10.1093/bioinformatics/15.7.563; HOCH M, 1991, EMBO J, V10, P2267, DOI 10.1002/j.1460-2075.1991.tb07763.x; HOCH M, 1990, EMBO J, V9, P2587, DOI 10.1002/j.1460-2075.1990.tb07440.x; Hombria JCG, 2002, CURR BIOL, V12, pR569, DOI 10.1016/S0960-9822(02)01057-6; HOSHIZAKI DK, 1995, GENOME, V38, P497, DOI 10.1139/g95-065; KNIPPLE DC, 1985, NATURE, V317, P40, DOI 10.1038/317040a0; Kotarski MA, 1998, GENOME, V41, P295, DOI 10.1139/gen-41-2-295; KRAUT R, 1991, DEVELOPMENT, V111, P611; Kuhnlein RP, 1998, MECH DEVELOP, V79, P161, DOI 10.1016/S0925-4773(98)00183-X; La Rosee-Borggreve A, 1999, MECH DEVELOP, V89, P133, DOI 10.1016/S0925-4773(99)00219-1; LANGELAND JA, 1994, DEVELOPMENT, V120, P2945; LaRosee A, 1997, EMBO J, V16, P4403, DOI 10.1093/emboj/16.14.4403; LEHMANN R, 1994, METHOD CELL BIOL, V44, P575, DOI 10.1016/S0091-679X(08)60933-4; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; Liu XJ, 2000, DEV BIOL, V221, P419, DOI 10.1006/dbio.2000.9689; Michaut L, 2003, P NATL ACAD SCI USA, V100, P4024, DOI 10.1073/pnas.0630561100; Morrison DK, 2000, J CELL BIOL, V150, pF57, DOI 10.1083/jcb.150.2.F57; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Pagano A, 1999, J BIOL CHEM, V274, P7833, DOI 10.1074/jbc.274.12.7833; PANKRATZ MJ, 1992, SCIENCE, V255, P986, DOI 10.1126/science.1546296; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; PANKRATZ MJ, 1990, CELL, V61, P309, DOI 10.1016/0092-8674(90)90811-R; PREISS A, 1985, NATURE, V313, P27, DOI 10.1038/313027a0; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rajewsky N, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-30; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; Sanchez D, 2000, INT J DEV BIOL, V44, P349; Sanson B, 2001, EMBO REP, V2, P1083, DOI 10.1093/embo-reports/kve255; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SAUER F, 1995, EMBO J, V14, P4773, DOI 10.1002/j.1460-2075.1995.tb00159.x; Sauer F, 1996, PHILOS T ROY SOC B, V351, P579, DOI 10.1098/rstb.1996.0057; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; Shimell MJ, 2000, DEV BIOL, V218, P38, DOI 10.1006/dbio.1999.9576; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; SMITH DB, 1993, NUCLEIC ACIDS RES, V21, P359, DOI 10.1093/nar/21.2.359; Solano PJ, 2003, DEVELOPMENT, V130, P1243, DOI 10.1242/dev.00348; Thummel CS, 1992, DROS INF SERV, V71, P150; Tolias PP, 1998, DEV GENES EVOL, V208, P274, DOI 10.1007/s004270050182; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; WIESCHAUS E, 1984, DEV BIOL, V104, P172, DOI 10.1016/0012-1606(84)90046-0; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	64	10	10	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30689	30696		10.1074/jbc.M403345200	http://dx.doi.org/10.1074/jbc.M403345200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131112	Green Published, hybrid			2022-12-25	WOS:000222531900099
J	Wei, J; Sherman, F				Wei, J; Sherman, F			Sue1p is required for degradation of labile forms of altered cytochromes c in yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-DEPENDENT DEGRADATION; AMINO-ACID REPLACEMENTS; SACCHAROMYCES-CEREVISIAE; PROTEIN-DEGRADATION; SYNTHETIC OLIGONUCLEOTIDES; PHYSIOLOGICAL PARTNERS; ISO-1-CYTOCHROME C; ESCHERICHIA-COLI; HEME LYASE; IN-VIVO	Previous studies on certain altered holo-isocytochromes c revealed a rho(-)-dependent degradation (RDD) phenotype, in which certain altered holo-iso-1-cytochromes c are at normal or nearly normal levels in rho(+) strains, but are at low levels or absent in rho(-) strains, although wild-type holo-iso-1-cytochrome c is present at normal levels in both rho(+) and related rho(-) strains. The diminished levels of altered holo-iso-1-cytochrome c are due to the rapid degradation that is carried out by a novel proteolytic pathway in the IMS of mitochondria. SUE1, a nuclear gene that encodes a mitochondrial protein, was identified with a genetic screen for mutants that diminish RDD. The levels of RDD and certain other types of altered holo-iso-1-cytochrome c were elevated in rho(-) sue1 strains. Also, rho(+) sue1 strains containing certain altered holo- iso-1-cytochromes c grew better on non-fermentable carbon sources than the corresponding rho(+) SUE1 strains. These results indicate that Sue1p may play an important role in the degradation of abnormal holo-iso-1-cytochrome c in the mitochondria.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Sherman, F (corresponding author), Univ Rochester, Sch Med, Dept Biochem & Biophys, POB 712, Rochester, NY 14642 USA.	Fred_Sherman@urmc.rochester.edu			NIGMS NIH HHS [GM12702] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; DAS G, 1989, P NATL ACAD SCI USA, V86, P496, DOI 10.1073/pnas.86.2.496; DOWNIE JA, 1977, J MOL BIOL, V113, P369, DOI 10.1016/0022-2836(77)90147-4; DUMONT MD, 1990, J BIOL CHEM, V265, P2733; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; DUMONT ME, 1988, J BIOL CHEM, V263, P15928; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Goldberg AL, 1997, BIOL CHEM, V378, P131; Granot Z, 2003, MOL ENDOCRINOL, V17, P2461, DOI 10.1210/me.2003-0074; HICKEY DR, 1991, GENE, V105, P73, DOI 10.1016/0378-1119(91)90515-D; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Huang HC, 2001, J BIOL CHEM, V276, P3920, DOI 10.1074/jbc.M002937200; Kaser M, 2000, SEMIN CELL DEV BIOL, V11, P181, DOI 10.1006/scdb.2000.0166; Lee DH, 1996, MOL CELL BIOL, V16, P4773; LINSKEOCONNELL LI, 1995, BIOCHEMISTRY-US, V34, P7103, DOI 10.1021/bi00021a023; LINSKEOCONNELL LI, 1995, BIOCHEMISTRY-US, V34, P7094, DOI 10.1021/bi00021a022; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; MATNER RR, 1982, J BIOL CHEM, V257, P9811; Miller CA, 1998, NUCLEIC ACIDS RES, V26, P3577, DOI 10.1093/nar/26.15.3577; MOERSCHELL RP, 1988, P NATL ACAD SCI USA, V85, P524, DOI 10.1073/pnas.85.2.524; Pearce DA, 1998, ARCH BIOCHEM BIOPHYS, V352, P85, DOI 10.1006/abbi.1998.0591; Pearce DA, 1997, J BIOL CHEM, V272, P31829, DOI 10.1074/jbc.272.50.31829; PEARCE DA, 1995, P NATL ACAD SCI USA, V92, P3735, DOI 10.1073/pnas.92.9.3735; Porankiewicz J, 1999, MOL MICROBIOL, V32, P449, DOI 10.1046/j.1365-2958.1999.01357.x; Rehling P, 2001, CRIT REV BIOCHEM MOL, V36, P291, DOI 10.1080/20014091074200; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X; SHERMAN F, 1965, J MOL BIOL, V13, P21, DOI 10.1016/S0022-2836(65)80077-8; SHERMAN F, 1968, J BIOL CHEM, V243, P5446; SHERMAN F, 1964, BIOCHIM BIOPHYS ACTA, V90, P1, DOI 10.1016/0304-4165(64)90113-8; SHERMAN F, 1974, GENETICS, V77, P255; Sitte N, 1998, J BIOCHEM, V123, P408; SMITH M, 1979, CELL, V16, P753, DOI 10.1016/0092-8674(79)90091-6; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; YAMAMOTO T, 1992, YEAST, V8, P935, DOI 10.1002/yea.320081104; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	41	6	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30449	30458		10.1074/jbc.M403742200	http://dx.doi.org/10.1074/jbc.M403742200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123691	hybrid			2022-12-25	WOS:000222531900072
J	Le Gall, M; Giniger, E				Le Gall, M; Giniger, E			Identification of two binding regions for the suppressor of hairless protein within the intracellular domain of Drosophila Notch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANKYRIN REPEATS; CELL FATES; C-ELEGANS; RBP-J; TRANSCRIPTIONAL COACTIVATOR; ACTIVATES TRANSCRIPTION; NUCLEAR-LOCALIZATION; MOUSE NOTCH1; RECEPTOR; STABILITY	Notch is a phylogenetically conserved transmembrane receptor that is required for many aspects of animal development. Upon ligand stimulation, a fragment of Notch is released proteolytically and enters the nucleus to form a complex with the DNA-binding protein CSL (CBF1/Suppressor of Hairless/Lag1) and activate transcription of Notch-CSL target genes. The physical structure of the Notch-CSL complex remains unclear, however, clouding the interpretation of previous efforts to correlate Notch structure and function. We have, therefore, characterized the binding of Drosophila CSL (called Suppressor of Hairless, or Su(H)) to the intracellular domain of Drosophila Notch both in vitro and in vivo. We report the identification of two Su(H) binding regions in Notch. The first is in the juxtamembrane region (the "RAM" domain). The second is just C-terminal to the Notch ankyrin repeats, overlapping or identical to two previously proposed nuclear localization sequences, in a domain we term PPD (potential phosphorylated domain). The ankyrin repeats themselves do not bind to Su(H); however, they substantially enhance binding of Su(H) to the more C-terminal region. Consistent with this picture, removal of either the Ram or PPD binding sites, separately, modestly reduces Notch activity in vivo, whereas removal of both renders Notch severely defective. These results clarify the relationship between Notch and CSL, help to explain the importance of the ankyrin repeats in Notch signaling, and reconcile many apparently contradictory results from previous Notch structure/function studies. Moreover, they suggest a second function for the Notch nuclear localization sequence elements.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Giniger, E (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.	eginiger@fhcrc.org	Le Gall, Maude/C-3917-2017; Le Gall, Maude/W-2593-2019; Giniger, Edward/C-1764-2015	Le Gall, Maude/0000-0002-5372-4585; Le Gall, Maude/0000-0002-5372-4585; Giniger, Edward/0000-0002-8340-6158	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057830, R55GM057830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003013, Z01NS003013] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 57830] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 1997, J BIOL CHEM, V272, P11336; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Berdnik D, 2002, DEV CELL, V3, P221, DOI 10.1016/S1534-5807(02)00215-0; BRAND AH, 1993, DEVELOPMENT, V118, P401; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6; Foltz DR, 2001, BIOCHEM BIOPH RES CO, V286, P484, DOI 10.1006/bbrc.2001.5421; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Giniger E, 1998, NEURON, V20, P667, DOI 10.1016/S0896-6273(00)81007-7; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; Kato H, 1997, DEVELOPMENT, V124, P4133; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Kitagawa M, 2001, MOL CELL BIOL, V21, P4337, DOI 10.1128/MCB.21.13.4337-4346.2001; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Lai EC, 2002, CURR BIOL, V12, pR200, DOI 10.1016/S0960-9822(02)00749-2; Lai EC, 2002, CURR BIOL, V12, pR74, DOI 10.1016/S0960-9822(01)00679-0; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Lubman OY, 2004, MOL CELL, V13, P619, DOI 10.1016/S1097-2765(04)00120-0; Matsuno K, 2002, DEVELOPMENT, V129, P1049; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; Matsuno K, 1997, DEVELOPMENT, V124, P4265; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; Nam Y, 2003, J BIOL CHEM, V278, P21232, DOI 10.1074/jbc.M301567200; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; Petcherski AG, 2000, NATURE, V405, P364, DOI 10.1038/35012645; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; Roehl H, 1996, EMBO J, V15, P7002, DOI 10.1002/j.1460-2075.1996.tb01092.x; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Tani S, 2001, NUCLEIC ACIDS RES, V29, P1373, DOI 10.1093/nar/29.6.1373; Wesley CS, 2000, J CELL BIOL, V149, P683, DOI 10.1083/jcb.149.3.683; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Zweifel ME, 2003, PROTEIN SCI, V12, P2622, DOI 10.1110/ps.03279003; Zweifel ME, 2001, BIOCHEMISTRY-US, V40, P14344, DOI 10.1021/bi011435h; Zweifel ME, 2001, BIOCHEMISTRY-US, V40, P14357, DOI 10.1021/bi011436+	42	17	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29418	29426		10.1074/jbc.M404589200	http://dx.doi.org/10.1074/jbc.M404589200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123610	hybrid			2022-12-25	WOS:000222445300074
J	Lilja, L; Johansson, JU; Gromada, J; Mandic, SA; Fried, G; Berggren, PO; Bark, C				Lilja, L; Johansson, JU; Gromada, J; Mandic, SA; Fried, G; Berggren, PO; Bark, C			Cyclin-dependent kinase 5 associated with p39 promotes Munc18-1 phosphorylation and Ca2+-dependent exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATES NEUROTRANSMITTER RELEASE; PANCREATIC BETA-CELLS; CDK5 ACTIVATOR; PROTEIN-KINASE; INSULIN-RELEASE; NEGATIVE REGULATOR; SEC1 HOMOLOG; SYNTAXIN 1A; EXPRESSION; BRAIN	Cyclin-dependent kinase 5 (Cdk5) is a proline-directed serine/threonine protein kinase that requires association with a regulatory protein, p35 or p39, to form an active enzyme. Munc18-1 plays an essential role in membrane fusion, and its function is regulated by phosphorylation. We report here that both p35 and p39 were expressed in insulin-secreting beta-cells, where they exhibited individual subcellular distributions and associated with membranous organelles of different densities. Overexpression of Cdk5, p35, or p39 showed that Cdk5 and p39 augmented Ca2+-induced insulin exocytosis. Suppression of p39 and Cdk5, but not of p35, by antisense oligonucleotides selectively inhibited insulin exocytosis. Transient transfection of primary beta-cells with Munc18-1 templates mutated in potential Cdk5 or PKC phosphorylation sites, in combination with Cdk5 and the different Cdk5 activators, suggested that Cdk5/p39-promoted Ca2+-dependent insulin secretion from primary beta-cells by phosphorylating Munc18-1 at a biochemical step immediately prior to vesicle fusion.	Karolinska Univ Hosp, Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res L3, SE-17176 Stockholm, Sweden; Lilly Res Labs, D-22419 Hamburg, Germany; Karolinska Univ Hosp, Karolinska Inst, Dept Woman & Child Hlth, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Eli Lilly; Lilly Deutschland GmbH; Karolinska Institutet; Karolinska University Hospital	Berggren, PO (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res L3, SE-17176 Stockholm, Sweden.	per-olof.berggren@molmed.ki.se		Bark, Christina/0000-0002-0724-6017; Berggren, Per-Olof/0000-0001-8991-413X	NIDDK NIH HHS [DK58505] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R13DK058505] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersson J, 2000, EUR J CELL BIOL, V79, P781, DOI 10.1078/0171-9335-00106; Barclay JW, 2003, J BIOL CHEM, V278, P10538, DOI 10.1074/jbc.M211114200; Cai XH, 1997, NEUROSCI RES, V28, P355, DOI 10.1016/S0168-0102(97)00063-1; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; Cheng K, 2002, J BIOL CHEM, V277, P31988, DOI 10.1074/jbc.M201161200; Chergui K, 2004, P NATL ACAD SCI USA, V101, P2191, DOI 10.1073/pnas.0308652100; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Dieter B, 2002, PFLUG ARCH EUR J PHY, V443, P333, DOI 10.1007/s00424-001-0742-4; Dresbach T, 1998, J NEUROSCI, V18, P2923; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Floyd SR, 2001, J BIOL CHEM, V276, P8104, DOI 10.1074/jbc.M008932200; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; Gallwitz D, 2003, TRENDS BIOCHEM SCI, V28, P113, DOI 10.1016/S0968-0004(03)00028-8; Gerber SH, 2002, DIABETES, V51, pS3, DOI 10.2337/diabetes.51.2007.S3; Hanson PI, 2000, NAT STRUCT BIOL, V7, P347, DOI 10.1038/75103; HELLMAN B, 1965, ANN NY ACAD SCI, V131, P541, DOI 10.1111/j.1749-6632.1965.tb34819.x; Humbert S, 2000, J CELL SCI, V113, P975; Humbert S, 2000, NEUROREPORT, V11, P2213, DOI 10.1097/00001756-200007140-00030; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Janjic D, 1999, BIOCHEM PHARMACOL, V57, P639, DOI 10.1016/S0006-2952(98)00346-3; Ko J, 2001, J NEUROSCI, V21, P6758; Lee SY, 2004, P NATL ACAD SCI USA, V101, P546, DOI 10.1073/pnas.0307813100; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lilja L, 2001, J BIOL CHEM, V276, P34199, DOI 10.1074/jbc.M103776200; MARTELL AE, 1971, AMINO ACIDS AMINES, V2; MARTELL AE, 1971, AMINO ACIDS AMINES, V1; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nilden F, 1998, BBA-GENE STRUCT EXPR, V1398, P371, DOI 10.1016/S0167-4781(98)00073-6; NILSSON T, 1987, BIOCHEM J, V248, P329, DOI 10.1042/bj2480329; Paglini G, 1998, J NEUROSCI, V18, P9858; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Patzke H, 2002, J BIOL CHEM, V277, P8054, DOI 10.1074/jbc.M109645200; Pigino G, 1997, J CELL SCI, V110, P257; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rowe J, 1999, J CELL SCI, V112, P1865; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; Smith DS, 2001, CELL GROWTH DIFFER, V12, P277; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Tan TC, 2003, NAT CELL BIOL, V5, P701, DOI 10.1038/ncb1020; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tian JH, 2003, J BIOL CHEM, V278, P26265, DOI 10.1074/jbc.M300492200; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Toonen RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; UCHIDA T, 1994, FEBS LETT, V355, P35, DOI 10.1016/0014-5793(94)01163-X; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; WICK PF, 1993, J BIOL CHEM, V268, P10983; Wu DC, 2000, NEUROCHEM RES, V25, P923, DOI 10.1023/A:1007544106645; Wu MN, 1998, EMBO J, V17, P127, DOI 10.1093/emboj/17.1.127; Yang SN, 1999, P NATL ACAD SCI USA, V96, P10164, DOI 10.1073/pnas.96.18.10164; Zhang W, 2000, J BIOL CHEM, V275, P41521, DOI 10.1074/jbc.M005479200; Zheng M, 1998, J NEUROBIOL, V35, P141, DOI 10.1002/(SICI)1097-4695(199805)35:2<141::AID-NEU2>3.0.CO;2-4	65	57	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29534	29541		10.1074/jbc.M312711200	http://dx.doi.org/10.1074/jbc.M312711200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123626	hybrid			2022-12-25	WOS:000222445300087
J	Mizusawa, N; Kimura, Y; Ishii, A; Yamanari, T; Nakazawa, S; Teramoto, H; Ono, T				Mizusawa, N; Kimura, Y; Ishii, A; Yamanari, T; Nakazawa, S; Teramoto, H; Ono, T			Impact of replacement of D1 C-terminal alanine with glycine on structure and function of photosynthetic oxygen-evolving complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; II REACTION-CENTER; TYROSINE Y-Z; TRANSFORM INFRARED-SPECTROSCOPY; PHOTOSYSTEM-II; MANGANESE CLUSTER; POLYPEPTIDE LIGATE; CRYSTAL-STRUCTURE; REDOX PROPERTIES; MN-CLUSTER	The C-terminal alanine 344 (Ala-344) in the D1 protein of photosystem II is conserved in all of the organisms performing oxygenic photosynthesis. A free alpha-COO- of Ala-344 has been proposed to be responsible for ligating the Mn cluster. Here, we constructed a mutant having D1 in which D1-Ala-344 was replaced with glycine (Gly) in cyanobacterium Synechocystis sp. PCC 6803. The effects of this minimal change in the side group from methyl to hydrogen on the properties of the oxygen-evolving complex were comprehensively investigated using purified core particles. The mutant grew photoautotrophically, and little change was observed in the protein composition of the oxygen-evolving core particles. The Gly-substituted oxygen-evolving complex showed small but normal S-2 multiline and enhanced g = 4.1 electron spin resonance signals and S-2-state thermoluminescence bands with slightly elevated peak temperature. The Gly substitution resulted in distinct but relatively small changes in a few bands arising from the putative carboxylate ligand for the Mn cluster in the mid-frequency ( 1800 - 1000 cm(-1)) S-2/S-1 Fourier transform infrared difference spectrum. In contrast, the low frequency (670 - 350 cm(-1)) S-2/S-1 Fourier transform infrared difference spectrum was markedly changed by the substitution. The results indicate that the internal structure of the Mn cluster and/or the interaction between the Mn cluster and its ligand are considerably altered by a simple change in the side group, from methyl to hydrogen, at the C-terminal of the D1 protein.	RIKEN, Inst Phys & Chem Res, Photodynam Res Ctr, Lab Photobiol 1,Aoba Ku, Sendai, Miyagi 9800845, Japan; Hiroshima Univ, Fac Integrated Arts & Sci, Higashihiroshima 7398521, Japan	RIKEN; Hiroshima University	Ono, T (corresponding author), RIKEN, Inst Phys & Chem Res, Photodynam Res Ctr, Lab Photobiol 1,Aoba Ku, 519-1399 Aoba, Sendai, Miyagi 9800845, Japan.	takaaki@postman.riken.go.jp						Boussac A, 1996, BIOCHEMISTRY-US, V35, P6984, DOI 10.1021/bi960636w; Chu HA, 2000, BIOCHEMISTRY-US, V39, P14371, DOI 10.1021/bi001751g; Chu HA, 2004, BIOCHEMISTRY-US, V43, P3152, DOI 10.1021/bi035915f; CHU HA, 1994, BIOCHEMISTRY-US, V33, P6137, DOI 10.1021/bi00186a013; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5859, DOI 10.1021/bi00017a017; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5839, DOI 10.1021/bi00017a016; Chu HA, 2001, BIOCHEMISTRY-US, V40, P2312, DOI 10.1021/bi0022994; Chu HA, 2001, BBA-BIOENERGETICS, V1503, P69, DOI 10.1016/S0005-2728(00)00216-4; Chu HA, 1999, BIOCHEMISTRY-US, V38, P4533, DOI 10.1021/bi982807y; Debus RJ, 2000, BIOCHEMISTRY-US, V39, P470, DOI 10.1021/bi9917737; Debus RJ, 2000, BIOCHEMISTRY-US, V39, P6275, DOI 10.1021/bi992749w; Debus RJ, 2003, BIOCHEMISTRY-US, V42, P10600, DOI 10.1021/bi034859f; Debus RJ, 2001, BIOCHEMISTRY-US, V40, P3690, DOI 10.1021/bi002394c; Debus RJ, 2001, BBA-BIOENERGETICS, V1503, P164, DOI 10.1016/S0005-2728(00)00221-8; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DINER BA, 1988, J BIOL CHEM, V263, P8972; Diner BA, 2001, BBA-BIOENERGETICS, V1503, P147, DOI 10.1016/S0005-2728(00)00220-6; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Fromme P, 2002, PHILOS T R SOC B, V357, P1337, DOI 10.1098/rstb.2002.1143; Hasegawa K, 2000, J PHYS CHEM B, V104, P4253, DOI 10.1021/jp000157d; IKEUCHI M, 1988, PLANT CELL PHYSIOL, V29, P1233; JOLIOT P, 1969, PHOTOCHEM PHOTOBIOL, V10, P309, DOI 10.1111/j.1751-1097.1969.tb05696.x; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kimura Y, 2003, BIOCHEMISTRY-US, V42, P13170, DOI 10.1021/bi035420q; Kimura Y, 2002, BIOCHEMISTRY-US, V41, P5844, DOI 10.1021/bi016093u; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; KUSUNOKI M, 1992, RES PHOTOSYNTHESIS, V2, P297; LERS A, 1992, J BIOL CHEM, V267, P17494; MARDER JB, 1984, J BIOL CHEM, V259, P3900; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P942, DOI 10.1021/bi00118a041; NIXON PJ, 1994, BIOCHEM SOC T, V22, P338, DOI 10.1042/bst0220338; Noguchi T, 1999, BIOCHEMISTRY-US, V38, P10187, DOI 10.1021/bi990631+; NOGUCHI T, 1995, BBA-BIOENERGETICS, V1228, P189, DOI 10.1016/0005-2728(94)00171-Z; ONO T, 1986, BIOCHIM BIOPHYS ACTA, V850, P380, DOI 10.1016/0005-2728(86)90194-5; Onoda K, 2000, PHOTOSYNTH RES, V63, P47, DOI 10.1023/A:1006362118267; SHESTAKOV SV, 1994, J BIOL CHEM, V269, P19354; Smith JC, 1997, INORG CHIM ACTA, V255, P99, DOI 10.1016/S0020-1693(96)05350-9; Socrates G., 1994, INFRARED RAMAN CHARA; Tamura N, 1997, PLANT CELL PHYSIOL, V38, P578, DOI 10.1093/oxfordjournals.pcp.a029207; TANG XS, 1994, P NATL ACAD SCI USA, V91, P704, DOI 10.1073/pnas.91.2.704; TAYLOR MA, 1988, FEBS LETT, V237, P229, DOI 10.1016/0014-5793(88)80207-2; Visser H, 2002, J AM CHEM SOC, V124, P11008, DOI 10.1021/ja020409j; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	44	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29622	29627		10.1074/jbc.M402397200	http://dx.doi.org/10.1074/jbc.M402397200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123635	hybrid			2022-12-25	WOS:000222445300098
J	Saravanamuthu, A; Vickers, TJ; Bond, CS; Peterson, MR; Hunter, WN; Fairlamb, AH				Saravanamuthu, A; Vickers, TJ; Bond, CS; Peterson, MR; Hunter, WN; Fairlamb, AH			Two interacting binding sites for quinacrine derivatives in the active site of trypanothione reductase - A template for drug design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-CRUZI; CRITHIDIA-FASCICULATA; CRYSTAL-STRUCTURE; SUBSTRATE-SPECIFICITY; GLUTATHIONE-REDUCTASE; LEISHMANIA-DONOVANI; OXIDATIVE STRESS; INHIBITORS; PURIFICATION; PROGRAM	Trypanothione reductase is a key enzyme in the trypanothione-based redox metabolism of pathogenic trypanosomes. Because this system is absent in humans, being replaced with glutathione and glutathione reductase, it offers a target for selective inhibition. The rational design of potent inhibitors requires accurate structures of enzyme-inhibitor complexes, but this is lacking for trypanothione reductase. We therefore used quinacrine mustard, an alkylating derivative of the competitive inhibitor quinacrine, to probe the active site of this dimeric flavoprotein. Quinacrine mustard irreversibly inactivates Trypanosoma cruzi trypanothione reductase, but not human glutathione reductase, in a time-dependent manner with a stoichiometry of two inhibitors bound per monomer. The rate of inactivation is dependent upon the oxidation state of trypanothione reductase, with the NADPH-reduced form being inactivated significantly faster than the oxidized form. Inactivation is slowed by clomipramine and a melarsen oxide-trypanothione adduct ( both are competitive inhibitors) but accelerated by quinacrine. The structure of the trypanothione reductase-quinacrine mustard adduct was determined to 2.7 Angstrom, revealing two molecules of inhibitor bound in the trypanothione-binding site. The acridine moieties interact with each other through pi-stacking effects, and one acridine interacts in a similar fashion with a tryptophan residue. These interactions provide a molecular explanation for the differing effects of clomipramine and quinacrine on inactivation by quinacrine mustard. Synergism with quinacrine occurs as a result of these planar acridines being able to stack together in the active site cleft, thereby gaining an increased number of binding interactions, whereas antagonism occurs with nonplanar molecules, such as clomipramine, where stacking is not possible.	Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland	University of Dundee	Fairlamb, AH (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland.	a.h.fairlamb@dundee.ac.uk	Bond, Charles/AAF-9608-2020; Hunter, William/AAE-3947-2019; Bond, Charles S/B-4094-2011; Fairlamb, Alan/A-5272-2009	Bond, Charles/0000-0002-9584-6783; Bond, Charles S/0000-0002-9584-6783; Fairlamb, Alan/0000-0001-5134-0329	Wellcome Trust [079838] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABOAGYEKWARTENG T, 1992, MOL MICROBIOL, V6, P3089, DOI 10.1111/j.1365-2958.1992.tb01766.x; Ariyanayagam MR, 2001, MOL BIOCHEM PARASIT, V115, P189, DOI 10.1016/S0166-6851(01)00285-7; ATTWOOD D, 1995, ADV COLLOID INTERFAC, V55, P271, DOI 10.1016/0001-8686(94)00228-5; Augustyns K, 2001, CURR PHARM DESIGN, V7, P1117, DOI 10.2174/1381612013397564; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENSON TJ, 1992, BIOCHEM J, V286, P9, DOI 10.1042/bj2860009; Bond CS, 1999, STRUCTURE, V7, P81, DOI 10.1016/S0969-2126(99)80011-2; Bonse S, 1999, J MED CHEM, V42, P5448, DOI 10.1021/jm990386s; BORGES A, 1995, EUR J BIOCHEM, V228, P745, DOI 10.1111/j.1432-1033.1995.tb20319.x; BROCKLEHURST K, 1979, BIOCHEM J, V181, P775, DOI 10.1042/bj1810775; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CARLSON GM, 1984, BIOCHIM BIOPHYS ACTA, V789, P347, DOI 10.1016/0167-4838(84)90191-2; Chibale K, 2001, BIOORG MED CHEM LETT, V11, P2655, DOI 10.1016/S0960-894X(01)00528-5; Chitkul B, 2000, BIOORG MED CHEM LETT, V10, P2367, DOI 10.1016/S0960-894X(00)00471-6; COURSEIL.C, 1973, ACTA CRYSTALLOGR B, V29, P2349, DOI 10.1107/S0567740873006680; CUNNINGHAM ML, 1995, EUR J BIOCHEM, V230, P460, DOI 10.1111/j.1432-1033.1995.tb20583.x; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; FAIRLAMB AH, 1989, P NATL ACAD SCI USA, V86, P2607, DOI 10.1073/pnas.86.8.2607; Fletcher DA, 1996, J CHEM INF COMP SCI, V36, P746, DOI 10.1021/ci960015+; Fries D.S., 2003, BURGERS MED CHEM DRU, P1033; Garforth J, 1997, J ENZYM INHIB, V12, P161, DOI 10.3109/14756369709029312; HENDERSON GB, 1987, BIOCHEMISTRY-US, V26, P3023, DOI 10.1021/bi00385a011; Jacoby EM, 1996, PROTEINS, V24, P73, DOI 10.1002/(SICI)1097-0134(199601)24:1&lt;73::AID-PROT5&gt;3.0.CO;2-P; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUNG MJ, 1975, BIOCHEM BIOPH RES CO, V67, P301, DOI 10.1016/0006-291X(75)90316-2; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krauth-Siegel R.L., 1991, P493; Krieger S, 2000, MOL MICROBIOL, V35, P542, DOI 10.1046/j.1365-2958.2000.01721.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MANSONBAHR PEC, 1987, MANSONS TROPICAL DIS, P54; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OSULLIVAN MC, 1995, BIOORG MED CHEM LETT, V5, P1957, DOI 10.1016/0960-894X(95)00331-M; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OUELLETTE M, 1993, PARASITOL TODAY, V9, P150, DOI 10.1016/0169-4758(93)90135-3; Schmidt Armin, 2002, Current Topics in Medicinal Chemistry, V2, P1239, DOI 10.2174/1568026023393048; SHAMES SL, 1986, BIOCHEMISTRY-US, V25, P3519, DOI 10.1021/bi00360a007; Tovar J, 1998, P NATL ACAD SCI USA, V95, P5311, DOI 10.1073/pnas.95.9.5311; World Health Organization, 2002, WORLD REPORT VIOLENC, P169; WORTHINGTON DJ, 1974, EUR J BIOCHEM, V48, P167, DOI 10.1111/j.1432-1033.1974.tb03754.x; YIN H, 1996, CHEM COMMUN, V1, P973; Zani CL, 2003, MEM I OSWALDO CRUZ, V98, P565, DOI 10.1590/S0074-02762003000400026; Zhang YH, 1996, PROTEIN SCI, V5, P52	47	91	92	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29493	29500		10.1074/jbc.M403187200	http://dx.doi.org/10.1074/jbc.M403187200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15102853	hybrid, Green Accepted			2022-12-25	WOS:000222445300082
J	Zhang, QL; Dickson, A; Doupnik, CA				Zhang, QL; Dickson, A; Doupnik, CA			G beta gamma-activated inwardly rectifying K+ (GIRK) channel activation kinetics via G alpha(i) and G alpha(o)-coupled receptors are determined by G alpha-specific interdomain interactions that affect GDP release rates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN REGULATION; NUCLEOTIDE EXCHANGE; ACUTE DESENSITIZATION; MEDIATED ACTIVATION; GTP HYDROLYSIS; RGS PROTEINS; SUBUNITS; POTASSIUM; REGULATOR; BINDING	Gbetagamma-activated inwardly rectifying K+ (GIRK) channels have distinct gating properties when activated by receptors coupled specifically to Galpha(o) versus Galpha(i) subunit isoforms, with Galpha(o)-coupled currents having similar to3-fold faster agonist-evoked activation kinetics. To identify the molecular determinants in Galpha subunits mediating these kinetic differences, chimeras were constructed using pertussis toxin (PTX)-insensitive Galpha(oA) and Galpha(i2) mutant subunits (Galpha(oA(C351G)) and Galpha(i2(C352G))) and examined in PTX-treated Xenopus oocytes expressing muscarinic m2 receptors and Kir3.1/3.2a channels. These experiments revealed that the alpha-helical N-terminal region (amino acids 1 - 161) and the switch regions of Galpha(i2) ( amino acids 162 - 262) both partially contribute to slowing the GIRK activation time course when compared with the Galpha(oA(C351G))-coupled response. When present together, they fully reproduce Galpha(i2(C352G))- coupled GIRK kinetics. The Galpha(i2) C-terminal region (amino acids 263-355) had no significant effect on GIRK kinetics. Complementary responses were observed with chimeras substituting the Galpha(o) switch regions into the Galpha(i2(C352G)) subunit, which partially accelerated the GIRK activation rate. The Galpha(oA)/Galpha(i2) chimera results led us to examine an interaction between the alpha-helical domain and the Ras-like domain previously implicated in mediating a 4-fold slower in vitro basal GDP release rate in Galpha(i1) compared with Galpha(o). Mutations disrupting the interdomain contact in Galpha(i2(C352G)) at either the alphaD-alphaE loop (R145A) or the switch III loop (L233Q/A236H/E240T/ M241T), significantly accelerated the GIRK activation kinetics consistent with the Galpha(i2) interdomain interface regulating receptor-catalyzed GDP release rates in vivo. We propose that differences in Galpha(i) versus Galpha(o)-coupled GIRK activation kinetics are due to intrinsic differences in receptor-catalyzed GDP release that rate-limit Gbetagamma production and is attributed to heterogeneity in Galpha(i) and Galpha(o) interdomain contacts.	Univ S Florida, Coll Med, Dept Physiol & Biophys, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Doupnik, CA (corresponding author), Univ S Florida, Coll Med, Dept Physiol & Biophys, 12901 Bruce B Downs Blvd,MDC8, Tampa, FL 33612 USA.	cdoupnik@hsc.usf.edu	Doupnik, Craig A/I-3617-2012	Doupnik, Craig A/0000-0002-7314-0747				Azpiazu I, 2001, J BIOL CHEM, V276, P41742, DOI 10.1074/jbc.M104034200; Benians A, 2003, J BIOL CHEM, V278, P10851, DOI 10.1074/jbc.M212299200; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; Cavalli A, 2000, J BIOL CHEM, V275, P23693, DOI 10.1074/jbc.M910395199; Chuang HH, 1998, P NATL ACAD SCI USA, V95, P11727, DOI 10.1073/pnas.95.20.11727; CODINA J, 1994, J BIOL CHEM, V269, P29339; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DENKER BM, 1995, BIOCHEMISTRY-US, V34, P5544, DOI 10.1021/bi00016a028; Doupnik CA, 2004, METHOD ENZYMOL, V389, P131; Doupnik CA, 2001, BBA-GENE STRUCT EXPR, V1522, P97, DOI 10.1016/S0167-4781(01)00342-6; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1998, J BIOL CHEM, V273, P18405, DOI 10.1074/jbc.273.29.18405; Greif GJ, 2000, J NEUROPHYSIOL, V83, P1010, DOI 10.1152/jn.2000.83.2.1010; Grishina G, 1998, J BIOL CHEM, V273, P15053, DOI 10.1074/jbc.273.24.15053; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; LINDER ME, 1990, J BIOL CHEM, V265, P8243; Lutz LB, 2000, J BIOL CHEM, V275, P41512, DOI 10.1074/jbc.M006757200; Marin EP, 2001, J BIOL CHEM, V276, P23873, DOI 10.1074/jbc.M101197200; Marsh SR, 1998, MOL PHARMACOL, V53, P981; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Remmers AE, 1999, BIOCHEMISTRY-US, V38, P13795, DOI 10.1021/bi990887f; Saitoh O, 2001, J BIOL CHEM, V276, P5052, DOI 10.1074/jbc.M006917200; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Sheng YL, 2001, CURR BIOL, V11, P405, DOI 10.1016/S0960-9822(01)00123-3; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Stanfield PR, 2002, REV PHYSIOL BIOCH P, V145, P47, DOI 10.1007/BFb0116431; Stuhmer W., 1995, SINGLE CHANNEL RECOR, P341, DOI DOI 10.1007/978-1-4419-1229-9_15; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Warner DR, 1998, J BIOL CHEM, V273, P23976, DOI 10.1074/jbc.273.37.23976; Yamada M, 1998, PHARMACOL REV, V50, P723; Zhang QL, 2002, J PHYSIOL-LONDON, V545, P355, DOI 10.1113/jphysiol.2002.032151; Zhong HL, 2003, J BIOL CHEM, V278, P7278, DOI 10.1074/jbc.M208819200	41	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29787	29796		10.1074/jbc.M403359200	http://dx.doi.org/10.1074/jbc.M403359200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123672	hybrid			2022-12-25	WOS:000222445300115
J	Gazzarrini, S; Kang, M; Van Etten, JL; Tayefeh, S; Kast, SM; DiFrancesco, D; Thiel, G; Moroni, A				Gazzarrini, S; Kang, M; Van Etten, JL; Tayefeh, S; Kast, SM; DiFrancesco, D; Thiel, G; Moroni, A			Long distance interactions within the potassium channel pore are revealed by molecular diversity of viral proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; CHLORELLA VIRUSES; SELECTIVITY; CONDUCTION; ACTIVATION; DESIGN; DOMAIN; BLOCK; KAT1; CS+	Kcv is a 94-amino acid protein encoded by chlorella virus PBCV-1 that corresponds to the pore module of K+ channels. Therefore, Kcv can be a model for studying the protein design of K+ channel pores. We analyzed the molecular diversity generated by similar to1 billion years of evolution on kcv genes isolated from 40 additional chlorella viruses. Because the channel is apparently required for virus replication, the Kcv variants are all functional and contain multiple and dispersed substitutions that represent a repertoire of allowed sets of amino acid substitutions ( from 4 to 12 amino acids). Correlations between amino acid substitutions and the new properties displayed by these channels guided site-directed mutations that revealed synergistic amino acid interactions within the protein as well as previously unknown interactions between distant channel domains. The effects of these multiple changes were not predictable from a priori structural knowledge of the channel pore.	Univ Milan, Dept Biol, I-20133 Milan, Italy; Univ Milan, CNR, Ist Biofis Mi, I-20133 Milan, Italy; Univ Milan, Dept Biomol Sci & Biotechnol, I-20133 Milan, Italy; Univ Nebraska, Dept Plant Pathol, Lincoln, NE 68583 USA; Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE 68583 USA; Tech Univ Darmstadt, Inst Inorgan & Phys Chem, D-64287 Darmstadt, Germany; Tech Univ Darmstadt, Dept Bot, D-64287 Darmstadt, Germany; Unita Milano Univ, Ist Nazl Fis Mat, I-20133 Milan, Italy	University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); University of Milan; University of Milan; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; Technical University of Darmstadt; Technical University of Darmstadt; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Milan	Moroni, A (corresponding author), Univ Milan, Dept Biol, Via Celoria 26, I-20133 Milan, Italy.	anna.moroni@unimi.it	DiFrancesco, Dario/G-8408-2017; moroni, anna/H-2097-2014	DiFrancesco, Dario/0000-0002-7322-1790; moroni, anna/0000-0002-1860-406X; Thiel, Gerhard/0000-0002-2335-1351; Tayefeh, Sascha/0000-0002-3338-3488; gazzarrini, sabrina/0000-0003-3062-7536	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032441] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR 15635] Funding Source: Medline; NIGMS NIH HHS [GM 32441] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Becker D, 1996, P NATL ACAD SCI USA, V93, P8123, DOI 10.1073/pnas.93.15.8123; BRICKMANN J, 1995, DATA VISUALIZATION M, P83; Choe S, 2002, NAT REV NEUROSCI, V3, P115, DOI 10.1038/nrn727; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Garafoli S, 2003, BIOPHYS J, V84, P2814, DOI 10.1016/S0006-3495(03)70011-3; Gazzarrini S, 2003, FEBS LETT, V552, P12, DOI 10.1016/S0014-5793(03)00777-4; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Ichida AM, 1996, J MEMBRANE BIOL, V151, P53, DOI 10.1007/s002329900057; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Kang M, 2004, P NATL ACAD SCI USA, V101, P5318, DOI 10.1073/pnas.0307824100; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Lu Z, 2001, NATURE, V413, P809, DOI 10.1038/35101535; Lu Z, 2002, J GEN PHYSIOL, V120, P663, DOI 10.1085/jgp.20028696; MACKINNON R, 1991, J BIOENERG BIOMEMBR, V23, P647, DOI 10.1007/BF00785815; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; Minor DL, 1999, CELL, V96, P879, DOI 10.1016/S0092-8674(00)80597-8; Moroni A, 2002, FEBS LETT, V530, P65, DOI 10.1016/S0014-5793(02)03397-5; Plugge B, 2000, SCIENCE, V287, P1641, DOI 10.1126/science.287.5458.1641; Saven JG, 2002, CURR OPIN STRUC BIOL, V12, P453, DOI 10.1016/S0959-440X(02)00347-0; Thompson GA, 2000, J PHYSIOL-LONDON, V526, P231, DOI 10.1111/j.1469-7793.2000.00231.x; Tobin MB, 2000, CURR OPIN STRUC BIOL, V10, P421, DOI 10.1016/S0959-440X(00)00109-3; Tristani-Firouzi M, 2002, J BIOL CHEM, V277, P18994, DOI 10.1074/jbc.M200410200; Van Etten JL, 2003, ANNU REV GENET, V37, P153, DOI 10.1146/annurev.genet.37.110801.143915; Yellen G, 1999, CURR OPIN NEUROBIOL, V9, P267, DOI 10.1016/S0959-4388(99)80039-7; Yifrach O, 2002, CELL, V111, P231, DOI 10.1016/S0092-8674(02)01013-9	27	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28443	28449		10.1074/jbc.M401184200	http://dx.doi.org/10.1074/jbc.M401184200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15105432	hybrid			2022-12-25	WOS:000222265400078
J	Sesaki, H; Jensen, RE				Sesaki, H; Jensen, RE			Ugo1p links the Fzo1p and Mgm1p GTPases for mitochondrial fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED GTPASE; DOMINANT OPTIC ATROPHY; OUTER-MEMBRANE; SACCHAROMYCES-CEREVISIAE; YEAST REQUIRES; PROTEIN; DNA; DIVISION; FISSION; SHAPE	In yeast, mitochondrial fusion requires Ugo1p and two GTPases, Fzo1p and Mgm1p. Ugo1p is anchored in the mitochondrial outer membrane with its N terminus facing the cytosol and C terminus in the intermembrane space. Fzo1p is also an outer membrane protein, whereas Mgm1p is located in the intermembrane space. Recent studies suggest that these three proteins form protein complexes that mediate mitochondrial fusion. Here, we show that the cytoplasmic domain of Ugo1p directly interacts with Fzo1p, whereas its intermembrane space domain binds to Mgm1p. We identified the Ugo1p-binding site in Fzo1p and demonstrated that Ugo1p-Fzo1p interaction is essential for the formation of mitochondrial shape, maintenance of mitochondrial DNA, and fusion of mitochondria. Although the GTPase domains of Fzo1p and Mgm1p regulate mitochondrial fusion, they were not required for association with Ugo1p. Furthermore, we found that Ugo1p bridges the interaction between Fzo1p and Mgm1p in mitochondria. Our data indicate that distinct regions of Ugo1p bind directly to Fzo1p and Mgm1p and thereby link these two GTPases during mitochondrial fusion.	Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Sesaki, H (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725 N Wolfe St, Baltimore, MD 21205 USA.	hsesaki@jhmi.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054021] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 54021-06] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS A, 1997, METHODS YEAST GENETI, P145; Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Cerveny KL, 2001, MOL BIOL CELL, V12, P309, DOI 10.1091/mbc.12.2.309; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Fekkes P, 2000, J CELL BIOL, V151, P333, DOI 10.1083/jcb.151.2.333; Fritz S, 2001, J CELL BIOL, V152, P683, DOI 10.1083/jcb.152.4.683; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; Herlan M, 2003, J BIOL CHEM, V278, P27781, DOI 10.1074/jbc.M211311200; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; Jensen RE, 2000, MICROSC RES TECHNIQ, V51, P573, DOI 10.1002/1097-0029(20001215)51:6<573::AID-JEMT7>3.0.CO;2-2; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; McQuibban GA, 2003, NATURE, V423, P537, DOI 10.1038/nature01633; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; Mozdy AD, 2003, NAT REV MOL CELL BIO, V4, P468, DOI 10.1038/nrm1125; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Rapaport D, 1998, J BIOL CHEM, V273, P20150, DOI 10.1074/jbc.273.32.20150; Rojo M, 2002, J CELL SCI, V115, P1663; Santel A, 2001, J CELL SCI, V114, P867; Satoh M, 2003, BIOCHEM BIOPH RES CO, V300, P482, DOI 10.1016/S0006-291X(02)02874-7; Scott SV, 2003, CURR OPIN CELL BIOL, V15, P482, DOI 10.1016/S0955-0674(03)00070-X; Sesaki H, 2003, BIOCHEM BIOPH RES CO, V308, P276, DOI 10.1016/S0006-291X(03)01348-2; Sesaki H, 2003, MOL BIOL CELL, V14, P2342, DOI 10.1091/mbc.E02-12-0788; Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699; Sesaki H, 2001, J CELL BIOL, V152, P1123, DOI 10.1083/jcb.152.6.1123; Shepard KA, 1999, J CELL BIOL, V144, P711, DOI 10.1083/jcb.144.4.711; SIKORSKI RS, 1989, GENETICS, V122, P19; Tieu Q, 2000, J CELL BIOL, V151, P353, DOI 10.1083/jcb.151.2.353; Westermann B, 2003, BBA-MOL CELL RES, V1641, P195, DOI 10.1016/S0167-4889(03)00091-0; Wong ED, 2003, J CELL BIOL, V160, P303, DOI 10.1083/jcb.200209015; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341; Yaffe MP, 2003, NAT CELL BIOL, V5, P497, DOI 10.1038/ncb0603-497b	36	136	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28298	28303		10.1074/jbc.M401363200	http://dx.doi.org/10.1074/jbc.M401363200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15087460	hybrid			2022-12-25	WOS:000222265400061
J	Alexiadis, V; Lusser, A; Kadonaga, JT				Alexiadis, V; Lusser, A; Kadonaga, JT			A conserved N-terminal motif in Rad54 is important for chromatin remodeling and homologous strand pairing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINATION FACTORS RAD51; HISTONE METHYLATION; YEAST RAD51; DNA; PROTEIN; MECHANISMS; CATALYSIS; BREAKS; ACF1	The Swi2/Snf2-related protein Rad54 is a chromatin remodeling enzyme that is important for homologous strand pairing catalyzed by the eukaryotic recombinase Rad51. The chromatin remodeling and DNA-stimulated ATPase activities of Rad54 are significantly enhanced by Rad51. To investigate the functions of Rad54, we generated and analyzed a series of mutant Rad54 proteins. Notably, the deletion of an N-terminal motif ( amino acid residues 2 - 9), which is identical in Rad54 in Drosophila, mice, and humans, results in a complete loss of chromatin remodeling and strand pairing activities, and partial inhibition of the ATPase activity. In contrast, this conserved N-terminal motif has no apparent effect on the ability of DNA to stimulate the ATPase activity or of Rad51 to enhance the DNA-stimulated ATPase activity. Unexpectedly, as the N terminus of Rad54 is progressively truncated, the mutant proteins regain partial chromatin remodeling activity as well as essentially complete DNA-stimulated ATPase activity, both of which are no longer responsive to Rad51. These findings suggest that the N-terminal region of Rad54 contains an autoinhibitory activity that is relieved by Rad51.	Univ Calif San Diego, Mol Biol Sect, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Kadonaga, JT (corresponding author), Univ Calif San Diego, Mol Biol Sect, 0347,Pacific Hall,Rm 2212B,9500 Gilman Dr, La Jolla, CA 92093 USA.	jkadonaga@ucsd.edu		Lusser, Alexandra/0000-0002-2226-9081	NIGMS NIH HHS [GM46995] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046995] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexeev A, 2003, NAT STRUCT BIOL, V10, P182, DOI 10.1038/nsb901; Alexiadis V, 2002, GENE DEV, V16, P2767, DOI 10.1101/gad.1032102; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Cromie GA, 2001, MOL CELL, V8, P1163, DOI 10.1016/S1097-2765(01)00419-1; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Emerson BM, 2002, CELL, V109, P267, DOI 10.1016/S0092-8674(02)00740-7; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Flaus A, 2001, CURR OPIN GENET DEV, V11, P148, DOI 10.1016/S0959-437X(00)00172-6; Fyodorov DV, 2002, MOL CELL BIOL, V22, P6344, DOI 10.1128/MCB.22.18.6344-6353.2002; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; Haber JE, 2000, CURR OPIN CELL BIOL, V12, P286, DOI 10.1016/S0955-0674(00)00090-9; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Jaskelioff M, 2003, J BIOL CHEM, V278, P9212, DOI 10.1074/jbc.M211545200; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Lusser A, 2003, BIOESSAYS, V25, P1192, DOI 10.1002/bies.10359; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; Mazin AV, 2003, J BIOL CHEM, V278, P14029, DOI 10.1074/jbc.M212779200; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Peterson CL, 2002, CURR BIOL, V12, pR245, DOI 10.1016/S0960-9822(02)00782-0; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Sigurdsson S, 2002, J BIOL CHEM, V277, P42790, DOI 10.1074/jbc.M208004200; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Tan TLR, 2003, DNA REPAIR, V2, P787, DOI 10.1016/S1568-7864(03)00070-3; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Varga-Weisz P, 2001, ONCOGENE, V20, P3076, DOI 10.1038/sj.onc.1204332; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	35	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27824	27829		10.1074/jbc.M402648200	http://dx.doi.org/10.1074/jbc.M402648200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15105430	hybrid			2022-12-25	WOS:000222120400118
J	Qiu, GH; Tan, LKS; Loh, KS; Lim, CY; Srivastava, G; Tsai, ST; Tsao, SW; Tao, Q				Qiu, GH; Tan, LKS; Loh, KS; Lim, CY; Srivastava, G; Tsai, ST; Tsao, SW; Tao, Q			The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma	ONCOGENE			English	Article						3p21; NPC; BLU; RASSF1A; methylation; heat shock	EPSTEIN-BARR-VIRUS; HUMAN-CHROMOSOME 3P21.3; DE-NOVO METHYLATION; ABERRANT PROMOTER HYPERMETHYLATION; HOMOZYGOUS DELETION; LUNG-CANCER; CPG ISLANDS; SHORT ARM; REPRESSES TRANSCRIPTION; DNA METHYLATION	Loss of heterozygosity at 3p21 is common in various cancers including nasopharyngeal carcinoma (NPC). BLU is one of the candidate tumor suppressor genes (TSGs) in this region. Ectopic expression of BLU results in the inhibition of colony formation of cancer cells, suggesting that BLU is a tumor suppressor. We have identified a functional BLU promoter and found that it can be activated by environmental stresses such as heat shock, and is regulated by E2F. The promoter and first exon are located within a CpG island. BLU is highly expressed in testis and normal upper respiratory tract tissues including nasopharynx. However, in all seven NPC cell lines examined, BLU expression was downregulated and inversely correlated with promoter hypermethylation. Biallelic epigenetic inactivation of BLU was also observed in three cell lines. Hypermethylation was further detected in 19/29 (66%) of primary NPC tumors, but not in normal nasopharyngeal tissues. Treatment of NPC cell lines with 5-aza-2'-deoxycytidine activated BLU expression along with promoter demethylation. Although hypermethylation of RASSF1A, another TSG located immediately downstream of BLU, was detected in 20/27 (74%) of NPC tumors, no correlation between the hypermethylation of these two TSGs was observed (P=0.6334). In addition to methylation, homozygous deletion of BLU was found in 7/29 (24%) of tumors. Therefore, BLU is a stress-responsive gene, being disrupted in 83% (24/29) of NPC tumors by either epigenetic or genetic mechanisms. Our data are consistent with the interpretation that BLU is a TSG for NPC.	Div Johns Hopkins Singapore, Canc Epigenet Tumor Virol Lab, Singapore 117597, Singapore; Natl Univ Singapore, Dept Otolaryngol, Singapore 117548, Singapore; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Natl Cheng Kung Univ, Dept Otolaryngol, Tainan 70101, Taiwan; Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Johns Hopkins, Sydney Kimmel Comprehens Canc Ctr, Baltimore, MD USA	National University of Singapore; University of Hong Kong; National Cheng Kung University; University of Hong Kong; Johns Hopkins University; Johns Hopkins Medicine	Tao, Q (corresponding author), Div Johns Hopkins Singapore, Canc Epigenet Tumor Virol Lab, CRC MD11 Level 5,NUS,10 Med Dr, Singapore 117597, Singapore.	taoqia@jhs.com.sg	Tao, Qian/T-4743-2018; Tsao, George/C-4422-2009; QIU, GUO-HUA/B-5806-2011	Tao, Qian/0000-0001-5383-4808; QIU, GUO-HUA/0000-0001-6202-4284				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; AGATHANGGELOU A, 2002, AM ASS CANC RES 93 A; Armstrong RW, 2000, INT J EPIDEMIOL, V29, P991, DOI 10.1093/ije/29.6.991; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Balmain A, 2002, NATURE, V417, P235, DOI 10.1038/417235a; Baylin SB, 1998, ADV CANCER RES, V72, P141; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; Byun DS, 2001, CANCER RES, V61, P7034; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; CHAN ATC, 2004, IN PRESS J CLIN ONCO, V20; Chen YJ, 1999, GENE CHROMOSOME CANC, V25, P169, DOI 10.1002/(SICI)1098-2264(199906)25:2<169::AID-GCC13>3.3.CO;2-9; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Cheung ST, 1999, INT J CANCER, V83, P121, DOI 10.1002/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO;2-F; Chien G, 2001, CANCER GENET CYTOGEN, V126, P63, DOI 10.1016/S0165-4608(00)00392-7; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Deng LW, 1998, GENE CHROMOSOME CANC, V23, P21, DOI 10.1002/(SICI)1098-2264(199809)23:1<21::AID-GCC4>3.0.CO;2-8; Dong SM, 2001, J NATL CANCER I, V93, P858, DOI 10.1093/jnci/93.11.858; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; Esteller M, 1999, CANCER RES, V59, P67; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Fang Y, 2001, GENE CHROMOSOME CANC, V30, P254, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1086>3.0.CO;2-D; Feng P, 2000, J GEN VIROL, V81, P2417, DOI 10.1099/0022-1317-81-10-2417; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; Goessl C, 2000, CANCER RES, V60, P5941; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Hu LF, 1996, GENE CHROMOSOME CANC, V17, P118, DOI 10.1002/(SICI)1098-2264(199610)17:2<118::AID-GCC7>3.0.CO;2-8; HUANG DP, 1991, CANCER GENET CYTOGEN, V54, P91, DOI 10.1016/0165-4608(91)90035-S; HUANG DP, 1994, CANCER RES, V54, P4003; Hui ABY, 1999, INT J CANCER, V82, P498, DOI 10.1002/(SICI)1097-0215(19990812)82:4<498::AID-IJC5>3.0.CO;2-S; Jalbout M, 2003, CANCER LETT, V193, P75, DOI 10.1016/S0304-3835(02)00697-3; Ji L, 2002, CANCER RES, V62, P2715; Kochetkova M, 2002, CANCER RES, V62, P4599; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kourea HP, 1999, AM J PATHOL, V155, P1855, DOI 10.1016/S0002-9440(10)65504-6; LeBoeuf RD, 1998, J BIOL CHEM, V273, P361, DOI 10.1074/jbc.273.1.361; Lee MG, 2001, CANCER RES, V61, P6688; Lerman MI, 2000, CANCER RES, V60, P6116; Liu L, 2000, J Tongji Med Univ, V20, P336; LIU L, 2000, J TONGJI MED U, V20, P342; Lo KW, 1996, CANCER RES, V56, P2721; Lo KW, 2000, CANCER RES, V60, P3348; Lo KW, 2001, CANCER RES, V61, P3877; LO KW, 1994, INT J ONCOL, V4, P1359; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Murray PG, 2004, ONCOGENE, V23, P1326, DOI 10.1038/sj.onc.1207313; Nass SJ, 2000, CANCER RES, V60, P4346; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; Nosaka K, 2000, CANCER RES, V60, P1043; Palmisano WA, 2000, CANCER RES, V60, P5954; Raab-Traub N, 1992, Semin Cancer Biol, V3, P297; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rosas SLB, 2001, CANCER RES, V61, P939; Singal R, 2001, BLOOD, V98, P3441, DOI 10.1182/blood.V98.12.3441; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Srivastava G, 2000, BLOOD, V95, P2443, DOI 10.1182/blood.V95.7.2443.007k18_2443_2445; SUN Y, 1993, ONCOGENE, V8, P791; Sung NS, 2000, INT J CANCER, V86, P244, DOI 10.1002/(SICI)1097-0215(20000415)86:2<244::AID-IJC14>3.3.CO;2-M; Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7; Tao Q, 1998, BLOOD, V91, P1373, DOI 10.1182/blood.V91.4.1373; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Tsang YS, 1999, INT J CANCER, V83, P305, DOI 10.1002/(SICI)1097-0215(19991029)83:3<305::AID-IJC3>3.0.CO;2-D; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599; VANGROENINGEN CJ, 1986, CANCER RES, V46, P4831; Vokes EE, 1997, LANCET, V350, P1087, DOI 10.1016/S0140-6736(97)07269-3; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956; Yan PS, 2003, CANCER RES, V63, P6178; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; ZHANG SH, 1983, INT J CANCER, V31, P587, DOI 10.1002/ijc.2910310509	75	109	121	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4793	4806		10.1038/sj.onc.1207632	http://dx.doi.org/10.1038/sj.onc.1207632			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122337				2022-12-25	WOS:000221799200015
J	Xie, TX; Wei, DY; Liu, MG; Gao, AC; Ali-Osman, F; Sawaya, R; Huang, SY				Xie, TX; Wei, DY; Liu, MG; Gao, AC; Ali-Osman, F; Sawaya, R; Huang, SY			Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis	ONCOGENE			English	Article						Stat3; MMP-2; invasion; metastasis; melanoma	PROSTATE-CANCER CELLS; IV COLLAGENASE; GELATINASE-A; TISSUE INHIBITOR; GROWTH-FACTOR; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTORS; MELANOMA PROGRESSION; MALIGNANT-MELANOMA; SUPPRESSES GROWTH	The expression of matrix metalloproteinase-2 (MMP-2) has been linked with tumor invasion, angiogenesis, and metastasis. However, the molecular basis for MMP-2 overexpression in tumor cells remains unclear. In this study, by using K-1735 melanoma system, we demonstrated that highly metastatic C4, M 2, and X21 tumor cells express elevated MMP-2 mRNA and enzymatic activity, whereas poorly metastatic C10, C19, and C23 tumor cells express much lower levels. Moreover, a concomitant elevated Stat3 activity has been detected in these metastatic tumor cells that overexpress MMP-2. Transfection of constitutively activated Stat3 into poorly metastatic C23 tumor cells directly activated the MMP-2 promoter, whereas the expression of a dominant-negative Stat3 in highly metastatic C4 tumor cells inhibited the MMP-2 promoter. A high-affinity Stat3-binding element was identified in the MMP-2 promoter and Stat3 protein bound directly to the MMP-2 promoter. Blockade of activated Stat3 through expression of a dominant-negative Stat3 significantly suppressed MMP-2 expression in the metastatic tumor cells. Therefore, overexpression of MMP-2 in the metastatic melanoma cells can be attributed to elevated Stat3 activity, and Stat3 upregulates the transcription of MMP-2 through direct interaction with the MMP-2 promoter. Furthermore, blockade of activated Stat3 in highly metastatic C4 cells significantly suppressed the invasiveness of the tumor cells, inhibited tumor growth, and prevented metastasis in nude mice. Collectively, these studies suggest that Stat3 signaling directly regulates MMP-2 expression, tumor invasion, and metastasis, and that Stat3 activation might be a crucial event in the development of metastasis.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Unit 064, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Roswell Pk Canc Inst, Dept Med & Pharmacol, Buffalo, NY 14263 USA; Univ Texas, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Roswell Park Cancer Institute; University of Texas System; University of Texas System; UTMD Anderson Cancer Center	Huang, SY (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Unit 064, 1515 Holcombe Blvd, Houston, TX 77030 USA.	suhuang@mdanderson.org						AUKERMAN SL, 1986, JNCI-J NATL CANCER I, V77, P915; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; En-Nia A, 2002, BIOCHEM J, V362, P693, DOI 10.1042/0264-6021:3620693; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; FIDLER IJ, 1986, CANCER RES, V46, P5167; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; Hofmann UB, 2000, J PATHOL, V191, P245; Hofmann UB, 1999, BRIT J CANCER, V81, P774, DOI 10.1038/sj.bjc.6690763; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang SY, 2002, J NATL CANCER I, V94, P1134; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Itoh T, 1998, CANCER RES, V58, P1048; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Kossakowska AE, 1999, BLOOD, V94, P2080, DOI 10.1182/blood.V94.6.2080.418k30_2080_2089; KRIPKE ML, 1979, JNCI-J NATL CANCER I, V63, P541, DOI 10.1093/jnci/63.3.541; Kurschat P, 1999, J BIOL CHEM, V274, P21056, DOI 10.1074/jbc.274.30.21056; Kurschat P, 2002, J PATHOL, V197, P179, DOI 10.1002/path.1080; Lee AY, 1997, P NATL ACAD SCI USA, V94, P4424, DOI 10.1073/pnas.94.9.4424; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Luca M, 1997, AM J PATHOL, V151, P1105; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Miyake H, 1997, J UROLOGY, V157, P2351, DOI 10.1016/S0022-5347(01)64779-7; Moon A, 2000, INT J CANCER, V85, P176, DOI 10.1002/(SICI)1097-0215(20000115)85:2<176::AID-IJC5>3.0.CO;2-E; Moses MA, 1997, STEM CELLS, V15, P180, DOI 10.1002/stem.150180; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Ni Z, 2000, CANCER RES, V60, P1225; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niu GL, 1999, CANCER RES, V59, P5059; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; SEFTOR REB, 1993, CANCER RES, V53, P3411; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Stetler-Stevenson W G, 2001, Surg Oncol Clin N Am, V10, P383; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TALMADGE JE, 1982, J NATL CANCER I, V69, P975; Thant AA, 1999, ONCOGENE, V18, P6555, DOI 10.1038/sj.onc.1203049; Vaisanen A, 1996, J PATHOL, V180, P283; Vaisanen A, 1998, J PATHOL, V186, P51; van der Zee E, 1998, J PERIODONTAL RES, V33, P65; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200; Yu AE, 1996, BIOCHEM CELL BIOL, V74, P823, DOI 10.1139/o96-088; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	59	431	483	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3550	3560		10.1038/sj.onc.1207383	http://dx.doi.org/10.1038/sj.onc.1207383			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116091				2022-12-25	WOS:000221101700006
J	Bouhss, A; Crouvoisier, M; Blanot, D; Mengin-Lecreulx, D				Bouhss, A; Crouvoisier, M; Blanot, D; Mengin-Lecreulx, D			Purification and characterization of the bacterial MraY translocase catalyzing the first membrane step of peptidoglycan biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLMURAMYL-PENTAPEPTIDE-TRANSLOCASE; ESCHERICHIA-COLI; OVER-PRODUCTION; D-GLUTAMATE; L-ALANINE; GENE; TUNICAMYCIN; TRANSFERASE; INHIBITION; PHOSPHATE	The MraY translocase catalyzes the first membrane step of bacterial cell wall peptidoglycan synthesis (i.e. the transfer of the phospho-N-acetylmuramoyl-pentapeptide motif onto the undecaprenyl phosphate carrier lipid), a reversible reaction yielding undecaprenyl-pyrophosphoryl-N-acetylmuramoyl-pentapeptide ( lipid intermediate I). This essential integral membrane protein, which is considered as a very promising target for the search of new antibacterial compounds, has thus far been clearly underexploited due to its intrinsic refractory nature to overexpression and purification. We here report conditions for the high level overproduction and for the first time the purification to homogeneity of milligram quantities of MraY protein. The kinetic parameters and effects of pH, salts, cations, and detergents on enzyme activity are described, taking the Bacillus subtilis MraY translocase as a model.	Univ Paris 11, Inst Biochim & Biophys Mol & Cellulaire, UMR 8619, CNRS, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Bouhss, A (corresponding author), Univ Paris 11, Inst Biochim & Biophys Mol & Cellulaire, UMR 8619, CNRS, Bat 430, F-91405 Orsay, France.	ahmed.bouhss@ebp.u-psud.fr		MENGIN-LECREULX, Dominique/0000-0003-3205-0275; Muriel, CROUVOISIER/0000-0003-2281-5326				Auger G, 1998, PROTEIN EXPRES PURIF, V13, P23, DOI 10.1006/prep.1997.0850; Bernhardt TG, 2000, P NATL ACAD SCI USA, V97, P4297, DOI 10.1073/pnas.97.8.4297; BLANOT D, 1994, CARBOHYD RES, V252, P107; Bouhss A, 1999, MOL MICROBIOL, V34, P576, DOI 10.1046/j.1365-2958.1999.01623.x; Boyle DS, 1998, J BACTERIOL, V180, P6429; Brandish PE, 1996, J BIOL CHEM, V271, P7609, DOI 10.1074/jbc.271.13.7609; Brandish PE, 1996, ANTIMICROB AGENTS CH, V40, P1640, DOI 10.1128/AAC.40.7.1640; BUGG TDH, 1994, FEMS MICROBIOL LETT, V119, P255; Cadene M, 2000, ANAL CHEM, V72, P5655, DOI 10.1021/ac000811l; Crouvoisier M, 1999, FEBS LETT, V449, P289, DOI 10.1016/S0014-5793(99)00412-3; DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9; Dementin S, 2001, EUR J BIOCHEM, V268, P5800, DOI 10.1046/j.0014-2956.2001.02524.x; Dini C, 2000, BIOORG MED CHEM LETT, V10, P1839, DOI 10.1016/S0960-894X(00)00349-8; ELBEIN AD, 1979, ARCH BIOCHEM BIOPHYS, V196, P311, DOI 10.1016/0003-9861(79)90583-6; FLOURET B, 1981, ANAL BIOCHEM, V114, P59, DOI 10.1016/0003-2697(81)90451-6; Gordon E, 2001, J BIOL CHEM, V276, P10999, DOI 10.1074/jbc.M009835200; Gruber G, 2002, BIOCHEM BIOPH RES CO, V298, P383, DOI 10.1016/S0006-291X(02)02468-3; HAROLD FM, 1996, ESCHERICHIA COLI SAL, V1, P283; HEIFETZ A, 1979, BIOCHEMISTRY-US, V18, P2186, DOI 10.1021/bi00578a008; Hyland SA, 2003, ANAL BIOCHEM, V317, P156, DOI 10.1016/S0003-2697(03)00088-5; IKEDA M, 1991, J BACTERIOL, V173, P1021, DOI 10.1128/jb.173.3.1021-1026.1991; LIGER D, 1995, EUR J BIOCHEM, V230, P80, DOI 10.1111/j.1432-1033.1995.0080i.x; McDonald LA, 2002, J AM CHEM SOC, V124, P10260, DOI 10.1021/ja017748h; MENGINLECREULX D, 1990, NUCLEIC ACIDS RES, V18, P2810, DOI 10.1093/nar/18.9.2810; MENGINLECREULX D, 1982, J BACTERIOL, V151, P1109, DOI 10.1128/JB.151.3.1109-1117.1982; MENGINLECREULX D, 1989, J BACTERIOL, V171, P6126, DOI 10.1128/jb.171.11.6126-6134.1989; Miller J.H., 1972, EXPT MOL GENETICS; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Nanninga N, 1998, MICROBIOL MOL BIOL R, V62, P110, DOI 10.1128/MMBR.62.1.110-129.1998; NEUHAUS FC, 1971, ACCOUNTS CHEM RES, V4, P297, DOI 10.1021/ar50045a001; PIGEON RP, 1994, MOL MICROBIOL, V14, P871, DOI 10.1111/j.1365-2958.1994.tb01323.x; PLESS DD, 1973, J BIOL CHEM, V248, P1568; Rogers H.J., 1980, MICROBIAL CELL WALLS, P239; Sambrook J., 2002, MOL CLONING LAB MANU; Stachyra T, 2004, ANTIMICROB AGENTS CH, V48, P897, DOI 10.1128/AAC.48.3.897-902.2004; Thanassi JA, 2002, NUCLEIC ACIDS RES, V30, P3152, DOI 10.1093/nar/gkf418; UMBREIT JN, 1972, J BACTERIOL, V112, P1306, DOI 10.1128/JB.112.3.1306-1309.1972; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219	39	127	130	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29974	29980		10.1074/jbc.M314165200	http://dx.doi.org/10.1074/jbc.M314165200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131133	hybrid			2022-12-25	WOS:000222531900014
J	Kim, SY; Kim, HI; Kim, TH; Im, SS; Park, SK; Lee, IK; Kim, KS; Ahn, YH				Kim, SY; Kim, HI; Kim, TH; Im, SS; Park, SK; Lee, IK; Kim, KS; Ahn, YH			SREBP-1c mediates the insulin-dependent hepatic glucokinase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEINS; LIPOGENIC ENZYME GENES; REGULATORY PROTEIN; TRANSCRIPTION FACTOR; GLUCOSE-HOMEOSTASIS; STEROL REGULATION; LIVER-CELLS; PROMOTER; ACID; MICE	The regulation of hepatic glucose metabolism is important in glucose homeostasis, and liver glucokinase (LGK) plays a central role in this process. Hepatic glucokinase expression is known to be regulated by insulin. Recently it has been suggested that sterol regulatory element binding protein-1c (SREBP-1c) mediates the action of insulin on LGK transcription; however, the precise mechanism is not, to date, well known. In the present study, we identified two functional SREBP-1c response elements, SREa and SREb, in the rat LGK promoter. SREBP-1c could bind to these SREs and activate the LGK promoter, and insulin activated the LGK promoter in Alexander cells. The physical interaction between the protein and SREs of the LGK promoter in vivo was also confirmed. Insulin selectively increased SREBP-1c and LGK expression in primary hepatocytes. Adenoviral expression of SREBP-1c stimulated LGK expression, and the dominant negative mutant of SREBP-1c blocked the increased gene expression of LGK by insulin and SREBP-1c. A chromatin immunoprecipitation assay using primary hepatocytes showed increased binding of SREBP-1 to SREs of the LGK promoter by insulin.	Dept Biochem & Mol Biol, Seoul 120752, South Korea; Brain Korea 21 Project Med Sci, Seoul 120752, South Korea; Ctr Chron Metab Dis Res, Seoul 120752, South Korea; Inst Genet Sci, Seoul 120752, South Korea; Keimyung Univ, Sch Med, Dept Internal Med, Taegu, South Korea	Keimyung University	Ahn, YH (corresponding author), Dept Biochem & Mol Biol, 134 Shinchon Dong, Seoul 120752, South Korea.	yha111@yumc.yonsei.ac.kr	Kim, Hail/C-1849-2011; Kim, So-Youn/H-4368-2016; AHN, Yong Ho/H-6712-2017	Kim, Hail/0000-0002-6652-1349; Kim, So-Youn/0000-0003-1013-6852; Kim, Kyung-sup/0000-0001-8483-8537; AHN, Yong Ho/0000-0002-4133-0757				Becard D, 2001, DIABETES, V50, P2425, DOI 10.2337/diabetes.50.11.2425; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Cha JY, 2000, J BIOL CHEM, V275, P18358, DOI 10.1074/jbc.M909536199; Choi YK, 2003, GENE THER, V10, P559, DOI 10.1038/sj.gt.3301926; Ferre T, 1996, FASEB J, V10, P1213, DOI 10.1096/fasebj.10.10.8751724; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Foufelle F, 2002, BIOCHEM J, V366, P377, DOI 10.1042/BJ20020430; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; Kim H, 2000, DIABETES, V49, P1517, DOI 10.2337/diabetes.49.9.1517; Kim HI, 2002, DIABETES, V51, P676, DOI 10.2337/diabetes.51.3.676; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kim JW, 1998, BIOCHEM J, V336, P83, DOI 10.1042/bj3360083; Koo SH, 2001, J BIOL CHEM, V276, P9437, DOI 10.1074/jbc.M010029200; Magana MM, 1997, J LIPID RES, V38, P1630; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; Matschinsky FM, 2000, FRONT DIABETES, V15, P99; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Moon YA, 2000, J BIOL CHEM, V275, P30280, DOI 10.1074/jbc.M001066200; Niswender KD, 1997, J BIOL CHEM, V272, P22570, DOI 10.1074/jbc.272.36.22570; Oh SY, 2003, J BIOL CHEM, V278, P28410, DOI 10.1074/jbc.M300553200; Sato R, 2000, J BIOL CHEM, V275, P12497, DOI 10.1074/jbc.275.17.12497; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; VANDERCAMMEN A, 1993, BIOCHEM J, V294, P551, DOI 10.1042/bj2940551; VANDERCAMMEN A, 1990, EUR J BIOCHEM, V191, P483, DOI 10.1111/j.1432-1033.1990.tb19147.x; VANSCHAFTINGEN E, 1994, FASEB J, V8, P414, DOI 10.1096/fasebj.8.6.8168691	33	80	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30823	30829		10.1074/jbc.M313223200	http://dx.doi.org/10.1074/jbc.M313223200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123649	hybrid			2022-12-25	WOS:000222531900114
J	Pokidysheva, E; Milbradt, AG; Meier, S; Renner, C; Haussinger, D; Bachinger, HP; Moroder, L; Grzesiek, S; Holstein, TW; Ozbek, S; Engel, J				Pokidysheva, E; Milbradt, AG; Meier, S; Renner, C; Haussinger, D; Bachinger, HP; Moroder, L; Grzesiek, S; Holstein, TW; Ozbek, S; Engel, J			The structure of the Cys-rich terminal domain of hydra minicollagen, which is involved in disulfide networks of the nematocyst wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE; IV COLLAGEN; PROTEIN; BONDS; LINKAGE; SYSTEM; SWITCH; CORAL	The minicollagens found in the nematocysts of Hydra constitute a family of invertebrate collagens with unusual properties. They share a common modular architecture with a central collagen sequence ranging from 14 to 16 Gly-X-Y repeats flanked by polyproline/hydroxyproline stretches and short terminal domains that show a conserved cysteine pattern (CXXXCXXXCXXXCXXXCC). The minicollagen cysteine-rich domains are believed to function in a switch of the disulfide connectivity from intra- to intermolecular bonds during maturation of the capsule wall. The solution structure of the C-terminal fragment including a minicollagen cysteine-rich domain of minicollagen-1 was determined in two independent groups by H-1 NMR. The corresponding peptide comprising the last 24 residues of the molecule was produced synthetically and refolded by oxidation under low protein concentrations. Both presented structures are identical in their fold and disulfide connections (Cys(2)-Cys(18), Cys(6)-Cys(14), and Cys(10)-Cys(19)) revealing a robust structural motif that is supposed to serve as the polymerization module of the nematocyst capsule.	Univ Basel, Dept Biol Struct, Biozentrum, CH-4051 Basel, Switzerland; Univ Basel, Dept Biophys Chem, Biozentrum, CH-4051 Basel, Switzerland; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Shriners Hosp Children, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Tech Univ Darmstadt, Inst Zool, D-64287 Darmstadt, Germany	University of Basel; University of Basel; Max Planck Society; Oregon Health & Science University; Technical University of Darmstadt	Grzesiek, S (corresponding author), Univ Basel, Dept Biol Struct, Biozentrum, Klingelbergstr 70, CH-4051 Basel, Switzerland.	stephan.grzesiek@unibas.ch; suat.oezbek@unibas.ch	Özbek, Suat/D-3701-2014; Meier, Sebastian/A-4279-2015; Häussinger, Daniel/C-6617-2016	Meier, Sebastian/0000-0003-3761-3217; Häussinger, Daniel/0000-0002-4798-0072; Holstein, Thomas/0000-0003-0480-4674; Moroder, Luis/0000-0001-9570-5713; Grzesiek, Stephan/0000-0003-1998-4225; Ozbek, Suat/0000-0003-2569-3942				Barth D, 2003, CHEM-EUR J, V9, P3703, DOI 10.1002/chem.200304918; BATEMAN JF, 1996, MOL COMPONENTS INTER, V2; BLANQUET R, 1966, SCIENCE, V154, P152, DOI 10.1126/science.154.3745.152; Boudko SP, 2004, J MOL BIOL, V335, P1289, DOI 10.1016/j.jmb.2003.11.054; BRUCKNER P, 1978, EUR J BIOCHEM, V90, P595, DOI 10.1111/j.1432-1033.1978.tb12640.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Creighton TE, 1997, BIOL CHEM, V378, P731; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; Engel J, 1997, SCIENCE, V277, P1785, DOI 10.1126/science.277.5333.1785; Engel U, 2001, EMBO J, V20, P3063, DOI 10.1093/emboj/20.12.3063; ENGEL U, 2002, J CELL SCI, V115; FAINZILBER M, 1995, BIOCHEMISTRY-US, V34, P8649, DOI 10.1021/bi00027a014; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Gunwar S, 1998, J BIOL CHEM, V273, P8767, DOI 10.1074/jbc.273.15.8767; Handford PA, 2000, BBA-MOL CELL RES, V1498, P84, DOI 10.1016/S0167-4889(00)00085-9; HOLSTEIN T, 1984, SCIENCE, V223, P830, DOI 10.1126/science.6695186; Housset D, 2000, ACTA CRYSTALLOGR D, V56, P151, DOI 10.1107/S0907444999014948; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; Koradi R, 1996, J MOL GRAPHICS, V14, P29; KUHN K, 1995, MATRIX BIOL, V14, P439, DOI 10.1016/0945-053X(95)90001-2; KURZ EM, 1991, J CELL BIOL, V115, P1159, DOI 10.1083/jcb.115.4.1159; Laederach A, 2002, BIOCHEMISTRY-US, V41, P12359, DOI 10.1021/bi026185z; LENHOFF HM, 1957, BIOCHIM BIOPHYS ACTA, V26, P204, DOI 10.1016/0006-3002(57)90074-4; Li PP, 2002, P NATL ACAD SCI USA, V99, P1353, DOI 10.1073/pnas.032668699; Mandard N, 2002, EUR J BIOCHEM, V269, P1190, DOI 10.1046/j.0014-2956.2002.02760.x; MEIER S, 2004, IN PRESS FEBS LETT; Milbradt AG, 2003, BIOCHEMISTRY-US, V42, P2404, DOI 10.1021/bi020628h; Mullen GED, 2003, P NATL ACAD SCI USA, V100, P3919, DOI 10.1073/pnas.0630495100; Ozbek S, 2002, J BIOL CHEM, V277, P49200, DOI 10.1074/jbc.M209401200; Ozbek S, 2002, J STRUCT BIOL, V137, P11, DOI 10.1006/jsbi.2002.4436; Ricard-Blum S, 2000, UNCONVENTIONAL COLLA; Tamaoki H, 1998, PROTEIN ENG, V11, P649, DOI 10.1093/protein/11.8.649; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; Vollmer SV, 2002, SCIENCE, V296, P2023, DOI 10.1126/science.1069524; WAGNER DD, 1987, BLOOD, V69, P27; WANG WQ, 1995, GENE, V152, P195, DOI 10.1016/0378-1119(95)00644-L; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Welker E, 2001, BIOCHEMISTRY-US, V40, P9059, DOI 10.1021/bi010409g; Wieringa R, 2003, J VIROL, V77, P12996, DOI 10.1128/JVI.77.24.12996-13004.2003; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZHANG RM, 1989, J BIOL CHEM, V264, P18472	44	27	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30395	30401		10.1074/jbc.M403734200	http://dx.doi.org/10.1074/jbc.M403734200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123641	hybrid			2022-12-25	WOS:000222531900065
J	Anuradha, S; Muniyappa, K				Anuradha, S; Muniyappa, K			Saccharomyces cerevisiae hop1 zinc finger motif is the minimal region required for its function in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTONEMAL COMPLEX PROTEIN; DNA-BINDING DOMAIN; MEIOTIC CHROMOSOMES; QUADRUPLEX DNA; TELOMERIC DNA; HOMOLOGOUS CHROMOSOMES; CIRCULAR-DICHROISM; YEAST ADR1; MEIOSIS; SYNAPSIS	Saccharomyces cerevisiae meiosis-specific HOP1, which encodes a core component of synaptonemal complex, plays a key role in proper pairing of homologous chromosomes and processing of meiotic DNA double strand breaks. Isolation and analysis of hop1 mutants indicated that these functions require Cys(371) of Hop1 embedded in a region ( residues 343 - 378) sharing homology to a zinc finger motif (ZnF). However, the precise biochemical function of Hop1, or its putative ZnF, in these processes is poorly understood. Our previous studies revealed that Hop1 is a DNA-binding protein, showed substantially higher binding affinity for G4 DNA, and enhances its formation. We report herein that ZnF appears to be sufficient for both zinc as well as DNA-binding activities. Molecular modeling studies suggested that Hop1 ZnF differs from the previously characterized natural ZnFs. The zinc-binding assay showed that the affinity for zinc is weaker for C371S ZnF mutant compared with the wild type (WT) ZnF. Analysis of CD spectra indicated that zinc and DNA induce substantial conformational changes in WT ZnF, but not in C371S ZnF mutant. The results from a number of different experimental approaches suggested that the DNA-binding properties of ZnF are similar to those of full-length Hop1 and that interaction with DNA rich in G residues is particularly robust. Significantly, WT ZnF by itself, but not C371S mutant, was able to bind duplex DNA and promote interstitial pairing of DNA double helices via the formation of guanine quartets. Together, these results implicate a direct role for Hop1 in pairing of homologous chromosomes during meiosis.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Muniyappa, K (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	kmbc@biochem.iisc.ernet.in						Agarwal S, 2000, CELL, V102, P245, DOI 10.1016/S0092-8674(00)00029-5; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Anuradha S, 2004, NUCLEIC ACIDS RES, V32, P2378, DOI 10.1093/nar/gkh559; ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; Arthanari H, 2001, CHEM BIOL, V8, P221, DOI 10.1016/S1074-5521(01)00007-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; Brown BA, 1998, BIOCHEMISTRY-US, V37, P16325, DOI 10.1021/bi981354u; Chua PR, 1998, CELL, V93, P349, DOI 10.1016/S0092-8674(00)81164-2; Cook CR, 2003, J BIOL CHEM, V278, P36051, DOI 10.1074/jbc.M306049200; CUNNINGHAM RP, 1980, CELL, V20, P223, DOI 10.1016/0092-8674(80)90250-0; de los Santos T, 1999, J BIOL CHEM, V274, P1783, DOI 10.1074/jbc.274.3.1783; Donaldson IM, 2000, J BIOL CHEM, V275, P13780, DOI 10.1074/jbc.275.18.13780; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; FRIEDMAN DB, 1994, GENETICS, V136, P449; GIRALDO R, 1994, P NATL ACAD SCI USA, V91, P7658, DOI 10.1073/pnas.91.16.7658; GREEN LM, 1989, P NATL ACAD SCI USA, V86, P4047, DOI 10.1073/pnas.86.11.4047; Hiraoka Y, 1998, GENES CELLS, V3, P405, DOI 10.1046/j.1365-2443.1998.00205.x; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; Hollingsworth NM, 1997, GENETICS, V147, P33; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; Isalan M, 2001, BIOCHEMISTRY-US, V40, P830, DOI 10.1021/bi001728v; Jamieson AC, 1996, P NATL ACAD SCI USA, V93, P12834, DOI 10.1073/pnas.93.23.12834; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JOHNSTON M, 1987, P NATL ACAD SCI USA, V84, P2401, DOI 10.1073/pnas.84.8.2401; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Kironmai KM, 1998, MOL CELL BIOL, V18, P1424, DOI 10.1128/MCB.18.3.1424; KLECKNER N, 1993, COLD SPRING HARB SYM, V58, P553, DOI 10.1101/SQB.1993.058.01.062; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; Leu JY, 1998, CELL, V94, P375, DOI 10.1016/S0092-8674(00)81480-4; LOIDL J, 1994, J CELL BIOL, V125, P1191, DOI 10.1083/jcb.125.6.1191; Muniyappa K, 2000, MOL CELL BIOL, V20, P1361, DOI 10.1128/MCB.20.4.1361-1369.2000; NAG DK, 1995, GENETICS, V141, P75; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; ROCKMILL B, 1988, P NATL ACAD SCI USA, V85, P6057, DOI 10.1073/pnas.85.16.6057; Rockmill B, 1998, GENE DEV, V12, P2574, DOI 10.1101/gad.12.16.2574; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Salazar M, 1996, BIOCHEMISTRY-US, V35, P16110, DOI 10.1021/bi961442j; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schaffitzel C, 2001, P NATL ACAD SCI USA, V98, P8572, DOI 10.1073/pnas.141229498; SCHERTHAN H, 1992, CHROMOSOMA, V101, P590, DOI 10.1007/BF00360535; Scherthan H, 1996, J CELL BIOL, V134, P1109, DOI 10.1083/jcb.134.5.1109; SCHIFF LA, 1988, P NATL ACAD SCI USA, V85, P4195, DOI 10.1073/pnas.85.12.4195; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Shafer RH, 2001, BIOPOLYMERS, V56, P209, DOI 10.1002/1097-0282(2000/2001)56:3<209::AID-BIP10018>3.0.CO;2-Y; Smith AV, 1997, J CELL BIOL, V136, P957, DOI 10.1083/jcb.136.5.957; Sun D, 1999, BIOCHEMISTRY-US, V38, P4037, DOI 10.1021/bi982249n; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SYM M, 1995, J CELL BIOL, V128, P455, DOI 10.1083/jcb.128.4.455; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TREICH I, 1991, J BIOL CHEM, V266, P21971; VALLEE BL, 1984, ADV ENZYMOL RAMB, V56, P283; Voloshin ON, 1996, SCIENCE, V272, P868, DOI 10.1126/science.272.5263.868; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Zickler D, 1999, ANNU REV GENET, V33, P603, DOI 10.1146/annurev.genet.33.1.603; Zickler D, 1998, ANNU REV GENET, V32, P619, DOI 10.1146/annurev.genet.32.1.619	62	10	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28961	28969		10.1074/jbc.M403727200	http://dx.doi.org/10.1074/jbc.M403727200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123624	hybrid			2022-12-25	WOS:000222445300018
J	Bednarski, JJ; Lyssiotis, CA; Roush, R; Boitano, AE; Glick, GD; Opipari, AW				Bednarski, JJ; Lyssiotis, CA; Roush, R; Boitano, AE; Glick, GD; Opipari, AW			A novel benzodiazepine increases the sensitivity of B cells to receptor stimulation with synergistic effects on calcium signaling and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; MONOCLONAL-ANTIBODIES; DEPENDENT APOPTOSIS; AUTOIMMUNE-DISEASE; SUPEROXIDE ANION; SURFACE IGM; LYMPHOCYTES; ACTIVATION; RELEASE; LYMPHOMA	Bz-423 is a 1,4-benzodiazepine with selective lymphotoxic properties and potent therapeutic activity against lupus-like disease in autoimmune mice. In NZB/W lupus-prone mice, Bz-423 specifically kills germinal center B cells, which are the cells that drive disease both in this model and in human systemic lupus erythematosus. In this report, the mechanistic basis for the selective action of Bz-423 is investigated. We show that Bz-423-induces superoxide as an immediate early response and that this reactive oxygen species is more effective as a second messenger death signal in B cells activated by B cell receptor stimulation compared with resting cells. As a result, low [Bz-423] that are not cytotoxic to non-stimulated cells kill stimulated cells in synergy with anti-immunoglobulin M antibodies. Subsequent experiments demonstrated that Bz-423 extends the rise in intracellular calcium that accompanies anti-immunoglobulin M stimulation, and this effect mediates the synergistic death response. Because B cell hyperactivation and altered calcium signaling is a distinguishing feature of autoreactive lymphocytes in lupus, the mechanism by which Bz-423 induces apoptosis preferentially targets disease-causing cells on the basis of their activation state. Thus, molecules like Bz-423 could form the basis for new and selective anti-lupus agents.	Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Opipari, AW (corresponding author), Univ Michigan, Dept Obstet & Gynecol, 1500 E Med Ctr Dr,L4602 WH, Ann Arbor, MI 48109 USA.	aopipari@umich.edu	Bednarski, Jeff/GLN-6651-2022; Lyssiotis, Costas A/AAI-1923-2019	Lyssiotis, Costas A/0000-0001-9309-6141	NCI NIH HHS [CA104561] Funding Source: Medline; NIAID NIH HHS [AI47450] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI047450, R01AI047450] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Antunes F, 2000, FEBS LETT, V475, P121, DOI 10.1016/S0014-5793(00)01638-0; Bednarski JJ, 2003, ARTHRITIS RHEUM-US, V48, P757, DOI 10.1002/art.10968; BIJSTERBOSCH MK, 1986, BIOCHEM BIOPH RES CO, V137, P500, DOI 10.1016/0006-291X(86)91238-6; Blatt NB, 2002, J CLIN INVEST, V110, P1123, DOI 10.1172/JCI200216029; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; BUNIN BA, 1994, P NATL ACAD SCI USA, V91, P4708, DOI 10.1073/pnas.91.11.4708; BURTON KP, 1990, J MOL CELL CARDIOL, V22, P1035, DOI 10.1016/0022-2828(90)91043-7; Cai S, 1997, J MEMBRANE BIOL, V158, P147, DOI 10.1007/s002329900252; Cheng Genhong, 2002, Curr Dir Autoimmun, V5, P51; Chinn P, 2003, CANCER IMMUNOL IMMUN, V52, P257, DOI 10.1007/s00262-002-0347-6; Choi YS, 1997, IMMUNOL RES, V16, P161, DOI 10.1007/BF02786360; Cragg MS, 1999, BRIT J CANCER, V79, P850, DOI 10.1038/sj.bjc.6690136; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DIAMOND B, 1992, ANNU REV IMMUNOL, V10, P731, DOI 10.1146/annurev.iy.10.040192.003503; DiPolo R, 2002, PROG BIOPHYS MOL BIO, V80, P43, DOI 10.1016/S0079-6107(02)00014-7; Dixon F J, 1978, Arthritis Rheum, V21, pS64, DOI 10.1002/art.1780210909; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Donjerkovic D, 2000, CELL RES, V10, P179, DOI 10.1038/sj.cr.7290047; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Gessner PK, 1995, TOXICOLOGY, V105, P161, DOI 10.1016/0300-483X(95)03210-7; Grafton G, 1997, CELL IMMUNOL, V182, P45, DOI 10.1006/cimm.1997.1205; GUSKOVA RA, 1984, BIOCHIM BIOPHYS ACTA, V778, P579, DOI 10.1016/0005-2736(84)90409-7; Guzman-Rojas L, 2002, IMMUNOLOGY, V107, P167, DOI 10.1046/j.1365-2567.2002.01494.x; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; Hirst RA, 1999, METH MOL B, V114, P31; Jeulin C, 2002, PFLUG ARCH EUR J PHY, V443, P574, DOI 10.1007/s00424-001-0733-5; Kim D, 2002, HUM IMMUNOL, V63, P576, DOI 10.1016/S0198-8859(02)00405-6; Kiselyov K, 2001, BIOCHEM J, V360, P17, DOI 10.1042/0264-6021:3600017; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; Kourie JI, 1998, AM J PHYSIOL-CELL PH, V275, pC1, DOI 10.1152/ajpcell.1998.275.1.C1; Kozono Y, 1996, J IMMUNOL, V156, P4498; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Moriyama M, 1997, ONCOGENE, V14, P2465, DOI 10.1038/sj.onc.1201084; Qin SF, 2000, P NATL ACAD SCI USA, V97, P7118, DOI 10.1073/pnas.130198197; RUBIN LA, 1985, Q J MED, V55, P87; Shlomchik MJ, 2001, NAT REV IMMUNOL, V1, P147, DOI 10.1038/35100573; Takano T, 2002, ANTIOXID REDOX SIGN, V4, P533, DOI 10.1089/15230860260196335; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; WATSON ML, 1992, J EXP MED, V176, P1645, DOI 10.1084/jem.176.6.1645	43	14	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29615	29621		10.1074/jbc.M403507200	http://dx.doi.org/10.1074/jbc.M403507200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123639	hybrid			2022-12-25	WOS:000222445300097
J	Gregory, LA; Thielens, NM; Matsushita, M; Sorensen, R; Arlaud, GJ; Fontecilla-Camps, JC; Gaboriaud, C				Gregory, LA; Thielens, NM; Matsushita, M; Sorensen, R; Arlaud, GJ; Fontecilla-Camps, JC; Gaboriaud, C			The X-ray structure of human mannan-binding lectin-associated protein 19 (MAp19) and its interaction site with mannan-binding lectin and L-ficolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURALLY-OCCURRING MUTATIONS; SERINE PROTEASES-1 AND-2; COMPLEMENT PATHWAY; ACTIVATES COMPLEMENT; CLASSICAL PATHWAY; DOMAIN; COMPLEXES; SYSTEM; REGION; MBL	MAp19 is an alternative splicing product of the MASP-2 gene comprising the N-terminal CUB1-epidermal growth factor (EGF) segment of MASP-2, plus four additional residues at its C-terminal end. Like full-length MASP-2, it forms Ca2+-dependent complexes with mannan-binding lectin (MBL) and L-ficolin. The x-ray structure of human MAp19 was solved to a resolution of 2.5 Angstrom. It shows a head to tail homodimer held together by interactions between the CUB1 module of one monomer and the EGF module of its counterpart. A Ca2+ ion bound to each EGF module stabilizes the dimer interfaces. A second Ca2+ ion is bound to the distal end of each CUB1 module, through six ligands contributed by Glu(52), Asp(60), Asp(105), Ser(107), Asn(108), and a water molecule. Compared with its counterpart in human C1s, the N-terminal end of the MAp19 CUB1 module contains a 7-residue extension that forms additional inter-monomer contacts. To identify the residues involved in the interaction of MAp19 with MBL and L-ficolin, point mutants were generated and their binding ability was determined using surface plasmon resonance spectroscopy. Six mutations at Tyr(59), Asp(60), Glu(83), Asp(105), Tyr(106), and Glu(109) either strongly decreased or abolished interaction with both MBL and L-ficolin. These mutations map a common binding site for these proteins located at the distal end of each CUB1 module and stabilized by the Ca2+ ion.	Inst Biol Struct, Cristallog & Cristallogenese Prot Lab, F-38027 Grenoble 1, France; Inst Biol Struct, Lab Enzymol Mol, F-38027 Grenoble 1, France; Tokai Univ, Dept Appl Biochem, Kanagawa 2591292, Japan; Tokai Univ, Inst Glycobiol, Kanagawa 2591292, Japan; Aarhus Univ, Dept Med Microbiol & Immunol, DK-8000 Aarhus, Denmark	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Tokai University; Tokai University; Aarhus University	Gaboriaud, C (corresponding author), Inst Biol Struct, Cristallog & Cristallogenese Prot Lab, F-38027 Grenoble 1, France.	christine.gaboriaud@ibs.fr	Thielens, Nicole M/F-2512-2013	Thielens, Nicole M/0000-0002-7354-0302				BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; Chen CB, 2001, J BIOL CHEM, V276, P25894, DOI 10.1074/jbc.M103539200; Cseh S, 2002, J IMMUNOL, V169, P5735, DOI 10.4049/jimmunol.169.10.5735; Dahl MR, 2001, IMMUNITY, V15, P127, DOI 10.1016/S1074-7613(01)00161-3; Feinberg H, 2003, EMBO J, V22, P2348, DOI 10.1093/emboj/cdg236; Fujita T, 2002, NAT REV IMMUNOL, V2, P346, DOI 10.1038/nri800; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gregory LA, 2003, J BIOL CHEM, V278, P32157, DOI 10.1074/jbc.M305175200; Harding MM, 1999, ACTA CRYSTALLOGR D, V55, P1432, DOI 10.1107/S0907444999007374; Holmskov U, 2003, ANNU REV IMMUNOL, V21, P547, DOI 10.1146/annurev.immunol.21.120601.140954; IKEDA K, 1987, J BIOL CHEM, V262, P7451; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Lacroix M, 1997, BIOCHEMISTRY-US, V36, P6270, DOI 10.1021/bi962719i; LU J, 1990, J IMMUNOL, V144, P2287; Matsushita M, 2000, J IMMUNOL, V164, P2281, DOI 10.4049/jimmunol.164.5.2281; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; Matsushita M, 2002, J IMMUNOL, V168, P3502, DOI 10.4049/jimmunol.168.7.3502; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Rainey JK, 2002, PROTEIN SCI, V11, P2748, DOI 10.1110/ps.0218502; REID KBM, 1986, IMMUNOL TODAY, V7, P230, DOI 10.1016/0167-5699(86)90110-6; ROMERO A, 1997, NAT STRUCT BIOL, V5, P458; Rossi V, 2001, J BIOL CHEM, V276, P40880, DOI 10.1074/jbc.M105934200; Stengaard-Pedersen K, 2003, NEW ENGL J MED, V349, P554, DOI 10.1056/NEJMoa022836; Stover CM, 1999, J IMMUNOL, V162, P3481; Takahashi M, 1999, INT IMMUNOL, V11, P859, DOI 10.1093/intimm/11.5.859; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Thielens NM, 2001, J IMMUNOL, V166, P5068, DOI 10.4049/jimmunol.166.8.5068; Vorup-Jensen T, 2000, J IMMUNOL, V165, P2093, DOI 10.4049/jimmunol.165.4.2093; Wallis R, 2004, J BIOL CHEM, V279, P14065, DOI 10.1074/jbc.M400171200; Wallis R, 2000, J BIOL CHEM, V275, P30962, DOI 10.1074/jbc.M004030200; Zundel S, 2004, J IMMUNOL, V172, P4342, DOI 10.4049/jimmunol.172.7.4342	34	51	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29391	29397		10.1074/jbc.M402687200	http://dx.doi.org/10.1074/jbc.M402687200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15117939	hybrid			2022-12-25	WOS:000222445300071
J	Meshorer, E; Toiber, D; Zurel, D; Sahly, I; Dori, A; Cagnano, E; Schreiber, L; Grisaru, D; Tronche, F; Soreq, H				Meshorer, E; Toiber, D; Zurel, D; Sahly, I; Dori, A; Cagnano, E; Schreiber, L; Grisaru, D; Tronche, F; Soreq, H			Combinatorial complexity of 5 ' alternative acetylcholinesterase transcripts and protein products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCLEAVED SIGNAL PEPTIDE; ANOMALOUS MOLECULAR-FORM; TERMINAL T-PEPTIDE; MESSENGER-RNA; MOUSE ACETYLCHOLINESTERASE; ALZHEIMERS-DISEASE; MEMBRANE ANCHOR; EXPRESSION; GENE; PROMOTER	To explore the scope and significance of alternate promoter usage and its putative inter-relationship to alternative splicing, we searched expression sequence tags for the 5' region of acetylcholinesterase ( ACHE) genes. Three and five novel first exons were identified in human and mouse ACHE genes, respectively. Reverse transcription-PCR and in situ hybridization validated most of the predicted transcripts, and sequence analyses of the corresponding genomic DNA regions suggest evolutionarily conserved promoters for each of the novel exons identified. Distinct tissue specificity and stress-related expression patterns of these exons predict combinatorial complexity with known 3' alternative AChE mRNA transcripts. Unexpectedly one of the 5' exons encodes an extended N terminus in-frame with the known AChE sequence, extending the increased complexity to the protein level. The resultant membrane variant(s), designated N-AChE, is developmentally regulated in human brain neurons and blood mononuclear cells. Alternative promoter usage combined with alternative splicing may thus lead to stress-dependent combinatorial complexity of AChE mRNA transcripts and their protein products.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Israel Ctr Neuronal Computat, IL-91904 Jerusalem, Israel; Coll France, Inst Biol, CNRS FRE2401, F-75231 Paris 5, France; Soroka Univ Med Ctr, Dept Pathol, IL-64239 Tel Aviv, Israel; Tel Aviv Univ, Sourasky Med Ctr, Dept Pathol, IL-84105 Tel Aviv, Israel; Tel Aviv Univ, Sourasky Med Ctr, Dept Obstet & Gynecol, IL-84105 Tel Aviv, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; UDICE-French Research Universities; PSL Research University Paris; College de France; Ben Gurion University; Soroka Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Soreq, H (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	soreq@cc.huji.ac.il	TRONCHE, François/F-3895-2011; Dori, Amir/E-5623-2013	Meshorer, Eran/0000-0003-4777-986X; Soreq, Hermona/0000-0002-0955-526X; Dori, Amir/0000-0003-4633-1481				Atanasova E, 1999, J BIOL CHEM, V274, P21078, DOI 10.1074/jbc.274.30.21078; Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798; Belbeoc'h S, 2003, EMBO J, V22, P3536, DOI 10.1093/emboj/cdg360; Ben Aziz-Aloya R, 1993, Prog Brain Res, V98, P147; Brenner T, 2003, FASEB J, V17, P214, DOI 10.1096/fj.02-0609com; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; Darreh-Shori T, 2004, J NEUROCHEM, V88, P1102, DOI 10.1046/j.1471-4159.2003.02230.x; Drukker M, 2002, P NATL ACAD SCI USA, V99, P9864, DOI 10.1073/pnas.142298299; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Job C, 2001, NAT REV NEUROSCI, V2, P889, DOI 10.1038/35104069; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Kawashima K, 2000, PHARMACOL THERAPEUT, V86, P29, DOI 10.1016/S0163-7258(99)00071-6; LI Y, 1991, J BIOL CHEM, V266, P23083; Massoulie J, 2002, NEUROSIGNALS, V11, P130, DOI 10.1159/000065054; McKiernan CJ, 1999, J BIOL CHEM, V274, P38177, DOI 10.1074/jbc.274.53.38177; Meshorer E, 2002, SCIENCE, V295, P508, DOI 10.1126/science.1066752; Modrek B, 2001, NUCLEIC ACIDS RES, V29, P2850, DOI 10.1093/nar/29.13.2850; Morel N, 2001, J BIOL CHEM, V276, P37379, DOI 10.1074/jbc.M103192200; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; NAVARATNAM DS, 1991, LANCET, V337, P447, DOI 10.1016/0140-6736(91)93391-L; Panganiban G, 2002, DEVELOPMENT, V129, P4371; Perrier AL, 2002, NEURON, V33, P275, DOI 10.1016/S0896-6273(01)00584-0; Perrier NA, 2003, EUR J NEUROSCI, V18, P1837, DOI 10.1046/j.1460-9568.2003.02914.x; PICK M, 2004, IN PRESS INT J DEV N; PODLESKI T, 1967, SCIENCE, V157, P1579, DOI 10.1126/science.157.3796.1579; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; Shapira M, 2000, HUM MOL GENET, V9, P1273, DOI 10.1093/hmg/9.9.1273; Shen ZX, 1997, NEUROREPORT, V8, P3229, DOI 10.1097/00001756-199710200-00009; Sorek R, 2003, NUCLEIC ACIDS RES, V31, P1067, DOI 10.1093/nar/gkg170; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; TALJANIDISZ J, 1989, BIOCHEMISTRY-US, V28, P10054, DOI 10.1021/bi00452a026; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; Weiner AM, 2002, CURR OPIN CELL BIOL, V14, P343, DOI 10.1016/S0955-0674(02)00338-1; Wilson MD, 2001, NUCLEIC ACIDS RES, V29, P1352, DOI 10.1093/nar/29.6.1352; Xie HQ, 2002, GENOMICS, V80, P326, DOI 10.1006/geno.2002.6841	40	99	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29740	29751		10.1074/jbc.M402752200	http://dx.doi.org/10.1074/jbc.M402752200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123727	hybrid			2022-12-25	WOS:000222445300110
J	Robson-Dixon, ND; Garcia-Blanco, MA				Robson-Dixon, ND; Garcia-Blanco, MA			MAZ elements alter transcription elongation and silencing of the fibroblast growth factor receptor 2 exon IIIb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SPLICE-SITE SELECTION; TRACT BINDING-PROTEIN; MESSENGER-RNA; HNRNP-H; ALTERNATIVE EXON; IN-VITRO; PAUSE SITE; TERMINATION; GENE	The fibroblast growth factor receptor 2 (FGFR2) gene exons IIIb and IIIc are alternatively spliced in a mutually exclusive and cell type-specific manner. FGFR2 exon choice depends on both activation and silencing. Exon IIIb silencing requires cis-acting elements upstream and downstream of the exon. To examine the influence of transcription on exon IIIb silencing, the putative RNA polymerase II (RNAPII)-pausing MAZ4 element was inserted at different positions within the FGFR2 minigene construct. MAZ4 insertions 5' to the upstream silencing elements or between exon IIIb and downstream silencing elements result in decreased silencing. An insertion 3' of the downstream silencing elements, however, has no effect on splicing. An RT-PCR elongation assay shows that the MAZ4 site in these constructs is likely to be a RNAPII pause site. Insertion of another RNAPII pause site into the minigene has a similar effect on exon IIIb silencing. Transfection of in vitro transcribed RNA demonstrates that the cell type specificity of FGFR2 alternative splicing requires co-transcriptional splicing. Additionally, changing the promoter alters both FGFR2 minigene splicing and the MAZ4 effect. We propose that RNAPII pauses at the MAZ4 elements resulting in a change in the transcription elongation complex that influences alternative splicing decisions downstream.	Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University; Duke University	Garcia-Blanco, MA (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA.	garci001@mc.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM067466, R01GM063090] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM063090, 1 F32 GM067466-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHFIELD R, 1991, EMBO J, V10, P4197, DOI 10.1002/j.1460-2075.1991.tb04998.x; Caputi M, 2002, EMBO J, V21, P845, DOI 10.1093/emboj/21.4.845; Caputi M, 2001, J BIOL CHEM, V276, P43850, DOI 10.1074/jbc.M102861200; Carstens RP, 1997, ONCOGENE, V15, P3059, DOI 10.1038/sj.onc.1201498; Carstens RP, 1998, MOL CELL BIOL, V18, P2205, DOI 10.1128/MCB.18.4.2205; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Chou MY, 1999, MOL CELL BIOL, V19, P69; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; de la Mata M, 2003, MOL CELL, V12, P525, DOI 10.1016/j.molcel.2003.08.001; De Moerlooze L, 2000, DEVELOPMENT, V127, P483; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DELGATTO F, 1995, MOL CELL BIOL, V15, P4825; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; DWARKI VJ, 1993, METHOD ENZYMOL, V217, P644; ENRIQUEZHARRIS P, 1991, EMBO J, V10, P1833, DOI 10.1002/j.1460-2075.1991.tb07709.x; Fogel BL, 2000, J BIOL CHEM, V275, P32371, DOI 10.1074/jbc.M005000200; Fong YW, 2001, NATURE, V414, P929, DOI 10.1038/414929a; Furger A, 2002, GENE DEV, V16, P2792, DOI 10.1101/gad.983602; Ghosh S, 2000, RNA, V6, P1325, DOI 10.1017/S1355838200992537; GILBERT E, 1993, MOL CELL BIOL, V13, P5461, DOI 10.1128/MCB.13.9.5461; Goldstrohm AC, 2001, MOL CELL BIOL, V21, P7617, DOI 10.1128/MCB.21.22.7617-7628.2001; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; GOODING C, 1994, EMBO J, V13, P3861, DOI 10.1002/j.1460-2075.1994.tb06697.x; GRAESSMANN M, 1982, EMBO J, V1, P1081, DOI 10.1002/j.1460-2075.1982.tb01300.x; GREEN MR, 1983, CELL, V32, P681, DOI 10.1016/0092-8674(83)90054-5; GREENBERG ME, 1998, CURRENT PROTOCOLS MO, V1; GREENLEAF AL, 1993, TRENDS BIOCHEM SCI, V18, P117, DOI 10.1016/0968-0004(93)90016-G; Hajihosseini MK, 2001, P NATL ACAD SCI USA, V98, P3855, DOI 10.1073/pnas.071586898; Harju S, 2001, BIOTECHNIQUES, V30, P1198, DOI 10.2144/01306bm02; Hastings ML, 2001, RNA, V7, P859, DOI 10.1017/S1355838201002084; Howe KJ, 2002, BBA-GENE STRUCT EXPR, V1577, P308, DOI 10.1016/S0167-4781(02)00460-8; Howe KJ, 2003, RNA, V9, P993, DOI 10.1261/rna.5390803; Jacquenet S, 2001, J BIOL CHEM, V276, P40464, DOI 10.1074/jbc.M104070200; Kadener S, 2002, P NATL ACAD SCI USA, V99, P8185, DOI 10.1073/pnas.122246099; Kadener S, 2001, EMBO J, V20, P5759, DOI 10.1093/emboj/20.20.5759; Kwek KY, 2002, NAT STRUCT BIOL, V9, P800, DOI 10.1038/nsb862; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Nogues G, 2002, J BIOL CHEM, V277, P43110, DOI 10.1074/jbc.M208418200; Peterson ML, 2002, MOL CELL BIOL, V22, P5606, DOI 10.1128/MCB.22.15.5606-5615.2002; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; Roberts GC, 1998, NUCLEIC ACIDS RES, V26, P5568, DOI 10.1093/nar/26.24.5568; Rosonina E, 2003, J BIOL CHEM, V278, P43034, DOI 10.1074/jbc.M307289200; STRUHL K, 1998, CURRENT PROTOCOLS MO, V2; Sune C, 1999, MOL CELL BIOL, V19, P4719; Tasic B, 2002, MOL CELL, V10, P21, DOI 10.1016/S1097-2765(02)00578-6; Taylor A, 1997, GENET RES, V69, P101, DOI 10.1017/S0016672397002681; Tian HC, 2001, FEBS LETT, V509, P282, DOI 10.1016/S0014-5793(01)03188-X; Wagner EJ, 2003, RNA, V9, P1552, DOI 10.1261/rna.5840803; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wilkie AOM, 2002, AM J MED GENET, V112, P266, DOI 10.1002/ajmg.10775; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yeh BK, 2003, P NATL ACAD SCI USA, V100, P2266, DOI 10.1073/pnas.0436500100; Yonaha M, 2000, EMBO J, V19, P3770, DOI 10.1093/emboj/19.14.3770; Yonaha M, 1999, MOL CELL, V3, P593, DOI 10.1016/S1097-2765(00)80352-4	59	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29075	29084		10.1074/jbc.M312747200	http://dx.doi.org/10.1074/jbc.M312747200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15126509	hybrid			2022-12-25	WOS:000222445300031
J	Schiaretti, F; Bettati, S; Viappiani, C; Mozzarelli, A				Schiaretti, F; Bettati, S; Viappiani, C; Mozzarelli, A			pH dependence of tryptophan synthase catalytic mechanism - I. The first stage, the beta-elimination reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-LIGAND COMPLEXES; MONOVALENT CATION ACTION; ALPHA(2)BETA(2) COMPLEX; ESCHERICHIA-COLI; L-SERINE; ALLOSTERIC REGULATION; BIENZYME COMPLEX; ALPHA-SUBUNIT; FREE-ENERGY; INTERSUBUNIT COMMUNICATION	The pyridoxal 5'-phosphate-dependent beta-subunit of the tryptophan synthase alpha(2)beta(2) complex catalyzes the condensation of L-serine with indole to form L-tryptophan. The first stage of the reaction is a beta-elimination that involves a very fast interconversion of the internal aldimine in a highly fluorescent L-serine external aldimine that decays, via the alpha-carbon proton removal and beta-hydroxyl group release, to the alpha-aminoacrylate Schiff base. This reaction is influenced by protons, monovalent cations, and alpha-subunit ligands that modulate the distribution between open and closed conformations. In order to identify the ionizable residues that might assist catalysis, we have investigated the pH dependence of the rate of the external aldimine decay by rapid scanning UV-visible absorption and single wavelength fluorescence stopped flow. In the pH range 6-9, the reaction was found to be biphasic with the first phase (rate constants k(1)) accounting for more than 70% of the signal change. In the absence of monovalent cations or in the presence of sodium and potassium ions, the pH dependence of k1 exhibits a bell shaped profile characterized by a pK(a1) of about 6 and a pK(a2) of about 9, whereas in the presence of cesium ions, the pH dependence exhibits a saturation profile characterized by a single pK(a) of 9. The presence of the allosteric effector indole acetylglycine increases the rate of reaction without altering the pH profile and pKa values. By combining structural information for the internal aldimine, the external aldimine, and the alpha-aminoacrylate with kinetic data on the wild type enzyme and beta-active site mutants, we have tentatively assigned pK(a1) to betaAsp-305 and pK(a2) to betaLys-87. The loss of pK(a1) in the presence of cesium ions might be due to a shift to lower values, caused by the selective stabilization of a closed form of the beta-subunit.	Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy; Univ Parma, Dept Publ Hlth, I-43100 Parma, Italy; Univ Parma, Dept Phys, I-43100 Parma, Italy; Univ Parma, Natl Inst Phys Matter, I-43100 Parma, Italy	University of Parma; University of Parma; University of Parma; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Parma	Mozzarelli, A (corresponding author), Univ Parma, Dept Biochem & Mol Biol, Parco Area Sci 23-A, I-43100 Parma, Italy.	biochim@unipr.it	Bettati, Stefano/V-9975-2018; Mozzarelli, Andrea/C-3615-2014; Viappiani, Cristiano/AAC-7579-2019	Bettati, Stefano/0000-0001-6787-0594; Mozzarelli, Andrea/0000-0003-3762-0062; Viappiani, Cristiano/0000-0001-7470-4770				ABRAHAM DJ, 1987, PROTEINS, V2, P130, DOI 10.1002/prot.340020207; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BRZOVIC PS, 1992, J BIOL CHEM, V267, P13028; BRZOVIC PS, 1993, BIOCHEMISTRY-US, V32, P10404, DOI 10.1021/bi00090a016; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P1180, DOI 10.1021/bi00119a030; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; Burnett JC, 2000, BIOCHEMISTRY-US, V39, P1622, DOI 10.1021/bi991724u; Burnett JC, 2001, PROTEINS, V42, P355, DOI 10.1002/1097-0134(20010215)42:3<355::AID-PROT60>3.0.CO;2-F; Cozzini P, 2004, CURR MED CHEM, V11, P3093, DOI 10.2174/0929867043363929; Cozzini P, 2002, J MED CHEM, V45, P2469, DOI 10.1021/jm0200299; CRAWFORD IP, 1960, BIOCHIM BIOPHYS ACTA, V45, P405, DOI 10.1016/0006-3002(60)91474-8; DIXON HBF, 1991, BIOCHEM J, V278, P279, DOI 10.1042/bj2780279; DREWE WF, 1986, BIOCHEMISTRY-US, V25, P2494, DOI 10.1021/bi00357a032; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; FAEDER EJ, 1970, BIOCHEMISTRY-US, V9, P4043, DOI 10.1021/bi00823a003; Ferrari D, 2003, BIOCHEMISTRY-US, V42, P7807, DOI 10.1021/bi034291a; Ferrari D, 2001, BIOCHEMISTRY-US, V40, P7421, DOI 10.1021/bi002892l; FERSHT A, 1984, ENZYME STRUCTURE MEC, P155; Fornabaio M, 2003, J MED CHEM, V46, P4487, DOI 10.1021/jm0302593; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; GOLDBERG ME, 1967, BIOCHEMISTRY-US, V6, P2113, DOI 10.1021/bi00859a032; Hur O, 2002, BIOCHEMISTRY-US, V41, P9991, DOI 10.1021/bi025568u; HYDE CC, 1988, J BIOL CHEM, V263, P17857; Kellogg GE, 2000, EUR J MED CHEM, V35, P651, DOI 10.1016/S0223-5234(00)00167-7; KELLOGG GE, 1991, J COMPUT AID MOL DES, V5, P545, DOI 10.1007/BF00135313; Kellogg GE, 2001, J COMPUT AID MOL DES, V15, P381, DOI 10.1023/A:1011136228678; Kulik V, 2002, J MOL BIOL, V324, P677, DOI 10.1016/S0022-2836(02)01109-9; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LU ZC, 1993, J BIOL CHEM, V268, P8727; Marabotti A, 2001, J BIOL CHEM, V276, P17747, DOI 10.1074/jbc.M011781200; Marabotti A, 2000, BBA-PROTEIN STRUCT M, V1476, P287, DOI 10.1016/S0167-4838(99)00242-3; Miles E W, 1995, Subcell Biochem, V24, P207; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1989, J BIOL CHEM, V264, P6280; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; Mozzarelli A, 2000, J BIOL CHEM, V275, P6956, DOI 10.1074/jbc.275.10.6956; Osborne A, 2003, J BIOL CHEM, V278, P44083, DOI 10.1074/jbc.M308276200; Pan P, 1997, TRENDS BIOCHEM SCI, V22, P22, DOI 10.1016/S0968-0004(96)10066-9; PERACCHI A, 1995, BIOCHEMISTRY-US, V34, P9459, DOI 10.1021/bi00029a022; Peracchi A, 1996, BIOCHEMISTRY-US, V35, P1872, DOI 10.1021/bi951889c; PHILLIPS RS, 1991, BIOCHEMISTRY-US, V30, P5927, DOI 10.1021/bi00238a017; Rhee S, 1998, BIOCHEMISTRY-US, V37, P10653, DOI 10.1021/bi980779d; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; Ro HS, 1999, J BIOL CHEM, V274, P31189, DOI 10.1074/jbc.274.44.31189; Ro HS, 1999, J BIOL CHEM, V274, P36439, DOI 10.1074/jbc.274.51.36439; RUVINOV SB, 1995, J BIOL CHEM, V270, P17333, DOI 10.1074/jbc.270.29.17333; Sam MD, 1999, BIOCHEMISTRY-US, V38, P6576, DOI 10.1021/bi9901580; SCHNACKERZ KD, 1995, BIOCHEMISTRY-US, V34, P12152, DOI 10.1021/bi00038a008; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; Vaccari S, 1996, BIOPHYS CHEM, V61, P9, DOI 10.1016/0301-4622(96)00020-8; Weyand M, 2002, J BIOL CHEM, V277, P10653, DOI 10.1074/jbc.M111031200; Weyand M, 2002, J BIOL CHEM, V277, P10647, DOI 10.1074/jbc.M111285200; Weyand M, 2000, J BIOL CHEM, V275, P41058, DOI 10.1074/jbc.C000479200; Woehl E, 1999, BIOCHEMISTRY-US, V38, P7131, DOI 10.1021/bi982919p; Woehl E, 1999, BIOCHEMISTRY-US, V38, P7118, DOI 10.1021/bi982918x; WOEHL EU, 1995, BIOCHEMISTRY-US, V34, P9466, DOI 10.1021/bi00029a023; Yang LH, 1996, PROTEIN EXPRES PURIF, V8, P126, DOI 10.1006/prep.1996.0082; YANOFSKY C, 1972, ENZYMES, V7, P1; YORK SS, 1972, BIOCHEMISTRY-US, V11, P2733, DOI 10.1021/bi00764a029	64	10	10	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29572	29582		10.1074/jbc.M401895200	http://dx.doi.org/10.1074/jbc.M401895200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15117965	hybrid			2022-12-25	WOS:000222445300092
J	van der Horst, A; Tertoolen, LGJ; de Vries-Smits, LMM; Frye, RA; Medema, RH; Burgering, BMT				van der Horst, A; Tertoolen, LGJ; de Vries-Smits, LMM; Frye, RA; Medema, RH; Burgering, BMT			FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; PROMOTES CELL-SURVIVAL; CAENORHABDITIS-ELEGANS; OXIDATIVE STRESS; LIFE-SPAN; KINASE-B; GROWTH; DAF-16; P53; AFX	FOXO transcription factors have important roles in metabolism, cellular proliferation, stress tolerance, and aging. FOXOs are negatively regulated by protein kinase B/c-Akt-mediated phosphorylation. Here we show that FOXO factors are also subject to regulation by reversible acetylation. We provide evidence that the acetyltransferase CREB-binding protein (CBP) binds FOXO resulting in acetylation of FOXO. This acetylation inhibits FOXO transcriptional activity. Binding of CBP and acetylation are induced after treatment of cells with peroxide stress. Deacetylation of FOXOs involves binding of the NAD-dependent deacetylase hSir2(SIRT1). Accordingly, hSir2(SIRT1)-mediated deacetylation precludes FOXO inhibition through acetylation and thereby prolongs FOXO-dependent transcription of stress-regulating genes. These data demonstrate that acetylation functions in a second pathway of negative control for FOXO factors and provides a novel mechanism whereby hSir2(SIRT1) can promote cellular survival and increase lifespan.	Univ Med Ctr Utrecht, Ctr Biomed Genet, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Univ Pittsburgh, Dept Pathol, Pittsburgh Vet Affairs Med Ctr 132L, Pittsburgh, PA 15240 USA; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Netherlands Cancer Institute	Burgering, BMT (corresponding author), Univ Med Ctr Utrecht, Ctr Biomed Genet, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands.	B.M.T.Burgering@med.uu.nl	Medema, Rene H/E-2981-2013; Medema, Rene H/G-5415-2011	Medema, Rene/0000-0002-6754-0381				Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Goodman RH, 2000, GENE DEV, V14, P1553; GOTTLIEB S, 1994, GENETICS, V137, P107; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kaestner KH, 2000, GENE DEV, V14, P142; Kalkhoven E, 2002, MOL CELL BIOL, V22, P1961, DOI 10.1128/MCB.22.7.1961-1970.2002; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mahmud DL, 2002, ONCOGENE, V21, P1556, DOI 10.1038/sj.onc.1205230; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Murakami S, 1996, GENETICS, V143, P1207; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Rahman I, 2002, MOL CELL BIOCHEM, V234, P239, DOI 10.1023/A:1015905010086; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vries RGJ, 2001, EMBO J, V20, P6095, DOI 10.1093/emboj/20.21.6095	33	441	451	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28873	28879		10.1074/jbc.M401138200	http://dx.doi.org/10.1074/jbc.M401138200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15126506	hybrid			2022-12-25	WOS:000222445300007
J	Wang, XY; Wang, RH; Li, WM; Xu, XL; Hollander, MC; Fornace, AJ; Deng, CX				Wang, XY; Wang, RH; Li, WM; Xu, XL; Hollander, MC; Fornace, AJ; Deng, CX			Genetic interactions between Brca1 and Gadd45a in centrosome duplication, genetic stability, and neural tube closure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINT; NEK2 PROTEIN-KINASE; FULL-LENGTH ISOFORM; DNA-DAMAGE REPAIR; CANCER SUSCEPTIBILITY; APOPTOSIS; MOUSE; MICE; INSTABILITY; P53	GADD45a is a transcription target of the breast tumor suppressor gene BRCA. It was recently shown that mouse embryonic fibroblast cells carrying a targeted deletion of exon 11 of Brca1 (Brca1(Delta11/Delta11)) or a Gadd45A-null mutation (Gadd45a(-/-)) suffer centrosome amplification. To study genetic interactions between these genes during centrosome duplication, we generated Brca1(Delta11/Delta11)Gadd45a(-/-) mice by crossing each mutant. We found that all Brca1(Delta11/Delta11)Gadd45a(-/-) embryos at embryonic days 9.5-10.5 were exencephalic and exhibited a high incidence of apoptosis accompanied by altered levels of BAX, BCL-2, and p53. The trigger for these events is likely the genetic instability arising from centrosome amplification that is associated, at least in part, with decreased expression of the NIMA-related kinase NEK2. We demonstrate that small interfering RNA-mediated suppression of Brca1 decreased Nek2 more dramatically in Gadd45a(-/-) cells than in wild-type cells and, conversely, that overexpression of Brca1 and/or Gadd45a up-regulated transcription of Nek2. Furthermore, we show that overexpression of Nek2 in Brca1-specific small interfering RNA-treated wild-type and Gadd45a(-/-) cells repressed abnormal centrosome amplification. These observations suggest that NEK2 plays a role in mediating the actions of BRCA1 and GADD45a in regulating centrosome duplication and in maintaining genetic stability.	NIDDK, GDDB, NIH, Bethesda, MD 20892 USA; NCI, Gene Response Sect, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Deng, CX (corresponding author), NIDDK, GDDB, NIH, Bldg 10,Rm 9N105,10 Ctr Dr, Bethesda, MD 20892 USA.	chuxiad@bdg10.niddk.nih.gov	Fornace, Albert J/A-7407-2008; deng, chuxia/N-6713-2016	Fornace, Albert J/0000-0001-9695-085X; 	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; Bachelier R, 2003, ONCOGENE, V22, P528, DOI 10.1038/sj.onc.1206208; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Bulavin DV, 2003, MOL CELL BIOL, V23, P3859, DOI 10.1128/MCB.23.11.3859-3871.2003; Cao L, 2003, GENE DEV, V17, P201, DOI 10.1101/gad.1050003; Carrier F, 1999, MOL CELL BIOL, V19, P1673; COPP AJ, 1990, PROG NEUROBIOL, V35, P363, DOI 10.1016/0301-0082(90)90037-H; Copp Andrew J., 1994, Current Opinion in Pediatrics, V6, P624, DOI 10.1097/00008480-199412000-00002; Deng CX, 2003, HUM MOL GENET, V12, pR113, DOI 10.1093/hmg/ddg082; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Edmonds L D, 1990, MMWR CDC Surveill Summ, V39, P19; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fry AM, 2002, ONCOGENE, V21, P6184, DOI 10.1038/sj.onc.1205711; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hames RS, 2002, BIOCHEM J, V361, P77, DOI 10.1042/0264-6021:3610077; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hildesheim J, 2002, CANCER RES, V62, P7305; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hsu LC, 2001, CANCER RES, V61, P7713; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Juriloff DM, 2000, HUM MOL GENET, V9, P993, DOI 10.1093/hmg/9.6.993; Kovalsky O, 2001, J BIOL CHEM, V276, P39330, DOI 10.1074/jbc.M105115200; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Lange BMH, 2002, CURR OPIN CELL BIOL, V14, P35, DOI 10.1016/S0955-0674(01)00291-5; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Pihan GA, 1998, CANCER RES, V58, P3974; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; SHAW GM, 1994, TERATOLOGY, V49, P143, DOI 10.1002/tera.1420490210; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Winey M, 1996, CURR BIOL, V6, P962, DOI 10.1016/S0960-9822(02)00639-5; Xu XL, 2003, DEVELOPMENT, V130, P2001, DOI 10.1242/dev.00410; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968	51	29	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29606	29614		10.1074/jbc.M312279200	http://dx.doi.org/10.1074/jbc.M312279200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123655	hybrid			2022-12-25	WOS:000222445300096
J	Erez, A; Perelman, M; Hewitt, SM; Cojacaru, G; Goldberg, I; Shahar, I; Yaron, P; Muler, I; Campaner, S; Amariglio, N; Rechavi, G; Kirsch, IR; Krupsky, M; Kaminski, N; Izraeli, S				Erez, A; Perelman, M; Hewitt, SM; Cojacaru, G; Goldberg, I; Shahar, I; Yaron, P; Muler, I; Campaner, S; Amariglio, N; Rechavi, G; Kirsch, IR; Krupsky, M; Kaminski, N; Izraeli, S			Sil overexpression in lung cancer characterizes tumors with increased mitotic activity	ONCOGENE			English	Article						Sil; mitosis; lung cancer; carcinogenesis	CELL-CYCLE; GENE; CHECKPOINT; EXPRESSION; IDENTIFICATION	Sil (SCL interrupting locus) was cloned from the most common chromosomal rearrangement in T-cell acute lymphoblastic leukemia. It is an immediate early gene whose expression is associated with cell proliferation. Sil protein levels are tightly regulated during the cell cycle, reaching peak levels in mitosis and disappearing on transition to G1. A recent study found Sil to be one of 17 genes whose overexpression in primary adenocarcinomas predicts metastatic spread. We hypothesized that Sil might have a role in carcinogenesis. To address this question, we utilized several approaches. Using a multi-tumor tissue array, we found that Sil protein expression was increased mostly in lung cancer, but also at lower levels, in a subset of other tumors. Microarray gene expression analysis and immunohistochemistry of lung cancer samples verified these observations. Sil gene expression in lung cancer correlated with the expression of several kinetochore check-point genes and with the histopathologic mitotic index. The se observations suggest that overexpression of the Sil gene characterizes tumors with increased mitotic activity.	Chaim Sheba Med Ctr, Chaim Sheba Canc Res Ctr, Dept Pediat Hematooncol, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Chaim Sheba Canc Res Ctr, Dept Pathol, IL-52621 Tel Hashomer, Israel; NIH, Ctr Adv Technol, Bethesda, MD 20892 USA; Chaim Sheba Med Ctr, Chaim Sheba Canc Res Ctr, Dept Funct Gen, IL-52621 Tel Hashomer, Israel; Compugen LTD, Tel Aviv, Israel; Chaim Sheba Med Ctr, Chaim Sheba Canc Res Ctr, Dept Pulm Med, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; NCI, NIH, Bethesda, MD 20892 USA; Univ Pittsburgh, Med Ctr, Dorothy P & Richard P Simmons Ctr, Pittsburgh, PA 15261 USA	Chaim Sheba Medical Center; Chaim Sheba Medical Center; National Institutes of Health (NIH) - USA; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kaminski, N (corresponding author), Univ Pittsburgh, Med Ctr, Dorothy P & Richard P Simmons Ctr Interstitial Lu, NW 628 MUH,3459 5th Av, Pittsburgh, PA 15261 USA.	kaminskin@upmc.edu; sizraeli@post.tau.ac.il		Kaminski, Naftali/0000-0001-5917-4601; CAMPANER, Stefano/0000-0003-4547-6849; Hewitt, Stephen/0000-0001-8283-1788	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC006579] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01SC010364] Funding Source: NIH RePORTER	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1991, MOL CELL BIOL, V11, P5462, DOI 10.1128/MCB.11.11.5462; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; CollazoGarcia N, 1995, GENOMICS, V30, P506, DOI 10.1006/geno.1995.1271; Golling G, 2002, NAT GENET, V31, P135, DOI 10.1038/ng896; Izraeli S, 2001, GENESIS, V31, P72, DOI 10.1002/gene.10004; Izraeli S, 1999, NATURE, V399, P691, DOI 10.1038/21429; Izraeli S, 1997, CELL GROWTH DIFFER, V8, P1171; Kaminski N, 2002, AM J RESP CELL MOL, V27, P125, DOI 10.1165/ajrcmb.27.2.f247; Liu ST, 2003, MOL BIOL CELL, V14, P1638, DOI 10.1091/mbc.02-05-0074; Lynch J, 2002, J PATHOL, V196, P275, DOI 10.1002/path.1045; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Ortiz LA, 2003, P NATL ACAD SCI USA, V100, P8407, DOI 10.1073/pnas.1432929100; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rattner JB, 1996, J CELL BIOL, V134, P1097, DOI 10.1083/jcb.134.5.1097; Starr DA, 2000, J CELL SCI, V113, P1939; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Travis WD, 1999, HISTOLOGICAL TYPING; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Zhou J, 2002, J CELL SCI, V115, P3547, DOI 10.1242/jcs.00029	22	44	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5371	5377		10.1038/sj.onc.1207685	http://dx.doi.org/10.1038/sj.onc.1207685			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15107824				2022-12-25	WOS:000222491600012
J	Yokota, T; Matsuzaki, Y; Miyazawa, K; Zindy, F; Roussel, MF; Sakai, T				Yokota, T; Matsuzaki, Y; Miyazawa, K; Zindy, F; Roussel, MF; Sakai, T			Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter	ONCOGENE			English	Article						histone deacetylase inhibitors; p19(INK4d); Sp1; Sp3; HDAC2; promoter activation	DEPENDENT KINASE INHIBITOR; CELL-CYCLE ARREST; TRICHOSTATIN-A; TRANSCRIPTIONAL REPRESSION; RETINOBLASTOMA PROTEIN; P21/WAF1/CIP1 GENE; N-COR; BUTYRATE; P19(INK4D); REGULATORS	Histone deacetylase (HDAC) inhibitors are known to arrest human tumor cells at the G1 phase of the cell cycle and activate the cyclin-dependent kinase inhibitor, p21(WAF1/Cip1). However, several studies have suggested the existence of a p21(WAF1/Cip1)-independent molecular pathway. We report here that HDAC inhibitors activate a member of the INK4 family, the INK4d gene, causing G1 phase arrest, in the human T cell leukemia cell line, Jurkat. One of the major Trichostatin A (TSA)-responsive elements is a specific Sp1 binding site in the INK4d promoter. Electrophoretic mobility-shift assay revealed that Sp1 and Sp3 can specifically interact with this Sp1 binding site. Furthermore, using chromatin immunoprecipitation assay, we demonstrated that HDAC2 was present in the INK4d proximal promoter region in the absence, but not the presence, of TSA. Taken together, these results suggest that treatment with TSA transcriptionally activates INK4d by releasing HDAC2 from the histone-DNA complex at the INK4d promoter. Using a p21(WAF1/Cip1)-deleted human colorectal carcinoma cell line, HCT116 p21 (-/-), we show that upregulation of p19(INK4d) by TSA is associated with inhibition of cell proliferation. Moreover, mouse embryo fibroblasts lacking Ink4d were resistant to the growth inhibitory effects of TSA as compared to their wild-type counterpart. Our findings suggest that p19(INK4d) in addition to p21(WAF1/Cip1) is an important molecular target of HDAC inhibitors inducing growth arrest.	Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Prefectural Univ Med, Dept Digest Surg, Kamigyo Ku, Kyoto 6028566, Japan; St Jude Childrens Res Hosp, Dept Tumor Cell Biol & Genet, Memphis, TN 38105 USA	Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine; St Jude Children's Research Hospital	Sakai, T (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan.	tsakai@koto.kpu-m.ac.jp	Roussel, Martine F/F-1469-2016	Roussel, Martine F/0000-0002-1740-8139	NATIONAL CANCER INSTITUTE [P30CA021765, P01CA071907] Funding Source: NIH RePORTER; NCI NIH HHS [CA71907, CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; BORGONOVO BL, 1996, EUR J HAEMATOL, V56, P313; Chang ST, 1996, BIOCHEM BIOPH RES CO, V221, P594, DOI 10.1006/bbrc.1996.0641; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Choi HS, 2002, BIOCHEM BIOPH RES CO, V296, P1005, DOI 10.1016/S0006-291X(02)02001-6; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hitomi T, 2003, FEBS LETT, V554, P347, DOI 10.1016/S0014-5793(03)01186-4; Kim YB, 2000, J ANTIBIOT, V53, P1191, DOI 10.7164/antibiotics.53.1191; Lagger G, 2003, MOL CELL BIOL, V23, P2669, DOI 10.1128/MCB.23.8.2669-2679.2003; Matsuzaki Y, 2002, FEBS LETT, V517, P272, DOI 10.1016/S0014-5793(02)02647-9; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Piekarz RL, 2001, BLOOD, V98, P2865, DOI 10.1182/blood.V98.9.2865; Ruas M, 1998, BIOCHIM BIOPHYS ACTA, V1378, P115, DOI 10.1016/s0304-419x(98)00017-1; SAKAI T, 1996, JPN J HYG, V50, P1036; SAMBROOK J, 2001, CLONING LAB MANUAL; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sowa Y, 1999, CANCER RES, V59, P4266; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Sowa Y, 2000, BIOFACTORS, V12, P283, DOI 10.1002/biof.5520120142; Sun JM, 2002, J BIOL CHEM, V277, P35783, DOI 10.1074/jbc.C200378200; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Vaziri C, 1998, CELL GROWTH DIFFER, V9, P465; Wharton W, 2000, J BIOL CHEM, V275, P33981, DOI 10.1074/jbc.M005600200; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zariwala M, 1996, ONCOGENE, V13, P2033; Zhang Y, 2002, J BIOL CHEM, V277, P33431, DOI 10.1074/jbc.M204417200; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000	40	73	76	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	2004	23	31					5340	5349		10.1038/sj.onc.1207689	http://dx.doi.org/10.1038/sj.onc.1207689			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15107822				2022-12-25	WOS:000222491600009
J	Agou, F; Traincard, F; Vinolo, E; Courtois, G; Yamaoka, S; Israel, A; Veron, M				Agou, F; Traincard, F; Vinolo, E; Courtois, G; Yamaoka, S; Israel, A; Veron, M			The trimerization domain of nemo is composed of the interacting C-terminal CC2 and LZ coiled-coil subdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GAMMA IKK-GAMMA; KINASE COMPLEX; ACTIVATION; PHOSPHORYLATION; OLIGOMERIZATION; PROTEINS; BETA; CLASSIFICATION; UBIQUITINATION	NEMO (NF-kappaB essential modulator) plays a key role in the canonical NF-kappaB pathway as the scaffold/regulatory component of the IkappaB kinase (IKK) complex. The self-association of NEMO involves the C-terminal halves of the polypeptide chains containing two putative coiled-coil motifs (a CC2 and a LZ leucine zipper), a proline-rich region, and a ZF zinc finger motif. Using purified truncation mutants, we showed that the minimal oligomerization domain of NEMO is the CC2-LZ segment and that both CC2 and LZ subdomains are necessary to restore the LPS-dependent activation of the NF-kappaB pathway in a NEMO-deficient cell line. We confirmed the association of the oligomerization domain in a trimer and investigated the specific role of CC2 and LZ subdomains in the building of the oligomer. Whereas a recombinant CC2-LZ polypeptide self-associated into a trimer with an association constant close to that of the wildtype protein, the isolated CC2 and LZ peptides, respectively, formed trimers and dimers with weaker association constants. Upon mixing, isolated CC2 and LZ peptides associated to form a stable hetero-hexamer as shown by gel filtration and fluorescence anisotropy experiments. We propose a structural model for the organization of the oligomerization domain of activated NEMO in which three C-terminal domains associate into a pseudo-hexamer forming a six-helix bundle. This model is discussed in relation to the mechanism of activation of the IKK complex by upstream activators.	Inst Pasteur, CNRS, URA 2185, Unite Regulat Enzymat Act Cellulaires, F-75724 Paris 15, France; Inst Pasteur, CNRS, URA 2582, Unite Biol Mol Express Gen, F-75724 Paris 15, France; Tokyo Med & Dent Univ, Sch Med, Dept Microbiol, Bunkyo Ku, Tokyo 113, Japan	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Tokyo Medical & Dental University (TMDU)	Agou, F (corresponding author), Inst Pasteur, CNRS, URA 2185, Unite Regulat Enzymat Act Cellulaires, 25 Rue Dr Roux, F-75724 Paris 15, France.	fagou@pasteur.fr	, AGOU/GXA-2760-2022	COURTOIS, Gilles/0000-0003-3117-9595				Agou F, 1999, J BIOL CHEM, V274, P19630, DOI 10.1074/jbc.274.28.19630; Agou F, 1996, J BIOL CHEM, V271, P29295, DOI 10.1074/jbc.271.46.29295; Agou F, 2002, J BIOL CHEM, V277, P17464, DOI 10.1074/jbc.M201964200; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan WC, 2000, FMOC SOLID PHASE PEP; Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076; Courtois G, 2001, TRENDS MOL MED, V7, P427, DOI 10.1016/S1471-4914(01)02154-2; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gunasekaran K, 2003, TRENDS BIOCHEM SCI, V28, P81, DOI 10.1016/S0968-0004(03)00003-3; Huang GJ, 2002, FEBS LETT, V531, P494, DOI 10.1016/S0014-5793(02)03590-1; Huang TT, 2002, MOL CELL BIOL, V22, P5813, DOI 10.1128/MCB.22.16.5813-5825.2002; Inohara N, 2000, J BIOL CHEM, V275, P27823; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Johnson M.L., 1994, MODERN ANAL ULTRACEN, P37; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mousson F, 2002, BIOCHEMISTRY-US, V41, P13611, DOI 10.1021/bi026274b; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Poyet JL, 2001, J BIOL CHEM, V276, P3183, DOI 10.1074/jbc.C000792200; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; SIEGEL LM, 1965, BIOCHEM BIOPH RES CO, V19, P494, DOI 10.1016/0006-291X(65)90152-X; Smahi A, 2000, NATURE, V405, P466; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	40	59	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27861	27869		10.1074/jbc.M314278200	http://dx.doi.org/10.1074/jbc.M314278200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15107419	Green Published, hybrid			2022-12-25	WOS:000222265400007
J	Yakovlev, AG; Di Giovanni, S; Wang, GP; Liu, WF; Stoica, B; Faden, AI				Yakovlev, AG; Di Giovanni, S; Wang, GP; Liu, WF; Stoica, B; Faden, AI			BOK and NOXA are essential mediators of p53-dependent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; PROGRAMMED CELL-DEATH; ETOPOSIDE-INDUCED APOPTOSIS; STRESS-INDUCED APOPTOSIS; MITOCHONDRIAL DYSFUNCTION; BH3-ONLY PROTEINS; P53-INDUCED APOPTOSIS; GENE-EXPRESSION; BCL-2 PROTEIN; CANCER CELLS	Cellular stress leads to DNA damage and activation of the intrinsic apoptotic pathway in which translocation of mitochondrial cytochrome c to the cytosol plays a critical role. Previous studies have suggested alternative mechanisms responsible for this process. We examined initiation mechanisms of the intrinsic apoptotic pathway using human neuroblastoma and breast cancer cells. Results indicated that translocation of cytochrome c does not require prior activation of caspases but rather depends on activation of specific BCL-2 family members, depending upon the type of death signal. Thus, DNA damage-induced apoptosis requires new protein synthesis, accumulation of p53 tumor suppressor protein, and p53-dependent induction of BOK and NOXA genes, while a role for BAX in this pathway is not essential. In contrast, apoptosis induced by staurosporine does not require protein synthesis but is characterized by translocation of BAX. Based on these findings, we propose a model of the intrinsic apoptotic cascade induced by DNA damage where proapoptotic BOK substitutes for a function of BAX.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA	Georgetown University	Yakovlev, AG (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Res Bldg,WP-14,3970 Reservoir Rd NW, Washington, DC 20007 USA.	ayakou01@georgetown.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038941] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 38941] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; Chinnaiyan Arul M., 1999, Neoplasia (New York), V1, P5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Gao CF, 2001, EXP CELL RES, V265, P145; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Igata E, 1999, GENE, V238, P407, DOI 10.1016/S0378-1119(99)00348-0; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lowe B, 2003, ANAL BIOCHEM, V315, P95, DOI 10.1016/S0003-2697(02)00695-4; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; NAKAJIMA M, 1994, NEUROSCI LETT, V176, P161, DOI 10.1016/0304-3940(94)90072-8; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Pearson AS, 2000, CLIN CANCER RES, V6, P887; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; Seo YW, 2003, J BIOL CHEM, V278, P48292, DOI 10.1074/jbc.M308785200; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SUN XM, 1994, BIOCHEM PHARMACOL, V47, P187; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; WALKER PR, 1991, CANCER RES, V51, P1078; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhang H, 2000, J BIOL CHEM, V275, P27303; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	50	114	123	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28367	28374		10.1074/jbc.M313526200	http://dx.doi.org/10.1074/jbc.M313526200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102863	hybrid			2022-12-25	WOS:000222265400069
J	Lin, ZP; Belcourt, MF; Cory, JG; Sartorelli, AC				Lin, ZP; Belcourt, MF; Cory, JG; Sartorelli, AC			Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITUMOR-ACTIVITY; CYCLE CHECKPOINT; MAMMALIAN-CELLS; ENZYMATIC ASSAY; IN-VITRO; P53; PROTEIN; GENE; EXPRESSION; RESISTANCE	Ribonucleotide reductase catalyzes the production of deoxyribonucleoside diphosphates, the precursors of deoxyribonucleoside triphosphates for DNA synthesis. Mammalian ribonucleotide reductase (RNR) is a tetramer consisting of two non-identical homodimers, R1 and either R2 or p53R2, which are considered to be involved in DNA replication and repair, respectively. We have demonstrated that DNA damage by doxorubicin and cisplatin caused a steady elevation of the R2 protein in p53(-/-) HCT-116 human colon carcinoma cells but induced degradation of the protein in p53(+/+) cells. To evaluate the involvement of R2 in response to DNA damage, p53(-/-) HCT-116 cells were stably transfected with an expression vector transcribing short hairpin/short interference RNA directed against R2 mRNA. Stably transfected clones exhibited a pronounced reduction of the R2 protein with no change in the cellular growth rate. Furthermore, short interference RNA-mediated reduction of the R2 protein caused a marked increase in sensitivity to the DNA-damaging agent cisplatin as well as to the RNR inhibitors Triapine(R) and hydroxyurea. Ectopic expression of p53R2 partially reversed the cytotoxicity of cisplatin but not that of RNR inhibitors to R2 knockdown cells. The increase in sensitivity to cisplatin and RNR inhibitors was correlated with the suppression of dATP and dGTP levels caused by stable expression of R2-targeted short interference RNA. These results indicated that DNA damage resulted in elevated levels of the R2 protein and dNTPs and, consequently, enhanced the survival of p53(-/-) HCT-116 cells. The findings provide evidence that R2- RNR can be employed to supply dNTPs for the repair of DNA damage in cells with an impaired p53-dependent induction of p53R2.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ctr Canc, New Haven, CT 06520 USA; Vion Pharmaceut Inc, New Haven, CT 06511 USA; E Carolina Univ, Sch Med, Dept Biochem, Greenville, NC 27834 USA	Yale University; Yale University; Vion Pharmaceuticals, Inc.; University of North Carolina; East Carolina University	Sartorelli, AC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	alan.sartorelli@yale.edu						BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; CORY JG, 1994, BIOCHEM PHARMACOL, V48, P335, DOI 10.1016/0006-2952(94)90105-8; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; ELFORD HL, 1970, J BIOL CHEM, V245, P5228; ELLEDGE SJ, 1989, MOL CELL BIOL, V9, P4932, DOI 10.1128/MCB.9.11.4932; ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; FAN SJ, 1995, CANCER RES, V55, P1649; Filatov D, 1996, J BIOL CHEM, V271, P23698, DOI 10.1074/jbc.271.39.23698; Finch RA, 1999, ADV ENZYME REGUL, V39, P3, DOI 10.1016/S0065-2571(98)00017-X; Finch RA, 2000, BIOCHEM PHARMACOL, V59, P983, DOI 10.1016/S0006-2952(99)00419-0; Fritzer-Szekeres M, 2002, BIOCHEM PHARMACOL, V64, P481, DOI 10.1016/S0006-2952(02)01186-3; Furuta T, 2002, CANCER RES, V62, P4899; GAO WY, 1994, ANAL BIOCHEM, V222, P116, DOI 10.1006/abio.1994.1462; Guittet O, 2001, J BIOL CHEM, V276, P40647, DOI 10.1074/jbc.M106088200; Hawkins DS, 1996, CANCER RES, V56, P892; HURTA RAR, 1992, J BIOL CHEM, V267, P7066; Inayat MS, 2002, CANCER BIOL THER, V1, P539, DOI 10.4161/cbt.1.5.174; KIMURA M, 1994, BBA-GENE STRUCT EXPR, V1219, P653, DOI 10.1016/0167-4781(94)90224-0; KUNZ BA, 1994, MUTAT RES-REV GENET, V318, P1, DOI 10.1016/0165-1110(94)90006-X; Kuo ML, 1998, CANCER RES, V58, P2245; Lee Y, 2003, CANCER RES, V63, P2802; LIU MC, 1992, J MED CHEM, V35, P3672, DOI 10.1021/jm00098a012; MANN GJ, 1988, CANCER RES, V48, P5151; MULSANT P, 1988, SOMAT CELL MOLEC GEN, V14, P243, DOI 10.1007/BF01534585; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; PINTO A L, 1985, Biochimica et Biophysica Acta, V780, P167, DOI 10.1016/0304-419X(85)90001-0; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sablina AA, 2001, ONCOGENE, V20, P899, DOI 10.1038/sj.onc.1204156; Shao JM, 2004, CANCER RES, V64, P1, DOI 10.1158/0008-5472.CAN-03-3048; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; THELANDER M, 1985, J BIOL CHEM, V260, P2737; WEBER G, 1980, ONCOLOGY, V37, P19, DOI 10.1159/000225492; Yamaguchi T, 2001, CANCER RES, V61, P8256; Zhou BS, 2003, CANCER RES, V63, P6583	43	66	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27030	27038		10.1074/jbc.M402056200	http://dx.doi.org/10.1074/jbc.M402056200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096505	hybrid			2022-12-25	WOS:000222120400029
J	Mishina, Y; Starbuck, MW; Gentile, MA; Fukuda, T; Kasparcova, V; Seedor, JG; Hanks, MC; Amling, M; Pinero, GJ; Harada, S; Behringer, RR				Mishina, Y; Starbuck, MW; Gentile, MA; Fukuda, T; Kasparcova, V; Seedor, JG; Hanks, MC; Amling, M; Pinero, GJ; Harada, S; Behringer, RR			Bone morphogenetic protein type IA receptor signaling regulates postnatal osteoblast function and bone remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA-SUPERFAMILY; MOUSE OSTEOCALCIN GENE; OSTEOCLAST FORMATION; CRE RECOMBINASE; EXPRESSION; MICE; DIFFERENTIATION; CELLS; LIMB; MEMBER	Bone morphogenetic proteins (BMPs) function during various aspects of embryonic development including skeletogenesis. However, their biological functions after birth are less understood. To investigate the role of BMPs during bone remodeling, we generated a postnatal osteoblast-specific disruption of Bmpr1a that encodes the type IA receptor for BMPs in mice. Mutant mice were smaller than controls up to 6 months after birth. Irregular calcification and low bone mass were observed, but there were normal numbers of osteoblasts. The ability of the mutant osteoblasts to form mineralized nodules in culture was severely reduced. Interestingly, bone mass was increased in aged mutant mice due to reduced bone resorption evidenced by reduced bone turnover. The mutant mice lost more bone after ovariectomy likely resulting from decreased osteoblast function which could not overcome ovariectomy-induced bone resorption. In organ culture of bones from aged mice, ablation of the Bmpr1a gene by adenoviral Cre recombinase abolished the stimulatory effects of BMP4 on the expression of lysosomal enzymes essential for osteoclastic bone resorption. These results demonstrate essential and age-dependent roles for BMP signaling mediated by BMPRIA ( a type IA receptor for BMP) in osteoblasts for bone remodeling.	NIEHS, LRDT, NIH, Res Triangle Pk, NC 27709 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Merck Res Labs, Dept Mol Endocrinol Bone Biol, West Point, PA 19486 USA; Procter & Gamble Pharmaceut, Hlth Care Res Ctr, Mason, OH USA; Univ Hamburg, Dept Trauma Surg, Hamburg, Germany; Univ Texas, Dent Branch, Dept Basic Sci, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; UTMD Anderson Cancer Center; Merck & Company; Procter & Gamble; University of Hamburg; University of Texas System	Mishina, Y (corresponding author), NIEHS, LRDT, NIH, 111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	mishina@niehs.nih.gov	Fukuda, Tomokazu/O-1257-2018	Fukuda, Tomokazu/0000-0001-8456-0483	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042919] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071003] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42919] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663; ARAKI K, 1995, P NATL ACAD SCI USA, V92, P160, DOI 10.1073/pnas.92.1.160; Baur ST, 2000, DEVELOPMENT, V127, P605; Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; Devlin RD, 2003, ENDOCRINOLOGY, V144, P1972, DOI 10.1210/en.2002-220918; DEWULF N, 1995, ENDOCRINOLOGY, V136, P2652, DOI 10.1210/en.136.6.2652; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; DUCY P, 1995, MOL CELL BIOL, V15, P1858; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509; HENTUNEN TA, 1995, BIOCHEM BIOPH RES CO, V209, P433, DOI 10.1006/bbrc.1995.1521; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; ISHIDOU Y, 1995, J BONE MINER RES, V10, P1651; Itoh K, 2001, ENDOCRINOLOGY, V142, P3656, DOI 10.1210/en.142.8.3656; Kaneko H, 2000, BONE, V27, P479, DOI 10.1016/S8756-3282(00)00358-6; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Katagiri T, 1998, DEV GENET, V22, P340, DOI 10.1002/(SICI)1520-6408(1998)22:4<340::AID-DVG4>3.0.CO;2-6; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; Koide M, 1999, BIOCHEM BIOPH RES CO, V259, P97, DOI 10.1006/bbrc.1999.0715; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Mishina Y, 2003, FRONT BIOSCI-LANDMRK, V8, pD855, DOI 10.2741/1097; Mishina Y, 2002, GENESIS, V32, P69, DOI 10.1002/gene.10038; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; Nagy A, 2000, GENESIS, V26, P99, DOI 10.1002/(SICI)1526-968X(200002)26:2<99::AID-GENE1>3.0.CO;2-B; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Solloway MJ, 1998, DEV GENET, V22, P321, DOI 10.1002/(SICI)1520-6408(1998)22:4<321::AID-DVG3>3.3.CO;2-7; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; Styrkarsdottir U, 2003, PLOS BIOL, V1, P351, DOI 10.1371/journal.pbio.0000069; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; Takeda S, 2003, ANNU REV NUTR, V23, P403, DOI 10.1146/annurev.nutr.23.011702.073312; Thomas JT, 1997, NAT GENET, V17, P58, DOI 10.1038/ng0997-58; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315; Traianedes K, 1998, ENDOCRINOLOGY, V139, P3178, DOI 10.1210/en.139.7.3178; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Weinstein RS, 1997, ENDOCRINOLOGY, V138, P4013, DOI 10.1210/en.138.9.4013; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Yi SE, 2000, DEVELOPMENT, V127, P621; YOKOUCHI Y, 1996, DEVELOPMENT CAMB, V122, P3723; Zhang HB, 1996, DEVELOPMENT, V122, P2977; Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191	43	150	160	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27560	27566		10.1074/jbc.M404222200	http://dx.doi.org/10.1074/jbc.M404222200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15090551	hybrid			2022-12-25	WOS:000222120400089
J	Chiu, A; Revenkova, E; Jessberger, R				Chiu, A; Revenkova, E; Jessberger, R			DNA interaction and dimerization of eukaryotic SMC hinge domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID COHESION; CHROMOSOME CONDENSATION; STRUCTURAL MAINTENANCE; RECOMBINATION COMPLEX; PROTEIN COMPLEXES; 13S CONDENSIN; IN-VITRO; MEIOSIS; REPAIR; BIND	The eukaryotic SMC1/SMC3 heterodimer is essential for sister chromatid cohesion and acts in DNA repair and recombination. Dimerization depends on the central hinge domain present in all SMC proteins, which is flanked at each side by extended coiled-coil regions that terminate in specific globular domains. Here we report on DNA interactions of the eukaryotic, heterodimeric SMC1/SMC3 hinge regions, using the two known isoforms, SMC1alpha/SMC3 and the meiotic SMC1beta/SMC3. Both dimers bind DNA with a preference for double-stranded DNA and DNA rich in potential secondary structures. Both dimers form large protein-DNA networks and promote reannealing of complementary DNA strands. DNA binding but not dimerization depends on approximately 20 amino acids of transitional sequence into the coiled-coil region. Replacement of three highly conserved glycine residues, thought to be required for dimerization, in one of the two hinge domains still allows formation of a stable dimer, but if two hinge domains are mutated dimerization fails. Single-mutant dimers bind DNA, but hinge monomers do not. Together, we show that eukaryotic hinge dimerization does not require conserved glycines in both hinge domains, that only the transition into the coiled-coil region rather than the entire coiled-coil region is necessary for DNA binding, and that dimerization is required but not sufficient for DNA binding of the eukaryotic hinge heterodimer.	Mt Sinai Sch Med, Ctr Gene Therapy & Mol Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Jessberger, R (corresponding author), Mt Sinai Sch Med, Ctr Gene Therapy & Mol Med, 1 Gustave L Levy Pl,Box 1496, New York, NY 10029 USA.	rolf.jessberger@mssm.edu			NIGMS NIH HHS [GM 62517] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062517] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhmedov AT, 1999, J BIOL CHEM, V274, P38216, DOI 10.1074/jbc.274.53.38216; Akhmedov AT, 1998, J BIOL CHEM, V273, P24088, DOI 10.1074/jbc.273.37.24088; Anderson DE, 2002, J CELL BIOL, V156, P419, DOI 10.1083/jcb.200111002; Bazett-Jones DP, 2002, MOL CELL, V9, P1183, DOI 10.1016/S1097-2765(02)00546-4; Blat Y, 1999, CELL, V98, P249, DOI 10.1016/S0092-8674(00)81019-3; Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025; CHOW SA, 1985, P NATL ACAD SCI USA, V82, P5646, DOI 10.1073/pnas.82.17.5646; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Cobbe N, 2000, J STRUCT BIOL, V129, P123, DOI 10.1006/jsbi.2000.4255; Fousteri MI, 2000, EMBO J, V19, P1691, DOI 10.1093/emboj/19.7.1691; GANEA D, 1987, MOL CELL BIOL, V7, P3124, DOI 10.1128/MCB.7.9.3124; Gruber S, 2003, CELL, V112, P765, DOI 10.1016/S0092-8674(03)00162-4; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Hagstrom KA, 2003, NAT REV GENET, V4, P520, DOI 10.1038/nrg1110; Hagstrom KA, 2002, GENE DEV, V16, P729, DOI 10.1101/gad.968302; Hirano M, 2002, EMBO J, V21, P5733, DOI 10.1093/emboj/cdf575; Hirano M, 2001, EMBO J, V20, P3238, DOI 10.1093/emboj/20.12.3238; Hirano M, 1998, EMBO J, V17, P7139, DOI 10.1093/emboj/17.23.7139; Hirano T, 2002, GENE DEV, V16, P399, DOI 10.1101/gad.955102; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; Jessberger R, 2003, IUBMB LIFE, V55, P643, DOI 10.1080/15216540310001639661; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Jessberger R, 2002, NAT REV MOL CELL BIO, V3, P767, DOI 10.1038/nrm930; Kim JS, 2002, J BIOL CHEM, V277, P45149, DOI 10.1074/jbc.M209123200; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; LEHMANN AR, 1995, MOL CELL BIOL, V15, P7067; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Losada A, 2001, CURR BIOL, V11, P268, DOI 10.1016/S0960-9822(01)00066-5; Lowe J, 2001, J MOL BIOL, V306, P25, DOI 10.1006/jmbi.2000.4379; Megee PC, 1999, MOL CELL, V4, P445, DOI 10.1016/S1097-2765(00)80347-0; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Revenkova E, 2001, MOL CELL BIOL, V21, P6984, DOI 10.1128/MCB.21.20.6984-6998.2001; Sakai A, 2003, EMBO J, V22, P2764, DOI 10.1093/emboj/cdg247; Stursberg S, 1999, GENE, V228, P1, DOI 10.1016/S0378-1119(99)00021-9; Sutani T, 1997, NATURE, V388, P798, DOI 10.1038/42062; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4; WARBURTON PE, 1990, J MOL BIOL, V216, P3, DOI 10.1016/S0022-2836(05)80056-7; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702	46	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26233	26242		10.1074/jbc.M402439200	http://dx.doi.org/10.1074/jbc.M402439200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087462	hybrid			2022-12-25	WOS:000222003000040
J	Chauhan, D; Li, GL; Hideshima, T; Podar, K; Shringarpure, R; Mitsiades, C; Munshi, N; Yew, PR; Anderson, KC				Chauhan, D; Li, GL; Hideshima, T; Podar, K; Shringarpure, R; Mitsiades, C; Munshi, N; Yew, PR; Anderson, KC			Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341	ONCOGENE			English	Article						Bortezomib/PS-341; multiple myeloma; apoptosis; 2-Methoxyestradiol; dexamethasone	MULTIPLE-MYELOMA; INDUCED APOPTOSIS; POLY(ADP-RIBOSE) POLYMERASE; OLIGONUCLEOTIDE ARRAYS; MITOCHONDRIAL PROTEIN; DRUG-RESISTANCE; CELL-CYCLE; MM CELLS; INTERLEUKIN-6; DEXAMETHASONE	The ubiquitin-conjugating enzyme CDC34 (UBC3) is linked to cell cycle progression in diverse cell types; however, its role in multiple myeloma ( MM) pathogenesis is unclear. Here, we show that CDC34 is highly expressed in patient MM cells and MM cell lines versus normal cells. Blocking CDC34 using a dominant-negative strategy enhances the anti-MM activity of Bortezomib/ Proteasome inhibitor PS-341, dexamethasone (Dex) and 2-Methoxyestradiol (2ME2). The expression of wild-type CDC34 reduces Dex-induced cytotoxicity in MM cells. Moreover, inhibition of CDC34 enzymatic activity abrogates interleukin-6-induced protection against Dex-induced apoptosis. Together, these findings provide evidence that ( 1) CDC34 expression is associated with growth and survival of MM cells and ( 2) blocking CDC34 activity not only enhances anti-MM activity of Bortezomib and 2ME2 but also overcomes IL-6-triggered Dex-resistance.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Texas System; University of Texas Health San Antonio	Anderson, KC (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu	Munshi, Nikhil/ABE-2338-2021; Podar, Klaus/ABD-1112-2020	Podar, Klaus/0000-0002-7414-3632	NCI NIH HHS [R01 CA50947, P01 CA 78373, IP50 CA 10070] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050947] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Block K, 2001, J BIOL CHEM, V276, P41049, DOI 10.1074/jbc.M106453200; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chauhan D, 2003, BLOOD, V102, P3379, DOI 10.1182/blood-2003-05-1417; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Chauhan D, 2003, BLOOD, V101, P3606, DOI 10.1182/blood-2002-10-3146; Chauhan D, 2002, BLOOD, V100, P2187, DOI 10.1182/blood-2002-02-0376; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Chen YH, 1996, BLOOD, V87, P314, DOI 10.1182/blood.V87.1.314.bloodjournal871314; De Vos J, 2002, ONCOGENE, V21, P6848, DOI 10.1038/sj.onc.1205868; DESNOYERS S, 1994, ANAL BIOCHEM, V218, P470, DOI 10.1006/abio.1994.1212; Eliseeva E, 2001, CELL GROWTH DIFFER, V12, P427; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HARDIN J, 1994, BLOOD, V84, P3063; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Hwang GW, 2002, FASEB J, V16, P709, DOI 10.1096/fj.01-0899fje; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Li YZ, 1999, MOL MED, V5, P232, DOI 10.1007/BF03402120; MOALLI PA, 1992, BLOOD, V79, P213; Rowley M, 2000, BLOOD, V96, P3175, DOI 10.1182/blood.V96.9.3175.h8003175_3175_3180; Tanaka K, 2001, BBA-MOL BASIS DIS, V1536, P1, DOI 10.1016/S0925-4439(01)00026-6; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672	25	45	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3597	3602		10.1038/sj.onc.1207458	http://dx.doi.org/10.1038/sj.onc.1207458			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15094775				2022-12-25	WOS:000221101700011
J	Hashimoto, M; Ichihara, M; Watanabe, T; Kawai, K; Koshikawa, K; Yuasa, N; Takahashi, T; Yatabe, Y; Murakumo, Y; Zhang, JM; Nimura, Y; Takahashi, M				Hashimoto, M; Ichihara, M; Watanabe, T; Kawai, K; Koshikawa, K; Yuasa, N; Takahashi, T; Yatabe, Y; Murakumo, Y; Zhang, JM; Nimura, Y; Takahashi, M			Expression of CD109 in human cancer	ONCOGENE			English	Article						CD109; squamous cell carcinoma; lung carcinoma; esophageal carcinoma	PLATELETS; PROTEINS; CELLS	It was recently reported that the human CD109 gene encodes a glycosyl-phosphatidylinositol-anchored glycoprotein that is a member of the alpha(2)-macroglobulin/C3, C4, C5 family of thioester-containing proteins. In this study, we found that the expression of mouse CD109 gene was upregulated in NIH3T3 cells expressing RET tyrosine kinase with a multiple endocrine neoplasia 2B mutation. Northern blot analysis showed a high level of expression of the CD109 gene only in the testis in normal human and mouse tissues. In addition, its expression was high in some human tumor cell lines, which included squamous cell carcinoma and glioblastoma cell lines, whereas it was undetectable in neuroblastoma and small-cell lung carcinoma cell lines. When CD109 expression was examined in 33 cases of human lung cell carcinomas by quantitative RT-PCR, a significant high expression of CD109 was detected in about half of squamous cell carcinomas examined, but not in adenocarcinoma, large-cell carcinoma and small-cell carcinoma. Similarly, upregulation of CD109 was observed in nine out of 17 esophageal squamous cell carcinomas. Thus, these results suggested that CD109 might be a useful molecular target for the development of new therapeutics for malignant tumors, such as squamous cell carcinoma.	Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Surg, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Ctr Neural Dis & Canc, Div Mol Pathol,Showa Ku, Nagoya, Aichi 4668550, Japan; Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Dept Pathol & Mol Diagnost, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Nagoya University; Nagoya University; Nagoya University; Aichi Cancer Center; Aichi Cancer Center	Takahashi, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	mtakaha@med.nagoya-u.ac.jp	Takahashi, Takashi/I-7262-2014; Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014; Kumi, Kawai/I-6275-2014; YATABE, Yasushi/J-6461-2014	Takahashi, Takashi/0000-0003-0615-7001; Takahashi, Masahide/0000-0002-2803-2683; Kumi, Kawai/0000-0002-7772-2605; YATABE, Yasushi/0000-0003-1788-559X				HAREGEWOIN A, 1994, CELL IMMUNOL, V156, P357, DOI 10.1006/cimm.1994.1181; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Lin M, 2002, BLOOD, V99, P1683, DOI 10.1182/blood.V99.5.1683; Murray LJ, 1999, EXP HEMATOL, V27, P1282, DOI 10.1016/S0301-472X(99)00071-5; Rappold I, 1997, BLOOD, V90, P111; SMITH JW, 1995, BLOOD, V86, P2807; Solomon KR, 1998, BIOCHEM J, V334, P325, DOI 10.1042/bj3340325; SUTHERLAND DR, 1991, BLOOD, V77, P84; SUTHERLAND DR, 1998, LEUKOCYTE TYPING, V6, P714; SUTHERLAND DR, 1995, LEUKOCYTE TYPING, V5, P1767; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Watanabe T, 2002, AM J PATHOL, V161, P249, DOI 10.1016/S0002-9440(10)64176-4; YEO EL, 1992, BLOOD, V80, P56	13	68	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3716	3720		10.1038/sj.onc.1207418	http://dx.doi.org/10.1038/sj.onc.1207418			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116102				2022-12-25	WOS:000221101700024
J	Terrinoni, A; Ranalli, M; Cadot, B; Leta, A; Bagetta, G; Vousden, KH; Melino, G				Terrinoni, A; Ranalli, M; Cadot, B; Leta, A; Bagetta, G; Vousden, KH; Melino, G			p73-alpha is capable of inducing scotin and ER stress	ONCOGENE			English	Article						apoptosis; p73; p63; p53; scotin; endoplasmic reticulum; ER; calnexin; gadd 153	KINASE C-ABL; ENDOPLASMIC-RETICULUM; APOPTOTIC RESPONSE; P73; P53; GENE; DIFFERENTIATION; TARGET; P63; NEUROBLASTOMA	p73, like its family member p53, can induce programmed cell death following DNA damage. Here, we report that this mechanism also involves endoplasmic reticulum (ER) stress and the transactivation of scotin, a protein identified recently as a p53 target able to induce ER stress. By using Tet-On inducible cell lines (Saos 2 osteosarcoma cells that lack p53), we observed that TAp73alpha elicits significant alterations in the morphology of the ER system, namely in the. ne subcellular localization of calnexin. We found that both TAp73alpha and p53 are strong inducers of scotin. On the other hand, the transcriptionally deficient short isoforms DeltaNp73alpha did not upregulate the steady-state mRNA level of scotin, as evaluated by real-time RT-PCR. Following the induction of scotin, ER staining with calnexin showed evidence of morphological alteration, with variations in the intracellular concentration of free calcium, visualized by fluo-3 staining. The induction of ER stress by p73 was further supported by the transcriptional induction of Gadd 153, a transcription factor induced under ER stress conditions. In conclusion, the data reported indicate the ability of TAp73alpha and p53 (not DeltaNp73alpha) to elicit scotin transactivation and ER stress. This molecular mechanism might contribute to the effector events inducing apoptosis downstream of p73.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, IRCCS, IDI,Biochem Lab, I-00133 Rome, Italy; Univ Calabria, Dept Pharmacobiol, I-87036 Cosenza, Italy; Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; University of Calabria; Beatson Institute; University of Leicester	Melino, G (corresponding author), Via Montpellier 1, I-00133 Rome, Italy.	gerry.melino@uniroma2.it	Bagetta, Giacinto/N-9716-2018; CADOT, bruno/E-1710-2013; Bagetta, Giacinto/E-8402-2012; TERRINONI, Alessandro/J-1533-2012	Bagetta, Giacinto/0000-0001-8540-6218; CADOT, bruno/0000-0002-1888-3898; Bagetta, Giacinto/0000-0001-8540-6218; TERRINONI, Alessandro/0000-0002-7442-2252	Telethon [E.1224] Funding Source: Medline	Telethon(Fondazione Telethon)		Agami R, 1999, NATURE, V399, P809; Bourdon JC, 2002, J CELL BIOL, V158, P235, DOI 10.1083/jcb.200203006; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Gong JG, 1999, NATURE, V399, P806; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Tschan MP, 2000, BIOCHEM BIOPH RES CO, V277, P62, DOI 10.1006/bbrc.2000.3627; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhu JH, 1998, CANCER RES, V58, P5061; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	28	44	46	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3721	3725		10.1038/sj.onc.1207342	http://dx.doi.org/10.1038/sj.onc.1207342			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116103				2022-12-25	WOS:000221101700025
J	Macdonald, M; Wan, Y; Wang, W; Roberts, E; Cheung, TH; Erickson, R; Knuesel, MT; Liu, XD				Macdonald, M; Wan, Y; Wang, W; Roberts, E; Cheung, TH; Erickson, R; Knuesel, MT; Liu, XD			Control of cell cycle-dependent degradation of c-Ski proto-oncoprotein by Cdc34	ONCOGENE			English	Article						Cdc34; Ski; SnoN; protein degradation; ubiquitin; cell cycle	TRANSFORMING-GROWTH-FACTOR; HISTONE DEACETYLASE COMPLEX; ANAPHASE-PROMOTING COMPLEX; SKELETAL-MUSCLE; INDUCED TRANSCRIPTION; UBIQUITIN LIGASE; SMAD PROTEINS; CDNA CLONES; IN-VIVO; SNON	It is known that excess amounts of Ski, or any member of its proto-oncoprotein family, causes disruption of the transforming growth factor beta signal transduction pathway, thus causing oncogenic transformation of cells. Previous studies indicate that Ski is a relatively unstable protein whose expression levels can be regulated by ubiquitin-mediated proteolysis. Here, we investigate the mechanism by which the stability of Ski is regulated. We show that the steady-state levels of Ski protein are controlled post-translationally by cell cycle-dependent proteolysis, wherein Ski is degraded during the interphase of the cell cycle but is relatively stable during mitosis. Furthermore, we demonstrate that the ubiquitin-conjugating enzyme Cdc34 mediates cell cycle-dependent Ski degradation both in vitro and in vivo. Overexpression of dominant-negative Cdc34 stabilizes Ski and enhances its ability to antagonize TGF-beta signaling. Our data suggest that regulated proteolysis of Ski is one of the key mechanisms that control the threshold levels of this proto-oncoprotein, and thus prevents epithelial cells from becoming TGF-beta resistant.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	University of Colorado System; University of Colorado Boulder; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Liu, XD (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.	xuedong.liu@colorado.edu		LIU, XUEDONG/0000-0001-7209-4964; Knuesel, Matthew/0000-0002-1441-8614	NATIONAL CANCER INSTITUTE [R01CA095527] Funding Source: NIH RePORTER; NCI NIH HHS [CA95527-01, R01 CA095527] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; AMBROSE MR, 1995, DNA CELL BIOL, V14, P701, DOI 10.1089/dna.1995.14.701; Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; BOYER PL, 1993, ONCOGENE, V8, P457; Cohen SB, 1999, NUCLEIC ACIDS RES, V27, P1006, DOI 10.1093/nar/27.4.1006; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; FUMAGALLI S, 1993, MELANOMA RES, V3, P23, DOI 10.1097/00008390-199304000-00004; GRIMES HL, 1993, ONCOGENE, V8, P2863; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Jin JP, 2003, CANCER CELL, V3, P517, DOI 10.1016/S1535-6108(03)00145-4; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Luo KX, 2003, J BONE JOINT SURG AM, V85A, P39, DOI 10.2106/00004623-200300003-00008; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Medrano EE, 2003, ONCOGENE, V22, P3123, DOI 10.1038/sj.onc.1206452; Michael WM, 1998, SCIENCE, V282, P1886, DOI 10.1126/science.282.5395.1886; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NAGASE T, 1993, J BIOL CHEM, V268, P13710; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Pati D, 1999, MOL CELL BIOL, V19, P5001; PEARSONWHITE S, 1993, NUCLEIC ACIDS RES, V21, P4632, DOI 10.1093/nar/21.19.4632; PearsonWhite S, 1997, NUCLEIC ACIDS RES, V25, P2930, DOI 10.1093/nar/25.14.2930; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; Prunier C, 2003, J BIOL CHEM, V278, P26249, DOI 10.1074/jbc.M304459200; Reed JA, 2001, CANCER RES, V61, P8074; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; Sutrave P, 2000, GENE, V241, P107, DOI 10.1016/S0378-1119(99)00461-8; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672; Zhang F, 2003, CANCER RES, V63, P5005; Zheng GX, 1997, J BIOL CHEM, V272, P31855, DOI 10.1074/jbc.272.50.31855	50	22	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5643	5653		10.1038/sj.onc.1207733	http://dx.doi.org/10.1038/sj.onc.1207733			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15122324				2022-12-25	WOS:000222629500009
J	Meyer, RD; Singh, A; Majnoun, F; Latz, C; Lashkari, K; Rahimi, N				Meyer, RD; Singh, A; Majnoun, F; Latz, C; Lashkari, K; Rahimi, N			Substitution of C-terminus of VEGFR-2 with VEGFR-1 promotes VEGFR-1 activation and endothelial cell proliferation	ONCOGENE			English	Article						VEGFR-1; VEGFR-2; angiogenesis; tyrosine kinase activation; tyrosine phosphorylation; endothelial cells	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; SIGNAL-TRANSDUCTION; CARBOXYL-TERMINUS; FLT-1 VEGFR-1; KDR; DOMAIN; PHOSPHORYLATION; ANGIOGENESIS; NEUROPILIN-1	VEGFR-1 is devoid of ligand-dependent tyrosine autophosphorylation and its activation is not associated with proliferation of endothelial cells. The molecular mechanism responsible for this characteristic of VEGFR-1 is not known. In this study, we show that VEGFR-1 is devoid of ligand-dependent downregulation and failed to stimulate intracellular calcium release, cell migration and angiogenesis in vitro. To understand the molecular mechanisms responsible for the poor tyrosine autophosphorylation of VEGFR-1, we have either deleted the carboxyl terminus of VEGFR-1 or exchanged it with the carboxyl terminus of VEGFR-2. The deletion of carboxyl terminus of VEGFR-1 did not reverse its defective ligand-dependent autophosphorylation. The carboxyl terminus-swapped VEGFR-1, however, displayed ligand-dependent autophosphorylation, downregulation and also conveyed strong mitogenic responses. Thus, the carboxyl tail of VEGFR-1 restrains the ligand-dependent kinase activation and. downregulation of VEGFR-1 and its ability to convey the angiogenic responses in endothelial cells.	Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst, Boston, MA 02114 USA	Boston University; Boston University; Harvard University; Harvard Medical School; Schepens Eye Research Institute	Rahimi, N (corresponding author), Boston Univ, Sch Med, Dept Ophthalmol, 715 Albany St,Room 921L, Boston, MA 02118 USA.	nrahimi@bu.edu	Latz, Catharina/AAM-9079-2020	Rahimi, Nader/0000-0002-6745-1725; Lashkari, Kameran/0000-0003-3855-0246	NATIONAL EYE INSTITUTE [R01EY012997, R03EY013706] Funding Source: NIH RePORTER; NEI NIH HHS [R03 EY013706, EY 0137061, EY 012997, R01 EY012997] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALIMANDI M, 1995, ONCOGENE, V10, P1813; Athanassiades A, 1998, PLACENTA, V19, P465, DOI 10.1016/S0143-4004(98)91039-6; Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Breier G, 2000, ADV EXP MED BIOL, V476, P57; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Kearney JB, 2002, BLOOD, V99, P2397, DOI 10.1182/blood.V99.7.2397; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Klepeis VE, 2001, J CELL SCI, V114, P4185; Korff T, 1999, J CELL SCI, V112, P3249; Lee P, 2002, P NATL ACAD SCI USA, V99, P10470, DOI 10.1073/pnas.162366299; LI W, 1991, CELL REGUL, V2, P641, DOI 10.1091/mbc.2.8.641; Mashiba S, 1999, BIOCHEM BIOPH RES CO, V258, P674, DOI 10.1006/bbrc.1999.0611; Meyer RD, 2004, J BIOL CHEM, V279, P735, DOI 10.1074/jbc.M305575200; Meyer RD, 2003, J BIOL CHEM, V278, P16347, DOI 10.1074/jbc.M300259200; Meyer RD, 2002, J BIOL CHEM, V277, P27081, DOI 10.1074/jbc.M110544200; MOSSIE K, 1995, ONCOGENE, V11, P2179; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Neufeld G, 1996, CANCER METAST REV, V15, P153, DOI 10.1007/BF00437467; Niu XL, 2002, J BIOL CHEM, V277, P31768, DOI 10.1074/jbc.M203995200; Parks AL, 2000, DEVELOPMENT, V127, P1373; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; SEEDORF K, 1992, MOL CELL BIOL, V12, P4347, DOI 10.1128/MCB.12.10.4347; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Suarez S, 2001, J CELL SCI, V114, P1229; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WALTON GM, 1990, J BIOL CHEM, V265, P1750; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zeng HY, 2003, J BIOL CHEM, V278, P20738, DOI 10.1074/jbc.M209712200	45	25	25	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5523	5531		10.1038/sj.onc.1207712	http://dx.doi.org/10.1038/sj.onc.1207712			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15107818	Green Accepted			2022-12-25	WOS:000222588400012
J	Schmidt-Hansen, B; Ornas, D; Grigorian, M; Klingelhofer, J; Tulchinsky, E; Lukanidin, E; Ambartsumian, N				Schmidt-Hansen, B; Ornas, D; Grigorian, M; Klingelhofer, J; Tulchinsky, E; Lukanidin, E; Ambartsumian, N			Extracellular S100A4(mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity	ONCOGENE			English	Article						metastasis-promoting; S100A4; extracellular; activity; MMP-13 induction; angiogenesis	METASTASIS-ASSOCIATED PROTEIN; FACTOR-KAPPA-B; TUMOR-CELLS; IN-VITRO; DIFFERENTIAL REGULATION; PLASMINOGEN-ACTIVATOR; COLLAGENASE-3 MMP-13; PROGNOSTIC MARKERS; SIGNALING PATHWAYS; OSTEOSARCOMA CELLS	S100A4(mts1) protein expression has been strongly associated with metastatic tumor progression. It has been suggested as a prognostic marker for a number of human cancers. It is proposed that extracellular S100A4 accelerates cancer progression by stimulating the motility of endothelial cells, thereby promoting angiogenesis. Here we show that in 3D culture mouse endothelial cells (SVEC 4-10) respond to recombinant S100A4 by stimulating invasive growth of capillary-like structures. The outgrowth is not dependent on the stimulation of cell proliferation, but rather correlates with the transcriptional modulation of genes involved in the proteolytic degradation of extracellular matrix (ECM). Treatment of SVEC 4-10 with the S100A4 protein leads to the transcriptional activation of collagenase 3 (MMP-13) mRNA followed by subsequent release of the protein from the cells. beta-Casein zymography demonstrates enhancement of proteolytic activity associated with MMP-13. This observation indicates that extracellular S100A4 stimulates the production of ECM degrading enzymes from endothelial cells, thereby stimulating the remodeling of ECM. This could explain the angiogenic and metastasis-stimulating activity of S100A4(mts1).	Danish Canc Soc, Dept Mol Canc Biol, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE 7LX, Leics, England	Danish Cancer Society; University of Leicester	Ambartsumian, N (corresponding author), Danish Canc Soc, Dept Mol Canc Biol, Inst Canc Biol, Strand Blvd 49, DK-2100 Copenhagen, Denmark.	na@cancer.dk	Tulchinsky, Eugene/ABD-7070-2021; Klingelhöfer, Jörg/C-1676-2013					Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Ambartsumian N, 2001, ONCOGENE, V20, P4685, DOI 10.1038/sj.onc.1204636; AMBARTSUMIAN N, IN PRESS CELL BIOL L; Ambartsumian NS, 1996, ONCOGENE, V13, P1621; Andersen K, 1998, ANTICANCER RES, V18, P3299; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Belot N, 2002, BBA-PROTEINS PROTEOM, V1600, P74, DOI 10.1016/S1570-9639(02)00447-8; Bjornland K, 2001, J PEDIATR SURG, V36, P1040, DOI 10.1053/jpsu.2001.24735; Bjornland K, 1999, CANCER RES, V59, P4702; Bond M, 2001, CARDIOVASC RES, V50, P556, DOI 10.1016/S0008-6363(01)00220-6; BRAUNHUT SJ, 1994, J BIOL CHEM, V269, P13472; Cazorla M, 1998, J PATHOL, V186, P144, DOI 10.1002/(SICI)1096-9896(1998100)186:2<144::AID-PATH147>3.0.CO;2-#; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Davies BR, 2002, J PATHOL, V196, P292, DOI 10.1002/path.1051; Davies MPA, 1996, ONCOGENE, V13, P1631; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Duarte WR, 2003, J BONE MINER RES, V18, P493, DOI 10.1359/jbmr.2003.18.3.493; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; Endo H, 2002, J BIOL CHEM, V277, P26396, DOI 10.1074/jbc.M202244200; FERNANDEZRESA P, 1995, ANAL BIOCHEM, V224, P434, DOI 10.1006/abio.1995.1063; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FORD HL, 1995, ONCOGENE, V10, P1597; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Grigorian M, 1996, INT J CANCER, V67, P831, DOI 10.1002/(SICI)1097-0215(19960917)67:6<831::AID-IJC13>3.0.CO;2-4; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hattori Y, 2003, EXP MOL PATHOL, V74, P230, DOI 10.1016/S0014-4800(03)00014-5; Heikkila P, 2002, ANTI-CANCER DRUG, V13, P245, DOI 10.1097/00001813-200203000-00006; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Johansson N, 1999, AM J PATHOL, V154, P469, DOI 10.1016/S0002-9440(10)65293-5; Johansson N, 1997, AM J PATHOL, V151, P499; Kim HG, 2000, BIOCHEM BIOPH RES CO, V269, P401; Kriajevska M, 1998, J BIOL CHEM, V273, P9852, DOI 10.1074/jbc.273.16.9852; Kriajevska M, 2002, J BIOL CHEM, V277, P5229, DOI 10.1074/jbc.M110976200; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Lemaitre V, 1997, BIOCHEM BIOPH RES CO, V230, P202, DOI 10.1006/bbrc.1996.5924; Lloyd BH, 1998, ONCOGENE, V17, P465, DOI 10.1038/sj.onc.1201948; Maelandsmo GM, 1996, CANCER RES, V56, P5490; Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4; Mikkelsen SE, 2001, J NEUROCHEM, V79, P767, DOI 10.1046/j.1471-4159.2001.00605.x; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; OCONNELL KA, 1990, J IMMUNOL, V144, P521; Peeters-Joris C, 1998, BBA-MOL CELL RES, V1405, P14, DOI 10.1016/S0167-4889(98)00094-9; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Philip S, 2003, J BIOL CHEM, V278, P14487, DOI 10.1074/jbc.M207309200; Platt-Higgins AM, 2000, INT J CANCER, V89, P198, DOI 10.1002/(SICI)1097-0215(20000320)89:2<198::AID-IJC16>3.0.CO;2-L; Qian XH, 1997, EXP CELL RES, V235, P403, DOI 10.1006/excr.1997.3681; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Takenaga K, 1997, ONCOGENE, V14, P331, DOI 10.1038/sj.onc.1200820; Tulchinsky E, 1997, J BIOL CHEM, V272, P4828, DOI 10.1074/jbc.272.8.4828; Uozumi M, 2000, CANCER LETT, V149, P135, DOI 10.1016/S0304-3835(99)00352-3; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Vincenti MP, 2002, ARTHRITIS RES, V4, P157, DOI 10.1186/ar401; Wang H, 2000, BIOCHEM BIOPH RES CO, V272, P900, DOI 10.1006/bbrc.2000.2852; Wilasrusmee C, 2002, J SURG RES, V104, P131, DOI 10.1006/jsre.2002.6429; Yeow KM, 2002, MATRIX BIOL, V21, P75, DOI 10.1016/S0945-053X(01)00180-9; Yonemura Y, 2000, CLIN CANCER RES, V6, P4234; Yu WH, 2001, ANAL BIOCHEM, V293, P38, DOI 10.1006/abio.2001.5099; Zaragoza C, 2002, KIDNEY INT, V61, P804, DOI 10.1046/j.1523-1755.2002.00224.x; Zaragoza C, 2002, MOL PHARMACOL, V62, P927, DOI 10.1124/mol.62.4.927	66	171	181	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5487	5495		10.1038/sj.onc.1207720	http://dx.doi.org/10.1038/sj.onc.1207720			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15122322				2022-12-25	WOS:000222588400008
J	Bonnevier, J; Arner, A				Bonnevier, J; Arner, A			Actions downstream of cyclic GMP/protein kinase G can reverse protein kinase C-mediated phosphorylation of CPI-17 and Ca2+ sensitization in smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN DEPHOSPHORYLATION; MYOSIN-BINDING SUBUNIT; SIGNAL-TRANSDUCTION; INHIBITORY PHOSPHOPROTEIN; RHO-KINASE; PHOSPHATASE; ACTIVATION; CONTRACTION; SENSITIVITY; MODULATION	Ca2+ sensitivity of smooth muscle contraction is modulated by several systems converging on myosin light chain phosphatase (MLCP). Rho-Rho kinase is considered to inhibit MLCP via phosphorylation, whereas protein kinase C (PKC) induced sensitization has been shown to be dependent on phosphorylation of the inhibitory protein CPI-17. We have explored the interaction of cGMP-dependent protein kinase (PKG) with Ca2+ sensitization pathways using permeabilized mouse smooth muscle. Three conditions giving similar to 50% of maximal active force were compared in small intestinal preparations: 1) Ca2+-activated unsensitized muscle (pCa 5.9 with Rho kinase inhibitor Y27632); 2) Rho-Rho kinase-sensitized muscle (pCa 6.1 with guanosine 5'-3-O-(thio) triphosphate); and 3) PKC-sensitized muscle ( pCa 6.0 with Y27632 and PKC activator phorbol 12,13-dibutyrate). 8-Br-cGMP relaxed the sensitized muscles but had marginal effects on unsensitized preparations, showing that PKG reverses both PKC and Rho-mediated Ca2+ sensitization. CPI-17 was present in permeabilized intestinal tissue. In PKC-sensitized preparations, CPI-17 phosphorylation decreased in response to 8-Br-cGMP. The rate of PKC-mediated phosphorylation in the presence of the MLCP inhibitor microcystin-LR was not influenced by 8-Br-cGMP. PKC-induced Ca2+ sensitization also was reversed in vascular smooth muscle tissues ( portal vein and femoral artery). We conclude that actions downstream of cGMP/PKG can reverse PKC-mediated phosphorylation of CPI-17 and Ca2+ sensitization in smooth muscle.	Lund Univ, Dept Physiol Sci, SE-22184 Lund, Sweden	Lund University	Arner, A (corresponding author), Lund Univ, Dept Physiol Sci, BMC F11, SE-22184 Lund, Sweden.	Anders.Arner@mphy.lu.se						Arner A, 1999, Rev Physiol Biochem Pharmacol, V134, P63; Beall AC, 1997, J BIOL CHEM, V272, P11283; Bonnevier J, 2004, J BIOL CHEM, V279, P5146, DOI 10.1074/jbc.M306532200; Borman MA, 2002, J BIOL CHEM, V277, P23441, DOI 10.1074/jbc.M201597200; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; Dawson John F., 1999, Frontiers in Bioscience, V4, pd646, DOI 10.2741/Dawson; Deng JT, 2002, BIOCHEM J, V367, P517, DOI 10.1042/BJ20020522; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Dubois T, 2003, BIOCHEM BIOPH RES CO, V302, P186, DOI 10.1016/S0006-291X(03)00130-X; Erdodi F, 2003, BIOCHEM BIOPH RES CO, V306, P382, DOI 10.1016/S0006-291X(03)00976-8; Eto M, 2002, NEURON, V36, P1145, DOI 10.1016/S0896-6273(02)01107-8; ETO M, 1995, J BIOCHEM, V118, P1104, DOI 10.1093/oxfordjournals.jbchem.a124993; Etter EF, 2001, J BIOL CHEM, V276, P34681, DOI 10.1074/jbc.M104737200; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Hamaguchi T, 2000, BIOCHEM BIOPH RES CO, V274, P825, DOI 10.1006/bbrc.2000.3225; Hartshorne DJ, 1998, ACTA PHYSIOL SCAND, V164, P483; Hayashi Y, 2001, J BIOL CHEM, V276, P39858, DOI 10.1074/jbc.M107302200; Hofmann F, 2000, J CELL SCI, V113, P1671; JIANG H, 1992, J BIOL CHEM, V267, P1015; Khatri JJ, 2001, J BIOL CHEM, V276, P37250, DOI 10.1074/jbc.M105275200; Kitazawa T, 1999, J PHYSIOL-LONDON, V520, P139, DOI 10.1111/j.1469-7793.1999.00139.x; Kitazawa T, 2000, J BIOL CHEM, V275, P9897, DOI 10.1074/jbc.275.14.9897; Kitazawa T, 2003, J PHYSIOL-LONDON, V546, P879, DOI 10.1113/jphysiol.2002.029306; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; Koyama M, 2000, FEBS LETT, V475, P197, DOI 10.1016/S0014-5793(00)01654-9; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; LINCOLN TM, 1990, AM J PHYSIOL, V258, pC399, DOI 10.1152/ajpcell.1990.258.3.C399; Lucius C, 1998, J PHYSIOL-LONDON, V506, P83, DOI 10.1111/j.1469-7793.1998.083bx.x; MacDonald JA, 2001, FEBS LETT, V493, P91, DOI 10.1016/S0014-5793(01)02277-3; Muranyi A, 2002, BIOCHEM J, V366, P211, DOI 10.1042/BJ20020401; Nakamura M, 1999, CELL SIGNAL, V11, P671, DOI 10.1016/S0898-6568(99)00036-4; Ohama T, 2003, J BIOL CHEM, V278, P48794, DOI 10.1074/jbc.M310166200; Ohki SY, 2003, J MOL BIOL, V326, P1539, DOI 10.1016/S0022-2836(03)00048-2; Otto B, 1996, J PHYSIOL-LONDON, V496, P317, DOI 10.1113/jphysiol.1996.sp021687; Rembold CM, 2000, J PHYSIOL-LONDON, V524, P865, DOI 10.1111/j.1469-7793.2000.00865.x; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Senba S, 1999, J BIOCHEM-TOKYO, V125, P354, DOI 10.1093/oxfordjournals.jbchem.a022294; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; STULL JT, 1993, MOL CELL BIOCHEM, V128, P229, DOI 10.1007/BF01076774; Surks HK, 2003, CELL SIGNAL, V15, P937, DOI 10.1016/S0898-6568(03)00057-3; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Takizawa N, 2002, FEBS LETT, V515, P127, DOI 10.1016/S0014-5793(02)02451-1; Takizawa N, 2002, BIOCHEM BIOPH RES CO, V297, P773, DOI 10.1016/S0006-291X(02)02302-1; Toth A, 2000, FEBS LETT, V484, P113, DOI 10.1016/S0014-5793(00)02138-4; Watanabe Y, 2001, BLOOD, V97, P3798, DOI 10.1182/blood.V97.12.3798; Woodsome TP, 2001, J PHYSIOL-LONDON, V535, P553, DOI 10.1111/j.1469-7793.2001.t01-1-00553.x; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362	53	37	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28998	29003		10.1074/jbc.M404259200	http://dx.doi.org/10.1074/jbc.M404259200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123611	hybrid			2022-12-25	WOS:000222445300022
J	Chen, C; Koh, AJ; Datta, NS; Zhang, J; Keller, ET; Xiao, GZ; Franceschi, RT; D'Silva, NJ; McCauley, LK				Chen, C; Koh, AJ; Datta, NS; Zhang, J; Keller, ET; Xiao, GZ; Franceschi, RT; D'Silva, NJ; McCauley, LK			Impact of the mitogen-activated protein kinase pathway on parathyroid hormone-related protein actions in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MESSENGER-RNA LEVELS; CYCLIC-AMP; MAP KINASE; CELL-PROLIFERATION; INTERLEUKIN-6 PROMOTER; TRANSCRIPTION FACTORS; PTH/PTHRP RECEPTOR; REGULATED KINASE; MC3T3-E1 CELLS	Parathyroid hormone-related protein ( PTHrP) regulates proliferation and differentiation of osteoblastic cells via binding to the parathyroid hormone receptor (PTH-1R). The cAMP-dependent protein kinase A pathway governs the majority of these effects, but recent evidence also implicates the MAPK pathway. MC3T3-E1 subclone 4 cells (MC4) were treated with the MAPK inhibitor U0126 and PTHrP. In differentiated MC4 cells, osteocalcin and bone sialoprotein gene expression were both down-regulated by PTHrP and also by inhibition of the MAPK pathway. PTHrP-mediated down-regulation of PTH-1R mRNA and up-regulation of c-fos mRNA were MAPK-independent, whereas PTHrP stimulation of fra-2 and interleukin-6 (IL-6) mRNA was MAPK-dependent. Luciferase promoter assays revealed that regulation of IL-6 involved the cAMP-dependent protein kinase A and MAPK pathways with a potential minor role of the protein kinase C pathway, and a promoter region containing an activator protein-1 site was necessary for PTHrP-induced IL-6 gene transcription. An alternative pathway, through cAMP/Epac/Rap1/MAPK, mediated ERK phosphorylation but was not sufficient for IL-6 promoter activation. Phosphorylation of the transcription factor CREB was also necessary but not sufficient for PTHrP-mediated IL-6 promoter activity. Most interesting, a bidirectional effect was found with PTHrP increasing phosphorylated ERK in undifferentiated MC4 cells but decreasing phosphorylated ERK in differentiated cells. These data indicate that inactivation of the MAPK pathway shows differential regulation of PTHrP-stimulated activator protein-1 members, blocks PTHrP-stimulated IL-6, and synergistically down-regulates certain osteoblastic markers associated with differentiation. These novel findings indicate that the MAPK pathway plays a selective but important role in the actions of PTHrP.	Univ Michigan, Dept Periodont Prevent Geriatr, Ann Arbor, MI 48109 USA; Univ Michigan, Unit Lab Anim Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Oral Med Pathol Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	McCauley, LK (corresponding author), Univ Michigan, Dept Periodont Prevent Geriatr, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.	mccauley@umich.edu	ZHANG, JIAN/Q-6334-2018; D'Silva, Nisha J/B-4734-2013; Keller, Evan T/M-1446-2016	Keller, Evan T/0000-0002-7592-7535	NATIONAL CANCER INSTITUTE [R01CA098513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053904] Funding Source: NIH RePORTER; NCI NIH HHS [CA098513] Funding Source: Medline; NIDDK NIH HHS [DK53904] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Baccam M, 2003, J IMMUNOL, V170, P3099, DOI 10.4049/jimmunol.170.6.3099; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Carpio L, 2001, AM J PHYSIOL-ENDOC M, V281, pE489, DOI 10.1152/ajpendo.2001.281.3.E489; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; Chan GK, 2001, ENDOCRINOLOGY, V142, P4900, DOI 10.1210/en.142.11.4900; Chaudhary LR, 1998, MOL CELL BIOCHEM, V178, P59, DOI 10.1023/A:1006807221545; Chen HL, 2002, J BIOL CHEM, V277, P19374, DOI 10.1074/jbc.M108913200; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Fujita T, 2002, J BIOL CHEM, V277, P22191, DOI 10.1074/jbc.M110364200; FUKAYAMA S, 1994, ENDOCRINOLOGY, V134, P1851, DOI 10.1210/en.134.4.1851; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hershko DD, 2002, AM J PHYSIOL-REG I, V283, pR1140, DOI 10.1152/ajpregu.00161.2002; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; Kaiser E, 2003, BIOCHEM BIOPH RES CO, V305, P573, DOI 10.1016/S0006-291X(03)00820-9; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Keller ET, 1996, J BIOL CHEM, V271, P26267, DOI 10.1074/jbc.271.42.26267; Klinger M, 2002, J BIOL CHEM, V277, P32490, DOI 10.1074/jbc.M200556200; Koh AJ, 1999, ENDOCRINOLOGY, V140, P3154, DOI 10.1210/en.140.7.3154; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; McCauley LK, 1997, ENDOCRINOLOGY, V138, P5427, DOI 10.1210/en.138.12.5427; McCauley LK, 2001, ENDOCRINOLOGY, V142, P1975, DOI 10.1210/en.142.5.1975; MCCAULEY LK, 1994, MOL CELL ENDOCRINOL, V101, P331, DOI 10.1016/0303-7207(94)90250-X; McCauley LK, 1996, J CELL BIOCHEM, V61, P638, DOI 10.1002/(SICI)1097-4644(19960616)61:4<638::AID-JCB18>3.0.CO;2-B; MCCAULEY LK, 1995, J BONE MINER RES, V10, P1243, DOI 10.1002/jbmr.5650100815; Miao DS, 2001, J BIOL CHEM, V276, P32204, DOI 10.1074/jbc.M101084200; Motomura T, 1998, J BONE MINER RES, V13, P1084, DOI 10.1359/jbmr.1998.13.7.1084; Nagy Z, 2001, J BONE MINER RES, V16, P1220, DOI 10.1359/jbmr.2001.16.7.1220; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Onyia JE, 1997, J CELL BIOCHEM, V67, P265, DOI 10.1002/(SICI)1097-4644(19971101)67:2<265::AID-JCB12>3.0.CO;2-E; Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715; Qin L, 2003, J BIOL CHEM, V278, P19723, DOI 10.1074/jbc.M212226200; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; Radeff JM, 2001, EXP CELL RES, V268, P179, DOI 10.1006/excr.2001.5283; RENKAWITZ R, 1979, MOL GEN GENET, V173, P1, DOI 10.1007/BF00267685; ROBISON GA, 1968, ANNU REV BIOCHEM, V37, P149, DOI 10.1146/annurev.bi.37.070168.001053; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378-1119(01)00798-3; Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; VANSNICK J, 1988, EUR J IMMUNOL, V18, P193; VERHEIJEN MH, 1997, J BIOL CHEM, V271, P7508; VERHEIJEN MHG, 1995, ENDOCRINOLOGY, V136, P3331, DOI 10.1210/en.136.8.3331; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200; Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101; YOUNG MF, 1994, MAMM GENOME, V5, P108, DOI 10.1007/BF00292337; Zhang J, 2001, ANTIOXID REDOX SIGN, V3, P493, DOI 10.1089/15230860152409121; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	62	60	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29121	29129		10.1074/jbc.M313000200	http://dx.doi.org/10.1074/jbc.M313000200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15128746	hybrid			2022-12-25	WOS:000222445300037
J	Dutkiewicz, R; Schilke, B; Cheng, S; Knieszner, H; Craig, EA; Marszalek, J				Dutkiewicz, R; Schilke, B; Cheng, S; Knieszner, H; Craig, EA; Marszalek, J			Sequence-specific interaction between mitochondrial Fe-S scaffold protein Isu and Hsp70 Ssq1 is essential for their in vivo function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; HSC66-HSC20 CHAPERONE SYSTEM; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; DNAK CHAPERONE; ISCU; BIOGENESIS; IDENTIFICATION; BIOSYNTHESIS	Isu, the scaffold for assembly of Fe-S clusters in the yeast mitochondrial matrix, is a substrate protein for the Hsp70 Ssq1 and the J-protein Jac1 in vitro. As expected for an Hsp70-substrate interaction, the formation of a stable complex between Isu and Ssq1 requires Jac1 in the presence of ATP. Here we report that a conserved tripeptide, PVK, of Isu is critical for interaction with Ssq1 because amino acid substitutions in this tripeptide inhibit both the formation of the Isu-Ssq1 complex and the ability of Isu to stimulate the ATPase activity of Ssq1. These biochemical defects correlate well with the growth defects of cells expressing mutant Isu proteins. We conclude that the Ssq1-Isu substrate interaction is critical for Fe-S cluster biogenesis in vivo. The ability of Jac1 and mutant Isu proteins to cooperatively stimulate the ATPase activity of Ssq1 was also measured. Increasing the concentration of Jac1 and mutant Isu together but not individually partially overcame the effect of the reduced affinity of the Isu mutant proteins for Ssq1. These results, along with the observation that overexpression of Jac1 was able to suppress the growth defect of an ISU mutant, support the hypothesis that Isu is "targeted" to Ssq1 by Jac1, with a preformed Jac1-Isu complex interacting with Ssq1.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Gdansk, Dept Mol & Cellular Biol, PL-80822 Gdansk, Poland	University of Wisconsin System; University of Wisconsin Madison; Fahrenheit Universities; University of Gdansk	Craig, EA (corresponding author), Univ Wisconsin, Dept Biochem, 441E Biochem Addit,433 Babcock Dr, Madison, WI 53706 USA.	ecraig@wisc.edu	Marszalek, Jaroslaw/F-5824-2011; Dutkiewicz, Rafal/F-5956-2011; Dutkiewicz, Rafal/ABE-6979-2020	Dutkiewicz, Rafal/0000-0003-4150-0450; Marszalek, Jaroslaw/0000-0002-6978-1189	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027870] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM27870] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Bertini I, 2003, J MOL BIOL, V331, P907, DOI 10.1016/S0022-2836(03)00768-X; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Craig EA, 2002, CELL MOL LIFE SCI, V59, P1658, DOI 10.1007/PL00012493; Dutkiewicz R, 2003, J BIOL CHEM, V278, P29719, DOI 10.1074/jbc.M303527200; Frazzon J, 2003, CURR OPIN CHEM BIOL, V7, P166, DOI 10.1016/S1367-5931(03)00021-8; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hoff KG, 2003, J BIOL CHEM, V278, P37582, DOI 10.1074/jbc.M305292200; Hoff KG, 2002, J BIOL CHEM, V277, P27353, DOI 10.1074/jbc.M202814200; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Horst M, 1997, EMBO J, V16, P1842, DOI 10.1093/emboj/16.8.1842; Kim R, 2001, J BIOL CHEM, V276, P17524, DOI 10.1074/jbc.M010695200; Knight SAB, 1998, J BIOL CHEM, V273, P18389, DOI 10.1074/jbc.273.29.18389; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lutz T, 2001, J MOL BIOL, V307, P815, DOI 10.1006/jmbi.2001.4527; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; Nuth M, 2002, J AM CHEM SOC, V124, P8774, DOI 10.1021/ja0264596; PFUND C, 2001, MOL CHAPERONES CELL, P119; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; Schilke B, 1996, J CELL BIOL, V134, P603, DOI 10.1083/jcb.134.3.603; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; Sherman F, 1986, LAB COURSE MANUAL ME; SIKORSKI RS, 1989, GENETICS, V122, P19; Silberg JJ, 1998, J BACTERIOL, V180, P6617, DOI 10.1128/JB.180.24.6617-6624.1998; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; Young JC, 2003, TRENDS BIOCHEM SCI, V28, P541, DOI 10.1016/j.tibs.2003.08.009; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	38	77	80	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29167	29174		10.1074/jbc.M402947200	http://dx.doi.org/10.1074/jbc.M402947200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123690	hybrid			2022-12-25	WOS:000222445300043
J	Fu, MF; Rao, M; Wu, KM; Wang, CG; Zhang, XP; Hessien, M; Yeung, YG; Gioeli, D; Weber, MJ; Pestell, RG				Fu, MF; Rao, M; Wu, KM; Wang, CG; Zhang, XP; Hessien, M; Yeung, YG; Gioeli, D; Weber, MJ; Pestell, RG			The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE-A; PROSTATE-CANCER CELLS; HISTONE H3; TERMINAL DOMAIN; BINDING DOMAIN; IN-VITRO; DEPENDENT TRANSCRIPTION; PHOSPHORYLATION SITES; INDUCED APOPTOSIS	The androgen receptor (AR) regulates ligand-dependent gene transcription upon binding specific DNA sequences. The AR conveys both trans-activation and trans-repression functions, which together contribute to prostate cellular growth, differentiation, and apoptosis. Like histone H3, the AR is post-translationally modified by both acetylation and phosphorylation. The histone acetyltransferase p300 transactivates the AR and directly acetylates the AR in vitro at a conserved motif. Point mutations of the AR acetylation motif that abrogate acetylation reduce trans-activation by p300 without affecting the trans-repression function of the AR. The current studies assessed the functional relationship between acetylation and phosphorylation of the AR. Herein trans-activation of the AR acetylation site mutants were enhanced by the p42/p44 MAPK pathway but were defective in regulation by protein kinase A (PKA) signaling. PKA inhibition augmented ARwt activity but not AR acetylation mutant gene reporter activity and association at an androgen response element in chromatin immunoprecipitation assays. Mutations of the lysine residues at the AR acetylation site reduced trichostatin A (TSA) responsiveness and ligand-induced phosphorylation of the AR. The AR acetylation site mutant formed ligand-induced phosphorylation-dependent isoforms with distinguishable characteristics from wild type AR as determined with two-dimensional electrophoresis. Conversely, point mutation of a subset of AR phosphorylation sites reduced trichostatin A responsiveness and trans-activation by histone acetyltransferases. Together these studies suggest that acetylation and phosphorylation of the AR are linked events and that the conserved AR lysine motif contributes to a select subset of pathways governing AR activity.	Georgetown Univ, Med Ctr, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22908 USA	Georgetown University; Yeshiva University; Albert Einstein College of Medicine; University of Virginia; University of Virginia	Pestell, RG (corresponding author), Georgetown Univ, Med Ctr, Dept Oncol, Lombardi Comprehens Canc Ctr, Res Bldg,Rm E501,3970 Reservoir Rd NW,Box 571468, Washington, DC 20057 USA.	pestell@georgetown.edu		Hessien, Mohamed/0000-0002-3782-1633	NCI NIH HHS [R01CA93596-01, R01CA75503, R01CA70896, P30CA51008-14, P01CA 76465, P01CA 40042, CA26504, R01CA86072] Funding Source: Medline; NIDDK NIH HHS [R21 DK0652201-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042, R01CA026504, P30CA051008, R01CA086072, R37CA026504, R01CA070896, R01CA075503, P01CA076465, R01CA093596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Alen P, 1999, MOL CELL BIOL, V19, P6085; Asahara H, 2001, MOL CELL BIOL, V21, P7892, DOI 10.1128/MCB.21.23.7892-7900.2001; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Ben Abdelkhalek M, 1999, BIOCHEM BIOPH RES CO, V266, P15, DOI 10.1006/bbrc.1999.1764; Bergel M, 2000, J BIOL CHEM, V275, P11514, DOI 10.1074/jbc.275.15.11514; Blok LJ, 1998, BIOCHEMISTRY-US, V37, P3850, DOI 10.1021/bi9724422; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Chiarugi V, 1998, ONCOL RES, V10, P55; Espinos E, 1999, MOL CELL BIOL, V19, P3474; Fu MF, 2003, MOL CELL BIOL, V23, P8563, DOI 10.1128/MCB.23.23.8563-8575.2003; Fu MF, 2002, MOL CELL BIOL, V22, P3373, DOI 10.1128/MCB.22.10.3373-3388.2002; Fu MF, 2002, CYTOKINE GROWTH F R, V13, P259, DOI 10.1016/S1359-6101(02)00003-5; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Hauser C, 2002, MOL CELL BIOL, V22, P7820, DOI 10.1128/MCB.22.22.7820-7830.2002; HIDAKA H, 1991, METHOD ENZYMOL, V201, P328; HSU SC, 1992, EMBO J, V11, P3457, DOI 10.1002/j.1460-2075.1992.tb05425.x; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; JENSTER G, 1994, BIOCHEMISTRY-US, V33, P14064, DOI 10.1021/bi00251a015; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kumar BRP, 2001, J BIOL CHEM, V276, P16804, DOI 10.1074/jbc.M100934200; Lee YF, 1999, P NATL ACAD SCI USA, V96, P14724, DOI 10.1073/pnas.96.26.14724; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lu Q, 2003, J BIOL CHEM, V278, P15727, DOI 10.1074/jbc.M300546200; Mahmud DL, 2002, ONCOGENE, V21, P1556, DOI 10.1038/sj.onc.1205230; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marhefka CA, 2001, J MED CHEM, V44, P1729, DOI 10.1021/jm0005353; Martin LA, 2003, J BIOL CHEM, V278, P30458, DOI 10.1074/jbc.M305226200; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; NAKAO M, 1992, ARCH BIOCHEM BIOPHYS, V298, P340, DOI 10.1016/0003-9861(92)90420-2; Nakashio A, 2000, CANCER RES, V60, P5303; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; O'Farrell P H, 1977, Methods Cell Biol, V16, P407; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Poukka H, 2000, J CELL SCI, V113, P2991; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Rana S, 1999, J MOL BIOL, V286, P669, DOI 10.1006/jmbi.1998.2505; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schreihofer DA, 2001, ENDOCRINOLOGY, V142, P3361, DOI 10.1210/en.142.8.3361; STAMATIADIS D, 1992, J STEROID BIOCHEM, V41, P43, DOI 10.1016/0960-0760(92)90223-6; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Wang LG, 1998, BIOCHEM PHARMACOL, V55, P1427, DOI 10.1016/S0006-2952(97)00657-6; Wang LG, 1999, BIOCHEM BIOPH RES CO, V259, P21, DOI 10.1006/bbrc.1999.0655; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Watanabe G, 1997, J BIOL CHEM, V272, P20063, DOI 10.1074/jbc.272.32.20063; Yang L, 2003, BIOCHEM BIOPH RES CO, V305, P462, DOI 10.1016/S0006-291X(03)00792-7; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhong SP, 2003, ONCOGENE, V22, P5291, DOI 10.1038/sj.onc.1206507	68	67	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29436	29449		10.1074/jbc.M313466200	http://dx.doi.org/10.1074/jbc.M313466200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123687	hybrid			2022-12-25	WOS:000222445300076
J	Gange, CT; Quinn, JMW; Zhou, H; Kartsogiannis, V; Gillespie, MT; Ng, KW				Gange, CT; Quinn, JMW; Zhou, H; Kartsogiannis, V; Gillespie, MT; Ng, KW			Characterization of sugar binding by osteoclast inhibitory lectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTIN; CARBOHYDRATE-RECOGNITION DOMAIN; KILLER-CELL RECEPTOR; CHONDROITIN SULFATES; CRYSTAL-STRUCTURE; LIGAND-BINDING; PROTEIN; TISSUES; FAMILY; RAT	Osteoclast inhibitory lectin (OCIL) is a membrane-bound C-type lectin that blocks osteoclast differentiation and, via binding to its cognate receptor NKRP1D, inhibits natural killer cell-mediated cytotoxicity. OCIL is a member of the natural killer cell receptor C-type lectin group that includes CD69 and NKRP1D. We investigated carbohydrate binding of soluble recombinant human and mouse OCIL in enzyme-linked immunosorbent assay-based assays. OCIL bound immobilized high molecular weight sulfated glycosaminoglycans, including fucoidan, lambda-carrageenan, and dextran sulfate, but not unsulfated dextran or sialated hyaluronic acid. Carbohydrate binding was Ca2+-independent. Binding of immobilized low molecular weight glycosaminoglycans, including chondroitin sulfate ( A, B, and C forms) and heparin, was not observed. However, the soluble forms of these low molecular weight glycosaminoglycans competed for OCIL binding of immobilized fucoidan ( as did soluble fucoidan, dextran sulfate, and lambda-carrageenan), indicating that OCIL does recognize these carbohydrates. Inhibition constants for chondroitin sulfate A and heparin binding were 380 and 5 nM, respectively. Immobilized and soluble monosaccharides did not bind OCIL. The presence of saturating levels of fucoidan, dextran sulfate, and lambda-carrageenan did not affect OCIL inhibition of osteoclast formation. The fucoidan-binding lectins Ulex europaeus agglutinin I and Anguilla anguilla agglutinin did not block osteoclast formation or affect the inhibitory action of OCIL. Although the osteoclast inhibitory action of OCIL is independent of sugar recognition, we have found that OCIL, a lectin widely distributed, but notably localized in bone, skin, and other connective tissues, binds a range of physiologically important glycosaminoglycans, and this property may modulate OCIL actions upon other cells.	St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; St Vincents Hosp, Dept Endocrinol & Diabet, Fitzroy, Vic 3065, Australia	St. Vincent's Institute of Medical Research; St Vincent's Hospital Melbourne	Quinn, JMW (corresponding author), St Vincents Inst Med Res, 9 Princes St, Fitzroy, Vic 3065, Australia.	j.quinn@medicine.unimelb.edu.au		Gillespie, Matthew/0000-0001-6543-8909; Zhou, Hong/0000-0001-5899-9660				Bali JP, 2001, SEMIN ARTHRITIS RHEU, V31, P58, DOI 10.1053/sarh.2000.24874; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; BRENNAN J, 1995, J BIOL CHEM, V270, P9691, DOI 10.1074/jbc.270.17.9691; Childs RA, 1999, BIOCHEM BIOPH RES CO, V266, P19, DOI 10.1006/bbrc.1999.1762; DANIELS BF, 1994, IMMUNITY, V1, P785, DOI 10.1016/S1074-7613(94)80020-0; FULLER K, 1991, J CELL PHYSIOL, V147, P208, DOI 10.1002/jcp.1041470204; HAGIWARA H, 1995, HISTOCHEM CELL BIOL, V103, P213, DOI 10.1007/BF01454026; Horwood NJ, 2001, J IMMUNOL, V166, P4915, DOI 10.4049/jimmunol.166.8.4915; Hu YS, 2004, J BONE MINER RES, V19, P89, DOI 10.1359/JBMR.0301215; Iizuka K, 2003, NAT IMMUNOL, V4, P801, DOI 10.1038/ni954; Kartsogiannis V, 1999, BONE, V25, P525, DOI 10.1016/S8756-3282(99)00214-8; Katsu Y, 2003, ENDOCRINOLOGY, V144, P2597, DOI 10.1210/en.2002-220980; Lam J, 2001, J CLIN INVEST, V108, P971, DOI 10.1172/JCI13890; MULLIN NP, 1994, J BIOL CHEM, V269, P28405; Natarajan K, 1999, IMMUNITY, V11, P591, DOI 10.1016/S1074-7613(00)80134-X; Plougastel B, 2001, IMMUNOGENETICS, V53, P209, DOI 10.1007/s002510100319; PRINCE CW, 1984, BIOCHEM J, V224, P941, DOI 10.1042/bj2240941; SANCHEZMATEOS P, 1989, IMMUNOLOGY, V68, P72; Takada T, 2003, J BIOL CHEM, V278, P43229, DOI 10.1074/jbc.M300937200; Tormo J, 1999, NATURE, V402, P623, DOI 10.1038/45170; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Wragg S, 1999, J BIOL CHEM, V274, P35400, DOI 10.1074/jbc.274.50.35400; Zhou H, 2001, J BIOL CHEM, V276, P14916, DOI 10.1074/jbc.M011554200; Zhou H, 2002, J BIOL CHEM, V277, P48808, DOI 10.1074/jbc.M209059200	27	26	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29043	29049		10.1074/jbc.M312518200	http://dx.doi.org/10.1074/jbc.M312518200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123656	hybrid			2022-12-25	WOS:000222445300027
J	Garate, M; Cao, ZY; Bateman, E; Panjwani, N				Garate, M; Cao, ZY; Bateman, E; Panjwani, N			Cloning and characterization of a novel mannose-binding protein of Acanthamoeba	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNEAL EPITHELIUM; LECTIN; CASTELLANII; KERATITIS; SEQUENCE; IDENTIFICATION; CONTAMINATION; PREDICTION; ADHERENCE; CLEAVAGE	Acanthamoebae produce a painful, blinding infection of the cornea. The mannose-binding protein (MBP) of Acanthamoeba is thought to play a key role in the pathogenesis of the infection by mediating the adhesion of parasites to the host cells. We describe here the isolation and molecular cloning of Acanthamoeba MBP. The MBP was isolated by chromatography on the mannose affinity gel. Gel filtration experiments revealed that the Acanthamoeba lectin is a similar to400-kDa protein that is constituted of multiple 130-kDa subunits. Cloning and sequencing experiments indicated that the Acanthamoeba MBP gene is composed of 6 exons and 5 introns that span 3.6 kb of the amoeba genome and that MBP cDNA codes for a precursor protein of 833 amino acids. That the cloned cDNA encodes authentic MBP was demonstrated by showing that: (i) recombinant MBP possesses mannose binding activity, and (ii) polyclonal antibodies prepared against Acanthamoeba MBP bound to the recombinant protein. Sequence analysis revealed that the MBP contains a large N-terminal extracellular domain, a transmembrane domain, and a short C-terminal cytoplasmic domain. Despite extensive BLAST searches using the MBP sequence, no significant matches were retrieved. The most striking feature of the Acanthamoeba MBP sequence is the presence of a cysteine-rich region containing 14 CXCXC motifs within the extracellular domain. In summary, we have isolated, cloned, and characterized a novel MBP from Acanthamoeba. Because the presence of antibodies to MBP in tears provides protection against infection, the availability of the MBP cDNA sequence and rMBP should help develop: ( i) a tear-based test to identify individuals who are at risk of developing the keratitis and ( ii) strategies to immunize high-risk individuals.	Tufts Univ, Sch Med, Ctr Vis Res, Dept Ophthalmol, Boston, MA 02111 USA; Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Univ Vermont, Markey Ctr Mol Genet, Dept Microbiol, Burlington, VT 05405 USA	Tufts University; Tufts University; Tufts University; University of Vermont	Panjwani, N (corresponding author), Tufts Univ, Sch Med, Ctr Vis Res, Dept Ophthalmol, 136 Harrison Ave, Boston, MA 02111 USA.	Noorjahan.Panjwani@tufts.edu			NATIONAL EYE INSTITUTE [R01EY008706, P30EY013078, R29EY008706, R01EY009349] Funding Source: NIH RePORTER; NEI NIH HHS [EYP30-13078, EY09349, EY08706] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADLER P, 1995, J BIOL CHEM, V270, P5164, DOI 10.1074/jbc.270.10.5164; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Burge CB, 1998, N COMP BIOC, V32, P129; Cao ZY, 1998, J BIOL CHEM, V273, P15838, DOI 10.1074/jbc.273.25.15838; Case ST, 1997, J MOL EVOL, V44, P452, DOI 10.1007/PL00006165; Cohen EJ, 1996, CORNEA, V15, P566, DOI 10.1097/00003226-199611000-00005; DEJONCKHEERE JF, 1980, APPL ENVIRON MICROB, V39, P681, DOI 10.1128/AEM.39.4.681-685.1980; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Drickamer K, 1999, GLYCOBIOLOGY, V9, P1357, DOI 10.1093/glycob/9.12.1357; Fomenko DE, 2003, BIOCHEMISTRY-US, V42, P11214, DOI 10.1021/bi034459s; Gupta Ramneek, 2002, Pac Symp Biocomput, P310; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; JENSEN T, 1970, J PARASITOL, V56, P904, DOI 10.2307/3277503; Joukov V, 1996, EMBO J, V15, P290; Kilvington S, 2004, INVEST OPHTH VIS SCI, V45, P165, DOI 10.1167/iovs.03-0559; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kumar R, 2002, CLIN INFECT DIS, V35, P434, DOI 10.1086/341487; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKIN DFP, 1990, BRIT J OPHTHALMOL, V74, P133, DOI 10.1136/bjo.74.3.133; LARKIN DFP, 1991, EYE, V5, P70, DOI 10.1038/eye.1991.14; Lee RT, 2000, GLYCOCONJUGATE J, V17, P543, DOI 10.1023/A:1011070425430; Madden TL, 1996, METHOD ENZYMOL, V266, P131; MANN BJ, 1991, P NATL ACAD SCI USA, V88, P3248, DOI 10.1073/pnas.88.8.3248; Marciano-Cabral F, 2003, CLIN MICROBIOL REV, V16, P273, DOI 10.1128/CMR.16.2.273-307.2003; Marciano-Cabral F, 2000, J EUKARYOT MICROBIOL, V47, P29, DOI 10.1111/j.1550-7408.2000.tb00007.x; McCulley James P., 2000, CLAO Journal, V26, P47; MOORE MB, 1991, CORNEA, V10, P291, DOI 10.1097/00003226-199107000-00003; MORTON LD, 1991, INFECT IMMUN, V59, P3819, DOI 10.1128/IAI.59.10.3819-3822.1991; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Panjwani N, 1997, INVEST OPHTH VIS SCI, V38, P1858; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Radford CF, 2002, BRIT J OPHTHALMOL, V86, P536, DOI 10.1136/bjo.86.5.536; Sack RA, 2002, ADV EXP MED BIOL, V506, P539; SAMBROOK J, 1989, MOL CLONING, V2, P9; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sathe S, 1998, CURR EYE RES, V17, P348, DOI 10.1080/02713689808951215; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; Srinivasan Muthaiah, 2003, Med Sci Monit, V9, pCR125; STEHRGREEN JK, 1989, AM J OPHTHALMOL, V107, P331, DOI 10.1016/0002-9394(89)90654-5; TANNICH E, 1991, P NATL ACAD SCI USA, V88, P1849, DOI 10.1073/pnas.88.5.1849; TIMMONS TM, 1990, METHOD ENZYMOL, V182, P679; VANKLINK F, 1992, CURR EYE RES, V11, P1207, DOI 10.3109/02713689208999546; WONG JM, 1992, NUCLEIC ACIDS RES, V20, P4817, DOI 10.1093/nar/20.18.4817; Yang ZT, 1997, INFECT IMMUN, V65, P439, DOI 10.1128/IAI.65.2.439-445.1997	45	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29849	29856		10.1074/jbc.M402334200	http://dx.doi.org/10.1074/jbc.M402334200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15117936	hybrid			2022-12-25	WOS:000222445300122
J	Akache, B; MacPherson, S; Sylvain, MA; Turcotte, B				Akache, B; MacPherson, S; Sylvain, MA; Turcotte, B			Complex interplay among regulators of drug resistance genes in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; ZINC CLUSTER PROTEINS; MULTIDRUG-RESISTANCE; DNA-BINDING; PLEIOTROPIC DRUG; TRANSCRIPTIONAL ACTIVATION; INDUCED EXPRESSION; CRYSTAL-STRUCTURE; ENCODING GENE; ABC PROTEINS	The Gal4p family of yeast zinc cluster proteins comprises regulators of multidrug resistance genes. For example, Pdr1p and Pdr3p bind as homo- or heterodimers to pleiotropic drug response elements (PDREs) found in promoters of target genes. Other zinc cluster activators of multidrug resistance genes include Stb5p and Yrr1p. To better understand the interplay among these activators, we have performed native co-immunoprecipitation experiments using strains expressing tagged zinc cluster proteins from their natural chromosomal locations. Interestingly, Stb5p is found predominantly as a Pdr1p heterodimer and shows little homodimerization. No interactions of Stb5p with Pdr3p or Yrr1p could be detected in our assays. In contrast to Stb5p, Yrr1p is only detected as a homodimer. Similar results were obtained using glutathione S-transferase pull-down assays. Importantly, the purified DNA binding domains of Stb5p and Pdr1p bound to a PDRE as heterodimers in vitro. These results suggest that the DNA binding domains of Pdr1p and Stb5p are sufficient for heterodimerization. Our data demonstrate a complex interplay among these activators and suggest that Pdr1p is a master drug regulator involved in recruiting other zinc cluster proteins to fine tune the regulation of multidrug resistance genes.	McGill Univ, Royal Victoria Hosp, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Dept Microbiol & Immunol, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital	Turcotte, B (corresponding author), McGill Univ, Royal Victoria Hosp, Dept Med, Montreal, PQ H3A 1A1, Canada.	bernard.turcotte@mcgill.ca		Akache, Bassel/0000-0002-5377-7193				ADAMS A, 1997, METHODS YEAST GENETI, P145; Akache B, 2002, J BIOL CHEM, V277, P21254, DOI 10.1074/jbc.M202566200; Akache B, 2001, NUCLEIC ACIDS RES, V29, P2181, DOI 10.1093/nar/29.10.2181; Alarco AM, 1997, J BIOL CHEM, V272, P19304, DOI 10.1074/jbc.272.31.19304; Amar N, 2000, MOL CELL BIOL, V20, P2087, DOI 10.1128/MCB.20.6.2087-2097.2000; BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; Brachmann CB, 1998, YEAST, V14, P115; BRICMONT PA, 1991, MOL CELL BIOL, V11, P1161, DOI 10.1128/MCB.11.2.1161; Broco N, 1999, YEAST, V15, P1595; COORNAERT D, 1991, GENE, V97, P163, DOI 10.1016/0378-1119(91)90048-G; Cui Z, 1998, MOL MICROBIOL, V29, P1307, DOI 10.1046/j.1365-2958.1998.01027.x; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; Hallstrom TC, 1998, J BIOL CHEM, V273, P2098, DOI 10.1074/jbc.273.4.2098; Hellauer K, 1996, MOL CELL BIOL, V16, P6096; Hellauer K, 2002, J BIOL CHEM, V277, P17671, DOI 10.1074/jbc.M201637200; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; Karpichev IV, 1997, MOL CELL BIOL, V17, P69, DOI 10.1128/MCB.17.1.69; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; King DA, 1999, NAT STRUCT BIOL, V6, P64; Kolaczkowska A, 1999, DRUG RESIST UPDATE, V2, P403, DOI 10.1054/drup.1999.0113; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; Le Crom S, 2002, MOL CELL BIOL, V22, P2642, DOI 10.1128/MCB.22.8.2642-2649.2002; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; Lucau-Danila A, 2003, J BIOL CHEM, V278, P52641, DOI 10.1074/jbc.M309580200; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; Mamnun YM, 2004, FEBS LETT, V559, P111, DOI 10.1016/S0014-5793(04)00046-8; Mamnun YM, 2002, MOL MICROBIOL, V46, P1429, DOI 10.1046/j.1365-2958.2002.03262.x; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; Noel J, 1998, J BIOL CHEM, V273, P17463, DOI 10.1074/jbc.273.28.17463; Nourani A, 1997, MOL CELL BIOL, V17, P5453, DOI 10.1128/MCB.17.9.5453; Rottensteiner H, 1997, EUR J BIOCHEM, V247, P776, DOI 10.1111/j.1432-1033.1997.00776.x; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; SCHNELL N, 1991, EUR J BIOCHEM, V200, P487, DOI 10.1111/j.1432-1033.1991.tb16209.x; SIKORSKI RS, 1989, GENETICS, V122, P19; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; TALIBI D, 1995, NUCLEIC ACIDS RES, V23, P550, DOI 10.1093/nar/23.4.550; Todd RB, 1997, FUNGAL GENET BIOL, V21, P388, DOI 10.1006/fgbi.1997.0993; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; Walters KJ, 1997, NAT STRUCT BIOL, V4, P744, DOI 10.1038/nsb0997-744; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; Wolfger H, 1997, FEBS LETT, V418, P269, DOI 10.1016/S0014-5793(97)01382-3; Wolfger H, 2001, RES MICROBIOL, V152, P375, DOI 10.1016/S0923-2508(01)01209-8; WU AL, 1993, J BIOL CHEM, V268, P18850; Zhang XT, 2001, J BIOL CHEM, V276, P8812, DOI 10.1074/jbc.M010686200	53	56	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27855	27860		10.1074/jbc.M403487200	http://dx.doi.org/10.1074/jbc.M403487200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123673	hybrid			2022-12-25	WOS:000222265400006
J	Oestergaard, VH; Giangiacomo, L; Bjergbaek, L; Knudsen, BR; Andersen, AH				Oestergaard, VH; Giangiacomo, L; Bjergbaek, L; Knudsen, BR; Andersen, AH			Hindering the strand passage reaction of human topoisomerase II alpha without disturbing DNA cleavage, ATP hydrolysis, or the operation of the N-terminal clamp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GYRASE-B-PROTEIN; DROSOPHILA-MELANOGASTER; BINDING-SITE; DOMAIN; MECHANISM; SUBUNIT; FRAGMENT	DNA topoisomerase II is an essential enzyme that releases a topological strain in DNA by introduction of transient breaks in one DNA helix through which another helix is passed. While changing DNA topology, ATP is required to drive the enzyme through a series of conformational changes dependent on interdomain communication. We have characterized a human topoisomerase IIalpha enzyme with a two-amino acid insertion at position 351 in the transducer domain. The mutation specifically abolishes the DNA strand passage event of the enzyme, probably because of a sterical hindrance of T-segment transport. Thus, the enzyme fails to decatenate and relax DNA, even though it is fully capable of ATP hydrolysis, closure of the N-terminal clamp, and DNA cleavage. The cleavage activity is increased, suggesting that the transducer domain has a role in regulating DNA cleavage. Furthermore, the enzyme has retained a tendency to increase DNA cleavage upon nucleotide binding and also responds to DNA with elevated ATP hydrolysis. However, the DNA-mediated increase in ATP hydrolysis is lower than that obtained with the wild-type enzyme but similar to that of a cleavage-deficient topoisomerase IIalpha enzyme. Our results strongly suggest that the strand passage event is required for efficient DNA stimulation of topoisomerase II-mediated ATP hydrolysis, whereas the stimulation occurs independent of the DNA cleavage reaction per se. A comparison of the strand passage deficient-enzyme described here and the cleavage-deficient enzyme may have applications in other studies where a clear distinction between strand passage and topoisomerase II-mediated DNA cleavage is desirable.	Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark	Aarhus University	Andersen, AH (corresponding author), Aarhus Univ, Dept Mol Biol, CF Mollers Alle,Bldg 130, DK-8000 Aarhus C, Denmark.	aha@mb.au.dk	Andersen, Anni/O-1162-2017; Oestergaard, Vibe Hallundbæk/B-7254-2015; Bjergbæk, Lotte/AAW-6302-2021	Oestergaard, Vibe Hallundbæk/0000-0002-1633-0560; Bjergbaek, Lotte/0000-0002-8233-3356; Knudsen, Birgitta Ruth/0000-0002-3484-3802; Andersen, Anni/0000-0001-7194-3258				ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ANDERSEN AH, 1991, J BIOL CHEM, V266, P9203; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Bjergbaek L, 2000, J BIOL CHEM, V275, P13041, DOI 10.1074/jbc.275.17.13041; Classen S, 2003, P NATL ACAD SCI USA, V100, P10629, DOI 10.1073/pnas.1832879100; Corbett KD, 2003, EMBO J, V22, P151, DOI 10.1093/emboj/cdg008; CRENSHAW DG, 1993, J BIOL CHEM, V268, P21335; DeLano W, 2002, PYMOL 0 99; Hu T, 1998, J BIOL CHEM, V273, P9586, DOI 10.1074/jbc.273.16.9586; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jensen S, 1996, MOL CELL BIOL, V16, P3866; Lamour V, 2002, J BIOL CHEM, V277, P18947, DOI 10.1074/jbc.M111740200; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; Morris SNK, 1999, J BIOL CHEM, V274, P3446, DOI 10.1074/jbc.274.6.3446; Oestergaard VH, 2004, J BIOL CHEM, V279, P28100, DOI 10.1074/jbc.M402119200; Oestergaard VH, 2004, J BIOL CHEM, V279, P1684, DOI 10.1074/jbc.M309624200; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; REECE RJ, 1991, NUCLEIC ACIDS RES, V19, P1399, DOI 10.1093/nar/19.7.1399; SANDER M, 1983, J BIOL CHEM, V258, P8421; SHIOZAKI K, 1991, MOL CELL BIOL, V11, P6093, DOI 10.1128/MCB.11.12.6093; Skouboe C, 2003, J BIOL CHEM, V278, P5768, DOI 10.1074/jbc.M210332200; TAMURA JK, 1990, J BIOL CHEM, V265, P21342; Tingey AP, 1996, NUCLEIC ACIDS RES, V24, P4868, DOI 10.1093/nar/24.24.4868; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; Williams NL, 1999, BIOCHEMISTRY-US, V38, P14157, DOI 10.1021/bi991478m; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	29	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28093	28099		10.1074/jbc.M402120200	http://dx.doi.org/10.1074/jbc.M402120200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123700	hybrid			2022-12-25	WOS:000222265400034
J	Perdomo, G; Commerford, SR; Richard, AMT; Adams, SH; Corkey, BE; O'Doherty, RM; Brown, NF				Perdomo, G; Commerford, SR; Richard, AMT; Adams, SH; Corkey, BE; O'Doherty, RM; Brown, NF			Increased beta-oxidation in muscle cells enhances insulin-stimulated glucose metabolism and protects against fatty acid-induced insulin resistance despite intramyocellular lipid accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKELETAL-MUSCLE; CARNITINE PALMITOYLTRANSFERASE-I; DEPENDENT DIABETES-MELLITUS; KINASE-C; WEIGHT-LOSS; QUANTITATIVE MEASUREMENT; P38 MAPK; SENSITIVITY; TRANSPORT; RATS	Skeletal muscle insulin resistance may be aggravated by intramyocellular accumulation of fatty acid-derived metabolites that inhibit insulin signaling. We tested the hypothesis that enhanced fatty acid oxidation in myocytes should protect against fatty acid-induced insulin resistance by limiting lipid accumulation. L6 myotubes were transduced with adenoviruses encoding carnitine palmitoyltransferase I (CPT I) isoforms or beta-galactosidase (control). Two to 3-fold overexpression of L-CPT I, the endogenous isoform in L6 cells, proportionally increased oxidation of the long-chain fatty acids palmitate and oleate and increased insulin stimulation of [C-14] glucose incorporation into glycogen by 60% while enhancing insulin-stimulated phosphorylation of p38MAPK. Incubation of control cells with 0.2 mM palmitate for 18 h caused accumulation of triacylglycerol, diacylglycerol, and ceramide ( but not long-chain acyl-CoA) and decreased insulin-stimulated [C-14] glucose incorporation into glycogen ( 60%), [H-3] deoxyglucose uptake ( 60%), and protein kinase B phosphorylation (20%). In the context of L-CPT I overexpression, palmitate preincubation produced a relative decrease in insulin-stimulated incorporation of [C-14] glucose into glycogen ( 60%) and [H-3] deoxyglucose uptake (40%) but did not inhibit phosphorylation of protein kinase B. Due to the enhancement of insulin-stimulated glucose metabolism induced by L-CPT I overexpression itself, net insulin-stimulated incorporation of [C-14] glucose into glycogen and [H-3] deoxyglucose uptake in L-CPT I-transduced, palmitate-treated cells were significantly greater than in palmitate-treated control cells ( 71 and 75% greater, respectively). However, L-CPT I overexpression failed to decrease intracellular triacylglycerol, diacylglycerol, ceramide, or long-chain acyl-CoA. We propose that accelerated beta-oxidation in muscle cells exerts an insulin-sensitizing effect independently of changes in intracellular lipid content.	Univ Pittsburgh, Div Endocrinol & Metab, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Obes Res Ctr, Boston, MA 02118 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Boston University; Boston University; Boston University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Brown, NF (corresponding author), Univ Pittsburgh, Div Endocrinol & Metab, Dept Med, E1140 BST,200 Lothrop St, Pittsburgh, PA 15261 USA.	brownn@msx.dept-med.pitt.edu	Perdomo, German/K-6703-2014; Corkey, Barbara/E-7712-2015	Perdomo, German/0000-0002-2301-0012; Corkey, Barbara/0000-0002-5467-1630	NIDDK NIH HHS [R01 DK58855-01, DK46204, T32-DK07052] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007052, R01DK058855] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balon TW, 2001, MED SCI SPORT EXER, V33, P382, DOI 10.1097/00005768-200103000-00008; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BERRY MN, 1991, ISOLATED HEPATOCYTES, P172; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BODEN G, 1991, J CLIN INVEST, V88, P960, DOI 10.1172/JCI115399; Brown NF, 1997, BIOCHEM J, V327, P225, DOI 10.1042/bj3270225; Brown Nicholas F, 2003, Methods Mol Biol, V228, P281, DOI 10.1385/1-59259-400-X:281; Buettner R, 2000, AM J PHYSIOL-ENDOC M, V278, pE563, DOI 10.1152/ajpendo.2000.278.3.E563; Cazzolli R, 2001, DIABETES, V50, P2210, DOI 10.2337/diabetes.50.10.2210; Cooney GJ, 2002, ANN NY ACAD SCI, V967, P196; DANNO H, 1992, J NUTR SCI VITAMINOL, V38, P517, DOI 10.3177/jnsv.38.517; de Alvaro C, 2004, J BIOL CHEM, V279, P17070, DOI 10.1074/jbc.M312021200; Dobbins RL, 2001, DIABETES, V50, P123, DOI 10.2337/diabetes.50.1.123; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; DZCZEPANIAK LS, 1999, AM J PHYSIOL, V276, pE977; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Garcia-Martinez C, 2001, FASEB J, V15, P2033, DOI 10.1096/fj.00-0828fje; Goodpaster BH, 2001, J CLIN ENDOCR METAB, V86, P5755, DOI 10.1210/jc.86.12.5755; Goodpaster BH, 1997, DIABETES, V46, P1579, DOI 10.2337/diabetes.46.10.1579; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Hajduch E, 2001, FEBS LETT, V492, P199, DOI 10.1016/S0014-5793(01)02242-6; Hajduch E, 2001, DIABETOLOGIA, V44, P173, DOI 10.1007/s001250051596; Helge JW, 2003, DIABETES, V52, P1881, DOI 10.2337/diabetes.52.8.1881; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; Hulver MW, 2003, AM J PHYSIOL-ENDOC M, V284, pE741, DOI 10.1152/ajpendo.00514.2002; Huppertz C, 2001, J BIOL CHEM, V276, P12520, DOI 10.1074/jbc.M011708200; Ide T, 2000, METABOLISM, V49, P521, DOI 10.1016/S0026-0495(00)80019-0; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; KELLEY DE, 1994, J CLIN INVEST, V94, P2349, DOI 10.1172/JCI117600; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; KELLEY DE, 1993, J CLIN INVEST, V92, P91, DOI 10.1172/JCI116603; KELLEY DE, 1990, J CLIN INVEST, V86, P1999, DOI 10.1172/JCI114935; Kern PA, 1999, J CLIN ENDOCR METAB, V84, P4185, DOI 10.1210/jc.84.11.4185; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; Kim JY, 2000, AM J PHYSIOL-ENDOC M, V279, pE1039, DOI 10.1152/ajpendo.2000.279.5.E1039; Koistinen HA, 2003, DIABETOLOGIA, V46, P1324, DOI 10.1007/s00125-003-1196-3; Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123; Lau R, 2001, AM J PHYSIOL-ENDOC M, V281, pE122, DOI 10.1152/ajpendo.2001.281.1.E122; Lee JY, 2000, J CELL BIOL, V150, P1085, DOI 10.1083/jcb.150.5.1085; Magnan C, 1996, LIPIDS, V31, P1141, DOI 10.1007/BF02524288; Martin A, 1997, ONCOGENE, V14, P1571, DOI 10.1038/sj.onc.1200987; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Niu WY, 2003, J BIOL CHEM, V278, P17953, DOI 10.1074/jbc.M211136200; Phillips DIW, 1996, METABOLISM, V45, P947, DOI 10.1016/S0026-0495(96)90260-7; PREISS J, 1986, J BIOL CHEM, V261, P8597; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; Price NT, 2002, GENOMICS, V80, P433, DOI 10.1006/geno.2002.6845; RANDLE PJ, 1963, LANCET, V1, P785; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; Rubi B, 2002, BIOCHEM J, V364, P219, DOI 10.1042/bj3640219; Schmitz-Peiffer C, 2000, CELL SIGNAL, V12, P583, DOI 10.1016/S0898-6568(00)00110-8; Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202; SchmitzPeiffer C, 1997, DIABETES, V46, P169, DOI 10.2337/diabetes.46.2.169; Simoneau JA, 1999, FASEB J, V13, P2051, DOI 10.1096/fasebj.13.14.2051; Simoneau JA, 1997, J APPL PHYSIOL, V83, P166, DOI 10.1152/jappl.1997.83.1.166; SPRINGER ML, 1997, CURRENT PROTOCOLS HU; Steinberg GR, 2002, AM J PHYSIOL-ENDOC M, V282, pE593, DOI 10.1152/ajpendo.00303.2001; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; Storz P, 1999, EUR J BIOCHEM, V266, P17, DOI 10.1046/j.1432-1327.1999.00809.x; Thong FSL, 2002, CAN J APPL PHYSIOL, V27, P152, DOI 10.1139/h02-011; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Tremblay F, 2001, J BIOL CHEM, V276, P38052; TURINSKY J, 1990, J BIOL CHEM, V265, P16880; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wasada T, 2002, INTERNAL MED, V41, P84, DOI 10.2169/internalmedicine.41.84; Webster JM, 1996, BBA-MOL BASIS DIS, V1316, P109, DOI 10.1016/0925-4439(96)00011-7; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4; WOELTJE KF, 1987, J BIOL CHEM, V262, P9822; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788	71	125	131	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27177	27186		10.1074/jbc.M403566200	http://dx.doi.org/10.1074/jbc.M403566200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15105415	hybrid			2022-12-25	WOS:000222120400044
J	Lakka, SS; Gondi, CS; Yanamandra, N; Olivero, WC; Dinh, DH; Gujrati, M; Rao, JS				Lakka, SS; Gondi, CS; Yanamandra, N; Olivero, WC; Dinh, DH; Gujrati, M; Rao, JS			Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis	ONCOGENE			English	Article						siRNA; proteases; glioma; invasion; angiogenesis	HUMAN BRAIN-TUMORS; IN-VITRO; MATRIX METALLOPROTEINASES; IV COLLAGENASE; ANTISENSE OLIGONUCLEOTIDES; BASEMENT-MEMBRANE; MAMMALIAN-CELLS; PLASMA-MEMBRANE; MESSENGER-RNA; MATRIX-METALLOPROTEINASE-9	Extracellular proteases have been shown to cooperatively influence matrix degradation and tumor cell invasion through proteolytic cascades, with individual proteases having distinct roles in tumor growth, invasion, migration and angiogenesis. Matrix metalloproteases (MMP)-9 and cathepsin B have been shown to participate in the processes of tumor growth, vascularization and invasion of gliomas. In the present study, we used a cytomegalovirus promoter-driven DNA template approach to induce hairpin RNA (hpRNA)-triggered RNA interference (RNAi) to block MMP-9 and cathepsin B gene expression with a single construct. Transfection of a plasmid vector-expressing double-stranded RNA (dsRNA) for MMP-9 and cathepsin B significantly inhibited MMP-9 and cathepsin B expression and reduced the invasive behavior of SNB19, glioblastoma cell line in Matrigel and spheroid invasion models. Downregulation of MMP-9 and cathepsin B using RNAi in SNB19 cells reduced cell-cell interaction of human microvascular endothelial cells, resulting in the disruption of capillary network formation in both in vitro and in vivo models. Direct intratumoral injections of plasmid DNA expressing hpRNA for MMP-9 and cathepsin B significantly inhibited established glioma tumor growth and invasion in intracranial tumors in vivo. Further intraperitoneal (ip) injections of plasmid DNA expressing hpRNA for MMP-9 and cathepsin B completely regressed pre-established tumors for a long time (4 months) without any indication of these tumor cells. For the first time, these observations demonstrate that the simultaneous RNAi-mediated targeting of MMP-9 and cathepsin B has potential application for the treatment of human gliomas.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Program Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Dept Neurosurg, Peoria, IL USA; Univ Illinois, Dept Pathol, Peoria, IL USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Program Canc Biol, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu		Gondi, Christopher/0000-0002-3036-9920	NATIONAL CANCER INSTITUTE [R01CA085216, R01CA075557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047699] Funding Source: NIH RePORTER; NCI NIH HHS [CA 75557, CA 85216] Funding Source: Medline; NINDS NIH HHS [NS47699] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arkona C, 1996, BIOL CHEM, V377, P695, DOI 10.1515/bchm3.1996.377.11.695; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bertrand JR, 2002, BIOCHEM BIOPH RES CO, V296, P1000, DOI 10.1016/S0006-291X(02)02013-2; Bervar A, 2003, BIOL CHEM, V384, P447, DOI 10.1515/BC.2003.050; Boike G, 1992, Melanoma Res, V1, P333, DOI 10.1097/00008390-199201000-00004; Chandrasekar N, 2000, CLIN EXP METASTAS, V18, P337, DOI 10.1023/A:1010833730407; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; EMMERTBUCK MR, 1994, AM J PATHOL, V145, P1285; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; GUINEC N, 1993, BIOL CHEM H-S, V374, P1135, DOI 10.1515/bchm3.1993.374.7-12.1135; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; Hua J, 1996, CANCER RES, V56, P5279; Itoh T, 1999, CLIN EXP METASTAS, V17, P177, DOI 10.1023/A:1006603723759; Jen KY, 2000, STEM CELLS, V18, P307, DOI 10.1634/stemcells.18-5-307; Kachra Z, 1999, CLIN EXP METASTAS, V17, P555, DOI 10.1023/A:1006760632766; KOBAYASHI H, 1992, CANCER RES, V52, P3610; KOBAYASHI H, 1993, BIOCHIM BIOPHYS ACTA, V1178, P55, DOI 10.1016/0167-4889(93)90109-3; Kondraganti S, 2000, CANCER RES, V60, P6851; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; Lakka SS, 2002, ONCOGENE, V21, P8011, DOI 10.1038/sj.onc.1205894; Lakka SS, 2000, CLIN EXP METASTAS, V18, P245, DOI 10.1023/A:1006724826083; LEUNIG M, 1992, CANCER RES, V52, P6553; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; Mai JX, 2002, BIOL CHEM, V383, P1407, DOI 10.1515/BC.2002.159; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; Miyagishi M, 2003, ANTISENSE NUCLEIC A, V13, P1, DOI 10.1089/108729003764097296; Mohanam S, 2001, ONCOGENE, V20, P3665, DOI 10.1038/sj.onc.1204480; Pozzi A, 2002, ONCOGENE, V21, P272, DOI 10.1038/sj.onc.1205045; Premzl A, 2003, EXP CELL RES, V283, P206, DOI 10.1016/S0014-4827(02)00055-1; Raithatha SA, 2000, NEURO-ONCOLOGY, V2, P145, DOI 10.1093/neuonc/2.3.145; RAO JS, 1993, CANCER RES, V53, P2208; REDWOOD SM, 1992, CANCER, V69, P1212; Rooprai HK, 1998, INT J ONCOL, V13, P1153; Simon C, 1998, CANCER RES, V58, P1135; SLOANE BF, 1986, P NATL ACAD SCI USA, V83, P2483, DOI 10.1073/pnas.83.8.2483; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901-746	43	245	276	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4681	4689		10.1038/sj.onc.1207616	http://dx.doi.org/10.1038/sj.onc.1207616			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122332				2022-12-25	WOS:000221799200004
J	Dong, ZZ; Liu, LH; Han, BG; Pincheira, R; Zhang, JT				Dong, ZZ; Liu, LH; Han, BG; Pincheira, R; Zhang, JT			Role of eIF3 p170 in controlling synthesis of ribonucleotide reductase M2 and cell growth	ONCOGENE			English	Article						eIF3; anchorage-independent cell growth; p170; ribonucleotide reductase; translation initiation factor; antisense cDNA	MALIGNANT-TRANSFORMATION; PROTEIN-SYNTHESIS; GENE-EXPRESSION; MESSENGER-RNA; SUBUNIT; TRANSLATION; CYCLE; R2; OVEREXPRESSION; PROLIFERATION	Translation initiation in eukaryotes is a rate-limiting step in protein synthesis. It is a complicated process that involves many eukaryotic initiation factors (eIFs). Altering the expression level or the function of eIFs may influence the synthesis of some proteins and consequently cause abnormal cell growth and malignant transformation. P170, the largest putative subunit of eIF3, has been found elevated in human breast, cervical, esophageal, and lung cancers, suggesting that p170 may have a potential role in malignant transformation and/or cell growth control. Our recent studies suggested that p170 is likely a translational regulator and it may mediate the effect of mimosine on the translation of a subset mRNAs. Mimosine, a plant nonprotein amino acid, inhibits mammalian DNA synthesis, an essential event of cell growth. The rate-limiting step in DNA synthesis is the conversion of the ribonucleotides to their corresponding deoxyribonucleotides catalysed by ribonucleotide reductase of which the activity is regulated by the level of its M2 subunit. It has been reported that inhibiting the activity of M2 also inhibits cell growth. To understand the relationship between protein and DNA synthesis and between p170 and cell growth control, we investigated in this study whether p170 regulates the synthesis of M2 and, thus, cell growth. We found that altering the expression level of p170 changes the synthesis rate of both M2 and DNA. Decreasing p170 expression in human lung cancer cell line H1299 and breast cancer cell line MCF7 significantly reversed their malignant growth phenotype. However, the overall [S-35] methionine incorporation following dramatic decrease in p170 expression was only similar to25% less than the control cells. These observations, together with our previous findings, suggest that p170 may regulate the translation of a subset mRNAs and its elevated expression level may be important for cancer cell growth and for maintaining their malignant phenotype.	Indiana Univ, Sch Med,Ctr Canc, Dept Pharmacol & Toxicol, Walther Oncol Ctr,Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Zhang, JT (corresponding author), Indiana Univ, Sch Med,Ctr Canc, Dept Pharmacol & Toxicol, Walther Oncol Ctr,Walther Canc Inst, 1044 W Walnut St,R4-166, Indianapolis, IN 46202 USA.	jianzhan@iupui.edu	Zhang, Jian-Ting/L-8334-2015	Pincheira, Roxana/0000-0003-4277-5245	NCI NIH HHS [CA64539, CA94961] Funding Source: Medline; NIGMS NIH HHS [GM59475] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094961, R01CA064539, R29CA064539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059475] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abid MR, 1999, J BIOL CHEM, V274, P35991, DOI 10.1074/jbc.274.50.35991; AMARA FM, 1994, J BIOL CHEM, V269, P6709; Andrus L, 1998, BIOCHEM PHARMACOL, V55, P1807, DOI 10.1016/S0006-2952(98)00053-7; Bachmann F, 1997, CANCER RES, V57, P988; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; BJORKLUND S, 1992, EMBO J, V11, P4953, DOI 10.1002/j.1460-2075.1992.tb05602.x; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; Buratti E, 1998, NUCLEIC ACIDS RES, V26, P3179, DOI 10.1093/nar/26.13.3179; Chaudhuri J, 1997, J BIOL CHEM, V272, P30975, DOI 10.1074/jbc.272.49.30975; Chen GP, 1999, INT J CANCER, V84, P95, DOI 10.1002/(SICI)1097-0215(19990420)84:2<95::AID-IJC1>3.0.CO;2-N; Chen SY, 2000, ANTISENSE NUCLEIC A, V10, P111, DOI 10.1089/oli.1.2000.10.111; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; Dellas A, 1998, CANCER, V83, P1376, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1376::AID-CNCR15>3.0.CO;2-1; Dong ZZ, 1998, AM J PHYSIOL-GASTR L, V274, pG535, DOI 10.1152/ajpgi.1998.274.3.G535; Dong ZZ, 2003, MOL BIOL CELL, V14, P3942, DOI 10.1091/mbc.E02-12-0784; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; Fan HZ, 1996, P NATL ACAD SCI USA, V93, P14036, DOI 10.1073/pnas.93.24.14036; Fernandez J, 2002, J BIOL CHEM, V277, P2050, DOI 10.1074/jbc.M109199200; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; Han BG, 2002, MOL CELL BIOL, V22, P7372, DOI 10.1128/MCB.22.21.7372-7384.2002; HANAUSKEABEL HM, 1994, BBA-MOL CELL RES, V1221, P115, DOI 10.1016/0167-4889(94)90003-5; HANAUSKEABEL HM, 1995, FEBS LETT, V366, P92, DOI 10.1016/0014-5793(95)00493-S; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P637; HURTA RAR, 1995, J CELL BIOCHEM, V57, P543, DOI 10.1002/jcb.240570319; JIANG W, 1993, ONCOGENE, V8, P3447; Kalejta RF, 1997, EXP CELL RES, V231, P173, DOI 10.1006/excr.1996.3444; KANG HA, 1994, J BIOL CHEM, V269, P3934; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lee Y, 2003, CANCER RES, V63, P2802; Li Q, 1998, TOXICOL APPL PHARM, V150, P154, DOI 10.1006/taap.1998.8394; Manjeshwar S, 1999, MOL CARCINOGEN, V24, P188, DOI 10.1002/(SICI)1098-2744(199903)24:3<188::AID-MC5>3.0.CO;2-#; MANN GJ, 1988, CANCER RES, V48, P5151; Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; Park JB, 2000, BIOCHEM BIOPH RES CO, V267, P651, DOI 10.1006/bbrc.1999.1980; Pincheira R, 2001, BRIT J CANCER, V84, P1520, DOI 10.1054/bjoc.2001.1828; Sambrook J, 1989, MOL CLONING; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; WRIGHT JA, 1990, BIOCHEM CELL BIOL, V68, P1364, DOI 10.1139/o90-199; YARBRO JW, 1992, SEMIN ONCOL, V19, P1; Zhou B, 2001, CYTOGENET CELL GENET, V95, P52, DOI 10.1159/000057017; ZHOU BS, 1995, CANCER RES, V55, P1328; Zhou BS, 1998, CLIN EXP METASTAS, V16, P43	50	83	97	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3790	3801		10.1038/sj.onc.1207465	http://dx.doi.org/10.1038/sj.onc.1207465			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15094776				2022-12-25	WOS:000221242500006
J	Dai, ZY; Popkie, AP; Zhu, WG; Timmers, CD; Raval, A; Tannehill-Gregg, S; Morrison, CD; Auer, H; Kratzke, RA; Niehans, G; Amatschek, S; Sommergruber, W; Leone, GW; Rosol, T; Otterson, GA; Plass, C				Dai, ZY; Popkie, AP; Zhu, WG; Timmers, CD; Raval, A; Tannehill-Gregg, S; Morrison, CD; Auer, H; Kratzke, RA; Niehans, G; Amatschek, S; Sommergruber, W; Leone, GW; Rosol, T; Otterson, GA; Plass, C			Bone morphogenetic protein 3B silencing in non-small-cell lung cancer	ONCOGENE			English	Article						bone morphogenetic protein 3B (BMP3B); DNA methylation; non-small-cell lung cancer	GROWTH-FACTOR-BETA; DIFFERENTIALLY METHYLATED SEQUENCES; CPG ISLAND AMPLIFICATION; TUMOR-SUPPRESSOR; DNA METHYLATION; MESSENGER-RNAS; CDNA CLONING; EXPRESSION; GENE; IDENTIFICATION	Bone morphogenetic protein 3B (BMP3B) is a member of the TGF-beta superfamily. The BMP3B promoter sequence was previously identified as a target for aberrant DNA methylation in non-small-cell lung cancer (NSCLC). Aberrant DNA hypermethylation in the BMP3B promoter is associated with downregulation of BMP3B transcription in both primary human lung cancers as well as lung cancer cell lines. In order to understand the mechanisms of BMP3B silencing in lung cancer, a sample set of 91 primary NSCLCs was used to detect aberrant BMP3B promoter methylation, mutations in the coding sequence of BMP3B, and loss of heterozygosity (LOH). Our results showed that 45 of 91 ( or 49.5%) tested primary NSCLCs exhibited increased promoter methylation, and 40% demonstrated LOH in at least one of the flanking microsatellite markers sJRH and D10S196 (63 kb upstream or 3.338 Mbp downstream of BMP3B). The lung cancer cell line A549, a type II alveolar epithelial human lung cancer cell line, is characterized by aberrant DNA promoter methylation. We used retroviral vector constructs containing the BMP3B cDNA to re-express the gene in A549 cells and to investigate the effects on cell growth. No change in the cell growth rate was observed after BMP3B re-expression, as compared to the vector controls. Although the number of colonies formed in anchorage-dependent assays was only slightly decreased, the colony-forming ability of A549 cells after BMP3B expression in anchorage-independent assays in soft agar was significantly reduced to 10% (P<0.005, t-test). Moreover, the in vivo tumorigenicity assay in nude mice indicated that cells re-expressing BMP3B grew significantly slower than cells not expressing BMP3B (P<0.05, t-test). In conclusion, this study provides evidence that BMP3B expression is repressed by different mechanisms in lung cancer, and that the silencing of BMP3B promotes lung tumor development.	Ohio State Univ, Div Human Canc Genet, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Hematol Oncol, Columbus, OH 43210 USA; Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Minneapolis VA Med Ctr, Minneapolis, MN 55417 USA; Boehringer Ingelheim, A-1120 Vienna, Austria; Univ Vienna, Dept Dermatol, A-1090 Vienna, Austria	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Boehringer Ingelheim; University of Vienna	Plass, C (corresponding author), Ohio State Univ, Div Human Canc Genet, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Med Res Facil 494A,420 W 12th Ave, Columbus, OH 43210 USA.	plass-1@medctr.osu.edu	zhu, wei-guo/E-1334-2012; Rosol, Thomas/G-9585-2011; Plass, Christoph/H-7192-2014	Rosol, Thomas/0000-0003-3737-1190; Zhu, Wei-Guo/0000-0001-8385-6581	NCI NIH HHS [R01 CA93548, P30 CA16058] Funding Source: Medline; NIDCR NIH HHS [R01 DE13123] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058, R01CA093548] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013123] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akhurst RJ, 2002, J CLIN INVEST, V109, P1533, DOI 10.1172/JCI200215970; Baylin SB, 1998, ADV CANCER RES, V72, P141; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; Colasante A, 1997, AM J RESP CRIT CARE, V156, P968, DOI 10.1164/ajrccm.156.3.9701122; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DERYNCK R, 1987, CANCER RES, V47, P707; Faucheux C, 1997, BIOCHEM BIOPH RES CO, V241, P787, DOI 10.1006/bbrc.1997.7792; Girard L, 2000, CANCER RES, V60, P4894; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hino J, 1996, BIOCHEM BIOPH RES CO, V223, P304, DOI 10.1006/bbrc.1996.0889; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; Kiemer AK, 2001, ONCOGENE, V20, P6679, DOI 10.1038/sj.onc.1204872; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Liang GG, 2002, METHODS, V27, P150, DOI 10.1016/S1046-2023(02)00068-3; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Plass C, 2002, EUR J HUM GENET, V10, P6, DOI 10.1038/sj.ejhg.5200768; Ridley A, 2000, NATURE, V406, P466, DOI 10.1038/35020170; Samuel W, 2002, J BIOL CHEM, V277, P59, DOI 10.1074/jbc.M108730200; Sasaki H, 2002, JPN J CLIN ONCOL, V32, P85, DOI 10.1093/jjco/hyf021; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; Smiraglia DJ, 2002, ONCOGENE, V21, P5414, DOI 10.1038/sj.onc.1205608; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Toyota M, 1999, CANCER RES, V59, P2307; Toyota Minoru, 2002, Methods Mol Biol, V200, P101; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970; Zhu WG, 2001, CANCER RES, V61, P1327	36	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3521	3529		10.1038/sj.onc.1207441	http://dx.doi.org/10.1038/sj.onc.1207441			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116090				2022-12-25	WOS:000221101700003
J	Egawa, T; Hishiki, T; Ichikawa, Y; Kanamori, Y; Shimada, H; Takahashi, S; Kitagawa, T; Ishimura, Y				Egawa, T; Hishiki, T; Ichikawa, Y; Kanamori, Y; Shimada, H; Takahashi, S; Kitagawa, T; Ishimura, Y			Refolding processes of cytochrome P450(cam) from ferric and ferrous acid forms to the native conformation - Formations of folding intermediates with non-native heme coordination state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTRA; PSEUDOMONAS-PUTIDA CYTOCHROME-P-450; CRYSTAL-STRUCTURE; ELECTRON-TRANSFER; LIVER-MICROSOMES; LOW-PH; HORSERADISH-PEROXIDASE; CIRCULAR-DICHROISM; HIGH-PRESSURE; NITRIC-OXIDE	Changes in heme coordination state and protein conformation of cytochrome P450(cam) (P450(cam)), a b-type heme protein, were investigated by employing pH jump experiments coupled with time-resolved optical absorption, fluorescence, circular dichroism, and resonance Raman techniques. We found a partially unfolded form ( acid form) of ferric P450(cam) at pH 2.5, in which a Cys(-)-heme coordination bond in the native conformation was ruptured. When the pH was raised to pH 7.5, the acid form refolded to the native conformation through a distinctive intermediate. Formations of similar acid and intermediate forms were also observed for ferrous P450(cam). Both the ferric and ferrous forms of the intermediate were found to have an unidentified axial ligand of the heme at the 6th coordination sphere, which is vacant in the high spin ferric and ferrous forms at the native conformation. For the ferrous form, it was also indicated that the 5th axial ligand is different from the native cysteinate. The folding intermediates identified in this study demonstrate occurrences of non-native coordination state of heme during the refolding processes of the large b-type heme protein, being akin to the well known folding intermediates of cytochromes c, in which c-type heme is covalently attached to a smaller protein.	Keio Univ, Sch Med, Dept Biochem, Shinjuku Ku, Tokyo 1608582, Japan; Osaka Univ, Inst Prot Res, Div Phys Chem, Suita, Osaka 5650871, Japan; Okazaki Natl Res Inst, Inst Mol Sci, Okazaki, Aichi 4448585, Japan	Keio University; Osaka University; National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Okazaki Institute for Integrative Bioscience (OIIB)	Egawa, T (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.	tegawa@aecom.yu.edu						ANDERSSON LA, 1989, J BIOL CHEM, V264, P19099; Antonini E., 1971, FRONT BIOL, P13; ASAKURA T, 1974, J BIOL CHEM, V249, P4495; CHAMPION PM, 1978, J AM CHEM SOC, V100, P3743, DOI 10.1021/ja00480a015; CHAMPION PM, 1982, J AM CHEM SOC, V104, P5469, DOI 10.1021/ja00384a037; Chen EF, 1999, J AM CHEM SOC, V121, P3811, DOI 10.1021/ja983169+; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHING T, 1973, J BIOL CHEM, V248, P2889; CREIGHTON TE, 1994, NAT STRUCT BIOL, V1, P135, DOI 10.1038/nsb0394-135; Davydov DR, 1999, BIOCHEMISTRY-US, V38, P751, DOI 10.1021/bi981397a; DAWSON JH, 1983, J BIOL CHEM, V258, P3637; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; Dyer RB, 1998, ACCOUNTS CHEM RES, V31, P709, DOI 10.1021/ar970343a; Egawa T, 2000, J BIOL CHEM, V275, P34858, DOI 10.1074/jbc.M004026200; ELOVE GA, 1994, BIOCHEMISTRY-US, V33, P6925, DOI 10.1021/bi00188a023; FREIRE E, 1995, ANNU REV BIOPH BIOM, V24, P141, DOI 10.1146/annurev.bb.24.060195.001041; GRIFFIN BW, 1972, BIOCHEMISTRY-US, V11, P4740, DOI 10.1021/bi00775a017; Gunsalus I.C., 1974, MOL MECHANISMS OXYGE, P559; HASHIMOTOYUTSUDO C, 1980, J BIOCHEM-TOKYO, V88, P505, DOI 10.1093/oxfordjournals.jbchem.a132997; Hishiki T, 2000, J BIOCHEM, V128, P965, DOI 10.1093/oxfordjournals.jbchem.a022848; HOA GHB, 1989, BIOCHEMISTRY-US, V28, P651; HOA GHB, 1990, BIOCHEMISTRY-US, V29, P6810, DOI 10.1021/bi00481a008; ICHIKAWA Y, 1967, BIOCHIM BIOPHYS ACTA, V131, P490, DOI 10.1016/0005-2728(67)90008-4; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; IMAI Y, 1974, J BIOCHEM-TOKYO, V75, P689, DOI 10.1093/oxfordjournals.jbchem.a130441; KIEFHABER T, 1995, P NATL ACAD SCI USA, V92, P9029, DOI 10.1073/pnas.92.20.9029; KITAGAWA T, 1976, J AM CHEM SOC, V98, P5169, DOI 10.1021/ja00433a019; Lakowicz J.R., 1983, PRINC FLUORESC SPECT, P341, DOI [10.1007/978-1-4615-7658-7_11, DOI 10.1007/978-1-4615-7658-7_11]; Lamb DC, 1998, J AM CHEM SOC, V120, P2981, DOI 10.1021/ja973781l; MONTELIONE GT, 1989, ACCOUNTS CHEM RES, V22, P70, DOI 10.1021/ar00158a004; OMURA T, 1964, J BIOL CHEM, V239, P2370; OMURA T, 1984, J BIOCHEM-TOKYO, V96, P1491, DOI 10.1093/oxfordjournals.jbchem.a134978; OZAKI Y, 1978, BIOCHEMISTRY-US, V17, P5826, DOI 10.1021/bi00619a033; Parker MJ, 1998, BIOCHEMISTRY-US, V37, P2538, DOI 10.1021/bi972459k; Perera R, 2003, P NATL ACAD SCI USA, V100, P3641, DOI 10.1073/pnas.0737142100; Plaxco KW, 1996, CURR OPIN STRUC BIOL, V6, P630, DOI 10.1016/S0959-440X(96)80029-7; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1985, J BIOL CHEM, V260, P6122; Prasad S, 2002, BIOCHEMISTRY-US, V41, P14499, DOI 10.1021/bi026379e; PRUSAKOV VE, 1985, FEBS LETT, V186, P158, DOI 10.1016/0014-5793(85)80700-6; REMBA RD, 1979, BIOCHEMISTRY-US, V18, P2280, DOI 10.1021/bi00578a023; RODER H, 1989, METHOD ENZYMOL, V176, P446; RodriguezCrespo I, 1997, BIOCHEMISTRY-US, V36, P8530, DOI 10.1021/bi970192j; Rothwarf DM, 1998, BIOCHEMISTRY-US, V37, P3760, DOI 10.1021/bi972822n; SAGE JT, 1991, BIOCHEMISTRY-US, V30, P1227, DOI 10.1021/bi00219a010; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SCHONBAUM GR, 1972, J BIOL CHEM, V247, P3353; Simmons DA, 2002, BIOCHEMISTRY-US, V41, P1906, DOI 10.1021/bi011697j; SMITH ML, 1991, P NATL ACAD SCI USA, V88, P882, DOI 10.1073/pnas.88.3.882; Smulevich G, 1997, BIOCHEMISTRY-US, V36, P640, DOI 10.1021/bi960427b; SONO M, 1985, J BIOL CHEM, V260, P5530; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; SPIRO TG, 1976, J AM CHEM SOC, V98, P5482, DOI 10.1021/ja00434a013; SPIRO TG, 1979, J AM CHEM SOC, V101, P2648, DOI 10.1021/ja00504a027; SPIRO TG, 1974, J AM CHEM SOC, V96, P338, DOI 10.1021/ja00809a004; Takahashi S, 1997, NAT STRUCT BIOL, V4, P44, DOI 10.1038/nsb0197-44; Telford JR, 1998, ACCOUNTS CHEM RES, V31, P755, DOI 10.1021/ar970078t; TERAOKA J, 1980, J PHYS CHEM-US, V84, P1928, DOI 10.1021/j100452a013; VONBODMAN SB, 1986, P NATL ACAD SCI USA, V83, P9443; WELLS AV, 1992, BIOCHEMISTRY-US, V31, P4384, DOI 10.1021/bi00133a002; Wittung-Stafshede P, 1999, P NATL ACAD SCI USA, V96, P6587, DOI 10.1073/pnas.96.12.6587; Wittung-Stafshede P, 2002, ACCOUNTS CHEM RES, V35, P201, DOI 10.1021/ar010106e; Yeh SR, 1997, NAT STRUCT BIOL, V4, P51, DOI 10.1038/nsb0197-51; YONETANI T, 1987, J BIOL CHEM, V262, P9547; Yoshioka S, 2001, EUR J BIOCHEM, V268, P252, DOI 10.1046/j.1432-1033.2001.01872.x; YU CA, 1974, J BIOL CHEM, V249, P102; YU CA, 1974, J BIOL CHEM, V249, P107	67	7	7	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32008	32017		10.1074/jbc.M310810200	http://dx.doi.org/10.1074/jbc.M310810200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15128748	hybrid			2022-12-25	WOS:000222849700004
J	Tahiri-Alaoui, A; Gill, AC; Disterer, P; James, W				Tahiri-Alaoui, A; Gill, AC; Disterer, P; James, W			Methionine 129 variant of human prion protein oligomerizes more rapidly than the valine 129 variant - Implications for disease susceptibility to Creutzfeldt-Jakob disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-BIOLOGY; SPONGIFORM ENCEPHALOPATHIES; TRANSITION-STATE; STRAIN VARIATION; NMR STRUCTURE; GENE; PRP; POLYMORPHISM; MUTATIONS; CLASSIFICATION	The human PrP gene (PRNP) has two common alleles that encode either methionine or valine at codon 129. This polymorphism modulates disease susceptibility and phenotype of human transmissible spongiform encyphalopathies, but the molecular mechanism by which these effects are mediated remains unclear. Here, we compared the misfolding pathway that leads to the formation of beta-sheet-rich oligomeric isoforms of the methionine 129 variant of PrP to that of the valine 129 variant. We provide evidence for differences in the folding behavior between the two variants at the early stages of oligomer formation. We show that Met(129) has a higher propensity to form beta-sheet-rich oligomers, whereas Val(129) has a higher tendency to fold into alpha-helical-rich monomers. An equimolar mixture of both variants displayed an intermidate folding behavior. We show that the oligomers of both variants are initially a mixture of alpha- and beta-rich conformers that evolve with time to an increasingly homogeneous beta-rich form. This maturation process, which involves no further change in proteinase K resistance, occurs more rapidly in the Met(129) form than the Val(129) form. Although the involvement of such beta-rich oligomers in prion pathogenesis is speculative, the misfolding behavior could, in part, explain the higher susceptibility of individuals that are methionine homozygote to both sporadic and variant Creutzfeldt-Jakob disease.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Inst Anim Hlth, Newbury RG20 7NN, Berks, England	University of Oxford; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Tahiri-Alaoui, A (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	abdou.tahiri-alaoui@path.ox.ac.uk	Gill, ANdrew/GRO-1248-2022; Gill, Andrew C/A-5219-2009; james, william/H-4289-2013; Disterer, Petra/C-9709-2014	Gill, Andrew C/0000-0001-5201-9473; james, william/0000-0002-2506-1198; Disterer, Petra/0000-0001-9702-9974	Biotechnology and Biological Sciences Research Council [BBS/E/I/00000973, BBS/E/I/00000877] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Alonso DOV, 2001, P NATL ACAD SCI USA, V98, P2985, DOI 10.1073/pnas.061555898; BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2000, BIOCHEMISTRY-US, V39, P2792, DOI 10.1021/bi9923353; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BROWN P, 1994, NEUROLOGY, V44, P291, DOI 10.1212/WNL.44.2.291; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Cervenakova L, 1998, P NATL ACAD SCI USA, V95, P13239, DOI 10.1073/pnas.95.22.13239; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Croes EA, 2003, ANN NEUROL, V54, P275, DOI 10.1002/ana.10658; Dermaut B, 2003, ANN NEUROL, V53, P409, DOI 10.1002/ana.10507; DLOUHY SR, 1992, NAT GENET, V1, P64, DOI 10.1038/ng0492-64; FASMAN GD, 1989, TRENDS BIOCHEM SCI, V14, P295, DOI 10.1016/0968-0004(89)90068-6; Gill AC, 2000, EMBO J, V19, P5324, DOI 10.1093/emboj/19.20.5324; GOLDFARB LG, 1991, LANCET, V337, P425, DOI 10.1016/0140-6736(91)91198-4; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; Hauw JJ, 2000, NEUROLOGY, V54, P1641, DOI 10.1212/WNL.54.8.1641; Hill AF, 2003, BRAIN, V126, P1333, DOI 10.1093/brain/awg125; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Jackson GS, 1999, BBA-PROTEIN STRUCT M, V1431, P1, DOI 10.1016/S0167-4838(99)00038-2; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; Landon, 1977, Methods Enzymol, V47, P145; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Lu BY, 2001, EUR J BIOCHEM, V268, P3767, DOI 10.1046/j.1432-1327.2001.02283.x; Lu BY, 2001, BIOCHEMISTRY-US, V40, P13390, DOI 10.1021/bi011111t; MATOUSCHEK A, 1989, NATURE, V340, P122, DOI 10.1038/340122a0; Mead S, 2003, SCIENCE, V300, P640, DOI 10.1126/science.1083320; NGUYEN J, 1995, BIOCHEMISTRY-US, V34, P4186, DOI 10.1021/bi00013a006; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; Prusiner SB, 1996, TRENDS BIOCHEM SCI, V21, P482, DOI 10.1016/S0968-0004(96)10063-3; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Rhie A, 2003, J BIOL CHEM, V278, P39697, DOI 10.1074/jbc.M305297200; Riek R, 1998, P NATL ACAD SCI USA, V95, P11667, DOI 10.1073/pnas.95.20.11667; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Santini S, 2003, PROTEINS, V51, P258, DOI 10.1002/prot.10348; Sayer NM, 2004, J BIOL CHEM, V279, P13102, DOI 10.1074/jbc.M310928200; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; Tahiri-Alaoui A, 2003, PROTEIN SCI, V12, P600, DOI 10.1110/ps.0236703; Vendruscolo M, 2001, NATURE, V409, P641, DOI 10.1038/35054591; Weissmann C, 1996, FEBS LETT, V389, P3, DOI 10.1016/0014-5793(96)00610-2; Wildegger G, 1999, NAT STRUCT BIOL, V6, P550, DOI 10.1038/9323; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Windl O, 1996, HUM GENET, V98, P259, DOI 10.1007/s004390050204; Wong KB, 2000, J MOL BIOL, V296, P1257, DOI 10.1006/jmbi.2000.3523; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145	53	56	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31390	31397		10.1074/jbc.M401754200	http://dx.doi.org/10.1074/jbc.M401754200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15131108	hybrid, Green Accepted			2022-12-25	WOS:000222726800060
J	Cheng, LL; Jia, HY; Lohr, M; Bagherzadeh, A; Holmes, DIR; Selwood, D; Zachary, I				Cheng, LL; Jia, HY; Lohr, M; Bagherzadeh, A; Holmes, DIR; Selwood, D; Zachary, I			Anti-chemorepulsive effects of vascular endothelial growth factor and placental growth factor-2 in dorsal root ganglion neurons are mediated via neuropilin-1 and cyclooxygenase-derived prostanoid production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SENSORY NEURONS; STIMULATES AXONAL OUTGROWTH; PROTEIN-KINASE-C; CELL PROLIFERATION; FACTOR VEGF; IN-VITRO; PROSTACYCLIN PRODUCTION; PROSTAGLANDIN E(2); NERVOUS-SYSTEM; SEMAPHORIN-III	Vascular endothelial growth factor (VEGF) displays neurotrophic and neuroprotective activities, but the mechanisms underlying these effects have not been defined. Neuropilin-1 (NP-1) is a receptor for VEGF(165) and placental growth factor-2 (PlGF-2), but the role of NP-1 in VEGF-dependent neurotrophic actions is unclear. Dorsal root ganglion (DRG) neurons expressed high levels of NP-1 mRNA and protein, much lower levels of KDR, and no detectable Flt-1. VEGF(165) and PlGF-2 promoted DRG growth cone formation with an effect similar to that of nerve growth factor, whereas the Flt-1-specific ligand, PlGF-1, and the KDR/Flt-4 ligand, VEGF-D, had no effect. The chemorepellent NP-1 ligand, semaphorin 3A, antagonized the response to VEGF and PlGF-2. The specific KDR inhibitor, SU5614, did not affect the anti-chemorepellent effects of VEGF and PlGF-2, whereas a novel, specific antagonist of VEGF binding to NP-1, called EG3287, prevented inhibition of growth cone collapse. VEGF stimulated prostacyclin and prostaglandin E(2) production in DRG cultures that was blocked by inhibitors of cyclooxygenases; the anti-chemorepellent activities of VEGF and PlGF-2 were abrogated by cyclooxygenase inhibitors, and a variety of prostacyclin analogues and prostaglandins strikingly inhibited growth cone collapse. These findings support a specific role for NP-1 in mediating neurotrophic actions of VEGF family members and also identify a novel role for prostanoids in the inhibition of neuronal chemorepulsion.	UCL, Rayne Inst, Dept Med, London WC1E 6JJ, England; UCL, Rayne Inst, Ark Therapeut Ltd, London WC1E 6JJ, England; UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	University of London; King's College London; University College London; University of London; King's College London; University College London; University of London; University College London	Zachary, I (corresponding author), UCL, Rayne Inst, Dept Med, 5 Univ St, London WC1E 6JJ, England.	i.zachary@ucl.ac.uk	Selwood, David/C-1571-2008	Selwood, David/0000-0002-6817-5064; Holmes, David/0000-0002-4560-3572				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Cai HB, 1999, J NEUROSCI, V19, P6519; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Cheng LL, 1996, NEURON, V16, P309, DOI 10.1016/S0896-6273(00)80049-5; DAVIES P, 1984, ANNU REV IMMUNOL, V2, P335, DOI 10.1146/annurev.immunol.2.1.335; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fujisawa H, 1997, CELL TISSUE RES, V290, P465, DOI 10.1007/s004410050954; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Gliki G, 2001, BIOCHEM J, V353, P503, DOI 10.1042/0264-6021:3530503; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; HINGTGEN CM, 1995, J NEUROSCI, V15, P5411; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Laitinen M, 1997, HUM GENE THER, V8, P1737, DOI 10.1089/hum.1997.8.15-1737; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Matsumoto H, 2002, J BIOL CHEM, V277, P29260, DOI 10.1074/jbc.M203996200; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; NEGREAMINOU P, 1993, J NEUROCHEM, V60, P1126, DOI 10.1111/j.1471-4159.1993.tb03263.x; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; NICOL GD, 1994, J PHYSIOL-LONDON, V480, P485, DOI 10.1113/jphysiol.1994.sp020377; OIDA H, 1995, BRIT J PHARMACOL, V116, P2828, DOI 10.1111/j.1476-5381.1995.tb15933.x; Rowlands DK, 2001, BRIT J PHARMACOL, V133, P13, DOI 10.1038/sj.bjp.0704028; SELWOOD D, 2003, Patent No. 03082918; Smith JAM, 1998, BRIT J PHARMACOL, V124, P513, DOI 10.1038/sj.bjp.0701853; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Southall MD, 2001, J BIOL CHEM, V276, P16083, DOI 10.1074/jbc.M011408200; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Takashima S, 2002, P NATL ACAD SCI USA, V99, P3657, DOI 10.1073/pnas.022017899; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; VASKO MR, 1994, J NEUROSCI, V14, P4987; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wheeler-Jones C, 1997, FEBS LETT, V420, P28, DOI 10.1016/S0014-5793(97)01481-6; Williams RSB, 2002, NATURE, V417, P292, DOI 10.1038/417292a; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200	52	42	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30654	30661		10.1074/jbc.M402488200	http://dx.doi.org/10.1074/jbc.M402488200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15126502	hybrid			2022-12-25	WOS:000222531900095
J	Muhlethaler-Mottet, A; Bourloud, KB; Auderset, K; Joseph, JM; Gross, N				Muhlethaler-Mottet, A; Bourloud, KB; Auderset, K; Joseph, JM; Gross, N			Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-x(L) and RIP	ONCOGENE			English	Article						apoptosis; TRAIL; caspase-8; neuroblastoma; chemotherapeutic drugs; cycloheximide	DEATH RECEPTORS 4; CYTOCHROME-C; LIGAND TRAIL; APO-2 LIGAND; TUMOR-CELLS; EXPRESSION; PROTEIN; CD95; AMPLIFICATION; RESISTANCE	Neuroblastorna (NB) is a childhood neoplasm which heterogeneous behavior can be explained by differential regulation of apoptosis. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces rapid apoptosis in most tumor cells and thus represents a promising anticancer agent. We have reported silencing of caspase-8 expression in highly malignant NB cells as a possible mechanism of resistance to TRAIL-induced apoptosis. To explore the particular contribution of caspase-8 in such resistance, retroviral-mediated stable caspase-8 expression was induced in the IGR-N91 cells. As a result, sensitivity to TRAIL was fully restored in the caspase-8-complemented cells. TRAIL-induced cell death could be further enhanced by cotreatment of IGR-N91-C8 and SH-EP cells with cycloheximide or subtoxic concentrations of chemotherapeutic drugs in a caspase-dependent manner. Sensitization to TRAIL involved enhanced death receptor DR5 expression, activation of Bid and the complete caspases cascade. Interestingly, combined treatments also enhanced the cleavage-mediated inactivation of antiapoptotic molecules, XIAP, Bcl-x(L) and RIP. Our results show that restoration of active caspase-8 expression in a caspase-8-deficient NB cell line is necessary and sufficient to fully restore TRAIL sensitivity. Moreover, the synergistic effect of drugs and TRAIL results from activation of the caspase cascade via a mitochondrial pathway-mediated amplification loop and from the inactivation of apoptosis inhibitors.	CHU Vaudois, Dept Pediat, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Gross, N (corresponding author), CHU Vaudois, Dept Pediat, CH-1011 Lausanne, Switzerland.	nicole.gross@chuv.hospvd.ch	Mühlethaler-Mottet, Annick/H-2848-2019	Mühlethaler-Mottet, Annick/0000-0001-8274-0907				Altieri DC, 2003, ADV CANCER RES, V88, P31, DOI 10.1016/S0065-230X(03)88303-3; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Benedict CA, 2001, J BIOL CHEM, V276, P3270, DOI 10.1074/jbc.M008218200; Brambilla E, 1996, AM J PATHOL, V149, P1941; Brodeur GM, 1997, J PEDIAT HEMATOL ONC, V19, P93, DOI 10.1097/00043426-199703000-00001; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Eggert A, 2001, CANCER RES, V61, P1314; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Fulda S, 2000, CANCER RES, V60, P3947; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Harada K, 2002, CANCER RES, V62, P5897; Hopkins-Donaldson S, 2002, ONCOGENE, V21, P6132, DOI 10.1038/sj.onc.1205879; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jazirehi AR, 2001, CLIN CANCER RES, V7, P3874; Johnson DE, 2000, CANCER RES, V60, P1818; Keane MM, 1999, CANCER RES, V59, P734; Kim JW, 2000, ONCOGENE, V19, P4491, DOI 10.1038/sj.onc.1203796; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Lacour S, 2003, ONCOGENE, V22, P1807, DOI 10.1038/sj.onc.1206127; Lacour S, 2001, CANCER RES, V61, P1645; Lee SH, 1999, CANCER RES, V59, P5683; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Micheau O, 1999, BIOCHEM BIOPH RES CO, V256, P603, DOI 10.1006/bbrc.1999.0391; Mizutani Y, 1999, CLIN CANCER RES, V5, P2605; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Park WS, 2002, ONCOGENE, V21, P2919, DOI 10.1038/sj.onc.1205394; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; REED JC, 1991, CANCER RES, V51, P6529; Rodriguez-Lopez AM, 2001, MOL PHARMACOL, V59, P135, DOI 10.1124/mol.59.1.135; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sheikh MS, 1998, CANCER RES, V58, P1593; Shin MS, 2001, CANCER RES, V61, P4942; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sokol RJ, 2001, PEDIATR RES, V49, P519, DOI 10.1203/00006450-200104000-00014; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; THORNE M, 1997, NATURE, V386, P517; Vassal G, 1997, EUR J CANCER, V33, P2011, DOI 10.1016/S0959-8049(97)00296-7; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yang XH, 2003, CANCER LETT, V197, P137, DOI 10.1016/S0304-3835(03)00093-4; Zhang XD, 1999, CANCER RES, V59, P2747; Zhang XD, 2001, CANCER RES, V61, P7339	59	61	66	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5415	5425		10.1038/sj.onc.1207704	http://dx.doi.org/10.1038/sj.onc.1207704			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15094781				2022-12-25	WOS:000222588400001
J	Guidi, BW; Bjornsdottir, G; Hopkins, DC; Lacomis, L; Erdjument-Bromage, H; Tempst, P; Myers, LC				Guidi, BW; Bjornsdottir, G; Hopkins, DC; Lacomis, L; Erdjument-Bromage, H; Tempst, P; Myers, LC			Mutual targeting of mediator and the TFIIH kinase Kin28	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; CYCLIN-DEPENDENT KINASES; FACTOR TF IIE; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL REGULATION; REPEAT DOMAIN; YEAST MEDIATOR; PHOSPHORYLATION; COMPLEX	In Saccharomyces cerevisiae, Kin28 is a member of the cyclin-dependent kinase family. Kin28 is a subunit of the basal transcription factor holo-TFIIH and its trimeric sub-complex TFIIK. Kin28 is the primary kinase that phosphorylates the RNA polymerase II (RNA pol II) C-terminal domain (CTD) within a transcription initiation complex. Mediator, a global transcriptional co-activator, dramatically enhances the phosphorylation of the CTD of RNA pol II by holo-TFIIH in vitro. Using purified proteins we have determined that the subunits of TFIIK are sufficient for Mediator to enhance Kin28 CTD kinase activity and that Mediator enhances phosphorylation of a glutathione S-transferase-CTD fusion protein, despite the absence of multiple Mediator and/or TFIIH interactions with polymerase. Mediator does not stimulate the activity of several other CTD kinases, suggesting that the specific enhancement of TFIIH kinase activity results in Kin28 being the primary CTD kinase at initiation. In addition, we have found that Kin28 phosphorylates Mediator subunit Med4 in an assay, including purified holo-TFIIH, and either Mediator or recombinant Med4 alone. Furthermore, Kin28 appears to be, at least in part, responsible for the phosphorylation of Med4 in vivo. We have identified Thr-237 as the site of phosphorylation of Med4 by Kin28 in vitro. The mutation of Thr-237 to Ala has no effect on the growth of a yeast strain under normal conditions but confirms that Thr-237 is also the site of Med4 phosphorylation in vivo.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Dartmouth College; Memorial Sloan Kettering Cancer Center	Myers, LC (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	larry.myers@dartmouth.edu		Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062483] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA08748] Funding Source: Medline; NIGMS NIH HHS [R01 GM062483, GM62483] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Balciunas D, 2003, J BIOL CHEM, V278, P3831, DOI 10.1074/jbc.M206946200; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Borggrefe T, 2002, J BIOL CHEM, V277, P44202, DOI 10.1074/jbc.M207195200; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; Cooper KF, 1999, GENE EXPRESSION, V8, P43; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Davis JA, 2002, MOL CELL, V10, P409, DOI 10.1016/S1097-2765(02)00598-1; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Hallberg M, 2004, P NATL ACAD SCI USA, V101, P3370, DOI 10.1073/pnas.0400221101; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; JIANG YW, 1992, MOL CELL BIOL, V12, P4503, DOI 10.1128/MCB.12.10.4503; Keogh MC, 2003, MOL CELL BIOL, V23, P7005, DOI 10.1128/MCB.23.19.7005-7018.2003; Keogh MC, 2002, MOL CELL BIOL, V22, P1288, DOI 10.1128/MCB.22.5.1288-1297.2002; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; Liu Y, 2001, J BIOL CHEM, V276, P7169, DOI 10.1074/jbc.M009586200; Liu Y, 2004, MOL CELL BIOL, V24, P1721, DOI 10.1128/MCB.24.4.1721-1735.2004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Lucast LJ, 2001, BIOTECHNIQUES, V30, P544, DOI 10.2144/01303st06; Myers LC, 1997, METHODS, V12, P212, DOI 10.1006/meth.1997.0473; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; NONET ML, 1989, GENETICS, V123, P715; Posewitz MC, 1999, ANAL CHEM, V71, P2883, DOI 10.1021/ac981409y; Prelich G, 2002, EUKARYOT CELL, V1, P153, DOI 10.1128/EC.1.2.153-162.2002; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; Rodriguez CR, 2000, MOL CELL BIOL, V20, P104, DOI 10.1128/MCB.20.1.104-112.2000; Sakurai H, 1998, J BIOL CHEM, V273, P9534, DOI 10.1074/jbc.273.16.9534; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; SERIZAWA H, 1994, J BIOL CHEM, V269, P20750; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; Shilatifard A, 2003, ANNU REV BIOCHEM, V72, P693, DOI 10.1146/annurev.biochem.72.121801.161551; SIKORSKI RS, 1989, GENETICS, V122, P19; Spahr H, 2000, J BIOL CHEM, V275, P1351, DOI 10.1074/jbc.275.2.1351; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; Takagi Y, 2003, J BIOL CHEM, V278, P43897, DOI 10.1074/jbc.C300417200; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; Trigon S, 1998, J BIOL CHEM, V273, P6769, DOI 10.1074/jbc.273.12.6769; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0; XIAO H, 1994, MOL CELL BIOL, V14, P7507, DOI 10.1128/MCB.14.11.7507; Zurita M, 2003, TRENDS GENET, V19, P578, DOI 10.1016/j.tig.2003.08.005	52	39	41	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29114	29120		10.1074/jbc.M404426200	http://dx.doi.org/10.1074/jbc.M404426200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15126497	hybrid			2022-12-25	WOS:000222445300036
J	Lei, WL; Rushton, JJ; Davis, LM; Liu, F; Ness, SA				Lei, WL; Rushton, JJ; Davis, LM; Liu, F; Ness, SA			Positive and negative determinants of target gene specificity in Myb transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEMATOPOIETIC-CELLS; RECEPTOR FUSION PROTEIN; SMOOTH-MUSCLE CELLS; C-MYB; V-MYB; B-MYB; A-MYB; REGULATORY DOMAIN; PHOSPHORYLATION SITE; ACTIVATION DOMAINS	The A-Myb and c-Myb transcription factors share a highly conserved DNA-binding domain and activate the same promoters in reporter gene assays. However, the two proteins have distinct biological activities, and expressing them individually in human cells leads to the activation of distinct sets of endogenous genes, suggesting that each protein has a unique transcriptional specificity. Here, the structural and functional features of the Myb proteins were compared, using assays of endogenous gene expression to measure changes in specificity. When the Myb proteins were tested in different cell types, they activated unique and nearly nonoverlapping sets of genes in each cellular context. Deletion and domain swap experiments identified small, discreet positive and negative elements in A-Myb and c-Myb that were required for the regulation of specific genes, such as DHRS2, DSIPI, and mim-1. The results suggest that individual functional elements in the transcriptional activation domains are responsible for activating specific cellular genes in a context-specific manner. The results also have important implications for interpreting results from reporter gene assays, which fail to detect the differences in activity identified through endogenous gene assays, and fusion protein constructs that alter the transcriptional activation domains and the activities of the Myb proteins.	Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center	Ness, SA (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, MSC08 4660,915 Camino Salud NE, Albuquerque, NM 87131 USA.	ness@unm.edu	Ness, Scott/AAV-4009-2020	Ness, Scott/0000-0001-6965-8909	NATIONAL CANCER INSTITUTE [R01CA058443] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZIZ N, 1993, ONCOGENE, V8, P2259; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; Bies J, 2000, ONCOGENE, V19, P2846, DOI 10.1038/sj.onc.1203613; Bies J, 2001, BLOOD CELL MOL DIS, V27, P422, DOI 10.1006/bcmd.2001.0400; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; BOUWMEESTER T, 1994, ONCOGENE, V9, P1029; BROWN KE, 1992, J BIOL CHEM, V267, P4625; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; Dahle O, 2003, EUR J BIOCHEM, V270, P1338, DOI 10.1046/j.1432-1033.2003.03504.x; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; DYSON PJ, 1989, DIFFERENTIATION, V42, P24, DOI 10.1111/j.1432-0436.1989.tb00603.x; Engelke U, 1997, J VIROL, V71, P3760, DOI 10.1128/JVI.71.5.3760-3766.1997; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; Golay J, 1996, BLOOD, V87, P1900; Golay J, 1997, LEUKEMIA LYMPHOMA, V26, P271, DOI 10.3109/10428199709051776; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hibi K, 1998, CANCER RES, V58, P5690; Hodges LC, 2003, MOL CANCER RES, V1, P300; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KASTAN MB, 1989, BLOOD, V73, P1444; LAM EWF, 1992, ONCOGENE, V7, P1885; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; LYON JJ, 1995, DIFFERENTIATION, V59, P171, DOI 10.1046/j.1432-0436.1995.5930171.x; Marhamati DJ, 1997, MOL CELL BIOL, V17, P2448, DOI 10.1128/MCB.17.5.2448; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Ness SA, 2003, BLOOD CELL MOL DIS, V31, P192, DOI 10.1016/S1079-9796(03)00151-7; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NESS SA, 1996, BIOCHIM BIOPHYS ACTA, V1288, P123; RAMSAY RG, 1995, ONCOGENE, V11, P2113; Raschella G, 1999, CANCER RES, V59, P3365; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; Rushton JJ, 2001, BLOOD CELL MOL DIS, V27, P459, DOI 10.1006/bcmd.2001.0405; Sano Y, 2001, J BIOL CHEM, V276, P3674, DOI 10.1074/jbc.M006896200; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; Wang DM, 2002, ONCOGENE, V21, P1611, DOI 10.1038/sj.onc.1205236; Winn LM, 2003, CELL CYCLE, V2, P258, DOI 10.4161/cc.2.3.383; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597	46	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29519	29527		10.1074/jbc.M403133200	http://dx.doi.org/10.1074/jbc.M403133200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15105423	hybrid			2022-12-25	WOS:000222445300085
J	Li, WQ; Jiang, Q; Khaled, AR; Keller, JR; Durum, SK				Li, WQ; Jiang, Q; Khaled, AR; Keller, JR; Durum, SK			Interleukin-7 inactivates the pro-apoptotic protein bad promoting T cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-DEFICIENT MICE; DEFECTIVE LYMPHOID DEVELOPMENT; MITOCHONDRIAL APOPTOSIS; GAMMA-CHAIN; BCL-2; PHOSPHORYLATION; KINASE; DEATH; CYTOKINE; IL-7	Interleukin-7 (IL-7) is a cytokine that is required for T cell development and survival. The anti-apoptotic function of IL-7 is partly through induction of Bcl-2 synthesis and cytosolic retention of Bax. Here we show that the Bcl-2 homology 3 domain-only protein, Bad, is involved in cell death following IL-7 withdrawal from D1 cells, an IL-7-dependent murine thymocyte cell line. IL-7 stimulation resulted in the inactivation of Bad by phosphorylation at Ser-112, -136, and -155. The phosphoinositide 3-kinase (PI3K)/Akt pathway has been implicated previously in Bad phosphorylation. In response to IL-7, the PI3K/Akt pathway induced phosphorylation at Ser-136 and -155, but Ser-112 was partly independent of the PI3K/Akt pathway, indicating an as yet unknown pathway in this response. Following IL-7 withdrawal, dephosphorylated Bad translocated from cytosol to mitochondria, bound to Bcl-2, and accelerated cell death. Thus, the inactivation of Bad contributes to the survival function of IL-7.	NCI, Mol Immunoregulat Lab, Ctr Canc Res, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Durum, SK (corresponding author), NCI, Mol Immunoregulat Lab, Ctr Canc Res, NIH, Rm 31-71,Bldg 560, Frederick, MD 21702 USA.	durums@mail.ncifcrf.gov	Keller, Jonathan R./O-6677-2018	durum, scott/0000-0003-1307-9582	NATIONAL CANCER INSTITUTE [Z01BC010001, ZIABC009287, Z01BC009287, ZIABC010001] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hofmeister R, 1999, CYTOKINE GROWTH F R, V10, P41, DOI 10.1016/S1359-6101(98)00025-2; Khaled AR, 2002, IMMUNITY, V17, P561, DOI 10.1016/S1074-7613(02)00450-8; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kim K, 1998, J IMMUNOL, V160, P5735; Kim K, 2003, J IMMUNOL METHODS, V274, P177, DOI 10.1016/S0022-1759(02)00513-6; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; Nakajima H, 1999, J IMMUNOL, V162, P782; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nolan GP, 1998, CURR OPIN BIOTECH, V9, P447, DOI 10.1016/S0958-1669(98)80027-X; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Schluns KS, 2000, NAT IMMUNOL, V1, P426, DOI 10.1038/80868; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Seddon B, 2003, NAT IMMUNOL, V4, P680, DOI 10.1038/ni946; SHARFE N, 1995, BLOOD, V86, P2077, DOI 10.1182/blood.V86.6.2077.bloodjournal8662077; Tan JT, 2001, P NATL ACAD SCI USA, V98, P8732, DOI 10.1073/pnas.161126098; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; VENKITARAMAN AR, 1994, EUR J IMMUNOL, V24, P2168, DOI 10.1002/eji.1830240935; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Wang JL, 2000, CANCER RES, V60, P1498; Williams O, 1998, J EXP MED, V188, P1125, DOI 10.1084/jem.188.6.1125; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	43	77	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29160	29166		10.1074/jbc.M401656200	http://dx.doi.org/10.1074/jbc.M401656200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123689	hybrid			2022-12-25	WOS:000222445300042
J	Douglas, MW; Diefenbach, RJ; Homa, FL; Miranda-Saksena, M; Rixon, FJ; Vittone, V; Byth, K; Cunningham, AL				Douglas, MW; Diefenbach, RJ; Homa, FL; Miranda-Saksena, M; Rixon, FJ; Vittone, V; Byth, K; Cunningham, AL			Herpes simplex virus type 1 capsid protein VP26 interacts with dynein light chains RP3 and Tctex1 and plays a role in retrograde cellular transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DYNEIN; INTERMEDIATE CHAIN; RECOMBINANT BACULOVIRUSES; SUBUNIT HETEROGENEITY; ANTEROGRADE TRANSPORT; PRIMARY ENVELOPMENT; HEAVY-CHAIN; LOCALIZATION; COMPLEX; BINDING	Cytoplasmic dynein is the major molecular motor involved in minus-end-directed cellular transport along microtubules. There is increasing evidence that the retrograde transport of herpes simplex virus type 1 along sensory axons is mediated by cytoplasmic dynein, but the viral and cellular proteins involved are not known. Here we report that the herpes simplex virus outer capsid protein VP26 interacts with dynein light chains RP3 and Tctex1 and is sufficient to mediate retrograde transport of viral capsids in a cellular model. A library of herpes simplex virus capsid and tegument structural genes was constructed and tested for interactions with dynein subunits in a yeast two-hybrid system. A strong interaction was detected between VP26 and the homologous 14-kDa dynein light chains RP3 and Tctex1. In vitro pull-down assays confirmed binding of VP26 to RP3, Tctex1, and intact cytoplasmic dynein complexes. Recombinant herpes simplex virus capsids were constructed either with or without VP26. In pull-down assays VP26+ capsids bound to RP3; VP26- capsids did not. To investigate intracellular transport, the recombinant viral capsids were microinjected into living cells and incubated at 37degreesC. After 1 h VP26+ capsids were observed to co-localize with RP3, Tctex1, and microtubules. After 2 or 4 h VP26+ capsids had moved closer to the cell nucleus, whereas VP26- capsids remained in a random distribution. We propose that VP26 mediates binding of incoming herpes simplex virus capsids to cytoplasmic dynein during cellular infection, through interactions with dynein light chains.	Univ Sydney, Westmead Millennium Inst, Ctr Virus Res, Westmead, NSW 2145, Australia; Westmead Hosp, Westmead, NSW 2145, Australia; Pharmacia Corp, Infect Dis Biol, Kalamazoo, MI 49001 USA; Inst Virol, MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland	University of Sydney; Westmead Institute for Medical Research; University of Sydney; Pfizer; University of Glasgow	Diefenbach, RJ (corresponding author), Univ Sydney, Westmead Millennium Inst, Ctr Virus Res, POB 412, Westmead, NSW 2145, Australia.	russell_diefenbach@wmi.usyd.edu.au	Diefenbach, Russell J./E-9602-2015; Douglas, Mark/D-5513-2011	Diefenbach, Russell J./0000-0002-8433-4336; Douglas, Mark/0000-0003-4621-3485; Cunningham, Anthony/0000-0002-6744-5667; Byth Wilson, Karen/0000-0002-1253-6393				Alonso C, 2001, J VIROL, V75, P9819, DOI 10.1128/JVI.75.20.9819-9827.2001; Bearer EL, 2000, P NATL ACAD SCI USA, V97, P8146, DOI 10.1073/pnas.97.14.8146; Bowman BR, 2003, EMBO J, V22, P757, DOI 10.1093/emboj/cdg086; Cassady KA, 1998, J VIROL, V72, P7005; Chen DH, 2001, J VIROL, V75, P11863, DOI 10.1128/JVI.75.23.11863-11867.2001; Chuang JZ, 2001, J NEUROSCI, V21, P5501, DOI 10.1523/JNEUROSCI.21-15-05501.2001; COHEN GH, 1980, J VIROL, V34, P521, DOI 10.1128/JVI.34.2.521-531.1980; Crackower MA, 1999, GENOMICS, V55, P257, DOI 10.1006/geno.1998.5665; CUNNINGHAM C, 1993, VIROLOGY, V197, P116, DOI 10.1006/viro.1993.1572; Desai P, 1996, VIROLOGY, V220, P516, DOI 10.1006/viro.1996.0341; Desai P, 2003, J VIROL, V77, P391, DOI 10.1128/JVI.77.1.391-404.2003; Desai P, 1998, VIROLOGY, V247, P115, DOI 10.1006/viro.1998.9230; Diefenbach RJ, 1998, BIOCHEMISTRY-US, V37, P16663, DOI 10.1021/bi981163r; Diefenbach RJ, 2002, BIOCHEMISTRY-US, V41, P14906, DOI 10.1021/bi026417u; Diefenbach RJ, 2002, J VIROL, V76, P3282, DOI 10.1128/JVI.76.7.3282-3291.2002; Dohner K, 2002, MOL BIOL CELL, V13, P2795, DOI 10.1091/mbc.01-07-0348; Elliott G, 1999, J VIROL, V73, P4110, DOI 10.1128/JVI.73.5.4110-4119.1999; Enquist LW, 2002, VET MICROBIOL, V86, P5, DOI 10.1016/S0378-1135(01)00486-2; Farnsworth A, 2003, J VIROL, V77, P8481, DOI 10.1128/JVI.77.15.8481-8494.2003; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Holland DJ, 1999, J VIROL, V73, P8503, DOI 10.1128/JVI.73.10.8503-8511.1999; Holleran EA, 1998, INT REV CYTOL, V182, P69, DOI 10.1016/S0074-7696(08)62168-3; Jacob Y, 2000, J VIROL, V74, P10217, DOI 10.1128/JVI.74.21.10217-10222.2000; King SM, 2000, BBA-MOL CELL RES, V1496, P60, DOI 10.1016/S0167-4889(00)00009-4; King SM, 1996, J BIOL CHEM, V271, P32281, DOI 10.1074/jbc.271.50.32281; King SM, 1998, BIOCHEMISTRY-US, V37, P15033, DOI 10.1021/bi9810813; Klupp BG, 2000, J VIROL, V74, P10063, DOI 10.1128/JVI.74.21.10063-10073.2000; Kramer MF, 1998, J VIROL, V72, P1177, DOI 10.1128/JVI.72.2.1177-1185.1998; LYCKE E, 1984, J GEN VIROL, V65, P55, DOI 10.1099/0022-1317-65-1-55; MACNABBAIN SJ, 1999, THESIS U GLASGOW GLA; Makokha M, 2002, BIOCHEMISTRY-US, V41, P4302, DOI 10.1021/bi011970h; Martinez-Moreno M, 2003, FEBS LETT, V544, P262, DOI 10.1016/S0014-5793(03)00516-7; McCLelland DA, 2002, J VIROL, V76, P7407, DOI 10.1128/JVI.76.15.7407-7417.2002; McDonald D, 2002, J CELL BIOL, V159, P441, DOI 10.1083/jcb.200203150; Miranda-Saksena M, 2000, J VIROL, V74, P1827, DOI 10.1128/JVI.74.4.1827-1839.2000; Miranda-Saksena M, 2002, J VIROL, V76, P9934, DOI 10.1128/JVI.76.19.9934-9951.2002; Mok YK, 2001, J BIOL CHEM, V276, P14067, DOI 10.1074/jbc.M011358200; Morrison EE, 1998, J GEN VIROL, V79, P2517, DOI 10.1099/0022-1317-79-10-2517; Morrison EE, 1998, J VIROL, V72, P7108, DOI 10.1128/JVI.72.9.7108-7114.1998; Mueller S, 2002, J BIOL CHEM, V277, P7897, DOI 10.1074/jbc.M111937200; NICHOLSON P, 1994, J GEN VIROL, V75, P1091, DOI 10.1099/0022-1317-75-5-1091; Ojala PM, 2000, MOL CELL BIOL, V20, P4922, DOI 10.1128/MCB.20.13.4922-4931.2000; Raux H, 2000, J VIROL, V74, P10212, DOI 10.1128/JVI.74.21.10212-10216.2000; Reynolds AE, 2002, J VIROL, V76, P8939, DOI 10.1128/JVI.76.17.8939-8952.2002; Roizman B, 1996, FIELDS VIROLOGY, P2231; Roller RJ, 2000, J VIROL, V74, P117, DOI 10.1128/JVI.74.1.117-129.2000; Rozen S, 2000, Methods Mol Biol, V132, P365; Sodeik B, 1997, J CELL BIOL, V136, P1007, DOI 10.1083/jcb.136.5.1007; Tai AW, 2001, J CELL BIOL, V153, P1499, DOI 10.1083/jcb.153.7.1499; TATMAN JD, 1994, J GEN VIROL, V75, P1101, DOI 10.1099/0022-1317-75-5-1101; THOMSEN DR, 1994, J VIROL, V68, P2442, DOI 10.1128/JVI.68.4.2442-2457.1994; Tomishima MJ, 2001, TRAFFIC, V2, P429, DOI 10.1034/j.1600-0854.2001.020701.x; TRUS BL, 1995, J VIROL, V69, P7362, DOI 10.1128/JVI.69.11.7362-7366.1995; Willard M, 2002, J VIROL, V76, P5220, DOI 10.1128/JVI.76.10.5220-5232.2002; Wingfield PT, 1997, J VIROL, V71, P8955, DOI 10.1128/JVI.71.12.8955-8961.1997; Ye GJ, 2000, J VIROL, V74, P1355, DOI 10.1128/JVI.74.3.1355-1363.2000; Zhou ZH, 1999, J VIROL, V73, P3210, DOI 10.1128/JVI.73.4.3210-3218.1999; ZHOU ZH, 1995, NAT STRUCT BIOL, V2, P1026, DOI 10.1038/nsb1195-1026	58	128	136	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28522	28530		10.1074/jbc.M311671200	http://dx.doi.org/10.1074/jbc.M311671200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117959	hybrid			2022-12-25	WOS:000222265400088
J	Li, Q; Luo, X; Muallem, S				Li, Q; Luo, X; Muallem, S			Functional mapping of Ca2+ signaling complexes in plasma membrane microdomains of polarized cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; SALIVARY-GLAND CELLS; INOSITOL TRISPHOSPHATE; WAVES; OSCILLATIONS; CALCIUM; PROPAGATION; INITIATION; EXPRESSION; SECRETION	Many cells cluster signaling complexes in plasma membrane microdomains. Polarized secretory cells cluster all Ca2+ signaling proteins, including GPCRs, at the apical pole. The functional significance of such an arrangement is not known because of a lack of techniques for functional mapping of signaling complexes at plasma membrane patches. In the present work, we developed such a technique based on the use of two patch pipettes, a recording and a stimulating pipette (SP). Including 20% glycerol in the SP solution increased the viscosity and the hydrophobicity to prevent leakage and formation of tight seals on the plasma membrane. This allowed moving the SP between sites to stimulate multiple patches of the same cell and with the same agonist concentrations. Functional mapping of Ca2+ signaling in pancreatic acinar cells revealed that the M3, cholecystokinin, and bombesin signaling complexes at the apical pole are much more sensitive to stimulation than those at the basal pole. Furthermore, at physiological agonist concentrations, Ca2+ signals could be evoked only by stimulation of membrane patches at the apical pole. [Ca2+](i) imaging revealed that Ca2+ waves were invariably initiated at the site of apical membrane patch stimulation, suggesting that long range diffusion of second messengers is not obligatory to initiate and propagate apical-to-basal Ca2+ waves. The present studies reveal a remarkable heterogeneity in responsiveness of Ca2+ signaling complexes at membrane microdomains, with the most responsive complexes confined to the apical pole, probably to restrict the Ca2+ signals to the site of exocytosis and allow the polarized functions of secretory cells.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	SHMUEL.MUALLEM@utsouthwestern.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 12902] Funding Source: Medline; NIDDK NIH HHS [DK 38938] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Ashby MC, 2003, J BIOL CHEM, V278, P20860, DOI 10.1074/jbc.M302599200; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; Kiselyov K, 2003, CELL SIGNAL, V15, P243, DOI 10.1016/S0898-6568(02)00074-8; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Lee MG, 1997, J BIOL CHEM, V272, P15771, DOI 10.1074/jbc.272.25.15771; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; Park MK, 2004, CELL CALCIUM, V35, P367, DOI 10.1016/j.ceca.2003.10.003; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; Pfeiffer F, 1998, AM J PHYSIOL-CELL PH, V274, pC663; Rios JD, 1999, INVEST OPHTH VIS SCI, V40, P1102; Shin DM, 2001, J BIOL CHEM, V276, P44146, DOI 10.1074/jbc.M105203200; STAUFFER PL, 1993, J BIOL CHEM, V268, P19769; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; Williams JA, 2001, ANNU REV PHYSIOL, V63, P77, DOI 10.1146/annurev.physiol.63.1.77; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684; Yule DI, 1996, AM J PHYSIOL-CELL PH, V271, pC1285, DOI 10.1152/ajpcell.1996.271.4.C1285; Yule DI, 1997, J BIOL CHEM, V272, P9093; Zeng WZ, 1996, J BIOL CHEM, V271, P18520, DOI 10.1074/jbc.271.31.18520	23	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27837	27840		10.1074/jbc.C400184200	http://dx.doi.org/10.1074/jbc.C400184200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123684	hybrid			2022-12-25	WOS:000222265400002
J	Akula, SM; Ford, PW; Whitman, AG; Hamden, KE; Shelton, JG; McCubrey, JA				Akula, SM; Ford, PW; Whitman, AG; Hamden, KE; Shelton, JG; McCubrey, JA			Raf promotes human herpesvirus-8 (HHV-8/KSHV) infection	ONCOGENE			English	Article						HHV-8; KSHV; Raf; VEGF; HB-EGF	SARCOMA-ASSOCIATED HERPESVIRUS; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR SYNTHESIS; IMMUNODEFICIENCY-VIRUS TYPE-1; ABROGATE CYTOKINE DEPENDENCY; SIGNAL-REGULATED KINASE; SMOOTH-MUSCLE-CELLS; KAPOSIS-SARCOMA; ENDOTHELIAL-CELLS; TARGET-CELLS	Human herpesvirus-8 (HHV-8/KSHV) is etiologically associated with Kaposi's sarcoma (KS) and other tumors. Constitutive activation of the mitogen-activated protein kinase ( MAPK) signaling pathway has been associated with a variety of tumors, including AIDS-related KS. The oncoprotein Raf is situated at a pivotal position in regulating the MAPK pathway. Hence, we analysed the effect of oncoprotein Raf on HHV-8 infectious entry into target cells. Here we report Raf expression to significantly enhance HHV-8 infection of target cells. These findings implicate a role for Raf not only in the infectious entry of HHV-8 but also in modulating KS pathogenesis.	E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA	University of North Carolina; East Carolina University	Akula, SM (corresponding author), E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA.	akulas@mail.ecu.edu		McCubrey, James/0000-0001-6027-3156	NCI NIH HHS [R01CA098195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ablashi DV, 2002, CLIN MICROBIOL REV, V15, P439, DOI 10.1128/CMR.15.3.439-464.2002; ADAMS V, 1995, J MED VIROL, V46, P189, DOI 10.1002/jmv.1890460304; Akula SM, 2003, J VIROL, V77, P7978, DOI 10.1128/JVI.77.14.7978-7990.2003; Akula SM, 2002, CELL, V108, P407, DOI 10.1016/S0092-8674(02)00628-1; Akula SM, 2001, VIROLOGY, V282, P245, DOI 10.1006/viro.2000.0851; Akula SM, 2001, VIROLOGY, V284, P235, DOI 10.1006/viro.2001.0921; Aoki Y, 2001, LEUKEMIA LYMPHOMA, V41, P229, DOI 10.3109/10428190109057978; Aoki Y, 2000, J HEMATOTH STEM CELL, V9, P137, DOI 10.1089/152581600319351; BAILER RT, 1995, J INTERF CYTOK RES, V15, P473, DOI 10.1089/jir.1995.15.473; Bairey O, 2004, LEUKEMIA RES, V28, P243, DOI 10.1016/S0145-2126(03)00256-X; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; Birkmann A, 2001, J VIROL, V75, P11583, DOI 10.1128/JVI.75.23.11583-11593.2001; Blackbourn DJ, 2000, AIDS, V14, P1123, DOI 10.1097/00002030-200006160-00009; Blasig C, 1997, J VIROL, V71, P7963, DOI 10.1128/JVI.71.10.7963-7968.1997; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890, DOI 10.1073/pnas.91.8.2890; Cerimele F, 2001, J VIROL, V75, P2435, DOI 10.1128/JVI.75.5.2435-2443.2001; Chandran B, 1998, VIROLOGY, V243, P208, DOI 10.1006/viro.1998.9055; Chang FM, 2001, ONCOGENE, V20, P4354, DOI 10.1038/sj.onc.1204564; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Clercq E, 2001, REV MED VIROL, V11, P381, DOI 10.1002/rmv.336; De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771; ELLIS PD, 2001, BIOCHEM J, V15, P99; Ensoli B, 2000, SEMIN CANCER BIOL, V10, P367, DOI 10.1006/scbi.2000.0329; Ensoli B, 2001, EUR J CANCER, V37, P1251, DOI 10.1016/S0959-8049(01)00121-6; Faris M, 1996, AIDS, V10, P369, DOI 10.1097/00002030-199604000-00004; Gallo RC, 1998, SCIENCE, V282, P1837, DOI 10.1126/science.282.5395.1837; Ganem D, 1998, CURR CLIN TOPICS INF, V18, P237; Geraminejad P, 2002, J AM ACAD DERMATOL, V47, P641, DOI 10.1067/mjd.2002.128383; GIRALDO G, 1980, INT J CANCER, V26, P23, DOI 10.1002/ijc.2910260105; Gorden A, 2003, CANCER RES, V63, P3955; Hayward GS, 2003, CANCER CELL, V3, P1, DOI 10.1016/S1535-6108(03)00002-3; Hermouet S, 2003, NEW ENGL J MED, V348, P178, DOI 10.1056/NEJM200301093480219; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Hilger RA, 2002, ONKOLOGIE, V25, P511, DOI 10.1159/000068621; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; Iivanainen E, 2003, FASEB J, V17, P1609, DOI 10.1096/fj.02-0939com; Ingram JL, 2003, AM J PHYSIOL-LUNG C, V284, pL774, DOI 10.1152/ajplung.00189.2002; Janssen RAJ, 1998, J BIOL CHEM, V273, P32182, DOI 10.1074/jbc.273.48.32182; Karkkainen MJ, 2000, ONCOGENE, V19, P5598, DOI 10.1038/sj.onc.1203855; Kempf W, 1996, BIOCHEM MOL MED, V58, P1, DOI 10.1006/bmme.1996.0025; Le Gall M, 2003, J CELL PHYSIOL, V196, P98, DOI 10.1002/jcp.10276; Lee John T Jr, 2002, Expert Opin Ther Targets, V6, P659; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; Masood R, 2002, AM J PATHOL, V160, P23, DOI 10.1016/S0002-9440(10)64344-1; Masson-Gadais B, 2003, CELL STRESS CHAPERON, V8, P37, DOI 10.1379/1466-1268(2003)8<37:IVRFVA>2.0.CO;2; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Monini P, 1996, INT J CANCER, V66, P717, DOI 10.1002/(SICI)1097-0215(19960611)66:6<717::AID-IJC1>3.3.CO;2-N; Morand P, 1999, LEUKEMIA LYMPHOMA, V35, P379, DOI 10.3109/10428199909145743; Myoung H, 2003, CANCER SCI, V94, P215, DOI 10.1111/j.1349-7006.2003.tb01422.x; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Naranatt PP, 2003, J VIROL, V77, P1524, DOI 10.1128/JVI.77.2.1524-1539.2003; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Planz O, 2001, J VIROL, V75, P4871, DOI 10.1128/JVI.75.10.4871-4877.2001; Popik W, 1996, MOL CELL BIOL, V16, P6532; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Shelton JG, 2003, LEUKEMIA, V17, P1765, DOI 10.1038/sj.leu.2403052; SHEN H, 1993, BLOOD, V81, P2767; Sirianni MC, 1997, LANCET, V349, P255, DOI 10.1016/S0140-6736(05)64866-0; Spear PG, 2003, J VIROL, V77, P10179, DOI 10.1128/JVI.77.19.10179-10185.2003; Takenaka M, 2003, BIOCHEM BIOPH RES CO, V301, P198, DOI 10.1016/S0006-291X(02)03014-0; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; Tokuda H, 2003, ARCH BIOCHEM BIOPHYS, V415, P117, DOI 10.1016/S0003-9861(03)00225-X; Vieira J, 2001, J VIROL, V75, P1378, DOI 10.1128/JVI.75.3.1378-1386.2001; Wang FZ, 2001, J VIROL, V75, P7517, DOI 10.1128/JVI.75.16.7517-7527.2001; Wang H, 1998, CIRC RES, V83, P832, DOI 10.1161/01.RES.83.8.832; Weinstein-Oppenheimer CR, 2002, CANCER BIOL THER, V1, P256, DOI 10.4161/cbt.77; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Yang SY, 2002, ARTERIOSCL THROM VAS, V22, P1797, DOI 10.1161/01.ATV.0000038995.31179.24; Yang XY, 1999, J VIROL, V73, P3460, DOI 10.1128/JVI.73.4.3460-3466.1999; Yoshiizumi K, 2003, BIOORGAN MED CHEM, V11, P433, DOI 10.1016/S0968-0896(02)00426-1; Zhang L, 2002, CANCER RES, V62, P5463; Zhu LJ, 1999, VIROLOGY, V262, P237, DOI 10.1006/viro.1999.9900	84	33	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5227	5241		10.1038/sj.onc.1207643	http://dx.doi.org/10.1038/sj.onc.1207643			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122343				2022-12-25	WOS:000222382500012
J	Yeh, PY; Chuang, SE; Yeh, KH; Song, YC; Chang, LLY; Cheng, AL				Yeh, PY; Chuang, SE; Yeh, KH; Song, YC; Chang, LLY; Cheng, AL			Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death	ONCOGENE			English	Article						ERK2; p53; p53Thr55; doxorubicin; Bcl-2	TUMOR-SUPPRESSOR P53; IN-VITRO; PROTEIN-KINASE; TARGET GENES; CISPLATIN; CANCER; APOPTOSIS; BCL-2; VIVO; INHIBITION	We recently reported that exposure of human cervical carcinoma cells to doxorubicin results in extracellular signal-regulated kinase (ERK) 2 activation, which in turn phosphorylates p53 on a previously uncharacterized site, Thr55. This study sought to clarify the biological significance of doxorubicin-induced Thr55 phosphorylation. In breast carcinoma MCF7 cells, doxorubicin (300 nM) activated ERK2 and induced phosphorylation of p53 on Thr55 residues. Pretreatment of MCF7 cells with an ERK2 chemical inhibitor, PD98059 or U0126, blocked doxorubicin-induced p53 activation and suppressed phosphorylation of p53Thr55. MCF55a cells were established by transfection of full-length p53 carrying Thr55 mutation (Thr to Ala) into MCF7 cells. Doxorubicin ( 500 nM) could not induce p53 activation in MCF55a cells, which showed significantly increased drug resistance toward doxorubicin. While the expression of the apoptotic protein, Bax, showed no difference between MCF7 and MCF55a cells, Bcl-2, an antiapoptotic protein, was constitutively expressed in MCF55a cells. The increase of Bcl-2 protein and/or Bcl-2/Bax ratio might at least partly contribute to the drug resistance of MCF55a cells. In summary, our results suggest that phosphorylation of p53Thr55 by ERK2 is important for doxorubicin-induced p53 activation and cell death.	Natl Taiwan Univ Hosp, Dept Oncol, Taipei 10016, Taiwan; Natl Taiwan Univ, Coll Med, Ctr Canc Res, Taipei 10018, Taiwan; Natl Hlth Res Inst, Div Canc Res, Taipei, Taiwan; Far Eastern Mem Hosp, Dept Med Res, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 10016, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei 10018, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Health Research Institutes - Taiwan; Far Eastern Memorial Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Cheng, AL (corresponding author), Natl Taiwan Univ Hosp, Dept Oncol, Taipei 10016, Taiwan.	andrew@ha.mc.ntu.edu.tw	Yeh, Kun-Huei/HGD-3316-2022; Chuang, Shuang-En/D-2080-2010	YEH, Kun-Huei/0000-0002-7306-174X; Cheng, Ann-Lii/0000-0002-9152-6512; Song, Ying-Chyi/0000-0003-0279-4652				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; de Almodovar CR, 2001, ONCOGENE, V20, P7128, DOI 10.1038/sj.onc.1204887; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FAN SJ, 1995, CANCER RES, V55, P1649; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HALDAR S, 1994, CANCER RES, V54, P2095; Hayakawa J, 1999, J BIOL CHEM, V274, P31648, DOI 10.1074/jbc.274.44.31648; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Liu L, 1999, MOL CELL BIOL, V19, P1202; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Persons DL, 1999, CLIN CANCER RES, V5, P1007; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Woessmann W, 2002, CANCER CHEMOTH PHARM, V50, P397, DOI 10.1007/s00280-002-0502-y; Yeh PY, 2002, BIOCHEM PHARMACOL, V63, P1423, DOI 10.1016/S0006-2952(02)00908-5; Yeh PY, 2001, BIOCHEM BIOPH RES CO, V284, P880, DOI 10.1006/bbrc.2001.5043; Zhao RB, 2000, GENE DEV, V14, P981	48	65	66	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3580	3588		10.1038/sj.onc.1207426	http://dx.doi.org/10.1038/sj.onc.1207426			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116093				2022-12-25	WOS:000221101700009
J	Karunakaran, C; Zhang, H; Crow, JP; Antholine, WE; Kalyanaraman, B				Karunakaran, C; Zhang, H; Crow, JP; Antholine, WE; Kalyanaraman, B			Direct probing of copper active site and free radical formed during bicarbonate-dependent peroxidase activity of bovine and human copper, zinc-superoxide dismutases - Low-temperature electron paramagnetic resonance and electron nuclear double resonance studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; HIGH-FIELD EPR; CU,ZN-SUPEROXIDE DISMUTASE; RIBONUCLEOTIDE REDUCTASE; HYDROGEN-PEROXIDE; ENDOR; TRYPTOPHAN; OXIDATION; ENZYME; SPECTROSCOPY	Using X-band electron paramagnetic resonance (EPR) and electron nuclear double resonance (ENDOR) spectroscopy at liquid helium temperatures, the Cu(II) coordination geometry at the active site of bovine and human copper, zinc-superoxide dismutases (bSOD1 and hSOD1) treated with H2O2 and bicarbonate (HCO3-) was examined. The time course EPR of wild type human SOD1 (WT hSOD1), W32F hSOD1 mutant ( tryptophan 32 substituted with phenylalanine), and bSOD1 treated with H2O2 and HCO3- shows an initial reduction of active site Cu( II) to Cu(I) followed by its oxidation back to Cu(II) in the presence of H2O2. However, HCO3- induced a Trp-32-derived radical from WT hSOD1 but not from bSOD1. The mutation of Trp-32 by phenylalanine totally eliminated the Trp-32 radical signal generated from W32F hSOD1 treated with HCO3- and H2O2. Further characterization of the free radical was performed by UV irradiation of WT hSOD1 and bSOD1 that generated tryptophanyl and tyrosyl radicals. Both proton (H-1) and nitrogen (N-14) ENDOR studies of bSOD1 and hSOD1 in the presence of H2O2 revealed a change in the geometry of His-46 (or His-44) and His-48 (or His-46) coordinated to Cu( II) at the active site of WT hSOD1 and bSOD1, respectively. However, in the presence of HCO3- and H2O2, both H-1 and N-14 ENDOR spectra were almost identical to those derived from native bSOD1. We conclude that HCO3--derived oxidant does not alter significantly the Cu(II) active site geometry and histidine coordination to Cu( II) in SOD1 as does H2O2 alone; however, the oxidant derived from HCO3- (i.e. carbonate anion radical) reacts with surface-associated Trp-32 in hSOD1 to form the corresponding radical.	Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA; Univ Arkansas, Dept Med & Pharmacol, Little Rock, AR 72205 USA	Medical College of Wisconsin; Medical College of Wisconsin; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Dept Biophys, 8701 Watertown Plank Rd,POB 26509, Milwaukee, WI 53226 USA.	balarama@mcw.edu			NCRR NIH HHS [RR01008] Funding Source: Medline; NIGMS NIH HHS [GM34009] Funding Source: Medline; NINDS NIH HHS [NS40494] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040494] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abragam A., 1986, ELECT PARAMAGNETIC R; ATTANASIO D, 1977, J MAGN RESON, V26, P81, DOI 10.1016/0022-2364(77)90237-2; Ayala I, 2002, J AM CHEM SOC, V124, P5496, DOI 10.1021/ja0164327; BANCI L, 1990, INORG CHEM, V29, P4867, DOI 10.1021/ic00349a011; BELFORD RL, 1973, J CHEM PHYS, V59, P853, DOI 10.1063/1.1680104; Bleifuss G, 2001, BIOCHEMISTRY-US, V40, P15362, DOI 10.1021/bi010707d; DeGray JA, 1997, J BIOL CHEM, V272, P2359; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Elam JS, 2003, J BIOL CHEM, V278, P21032, DOI 10.1074/jbc.M300484200; Flores M, 2000, BIOPHYS J, V78, P2107, DOI 10.1016/S0006-3495(00)76757-9; Goss SPA, 1999, J BIOL CHEM, V274, P28233, DOI 10.1074/jbc.274.40.28233; GREINER SP, 1992, J PHYS CHEM-US, V96, P9132, DOI 10.1021/j100202a012; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; Hoffman BM, 2003, ACCOUNTS CHEM RES, V36, P522, DOI 10.1021/ar0202565; Hoffman BM, 2003, P NATL ACAD SCI USA, V100, P3575, DOI 10.1073/pnas.0636464100; HOFFMAN BM, 1993, BIOL MAGN RESON, V13, P151; Ivancich A, 2001, J AM CHEM SOC, V123, P5050, DOI 10.1021/ja0036514; Kalyanaraman B, 2001, ADV EXP MED BIOL, V500, P175; LIEBERMAN RA, 1982, J BIOL CHEM, V257, P336; Liochev SI, 2002, J BIOL CHEM, V277, P34674, DOI 10.1074/jbc.M204726200; Liochev SI, 1999, FREE RADICAL BIO MED, V27, P1444, DOI 10.1016/S0891-5849(99)00190-2; Liochev SI, 2003, FREE RADICAL BIO MED, V34, P1383, DOI 10.1016/S0891-5849(03)00153-9; Potsch S, 1999, J BIOL CHEM, V274, P17696, DOI 10.1074/jbc.274.25.17696; REINHARD H, 1994, J PHYS CHEM-US, V98, P8806, DOI 10.1021/j100086a035; SAHLIN M, 1982, J BIOL CHEM, V257, P366; Sankarapandi S, 1999, J BIOL CHEM, V274, P1226, DOI 10.1074/jbc.274.3.1226; SATO K, 1992, J BIOL CHEM, V267, P25371; Scholl HJ, 1998, INORG CHIM ACTA, V273, P131, DOI 10.1016/S0020-1693(97)06014-3; SCHOLL HJ, 1992, J PHYS CHEM-US, V96, P9684, DOI 10.1021/j100203a023; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P12912, DOI 10.1073/pnas.95.22.12912; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P6675, DOI 10.1073/pnas.95.12.6675; STONE EW, 1962, J CHEM PHYS, V37, P1326, DOI 10.1063/1.1733281; SWALEN JD, 1970, J CHEM PHYS, V52, P4078, DOI 10.1063/1.1673613; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; Telser J, 2000, J AM CHEM SOC, V122, P182, DOI 10.1021/ja992386n; Zhang H, 2000, J BIOL CHEM, V275, P14038, DOI 10.1074/jbc.275.19.14038; Zhang H, 2003, J BIOL CHEM, V278, P24078, DOI 10.1074/jbc.M302051200; Zhang H, 2002, J BIOL CHEM, V277, P1013, DOI 10.1074/jbc.M108585200; ZHAO LJ, 1993, METHOD ENZYMOL, V217, P218; [No title captured]	41	28	28	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32534	32540		10.1074/jbc.M314272200	http://dx.doi.org/10.1074/jbc.M314272200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15123612	hybrid			2022-12-25	WOS:000222849700068
J	Chen, SF; Yakunin, AF; Kuznetsova, E; Busso, D; Pufan, R; Proudfoot, M; Kim, R; Kim, SH				Chen, SF; Yakunin, AF; Kuznetsova, E; Busso, D; Pufan, R; Proudfoot, M; Kim, R; Kim, SH			Structural and functional characterization of a novel phosphodiesterase from Methanococcus jannaschii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURPLE ACID-PHOSPHATASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; PROTEINS; ENZYME; CRYSTALLOGRAPHY; DATABASE; SITE	Methanococcus jannaschii MJ0936 is a hypothetical protein of unknown function with over 50 homologs found in many bacteria and Archaea. To help define the molecular ( biochemical and biophysical) function of MJ0936, we determined its crystal structure at 2.4-Angstrom resolution and performed a series of biochemical screens for catalytic activity. The overall fold of this single domain protein consists of a four-layered structure formed by two beta-sheets flanked by alpha-helices on both sides. The crystal structure suggested its biochemical function to be a nuclease, phosphatase, or nucleotidase, with a requirement for some metal ions. Crystallization in the presence of Ni2+ or Mn2+ produced a protein containing a binuclear metal center in the putative active site formed by a cluster of conserved residues. Analysis of MJ0936 against a panel of general enzymatic assays revealed catalytic activity toward bis-p-nitrophenyl phosphate, an indicator substrate for phosphodiesterases and nucleases. Significant activity was also found with two other phosphodiesterase substrates, thymidine 5'-monophosphate p-nitrophenyl ester and p-nitrophenylphosphorylcholine, but no activity was found for cAMP or cGMP. Phosphodiesterase activity of MJ0936 had an absolute requirement for divalent metal ions with Ni2+] and Mn2+ being most effective. Thus, our structural and enzymatic studies have identified the biochemical function of MJ0936 as that of a novel phosphodiesterase.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley Struct Genom Ctr, Berkeley, CA 94720 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Toronto	Kim, SH (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	shkim@lbl.gov	Yakunin, Alexander/J-1519-2014	Yakunin, Alexander/0000-0003-0813-6490	NIGMS NIH HHS [GM 62412] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062412] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Frishman D, 2003, NUCLEIC ACIDS RES, V31, P207, DOI 10.1093/nar/gkg005; Guddat LW, 1999, STRUCT FOLD DES, V7, P757, DOI 10.1016/S0969-2126(99)80100-2; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELLEY RL, 1988, METHOD ENZYMOL, V161, P307; Kim R, 1998, BIOTECHNOL LETT, V20, P207, DOI 10.1023/A:1005305330517; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Knofel T, 1999, NAT STRUCT BIOL, V6, P448; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURIOKA S, 1976, ANAL BIOCHEM, V75, P281, DOI 10.1016/0003-2697(76)90078-6; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sanishvili R, 2003, J BIOL CHEM, V278, P26039, DOI 10.1074/jbc.M303867200; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; Voegtli WC, 2000, BIOCHEMISTRY-US, V39, P15365, DOI 10.1021/bi0021030; Vogel A, 2002, J BIOL CHEM, V277, P29078, DOI 10.1074/jbc.M112047200; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Yang ZR, 2003, J BIOL CHEM, V278, P8804, DOI 10.1074/jbc.M211892200	29	47	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31854	31862		10.1074/jbc.M401059200	http://dx.doi.org/10.1074/jbc.M401059200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15128743	hybrid			2022-12-25	WOS:000222726800112
J	Hama, E; Shirotani, K; Iwata, N; Saido, TC				Hama, E; Shirotani, K; Iwata, N; Saido, TC			Effects of neprilysin chimeric proteins targeted to subcellular compartments on amyloid beta peptide clearance in primary neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; PLAQUE-FORMATION; DEGRADING ENDOPEPTIDASE; EC 3.4.24.11; MOUSE MODEL; BRAIN; LOCALIZATION; IDENTIFICATION	Neprilysin (NEP) is a rate-limiting amyloid beta peptide (Abeta)-degrading enzyme in the brain. We demonstrated previously that overexpression of neprilysin in primary cortical neurons remarkably decreased not only extracellular but also intracellular Abeta levels. To investigate the subcellular compartments where neprilysin degrades Abeta most efficiently, we expressed neprilysin chimeric proteins containing various subcellular compartment-targeting domains in neurons. Sec12-NEP, beta-galactoside alpha2,6-sialyltransferase-NEP, transferrin receptor-NEP, and growth-associated protein 43-NEP were successfully sorted to the endoplasmic reticulum, trans-Golgi network, early/recycling endosomes, and lipid rafts, respectively. We found that intracellularly, wild-type neprilysin and all the chimeras showed equivalent Abeta40-degrading activities. Abeta40 was more effectively cleared than Abeta42, and this tendency was greater for intracellular Abeta than for extracellular Abeta. Wild-type and trans-Golgi network- targeted ST-NEP cleared more intracellular Abeta42 than the other chimeras. Wild-type neprilysin cleared extracellular Abeta more effectively than any of the chimeras, among which endoplasmic reticulum-targeted Sec12-NEP was the least effective. These observations indicate that different intracellular compartments may be involved in the metabolism of distinct pools of Abeta (Abeta40 and Abeta42) to be retained or recycled intracellularly and to be secreted extracellularly, and that the endogenous targeting signal in wildtype neprilysin is well optimized for the overall neuronal clearance of Abeta.	RIKEN Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan	RIKEN	Saido, TC (corresponding author), RIKEN Brain Sci Inst, Lab Proteolyt Neurosci, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	saido@brain.riken.go.jp	Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903				ALMEIDA CG, 2003, 6678 SOC NEUR; Angelisova P, 1999, BLOOD, V93, P1437, DOI 10.1182/blood.V93.4.1437a; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; BARNES K, 1993, NEUROSCIENCE, V53, P1073, DOI 10.1016/0306-4522(93)90490-7; Buxbaum JD, 1998, J NEUROSCI, V18, P9629; Cailler F, 1998, BBA-BIOMEMBRANES, V1415, P1, DOI 10.1016/S0005-2736(98)00167-9; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; DeMattos RB, 2002, P NATL ACAD SCI USA, V99, P10843, DOI 10.1073/pnas.162228299; DEVAULT A, 1988, J BIOL CHEM, V263, P4033; Echeverria V, 2002, MOL NEUROBIOL, V26, P299, DOI 10.1385/MN:26:2-3:299; Eckman EA, 2003, J BIOL CHEM, V278, P2081, DOI 10.1074/jbc.C200642200; Fagan AM, 2002, NEUROBIOL DIS, V9, P305, DOI 10.1006/nbdi.2002.0483; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Fukami S, 2002, NEUROSCI RES, V43, P39, DOI 10.1016/S0168-0102(02)00015-9; Hama E, 2001, J BIOCHEM-TOKYO, V130, P721, DOI 10.1093/oxfordjournals.jbchem.a003040; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Holtzman DM, 2000, ANN NEUROL, V47, P739, DOI 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; Iwata N, 2004, J NEUROSCI, V24, P991, DOI 10.1523/JNEUROSCI.4792-03.2004; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Iwata N, 2002, J NEUROSCI RES, V70, P493, DOI 10.1002/jnr.10390; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Kakio A, 2002, BIOCHEMISTRY-US, V41, P7385, DOI 10.1021/bi0255874; Kanemitsu H, 2003, NEUROSCI LETT, V350, P113, DOI 10.1016/S0304-3940(03)00898-X; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Ling Y, 2003, INT J BIOCHEM CELL B, V35, P1505, DOI 10.1016/S1357-2725(03)00133-X; MARCEL D, 1990, J NEUROSCI, V10, P2804; MATSUBARA E, 1995, J BIOL CHEM, V270, P7563, DOI 10.1074/jbc.270.13.7563; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; NUKINA N, 1983, P JPN ACAD B-PHYS, V59, P284, DOI 10.2183/pjab.59.284; Saido T.C., 2003, ABETA METABOLISM ALZ, P61; Saido T. C., 2000, NEUROSCI NEWS, V3, P52; SAITO T, 2003, SCI AGING KNOWLEDGE, pPE1; Saria A, 1997, NEUROSCI LETT, V234, P27, DOI 10.1016/S0304-3940(97)00660-5; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; Schmitz A, 2004, TRAFFIC, V5, P89, DOI 10.1111/j.1600-0854.2004.00159.x; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shie FS, 2003, NEUROREPORT, V14, P123, DOI 10.1097/00001756-200301200-00023; Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Takaki Y, 2000, J BIOCHEM-TOKYO, V128, P897, DOI 10.1093/oxfordjournals.jbchem.a022839; West AE, 1997, J NEUROSCI, V17, P6038; Wirths O, 2001, NEUROSCI LETT, V306, P116, DOI 10.1016/S0304-3940(01)01876-6; Wolozin B, 2001, P NATL ACAD SCI USA, V98, P5371, DOI 10.1073/pnas.101123198; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; Yasojima K, 2001, NEUROSCI LETT, V297, P97, DOI 10.1016/S0304-3940(00)01675-X; Yasojima K, 2001, BRAIN RES, V919, P115, DOI 10.1016/S0006-8993(01)03008-6	50	45	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30259	30264		10.1074/jbc.M401891200	http://dx.doi.org/10.1074/jbc.M401891200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15100223	hybrid			2022-12-25	WOS:000222531900050
J	Seidel, B; Braeg, S; Adler, G; Wedlich, D; Menke, A				Seidel, B; Braeg, S; Adler, G; Wedlich, D; Menke, A			E- and N-cadherin differ with respect to their associated p120(ctn) isoforms and their ability to suppress invasive growth in pancreatic cancer cells	ONCOGENE			English	Article						pancreatic cancer; E-cadherin; N-cadherin; p120(ctn) isoforms; tyrosine phosphorylation	MEMBRANE-PROXIMAL REGION; LYMPH-NODE METASTASIS; CYTOPLASMIC DOMAIN; P120 CATENIN; TYROSINE PHOSPHORYLATION; ADHESION ACTIVITY; ALPHA-CATENIN; BETA-CATENIN; V-SRC; DISTINCT MECHANISMS	E-cadherin functions as suppressor of invasion in epithelial cells and its loss is described in many invasive carcinomas. In some tumours, the disappearance of E-cadherin has been correlated with upregulation of other classical cadherins, such as N- or P-cadherin. To analyse the different cellular functions of cadherin molecules, we stably expressed E-cadherin or N-cadherin in the E- and N-cadherin-deficient pancreatic tumour cell line MIA PaCa-2. Only E-cadherin was able to induce a mesenchymal-epithelial transition and suppressed invasion of MIA PaCa-2 cells. Furthermore, only re-expression of E-cadherin resulted in an upregulation of alpha- and beta-catenin mRNAs and protein concentrations. Ectopically expressed N-cadherin failed to assemble cadherin/catenin Adhesion complexes and failed to inhibit invasion. Analysis of p12(ctn), which was associated with both cadherins, demonstrated that E-cadherin was linked to a shorter isoform of p120(ctn). In contrast, N-cadherin was associated with the long, 120 kDa p120(ctn) isoforms. In addition, p120(ctn) connected with N-cadherin was phosphorylated at tyrosine residues, whereas the isoform linked to E-cadherin was not phosphorylated. Thus, the differences between E- and N-cadherin in recruiting different phosphorylated isoforms of p120(ctn) to the membrane might be responsible for the inability of N-cadherin to replace E-cadherin as suppressor of invasion in pancreatic carcinoma cells.	Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Karlsruhe, Inst Zool 2, D-76131 Karlsruhe, Germany	Ulm University; Helmholtz Association; Karlsruhe Institute of Technology	Menke, A (corresponding author), Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany.	andre.menke@medizin.uni-ulm.de						Aho S, 2002, J CELL SCI, V115, P1391; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Birchmeier C, 1996, ACTA ANAT, V156, P217; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Bruns Christiane J., 1999, Neoplasia (New York), V1, P50, DOI 10.1038/sj.neo.7900005; Chen HY, 1997, J CELL SCI, V110, P345; Christofori G, 2003, EMBO J, V22, P2318, DOI 10.1093/emboj/cdg228; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; Finnemann S, 1997, J BIOL CHEM, V272, P11856, DOI 10.1074/jbc.272.18.11856; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Giehl K, 2000, ONCOGENE, V19, P2930, DOI 10.1038/sj.onc.1203612; Grosheva I, 2001, J CELL SCI, V114, P695; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Jaggi M, 2002, CELL COMMUN ADHES, V9, P103, DOI 10.1080/15419060214150; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Karayiannakis AJ, 2001, ANTICANCER RES, V21, P4127; Karayiannakis AJ, 1998, ANTICANCER RES, V18, P4177; Keilhack H, 2000, J BIOL CHEM, V275, P26376, DOI 10.1074/jbc.M001315200; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kern S, 2001, CANCER RES, V61, P4923; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; Lowy AM, 2002, SURGERY, V132, P141, DOI 10.1067/msy.2002.125168; Mareel M, 1997, J CELL PHYSIOL, V173, P271, DOI 10.1002/(SICI)1097-4652(199711)173:2<271::AID-JCP34>3.0.CO;2-G; Menke A, 2001, CANCER RES, V61, P3508; Menke A, 1997, GASTROENTEROLOGY, V113, P295, DOI 10.1016/S0016-5085(97)70107-0; Mo YY, 1996, CANCER RES, V56, P2633; Montonen O, 2001, J HISTOCHEM CYTOCHEM, V49, P1487, DOI 10.1177/002215540104901202; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Ozawa M, 2003, J BIOL CHEM, V278, P46014, DOI 10.1074/jbc.M307778200; Ozawa M, 2001, J CELL SCI, V114, P503; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; Papkoff J, 1997, J BIOL CHEM, V272, P4536; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; PIGNATELLI M, 1994, J PATHOL, V174, P243, DOI 10.1002/path.1711740403; POSTON GJ, 1991, GUT, V32, P800, DOI 10.1136/gut.32.7.800; RASBRIDGE SA, 1993, J PATHOL, V169, P245, DOI 10.1002/path.1711690211; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Tran NL, 1999, AM J PATHOL, V155, P787, DOI 10.1016/S0002-9440(10)65177-2; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Weinel RJ, 1996, INT J PANCREATOL, V19, P25; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156	60	66	70	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5532	5542		10.1038/sj.onc.1207718	http://dx.doi.org/10.1038/sj.onc.1207718			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15107817				2022-12-25	WOS:000222588400013
J	Bjorklund, M; Heikkila, P; Koivunen, E				Bjorklund, M; Heikkila, P; Koivunen, E			Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR RECEPTOR; UROKINASE RECEPTOR; SURFACE ASSOCIATION; FIBROSARCOMA CELLS; EPITHELIAL-CELLS; GELATINASE-B; INTEGRIN; ANGIOGENESIS; BINDING; VITRONECTIN	Migration of invasive cells appears to be dependent on matrix metalloproteinases (MMPs) anchored on the cell surface through integrins. We have previously demonstrated an interaction between the integrin alpha-subunit I domain and the catalytic domain of MMP-9. We now show that there is also an interaction between the integrin beta subunit and MMP-9. Using phage display, we have developed MMP-9 inhibitors that bind either to the MMP-9 catalytic domain, the collagen binding domain, or the C-terminal hemopexin-like domain. The C-terminal domain-binding peptide mimics an activation epitope in the stalk of the integrin beta chain and inhibits the association of MMP-9 C-terminal domain with alpha(V)beta(5) integrin. Unlike other MMP-9 binding peptides, it does not directly inhibit catalytic activity of MMP-9, but still prevents proenzyme activation and cell migration in vitro and tumor xenograft growth in vivo. We also find an association between MMP-9 and urokinase-plasminogen activator receptor and find that urokinase-plasminogen activator receptor is cleaved by MMP-9. Collectively, we have defined molecular details for several interactions mediated by the different MMP-9 domains.	Viikki Bioctr, Dept Biol & Environm Sci, Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Oral & Maxillofacial Dis, Inst Dent, FIN-00014 Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital	Koivunen, E (corresponding author), Viikki Bioctr, Dept Biol & Environm Sci, Viikinkaari 5D, Helsinki, Finland.	erkki.koivunen@helsinki.fi	Bjorklund, Mikael/AAA-2894-2020; Björklund, Mikael/D-3362-2009	Björklund, Mikael/0000-0002-2176-681X; Koivunen, Erkki/0000-0002-6443-9595				Andolfo A, 2002, THROMB HAEMOSTASIS, V88, P298; Bannikov GA, 2002, J BIOL CHEM, V277, P16022, DOI 10.1074/jbc.M110931200; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; BEHRENDT N, 1993, METHOD ENZYMOL, V223, P207; Bjorklund M, 2003, COMB CHEM HIGH T SCR, V6, P29; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Carriero MV, 1999, CANCER RES, V59, P5307; Cha HJ, 2002, J MOL BIOL, V320, P1065, DOI 10.1016/S0022-2836(02)00558-2; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Festuccia C, 2002, EXP CELL RES, V280, P1, DOI 10.1006/excr.2002.5609; Filardo EJ, 1996, J CELL SCI, V109, P1615; Fridman R, 2003, CANCER METAST REV, V22, P153, DOI 10.1023/A:1023091214123; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Ginestra A, 1997, J BIOL CHEM, V272, P17216, DOI 10.1074/jbc.272.27.17216; Giordano RJ, 2001, NAT MED, V7, P1249, DOI 10.1038/nm1101-1249; Hamano Y, 2003, CANCER CELL, V3, P589, DOI 10.1016/S1535-6108(03)00133-8; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Koivunen E, 1999, METH MOL B, V129, P3; Koivunen E, 2001, J CELL BIOL, V153, P905, DOI 10.1083/jcb.153.5.905; Koolwijk P, 2001, BLOOD, V97, P3123, DOI 10.1182/blood.V97.10.3123; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Montuori N, 2002, J BIOL CHEM, V277, P46932, DOI 10.1074/jbc.M207494200; Myohanen H, 2001, BIOL CHEM, V382, P1563, DOI 10.1515/BC.2001.191; Nyberg P, 2003, J BIOL CHEM, V278, P22404, DOI 10.1074/jbc.M210325200; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; PASQUALINI R, 1993, J CELL SCI, V105, P101; Pedersen TL, 2000, ULTRASTRUCT PATHOL, V24, P175, DOI 10.1080/01913120050132912; Pozzi A, 2002, ONCOGENE, V21, P272, DOI 10.1038/sj.onc.1205045; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; ROLLI M, 2003, P NATL ACAD SCI USA, V21, P21; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; Sorsa T, 1997, J BIOL CHEM, V272, P21067, DOI 10.1074/jbc.272.34.21067; Stefanidakis M, 2004, J IMMUNOL, V172, P7060, DOI 10.4049/jimmunol.172.11.7060; Stefanidakis M, 2003, J BIOL CHEM, V278, P34674, DOI 10.1074/jbc.M302288200; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Stricker TP, 2001, J BIOL CHEM, V276, P29375, DOI 10.1074/jbc.M102217200; Tamura Y, 1998, J MED CHEM, V41, P640, DOI 10.1021/jm9707582; Toth M, 1997, CANCER RES, V57, P3159; Trexler M, 2003, J BIOL CHEM, V278, P12241, DOI 10.1074/jbc.M210116200; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WANG XQ, 2003, J BIOL CHEM, V30, P30; Xue W, 1997, CANCER RES, V57, P1682; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	48	66	69	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29589	29597		10.1074/jbc.M401601200	http://dx.doi.org/10.1074/jbc.M401601200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123665	hybrid			2022-12-25	WOS:000222445300094
J	Chang, CJ; Freeman, DJ; Wu, H				Chang, CJ; Freeman, DJ; Wu, H			PTEN regulates Mdm2 expression through the P1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53 PROTEIN; PROSTATE-CANCER; GENE; DEGRADATION; ONCOPROTEIN; CHEMOTHERAPY; TRANSACTIVATION; UBIQUITINATION; AMPLIFICATION; ACTIVATION	MDM2 is an oncoprotein that controls tumorigenesis through both p53-dependent and - independent mechanisms. Mdm2 mRNA level is transcriptionally regulated by p53 in response to stress such as DNA damage, and its protein level and subcellular localization are post-translationally modulated by the AKT serine/threonine kinase. Previous studies showed that PTEN, a dual specificity phosphatase that antagonizes phosphatidylinositol 3-kinase/ AKT signaling, is capable of blocking MDM2 nuclear translocation and destabilizing the MDM2 protein. Results from our current study demonstrate an additional role for PTEN in regulating MDM2 functions; PTEN modulates Mdm2 transcription and isoform selection by negatively regulating its P1 promoter. In Pten-null cell lines and prostate cancer tissues, Mdm2 P1 promoter activity is up-regulated, resulting in increased L-Mdm2 expression and enhanced p90(MDM2) isoform production. Furthermore, PTEN controls Mdm2 P1 promoter activity through its lipid phosphatase activity, independent of p53. Thus, our results provide a novel mechanism for PTEN in controlling MDM2 oncoprotein functions.	Univ Calif Los Angeles, Sch Med, Howard Hughes Med Inst, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Wu, H (corresponding author), Univ Calif Los Angeles, Sch Med, Howard Hughes Med Inst, Dept Mol & Med Pharmacol, CHS 23-214,650 CE Young Dr S, Los Angeles, CA 90095 USA.	hwu@mednet.ucla.edu		Chang, Chunju/0000-0003-2887-9603	NATIONAL CANCER INSTITUTE [R01CA107166, P50CA092131, U01CA084128, P50CA086306] Funding Source: NIH RePORTER; NCI NIH HHS [CA092131, CA-86306, CA84128, CA107166] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Jones SN, 1996, GENE, V175, P209, DOI 10.1016/0378-1119(96)00151-5; JUVEN T, 1993, ONCOGENE, V8, P3411; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Leite KRM, 2001, MODERN PATHOL, V14, P428, DOI 10.1038/modpathol.3880330; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Mendrysa SM, 2001, GENE, V264, P139, DOI 10.1016/S0378-1119(00)00589-8; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Perry ME, 2000, J BIOL CHEM, V275, P5733, DOI 10.1074/jbc.275.8.5733; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Saucedo LJ, 1999, J BIOL CHEM, V274, P8161, DOI 10.1074/jbc.274.12.8161; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Vargas DA, 2003, ADV CANCER RES, V89, P1, DOI 10.1016/S0065-230X(03)01001-7; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhang Z, 2003, P NATL ACAD SCI USA, V100, P11636, DOI 10.1073/pnas.1934692100; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou MX, 2003, CANCER RES, V63, P6357	36	76	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29841	29848		10.1074/jbc.M401488200	http://dx.doi.org/10.1074/jbc.M401488200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15090541	hybrid			2022-12-25	WOS:000222445300121
J	Christodoulou, J; Malmendal, A; Harper, JF; Chazin, WJ				Christodoulou, J; Malmendal, A; Harper, JF; Chazin, WJ			Evidence for differing roles for each lobe of the calmodulin-like domain in a calcium-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-ANGLE SCATTERING; INTRAMOLECULAR BINDING; TARGET RECOGNITION; NMR-SPECTROSCOPY; CA2+ BINDING; ACTIVATION; PEPTIDE; AFFINITY; COMPLEX; N-15	Calcium-dependent protein kinases (CDPKs) are structurally unique Ser/Thr kinases found in plants and certain protozoa. They are distinguished by a calmodulin-like regulatory apparatus (calmodulin-like domain (CaM-LD)) that is joined via a junction (J) region to the C-terminal end of the kinase catalytic domain. Like CaM, the CaM-LD is composed of two globular EF structural domains (N-lobe,C-lobe), each containing a pair of Ca2+ binding sites. Spectroscopic analysis shows that the CaM-LD is comprised of helical elements, but the isolated CaM-LD does not form a conformationally homogeneous tertiary structure in the absence of Ca2+. The addition of substoichiometric amounts of Ca2+ is sufficient to stabilize the C-terminal lobe in a construct containing J and CaM-LD (JC) but not in the CaM-LD alone. Moreover, as J is titrated into Ca2+-saturated CaM-LD, interactions are stronger with the C-lobe than the N-lobe of the CaM-LD. Measurements of Ca2+ affinity for JC reveal two cooperatively interacting high affinity binding sites (K-d,(mean) = 5.6 nM at 20 mM KCl) in the C-lobe and two weaker sites in the N-lobe (K-d,K-mean = 110 nM at 20 mM KCl). The corresponding Ca2+ binding constants in the isolated CaM-LD are lower by more than 2 orders of magnitude, which indicates that the J region has an essential role in stabilizing the structure of the CDPK regulatory apparatus. The large differential affinity between the two domains together with previous studies on a plasmodium CDPK (Zhao, Y., Pokutta, S., Maurer, P., Lindt, M., Franklin, R. M., and Kappes, B. (1994) Biochemistry 33, 3714-3721) suggests a model whereby even at normally low cytosolic levels of Ca2+, the C-lobe interacts with the junction, but the kinase remains in an autoinhibited state. Activation then occurs when Ca2+ levels rise to fill the two weaker affinity binding sites in the N-lobe, thereby triggering a conformational change that leads to release of the autoinhibitory region.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Vanderbilt Univ, Ctr Struct Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Phys, Nashville, TN 37232 USA; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Aarhus Univ, Dept Chem, NMR Ctr, DK-8000 Aarhus, Denmark; Aarhus Univ, Dept Chem, Interdisciplinary Nanosci Ctr, DK-8000 Aarhus, Denmark	Scripps Research Institute; Scripps Research Institute; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Cambridge; Aarhus University; Aarhus University	Harper, JF (corresponding author), Scripps Res Inst, Dept Cell Biol, BCC 283, La Jolla, CA 92037 USA.	harper@scripps.edu	Malmendal, Anders/F-1198-2017; Malmendal, Anders/S-2014-2019	Malmendal, Anders/0000-0002-8413-9717; Malmendal, Anders/0000-0002-8413-9717; Christodoulou, John/0000-0002-6710-3843	NIGMS NIH HHS [GM 40120] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040120, R29GM040120] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andre I, 2002, ANAL BIOCHEM, V305, P195, DOI 10.1006/abio.2002.5661; Bayley PM, 1996, PROTEIN SCI, V5, P1215, DOI 10.1002/pro.5560050701; Biekofsky RR, 1998, BIOCHEMISTRY-US, V37, P7617, DOI 10.1021/bi9800449; Cheng SH, 2002, PLANT PHYSIOL, V129, P469, DOI 10.1104/pp.005645; Christodoulou J, 2002, J BIOMOL NMR, V23, P249, DOI 10.1023/A:1019875822571; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Elshorst B, 1999, BIOCHEMISTRY-US, V38, P12320, DOI 10.1021/bi9908235; Fersht A., 1999, STRUCTURE MECH PROTE; Harmon AC, 2000, TRENDS PLANT SCI, V5, P154, DOI 10.1016/S1360-1385(00)01577-6; HARPER JF, 1993, BIOCHEMISTRY-US, V32, P3282, DOI 10.1021/bi00064a010; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; Hrabak EM, 2003, PLANT PHYSIOL, V132, P666, DOI 10.1104/pp.102.011999; Huang JF, 1996, BIOCHEMISTRY-US, V35, P13222, DOI 10.1021/bi960498a; Krueger JK, 1998, BIOCHEMISTRY-US, V37, P17810, DOI 10.1021/bi981656w; Lee JY, 1998, BIOCHEMISTRY-US, V37, P6801, DOI 10.1021/bi980062q; LI MX, 1995, BIOCHEMISTRY-US, V34, P8330, DOI 10.1021/bi00026a014; LINSE S, 1991, BIOCHEMISTRY-US, V30, P154, DOI 10.1021/bi00215a023; LINSE S, 1991, J BIOL CHEM, V266, P8050; Martin SR, 1996, BIOCHEMISTRY-US, V35, P3508, DOI 10.1021/bi952522a; MARTIN SR, 1986, BIOCHEM J, V238, P485, DOI 10.1042/bj2380485; MAUNE JF, 1992, BIOCHEMISTRY-US, V31, P7779, DOI 10.1021/bi00149a006; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P12800, DOI 10.1021/bi00209a011; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Peersen OB, 1997, PROTEIN SCI, V6, P794; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Rutschmann F, 2002, PLANT PHYSIOL, V129, P156, DOI 10.1104/pp.000869; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; SUEN KL, 1991, PLANT MOL BIOL, V17, P581, DOI 10.1007/BF00037045; Vitart V, 2000, BIOCHEMISTRY-US, V39, P4004, DOI 10.1021/bi992373m; Weljie AM, 2003, PROTEIN SCI, V12, P228, DOI 10.1110/ps.0226203; Weljie AM, 2000, PROTEINS, V39, P343, DOI 10.1002/(SICI)1097-0134(20000601)39:4<343::AID-PROT70>3.0.CO;2-2; Yoo BC, 1996, BIOCHEMISTRY-US, V35, P12029, DOI 10.1021/bi9606612; ZHAO Y, 1992, EUR J BIOCHEM, V207, P305, DOI 10.1111/j.1432-1033.1992.tb17051.x; ZHAO Y, 1994, BIOCHEMISTRY-US, V33, P3714, DOI 10.1021/bi00178a031	35	53	59	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29092	29100		10.1074/jbc.M401297200	http://dx.doi.org/10.1074/jbc.M401297200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15126505	hybrid			2022-12-25	WOS:000222445300033
J	Hu, YF; Fang, XH; Dunham, SM; Prada, C; Stachowiak, EK; Stachowiak, MK				Hu, YF; Fang, XH; Dunham, SM; Prada, C; Stachowiak, EK; Stachowiak, MK			90-kDa ribosomal S6 kinase is a direct target for the nuclear fibroblast growth factor receptor 1 (FGFR1) - Role in FGFR1 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PATHWAY MEDIATES ACTIVATION; ADRENAL-MEDULLARY CELLS; ADAPTER PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; ANGIOTENSIN-II; SH2 DOMAIN; GENE; IDENTIFICATION; PHOSPHORYLATION	Fibroblast growth factor receptor 1 (FGFR1) is a transmembrane protein capable of transducing stimulation by secreted FGFs. In addition, newly synthesized FGFR1 enters the nucleus in response to cellular stimulation and during development. Nuclear FGFR1 can transactivate CRE (cAMP responsive element), activate CRE-binding protein (CREB)-binding protein (CBP) and gene activities causing cellular growth and differentiation. Here, a yeast two-hybrid assay was performed to identify FGFR1-binding proteins and the mechanism of nuclear FGFR1 action. Ten FGFR1-binding proteins were identified. Among the proteins detected with the intracellular FGFR1 domain was a 90-kDa ribosomal S6 kinase (RSK1), a regulator of CREB, CBP, and histone phosphorylation. FGFR1 bound to the N-terminal region of RSK1. The FGFR1-RSK1 interaction was confirmed by co-immunoprecipitation and colocalization in the nucleus and cytoplasm of mammalian cells. Predominantly nuclear FGFR1-RSK1 interaction was observed in the rat brain during neurogenesis and in cAMP-stimulated cultured neural cells. In TE671 cells, transfected FGFR1 colocalized and coimmunoprecipitated, almost exclusively, with nuclear RSK1. Nuclear RSK1 kinase activity and RSK1 activation of CREB were enhanced by transfected FGFR1. In contrast, kinase-deleted FGFR1 (TK-), which did not bind to RSK1 failed to stimulate nuclear RSK1 activity or RSK1 activation of CREB. Kinase inactive FGFR1 (K514A) bound effectively to nuclear RSK1, but it failed to stimulate RSK1. Thus, active FGFR1 kinase regulates the functions of nuclear RSK1. The interaction of nuclear FGFR1 with pluripotent RSK1 offers a new mechanism through which FGFR1 may control fundamental cellular processes.	SUNY Buffalo, Dept Pathol & Anat Sci, Mol & Struct Neurobiol & Gene Therapy Program, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Stachowiak, MK (corresponding author), SUNY Buffalo, Dept Pathol & Anat Sci, Mol & Struct Neurobiol & Gene Therapy Program, Buffalo, NY 14214 USA.	mks4@buffalo.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS043621] Funding Source: NIH RePORTER; NINDS NIH HHS [NS43621-01HL-49376] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bell SM, 1997, GENOMICS, V44, P163, DOI 10.1006/geno.1997.4849; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BEREZNEY R, 1981, BIOCHEMISTRY-US, V20, P4995, DOI 10.1021/bi00520a028; BEREZNEY R, 1977, J CELL BIOL, V73, P616, DOI 10.1083/jcb.73.3.616; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Buzanska L, 2002, J CELL SCI, V115, P2131; CARPENTER CL, 1996, BIOCH BIOPHYS ACTA R, V1288, P11; Cavet ME, 2003, J BIOL CHEM, V278, P18376, DOI 10.1074/jbc.M208475200; Chen M, 1998, J BIOL CHEM, V273, P25171, DOI 10.1074/jbc.273.39.25171; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; HANNEKEN A, 1995, J CELL BIOL, V128, P1221, DOI 10.1083/jcb.128.6.1221; Horbinski C, 2002, J NEUROCHEM, V80, P54, DOI 10.1046/j.0022-3042.2001.00657.x; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; Kikuno R, 1999, DNA Res, V6, P197, DOI 10.1093/dnares/6.3.197; Kim KW, 2001, J BIOL CHEM, V276, P13186, DOI 10.1074/jbc.M008092200; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Meijerink PHS, 1998, EUR J BIOCHEM, V254, P297, DOI 10.1046/j.1432-1327.1998.2540297.x; Merienne K, 2001, MOL CELL BIOL, V21, P7089, DOI 10.1128/MCB.21.20.7089-7096.2001; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Myers JM, 2003, J CELL BIOCHEM, V88, P1273, DOI 10.1002/jcb.10476; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; OLAH Z, 1991, EXP BRAIN RES, V84, P403; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Peng H, 2002, J NEUROCHEM, V81, P506, DOI 10.1046/j.1471-4159.2002.00833.x; Peng H, 2001, MOL BIOL CELL, V12, P449, DOI 10.1091/mbc.12.2.449; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Reilly JF, 2000, J BIOL CHEM, V275, P7771, DOI 10.1074/jbc.275.11.7771; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; Richards SA, 2001, MOL CELL BIOL, V21, P7470, DOI 10.1128/MCB.21.21.7470-7480.2001; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROEBROEK AJM, 1993, J BIOL CHEM, V268, P13439; Roebroek AJM, 1996, GENOMICS, V32, P191, DOI 10.1006/geno.1996.0105; Romisch K, 1999, J CELL SCI, V112, P4185; Ryan PJ, 1998, BIOCHEM BIOPH RES CO, V244, P763, DOI 10.1006/bbrc.1998.8326; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Somanathan S, 2003, J CELL BIOCHEM, V90, P856, DOI 10.1002/jcb.10672; Stachowiak EK, 2003, J NEUROCHEM, V84, P1296, DOI 10.1046/j.1471-4159.2003.01624.x; Stachowiak EK, 1997, ONCOGENE, V14, P2201, DOI 10.1038/sj.onc.1201057; Stachowiak MK, 1996, MOL BIOL CELL, V7, P1299, DOI 10.1091/mbc.7.8.1299; Stachowiak MK, 2003, J CELL BIOCHEM, V90, P662, DOI 10.1002/jcb.10606; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; Stachowiak MK, 1997, MOL NEUROBIOL, V15, P257, DOI 10.1007/BF02740663; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; Tang J, 1999, P NATL ACAD SCI USA, V96, P9775, DOI 10.1073/pnas.96.17.9775; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; Wu JM, 2002, J BIOL CHEM, V277, P42669, DOI 10.1074/jbc.M205501200; Wu M, 2000, GENE DEV, V14, P301; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; Zini N, 1996, HISTOCHEM CELL BIOL, V106, P457, DOI 10.1007/BF02473307	67	44	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29325	29335		10.1074/jbc.M311144200	http://dx.doi.org/10.1074/jbc.M311144200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15117958	hybrid			2022-12-25	WOS:000222445300063
J	Rundle, DR; Gorbsky, G; Tsiokas, L				Rundle, DR; Gorbsky, G; Tsiokas, L			PKD2 interacts and co-localizes with mDia1 to mitotic spindles of dividing cells - Role of mDia1 in PKD2 localization to mitotic spindles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC KIDNEY-DISEASE; ACTIN CYTOSKELETON; MAMMALIAN HOMOLOG; GENE-PRODUCT; SMALL GTPASE; 2ND GENE; PROTEIN; RHO; ACTIVATION; DROSOPHILA	Mutations in pkd2 result in the type 2 form of autosomal dominant polycystic kidney disease, which accounts for similar to15% of all cases of the disease. PKD2, the protein product of pkd2, belongs to the transient receptor potential superfamily of cation channels, and it can function as a mechanosensitive channel in the primary cilium of kidney cells, an intracellular Ca2+ release channel in the endoplasmic reticulum, and/or a nonselective cation channel in the plasma membrane. We have identified mDia1/Drf1 ( mammalian Diaphanous or Diaphanous-related formin 1 protein) as a PKD2-interacting protein by yeast two-hybrid screen. mDia1 is a member of the RhoA GTPase-binding formin homology protein family that participates in cytoskeletal organization, cytokinesis, and signal transduction. We show that mDia1 and PKD2 interact in native and in transfected cells, and binding is mediated by the cytoplasmic C terminus of PKD2 binding to the mDia1 N terminus. The interaction is more prevalent in dividing cells in which endogenous PKD2 and mDia1 co-localize to the mitotic spindles. RNA interference experiments reveal that endogenous mDia1 knockdown in HeLa cells results in the loss of PKD2 from mitotic spindles and alters intracellular Ca2+ release. Our results suggest that mDia1 facilitates the movement of PKD2 to a centralized position during cell division and has a positive effect on intracellular Ca2+ release during mitosis. This may be important to ensure equal segregation of PKD2 to the daughter cell to maintain a necessary level of channel activity. Alternatively, PKD2 channel activity may be important in the cell division process or in cell fate decisions after division.	Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Mol Cell & Dev Biol Res Program, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation	Tsiokas, L (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.	leonidas-tsiokas@ouhsc.edu		Gorbsky, Gary/0000-0003-3076-4725; Tsiokas, Leonidas/0000-0002-3659-1813	NIDDK NIH HHS [DK59599] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK059599, R01DK059599] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Arnould T, 1999, MOL CELL BIOL, V19, P3423; Barr MM, 2001, CURR BIOL, V11, P1341, DOI 10.1016/S0960-9822(01)00423-7; BELL PE, 1988, KIDNEY INT, V34, P683, DOI 10.1038/ki.1988.233; Bhunia AK, 2002, CELL, V109, P157, DOI 10.1016/S0092-8674(02)00716-X; Boletta A, 2003, TRENDS CELL BIOL, V13, P484, DOI 10.1016/S0962-8924(03)00169-7; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; CARONE FA, 1995, KIDNEY INT, V47, P861, DOI 10.1038/ki.1995.129; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; Fujiwara T, 2000, BIOCHEM BIOPH RES CO, V271, P626, DOI 10.1006/bbrc.2000.2671; Gachet Y, 1999, J CELL SCI, V112, P1257; Geneste O, 2002, J CELL BIOL, V157, P831, DOI 10.1083/jcb.200203126; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; Kato T, 2001, J CELL SCI, V114, P775; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Kramer J, 2003, NAT CELL BIOL, V5, P261, DOI 10.1038/ncb944; Krebs A, 2001, J CELL SCI, V114, P3663; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Lin FM, 2003, P NATL ACAD SCI USA, V100, P5286, DOI 10.1073/pnas.0836980100; Lubarsky B, 2003, CELL, V112, P19, DOI 10.1016/S0092-8674(02)01283-7; Luo Y, 2003, MOL CELL BIOL, V23, P2600, DOI 10.1128/MCB.23.7.2600-2607.2003; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Ma R, 2003, J BIOL CHEM, V278, P52763, DOI 10.1074/jbc.M309610200; MARTINEZ JR, 1995, DM-DIS MON, V41, P698, DOI 10.1016/S0011-5029(05)80007-0; Mitsuyama F, 2001, INT J DEV BIOL, V45, P861; Mitsuyama F, 1999, DEV BIOL, V214, P160, DOI 10.1006/dbio.1999.9416; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Mollinari C, 2002, J CELL BIOL, V157, P1175, DOI 10.1083/jcb.200111052; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Otto EA, 2003, NAT GENET, V34, P413, DOI 10.1038/ng1217; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Pazour GJ, 2002, CURR BIOL, V12, pR378, DOI 10.1016/S0960-9822(02)00877-1; Peng J, 2003, CURR BIOL, V13, P534, DOI 10.1016/S0960-9822(03)00170-2; PETERS DJM, 1993, NAT GENET, V5, P359, DOI 10.1038/ng1293-359; Petersen J, 1998, J CELL BIOL, V141, P1217, DOI 10.1083/jcb.141.5.1217; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Scheffers MS, 2002, HUM MOL GENET, V11, P59, DOI 10.1093/hmg/11.1.59; Shimada A, 2004, MOL CELL, V13, P511, DOI 10.1016/S1097-2765(04)00059-0; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; Vicente-Manzanares M, 2003, J IMMUNOL, V171, P1023, DOI 10.4049/jimmunol.171.2.1023; VOLPI M, 1988, J CELL BIOL, V107, P2533, DOI 10.1083/jcb.107.6.2533; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25	50	88	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29728	29739		10.1074/jbc.M400544200	http://dx.doi.org/10.1074/jbc.M400544200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123714	hybrid			2022-12-25	WOS:000222445300109
J	Sherrill, KW; Byrd, MP; Van Eden, ME; Lloyd, RE				Sherrill, KW; Byrd, MP; Van Eden, ME; Lloyd, RE			BCL-2 translation is mediated via internal ribosome entry during cell stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRES-DEPENDENT TRANSLATION; EUKARYOTIC MESSENGER-RNAS; 5' NONTRANSLATED REGION; ENDOPLASMIC-RETICULUM; FOLLICULAR LYMPHOMA; APOPTOSIS PROTEIN; X-L; EXPRESSION; GENE; INITIATION	The cellular response to stress involves a rapid inhibition of cap-dependent translation via multiple mechanisms, yet some translation persists. This residual translation may include proteins critical to the cellular stress response. BCL-2 is a key inhibitor of intrinsic apoptotic signaling. Its primary transcript contains a 1.45-kb 5'-untranslated region (UTR) including 10 upstream AUGs that may restrict translation initiation via cap-dependent ribosome scanning. Thus, we hypothesized that this 5'-UTR may contain an internal ribosome entry site (IRES) that facilitates BCL-2 translation, particularly during cell stress. Here we show that the BCL-2 5'-UTR demonstrated IRES activity both when translated in vitro and also when m(7)G-capped and polyadenylated mRNA was transiently transfected into 293T cells. The activity of this IRES in unstressed cells was similar to6% the strength of the hepatitis C virus IRES but was induced 3-6-fold in a dose-dependent manner following short term treatment with either etoposide or sodium arsenite. Thus, the IRES-mediated translation of BCL-2 may enable the cell to replenish levels of this critical protein during cell stress, when cap-dependent translation is repressed, thereby maintaining the balance between pro-and anti-apoptotic BCL-2 family members in the cell and preventing unwarranted induction of apoptosis.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine	Lloyd, RE (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Rm 860E,1 Baylor Plaza, Houston, TX 77030 USA.	rlloyd@bcm.tmc.edu			NIAID NIH HHS [T32 AI0747-7/10, AI 50237] Funding Source: Medline; NIGMS NIH HHS [GM 59803] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000747, R01AI050237, R56AI050237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059803] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; BORNER C, 1994, BIOCHEM CELL BIOL, V72, P463, DOI 10.1139/o94-062; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHLEQDESCHAMPS CM, 1993, BLOOD, V81, P293; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; GLISSON BS, 1984, BIOCHIM BIOPHYS ACTA, V783, P74, DOI 10.1016/0167-4781(84)90080-0; Greider C, 2002, ONCOGENE, V21, P7765, DOI 10.1038/sj.onc.1205928; Haile S, 2003, RNA, V9, P1491, DOI 10.1261/rna.5940703; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Harigai M, 1996, ONCOGENE, V12, P1369; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Honda M, 2000, GASTROENTEROLOGY, V118, P152, DOI 10.1016/S0016-5085(00)70424-0; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Jiang M, 2003, GENE DEV, V17, P832, DOI 10.1101/gad.252603; Kim YK, 2003, RNA, V9, P599, DOI 10.1261/rna.2185603; Koev G, 2002, VIROLOGY, V297, P195, DOI 10.1006/viro.2002.1455; Koh DCY, 2003, J BIOL CHEM, V278, P20565, DOI 10.1074/jbc.M210212200; KONDO E, 1992, BLOOD, V80, P2044; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Liang Y, 2002, MOL PHARMACOL, V61, P142, DOI 10.1124/mol.61.1.142; Lin H, 2000, EXP CELL RES, V261, P180, DOI 10.1006/excr.2000.5036; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; Nevins TA, 2003, J BIOL CHEM, V278, P3572, DOI 10.1074/jbc.M206781200; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Ravazoula P, 2002, ANTICANCER RES, V22, P1799; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Saleh H A, 1999, Pathol Oncol Res, V5, P273, DOI 10.1053/paor.1999.0231; SATO T, 1994, GENE, V140, P291, DOI 10.1016/0378-1119(94)90561-4; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Sheikh MS, 1999, ONCOGENE, V18, P6121, DOI 10.1038/sj.onc.1203131; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Subkhankulova T, 2001, BIOCHEM J, V359, P183, DOI 10.1042/0264-6021:3590183; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Tu YP, 1996, BLOOD, V88, P1805, DOI 10.1182/blood.V88.5.1805.bloodjournal8851805; Van Eden ME, 2004, RNA, V10, P720, DOI 10.1261/rna.5225204; Van Eden ME, 2004, RNA, V10, P469, DOI 10.1261/rna.5156804; van Hoof A, 2002, CURR BIOL, V12, pR285, DOI 10.1016/S0960-9822(02)00802-3; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Warnakulasuriyarachchi D, 2004, J BIOL CHEM, V279, P17148, DOI 10.1074/jbc.M308737200; Yamagiwa Y, 2004, CANCER RES, V64, P1293, DOI 10.1158/0008-5472.CAN-03-2517; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	60	117	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29066	29074		10.1074/jbc.M402727200	http://dx.doi.org/10.1074/jbc.M402727200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123638	hybrid			2022-12-25	WOS:000222445300030
J	Yuzawa, S; Ogura, K; Horiuchi, M; Suzuki, NN; Fujioka, Y; Kataoka, M; Sumimoto, H; Inagaki, F				Yuzawa, S; Ogura, K; Horiuchi, M; Suzuki, NN; Fujioka, Y; Kataoka, M; Sumimoto, H; Inagaki, F			Solution structure of the tandem src homology 3 domains of p47(phox) in an autoinhibited form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGOCYTE NADPH OXIDASE; RESIDUAL DIPOLAR COUPLINGS; RESPIRATORY BURST OXIDASE; PHOSPHORYLATION-INDUCED ACTIVATION; PROTEIN-KINASE-C; SH3 DOMAIN; BIOLOGICAL MACROMOLECULES; CONFORMATIONAL-CHANGE; MOLECULAR-MECHANISM; INTERTWINED DIMER	The phagocyte NADPH oxidase is a multisubunit enzyme responsible for the generation of superoxide anions (O-2(radical anion)) that kill invading microorganisms. p47(phox) is a cytosolic subunit of the phagocyte NADPH oxidase, which plays a crucial role in the assembly of the activated NADPH oxidase complex. The molecular shapes of the p47(phox) tandem SH3 domains either with or without a polybasic/autoinhibitory region (PBR/AIR) at the C terminus were studied using small angle x-ray scattering. The tandem SH3 domains with PBR/AIR formed a compact globular structure, whereas the tandem SH3 domains lacking the PBR/AIR formed an elongated structure. Alignment anisotropy analysis by NMR based on the residual dipolar couplings revealed that the tandem SH3 domains with PBR/AIR were in good agreement with a globular module corresponding to the split half of the intertwisted dimer in crystalline state. The structure of the globular module was elucidated to represent a solution structure of the tandem SH3 domain in the autoinhibited form, where the PBR/AIR bundled the tandem SH3 domains and the linker forming a closed structure. Once PBR/AIR is released by phosphorylation, rearrangements of the SH3 domains may occur, forming an open structure that binds to the cytoplasmic proline-rich region of membrane-bound p22(phox).	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Sapporo, Hokkaido 0600812, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan; Nara Inst Sci & Technol, Dept Mat Sci, Nara 6300101, Japan; Kyushu Univ, Med Inst Bioregulat, Fukuoka 8128582, Japan	Hokkaido University; Japan Science & Technology Agency (JST); Nara Institute of Science & Technology; Kyushu University	Inagaki, F (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Sapporo, Hokkaido 0600812, Japan.	finagaki@pharm.hokudai.ac.jp	Kataoka, Mikio/H-4402-2011; Horiuchi, Masataka/D-5491-2012; Noda, Nobuo/P-1397-2015	Fujioka, Yuko/0000-0002-6905-0669; Yuzawa, Satoru/0000-0002-1031-5781; Noda, Nobuo/0000-0002-6940-8069				Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cornilescu G, 1998, J AM CHEM SOC, V120, P6836, DOI 10.1021/ja9812610; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Delano W. L., 2001, PYMOL MOL GRAPHICS S; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; Dosset P, 2001, J BIOMOL NMR, V20, P223, DOI 10.1023/A:1011206132740; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fischer MWF, 1999, BIOCHEMISTRY-US, V38, P9013, DOI 10.1021/bi9905213; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; Guinier A., 1955, SMALL ANGLE SCATTERI; Hoyal CR, 2003, P NATL ACAD SCI USA, V100, P5130, DOI 10.1073/pnas.1031526100; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; KATAOKA M, 1989, P NATL ACAD SCI USA, V86, P6944, DOI 10.1073/pnas.86.18.6944; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; Kishan KVR, 2001, PROTEIN SCI, V10, P1046, DOI 10.1110/ps.50401; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; Lambeth JD, 2000, J BIOCHEM MOL BIOL, V33, P427; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; Mal TK, 2002, BIOCHEMISTRY-US, V41, P12899, DOI 10.1021/bi0264162; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Ottiger M, 1998, J BIOMOL NMR, V12, P361, DOI 10.1023/A:1008366116644; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Skrynnikov NR, 2000, J MOL BIOL, V295, P1265, DOI 10.1006/jmbi.1999.3430; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Swain SD, 1997, J BIOL CHEM, V272, P29502, DOI 10.1074/jbc.272.47.29502; Takeya R, 2003, MOL CELLS, V16, P271; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111; UEKI T, 1985, BIOPHYS CHEM, V23, P115, DOI 10.1016/0301-4622(85)80069-7; Ulmer TS, 2002, STRUCTURE, V10, P901, DOI 10.1016/S0969-2126(02)00781-5; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; Wiesner S, 2002, J MOL BIOL, V324, P807, DOI 10.1016/S0022-2836(02)01145-2; Yuzawa S, 2004, GENES CELLS, V9, P443, DOI 10.1111/j.1356-9597.2004.00733.x; Yuzawa S, 2003, ACTA CRYSTALLOGR D, V59, P1479, DOI 10.1107/S0907444903011636; Yuzawa S, 2001, J MOL BIOL, V306, P527, DOI 10.1006/jmbi.2000.4396; YUZAWA S, 2004, IN PRESS J BIOMOL NM	48	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29752	29760		10.1074/jbc.M401457200	http://dx.doi.org/10.1074/jbc.M401457200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123602	hybrid			2022-12-25	WOS:000222445300111
J	Iida, S; Hirota, T; Morisaki, T; Marumoto, T; Hara, T; Kuninaka, S; Honda, S; Kosai, K; Kawasuji, M; Pallas, DC; Saya, H				Iida, S; Hirota, T; Morisaki, T; Marumoto, T; Hara, T; Kuninaka, S; Honda, S; Kosai, K; Kawasuji, M; Pallas, DC; Saya, H			Tumor suppressor WARTS ensures genomic integrity by regulating both mitotic progression and G(1) tetraploidy checkpoint function	ONCOGENE			English	Article						cell cycle; mitotic kinase; spindle checkpoint; p53; polyploid	HUMAN HOMOLOG; SPINDLE; KINASE; CELLS; TRANSITION; ANAPHASE; MITOSIS; LATS1; CENTROSOME; METAPHASE	Defects in chromosomes or mitotic spindles activate the spindle checkpoint, resulting in cell cycle arrest at prometaphase. The prolonged activation of spindle checkpoint generally leads to mitotic exit without segregation after a transient mitotic arrest and the consequent formation of tetraploid G(1) cells. These tetraploid cells are usually blocked to enter the subsequent S phase by the activation of p53/pRb pathway, which is referred to as the G(1) tetraploidy checkpoint. A human homologue of the Drosophila warts tumor suppressor, WARTS, is an evolutionarily conserved serine-threonine kinase and implicated in development of human tumors. We previously showed that WARTS plays a crucial role in controlling mitotic progression by forming a regulatory complex with zyxin, a regulator of actin. lament assembly, on mitotic apparatus. However, when WARTS is activated during cell cycle and how the loss of WARTS function leads to tumorigenesis have not been elucidated. Here we show that WARTS is activated during mitosis in mammalian cells, and that overexpression of a kinase-inactive WARTS in Rat1 fibroblasts significantly induced mitotic delay. This delay resulted from prolonged activation of the spindle assembly checkpoint and was frequently followed by mitotic slippage and the development of tetraploidy. The resulting tetraploid cells then abrogated the G(1) tetraploidy checkpoint and entered S phase to achieve a DNA content of 8N. This impairment of G(1) tetraploidy checkpoint was caused as a consequence of failure to induce p53 expression by expressing a kinase-inactive WARTS. WARTS thus plays a critical role in maintenance of ploidy through its actions in both mitotic progression and the G(1) tetraploidy checkpoint.	Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Cardiovasc Surg, Kumamoto 8608556, Japan; Kurume Univ, Cognit & Mol Res Inst Brain Dis, Div Gene Therapy & Regenerat Med, Kurume, Fukuoka 8300011, Japan; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA	Kumamoto University; Kumamoto University; Kurume University; Emory University; Emory University	Saya, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Saya, Hideyuki/J-4325-2013; Kuninaka, Shinji/J-7158-2013		NCI NIH HHS [R01 CA057327] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hisaoka M, 2002, LAB INVEST, V82, P1427, DOI 10.1097/01.LAB.0000032381.68634.CA; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; SHACKNEY SE, 1989, CANCER RES, V49, P3344; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; TOYN JH, 1994, EMBO J, V13, P1103, DOI 10.1002/j.1460-2075.1994.tb06359.x; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Xia H, 2002, ONCOGENE, V21, P1233, DOI 10.1038/sj.onc.1205174; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	24	70	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5266	5274		10.1038/sj.onc.1207623	http://dx.doi.org/10.1038/sj.onc.1207623			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15122335				2022-12-25	WOS:000222491600002
J	Aoyama, T; Okamoto, T; Nagayama, S; Nishijo, K; Ishibe, T; Yasura, K; Nakayama, T; Nakamura, T; Toguchida, J				Aoyama, T; Okamoto, T; Nagayama, S; Nishijo, K; Ishibe, T; Yasura, K; Nakayama, T; Nakamura, T; Toguchida, J			Methylation in the core-promoter region of the chondromodulin-I gene determines the cell-specific expression by regulating the binding of transcriptional activator Sp3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESENCHYMAL STEM-CELLS; OSTEOCALCIN GENE; CARTILAGE; GROWTH; DIFFERENTIATION; VITRO; HETEROGENEITY; CHONDROCYTES; CLONING; MATRIX	Transcriptional regulation of cell- and stage-specific genes is a crucial process in the development of mesenchymal tissues. Here we have investigated the regulatory mechanism of the expression of the chondromodulin-I (ChM-I) gene, one of the chondrocyte-specific genes, in osteogenic cells using osteosarcoma ( OS) cells as a model. Methylation-specific sequence analyses revealed that the extent of methylation in the core-promoter region of the ChM-I gene was correlated inversely with the expression of the ChM-I gene in OS primary tumors and cell lines. 5-Aza-deoxycytidine treatment induced the expression of the ChM-I gene in ChM-I-negative OS cell lines, and the induction of expression was associated tightly with the demethylation of cytosine at -52 (C(-52)) in the middle of an Sp1/3 binding site to which the Sp3, but not Sp1, bound. The replacement of C(-52) with methyl-cytosine or thymine abrogated Sp3 binding and also the transcription activity of the genomic fragment including C(-52). The inhibition of Sp3 expression by small interfering RNA reduced the expression of the ChM-I gene in ChM-I-positive normal chondrocytes, indicating Sp3 as a physiological transcriptional activator of the ChM-I gene. These results suggest that the methylation status of the core-promoter region is one of the mechanisms to determine the cell-specific expression of the ChM-I gene through the regulation of the binding of Sp3.	Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Orthoped Surg, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Surg Oncol, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kyoto University	Toguchida, J (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, 53 Kawahara Cho, Kyoto 6068507, Japan.	togjun@frontier.kyoto-u.ac.jp						ALI NN, 1993, BONE, V14, P847, DOI 10.1016/8756-3282(93)90314-Z; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; Bouwman P, 2000, EMBO J, V19, P655, DOI 10.1093/emboj/19.4.655; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; de Crombrugghe B, 2000, MATRIX BIOL, V19, P389, DOI 10.1016/S0945-053X(00)00094-9; DORFMAN HD, 1995, CANCER, V75, P203, DOI 10.1002/1097-0142(19950101)75:1+<203::AID-CNCR2820751308>3.0.CO;2-V; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Gerstenfeld LC, 1996, LAB INVEST, V74, P895; Gollner H, 2001, MECH DEVELOP, V106, P77, DOI 10.1016/S0925-4773(01)00420-8; HAGAN G, 1994, EMBO J, V13, P3843; Hayami T, 1999, FEBS LETT, V458, P436, DOI 10.1016/S0014-5793(99)01201-6; HIRAKI Y, 1991, BIOCHEM BIOPH RES CO, V175, P971, DOI 10.1016/0006-291X(91)91660-5; Hiraki Y, 1997, J BIOL CHEM, V272, P32419, DOI 10.1074/jbc.272.51.32419; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; ISHII S, 1982, INT ORTHOP, V6, P215; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KalffSuske M, 1996, GENOMICS, V37, P410, DOI 10.1006/geno.1996.0582; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Lock GSH, 1998, T CAN SOC MECH ENG, V22, P207; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Muraglia A, 2000, J CELL SCI, V113, P1161; Murakami H, 2002, CANCER LETT, V182, P203, DOI 10.1016/S0304-3835(02)00096-4; Okamoto T, 2002, BIOCHEM BIOPH RES CO, V295, P354, DOI 10.1016/S0006-291X(02)00661-7; PROKOP DJ, 1997, SCIENCE, V276, P71; Ryhanen S, 1997, J CELL BIOCHEM, V66, P404, DOI 10.1002/(SICI)1097-4644(19970901)66:3<404::AID-JCB12>3.0.CO;2-E; Shukunami C, 1999, INT J DEV BIOL, V43, P39; Shukunami C, 1998, BIOCHEM BIOPH RES CO, V249, P885, DOI 10.1006/bbrc.1998.9233; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Unni KK, 1996, DAHLINS BONE TUMORS; Villagra A, 2002, J CELL BIOCHEM, V85, P112, DOI 10.1002/jcb.10113; Yanagihara I, 2000, J BONE MINER RES, V15, P421, DOI 10.1359/jbmr.2000.15.3.421; Yusa N, 2000, J LEUKOCYTE BIOL, V68, P772	35	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28789	28797		10.1074/jbc.M401273200	http://dx.doi.org/10.1074/jbc.M401273200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15107420	hybrid			2022-12-25	WOS:000222265400117
J	Frirdich, E; Vinogradov, E; Whitfield, C				Frirdich, E; Vinogradov, E; Whitfield, C			Biosynthesis of a novel 3-deoxy-D-manno-oct-2-ulosonic acid-containing outer core oligosaccharide in the lipopolysaccharide of Klebsiella pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI LIPOPOLYSACCHARIDE; EXTRACELLULAR TOXIC COMPLEX; UDP-N-ACETYLGLUCOSAMINE; GENE-CLUSTER; INNER-CORE; N-ACETYLGLUCOSAMINE-1-PHOSPHATE URIDYLTRANSFERASE; GLUCOSAMINE-1-PHOSPHATE ACETYLTRANSFERASE; LIPOOLIGOSACCHARIDE BIOSYNTHESIS; SALMONELLA-ENTERICA; HAEMOPHILUS-DUCREYI	The core oligosaccharide region of Klebsiella pneumoniae lipopolysaccharide contains some novel features that distinguish it from the corresponding lipopolysaccharide region in other members of the Enterobacteriaceae family, such as Escherichia coli and Salmonella. The conserved Klebsiella outer core contains the unusual trisaccharide 3-deoxy-D-manno-oct-2-ulosonic acid (Kdo)-(2,6)- GlcN-(1,4)- GalUA. In general, Kdo residues are normally found in the inner core, but in K. pneumoniae, this Kdo residue provides the ligation site for O polysaccharide. The outer core Kdo residue can also be non-stoichiometrically substituted with an L-glycero-D-manno-heptopyranose (Hep) residue, another component more frequently found in the inner core. To understand the genetics and biosynthesis of core oligosaccharide synthesis in Klebsiella, the gene products involved in the addition of the outer core GlcN (WabH), Kdo (WabI), and Hep (WabJ) residues as well as the inner core HepIII residue ( WaaQ) were identified. Non-polar mutations were created in each of the genes, and the resulting mutant lipopolysaccharide was analyzed by mass spectrometry. The in vitro glycosyltransferase activity of WabI and WabH was verified. WabI transferred a Kdo residue from CMP-Kdo onto the acceptor lipopolysaccharide. The activated precursor required for GlcN addition has not been identified. However, lysates overexpressing WabH were able to transfer a GlcNAc residue from UDP-GlcNAc onto the acceptor GalUA residue in the outer core.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Guelph; National Research Council Canada	Whitfield, C (corresponding author), Univ Guelph, Dept Microbiol, 50 Stone Rd E, Guelph, ON N1G 2W1, Canada.	cwhitfie@uoguelph.ca		Vinogradov, Evgeny/0000-0002-5364-1376				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BINOTTO J, 1991, CAN J MICROBIOL, V37, P474, DOI 10.1139/m91-078; Campbell GRO, 2002, P NATL ACAD SCI USA, V99, P3938, DOI 10.1073/pnas.062425699; DOMENICO P, 1985, CAN J MICROBIOL, V31, P472, DOI 10.1139/m85-088; Enderle PJ, 1998, BIOTECHNIQUES, V25, P954, DOI 10.2144/98256bm05; Finan TM, 2001, P NATL ACAD SCI USA, V98, P9889, DOI 10.1073/pnas.161294698; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; Frirdich E, 2003, J BACTERIOL, V185, P1659, DOI 10.1128/JB.185.5.1659-1671.2003; Fry BN, 1998, MICROBIOL-SGM, V144, P2049, DOI 10.1099/00221287-144-8-2049; GABRIEL O, 1982, METHOD ENZYMOL, V83, P332; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; Gehring AM, 1996, BIOCHEMISTRY-US, V35, P579, DOI 10.1021/bi952275a; Gibson BW, 1997, J BACTERIOL, V179, P5062, DOI 10.1128/jb.179.16.5062-5071.1997; Gronow S, 2000, EUR J BIOCHEM, V267, P6602, DOI 10.1046/j.1432-1327.2000.01754.x; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Heinrichs DE, 1998, J BIOL CHEM, V273, P8849, DOI 10.1074/jbc.273.15.8849; Heinrichs DE, 1998, J BIOL CHEM, V273, P29497, DOI 10.1074/jbc.273.45.29497; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; Holst O, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P115; Holst O, 2000, METH MOL B, V145, P345; HOLST O, 1994, EUR J BIOCHEM, V222, P183, DOI 10.1111/j.1432-1033.1994.tb18856.x; HULL RA, 1981, INFECT IMMUN, V33, P933, DOI 10.1128/IAI.33.3.933-938.1981; Izquierdo L, 2003, J BACTERIOL, V185, P7213, DOI 10.1128/JB.185.24.7213-7221.2003; Izquierdo L, 2002, MICROBIOL-SGM, V148, P3485, DOI 10.1099/00221287-148-11-3485; Izquierdo L, 2002, FEMS MICROBIOL LETT, V216, P211, DOI 10.1016/S0378-1097(02)01027-3; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; KAST P, 1994, GENE, V138, P109, DOI 10.1016/0378-1119(94)90790-0; KORNFELD S, 1962, J BIOL CHEM, V237, P3052; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MENARD R, 1993, J BACTERIOL, V175, P5899; MENGINLECREULX D, 1994, J BACTERIOL, V176, P5788, DOI 10.1128/JB.176.18.5788-5795.1994; MENGINLECREULX D, 1993, J BACTERIOL, V175, P6150, DOI 10.1128/JB.175.19.6150-6157.1993; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Niedziela T, 2002, J BIOL CHEM, V277, P11653, DOI 10.1074/jbc.M111885200; Noah C, 2001, J ENDOTOXIN RES, V7, P25, DOI 10.1179/096805101101532495; Olsthoorn MMA, 1999, J MASS SPECTROM, V34, P622, DOI 10.1002/(SICI)1096-9888(199906)34:6<622::AID-JMS814>3.3.CO;2-M; Podschun R, 1998, CLIN MICROBIOL REV, V11, P589, DOI 10.1128/CMR.11.4.589; Pompeo F, 2001, J BIOL CHEM, V276, P3833, DOI 10.1074/jbc.M004788200; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rahn A, 2003, MOL MICROBIOL, V47, P1045, DOI 10.1046/j.1365-2958.2003.03354.x; RAY PH, 1982, METHOD ENZYMOL, V83, P535; Regue M, 2004, INFECT IMMUN, V72, P54, DOI 10.1128/IAI.72.1.54-61.2004; Regue M, 2001, J BACTERIOL, V183, P3564, DOI 10.1128/JB.183.12.3564-3573.2001; Reuhs BL, 1998, APPL ENVIRON MICROB, V64, P4930; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SLAUCH JM, 1995, INFECT IMMUN, V63, P437, DOI 10.1128/IAI.63.2.437-441.1995; Stevens MK, 1997, INFECT IMMUN, V65, P651, DOI 10.1128/IAI.65.2.651-660.1997; STRAUS DC, 1985, INFECT IMMUN, V50, P787, DOI 10.1128/IAI.50.3.787-795.1985; STRAUS DC, 1987, INFECT IMMUN, V55, P44, DOI 10.1128/IAI.55.1.44-48.1987; Susskind M, 1998, J BIOL CHEM, V273, P7006, DOI 10.1074/jbc.273.12.7006; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Tullius MV, 2002, INFECT IMMUN, V70, P2853, DOI 10.1128/IAI.70.6.2853-2861.2002; Vinogradov E, 2002, J BIOL CHEM, V277, P25070, DOI 10.1074/jbc.M202683200; Vinogradov E, 2001, CARBOHYD RES, V335, P291, DOI 10.1016/S0008-6215(01)00216-6; Wang L, 2001, GENE, V270, P231, DOI 10.1016/S0378-1119(01)00471-1; WHITFIELD C, 1991, J BACTERIOL, V173, P1420, DOI 10.1128/jb.173.4.1420-1431.1991; Yethon JA, 1998, J BIOL CHEM, V273, P26310, DOI 10.1074/jbc.273.41.26310	58	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27928	27940		10.1074/jbc.M402549200	http://dx.doi.org/10.1074/jbc.M402549200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15090547	hybrid			2022-12-25	WOS:000222265400014
J	Harrison, CA; Gray, PC; Fischer, WH; Donaldson, C; Choe, S; Vale, W				Harrison, CA; Gray, PC; Fischer, WH; Donaldson, C; Choe, S; Vale, W			An activin mutant with disrupted ALK4 binding blocks signaling via type II receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; VERTEBRATE DEVELOPMENT; BIOLOGICAL-ACTIVITY; BETA; IDENTIFICATION; COMPLEX; CELL; FOLLISTATIN; INHIBIN; LIGAND	Activins control many physiologic and pathophysiologic processes in multiple tissues and, like other TGF-beta superfamily members, signal via type II (ActRII/IIB) and type I (ALK4) receptor serine kinases. ActRII/IIB are promiscuous receptors known to bind at least a dozen TGF-beta superfamily ligands including activins, myostatin, several BMPs, and nodal. Here we utilize a new screening procedure to rapidly identify activin-A mutants with loss of signaling activity. Our goal was to identify activin-A mutants able to bind ActRII but unable to bind ALK4 and which would be, therefore, candidate type II activin receptor antagonists. Using the structure of BMP-2 bound to its type I receptor (ALK3) as a guide, we introduced mutations in the context of the inhibin betaA cDNA and assessed the signaling activity of the resulting mutant proteins. We identified several mutants in the finger ( M91E, I105E, M108A) and wrist ( activin A/activin C chimera, S60P, I63P) regions of activin-A with reduced signaling activity. Of these the M108A mutant displayed the lowest signaling activity while retaining wild-type-like affinity for ActRII. Unlike wild-type activin-A, the M108A mutant was unable to form a cross-linked complex with ALK4 in the presence of ActRII indicating that its ability to bind ALK4 was disrupted. This data suggested that the M108A mutant might be capable of modulating signaling of activin and related ligands. Indeed, the M108A mutant antagonized activin-A and myostatin, but not TGF-beta, signaling in 293T cells, indicating it may be generally capable of blocking ligands that signal via ActRII/IIB.	Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA	Salk Institute; Salk Institute	Vale, W (corresponding author), Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	vale@salk.edu		Harrison, Craig/0000-0003-1059-3682	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD013527] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 13527] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Attisano L, 1996, MOL CELL BIOL, V16, P1066; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BILEZIKJIAN LM, 1993, ENDOCRINOLOGY, V133, P2554, DOI 10.1210/en.133.6.2554; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; Chabicovsky M, 2003, ENDOCRINOLOGY, V144, P3497, DOI 10.1210/en.2003-0388; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Coerver KA, 1996, MOL ENDOCRINOL, V10, P534, DOI 10.1210/me.10.5.534; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; Gray PC, 2000, J BIOL CHEM, V275, P3206, DOI 10.1074/jbc.275.5.3206; Greenwald J, 2003, MOL CELL, V11, P605, DOI 10.1016/S1097-2765(03)00094-7; Harrison CA, 2003, J BIOL CHEM, V278, P21129, DOI 10.1074/jbc.M302015200; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; HUSKENHINDI P, 1994, J BIOL CHEM, V269, P19380; Kirsch T, 2000, EMBO J, V19, P3314, DOI 10.1093/emboj/19.13.3314; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; Lebrun JJ, 1997, MOL CELL BIOL, V17, P1682, DOI 10.1128/MCB.17.3.1682; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Mellor SL, 2000, J CLIN ENDOCR METAB, V85, P4851, DOI 10.1210/jc.85.12.4851; Mittl PRE, 1996, PROTEIN SCI, V5, P1261, DOI 10.1002/pro.5560050705; Pernasetti F, 2001, ENDOCRINOLOGY, V142, P2284, DOI 10.1210/en.142.6.2284; Phillips DJ, 2000, BIOESSAYS, V22, P689, DOI 10.1002/1521-1878(200008)22:8<689::AID-BIES2>3.0.CO;2-5; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; Scheufler C, 1999, J MOL BIOL, V287, P103, DOI 10.1006/jmbi.1999.2590; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Takabe K, 2003, HEPATOLOGY, V38, P1107, DOI 10.1053/jhep.2003.50483; Thompson TB, 2003, EMBO J, V22, P1555, DOI 10.1093/emboj/cdg156; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; VALE W, 1988, LAUR HORM C REC PROG, P1; Vitt UA, 2001, MOL ENDOCRINOL, V15, P681, DOI 10.1210/me.15.5.681; Wankell M, 2003, ANN NY ACAD SCI, V995, P48, DOI 10.1111/j.1749-6632.2003.tb03209.x; Wankell M, 2001, EMBO J, V20, P5361, DOI 10.1093/emboj/20.19.5361; Wuytens G, 1999, J BIOL CHEM, V274, P9821, DOI 10.1074/jbc.274.14.9821; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002; Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525	39	58	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28036	28044		10.1074/jbc.M402782200	http://dx.doi.org/10.1074/jbc.M402782200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123686	hybrid			2022-12-25	WOS:000222265400027
J	Shibata, R; Ouchi, N; Kihara, S; Sato, K; Funahashi, T; Walsh, K				Shibata, R; Ouchi, N; Kihara, S; Sato, K; Funahashi, T; Walsh, K			Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of AMP-activated protein kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; PLASMA-PROTEIN; INSULIN-RESISTANCE; METABOLIC SYNDROME; GLUCOSE-TRANSPORT; ENDOTHELIAL-CELLS; GLOBULAR DOMAIN; GROWTH-FACTOR; NITRIC-OXIDE; ASSOCIATION	Obesity is a risk factor for the development of cardiovascular diseases that are associated with impaired angiogenesis. Adiponectin is an adipocyte-specific adipocytokine with anti-atherogenic and anti-diabetic properties, and its plasma levels are reduced in association with obesity-linked diseases. Here, we investigated whether adiponectin regulates angiogenesis in response to tissue ischemia using adiponectin knock-out ( KO) mice. Angiogenic repair of ischemic hind limbs was impaired in adiponectin-KO mice compared with wildtype (WT) mice as evaluated by laser Doppler flow method and capillary density analyses. Adenovirus-mediated supplement of adiponectin accelerated angiogenic repair in both adiponectin-KO and WT mice. Intramuscular injection of an adenovirus encoding dominant-negative AMP-activated kinase diminished the improvement in limb perfusion seen in WT mice and abolished the adiponectin-induced enhancement of perfusion. These data indicate that adiponectin can function to stimulate angiogenesis in response to ischemic stress by promoting AMP-activated kinase signaling. Therefore, adiponectin may be useful in the treatment for obesity-related vascular deficiency diseases.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan	Boston University; Osaka University	Walsh, K (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,W611, Boston, MA 02118 USA.	kxwalsh@bu.edu	OUCHI, Noriyuki/I-7306-2014		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015052, R01AG017241, R37AG015052] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 40197] Funding Source: Medline; NIA NIH HHS [AG 15052, AG 17241] Funding Source: Medline; PHS HHS [HE 23641] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Arita Y, 2002, CIRCULATION, V105, P2893, DOI 10.1161/01.CIR.0000018622.84402.FF; Blazquez C, 2001, FEBS LETT, V489, P149, DOI 10.1016/S0014-5793(01)02089-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brakenhielm E, 2004, P NATL ACAD SCI USA, V101, P2476, DOI 10.1073/pnas.0308671100; Chen H, 2003, J BIOL CHEM, V278, P45021, DOI 10.1074/jbc.M307878200; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Grundy SM, 2004, ARTERIOSCL THROM VAS, V24, pE13, DOI 10.1161/01.ATV.0000111245.75752.C6; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kobayashi H, 2004, CIRC RES, V94, pE27, DOI 10.1161/01.RES.0000119921.86460.37; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; Kumada M, 2003, ARTERIOSCL THROM VAS, V23, P85, DOI 10.1161/01.ATV.0000048856.22331.50; LIND L, 1993, AM HEART J, V125, P1494, DOI 10.1016/0002-8703(93)90446-G; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Matsuda M, 2002, J BIOL CHEM, V277, P37487, DOI 10.1074/jbc.M206083200; Matsuzawa Y, 2004, ARTERIOSCL THROM VAS, V24, P29, DOI 10.1161/01.ATV.0000099786.99623.EF; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Noon JP, 1997, J CLIN INVEST, V99, P1873, DOI 10.1172/JCI119354; Okamoto Y, 2002, CIRCULATION, V106, P2767, DOI 10.1161/01.CIR.0000042707.50032.19; Ouchi N, 2003, HYPERTENSION, V42, P231, DOI 10.1161/01.HYP.0000083488.67550.B8; Ouchi N, 2004, J BIOL CHEM, V279, P1304, DOI 10.1074/jbc.M310389200; Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057; Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473; Sata M, 2004, HYPERTENSION, V43, P1214, DOI 10.1161/01.HYP.0000126186.29571.41; Takahashi A, 2002, MOL CELL BIOL, V22, P4803, DOI 10.1128/MCB.22.13.4803-4814.2002; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; WARLEY A, 1995, DIABETOLOGIA, V38, P413, DOI 10.1007/s001250050300; Wu XD, 2003, DIABETES, V52, P1355, DOI 10.2337/diabetes.52.6.1355; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; YILMAZ MB, 2003, INT J OBESITY, V27, P15451	34	260	295	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28670	28674		10.1074/jbc.M402558200	http://dx.doi.org/10.1074/jbc.M402558200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123726	hybrid			2022-12-25	WOS:000222265400103
J	Yasumoto, K; Watabe, H; Valencia, JC; Kushimoto, T; Kobayashi, T; Appella, E; Hearing, VJ				Yasumoto, K; Watabe, H; Valencia, JC; Kushimoto, T; Kobayashi, T; Appella, E; Hearing, VJ			Epitope mapping of the melanosomal matrix protein gp100 (PMEL17) - Rapid processing in the endoplasmic reticulum and glycosylation in the early Golgi compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERMANSKY-PUDLAK-SYNDROME; ANTIBODIES NKI-BETEB; VESICLE FORMATION; MELANOMA-CELLS; ANTIGEN GENES; TYROSINASE; TRAFFICKING; EXPRESSION; MODEL; CORTICOSTERONE	Melanosomes, specific organelles produced only by melanocytes, undergo a unique maturation process that involves their transition form amorphous rounded vesicles to fibrillar ellipsoid organelles, during which they move from the perinuclear to the distal areas of the cells. This depends upon the trafficking and processing of gp100 (also known as Pmel17 and the silver protein), a protein of great interest, because it elicits immune responses in melanoma patients but in which specific function(s) remains elusive. In this study, we have used biochemical and immunochemical approaches to more critically assess the synthesis, processing, glycosylation, and trafficking of gp100. We now report that gp100 is processed and sorted in a manner distinct from other melanosomal proteins (such as tyrosinase, Tyrp1 and Dct) and is predominantly delivered directly to immature melanosomes following its rapid processing in the endoplasmic reticulum and cis-Golgi. Following its arrival, gp100 is cleaved at the amino and at the carboxyl termini in a series of specific steps that result in the reorganization of immature melanosomes to the fibrillar mature melanosomes. Once this structural reorganization occurs, melanogenic enzymes begin to be targeted to the melanosomes, which are then competent to synthesize melanin pigment.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Japan Sci & Technol Corp, Exploratory Res Adv Technol, Nagoya, Aichi 4600012, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Japan Science & Technology Agency (JST)	Hearing, VJ (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Rm 1B25, Bethesda, MD 20892 USA.	hearingv@nih.gov		Kobayashi, Takeshi/0000-0002-4372-5285; Yasumoto, Ken-ichi/0000-0002-8090-1161	DIVISION OF BASIC SCIENCES - NCI [Z01BC009100] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMOWITZ J, 1978, ARCH DERMATOL RES, V261, P303, DOI 10.1007/BF00455300; ABRAMOWITZ J, 1979, ARCH DERMATOL RES, V264, P293, DOI 10.1007/BF00412656; ADEMA GJ, 1993, AM J PATHOL, V143, P1579; ADEMA GJ, 1994, J BIOL CHEM, V269, P20126; Adema GJ, 1996, BRIT J CANCER, V73, P1044, DOI 10.1038/bjc.1996.202; BAKKER ABH, 1994, J EXP MED, V179, P1005, DOI 10.1084/jem.179.3.1005; Basrur V, 2003, J PROTEOME RES, V2, P69, DOI 10.1021/pr025562r; Berson JF, 2003, J CELL BIOL, V161, P521, DOI 10.1083/jcb.200302072; Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451; Bertolotto C, 1998, ONCOGENE, V16, P1665, DOI 10.1038/sj.onc.1201685; Costin GE, 2003, J CELL SCI, V116, P3203, DOI 10.1242/jcs.00598; Dell'Angelica EC, 2003, TRENDS CELL BIOL, V13, P503, DOI 10.1016/j.tcb.2003.08.001; Forslund KO, 2001, EXP CELL RES, V265, P185, DOI 10.1006/excr.2001.5173; Huizing M, 2002, PIGM CELL RES, V15, P405, DOI 10.1034/j.1600-0749.2002.02074.x; Huizing M, 2001, THROMB HAEMOSTASIS, V86, P233, DOI 10.1055/s-0037-1616221; Huizing M, 2001, MOL BIOL CELL, V12, P2075, DOI 10.1091/mbc.12.7.2075; JIMENEZ M, 1988, P NATL ACAD SCI USA, V85, P3830, DOI 10.1073/pnas.85.11.3830; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458; KOBAYASHI T, 1994, J BIOL CHEM, V269, P29198; Kushimoto T, 2003, PIGM CELL RES, V16, P237, DOI 10.1034/j.1600-0749.2003.00034.x; Kushimoto T, 2001, P NATL ACAD SCI USA, V98, P10698, DOI 10.1073/pnas.191184798; KWON BS, 1987, MOL BIOL MED, V4, P339; MARESH GA, 1994, ARCH BIOCHEM BIOPHYS, V311, P95, DOI 10.1006/abbi.1994.1213; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Nichols SE, 2003, J INVEST DERMATOL, V121, P821, DOI 10.1046/j.1523-1747.2003.12474.x; Peters EMJ, 2000, J INVEST DERMATOL, V114, P430, DOI 10.1046/j.1523-1747.2000.00913.x; Raposo G, 2002, TRAFFIC, V3, P237, DOI 10.1034/j.1600-0854.2002.030401.x; SEIJI M, 1963, ANN NY ACAD SCI, V100, P497, DOI 10.1111/j.1749-6632.1963.tb42911.x; Setaluri V, 2003, J INVEST DERMATOL, V121, P650, DOI 10.1046/j.1523-1747.2003.12500.x; Setaluri V, 2000, PIGM CELL RES, V13, P128, DOI 10.1034/j.1600-0749.2000.130302.x; Spritz RA, 2000, PIGM CELL RES, V13, P15, DOI 10.1034/j.1600-0749.2000.130104.x; Swank RT, 2000, PIGM CELL RES, V13, P59, DOI 10.1034/j.1600-0749.13.s8.12.x; Takeuchi H, 2003, CANCER RES, V63, P441; Touloukian CE, 2001, CANCER RES, V61, P8100; Toyofuku K, 2001, FASEB J, V15, P2149, DOI 10.1096/fj.01-0216com; VARKI A, 2002, ESSENTIALS GLYCOBIOL; Virador V, 2001, PIGM CELL RES, V14, P289, DOI 10.1034/j.1600-0749.2001.140410.x; Watabe H, 2004, J BIOL CHEM, V279, P7971, DOI 10.1074/jbc.M309714200	38	53	60	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28330	28338		10.1074/jbc.M401269200	http://dx.doi.org/10.1074/jbc.M401269200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15096515	hybrid			2022-12-25	WOS:000222265400065
J	Yu, MK; Moos, PJ; Cassidy, P; Wade, M; Fitzpatrick, FA				Yu, MK; Moos, PJ; Cassidy, P; Wade, M; Fitzpatrick, FA			Conditional expression of 15-lipoxygenase-1 inhibits the selenoenzyme thioredoxin reductase - Modulation of selenoproteins by lipoxygenase enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLORECTAL-CANCER CELLS; ACTIVATED RECEPTOR-GAMMA; DRUG-INDUCED APOPTOSIS; MOLECULAR TARGET; COLON-CANCER; SUICIDE INACTIVATION; ARACHIDONIC-ACID; CARCINOMA-CELLS; GENE-EXPRESSION; LINOLEIC-ACID	The selenoenzyme thioredoxin reductase regulates redox-sensitive proteins involved in inflammation and carcinogenesis, including ribonucleotide reductase, p53, NFkappaB, and others. Little is known about endogenous cellular factors that modulate thioredoxin reductase activity. Here we report that several metabolites of 15-lipoxygenase-1 inhibit purified thioredoxin reductase in vitro. 15(S)-Hydroperoxy-5,8,11-cis-13-trans-eicosatetraenoic acid, a metastable hydroperoxide generated by 15-lipoxygenase-1, and 4-hydroxy-2-nonenal, its non-enzymatic rearrangement product inhibit thioredoxin reductase with IC50 = 13 +/- 1.5 muM and 1 +/- 0.2 muM, respectively. Endogenously generated metabolites of 15-lipoxygenase- 1 also inhibit thioredoxin reductase in HEK-293 cells that harbor a 15-LOX-1 gene under the control of an inducible promoter complex. Conditional, highly selective induction of 15-lipoxygenase- 1 caused an inhibition of ribonucleotide reductase activity, cell cycle arrest in G(1), impairment of anchorage-independent growth, and accumulation of the pro-apoptotic protein BAX. All of these responses are consistent with inhibition of thioredoxin reductase via 15-lipoxygenase- 1 overexpression. In contrast, metabolites of 5-lipoxygenase were poor inhibitors of isolated thioredoxin reductase, and the overexpression of 5-lipoxygenase did not inhibit thioredoxin reductase or cause a G(1) cell cycle arrest. The influences of 15-lipoxygenase- 1 on inflammation, cell growth, and survival may be attributable, in part, to inhibition of thioredoxin reductase and several redox-sensitive processes subordinate to thioredoxin reductase.	Univ Utah Hlth Sci, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah Hlth Sci, Huntsman Canc Inst, Dept Med Chem, Salt Lake City, UT 84112 USA; Univ Utah Hlth Sci, Huntsman Canc Inst, Dept Internal Med, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; University of Utah Hospital; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; University of Utah Hospital; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; University of Utah Hospital	Fitzpatrick, FA (corresponding author), Univ Utah Hlth Sci, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA.	frank.fitzpatrick@hci.utah.edu		Moos, Philip/0000-0002-8223-442X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026730] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 26730] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Baek SJ, 2002, J PHARMACOL EXP THER, V301, P1126, DOI 10.1124/jpet.301.3.1126; BAUER KD, 1993, CLIN FLOW CYTOMETRY, P44; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; Bortuzzo C, 1996, BBA-LIPID LIPID MET, V1300, P240, DOI 10.1016/0005-2760(96)00003-3; Bosch-Morell F, 1999, FREE RADICAL BIO MED, V26, P1383, DOI 10.1016/S0891-5849(98)00335-9; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; BRYANT RW, 1982, J BIOL CHEM, V257, P6050; Burcham PC, 1998, MUTAGENESIS, V13, P287, DOI 10.1093/mutage/13.3.287; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Cenas N, 2004, J BIOL CHEM, V279, P2583, DOI 10.1074/jbc.M310292200; Chen GG, 2003, INT J CANCER, V107, P837, DOI 10.1002/ijc.11447; GARDNER HW, 1975, J AGR FOOD CHEM, V23, P129, DOI 10.1021/jf60198a012; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Hawcroft G, 2002, CARCINOGENESIS, V23, P107, DOI 10.1093/carcin/23.1.107; Hsi LC, 2001, J BIOL CHEM, V276, P34545, DOI 10.1074/jbc.M100280200; Ikawa H, 1999, CANCER RES, V59, P360; Ji C, 2001, J BIOL CHEM, V276, P18223, DOI 10.1074/jbc.M101266200; Kamitani H, 1998, J BIOL CHEM, V273, P21569, DOI 10.1074/jbc.273.34.21569; Kelavkar Uddhav, 2002, Curr Urol Rep, V3, P207, DOI 10.1007/s11934-002-0066-8; Kelavkar UP, 2000, CARCINOGENESIS, V21, P1777; Kelavkar UP, 2001, CARCINOGENESIS, V22, P1765, DOI 10.1093/carcin/22.11.1765; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Mariadason JM, 2000, CANCER RES, V60, P4561; Moos PJ, 2003, J BIOL CHEM, V278, P745, DOI 10.1074/jbc.M211134200; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; NASSAR GM, 1994, J BIOL CHEM, V269, P27631; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Nordberg J, 1998, J BIOL CHEM, V273, P10835, DOI 10.1074/jbc.273.18.10835; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Powis G, 1997, ONCOL RES, V9, P303; Profita M, 2002, J PHARMACOL EXP THER, V300, P868, DOI 10.1124/jpet.300.3.868; Saez E, 2000, P NATL ACAD SCI USA, V97, P14512, DOI 10.1073/pnas.260499497; Schneider C, 2001, J BIOL CHEM, V276, P20831, DOI 10.1074/jbc.M101821200; Shappell SB, 2001, CANCER RES, V61, P497; Shibata T, 2003, J BIOL CHEM, V278, P26046, DOI 10.1074/jbc.M303690200; Shureiqi I, 2000, J NATL CANCER I, V92, P1136, DOI 10.1093/jnci/92.14.1136; Shureiqi I, 2000, CANCER RES, V60, P6846; Shureiqi I, 1999, CARCINOGENESIS, V20, P1985, DOI 10.1093/carcin/20.10.1985; Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100; Shureiqi I, 2001, CANCER RES, V61, P6307; Song I, 2001, BIOCHEM BIOPH RES CO, V289, P869, DOI 10.1006/bbrc.2001.6071; Stewart ZA, 1999, CANCER RES, V59, P3831; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; TANG S, 2000, J BIOL CHEM, V277, P16189; Valderrama B, 2002, CHEM BIOL, V9, P555, DOI 10.1016/S1074-5521(02)00149-7; Wu G, 2001, J BIOL CHEM, V276, P19879, DOI 10.1074/jbc.M100628200; YEH YC, 1978, J BIOL CHEM, V253, P1323; Zhang ZH, 2000, GASTROENTEROLOGY, V118, P1012, DOI 10.1016/S0016-5085(00)70352-0	52	31	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28028	28035		10.1074/jbc.M313939200	http://dx.doi.org/10.1074/jbc.M313939200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123685	hybrid			2022-12-25	WOS:000222265400026
J	Pulfer, MK; Murphy, RC				Pulfer, MK; Murphy, RC			Formation of biologically active oxysterols during ozonolysis of cholesterol present in lung surfactant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; PROMOTER-BINDING PROTEIN; OZONATION PRODUCTS; REVISED MECHANISM; EPITHELIAL-CELLS; MAP KINASE; CN-TPBP; OZONE; METABOLISM; INHIBITION	Exposure of the lung to concentrations of ozone found in ambient air is known to cause toxicity to the epithelial cells of the lung. Because of the chemical reactivity of ozone, it likely reacts with target molecules in pulmonary surfactant, a lipid-rich material that lines the epithelial cells in the airways. Phospholipids containing unsaturated fatty acyl groups and cholesterol would be susceptible to attack by ozone, which may lead to the formation of cytotoxic products. Whereas free radical-derived oxidized cholesterol products have been frequently studied for their cytotoxic effects, ozonized cholesterol products have not been studied, although they could reasonably play a role in the toxicity of ozone. The reaction of ozone with cholesterol yielded a complex series of products including 3beta-hydroxy-5-oxo-5,6-secocholestan-6-al, 5-hydroperoxy-B-homo-6-oxa-cholestan-3beta,7a-diol, and 5beta,6beta-epoxycholesterol. Mass spectrometry and radioactive monitoring were used to identify the major cholesterol-derived product during the reaction of 2 ppm ozone in surfactant as 5beta,6beta-epoxycholesterol, which is only a minor product during ozonolysis of cholesterol in solution. A dose-dependent formation of 5beta,6beta-epoxycholesterol was also seen during direct exposure of intact cultured human bronchial epithelial cells (16-HBE) to ozone. Studies of the metabolism of this epoxide in lung epithelial cells yielded small amounts of the expected metabolite, cholestan-3beta,5alpha,6beta-triol, and more abundant levels of an unexpected metabolite, cholestan-6-oxo-3beta,5alpha-diol. Both 5beta,6beta-epoxycholesterol and cholestan-6-oxo-3beta,5alpha-diol were shown to be cytotoxic to cultured 16-HBE cells. A possible mechanism for cytotoxicity is the ability of these oxysterols to inhibit isoprenoid-based cholesterol biosynthesis in these cells.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Murphy, RC (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.	murphyr@njc.org			NHLBI NIH HHS [HL34303] Funding Source: Medline; NIEHS NIH HHS [ES012347] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F30ES012347] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Antonio V, 2003, BIOCHEM J, V376, P351, DOI 10.1042/BJ20030098; Ares MPS, 2000, ATHEROSCLEROSIS, V153, P23, DOI 10.1016/S0021-9150(00)00380-4; ARINGER L, 1974, J LIPID RES, V15, P389; ARIS RM, 1993, AM REV RESPIR DIS, V148, P1363, DOI 10.1164/ajrccm/148.5.1363; Awad AB, 2003, J NUTR BIOCHEM, V14, P111, DOI 10.1016/S0955-2863(02)00274-7; Azuma A, 1997, BIOL PHARM BULL, V20, P6; BAILEY PS, 1958, CHEM REV, V58, P925, DOI 10.1021/cr50023a005; BAILEY PS, 1985, J ORG CHEM, V50, P231, DOI 10.1021/jo00202a015; Balmes JR, 1996, AM J RESP CRIT CARE, V153, P904, DOI 10.1164/ajrccm.153.3.8630571; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUDZIKIEWICZ H, 1972, BIOCH APPLICATIONS M, P262; CAO J, 1995, P SOC EXP BIOL MED, V209, P195; CASEY PJ, 1992, J LIPID RES, V33, P1731; CONNOR LM, 2004, AM J PHYSIOL, V286, pL1109; Degraeve F, 2001, J BIOL CHEM, V276, P46849, DOI 10.1074/jbc.M104197200; ENDO Y, 1993, BIOCHEM BIOPH RES CO, V194, P1529, DOI 10.1006/bbrc.1993.1998; FIESER LF, 1949, J AM CHEM SOC, V71, P3938, DOI 10.1021/ja01180a016; FIESER LF, 1959, REAGENTS ORGANIC SYN, P796; Ghelli A, 2002, ARCH BIOCHEM BIOPHYS, V402, P208, DOI 10.1016/S0003-9861(02)00085-1; Goldberg MS, 2001, AM J EPIDEMIOL, V154, P817, DOI 10.1093/aje/154.9.817; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRUENERT DC, 1988, P NATL ACAD SCI USA, V85, P5951, DOI 10.1073/pnas.85.16.5951; GUMULKA J, 1983, J AM CHEM SOC, V105, P1972, DOI 10.1021/ja00345a052; HASHIMOTO Y, 1990, BIOCHEM BIOPH RES CO, V166, P1126, DOI 10.1016/0006-291X(90)90983-T; JAWORSKI K, 1988, J ORG CHEM, V53, P545, DOI 10.1021/jo00238a014; Kafoury RM, 1999, AM J RESP CRIT CARE, V160, P1934, DOI 10.1164/ajrccm.160.6.9902025; KANDUTSCH AA, 1973, J BIOL CHEM, V248, P8408; KANDUTSCH AA, 1978, LIPIDS, V13, P704, DOI 10.1007/BF02533749; KANOFSKY JR, 1995, ARCH BIOCHEM BIOPHYS, V316, P52, DOI 10.1006/abbi.1995.1009; Koken PJM, 2003, ENVIRON HEALTH PERSP, V111, P1312, DOI 10.1289/ehp.5957; Loscalzo J, 2004, NEW ENGL J MED, V350, P834, DOI 10.1056/NEJMcibr033352; Monick MM, 2003, J IMMUNOL, V171, P2625, DOI 10.4049/jimmunol.171.5.2625; O'Callaghan YC, 2001, CELL BIOL TOXICOL, V17, P127, DOI 10.1023/A:1010914306375; O'Sullivan AJ, 2003, J APPL TOXICOL, V23, P191, DOI 10.1002/jat.906; Panini SR, 2001, J LIPID RES, V42, P1678; PARYZEK Z, 1988, CAN J CHEM, V66, P2130, DOI 10.1139/v88-338; Paryzek Z, 1997, J CHEM SOC PERK T 2, P2313, DOI 10.1039/a702633a; PARYZEK Z, 1990, J CHEM SOC PERK T 1, P1222, DOI 10.1039/p19900001222; PRYOR WA, 1992, BIOCHEM BIOPH RES CO, V188, P618, DOI 10.1016/0006-291X(92)91101-U; PRYOR WA, 1994, FREE RADICAL BIO MED, V17, P451, DOI 10.1016/0891-5849(94)90172-4; PRYOR WA, 1995, FREE RADICAL BIO MED, V19, P934; Pulfer MK, 2004, J AM SOC MASS SPECTR, V15, P194, DOI 10.1016/j.jasms.2003.10.011; RAAPHORST GP, 1987, BIOCHEM PHARMACOL, V36, P2369, DOI 10.1016/0006-2952(87)90605-8; ROSCOE HG, 1971, J LIPID RES, V12, P17; SEVANIAN A, 1987, LIPIDS, V22, P627, DOI 10.1007/BF02533940; SEVANIAN A, 1979, LIPIDS, V14, P634, DOI 10.1007/BF02533449; SEVANIAN A, 1991, J LIPID RES, V32, P147; Suwabe A, 1996, ARCH BIOCHEM BIOPHYS, V327, P285, DOI 10.1006/abbi.1996.0123; Uhlson C, 2002, CHEM RES TOXICOL, V15, P896, DOI 10.1021/tx010183i; UPPU RM, 1995, ARCH BIOCHEM BIOPHYS, V319, P257, DOI 10.1006/abbi.1995.1290; van de Donk NWCJ, 2003, BLOOD, V102, P3354, DOI 10.1182/blood-2003-03-0970; WEIBEL ER, 1984, PATHWAY OXYGEN STRUC, P325; Wentworth P, 2003, SCIENCE, V302, P1053, DOI 10.1126/science.1089525	53	91	94	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26331	26338		10.1074/jbc.M403581200	http://dx.doi.org/10.1074/jbc.M403581200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15096493	hybrid			2022-12-25	WOS:000222003000052
J	Kandouz, M; Bier, A; Carystinos, GD; Alaoui-Jamali, MA; Batist, G				Kandouz, M; Bier, A; Carystinos, GD; Alaoui-Jamali, MA; Batist, G			Connexin43 pseudogene is expressed in tumor cells and inhibits growth	ONCOGENE			English	Article						Connexin43; pseudogene; transcription; translation; cancer	LIVE MAMMALIAN-CELLS; GAP-JUNCTIONS; CHROMOSOMAL LOCALIZATION; PROCESSED PSEUDOGENES; PROTEOME EVOLUTION; BREAST-CANCER; GENE FAMILY; MUTATIONS; COMMUNICATION; PROMOTER	Pseudogenes are classically thought of as nonfunctional DNA sequences due to their inability to be translated, or to produce a functional protein. Gap junctions, a multiprotein complex made of proteins called connexins, are involved in intercellular communication and are deregulated in many cancers. Connexin43 (Cx43) is the only connexin for which a pseudogene has been reported so far. The Cx43 pseudogene (PsiCx43) has all of the features of an expressed gene. We identified the presence of a PsiCx43 mRNA transcript in several cancer cell lines and in none of the normal mammary epithelial cells studied. Using an in vitro translation assay, we found that the PsiCx43 coding plasmid could be translated into a 43 kDa protein. This was further confirmed by expressing a PsiCx43-green fluorescence protein fusion protein in breast cancer MCF-7 cells. We then examined the functional significance of the PsiCx43. In both MTT growth and colony formation assays, significant growth inhibition was observed, a feature common to cells overexpressing the Cx43 gene. However, using a scrape-loading assay, we could not detect any effect on gap junctional intercellular communication. Based on our findings, PsiCx43 joins and enlarges the thus far restricted group of functionally transcribed and translated pseudogenes.	McGill Univ, Lady Davis Inst Med Res, Montreal Ctr Expt Therapeut Canc, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst Med Res, Montreal Ctr Expt Therapeut Canc, Dept Pharmacol & Therapeut, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst Med Res, Montreal Ctr Expt Therapeut Canc, Dept Expt Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University	Batist, G (corresponding author), McGill Univ, Lady Davis Inst Med Res, Montreal Ctr Expt Therapeut Canc, Dept Oncol, Montreal, PQ H3T 1E2, Canada.	gbatist@onc.jgh.mcgill.ca						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDREA JE, 1995, BIOCHEM J, V310, P835, DOI 10.1042/bj3100835; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; Boschan C, 2002, GENOMICS, V79, P387, DOI 10.1006/geno.2001.6715; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; Cai J, 1998, INT J MOL MED, V1, P273; Carystinos GD, 2001, J MAMMARY GLAND BIOL, V6, P431, DOI 10.1023/A:1014787014851; Carystinos GD, 2003, MOL PHARMACOL, V63, P821, DOI 10.1124/mol.63.4.821; CHAKRABARTI R, 1995, GENE, V153, P163, DOI 10.1016/0378-1119(94)00751-D; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; FISHMAN GI, 1991, GENOMICS, V10, P250, DOI 10.1016/0888-7543(91)90507-B; FLAGGNEWTON J, 1979, J MEMBRANE BIOL, V50, P65, DOI 10.1007/BF01868788; Foote CI, 1998, J CELL BIOL, V140, P1187, DOI 10.1083/jcb.140.5.1187; Harrison P, 2002, J MOL BIOL, V316, P409, DOI 10.1006/jmbi.2001.5343; Harrison PM, 2002, J MOL BIOL, V318, P1155, DOI 10.1016/S0022-2836(02)00109-2; Hirotsune S, 2003, NATURE, V423, P91, DOI 10.1038/nature01535; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Jordan K, 1999, MOL BIOL CELL, V10, P2033, DOI 10.1091/mbc.10.6.2033; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kleene KC, 1999, GENOMICS, V61, P194, DOI 10.1006/geno.1999.5945; Korneev SA, 1999, J NEUROSCI, V19, P7711; Laird DW, 1999, CANCER RES, V59, P4104; Laird DW, 2001, METH MOL B, V154, P135; MCCARREY JR, 1990, NUCLEIC ACIDS RES, V18, P949, DOI 10.1093/nar/18.4.949; Mighell AJ, 2000, FEBS LETT, V468, P109, DOI 10.1016/S0014-5793(00)01199-6; Moorby C, 2001, EXP CELL RES, V271, P238, DOI 10.1006/excr.2001.5357; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; Paznekas WA, 2003, AM J HUM GENET, V72, P408, DOI 10.1086/346090; Puget N, 2002, AM J HUM GENET, V70, P858, DOI 10.1086/339434; RENAUDIE F, 1992, MAMM GENOME, V2, P143, DOI 10.1007/BF00302872; SORGE J, 1990, J CLIN INVEST, V86, P1137, DOI 10.1172/JCI114818; Sun D, 1998, CYTOGENET CELL GENET, V81, P79, DOI 10.1159/000014993; Tanooka H, 1998, CANCER RES, V58, P5649; Thiele H, 2000, EUR J BIOCHEM, V267, P5473, DOI 10.1046/j.1432-1327.2000.01609.x; Torrents D, 2003, GENOME RES, V13, P2559, DOI 10.1101/gr.1455503; Uechi T, 2002, NUCLEIC ACIDS RES, V30, P5369, DOI 10.1093/nar/gkf696; VENANCE L, 1995, NATURE, V376, P590, DOI 10.1038/376590a0; Vine AL, 2002, CANCER METAST REV, V21, P199, DOI 10.1023/A:1021250624933; WILLECKE K, 1990, EUR J CELL BIOL, V53, P275; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Zhang CL, 2000, ONCOGENE, V19, P4346, DOI 10.1038/sj.onc.1203795; Zhang ZL, 2003, GENOME RES, V13, P2541, DOI 10.1101/gr.1429003	43	71	76	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4763	4770		10.1038/sj.onc.1207506	http://dx.doi.org/10.1038/sj.onc.1207506			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122329				2022-12-25	WOS:000221799200011
J	Massoud, TF; Paulmurugan, R; Gambhir, SS				Massoud, TF; Paulmurugan, R; Gambhir, SS			Molecular imaging of homodimeric protein-protein interactions in living subjects	FASEB JOURNAL			English	Article						bioluminescence; luciferase; Renilla; complementation; dimerization; thymidine kinase	SIMPLEX-VIRUS TYPE-1; RESONANCE ENERGY-TRANSFER; GREEN FLUORESCENT PROTEIN; REPORTER GENE-EXPRESSION; THYMIDINE KINASE; RECEPTOR DIMERIZATION; FRET MICROSCOPY; CELL-SURFACE; COMPLEMENTATION; COMPLEX	Homodimeric protein interactions are potent regulators of cellular functions, but are particularly challenging to study in vivo. We used a split synthetic renilla luciferase (hRLUC) complementation-based bioluminescence assay to study homodimerization of herpes simplex virus type 1 thymidine kinase (TK) in mammalian cells and in living mice. We quantified and imaged homodimerization of TK chimeras containing N-terminal (N-hRLUC) or C-terminal (C-hRLUC) fragments of hRLUC in the upstream and downstream positions, respectively (tail-to-head homodimer). This was monitored using luminometry (68-fold increase, and was significantly [P< 0.01] above background light emission) and by CCD camera imaging of living mice implanted with ex vivo transfected 293T cells (2.7-fold increase, and is significantly [P< 0.01] above background light emission). We also made a mutant-TK to generate N-hRLUC mutant TK and mutant TK-C-hRLUC by changing a single amino acid at position 318 from arginine to cysteine, a key site that has previously been reported to be essential for TK homodimerization, to support the specificity of the hRLUC complementation signal from TK homodimerization. Ex vivo substrate (8-H-3 Penciclovir) accumulation assays in 293T cells expressing the TK protein chimeras showed active TK enzyme. We also devised an experimental strategy by constructing variant TK chimeras ( possessing extra N-hRLUC or C-hRLUC 'spacers') to monitor incremental lack of association of the tail-to-head TK homodimer. Application of this potentially generalizable assay to screen for molecules that promote or disrupt ubiquitous homodimeric protein - protein interactions could serve not only as an invaluable tool to understand biological networks but could also be applied to drug discovery and validation in living subjects.	Stanford Univ, Sch Med, James H Clark Ctr, Dept Radiol, Stanford, CA 94305 USA; Univ Calif Los Angeles, David Geffen Sch Med, Crump Inst Mol Imaging, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Cambridge, Sch Clin Med, Dept Radiol, Cambridge CB2 2QQ, England; Univ Cambridge, Sch Clin Med, Dept Oncol, Cambridge CB2 2QQ, England; Med Coll Wisconsin, Dept Radiol, Milwaukee, WI 53226 USA; Stanford Univ, Sch Med, James H Clark Ctr, Bio X Program, Stanford, CA 94305 USA	Stanford University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Cambridge; University of Cambridge; Medical College of Wisconsin; Stanford University	Gambhir, SS (corresponding author), Stanford Univ, Sch Med, James H Clark Ctr, Dept Radiol, 318 Campus Dr,East Wing,1st Floor, Stanford, CA 94305 USA.	sgambhir@stanford.edu		Paulmurugan, Ramasamy/0000-0001-7155-4738	NATIONAL CANCER INSTITUTE [R01CA082214, U54CA119367, P50CA114747] Funding Source: NIH RePORTER; NCI NIH HHS [U54 CA119367, R01 CA082214, P50 CA114747, 2R01 CA82214-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Bardsley B, 1998, CHIRALITY, V10, P14; Bhaumik S, 2002, P NATL ACAD SCI USA, V99, P377, DOI 10.1073/pnas.012611099; Blakely BT, 2000, NAT BIOTECHNOL, V18, P218, DOI 10.1038/72686; Bollag D M, 1994, Methods Mol Biol, V36, P1; Contag CH, 2002, ANNU REV BIOMED ENG, V4, P235, DOI 10.1146/annurev.bioeng.4.111901.093336; Doyle ML, 1997, CURR OPIN BIOTECH, V8, P31, DOI 10.1016/S0958-1669(97)80154-1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gambhir SS, 2000, P NATL ACAD SCI USA, V97, P2785, DOI 10.1073/pnas.97.6.2785; Gautier I, 2001, BIOPHYS J, V80, P3000, DOI 10.1016/S0006-3495(01)76265-0; HANSEN JC, 1994, BIOCHEMISTRY-US, V33, P13155, DOI 10.1021/bi00249a001; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; Lakey JH, 1998, CURR OPIN STRUC BIOL, V8, P119, DOI 10.1016/S0959-440X(98)80019-5; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Lu L, 2002, PROTEINS, V49, P350, DOI 10.1002/prot.10222; Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Nooren IMA, 2003, J MOL BIOL, V325, P991, DOI 10.1016/S0022-2836(02)01281-0; Paulmurugan R, 2003, ANAL CHEM, V75, P1584, DOI 10.1021/ac020731c; Paulmurugan R, 2002, P NATL ACAD SCI USA, V99, P15608, DOI 10.1073/pnas.242594299; Ponstingl H, 2000, PROTEINS, V41, P47; Ray P, 2002, P NATL ACAD SCI USA, V99, P3105, DOI 10.1073/pnas.052710999; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Saijo M, 2002, J MED VIROL, V66, P388, DOI 10.1002/jmv.2157; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Tavare JM, 2001, J ENDOCRINOL, V170, P297, DOI 10.1677/joe.0.1700297; Valdar WSJ, 2001, PROTEINS, V42, P108; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Veselovsky AV, 2002, J MOL RECOGNIT, V15, P405, DOI 10.1002/jmr.597; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Wild K, 1997, PROTEIN SCI, V6, P2097; Williams NE, 2000, METHOD CELL BIOL, V62, P449; Wurth C, 2001, J MOL BIOL, V313, P657, DOI 10.1006/jmbi.2001.5060; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	34	45	54	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2004	18	7					1105	+		10.1096/fj.03-1128fje	http://dx.doi.org/10.1096/fj.03-1128fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132989	Green Accepted			2022-12-25	WOS:000221883200025
J	Maschler, S; Grunert, S; Danielopol, A; Beug, H; Wirl, G				Maschler, S; Grunert, S; Danielopol, A; Beug, H; Wirl, G			Enhanced tenascin-C expression and matrix deposition during Ras/TGF-beta-induced progression of mammary tumor cells	ONCOGENE			English	Article						tenascin-C; Ha-Ras; TGF beta; mammary tumorigenesis; epithelial/mesenchymal transition	GROWTH-FACTOR-BETA; SIGNAL-REGULATED KINASE; EXTRACELLULAR-MATRIX; BREAST-CANCER; EPITHELIAL-CELLS; SURFACE TRANSGLUTAMINASE; DIFFERENTIAL EXPRESSION; DOWN-REGULATION; PROTEIN CAUSES; H-RAS	Overexpression of tenascin-C (TN-C) in breast carcinomas has been associated with a migratory or even invasive tumor cell phenotype. The mechanisms regulating expression and matrix deposition of TN-C in normal and cancerous breast tissues are, however, little understood. Here, we demonstrate that mouse mammary epithelial cells (EpH4) trans formed by oncogenic Ha-Ras (EpRas) overexpress TN-C, which accumulates in the cytoplasm. When EpRas cells undergo epithelial-mesenchymal transition (EMT) in response to TGFbeta1, they secrete TN-C into the culture medium. In EpRas cells undergoing TGFbeta1-induced EMT in three-dimensional (3D)-collagen gel cultures, TN-C was deposited into an extracellular matrix (ECM) already containing fibronectin and perlecan. Under less physiological 2D plastic cultures, EpRas cells undergoing EMT failed to deposit TN-C into an ( apparently incomplete) ECM. Ras-downstream signaling was dissected by pharmacological inhibitors and effector-specific Ras mutants (V12S35, V12C40), specifically inhibiting or activating ERK/MAPK or PI3K signaling, respectively. We showed that TN-C overexpression required a hyperactive ERK/MAPK-signaling pathway, while elevated PI3K signaling did not enhance TN-C expression. Similarly, tumors induced by cells exhibiting hyperactive ERK/MAPK signaling showed expression of TN-C in the tumor cells themselves, while only endothelial cells expressed TN-C in tumors caused by the V12C40 mutant ( incapable of EMT in vivo). Taken together, our data indicate that hyperactive ERK/MAPK signaling causes enhanced expression of TN-C, while its secretion is induced by TGFb1 and both signals cooperate in TN-C matrix deposition. Importantly, both signals also cooperate to induce EMT in vitro and tumor progression/ metastasis in vivo.	Inst Mol Pathol, A-1030 Vienna, Austria; Austrian Acad Sci, Inst Mol Biol, A-5020 Salzburg, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Austrian Academy of Sciences	Beug, H (corresponding author), Inst Mol Pathol, Dr Bohrgasse 7, A-1030 Vienna, Austria.	beug@nt.imp.univie.ac.at	Gruenert, Stefan/B-7598-2016; Gruenert, Stefan/T-7755-2019	Gruenert, Stefan/0000-0003-0241-9297; Gruenert, Stefan/0000-0003-0241-9297				Adams M, 2002, CANCER RES, V62, P3289; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akhurst RJ, 2002, J CLIN INVEST, V109, P1533, DOI 10.1172/JCI200215970; Akimov SS, 2001, J CELL SCI, V114, P2989; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; BOS JL, 1989, CANCER RES, V49, P4682; Brenner KA, 2000, ONCOGENE, V19, P3156, DOI 10.1038/sj.onc.1203626; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; CANFIELD AE, 1995, J CELL SCI, V108, P797; CARNEMOLLA B, 1992, EUR J BIOCHEM, V205, P561, DOI 10.1111/j.1432-1033.1992.tb16813.x; CHAMMAS R, 1994, J CELL SCI, V107, P1031; Chen YH, 2000, MOL BIOL CELL, V11, P849, DOI 10.1091/mbc.11.3.849; Chiquet-Ehrismann R, 2003, J PATHOL, V200, P488, DOI 10.1002/path.1415; CHIQUETEHRISMANN R, 1991, CELL REGUL, V2, P927, DOI 10.1091/mbc.2.11.927; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; CHIQUETEHRISMANN R, 1988, CELL, V53, P383, DOI 10.1016/0092-8674(88)90158-4; CHIQUETEHRISMANN R, 1989, CANCER RES, V49, P4322; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG CY, 1995, J BIOL CHEM, V270, P29012, DOI 10.1074/jbc.270.48.29012; Chung CY, 1997, J CELL SCI, V110, P1413; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Dandachi N, 2001, J PATHOL, V193, P181, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH752>3.0.CO;2-V; Defilippi P, 1997, ONCOGENE, V14, P1933, DOI 10.1038/sj.onc.1201027; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Deryugina EI, 1996, J CELL SCI, V109, P643; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Huang WT, 2001, CANCER RES, V61, P8586; Jahkola T, 1998, BRIT J CANCER, V78, P1507, DOI 10.1038/bjc.1998.714; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; Jansen B, 1999, P NATL ACAD SCI USA, V96, P14019, DOI 10.1073/pnas.96.24.14019; Jechlinger M, 2003, ONCOGENE, V22, P7155, DOI 10.1038/sj.onc.1206887; Jones FS, 2000, DEV DYNAM, V218, P235, DOI 10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.3.CO;2-7; Jones PL, 2000, MATRIX BIOL, V19, P581, DOI 10.1016/S0945-053X(00)00106-2; Jones PL, 2001, LANCET, V357, P1992, DOI 10.1016/S0140-6736(00)05133-3; LIGHTNER VA, 1994, EXP CELL RES, V210, P177, DOI 10.1006/excr.1994.1027; Martin D, 2003, J CELL BIOL, V160, P171, DOI 10.1083/jcb.200206109; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; Midwood KS, 2002, MOL BIOL CELL, V13, P3601, DOI 10.1091/mbc.E02-05-0292; Miyakis S, 1998, BIOCHEM BIOPH RES CO, V251, P609, DOI 10.1006/bbrc.1998.9527; Moon A, 2000, INT J CANCER, V85, P176, DOI 10.1002/(SICI)1097-0215(20000115)85:2<176::AID-IJC5>3.0.CO;2-E; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Nagata M, 2003, INT J CANCER, V106, P683, DOI 10.1002/ijc.11283; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RETTIG WJ, 1994, J CELL SCI, V107, P487; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; SAGINATI M, 1992, EUR J BIOCHEM, V205, P545, DOI 10.1111/j.1432-1033.1992.tb16811.x; SAKAI T, 1995, INT J CANCER, V63, P720, DOI 10.1002/ijc.2910630519; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Swindle CS, 2001, J CELL BIOL, V154, P459, DOI 10.1083/jcb.200103103; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; Tokes AM, 1999, PATHOL RES PRACT, V195, P821; Tsunoda T, 2003, AM J PATHOL, V162, P1857, DOI 10.1016/S0002-9440(10)64320-9; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Weeks BH, 2001, CANCER RES, V61, P7435; WELLER A, 1991, J CELL BIOL, V112, P355, DOI 10.1083/jcb.112.2.355; WIRL G, 1995, J CELL SCI, V108, P2445; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333; Yoshida T, 1997, J PATHOL, V182, P421; Zagzag D, 2002, CANCER RES, V62, P2660	77	41	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3622	3633		10.1038/sj.onc.1207403	http://dx.doi.org/10.1038/sj.onc.1207403			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116096				2022-12-25	WOS:000221101700014
J	Hleb, M; Murphy, S; Wagner, EF; Hanna, NN; Sharma, N; Park, J; Li, XC; Strom, TB; Padbury, JF; Tseng, YT; Sharma, S				Hleb, M; Murphy, S; Wagner, EF; Hanna, NN; Sharma, N; Park, J; Li, XC; Strom, TB; Padbury, JF; Tseng, YT; Sharma, S			Evidence for cyclin D3 as a novel target of rapamycin in human T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; CELL-CYCLE; CYCLOSPORINE-A; DOWN-REGULATION; MESSENGER-RNA; IMMUNOSUPPRESSANT RAPAMYCIN; RETINOBLASTOMA PROTEIN; SIGNAL-TRANSDUCTION; GROWTH-INHIBITION; MAMMALIAN TARGET	The immunosuppressant rapamycin has been shown to inhibit G(1)/S transition of the cell cycle. This inhibition is thought to be mediated by maintenance of the threshold levels of cyclin-dependent kinase (CDK) inhibitor p27(Kip1) (p27) and inhibition of p70 s6 kinase (p70(s6k)). However, recent evidence suggests that cells still remain sensitive to rapamycin in the absence of functional p27 or p70(s6k). Here, we show that rapamycin represses cyclin D3 levels in activated human T lymphocytes with no inhibitory effects on cyclin D2. Furthermore, rapamycin elicits similar cyclin D3 modulatory effects in B lymphocytes. The overall effect of rapamycin on cyclin D3 leads to impaired formation of active complexes with Cdk4 or Cdk6 and subsequent inhibition of cyclin D3/CDK kinase activity. Decrease in cyclin D3 protein levels is due to translational repression and not due to attenuated transcription of the cyclin D3 gene. Importantly, stable overexpression of cyclin D3 ( 2 - 2.5 fold) in Jurkat T cell transfectants renders them resistant to lower doses ( 1 - 10 ng/ml) of rapamycin. These results point to a critical role of cyclin D3 in rapamycin-mediated immunosuppressive effects in T cells and cell cycle regulation in lymphocytes in general.	Women & Infants Hosp Rhode Isl, Brown Med Sch, Dept Pediat, Providence, RI 02905 USA; Women & Infants Hosp Rhode Isl, Brown Med Sch, Dept Pathol, Providence, RI 02905 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Immunol, Boston, MA 02215 USA	Brown University; Women & Infants Hospital Rhode Island; Brown University; Women & Infants Hospital Rhode Island; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Sharma, S (corresponding author), Women & Infants Hosp Rhode Isl, Brown Med Sch, Dept Pediat, 101 Dudley St, Providence, RI 02905 USA.	ssharma@wihri.org	Hanna, Nazeeh/W-1996-2019; Strom, Terry B./E-9268-2010	Strom, Terry B./0000-0002-7570-0736; hanna, nazeeh/0000-0003-2167-5712; Li, Xian Chang/0000-0002-5981-2762	NCRR NIH HHS [1P20 RR018728-01] Funding Source: Medline; NIAID NIH HHS [AI/GF41521, AI42298, P01 AI041521] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042298, P01AI041521] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ALBERS MW, 1993, J BIOL CHEM, V268, P22825; ARVANITAKIS L, 1995, J IMMUNOL, V155, P1047; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BIERER BE, 1993, CURR OPIN IMMUNOL, V5, P763, DOI 10.1016/0952-7915(93)90135-F; BIERER BE, 1995, P ASSOC AM PHYSICIAN, V107, P28; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; Boonen GJJC, 1999, J BIOL CHEM, V274, P34676, DOI 10.1074/jbc.274.49.34676; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; Combadiere B, 1998, IMMUNITY, V9, P305, DOI 10.1016/S1074-7613(00)80613-5; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Decker T, 2003, BLOOD, V101, P278, DOI 10.1182/blood-2002-01-0189; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dumont F J, 1996, Life Sci, V58, P373; DUMONT FJ, 1994, J IMMUNOL, V152, P992; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Juan G, 1996, CELL PROLIFERAT, V29, P259, DOI 10.1046/j.1365-2184.1996.01000.x; Kawamata S, 1998, BLOOD, V91, P561, DOI 10.1182/blood.V91.2.561.561_561_569; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kuchiki H, 2000, INT J CANCER, V85, P113, DOI 10.1002/(SICI)1097-0215(20000101)85:1<113::AID-IJC20>3.0.CO;2-3; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Marx SO, 1999, MOL CELL BIOL, V19, P6041; Materna T, 1998, ANAL BIOCHEM, V255, P161, DOI 10.1006/abio.1997.2464; MIYATAKE S, 1995, J EXP MED, V182, P401, DOI 10.1084/jem.182.2.401; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Naderi S, 2000, EUR J IMMUNOL, V30, P1757, DOI 10.1002/1521-4141(200006)30:6<1757::AID-IMMU1757>3.0.CO;2-N; Nagasawa M, 1997, J IMMUNOL, V158, P5146; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Piva R, 1999, J NEUROPATH EXP NEUR, V58, P691, DOI 10.1097/00005072-199907000-00002; Powell JD, 1999, J IMMUNOL, V162, P2775; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; Sehgal SN, 1998, CLIN BIOCHEM, V31, P335, DOI 10.1016/S0009-9120(98)00045-9; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Suthanthiran M, 1997, PEDIATR NEPHROL, V11, P651, DOI 10.1007/s004670050359; Takahama Y, 1996, J IMMUNOL, V157, P1508; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; TERADA N, 1993, J BIOL CHEM, V268, P12062; TERADA N, 1995, J IMMUNOL, V155, P3418; Wagner EF, 1998, J IMMUNOL, V161, P1123; Watson DS, 1999, ONCOLOGY-BASEL, V56, P66, DOI 10.1159/000011932	68	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31948	31955		10.1074/jbc.M400638200	http://dx.doi.org/10.1074/jbc.M400638200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15131122	hybrid			2022-12-25	WOS:000222726800123
J	Jensen, LT; Sanchez, RJ; Srinivasan, C; Valentine, JS; Culotta, VC				Jensen, LT; Sanchez, RJ; Srinivasan, C; Valentine, JS; Culotta, VC			Mutations in Saccharomyces cerevisiae iron-sulfur cluster assembly genes and oxidative stress relevant to Cu,Zn superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; YEAST-CELLS; ENCODING GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; PROTEINS; HOMEOSTASIS; COPPER; MITOCHONDRIA; BIOGENESIS; FRATAXIN; DAMAGE	Saccharomyces cerevisiae lacking Cu,Zn superoxide dismutase (SOD1) show several metabolic defects including aerobic blockages in methionine and lysine biosynthesis. We have previously shown that mutations in genes implicated in the formation of iron-sulfur clusters, designated seo ( suppressors of endogenous oxidation), reverse the oxygen-dependent methionine and lysine auxotrophies of a sod1Delta strain. We now report the surprising finding that seo mutants do not reduce oxidative damage as shown by the lack of reduction of EPR-detectable "free" iron, which is characteristic of sod1Delta mutants. In fact, they exhibit increased oxidative damage as evidenced by increased accumulation of protein carbonyls. The seo class of mutants overaccumulates mitochondrial iron, and this iron accumulation is critical for suppression of the sod1Delta biosynthetic defects. Blocking overaccumulation of mitochondrial iron abolished the ability of the seo mutants to suppress the sod1Delta auxotrophies. By contrast, increasing the mitochondrial iron content of sod1Delta yeast using high copy MMT1, which encodes a mitochondrial iron transporter, was sufficient to mimic the seo mutants. Our studies indicated that suppression of the sod1Delta methionine auxotrophy was dependent on the pentose phosphate pathway, which is a major source of NADPH production. By comparison, the sod1Delta lysine auxotrophy appears to be reversed in the seo mutants by increased expression of genes in the lysine biosynthetic pathway, perhaps through sensing of mitochondrial damage by the retrograde response.	Johns Hopkins Univ, Dept Environm Hlth Sci, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of California System; University of California Los Angeles	Jensen, LT (corresponding author), Johns Hopkins Univ, Dept Environm Hlth Sci, Bloomberg Sch Publ Hlth, 615 N Wolfe St,Rm 7032, Baltimore, MD 21205 USA.	ljensen@jhsph.edu	Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X; Jensen, Laran/0000-0003-3199-1743	NIDDK NIH HHS [DK 46828] Funding Source: Medline; NIGMS NIH HHS [GM 50016] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM050016, R01GM050016] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BERMINGHAMMCDONOGH O, 1988, P NATL ACAD SCI USA, V85, P4789, DOI 10.1073/pnas.85.13.4789; BHATTACH.JK, 1972, MOL GEN GENET, V115, P26, DOI 10.1007/BF00272214; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; CHANG EC, 1990, J BACTERIOL, V172, P1840, DOI 10.1128/jb.172.4.1840-1845.1990; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Dilova I, 2002, CURR BIOL, V12, P389, DOI 10.1016/S0960-9822(02)00677-2; Eaton JW, 2002, FREE RADICAL BIO MED, V32, P833, DOI 10.1016/S0891-5849(02)00772-4; Feller A, 1997, YEAST, V13, P1337, DOI 10.1002/(SICI)1097-0061(199711)13:14<1337::AID-YEA186>3.0.CO;2-O; Foury F, 2002, J BIOL CHEM, V277, P24475, DOI 10.1074/jbc.M111789200; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488; Knight SAB, 1998, J BIOL CHEM, V273, P18389, DOI 10.1074/jbc.273.29.18389; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Li LT, 1997, J BIOL CHEM, V272, P28485, DOI 10.1074/jbc.272.45.28485; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; Lin SJ, 1996, MOL CELL BIOL, V16, P6303; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; LIU XF, 1992, J BIOL CHEM, V267, P18298; LIU XF, 1994, MOL CELL BIOL, V14, P7037, DOI 10.1128/MCB.14.11.7037; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; Sherman F., 1978, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Sipos K, 2002, J BIOL CHEM, V277, P26944, DOI 10.1074/jbc.M200677200; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; Srinivasan C, 2000, J BIOL CHEM, V275, P29187, DOI 10.1074/jbc.M004239200; Srinivasan C, 2002, METHOD ENZYMOL, V349, P173, DOI 10.1016/S0076-6879(02)49333-0; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Sturtz LA, 2002, METHOD ENZYMOL, V349, P167, DOI 10.1016/S0076-6879(02)49332-9; THOMAS D, 1991, EMBO J, V10, P547, DOI 10.1002/j.1460-2075.1991.tb07981.x; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793	49	26	28	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29938	29943		10.1074/jbc.M402795200	http://dx.doi.org/10.1074/jbc.M402795200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15107423	hybrid			2022-12-25	WOS:000222531900010
J	Elhasid, R; Sahar, D; Merling, A; Zivony, Y; Rotem, A; Ben-Arush, M; Izraeli, S; Bercovich, D; Larisch, S				Elhasid, R; Sahar, D; Merling, A; Zivony, Y; Rotem, A; Ben-Arush, M; Izraeli, S; Bercovich, D; Larisch, S			Mitochondrial pro-apoptotic ARTS protein is lost in the majority of acute lymphoblastic leukemia patients	ONCOGENE			English	Article						ARTS; mitochandria; apoptosis; leukemia	ACUTE MYELOID-LEUKEMIA; SEPTIN-LIKE FUSION; DNA METHYLATION; GENE; MLL; HEMATOPOIESIS; EXPRESSION; REGION; TUMORS; DEATH	Acquired resistance towards apoptosis is the hallmark of most if not all types of cancer. We have previously identified and characterized ARTS, a broadly expressed protein localized to mitochondria. ARTS was initially shown to mediate TGF-beta induced apoptosis. Recently, we have found that high levels of ARTS induce apoptosis without additional pro-apoptotic stimuli. Further, ARTS promotes apoptosis in response to a wide variety of proapoptotic stimuli. Here, we report that the expression of ARTS is lost in all lymphoblasts of more than 70% of childhood acute lymphoblastic leukemia (ALL) patients. The loss of ARTS is specific, as the related non-apoptotic protein H5, bearing 83% identity to ARTS, is unaffected. During remission, ARTS expression is detected again in almost all patients. Two leukemic cell lines, ALL-1 and HL-60 lacking ARTS, were resistant to apoptotic induction by ara-C. Transfection of ARTS into these cells restored their ability to undergo apoptosis in response to this chemotherapeutic agent. We found that methylation process contributes to the loss of ARTS expression. We conclude that the loss of ARTS may provide a selective advantage for cells to escape apoptosis thereby contributing to their transformation to malignant lymphoblasts. We therefore propose that ARTS can function as a tumor suppressor protein in childhood ALL.	Rambam Med Ctr, Apoptosis & Carcinogenesis Res Lab, Dept Pathol, IL-31096 Haifa, Israel; Rambam Med Ctr, Pediat Hematooncol Dept, IL-31096 Haifa, Israel; Rambam Med Ctr, Mol Hematol Lab, IL-31096 Haifa, Israel; Tel Aviv Univ, Sackler Fac Med, Sheba Med Ctr, Canc Res Ctr, IL-52621 Tel Hashomer, Israel; Migal Galilee Technol Ctr, IL-11016 Kiryat Shmona, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Larisch, S (corresponding author), Rambam Med Ctr, Apoptosis & Carcinogenesis Res Lab, Dept Pathol, IL-31096 Haifa, Israel.	s_larisch@rambam.health.gov.il						Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Domen J, 2000, IMMUNOL RES, V22, P83, DOI 10.1385/IR:22:2-3:83; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Gottfried Y, 2004, EMBO J, V23, P1627, DOI 10.1038/sj.emboj.7600155; Greaves M, 2002, BRIT MED J, V324, P283, DOI 10.1136/bmj.324.7332.283; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jain PK, 2003, ANN NY ACAD SCI, V983, P71, DOI 10.1111/j.1749-6632.2003.tb05963.x; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Kalikin LM, 2000, GENOMICS, V63, P165, DOI 10.1006/geno.1999.6077; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Kartmann B, 2001, J CELL SCI, V114, P839; Kinoshita M, 2002, DEV CELL, V3, P791, DOI 10.1016/S1534-5807(02)00366-0; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Malfoy B., 2000, J CELL SCI, V113, P3887; McKenna SL, 1997, ADV CANCER RES, V71, P121, DOI 10.1016/S0065-230X(08)60098-6; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; PUI CH, 1995, NEW ENGL J MED, V332, P1618, DOI 10.1056/NEJM199506153322407; Rinkenberger JL, 1997, CURR OPIN GENET DEV, V7, P589, DOI 10.1016/S0959-437X(97)80004-4; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Rubnitz JE, 2003, CANCER TREAT REV, V29, P31, DOI 10.1016/S0305-7372(02)00106-8; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; ZAGONEL V, 1993, LEUKEMIA, V7, P30	36	56	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5468	5475		10.1038/sj.onc.1207725	http://dx.doi.org/10.1038/sj.onc.1207725			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15122323				2022-12-25	WOS:000222588400006
J	Citovsky, V; Kapelnikov, A; Oliel, S; Zakai, N; Rojas, MR; Gilbertson, RL; Tzfira, T; Loyter, A				Citovsky, V; Kapelnikov, A; Oliel, S; Zakai, N; Rojas, MR; Gilbertson, RL; Tzfira, T; Loyter, A			Protein interactions involved in nuclear import of the Agrobacterium VirE2 protein in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMEFACIENS-MEDIATED TRANSFORMATION; T-DNA TRANSFER; LOCALIZATION SIGNAL; VIRD2 PROTEIN; PLANT-CELLS; CYTOSOLIC FACTORS; BINDING-PROTEIN; HIV-1 VPR; TRANSPORT; INTEGRATION	Agrobacterium, the only known organism capable of trans-kingdom DNA transfer, genetically transforms plants by transferring a segment of its DNA, T-DNA, into the nucleus of the host cell where it integrates into the plant genome. One of the central events in this genetic transformation process is nuclear import of the T-DNA molecule, which to a large degree is mediated by the bacterial virulence protein VirE2. VirE2 is distinguished by its nuclear targeting, which occurs only in plant but not in animal cells and is facilitated by the cellular VIP1 protein. The molecular mechanism of the VIP1 function is still unclear. Here, we used in vitro assays for nuclear import and quantification of protein-protein interactions to directly demonstrate formation of ternary complexes between VirE2, VIP1, and a component of the cellular nuclear import machinery, karyopherin alpha. Our results indicate that VIP1 functions as a molecular bridge between VirE2 and karyopherin alpha, allowing VirE2 to utilize the host cell nuclear import machinery even without being directly recognized by its components.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Davis, CA 95616 USA; Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Hebrew University of Jerusalem; University of California System; University of California Davis; University of California System; University of California Davis	Citovsky, V (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	vitaly.citovsky@stonybrook.edu		Citovsky, Vitaly/0000-0003-2024-6844				Armon-Omer A, 2004, J MOL BIOL, V336, P1117, DOI 10.1016/j.jmb.2003.11.057; Ballas N, 1997, P NATL ACAD SCI USA, V94, P10723, DOI 10.1073/pnas.94.20.10723; Broder YC, 1997, FEBS LETT, V412, P535, DOI 10.1016/S0014-5793(97)00855-7; Bukrinsky M, 1999, REV MED VIROL, V9, P39, DOI 10.1002/(SICI)1099-1654(199901/03)9:1<39::AID-RMV235>3.0.CO;2-3; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; CITOVSKY V, 1991, P NATL ACAD SCI USA, V88, P2476, DOI 10.1073/pnas.88.6.2476; CITOVSKY V, 1994, P NATL ACAD SCI USA, V91, P3210, DOI 10.1073/pnas.91.8.3210; CITOVSKY V, 1992, SCIENCE, V256, P1802, DOI 10.1126/science.1615325; de Groot MJA, 1998, NAT BIOTECHNOL, V16, P839, DOI 10.1038/nbt0998-839; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Fineberg K, 2003, BIOCHEMISTRY-US, V42, P2625, DOI 10.1021/bi0206199; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; Friedler A, 1998, BIOCHEMISTRY-US, V37, P5616, DOI 10.1021/bi972878h; Gelvin SB, 2000, ANNU REV PLANT PHYS, V51, P223, DOI 10.1146/annurev.arplant.51.1.223; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Guralnick B, 1996, PLANT CELL, V8, P363, DOI 10.1105/tpc.8.3.363; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Hicks GR, 1996, PLANT CELL, V8, P1337, DOI 10.1105/tpc.8.8.1337; HIROOKA T, 1987, J BACTERIOL, V169, P1529, DOI 10.1128/jb.169.4.1529-1536.1987; HOWARD EA, 1992, CELL, V68, P109, DOI 10.1016/0092-8674(92)90210-4; Karni O, 1998, FEBS LETT, V429, P421, DOI 10.1016/S0014-5793(98)00645-0; KOUKOLIKOVANICOLA Z, 1993, J BACTERIOL, V175, P723; Krichevsky A, 2003, VIROLOGY, V305, P77, DOI 10.1006/viro.2002.1765; Kunik T, 2001, P NATL ACAD SCI USA, V98, P1871, DOI 10.1073/pnas.041327598; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; Mysore KS, 1998, MOL PLANT MICROBE IN, V11, P668, DOI 10.1094/MPMI.1998.11.7.668; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NOUEIRY AO, 1994, CELL, V76, P925, DOI 10.1016/0092-8674(94)90366-2; Piers KL, 1996, P NATL ACAD SCI USA, V93, P1613, DOI 10.1073/pnas.93.4.1613; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; Rhee Y, 2000, NAT BIOTECHNOL, V18, P433, DOI 10.1038/74500; Rojas MR, 1997, VIROLOGY, V237, P283, DOI 10.1006/viro.1997.8777; ROSSI L, 1993, MOL GEN GENET, V239, P345, DOI 10.1007/BF00276932; STACHEL SE, 1989, NATURE, V340, P190, DOI 10.1038/340190a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Subramaniam PS, 1999, J BIOL CHEM, V274, P403, DOI 10.1074/jbc.274.1.403; Tzfira T, 2000, ANNU REV MICROBIOL, V54, P187, DOI 10.1146/annurev.micro.54.1.187; Tzfira T, 2001, EMBO J, V20, P3596, DOI 10.1093/emboj/20.13.3596; Tzfira T, 2002, P NATL ACAD SCI USA, V99, P10435, DOI 10.1073/pnas.162304099; Tzfira T, 2002, TRENDS CELL BIOL, V12, P121, DOI 10.1016/S0962-8924(01)02229-2; Tzfira T, 2001, MOL PLANT PATHOL, V2, P171, DOI 10.1046/j.1364-3703.2001.00065.x; Ward DV, 2001, P NATL ACAD SCI USA, V98, P385, DOI 10.1073/pnas.98.2.385; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Ziemienowicz A, 1999, P NATL ACAD SCI USA, V96, P3729, DOI 10.1073/pnas.96.7.3729; Ziemienowicz A, 2001, PLANT CELL, V13, P369, DOI 10.1105/tpc.13.2.369; Zupan J, 2000, PLANT J, V23, P11, DOI 10.1046/j.1365-313x.2000.00808.x; Zupan J, 1997, CRIT REV PLANT SCI, V16, P279, DOI 10.1080/713608150; Zupan JR, 1996, P NATL ACAD SCI USA, V93, P2392, DOI 10.1073/pnas.93.6.2392	49	47	55	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29528	29533		10.1074/jbc.M403159200	http://dx.doi.org/10.1074/jbc.M403159200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123622	hybrid			2022-12-25	WOS:000222445300086
J	Fabian, MR; White, KA				Fabian, MR; White, KA			5 '-3 ' RNA-RNA interaction facilitates cap- and poly(A) tail-independent translation of tomato bushy stunt virus mRNA - A potential common mechanism for Tombusviridae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YELLOW DWARF VIRUS; SATELLITE TOBACCO; BINDING-PROTEIN; STIMULATES TRANSLATION; 3'-UNTRANSLATED REGION; UNTRANSLATED REGIONS; MOLECULAR-BIOLOGY; SEQUENCE; ELEMENT; INITIATION	Tomato bushy stunt virus (TBSV) is the prototypical member of the genus Tombusvirus in the family Tombusviridae. The (+)-strand RNA genome of TBSV lacks both a 5' cap and a 3' poly( A) tail and instead contains a 3'-terminal RNA sequence that acts as a cap-independent translational enhancer (3' CITE). In this study, we have determined the RNA secondary structure of the translation-specific central segment of the 3' CITE, termed region 3.5 (R3.5). MFOLD structural modeling combined with solution structure mapping and comparative sequence analysis indicate that R3.5 adopts a branched structure that contains three major helices. Deletion and substitution studies revealed that two of these extended stem-loop (SL) structures are essential for 3' CITE activity in vivo. In particular, the terminal loop of one of these SLs, SL-B, was found to be critical for translation. Compensatory mutational analysis showed that SL-B functions by base pairing with another SL, SL3, in the 5' untranslated region of the TBSV genome. Thus, efficient translation of TBSV mRNA in vivo requires a 5'-3' RNA-RNA interaction that effectively circularizes the message. Similar types of interactions are also predicted to occur in TBSV subgenomic mRNAs between their 5' untranslated regions and the 3' CITE, and both genomic and subgenomic 5'-3' interactions are well conserved in all members of the genus Tombusvirus. In addition, a survey of other genera in Tombusviridae revealed the potential for similar 5'-3' RNA-RNA-based interactions in their viral mRNAs, suggesting that this mechanism extends throughout this large virus family.	York Univ, Dept Biol, Toronto, ON M3J 1P3, Canada	York University - Canada	White, KA (corresponding author), York Univ, Dept Biol, 4700 Keele St, Toronto, ON M3J 1P3, Canada.	kawhite@yorku.ca						Allen E, 1999, VIROLOGY, V253, P139, DOI 10.1006/viro.1998.9507; Bailey-Serres J, 1999, TRENDS PLANT SCI, V4, P142, DOI 10.1016/S1360-1385(99)01386-2; Barry JK, 2002, P NATL ACAD SCI USA, V99, P11133, DOI 10.1073/pnas.162223099; Barton DJ, 1999, J VIROL, V73, P10104, DOI 10.1128/JVI.73.12.10104-10112.1999; Borman AM, 2000, NUCLEIC ACIDS RES, V28, P4068, DOI 10.1093/nar/28.21.4068; Bushell M, 2002, J CELL BIOL, V158, P395, DOI 10.1083/jcb.200205044; Choi IR, 2002, J BIOL CHEM, V277, P3760, DOI 10.1074/jbc.M109067200; Choi IR, 2001, J BIOL CHEM, V276, P41761, DOI 10.1074/jbc.M106727200; DANTHINNE X, 1993, MOL CELL BIOL, V13, P3340, DOI 10.1128/MCB.13.6.3340; Fabian MR, 2003, VIROLOGY, V313, P567, DOI 10.1016/S0042-6822(03)00349-0; Franch T, 2000, CURR OPIN MICROBIOL, V3, P159, DOI 10.1016/S1369-5274(00)00069-2; Gallie DR, 2002, PLANT MOL BIOL, V50, P949, DOI 10.1023/A:1021220910664; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; Gamarnik AV, 1998, GENE DEV, V12, P2293, DOI 10.1101/gad.12.15.2293; Gazo BM, 2004, J BIOL CHEM, V279, P13584, DOI 10.1074/jbc.M311361200; Guo L, 2001, MOL CELL, V7, P1103, DOI 10.1016/S1097-2765(01)00252-0; Guo L, 2000, RNA, V6, P1808, DOI 10.1017/S1355838200001539; HEARNE PQ, 1990, VIROLOGY, V177, P141, DOI 10.1016/0042-6822(90)90468-7; HULL R, 2002, MATHEWS PLANT VIRUSE; Jucker FM, 1996, J MOL BIOL, V264, P968, DOI 10.1006/jmbi.1996.0690; Kawaguchi R, 2002, CURR OPIN PLANT BIOL, V5, P460, DOI 10.1016/S1369-5266(02)00290-X; Khromykh AA, 2001, J VIROL, V75, P6719, DOI 10.1128/JVI.75.14.6719-6728.2001; Kim KH, 1999, RNA, V5, P636, DOI 10.1017/S1355838299982006; Koh DCY, 2002, J VIROL, V76, P1144, DOI 10.1128/JVI.76.3.1144-1153.2002; Lindenbach BD, 2002, J VIROL, V76, P3905, DOI 10.1128/JVI.76.8.3905-3919.2002; Ling J, 2002, MOL CELL BIOL, V22, P7853, DOI 10.1128/MCB.22.22.7853-7867.2002; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Mayo MA, 1996, ADV VIRUS RES, V46, P413, DOI 10.1016/S0065-3527(08)60077-9; Meulewaeter F, 2004, NUCLEIC ACIDS RES, V32, P1721, DOI 10.1093/nar/gkh338; Meulewaeter F, 1998, PLANT J, V14, P169, DOI 10.1046/j.1365-313X.1998.00104.x; Michel YM, 2001, MOL CELL BIOL, V21, P4097, DOI 10.1128/MCB.21.13.4097-4109.2001; Miller WA, 2002, MOL PLANT PATHOL, V3, P177, DOI 10.1046/j.1364-3703.2002.00112.x; Mizumoto H, 2003, J VIROL, V77, P12113, DOI 10.1128/JVI.77.22.12113-12121.2003; MOLINARO M, 1995, NUCLEIC ACIDS RES, V23, P3056, DOI 10.1093/nar/23.15.3056; Oster SK, 1998, J VIROL, V72, P5845, DOI 10.1128/JVI.72.7.5845-5851.1998; Panavas T, 2003, J VIROL, V77, P258, DOI 10.1128/JVI.77.1.258-269.2003; Piron M, 1998, EMBO J, V17, P5811, DOI 10.1093/emboj/17.19.5811; Pogany J, 2003, EMBO J, V22, P5602, DOI 10.1093/emboj/cdg523; Qiu WP, 2002, MOL PLANT MICROBE IN, V15, P269, DOI 10.1094/MPMI.2002.15.3.269; Qu F, 2002, MOL PLANT MICROBE IN, V15, P193, DOI 10.1094/MPMI.2002.15.3.193; Qu F, 2000, J VIROL, V74, P1085, DOI 10.1128/JVI.74.3.1085-1093.2000; Ray D, 2003, RNA, V9, P1232, DOI 10.1261/rna.5630203; Ray D, 2003, J VIROL, V77, P245, DOI 10.1128/JVI.77.1.245-257.2003; Ray D, 1999, VIROLOGY, V256, P162, DOI 10.1006/viro.1999.9630; RUSSO M, 1994, ADV VIRUS RES, V44, P381, DOI 10.1016/S0065-3527(08)60334-6; Schneider RJ, 2003, TRENDS BIOCHEM SCI, V28, P130, DOI 10.1016/S0968-0004(03)00029-X; SCHOLTHOF HB, 1995, VIROLOGY, V213, P425, DOI 10.1006/viro.1995.0015; SCHOLTHOF KBG, 1995, VIROLOGY, V208, P365, DOI 10.1006/viro.1995.1162; Shen RZ, 2004, J VIROL, V78, P4655, DOI 10.1128/JVI.78.9.4655-4664.2004; Sit TL, 1998, SCIENCE, V281, P829, DOI 10.1126/science.281.5378.829; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TIMMER RT, 1993, J BIOL CHEM, V268, P9504; van Lipzig R, 2001, NUCLEIC ACIDS RES, V29, P1080, DOI 10.1093/nar/29.5.1080; WANG SP, 1995, J BIOL CHEM, V270, P13446, DOI 10.1074/jbc.270.22.13446; Wang SP, 1997, EMBO J, V16, P4107, DOI 10.1093/emboj/16.13.4107; WHITE KA, 1994, J VIROL, V68, P14, DOI 10.1128/JVI.68.1.14-24.1994; Wu BD, 2001, J MOL BIOL, V305, P741, DOI 10.1006/jmbi.2000.4298; Wu BD, 1999, J VIROL, V73, P8982, DOI 10.1128/JVI.73.11.8982-8988.1999; You SY, 2001, J BIOL CHEM, V276, P15581, DOI 10.1074/jbc.M010923200; Zhang GC, 1999, RNA, V5, P550, DOI 10.1017/S1355838299982080; Zuker M., 1999, V70, P11	61	97	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28862	28872		10.1074/jbc.M401272200	http://dx.doi.org/10.1074/jbc.M401272200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123633	hybrid			2022-12-25	WOS:000222445300006
J	Guo, Q; Shen, YQ; Zhukovskaya, NL; Florian, J; Tang, WJ				Guo, Q; Shen, YQ; Zhukovskaya, NL; Florian, J; Tang, WJ			Structural and kinetic analyses of the interaction of anthrax adenylyl cyclase toxin with reaction products cAMP and pyrophosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY DNA-POLYMERASE; P-SITE INHIBITION; EDEMA FACTOR; BACILLUS-ANTHRACIS; CRYSTAL-STRUCTURE; CATALYTIC MECHANISM; X-RAY; CALMODULIN; COMPLEX; BINDING	Anthrax edema factor (EF) raises host intracellular cAMP to pathological levels through a calcium-calmodulin (CaM)-dependent adenylyl cyclase activity. Here we report the structure of EF.CaM in complex with its reaction products, cAMP and PPi. Mutational analysis confirmed the interaction of EF with cAMP and PPi as depicted in the structural model. While both cAMP and PPi have access to solvent channels to exit independently, PPi is likely released first. EF can synthesize ATP from cAMP and PPi, and the estimated rate constants of this reaction at two physiologically relevant calcium concentrations were similar to those of adenylyl cyclase activity of EF. Comparison of the conformation of adenosine in the structures of EF.CaM.cAMP.PPi with EF.CaM.3' dATP revealed about 160 rotation in the torsion angle of N-glycosyl bond from the +anti conformation in 3' dATP to -syn in cAMP; such a rotation could serve to distinguish against substrates with the N-2 amino group of purine. The catalytic rate of EF for ITP was about 2 orders of magnitude better than that for GTP, supporting the potential role of this rotation in substrate selectivity of EF. The anomalous difference Fourier map revealed that two ytterbium ions (Yb3+) could bind the catalytic site of EF.CaM in the presence of cAMP and PPi, suggesting the presence of two magnesium ions at the catalytic site of EF. We hypothesize that EF could use a "histidine and two-metal ion" hybrid mechanism to facilitate the cyclization reaction.	Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Univ Chicago, Comm Neurobiol, Chicago, IL 60637 USA; Loyola Univ, Dept Chem, Chicago, IL 60626 USA	University of Chicago; University of Chicago; Loyola University Chicago	Tang, WJ (corresponding author), Univ Chicago, Ben May Inst Canc Res, 924 E 57th St, Chicago, IL 60637 USA.	wtang@uchicago.edu	Florian, Jan/E-1554-2012	Florian, Jan/0000-0003-2669-4293; Tang, Wei-Jen/0000-0002-8267-8995				Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; Brautigam CA, 1999, CHEM BIOL, V6, P901, DOI 10.1016/S1074-5521(00)80009-5; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dessauer CW, 1999, TRENDS PHARMACOL SCI, V20, P205, DOI 10.1016/S0165-6147(99)01310-3; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; Drum CL, 2001, ACTA CRYSTALLOGR D, V57, P1881, DOI 10.1107/S0907444901014937; Drum CL, 2000, J BIOL CHEM, V275, P36334, DOI 10.1074/jbc.M004778200; ECKSTEIN F, 1981, J BIOL CHEM, V256, P9118; Elliott JL, 2000, BIOCHEMISTRY-US, V39, P6706, DOI 10.1021/bi000310u; FARNDALE RW, 1992, SIGNAL TRANSDUCTION, P75; Florian J, 1998, J PHYS CHEM B, V102, P719, DOI 10.1021/jp972182y; Florian J, 2003, J AM CHEM SOC, V125, P8163, DOI 10.1021/ja028997o; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Garcia-Viloca M, 2004, SCIENCE, V303, P186, DOI 10.1126/science.1088172; GERLT JA, 1980, J BIOL CHEM, V255, P331; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Kraut DA, 2003, ANNU REV BIOCHEM, V72, P517, DOI 10.1146/annurev.biochem.72.121801.161617; Ladant D, 1999, TRENDS MICROBIOL, V7, P172, DOI 10.1016/S0966-842X(99)01468-7; Linder JU, 2003, CELL SIGNAL, V15, P1081, DOI 10.1016/S0898-6568(03)00130-X; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Mock M, 2001, ANNU REV MICROBIOL, V55, P647, DOI 10.1146/annurev.micro.55.1.647; Mourez M, 2002, TRENDS MICROBIOL, V10, P287, DOI 10.1016/S0966-842X(02)02369-7; MUNIER H, 1992, J BIOL CHEM, V267, P9816; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Shen Y, 2004, BIOCHEM BIOPH RES CO, V317, P309, DOI 10.1016/j.bbrc.2004.03.046; Shen YQ, 2004, P NATL ACAD SCI USA, V101, P3242, DOI 10.1073/pnas.0306552101; Shen YQ, 2002, EMBO J, V21, P6721, DOI 10.1093/emboj/cdf681; Soelaiman S, 2003, J BIOL CHEM, V278, P25990, DOI 10.1074/jbc.M301232200; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Tesmer JJG, 2000, BIOCHEMISTRY-US, V39, P14464, DOI 10.1021/bi0015562; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Ulmer TS, 2003, J BIOL CHEM, V278, P29261, DOI 10.1074/jbc.M302837200; Yahr TL, 1998, P NATL ACAD SCI USA, V95, P13899, DOI 10.1073/pnas.95.23.13899	40	45	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29427	29435		10.1074/jbc.M402689200	http://dx.doi.org/10.1074/jbc.M402689200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15131111	hybrid			2022-12-25	WOS:000222445300075
J	Stahelin, RV; Digman, MA; Medkova, M; Ananthanarayanan, B; Rafter, JD; Melowic, HR; Cho, WH				Stahelin, RV; Digman, MA; Medkova, M; Ananthanarayanan, B; Rafter, JD; Melowic, HR; Cho, WH			Mechanism of diacylglycerol-induced membrane targeting and activation of protein kinase C delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; CYTOSOLIC PHOSPHOLIPASE A(2); PHORBOL ESTER RECEPTORS; SMOOTH-MUSCLE-CELLS; PKC-DELTA; DIFFERENTIAL ROLES; MOLECULAR-BASIS; C2-LIKE DOMAIN; MITOCHONDRIAL TRANSLOCATION; MACROMOLECULAR INTERACTIONS	The regulatory domains of novel protein kinases C (PKC) contain two C1 domains (C1A and C1B), which have been identified as the interaction site for sn-1,2-diacylglycerol (DAG) and phorbol ester, and a C2 domain that may be involved in interaction with lipids and/or proteins. Although recent reports have indicated that C1A and C1B domains of conventional PKCs play different roles in their DAG-mediated membrane binding and activation, the individual roles of C1A and C1B domains in the DAG-mediated activation of novel PKCs have not been fully understood. In this study, we determined the roles of C1A and C1B domains of PKCdelta by means of in vitro lipid binding analyses and cellular protein translocation measurements. Isothermal titration calorimetry and surface plasmon resonance measurements showed that isolated C1A and C1B domains of PKCdelta have opposite affinities for DAG and phorbol ester; i.e. the C1A domain with high affinity for DAG and the C1B domain with high affinity for phorbol ester. Furthermore, in vitro activity and membrane binding analyses of PKCdelta mutants showed that the C1A domain is critical for the DAG-induced membrane binding and activation of PKCdelta. The studies also indicated that an anionic residue, Glu(177), in the C1A domain plays a key role in controlling the DAG accessibility of the conformationally restricted C1A domain in a phosphatidylserine-dependent manner. Cell studies with enhanced green fluorescent protein-tagged PKCdelta and mutants showed that because of its phosphatidylserine specificity PKCdelta preferentially translocated to the plasma membrane under the conditions in which DAG is randomly distributed among intracellular membranes of HEK293 cells. Collectively, these results provide new insight into the differential roles of C1 domains in the DAG-induced membrane activation of PKCdelta and the origin of its specific subcellular localization in response to DAG.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, WH (corresponding author), M-C 111,845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu	Stahelin, Robert/L-3567-2019	Stahelin, Robert/0000-0001-5443-7863	NIGMS NIH HHS [GM68849, GM53987, GM52598] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598, R01GM068849, R01GM053987] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ananthanarayanan B, 2003, J BIOL CHEM, V278, P46886, DOI 10.1074/jbc.M307853200; Ananthanarayanan B, 2002, J BIOL CHEM, V277, P3568, DOI 10.1074/jbc.M109705200; Aroca P, 2000, FEBS LETT, V483, P27, DOI 10.1016/S0014-5793(00)02075-5; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P6776, DOI 10.1021/bi00418a020; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; Bogi K, 1998, CANCER RES, V58, P1423; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Caruso M, 2001, J BIOL CHEM, V276, P45088, DOI 10.1074/jbc.M105451200; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cho Wonhwa, 2003, Methods Mol Biol, V233, P291; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Clarke H, 2000, KIDNEY INT, V58, P1004, DOI 10.1046/j.1523-1755.2000.00258.x; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Irie K, 1998, J AM CHEM SOC, V120, P9159, DOI 10.1021/ja981087f; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P14679, DOI 10.1074/jbc.270.24.14679; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; Leitges M, 2002, MOL CELL BIOL, V22, P3970, DOI 10.1128/MCB.22.12.3970-3980.2002; Liu HP, 2001, AM J PHYSIOL-HEART C, V281, pH404, DOI 10.1152/ajpheart.2001.281.1.H404; Lopez-Lluch G, 2001, BIOCHEM J, V357, P39, DOI 10.1042/0264-6021:3570039; Lorenzo PS, 1999, CANCER RES, V59, P6137; Mackay K, 2001, J MOL CELL CARDIOL, V33, P1301, DOI 10.1006/jmcc.2001.1400; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; Mozsolits H, 2003, J PEPT SCI, V9, P77, DOI 10.1002/psc.439; Mozsolits H, 2002, BIOPOLYMERS, V66, P3, DOI 10.1002/bip.10200; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Newton Alexandra C, 2003, Methods Mol Biol, V233, P3; Ochoa WF, 2001, J MOL BIOL, V311, P837, DOI 10.1006/jmbi.2001.4910; ONO Y, 1988, J BIOL CHEM, V263, P6927; Pappa H, 1998, STRUCT FOLD DES, V6, P885, DOI 10.1016/S0969-2126(98)00090-2; Pappa H, 1998, ACTA CRYSTALLOGR D, V54, P693, DOI 10.1107/S0907444997019732; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Pepio AM, 2001, J BIOL CHEM, V276, P3846, DOI 10.1074/jbc.M006339200; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Slater SJ, 1996, J BIOL CHEM, V271, P4627; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Stahelin RV, 2003, J BIOL CHEM, V278, P14469, DOI 10.1074/jbc.M212579200; Stahelin RV, 2003, J BIOL CHEM, V278, P12452, DOI 10.1074/jbc.M212864200; Stahelin RV, 2002, J BIOL CHEM, V277, P26379, DOI 10.1074/jbc.M201106200; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Stahelin RV, 2001, BIOCHEM J, V359, P679, DOI 10.1042/0264-6021:3590679; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Szallasi Z, 1996, J BIOL CHEM, V271, P18299, DOI 10.1074/jbc.271.31.18299; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; Wakino S, 2001, J BIOL CHEM, V276, P47650, DOI 10.1074/jbc.M108719200; Wan QJ, 2000, J BIOL CHEM, V275, P12136, DOI 10.1074/jbc.275.16.12136; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Wang QMJ, 2001, J BIOL CHEM, V276, P19580, DOI 10.1074/jbc.M010089200; Wang WJ, 1997, J BIOL CHEM, V272, P76; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; Yang CF, 2003, TRENDS PHARMACOL SCI, V24, P602, DOI 10.1016/j.tips.2003.09.003; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	84	118	119	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29501	29512		10.1074/jbc.M403191200	http://dx.doi.org/10.1074/jbc.M403191200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15105418	hybrid			2022-12-25	WOS:000222445300083
J	Cabrera-Poch, N; Sanchez-Ruiloba, L; Rodriguez-Martinez, M; Iglesias, T				Cabrera-Poch, N; Sanchez-Ruiloba, L; Rodriguez-Martinez, M; Iglesias, T			Lipid raft disruption triggers protein kinase C and Src-dependent protein kinase D activation and Kidins220 phosphorylation in neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAVEOLAE-LIKE DOMAINS; PLECKSTRIN HOMOLOGY DOMAIN; D PKD ACTIVATION; DOWNSTREAM TARGET; TYROSINE KINASE; PHORBOL ESTERS; LOOP SER(744); DNA-SYNTHESIS; INTACT-CELLS; MU	Kidins220 ( kinase D-interacting substrate of 220 kDa) is a novel neurospecific protein recently cloned as the first substrate for the Ser/Thr kinase protein kinase D (PKD). Herein we report that Kidins220 is constitutively associated to lipid rafts in PC12 cells, rat primary cortical neurons, and brain synaptosomes. Immunocytochemistry and confocal microscopy together with sucrose gradient fractionation show co-localization of Kidins220 and lipid raft-associated proteins. In addition, cholesterol depletion of cell membranes with methyl-beta-cyclodextrin dramatically alters Kidins220 localization and detergent solubility. By studying the putative involvement of lipid rafts in PKD activation and signaling we have found that active PKD partitions in lipid raft fractions after sucrose gradient centrifugation and that green fluorescent protein-PKD translocates to lipid raft microdomains at the plasma membrane after phorbol ester treatment. Strikingly, lipid rafts disruption by methyl-beta-cyclodextrin delays green fluorescent protein-PKD translocation, as determined by live cell confocal microscopy, and activates PKD, increasing Kidins220 phosphorylation on Ser(919) by a mechanism involving PKCepsilon and the small soluble tyrosine kinase Src. Collectively, these results reveal the importance of lipid rafts on PKD activation, translocation, and downstream signaling to its substrate Kidins220.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Iglesias, T (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, C Arturo Duperier 4, Madrid 28029, Spain.	tiglesias@iib.uam.es	Vacas, Teresa Iglesias/ABF-8663-2020	Vacas, Teresa Iglesias/0000-0002-4326-9005; Sanchez-Ruiloba, Lucia/0000-0001-5418-2290				Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Brandlin I, 2002, J BIOL CHEM, V277, P45451, DOI 10.1074/jbc.M205299200; Brandlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200; BREWER GJ, 1989, BRAIN RES, V494, P65, DOI 10.1016/0006-8993(89)90144-3; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown RE, 1998, J CELL SCI, V111, P1; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Chiu T, 2001, FEBS LETT, V489, P101, DOI 10.1016/S0014-5793(01)02076-2; Colman DR, 1999, NEURON, V23, P649, DOI 10.1016/S0896-6273(01)80024-6; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; GRAY EG, 1962, J ANAT, V96, P79; Guha S, 2002, CANCER RES, V62, P1632; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hausser A, 2001, FEBS LETT, V492, P39, DOI 10.1016/S0014-5793(01)02219-0; Herreros J, 2001, MOL BIOL CELL, V12, P2947, DOI 10.1091/mbc.12.10.2947; Higuchi H, 2003, EMBO J, V22, P1790, DOI 10.1093/emboj/cdg177; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; Huang C, 1999, J BIOL CHEM, V274, P36707, DOI 10.1074/jbc.274.51.36707; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Hurd C, 2002, ONCOGENE, V21, P2154, DOI 10.1038/sj.onc.1205290; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Kong HY, 2001, J NEUROSCI, V21, P176, DOI 10.1523/JNEUROSCI.21-01-00176.2001; Kranenburg O, 2001, CURR BIOL, V11, P1880, DOI 10.1016/S0960-9822(01)00582-6; Lang ML, 2002, BIOCHEM J, V364, P517, DOI 10.1042/BJ20011696; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Masserini M, 1999, J NEUROCHEM, V73, P1, DOI 10.1046/j.1471-4159.1999.0730001.x; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Mukherjee A, 2003, J BIOL CHEM, V278, P40806, DOI 10.1074/jbc.M306440200; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Oancea E, 2003, DEV CELL, V4, P561, DOI 10.1016/S1534-5807(03)00087-X; Paolucci L, 1999, CANCER RES, V59, P572; Paratcha G, 2002, CURR OPIN NEUROBIOL, V12, P542, DOI 10.1016/S0959-4388(02)00363-X; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Peiro S, 2000, J BIOL CHEM, V275, P37846, DOI 10.1074/jbc.M000487200; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rey O, 2003, J CELL PHYSIOL, V196, P483, DOI 10.1002/jcp.10323; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Schultz J, 1997, PROTEIN SCI, V6, P249; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Storz P, 2003, J BIOL CHEM, V278, P17969, DOI 10.1074/jbc.M213224200; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; Tsui-Pierchala BA, 2002, TRENDS NEUROSCI, V25, P412, DOI 10.1016/S0166-2236(02)02215-4; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; van Deurs B, 2003, TRENDS CELL BIOL, V13, P92, DOI 10.1016/S0962-8924(02)00039-9; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; Zhukova E, 2001, J BIOL CHEM, V276, P40298, DOI 10.1074/jbc.M106512200; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	80	53	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28592	28602		10.1074/jbc.M312242200	http://dx.doi.org/10.1074/jbc.M312242200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15096499	hybrid			2022-12-25	WOS:000222265400095
J	Diebold, BA; Fowler, B; Lu, J; Dinauer, MC; Bokoch, GM				Diebold, BA; Fowler, B; Lu, J; Dinauer, MC; Bokoch, GM			Antagonistic cross-talk between Rac and Cdc42 GTPases regulates generation of reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL RESPIRATORY BURST; NADPH OXIDASE; SUPEROXIDE-PRODUCTION; EFFECTOR REGION; INSERT REGION; ACTIVATION; RHO; BINDING; PROTEIN; DOMAIN	Cross-talk between Rho GTPase family members (Rho, Rac, and Cdc42) plays important roles in modulating and coordinating downstream cellular responses resulting from Rho GTPase signaling. The NADPH oxidase of phagocytes and nonphagocytic cells is a Rac GTPase-regulated system that generates reactive oxygen species (ROS) for the purposes of innate immunity and intracellular signaling. We recently demonstrated that NADPH oxidase activation involves sequential interactions between Rac and the flavocytochrome b(558) and p67(phox) oxidase components to regulate electron transfer from NADPH to molecular oxygen. Here we identify an antagonistic interaction between Rac and the closely related GTPase Cdc42 at the level of flavocytochrome b558 that regulates the formation of ROS. Cdc42 is unable to stimulate ROS formation by NADPH oxidase, but Cdc42, like Rac1 and Rac2, was able to specifically bind to flavocytochrome b(558) in vitro. Cdc42 acted as a competitive inhibitor of Rac1- and Rac2- mediated ROS formation in a recombinant cell-free oxidase system. Inhibition was dependent on the Cdc42 insert domain but not the Switch I region. Transient expression of Cdc42Q61L inhibited ROS formation induced by constitutively active Rac1 in an NADPH oxidase-expressing Cos7 cell line. Inhibition of Cdc42 activity by transduction of the Cdc42-binding domain of Wiscott-Aldrich syndrome protein into human neutrophils resulted in an enhanced fMetLeuPhe-induced oxidative response, consistent with inhibitory cross-talk between Rac and Cdc42 in activated neutrophils. We propose here a novel antagonism between Rac and Cdc42 GTPases at the level of the Nox proteins that modulates the generation of ROS used for host defense, cell signaling, and transformation.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Dept Pediat Hematol Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Dept Microbiol Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Dept Med & Mol Genet, Indianapolis, IN 46202 USA	Scripps Research Institute; Scripps Research Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Bokoch, GM (corresponding author), Scripps Res Inst, Dept Immunol & Cell Biol, IMM-14,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	bokoch@scripps.edu			NCRR NIH HHS [M01 RR 00833] Funding Source: Medline; NHLBI NIH HHS [HL 48008, HL 45635] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008, R01HL045635] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; Burridge K, 1999, SCIENCE, V283, P2028, DOI 10.1126/science.283.5410.2028; Catz SD, 1996, J LEUKOCYTE BIOL, V59, P591, DOI 10.1002/jlb.59.4.591; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Gardiner EM, 2002, CURR BIOL, V12, P2029, DOI 10.1016/S0960-9822(02)01334-9; Geiszt M, 2003, J BIOL CHEM, V278, P20006, DOI 10.1074/jbc.M301289200; Geiszt M, 2003, FASEB J, V17, P1502, DOI 10.1096/fj.02-1104fje; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; Gruenheid S, 2003, NATURE, V422, P775, DOI 10.1038/nature01603; Haddad E, 2001, BLOOD, V97, P33, DOI 10.1182/blood.V97.1.33; Han HS, 2003, J EXP MED, V197, P63, DOI 10.1084/jem.20021638; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Juris SJ, 2002, CELL MICROBIOL, V4, P201, DOI 10.1046/j.1462-5822.2002.00182.x; Kim C, 2001, J IMMUNOL, V166, P1223, DOI 10.4049/jimmunol.166.2.1223; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Lapouge K, 2002, J BIOL CHEM, V277, P10121, DOI 10.1074/jbc.M112065200; Leverrier Y, 2001, J IMMUNOL, V166, P4831, DOI 10.4049/jimmunol.166.8.4831; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Matozaki T, 2000, CELL SIGNAL, V12, P515, DOI 10.1016/S0898-6568(00)00102-9; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; Price MO, 2002, BLOOD, V99, P2653, DOI 10.1182/blood.V99.8.2653; Rabiet MJ, 2002, BLOOD, V100, P1835, DOI 10.1182/blood-2001-12-0193; Ridley AJ, 2001, J CELL SCI, V114, P2713; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sohn HY, 2000, J BIOL CHEM, V275, P18745, DOI 10.1074/jbc.M000026200; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Thrasher AJ, 2002, NAT REV IMMUNOL, V2, P635, DOI 10.1038/nri884; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V186, P509, DOI 10.1016/S0006-291X(05)80837-X; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; Wadia JS, 2003, CURR PROTEIN PEPT SC, V4, P97, DOI 10.2174/1389203033487289; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042	55	68	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28136	28142		10.1074/jbc.M313891200	http://dx.doi.org/10.1074/jbc.M313891200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123662	hybrid			2022-12-25	WOS:000222265400040
J	Feng, ZH; Kachnic, L; Zhang, JR; Powell, SN; Xia, F				Feng, ZH; Kachnic, L; Zhang, JR; Powell, SN; Xia, F			DNA damage induces p53-dependent BRCA1 nuclear export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; CELL-CYCLE REGULATION; OVARIAN-CANCER CELLS; SUBCELLULAR-LOCALIZATION; INDUCED PHOSPHORYLATION; IONIZING IRRADIATION; GENOTOXIC STRESS; EPITHELIAL-CELLS; GROWTH ARREST; MEIOTIC CELLS	The tumor suppressor gene BRCA1 plays an important role in the response to DNA damage. BRCA1 function is regulated by a variety of mechanisms including transcriptional control, phosphorylation, and protein-protein interactions. Recent studies have shown that BRCA1 is a nuclear-cytoplasmic shuttle protein. Its subcellular localization is controlled by a nuclear localization signal-mediated nuclear import via the importin receptor pathway and a nuclear export signal-facilitated nuclear export through a CRM1-dependent pathway. Using the human breast cancer cell line, MCF7, the subcellular distribution of BRCA1 was assessed by immunohistochemical staining and Western blotting analyses of fractionated subcellullar extracts. Ionizing radiation stimulated BRCA1 nuclear export in a dose-dependent manner. This DNA damage-induced BRCA1 nuclear export utilized a CRM1-dependent mechanism and also required wild-type p53, whose function was abrogated by the E6 protein in MCF7 cells. In addition, the dependence on p53 was confirmed using a second cell type operating a tetracycline-inducible system. The effect of ionizing radiation on BRCA1 export was observed in every phase of the cell cycle, although BRCA1 localization did vary between the G(1), S, and G(2)/M phases. These results imply that, in addition to ATM-, ATR-, and Chk2-dependent phosphorylations, cytoplasmic relocalization of BRCA1 protein is a mechanism whereby BRCA1 function is regulated in response to DNA damage.	Massachusetts Gen Hosp, Dept Radiat Oncol, Charlestown, MA 02139 USA; Harvard Univ, Sch Med, Charlestown, MA 02139 USA	Harvard University; Massachusetts General Hospital; Harvard University	Xia, F (corresponding author), Vanderbilt Univ, Sch Med, Dept Radiat Oncol, 1301 22nd Ave, Nashville, TN 37232 USA.	fen.xia@vanderbilt.edu	Xia, Fen/G-3708-2013					Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Arizti P, 2000, MOL CELL BIOL, V20, P7450, DOI 10.1128/MCB.20.20.7450-7459.2000; Bellamy COC, 1997, BRIT MED BULL, V53, P522; Bertwistle D, 1997, CANCER RES, V57, P5485; BHATIA U, Z CLIN CANC RES, V1, P873; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Brown MA, 2002, TRANSGENIC RES, V11, P467, DOI 10.1023/A:1020348025139; Brzovic PS, 2001, J BIOL CHEM, V276, P41399, DOI 10.1074/jbc.M106551200; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen JJ, 2000, CANCER RES, V60, P5037; Chen YM, 1996, CANCER RES, V56, P3168; Chodosh LA, 1998, J MAMMARY GLAND BIOL, V3, P389, DOI 10.1023/A:1018784031651; Choisy-Rossi C, 1998, TOXICOL LETT, V103, P491, DOI 10.1016/S0378-4274(98)00238-0; Choudhary SK, 2002, J CELL BIOCHEM, V84, P666, DOI 10.1002/jcb.10081; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Fan SJ, 1998, INT J CANCER, V77, P600, DOI 10.1002/(SICI)1097-0215(19980812)77:4<600::AID-IJC21>3.0.CO;2-8; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; Gatei M, 2000, CANCER RES, V60, P3299; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Gurley KE, 1998, CANCER RES, V58, P3111; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hofmann W, 2000, J CANCER RES CLIN, V126, P487, DOI 10.1007/s004320000140; Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Liu YL, 2002, BREAST CANCER RES, V4, P9, DOI 10.1186/bcr417; MacLachlan TK, 2000, J BIOL CHEM, V275, P31869, DOI 10.1074/jbc.M003338200; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; Miura M, 1999, J RADIAT RES, V40, P1, DOI 10.1269/jrr.40.1; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Rosen EM, 2001, CANCER INVEST, V19, P396, DOI 10.1081/CNV-100103134; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 2000, ONCOGENE, V19, P6176, DOI 10.1038/sj.onc.1203971; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Vaughn JP, 1996, CANCER RES, V56, P4590; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wenz F, 1998, RADIAT RES, V149, P32, DOI 10.2307/3579679; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	65	58	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28574	28584		10.1074/jbc.M404137200	http://dx.doi.org/10.1074/jbc.M404137200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15087457	hybrid			2022-12-25	WOS:000222265400093
J	Fu, T; Mukhopadhyay, D; Davidson, NO; Borensztajn, J				Fu, T; Mukhopadhyay, D; Davidson, NO; Borensztajn, J			The peroxisome proliferator-activated receptor alpha (PPAR alpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice - Effects on plasma lipoproteins and the development of atherosclerotic lesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SR-BI; TRANSGENIC MICE; APO-B; CHOLESTEROL; OVEREXPRESSION; MOUSE; HYPERCHOLESTEROLEMIA; EXPRESSION; SECRETION; CLEARANCE	Low density lipoprotein receptor (LDLR)-deficient mice fed a chow diet have a mild hypercholesterolemia caused by the abnormal accumulation in the plasma of apolipoprotein B (apoB)-100- and apoB-48-carrying intermediate density lipoproteins (IDL) and low density lipoproteins (LDL). Treatment of LDLR-deficient mice with ciprofibrate caused a marked decrease in plasma apoB-48-carrying IDL and LDL but at the same time caused a large accumulation of triglyceride-depleted apoB-100-carrying IDL and LDL, resulting in a significant increase in plasma cholesterol levels. These plasma lipoprotein changes were associated with an increase in the hepatic secretion of apoB-100-carrying very low density lipoproteins ( VLDL) and a decrease in the secretion of apoB-48-carrying VLDL, accompanied by a significant decrease in hepatic apoB mRNA editing. Hepatic apobec-1 complementation factor mRNA and protein abundance were significantly decreased, whereas apobec-1 mRNA and protein abundance remained unchanged. No changes in apoB mRNA editing occurred in the intestine of the treated animals. After 150 days of treatment with ciprofibrate, consistent with the increased plasma accumulation of apoB-100-carrying IDL and LDL, the LDLR-deficient mice displayed severe atherosclerotic lesions in the aorta. These findings demonstrate that ciprofibrate treatment decreases hepatic apoB mRNA editing and alters the pattern of hepatic lipoprotein secretion toward apoB-100-associated VLDL, changes that in turn lead to increased atherosclerosis.	Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA; Washington Univ, Dept Internal Med, St Louis, MO 63110 USA	Northwestern University; Feinberg School of Medicine; Washington University (WUSTL)	Borensztajn, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	jbb@northwestern.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038180, R01HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38180] Funding Source: Medline; NIDDK NIH HHS [DK 52574] Funding Source: Medline; PHS HHS [DL 56260] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Anant S, 2002, TRENDS CARDIOVAS MED, V12, P311, DOI 10.1016/S1050-1738(02)00180-9; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Barbier O, 2002, ARTERIOSCL THROM VAS, V22, P717, DOI 10.1161/01.ATV.0000015598.86369.04; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; BORENSZTAJN J, 1976, BIOCHEM J, V156, P539, DOI 10.1042/bj1560539; Covey SD, 2003, ARTERIOSCL THROM VAS, V23, P1589, DOI 10.1161/01.ATV.0000083343.19940.A0; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; Duez H, 2002, J BIOL CHEM, V277, P48051, DOI 10.1074/jbc.M206966200; Fruchart J C, 2001, Curr Atheroscler Rep, V3, P83, DOI 10.1007/s11883-001-0015-x; Fu T, 2003, J BIOL CHEM, V278, P52559, DOI 10.1074/jbc.M310892200; Fu T, 2003, BIOCHEM J, V373, P941, DOI 10.1042/BJ20030105; Havel RJ, 1998, ATHEROSCLEROSIS, V141, pS1; HAYASHI H, 1990, AM J PHYSIOL, V259, pG709, DOI 10.1152/ajpgi.1990.259.5.G709; Huszar D, 2000, ARTERIOSCL THROM VAS, V20, P1068, DOI 10.1161/01.ATV.20.4.1068; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Krause BR, 1998, ATHEROSCLEROSIS, V140, P15, DOI 10.1016/S0021-9150(98)00141-5; Li XH, 1996, J LIPID RES, V37, P210; Linden D, 2002, J BIOL CHEM, V277, P23044, DOI 10.1074/jbc.M110416200; Linton M F, 2000, Curr Atheroscler Rep, V2, P29, DOI 10.1007/s11883-000-0092-2; Mardones P, 2003, J BIOL CHEM, V278, P7884, DOI 10.1074/jbc.M211627200; Mukhopadhyay D, 2003, ENDOCRINOLOGY, V144, P711, DOI 10.1210/en.2002-220741; Okochi E, 1999, BBA-MOL CELL BIOL L, V1437, P393, DOI 10.1016/S1388-1981(99)00024-4; Powell-Braxton L, 1998, NAT MED, V4, P934, DOI 10.1038/nm0898-934; Rubins HB, 2000, EUR HEART J, V21, P1113, DOI 10.1053/euhj.1999.2024; Smith JD, 1997, J INTERN MED, V242, P99, DOI 10.1046/j.1365-2796.1997.00197.x; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; Veniant MM, 1998, J CLIN INVEST, V102, P1559, DOI 10.1172/JCI4164; Veniant MM, 2000, J CLIN INVEST, V106, P1501, DOI 10.1172/JCI10695; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Webb NR, 2002, J LIPID RES, V43, P1421, DOI 10.1194/jlr.M200026-JLR200	31	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28662	28669		10.1074/jbc.M403271200	http://dx.doi.org/10.1074/jbc.M403271200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123680	hybrid			2022-12-25	WOS:000222265400102
J	Ogawa, H; Qiu, Y; Ogata, CM; Misono, KS				Ogawa, H; Qiu, Y; Ogata, CM; Misono, KS			Crystal structure of hormone-bound atrial natriuretic peptide receptor extracellular domain - Rotation mechanism for transmembrane signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLYL-CYCLASE; ERYTHROPOIETIN RECEPTOR; VASORELAXANT ACTIVITY; MOLECULAR-BIOLOGY; BINDING DOMAIN; ANP RECEPTOR; ACTIVATION; SYSTEM; EXPRESSION; HYPERTENSION	A cardiac hormone, atrial natriuretic peptide (ANP), plays a major role in blood pressure and volume regulation. ANP activities are mediated by a single span transmembrane receptor carrying intrinsic guanylate cyclase activity. ANP binding to its extracellular domain stimulates guanylate cyclase activity by an as yet unknown mechanism. Here we report the crystal structure of dimerized extracellular hormone-binding domain in complex with ANP. The structural comparison with the unliganded receptor reveals that hormone binding causes the two receptor monomers to undergo an intermolecular twist with little intramolecular conformational change. This motion produces a Ferris wheel-like translocation of two juxtamembrane domains in the dimer with essentially no change in the interdomain distance. This movement alters the relative orientation of the two domains by a shift equivalent to counterclock-wise rotation of each by 24degrees. These results suggest that transmembrane signaling by the ANP receptor is initiated via a hormone-induced rotation mechanism.	Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Argonne Natl Lab, Adv Photon Source, Argonne, IL 60439 USA	Cleveland Clinic Foundation; United States Department of Energy (DOE); Argonne National Laboratory	Misono, KS (corresponding author), Univ Nevada, Sch Med, Dept Biochem, Reno, NV 89557 USA.	kmisono@unr.edu			NHLBI NIH HHS [HL 54329] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054329] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOVY PR, 1990, MED RES REV, V10, P115, DOI 10.1002/med.2610100105; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; Cohen D, 1996, J BIOL CHEM, V271, P9863, DOI 10.1074/jbc.271.16.9863; CURRIE MG, 1983, SCIENCE, V221, P71, DOI 10.1126/science.6857267; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; FULLE HJ, 1995, P NATL ACAD SCI USA, V92, P3571, DOI 10.1073/pnas.92.8.3571; FULLER F, 1988, J BIOL CHEM, V263, P9395; GRAMMER RT, 1983, BIOCHEM BIOPH RES CO, V116, P696, DOI 10.1016/0006-291X(83)90581-8; HE XL, 1995, BIOCONJUGATE CHEM, V6, P541, DOI 10.1021/bc00035a007; He XL, 2001, SCIENCE, V293, P1657, DOI 10.1126/science.1062246; Huo XW, 1999, BIOCHEMISTRY-US, V38, P16941, DOI 10.1021/bi9919448; JOHN SWM, 1995, SCIENCE, V267, P679, DOI 10.1126/science.7839143; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUROSE H, 1987, FEBS LETT, V219, P375, DOI 10.1016/0014-5793(87)80256-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Misono KS, 2000, CIRC RES, V86, P1135; Misono KS, 1999, BIOCHEMISTRY-US, V38, P516, DOI 10.1021/bi982127v; MISONO KS, 1984, BIOCHEM BIOPH RES CO, V123, P444, DOI 10.1016/0006-291X(84)90250-X; Miyagi M, 2000, EUR J BIOCHEM, V267, P5758, DOI 10.1046/j.1432-1327.2000.01647.x; Miyagi M, 2000, BBA-PROTEIN STRUCT M, V1478, P30, DOI 10.1016/S0167-4838(00)00002-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakane M, 1994, Adv Pharmacol, V26, P7, DOI 10.1016/S1054-3589(08)60048-4; NAKAO K, 1992, J HYPERTENS, V10, P907; NAKAO K, 1992, J HYPERTENS, V10, P1111, DOI 10.1097/00004872-199210000-00002; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ogawa H, 2003, ACTA CRYSTALLOGR D, V59, P1831, DOI 10.1107/S0907444903016445; Oliver PM, 1997, P NATL ACAD SCI USA, V94, P14730, DOI 10.1073/pnas.94.26.14730; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Qiu Y, 2004, J BIOL CHEM, V279, P6115, DOI 10.1074/jbc.M310225200; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; van den Akker F, 2000, NATURE, V406, P101, DOI 10.1038/35017602; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025	43	113	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28625	28631		10.1074/jbc.M313222200	http://dx.doi.org/10.1074/jbc.M313222200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117952	hybrid			2022-12-25	WOS:000222265400098
J	Peng, Y; Jiang, BH; Yang, PH; Cao, ZX; Shi, XL; Lin, MCM; He, ML; Kung, HF				Peng, Y; Jiang, BH; Yang, PH; Cao, ZX; Shi, XL; Lin, MCM; He, ML; Kung, HF			Phosphatidylinositol 3-kinase signaling is involved in neurogenesis during Xenopus embryonic development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; NF-KAPPA-B; SERINE-THREONINE KINASE; NITRIC-OXIDE SYNTHASE; HOMEOBOX GENE; PHOSPHOINOSITIDE 3-KINASE; DEPENDENT PHOSPHORYLATION; ENDOTHELIAL-CELLS; CORTICAL ROTATION; NEURAL INDUCTION	Phosphatidylinositol 3-kinase (PI3K) has numerous cellular functions, including cell survival and proliferation. In this study, we demonstrated that the expression of the active form of PI3K induced dorsal differentiation and axis duplication and strongly induced the expression of neural markers. In contrast, the inhibition of PI3K activity by its dominant negative mutant induced the phenotype of losing posterior structures and the expression of ventral markers. Akt is an essential target of PI3K for neurogenesis. The expression of the active form of Akt induced axis duplication and increased the expression of neural markers. Inhibition of the Akt activity abolished the PI3K-induced double heads and axes. This signal transmits through its target, glycogen synthase kinase 3beta, which is known to mediate Wnt signaling for Xenopus development. These results identify a new function of PI3K/Akt signaling in axis formation and neurogenesis during Xenopus embryonic development and provide a direct link between growth factor-mediated PI3K/Akt signaling and Wnt signaling during embryonic development.	Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; First Mil Med Univ, Nanfang Hosp, Dept Neurol, Guangzhou 510515, Peoples R China; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; Chinese Acad Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China	University of Hong Kong; Southern Medical University - China; West Virginia University; Chinese Academy of Sciences	Kung, HF (corresponding author), Univ Hong Kong, Inst Mol Biol, 8-F,Kadoorie Biol Sci Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	hkung@hkucc.hku.hk	HE, Ming-Liang/AAG-3397-2022; HE, Ming-Liang/AFK-4738-2022; Shi, Xianglin/B-8588-2012	He, Ming-Liang/0000-0002-4317-2836; HE, Mingliang/0000-0002-9942-9151; Jiang, Bing-Hua/0000-0003-4526-2031	NCRR NIH HHS [RR 16440] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016440] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; BLITZ IL, 1995, DEVELOPMENT, V121, P993; Carballada R, 2001, DEVELOPMENT, V128, P35; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DAWID IB, 1994, J BIOL CHEM, V269, P6259; DEL PL, 1997, SCIENCE, V278, P687; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dominguez I, 2000, DEVELOPMENT, V127, P861; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GERHART J, 1989, DEVELOPMENT, V107, P37; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; Izuhara K, 1996, BLOOD, V88, P3910, DOI 10.1182/blood.V88.10.3910.bloodjournal88103910; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; KARNITZ LM, 1994, J EXP MED, V179, P1799, DOI 10.1084/jem.179.6.1799; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KINTNER CR, 1987, DEVELOPMENT, V99, P311; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Ozes ON, 1999, NATURE, V401, P82; PANNESE M, 1995, DEVELOPMENT, V121, P707; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Suzuki A, 1997, DEVELOPMENT, V124, P3037; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; WRIGHT CVE, 1990, DEVELOPMENT, V109, P225; Xu RH, 1997, MOL CELL BIOL, V17, P436, DOI 10.1128/MCB.17.1.436; Xu RH, 1997, J NEUROSCI, V17, P6892	48	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28509	28514		10.1074/jbc.M402294200	http://dx.doi.org/10.1074/jbc.M402294200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123704	Green Published, hybrid			2022-12-25	WOS:000222265400086
J	Rossner, S; Fuchsbrunner, K; Lange-Dohna, C; Hartlage-Rubsamen, M; Bigl, V; Betz, A; Reim, K; Brose, N				Rossner, S; Fuchsbrunner, K; Lange-Dohna, C; Hartlage-Rubsamen, M; Bigl, V; Betz, A; Reim, K; Brose, N			Munc13-1-mediated vesicle priming contributes to secretory amyloid precursor protein processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; BETA-SECRETASE; PHORBOL ESTERS; MUNC13-1; ALPHA; PHOSPHORYLATION; CLEAVAGE; RELEASE; DIACYLGLYCEROL; PEPTIDE	The amyloid precursor protein (APP) gives rise to beta-amyloid peptides, which are the main constituents of senile plaques in brains of Alzheimer's disease patients. Non-amyloidogenic processing of the APP can be stimulated by phorbol esters (PEs) and by intracellular diacylglycerol (DAG) generation. This led to the hypothesis that classical and novel protein kinase Cs (PKCs), which are activated by DAG/PEs, regulate APP processing. However, in addition to PKCs, there are other DAG/PE receptors present in neurons that may participate in the modulation of APP processing. Munc13-1, a presynaptic protein with an essential role in synaptic vesicle priming, represents such an alternative target of the DAG second messenger pathway. Using Munc13-1 knock- out mice and knock- in mice expressing a Munc13-1(H567K) variant deficient in DAG/PE binding, we determined the relative contributions of PKCs and Munc13-1 to PE-stimulated secretory APP processing. We establish that, in addition to PKC, Munc13-1 significantly contributes to the regulation of secretory APP metabolism.	Paul Flechsig Inst Brain Res, Dept Neurochem, D-04109 Leipzig, Germany; Max Planck Inst Expt Med, Abt Mol Neurobiol, D-37075 Gottingen, Germany	Max Planck Society	Rossner, S (corresponding author), Paul Flechsig Inst Brain Res, Dept Neurochem, Jahnallee 59, D-04109 Leipzig, Germany.	rossn@medizin.uni-leipzig.de	Hartlage-Rübsamen, Maike/A-5056-2017; Rossner, Steffen/A-5184-2017					Augustin I, 2001, J NEUROSCI, V21, P10, DOI 10.1523/JNEUROSCI.21-01-00010.2001; Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Bruckner G, 2001, EXP BRAIN RES, V137, P83; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Rhee JS, 2002, CELL, V108, P121, DOI 10.1016/S0092-8674(01)00635-3; Rossner S, 2000, EUR J NEUROSCI, V12, P3191, DOI 10.1046/j.1460-9568.2000.00211.x; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; Sheu L, 2003, J BIOL CHEM, V278, P27556, DOI 10.1074/jbc.M303203200; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; SLACK BE, 1993, J BIOL CHEM, V268, P21097; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243	22	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27841	27844		10.1074/jbc.C400122200	http://dx.doi.org/10.1074/jbc.C400122200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123597	hybrid			2022-12-25	WOS:000222265400003
J	Thomas, SK; Messam, CA; Spengler, BA; Biedler, JL; Ross, RA				Thomas, SK; Messam, CA; Spengler, BA; Biedler, JL; Ross, RA			Nestin is a potential mediator of malignancy in human neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE-FILAMENT NESTIN; N-MYC; TRANSCRIPTION FACTOR; GENE-EXPRESSION; PROTEIN; VIMENTIN; DNA; LINES; DIFFERENTIATION; IDENTIFICATION	Amplification of the N-myc proto-oncogene signifies aggressive behavior in human neuroblastoma. Likewise, overexpression of the intermediate filament nestin, a neuroectodermal stem cell marker, is linked to increased aggressiveness in several nervous system tumors. We investigated the interaction of these two proteins in human neuroblastoma cells. Neuroblastic cell variants with high levels of N-Myc protein have significantly higher nestin protein levels than non-amplified cell lines, suggesting that the transcription factor N-Myc may regulate nestin expression. Stable transfection of a nestin antisense sequence into neuroblastic, N-myc-amplified, LA1-55n cells results in a 2-fold reduction in nestin protein without altering N-Myc expression. However, cell functions attributed to N-Myc ( growth rate, anchorage-independent growth, and motility) all decrease significantly. Transfection studies that modulate N-Myc levels also result in commensurate changes in nestin mRNA and protein amounts as well as in cell proliferation and motility. Thus, nestin appears to be downstream of and regulated by N-Myc. Gel mobility shift assays show that N-Myc binds specifically to E-box sequences in the regulatory second intron of the nestin gene and nuclear run-off studies show that increases in N-Myc protein up-regulate nestin transcription rate. Subcellular fractionation and immunoblot studies indicate that nestin is present in the nucleus as well as in the cytoplasm of neuroblastoma cell lines. Finally, DNA cross-linking experiments show that nestin binds DNA in N-myc-amplified N-type cell lines. Thus, nestin may be one mediator of N-myc-associated tumor aggressiveness of human neuroblastoma.	Fordham Univ, Dept Biol Sci, Neurobiol Lab, Bronx, NY 10458 USA; Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA	Fordham University; University of Pennsylvania	Ross, RA (corresponding author), Fordham Univ, Dept Biol Sci, Neurobiol Lab, 441 E Fordham Rd, Bronx, NY 10458 USA.	rross@fordham.edu			NATIONAL CANCER INSTITUTE [R01CA077593] Funding Source: NIH RePORTER; NCI NIH HHS [CA 77593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1987, CANCER RES, V47, P3239; Aubry S, 2000, DNA CELL BIOL, V19, P353, DOI 10.1089/10445490050043326; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; CLASSON M, 1993, GENE, V133, P153, DOI 10.1016/0378-1119(93)90633-E; COHN SL, 1990, ONCOGENE, V5, P1821; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; DAHLSTRAND J, 1992, J CELL SCI, V103, P589; Duggal N, 1997, BRAIN RES, V768, P1, DOI 10.1016/S0006-8993(97)00588-X; FERRARO A, 1991, BIOCHEM BIOPH RES CO, V178, P1365, DOI 10.1016/0006-291X(91)91044-D; FLORENES VA, 1994, CANCER RES, V54, P354; FOLEY J, 1991, CANCER RES, V51, P6338; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; FRESHNEY RI, 1994, CULTURE ANIMAL CELLS, P282; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Hartig R, 1998, J CELL SCI, V111, P3573; Hendrix MJC, 1996, CANCER METAST REV, V15, P413, DOI 10.1007/BF00054009; Hildebrandt AL, 2000, AM J PHYSIOL-ENDOC M, V278, pE1078, DOI 10.1152/ajpendo.2000.278.6.E1078; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; Lazarova DL, 1999, ONCOGENE, V18, P2703, DOI 10.1038/sj.onc.1202621; Lothian C, 1997, EUR J NEUROSCI, V9, P452, DOI 10.1111/j.1460-9568.1997.tb01622.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; Lutz W, 1996, ONCOGENE, V13, P803; Messam CA, 2000, EXP NEUROL, V161, P585, DOI 10.1006/exnr.1999.7319; Norris MD, 2000, MED PEDIATR ONCOL, V35, P585, DOI 10.1002/1096-911X(20001201)35:6<585::AID-MPO20>3.3.CO;2-G; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; Rutka JT, 1999, INT J DEV NEUROSCI, V17, P503, DOI 10.1016/S0736-5748(99)00049-0; Shohet JM, 2002, CANCER RES, V62, P1123; Spencer VA, 1998, J BIOL CHEM, V273, P29093, DOI 10.1074/jbc.273.44.29093; Spencer VA, 2000, CANCER RES, V60, P288; Spengler BA, 1997, ONCOL RES, V9, P467; Sugiura Y, 1999, CANCER RES, V59, P1327; THOMAS SK, 2003, THESIS FORDHAM U NEW; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TOHYAMA T, 1992, LAB INVEST, V66, P303; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; WADA RK, 1993, CANCER, V72, P3346, DOI 10.1002/1097-0142(19931201)72:11<3346::AID-CNCR2820721134>3.0.CO;2-E; Wakamatsu Y, 1997, DEVELOPMENT, V124, P1953; Wang X, 1996, DNA CELL BIOL, V15, P209, DOI 10.1089/dna.1996.15.209; Weggen S, 1997, BRAIN PATHOL, V7, P731, DOI 10.1111/j.1750-3639.1997.tb01059.x; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1	44	79	84	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27994	27999		10.1074/jbc.M312663200	http://dx.doi.org/10.1074/jbc.M312663200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117961	hybrid			2022-12-25	WOS:000222265400022
J	Umland, TC; Wolff, EC; Park, MH; Davies, DR				Umland, TC; Wolff, EC; Park, MH; Davies, DR			A new crystal structure of deoxyhypusine synthase reveals the configuration of the active enzyme and of an enzyme center dot NAD center dot inhibitor ternary complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 5A; HYPUSINE-CONTAINING PROTEIN; SUBSTRATE INTERMEDIATE; CELL-CYCLE; SPERMIDINE; HOMOSPERMIDINE; FEATURES; BINDING; IDENTIFICATION; EXPRESSION	Deoxyhypusine synthase catalyzes the first step in the two-step post-translational synthesis of hypusine, which is uniquely present in eukaryotic initiation factor 5A (eIF5A). Deoxyhypusine synthase and eIF5A are conserved throughout the eukaryotic kingdom, and both are essential for cell proliferation and survival. A previous study (Liao, D. I., Wolff, E. C., Park, M. H., and Davies, D. R. ( 1998) Structure 6, 23-32) of human deoxyhypusine synthase revealed four active sites of the homotetrameric enzyme located within deep tunnels. These Form I crystals were obtained under conditions of acidic pH and high ionic strength and likely contain an inactive enzyme. Each active-site entrance is blocked by a ball-and-chain motif composed of a region of extended structure capped by a two-turn alpha-helix. We report here at 2.2 Angstrom a new Form II crystal of the deoxyhypusine synthase: NAD holoenzyme grown at low ionic strength and pH 8.0, near the optimal pH for enzymatic activity. The ball-and-chain motif could not be detected in the electron density, suggesting that it swings freely and thus it no longer obstructs the active-site entrance. The deoxyhypusine synthase competitive inhibitor N-1-guanyl-1,7-diaminoheptane (GC(7)) is observed bound within the putative active site of the enzyme in the new crystal form ( Form II) after exposure to the inhibitor. This first structure of a deoxyhypusine synthase.NAD.inhibitor ternary complex under physiological conditions now provides a structural context to discuss the results of previous biochemical investigations of the deoxyhypusine synthase reaction mechanism. This structure also provides a basis for the development of improved inhibitors and antiproliferative agents.	NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Davies, DR (corresponding author), NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	david.davies@nih.gov		Umland, Timothy/0000-0002-0772-9510	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036109] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILLON JG, 1988, EUR J BIOCHEM, V176, P237, DOI 10.1111/j.1432-1033.1988.tb14274.x; BARTIG D, 1992, EUR J BIOCHEM, V204, P751, DOI 10.1111/j.1432-1033.1992.tb16690.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chen KY, 1997, BIOL SIGNAL, V6, P105; Chen ZP, 1996, CANCER LETT, V105, P233, DOI 10.1016/0304-3835(96)04287-5; GORDON ED, 1987, J BIOL CHEM, V262, P16585; HANAUSKEABEL HM, 1994, BBA-MOL CELL RES, V1221, P115, DOI 10.1016/0167-4889(94)90003-5; JAKUS J, 1993, J BIOL CHEM, V268, P13151; Jansson BPM, 2000, J BACTERIOL, V182, P1158, DOI 10.1128/JB.182.4.1158-1161.2000; JOE YA, 1994, J BIOL CHEM, V269, P25916; JOE YA, 1995, J BIOL CHEM, V270, P22386, DOI 10.1074/jbc.270.38.22386; Joe YA, 1997, J BIOL CHEM, V272, P32679, DOI 10.1074/jbc.272.51.32679; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kang KR, 1999, EXP MOL MED, V31, P210, DOI 10.1038/emm.1999.34; Kim KK, 1998, P NATL ACAD SCI USA, V95, P10419, DOI 10.1073/pnas.95.18.10419; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee CH, 2000, BIOCHEM J, V352, P851, DOI 10.1042/0264-6021:3520851; Lee GH, 2001, BIOCHEM J, V355, P841, DOI 10.1042/bj3550841; Lee YB, 1999, BIOCHEM J, V340, P273, DOI 10.1042/0264-6021:3400273; Lee YB, 1998, BIOORGAN MED CHEM, V6, P253, DOI 10.1016/S0968-0896(97)10030-X; Liao DI, 1998, STRUCTURE, V6, P23, DOI 10.1016/S0969-2126(98)00004-5; Lipowsky G, 2000, EMBO J, V19, P4362, DOI 10.1093/emboj/19.16.4362; MURPHEY RJ, 1987, J BIOL CHEM, V262, P15033; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishimura K, 2002, BIOCHEM J, V363, P761, DOI 10.1042/0264-6021:3630761; Ober D, 2003, J BIOL CHEM, V278, P12805, DOI 10.1074/jbc.M207112200; Ober D, 2003, PHYTOCHEMISTRY, V62, P339, DOI 10.1016/S0031-9422(02)00553-8; Ober D, 1999, J BIOL CHEM, V274, P32040, DOI 10.1074/jbc.274.45.32040; Ober D, 1999, P NATL ACAD SCI USA, V96, P14777, DOI 10.1073/pnas.96.26.14777; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park JH, 2003, J BIOL CHEM, V278, P32683, DOI 10.1074/jbc.M304247200; PARK MH, 1994, J BIOL CHEM, V269, P27827; Park MH, 1997, BIOL SIGNAL, V6, P115; Peat TS, 1998, STRUCT FOLD DES, V6, P1207, DOI 10.1016/S0969-2126(98)00120-8; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Wolff EC, 1999, YEAST, V15, P43; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; Wolff EC, 1997, J BIOL CHEM, V272, P15865, DOI 10.1074/jbc.272.25.15865; Wolff EC, 2000, J BIOL CHEM, V275, P9170, DOI 10.1074/jbc.275.13.9170; Xu AG, 2001, J BIOL CHEM, V276, P2555, DOI 10.1074/jbc.M008982200; Yao M, 2003, J BIOCHEM, V133, P75, DOI 10.1093/jb/mvg011	43	63	66	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28697	28705		10.1074/jbc.M404095200	http://dx.doi.org/10.1074/jbc.M404095200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15100216	hybrid			2022-12-25	WOS:000222265400107
J	Saleem, M; Afaq, F; Adhami, VM; Mukhtar, H				Saleem, M; Afaq, F; Adhami, VM; Mukhtar, H			Lupeol modulates NF-kappa B and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice	ONCOGENE			English	Article						lupeol; chemoprevention; NF-kappa B; PI3K/Akt; skin cancer	ORNITHINE-DECARBOXYLASE ACTIVITY; SENCAR MOUSE SKIN; GREEN TEA; TUMOR PROMOTION; ANTIINFLAMMATORY TRITERPENOIDS; SIGNAL-TRANSDUCTION; PROSTATE-CANCER; CELL-LINE; IN-VITRO; CHEMOPREVENTION	Chemoprevention has become an effective cancer control modality; however, the search for novel agent(s) for the armamentarium of cancer chemoprevention continues. We argue that agents capable for inhibition of promotion stage of tumorigenesis with the ability to intervene at several critical pathways in the tumorigenesis process will have greater advantage over other single-target agents. Lupeol, a triterpene, is the principal constituent of common fruit plants such as olive, mango,. g and medicinal herbs that have been used to treat skin aliments. Lupeol has been reported to possess a wide range of medicinal properties that include strong antioxidant, antimutagenic, anti-inflammatory and antiarthritic effects. In the present study, we show that Lupeol possesses antitumor-promoting effects in a mouse skin tumorigenesis model. We first determined the effect of topical application of Lupeol to CD-1 mouse against 12-O-tetradecanoylphorbol- 13-acetate (TPA)-induced conventional markers and other novel markers of skin tumor promotion. We found that topical application of Lupeol (1 - 2 mg/mouse) 30 min prior to TPA (3.2 nmol/mouse) application onto the skin of CD-1 mice afforded significant inhibition, in a time- and dose-dependent manner, against TPA-mediated increase in (i) skin edema and hyperplasia, (ii) epidermal ornithine decarboxylase (ODC) activity, and (iii) protein expression of ODC, cyclo-oxygenase-2 and nitric oxide synthase. As of the role of nuclear factor kappa B (NF-kappaB) and phosphatidyl inositol 3-kinase (PI3K)/Akt signaling in tumor promotion, we next determined the effect of topical application of Lupeol to mouse skin against these signaling pathways. We found that Lupeol treatment to mouse skin resulted in the inhibition of TPA-induced ( i) activation of PI3K, ( ii) phosphorylation of Akt at Thr(308), ( iii) activation of NF-kappaB and IKKalpha, and (iv) degradation and phosphorylation of IkappaBalpha. The animals pretreated with Lupeol showed significantly reduced tumor incidence, lower tumor body burden and a significant delay in the latency period for tumor appearance. At the termination of the experiment at 28 weeks, 100% of the animals in TPA-treated group exhibited seven to eight tumors/mouse, whereas only 53% of the mice receiving Lupeol prior to TPA treatment exhibited one to three tumors/mouse. These results for the first time provide evidence that Lupeol possesses antiskin tumor-promoting effects in CD-1 mouse and inhibits conventional as well as novel biomarkers of tumor promotion. We suggest that Lupeol is an attractive antitumor-promoting agent that must be evaluated in tumor models other than skin carcinogenesis.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Mukhtar, H (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, 1300 Univ Ave,B-25, Madison, WI 53706 USA.	hmukhtar@wisc.edu	Saleem, Mohammad/GVS-9221-2022; Adhami, Vaqar/AAY-2837-2020	Saleem, Mohammad/0000-0002-7422-7967; Adhami, Vaqar/0000-0002-2048-4570	NATIONAL CANCER INSTITUTE [R03CA099909, R01CA078809] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 78809, R03 CA 99909] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afaq F, 2003, ONCOGENE, V22, P1035, DOI 10.1038/sj.onc.1206206; Ahmad N, 2000, CLIN CANCER RES, V6, P1524; Ahmad N, 2001, AM J PATHOL, V159, P885, DOI 10.1016/S0002-9440(10)61764-6; ANJANEYLU V, 1982, Indian Journal of Pharmaceutical Sciences, V44, P58; Auvinen M, 1997, JNCI-J NATL CANCER I, V89, P533, DOI 10.1093/jnci/89.8.533; Badria FA, 2003, Z NATURFORSCH C, V58, P505; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beveridge THJ, 2002, J AGR FOOD CHEM, V50, P744, DOI 10.1021/jf010701v; BHIMANI RS, 1993, CANCER RES, V53, P4528; Bickers D R, 2000, J Dermatol, V27, P691; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; Callejas NA, 1999, J CELL SCI, V112, P3147; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chun Kyung-Soo, 2002, Journal of Environmental Pathology Toxicology and Oncology, V21, P131; Conney AH, 1997, P SOC EXP BIOL MED, V216, P234, DOI 10.3181/00379727-216-44173; DIGIOVANNI J, 1991, PROG EXP TUMOR RES, V33, P192; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Einspahr JG, 2003, RECENT RESULTS CANC, V163, P151; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; Fernandez MA, 2001, J PHARM PHARMACOL, V53, P1533, DOI 10.1211/0022357011777909; FOURNET A, 1992, J ETHNOPHARMACOL, V37, P159, DOI 10.1016/0378-8741(92)90074-2; FURSTENBERGER G, 1985, ARACHIDONIC ACID MET, P49; Geetha T, 2001, J ETHNOPHARMACOL, V76, P77, DOI 10.1016/S0378-8741(01)00175-1; Geetha T, 1999, MOL CELL BIOCHEM, V201, P83, DOI 10.1023/A:1007056300503; Guevara AP, 1996, MUTAT RES-ENVIR MUTA, V361, P67, DOI 10.1016/S0165-1161(96)90240-X; Gupta S, 2002, CANCER METAST REV, V21, P363, DOI 10.1023/A:1021275330385; Gupta S, 2001, SKIN PHARMACOL APPL, V14, P373, DOI 10.1159/000056371; Gupta S, 1999, CANCER RES, V59, P2115; Hasmeda M, 1999, PLANTA MED, V65, P14, DOI 10.1055/s-1999-13954; Hata K, 2003, J BIOCHEM, V134, P441, DOI 10.1093/jb/mvg162; Hata K, 2002, J NAT PROD, V65, P645, DOI 10.1021/np0104673; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Hodges LD, 2003, MOL CELL BIOCHEM, V252, P97, DOI 10.1023/A:1025569805468; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; Kakuda R, 2002, PHYTOCHEMISTRY, V59, P791, DOI 10.1016/S0031-9422(02)00021-3; Katiyar SK, 1999, CARCINOGENESIS, V20, P2117, DOI 10.1093/carcin/20.11.2117; Katiyar SK, 1996, CANCER RES, V56, P1023; Katiyar SK, 1997, CARCINOGENESIS, V18, P497, DOI 10.1093/carcin/18.3.497; Katiyar SK, 1997, CARCINOGENESIS, V18, P1911, DOI 10.1093/carcin/18.10.1911; Kim DJ, 2003, MUTAT RES-FUND MOL M, V523, P99, DOI 10.1016/S0027-5107(02)00325-1; Liang YC, 2002, NUTR CANCER, V42, P217, DOI 10.1207/S15327914NC422_11; Lin LC, 2001, J NAT PROD, V64, P674, DOI 10.1021/np000569d; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Mills GB, 2003, SEMIN ONCOL, V30, P93, DOI 10.1053/j.seminoncol.2003.08.011; Miura K, 2001, PHYTOCHEMISTRY, V58, P1171, DOI 10.1016/S0031-9422(01)00341-7; Mohan RR, 1999, CLIN CANCER RES, V5, P143; Moriarity DM, 1998, PLANTA MED, V64, P370, DOI 10.1055/s-2006-957454; Nagaraj M, 2000, J APPL TOXICOL, V20, P413, DOI 10.1002/1099-1263(200009/10)20:5<413::AID-JAT706>3.0.CO;2-Y; NAKADATE T, 1985, JPN J PHARMACOL, V37, P253, DOI 10.1254/jjp.37.253; Nikiema JB, 2001, PHYTOTHER RES, V15, P131, DOI 10.1002/ptr.700; Osaki M, 2004, J CANCER RES CLIN, V130, P8, DOI 10.1007/s00432-003-0505-z; Pereira AD, 2003, Z NATURFORSCH C, V58, P201; Rajic A, 2000, PLANTA MED, V66, P206, DOI 10.1055/s-2000-8657; Saeed MA, 2002, FITOTERAPIA, V73, P417, DOI 10.1016/S0367-326X(02)00127-2; Saleem M, 2001, PHARMACOL RES, V43, P127, DOI 10.1006/phrs.2000.0710; Saleem R, 2003, BIOL PHARM BULL, V26, P41, DOI 10.1248/bpb.26.41; Seo HJ, 2002, INT J CANCER, V100, P456, DOI 10.1002/ijc.10489; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SOSA A, 1963, B SOC CHIM BIOL, V45, P117; Stambolic V, 1999, ONCOGENE, V18, P6094, DOI 10.1038/sj.onc.1203126; Sunitha S, 2001, FITOTERAPIA, V72, P516, DOI 10.1016/S0367-326X(01)00259-3; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Thomas T, 2003, J CELL MOL MED, V7, P113, DOI 10.1111/j.1582-4934.2003.tb00210.x; Ulubelen A, 1997, J NAT PROD, V60, P1275, DOI 10.1021/np9700681; VERMA AK, 1979, CANCER RES, V39, P419; Vidya L, 2002, PHYTOTHER RES, V16, P514, DOI 10.1002/ptr.940; Wada S, 2001, J NAT PROD, V64, P1545, DOI 10.1021/np010176u; Ziegler HL, 2002, ANTIMICROB AGENTS CH, V46, P1441, DOI 10.1128/AAC.46.5.1441-1446.2002	72	201	212	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5203	5214		10.1038/sj.onc.1207641	http://dx.doi.org/10.1038/sj.onc.1207641			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122342				2022-12-25	WOS:000222382500010
J	Wickremasinghe, MI; Thomas, LH; O'Kane, CM; Uddin, J; Friedland, JS				Wickremasinghe, MI; Thomas, LH; O'Kane, CM; Uddin, J; Friedland, JS			Transcriptional mechanisms regulating alveolar epithelial cell-specific CCL5 secretion in pulmonary tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; INTERLEUKIN-1 RECEPTOR ANTAGONIST; RANTES GENE-EXPRESSION; MYCOBACTERIUM-TUBERCULOSIS; COOPERATIVE INTERACTION; INDUCIBLE EXPRESSION; ACTIVATOR PROTEIN-1; ENDOTHELIAL-CELLS; PROMOTER ACTIVITY	CCL5 ( or RANTES ( regulated upon activation, normal T cell expressed and secreted)) recruits T lymphocytes and monocytes. The source and regulation of CCL5 in pulmonary tuberculosis are unclear. Infection of the human alveolar epithelial cell line (A549) by Mycobacterium tuberculosis caused no CCL5 secretion and little monocyte secretion. Conditioned medium from tuberculosis-infected human monocytes (CoMTB) stimulated significant CCL5 secretion from A549 cells and from primary alveolar, but not upper airway, epithelial cells. Differential responsiveness of small airway and normal human bronchial epithelial cells to CoMTB but not to conditioned medium from unstimulated human monocytes was specific to CCL5 and not to CXCL8. CoMTB induced CCL5 mRNA accumulation in A549 cells and induced nuclear translocation of nuclear factor kappaB (NFkappaB) subunits p50, p65, and c-rel at 1 h; nuclear binding of activator protein (AP)-1 (c-Fos, FosB, and c-Jun) at 4 - 8 h; and binding of NF-interleukin (IL)-6 at 24 h. CCL5 promoter-reporter analysis using deletion and site-specific mutagenesis constructs demonstrated a key role for AP-1, NF-IL-6, and NFkappaB in driving CoMTB-induced promoter activity. The IL-1 receptor antagonist inhibited A549 and small airway epithelial cell CCL5 secretion, gene expression, and promoter activity. CoMTB contained IL-1beta, and recombinant IL-1beta reproduced CoMTB effects. Monocyte alveolar, but not upper airway, epithelial cell networks in pulmonary tuberculosis cause AP-1-, NF-IL-6-, and NFkappaB-dependent CCL5 secretion. IL-1beta is the critical regulator of tuberculosis-stimulated CCL5 secretion in the lung.	Hammersmith Hosp, Imperial Coll, Dept Infect Dis, London W12 0NN, England	Imperial College London	Friedland, JS (corresponding author), Hammersmith Hosp, Imperial Coll, Dept Infect Dis, Du Cane Rd, London W12 0NN, England.	j.friedland@ic.ac.uk		Friedland, Jonathan S/0000-0001-7789-9649; O'Kane, Cecilia/0000-0002-7138-5396				Arend WP, 1998, ANNU REV IMMUNOL, V16, P27, DOI 10.1146/annurev.immunol.16.1.27; Atsuta J, 1997, AM J RESP CELL MOL, V17, P571, DOI 10.1165/ajrcmb.17.5.2685; Ayad O, 1998, J IMMUNOL, V161, P2594; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bergeron A, 1997, J IMMUNOL, V159, P3034; Berkman N, 1996, IMMUNOLOGY, V87, P599, DOI 10.1046/j.1365-2567.1996.477579.x; Bermudez LE, 1996, INFECT IMMUN, V64, P1400, DOI 10.1128/IAI.64.4.1400-1406.1996; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brasier AR, 1998, J BIOL CHEM, V273, P3551, DOI 10.1074/jbc.273.6.3551; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Casola A, 2002, AM J PHYSIOL-LUNG C, V283, pL1280, DOI 10.1152/ajplung.00162.2002; Casola A, 2001, J VIROL, V75, P6428, DOI 10.1128/JVI.75.14.6428-6439.2001; Chensue SW, 1999, J IMMUNOL, V163, P165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DEVERGNE O, 1994, J EXP MED, V179, P1689, DOI 10.1084/jem.179.5.1689; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; FRIEDLAND JS, 1992, EUR J IMMUNOL, V22, P1373, DOI 10.1002/eji.1830220607; Hashimoto S, 2000, AM J RESP CRIT CARE, V162, P1075, DOI 10.1164/ajrccm.162.3.9911099; HEEGER P, 1992, KIDNEY INT, V41, P220, DOI 10.1038/ki.1992.31; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Horai R, 2000, J EXP MED, V191, P313, DOI 10.1084/jem.191.2.313; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; Jamaluddin M, 1996, J VIROL, V70, P1554, DOI 10.1128/JVI.70.3.1554-1563.1996; Koga T, 1999, P NATL ACAD SCI USA, V96, P5680, DOI 10.1073/pnas.96.10.5680; Kurashima K, 1997, AM J RESP CRIT CARE, V155, P1474, DOI 10.1164/ajrccm.155.4.9105097; KWON OJ, 1995, AM J RESP CELL MOL, V12, P488, DOI 10.1165/ajrcmb.12.5.7537968; Lakshminarayanan V, 1998, J BIOL CHEM, V273, P32670, DOI 10.1074/jbc.273.49.32670; Law K, 1996, AM J RESP CRIT CARE, V153, P799, DOI 10.1164/ajrccm.153.2.8564135; Levine SJ, 1997, J IMMUNOL, V158, P5949; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; Lin YG, 1998, INFECT IMMUN, V66, P1121, DOI 10.1128/IAI.66.3.1121-1126.1998; Manni A, 1996, BIOCHEM BIOPH RES CO, V220, P120, DOI 10.1006/bbrc.1996.0367; MARFAINGKOKA A, 1995, J IMMUNOL, V154, P1870; Martin T, 1997, EUR J IMMUNOL, V27, P1091, DOI 10.1002/eji.1830270508; Mastronarde JG, 1998, J INFECT DIS, V177, P1275, DOI 10.1086/515279; MCDONOUGH KA, 1995, INFECT IMMUN, V63, P4802, DOI 10.1128/IAI.63.12.4802-4811.1995; Miyamoto NG, 2000, J NEUROIMMUNOL, V105, P78, DOI 10.1016/S0165-5728(00)00195-8; Moriuchi H, 1997, J IMMUNOL, V158, P3483; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Naumann M, 1997, J EXP MED, V186, P247, DOI 10.1084/jem.186.2.247; NELSON PJ, 1993, J IMMUNOL, V151, P2601; Newton R, 1998, EUR J BIOCHEM, V254, P81, DOI 10.1046/j.1432-1327.1998.2540081.x; Nicholson S, 1996, J EXP MED, V183, P2293, DOI 10.1084/jem.183.5.2293; NOAH TL, 1993, AM J PHYSIOL, V265, pL472, DOI 10.1152/ajplung.1993.265.5.L472; Pazdrak K, 2002, AM J PHYSIOL-LUNG C, V283, pL364, DOI 10.1152/ajplung.00331.2001; Propst SM, 2002, J BIOL CHEM, V277, P37054, DOI 10.1074/jbc.M205778200; RATHANASWAMI P, 1993, J BIOL CHEM, V268, P5834; Roebuck KA, 1999, J LEUKOCYTE BIOL, V65, P291, DOI 10.1002/jlb.65.3.291; ROSSI GA, 1990, AM J RESP CELL MOL, V3, P431, DOI 10.1165/ajrcmb/3.5.431; Sadek MI, 1998, AM J RESP CELL MOL, V19, P513, DOI 10.1165/ajrcmb.19.3.2815; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; Song A, 1999, IMMUNITY, V10, P93, DOI 10.1016/S1074-7613(00)80010-2; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; STELLATO C, 1995, J IMMUNOL, V155, P410; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; Thomas LH, 1998, J IMMUNOL, V161, P1007; THURLBEC.WM, 1967, THORAX, V22, P483, DOI 10.1136/thx.22.6.483; TOOSSI Z, 1995, J IMMUNOL, V154, P465; Wickremasinghe MI, 1999, J IMMUNOL, V163, P3936; Wilkinson RJ, 1999, J EXP MED, V189, P1863, DOI 10.1084/jem.189.12.1863; ZHANG YH, 1993, J CLIN INVEST, V91, P2076, DOI 10.1172/JCI116430	66	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27199	27210		10.1074/jbc.M403107200	http://dx.doi.org/10.1074/jbc.M403107200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15117956	hybrid			2022-12-25	WOS:000222120400047
J	Flogel, U; Godecke, A; Klotz, LO; Schrader, J				Flogel, U; Godecke, A; Klotz, LO; Schrader, J			Role of myoglobin in the antioxidant defense of the heart	FASEB JOURNAL			English	Article						reactive oxygen species; reperfusion; ischemia; cardiac function and energetics	ISCHEMIA-REPERFUSION INJURY; SPERM-WHALE MYOGLOBIN; NITRIC-OXIDE; HYDROGEN-PEROXIDE; CREATINE-KINASE; FREE-RADICALS; MYOCARDIAL-ISCHEMIA; ENZYMATIC FUNCTION; MICE; SUPEROXIDE	Although the primary function of myoglobin (Mb) has been considered to be cellular O-2 storage and supply, recent studies have shown that Mb in addition can act as NO oxidase. Here we report that Mb also significantly contributes to the attenuation of oxidative stress in cardiac muscle. In support of this hypothesis, we found that in isolated perfused hearts of Mb-deficient (myo(-/-)) mice oxidative challenge by intracoronary infused H2O2 ( 1- 300 muM) or superoxide formed by 2,3-dimethoxy-1,4-naphtoquinone (0.1-30 muM), respectively, depressed cardiac contractility to a greater extent than in wild-type (WT) hearts, e.g., up to [H2O2] = 10 muM there was a significant left ventricular developed pressure ( LVDP) decrease in myo(-/-) hearts only (90.4 +/- 4.2 vs. 98.1 +/- 0.7% of control, n=6, P< 0.05). Likewise in an ischemia/reperfusion protocol, myo-/- hearts showed a delayed recovery of postischemic function as compared with WT controls (e.g., LVDP was 35.6 +/- 7.5 vs. 22.4 +/- 5.3 mmHg, respectively, after 10 min of reperfusion, P< 0.05, n=8), which correlated well with an enhanced release of reactive oxygen species in myo-/- hearts as measured by online lucigenin-enhanced chemiluminescence [e.g. 465 +/- 87 relative light units (RLU) in myo(-/-) vs. 287 +/- 73 RLU in WT after 2.5 min of reperfusion, P< 0.05, n=8]. P-31 NMR spectroscopy revealed concomitantly a more pronounced phosphocreatine overshoot during reperfusion in the knockout but only minute alterations in ATP and pH(i). Our data show that lack of Mb leads to increased vulnerability of cardiac function to oxidative challenge either pharmacologically induced or endogenously generated. We propose that Mb is a key element influencing redox pathways in cardiac muscle to functionally and metabolically protect the heart from oxidative damage.	Univ Dusseldorf, Inst Herz & Kreislaufphysiol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Inst Biochem & Mol Biol 1, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Flogel, U (corresponding author), Univ Dusseldorf, Inst Herz & Kreislaufphysiol, Univ Str 1, D-40225 Dusseldorf, Germany.	floegel@uni-duesseldorf.de	Klotz, Lars Oliver/AAC-5051-2019	Klotz, Lars Oliver/0000-0002-1261-8911				Alayash AI, 1999, J BIOL CHEM, V274, P2029, DOI 10.1074/jbc.274.4.2029; Alayash AI, 2001, ANTIOXID REDOX SIGN, V3, P313, DOI 10.1089/152308601300185250; ALLENTOFF AJ, 1992, J AM CHEM SOC, V114, P9744, DOI 10.1021/ja00051a003; ARDUINI A, 1990, FREE RADICAL BIO MED, V9, P511, DOI 10.1016/0891-5849(90)90130-B; ARDUINI A, 1991, OXIDATIVE DAMAGE REP, P406; BANERJEE A, 1991, AM J PHYSIOL, V261, pH590, DOI 10.1152/ajpheart.1991.261.2.H590; BROWN JM, 1989, SURGERY, V105, P496; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P209, DOI 10.1016/S0968-0004(01)01824-2; FERRARI R, 1991, AM J CLIN NUTR, V53, pS215, DOI 10.1093/ajcn/53.1.215S; FLAHERTY JT, 1988, FREE RADICAL BIO MED, V5, P409, DOI 10.1016/0891-5849(88)90115-3; FLAHERTY JT, 1982, CIRCULATION, V65, P561, DOI 10.1161/01.CIR.65.3.561; Flogel U, 1999, J MOL CELL CARDIOL, V31, P827, DOI 10.1006/jmcc.1998.0921; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Frauenfelder H, 2001, P NATL ACAD SCI USA, V98, P2370, DOI 10.1073/pnas.041614298; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; GARLICK PB, 1987, CIRC RES, V61, P757, DOI 10.1161/01.RES.61.5.757; Garry DJ, 2003, TRENDS CARDIOVAS MED, V13, P111, DOI 10.1016/S1050-1738(02)00256-6; Garry DJ, 1998, NATURE, V395, P905, DOI 10.1038/27681; GEORGE P, 1951, NATURE, V168, P164, DOI 10.1038/168164b0; GEORGE P, 1952, BIOCHEM J, V52, P511, DOI 10.1042/bj0520511; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P9943, DOI 10.1073/pnas.180155397; Godecke A, 1999, P NATL ACAD SCI USA, V96, P10495, DOI 10.1073/pnas.96.18.10495; Godecke A, 2003, J BIOL CHEM, V278, P21761, DOI 10.1074/jbc.M302573200; Gunther MR, 1999, FREE RADICAL BIO MED, V26, P1388, DOI 10.1016/S0891-5849(98)00338-4; GUYTON GP, 1995, J APPL PHYSIOL, V79, P1148, DOI 10.1152/jappl.1995.79.4.1148; HAGLER L, 1979, J BIOL CHEM, V254, P6505; Ho YS, 1998, J BIOL CHEM, V273, P7765, DOI 10.1074/jbc.273.13.7765; ICHIHARA K, 1984, AM HEART J, V108, P1594, DOI 10.1016/0002-8703(84)90735-X; KAPLAN LJ, 1993, J SURG RES, V54, P311, DOI 10.1006/jsre.1993.1049; Kaplan LJ, 1996, J SURG RES, V62, P103, DOI 10.1006/jsre.1996.0181; Kobert R, 1900, ARCH GESAMTE PHYSIOL, V82, P603, DOI 10.1007/BF01795645; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; LIVINGSTON DJ, 1985, J BIOL CHEM, V260, P5699; Mates JM, 1999, CLIN BIOCHEM, V32, P595, DOI 10.1016/S0009-9120(99)00075-2; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Meeson AP, 2001, CIRC RES, V88, P713, DOI 10.1161/hh0701.089753; Merx Marc W., 2001, FASEB Journal, V15, P1077; Moller JKS, 2002, CHEM REV, V102, P1167, DOI 10.1021/cr000078y; Moore KP, 1998, J BIOL CHEM, V273, P31731, DOI 10.1074/jbc.273.48.31731; OSAWA Y, 1991, P NATL ACAD SCI USA, V88, P7081, DOI 10.1073/pnas.88.16.7081; Patel RP, 1996, FREE RADICAL RES, V25, P117, DOI 10.3109/10715769609149916; Schenkman KA, 1997, J APPL PHYSIOL, V82, P86, DOI 10.1152/jappl.1997.82.1.86; Schlieper G, 2004, AM J PHYSIOL-REG I, V286, pR786, DOI 10.1152/ajpregu.00043.2003; SHI MM, 1994, J BIOL CHEM, V269, P26512; SIMPSON PJ, 1987, J LAB CLIN MED, V110, P13; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Svistunenko DA, 1997, J BIOL CHEM, V272, P7114, DOI 10.1074/jbc.272.11.7114; Tarpey MM, 2001, CIRC RES, V89, P224, DOI 10.1161/hh1501.094365; Vuletich JL, 1998, ANAL BIOCHEM, V265, P375, DOI 10.1006/abio.1998.2926; Wan LL, 1998, P NATL ACAD SCI USA, V95, P12825, DOI 10.1073/pnas.95.22.12825; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; WHITBURN KD, 1987, ARCH BIOCHEM BIOPHYS, V253, P419, DOI 10.1016/0003-9861(87)90195-0; WHITBURN KD, 1985, J INORG BIOCHEM, V24, P35, DOI 10.1016/0162-0134(85)85012-1; Wittenberg JB, 2003, J EXP BIOL, V206, P2011, DOI 10.1242/jeb.00243; Witting PK, 2002, BIOCHEMISTRY-US, V41, P11495, DOI 10.1021/bi025835w; WU H, 1923, J BIOCHEM-TOKYO, V2, P189; Wunderlich C, 2003, CIRC RES, V92, P1352, DOI 10.1161/01.RES.0000079026.70629.E5; Yasmin W, 1997, CARDIOVASC RES, V33, P422, DOI 10.1016/S0008-6363(96)00254-4; YUSA K, 1987, BIOCHEMISTRY-US, V26, P6684, DOI 10.1021/bi00395a018	62	125	126	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1156	+		10.1096/fj.03-1382fje	http://dx.doi.org/10.1096/fj.03-1382fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132981				2022-12-25	WOS:000221883200016
J	Schulze, PC; Yoshioka, J; Takahashi, T; He, ZH; King, GL; Lee, RT				Schulze, PC; Yoshioka, J; Takahashi, T; He, ZH; King, GL; Lee, RT			Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UP-REGULATED PROTEIN-1; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; MAMMALIAN THIOREDOXIN; DEPENDENT ACTIVATION; ENDOTHELIAL-CELLS; NAD(P)H OXIDASE; GENE-EXPRESSION; KINASE-C; SUPEROXIDE	Increased intracellular reactive oxygen species (ROS) contribute to vascular disease and pro-atherosclerotic effects of diabetes mellitus may be mediated by oxidative stress. Several ROS-scavenging systems tightly control cellular redox balance; however, their role in hyperglycemia-induced oxidative stress is unclear. A ubiquitous antioxidative mechanism for regulating cellular redox balance is thioredoxin, a highly conserved thiol reductase that interacts with an endogenous inhibitor, thioredoxin-interacting protein (Txnip). Here we show that hyperglycemia inhibits thioredoxin ROS-scavenging function through p38 MAPK-mediated induction of Txnip. Overexpression of Txnip increased oxidative stress, while Txnip gene silencing restored thioredoxin activity in hyperglycemia. Diabetic animals exhibited increased vascular expression of Txnip and reduced thioredoxin activity, which normalized with insulin treatment. These results provide evidence for the impairment of a major ROS-scavenging system in hyperglycemia. These studies implicate reduced thioredoxin activity through interaction with Txnip as an important mechanism for vascular oxidative stress in diabetes mellitus.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Cardiovasc Div, Cambridge, MA 02139 USA; Joslin Diabet Ctr, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Cambridge, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Joslin Diabetes Center, Inc.; Harvard University	Lee, RT (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Cardiovasc Div, 65 Landsdowne St, Cambridge, MA 02139 USA.	rlee@rics.bwh.harvard.edu	Schulze, Christian/AGJ-7744-2022	Schulze, Christian/0000-0001-9442-7141				Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Ceriello A, 1996, DIABETES, V45, P471, DOI 10.2337/diabetes.45.4.471; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Federici M, 2002, CIRCULATION, V106, P466, DOI 10.1161/01.CIR.0000023043.02648.51; Griendling KK, 2000, ARTERIOSCL THROM VAS, V20, P2175, DOI 10.1161/01.ATV.20.10.2175; Griendling KK, 1997, CIRCULATION, V96, P3264; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; Hink HU, 2002, ARTERIOSCL THROM VAS, V22, P1402, DOI 10.1161/01.ATV.0000027524.86752.02; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota T, 2002, J BIOL CHEM, V277, P44244, DOI 10.1074/jbc.M206233200; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Inoguchi T, 2000, DIABETES, V49, P1939, DOI 10.2337/diabetes.49.11.1939; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Kobayashi T, 2003, KIDNEY INT, V64, P1632, DOI 10.1046/j.1523-1755.2003.00263.x; Landmesser U, 2003, J CLIN INVEST, V111, P1201, DOI 10.1172/JCI200314172; Li WG, 2001, J BIOL CHEM, V276, P29251, DOI 10.1074/jbc.M102124200; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Munzel T, 2002, ARTERIOSCL THROM VAS, V22, P1761, DOI 10.1161/01.ATV.0000034022.11764.EC; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Pekkari K, 2003, FEBS LETT, V539, P143, DOI 10.1016/S0014-5793(03)00214-X; Prieto-Alamo MJ, 2000, J BIOL CHEM, V275, P13398, DOI 10.1074/jbc.275.18.13398; Rosen P, 2001, DIABETES-METAB RES, V17, P189, DOI 10.1002/dmrr.196; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; Schulze PC, 2002, CIRC RES, V91, P689, DOI 10.1161/01.RES.0000037982.55074.F6; Shalev A, 2002, ENDOCRINOLOGY, V143, P3695, DOI 10.1210/en.2002-220564; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Szocs K, 2002, ARTERIOSCL THROM VAS, V22, P21, DOI 10.1161/hq0102.102189; Tanudji M, 2003, AM J PHYSIOL-CELL PH, V284, pC1272, DOI 10.1152/ajpcell.00521.2002; Wang YL, 2002, J BIOL CHEM, V277, P26496, DOI 10.1074/jbc.M202133200; Way KJ, 2001, DIABETIC MED, V18, P945, DOI 10.1046/j.0742-3071.2001.00638.x; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4; Zou MH, 2002, J CLIN INVEST, V109, P817, DOI 10.1172/JCI200214442	39	292	313	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30369	30374		10.1074/jbc.M400549200	http://dx.doi.org/10.1074/jbc.M400549200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15128745	hybrid			2022-12-25	WOS:000222531900062
J	Gunawardena, RW; Siddiqui, H; Solomon, DA; Mayhew, CN; Held, J; Angus, SP; Knudsen, ES				Gunawardena, RW; Siddiqui, H; Solomon, DA; Mayhew, CN; Held, J; Angus, SP; Knudsen, ES			Hierarchical requirement of SWI/SNF in retinoblastoma tumor suppressor-mediated repression of Plk1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLO-LIKE-KINASE; CELL-CYCLE; TRANSCRIPTIONAL REPRESSION; PROGNOSTIC-SIGNIFICANCE; DOWN-REGULATION; RB/E2F PATHWAY; RB; E2F; EXPRESSION; COMPLEXES	Plk1 (Polo-like kinase 1) is a critical regulator of cell cycle progression that harbors oncogenic activity and exhibits aberrant expression in multiple tumors. However, the mechanism through which Plk1 expression is regulated has not been extensively studied. Here we demonstrate that Plk1 is a target of the retinoblastoma tumor suppressor (RB) pathway. Activation of RB and related pocket proteins p107/p130 mediate attenuation of Plk1. Conversely, RB loss deregulates the control of Plk1 expression. RB pathway activation resulted in the repression of Plk1 promoter activity, and this action was dependent on the SWI/SNF chromatin remodeling complex. Although SWI/SNF subunits are lost during tumorigenesis and cooperate with RB for transcriptional repression, the mechanism through which SWI/SNF impinges on RB action is unresolved. Therefore, we delineated the requirement of SWI/SNF for three critical facets of Plk1 promoter regulation: transcription factor binding, corepressor binding, and histone modification. We find that E2F4 and pocket protein association with the Plk1 promoter is independent of SWI/SNF. However, these analyses revealed that SWI/SNF is required for histone deacetylation of the Plk1 promoter. The importance of SWI/SNF-dependent histone deacetylation of the Plk1 promoter was evident, because blockade of this event restored Plk1 expression in the presence of active RB. In summary, these data demonstrate that Plk1 is a target of the RB pathway. Moreover, these findings demonstrate a hierarchical role for SWI/SNF in the control of promoter activity through histone modification.	Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Knudsen, ES (corresponding author), Univ Cincinnati, Coll Med, Vontz Ctr Mol Studies, Dept Cell Biol, Cincinnati, OH 45267 USA.	Erik.Knudsen@UC.edu	Mayhew, Christopher N/AGB-4929-2022	Angus, Steven/0000-0002-7655-657X	NATIONAL CANCER INSTITUTE [R01CA106471, T32CA059268] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA59268, CA106471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angus SP, 2003, MOL CELL BIOL, V23, P8172, DOI 10.1128/MCB.23.22.8172-8188.2003; Angus SP, 2002, EXP CELL RES, V276, P201, DOI 10.1006/excr.2002.5510; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; Golsteyn R M, 1996, Prog Cell Cycle Res, V2, P107; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, CURR OPIN CELL BIOL, V12, P685, DOI 10.1016/S0955-0674(00)00152-6; Harbour JW, 2001, CURR TOP MICROBIOL, V254, P137; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Knecht R, 1999, CANCER RES, V59, P2794; Kneisel L, 2002, J CUTAN PATHOL, V29, P354, DOI 10.1034/j.1600-0560.2002.290605.x; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Leung GC, 2003, CELL, V115, P3, DOI 10.1016/S0092-8674(03)00761-X; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Markey MP, 2002, CANCER RES, V62, P6587; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Reisman DN, 2003, CANCER RES, V63, P560; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Sherr C J, 2000, Harvey Lect, V96, P73; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Siddiqui H, 2003, MOL CELL BIOL, V23, P7719, DOI 10.1128/MCB.23.21.7719-7731.2003; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; Takahashi T, 2003, CANCER SCI, V94, P148, DOI 10.1111/j.1349-7006.2003.tb01411.x; Takahashi Y, 2000, GENE DEV, V14, P804; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; Vooijs M, 2002, CANCER RES, V62, P1862; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Yuan JP, 1997, AM J PATHOL, V150, P1165; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhu HM, 2002, CELL CYCLE, V1, P59, DOI 10.4161/cc.1.1.101	55	39	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29278	29285		10.1074/jbc.M400395200	http://dx.doi.org/10.1074/jbc.M400395200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15105433	hybrid			2022-12-25	WOS:000222445300057
J	Mayasundari, A; Whittemore, NA; Serpersu, EH; Peterson, CB				Mayasundari, A; Whittemore, NA; Serpersu, EH; Peterson, CB			The solution structure of the N-terminal domain of human vitronectin - Proximal sites that regulate fibrinolysis and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; SOMATOMEDIN-B-DOMAIN; UROKINASE RECEPTOR; NMR-SPECTROSCOPY; BREAST-CANCER; CYSTINE KNOT; IN-VIVO; EXTRACELLULAR-MATRIX; DISTANCE GEOMETRY; INTEGRIN FUNCTION	The three-dimensional structure of an N-terminal fragment comprising the first 51 amino acids from human plasma vitronectin, the somatomedin B (SMB) domain, has been determined by two-dimensional NMR approaches. An average structure was calculated, representing the overall fold from a set of 20 minimized structures. The core residues (18-41) overlay with a root mean square deviation of 2.29 +/- 0.62 Angstrom. The N- and C-terminal segments exhibit higher root mean square deviations, reflecting more flexibility in solution and/or fewer long-range NOEs for these regions. Residues 26-30 form a unique single-turn alpha-helix, the locus where plasminogen activator inhibitor type-1 (PAI-1) is bound. This structure of this helix is highly homologous with that of a recombinant SMB domain solved in a co-crystal with PAI-1 (Zhou, A., Huntington, J. A., Pannu, N. S., Carrell, R. W., and Read, R. J. (2003) Nat. Struct. Biol. 10, 541-544), although the remainder of the structure differs. Significantly, the pattern of disulfide cross-links observed in this material isolated from human plasma is altogether different from the disulfides proposed for recombinant forms. The NMR structure reveals the relative orientation of binding sites for cell surface receptors, including an integrin-binding site at residues 45 47, which was disordered and did not diffract in the co-crystal, and a site for the urokinase receptor, which overlaps with the PAI-1-binding site.	Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA; Univ Tennessee, Ctr Excellence Struct Biol, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville	Peterson, CB (corresponding author), Univ Tennessee, Dept Biochem & Cellular & Mol Biol, M407 Walters Life Sci Bldg, Knoxville, TN 37996 USA.	cynthia-peterson@utk.edu		Serpersu, Engin H./0000-0003-1420-455X	NHLBI NIH HHS [HL50676] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050676, R01HL050676] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aaboe M, 2003, BBA-MOL BASIS DIS, V1638, P72, DOI 10.1016/S0925-4439(03)00059-0; ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; BenMenahem D, 1997, J BIOL CHEM, V272, P6827, DOI 10.1074/jbc.272.11.6827; Carreiras F, 1999, GYNECOL ONCOL, V72, P312, DOI 10.1006/gyno.1998.5262; Carriero MV, 1999, CANCER RES, V59, P5307; Chen J, 2001, J BIOL CHEM, V276, P47901, DOI 10.1074/jbc.M107574200; CLUBB RT, 1994, BIOCHEMISTRY-US, V33, P2761, DOI 10.1021/bi00176a004; De Prada NA, 2002, EUR J BIOCHEM, V269, P184, DOI 10.1046/j.0014-2956.2002.02639.x; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; Deng G, 2001, J CELL PHYSIOL, V189, P23, DOI 10.1002/jcp.1133; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; Eitzman DT, 1996, BLOOD, V87, P4718; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; Gutierrez LS, 2000, CANCER RES, V60, P5839; HEITZ A, 1989, BIOCHEMISTRY-US, V28, P2392, DOI 10.1021/bi00432a009; Hymowitz SG, 2001, EMBO J, V20, P5332, DOI 10.1093/emboj/20.19.5332; Jang YC, 2000, SURGERY, V127, P696, DOI 10.1067/msy.2000.105858; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jensen JK, 2004, FEBS LETT, V556, P175, DOI 10.1016/S0014-5793(03)01405-4; Jensen JK, 2002, FEBS LETT, V521, P91, DOI 10.1016/S0014-5793(02)02830-2; Kamikubo Y, 2002, J BIOL CHEM, V277, P27109, DOI 10.1074/jbc.M200354200; KLAUS W, 1993, J MOL BIOL, V232, P897, DOI 10.1006/jmbi.1993.1438; KOBAYASHI Y, 1991, BIOPOLYMERS, V31, P1213, DOI 10.1002/bip.360311009; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; Minor KH, 2002, J BIOL CHEM, V277, P10337, DOI 10.1074/jbc.M109564200; Muller YA, 2002, J BIOL CHEM, V277, P43410, DOI 10.1074/jbc.M206438200; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OGG RJ, 1994, J MAGN RESON SER B, V104, P1, DOI 10.1006/jmrb.1994.1048; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Podor TJ, 2002, J BIOL CHEM, V277, P7520, DOI 10.1074/jbc.M109677200; Podor TJ, 2000, J BIOL CHEM, V275, P25402, DOI 10.1074/jbc.M000362200; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; Preissner KT, 1998, THROMB RES, V89, P1, DOI 10.1016/S0049-3848(97)00298-3; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REDFIELD C, 1993, NMR MACROMOLECULES P, P71; Sato A, 1997, J BIOL CHEM, V272, P18098, DOI 10.1074/jbc.272.29.18098; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; Smallcombe SH, 1995, J MAGN RESON SER A, V117, P295, DOI 10.1006/jmra.1995.0759; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; Tamaoki H, 1998, PROTEIN ENG, V11, P649, DOI 10.1093/protein/11.8.649; Tarui T, 2001, J BIOL CHEM, V276, P3983, DOI 10.1074/jbc.M008220200; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P4103, DOI 10.1021/bi00411a029; van der Pluijm G, 2001, AM J PATHOL, V159, P971, DOI 10.1016/S0002-9440(10)61773-7; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wilcox-Adelman SA, 2000, CELL ADHES COMMUN, V7, P477, DOI 10.3109/15419060009040305; WILLIAMSON PM, 1985, J MOL BIOL, P295; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130; Xu D, 2001, PROTEINS, V44, P312, DOI 10.1002/prot.1096; Xue W, 1997, CANCER RES, V57, P1682; Yoneda A, 1998, BIOCHEMISTRY-US, V37, P6351, DOI 10.1021/bi972247n; Zhou AW, 2003, NAT STRUCT BIOL, V10, P541, DOI 10.1038/nsb943; Zhuang P, 1996, J BIOL CHEM, V271, P14323, DOI 10.1074/jbc.271.24.14323	65	33	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29359	29366		10.1074/jbc.M401279200	http://dx.doi.org/10.1074/jbc.M401279200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123712	hybrid			2022-12-25	WOS:000222445300067
J	Schmidt, AE; Ogawa, T; Gailani, D; Bajaj, SP				Schmidt, AE; Ogawa, T; Gailani, D; Bajaj, SP			Structural role of Gly(193) in serine proteases - Investigations of a G555E (Gly(193) in chymotrypsin) mutant of blood coagulation factor XI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA THROMBOPLASTIN ANTECEDENT; BETA-PROTEIN PRECURSOR; RAY CRYSTAL-STRUCTURE; FACTOR-IX; HEMOPHILIA-B; BINDING-SITE; INHIBITOR DOMAIN; CHRISTMAS-FACTOR; TISSUE FACTOR; ACTIVE-SITE	In serine proteases, Gly(193) is highly conserved with few exceptions. A patient with inherited deficiency of the coagulation serine protease factor XI (FXI) was reported to be homozygous for a Gly(555)-->Glu substitution. Gly(555) in FXI corresponds to Gly(193) in chymotrypsin, which is the numbering system used subsequently. To investigate the abnormality in FXIG193E, we expressed and purified recombinant FXIa(G193E), activated it to FXIa(G193E), and compared its activity to wild type-activated FXI ( FXIa(WT)). FXIa(G193E) activated FIX with similar to300-fold reduced k(cat) and similar K-m, and hydrolyzed synthetic substrate with similar to10-fold reduced K-m and modestly reduced kcat. Binding of antithrombin and the amyloid beta-precursor protein Kunitz domain inhibitor (APPI) to FXIa(G193E) was impaired similar to 8,000- and similar to 100,000-fold, respectively. FXIaG193E inhibition by diisopropyl fluorophosphate was similar to 30-fold slower and affinity for p-aminobenzamidine (S1 site probe) was 6-fold weaker than for FXIa(WT). The rate of carbamylation of NH2-Ile(16), which forms a salt bridge with Asp(194) in active serine proteases, was 4-fold faster for FXIa(G193E). These data indicate that the unoccupied active site of FXIa(G193E) is incompletely formed, and the amide N of Glu(193) may not point toward the oxyanion hole. Inclusion of saturating amounts of p-aminobenzamidine resulted in comparable rates of carbamylation for FXIaWT and FXIa(G193E), suggesting that the occupied active site has near normal conformation. Thus, binding of small synthetic substrates or inhibitors provides sufficient energy to allow the amide N of Glu(193) to point correctly toward the oxyanion hole. Homology modeling also indicates that the inability of FXIa(G193E) to bind antithrombin/APPI or activate FIX is caused, in part, by impaired accessibility of the S2' site because of a steric clash with Glu(193). Such arguments will apply to other serine proteases with substitutions of Gly(193) with a non-glycine residue.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Orthopaed Surg, Orthopaed Hosp, Los Angeles, CA 90095 USA; St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Saint Louis University; Vanderbilt University	Bajaj, SP (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Orthopaed Surg, Orthopaed Hosp, 1000 Vet Ave,Rehab Bldg,Rm 21-31, Los Angeles, CA 90095 USA.	pbajaj@mednet.ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL036365, R56HL036365, R01HL036365, K08HL002917, R01HL058837, R01HL070369] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL70369, HL58837, HL36365, HL02917] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aktimur A, 2003, J BIOL CHEM, V278, P7981, DOI 10.1074/jbc.M212748200; BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; Bajaj MS, 2001, THROMB HAEMOSTASIS, V86, P959; BAJAJ SP, 1993, METHOD ENZYMOL, V222, P96; BAJAJ SP, 1990, J BIOL CHEM, V265, P2956; Bernardi F, 1996, HUM MUTAT, V8, P108; BERNARDI F, 1994, BRIT J HAEMATOL, V86, P610, DOI 10.1111/j.1365-2141.1994.tb04793.x; BLOW DM, 1976, ACCOUNTS CHEM RES, V9, P145, DOI 10.1021/ar50100a004; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; Camire RM, 2002, J BIOL CHEM, V277, P37863, DOI 10.1074/jbc.M203692200; Cavarelli J, 1997, STRUCTURE, V5, P813, DOI 10.1016/S0969-2126(97)00235-9; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COPELAND RA, 1996, ENZYMES PRACTICAL IN, P225; CRAIG DA, 1993, TRENDS PHARMACOL SCI, V14, P89, DOI 10.1016/0165-6147(93)90070-Z; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GIANNELLI F, 1994, NUCLEIC ACIDS RES, V22, P3534, DOI 10.1093/nar/22.17.3534; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Gunasekaran K, 1998, J MOL BIOL, V284, P1505, DOI 10.1006/jmbi.1998.2154; Halfman C J, 1981, Methods Enzymol, V74 Pt C, P481; Halfon S., 1998, HDB PROTEOLYTIC ENZY, P12; Helland R, 1999, J MOL BIOL, V287, P923, DOI 10.1006/jmbi.1999.2654; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; HYNES TR, 1990, BIOCHEMISTRY-US, V29, P10018, DOI 10.1021/bi00495a002; Katona G, 2002, J MOL BIOL, V315, P1209, DOI 10.1006/jmbi.2001.5305; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBA H, 1965, BRIT J HAEMATOL, V11, P654, DOI 10.1111/j.1365-2141.1965.tb00114.x; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; Lu DS, 1999, J MOL BIOL, V292, P361, DOI 10.1006/jmbi.1999.3089; Marquardt U, 2002, J MOL BIOL, V321, P491, DOI 10.1016/S0022-2836(02)00625-3; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NAITO K, 1991, J BIOL CHEM, V266, P7353; Navaneetham D, 2003, BLOOD, V102, p127A; Papageorgiou AC, 2000, PROTEIN SCI, V9, P610; Parry MAA, 1998, STRUCT FOLD DES, V6, P1195, DOI 10.1016/S0969-2126(98)00119-1; Pjura PE, 2000, J MOL BIOL, V300, P235, DOI 10.1006/jmbi.2000.3851; RAPAPORT SI, 1961, BLOOD, V18, P149, DOI 10.1182/blood.V18.2.149.149; SAAD S, 1994, THROMB HAEMOSTASIS, V71, P563; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Scheidig AJ, 1997, PROTEIN SCI, V6, P1806, DOI 10.1002/pro.5560060902; Schmidt AE, 2003, BLOOD, V102, p303A; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; STRYER L, 1995, BIOCHEMISTRY-US, P224; Sun MF, 1999, J BIOL CHEM, V274, P36373, DOI 10.1074/jbc.274.51.36373; Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023; THOMPSON AR, 1992, THROMB RES, V65, P289, DOI 10.1016/0049-3848(92)90249-A; Timm DE, 1997, PROTEIN SCI, V6, P1418, DOI 10.1002/pro.5560060706; TULINSKY A, 1987, J BIOL CHEM, V262, P7737; vandeWater NS, 1996, HAEMOPHILIA, V2, P24, DOI 10.1111/j.1365-2516.1996.tb00005.x; Vath GM, 1997, BIOCHEMISTRY-US, V36, P1559, DOI 10.1021/bi962614f; WALTER J, 1982, ACTA CRYSTALLOGR B, V38, P1462, DOI 10.1107/S0567740882006153; WANG DC, 1985, J MOL BIOL, V185, P595, DOI 10.1016/0022-2836(85)90074-9; ZIVELIN A, 2001, THROMB HAEMOSTASIS S, pP1111	56	24	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29485	29492		10.1074/jbc.M402971200	http://dx.doi.org/10.1074/jbc.M402971200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15090552	hybrid			2022-12-25	WOS:000222445300081
J	Silletti, S; Yebra, M; Perez, B; Cirulli, V; McMahon, M; Montgomery, AMP				Silletti, S; Yebra, M; Perez, B; Cirulli, V; McMahon, M; Montgomery, AMP			Extracellular signal-regulated kinase (ERK)-dependent gene expression contributes to L1 cell adhesion molecule-dependent motility and invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NEURITE OUTGROWTH; INTEGRIN ALPHA(V)BETA(3); CATHEPSINS-B; MIGRATION; MELANOMA; BINDING; GROWTH; MOUSE; CASCADE	The cell adhesion molecule L1 has been implicated in a variety of motile processes, including neurite extension, cerebellar cell migration, extravasation, and metastasis. Homophilic or heterophilic L1 binding and concomitant signaling have been shown to promote cell motility in the short term. In this report, L1 is also shown to induce and maintain a motile and invasive phenotype by promoting gene transcription. In the presence of serum or platelet-derived growth factor, L1 promotes heightened and sustained activation of the extracellular signal-regulated kinase pathway. Activation of this pathway then induces the expression of motility- and invasion-associated gene products, including the beta(3)-integrin subunit, small GTPases, and the cysteine proteases cathepsin-L and - B. Induction of integrin alpha(v)beta(3) and rac-1 is shown to contribute directly to L1-dependent haptotaxis, whereas induction of cathepsins-L and - B promotes matrix invasion. This study provides a novel translational mechanism to account for the association between L1 expression and motile processes involved in metastasis and development.	Univ Calif San Diego, Whittier Inst, Dept Pediat, La Jolla, CA 92037 USA; Univ Calif San Diego, Moores Comprehens Canc Ctr, La Jolla, CA 92037 USA; Univ Calif San Francisco, Mt Zion Comprehens Canc Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; UCSF Medical Center at Mount Zion	Montgomery, AMP (corresponding author), Univ Calif San Diego, Whittier Inst, Dept Pediat, 9894 Genesee Ave, La Jolla, CA 92037 USA.	ammontgo@ucsd.edu			NATIONAL CANCER INSTITUTE [R01CA069112] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055183] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA69112-01] Funding Source: Medline; NHLBI NIH HHS [R01 HL62477-01] Funding Source: Medline; NIDDK NIH HHS [R01 DK55183S1, R01 DK55183] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBELDA SM, 1990, CANCER RES, V50, P6757; ALTETSEE C, 2001, AUDIOL NEURO-OTOL, V2, P57; Balaian LB, 2000, EUR J IMMUNOL, V30, P938; Bartsch U, 2003, FRONT BIOSCI-LANDMRK, V8, pD477, DOI 10.2741/1028; Bednarski E, 1997, J NEUROSCI, V17, P4006; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BRUMMENDORF T, 1993, J NEUROCHEM, V61, P1207, DOI 10.1111/j.1471-4159.1993.tb13611.x; Calvo A, 2002, CANCER RES, V62, P5325; CROSSIN KL, 1990, EXP NEUROL, V109, P6, DOI 10.1016/S0014-4886(05)80004-4; Dahme M, 1997, NAT GENET, V17, P346, DOI 10.1038/ng1197-346; Debiec H, 1998, J CELL BIOL, V143, P2067, DOI 10.1083/jcb.143.7.2067; Demyanenko GP, 1999, J NEUROSCI, V19, P4907; Di Sciullo G, 1998, J EXP MED, V187, P1953, DOI 10.1084/jem.187.12.1953; Ebeling O, 1996, EUR J IMMUNOL, V26, P2508, DOI 10.1002/eji.1830261035; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; Fogel M, 2003, CANCER LETT, V189, P237, DOI 10.1016/S0304-3835(02)00513-X; Govindarajan B, 2003, J BIOL CHEM, V278, P9790, DOI 10.1074/jbc.M212929200; Hangan D, 1997, CANCER RES, V57, P3812; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Hortsch M, 1996, NEURON, V17, P587, DOI 10.1016/S0896-6273(00)80192-0; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; Islam R, 2004, MOL BIOL CELL, V15, P2003, DOI 10.1091/mbc.e03-05-0333; Ivins JK, 2000, J NEUROSCI, V20, P6551, DOI 10.1523/JNEUROSCI.20-17-06551.2000; Izumoto S, 1996, CANCER RES, V56, P1440; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; Jessen U, 2001, J NEUROCHEM, V79, P1149, DOI 10.1046/j.1471-4159.2001.00636.x; Kamiguchi H, 1998, J NEUROSCI, V18, P5311, DOI 10.1523/JNEUROSCI.18-14-05311.1998; Koistinen P, 2002, J BIOL CHEM, V277, P24835, DOI 10.1074/jbc.M203149200; Kolkova K, 2000, J NEUROSCI, V20, P2238; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; LINNEMANN D, 1989, INT J CANCER, V43, P709, DOI 10.1002/ijc.2910430428; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIURA M, 1992, J BIOL CHEM, V267, P10752; Montgomery AMP, 1996, J CELL BIOL, V132, P475, DOI 10.1083/jcb.132.3.475; Moses S, 2001, ARCH BIOCHEM BIOPHYS, V396, P133, DOI 10.1006/abbi.2001.2578; Nayeem N, 1999, J CELL SCI, V112, P4739; Nolte C, 1999, CELL TISSUE RES, V298, P261, DOI 10.1007/s004419900063; Pancook JD, 1997, J IMMUNOL, V158, P4413; Petitclerc E, 1999, CANCER RES, V59, P2724; Primiano T, 2003, CANCER CELL, V4, P415, DOI 10.1016/S1535-6108(03)00274-5; RELVAS JB, 2001, CURR BIOL, V6, P1445; Ridley AJ, 1999, BIOCHEM SOC SYMP, V65, P111; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schaefer AW, 1999, J BIOL CHEM, V274, P37965, DOI 10.1074/jbc.274.53.37965; Schmid RS, 2000, J NEUROSCI, V20, P4177; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Thelen K, 2002, J NEUROSCI, V22, P4918, DOI 10.1523/JNEUROSCI.22-12-04918.2002; Thies A, 2002, EUR J CANCER, V38, P1708, DOI 10.1016/S0959-8049(02)00105-3; Thompson RD, 2000, J IMMUNOL, V165, P426, DOI 10.4049/jimmunol.165.1.426; THOR G, 1987, EMBO J, V6, P2581, DOI 10.1002/j.1460-2075.1987.tb02548.x; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; Voura EB, 2001, MOL BIOL CELL, V12, P2699, DOI 10.1091/mbc.12.9.2699; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Welch DR, 2000, CANCER RES, V60, P1552; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75; Yip PM, 1998, MOL BIOL CELL, V9, P277, DOI 10.1091/mbc.9.2.277; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	61	125	128	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28880	28888		10.1074/jbc.M404075200	http://dx.doi.org/10.1074/jbc.M404075200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15128735	hybrid			2022-12-25	WOS:000222445300008
J	Yang, RY; Hsu, DK; Yu, L; Chen, HY; Liu, FT				Yang, RY; Hsu, DK; Yu, L; Chen, HY; Liu, FT			Galectin-12 is required for adipogenic signaling and adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC CLONAL EXPANSION; BINDING-PROTEIN-BETA; SMALL INTERFERING RNAS; C/EBP-ALPHA; PPAR-GAMMA; ADIPOSE-TISSUE; MAMMALIAN-CELLS; KINASE-B; TRANSCRIPTIONAL REGULATION; MOLECULAR REGULATION	Galectin-12 is a member of the galectin family consisting of beta-galactoside-binding proteins with conserved carbohydrate recognition domains. This protein is preferentially expressed in peripheral blood leukocytes and adipocytes. We previously showed that galectin-12 is induced by cell cycle block at the G(1) phase and causes G(1) arrest when overexpressed ( Yang, R.-Y., Hsu, D. K., Yu, L., Ni, J., and Liu, F.- T. ( 2001) J. Biol. Chem. 276, 20252 20260). Here, we show that the galectin-12 gene is expressed in mouse preadipocytes and is up-regulated when preadipocytes undergo cell cycle arrest, concomitant with acquisition of the competence to undergo differentiation in response to adipogenic hormone stimulation. Following a brief down-regulation 1 day after adipogenic treatment, its expression was once again markedly elevated when cells underwent terminal differentiation. Down-regulation of endogenous galectin-12 expression by RNA interference greatly reduced the expression of the adipogenic transcription factors CCAAT/enhancer-binding protein-beta and -alpha and peroxisome proliferator-activated receptor-gamma and severely suppressed adipocyte differentiation as a result of defective adipogenic signaling. We conclude that galectin-12 is required for signal transduction that conveys hormone stimulation to the induction of adipogenic factors essential for adipocyte differentiation. The findings suggest that galectin-12 is a major regulator of adipose tissue development.	Univ Calif Davis, Sch Med, Dept Dermatol, Sacramento, CA 95817 USA	University of California System; University of California Davis	Yang, RY (corresponding author), Univ Calif Davis, Sch Med, Dept Dermatol, Res 3 Bldg,Rm 3100C,4645 2nd Ave, Sacramento, CA 95817 USA.	ryyang@ucdavis.edu	Yang, Riyao/R-7593-2019; Liu, FU-TONG/A-5749-2019	Yang, Riyao/0000-0002-0278-4385; Liu, FU-TONG/0000-0002-3354-1001	NIAID NIH HHS [R01 AI20958, R01 AI39620] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020958, R01AI039620] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; Akahani S, 1997, CANCER RES, V57, P5272; Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Belmonte N, 2001, MOL ENDOCRINOL, V15, P2037, DOI 10.1210/me.15.11.2037; Calkhoven CF, 2000, GENE DEV, V14, P1920; CATALANO RA, 1975, STAIN TECHNOL, V50, P297, DOI 10.3109/10520297509117078; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chi JT, 2003, P NATL ACAD SCI USA, V100, P6343, DOI 10.1073/pnas.1037853100; Cooper DNW, 2002, BBA-GEN SUBJECTS, V1572, P209, DOI 10.1016/S0304-4165(02)00310-0; Cowherd RM, 1999, SEMIN CELL DEV BIOL, V10, P3, DOI 10.1006/scdb.1998.0276; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Fasshauer M, 2002, EUR J ENDOCRINOL, V147, P553, DOI 10.1530/eje.0.1470553; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; Gagnon A, 1999, DIABETES, V48, P691, DOI 10.2337/diabetes.48.4.691; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREEN H, 1979, J CELL PHYSIOL, V101, P169, DOI 10.1002/jcp.1041010119; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Havel PJ, 2000, P NUTR SOC, V59, P359, DOI 10.1017/S0029665100000410; Hikita C, 2000, J CELL BIOL, V151, P1235, DOI 10.1083/jcb.151.6.1235; Hotta K, 2001, J BIOL CHEM, V276, P34089, DOI 10.1074/jbc.M105097200; Janderova L, 2003, OBES RES, V11, P65, DOI 10.1038/oby.2003.11; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Koopman R, 2001, HISTOCHEM CELL BIOL, V116, P63; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; Liu FT, 2000, CLIN IMMUNOL, V97, P79, DOI 10.1006/clim.2000.4912; Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6; LIU FT, 1995, AM J PATHOL, V147, P1016; Lowe JB, 2001, CELL, V104, P809, DOI 10.1016/S0092-8674(01)00277-X; Magun R, 1996, ENDOCRINOLOGY, V137, P3590, DOI 10.1210/en.137.8.3590; Mehul B, 1997, J CELL SCI, V110, P1169; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Rabinovich GA, 2002, TRENDS IMMUNOL, V23, P313, DOI 10.1016/S1471-4906(02)02232-9; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Reichert M, 1999, ONCOGENE, V18, P459, DOI 10.1038/sj.onc.1202308; Ren DL, 2002, GENE DEV, V16, P27, DOI 10.1101/gad.953802; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; SEVE AP, 1994, EXP CELL RES, V213, P191, DOI 10.1006/excr.1994.1190; Sorisky A, 1999, CRIT REV CL LAB SCI, V36, P1, DOI 10.1080/10408369991239169; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P44, DOI 10.1073/pnas.0137044100; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Trayhurn P, 2001, P NUTR SOC, V60, P329, DOI 10.1079/PNS200194; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Worrall DS, 2002, MOL ENDOCRINOL, V16, P378, DOI 10.1210/me.16.2.378; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yang RY, 2003, CELL MOL LIFE SCI, V60, P267, DOI 10.1007/s000180300022; Yang RY, 1998, BIOCHEMISTRY-US, V37, P4086, DOI 10.1021/bi971409c; Yang RY, 2001, J BIOL CHEM, V276, P20252, DOI 10.1074/jbc.M010914200; Zhang JW, 2004, J BIOL CHEM, V279, P4471, DOI 10.1074/jbc.M311327200	70	54	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29761	29766		10.1074/jbc.M401303200	http://dx.doi.org/10.1074/jbc.M401303200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15131127	hybrid			2022-12-25	WOS:000222445300112
J	Pierchala, BA; Ahrens, RC; Paden, AJ; Johnson, EM				Pierchala, BA; Ahrens, RC; Paden, AJ; Johnson, EM			Nerve growth factor promotes the survival of sympathetic neurons through the cooperative function of the protein kinase C and phosphatidylinositol 3-kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CELL-DEATH; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; DOWN-REGULATION; FACTOR RECEPTOR; NGF; PHOSPHORYLATION; ACTIVATION; JUN	The signaling pathways activated by nerve growth factor (NGF) that account for its ability to promote the survival of neurons are not completely understood. Phosphatidylinositol 3-kinase (PI3K) is critical for the survival of several cell types, including neurons. To determine whether additional signaling pathways cooperate with PI3K to promote survival, we examined other pathways known to be activated by NGF. NGF activated protein kinases C (PKCs) in sympathetic neurons, and pharmacologic PKC activation rescued neurons from apoptosis induced by the withdrawal of NGF. Inhibition of PKCs did not inhibit the survival of NGF-maintained neurons. Similarly, inhibition of PI3K caused only a modest attrition of neurons in the presence of NGF. In contrast, the simultaneous inhibition of both PKCs and PI3K induced the apoptotic death of NGF-maintained sympathetic neurons. Inhibition of both PI3K and PKCs promoted the expression and phosphorylation of the proapoptotic transcription factor c-Jun, indicating that these pathways inhibit programmed cell death at the stage of proapoptotic gene expression. In culture conditions under which PI3K inhibition alone kills NGF-maintained neurons, PKC inhibition also led to a significant loss of viability, indicating that both pathways are required. Therefore, PKC and PI3K, regardless of the culture conditions, cooperate to promote the NGF-dependent survival of sympathetic neurons.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Pierchala, BA (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, 4566 Scott Ave,Box 8103, St Louis, MO 63110 USA.	btp@msnotes.wustl.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K01NS045221, R01NS038651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG012947] Funding Source: NIH RePORTER; NIA NIH HHS [R38 AG 12947] Funding Source: Medline; NINDS NIH HHS [R01 NS 38651, K01 NS 045221] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Battaini F, 2001, PHARMACOL RES, V44, P353, DOI 10.1006/phrs.2001.0893; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Crowder RJ, 1998, J NEUROSCI, V18, P2933; DECKER SJ, 1984, MOL CELL BIOL, V4, P1718, DOI 10.1128/MCB.4.9.1718; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Deshmukh M, 1996, J CELL BIOL, V135, P1341, DOI 10.1083/jcb.135.5.1341; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hurd C, 2002, ONCOGENE, V21, P2154, DOI 10.1038/sj.onc.1205290; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; LOEB DM, 1994, J BIOL CHEM, V269, P8901; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; Mazzoni IE, 1999, J NEUROSCI, V19, P9716; Musashi M, 2000, INT J HEMATOL, V72, P12; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Palmada M, 2002, J CELL BIOL, V158, P453, DOI 10.1083/jcb.200112129; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Sarmiere PD, 2001, MOL CELL NEUROSCI, V18, P320, DOI 10.1006/mcne.2001.1021; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Tanaka S, 2001, NEUROSCI LETT, V313, P9, DOI 10.1016/S0304-3940(01)02193-0; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Tsui-Pierchala B, 2002, NEURON, V33, P261, DOI 10.1016/S0896-6273(01)00585-2; Tsui-Pierchala BA, 2000, J NEUROSCI, V20, P7228; Vaillant AR, 1999, J CELL BIOL, V146, P955, DOI 10.1083/jcb.146.5.955; VIRDEE K, 1999, BRAIN RES; Wooten MW, 1999, J NEUROSCI RES, V58, P607, DOI 10.1002/(SICI)1097-4547(19991201)58:5<607::AID-JNR1>3.0.CO;2-M	47	39	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27986	27993		10.1074/jbc.M312237200	http://dx.doi.org/10.1074/jbc.M312237200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117960	hybrid			2022-12-25	WOS:000222265400021
J	Schaap, FG; Rensen, PCN; Voshol, PJ; Vrins, C; van der Vliet, HN; Chamuleau, RAFM; Havekes, LM; Groen, AK; van Dijk, KW				Schaap, FG; Rensen, PCN; Voshol, PJ; Vrins, C; van der Vliet, HN; Chamuleau, RAFM; Havekes, LM; Groen, AK; van Dijk, KW			ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN A-V; ACTIVATED RECEPTOR-ALPHA; TRANSGENIC MICE; IN-VIVO; GENE; CHOLESTEROL; LIVER; HOMEOSTASIS; DETERMINANT; SECRETION	ApoAV has been discovered recently as a novel modifier of triglyceride (TG) metabolism, but the pathways involved are currently unknown. To gain insight into the function of apoAV, adenovirus-mediated gene transfer of murine apoa5 to C57Bl/6 mice was employed. The injection of low doses of Ad-apoa5 (1 - 5 x 10(8) plaque-forming units/mouse) dose-dependently reduced plasma very low density lipoprotein ( VLDL)- TG levels. First, we evaluated whether a reduced hepatic VLDL production contributed to the TG-lowering effect. Ad-apoa5 treatment dose-dependently diminished ( 29 - 37%) the VLDL-TG production rate without affecting VLDL particle production, suggesting that apoAV impairs the lipidation of apoB. Second, Ad-apoa5 treatment dose-dependently reduced ( 68 - 88%) the postprandial hypertriglyceridemia following an intragastric fat load, suggesting that apoAV also stimulates the lipoprotein lipase (LPL)-dependent clearance of TG-rich lipoproteins. Indeed, recombinant apoAV was found to dose-dependently stimulate LPL activity up to 2.3-fold in vitro. Accordingly, intravenously injected VLDL-like TG-rich emulsions were cleared at an accelerated rate concomitant with the increased uptake of emulsion TG-derived fatty acids by skeletal muscle and white adipose tissue in Ad-apoa5-treated mice. From these data, we conclude that apoAV is a potent stimulator of LPL activity. Thus, apoAV lowers plasma TG by both reducing the hepatic VLDL-TG production rate and by enhancing the lipolytic conversion of TG-rich lipoproteins.	AMC Liver Ctr, NL-1105 BK Amsterdam, Netherlands; TNO Prevent & Hlth, Gaubius Lab, NL-2333 CK Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Gen Internal Med, NL-2333 ZA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Endocrinol, NL-2333 ZA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 ZA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Cardiol, NL-2333 ZA Leiden, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Netherlands Organization Applied Science Research; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Schaap, FG (corresponding author), AMC Liver Ctr, Meibergdreef 69-71, NL-1105 BK Amsterdam, Netherlands.	f.g.schaap@amc.uva.nl	Rensen, Patrick C.N./D-7176-2018; van Dijk, Ko Willems/A-1798-2008; van Dijk, Ko Willems/AAT-4681-2021	Rensen, Patrick C.N./0000-0002-8455-4988; van Dijk, Ko Willems/0000-0002-2172-7394; van Dijk, Ko Willems/0000-0002-2172-7394; Schaap, Frank/0000-0002-1597-572X				Aouizerat BE, 2003, J LIPID RES, V44, P1167, DOI 10.1194/jlr.M200480-JLR200; Beckstead JA, 2003, BIOCHEMISTRY-US, V42, P9416, DOI 10.1021/bi034509t; Cullen P, 2000, AM J CARDIOL, V86, P943, DOI 10.1016/S0002-9149(00)01127-9; Endo K, 2002, HUM GENET, V111, P570, DOI 10.1007/s00439-002-0825-0; Gerritsen G, 2003, J LIPID RES, V44, P408, DOI 10.1194/jlr.M200313-JLR200; Greene DJ, 2001, J BIOL CHEM, V276, P4804, DOI 10.1074/jbc.M008725200; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; Ishida T, 2003, J CLIN INVEST, V111, P347, DOI [10.1172/JCI200316306, 10.1172/JCI16306]; Kao JT, 2003, HUM MOL GENET, V12, P2533, DOI 10.1093/hmg/ddg255; Kypreos KE, 2001, J BIOL CHEM, V276, P19778, DOI 10.1074/jbc.M100418200; LevakFrank S, 1997, J BIOL CHEM, V272, P17182, DOI 10.1074/jbc.272.27.17182; LIU MS, 1994, J BIOL CHEM, V269, P11417; OTWAY S, 1967, J PHYSIOL-LONDON, V190, P321, DOI 10.1113/jphysiol.1967.sp008211; Pennacchio LA, 2002, HUM MOL GENET, V11, P3031, DOI 10.1093/hmg/11.24.3031; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; Prieur X, 2003, J BIOL CHEM, V278, P25468, DOI 10.1074/jbc.M301302200; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; RENSEN PCN, 1995, NAT MED, V1, P221, DOI 10.1038/nm0395-221; Rensen PCN, 1997, J LIPID RES, V38, P1070; Rensen PCN, 1996, J BIOL CHEM, V271, P14791, DOI 10.1074/jbc.271.25.14791; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; Tao NJ, 2001, MOL THER, V3, P28, DOI 10.1006/mthe.2000.0227; van der Vliet HN, 2002, BIOCHEM BIOPH RES CO, V295, P1156, DOI 10.1016/S0006-291X(02)00808-2; van der Vliet HN, 2001, J BIOL CHEM, V276, P44512, DOI 10.1074/jbc.M106888200; Vu-Dac N, 2003, J BIOL CHEM, V278, P17982, DOI 10.1074/jbc.M212191200; Weinberg RB, 2003, J BIOL CHEM, V278, P34438, DOI 10.1074/jbc.M303784200; YAMADA N, 1986, J LIPID RES, V27, P910; ZSIGMOND E, 1994, J BIOL CHEM, V269, P18757	28	249	275	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27941	27947		10.1074/jbc.M403240200	http://dx.doi.org/10.1074/jbc.M403240200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15090553	hybrid			2022-12-25	WOS:000222265400015
J	Sone, T; Saeki, Y; Toh-e, A; Yokosawa, H				Sone, T; Saeki, Y; Toh-e, A; Yokosawa, H			Sem1p is a novel subunit of the 26 S proteasome from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME CORE PARTICLE; YEAST 26S PROTEASOME; DNA-REPAIR; REGULATORY PARTICLE; USTILAGO-MAYDIS; CANCER SUSCEPTIBILITY; GENOME STABILITY; CANDIDATE GENE; BRCA2; RECOMBINATION	The 26 S proteasome, which catalyzes degradation of polyubiquitinated proteins, is composed of the 20 S proteasome and the 19 S regulatory particle ( RP). The RP is composed of the lid and base subcomplexes and regulates the catalytic activity of the 20 S proteasome. In this study, we carried out affinity purification of the lid and base subcomplexes from the tagged strains of Saccharomyces cerevisiae, and we found that the lid contains a small molecular mass protein, Sem1. The Sem1 protein binds with the 26 S proteasome isolated from a mutant with deletion of SEM1 but not with the 26 S proteasome from the wild type. The lid lacking Sem1 is unstable at a high salt concentration. The 19 S RP was immunoprecipitated together with Sem1 by immunoprecipitation using hemagglutinin epitope-tagged Sem1 as bait. Degradation of polyubiquitinated proteins in vivo or in vitro is impaired in the Sem1-deficient 26 S proteasome. In addition, genetic interaction between SEM1 and RPN10 was detected. The human Sem1 homologue hDSS1 was found to be a functional homologue of Sem1 and capable of interacting with the human 26 S proteasome. The results suggest that Sem1, possibly hDSS1, is a novel subunit of the 26 S proteasome and plays a role in ubiquitin-dependent proteolysis.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biochem, Sapporo, Hokkaido 0600812, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 1130033, Japan	Hokkaido University; University of Tokyo	Yokosawa, H (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biochem, Sapporo, Hokkaido 0600812, Japan.	yoko@pharm.hokudai.ac.jp						Bailly E, 1999, MOL CELL BIOL, V19, P6872; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Ferguson DO, 1997, GENETICS, V145, P243; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jantti J, 1999, P NATL ACAD SCI USA, V96, P909, DOI 10.1073/pnas.96.3.909; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; Kojic M, 2002, MOL CELL, V10, P683, DOI 10.1016/S1097-2765(02)00632-9; Kojic M, 2003, MOL CELL, V12, P1043, DOI 10.1016/S1097-2765(03)00367-8; Kominami K, 1997, MOL BIOL CELL, V8, P171, DOI 10.1091/mbc.8.1.171; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Mannhaupt G, 1999, FEBS LETT, V450, P27, DOI 10.1016/S0014-5793(99)00467-6; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; Maytal-Kivity V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-28; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Rinaldi T, 1998, MOL BIOL CELL, V9, P2917, DOI 10.1091/mbc.9.10.2917; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V296, P813, DOI 10.1016/S0006-291X(02)02002-8; Saeki Y, 2000, BIOCHEM BIOPH RES CO, V273, P509, DOI 10.1006/bbrc.2000.2980; Santamaria PG, 2003, J BIOL CHEM, V278, P6687, DOI 10.1074/jbc.M209420200; Sasaki T, 2000, MOL CELL BIOL, V20, P7971, DOI 10.1128/MCB.20.21.7971-7979.2000; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Takeuchi J, 1999, MOL CELL BIOL, V19, P6575; Takeuchi J, 2001, BIOCHIMIE, V83, P333, DOI 10.1016/S0300-9084(01)01238-X; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071	42	104	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28807	28816		10.1074/jbc.M403165200	http://dx.doi.org/10.1074/jbc.M403165200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117943	hybrid			2022-12-25	WOS:000222265400119
J	Xie, J; Guo, Q				Xie, J; Guo, Q			Par-4 inhibits choline uptake by interacting with CHT1 and reducing its incorporation on the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; ALZHEIMERS-DISEASE; MOLECULAR-CLONING; BASAL FOREBRAIN; CELL-LINE; NEUROTROPHIC FACTORS; HIPPOCAMPAL-NEURONS; TRANSPORTER CHT1; SPATIAL MEMORY; UPTAKE CARRIER	CHT1 is a Na+- and Cl--dependent, hemicholinium-3 (HC-3)-sensitive, high affinity choline transporter. Par-4 (prostate apoptosis response-4) is a leucine zipper protein involved in neuronal degeneration and cholinergic signaling in Alzheimer's disease. We now report that Par-4 is a negative regulator of CHT1 choline uptake activity. Transfection of neural IMR-32 cells with human CHT1 conferred Na+-dependent, HC-3-sensitive choline uptake that was effectively inhibited by cotransfection of Par-4. Mapping studies indicated that the C-terminal half of Par-4 was physically involved in interacting with CHT1, and the absence of Par-4.CHT1 complex formation precluded the loss of CHT1-mediated choline uptake induced by Par-4, indicating that Par-4.CHT1 complex formation is essential. Kinetic and cell-surface biotinylation assays showed that Par-4 inhibited CHT1-mediated choline uptake by reducing CHT1 expression in the plasma membrane without significantly altering the affinity of CHT1 for choline or HC-3. These results suggest that Par-4 is directly involved in regulating choline uptake by interacting with CHT1 and by reducing its incorporation on the cell surface.	Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Guo, Q (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	qing-guo@ouhsc.edu			NINDS NIH HHS [R01 NS 043296] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043296] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Apparsundaram S, 2000, BIOCHEM BIOPH RES CO, V276, P862, DOI 10.1006/bbrc.2000.3561; Apparsundaram S, 2001, BIOCHEM SOC T, V29, P711, DOI 10.1042/0300-5127:0290711; Auld DS, 2002, PROG NEUROBIOL, V68, P209, DOI 10.1016/S0301-0082(02)00079-5; Bissette G, 1996, ANN NY ACAD SCI, V777, P197, DOI 10.1111/j.1749-6632.1996.tb34419.x; BREER H, 1990, J NEUROBIOL, V21, P269, DOI 10.1002/neu.480210202; Chan SL, 1999, J NEUROCHEM, V73, P502, DOI 10.1046/j.1471-4159.1999.0730502.x; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Dickinson-Anson H, 2003, MOL THER, V8, P51, DOI 10.1016/S1525-0016(03)00145-X; FINE A, 1985, P NATL ACAD SCI USA, V82, P5227, DOI 10.1073/pnas.82.15.5227; FISCHER W, 1987, NATURE, V329, P65, DOI 10.1038/329065a0; Friedrich A, 2001, BBA-BIOMEMBRANES, V1512, P299, DOI 10.1016/S0005-2736(01)00333-9; Fujii T, 2003, LIFE SCI, V72, P2131, DOI 10.1016/S0024-3205(03)00073-0; Gibbs RB, 1998, HORM BEHAV, V34, P98, DOI 10.1006/hbeh.1998.1451; GOTTFRIES CG, 1983, NEUROBIOL AGING, V4, P261, DOI 10.1016/0197-4580(83)90002-7; Guermonprez L, 2002, J NEUROCHEM, V82, P874, DOI 10.1046/j.1471-4159.2002.01044.x; Guo Q, 2004, J BIOL CHEM, V279, P4596, DOI 10.1074/jbc.M309811200; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Guo Q, 2001, BRAIN RES, V903, P13, DOI 10.1016/S0006-8993(01)02304-6; Guo Q, 2001, J BIOL CHEM, V276, P16040, DOI 10.1074/jbc.M010996200; Guo Q, 1999, P NATL ACAD SCI USA, V96, P4125, DOI 10.1073/pnas.96.7.4125; Guo Q, 2000, BRAIN RES, V874, P221, DOI 10.1016/S0006-8993(00)02559-2; Haberberger RV, 2002, J INVEST DERMATOL, V119, P943, DOI 10.1046/j.1523-1747.2002.00182.x; Kobayashi Y, 2002, NEUROSCI LETT, V317, P25, DOI 10.1016/S0304-3940(01)02413-2; Lips KS, 2002, CELL TISSUE RES, V307, P275, DOI 10.1007/s00441-002-0520-4; Lyness SA, 2003, NEUROBIOL AGING, V24, P1, DOI 10.1016/S0197-4580(02)00057-X; Mattson MP, 1999, J MOL NEUROSCI, V13, P17, DOI 10.1385/JMN:13:1-2:17; Okuda T, 2000, FEBS LETT, V484, P92, DOI 10.1016/S0014-5793(00)02134-7; Okuda T, 2003, NEUROCHEM RES, V28, P483, DOI 10.1023/A:1022809003997; Okuda T, 2002, J BIOL CHEM, V277, P45315, DOI 10.1074/jbc.M207742200; PASCUAL J, 1991, BRAIN RES, V552, P170, DOI 10.1016/0006-8993(91)90676-M; Pasinelli P, 2000, P NATL ACAD SCI USA, V97, P13901, DOI 10.1073/pnas.240305897; Pedersen WA, 2000, FASEB J, V14, P913, DOI 10.1096/fasebj.14.7.913; Pfeil U, 2003, LIFE SCI, V72, P2087, DOI 10.1016/S0024-3205(03)00088-2; Pfeil U, 2003, AM J RESP CELL MOL, V28, P473, DOI 10.1165/rcmb.2002-0190OC; Poppe R, 1997, J NEUROCHEM, V69, P84, DOI 10.1046/j.1471-4159.1997.69010084.x; PRICE DL, 1985, ANN NY ACAD SCI, V457, P35, DOI 10.1111/j.1749-6632.1985.tb20798.x; PRICE DL, 1993, PROG BRAIN RES, V98, P51; RABINOVSKY ED, 1992, J NEUROSCI, V12, P171; Ribeiro FM, 2003, J NEUROCHEM, V87, P136, DOI 10.1046/j.1471-4159.2003.01974.x; RODRIGUEZPUERTAS R, 1994, J NEURAL TRANSM-PARK, V8, P161, DOI 10.1007/BF02260937; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; Sirvio J, 1999, GERONTOLOGY, V45, P3, DOI 10.1159/000052759; SLOTKIN TA, 1994, J CLIN INVEST, V94, P696, DOI 10.1172/JCI117387; Wang YL, 2001, GENE, V268, P123, DOI 10.1016/S0378-1119(01)00421-8; Warburton EC, 2003, NEURON, V38, P987, DOI 10.1016/S0896-6273(03)00358-1; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; WINKLER J, 1995, NATURE, V375, P484, DOI 10.1038/375484a0; Xie J, 2001, BRAIN RES, V915, P1, DOI 10.1016/S0006-8993(01)02803-7; Zapata A, 2000, SYNAPSE, V35, P272, DOI 10.1002/(SICI)1098-2396(20000315)35:4<272::AID-SYN5>3.0.CO;2-B	50	21	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28266	28275		10.1074/jbc.M401495200	http://dx.doi.org/10.1074/jbc.M401495200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15090548	hybrid			2022-12-25	WOS:000222265400057
J	Goux, WJ; Kopplin, L; Nguyen, AD; Leak, K; Rutkofsky, M; Shanmuganandam, VD; Sharma, D; Inouye, H; Kirschner, DA				Goux, WJ; Kopplin, L; Nguyen, AD; Leak, K; Rutkofsky, M; Shanmuganandam, VD; Sharma, D; Inouye, H; Kirschner, DA			The formation of straight and twisted filaments from short tau peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; AMYLOID FIBRIL FORMATION; PROTEIN SECONDARY STRUCTURE; IN-VITRO; CIRCULAR-DICHROISM; ALZHEIMER-DISEASE; ABNORMAL PHOSPHORYLATION; MICROTUBULE INTERACTIONS; POLYPEPTIDE IAPP; AGGREGATION	We studied fibril formation in a family of peptides based on PHF6 (VQIVYK), a short peptide segment found in the microtubule binding region of tau protein. N-Acetylated peptides AcVYK-amide (AcVYK), AcIVYK-amide (AcPHF4), AcQIVYK-amide (AcPHF5), and AcV-QIVYK-amide (AcPHF6) rapidly formed straight filaments in the presence of 0.15 M NaCl, each composed of two laterally aligned protofilaments similar to5 nm in width. X-ray fiber diffraction showed the omnipresent sharp 4.7-Angstrom reflection indicating that the scattering objects are likely elongated along the hydrogen-bonding direction in a cross-beta conformation, and Fourier transform IR suggested the peptide chains were in a parallel (AcVYK, AcPHF6) or antiparallel (AcPHF4, AcPHF5) beta-sheet configuration. The dipeptide N-acetyl-YK-amide (AcYK) formed globular structures similar to200 nm to 1 mum in diameter. The polymerization rate, as measured by thioflavin S binding, increased with the length of the peptide going from AcYK 3 AcPHF6, and peptides that aggregated most rapidly displayed CD spectra consistent with beta-sheet structure. There was a 3-fold decrease in rate when Val was substituted for Ile or Gln, nearly a 10-fold decrease when Ala was substituted for Tyr, and an increase in polymerization rate when Glu was substituted for Lys. Twisted filaments, composed of four laterally aligned protofilaments (9-19 nm width, similar to90 nm half-periodicity), were formed by mixing AcPHF6 with AcVYK. Taken together these results suggest that the core of PHF6 is localized at VYK, and the interaction between small amphiphilic segments of tau may initiate nucleation and lead to filaments displaying paired helical filament morphology.	Univ Texas, Dept Chem, Richardson, TX 75083 USA; Boston Coll, Dept Biol, Chestnut Hill, MA 02467 USA	University of Texas System; University of Texas Dallas; Boston College	Goux, WJ (corresponding author), Univ Texas, Dept Chem, POB 830688, Richardson, TX 75083 USA.	wgoux@utdallas.edu		Sharma, Deepak/0000-0001-8436-1759; Kirschner, Daniel/0000-0003-3498-1452	NIA NIH HHS [1R03AG16042-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R03AG016042] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abraha A, 2000, J CELL SCI, V113, P3737; Azriel R, 2001, J BIOL CHEM, V276, P34156, DOI 10.1074/jbc.M102883200; Balbach JJ, 2000, BIOCHEMISTRY-US, V39, P13748, DOI 10.1021/bi0011330; BANDEKAR J, 1992, BIOCHIM BIOPHYS ACTA, V1120, P123, DOI 10.1016/0167-4838(92)90261-B; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; Barghorn S, 2002, BIOCHEMISTRY-US, V41, P14885, DOI 10.1021/bi026469j; Berriman J, 2003, P NATL ACAD SCI USA, V100, P9034, DOI 10.1073/pnas.1530287100; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Caplan MR, 2000, BIOMACROMOLECULES, V1, P627, DOI 10.1021/bm005586w; Caplan MR, 2002, BIOMATERIALS, V23, P219, DOI 10.1016/S0142-9612(01)00099-0; CHOMA CT, 1994, J AM CHEM SOC, V116, P856, DOI 10.1021/ja00082a005; CROWTHER RA, 1991, P NATL ACAD SCI USA, V88, P2288, DOI 10.1073/pnas.88.6.2288; CROWTHER RA, 1985, EMBO J, V4, P3661, DOI 10.1002/j.1460-2075.1985.tb04132.x; de la Paz ML, 2002, P NATL ACAD SCI USA, V99, P16052, DOI 10.1073/pnas.252340199; DICKSON DW, 1995, NEUROBIOL AGING, V16, P285, DOI 10.1016/0197-4580(95)00013-5; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Feany MB, 1996, J NEUROPATH EXP NEUR, V55, P53, DOI 10.1097/00005072-199601000-00006; Feany MB, 1996, ANN NEUROL, V40, P139, DOI 10.1002/ana.410400204; Friedhoff P, 1998, P NATL ACAD SCI USA, V95, P15712, DOI 10.1073/pnas.95.26.15712; Friedhoff P, 1998, BIOCHEMISTRY-US, V37, P10223, DOI 10.1021/bi980537d; Gamblin TC, 2003, BIOCHEMISTRY-US, V42, P2252, DOI 10.1021/bi0272510; Giannetti AM, 2000, PROTEIN SCI, V9, P2427, DOI 10.1110/ps.9.12.2427; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOUX WJ, 1980, J AM CHEM SOC, V102, P7080, DOI 10.1021/ja00543a033; Goux WJ, 2002, BIOCHEMISTRY-US, V41, P13798, DOI 10.1021/bi016079h; Goux WJ, 1996, J NEUROCHEM, V67, P723; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HARIS PI, 1995, BIOPOLYMERS, V37, P251, DOI 10.1002/bip.360370404; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Huang THJ, 2000, J MOL BIOL, V297, P73, DOI 10.1006/jmbi.2000.3559; Huang THJ, 2000, J BIOL CHEM, V275, P36436, DOI 10.1074/jbc.M005698200; Inouye H, 2000, J STRUCT BIOL, V130, P123, DOI 10.1006/jsbi.2000.4258; INOUYE H, 1993, BIOPHYS J, V64, P502, DOI 10.1016/S0006-3495(93)81393-6; Ishimaru D, 2003, BIOCHEMISTRY-US, V42, P9022, DOI 10.1021/bi034218k; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; Kad NM, 2003, J MOL BIOL, V330, P785, DOI 10.1016/S0022-2836(03)00583-7; KHATOON S, 1992, J NEUROCHEM, V59, P750, DOI 10.1111/j.1471-4159.1992.tb09432.x; King ME, 2000, J NEUROCHEM, V74, P1749, DOI 10.1046/j.1471-4159.2000.0741749.x; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; KOPKE E, 1993, J BIOL CHEM, V268, P24374; Kosik Kenneth S., 1994, P335; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; KSIEZAKREDING H, 1994, AM J PATHOL, V145, P1496; KSIEZAKREDING H, 1992, BRAIN RES, V597, P209, DOI 10.1016/0006-8993(92)91476-U; Lashuel HA, 2003, J MOL BIOL, V332, P795, DOI 10.1016/S0022-2836(03)00927-6; Lashuel HA, 2000, J AM CHEM SOC, V122, P5262, DOI 10.1021/ja9937831; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Li L, 2002, J BIOL CHEM, V277, P41390, DOI 10.1074/jbc.M206334200; Liu RT, 2004, J NEUROSCI RES, V75, P162, DOI 10.1002/jnr.10859; MacPhee CE, 2000, J MOL BIOL, V297, P1203, DOI 10.1006/jmbi.2000.3600; MAKOWSKI L, 1989, BROOKH S SYNCHR RAD, P341; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; Mandelkow EM, 1996, ANN NY ACAD SCI, V777, P96, DOI 10.1111/j.1749-6632.1996.tb34407.x; MANNING MC, 1988, BIOPHYS CHEM, V31, P77, DOI 10.1016/0301-4622(88)80011-5; Mazor Y, 2002, J MOL BIOL, V322, P1013, DOI 10.1016/S0022-2836(02)00887-2; Nilsson MR, 2003, BIOCHEMISTRY-US, V42, P375, DOI 10.1021/bi0204746; Nybo M, 1999, SCAND J IMMUNOL, V49, P219; OLDENBOURG R, 1986, REV SCI INSTRUM, V57, P2362, DOI 10.1063/1.1138680; Pace CN, 1995, METHOD ENZYMOL, V259, P538; POLLANEN MS, 1994, AM J PATHOL, V144, P869; Reches M, 2002, J BIOL CHEM, V277, P35475, DOI 10.1074/jbc.M206039200; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; Spillantini MG, 1997, P NATL ACAD SCI USA, V94, P4113, DOI 10.1073/pnas.94.8.4113; Sreerama N, 2003, PROTEIN SCI, V12, P384, DOI 10.1110/ps.0235003; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Tenidis K, 2000, J MOL BIOL, V295, P1055, DOI 10.1006/jmbi.1999.3422; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1259, DOI 10.1002/bip.360301310; von Bergen M, 2001, J BIOL CHEM, V276, P48165, DOI 10.1074/jbc.M105196200; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; West MW, 1999, P NATL ACAD SCI USA, V96, P11211, DOI 10.1073/pnas.96.20.11211; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1985, J CELL BIOL, V100, P1905, DOI 10.1083/jcb.100.6.1905; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; Woody R.W., 1996, CIRCULAR DICHROISM C, P25, DOI DOI 10.1007/978-1-4757-2508-7_2; WU J, 1992, ANAL BIOCHEM, V200, P359, DOI 10.1016/0003-2697(92)90479-Q; Yanagawa H, 1998, BIOCHEMISTRY-US, V37, P1979, DOI 10.1021/bi9724265; Zurdo J, 2001, J MOL BIOL, V311, P325, DOI 10.1006/jmbi.2001.4858; Zurdo J, 2001, J AM CHEM SOC, V123, P8141, DOI 10.1021/ja016229b	83	183	184	1	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26868	26875		10.1074/jbc.M402379200	http://dx.doi.org/10.1074/jbc.M402379200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15100221	hybrid			2022-12-25	WOS:000222120400010
J	Brabender, J; Marjoram, P; Salonga, D; Metzger, R; Schneider, PM; Park, JM; Schneider, S; Holscher, AH; Yin, J; Meltzer, SJ; Danenberg, KD; Danenberg, PV; Lord, RV				Brabender, J; Marjoram, P; Salonga, D; Metzger, R; Schneider, PM; Park, JM; Schneider, S; Holscher, AH; Yin, J; Meltzer, SJ; Danenberg, KD; Danenberg, PV; Lord, RV			A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus	ONCOGENE			English	Article						Barrett's esophagus; esophageal adenocarcinoma; gene expression; quantititative real-time RT-PCR	MESSENGER-RNA EXPRESSION; ARTIFICIAL NEURAL NETWORKS; CDNA MICROARRAYS; LUNG-CANCER; DISTINGUISH; METAPLASIA; APOPTOSIS; DYSPLASIA; SEQUENCE; SYNTHASE	In order to identify genes or combination of genes that have the power to discriminate between premalignant Barrett's esophagus and Barrett's associated adenocarcinoma, we analysed a panel of 23 genes using quantitative real-time RT-PCR (qRT-PCR, Taqman(R)) and bioinformatic tools. The genes chosen were either known to be associated with Barrett's carcinogenesis or were filtered from a previous cDNA microarray study on Barrett's adenocarcinoma. A total of 98 tissues, obtained from 19 patients with Barrett's esophagus (BE group) and 20 patients with Barrett's associated esophageal adenocarcinoma (EA group), were studied. Triplicate analysis for the full 23 gene of interest panel, and analysis of an internal control gene, was performed for all samples, for a total of more than 9016 single PCR reactions. We found distinct classes of gene expression patterns in the different types of tissues. The most informative genes clustered in six different classes and had significantly different expression levels in Barrett's esophagus tissues compared to adenocarcinoma tissues. Linear discriminant analysis (LDA) distinguished four genetically different groups. The normal squamous esophagus tissues from patients with BE or EA were not distinguishable from one another, but Barrett's esophagus tissues could be distinguished from adenocarcinoma tissues. Using the most informative genes, obtained from a logistic regression analysis, we were able to completely distinguish between benign Barrett's and Barrett's adenocarcinomas. This study provides the first non-array parallel mRNA quantitation analysis of a panel of genes in the Barrett's esophagus model of multistage carcinogenesis. Our results suggest that mRNA expression quantitation of a panel of genes can discriminate between premalignant and malignant Barrett's disease. Logistic regression and LDAs can be used to further identify, from the complete panel, gene subsets with the power to make these diagnostic distinctions. Expression analysis of a limited number of highly selected genes may have clinical usefulness for the treatment of patients with this disease.	Univ Cologne, Dept Visceral & Vasc Surg, D-50931 Cologne, Germany; Univ So Calif, Dept Prevent Med, Los Angeles, CA 90033 USA; Response Genet Inc, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; VA Med Ctr, Baltimore, MD 21201 USA; Univ So Calif, Keck Sch Med, Dept Surg, Los Angeles, CA 90033 USA	University of Cologne; University of Southern California; University of Southern California; University of Southern California; University System of Maryland; University of Maryland Baltimore; University of Southern California	Brabender, J (corresponding author), Univ Cologne, Dept Visceral & Vasc Surg, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.	jan.brabender@t-online.de	Marjoram, Paul/A-3066-2008	Lord, Reginald V N/0000-0001-7475-492X	NCI NIH HHS [CA95323, CA85069, CA77057, CA098450, CA01808, CA 71716] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077057, R01CA095323, R21CA098450, R01CA071716, U01CA085069, R01CA001808] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brabender J, 2002, J GASTROINTEST SURG, V6, P359, DOI 10.1016/S1091-255X(02)00003-3; Brabender J, 2003, BRIT J CANCER, V89, P1508, DOI 10.1038/sj.bjc.6601324; Brabender J, 2002, CLIN CANCER RES, V8, P438; Brabender J, 2001, J GASTROINTEST SURG, V5, P174, DOI 10.1016/S1091-255X(01)80031-7; Brabender J, 2001, J SURG RES, V99, P301, DOI 10.1006/jsre.2001.6186; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen O, 2001, CELL DEATH DIFFER, V8, P6, DOI 10.1038/sj.cdd.4400794; Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2; DUBOIT S, 2002, J AM STAT ASSOC, V8, P77; Eads CA, 1999, CANCER RES, V59, P2302; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Lord RVN, 2000, J GASTROINTEST SURG, V4, P135, DOI 10.1016/S1091-255X(00)80049-9; Lord RVN, 2001, SURGERY, V129, P267, DOI 10.1067/msy.2001.110856; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; SCHERF U, 2001, P ANN M AM ASS CANC, V42, pA3288; Selaru FM, 2002, GASTROENTEROLOGY, V122, P606, DOI 10.1053/gast.2002.31904; Selaru FM, 2002, ONCOGENE, V21, P475, DOI 10.1038/sj.onc.1205111; Suda Yasuo, 1999, Gastric Cancer, V2, P165, DOI 10.1007/s101200050041; Terashima M, 2002, ANTICANCER RES, V22, P761; Virmani AK, 2002, CANCER EPIDEM BIOMAR, V11, P291; Wilson KT, 1998, CANCER RES, V58, P2929; Woodward TA, 2000, ANTICANCER RES, V20, P2427; Xu Y, 2002, CANCER RES, V62, P3493; Zou TT, 2002, ONCOGENE, V21, P4855, DOI 10.1038/sj.onc.1205613	27	50	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	2004	23	27					4780	4788		10.1038/sj.onc.1207663	http://dx.doi.org/10.1038/sj.onc.1207663			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15107828				2022-12-25	WOS:000221799200013
J	Thomas-Mudge, RJ; Okada-Ban, M; Vandenbroucke, F; Vincent-Salomon, A; Girault, JM; Thiery, JP; Jouanneau, J				Thomas-Mudge, RJ; Okada-Ban, M; Vandenbroucke, F; Vincent-Salomon, A; Girault, JM; Thiery, JP; Jouanneau, J			Nuclear FGF-2 facilitates cell survival in vitro and during establishment of metastases	ONCOGENE			English	Article						nuclear FGF-2; metastases; apoptosis; survival	FIBROBLAST-GROWTH-FACTOR; GREEN FLUORESCENT PROTEIN; BLADDER-CARCINOMA CELLS; KINASE-C-DELTA; CANCER CELLS; REGULATES BCL-2; MELANOMA-CELLS; TUMOR-CELLS; FACTOR BFGF; EXPRESSION	Nuclear-targeted high molecular weight 24 kDa fibroblast growth factor 2 (FGF-2) may induce specific cell functions through intracrine mechanisms. The role of nuclear FGF-2 on the metastatic potential of carcinoma cells was examined by conditional FGF-2 expression, which demonstrated that spontaneous metastasis in nude mice is a direct consequence of its expression. The lung colonizing capacities of fluorescent nuclear FGF-2-expressing cells following intravenous injection was also investigated. All cells reaching the lung extravasated as soon as 5 min following injection with similar in vivo behavior during the first 24 h. However, after 2 days, dramatic differences were observed between the FGF-2 and parental cells: most control cells underwent apoptosis, while the FGF-2-producing cells instigated a survival program and proliferated. Therefore, sustained apoptosis in vivo prevents growth of metastatic foci, while nuclear FGF-2 induction of a survival program is responsible for growth of the lung metastases. In vitro serum deprivation assays also established that 24 kDa FGF-2 expression improves carcinoma cell survival. This study provides both in vitro and in vivo evidence that the role of the nuclear 24kDa FGF-2 isoform in carcinoma is the promotion of cell survival, thereby defining its association with poor prognosis in some human carcinomas.	Inst Curie, Div Res, CNRS, UMR 144, F-75248 Paris 05, France; Inst Curie, Div Med, Dept Biol, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Jouanneau, J (corresponding author), Inst Curie, Div Res, CNRS, UMR 144, F-75248 Paris 05, France.	Jacqueline.Jounneau@curie.fr	Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020; Mudge, Rachel/0000-0002-5727-3240				Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Arnaud E, 1999, MOL CELL BIOL, V19, P505; Boelaert K, 2003, J CLIN ENDOCR METAB, V88, P2341, DOI 10.1210/jc.2002-021113; Bold RJ, 2001, CANCER-AM CANCER SOC, V92, P1122, DOI 10.1002/1097-0142(20010901)92:5<1122::AID-CNCR1429>3.0.CO;2-H; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; Cameron MD, 2000, CANCER RES, V60, P2541; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Delrieu I, 2000, FEBS LETT, V468, P6, DOI 10.1016/S0014-5793(00)01189-3; Farina KL, 1998, CANCER RES, V58, P2528; Fukui S, 2003, CANCER, V97, P3061, DOI 10.1002/cncr.11450; Fukui S, 2002, J NEURO-ONCOL, V57, P221, DOI 10.1023/A:1015763725104; Funato N, 1997, BIOCHEM BIOPH RES CO, V240, P21, DOI 10.1006/bbrc.1997.7588; Gaubert F, 2001, J BIOL CHEM, V276, P1545, DOI 10.1074/jbc.M001184200; Giavazzi R, 2001, CANCER RES, V61, P309; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gualandris A, 1999, J CELL PHYSIOL, V181, P273, DOI 10.1002/(SICI)1097-4652(199911)181:2<273::AID-JCP9>3.0.CO;2-#; Hajihosseini MK, 1999, MOL CELL NEUROSCI, V14, P468, DOI 10.1006/mcne.1999.0800; Karsan A, 1997, AM J PATHOL, V151, P1775; Konig A, 1997, LEUKEMIA, V11, P258, DOI 10.1038/sj.leu.2400556; KOOP S, 1995, CANCER RES, V55, P2520; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Maloof P, 1999, BREAST CANCER RES TR, V56, P153; Miyake H, 1999, BRIT J CANCER, V79, P1651, DOI 10.1038/sj.bjc.6690264; Naumov GN, 1999, J CELL SCI, V112, P1835; Okada-Ban M, 1999, ONCOGENE, V18, P6719, DOI 10.1038/sj.onc.1203092; Okada-Ban M, 2000, INT J BIOCHEM CELL B, V32, P263, DOI 10.1016/S1357-2725(99)00133-8; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Pardo OE, 2003, MOL CELL BIOL, V23, P7600, DOI 10.1128/MCB.23.21.7600-7610.2003; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Rosini P, 2002, PROSTATE, V53, P310, DOI 10.1002/pros.10164; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; Sun CP, 2001, J CELL PHYSIOL, V186, P457, DOI 10.1002/1097-4652(2000)9999:999<000::AID-JCP1044>3.0.CO;2-2; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; TOYOSHIMA K, 1971, JNCI-J NATL CANCER I, V47, P979; Van den Berghe L, 2000, MOL ENDOCRINOL, V14, P1709, DOI 10.1210/me.14.11.1709; Wert MM, 2000, BIOCHEM J, V352, P175, DOI 10.1042/0264-6021:3520175; Wieder R, 1997, GROWTH FACTORS, V15, P41, DOI 10.3109/08977199709002111; Wong CW, 2001, CANCER RES, V61, P333	38	25	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4771	4779		10.1038/sj.onc.1207638	http://dx.doi.org/10.1038/sj.onc.1207638			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122340				2022-12-25	WOS:000221799200012
J	Chen, J; Yu, WM; Bunting, KD; Qu, CK				Chen, J; Yu, WM; Bunting, KD; Qu, CK			A negative role of SHP-2 tyrosine phosphatase in growth factor-dependent hematopoietic cell survival	ONCOGENE			English	Article						SHP-2; tyrosine phosphatase; hematopoietic cell survival; STAT5; IL-3	CYCLE PROGRESSION; BONE-MARROW; STAT5; PROTEIN; EXPRESSION; DIFFERENTIATION; PHOSPHORYLATION; APOPTOSIS; BINDING; DEATH	SHP-2 tyrosine phosphatase is highly expressed in hematopoietic cells; however, the function of SHP-2 in hematopoietic cell processes is not fully understood. Recent identification of SHP-2 mutations in childhood leukemia further emphasizes the importance of SHP-2 regulation in hematopoietic cells. We previously reported that SHP-2 played a positive role in IL-3-induced activation of Jak2 kinase in a catalytic-dependent manner. Interestingly, enforced expression of wild-type (WT) SHP-2 in Ba/F3 cells enhanced growth factor deprivation-induced apoptosis. Biochemical analyses revealed that although IL-3 activation of Jak2 kinase was increased, tyrosyl phosphorylation of its downstream substrate STAT5 was disproportionately decreased by the overexpression of SHP-2. Following IL-3 deprivation, the tyrosyl phosphorylation of STAT5 that is required for its antiapoptotic activity was rapidly diminished in SHP-2 overexpressing cells. As a result, reduction of the putative downstream targets of STAT5- Bcl-X-L and pim-1 was accelerated by overexpression of SHP-2. Further investigation showed that SHP-2 associated with STAT5, and that it was indeed able to dephosphorylate STAT5. Finally, overexpression of SHP-2 in primary bone marrow hematopoietic progenitor cells compromised their differentiative and proliferative potential, and enhanced growth factor withdrawal-induced cell death. And, the effect of SHP-2 overexpression on growth factor-dependent survival was diminished in STAT5-deficient hematopoietic cells. Taken together, these results suggest that SHP-2 tyrosine phosphatase negatively regulates hematopoietic cell survival by dephosphorylation of STAT5.	Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Hematopoiesis, Rockville, MD 20855 USA; George Washington Univ, Med Ctr, Dept Anat & Cell Biol, Washington, DC 20037 USA	American Red Cross; George Washington University	Qu, CK (corresponding author), Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Hematopoiesis, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	quc@usa.redcross.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059380] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL68212] Funding Source: Medline; NIDDK NIH HHS [R01 DK059380] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; Chan RJ, 2003, BLOOD, V102, P2074, DOI 10.1182/blood-2003-04-1171; CHEN Y, 2003, J BIOL CHEM, V278, P165; Chughtai N, 2002, J BIOL CHEM, V277, P31107, DOI 10.1074/jbc.M200156200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Qu CK, 1998, ONCOGENE, V17, P433, DOI 10.1038/sj.onc.1201920; Qu CK, 2002, BBA-MOL CELL RES, V1592, P297, DOI 10.1016/S0167-4889(02)00322-1; Qu CK, 2001, BLOOD, V97, P911, DOI 10.1182/blood.V97.4.911; Qu CK, 1998, MOL CELL BIOL, V18, P6075, DOI 10.1128/MCB.18.10.6075; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shelburne CP, 2003, BLOOD, V102, P1290, DOI 10.1182/blood-2002-11-3490; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; Wheadon H, 2003, BIOCHEM J, V376, P147, DOI 10.1042/BJ20031160; Wickremasinghe RG, 1999, BLOOD, V93, P3587, DOI 10.1182/blood.V93.11.3587.411k46_3587_3600; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; Yu WM, 2003, ONCOGENE, V22, P5995, DOI 10.1038/sj.onc.1206846; Yu WM, 2002, BLOOD, V99, P2351, DOI 10.1182/blood.V99.7.2351; Yuan LP, 2003, J BIOL CHEM, V278, P15208, DOI 10.1074/jbc.M211327200; Zamorano J, 1998, J IMMUNOL, V160, P3502; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	42	35	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3659	3669		10.1038/sj.onc.1207471	http://dx.doi.org/10.1038/sj.onc.1207471			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116097				2022-12-25	WOS:000221101700018
J	EL Naaman, C; Grum-Schwensen, B; Mansouri, A; Grigorian, M; Santoni-Rugiu, E; Hansen, T; Kriajevska, M; Schafer, BW; Heizmann, CW; Lukanidin, E; Ambartsumian, N				EL Naaman, C; Grum-Schwensen, B; Mansouri, A; Grigorian, M; Santoni-Rugiu, E; Hansen, T; Kriajevska, M; Schafer, BW; Heizmann, CW; Lukanidin, E; Ambartsumian, N			Cancer predisposition in mice deficient for the metastasis-associated Mts1(S100A4) gene	ONCOGENE			English	Article						animal models; Mts1(S100A4); p53; tumor development; tumor suppressor activity	TUMOR-SUPPRESSOR GENE; PROTEIN S100A4 P9KA; BINDING PROTEIN; WILD-TYPE; P53; EXPRESSION; CALCIUM; TARGET; CELLS; TP53	Metastasis-promoting Mts1(S100A4) protein belongs to the S100 family of Ca2+-binding proteins. A mouse strain with a germ-line inactivation of the S100A4 gene was generated. The mice were viable and did not display developmental abnormalities in the postnatal period. However, an abnormal sex ratio was observed in the litters with the S100A4-/- genotype, raising the possibility of a certain level of embryonic lethality in this strain. In all, 10% of 10-14-month-old S100A4-null animals developed tumors. This is a characteristic feature of mouse strains with inactivated tumor suppressor genes. Spontaneous tumors of S100A4-/- mice were p53 positive. Recently, we have shown that S100A4 interacts with p53 tumor suppressor protein and induces apoptosis. We proposed that impairment of this interaction could affect the apoptosis-promoting function of p53 that is involved in its tumor suppressor activity. The frequency of apoptosis in the spleen of S100A4-/- animals after whole-body gamma-irradiation was reduced compared to the wild-type animals. The same was true for the transcriptional activation of the p53 target genes - waf/p21/cip1 and bax. Taken together, these observations indicate that spontaneous tumors in S100A4-/- mice are a result of functional destabilization of p53 tumor suppressor gene.	Danish Canc Soc, Dept Mol Canc Biol, DK-2100 Copenhagen, Denmark; Max Planck Inst Biophys Chem, Dept Mol Cell Biol, D-37077 Gottingen, Germany; Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark; Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland	Danish Cancer Society; Max Planck Society; Rigshospitalet; University of Copenhagen; University of Zurich	Ambartsumian, N (corresponding author), Danish Canc Soc, Dept Mol Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.	na@cancer.dk	Santoni-Rugiu, Eric/H-4913-2019; Santoni-Rugiu, Eric/AAH-3368-2020; Hansen, Thomas Folkmann/O-5965-2014; Hansen, Thomas/GWZ-2858-2022	Santoni-Rugiu, Eric/0000-0002-2283-3535; Hansen, Thomas Folkmann/0000-0001-6703-7762; Grum-Schwensen, Birgitte/0000-0001-6677-1869; Schafer, Beat/0000-0001-5988-2915				Al-Haddad S, 1999, AM J PATHOL, V155, P2057, DOI 10.1016/S0002-9440(10)65524-1; Ambartsumian N, 2001, ONCOGENE, V20, P4685, DOI 10.1038/sj.onc.1204636; Ambartsumian N, 1999, INVAS METAST, V18, P96; Ambartsumian NS, 1996, ONCOGENE, V13, P1621; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Borresen-Dale AL, 2003, HUM MUTAT, V21, P292, DOI 10.1002/humu.10174; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Buzard GS, 1996, MUTAT RES-REV GENET, V365, P43, DOI 10.1016/S0165-1110(96)90011-1; Cazorla M, 1998, MOL CARCINOGEN, V21, P251, DOI 10.1002/(SICI)1098-2744(199804)21:4<251::AID-MC4>3.0.CO;2-N; Chen DS, 1996, BIOCHEM SOC T, V24, pS352, DOI 10.1042/bst024352s; Chen HL, 2001, BIOCHEM BIOPH RES CO, V286, P1212, DOI 10.1006/bbrc.2001.5517; Christensen CRL, 1998, CANCER RES, V58, P1238; Cohn MA, 2001, NUCLEIC ACIDS RES, V29, P3335, DOI 10.1093/nar/29.16.3335; Da Silva IDCG, 2000, INT J ONCOL, V16, P231; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Davies BR, 2002, J PATHOL, V196, P292, DOI 10.1002/path.1051; DAVIES M, 1995, DNA CELL BIOL, V14, P825, DOI 10.1089/dna.1995.14.825; Davies MPA, 1996, ONCOGENE, V13, P1631; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Du XJ, 2002, MOL CELL BIOL, V22, P2821, DOI 10.1128/MCB.22.8.2821-2829.2002; Duddy SK, 1999, TOXICOL APPL PHARM, V156, P106, DOI 10.1006/taap.1999.8631; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Endo H, 2002, J BIOL CHEM, V277, P26396, DOI 10.1074/jbc.M202244200; Fei PW, 2002, CANCER RES, V62, P7316; Feng G, 2001, CANCER RES, V61, P7999; FORD HL, 1995, ONCOGENE, V10, P1597; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Hakem R, 2001, ANNU REV GENET, V35, P209, DOI 10.1146/annurev.genet.35.102401.090432; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Hobbs JAR, 2003, MOL CELL BIOL, V23, P2564, DOI 10.1128/MCB.23.7.2564-2576.2003; Hsieh HL, 2002, J CELL SCI, V115, P3149; Iacopetta B, 2003, HUM MUTAT, V21, P271, DOI 10.1002/humu.10175; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johnson DG, 2000, MOL CARCINOGEN, V27, P151, DOI 10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C; Klingelhofer J, 1997, DEV DYNAM, V210, P87, DOI 10.1002/(SICI)1097-0177(199710)210:2<87::AID-AJA2>3.0.CO;2-5; Komarova EA, 2000, ONCOGENE, V19, P3791, DOI 10.1038/sj.onc.1203717; Kriajevska M, 2002, J BIOL CHEM, V277, P5229, DOI 10.1074/jbc.M110976200; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Lukanidin EM, 1996, CURR TOP MICROBIOL, V213, P171; Mandinova A, 1998, J CELL SCI, V111, P2043; Manitz MP, 2003, MOL CELL BIOL, V23, P1034, DOI 10.1128/MCB.23.3.1034-1043.2003; Mansouri A, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 3, P478; Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307; Mazzucchelli L, 2002, AM J PATHOL, V160, P7, DOI 10.1016/S0002-9440(10)64342-8; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; Meuwissen R, 2001, EXP CELL RES, V264, P100, DOI 10.1006/excr.2000.5146; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; Passey RJ, 1999, J IMMUNOL, V163, P2209; PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513; Pelc P, 2003, HISTOPATHOLOGY, V42, P387, DOI 10.1046/j.1365-2559.2003.01588.x; Platt-Higgins AM, 2000, INT J CANCER, V89, P198, DOI 10.1002/(SICI)1097-0215(20000320)89:2<198::AID-IJC16>3.0.CO;2-L; Ridinger K, 1998, BBA-MOL CELL RES, V1448, P254, DOI 10.1016/S0167-4889(98)00137-2; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SAUER B, 1993, METHOD ENZYMOL, V225, P890; Schafer BW, 2000, J BIOL CHEM, V275, P30623, DOI 10.1074/jbc.M002260200; Schuijer M, 2003, HUM MUTAT, V21, P285, DOI 10.1002/humu.10181; Staib F, 2003, HUM MUTAT, V21, P201, DOI 10.1002/humu.10176; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Teratani T, 2002, BIOCHEM BIOPH RES CO, V291, P623, DOI 10.1006/bbrc.2002.6494; TURUSOV V, 1994, PATHOLOGY TUMORS LAB, V2; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; WETERMAN MAJ, 1993, CANCER RES, V53, P6061; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Xiong ZG, 2000, EXP CELL RES, V257, P281, DOI 10.1006/excr.2000.4902; Yonemura Y, 2000, CLIN CANCER RES, V6, P4234	75	52	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3670	3680		10.1038/sj.onc.1207420	http://dx.doi.org/10.1038/sj.onc.1207420			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116098				2022-12-25	WOS:000221101700019
J	Sugano, M; Tsuchida, K; Hata, T; Makino, N				Sugano, M; Tsuchida, K; Hata, T; Makino, N			In vivo transfer of soluble TNF-alpha receptor 1 gene improves cardiac function and reduces infarct size after myocardial infarction in rats	FASEB JOURNAL			English	Article						soluble TNF-alpha receptor 1; gene therapy; sTNFR1; plasmid	TUMOR-NECROSIS-FACTOR; CHRONIC HEART-FAILURE; MONOCLONAL-ANTIBODY; TRANSGENIC MICE; EXPRESSION; ISCHEMIA; CARDIOMYOPATHY; HYPERTROPHY; REPERFUSION; APOPTOSIS	Increased circulating and cardiac TNF-alpha levels during myocardial ischemia have been found in both experimental animals and patients with ischemic heart disease and advanced heart failure. Soluble TNF-alpha receptor 1 (sTNFR1) is an antagonist to TNF-alpha. In the present study, we examined whether sTNFR1 improves cardiac function in rats after myocardial infarction. Male Wistar rats were subjected to left coronary artery (LCA) ligation. Immediately after the ligation, a total of 200 mug of either the sTNFR1 or LacZ plasmid was injected into three different sites in the left ventricular wall. From 1 to 21 days after LCA ligation, TNF-alpha bioactivity in the heart was higher in rats receiving LacZ plasmid than in sham-operated rats, whereas sTNFR1 plasmid significantly suppressed the increase. The LV diastolic dimension was significantly lower, and the fractional shortening was significantly higher in rats treated with the sTNFR1 plasmid than in those treated with the LacZ plasmid. At 21 days after LCA ligation, the LV end-diastolic pressure was also significantly lower in the rats treated with the sTNFR1 plasmid. In addition, the sTNFR1 expression plasmid had significantly reduced the infarct size. In conclusion, TNF-alpha bioactivity in the heart increased during the early stage of infarction and remained elevated. This elevation seemed partially responsible for the impairment of LV function and the increased infarct size. Suppression of TNF-alpha bioactivity from the early stage of infarction with the sTNFR1 plasmid improved cardiac function and reduced infarct size.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Clin Gerontol, Dept Mol & Cellular Biol, Beppu, Oita 8740838, Japan	Kyushu University	Sugano, M (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Clin Gerontol, Dept Mol & Cellular Biol, 4546 Tsurumihara, Beppu, Oita 8740838, Japan.	massy@tsurumi.beppu.kyushu-u.ac.jp						Black SC, 1998, J MOL CELL CARDIOL, V30, P733, DOI 10.1006/jmcc.1998.0660; Bozkurt B, 2001, CIRCULATION, V103, P1044, DOI 10.1161/01.CIR.103.8.1044; Bryant D, 1998, CIRCULATION, V97, P1375, DOI 10.1161/01.CIR.97.14.1375; Chung ES, 2003, CIRCULATION, V107, P3133, DOI 10.1161/01.CIR.0000077913.60364.D2; Gurevitch J, 1997, J AM COLL CARDIOL, V30, P1554, DOI 10.1016/S0735-1097(97)00328-8; HIMMLER A, 1990, DNA CELL BIOL, V9, P705, DOI 10.1089/dna.1990.9.705; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Irwin MW, 1999, CIRCULATION, V99, P1492, DOI 10.1161/01.CIR.99.11.1492; Iversen PO, 2001, AM J PHYSIOL-HEART C, V281, pH2211, DOI 10.1152/ajpheart.2001.281.5.H2211; Kajstura J, 1996, LAB INVEST, V74, P86; KAPADIA S, 1995, AM J PHYSIOL-HEART C, V268, pH517, DOI 10.1152/ajpheart.1995.268.2.H517; Kubota T, 2000, CIRCULATION, V101, P2518, DOI 10.1161/01.CIR.101.21.2518; Kubota T, 1997, CIRC RES, V81, P627, DOI 10.1161/01.RES.81.4.627; Kurrelmeyer KM, 2000, P NATL ACAD SCI USA, V97, P5456, DOI 10.1073/pnas.070036297; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; Li DY, 1999, AM HEART J, V137, P1145, DOI 10.1016/S0002-8703(99)70375-3; Makino N, 1996, J MOL CELL CARDIOL, V28, P507, DOI 10.1006/jmcc.1996.0047; MCMURRAY J, 1991, BRIT HEART J, V66, P356; Ono K, 1998, CIRCULATION, V98, P149, DOI 10.1161/01.CIR.98.2.149; Ridker PM, 2000, CIRCULATION, V101, P2149, DOI 10.1161/01.CIR.101.18.2149; Selinsky CL, 1998, IMMUNOLOGY, V94, P88; Song W, 2000, CARDIOVASC RES, V45, P595, DOI 10.1016/S0008-6363(99)00395-8; Su X, 1998, ARTHRITIS RHEUM-US, V41, P139, DOI 10.1002/1529-0131(199801)41:1<139::AID-ART17>3.3.CO;2-K; Sugano M, 2002, FASEB J, V16, P1421, DOI 10.1096/fj.01-0894fje; Takeshita S, 1996, LAB INVEST, V74, P1061; Tsurumi Y, 1997, CIRCULATION, V96, P382; VADDI K, 1994, CIRCULATION, V90, P694, DOI 10.1161/01.CIR.90.2.694; Yue P, 1998, AM J PHYSIOL-HEART C, V275, pH250, DOI 10.1152/ajpheart.1998.275.1.H250	28	42	49	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					911	+		10.1096/fj.03-1148fje	http://dx.doi.org/10.1096/fj.03-1148fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15117889				2022-12-25	WOS:000220522800001
J	Inari, A; Gallo, R; Palma, M; Alesse, E; Gulino, A				Inari, A; Gallo, R; Palma, M; Alesse, E; Gulino, A			Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA FAMILY PROTEINS; TRANSCRIPTION FACTOR E2F-1; APOPTOTIC TARGET GENES; KINASE C-ABL; HISTONE DEACETYLASE; REPRESS TRANSCRIPTION; ACETYLATION; DEGRADATION; PATHWAY; P53	E2F1, a member of the E2F family of transcription factors, plays a pivotal role in controlling both physiological cell-cycle progression and apoptotic cell death in response to DNA damage and oncogene activation. In response to genotoxic stresses, E2F1 is stabilized by signals that include ATM-dependent phosphorylation. We recently demonstrated that DNA damage induces also E2F1 acetylation, which is required for its recruitment onto apoptotic gene promoters. Here we show that E2F1 is stabilized in response to doxorubicin and cisplatin treatments even in the absence of either ATM-dependent phosphorylation or p53 and cAbl, two major transducers of DNA damage signaling. We found that acetylation of E2F1 is, instead, required to stabilize the protein in response to doxorubicin. Finally, we report that the formation of E2F1-p300/CREB-binding protein-associated factor (P/CAF) complexes is preferentially induced in doxorubicin-treated cells, and that P/CAF acetyltransferase (HAT), but not p300 HAT activity, is required for a significant E2F1 stabilization and accumulation. Our results unveil a differential role of P/CAF and p300 in acetylation-induced stabilization of E2F1, thus supporting a specific role for P/CAF HAT activity in E2F1-dependent apoptosis in response to DNA damage.	Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Neuromed Inst, I-86077 Pozzilli, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy	Sapienza University Rome; IRCCS Neuromed; University of L'Aquila	Gulino, A (corresponding author), Univ Roma La Sapienza, Dept Expt Med & Pathol, Piazzale Aldo Moro 5, I-00161 Rome, Italy.	Alberto.gulino@uniroma1.it	Palma, Marzia/AGN-7362-2022					Agami R, 1999, NATURE, V399, P809; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; Gong JG, 1999, NATURE, V399, P806; Harper JW, 1999, NAT CELL BIOL, V1, pE5, DOI 10.1038/8952; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Hsieh JK, 2002, MOL CELL BIOL, V22, P78, DOI 10.1128/MCB.22.1.78-93.2002; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Johnson DG, 2000, MOL CARCINOGEN, V27, P151, DOI 10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Lin WC, 2001, GENE DEV, V15, P1833; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Martelli F, 1999, P NATL ACAD SCI USA, V96, P2858, DOI 10.1073/pnas.96.6.2858; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Mundle SD, 2003, FASEB J, V17, P569, DOI 10.1096/fj.02-0431rev; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wikonkal NM, 2003, NAT CELL BIOL, V5, P655, DOI 10.1038/ncb1001; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829	38	69	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30830	30835		10.1074/jbc.M402403200	http://dx.doi.org/10.1074/jbc.M402403200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123636	hybrid			2022-12-25	WOS:000222531900115
J	Kasahara, T; Ishiguro, M; Kasahara, M				Kasahara, T; Ishiguro, M; Kasahara, M			Comprehensive chimeric analysis of amino acid residues critical for high affinity glucose transport by Hxt2 of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE RECOGNITION; ESCHERICHIA-COLI; GAL2; MECHANISM; PROTEINS; FAMILY	Chimeras of Hxt2 and Hxt1, high affinity and low affinity glucose transporters, respectively, of Saccharomyces cerevisiae, were previously constructed by random replacement of each of the 12 transmembrane segments (TMs) of Hxt2 with the corresponding region of Hxt1. Characterization of these chimeras revealed that at least TMs 1, 5, 7, and 8 of Hxt2 are required for high affinity transport activity. To determine which amino acid residues in these TMs are important for high affinity glucose transport, we systematically shuffled all of the 20 residues in these regions that differ between Hxt2 and Hxt1. Analysis of 60 independent mutant strains identified as expressing high affinity and high capacity glucose transport activity by selection on glucose-limited agar plates revealed that Leu-201 in TM5 of Hxt2 is most important for such activity and that either Cys-195 or Phe-198 is also required for maximal activity.	Teikyo Univ, Sch Med, Biophys Lab, Tokyo 1920395, Japan; Teikyo Univ, Genome Res Ctr, Tokyo 1920395, Japan; Suntory Inst Bioorgan Res, Osaka 6188503, Japan	Teikyo University; Teikyo University; Suntory Holdings Ltd	Kasahara, M (corresponding author), Teikyo Univ, Sch Med, Biophys Lab, Tokyo 1920395, Japan.	kasahara@main.teikyo-u.ac.jp						Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; Berg JM, 2002, BIOCHEMISTRY-US, V5th; Boles E, 1997, FEMS MICROBIOL REV, V21, P85, DOI 10.1016/S0168-6445(97)00052-1; Heymann JAW, 2003, J STRUCT BIOL, V144, P320, DOI 10.1016/j.jsb.2003.09.002; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Kasahara M, 1998, J BIOL CHEM, V273, P29106, DOI 10.1074/jbc.273.44.29106; Kasahara T, 2003, BIOCHEM J, V372, P247, DOI 10.1042/BJ20030044; Kasahara T, 1996, BIOCHEM J, V315, P177, DOI 10.1042/bj3150177; Kasahara T, 2000, J BIOL CHEM, V275, P4422, DOI 10.1074/jbc.275.6.4422; Kruckeberg AL, 1996, ARCH MICROBIOL, V166, P283, DOI 10.1007/s002030050385; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; NISHIZAWA K, 1995, J BIOL CHEM, V270, P2423, DOI 10.1074/jbc.270.6.2423; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Saraceni-Richards CA, 2000, J BIOL CHEM, V275, P6101, DOI 10.1074/jbc.275.9.6101; Ye L, 1999, J BACTERIOL, V181, P4673, DOI 10.1128/JB.181.15.4673-4675.1999	16	12	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30274	30278		10.1074/jbc.M403762200	http://dx.doi.org/10.1074/jbc.M403762200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15128737	hybrid			2022-12-25	WOS:000222531900052
J	Letzelter, C; Duguet, M; Serre, MC				Letzelter, C; Duguet, M; Serre, MC			Mutational analysis of the archaeal tyrosine recombinase SSV1 integrase suggests a mechanism of DNA cleavage in trans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; HOLLIDAY JUNCTION COMPLEX; HUMAN TOPOISOMERASE-I; LAMBDA-INTEGRASE; FLP RECOMBINASE; ACTIVE-SITE; VACCINIA TOPOISOMERASE; INT FAMILY; FUNCTIONAL-ANALYSIS; COVALENT CATALYSIS	The only tyrosine recombinase so far studied in archaea, the SSV1 integrase, harbors several changes in the canonical residues forming the catalytic pocket of this family of recombinases. This raised the possibility of a different mechanism for archaeal tyrosine recombinase. The residues of Int(SSV) tentatively involved in catalysis were modified by site-directed mutagenesis, and the properties of the corresponding mutants were studied. The results show that all of the targeted residues are important for activity, suggesting that the archaeal integrase uses a mechanism similar to that of bacterial or eukaryotic tyrosine recombinases. In addition, we show that Int(SSV) exhibits a type IB topoisomerase activity because it is able to relax both positive and negative supercoils. Interestingly, in vitro complementation experiments between the inactive integrase mutant Y314F and all other inactive mutants restore in all cases enzymatic activity. This suggests that, as for the yeast Flp recombinase, the active site is assembled by the interaction of the tyrosine from one monomer with the other residues from another monomer. The shared active site paradigm of the eukaryotic Flp protein may therefore be extended to the archaeal tyrosine recombinase Int(SSV).	Univ Paris 11, Inst Genet & Microbiol, Lab Enzymol Acides Nucleiques, F-91405 Orsay, France	UDICE-French Research Universities; Universite Paris Saclay	Serre, MC (corresponding author), Univ Paris 11, Inst Genet & Microbiol, Lab Enzymol Acides Nucleiques, Batiment 400, F-91405 Orsay, France.	serre@igmors.u-psud.fr	Serre, Marie-Claude/B-4159-2008	SERRE, Marie-Claude/0000-0002-7899-9833				ABREMSKI K, 1986, J BIOL CHEM, V261, P391; ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; Aihara H, 2003, MOL CELL, V12, P187, DOI 10.1016/S1097-2765(03)00268-5; ARCISZEWSKA LK, 1995, EMBO J, V14, P2112, DOI 10.1002/j.1460-2075.1995.tb07203.x; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; Blakely GW, 1997, J MOL BIOL, V265, P30, DOI 10.1006/jmbi.1996.0709; Blakely GW, 1996, MOL MICROBIOL, V20, P234, DOI 10.1111/j.1365-2958.1996.tb02505.x; Cao YH, 1999, J MOL BIOL, V289, P517, DOI 10.1006/jmbi.1999.2793; CHEN JW, 1992, MOL CELL BIOL, V12, P3757, DOI 10.1128/MCB.12.9.3757; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; Chen Y, 2003, J BIOL CHEM, V278, P24800, DOI 10.1074/jbc.M300853200; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; Conway AB, 2003, J MOL BIOL, V326, P425, DOI 10.1016/S0022-2836(02)01370-0; Cornet F, 1997, J BIOL CHEM, V272, P21927, DOI 10.1074/jbc.272.35.21927; DEVARGAS LM, 1988, CELL, V54, P923, DOI 10.1016/0092-8674(88)90107-9; Edgcomb SP, 2002, PROTEINS, V49, P1, DOI 10.1002/prot.10177; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; FORTERRE P, 1985, EMBO J, V4, P2123, DOI 10.1002/j.1460-2075.1985.tb03902.x; FRIESEN H, 1992, J MOL BIOL, V225, P313, DOI 10.1016/0022-2836(92)90924-9; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Grainge I, 2001, J MOL BIOL, V314, P717, DOI 10.1006/jmbi.2001.5194; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; HAN YPW, 1994, J MOL BIOL, V235, P908, DOI 10.1006/jmbi.1994.1048; HAN YPW, 1993, EMBO J, V12, P4577, DOI 10.1002/j.1460-2075.1993.tb06146.x; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; JAYARAM M, 1995, TRENDS GENET, V11, P432, DOI 10.1016/S0168-9525(00)89140-4; Jayaram M., 2002, MOBILE DNA, P192; KIKUCHI Y, 1979, P NATL ACAD SCI USA, V76, P3760, DOI 10.1073/pnas.76.8.3760; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 2002, P NATL ACAD SCI USA, V99, P1853, DOI 10.1073/pnas.032613199; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; Lee J, 1999, EMBO J, V18, P784, DOI 10.1093/emboj/18.3.784; LEE J, 1992, J MOL BIOL, V228, P1091, DOI 10.1016/0022-2836(92)90317-D; Mondragon A, 1997, NAT STRUCT BIOL, V4, P427, DOI 10.1038/nsb0697-427; MUSKHELISHVILI G, 1994, SYST APPL MICROBIOL, V16, P605; MUSKHELISHVILI G, 1993, MOL GEN GENET, V237, P334, DOI 10.1007/BF00279436; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; NUNESDUBY SE, 1994, EMBO J, V13, P4421, DOI 10.1002/j.1460-2075.1994.tb06762.x; Petersen BO, 1996, J MOL BIOL, V263, P181, DOI 10.1006/jmbi.1996.0568; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; REDDER P, 2002, MOBILE DNA, V2, P1060; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; REITER WD, 1989, NUCLEIC ACIDS RES, V17, P1907, DOI 10.1093/nar/17.5.1907; Serre MC, 2003, PROG NUCLEIC ACID RE, V74, P37, DOI 10.1016/S0079-6603(03)01010-9; SERRE MC, 1992, J MOL BIOL, V225, P643, DOI 10.1016/0022-2836(92)90391-V; Serre MC, 2002, J BIOL CHEM, V277, P16758, DOI 10.1074/jbc.M200707200; Shaikh AC, 2000, J MOL BIOL, V302, P27, DOI 10.1006/jmbi.2000.3967; Shaikh AC, 1997, J BIOL CHEM, V272, P5695, DOI 10.1074/jbc.272.9.5695; Sherratt DJ, 1998, CELL, V93, P149, DOI 10.1016/S0092-8674(00)81566-4; STARK WM, 1995, TRENDS GENET, V11, P121; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Van Duyne G.D., 2002, MOBILE DNA, VII, P93; WIERZBICKI A, 1987, J MOL BIOL, V195, P785, DOI 10.1016/0022-2836(87)90484-0; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001; Xu CJ, 1998, MOL CELL, V1, P729, DOI 10.1016/S1097-2765(00)80072-6; Yang Z, 2001, J BIOL CHEM, V276, P677, DOI 10.1074/jbc.M007593200	60	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28936	28944		10.1074/jbc.M403971200	http://dx.doi.org/10.1074/jbc.M403971200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123675	hybrid			2022-12-25	WOS:000222445300015
J	Ohshima, T; Koga, H; Shimotohno, K				Ohshima, T; Koga, H; Shimotohno, K			Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN RECEPTOR; COX-2 INHIBITION; E3 LIGASE; APOPTOSIS; NUCLEAR; CONJUGATION; GENE; PHOSPHORYLATION; PROTEINS; ADIPOGENESIS	Covalent modification of many transcription factors with SUMO-1 is emerging as a key role of trans-activational regulation. Here, we demonstrate that peroxisome proliferator-activated receptor (PPAR) gamma, which is a ligand-activated nuclear receptor, is modified by SUMO-1. Sumoylation of PPARgamma mainly occurs at a lysine residue within the activation function 1 domain. Furthermore, we show that the PIAS family proteins, PIAS1 and PIASxbeta, function as E3 ligases (ubiquitin-protein isopeptide ligase) for PPARgamma. PPARgamma interacts directly with PIASxbeta in a ligand-independent manner. Analysis using a PPARgamma mutant with a disrupted sumoylation site shows that modification of PPARgamma by SUMO-1 represses its transcriptional activity. Interestingly, PIASxbeta and Ubc9 enhance the transcriptional activity of PPARgamma independent of PPARgamma sumoylation. Furthermore, PPARgamma ligand-induced apoptosis in a human hepatoblastoma cell line, HepG2, is significantly enhanced by ectopic production of the sumoylation-mutant PPARgamma. These results suggest that the PPARgamma-dependent transactivation pathway seems to be modulated by SUMO-1 modification and may serve as a novel target for apoptosis-induction therapy in cancer cells.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Ohshima, T (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan.	tohshima@virus.kyoto-u.ac.jp		OHSHIMA, Takayuki/0000-0002-1501-6430				Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Camp HS, 1997, J BIOL CHEM, V272, P10811; Chakrabarti SR, 1999, P NATL ACAD SCI USA, V96, P7467, DOI 10.1073/pnas.96.13.7467; Eibl G, 2001, BIOCHEM BIOPH RES CO, V287, P522, DOI 10.1006/bbrc.2001.5619; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Horie K, 2002, ONCOGENE, V21, P7913, DOI 10.1038/sj.onc.1205917; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Li MY, 2003, WORLD J GASTROENTERO, V9, P1220, DOI 10.3748/wjg.v9.i6.1220; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Michael MS, 2003, INT J MOL MED, V11, P733; Mueller E, 2002, J BIOL CHEM, V277, P41925, DOI 10.1074/jbc.M206950200; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nagamine M, 2003, CANCER SCI, V94, P338, DOI 10.1111/j.1349-7006.2003.tb01443.x; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Ohshima T, 2003, J BIOL CHEM, V278, P50833, DOI 10.1074/jbc.M307533200; Ohshima T, 1999, BIOCHEM BIOPH RES CO, V264, P144, DOI 10.1006/bbrc.1999.1478; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pinsky BA, 2002, DEV CELL, V3, P4, DOI 10.1016/S1534-5807(02)00214-9; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rangwala SM, 2003, DEV CELL, V5, P657, DOI 10.1016/S1534-5807(03)00274-0; Rogers RS, 2003, J BIOL CHEM, V278, P30091, DOI 10.1074/jbc.M301344200; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Tojo M, 2002, J BIOL CHEM, V277, P46576, DOI 10.1074/jbc.M205987200; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Ungureanu D, 2003, BLOOD, V102, P3311, DOI 10.1182/blood-2002-12-3816; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang WL, 2001, CARCINOGENESIS, V22, P1379, DOI 10.1093/carcin/22.9.1379; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yoshizawa K, 2002, CANCER-AM CANCER SOC, V95, P2243, DOI 10.1002/cncr.10906; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	48	153	158	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29551	29557		10.1074/jbc.M403866200	http://dx.doi.org/10.1074/jbc.M403866200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123625	hybrid			2022-12-25	WOS:000222445300089
J	Simmen, RCM; Eason, RR; McQuown, JR; Linz, AL; Kang, TJ; Chatman, L; Till, SR; Fujii-Kuriyama, Y; Simmen, FA; Oh, SP				Simmen, RCM; Eason, RR; McQuown, JR; Linz, AL; Kang, TJ; Chatman, L; Till, SR; Fujii-Kuriyama, Y; Simmen, FA; Oh, SP			Subfertility, uterine hypoplasia, and partial progesterone resistance in mice lacking the Kruppel-like factor 9/basic transcription element-binding protein-1 (Bteb1) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR COACTIVATOR-1 SRC-1; ENDOMETRIAL EPITHELIAL-CELLS; LEUKOCYTE PROTEASE INHIBITOR; ARREST-SPECIFIC GENE-6; TYROSINE KINASES; MOUSE UTERUS; CANCER-CELLS; B ISOFORMS; CYCLIN D3; IN-VIVO	Progesterone receptor ( PR), a ligand-activated transcription factor, is a key regulator of cellular proliferation and differentiation in reproductive tissues. The transcriptional activity of PR is influenced by co-regulatory proteins typically expressed in a tissue- and cell-specific fashion. We previously demonstrated that basic transcription element-binding protein-1 (BTEB1), a member of the Sp/Kruppel-like family of transcription factors, functionally interacts with the two PR isoforms, PR-A and PR-B, to mediate progestin sensitivity of target genes in endometrial epithelial cells in vitro. Here we report that ablation of the Bteb1 gene in female mice results in uterine hypoplasia, reduced litter size, and increased incidence of neonatal deaths in offspring. The reduced litter size is solely a maternal genotype effect and results from fewer numbers of implantation sites, rather than defects in ovulation. In the early pregnant uterus, Bteb1 expression in stromal cells temporally coincides with PR-A isoform-dependent decidual formation at the time of implantation. Expression of two implantation-specific genes, Hoxa10 and cyclin D3, was decreased in uteri of early pregnant Bteb1-null mutants, whereas that of Bteb3, a related family member, was increased, the latter possibly compensating for the loss of Bteb1. Progesterone responsiveness of several uterine genes was altered with Bteb1-null mutation. These results identify Bteb1 as a functionally relevant PR-interacting protein and suggest its selective modulation of cellular processes that are regulated by PR-A in the uterine stroma.	Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Arkansas Childrens Nutr Ctr, Little Rock, AR 72202 USA; Univ Tsukuba, Tara Ctr, Tsukuba, Ibaraki 3058577, Japan; Univ Florida, Dept Anim Sci, Gainesville, FL 32611 USA; Univ Florida, Dept Physiol & Funct Genom, Gainesville, FL 32611 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Tsukuba; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Simmen, RCM (corresponding author), Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72202 USA.	simmenrosalia@uams.edu	Simmen, Frank A/J-9464-2012	Simmen, Frank/0000-0001-6842-7754	NICHD NIH HHS [R01 HD021961, HD21961] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021961, R29HD021961] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Attia GR, 2000, J CLIN ENDOCR METAB, V85, P2897, DOI 10.1210/jc.85.8.2897; Bagot CN, 2000, GENE THER, V7, P1378, DOI 10.1038/sj.gt.3301245; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Carson DD, 2000, DEV BIOL, V223, P217, DOI 10.1006/dbio.2000.9767; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Condon JC, 2003, P NATL ACAD SCI USA, V100, P9518, DOI 10.1073/pnas.1633616100; CONNEELY OM, 1989, J BIOL CHEM, V264, P14062; Daftary GS, 2004, MOL REPROD DEV, V67, P8, DOI 10.1002/mrd.20013; Das SK, 1999, J MOL ENDOCRINOL, V22, P91, DOI 10.1677/jme.0.0220091; Dey SK, 1996, REPROD ENDOCRINOLOGY, V1, P421; DING YQ, 1994, ENDOCRINOLOGY, V135, P2265, DOI 10.1210/en.135.5.2265; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Giangrande PH, 1997, J BIOL CHEM, V272, P32889, DOI 10.1074/jbc.272.52.32889; Hewitt SC, 2002, BIOL REPROD, V67, P1268, DOI [10.1095/biolreprod67.4.1268, 10.1095/biolreprod.102.002436]; HSIEHLI HM, 1995, DEVELOPMENT, V121, P1373; IMATAKA H, 1994, J BIOL CHEM, V269, P20668; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; King AE, 2003, BIOCHEM BIOPH RES CO, V310, P594, DOI 10.1016/j.bbrc.2003.08.151; King AE, 2003, J CLIN ENDOCR METAB, V88, P4426, DOI 10.1210/jc.2003-030239; Leonhardt SA, 1998, MOL ENDOCRINOL, V12, P1914, DOI 10.1210/me.12.12.1914; Leslie KK, 1997, ANN NY ACAD SCI, V828, P17, DOI 10.1111/j.1749-6632.1997.tb48520.x; Li XT, 2003, MOL CELL BIOL, V23, P3763, DOI 10.1128/MCB.23.11.3763-3773.2003; Lim HJ, 1999, MOL ENDOCRINOL, V13, P1005, DOI 10.1210/me.13.6.1005; Liu SF, 1997, BRIT J PHARMACOL, V121, P1241; Liu Z, 2001, P NATL ACAD SCI USA, V98, P12426, DOI 10.1073/pnas.231474798; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Ma L, 1998, DEV BIOL, V197, P141, DOI 10.1006/dbio.1998.8907; Martin KM, 2000, BIOCHEM J, V345, P529, DOI 10.1042/0264-6021:3450529; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Morita M, 2003, MOL CELL BIOL, V23, P2489, DOI 10.1128/MCB.23.7.2489-2500.2003; Mote PA, 2000, HUM REPROD, V15, P48, DOI 10.1093/humrep/15.suppl_3.48; Mulac-Jericevic B, 2000, SCIENCE, V289, P1751, DOI 10.1126/science.289.5485.1751; Mulac-Jericevic B, 2003, P NATL ACAD SCI USA, V100, P9744, DOI 10.1073/pnas.1732707100; MULHOLLAND J, 1994, REPROD BIOL, P33; Okulicz WC, 2003, BIOL REPROD, V69, P1593, DOI 10.1095/biolreprod.103.017525; Parandoosh Z, 1995, J REPROD FERTIL, V105, P215, DOI 10.1530/jrf.0.1050215; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Shiozawa T, 2003, J CLIN ENDOCR METAB, V88, P871, DOI 10.1210/jc.2002-020946; Simmen RCM, 2002, DNA CELL BIOL, V21, P115, DOI 10.1089/104454902753604998; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; Sun WS, 2003, ANN ONCOL, V14, P898, DOI 10.1093/annonc/mdg257; Sun WS, 2002, MOL HUM REPROD, V8, P552, DOI 10.1093/molehr/8.6.552; Tan J, 1999, ENDOCRINOLOGY, V140, P5310, DOI 10.1210/en.140.11.5310; Tan J, 2002, MECH DEVELOP, V111, P99, DOI 10.1016/S0925-4773(01)00614-1; Tang MY, 2002, MOL CELL ENDOCRINOL, V192, P45, DOI 10.1016/S0303-7207(02)00111-9; Taylor HS, 1998, J CLIN INVEST, V101, P1379, DOI 10.1172/JCI1057; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Wardell SE, 2002, MOL CELL BIOL, V22, P5451, DOI 10.1128/MCB.22.15.5451-5466.2002; Wong KHH, 2004, MOL ENDOCRINOL, V18, P184, DOI 10.1210/me.2003-0222; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; ZHANG D, 2002, ENDOCRINOLOGY, V140, P2517; Zhang DY, 2002, J BIOL CHEM, V277, P29999, DOI 10.1074/jbc.M203503200; Zhang XL, 2003, J BIOL CHEM, V278, P21474, DOI 10.1074/jbc.M212098200; Zhang XL, 2001, MOL CELL ENDOCRINOL, V181, P81, DOI 10.1016/S0303-7207(01)00536-6	67	75	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29286	29294		10.1074/jbc.M403139200	http://dx.doi.org/10.1074/jbc.M403139200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15117941	hybrid			2022-12-25	WOS:000222445300058
J	Basu, NK; Kubota, S; Meselhy, MR; Ciotti, M; Chowdhury, B; Hartori, M; Owens, IS				Basu, NK; Kubota, S; Meselhy, MR; Ciotti, M; Chowdhury, B; Hartori, M; Owens, IS			Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYTOESTROGEN GENISTEIN; BILIRUBIN; GLUCURONIDATION; EXPRESSION; CLONING; ALPHA; CELLS; CDNAS	Among gastrointestinal distributed isozymes encoded at the UGT1 locus, UDP-glucuronosyltransferase 1A10 (UGT1A10) metabolizes a number of important chemicals. Similar to broad conversion of phytoestrogens (Basu, N. K., Ciotti, M., Hwang, M. S., Kole, L., Mitra, P. S., Cho, J. W., and Owens, I. S. ( 2004) J. Biol. Chem. 279, 1429-1441), UGT1A10 metabolized estrogens and their derivatives, whereas UGT1A1, -1A3, -1A7, and -1A8 differentially exhibited reduced activity toward the same. UGT1A10 compared with UGT1A7, -1A8, and -1A3 generally exhibited high activity toward acidic nonsteroidal anti-inflammatory drugs and natural benzaldehyde derivatives, while UGT1A3 metabolized most efficiently aromatic transcinnamic acids known to be generated from flavonoid glycosides by microflora in the lower gastrointestinal tract. Finally UGT1A10, -1A7, -1A8, and -1A3 converted plant-based salicylic acids; methylsalicylic acid was transformed at high levels, and acetylsalicylic (aspirin) and salicylic acid were transformed at moderate to low levels. Atypically UGT1A10 transformed estrogens between pH 6 and 8 but acidic structures preferentially at pH 6.4. Furthermore evidence indicates UGT1A10 expressed in COS-1 cells depends upon phosphorylation; UGT1A10 versus its single, double, and triple mutants at three predicted protein kinase C phosphorylation sites incorporated [P-33]-orthophosphate and showed a progressive decrease with no detectable label or activity for the triple T73A/T202A/S432G-1A10 mutant. Single and double mutants revealed either null/full activity or null/additive activity, respectively. Additionally UGT1A10-expressing cultures glucuronidated 17beta-[C-14]estradiol, whereas cultures containing null mutants at protein kinase C sites showed no estrogen conversion. Importantly UGT1A10 in cells supported 10-fold higher glucuronidation of 17beta-estradiol than UGT1A1. In summary, our results suggest gastrointestinally distributed UGT1A10 is important for detoxifying estrogens/phytoestrogens and aromatic acids with complementary activity by UGT1A7, -1A8, -1A3, and/or -1A1 evidently dependent upon phosphorylation.	NICHD, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA; Toyama Med & Pharmaceut Univ, Res Inst Wakan Yaku, Toyama 93001, Japan	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Toyama	Owens, IS (corresponding author), NICHD, Heritable Disorders Branch, NIH, Bldg 10,Rm 9S-241, Bethesda, MD 20892 USA.	owensi@mail.nih.gov		M.R., Meselhy/0000-0002-3488-7522	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008751] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008751] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADEBE W, 2002, J CLIN PHARM THER, V27, P391; Akhand AK, 1999, J BIOL CHEM, V274, P25821, DOI 10.1074/jbc.274.36.25821; Basu NK, 2004, J BIOL CHEM, V279, P1429, DOI 10.1074/jbc.M306439200; Basu NK, 2003, BIOCHEM BIOPH RES CO, V303, P98, DOI 10.1016/S0006-291X(03)00241-9; Bock KW, 2002, BIOCHEM PHARMACOL, V63, P1683, DOI 10.1016/S0006-2952(02)00921-8; BROWN JP, 1980, MUTAT RES, V75, P243, DOI 10.1016/0165-1110(80)90029-9; Cheng ZQ, 1998, TOXICOL SCI, V45, P52, DOI 10.1093/toxsci/45.1.52; Ciotti M, 1997, PHARMACOGENETICS, V7, P485, DOI 10.1097/00008571-199712000-00007; Ciotti M, 1999, BIOCHEM BIOPH RES CO, V260, P199, DOI 10.1006/bbrc.1999.0453; Ciotti M, 1996, BIOCHEMISTRY-US, V35, P10119, DOI 10.1021/bi960584a; CIOTTI M, 1995, J BIOL CHEM, V270, P3284, DOI 10.1074/jbc.270.7.3284; DEMORAIS SMF, 1989, HEPATOLOGY, V10, P163, DOI 10.1002/hep.1840100207; Fitzpatrick LA, 1999, MAYO CLIN PROC, V74, P601, DOI 10.4065/74.6.601; Frigo DE, 2002, J NUTR, V132, P1848, DOI 10.1093/jn/132.7.1848; Gall WE, 1999, J STEROID BIOCHEM, V70, P101, DOI 10.1016/S0960-0760(99)00088-6; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; GUGLER R, 1975, EUR J CLIN PHARMACOL, V9, P229, DOI 10.1007/BF00614022; Jinno H, 2003, DRUG METAB DISPOS, V31, P528, DOI 10.1124/dmd.31.5.528; Kuhnau J, 1976, World Rev Nutr Diet, V24, P117; Lamartiniere CA, 2002, J NUTR, V132, p552S, DOI 10.1093/jn/132.3.552S; Liew R, 2003, FASEB J, V17, P1307, DOI 10.1096/fj.02-0760fje; Liew R, 2003, J PHARMACOL EXP THER, V304, P985, DOI 10.1124/jpet.102.042986; Rickard DJ, 2003, J CELL BIOCHEM, V89, P633, DOI 10.1002/jcb.10539; RITTER JK, 1993, J BIOL CHEM, V268, P23573; RITTER JK, 1992, BIOCHEMISTRY-US, V31, P3409, DOI 10.1021/bi00128a015; RITTER JK, 1991, J BIOL CHEM, V266, P1043; RITTER JK, 1990, J BIOL CHEM, V265, P7900; Seawright Alan A., 1995, Natural Toxins, V3, P227, DOI 10.1002/nt.2620030411; Strassburg CP, 2000, J BIOL CHEM, V275, P36164, DOI 10.1074/jbc.M002180200; Williams JA, 2002, DRUG METAB DISPOS, V30, P1266, DOI 10.1124/dmd.30.11.1266	30	47	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28320	28329		10.1074/jbc.M401396200	http://dx.doi.org/10.1074/jbc.M401396200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117964	hybrid			2022-12-25	WOS:000222265400064
J	Hirai, I; Sasaki, T; Wang, HG				Hirai, I; Sasaki, T; Wang, HG			Human hRad1 but not hRad9 protects hHus1 from ubiquitin-proteasomal degradation	ONCOGENE			English	Article						Hus1; ubiquitination; proteasomal degradation; checkpoint	DNA-DAMAGE CHECKPOINT; HUMAN RAD9; DEPENDENT PHOSPHORYLATION; SLIDING CLAMP; FACTOR-C; COMPLEX; PROTEINS; ACTIVATION; RADIATION; RESPONSES	Three of the Rad family proteins, Rad9, Rad1, and Hus1, can interact with each other and form a heterotrimeric complex that is thought to play a role in the sensing step of the DNA integrity checkpoint pathways, but the nature of the Rad9 - Rad1 - Hus1 complex assembly remains enigmatic. Here, we demonstrate that the human hRad1 protein plays a significant role as molecular chaperone in the process of the hRad9 - hRad1 - hHus1 heterotrimeric complex formation. In contrast to hRad1, hHus1 is an unstable protein that is actively degraded via the ubiquitin - proteasome pathway. We show that treating cells with proteasome-specific inhibitors stabilizes hHus1 expression. Moreover, hRad1 can associate with hHus1 in the absence of hRad9 and protect hHus1 from ubiquitination and degradation in the cytoplasm. Importantly, genotoxic stress induces hRad1 expression and stabilizes the hHus1 protein. Taken together, these findings suggest a novel role of hRad1 as a potential intrinsic chaperone in the stabilization of hHus1 for the hRad9 - hRad1 - hHus1 checkpoint complex formation.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Oncol, Tampa, FL 33612 USA; Sapporo Med Univ, Sch Med, Inst Canc, Dept Biochem, Sapporo, Hokkaido 0608556, Japan	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Sapporo Medical University	Wang, HG (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	wanghg@moffitt.usf.edu	Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571	NCI NIH HHS [CA90315] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090315] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316; Griffith JD, 2002, J BIOL CHEM, V277, P15233, DOI 10.1074/jbc.C200129200; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Hirai I, 2002, J BIOL CHEM, V277, P25722, DOI 10.1074/jbc.M203079200; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Kaur R, 2001, MOL BIOL CELL, V12, P3744, DOI 10.1091/mbc.12.12.3744; Kondo T, 1999, MOL CELL BIOL, V19, P1136; Lee MW, 2003, ONCOGENE, V22, P6340, DOI 10.1038/sj.onc.1206729; Majka J, 2003, P NATL ACAD SCI USA, V100, P2249, DOI 10.1073/pnas.0437148100; McBride WH, 2003, ONCOGENE, V22, P5755, DOI 10.1038/sj.onc.1206676; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Post S, 2001, P NATL ACAD SCI USA, V98, P13102, DOI 10.1073/pnas.231364598; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; St Onge RP, 2003, J BIOL CHEM, V278, P26620, DOI 10.1074/jbc.M303134200; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Wang X, 2003, GENE DEV, V17, P965, DOI 10.1101/gad.1065103; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	32	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5124	5130		10.1038/sj.onc.1207658	http://dx.doi.org/10.1038/sj.onc.1207658			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122316				2022-12-25	WOS:000222382500002
J	Babu, P; Deschenes, RJ; Robinson, LC				Babu, P; Deschenes, RJ; Robinson, LC			Akr1p-dependent palmitoylation of Yck2p yeast casein kinase 1 is necessary and sufficient for plasma membrane targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEROMONE RESPONSE PATHWAY; CONTAINING PROTEIN AKR1P; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; ANKYRIN REPEAT; BUDDING YEAST; GENE-PRODUCT; LOCALIZATION; MOTIF; COMPLEX	The Yck2 protein is a plasma membrane-associated casein kinase 1 isoform that attaches to membranes via palmitoylation of its C terminus. We have demonstrated that Yck2p traffics to the plasma membrane on secretory vesicles. Because Akr1p, the palmitoyl transferase for Yck2p, is located on Golgi membranes, it is likely that Yck2p first associates with Golgi membranes, and then is somehow recruited to budding plasma membrane-destined vesicles. We show here that residues 499 - 546 are sufficient for minimal Yck2p palmitoylation and plasma membrane localization. We previously described normal plasma membrane targeting of a Yck2p construct with the final five amino acids of Ras2p substituting for the final two Cys residues of Yck2p. This Yck2p variant no longer requires Akr1p for membrane association, but targets normally. We have generated the C-terminal deletions previously shown to affect Yck2p membrane association in this variant to determine which residues are important for targeting and/or modification. We find that all of the sequences previously identified as important for plasma membrane association are required only for Akr1p-dependent modification. Furthermore, palmitoylation is sufficient for specific association of Yck2p with secretory vesicles destined for the plasma membrane. Finally, both C-terminal Cys residues are palmitoylated, and dual acylation is required for efficient membrane association.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Genet Program, Iowa City, IA 52242 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Iowa; University of Iowa	Robinson, LC (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.	lrobin@lsuhsc.edu	Deschenes, Robert J/E-4926-2010	Deschenes, Robert J/0000-0001-8325-4257; Robinson, Lucy/0000-0001-6454-040X				ALLAND L, 1994, J BIOL CHEM, V269, P16701; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; Babu P, 2002, J CELL SCI, V115, P4957, DOI 10.1242/jcs.00203; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bartels DJ, 1999, MOL CELL BIOL, V19, P6775, DOI 10.1128/mcb.19.10.6775; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; DEMAGGIO AJ, 1992, P NATL ACAD SCI USA, V89, P7008, DOI 10.1073/pnas.89.15.7008; Dong XW, 2003, MOL CELL BIOL, V23, P6574, DOI 10.1128/MCB.23.18.6574-6584.2003; Feng Y, 2000, MOL CELL BIOL, V20, P5350, DOI 10.1128/MCB.20.14.5350-5359.2000; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Givan SA, 1997, MOL BIOL CELL, V8, P1317, DOI 10.1091/mbc.8.7.1317; Gonzalo S, 1998, MOL BIOL CELL, V9, P585, DOI 10.1091/mbc.9.3.585; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kao LR, 1996, MOL CELL BIOL, V16, P168; KWONG J, 1995, BIOCHEM BIOPH RES CO, V207, P868, DOI 10.1006/bbrc.1995.1266; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Linder ME, 2004, J CELL SCI, V117, P521, DOI 10.1242/jcs.00989; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Loranger SS, 2002, J BIOL CHEM, V277, P34303, DOI 10.1074/jbc.M202125200; Marchal C, 2000, J BIOL CHEM, V275, P23608, DOI 10.1074/jbc.M001735200; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Moriya H, 2004, P NATL ACAD SCI USA, V101, P1572, DOI 10.1073/pnas.0305901101; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; Pryciak PM, 1996, MOL CELL BIOL, V16, P2614; Putilina T, 1999, MOL CELL BIOCHEM, V195, P219, DOI 10.1023/A:1006932522197; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Robinson LC, 1999, MOL BIOL CELL, V10, P1077, DOI 10.1091/mbc.10.4.1077; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; Roth AF, 2002, J CELL BIOL, V159, P23, DOI 10.1083/jcb.200206120; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; Sherman F., 1986, METHODS YEAST GENETI; STIMMEL JB, 1990, BIOCHEMISTRY-US, V29, P9651, DOI 10.1021/bi00493a021; Sun BM, 2004, MOL BIOL CELL, V15, P1397, DOI 10.1091/mbc.E03-09-0682; TAYLOR RG, 1993, NUCLEIC ACIDS RES, V21, P1677, DOI 10.1093/nar/21.7.1677; VANCURA A, 1993, ARCH BIOCHEM BIOPHYS, V305, P47, DOI 10.1006/abbi.1993.1391; VANCURA A, 1994, J BIOL CHEM, V269, P19271; WANG PC, 1992, MOL BIOL CELL, V3, P275, DOI 10.1091/mbc.3.3.275; Wang XM, 1996, MOL CELL BIOL, V16, P5375; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; YURCHAK LK, 1995, MOL CELL BIOL, V15, P6914, DOI 10.1128/mcb.15.12.6914; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	57	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27138	27147		10.1074/jbc.M403071200	http://dx.doi.org/10.1074/jbc.M403071200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15105419	hybrid			2022-12-25	WOS:000222120400040
J	Borysik, AJH; Radford, SE; Ashcroft, AE				Borysik, AJH; Radford, SE; Ashcroft, AE			Co-populated conformational ensembles of beta(2)-microglobulin uncovered quantitatively by electrospray ionization mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHARGE-STATE DISTRIBUTIONS; HISTOCOMPATIBILITY ANTIGEN; AMYLOIDOGENIC PROTEIN; BETA-2-MICROGLOBULIN; HEMODIALYSIS; FORM; PATHOGENESIS; AGGREGATION; PRECURSOR; FIBRILS	Ordered assembly of monomeric human beta(2)-microglobulin (beta(2)m) into amyloid fibrils is associated with the disorder hemodialysis-related amyloidosis. Previously, we have shown that under acidic conditions ( pH < 5.0 at 37 degrees C), wild-type beta(2)m assembles spontaneously into fibrils with different morphologies. Under these conditions, beta(2)m populates a number of different conformational states in vitro. However, this equilibrium mixture of conformationally different species is difficult to resolve using ensemble techniques such as nuclear magnetic resonance or circular dichroism. Here we use electrospray ionization mass spectrometry to resolve different species of beta(2)m populated between pH 6.0 and 2.0. We show that by linear deconvolution of the charge state distributions, the extent to which each conformational ensemble is populated throughout the pH range can be determined and quantified. Thus, at pH 3.6, conditions under which short fibrils are produced, the conformational ensemble is dominated by a charge state distribution centered on the 9+ ions. By contrast, under more acidic conditions ( pH 2.6), where long straight fibrils are formed, the charge state distribution is dominated by the 10+ and 11+ ions. The data are reinforced by investigations on two variants of beta(2)m (V9A and F30A) that have reduced stability to pH denaturation and show changes in the pH dependence of the charge state distribution that correlate with the decrease in stability measured by tryptophan fluorescence. The data highlight the potential of electrospray ionization mass spectrometry to resolve and quantify complex mixtures of different conformational species, one or more of which may be important in the formation of amyloid.	Univ Leeds, Sch Biochem & Microbiol, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Ashcroft, AE (corresponding author), Univ Leeds, Sch Biochem & Microbiol, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England.	a.e.ashcroft@leeds.ac.uk		Radford, Sheena/0000-0002-3079-8039	Biotechnology and Biological Sciences Research Council [SF16972] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Cech NB, 2001, MASS SPECTROM REV, V20, P362, DOI 10.1002/mas.10008; Chiti F, 2001, J BIOL CHEM, V276, P46714, DOI 10.1074/jbc.M107040200; Chiti F, 2001, J MOL BIOL, V307, P379, DOI 10.1006/jmbi.2000.4478; CHOWDHURY SK, 1990, J AM CHEM SOC, V112, P9012, DOI 10.1021/ja00180a074; Dobo A, 2001, ANAL CHEM, V73, P4763, DOI 10.1021/ac010713f; Dobson CM, 2001, BIOCHEM SOC SYMP, V68, P1; Esposito G, 2000, PROTEIN SCI, V9, P831, DOI 10.1110/ps.9.5.831; Felitsyn N, 2002, J AM SOC MASS SPECTR, V13, P1432, DOI 10.1016/S1044-0305(02)00647-5; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FENN JB, 1993, J AM SOC MASS SPECTR, V4, P524, DOI 10.1016/1044-0305(93)85014-O; FLOEGE J, 1991, J LAB CLIN MED, V118, P153; GANEM B, 1991, J AM CHEM SOC, V113, P7818, DOI 10.1021/ja00020a085; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; GEJYO F, 1986, NEW ENGL J MED, V314, P585; GOREVIC PD, 1985, J CLIN INVEST, V76, P2425, DOI 10.1172/JCI112257; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; Grandori R, 2002, J MASS SPECTROM, V37, P191, DOI 10.1002/jms.272; Grandori R, 2003, J MASS SPECTROM, V38, P11, DOI 10.1002/jms.390; Hill DM, 2003, J BIOL CHEM, V278, P5630, DOI 10.1074/jbc.M208381200; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; Jones S, 2003, J MOL BIOL, V330, P935, DOI 10.1016/S0022-2836(03)00688-0; Kad NM, 2003, J MOL BIOL, V330, P785, DOI 10.1016/S0022-2836(03)00583-7; Kad NM, 2001, J MOL BIOL, V313, P559, DOI 10.1006/jmbi.2001.5071; Kaltashov IA, 2002, MASS SPECTROM REV, V21, P37, DOI 10.1002/mas.10017; KARLSSON FA, 1980, EUR J CLIN INVEST, V10, P293, DOI 10.1111/j.1365-2362.1980.tb00036.x; Katou H, 2002, PROTEIN SCI, V11, P2218, DOI 10.1110/ps.0213202; Khan AR, 2000, J IMMUNOL, V164, P6398, DOI 10.4049/jimmunol.164.12.6398; Konermann L, 1998, RAPID COMMUN MASS SP, V12, P435, DOI 10.1002/(SICI)1097-0231(19980430)12:8<435::AID-RCM181>3.0.CO;2-F; Konermann L, 1997, BIOCHEMISTRY-US, V36, P12296, DOI 10.1021/bi971266u; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MAYER G, 1988, AM J NEPHROL, V8, P280, DOI 10.1159/000167601; McParland VJ, 2002, NAT STRUCT BIOL, V9, P326, DOI 10.1038/nsb791; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; MIRZA UA, 1993, ANAL CHEM, V65, P1, DOI 10.1021/ac00049a003; Morgan CJ, 2001, J MOL BIOL, V309, P339, DOI 10.1006/jmbi.2001.4661; Ohashi K, 2001, PATHOL INT, V51, P1, DOI 10.1046/j.1440-1827.2001.01156.x; PITKANEN P, 1984, AM J PATHOL, V117, P391; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; Samalikova M, 2003, J AM CHEM SOC, V125, P13352, DOI 10.1021/ja037000u; Samalikova M, 2003, J MASS SPECTROM, V38, P941, DOI 10.1002/jms.507; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; Siuzdak G, 1996, CHEM BIOL, V3, P45, DOI 10.1016/S1074-5521(96)90083-6; Smith DP, 2003, J MOL BIOL, V330, P943, DOI 10.1016/S0022-2836(03)00687-9; Wanker EE, 2000, BIOL CHEM, V381, P937, DOI 10.1515/BC.2000.114; Yamaguchi I, 2001, BIOCHEMISTRY-US, V40, P8499, DOI 10.1021/bi0027128	47	58	59	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27069	27077		10.1074/jbc.M401472200	http://dx.doi.org/10.1074/jbc.M401472200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15100226	Green Accepted, hybrid			2022-12-25	WOS:000222120400033
J	Liu, YT; Flanagan, JJ; Barlowe, C				Liu, YT; Flanagan, JJ; Barlowe, C			Sec22p export from the endoplasmic reticulum is independent of SNARE pairing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; CRYSTAL-STRUCTURE; COPII VESICLES; RETROGRADE TRANSPORT; RAB GTPASE; PROTEINS; GOLGI; COMPLEX; FUSION; ER	Molecularly distinct sets of SNARE proteins localize to specific intracellular compartments and catalyze membrane fusion events. Although their central role in membrane fusion is appreciated, little is known about the mechanisms by which individual SNARE proteins are targeted to specific organelles. Here we investigated functional domains in Sec22p that direct this SNARE protein to the endoplasmic reticulum ( ER), to Golgi membranes, and into SNARE complexes with Bet1p, Bos1p, and Sed5p. A series of Sec22p deletion mutants were monitored in COPII budding assays, subcellular fractionation gradients, and SNARE complex immunoprecipitations. We found that the N-terminal " profilin-like" domain of Sec22p was required but not sufficient for COPII-dependent export of Sec22p from the ER. Interestingly, versions of Sec22p that lacked the N-terminal domain were assembled into ER/Golgi SNARE complexes. Analyses of Sec22p SNARE domain mutants revealed a second signal within the SNARE motif ( between layers -4 and -1) that was required for efficient ER export. Other SNARE domain mutants that contained this signal were efficiently packaged into COPII vesicles but failed to assemble into SNARE complexes. Together these results indicated that SNARE complex formation is neither required nor sufficient for Sec22p packaging into COPII transport vesicles and subsequent targeting to the Golgi complex. We propose that the COPII budding machinery has a preference for unassembled ER/Golgi SNARE proteins.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Barlowe, C (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Biochem HB 7200, Hanover, NH 03755 USA.	barlowe@dartmouth.edu						Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Barlowe C, 1997, J CELL BIOL, V139, P1097, DOI 10.1083/jcb.139.5.1097; Belden WJ, 1996, J BIOL CHEM, V271, P26939, DOI 10.1074/jbc.271.43.26939; Bhattacharya S, 2002, P NATL ACAD SCI USA, V99, P13867, DOI 10.1073/pnas.202335999; Burri L, 2003, P NATL ACAD SCI USA, V100, P9873, DOI 10.1073/pnas.1734000100; Calero M, 2002, FEBS LETT, V515, P89, DOI 10.1016/S0014-5793(02)02442-0; Cao XC, 2000, J CELL BIOL, V149, P55, DOI 10.1083/jcb.149.1.55; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; Dilcher M, 2003, EMBO J, V22, P3664, DOI 10.1093/emboj/cdg339; Dulubova I, 2002, EMBO J, V21, P3620, DOI 10.1093/emboj/cdf381; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fukuda R, 2000, NATURE, V407, P198, DOI 10.1038/35025084; Gonzalez LC, 2001, J BIOL CHEM, V276, P24203, DOI 10.1074/jbc.M101584200; Hasegawa H, 2003, MOL BIOL CELL, V14, P698, DOI 10.1091/mbc.E02-09-0556; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Joglekar AP, 2003, J BIOL CHEM, V278, P14121, DOI 10.1074/jbc.M300659200; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Lewis MJ, 1997, EMBO J, V16, P3017, DOI 10.1093/emboj/16.11.3017; Liu YT, 2002, MOL BIOL CELL, V13, P3314, DOI 10.1091/mbc.E02-04-0204; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Munson M, 2002, J BIOL CHEM, V277, P9375, DOI 10.1074/jbc.M111729200; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; Otte S, 2001, J CELL BIOL, V152, P503, DOI 10.1083/jcb.152.3.503; Parlati F, 2000, NATURE, V407, P194, DOI 10.1038/35025076; Pelham HRB, 1999, EXP CELL RES, V247, P1, DOI 10.1006/excr.1998.4356; Peng RW, 1999, P NATL ACAD SCI USA, V96, P3751, DOI 10.1073/pnas.96.7.3751; Powers J, 1998, J CELL BIOL, V142, P1209, DOI 10.1083/jcb.142.5.1209; Rowe T, 1998, SCIENCE, V279, P696, DOI 10.1126/science.279.5351.696; Sacher M, 1997, J BIOL CHEM, V272, P17134, DOI 10.1074/jbc.272.27.17134; SIKORSKI RS, 1989, GENETICS, V122, P19; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Spang A, 1998, J CELL BIOL, V143, P589, DOI 10.1083/jcb.143.3.589; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tochio H, 2001, SCIENCE, V293, P698, DOI 10.1126/science.1062950; Tsui MMK, 2000, J CELL SCI, V113, P145; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; Yamaguchi T, 2002, DEV CELL, V2, P295, DOI 10.1016/S1534-5807(02)00125-9; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	50	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27225	27232		10.1074/jbc.M312122200	http://dx.doi.org/10.1074/jbc.M312122200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15123693	hybrid			2022-12-25	WOS:000222120400050
J	Malinen, AM; Belogurov, GA; Salminen, M; Baykov, AA; Lahti, R				Malinen, AM; Belogurov, GA; Salminen, M; Baykov, AA; Lahti, R			Elucidating the role of conserved glutamates in H+-pyrophosphatase of Rhodospirillum rubrum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI INORGANIC PYROPHOSPHATASE; TRANSLOCATING PYROPHOSPHATASE; YEAST PYROPHOSPHATASE; DIRECTED MUTAGENESIS; INHIBITION; BINDING; CATALYSIS; SITE; RECONSTITUTION; APPARATUS	H+-pyrophosphatase (H+-PPase) catalyzes pyrophosphate-driven proton transport against the electrochemical potential gradient in various biological membranes. All 50 of the known H+-PPase amino acid sequences contain four invariant glutamate residues. In this study, we use site-directed mutagenesis in conjunction with functional studies to determine the roles of the glutamate residues Glu(197), Glu(202), Glu(550), and Glu(649) in the H+-PPase of Rhodospirillum rubrum (R-PPase). All residues were replaced with Asp and Ala. The resulting eight variant R-PPases were expressed in Escherichia coli and isolated as inner membrane vesicles. All substitutions, except E202A, generated enzymes capable of PPi hydrolysis and PPi-energized proton translocation, indicating that the negative charge of Glu(202) is essential for R-PPase function. The hydrolytic activities of all other PPase variants were impaired at low Mg2+ concentrations but were only slightly affected at high Mg2+ concentrations, signifying that catalysis proceeds through a three-metal pathway in contrast to wild-type R-PPase, which employs both two- and three-metal pathways. Substitution of Glu(197), Glu(202), and Glu(649) resulted in decreased binding affinity for the substrate analogues aminomethylenediphosphonate and methylenediphosphonate, indicating that these residues are involved in substrate binding as ligands for bridging metal ions. Following the substitutions of Glu(550) and Glu(649), R-PPase was more susceptible to inactivation by the sulfhydryl reagent mersalyl, highlighting a role of these residues in maintaining enzyme tertiary structure. None of the substitutions affected the coupling of PPi hydrolysis to proton transport.	Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia; Univ Turku, Dept Biochem & Food Chem, FIN-20014 Turku, Finland	Lomonosov Moscow State University; University of Turku	Baykov, AA (corresponding author), Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia.	baykov@genebee.msu.su; reijo.lahti@utu.fi	Baykov, Alexander A/C-7981-2012; Baykov, Alexander/AAH-5301-2021	Malinen, Anssi/0000-0003-2987-2649; Belogurov, Georgiy/0000-0002-3070-6843; Baykov, Alexander/0000-0002-2495-8200				BALTSCHEFFSKY M, 1986, METHOD ENZYMOL, V126, P538; Baltscheffsky M, 1999, FEBS LETT, V457, P525, DOI 10.1016/S0014-5793(99)00914-X; Baltscheffsky M, 1998, BBA-BIOENERGETICS, V1364, P301, DOI 10.1016/S0005-2728(98)00062-0; Baykov AA, 1996, BIOCHEMISTRY-US, V35, P4655, DOI 10.1021/bi952635u; Baykov AA, 1996, EUR J BIOCHEM, V236, P121, DOI 10.1111/j.1432-1033.1996.00121.x; BAYKOV AA, 1981, ANAL BIOCHEM, V116, P1, DOI 10.1016/0003-2697(81)90313-4; BAYKOV AA, 1993, FEBS LETT, V327, P199, DOI 10.1016/0014-5793(93)80169-U; BAYKOV AA, 1993, EUR J BIOCHEM, V217, P755, DOI 10.1111/j.1432-1033.1993.tb18303.x; Belogurov GA, 2000, BIOCHEMISTRY-US, V39, P13931, DOI 10.1021/bi000895s; BELOGUROV GA, 2002, J BIOL CHEM, V15, P15; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; Drozdowicz YM, 2001, TRENDS PLANT SCI, V6, P206, DOI 10.1016/S1360-1385(01)01923-9; Fabrichniy IP, 1997, BIOCHEMISTRY-US, V36, P7746, DOI 10.1021/bi9629844; Heikinheimo P, 1996, STRUCTURE, V4, P1491, DOI 10.1016/S0969-2126(96)00155-4; Hyytia T, 2001, BIOCHEMISTRY-US, V40, P4645, DOI 10.1021/bi010049x; KAPYLA J, 1995, BIOCHEMISTRY-US, V34, P792, DOI 10.1021/bi00003a012; KIM EJ, 1995, J BIOL CHEM, V270, P2630, DOI 10.1074/jbc.270.6.2630; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Maeshima M, 2000, BBA-BIOMEMBRANES, V1465, P37, DOI 10.1016/S0005-2736(00)00130-9; Martinez R, 2002, MOL BIOCHEM PARASIT, V120, P205, DOI 10.1016/S0166-6851(01)00456-X; McIntosh MT, 2001, MOL BIOCHEM PARASIT, V114, P183, DOI 10.1016/S0166-6851(01)00251-1; Merckel MC, 2001, STRUCTURE, V9, P289, DOI 10.1016/S0969-2126(01)00587-1; Nakanishi Y, 2003, J BIOCHEM, V134, P615, DOI 10.1093/jb/mvg184; Nakanishi Y, 2001, J BIOL CHEM, V276, P7654, DOI 10.1074/jbc.M009743200; NYREN P, 1991, BIOCHEMISTRY-US, V30, P2883, DOI 10.1021/bi00225a022; Pohjanjoki P, 2001, J BIOL CHEM, V276, P434, DOI 10.1074/jbc.M007360200; RAO PV, 1978, BIOCHEM BIOPH RES CO, V84, P465, DOI 10.1016/0006-291X(78)90192-4; REA PA, 1992, TRENDS BIOCHEM SCI, V17, P348, DOI 10.1016/0968-0004(92)90313-X; REA PA, 1986, PLANT PHYSIOL, V81, P126, DOI 10.1104/pp.81.1.126; SATO MH, 1994, J BIOL CHEM, V269, P6725; SATO MH, 1991, FEBS LETT, V290, P177, DOI 10.1016/0014-5793(91)81254-6; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; WU JJ, 1991, FEBS LETT, V283, P57, DOI 10.1016/0014-5793(91)80552-E; Zhen RG, 1997, J BIOL CHEM, V272, P22340, DOI 10.1074/jbc.272.35.22340	36	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26811	26816		10.1074/jbc.M404154200	http://dx.doi.org/10.1074/jbc.M404154200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15107429	hybrid			2022-12-25	WOS:000222120400003
J	Rabenau, KE; O'Toole, JM; Bassi, R; Kotanides, H; Witte, L; Ludwig, DL; Pereira, DS				Rabenau, KE; O'Toole, JM; Bassi, R; Kotanides, H; Witte, L; Ludwig, DL; Pereira, DS			DEGA/AMIGO-2, a leucine-rich repeat family member, differentially expressed in human gastric adenocarcinoma: effects on ploidy, chromosomal stability, cell adhesion/migration and tumorigenicity	ONCOGENE			English	Article						tumorigenicity; ploidy; chromosomal instability; leucine-rich repeat; gastric adenocarcinoma; antisense	GENOMIC INSTABILITY; FREQUENT AMPLIFICATION; MOLECULAR-BIOLOGY; GENE; CANCER; CARCINOMA; HER-2/NEU; ONCOGENE; MUTATION; LAMININ	We have discovered DEGA, a novel cDNA differentially expressed in human gastric adenocarcinomas. The DEGA gene product contains a signal peptide,five leucine-rich repeat motifs and a single IgG, and transmembrane domain, suggesting its residence on the plasma membrane. Transfection of 293 cells with a DEGA-GFP fusion construct confirmed its cell surface localization. Although the cytosolic portion of the DEGA gene product does not contain known protein domains, approximately one-fifth of these residues are either a serine or a threonine, suggesting that DEGA may play a role in signal transduction. BLAST searches revealed DEGA to be an exact match to AMIGO-2, a recently identified, but functionally uncharacterized protein related to AMIGO, a leucine-rich repeat containing cell adhesion molecule implicated in axon tract development. In this report, we show that DEGA/AMIGO-2 mRNA is differentially expressed in similar to45% of tumor versus normal tissue from gastric adenocarcinoma patients. Stable expression of a DEGA/AMIGO-2 antisense construct in the gastric adenocarcinoma cell line, AGS, led to altered morphology, increased ploidy, chromosomal instability, decreased cell adhesion/migration, and a nearly complete abrogation of tumorigenicity in nude mice. These findings suggest a potential etiologic role for DEGA/AMIGO-2 in gastric adenocarcinoma.	ImClone Syst Inc, Dept Mol & Cellular Biol, New York, NY 10014 USA; ImClone Syst Inc, Dept Immunol, New York, NY 10014 USA	Eli Lilly; Eli Lilly	Pereira, DS (corresponding author), ImClone Syst Inc, Dept Mol & Cellular Biol, 180 Varick St, New York, NY 10014 USA.	Daniel.Pereira@imclone.com						AKAMA Y, 1995, JPN J CANCER RES, V86, P617, DOI 10.1111/j.1349-7006.1995.tb02442.x; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Chan AOO, 1999, J GASTROEN HEPATOL, V14, P1150, DOI 10.1046/j.1440-1746.1999.02000.x; Crookes PF, 2002, CLIN OBSTET GYNECOL, V45, P892, DOI 10.1097/00003081-200209000-00036; Danesh J, 1999, ALIMENT PHARM THERAP, V13, P851; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Ebert MPA, 2000, EUR J GASTROEN HEPAT, V12, P795, DOI 10.1097/00042737-200012070-00013; El-Rifai W, 2002, SEMIN RADIAT ONCOL, V12, P128, DOI 10.1053/srao.2002.30815; Hocking AM, 1998, MATRIX BIOL, V17, P1; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Kono K, 2000, TUMOR BIOL, V21, P139, DOI 10.1159/000030120; Konturek P C, 2001, Med Sci Monit, V7, P1092; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kuja-Panula J, 2003, J CELL BIOL, V160, P963, DOI 10.1083/jcb.200209074; KUNIYASU H, 1993, INT J CANCER, V55, P72, DOI 10.1002/ijc.2910550114; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; MAFUNE K, 1992, J SURG RES, V52, P340, DOI 10.1016/0022-4804(92)90113-E; MAYER B, 1993, LANCET, V342, P1019, DOI 10.1016/0140-6736(93)92879-X; Moayyedi P, 2002, BMJ-BRIT MED J, V325, P1399, DOI 10.1136/bmj.325.7377.1399; Musio A, 2003, CANCER RES, V63, P2855; Nowak MA, 2002, P NATL ACAD SCI USA, V99, P16226, DOI 10.1073/pnas.202617399; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Ross JS, 2001, CANCER INVEST, V19, P554, DOI 10.1081/CNV-100103852; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; Shun CT, 2001, ONCOLOGY-BASEL, V60, P339, DOI 10.1159/000058530; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; TERRANOVA VP, 1986, P NATL ACAD SCI USA, V83, P465, DOI 10.1073/pnas.83.2.465; Tomlinson I, 1999, NAT MED, V5, P11, DOI 10.1038/4687; Woo DK, 2001, INT J CANCER, V95, P108, DOI 10.1002/1097-0215(20010320)95:2<108::AID-IJC1019>3.0.CO;2-#; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yasui W, 2001, Gastric Cancer, V4, P113, DOI 10.1007/PL00011733; YOKOZAKI H, 1994, CANCER LETT, V83, P229, DOI 10.1016/0304-3835(94)90324-7	38	43	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5056	5067		10.1038/sj.onc.1207681	http://dx.doi.org/10.1038/sj.onc.1207681			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15107827				2022-12-25	WOS:000222237300012
J	Tchaicheeyan, O				Tchaicheeyan, O			Is peptide bond cis/trans isomerization a key stage in the chemo-mechanical cycle of motor proteins?	FASEB JOURNAL			English	Article						energy transduction; kinesin; mechano-chemical coupling; molecular mechanism; myosin	SINGLE MYOSIN MOLECULE; CONFORMATION; HYDROLYSIS; MECHANICS; KINESINS; ATPASE	Motor proteins such as myosin and kinesin are responsible for actively directed movement in vivo. The physicochemical mechanism underlying their function is still obscure. A novel and unifying model concerning the motors driving mechanism is suggested here. This model resides within the framework of the well-studied "swinging lever-arm" hypothesis, stating that cis/trans peptide bond isomerization (CTI) is a key stage in the chemo-mechanical coupling within actomyosin-the complex of the motor ( myosin) and its specific track ( actin). CTI is suggested to propel myosin's lever-arm swing. The model addresses on the submolecular level a broad spectrum of actomyosin's functional characteristics, such as kinetics, energetics, force exertion, stepping, and directionality. The model may be tested first with relative ease in kinesin-a smaller motor that could be specifically modified with unnatural amino acids using bacterial expression. Suggested modifications may be used for labeling and functional decoupling.	Technion Israel Inst Technol, Dept Biomed Engn, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Tchaicheeyan, O (corresponding author), Technion Israel Inst Technol, Dept Biomed Engn, IL-32000 Haifa, Israel.	toren@tx.technion.ac.il						An SSA, 1999, J AM CHEM SOC, V121, P11558, DOI 10.1021/ja9930317; BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; Bauer CB, 2000, J BIOL CHEM, V275, P38494, DOI 10.1074/jbc.M005585200; Chin JW, 2003, SCIENCE, V301, P964, DOI 10.1126/science.1084772; CHUNG HH, 1993, P NATL ACAD SCI USA, V90, P10145, DOI 10.1073/pnas.90.21.10145; COREY RB, 1953, PROC R SOC SER B-BIO, V141, P10, DOI 10.1098/rspb.1953.0011; Dugave C, 2003, CHEM REV, V103, P2475, DOI 10.1021/cr0104375; Endow SA, 1999, NAT CELL BIOL, V1, pE163, DOI 10.1038/14113; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; Fischer G, 2000, CHEM SOC REV, V29, P119, DOI 10.1039/a803742f; Flint DG, 2002, CHEM BIOL, V9, P391, DOI 10.1016/S1074-5521(02)00109-6; Heroux A, 1999, BIOCHEMISTRY-US, V38, P14495, DOI 10.1021/bi990508i; Higuchi H, 2002, CURR OPIN CELL BIOL, V14, P50, DOI 10.1016/S0955-0674(01)00293-9; Houdusse A, 2001, CURR OPIN STRUC BIOL, V11, P182, DOI 10.1016/S0959-440X(00)00188-3; Howard J., 2001, MECH MOTOR PROTEINS; Hugel T, 2002, SCIENCE, V296, P1103, DOI 10.1126/science.1069856; Huxley AF, 2000, PHILOS T ROY SOC B, V355, P433, DOI 10.1098/rstb.2000.0584; Huxley HE, 2000, PHILOS T R SOC B, V355, P539, DOI 10.1098/rstb.2000.0595; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; Koumura N, 1999, NATURE, V401, P152, DOI 10.1038/43646; Ludwig ML, 1997, BIOCHEMISTRY-US, V36, P1259, DOI 10.1021/bi962180o; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; Murphy CT, 2001, NAT CELL BIOL, V3, P311, DOI 10.1038/35060110; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Reimer U, 2002, BIOPHYS CHEM, V96, P203, DOI 10.1016/S0301-4622(02)00013-3; Sablin EP, 2001, CURR OPIN STRUC BIOL, V11, P716, DOI 10.1016/S0959-440X(01)00265-2; Sasaki N, 2003, BIOCHEMISTRY-US, V42, P90, DOI 10.1021/bi026051l; Scherer G, 1998, J AM CHEM SOC, V120, P5568, DOI 10.1021/ja980181t; Schiene-Fischer C, 2002, NAT STRUCT BIOL, V9, P419, DOI 10.1038/nsb804; Schiene-Fischer C, 2001, J AM CHEM SOC, V123, P6227, DOI 10.1021/ja0042480; Schmid FX, 2002, ADV PROTEIN CHEM, V59, P243; Spudich JA, 2001, NAT REV MOL CELL BIO, V2, P387, DOI 10.1038/35073086; STEIN RL, 1993, ADV PROTEIN CHEM, V44, P1, DOI 10.1016/S0065-3233(08)60562-8; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; Vale RD, 2000, PHILOS T ROY SOC B, V355, P449, DOI 10.1098/rstb.2000.0586; Wang L, 2001, SCIENCE, V292, P498, DOI 10.1126/science.1060077; WIBERG KB, 1995, J AM CHEM SOC, V117, P2201, DOI 10.1021/ja00113a009; WOLEDGE R, 1985, ENERGETIC ASPECTS MU, V41	39	26	26	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					783	789		10.1096/fj.03-1027hyp	http://dx.doi.org/10.1096/fj.03-1027hyp			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15117883				2022-12-25	WOS:000221883200027
J	Robb, VA; Li, W; Gutmann, DH				Robb, VA; Li, W; Gutmann, DH			Disruption of 14-3-3 binding does not impair Protein 4.1B growth suppression	ONCOGENE			English	Article						14-3-3; Protein 4.1B; DAL-1; meningioma	TYROSINE KINASE SUBSTRATE; TUMOR-SUPPRESSOR; SPORADIC MENINGIOMAS; NF2 GENE; MERLIN EXPRESSION; HUMAN GLIOMA; CELL-GROWTH; LUNG-CANCER; DAL-1; ASSOCIATION	Meningiomas are common central nervous system tumors; however, the mechanisms underlying their pathogenesis are largely unknown. Collaborative studies from our laboratory demonstrated a direct association of 14-3-3 with the meningioma tumor suppressor Protein 4.1B, which was not observed with other members of the Protein 4.1 family, including the NF2 meningioma tumor suppressor, merlin/schwannomin. Given the role of 14-3-3 in the regulation of cell proliferation and apoptosis, we sought to determine the functional significance of 14-3-3 binding to Protein 4.1B growth suppression. Based on comparative binding studies performed with additional members of the Protein 4.1 family, we generated specific missense mutations within the minimal growth suppressor fragment of Protein 4.1B (DAL-1, differentially expressed in adenocarcinoma of the lung). Complementary in vitro GST affinity chromatography and in vivo interaction experiments demonstrated that the F359Y mutation abrogated binding to 14-3-3, but did not impair DAL-1 binding to other known Protein 4.1B interacting proteins. Similar to wild-type DAL-1, the expression of the F359Y DAL-1 14-3-3-binding mutant resulted in reduced Protein 4.1B-deficient IOMM-Lee and CH157-MN meningioma cell line colony formation. Moreover, similar to wild-type DAL-1, the stable expression of the DAL-1 F359Y mutant significantly reduced cell proliferation in independently isolated IOMM-Lee clones, as assessed by thymidine incorporation. Collectively, these results suggest that binding to 14-3-3 is not essential for the growth suppressor function of Protein 4.1B in meningiomas.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu		Gutmann, David/0000-0002-3127-5045	NCI NIH HHS [1-F32-CA-097816-01] Funding Source: Medline; NINDS NIH HHS [NS35848, NS41520] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA097816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035848, R01NS041520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Denisenko-Nehrbass N, 2003, EUR J NEUROSCI, V17, P411, DOI 10.1046/j.1460-9568.2003.02441.x; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; Gutmann DH, 2001, HUM MOL GENET, V10, P825, DOI 10.1093/hmg/10.8.825; Gutmann DH, 2001, NEUROBIOL DIS, V8, P266, DOI 10.1006/nbdi.2000.0376; Gutmann DH, 2000, HUM MOL GENET, V9, P1495, DOI 10.1093/hmg/9.10.1495; Huynh DP, 1997, J NEUROPATH EXP NEUR, V56, P382, DOI 10.1097/00005072-199704000-00007; LEE WH, 1990, NEUROSURGERY, V27, P389, DOI 10.1227/00006123-199009000-00008; Leone PE, 1999, ONCOGENE, V18, P2231, DOI 10.1038/sj.onc.1202531; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Perry A, 2000, J NEUROPATH EXP NEUR, V59, P872, DOI 10.1093/jnen/59.10.872; Robb VA, 2003, NEUROBIOL DIS, V13, P191, DOI 10.1016/S0969-9961(03)00071-8; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; Schulze KMM, 2002, HUM MOL GENET, V11, P69, DOI 10.1093/hmg/11.1.69; Scoles DR, 2000, HUM MOL GENET, V9, P1567, DOI 10.1093/hmg/9.11.1567; Scoles DR, 2002, HUM MOL GENET, V11, P3179, DOI 10.1093/hmg/11.25.3179; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sun CX, 2002, HUM MOL GENET, V11, P3167, DOI 10.1093/hmg/11.25.3167; Tran YK, 1999, CANCER RES, V59, P35; Tsai JC, 1999, LASER SURG MED, V24, P296, DOI 10.1002/(SICI)1096-9101(1999)24:4<296::AID-LSM7>3.0.CO;2-F; TSAI JC, 1995, J NEUROSURG, V82, P864, DOI 10.3171/jns.1995.82.5.0864; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Ueki K, 1999, CANCER RES, V59, P5995; Weber RG, 1997, P NATL ACAD SCI USA, V94, P14719, DOI 10.1073/pnas.94.26.14719; Yageta M, 2002, CANCER RES, V62, P5129; Yu TX, 2002, BIOCHEM J, V365, P783, DOI 10.1042/BJ20020060; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281	33	14	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3589	3596		10.1038/sj.onc.1207445	http://dx.doi.org/10.1038/sj.onc.1207445			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116094				2022-12-25	WOS:000221101700010
J	Bluher, M; Wilson-Fritch, L; Leszyk, J; Laustsen, PG; Corvera, S; Kahn, CR				Bluher, M; Wilson-Fritch, L; Leszyk, J; Laustsen, PG; Corvera, S; Kahn, CR			Role of insulin action and cell size on protein expression patterns in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; MICE LACKING; GLUCOSE; RECEPTOR; OBESITY; CLATHRIN; DISRUPTION; METABOLISM; MEMBRANES; STRESS	Mice with a fat-specific insulin receptor knock-out (FIRKO) exhibit a polarization of white adipose tissue into two populations of cells, one small ( diameter < 50 mu m) and one large ( diameter > 100 mum), accompanied by changes in insulin-stimulated glucose uptake, triglyceride synthesis, and lipolysis. To characterize these subclasses of adipocytes, we have used a proteomics approach in which isolated adipocytes from FIRKO and control (IR lox/lox) mice were separated by size, fractionated into cytosolic and membrane subfractions, and analyzed by sucrose gradient, SDS-PAGE, and mass spectrometry. A total of 27 alterations in protein expression at key steps in lipid and energy metabolism could be defined, which were coordinately regulated by adipocyte cell size, impaired insulin signaling, or both. Nine proteins, including vimentin, EH-domain-containing protein 2, elongation factor 2, glucose-regulated protein 78, transketolase, and succinyl-CoA transferase were primarily affected by presence or absence of insulin signaling, whereas 21 proteins, including myosin non-muscle form A, annexin 2, annexin A6, and Hsp47 were regulated in relation to adipocyte size. Of these 27 alterations in protein expression, 14 changes correlated with altered levels of mRNA, whereas the remaining 13 were the result of changes in protein translation or turnover. These data suggest an intrinsic heterogeneity in adipocytes with differences in protein expression patterns caused by transcriptional and post-transcriptional alterations related to insulin action and cellular lipid accumulation.	Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	Kahn, CR (corresponding author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.	c.ronald.kahn@joslin.harvard.edu	Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NIDDK NIH HHS [DK 30136] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Barnes JA, 2000, ANAT EMBRYOL, V202, P67, DOI 10.1007/s004290000090; Bluher M, 2004, J BIOL CHEM, V279, P31891, DOI 10.1074/jbc.M404569200; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; CHAKRABARTI R, 1994, J BIOL CHEM, V269, P7926; CORVERA S, 1990, J BIOL CHEM, V265, P2413; CUSHMAN SW, 1978, J LIPID RES, V19, P269; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; LEVENSON RM, 1989, J BIOL CHEM, V264, P11904; Lieber JG, 1996, J CELL SCI, V109, P3047; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; LYNCH CJ, 1993, AM J PHYSIOL, V264, pE621, DOI 10.1152/ajpendo.1993.264.4.E621; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Saltiel AR, 2001, NAT MED, V7, P887, DOI 10.1038/90911; Sehgal PB, 2002, J BIOL CHEM, V277, P12067, DOI 10.1074/jbc.M200018200; Seri M, 2000, NAT GENET, V26, P103; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; TeichertKuliszewska K, 1996, INT J OBESITY, V20, pS108; Uittenbogaard A, 2002, J BIOL CHEM, V277, P4925, DOI 10.1074/jbc.M109278200; Uysal KT, 2000, ENDOCRINOLOGY, V141, P3388, DOI 10.1210/en.141.9.3388; Wang SP, 2001, OBES RES, V9, P119, DOI 10.1038/oby.2001.15; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; WERTHEIMER E, 1991, P NATL ACAD SCI USA, V88, P2525, DOI 10.1073/pnas.88.6.2525; Yechoor VK, 2002, P NATL ACAD SCI USA, V99, P10587, DOI 10.1073/pnas.142301999	30	84	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31902	31909		10.1074/jbc.M404570200	http://dx.doi.org/10.1074/jbc.M404570200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15131120	hybrid			2022-12-25	WOS:000222726800117
J	Gu, BJ; Sluyter, R; Skarratt, KK; Shemon, AN; Dao-Ung, LP; Fuller, SJ; Barden, JA; Clarke, AL; Petrou, S; Wiley, JS				Gu, BJ; Sluyter, R; Skarratt, KK; Shemon, AN; Dao-Ung, LP; Fuller, SJ; Barden, JA; Clarke, AL; Petrou, S; Wiley, JS			An Arg(307) to Gln polymorphism within the ATP-binding site causes loss of function of the human P2X(7) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D ACTIVATION; PHAGOSOME-LYSOSOME FUSION; HUMAN-LYMPHOCYTES; EXTRACELLULAR ATP; PURINERGIC RECEPTORS; NUCLEOTIDE RECEPTOR; STRUCTURAL MOTIF; ALA POLYMORPHISM; PORE FORMATION; B-LYMPHOCYTES	The P2X(7) receptor is a ligand-gated channel that is highly expressed on mononuclear cells of the immune system and that mediates ATP-induced apoptosis. Wide variations in the function of the P2X(7) receptor have been observed, explained in part by loss-of-function polymorphisms that change Glu(496) to Ala (E496A) and Ile(568) to Asn (I568N). In this study, a third polymorphism, which substitutes an uncharged glutamine for the highly positively charged Arg(307) (R307Q), has been found in heterozygous dosage in 12 of 420 subjects studied. P2X(7) function was measured by ATP-induced fluxes of Rb+, Ba2+, and ethidium(+) into peripheral blood monocytes or various lymphocyte subsets and was either absent or markedly decreased. Transfection experiments showed that P2X(7) carrying the R307Q mutation lacked either channel or pore function despite robust protein synthesis and surface expression of the receptor. The monoclonal antibody (clone L4) that binds to the extracellular domain of wild type P2X(7) and blocks P2X(7) function failed to bind to the R307Q mutant receptor. Differentiation of monocytes to macrophages up-regulated P2X(7) function in cells heterozygous for the R307Q to a value 10 - 40% of that for wild type macrophages. However, macrophages from a subject who was double heterozygous for R307Q/I568N remained totally non-functional for P2X(7), and lymphocytes from the same subject also lacked ATP-stimulated phospholipase D activity. These data identify a third loss-of-function polymorphism affecting the human P2X(7) receptor, and since the affected Arg(307) is homologous to those amino acids essential for ATP binding to P2X(1) and P2X(2), it is likely that this polymorphism abolishes the binding of ATP to the extracellular domain of P2X(7).	Univ Sydney, Nepean Hosp, Dept Med, Penrith, NSW 2750, Australia; Univ Sydney, Dept Anat & Histol, Sydney, NSW 2006, Australia; Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Melbourne, Vic 3010, Australia	Nepean Hospital; University of Sydney; University of Sydney; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Wiley, JS (corresponding author), Univ Sydney, Nepean Hosp, Dept Med, Level 5,S Block, Penrith, NSW 2750, Australia.	wileyj@medicine.usyd.edu.au	Skarratt, Kristy/AAN-1479-2020; Sluyter, Ronald/B-5798-2009; Fuller, Stephen/W-6646-2019; Petrou, Steven/M-8332-2013	Sluyter, Ronald/0000-0003-4909-686X; Fuller, Stephen/0000-0003-4637-7391; Petrou, Steven/0000-0002-4960-6375; Wiley, James/0000-0001-9421-4154; Skarratt, Kristy/0000-0003-4971-2773; Gu, Ben/0000-0001-5500-4453				Boldt W, 2003, AM J PHYSIOL-CELL PH, V284, pC749, DOI 10.1152/ajpcell.00042.2002; BRETSCHNEIDER F, 1995, PFLUG ARCH EUR J PHY, V429, P691, DOI 10.1007/BF00373990; Buell G, 1998, BLOOD, V92, P3521, DOI 10.1182/blood.V92.10.3521.422k50_3521_3528; Coutinho-Silva R, 2003, IMMUNITY, V19, P403, DOI 10.1016/S1074-7613(03)00235-8; Coutinho-Silva R, 1999, AM J PHYSIOL-CELL PH, V276, pC1139, DOI 10.1152/ajpcell.1999.276.5.C1139; Denlinger LC, 2001, J IMMUNOL, V167, P1871, DOI 10.4049/jimmunol.167.4.1871; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; Ennion S, 2000, J BIOL CHEM, V275, P29361, DOI 10.1074/jbc.M003637200; Fairbairn IP, 2001, J IMMUNOL, V167, P3300, DOI 10.4049/jimmunol.167.6.3300; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Freist W, 1998, FEBS LETT, V434, P61, DOI 10.1016/S0014-5793(98)00958-2; Gargett CE, 1996, BIOCHEM J, V313, P529, DOI 10.1042/bj3130529; Gu B, 1998, BLOOD, V92, P946; Gu BJ, 2001, J BIOL CHEM, V276, P11135, DOI 10.1074/jbc.M010353200; Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189, DOI 10.1152/ajpcell.2000.279.4.C1189; Hansen MA, 1997, BIOCHEM BIOPH RES CO, V236, P670, DOI 10.1006/bbrc.1997.6815; HICKMAN SE, 1994, BLOOD, V84, P2452; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; Jamieson GP, 1996, J CELL PHYSIOL, V166, P637, DOI 10.1002/(SICI)1097-4652(199603)166:3<637::AID-JCP19>3.0.CO;2-3; Jiang LH, 2000, J BIOL CHEM, V275, P34190, DOI 10.1074/jbc.M005481200; Kim M, 2001, J BIOL CHEM, V276, P23262, DOI 10.1074/jbc.M102253200; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Klapperstuck M, 2001, J PHYSIOL-LONDON, V534, P25, DOI 10.1111/j.1469-7793.2001.00025.x; Kusner DJ, 2001, J IMMUNOL, V167, P3308, DOI 10.4049/jimmunol.167.6.3308; MOLLOY A, 1994, J EXP MED, V180, P1499, DOI 10.1084/jem.180.4.1499; NAUMOV AP, 1995, J PHYSIOL-LONDON, V486, P323, DOI 10.1113/jphysiol.1995.sp020815; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; NUTTLE LC, 1994, J BIOL CHEM, V269, P13988; Saunders BM, 2003, J IMMUNOL, V171, P5442, DOI 10.4049/jimmunol.171.10.5442; Sluyter R, 2002, INT IMMUNOL, V14, P1415, DOI 10.1093/intimm/dxf111; Sluyter R, 2001, CELL TISSUE RES, V304, P231, DOI 10.1007/s004410100372; Smart ML, 2003, J BIOL CHEM, V278, P8853, DOI 10.1074/jbc.M211094200; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; TATHAM PER, 1990, J GEN PHYSIOL, V95, P459, DOI 10.1085/jgp.95.3.459; Wen LT, 2003, MOL PHARMACOL, V63, P706, DOI 10.1124/mol.63.3.706; Wiley JS, 2003, J BIOL CHEM, V278, P17108, DOI 10.1074/jbc.M212759200; Wiley JS, 1998, AM J PHYSIOL-CELL PH, V275, pC1224, DOI 10.1152/ajpcell.1998.275.5.C1224; WILEY JS, 1992, ARCH BIOCHEM BIOPHYS, V292, P411, DOI 10.1016/0003-9861(92)90010-T; WILEY JS, 1993, ARCH BIOCHEM BIOPHYS, V305, P54, DOI 10.1006/abbi.1993.1392; Worthington RA, 2002, FEBS LETT, V512, P43, DOI 10.1016/S0014-5793(01)03311-7	43	109	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31287	31295		10.1074/jbc.M313902200	http://dx.doi.org/10.1074/jbc.M313902200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15123679	hybrid			2022-12-25	WOS:000222726800048
J	Pfeffer, LM; Kim, JG; Pfeffer, SR; Carrigan, DJ; Baker, DP; Wei, L; Homayouni, R				Pfeffer, LM; Kim, JG; Pfeffer, SR; Carrigan, DJ; Baker, DP; Wei, L; Homayouni, R			Role of nuclear factor-kappa B in the antiviral action of interferon and interferon-regulated gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL-SURVIVAL; PROTEIN-KINASE; ALPHA; ACTIVATION; TRANSCRIPTION; INDUCTION; INHIBITOR; CYTOKINES; PATHWAYS; STAT3	Interferons (IFNs) play critical roles in host defense by modulating the expression of various genes via tyrosine phosphorylation of STAT transcription factors. IFN-alpha/beta activates another important transcription factor, nuclear factor-kappaB (NF-kappaB), but its role in IFN-mediated activity is poorly understood. Sensitivity to the antiviral and gene-inducing effects of IFN was examined in normal fibroblasts and in NF-kappaB knockout fibroblasts from p50- and p65-null mice. Antiviral assays demonstrated that NF-kappaB knockout fibroblasts were sensitized to the antiviral action of IFN. Moreover, analysis of IFN-stimulated gene expression by real-time PCR demonstrated selective effects of NF-kappaB on gene expression. Our results demonstrate that a subset of IFN-stimulated genes is regulated through an NF-kappaB-dependent pathway and that NF-kappaB may regulate the sensitivity of cells to IFN-mediated antiviral activity.	Univ Tennessee, Hlth Sci Ctr, Dept Pathol & Lab Med, Memphis, TN 38103 USA; Univ Tennessee, Hlth Sci Ctr, Dept Neurol, Memphis, TN 38103 USA; Biogen Idec Inc, Cambridge, MA 02142 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Biogen	Pfeffer, LM (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Pathol & Lab Med, Rm 530,930 Madison Ave, Memphis, TN 38103 USA.	lpfeffer@utmem.edu	Homayouni, Ramin/U-2837-2019; Homayouni, Ramin/B-3547-2009; Wei, Lai/D-1088-2014	Homayouni, Ramin/0000-0003-0186-5076; Homayouni, Ramin/0000-0003-0186-5076; Pfeffer, Lawrence/0000-0003-2809-1234	NATIONAL CANCER INSTITUTE [R01CA073753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI048216] Funding Source: NIH RePORTER; NCI NIH HHS [CA73753] Funding Source: Medline; NIAID NIH HHS [AI48216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arduini RM, 2004, PROTEIN EXPRES PURIF, V34, P229, DOI 10.1016/j.pep.2003.11.004; Baechler EC, 2003, P NATL ACAD SCI USA, V100, P2610, DOI 10.1073/pnas.0337679100; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Chen J, 2000, J BIOL CHEM, V275, P36278, DOI 10.1074/jbc.M006975200; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; Geiss G, 2001, J BIOL CHEM, V276, P30178, DOI 10.1074/jbc.C100137200; IMPROTA T, 1992, J INTERFERON RES, V12, P87, DOI 10.1089/jir.1992.12.87; Jin HK, 1998, BIOCHEM GENET, V36, P311, DOI 10.1023/A:1018741312058; LARNER AC, 1986, J BIOL CHEM, V261, P453; Malakhov MP, 2003, J BIOL CHEM, V278, P16608, DOI 10.1074/jbc.M208435200; Melville MW, 1999, J BIOL CHEM, V274, P3797, DOI 10.1074/jbc.274.6.3797; Naschberger E, 2004, BIOCHEM J, V379, P409, DOI 10.1042/BJ20031873; Pfeffer LM, 1998, CANCER RES, V58, P2489; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SIMON A, 1991, J VIROL, V65, P968, DOI 10.1128/JVI.65.2.968-971.1991; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Valanciute A, 2004, J IMMUNOL, V172, P688, DOI 10.4049/jimmunol.172.1.688; Yang CH, 1998, P NATL ACAD SCI USA, V95, P5568, DOI 10.1073/pnas.95.10.5568; Yang CH, 2001, J BIOL CHEM, V276, P13756, DOI 10.1074/jbc.M011006200; Yang CH, 1996, J BIOL CHEM, V271, P8057, DOI 10.1074/jbc.271.14.8057; Yang CH, 2000, P NATL ACAD SCI USA, V97, P13631, DOI 10.1073/pnas.250477397	27	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31304	31311		10.1074/jbc.M308975200	http://dx.doi.org/10.1074/jbc.M308975200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15131130	hybrid			2022-12-25	WOS:000222726800050
J	Richter, W; Conti, M				Richter, W; Conti, M			The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CGMP-BINDING; PROTEIN-KINASE; MAP KINASE; ACTIVATION; PHOSPHORYLATION; DOMAINS; PDE4D3; (R)-ROLIPRAM; DIMERIZATION	PDE4 splice variants are classified into long and short forms depending on the presence or absence of two unique N-terminal domains termed upstream conserved regions 1 and 2 (UCR1 and -2). We have shown previously that the UCR module mediates dimerization of PDE4 long forms, whereas short forms, which lack UCR1, behave as monomers. In the present study, we demonstrate that dimerization is an essential structural element that determines the regulatory properties and inhibitor sensitivities of PDE4 enzymes. Comparing the properties of the dimeric wild type PDE4D3 with several monomeric mutant PDE4D3 constructs revealed that disruption of dimerization ablates the activation of PDE4 long forms by either protein kinase A phosphorylation or phosphatidic acid binding. Moreover, the analysis of heterodimers consisting of a catalytically active and a catalytically inactive PDE4D3 subunit indicates that protein kinase A phosphorylation of both subunits is essential to fully activate PDE4 enzymes. In addition to affecting enzyme regulation, disruption of dimerization reduces the sensitivity of the enzymes toward the prototypical PDE4 inhibitor rolipram. Parallel binding assays indicated that this shift in rolipram sensitivity is likely mediated by a decrease in the number of inhibitor binding sites in the high affinity rolipram binding state. Thus, although dimerization is not a requirement for high affinity rolipram binding, it functions to stabilize PDE4 long forms in their high affinity rolipram binding conformation. Taken together, our data indicate that dimerization defines the properties of PDE4 enzymes and suggest a common structural and functional organization for all PDEs.	Stanford Univ, Sch Med, Div Reprod Biol, Dept Obstet & Gynecol, Stanford, CA 94305 USA	Stanford University	Conti, M (corresponding author), Stanford Univ, Sch Med, Div Reprod Biol, Dept Obstet & Gynecol, 300 Pasteur Dr, Stanford, CA 94305 USA.	marco.conti@stanford.edu		Richter, Wito/0000-0001-5588-9060	NICHD NIH HHS [HD20788] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Baillie GS, 2000, BRIT J PHARMACOL, V131, P811, DOI 10.1038/sj.bjp.0703636; Beard MB, 2000, J BIOL CHEM, V275, P10349, DOI 10.1074/jbc.275.14.10349; Bolger GB, 2003, J BIOL CHEM, V278, P33351, DOI 10.1074/jbc.M303269200; Fink TL, 1999, J BIOL CHEM, V274, P34613, DOI 10.1074/jbc.274.49.34613; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; Grange M, 2000, J BIOL CHEM, V275, P33379, DOI 10.1074/jbc.M006329200; Hoffmann R, 1999, EMBO J, V18, P893, DOI 10.1093/emboj/18.4.893; Huston E, 1996, J BIOL CHEM, V271, P31334, DOI 10.1074/jbc.271.49.31334; Jin SLC, 1998, J BIOL CHEM, V273, P19672, DOI 10.1074/jbc.273.31.19672; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; Kenan Y, 2000, J BIOL CHEM, V275, P12331, DOI 10.1074/jbc.275.16.12331; KINCAID RL, 1985, J BIOL CHEM, V260, P9009; Kovala T, 1997, BIOCHEMISTRY-US, V36, P2968, DOI 10.1021/bi9613483; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laliberte F, 2000, BIOCHEMISTRY-US, V39, P6449, DOI 10.1021/bi992432w; Lee ME, 2002, FEBS LETT, V530, P53, DOI 10.1016/S0014-5793(02)03396-3; Lim J, 1999, J BIOL CHEM, V274, P19677, DOI 10.1074/jbc.274.28.19677; Liu S, 2001, BIOCHEMISTRY-US, V40, P10179, DOI 10.1021/bi010096p; MacKenzie SJ, 2002, BRIT J PHARMACOL, V136, P421, DOI 10.1038/sj.bjp.0704743; Martinez SE, 2002, P NATL ACAD SCI USA, V99, P13260, DOI 10.1073/pnas.192374899; Muradov KG, 2003, J BIOL CHEM, V278, P10594, DOI 10.1074/jbc.M208456200; Norton AW, 2000, J BIOL CHEM, V275, P38611, DOI 10.1074/jbc.M004606200; Oki N, 2000, J BIOL CHEM, V275, P10831, DOI 10.1074/jbc.275.15.10831; Richter W, 2002, J BIOL CHEM, V277, P40212, DOI 10.1074/jbc.M203585200; Rocque WJ, 1997, BIOCHEMISTRY-US, V36, P14250, DOI 10.1021/bi971112e; Rocque WJ, 1997, PROTEIN EXPRES PURIF, V9, P191, DOI 10.1006/prep.1996.0683; Rybalkin SD, 2003, EMBO J, V22, P469, DOI 10.1093/emboj/cdg051; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P18271; Shakur Y, 2001, PROG NUCLEIC ACID RE, V66, P241; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Tcheudji JFK, 2001, J MOL BIOL, V310, P781, DOI 10.1006/jmbi.2001.4813; TENOR H, 1999, PROG INFLAM RES, P87; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; WADA H, 1987, J BIOL CHEM, V262, P5139; YAMAMOTO T, 1983, J BIOL CHEM, V258, P2526; YAN C, 1995, P NATL ACAD SCI USA, V92, P9677, DOI 10.1073/pnas.92.21.9677	37	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30338	30348		10.1074/jbc.M312687200	http://dx.doi.org/10.1074/jbc.M312687200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131123	hybrid			2022-12-25	WOS:000222531900059
J	Zhu, H; Larade, K; Jackson, TA; Xie, JX; Ladoux, A; Acker, H; Berchner-Pfannschmidt, U; Fandrey, J; Cross, AR; Lukat-Rodgers, GS; Rodgers, KR; Bunn, HF				Zhu, H; Larade, K; Jackson, TA; Xie, JX; Ladoux, A; Acker, H; Berchner-Pfannschmidt, U; Fandrey, J; Cross, AR; Lukat-Rodgers, GS; Rodgers, KR; Bunn, HF			NCB5OR is a novel soluble NAD(P)H reductase localized in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME B(5) REDUCTASE; RESONANCE RAMAN; ELECTRON-TRANSFER; NITRATE REDUCTASE; GOLGI-APPARATUS; BINDING DOMAIN; HEME PROTEIN; OXYGEN; IDENTIFICATION; STABILITY	The NAD(P)H cytochrome b(5) oxidoreductase, Ncb5or (previously named b(5) + b5R), is widely expressed in human tissues and broadly distributed among the animal kingdom. NCB5OR is the first example of an animal flavohemoprotein containing cytochrome b(5) and cytochrome b(5) reductase domains. We initially reported human NCB5OR to be a 487-residue soluble protein that reduces cytochrome c, methemoglobin, ferricyanide, and molecular oxygen in vitro. Bioinformatic analysis of genomic sequences suggested the presence of an upstream start codon. We confirm that endogenous NCB5OR indeed has additional NH2-terminal residues. By performing fractionation of subcellular organelles and confocal microscopy, we show that NCB5OR colocalizes with calreticulin, a marker for endoplasmic reticulum. Recombinant NCB5OR is soluble and has stoichiometric amounts of heme and flavin adenine dinucleotide. Resonance Raman spectroscopy of NCB5OR presents typical signatures of a six-coordinate low-spin heme similar to those found in other cytochrome b(5) proteins. Kinetic measurements showed that full-length and truncated NCB5OR reduce cytochrome c actively in vitro. However, both full-length and truncated NCB5OR produce superoxide from oxygen with slow turnover rates: k(cat) = similar to0.05 and similar to1 s(-1), respectively.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol, Boston, MA 02115 USA; Max Planck Inst Mol Physiol, Lab Opt Syst Physiol, D-44227 Dortmund, Germany; Univ Klinikum Essen, Inst Physiol, D-45122 Essen, Germany; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; N Dakota State Univ, Dept Chem, Fargo, ND 58105 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Max Planck Society; University of Duisburg Essen; Scripps Research Institute; North Dakota State University Fargo	Zhu, H (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol, 221 Longwood Ave, Boston, MA 02115 USA.	haozhu@rics.bwh.harvard.edu; HFBunn@rics.bwh.harvard.edu	Acker, Helmut Anton Josef/AAS-6841-2020; LADOUX, ANNIE/S-2077-2019; Fandrey, Joachim/AAA-3524-2021; LADOUX, ANNIE/O-4267-2016	Acker, Helmut Anton Josef/0000-0001-5589-5508; LADOUX, ANNIE/0000-0003-3857-2621; LADOUX, ANNIE/0000-0003-3857-2621; Fandrey, Joachim/0000-0001-9585-0531	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK059901, R01DK056050] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR015566] Funding Source: Medline; NIAID NIH HHS [R01 AI024838, R01 AI24838] Funding Source: Medline; NIDDK NIH HHS [K01 DK059901-02, R01 DK56050, K01 DK059901-03, R01 DK056050, K01 DK59901] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anelli T, 2003, EMBO J, V22, P5015, DOI 10.1093/emboj/cdg491; BARKER PD, 1993, P NATL ACAD SCI USA, V90, P6542, DOI 10.1073/pnas.90.14.6542; BENDIAK B, 1990, BIOCHEM BIOPH RES CO, V170, P879, DOI 10.1016/0006-291X(90)92173-W; Borgese N, 1996, J CELL BIOL, V135, P1501, DOI 10.1083/jcb.135.6.1501; BRUNT CE, 1992, BIOCHEM J, V283, P87, DOI 10.1042/bj2830087; CANNONS AC, 1993, J BIOL CHEM, V268, P3268; Cohen JD, 1997, ARCH BIOCHEM BIOPHYS, V341, P321, DOI 10.1006/abbi.1997.9987; Cross AR, 1999, BIOCHEM J, V341, P251, DOI 10.1042/0264-6021:3410251; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; Curry BJ, 2004, GENOMICS, V83, P425, DOI 10.1016/j.ygeno.2003.08.020; Davis CA, 2002, ARCH BIOCHEM BIOPHYS, V400, P63, DOI 10.1006/abbi.2002.2783; DESBOIS A, 1989, BIOCHEMISTRY-US, V28, P8011, DOI 10.1021/bi00446a007; DESBOIS A, 1992, EUR BIOPHYS J BIOPHY, V20, P321, DOI 10.1007/BF00196591; FUJII H, 1995, J BIOL CHEM, V270, P12685, DOI 10.1074/jbc.270.21.12685; Garcia-Ranea JA, 2002, FEBS LETT, V529, P162, DOI 10.1016/S0014-5793(02)03321-5; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GUILLEMETTE JG, 1994, BIOCHIMIE, V76, P592, DOI 10.1016/0300-9084(94)90136-8; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; HURST JK, 1991, J BIOL CHEM, V266, P1627; ISOGAI Y, 1995, J BIOL CHEM, V270, P7853, DOI 10.1074/jbc.270.14.7853; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; Kawano M, 1998, BIOCHEM BIOPH RES CO, V245, P666, DOI 10.1006/bbrc.1998.8502; KITAGAWA T, 1982, BIOCHEMISTRY-US, V21, P1680, DOI 10.1021/bi00536a032; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; Lukat-Rodgers GS, 2000, BIOCHEMISTRY-US, V39, P9984, DOI 10.1021/bi0006870; NORTHRUP SH, 1993, BIOCHEMISTRY-US, V32, P6613, DOI 10.1021/bi00077a014; Oyadomari S, 2002, APOPTOSIS, V7, P335, DOI 10.1023/A:1016175429877; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Porwol T, 1998, EUR J BIOCHEM, V256, P16, DOI 10.1046/j.1432-1327.1998.2560016.x; Ratnam K, 1997, J BIOL CHEM, V272, P2122; Seetharaman R, 1996, BIOCHEMISTRY-US, V35, P12455, DOI 10.1021/bi9529723; SILVESTRINI MC, 1986, EUR J BIOCHEM, V161, P465, DOI 10.1111/j.1432-1033.1986.tb10467.x; Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200; SUGIYAMA T, 1985, BIOCHEMISTRY-US, V24, P3012, DOI 10.1021/bi00333a031; Sun YL, 1999, J MOL BIOL, V285, P347, DOI 10.1006/jmbi.1998.2295; Suokas M, 2003, BIOCHEM J, V370, P913, DOI 10.1042/BJ20021533; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Voet D., 1995, BIOCHEMISTRY; Wang ZQ, 2000, BIOPHYS CHEM, V83, P3, DOI 10.1016/S0301-4622(99)00119-2; WOOD PM, 1988, BIOCHEM J, V253, P287, DOI 10.1042/bj2530287; Xue LL, 1999, BIOCHEMISTRY-US, V38, P11961, DOI 10.1021/bi990893b; ZANDER R, 1989, J CLIN CHEM CLIN BIO, V27, P185; Zhang JY, 2003, J BIOL CHEM, V278, P7459, DOI 10.1074/jbc.M207976200; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002; Zhu H, 1999, RESP PHYSIOL, V115, P239, DOI 10.1016/S0034-5687(99)00024-9; Zhu H, 1999, P NATL ACAD SCI USA, V96, P14742, DOI 10.1073/pnas.96.26.14742; Zuber C, 2001, P NATL ACAD SCI USA, V98, P10710, DOI 10.1073/pnas.191359198	54	34	36	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30316	30325		10.1074/jbc.M402664200	http://dx.doi.org/10.1074/jbc.M402664200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131110	Green Accepted, hybrid			2022-12-25	WOS:000222531900057
J	Boukis, LA; Liu, N; Furuyama, S; Bruzik, JP				Boukis, LA; Liu, N; Furuyama, S; Bruzik, JP			Ser/Arg-rich protein-mediated communication between U1 and U2 small nuclear ribonucleoprotein particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; 3' SPLICE-SITE; SR PROTEINS; 5-SPLICE-SITE RECOGNITION; PREMESSENGER RNA; LEADER ADDITION; FACTOR SF1; SELECTION; CAENORHABDITIS; ENHANCERS	Previous work demonstrated that U1 small nuclear ribonucleoprotein particle ( snRNP), bound to a downstream 5' splice site, can positively influence utilization of an upstream 3' splice site via exon definition in both trans- and cis-splicing systems. Although exon definition results in the enhancement of splicing of an upstream intron, the nature of the factors involved has remained elusive. We assayed the interaction of U1 snRNP as well as the positive effect of a downstream 5' splice site on trans- splicing in nematode extracts containing either inactive ( early in development) or active ( later in development) serine/arginine-rich splicing factors (SR proteins). We have determined that U1 snRNP interacts with the 5' splice site in the downstream exon even in the absence of active SR proteins. In addition, we determined that U1 snRNP-directed loading of U2 snRNP onto the branch site as well as efficient transsplicing in these inactive extracts could be rescued upon the addition of active SR proteins. Identical results were obtained when we examined the interaction of U1 snRNP as well as the requirement for SR proteins in communication across a cis-spliced intron. Weakening of the 3' splice site uncovered distinct differences, however, in the ability of U1 snRNP to promote U2 addition, dependent upon its position relative to the branch site. These results demonstrate that SR proteins are required for communication between U1 and U2 snRNPs whether this interaction is across introns or exons.	Case Western Reserve Univ, Sch Med, Ctr RNA Mol Biol, Cleveland, OH 44106 USA	Case Western Reserve University	Bruzik, JP (corresponding author), Case Western Reserve Univ, Sch Med, Ctr RNA Mol Biol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	jxb83@po.cwru.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054204] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM R01 54204] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Berglund JA, 1998, GENE DEV, V12, P858, DOI 10.1101/gad.12.6.858; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; BLUMENTHAL T, 1997, C ELEGANS, V2, P117; Boukis LA, 2001, RNA, V7, P793, DOI 10.1017/S1355838201010524; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; BRUZIK JP, 1995, P NATL ACAD SCI USA, V92, P7056, DOI 10.1073/pnas.92.15.7056; Cartegni L, 2003, NAT STRUCT BIOL, V10, P120, DOI 10.1038/nsb887; Das R, 2000, MOL CELL, V5, P779, DOI 10.1016/S1097-2765(00)80318-4; Denker JA, 1996, RNA, V2, P746; Denker JA, 2002, NATURE, V417, P667, DOI 10.1038/nature00783; EPERON IC, 1993, EMBO J, V12, P3607, DOI 10.1002/j.1460-2075.1993.tb06034.x; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; Furuyama S, 2002, MOL CELL BIOL, V22, P5337, DOI 10.1128/MCB.22.15.5337-5346.2002; FURUYAMA S, 2003, ENCY HUMAN GENOME, V5, P623; Graveley BR, 2001, RNA, V7, P806, DOI 10.1017/S1355838201010317; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; HANNON GJ, 1991, J BIOL CHEM, V266, P22792; HANNON GJ, 1990, CELL, V61, P1247, DOI 10.1016/0092-8674(90)90689-C; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; JAMISON SF, 1995, NUCLEIC ACIDS RES, V23, P3260, DOI 10.1093/nar/23.16.3260; Kashima T, 2003, NAT GENET, V34, P460, DOI 10.1038/ng1207; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Lam BJ, 2002, RNA, V8, P1233, DOI 10.1017/S1355838202028030; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Maquat LE, 2001, NAT GENET, V27, P5, DOI 10.1038/83759; Maroney PA, 1996, RNA, V2, P735; Maroney PA, 2000, RNA, V6, P1905, DOI 10.1017/S1355838200001308; Mazroui R, 1999, RNA, V5, P1615, DOI 10.1017/S1355838299991872; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; Nilsen TW, 1998, COLD SPRING HARBOR M, P279; NILSEN TW, 1997, EUKARYOTIC MRNA PROC, P310; Nissim-Rafinia M, 2002, TRENDS GENET, V18, P123, DOI 10.1016/S0168-9525(01)02619-1; Page-McCaw PS, 1999, RNA, V5, P1548, DOI 10.1017/S1355838299991938; RAJKOVIC A, 1990, P NATL ACAD SCI USA, V87, P8879, DOI 10.1073/pnas.87.22.8879; Romfo CM, 2001, RNA, V7, P785, DOI 10.1017/S1355838201010263; Sanford JR, 1999, GENE DEV, V13, P1513, DOI 10.1101/gad.13.12.1513; Sanford JR, 1999, RNA, V5, P918, DOI 10.1017/S1355838299990234; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; Stover NA, 2001, P NATL ACAD SCI USA, V98, P5693, DOI 10.1073/pnas.101049998; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; TARN WY, 1995, P NATL ACAD SCI USA, V92, P2504, DOI 10.1073/pnas.92.7.2504; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; THOMAS JD, 1988, CELL, V54, P533, DOI 10.1016/0092-8674(88)90075-X; Van Buskirk C, 2002, DEV CELL, V2, P343, DOI 10.1016/S1534-5807(02)00128-4; Vandenberghe AE, 2001, GENE DEV, V15, P294, DOI 10.1101/gad.865401; VANDOREN K, 1988, NATURE, V335, P556; Wang X, 1999, EMBO J, V18, P4549, DOI 10.1093/emboj/18.16.4549; WANG Z, 1995, RNA, V1, P21; WILL CL, 1997, EUKARYOTIC MRNA PROC, P130; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; ZAHLER AM, 1995, P NATL ACAD SCI USA, V92, P2642, DOI 10.1073/pnas.92.7.2642; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031; Zorio DAR, 1999, NATURE, V402, P835, DOI 10.1038/45597; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	64	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29647	29653		10.1074/jbc.M313209200	http://dx.doi.org/10.1074/jbc.M313209200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15131126	hybrid			2022-12-25	WOS:000222445300101
J	Nigam, S; Patabhiraman, S; Ciccoli, R; Ishdorj, G; Schwarz, K; Petrucev, B; Kuhn, H; Haeggstrom, JZ				Nigam, S; Patabhiraman, S; Ciccoli, R; Ishdorj, G; Schwarz, K; Petrucev, B; Kuhn, H; Haeggstrom, JZ			The rat leukocyte-type 12-lipoxygenase exhibits an intrinsic hepoxilin A(3) synthase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; POSITIONAL SPECIFICITY; PRIMARY DETERMINANT; INHIBITION; LIPOXIN; PHENYLALANINE; METABOLISM; PRODUCTS; APLYSIA; CALCIUM	Hepoxilins are biologically relevant eicosanoids formed via the 12-lipoxygenase pathway of the arachidonic acid cascade. Although these eicosanoids exhibit a myriad of biological activities, their biosynthetic mechanism has not been investigated in detail. We examined the arachidonic acid metabolism of RINm5F rat insulinoma cells and found that they constitutively express a leukocyte-type 12S-lipoxygenase. Moreover, we observed that RINm5F cells exhibit an active hepoxilin A(3) synthase that converts exogenous 12S-HpETE (12S-5Z, 8Z, 10E, 14Z-12-hydro(pero)xy-eicosa-5,8,10,14-tetraenoic acid) or arachidonic acid predominantly to hepoxilin A(3). 12S-lipoxygenase and hepoxilin A(3) synthase activities were co-localized in the cytosol; immunoprecipitation with an anti-12S-lipoxygenase antibody co-precipitated the two catalytic activities. These data suggested that hepoxilin A(3) synthase activity may be considered an intrinsic catalytic property of the leukocyte-type 12S-lipoxygenase. To test this hypothesis we cloned the leukocytetype 12S-LOX from RINm5F cells, expressed it in Pichia pastoris, and found that the recombinant enzyme exhibited both 12S-lipoxygenase and hepoxilin A(3) synthase activities. The recombinant human platelet-type 12S-lipoxygenase and the porcine leukocyte-type 12S-lipoxygenase also exhibited hepoxilin A(3) synthase activity. In contrast, the native rabbit reticulocyte-type 15S-lipoxygenase did not convert 12S-HpETE to hepoxilin isomers. These data suggest that the positional specificity of lipoxygenases may be crucial for this catalytic function. This hypothesis was confirmed by site-directed mutagenesis studies that altered the positional specificity of the rat leukocyte-type 12S- and the rabbit reticulocyte-type 15-lipoxygenase. In summary, it may be concluded that naturally occurring 12S- lipoxygenases exhibit an intrinsic hepoxilin A(3) synthase activity that is minimal in lipoxygenase isoforms with different positional specificity.	Free Univ Berlin, Univ Med Ctr Berlin, Eicosanoid & Lipid Res Div, D-12200 Berlin, Germany; Free Univ Berlin, Univ Med Ctr Berlin, Ctr Expt Gynecol & Breast Res, D-12200 Berlin, Germany; Humboldt Univ, Univ Med Ctr Berlin, Inst Biochem, D-10098 Berlin, Germany; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Karolinska Institutet	Nigam, S (corresponding author), Free Univ Berlin, Univ Med Ctr Berlin, Eicosanoid & Lipid Res Div, Campus Benjamin Franklin, D-12200 Berlin, Germany.	nigam@zedat.fu-berlin.de						BELARDETTI F, 1989, NEURON, V3, P497, DOI 10.1016/0896-6273(89)90208-0; Borngraber S, 1996, J MOL BIOL, V264, P1145, DOI 10.1006/jmbi.1996.0702; Borngraber S, 1999, J BIOL CHEM, V274, P37345, DOI 10.1074/jbc.274.52.37345; BRYANT RW, 1979, PROSTAGLANDINS, V17, P9, DOI 10.1016/0090-6980(79)90071-6; DEMIN P, 1995, ANAL BIOCHEM, V226, P252, DOI 10.1006/abio.1995.1222; DHO S, 1990, BIOCHEM J, V266, P63, DOI 10.1042/bj2660063; GARSSEN GJ, 1976, EUR J BIOCHEM, V62, P33, DOI 10.1111/j.1432-1033.1976.tb10094.x; Ivanov I, 2001, BIOCHEMISTRY-US, V40, P10223, DOI 10.1021/bi010700w; KUHN H, 1986, FEBS LETT, V208, P248, DOI 10.1016/0014-5793(86)81026-2; LANEUVILLE O, 1993, BIOCHEM J, V295, P393, DOI 10.1042/bj2950393; MARGALIT A, 1993, P NATL ACAD SCI USA, V90, P2589, DOI 10.1073/pnas.90.7.2589; Moody JS, 2002, BIOCHEMISTRY-US, V41, P10297, DOI 10.1021/bi020320q; NIGAM S, 1990, BIOCHEM BIOPH RES CO, V171, P944, DOI 10.1016/0006-291X(90)90775-I; PACEASCIAK CR, 1995, J LIPID MEDIAT CELL, V12, P307, DOI 10.1016/0929-7855(95)00036-P; PACEASCIAK CR, 1995, LIPIDS, V30, P107, DOI 10.1007/BF02538262; PACEASCIAK CR, 1983, J BIOL CHEM, V258, P6835; PACEASCIAK CR, 1984, PROSTA LEUKOTR MED, V16, P173, DOI 10.1016/0262-1746(84)90069-6; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; PIOMELLI D, 1989, P NATL ACAD SCI USA, V86, P1721, DOI 10.1073/pnas.86.5.1721; REYNAUD D, 1994, J NEUROCHEM, V62, P126; Richards KM, 1999, BIOCHEMISTRY-US, V38, P16529, DOI 10.1021/bi991336s; ROMANO M, 1993, BIOCHEM J, V296, P127, DOI 10.1042/bj2960127; SCHEWE T, 1986, ADV ENZYMOL RAMB, V58, P191; Schwarz K, 2000, BIOCHEMISTRY-US, V39, P14515, DOI 10.1021/bi001447n; Serhan CN, 1999, CLIN CHEM LAB MED, V37, P299, DOI 10.1515/CCLM.1999.052; Shankaranarayanan P, 2003, FEBS LETT, V538, P107, DOI 10.1016/S0014-5793(03)00151-0; SHIMIZU T, 1984, P NATL ACAD SCI-BIOL, V81, P689, DOI 10.1073/pnas.81.3.689; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; Walther M, 2001, CHEM BIOL, V8, P779, DOI 10.1016/S1074-5521(01)00050-3; WATANABE T, 1993, BIOCHEM BIOPH RES CO, V192, P1023, DOI 10.1006/bbrc.1993.1519	30	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29023	29030		10.1074/jbc.M307576200	http://dx.doi.org/10.1074/jbc.M307576200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123652	hybrid			2022-12-25	WOS:000222445300025
J	Walker, JB; Bajzar, L				Walker, JB; Bajzar, L			The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; SOLUBLE FIBRIN; DEGRADATION-PRODUCTS; PROCARBOXYPEPTIDASE-B; THERMAL-STABILITY; TAFI; PLASMA; THROMBOMODULIN; PURIFICATION; MECHANISM	Activated thrombin-activable fibrinolysis inhibitor (TAFIa) is intrinsically unstable, a property that complicates the study of its role in regulating fibrinolysis. To investigate the effect of basic carboxypeptidases on fibrinolysis under conditions of constant carboxypeptidase activity, we employed pancreatic carboxypeptidase B (CPB), a homologous, stable basic carboxypeptidase, as a surrogate for TAFIa. Clots formed from TAFI-depleted plasma or from purified components were supplemented with tissue-type plasminogen activator and either CPB or TAFIa. The clot lysis data indicate that the down-regulation of fibrinolysis mediated by basic carboxypeptidases involves a threshold mechanism. At carboxypeptidase concentrations above the threshold, plasminogen activation is maintained in a fully down-regulated state; experiments in plasma showed that fibrinolysis is essentially halted by saturating concentrations of TAFIa and that fibrinolysis can be prolonged more than 45-fold by a stable carboxypeptidase. The threshold carboxypeptidase concentration was dependent on tissue-type plasminogen activator and antiplasmin concentrations, indicating that the threshold is determined by the steady-state plasmin concentration. Although obvious with CPB, the threshold was masked by the intrinsic instability of TAFIa and became apparent only when the effect of TAFIa was investigated over the picomolar concentration range. Because of the threshold effect and the instability of TAFIa, exponential increases in TAFIa concentration generate linear increases in lysis time. A model relating lysis time to TAFIa concentration, TAFIa half-life, and the threshold concentration of TAFIa is provided. The threshold effect has potentially important implications regarding the role of TAFIa and the regulation of clot lysis in vivo.	Henderson Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Hamilton, ON L8V 1C3, Canada	McMaster University	Bajzar, L (corresponding author), Henderson Res Ctr, 711 Consess St, Hamilton, ON L8V 1C3, Canada.	lbajzar@thrombosis.hhscr.org						ANONICK PK, 1991, BIOCHEM J, V275, P53, DOI 10.1042/bj2750053; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1998, J BIOL CHEM, V273, P2792, DOI 10.1074/jbc.273.5.2792; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Boffa MB, 2000, J BIOL CHEM, V275, P12868, DOI 10.1074/jbc.275.17.12868; EATON DL, 1991, J BIOL CHEM, V266, P21833; Frank PS, 2003, BIOCHEMISTRY-US, V42, P1078, DOI 10.1021/bi026917n; FREDENBURGH JC, 1992, J BIOL CHEM, V267, P26150; HENDRIKS D, 1990, BIOCHIM BIOPHYS ACTA, V1034, P86, DOI 10.1016/0304-4165(90)90157-R; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2183; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V155, P591, DOI 10.1016/S0006-291X(88)80535-7; Komura H, 2002, MICROBIOL IMMUNOL, V46, P217, DOI 10.1111/j.1348-0421.2002.tb02689.x; KOSHLAND DE, 1987, TRENDS BIOCHEM SCI, V12, P225, DOI 10.1016/0968-0004(87)90114-9; Leurs J, 2004, J THROMB HAEMOST, V2, P416, DOI 10.1111/j.1538-7836.2004.00605.x; LEURS J, 2003, J THROMB HAEMOST, V1, pOC66; LEWIS J, 1977, J THEOR BIOL, V65, P579, DOI 10.1016/0022-5193(77)90216-8; Marx PF, 2000, J BIOL CHEM, V275, P12410, DOI 10.1074/jbc.275.17.12410; Marx PF, 2004, J BIOL CHEM, V279, P6620, DOI 10.1074/jbc.M307337200; Marx PF, 2002, BIOCHEMISTRY-US, V41, P6688, DOI 10.1021/bi015982e; Mosnier LO, 2001, THROMB HAEMOSTASIS, V86, P1035; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; Ries M, 2003, BLOOD COAGUL FIBRIN, V14, P203, DOI 10.1097/00001721-200302000-00014; Sakharov DV, 1997, J BIOL CHEM, V272, P14477, DOI 10.1074/jbc.272.22.14477; Schneider M, 2004, J BIOL CHEM, V279, P13333, DOI 10.1074/jbc.M313164200; Schneider M, 2004, J BIOL CHEM, V279, P13340, DOI 10.1074/jbc.M313211200; Schneider M, 2003, J THROMB HAEMOST, V1, P147, DOI 10.1046/j.1538-7836.2003.00028.x; Schneider M, 2002, J BIOL CHEM, V277, P1021, DOI 10.1074/jbc.M104444200; SHINOHARA T, 1994, INT ARCH ALLERGY IMM, V103, P400, DOI 10.1159/000236661; SUENSON E, 1986, BIOCHIM BIOPHYS ACTA, V870, P510, DOI 10.1016/0167-4838(86)90260-8; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; SUENSON E, 1990, J BIOL CHEM, V265, P22228; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; THORSEN S, 1984, BIOCHEM J, V223, P179, DOI 10.1042/bj2230179; Walker JB, 1999, J BIOL CHEM, V274, P5201, DOI 10.1074/jbc.274.8.5201; Walker JB, 2003, J BIOL CHEM, V278, P8913, DOI 10.1074/jbc.M205006200; Walker JB, 2001, J BIOL CHEM, V276, P3138, DOI 10.1074/jbc.M005876200; WALKER JB, 2003, J THROMB HAEMOSTA S1, V1, pOC65; Wang HY, 2003, EUR J BIOCHEM, V270, P2023, DOI 10.1046/j.1432-1033.2003.03578.x; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; WIMAN B, 1980, BIOCHEM J, V191, P229, DOI 10.1042/bj1910229; YAMAMOTO KK, 1992, J BIOL CHEM, V267, P2575	44	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27896	27904		10.1074/jbc.M401027200	http://dx.doi.org/10.1074/jbc.M401027200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15128744	hybrid			2022-12-25	WOS:000222265400011
J	Ala-aho, R; Ahonen, M; George, SJ; Heikkila, J; Grenman, R; Kallajoki, M; Kahari, VM				Ala-aho, R; Ahonen, M; George, SJ; Heikkila, J; Grenman, R; Kallajoki, M; Kahari, VM			Targeted inhibition of human collagenase-3 (MMP-13) expression inhibits squamous cell carcinoma growth in vivo	ONCOGENE			English	Article						collagenase; squamous cell carcinoma; invasion; ribozyme	ACTIVATED PROTEIN-KINASE; MATRIX METALLOPROTEINASE-13; TISSUE INHIBITOR; HUMAN KERATINOCYTES; FACTOR-BETA; RIBOZYMES; INVASION; CANCER; INFLAMMATION; CHONDROCYTES	Squamous cell carcinomas (SCCs) of the head and neck are characterized by a high tendency for local invasion and metastasis to lymph nodes. Collagenase-3 (MMP-13) is specifically expressed by tumor cells in SCCs of the head and neck and its expression correlates with their invasion capacity. To specifically examine the role of MMP-13 in the growth and invasion of SCC, we constructed a hammerhead ribozyme targeted against human MMP-13 mRNA. The anti-MMP-13 ribozyme effectively cleaved MMP-13 transcripts in vitro. Adenoviral delivery of the anti-MMP-13 ribozyme to cutaneous metastatic SCC cells in culture resulted in potent and specific inhibition of the production of proMMP-13 and markedly suppressed invasion of SCC cells through Matrigel. In addition, adenoviral delivery of anti-MMP-13 ribozyme promoted apoptosis in SCC cells within 72 h. Intratumoral injection of anti-MMP-13 ribozyme coding adenovirus into human SCC xenografts established in SCID mice potently suppressed tumor growth, inhibited MMP-13 expression and gelatinolytic activity and reduced the number of proliferating cells within the tumors. These results provide evidence for an important role for MMP-13 in SCC growth and invasion and identify MMP-13 as a promising target for ribozyme-based therapy of SCC in vivo.	Univ Turku, Dept Med Biochem & Mol Biol, FIN-20520 Turku, Finland; Univ Turku, Dept Dermatol, FIN-20520 Turku, Finland; Univ Turku, Ctr Biotechnol, SF-20500 Turku, Finland; Bristol Royal Infirm & Gen Hosp, Bristol Heart Inst, Bristol BS2 8HW, Avon, England; Abo Akad Univ, Dept Biochem & Pharm, FIN-20520 Turku, Finland; Univ Turku, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, FIN-20520 Turku, Finland; Univ Turku, Cent Hosp, Dept Pathol, FIN-20520 Turku, Finland	University of Turku; University of Turku; University of Turku; Bristol Royal Infirmary; University of Bristol; Abo Akademi University; University of Turku; University of Turku	Kahari, VM (corresponding author), Univ Turku, Dept Med Biochem & Mol Biol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	veli-matti.kahari@utu.fi	Kahari, Veli-Matti/T-4925-2019; Kähäri, Veli-Matti/E-5144-2011	Kahari, Veli-Matti/0000-0003-2421-9368; Kähäri, Veli-Matti/0000-0003-2421-9368				Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292; Ahonen M, 2002, MOL THER, V5, P705, DOI 10.1006/mthe.2002.0606; Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; Ala-Aho R, 2002, INT J CANCER, V97, P283, DOI 10.1002/ijc.1619; Ala-Aho R, 2002, ONCOGENE, V21, P1187, DOI 10.1038/sj.onc.1205198; Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171; Bostrom PJ, 2000, INT J CANCER, V88, P417, DOI 10.1002/1097-0215(20001101)88:3<417::AID-IJC14>3.3.CO;2-7; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Cazorla M, 1998, J PATHOL, V186, P144, DOI 10.1002/(SICI)1096-9896(1998100)186:2<144::AID-PATH147>3.0.CO;2-#; Etoh T, 2000, GUT, V47, P50, DOI 10.1136/gut.47.1.50; Fernando FS, 2001, J MOL MED-JMM, V79, P695, DOI 10.1007/s001090100272; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; George SJ, 2000, CIRCULATION, V101, P296, DOI 10.1161/01.CIR.101.3.296; Hernandez YJ, 1999, J VIROL, V73, P8549, DOI 10.1128/JVI.73.10.8549-8558.1999; Hua J, 1996, CANCER RES, V56, P5279; Jarvis TC, 2000, J IMMUNOL, V165, P493, DOI 10.4049/jimmunol.165.1.493; Johansson N, 1999, AM J PATHOL, V154, P469, DOI 10.1016/S0002-9440(10)65293-5; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; Johansson N, 1997, CELL GROWTH DIFFER, V8, P243; Johansson N, 1997, AM J PATHOL, V151, P499; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, EUR J BIOCHEM, V248, P369, DOI 10.1111/j.1432-1033.1997.00369.x; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; Lewin AS, 2001, TRENDS MOL MED, V7, P221, DOI 10.1016/S1471-4914(01)01965-7; Lindy O, 1997, ARTHRITIS RHEUM-US, V40, P1391, DOI 10.1002/art.1780400806; Lu Y, 1998, DNA CELL BIOL, V17, P643, DOI 10.1089/dna.1998.17.643; Mao DL, 1999, BIOCHEM BIOPH RES CO, V261, P904, DOI 10.1006/bbrc.1999.1142; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nielsen BS, 2001, CANCER RES, V61, P7091; Nikkola J, 2001, MELANOMA RES, V11, P157, DOI 10.1097/00008390-200104000-00011; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Pavco PA, 2000, CLIN CANCER RES, V6, P2094; Ravanti L, 2001, FASEB J, V15, P1098, DOI 10.1096/fj.00-0588fje; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; Sukhova GK, 1999, CIRCULATION, V99, P2503, DOI 10.1161/01.CIR.99.19.2503; Uitto VJ, 1998, AM J PATHOL, V152, P1489; Uria JA, 1998, AM J PATHOL, V153, P91, DOI 10.1016/S0002-9440(10)65549-6; Usman N, 2000, J CLIN INVEST, V106, P1197, DOI 10.1172/JCI11631; Vaalamo M, 1998, AM J PATHOL, V152, P1005; Vaalamo M, 1997, J INVEST DERMATOL, V109, P96, DOI 10.1111/1523-1747.ep12276722; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233	51	63	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5111	5123		10.1038/sj.onc.1207678	http://dx.doi.org/10.1038/sj.onc.1207678			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15094779				2022-12-25	WOS:000222382500001
J	Fujioka, S; Schmidt, C; Sclabas, GM; Li, ZK; Pelicano, H; Peng, B; Yao, A; Niu, JG; Zhang, W; Evans, DB; Abbruzzese, JL; Huang, P; Chiao, PJ				Fujioka, S; Schmidt, C; Sclabas, GM; Li, ZK; Pelicano, H; Peng, B; Yao, A; Niu, JG; Zhang, W; Evans, DB; Abbruzzese, JL; Huang, P; Chiao, PJ			Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDE-INDUCED APOPTOSIS; HYDROGEN-PEROXIDE; TRANSCRIPTION FACTOR; MICE LACKING; FAS-LIGAND; CELL-DEATH; NUCLEAR TRANSLOCATION; LIVER DEGENERATION; OXIDATIVE STRESS; T-LYMPHOCYTES	Both pro- and antiapoptotic activities of NF-kappaB transcription factor have been observed; however, less is known about the mechanism by which NF-kappaB induces apoptosis. To elucidate how NF-kappaB regulates proapoptotic signaling, we performed functional analyses using wild-type, ikk1(-/-), ikk2(-/-), rela(-/-) murine fibroblasts, MDAPanc-28/Puro, MDAPanc-28/IkappaBalphaM, and HCT116/p53(+/+) and HCT116/p53(-/-) cells with investigational anticancer agent doxycycline as a superoxide inducer for generating apoptotic stimulus. In this report, we show that doxycycline increased superoxide generation and subsequently activated NF-kappaB, which in turn up-regulated p53 expression and increased the stability and DNA binding activity of p53. Consequently, NF-kappaB-dependent p53 activity induced the expression of p53-regulated genes PUMA and p21(waf1) as well as apoptosis. Importantly, lack of RelA, IKK, and p53 as well as expression of a dominant negative IkappaBalpha(IkappaBalphaM) inhibited NF-kappaB-dependent p53 activation and apoptosis. The doxycycline-induced NF-kappaB activation was not inhibited in HCT116/p53(+/+) cells. Our results demonstrate that NF-kappaB plays an essential role in activation of wild-type p53 tumor suppressor to initiate proapoptotic signaling in response to overgeneration of superoxide. Thus, these findings reveal a mechanism of NF-kappaB-regulated proapoptotic signaling.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 107, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Bern, Inselspital, CH-3010 Bern, Switzerland; Univ Texas, Hlth Sci Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Summer Student Program, Houston, TX 77030 USA; Univ Texas, Program Canc Biol, Grad Sch Biomed Sci, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Bern; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System	Chiao, PJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 107, 1515 Holcombe Blvd, Houston, TX 77030 USA.	pjchiao@mail.mdanderson.org		Schmidt, Christian/0000-0002-1260-9732	NCI NIH HHS [CA78778-01] Funding Source: Medline; PHS HHS [PA-98-029] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078778] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAMATSU H, 1992, ACTA DERM-VENEREOL, V72, P178; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Annunziata CM, 2000, BLOOD, V96, P2841; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berenson JR, 2001, SEMIN ONCOL, V28, P626, DOI 10.1053/sonc.2001.29542; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; Bonvin C, 2002, CELL SIGNAL, V14, P123, DOI 10.1016/S0898-6568(01)00219-4; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cammarano MS, 2001, J BIOL CHEM, V276, P25876, DOI 10.1074/jbc.M011345200; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; Cusack JC, 2001, CANCER RES, V61, P3535; de Erausquin GA, 2003, MOL PHARMACOL, V63, P784, DOI 10.1124/mol.63.4.784; Del Rio MJ, 2002, BIOCHEM PHARMACOL, V63, P677, DOI 10.1016/S0006-2952(01)00907-8; Demarchi F, 2001, J BIOL CHEM, V276, P31738, DOI 10.1074/jbc.M104457200; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; Duivenvoorden WCM, 2002, CANCER RES, V62, P1588; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fife RS, 1998, CANCER LETT, V127, P37, DOI 10.1016/S0304-3835(98)00003-2; Frazier ML, 1996, INT J PANCREATOL, V19, P31, DOI 10.1007/BF02788373; FRITSCHE M, 1993, ONCOGENE, V8, P307; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GILBERTSONBEADLING S, 1995, CANCER CHEMOTH PHARM, V36, P418, DOI 10.1007/BF00686191; Han SS, 1999, CLIN IMMUNOL, V93, P152, DOI 10.1006/clim.1999.4769; HARPER JW, 1993, CELL, V75, P805; Haudek SB, 2001, J MOL CELL CARDIOL, V33, P1263, DOI 10.1006/jmcc.2001.1388; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; Jabbur JR, 2000, ONCOGENE, V19, P6203, DOI 10.1038/sj.onc.1204017; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Jones BE, 2000, AM J PHYSIOL-GASTR L, V278, pG693, DOI 10.1152/ajpgi.2000.278.5.G693; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Khoshnan A, 2000, J IMMUNOL, V165, P1743, DOI 10.4049/jimmunol.165.4.1743; Kitamura Y, 1999, GLIA, V25, P154, DOI 10.1002/(SICI)1098-1136(19990115)25:2<154::AID-GLIA6>3.0.CO;2-S; KROON AM, 1985, BIOCHEM BIOPH RES CO, V128, P1190, DOI 10.1016/0006-291X(85)91066-6; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Li QT, 2000, GENE DEV, V14, P1729; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Lin BH, 1999, CELL DEATH DIFFER, V6, P570, DOI 10.1038/sj.cdd.4400528; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; Lokeshwar BL, 2002, INT J CANCER, V98, P297, DOI 10.1002/ijc.10168; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Matsui K, 1998, J IMMUNOL, V161, P3469; McInnis J, 2002, J PHARMACOL EXP THER, V301, P478, DOI 10.1124/jpet.301.2.478; Mitani K, 2001, Nihon Rinsho, V59, P2316; Nakai M, 2000, J NEUROCHEM, V74, P647, DOI 10.1046/j.1471-4159.2000.740647.x; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Prives C, 1999, J PATHOL, V187, P112; Qin ZH, 1999, J NEUROSCI, V19, P4023; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; VAN AD, 1996, SCIENCE, V274, P787; VANDENBOGERT C, 1981, CANCER RES, V41, P1943; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang WX, 1999, CLIN CANCER RES, V5, P119; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Yang CR, 2000, FASEB J, V14, P379, DOI 10.1096/fasebj.14.2.379; Yeh PY, 2002, BIOCHEM PHARMACOL, V63, P1423, DOI 10.1016/S0006-2952(02)00908-5; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	80	111	117	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27549	27559		10.1074/jbc.M313435200	http://dx.doi.org/10.1074/jbc.M313435200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102862	hybrid			2022-12-25	WOS:000222120400088
J	Fujii, K; Goldman, EH; Park, HR; Zhang, LX; Chen, J; Fu, HA				Fujii, K; Goldman, EH; Park, HR; Zhang, LX; Chen, J; Fu, HA			Negative control of apoptosis signal-regulating kinase 1 through phosphorylation of Ser-1034	ONCOGENE			English	Article						ASK1; apoptosis; phosphorylation; 14-3-3; kinase; survival signaling	ACTIVATED PROTEIN-KINASE; CELL-DEATH; 1 ASK1; PATHWAYS; STRESS; DISSOCIATION; THIOREDOXIN; INHIBITOR; SURVIVAL; LIFE	Apoptosis signal-regulating kinase 1 (ASK1) is a serine/threonine kinase that mediates cell stress signaling initiated by diverse stimuli, such as H2O2 and TNFalpha. Owing to its critical role in promoting apoptosis, ASK1 activity is highly controlled in cells. Phosphorylation of ASK1 at Thr-845 has been correlated with its activation, while phosphorylation at Ser-967 negatively controls its death promoting activity. Here, we report the identification of a novel phosphorylation site at Ser-1034 in the C-terminal regulatory domain of ASK1. Mutating Ser-1034 to an unphosphorylatable Ala led to increased catalytic activity of ASK1 and enhanced proapoptotic function of ASK1. Thus, the proapoptotic function of ASK1 is suppressed in part by phosphorylation at its C-terminal regulatory domain, which may couple upstream survival kinases to the death regulatory machinery.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Mol & Syst Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Fu, HA (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA.	hfu@emory.edu		Park, Hae Ryoun/0000-0003-1908-0824; Zhang, Lixin/0000-0003-0894-9520	NIGMS NIH HHS [GM60033, GM53165] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053165, R01GM053165, R01GM060033] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zou XH, 2001, MOL CELL BIOL, V21, P4818, DOI 10.1128/MCB.21.14.4818-4828.2001	28	37	40	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5099	5104		10.1038/sj.onc.1207668	http://dx.doi.org/10.1038/sj.onc.1207668			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15094778				2022-12-25	WOS:000222237300018
J	Gkika, D; Mahieu, F; Nilius, B; Hoenderop, JGJ; Bindels, RJM				Gkika, D; Mahieu, F; Nilius, B; Hoenderop, JGJ; Bindels, RJM			80K-H as a new Ca2+ sensor regulating the activity of the epithelial Ca2+ channel transient receptor potential cation channel V5 (TRPV5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-3-1-ALPHA-HYDROXYLASE KNOCKOUT MICE; PROTEIN-KINASE-C; ENDOPLASMIC-RETICULUM; GLUCOSIDASE-II; CALCIUM-ABSORPTION; DIETARY CA2+; IDENTIFICATION; EXPRESSION; CELLS; INACTIVATION	The epithelial Ca2+ channel transient receptor potential cation channel V5 (TRPV5) constitutes the apical Ca2+ entry pathway in the process of active Ca2+ reabsorption. Ca2+ influx through TRPV5 is tightly controlled by modulators of Ca2+ homeostasis, including 1,25-dihydroxyvitamin D-3 and dietary Ca2+. However, little is known about intracellular proteins that interact with TRPV5 and directly regulate the activation of this channel. By the use of cDNA microarrays, the present study identified 80K-H as the first protein involved in the Ca2+-dependent control of the epithelial Ca2+ channel TRPV5. 80K-H was initially identified as a protein kinase C substrate, but its biological function remains to be established. We demonstrated a specific interaction between 80K-H and TRPV5, co-localization of both proteins in the kidney, and similar transcriptional regulation by 1,25-dihydroxyvitamin D3 and dietary Ca2+. Furthermore, 80K-H directly bound Ca2+, and inactivation of its two EF-hand structures totally abolished Ca2+ binding. Electrophysiological studies using 80K-H mutants showed that three domains of 80K-H (the two EF-hand structures, the highly acidic glutamic stretch, and the His-Asp-Glu-Leu sequence) are critical determinants for TRPV5 activity. Importantly, inactivation of the EF-hand pair reduced the TRPV5-mediated Ca2+ current and increased the TRPV5 sensitivity to intracellular Ca2+, accelerating the feedback inhibition of the channel. None of the 80K-H mutants altered the TRPV5 plasma membrane localization nor the association of 80K-H with TRPV5, suggesting that 80K-H has a direct effect on TRPV5 activity. In conclusion, we report a novel function for 80K-H as a Ca2+ sensor controlling TRPV5 channel activity.	Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Physiol, NL-6500 HB Nijmegen, Netherlands; Katholieke Univ Leuven, Dept Physiol, B-3000 Louvain, Belgium	Radboud University Nijmegen; KU Leuven	Bindels, RJM (corresponding author), Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Physiol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	r.bindels@ncmls.kun.nl	Gkika, Dimitra/S-3054-2019; Bindels, René JM/B-9824-2013; Hoenderop, Joost G.J./H-8047-2014	Gkika, Dimitra/0000-0001-8612-0836; Bindels, René JM/0000-0003-1167-1339; Hoenderop, Joost G.J./0000-0002-1816-8544				Arendt CW, 1997, J BIOL CHEM, V272, P13117, DOI 10.1074/jbc.272.20.13117; BAKSH S, 1991, J BIOL CHEM, V266, P21458; Brule S, 2000, BIOL REPROD, V62, P642, DOI 10.1095/biolreprod62.3.642; Budde T, 2002, NAT REV NEUROSCI, V3, P873, DOI 10.1038/nrn959; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Dardenne O, 2001, ENDOCRINOLOGY, V142, P3135, DOI 10.1210/en.142.7.3135; de Jong JC, 2003, J BIOL CHEM, V278, P24302, DOI 10.1074/jbc.M303101200; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; HIRAI M, 1990, BIOCHEM J, V270, P583, DOI 10.1042/bj2700583; Hoenderop JGJ, 2000, J AM SOC NEPHROL, V11, P1171, DOI 10.1681/ASN.V1171171; Hoenderop JGJ, 2004, KIDNEY INT, V65, P531, DOI 10.1111/j.1523-1755.2004.00402.x; Hoenderop JGJ, 2003, J CLIN INVEST, V112, P1906, DOI 10.1172/JCI200319826; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Hoenderop JGJ, 2002, FASEB J, V16, P1398, DOI 10.1096/fj.02-0225com; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hoenderop JGJ, 1999, BIOCHEM BIOPH RES CO, V261, P488, DOI 10.1006/bbrc.1999.1059; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Lee A, 2000, J NEUROSCI, V20, P6830, DOI 10.1523/JNEUROSCI.20-18-06830.2000; Li YM, 1996, P NATL ACAD SCI USA, V93, P11047, DOI 10.1073/pnas.93.20.11047; Loffing J, 2001, AM J PHYSIOL-RENAL, V281, pF1021, DOI 10.1152/ajprenal.0085.2001; Madsen O, 2002, MOL BIOL EVOL, V19, P2150, DOI 10.1093/oxfordjournals.molbev.a004040; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Nijenhuis T, 2003, J AM SOC NEPHROL, V14, P2731, DOI 10.1097/01.ASN.0000094081.78893.E8; Nilius B, 2001, CELL CALCIUM, V29, P417, DOI 10.1054/ceca.2001.0201; Pagny S, 2000, PLANT CELL, V12, P739, DOI 10.1105/tpc.12.5.739; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Poirier O, 2001, DIABETES, V50, P1214, DOI 10.2337/diabetes.50.5.1214; Scott K, 1997, CELL, V91, P375, DOI 10.1016/S0092-8674(00)80421-3; Small KM, 2001, J BIOL CHEM, V276, P4917, DOI 10.1074/jbc.M008118200; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; Trouet D, 1997, PFLUG ARCH EUR J PHY, V434, P632, DOI 10.1007/s004240050445; Van Abel M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000022423.34922.2A; Van Cromphaut SJ, 2001, P NATL ACAD SCI USA, V98, P13324, DOI 10.1073/pnas.231474698; Van de Graaf SFJ, 2003, EMBO J, V22, P1478, DOI 10.1093/emboj/cdg162; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963	40	58	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26351	26357		10.1074/jbc.M403801200	http://dx.doi.org/10.1074/jbc.M403801200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15100231	hybrid, Green Published			2022-12-25	WOS:000222003000055
J	Malan, D; Ji, GJ; Schmidt, A; Addicks, K; Hescheler, J; Levi, RC; Bloch, W; Fleischmann, BK				Malan, D; Ji, GJ; Schmidt, A; Addicks, K; Hescheler, J; Levi, RC; Bloch, W; Fleischmann, BK			Nitric oxide, a key signaling molecule in the murine early embryonic heart	FASEB JOURNAL			English	Article						muscarinic signaling; regulation of I-Ca; embryonic development; ventricular cardiomyocytes	DEPENDENT PROTEIN-KINASE; BETA-ADRENERGIC MODULATION; PIG VENTRICULAR MYOCYTES; CALCIUM CURRENT; CA2+ CURRENT; MICE LACKING; CARDIAC MYOCYTES; CHOLINERGIC MODULATION; GUANYLATE-CYCLASE; CYCLIC-AMP	Nitric oxide ( NO) is thought to play an important role as a signaling molecule in embryonic and adult cardiomyocytes; however, its involvement in muscarinic signaling is still unclear. The aim of the present work was to analyze the muscarinic modulation of the L-type Ca2+ current (I-Ca) in early- and late-stage embryonic ventricular cardiomyocytes. Muscarinic stimulation depressed basal I-Ca by 30.1 +/- 3.2% (n = 27) in early-stage cardiomyocytes. Pharmacological evidence suggested that the muscarinic modulation was mediated through generation of NO, activation of cGMP-dependent phosphodiesterase (PDE) 2, and ensuing lowering of cyclic AMP/protein kinase A (cAMP/PKA) levels. Conversely, in late-stage cardiomyocytes, muscarinic regulation of I-Ca occurred in a NO-independent manner via inhibition of prestimulated adenylyl cyclase (AC). To unequivocally prove the involvement of NO and to identify the nitric oxide synthase (NOS) isoform(s), we analyzed muscarinic signaling in embryonic ventricular cardiomyocytes of NOS2 (-/-) and NOS3 (-/-) mice. The early- stage NOS3 (-/-) cardiomyocytes lacked muscarinic modulation, whereas it was preserved in NOS2 (-/-) cells. Moreover, at the late embryonic stage, muscarinic modulation of ICa was intact in both strains. Thus, NO is the key regulator of muscarinic signaling in the early embryonic ventricle, whereas at later stages, signaling occurs through a NO-independent pathway.	Univ Bonn, Inst Physiol 1, D-53115 Bonn, Germany; Univ Turin, INFM, Dept Anim & Human Biol, I-10124 Turin, Italy; Univ Cologne, Inst Neurophysiol, D-5000 Cologne, Germany; Univ Cologne, Inst Anat, D-5000 Cologne 41, Germany; German Sport Univ Cologne, Dept Mol & Cellular Sport Med, Cologne, Germany	University of Bonn; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Turin; University of Cologne; University of Cologne; German Sport University Cologne	Fleischmann, BK (corresponding author), Univ Bonn, Inst Physiol 1, Argelanderstr 2A, D-53115 Bonn, Germany.	bernd.fleischmann@uni-bonn.de						Abi-Gerges N, 2001, J PHYSIOL-LONDON, V531, P117, DOI 10.1111/j.1469-7793.2001.0117j.x; An RH, 1996, CIRC RES, V78, P371, DOI 10.1161/01.RES.78.3.371; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; Bett GCL, 2002, J PHYSIOL-LONDON, V542, P107, DOI 10.1113/jphysiol.2002.017335; Bloch W, 2001, J CELL BIOL, V154, P753, DOI 10.1083/jcb.200103011; Bloch W, 1999, CARDIOVASC RES, V43, P675, DOI 10.1016/S0008-6363(99)00160-1; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; FISCHMEISTER R, 1991, LIFE SCI, V48, P2365, DOI 10.1016/0024-3205(91)90369-M; Fleischmann M, 1998, FEBS LETT, V440, P370, DOI 10.1016/S0014-5793(98)01476-8; Godecke A, 2001, J PHYSIOL-LONDON, V532, P195, DOI 10.1111/j.1469-7793.2001.0195g.x; HAN X, 1994, J PHYSIOL-LONDON, V476, P309, DOI 10.1113/jphysiol.1994.sp020132; Han X, 1996, CIRC RES, V78, P998, DOI 10.1161/01.RES.78.6.998; Han XQ, 1998, P NATL ACAD SCI USA, V95, P6510, DOI 10.1073/pnas.95.11.6510; Hare JM, 1999, NAT MED, V5, P273, DOI 10.1038/6486; Herr C, 2001, MOL CELL BIOL, V21, P4119, DOI 10.1128/MCB.21.13.4119-4128.2001; Hescheler J, 1997, CARDIOVASC RES, V36, P149, DOI 10.1016/S0008-6363(97)00193-4; Hu H, 1997, CIRC RES, V81, P742; Ji GJ, 1999, FASEB J, V13, P313, DOI 10.1096/fasebj.13.2.313; Jiang LH, 2000, J BIOL CHEM, V275, P6135, DOI 10.1074/jbc.275.9.6135; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; KO FN, 1994, BLOOD, V84, P4226, DOI 10.1182/blood.V84.12.4226.bloodjournal84124226; Kojda G, 1999, CARDIOVASC RES, V42, P206, DOI 10.1016/S0008-6363(98)00315-0; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Lacampagne A, 1995, CARDIOVASC RES, V30, P799, DOI 10.1016/0008-6363(95)00128-X; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Liu LM, 1999, CELL DEATH DIFFER, V6, P937, DOI 10.1038/sj.cdd.4400578; Malan D, 2003, J CELL PHYSIOL, V197, P284, DOI 10.1002/jcp.10368; Maltsev VA, 1999, CIRC RES, V84, P136, DOI 10.1161/01.RES.84.2.136; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; Mery PF, 1997, LIFE SCI, V60, P1113, DOI 10.1016/S0024-3205(97)00055-6; Nagashima M, 2001, J MOL CELL CARDIOL, V33, P533, DOI 10.1006/jmcc.2000.1327; Poteser M, 2001, J BIOL CHEM, V276, P14797, DOI 10.1074/jbc.M008244200; Rassaf T, 2002, FREE RADICAL BIO MED, V33, P1590, DOI 10.1016/S0891-5849(02)01183-8; Rosemblit N, 1999, DEV BIOL, V206, P163, DOI 10.1006/dbio.1998.9120; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Stamler JS, 2001, PHYSIOL REV, V81, P209, DOI 10.1152/physrev.2001.81.1.209; Vandecasteele G, 1999, NAT MED, V5, P331, DOI 10.1038/6553; Vandecasteele G, 2001, J PHYSIOL-LONDON, V533, P329, DOI 10.1111/j.1469-7793.2001.0329a.x; Wang YG, 2000, CARDIOVASC RES, V48, P310, DOI 10.1016/S0008-6363(00)00178-4; Zakharov SI, 1996, CIRC RES, V78, P925, DOI 10.1161/01.RES.78.5.925	41	20	20	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2004	18	7					1108	+		10.1096/fj.03-1158fje	http://dx.doi.org/10.1096/fj.03-1158fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132985				2022-12-25	WOS:000221883200020
J	Popova, JS; Rasenick, MM				Popova, JS; Rasenick, MM			Clathrin-mediated endocytosis of m(3) muscarinic receptors - Roles for G beta gamma and tubulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARRESTIN-INDEPENDENT INTERNALIZATION; SH-SY5Y NEUROBLASTOMA-CELLS; ACETYLCHOLINE-RECEPTORS; HORMONE RECEPTOR; PLASMA-MEMBRANE; BETA(2)-ADRENERGIC RECEPTOR; CHOLINERGIC-RECEPTORS; COATED VESICLES; G-PROTEINS; DYNAMIN	Receptors as well as some G protein subunits internalize after agonist stimulation. It is not clear whether Galpha(q) or Gbetagamma undergo such regulated translocation. Recent studies demonstrate that m(3) muscarinic receptor activation in SK-N-SH neuroblastoma cells causes recruitment of tubulin to the plasma membrane. This subsequently transactivates Galpha(q) and activates phospholipase Cbeta(1). Interaction of tubulin-GDP with Gbetagamma at the offset of phospholipase Cbeta(1) signaling appears involved in translocation of tubulin and Gbetagamma to vesicle-like structures in the cytosol (Popova, J. S., and Rasenick, M. M. ( 2003) J. Biol. Chem. 278, 34299-34308). The relationship of this internalization to the clathrin-mediated endocytosis of the activated m(3) muscarinic receptors or Galpha(q) involvement in this process has not been clarified. To test this, SK-N-SH cells were treated with carbachol, and localization of Galpha(q), Gbetagamma, tubulin, clathrin, and m(3) receptors were analyzed by both cellular imaging and biochemical techniques. Upon agonist stimulation both tubulin and clathrin translocated to the plasma membrane and colocalized with receptors, Galpha(q) and Gbetagamma. Fifteen minutes later receptors, Gbetagamma and tubulin, but not Galpha(q), internalized with the clathrin-coated vesicles. Coimmunoprecipitation of m(3) receptors with Gbetagamma, tubulin, and clathrin from the cytosol of carbachol-treated cells was readily observed. These data suggested that Gbetagamma subunits might organize the formation of a multiprotein complex linking m3 receptors to tubulin since they interacted with both proteins. Such protein assemblies might explain the dynamin-dependent but beta-arrestin-independent endocytosis of m3 muscarinic receptors since tubulin interaction with dynamin might guide or insert the complex into clathrin-coated pits. This novel mechanism of internalization might prove important for other beta-arrestin-independent endocytic pathways. It also suggests cross-regulation between G protein-mediated signaling and the dynamics of the microtubule cytoskeleton.	Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Psychiat, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Popova, JS (corresponding author), Univ Illinois, Coll Med, Dept Physiol & Biophys, 835 S Wolcott Ave,M-C 901, Chicago, IL 60612 USA.	jsp@uic.edu			NIA NIH HHS [AG 15482] Funding Source: Medline; NIMH NIH HHS [MH 39595] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015482] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beattie EC, 2000, J NEUROSCI, V20, P7325; Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Dale LB, 2001, MOL PHARMACOL, V60, P1243, DOI 10.1124/mol.60.6.1243; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; Delaney KA, 2002, J BIOL CHEM, V277, P33439, DOI 10.1074/jbc.M205293200; Edwardson JM, 1999, LIFE SCI, V64, P487, DOI 10.1016/S0024-3205(98)00592-X; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Fishburn CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/jbc.274.26.18793; Fraile-Ramos A, 2003, TRAFFIC, V4, P243, DOI 10.1034/j.1600-0854.2003.00079.x; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Haga K, 1996, J BIOL CHEM, V271, P2776, DOI 10.1074/jbc.271.5.2776; Heding A, 2000, ENDOCRINOLOGY, V141, P299, DOI 10.1210/en.141.1.299; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hughes TE, 2001, J BIOL CHEM, V276, P4227, DOI 10.1074/jbc.M007608200; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; Lin HC, 1998, P NATL ACAD SCI USA, V95, P5057, DOI 10.1073/pnas.95.9.5057; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; Milano SK, 2002, BIOCHEMISTRY-US, V41, P3321, DOI 10.1021/bi015905j; MORO O, 1993, J BIOL CHEM, V268, P6862; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Popova JS, 1997, J BIOL CHEM, V272, P6760, DOI 10.1074/jbc.272.10.6760; Popova JS, 2000, J NEUROSCI, V20, P2774; Popova JS, 2003, J BIOL CHEM, V278, P34299, DOI 10.1074/jbc.M301748200; Popova JS, 2002, J NEUROSCI, V22, P1668, DOI 10.1523/JNEUROSCI.22-05-01668.2002; POPOVA JS, 1994, J BIOL CHEM, V269, P21748; Prasad SVN, 2001, J BIOL CHEM, V276, P18953, DOI 10.1074/jbc.M102376200; Razzini G, 2000, J BIOL CHEM, V275, P14873, DOI 10.1074/jbc.275.20.14873; Rondard P, 2001, P NATL ACAD SCI USA, V98, P6150, DOI 10.1073/pnas.101136198; ROYCHOWDHURY S, 1994, BIOCHEMISTRY-US, V33, P9800, DOI 10.1021/bi00198a052; Roychowdhury S, 1999, J BIOL CHEM, V274, P13485, DOI 10.1074/jbc.274.19.13485; Roychowdhury S, 1997, J BIOL CHEM, V272, P31576, DOI 10.1074/jbc.272.50.31576; Sarma T, 2003, FASEB J, V17, P848, DOI 10.1096/fj.02-0730com; Sever S, 2002, CURR OPIN CELL BIOL, V14, P463, DOI 10.1016/S0955-0674(02)00347-2; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Shiina T, 2001, J BIOL CHEM, V276, P33019, DOI 10.1074/jbc.M100140200; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SILVA WI, 1986, J BIOL CHEM, V261, P4788; Slowiejko DM, 1996, J NEUROCHEM, V66, P186; Sneddon WB, 2003, J BIOL CHEM, V278, P43787, DOI 10.1074/jbc.M306019200; Sorensen SD, 1999, EUR J PHARMACOL, V372, P325, DOI 10.1016/S0014-2999(99)00234-4; Sorensen SD, 1999, J PHARMACOL EXP THER, V290, P603; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; Vrecl M, 1998, MOL ENDOCRINOL, V12, P1818, DOI 10.1210/me.12.12.1818; WANG N, 1990, J BIOL CHEM, V265, P1239; Willets JM, 2002, J BIOL CHEM, V277, P15523, DOI 10.1074/jbc.M111217200; Willets JM, 2001, MOL PHARMACOL, V60, P321, DOI 10.1124/mol.60.2.321; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026	56	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30410	30418		10.1074/jbc.M402871200	http://dx.doi.org/10.1074/jbc.M402871200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15117940	hybrid			2022-12-25	WOS:000222531900067
J	Song, JJ; Lee, YJ				Song, JJ; Lee, YJ			Tryptophan 621 and serine 667 residues of Daxx regulate its nuclear export during glucose deprivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN DAXX; TRANSCRIPTIONAL REPRESSION; INDUCED APOPTOSIS; SIGNAL; CRM1; PHOSPHORYLATION; BINDING; ACTIVATION; PML; IDENTIFICATION	The cellular target responsible for the nuclear export of Daxx has been identified as chromosomal region maintenance 1 (CRM1), which is a carrier protein for nuclear export and a receptor for the nuclear export signal (NES) of Daxx. Binding of Daxx to CRM1 was increased early during glucose deprivation and then gradually decreased. This interaction was inhibited by leptomycin B, a specific inhibitor of CRM1-dependent nuclear export. Substitution of the serine 667 amino acid residue of Daxx with alanine reduced the interaction with CRM1 during glucose deprivation, suggesting that the phosphorylation of Ser-667 is required for its binding to CRM1 and for its subsequent nuclear export. Data from coupled transcription-translation studies reveal that the NES (amino acids 565-575) of Daxx is a binding site for CRM1. Interestingly, constitutive export of Daxx has occurred by replacement of the tryptophan 621 Daxx residue with alanine. These results suggest that this tryptophan residue plays a key role in masking the NES of Daxx from its receptor, CRM1, in the resting state, whereas phosphorylation of serine 667 would release the NES, which could then be recognized by the CRM1.	Univ Pittsburgh, Hillman Canc Ctr, Dept Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lee, YJ (corresponding author), Univ Pittsburgh, Hillman Canc Ctr, Dept Surg, 5117 Ctr Ave,Room G-5A, Pittsburgh, PA 15213 USA.	leeyj@msx.upmc.edu		Song, Jae/0000-0001-8183-9550	NCI NIH HHS [CA95191, CA96989, CA48000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095191, R01CA048000, R01CA096989] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Emelyanov AV, 2002, J BIOL CHEM, V277, P11156, DOI 10.1074/jbc.M111763200; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; FISHER U, 1995, CELL, V82, P475; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fridell RA, 1996, P NATL ACAD SCI USA, V93, P2936, DOI 10.1073/pnas.93.7.2936; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Lin DY, 2002, J BIOL CHEM, V277, P25446, DOI 10.1074/jbc.M200633200; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631	27	32	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30573	30578		10.1074/jbc.M404512200	http://dx.doi.org/10.1074/jbc.M404512200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15128734	hybrid			2022-12-25	WOS:000222531900087
J	Peschard, P; Ishiyama, N; Lin, T; Lipkowitz, S; Park, M				Peschard, P; Ishiyama, N; Lin, T; Lipkowitz, S; Park, M			A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CBL; PROTEIN; PHOSPHORYLATION; ZAP-70; REGION; CELLS; AUTOINHIBITION; TRANSMEMBRANE; DEGRADATION; HOMOLOGY	The activation and phosphorylation of Met, the receptor tyrosine kinase (RTK) for hepatocyte growth factor, initiates the recruitment of multiple signaling proteins, one of which is c-Cbl, a ubiquitin-protein ligase. c-Cbl promotes ubiquitination and enhances the down-modulation of the Met receptor and other RTKs, targeting them for lysosomal sorting and subsequent degradation. The ubiquitination of Met by c-Cbl requires the direct interaction of the c-Cbl tyrosine kinase binding (TKB) domain with tyrosine 1003 in the Met juxtamembrane domain. Although a consensus for c-Cbl TKB domain binding has been established ((D/N)XpYXX(D/E0Phi), this motif is not present in Met, suggesting that other c-Cbl TKB domain binding motifs may exist. By alanine-scanning mutagenesis, we have identified a DpYR motif including Tyr(1003) as being important for the direct recruitment of the c-Cbl TKB domain and for ubiquitination of the Met receptor. The substitution of Tyr(1003) with phenylalanine or substitution of either aspartate or arginine residues with alanine impairs c-Cbl-recruitment and ubiquitination of Met and results in the oncogenic activation of the Met receptor. We demonstrate that the TKB domain of Cbl-b, but not Cbl-3, binds to the Met receptor and requires an intact DpYR motif. Modeling studies suggest the presence of a salt bridge between the aspartate and arginine residues that would position pTyr(1003) for binding to the c-Cbl TKB domain. The DpYR motif is conserved in other members of the Met RTK family but is not present in previously identified c-Cbl-binding proteins, identifying DpYR as a new binding motif for c-Cbl and Cbl-b.	McGill Univ, Ctr Hlth, Mol Oncol Grp, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 1A1, Canada; NCI, Cellular & Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	McGill University; McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Park, M (corresponding author), McGill Univ, Ctr Hlth, Mol Oncol Grp, Dept Biochem, Montreal, PQ H3A 1A1, Canada.	morag.park@mcgill.ca		Peschard, Pascal/0000-0001-6395-5566	NATIONAL CANCER INSTITUTE [Z01SC007263, ZIASC007263] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Binns KL, 2000, MOL CELL BIOL, V20, P4791, DOI 10.1128/MCB.20.13.4791-4805.2000; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; Chang PM, 2003, MOL CELL BIOL, V23, P3067, DOI 10.1128/MCB.23.9.3067-3078.2003; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; Fenn TD, 2003, J APPL CRYSTALLOGR, V36, P944, DOI 10.1107/S0021889803006721; Fournier TM, 2000, MOL BIOL CELL, V11, P3397, DOI 10.1091/mbc.11.10.3397; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Kim M, 1999, GENE, V239, P145, DOI 10.1016/S0378-1119(99)00356-X; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nollau P, 2001, P NATL ACAD SCI USA, V98, P13531, DOI 10.1073/pnas.241215998; Penengo L, 2003, ONCOGENE, V22, P3669, DOI 10.1038/sj.onc.1206585; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Shen Y, 2000, CELL, V103, P501, DOI 10.1016/S0092-8674(00)00141-0; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359	43	91	96	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29565	29571		10.1074/jbc.M403954200	http://dx.doi.org/10.1074/jbc.M403954200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123609	Green Submitted, hybrid			2022-12-25	WOS:000222445300091
J	Francois, M; Richette, P; Tsagris, L; Raymondjean, M; Fulchignoni-Lataud, MC; Forest, C; Savouret, JF; Corvol, MT				Francois, M; Richette, P; Tsagris, L; Raymondjean, M; Fulchignoni-Lataud, MC; Forest, C; Savouret, JF; Corvol, MT			Peroxisome proliferator-activated receptor-gamma down-regulates chondrocyte matrix metalloproteinase-1 via a novel composite element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INDUCED MATRIX-METALLOPROTEINASE-9 EXPRESSION; COLLAGENASE GENE-EXPRESSION; TUMOR-NECROSIS-FACTOR; PPAR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); 2-CYANO-3,12-DIOXOOLEANA-1,9-DIEN-28-OIC ACID; SYNOVIAL FIBROBLASTS; SIGNALING PATHWAY; INDUCED ARTHRITIS	Interleukin-1beta (IL-1beta) induces degradation via hyper-expression of an array of genes, including metalloproteinases (MMP), in cartilage cells during articular degenerative diseases. In contrast, natural ligands for peroxisome proliferator-activated receptors (PPARs) display protective anti-cytokine effects in these cells. We used the PPAR agonist rosiglitazone (Rtz) to investigate PPAR-gamma isotype on IL-1beta-target genes. Immunocytochemistry, electrophoretic mobility shift, and transient transfection assays revealed a functional PPAR-gamma in chondrocytes in vitro. Rtz displayed significant inhibition of IL-1beta effects in chondrocytes. Low Rtz concentrations (close to K-d values for PPAR-gamma, 0.1 to 1 muM) inhibited the effects of IL-1beta on S-35-sulfated proteoglycan production and gelatinolytic activities and downregulated MMP1 expression at mRNA and protein levels. We have investigated the mechanism of action of Rtz against IL-1beta-mediated MMP1 gene hyperexpression. Rtz effect occurs at the transcriptional level of the MMP1 promoter, as observed in transiently transfected cells with pMMP1-luciferase vector. Transient expression of wild type PPAR-gamma enhanced Rtz inhibitory effect in chondrocytes, whereas a mutated dominant negative PPAR-gamma abolished it, supporting the role of PPAR-gamma in this effect. MMP1 gene promoter analysis revealed the involvement of a cis-acting element located at -83 to -77, shown to be a composite PPRE/AP1 site. Gel mobility and supershift assays demonstrated that PPAR-gamma and c-Fos/c-Jun proteins bind this cis-acting element in a mutually exclusive way. Our data highlight a new PPAR-gamma-dependent inhibitory mechanism on IL-1beta-mediated cartilage degradation occurring through DNA binding competition on the composite PPRE/AP1 site in the MMP1 promoter.	Univ Paris 05, UFR Biomed, INSERM, UMRS 530, F-75006 Paris, France; CNRS, UMR 7079, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	Corvol, MT (corresponding author), Univ Paris 05, UFR Biomed, INSERM, UMRS 530, 45 Rue St Peres, F-75006 Paris, France.	maite.corvol@univ-paris5.fr	francois, mathias/A-9604-2014	francois, mathias/0000-0002-9846-6882; Forest, Claude/0000-0003-3401-8148				Boyault S, 2001, FEBS LETT, V501, P24, DOI 10.1016/S0014-5793(01)02614-X; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; CHAMBERLAIN SH, 1993, J CELL BIOCHEM, V52, P337, DOI 10.1002/jcb.240520310; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chung SW, 2000, J BIOL CHEM, V275, P32681, DOI 10.1074/jbc.M002577200; COOPER WO, 1992, CLIN EXP IMMUNOL, V89, P244; CORVOL MT, 1975, BIOMED EXPRESS, V23, P103; CORVOL MT, 1987, ENDOCRINOLOGY, V120, P1422, DOI 10.1210/endo-120-4-1422; Daynes RA, 2002, NAT REV IMMUNOL, V2, P748, DOI 10.1038/nri912; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Eberhardt W, 2002, J BIOL CHEM, V277, P33518, DOI 10.1074/jbc.M202008200; Fahmi H, 2002, OSTEOARTHR CARTILAGE, V10, P100, DOI 10.1053/joca.2001.0485; Fahmi H, 2001, ARTHRITIS RHEUM, V44, P595, DOI 10.1002/1529-0131(200103)44:3<595::AID-ANR108>3.3.CO;2-#; Fleenor DL, 2003, INVEST OPHTH VIS SCI, V44, P3494, DOI 10.1167/iovs.02-0757; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Haffner SM, 2002, CIRCULATION, V106, P679, DOI 10.1161/01.CIR.0000025403.20953.23; Hamid QA, 2000, CYTOKINE, V12, P1609, DOI 10.1006/cyto.2000.0676; HENDERSON B, 1989, CLIN EXP IMMUNOL, V75, P306; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; Hetzel M, 2003, THORAX, V58, P778, DOI 10.1136/thorax.58.9.778; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Lapillonne H, 2003, CANCER RES, V63, P5926; LARSSON SE, 1974, CALC TISS RES, V14, P49, DOI 10.1007/BF02060282; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; Marx N, 2000, J IMMUNOL, V164, P6503, DOI 10.4049/jimmunol.164.12.6503; Mix KS, 2004, MOL PHARMACOL, V65, P309, DOI 10.1124/mol.65.2.309; Moon SK, 2004, J CELL PHYSIOL, V198, P417, DOI 10.1002/jcp.10435; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; Perez-Sala D, 2003, J BIOL CHEM, V278, P51251, DOI 10.1074/jbc.M309409200; Pritts EA, 2003, FERTIL STERIL, V80, P415, DOI 10.1016/S0015-0282(03)00600-9; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Riquet FB, 2001, J BIOL CHEM, V276, P38665, DOI 10.1074/jbc.M009881200; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Sabatini M, 2002, OSTEOARTHR CARTILAGE, V10, P673, DOI 10.1053/joca.2002.0827; Shu H, 2000, BIOCHEM BIOPH RES CO, V267, P345, DOI 10.1006/bbrc.1999.1968; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; Vincenti MP, 1998, ARTHRITIS RHEUM, V41, P1987, DOI 10.1002/1529-0131(199811)41:11<1987::AID-ART14>3.3.CO;2-#; White LA, 1995, MATRIX BIOL, V14, P715, DOI 10.1016/S0945-053X(05)80014-9; Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341; Worley JR, 2003, J BIOL CHEM, V278, P51340, DOI 10.1074/jbc.M310865200; Yamasaki S, 2002, CLIN EXP IMMUNOL, V129, P379, DOI 10.1046/j.1365-2249.2002.01876.x; Yee J, 1997, KIDNEY INT, V52, P120, DOI 10.1038/ki.1997.311	48	49	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28411	28418		10.1074/jbc.M312708200	http://dx.doi.org/10.1074/jbc.M312708200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15090544	hybrid			2022-12-25	WOS:000222265400074
J	Hua, G; Jurat-Fuentes, JL; Adang, MJ				Hua, G; Jurat-Fuentes, JL; Adang, MJ			Bt-R-1a extracellular cadherin repeat 12 mediates Bacillus thuringiensis Cry1Ab binding and cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANDUCA-SEXTA AMINOPEPTIDASE; BRUSH-BORDER MEMBRANE; DROSOPHILA S2 CELLS; HELIOTHIS-VIRESCENS; TOXIN BINDING; SPODOPTERA-FRUGIPERDA; DELTA-ENDOTOXIN; PORE FORMATION; DOMAIN-II; RECEPTOR	The cadherin protein Bt-R-1a is a receptor for Bacillus thuringiensis Cry1A toxins in Manduca sexta. Cry1Ab toxin is reported to bind specific epitopes located in extracellular cadherin repeat (CR) 7 and CR11 on Bt-R-1 (Gomez, B., Miranda-Rios, J., Riudino-Pinera, E., Oltean, D. I., Gill, S. S., Bravo, A., and Soberon, M. ( 2002) J. Biol. Chem. 277, 30137 - 30143; Dorsch, J. A., Candas, M., Griko, N., Maaty, W., Midboe, E., Vadlamudi, R., and Bulla, L. ( 2002) Insect Biochem. Mol. Biol. 32, 1025 - 1036). We transiently expressed CR domains of Bt-R-1a in Drosophila melanogaster Schneider 2 (S2) cells as fusion peptides between a signal peptide and a terminal region that included membrane-proximal, membrane-spanning, and cytoplasmic domains. A domain consisting of CR11 and 12 was the minimal I-125-Cry1Ab binding region detected under denaturing conditions. Only CR12 was essential for Cry1Ab binding and cytotoxicity to S2 cells when tested under native conditions. Under these conditions expressed CR12 bound I-125-Cry1Ab with high affinity (K-com = 2.9 nM). Flow cytometry assays showed that expression of CR12 conferred susceptibility to Cry1Ab in S2 cells. Derivatives of Bt-R-1a with separate deletions of CR7, 11, and 12 were expressed in S2 cells. Only deletion of CR12 caused loss of Cry1Ab binding and cytotoxicity. These results demonstrate that CR12 is the essential Cry1Ab binding component on Bt-R-1a that mediates Cry1Ab-induced cytotoxicity.	Univ Georgia, Dept Entomol, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Adang, MJ (corresponding author), Univ Georgia, Dept Entomol, Rm 413, Athens, GA 30602 USA.	adang@uga.edu	Jurat-Fuentes, Juan Luis/A-5104-2014	Jurat-Fuentes, Juan Luis/0000-0002-8945-1814	NIAID NIH HHS [R01 AI 29092-09] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029092] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Banks DJ, 2003, INSECT BIOCHEM MOLEC, V33, P499, DOI 10.1016/S0965-1748(03)00022-5; Betz FS, 2000, REGUL TOXICOL PHARM, V32, P156, DOI 10.1006/rtph.2000.1426; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Daniel A, 2002, APPL ENVIRON MICROB, V68, P2106, DOI 10.1128/AEM.68.5.2106-2112.2002; Dorsch JA, 2002, INSECT BIOCHEM MOLEC, V32, P1025, DOI 10.1016/S0965-1748(02)00040-1; Francis BR, 1997, INSECT BIOCHEM MOLEC, V27, P541, DOI 10.1016/S0965-1748(97)00029-5; Gahan LJ, 2001, SCIENCE, V293, P857, DOI 10.1126/science.1060949; Gomez I, 2003, BIOCHEMISTRY-US, V42, P10482, DOI 10.1021/bi034440p; Gomez I, 2001, J BIOL CHEM, V276, P28906, DOI 10.1074/jbc.M103007200; Gomez I, 2002, J BIOL CHEM, V277, P30137, DOI 10.1074/jbc.M203121200; Gomez I, 2002, FEBS LETT, V513, P242, DOI 10.1016/S0014-5793(02)02321-9; Hua G, 2004, INSECT BIOCHEM MOLEC, V34, P193, DOI 10.1016/j.ibmb.2003.10.006; KNIGHT PJK, 1994, MOL MICROBIOL, V11, P429, DOI 10.1111/j.1365-2958.1994.tb00324.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MK, 1996, BIOCHEM BIOPH RES CO, V220, P575, DOI 10.1006/bbrc.1996.0445; Luo K, 1999, APPL ENVIRON MICROB, V65, P457; MASSON L, 1990, BIOCHEM J, V269, P507, DOI 10.1042/bj2690507; Miranda R, 2001, INSECT BIOCHEM MOLEC, V31, P1155, DOI 10.1016/S0965-1748(01)00061-3; Morin S, 2003, P NATL ACAD SCI USA, V100, P5004, DOI 10.1073/pnas.0831036100; Nagamatsu Y, 1998, BIOSCI BIOTECH BIOCH, V62, P718, DOI 10.1271/bbb.62.718; Nagamatsu Y, 1999, FEBS LETT, V460, P385, DOI 10.1016/S0014-5793(99)01327-7; SANGADALA S, 1994, J BIOL CHEM, V269, P10088; Sangadala S, 2001, INSECT BIOCHEM MOLEC, V32, P97, DOI 10.1016/S0965-1748(01)00086-8; Schwartz JL, 1997, FEBS LETT, V412, P270, DOI 10.1016/S0014-5793(97)00801-6; Thomson JM, 1998, BIOTECHNIQUES, V24, P922, DOI 10.2144/98246bm04; Tsuda Y, 2003, BIOCHEM J, V369, P697, DOI 10.1042/BJ20021401; VADLAMUDI RK, 1995, J BIOL CHEM, V270, P5490, DOI 10.1074/jbc.270.10.5490; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; Zhuang MB, 2002, J BIOL CHEM, V277, P13863, DOI 10.1074/jbc.M110057200	29	83	95	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28051	28056		10.1074/jbc.M400237200	http://dx.doi.org/10.1074/jbc.M400237200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123702	hybrid			2022-12-25	WOS:000222265400029
J	Kang, D; Mariash, E; Kim, D				Kang, D; Mariash, E; Kim, D			Functional expression of TRESK-2, a new member of the tandem-pore K+ channel family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; POTASSIUM CHANNEL; CLONING; PH; ANESTHETICS; SUBUNITS; TWIK-1; TASK	A new member of the tandem-pore K+ (K-2P) channel family has been isolated from mouse testis complementary DNA. The new K-2P channel was named TRESK-2, as its amino acid sequence shares 65% identity with that of TRESK-1. Mouse TRESK-2 is a 394-amino acid protein and possesses four putative transmembrane segments and two pore-forming domains. TRESK-2 has a long cytoplasmic domain joining the second and third transmembrane segments and a short carboxyl terminus. In the rat, TRESK-2 mRNA transcripts were expressed abundantly in the thymus and spleen and at low levels in many other tissues, including heart, small intestine, skeletal muscle, uterus, testis, and placenta, as judged by Northern blot analysis. TRESK-2 mRNA was also expressed in mouse and human tissues. In COS-7 cells transfected with TRESK-2 DNA, a time-independent and noninactivating K+-selective current was recorded. TRESK-2 was insensitive to 1 mM tetraethylammonium, 100 nM apamin, 1 mM 4-aminopyridine, and 10 muM glybenclamide. TRESK-2 was inhibited by 10 muM quinidine, 20 muM arachidonate and acid ( pH 6.3) at 49, 43, and 23%, respectively. Single channel openings of TRESK-2 showed marked open channel noise. In symmetrical 150 mM KCl, the current-voltage relationship of TRESK-2 was slightly inwardly rectifying, with the single channel conductance 13 picosiemens (pS) at +60 mV and 16 pS at - 60 mV. In inside-out patches, TRESK-2 was unaffected by the intracellular application of 10 muM guanosine 5'-O( thiotriphosphate). These results show that TRESK-2 is a functional member of the K2P channel family and contributes to the background K+ conductance in many types of cells.	Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Physiol & Biophys, N Chicago, IL 60064 USA	Chicago Medical School; Rosalind Franklin University Medical & Science	Kim, D (corresponding author), Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Physiol & Biophys, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	donghee.kim@Rosalindfranklin.edu						Bang H, 2000, J BIOL CHEM, V275, P17412, DOI 10.1074/jbc.M000445200; Buckler KJ, 2000, J PHYSIOL-LONDON, V525, P135, DOI 10.1111/j.1469-7793.2000.00135.x; Cahalan MD, 2001, J CLIN IMMUNOL, V21, P235, DOI 10.1023/A:1010958907271; Chavez RA, 1999, J BIOL CHEM, V274, P7887, DOI 10.1074/jbc.274.12.7887; Czirjak B, 2004, J BIOL CHEM, V279, P18550, DOI 10.1074/jbc.M312229200; Decher N, 2001, FEBS LETT, V492, P84, DOI 10.1016/S0014-5793(01)02222-0; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Girard C, 2001, BIOCHEM BIOPH RES CO, V282, P249, DOI 10.1006/bbrc.2001.4562; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; Han J, 2003, AM J PHYSIOL-CELL PH, V285, pC529, DOI 10.1152/ajpcell.00601.2002; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; Kim D, 2003, TRENDS PHARMACOL SCI, V24, P648, DOI 10.1016/j.tips.2003.10.008; Kim D, 2001, BIOCHEM BIOPH RES CO, V284, P923, DOI 10.1006/bbrc.2001.5064; Kim D, 1998, CIRC RES, V82, P513, DOI 10.1161/01.RES.82.4.513; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; Lesage F, 2000, J BIOL CHEM, V275, P28398, DOI 10.1074/jbc.M002822200; Lesage F, 1996, EMBO J, V15, P6400, DOI 10.1002/j.1460-2075.1996.tb01031.x; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 2001, TRENDS NEUROSCI, V24, P339, DOI 10.1016/S0166-2236(00)01810-5; Patel AJ, 2000, J BIOL CHEM, V275, P28722, DOI 10.1074/jbc.M003755200; Pountney DJ, 1999, FEBS LETT, V450, P191, DOI 10.1016/S0014-5793(99)00495-0; Rajan S, 2001, J BIOL CHEM, V276, P7302, DOI 10.1074/jbc.M008985200; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; Sano Y, 2003, J BIOL CHEM, V278, P27406, DOI 10.1074/jbc.M206810200; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8	31	71	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28063	28070		10.1074/jbc.M402940200	http://dx.doi.org/10.1074/jbc.M402940200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123670	hybrid			2022-12-25	WOS:000222265400031
J	Jirakulaporn, T; Muslin, AJ				Jirakulaporn, T; Muslin, AJ			Cation diffusion facilitator proteins modulate Raf-1activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; KINASE-KINASE; RAF-1 KINASE; RAS; ACTIVATION; ZINC; PHOSPHORYLATION; 14-3-3-PROTEINS; BINDING; MEMBRANE	The Ras-extracellular signal-regulated kinase (ERK) cascade is a critical intracellular signaling pathway that regulates growth, survival, and differentiation. Previous work established that Ras-GTP binds to, and facilitates the activation of, the protein kinase Raf-1. Recently, it was demonstrated that the cation diffusion facilitator (CDF) proteins are involved in Ras-ERK signaling by use of a Caenorhabditis elegans genetic screen that identified suppressors of activated Ras. In the current work, we demonstrate that CDF proteins may function downstream of Ras, but upstream of Raf-1 in Xenopus oocytes. We also show that the C. elegans protein CDF-1 and its mammalian homologue ZnT-1 bind to the amino-terminal regulatory portion of Raf-1 and promote the biological and enzymatic activity of Raf-1. Furthermore, we show that Zn2+ inhibits Raf-1 binding to ZnT-1. We propose a model in which CDF protein binding facilitates Raf-1 activation.	Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Muslin, AJ (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Med, Box 8086,660 S Euclid Ave, St Louis, MO 63110 USA.	amuslin@imgate.wustl.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054670] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM54670] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Bruinsma JJ, 2002, DEV CELL, V2, P567, DOI 10.1016/S1534-5807(02)00151-X; COBB MH, 1994, CELL MOL BIOL RES, V40, P253; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Hoyos B, 2002, J BIOL CHEM, V277, P23949, DOI 10.1074/jbc.M110750200; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NOMIZU T, 1993, MOL REPROD DEV, V36, P419, DOI 10.1002/mrd.1080360403; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; Rommel C, 1996, ONCOGENE, V12, P609; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Tran NH, 2003, J BIOL CHEM, V278, P11221, DOI 10.1074/jbc.M210318200; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; Wu CL, 2002, MECH DEVELOP, V119, P45, DOI 10.1016/S0925-4773(02)00287-3; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	36	55	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27807	27815		10.1074/jbc.M401210200	http://dx.doi.org/10.1074/jbc.M401210200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096503	hybrid			2022-12-25	WOS:000222120400116
J	Kee, K; Vujcic, S; Merali, S; Diegelman, P; Kisiel, N; Powell, CT; Kramer, DL; Porter, CW				Kee, K; Vujcic, S; Merali, S; Diegelman, P; Kisiel, N; Powell, CT; Kramer, DL; Porter, CW			Metabolic and antiproliferative consequences of activated polyamine catabolism in LNCaP prostate carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERMIDINE SPERMINE N1-ACETYLTRANSFERASE; S-ADENOSYLMETHIONINE DECARBOXYLASE; ELEMENT-BINDING PROTEINS; ANALOG-INDUCED INCREASES; HUMAN-MELANOMA CELLS; HAMSTER OVARY CELLS; GENE-EXPRESSION; ALPHA-DIFLUOROMETHYLORNITHINE; BIS(ETHYL)POLYAMINE ANALOGS; IRREVERSIBLE INHIBITION	Depletion of intracellular polyamine pools invariably inhibits cell growth. Although this is usually accomplished by inhibiting polyamine biosynthesis, we reasoned that this might be more effectively achieved by activation of polyamine catabolism at the level of spermidine/ spermine N6(1)-acetyltransferase (SSAT); a strategy first validated in MCF-7 breast carcinoma cells. We now examine the possibility that, due to unique aspects of polyamine homeostasis in the prostate gland, tumor cells derived from it may be particularly sensitive to activated polyamine catabolism. Thus, SSAT was conditionally overexpressed in LNCaP prostate carcinoma cells via a tetracycline-regulatable (Tet-off) system. Tetracycline removal resulted in a rapid similar to10-fold increase in SSAT mRNA and an increase of similar to20-fold in enzyme activity. SSAT products N-1-acetylspermidine, N-1-acetylspermine, and N-1, N-12-diacetylspermine accumulated intracellularly and extracellularly. SSAT induction also led to a growth inhibition that was not accompanied by polyamine pool depletion as it was in MCF-7 cells. Rather, intracellular spermidine and spermine pools were maintained at or above control levels by a robust compensatory increase in ornithine decarboxylase and S-adenosylmethionine decarboxylase activities. This, in turn, gave rise to a high rate of metabolic flux through both the biosynthetic and catabolic arms of polyamine metabolism. Treatment with the biosynthesis inhibitor alpha-difluoromethylornithine during tetracycline removal interrupted flux and prevented growth inhibition. Thus, flux-induced growth inhibition appears to derive from overaccumulation of metabolic products and/or from depletion of metabolic precursors. Metabolic effects that were not excluded as possible contributing factors include high levels of putrescine and acetylated polyamines, a 50% reduction in S-adenosylmethionine, and a 45% decline in the SSAT cofactor acetyl-CoA. Overall, the study demonstrates that activation of polyamine catabolism in LNCaP cells elicits a compensatory increase in polyamine biosynthesis and downstream metabolic events that culminate in growth inhibition.	Roswell Pk Canc Inst, Grace Canc Drug Ctr, Buffalo, NY 14263 USA; NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10010 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA	Roswell Park Cancer Institute; New York University; Cleveland Clinic Foundation	Porter, CW (corresponding author), Roswell Pk Canc Inst, Grace Canc Drug Ctr, Buffalo, NY 14263 USA.	carl.porter@roswellpark.org	Deeb, Kristin K/H-5619-2016		NATIONAL CANCER INSTITUTE [R29CA072648, R01CA022153, P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09072-30, CA-16056, CA-72648, CA-22153] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alhonen L, 1998, J BIOL CHEM, V273, P1964, DOI 10.1074/jbc.273.4.1964; Bergeron RJ, 1997, J MED CHEM, V40, P1475, DOI 10.1021/jm960849j; Bettuzzi S, 2000, CANCER RES, V60, P1472; CASERO RA, 1989, CANCER RES, V49, P639; CASERO RA, 1989, CANCER RES, V49, P3829; Chen Y, 2003, MOL PHARMACOL, V64, P1153, DOI 10.1124/mol.64.5.1153; Chen Y, 2003, ONCOGENE, V22, P4964, DOI 10.1038/sj.onc.1206725; DANZIN C, 1990, BIOCHEM PHARMACOL, V40, P1499, DOI 10.1016/0006-2952(90)90446-R; Devens BH, 2000, PROSTATE CANCER P D, V3, P275, DOI 10.1038/sj.pcan.4500420; Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2; FOGELPETROVIC M, 1993, J BIOL CHEM, V268, P19118; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Gschwend JE, 1997, PROSTATE, V33, P166; Gupta S, 2000, CANCER RES, V60, P5125; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; Harrison GA, 1931, BIOCHEM J, V25, P1885, DOI 10.1042/bj0251885; HECTOR S, 2004, IN PRESS MOL CANC TH; HESTON WDW, 1987, BIOCHEM PHARMACOL, V36, P1849, DOI 10.1016/0006-2952(87)90250-4; HESTON WDW, 1991, CANCER SURV, V11, P217; KEE K, 2003, P AM ASSOC CANC RES, V44, P1277; KRAMER D, 1995, BIOCHEM PHARMACOL, V50, P1433, DOI 10.1016/0006-2952(95)02037-3; KRAMER D, 1995, J BIOL CHEM, V270, P2124, DOI 10.1074/jbc.270.5.2124; KRAMER DL, 1989, BIOCHEM J, V259, P325, DOI 10.1042/bj2590325; KRAMER DL, 1996, CRITICAL ROLES POLYA, P151; LIBBY PR, 1991, ARCH BIOCHEM BIOPHYS, V284, P238, DOI 10.1016/0003-9861(91)90291-P; LIBBY PR, 1989, BIOCHEM PHARMACOL, V38, P1435, DOI 10.1016/0006-2952(89)90182-2; Liu GS, 2003, ANAL CHEM, V75, P78, DOI 10.1021/ac0261505; MAMONT PS, 1978, BIOCHEM BIOPH RES CO, V81, P58, DOI 10.1016/0006-291X(78)91630-3; MANN T, 1964, BIOCH SEMEN MALE REP, P193; Maxwell PJ, 2003, CANCER RES, V63, P4602; McCloskey DE, 1999, J BIOL CHEM, V274, P6175, DOI 10.1074/jbc.274.10.6175; McCloskey DE, 2000, J BIOL CHEM, V275, P28708, DOI 10.1074/jbc.M004120200; Mi Z, 1998, PROSTATE, V34, P51, DOI 10.1002/(SICI)1097-0045(19980101)34:1<51::AID-PROS7>3.0.CO;2-N; PAJULA RL, 1979, FEBS LETT, V99, P343, DOI 10.1016/0014-5793(79)80988-6; PEGG AE, 1968, BIOCHEM J, V108, P533, DOI 10.1042/bj1080533; PEGG AE, 1989, J BIOL CHEM, V264, P11744; PEGG AE, 1984, BIOCHEM J, V224, P29, DOI 10.1042/bj2240029; Pietila M, 1997, J BIOL CHEM, V272, P18746, DOI 10.1074/jbc.272.30.18746; Porter C. W., 1992, V62, P301; PORTER CW, 1985, CANCER RES, V45, P2050; PORTER CW, 1991, CANCER RES, V51, P3715; PORTER CW, 1987, CANCER, V60, P1275, DOI 10.1002/1097-0142(19870915)60:6<1275::AID-CNCR2820600619>3.0.CO;2-I; REGENASS U, 1994, CANCER RES, V54, P3210; Rhodes DR, 2002, CANCER RES, V62, P4427; SEILER N, 1981, MED BIOL, V59, P334; SEILER N, 1980, BIOCHIM BIOPHYS ACTA, V633, P181, DOI 10.1016/0304-4165(80)90404-3; Seiler N, 2003, CURR DRUG TARGETS, V4, P537, DOI 10.2174/1389450033490885; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; SHAPPELL NW, 1992, ANTICANCER RES, V12, P1083; Swinnen JV, 2000, INT J CANCER, V88, P176, DOI 10.1002/1097-0215(20001015)88:2<176::AID-IJC5>3.0.CO;2-3; Swinnen JV, 1997, P NATL ACAD SCI USA, V94, P12975, DOI 10.1073/pnas.94.24.12975; Swinnen JV, 1997, CANCER RES, V57, P1086; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; Thomas T, 2003, J CELL MOL MED, V7, P113, DOI 10.1111/j.1582-4934.2003.tb00210.x; Vujcic S, 2000, J BIOL CHEM, V275, P38319, DOI 10.1074/jbc.M003270200; WILLIAMSASHMAN HG, 1982, BIOCHEM PHARMACOL, V31, P277, DOI 10.1016/0006-2952(82)90171-X; WILLIAMSASHMAN HG, 1979, PERSPECT BIOL MED, V22, P421; XIAO L, 1991, BIOCHEM BIOPH RES CO, V179, P407, DOI 10.1016/0006-291X(91)91385-P; YAMANAKA H, 1987, CANCER RES, V47, P1771; YARLETT N, 1988, MOL BIOCHEM PARASIT, V27, P1, DOI 10.1016/0166-6851(88)90019-9	61	41	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27050	27058		10.1074/jbc.M403323200	http://dx.doi.org/10.1074/jbc.M403323200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096507	hybrid			2022-12-25	WOS:000222120400031
J	Pacheco, TR; Gomes, AQ; Barbosa-Morais, NL; Benes, V; Ansorge, W; Wollerton, M; Smith, CW; Valcarcel, J; Carmo-Fonseca, M				Pacheco, TR; Gomes, AQ; Barbosa-Morais, NL; Benes, V; Ansorge, W; Wollerton, M; Smith, CW; Valcarcel, J; Carmo-Fonseca, M			Diversity of vertebrate splicing factor U2AF(35) - Identification of alternatively spliced U2AF1 mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUPLICATE MITF GENES; GENOME DUPLICATION; SMALL-SUBUNIT; PROTEIN; EXPRESSION; SITE; RECOGNITION; U2AF(65); CLONING; SUBFUNCTIONALIZATION	U2 small nuclear ribonucleoprotein auxiliary factor small subunit (U2AF(35)) is encoded by a conserved gene designated U2AF1. Here we provide evidence for the existence of alternative vertebrate transcripts encoding different U2AF35 isoforms. Three mRNA isoforms ( termed U2AF(35)a-c) were produced by alternative splicing of the human U2AF1 gene. U2AF(35)c contains a premature stop codon that targets the resulting mRNA to nonsense-mediated mRNA decay. U2AF(35)b differs from the previously described U2AF(35)a isoform in 7 amino acids located at the atypical RNA Recognition Motif involved in dimerization with U2AF(65). Biochemical experiments indicate that isoform U2AF(35)b, which has been highly conserved from fish to man, maintains the ability to interact with U2AF(65), stimulates U2AF(65) binding to a pre-mRNA, and promotes U2AF splicing activity in vitro. Real time, quantitative PCR analysis indicates that U2AF(35)a is the most abundant isoform expressed in murine tissues, although the ratio between U2AF(35)a and U2AF(35)b varies from 10-fold in the brain to 20-fold in skeletal muscle. We propose that post-transcriptional regulation of U2AF1 gene expression may provide a mechanism by which the relative cellular concentration and availability of U2AF(35) protein isoforms are modulated, thus contributing to the finely tuned control of splicing events in different tissues.	Univ Lisbon, Fac Med, Inst Mol Med, P-1649028 Lisbon, Portugal; EMBL, D-69112 Heidelberg, Germany; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	Universidade de Lisboa; European Molecular Biology Laboratory (EMBL); University of Cambridge	Carmo-Fonseca, M (corresponding author), Univ Lisbon, Fac Med, Inst Mol Med, Av Prof Egas Moniz, P-1649028 Lisbon, Portugal.	carmo.fonseca@fm.ul.pt	Ansorge, Wilhelm/AAN-8780-2020; Valcarcel, Juan/O-9814-2014; Gomes, Anita Q./C-3580-2014; Barbosa-Morais, Nuno L/I-2743-2013	Valcarcel, Juan/0000-0001-5398-3571; Gomes, Anita Q./0000-0002-3348-0448; Barbosa-Morais, Nuno L/0000-0002-1215-0538; Benes, Vladimir/0000-0002-0352-2547; Carmo-Fonseca, Maria/0000-0002-3402-7143; Pacheco, Teresa/0000-0002-5506-0233	Fundação para a Ciência e a Tecnologia [POCTI/MGI/36547/2000, SFRH/BD/84517/2012] Funding Source: FCT	Fundação para a Ciência e a Tecnologia		Altschmied J, 2002, GENETICS, V161, P259; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; Birney E, 1996, NUCLEIC ACIDS RES, V24, P2730, DOI 10.1093/nar/24.14.2730; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Brett D, 2002, NAT GENET, V30, P29, DOI 10.1038/ng803; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Burge CB, 1999, RNA WORLD, P525; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; CACERES JF, 1997, EUKARYOTIC MRNA PROC, P174; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Erfle H, 1997, NUCLEIC ACIDS RES, V25, P2229, DOI 10.1093/nar/25.11.2229; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; Force A, 1999, GENETICS, V151, P1531; Gama-Carvalho M, 2001, J BIOL CHEM, V276, P13104, DOI 10.1074/jbc.M008759200; GamaCarvalho M, 1997, J CELL BIOL, V137, P975, DOI 10.1083/jcb.137.5.975; Graveley BR, 2001, RNA, V7, P806, DOI 10.1017/S1355838201010317; Graveley BR, 2002, CELL, V109, P409, DOI 10.1016/S0092-8674(02)00750-X; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Guth S, 1999, MOL CELL BIOL, V19, P8263; Guth S, 2001, MOL CELL BIOL, V21, P7673, DOI 10.1128/MCB.21.22.7673-7681.2001; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Jumaa H, 1997, MOL CELL BIOL, V17, P3116, DOI 10.1128/MCB.17.6.3116; Jumaa H, 1997, EMBO J, V16, P5077, DOI 10.1093/emboj/16.16.5077; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Kaiser K, 1995, DNA CLONING, V1, P37; Kielkopf CL, 2001, CELL, V106, P595, DOI 10.1016/S0092-8674(01)00480-9; LEGUINER C, 2001, J BIOL CHEM, V76, P40638; Lewis BP, 2003, P NATL ACAD SCI USA, V100, P189, DOI 10.1073/pnas.0136770100; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; Lister JA, 2001, DEV BIOL, V237, P333, DOI 10.1006/dbio.2001.0379; Lynch M, 2000, GENETICS, V154, P459; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Maquat LE, 2002, CURR BIOL, V12, pR196, DOI 10.1016/S0960-9822(02)00747-9; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; Mendell JT, 2002, SCIENCE, V298, P419, DOI 10.1126/science.1074428; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; Meyer A, 1999, CURR OPIN CELL BIOL, V11, P699, DOI 10.1016/S0955-0674(99)00039-3; NEI M, 1986, MOL BIOL EVOL, V3, P418; Ohnishi T, 2003, MOL CELL, V12, P1187, DOI 10.1016/S1097-2765(03)00443-X; POPIELARZ M, 1995, J BIOL CHEM, V270, P17830, DOI 10.1074/jbc.270.30.17830; Roberts GC, 2002, CURR OPIN CHEM BIOL, V6, P375, DOI 10.1016/S1367-5931(02)00320-4; Rudner DZ, 1996, P NATL ACAD SCI USA, V93, P10333, DOI 10.1073/pnas.93.19.10333; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schell T, 2002, GENOME BIOL, V3; Schmittgen TD, 2003, INT J CANCER, V107, P323, DOI 10.1002/ijc.11402; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stoilov P, 2004, HUM MOL GENET, V13, P509, DOI 10.1093/hmg/ddh051; SUREAU A, 1994, P NATL ACAD SCI USA, V91, P932, DOI 10.1073/pnas.91.3.932; Sureau A, 2001, EMBO J, V20, P1785, DOI 10.1093/emboj/20.7.1785; Tassone F, 1999, GENE, V226, P211, DOI 10.1016/S0378-1119(98)00559-9; Taylor JS, 2003, GENOME RES, V13, P382, DOI 10.1101/gr.640303; Taylor JS, 2001, PHILOS T R SOC B, V356, P1661, DOI 10.1098/rstb.2001.0975; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VALCARCEL J, 1997, MRNA FORMATION FUNCT, P31; Van de Peer Y, 2001, J MOL EVOL, V53, P436, DOI 10.1007/s002390010233; VOSS H, 1993, BIOTECHNIQUES, V15, P714; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WentzHunter K, 1996, NUCLEIC ACIDS RES, V24, P1849, DOI 10.1093/nar/24.10.1849; Wilkinson MF, 2002, NAT CELL BIOL, V4, pE144, DOI 10.1038/ncb0602-e144; Wittbrodt J, 1998, BIOESSAYS, V20, P511, DOI 10.1002/(SICI)1521-1878(199806)20:6&lt;511::AID-BIES10&gt;3.0.CO;2-3; Wollerton MC, 2004, MOL CELL, V13, P91, DOI 10.1016/S1097-2765(03)00502-1; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; Yu WP, 2003, TRENDS GENET, V19, P180, DOI 10.1016/S0168-9525(03)00048-9; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814; Zorio DAR, 1999, NATURE, V402, P835, DOI 10.1038/45597; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	74	41	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27039	27049		10.1074/jbc.M402136200	http://dx.doi.org/10.1074/jbc.M402136200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096518	Green Published, hybrid			2022-12-25	WOS:000222120400030
J	Ueda, K; Nakamura, K; Hayashi, T; Inagaki, N; Takahashi, M; Arimura, T; Morita, H; Higashiuesato, Y; Hirano, Y; Yasunami, M; Takishita, S; Yamashina, A; Ohe, T; Sunamori, M; Hiraoka, M; Kimura, A				Ueda, K; Nakamura, K; Hayashi, T; Inagaki, N; Takahashi, M; Arimura, T; Morita, H; Higashiuesato, Y; Hirano, Y; Yasunami, M; Takishita, S; Yamashina, A; Ohe, T; Sunamori, M; Hiraoka, M; Kimura, A			Functional characterization of a trafficking-defective HCN4 mutation, D553N, associated with cardiac arrhythmia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; PACEMAKER CHANNELS; I-KR; MOLECULAR CHARACTERIZATION; VENTRICULAR-FIBRILLATION; ACTION-POTENTIALS; SINOATRIAL NODE; SODIUM-CHANNEL; SYNDROME GENES; SCN5A	Hyperpolarization-activated cyclic nucleotide-gated channel 4 gene HCN4 is a pacemaker channel that plays a key role in automaticity of sinus node in the heart, and an HCN4 mutation was reported in a patient with sinus node dysfunction. Expression of HCN4 in the heart is, however, not confined to the sinus node cells but is found in other tissues, including cells of the conduction system. On the other hand, mutations in another cardiac ion channel gene, SCN5A, also cause sinus node dysfunction as well as other cardiac arrhythmias, including long QT syndrome, Brugada syndrome, idiopathic ventricular fibrillation, and progressive cardiac conduction disturbance. These observations imply that HCN4 abnormalities may be involved in the pathogenesis of various arrhythmias, similar to the SCN5A mutations. In this study, we analyzed patients suffering from sinus node dysfunction, progressive cardiac conduction disease, and idiopathic ventricular fibrillation for mutations in HCN4. A missense mutation, D553N, was found in a patient with sinus node dysfunction who showed recurrent syncope, QT prolongation in electrocardiogram, and polymorphic ventricular tachycardia, torsade de pointes. In vitro functional study of the D553N mutation showed a reduced membranous expression associated with decreased If currents because of a trafficking defect of the HCN4 channel in a dominant-negative manner. These data suggest that the loss of function of HCN4 is associated with sinus nodal dysfunction and that a consequence of pacemaker channel abnormality might underlie clinical features of QT prolongation and polymorphic ventricular tachycardia developed under certain conditions.	Tokyo Med & Dent Univ, Inst Med Res, Dept Mol Pathogenesis, Chiyoda Ku, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Sch Biomed Sci, Lab Genome Divers, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Inst Med Res, Dept Cardiovasc Dis, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Thorac & Cardiovasc Surg, Tokyo 1010062, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Cardiovasc Med, Okayama 7008558, Japan; Tokyo Med Univ, Dept Internal Med 2, Tokyo 1608402, Japan; Univ Ryukyus, Fac Med, Dept Internal Med 3, Okinawa 9030215, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Okayama University; Tokyo Medical University; University of the Ryukyus	Kimura, A (corresponding author), Tokyo Med & Dent Univ, Inst Med Res, Dept Mol Pathogenesis, Chiyoda Ku, 2-3-10 Kandasurugadai, Tokyo 1010062, Japan.	akitis@mri.tmd.ac.jp	Kimura, Akinori/I-5989-2018; Arimura, Takuro/AAA-2745-2022	Kimura, Akinori/0000-0002-4933-2132; Arimura, Takuro/0000-0002-0929-3140				Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Akai J, 2000, FEBS LETT, V479, P29, DOI 10.1016/S0014-5793(00)01875-5; Benson DW, 2003, J CLIN INVEST, V112, P1019, DOI 10.1172/JCI200318062; Bianchi L, 1999, HUM MOL GENET, V8, P1499, DOI 10.1093/hmg/8.8.1499; Biel M, 2002, TRENDS CARDIOVAS MED, V12, P206, DOI 10.1016/S1050-1738(02)00162-7; BRACHMANN J, 1983, CIRCULATION, V68, P846, DOI 10.1161/01.CIR.68.4.846; Bucchi A, 2002, J GEN PHYSIOL, V120, P1, DOI 10.1085/jgp.20028593; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; Ishii TM, 1999, J BIOL CHEM, V274, P12835, DOI 10.1074/jbc.274.18.12835; JURKIEWICZ NK, 1993, CIRC RES, V72, P75, DOI 10.1161/01.RES.72.1.75; KURITA T, 1992, AM J CARDIOL, V69, P628, DOI 10.1016/0002-9149(92)90154-Q; Lees-Miller JP, 2003, MOL CELL BIOL, V23, P1856, DOI 10.1128/MCB.23.6.1856-1862.2003; Ludwig A, 2003, EMBO J, V22, P216, DOI 10.1093/emboj/cdg032; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Marban E, 2002, NATURE, V415, P213, DOI 10.1038/415213a; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Moosmang S, 2001, EUR J BIOCHEM, V268, P1646, DOI 10.1046/j.1432-1327.2001.02036.x; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; NISHI H, 1992, BIOCHEM BIOPH RES CO, V188, P379, DOI 10.1016/0006-291X(92)92396-F; Plaster NM, 2001, CELL, V105, P511, DOI 10.1016/S0092-8674(01)00342-7; Priori SG, 2001, CIRCULATION, V103, P196; RODEN DM, 1985, CIRC RES, V56, P857, DOI 10.1161/01.RES.56.6.857; Schulze-Bahr E, 2003, J CLIN INVEST, V111, P1537, DOI 10.1172/JCI200316387; Seifert R, 1999, P NATL ACAD SCI USA, V96, P9391, DOI 10.1073/pnas.96.16.9391; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Splawski I, 1998, GENOMICS, V51, P86, DOI 10.1006/geno.1998.5361; Stieber J, 2003, P NATL ACAD SCI USA, V100, P15235, DOI 10.1073/pnas.2434235100; Thollon C, 1997, EUR J PHARMACOL, V339, P43, DOI 10.1016/S0014-2999(97)01364-2; Wainger BJ, 2001, NATURE, V411, P805, DOI 10.1038/35081088; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wang Q, 1996, GENOMICS, V34, P9, DOI 10.1006/geno.1996.0236; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Zaza A, 1997, J PHYSIOL-LONDON, V505, P677, DOI 10.1111/j.1469-7793.1997.677ba.x; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	37	160	176	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27194	27198		10.1074/jbc.M311953200	http://dx.doi.org/10.1074/jbc.M311953200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15123648	hybrid			2022-12-25	WOS:000222120400046
J	Lavitrano, M; Smolenski, RT; Musumeci, A; Maccherini, M; Slominska, E; di Florio, E; Bracco, A; Mancini, A; Stassi, G; Patti, M; Giovannoni, R; Froio, A; Simeone, F; Forni, M; Bacci, ML; D'Alise, G; Cozzi, E; Otterbein, LE; Yacoub, MH; Bach, FH; Calise, F				Lavitrano, M; Smolenski, RT; Musumeci, A; Maccherini, M; Slominska, E; di Florio, E; Bracco, A; Mancini, A; Stassi, G; Patti, M; Giovannoni, R; Froio, A; Simeone, F; Forni, M; Bacci, ML; D'Alise, G; Cozzi, E; Otterbein, LE; Yacoub, MH; Bach, FH; Calise, F			Carbon monoxide improves cardiac energetics and safeguards the heart during reperfusion after cardiopulmonary bypass in pigs	FASEB JOURNAL			English	Article						ischemia reperfusion; heart arrest; apoptosis; hypoxia	HEME OXYGENASE-1 PROTECTS; LUNG INJURY; MYOCARDIAL PROTECTION; CLINICAL IMPLICATIONS; PROVIDES PROTECTION; BRIEF ISCHEMIA; CONSEQUENCES; SUPPRESSES; EXPRESSION; REJECTION	Ischemia-reperfusion injury, a clinical problem during cardiac surgery, involves worsened adenosine trisphosphate (ATP) generation and damage to the heart. We studied carbon monoxide ( CO) pretreatment, proven valuable in rodents but not previously tested in large animals, for its effects on pig hearts subjected to cardiopulmonary bypass with cardioplegic arrest. Hearts of CO-treated pigs showed significantly higher ATP and phosphocreatine levels, less interstitial edema, and apoptosis of cardiomyocytes and required fewer defibrillations after bypass. We conclude that treatment with CO improves the energy status, prevents edema formation and apoptosis, and facilitates recovery in a clinically relevant model of cardiopulmonary bypass surgery.	Univ Milano Bicocca, Dept Med Sperimentale Ambientale & Biotecnol Med, Mol Med Lab, I-20052 Milan, Italy; Harefield Hosp, Imperial Coll, Heart Sci Ctr, Harefield, Middx, England; Univ Naples Federico II, Dept Cardiac Surg, Naples, Italy; Univ Siena, Dept Cardiothorac Surg, I-53100 Siena, Italy; Med Univ Gdansk, Dept Biochem, Gdansk, Poland; AORN Cardarelli Hosp, Naples, Italy; Univ Palermo, Sch Med, Dept Surg & Oncol Sci, I-90133 Palermo, Italy; Univ Bologna, Dept Morfofisiol Vet & Prod Anim, Bologna, Italy; Azienda Osped Padova, CORIT, Padua, Italy; Univ Pittsburgh, Sch Med, Dept Pulm & Crit Care Med, Pittsburgh, PA USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA	University of Milano-Bicocca; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; University of Naples Federico II; University of Siena; Fahrenheit Universities; Medical University Gdansk; Antonio Cardarelli Hospital; University of Palermo; University of Bologna; University of Padua; Azienda Ospedaliera - Universita di Padova; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Lavitrano, M (corresponding author), Univ Milano Bicocca, Dept Med Sperimentale Ambientale & Biotecnol Med, Mol Med Lab, Via Cadore 48, I-20052 Milan, Italy.	marialuisa.lavitrano@unimib.it	Froio, Alberto/A-6727-2009; Smolenski, Ryszard T/B-9713-2013; Giovannoni, Roberto/A-1413-2009; Bacci, Maria Laura/B-8494-2013; Stassi, Giorgio/AAC-1175-2022; Lavitrano, Marialuisa/H-3417-2012	Giovannoni, Roberto/0000-0002-7706-0672; Smolenski, Ryszard/0000-0002-0190-9414; Cozzi, Emanuele/0000-0001-7855-5055; Forni, Monica/0000-0003-1310-6202; Slominska, Ewa/0000-0002-3037-1844; Bacci, Maria Laura/0000-0001-6702-5868				Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Caputo M, 1998, EUR J CARDIO-THORAC, V14, P467, DOI 10.1016/S1010-7940(98)00233-4; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; GALINANES M, 1990, CARDIOSCIENCE, V1, P127; Kloner RA, 2001, CIRCULATION, V104, P2981, DOI 10.1161/hc4801.100038; Kloner RA, 2001, CIRCULATION, V104, P3158, DOI 10.1161/hc5001.100039; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Miro O, 1998, PHARMACOL TOXICOL, V82, P199, DOI 10.1111/j.1600-0773.1998.tb01425.x; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; SMOLENSKI RT, 1990, J CHROMATOGR-BIOMED, V527, P414, DOI 10.1016/S0378-4347(00)82125-8; Soares MP, 2001, IMMUNOL REV, V184, P275, DOI 10.1034/j.1600-065x.2001.1840124.x; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; Vinten-Johansen J, 2003, ANN THORAC SURG, V75, pS691, DOI 10.1016/S0003-4975(02)04694-5; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Yet SF, 2001, CIRC RES, V89, P168, DOI 10.1161/hh1401.093314	21	98	102	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2004	18	7					1093	+		10.1096/fj.03-0996fje	http://dx.doi.org/10.1096/fj.03-0996fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132974				2022-12-25	WOS:000221883200009
J	Gelamo, EL; Itri, R; Tabak, M				Gelamo, EL; Itri, R; Tabak, M			Small angle X-ray scattering (SAXS) study of the extracellular hemoglobin of Glossoscolex paulistus - Effect of pH, iron oxidation state, and interaction with anionic SDS surfactant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; LUMBRICUS-TERRESTRIS HEMOGLOBIN; BOVINE SERUM-ALBUMIN; DODECAMER SUBUNIT; IONIC SURFACTANTS; FLUORESCENCE; BSA; DENATURATION; COMPLEXES; NEUTRON	pH effects on the oligomeric structure of giant Glossoscolex paulistus extracellular hemoglobin in the oxy- and met-forms have been studied as well as effects of the addition of anionic sodium dodecyl sulfate surfactant. A radius of gyration of 110 Angstrom is observed for a macromolecule. At 2 mM surfactant, the radius of gyration diminishes slightly for the oxy- form. However, the extrapolated initial scattering intensity (I(0)) decreases a factor of 2.5, indicating protein dissociation. At 20 mM surfactant, further I( 0) decrease is observed, with a reduction of radius of gyration to approximately 30 Angstrom consistent with dissociation into smaller subunits. At pH 9.0, the scattering curves are similar to that obtained for the protein in the presence of 20 mM surfactant at pH 7.0. A radius of gyration of approximately 35 Angstrom shows that the giant hemoglobin dissociation into small subunits also occurs at alkaline pH. From the I( 0) value, one can suggest that the tetramer is the main scatter at pH 9.0. At pH 7.0, the met-form dissociates to a larger extent at 2 mM surfactant as compared with the oxy- form, and the main scatters seem to be the 1/12 subunit. At pH 9.0, for the oxy- form, the addition of surfactant does not modify the scattering curve and a radius of gyration approximately 30 Angstrom is obtained, while for the met-form some kind of aggregation is observed. Our results give support to conclude that the iron oxidation state is an important factor modulating the oligomeric dissociation.	Univ Sao Paulo, Dept Quim Fis Mol, Inst Quim Sao Carlos, BR-13560970 Sao Paulo, Brazil; Univ Sao Paulo, Inst Fis, Dept Fis Aplicada, BR-05515970 Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo	Tabak, M (corresponding author), Univ Sao Paulo, Dept Quim Fis Mol, Inst Quim Sao Carlos, CP 780, BR-13560970 Sao Paulo, Brazil.	marcel@sc.usp.br	Tabak, Marcel/I-3173-2014; Itri, Rosangela/B-4312-2014	Itri, Rosangela/0000-0001-9311-0804				Agustinho SCM, 1996, BBA-PROTEIN STRUCT M, V1298, P148, DOI 10.1016/S0167-4838(96)00127-6; AJLOO D, 2002, J COLLOID INTERF SCI, V26, P185; Cabral CB, 2002, BIOPHYS CHEM, V97, P139, DOI 10.1016/S0301-4622(02)00046-7; Caetano W, 2002, J COLLOID INTERF SCI, V248, P149, DOI 10.1006/jcis.2001.8164; CHEN SH, 1986, PHYS REV LETT, V57, P2583, DOI 10.1103/PhysRevLett.57.2583; Cinelli S, 2001, BIOPHYS J, V81, P3522, DOI 10.1016/S0006-3495(01)75983-8; COSTA MCP, 1988, BRAZ J MED BIOL RES, V21, P115; deHaas F, 1997, BIOCHEMISTRY-US, V36, P7330, DOI 10.1021/bi970131l; Durchschlag H, 2001, J MOL STRUCT, V563, P449, DOI 10.1016/S0022-2860(00)00890-5; Gelamo EL, 2002, BBA-PROTEIN STRUCT M, V1594, P84, DOI 10.1016/S0167-4838(01)00287-4; Gelamo EL, 2000, SPECTROCHIM ACTA A, V56, P2255, DOI 10.1016/S1386-1425(00)00313-9; Ghosh S, 2002, BIOMACROMOLECULES, V3, P9, DOI 10.1021/bm005644d; Glatter O., 1982, SMALL ANGLE XRAYS SC; Guinier A., 1955, SMALL ANGLE SCATTERI; GUO XH, 1990, BIOPOLYMERS, V29, P335, DOI 10.1002/bip.360290206; HAYASHI T, 1995, BIOL PHARM BULL, V18, P540; IMASATO H, 1995, COMP BIOCHEM PHYS B, V112, P217, DOI 10.1016/0305-0491(95)00061-5; Inouye H, 1999, BIOPHYS J, V76, P423, DOI 10.1016/S0006-3495(99)77209-7; Jones M.N., 1995, MICELLES MONOLAYERS; JONES MN, 1992, CHEM SOC REV, V21, P127, DOI 10.1039/cs9922100127; Kelley D, 2003, FOOD HYDROCOLLOID, V17, P73, DOI 10.1016/S0268-005X(02)00040-1; Krebs A, 1996, BBA-PROTEIN STRUCT M, V1297, P115, DOI 10.1016/S0167-4838(96)00141-0; Krebs A, 1998, BIOPOLYMERS, V45, P289, DOI 10.1002/(SICI)1097-0282(19980405)45:4<289::AID-BIP3>3.0.CO;2-H; Krebs A, 1996, J BIOL CHEM, V271, P18695, DOI 10.1074/jbc.271.31.18695; Lamy JN, 1996, CHEM REV, V96, P3113, DOI 10.1021/cr9600058; Li GX, 1996, J ELECTROCHEM SOC, V143, pL24, DOI 10.1149/1.1836444; Martin PD, 1996, J MOL BIOL, V255, P170, DOI 10.1006/jmbi.1996.0014; Martin PD, 1996, J MOL BIOL, V255, P154, DOI 10.1006/jmbi.1996.0013; Nielsen AD, 2000, BBA-PROTEIN STRUCT M, V1479, P321, DOI 10.1016/S0167-4838(00)00012-1; Orthaber D, 2000, J APPL CRYSTALLOGR, V33, P218, DOI 10.1107/S0021889899015216; PERUSSI JR, 1990, PHYSIOL CHEM PHYS M, V22, P159; REYNOLDS JA, 1970, J BIOL CHEM, V245, P5161; Royer WE, 2000, P NATL ACAD SCI USA, V97, P7107, DOI 10.1073/pnas.97.13.7107; Santos SF, 2003, J COLLOID INTERF SCI, V262, P400, DOI 10.1016/S0021-9797(03)00109-7; Segel DJ, 1998, BIOCHEMISTRY-US, V37, P12443, DOI 10.1021/bi980535t; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Semisotnov GV, 1996, J MOL BIOL, V262, P559, DOI 10.1006/jmbi.1996.0535; SHINAGAWA S, 1994, LANGMUIR, V10, P1690, DOI 10.1021/la00018a015; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Svergun DI, 1997, J APPL CRYSTALLOGR, V30, P792, DOI 10.1107/S0021889897001039; Svergun DI, 2000, J APPL CRYSTALLOGR, V33, P530, DOI 10.1107/S0021889800001370; Tanford Ch., 1973, HYDROPHOBIC EFFECT F; TANNER RE, 1982, J CHEM PHYS, V76, P3866, DOI 10.1063/1.443528; TURRO NJ, 1995, LANGMUIR, V11, P2525, DOI 10.1021/la00007a035; WU CF, 1988, BIOPOLYMERS, V27, P1065, DOI 10.1002/bip.360270703; Zipper P, 2002, PROG COLL POL SCI S, V119, P141	46	25	25	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33298	33305		10.1074/jbc.M401982200	http://dx.doi.org/10.1074/jbc.M401982200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15100214	hybrid			2022-12-25	WOS:000223039700036
J	Ling, L; Lobie, PE				Ling, L; Lobie, PE			RhoA/ROCK activation by growth hormone abrogates p300/histone deacetylase 6 repression of Stat5-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE ACTIVITY; SERINE PHOSPHORYLATION; PROTEIN-KINASE; RHO-GTPASES; IN-VIVO; SIGNAL TRANSDUCER; PHOSPHOLIPASE-D; MAP KINASE; BINDING; STAT5	We demonstrate here that growth hormone (GH) stimulates the activation of RhoA and its substrate Rho kinase ( ROCK) in NIH-3T3 cells. GH-stimulated formation of GTP-bound RhoA requires JAK2-dependent dissociation of RhoA from its negative regulator p190 RhoGAP. Inactivation of RhoA does not affect GH-stimulated JAK2 tyrosine phosphorylation nor p44/42 MAPK activity. However, RhoA and ROCK activities are required for GH-stimulated, Stat5-mediated transcription. RhoA-dependent enhancement of GH-stimulated, Stat5-mediated transcription is due to repression of histone deacetylase 6 activity recruited by transcription cofactor p300 that negatively regulates GH-stimulated, Stat5-mediated transcription. We also demonstrate that RhoA is the pivot for cAMP-dependent protein kinase inhibition of GH-stimulated, Stat5-mediated transcription as a consequence of cAMP-dependent protein kinase inactivation of RhoA through serine residue 188 of RhoA. We have therefore provided a novel mechanism by which a Ras-like small GTPase, RhoA, can regulate Stat5-mediated transcription.	Univ Auckland, Liggins Inst, Auckland 1, New Zealand; Inst Mol & Cell Biol, Singapore 117609, Singapore	University of Auckland; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Lobie, PE (corresponding author), Univ Auckland, Liggins Inst, 2-6 Pk Ave,Private Bag 92019, Auckland 1, New Zealand.	p.lobie@auckland.ac.nz						Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; AZNAR BS, 2003, MOL BIOL CELL, V14, P3041; Aznar S, 2001, MOL BIOL CELL, V12, P3282, DOI 10.1091/mbc.12.10.3282; Baluchamy S, 2003, P NATL ACAD SCI USA, V100, P9524, DOI 10.1073/pnas.1633700100; Benitah SA, 2003, MOL BIOL CELL, V14, P40, DOI 10.1091/mbc.E02-08-0454; Boer AK, 2003, EXP HEMATOL, V31, P512, DOI 10.1016/S0301-472X(03)00075-4; Boer AK, 2002, BLOOD, V100, P467, DOI 10.1182/blood.V100.2.467; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Chan HM, 2001, J CELL SCI, V114, P2363; Chen JC, 2003, J BIOL CHEM, V278, P2807, DOI 10.1074/jbc.M207943200; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Diakonova M, 2002, J BIOL CHEM, V277, P10669, DOI 10.1074/jbc.M111138200; Ellerbroek SM, 2003, J BIOL CHEM, V278, P19023, DOI 10.1074/jbc.M213066200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Forget MA, 2002, BIOCHEM J, V361, P243, DOI 10.1042/0264-6021:3610243; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; GAUR S, 1996, AM J PHYSL, V270; Genth H, 2003, J BIOL CHEM, V278, P28523, DOI 10.1074/jbc.M301915200; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Goh ELK, 2002, ENDOCRINOLOGY, V143, P3590, DOI 10.1210/en.2002-220374; Goodman RH, 2000, GENE DEV, V14, P1553; Hansen LH, 1996, J BIOL CHEM, V271, P12669, DOI 10.1074/jbc.271.21.12669; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; Heusinger-Ribeiro J, 2001, J AM SOC NEPHROL, V12, P1853, DOI 10.1681/ASN.V1291853; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Jin SH, 2000, BIOCHEM BIOPH RES CO, V277, P718, DOI 10.1006/bbrc.2000.3744; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Krepinsky JC, 2003, J AM SOC NEPHROL, V14, P2790, DOI 10.1097/01.ASN.0000094085.04161.A7; Leemhuis J, 2002, J PHARMACOL EXP THER, V300, P1000, DOI 10.1124/jpet.300.3.1000; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Ling L, 2003, J BIOL CHEM, V278, P27301, DOI 10.1074/jbc.M302516200; Lucas L, 2002, INT J ONCOL, V21, P477; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Maisse C, 2003, BIOCHEM PHARMACOL, V66, P1555, DOI 10.1016/S0006-2952(03)00511-2; Mitsiou DJ, 2003, EMBO J, V22, P4501, DOI 10.1093/emboj/cdg419; Nam S Y, 2000, Obes Rev, V1, P73, DOI 10.1046/j.1467-789x.2000.00015.x; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Park SH, 2001, MOL ENDOCRINOL, V15, P2157, DOI 10.1210/me.15.12.2157; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Qiao J, 2003, AM J PHYSIOL-LUNG C, V284, pL972, DOI 10.1152/ajplung.00429.2002; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Rattan R, 2003, FREE RADICAL BIO MED, V35, P1037, DOI 10.1016/S0891-5849(03)00459-3; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; Rui LY, 2000, MOL CELL BIOL, V20, P3168, DOI 10.1128/MCB.20.9.3168-3177.2000; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; Simar-Blanchet AE, 1998, MOL ENDOCRINOL, V12, P391, DOI 10.1210/me.12.3.391; Sirotkin AV, 2002, ANIM REPROD SCI, V70, P111, DOI 10.1016/S0378-4320(01)00196-8; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Su LF, 2002, J BIOL CHEM, V277, P37037, DOI 10.1074/jbc.M111607200; Tatsis N, 1998, J BIOL CHEM, V273, P34631, DOI 10.1074/jbc.273.51.34631; VAN AL, 1997, GENE DEV, V11, P2295; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Yarwood SJ, 1998, MOL CELL ENDOCRINOL, V138, P41; Zhang WZ, 2002, AM J PHYSIOL-RENAL, V283, pF904, DOI 10.1152/ajprenal.00156.2002; Zhu T, 2002, J BIOL CHEM, V277, P45592, DOI 10.1074/jbc.M201385200; Zhu T, 2001, CELL SIGNAL, V13, P599, DOI 10.1016/S0898-6568(01)00186-3	66	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32737	32750		10.1074/jbc.M400601200	http://dx.doi.org/10.1074/jbc.M400601200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15102857	hybrid			2022-12-25	WOS:000222849700093
J	You, FL; Chiba, N; Ishioka, C; Parvin, JD				You, FL; Chiba, N; Ishioka, C; Parvin, JD			Expression of an amino-terminal BRCA1 deletion mutant causes a dominant growth inhibition in MCF10A cells	ONCOGENE			English	Article						BRCA1; apoptosis; centrosomes	POLYMERASE-II HOLOENZYME; DNA-DAMAGE RESPONSE; UBIQUITIN LIGASE; OVARIAN-CANCER; BREAST-CANCER; RNA HELICASE; PROTEIN; COMPLEX; TRANSCRIPTION; GENE	Expression of deletion mutants of the breast and ovarian cancer-specific tumor suppressor protein, BRCA1, in the mammary epithelial cell line MCF10A revealed a powerful growth suppressive effect by a mutant that has the amino-terminal 302 amino acids deleted (DeltaN-BRCA1). The growth suppression is associated with an increase in apoptosis and amplification in centrosome number. The growth inhibitory effect of DeltaN-BRCA1 was not observed in cervical epithelial HeLa cells, suggesting that the phenotypes of BRCA1 mutant proteins differ depending on the cell line being tested. An internal domain, including BRCA1 residues 303-1292, caused the suppression of MCF10A cell growth, and the amino terminus of BRCA1 autoinhibited the growth suppression. Single point mutations that disrupted the amino-terminal RING domain of BRCA1 caused significant suppression of growth in MCF10A cells. These results suggest that the proper function of the RING domain, likely to be ubiquitin ligase function, is important in regulating the growth of the mammary epithelial cell line and in autoregulating the powerful internal growth-inhibiting domain of the BRCA1 tumor suppressor.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Tohoku Univ, Dept Clin Oncol, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 9808575, Japan	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Tohoku University	Parvin, JD (corresponding author), Brigham & Womens Hosp, Dept Pathol, NRB 630,77 Ave Louis Pasteur, Boston, MA 02115 USA.	jparvin@rics.bwh.harvard.edu	Parvin, Jeffrey D/C-8955-2009	Ishioka, Chikashi/0000-0002-3023-1227	NCI NIH HHS [CA90281] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090281] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Andrews HN, 2002, J BIOL CHEM, V277, P26225, DOI 10.1074/jbc.M201316200; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chiba N, 2002, CANCER RES, V62, P4222; Chiba N, 2001, J BIOL CHEM, V276, P38549, DOI 10.1074/jbc.M105227200; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hsu LC, 2001, CANCER RES, V61, P7713; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Narita T, 2003, MOL CELL BIOL, V23, P1863, DOI 10.1128/MCB.23.6.1863-1873.2003; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Schlegel BP, 2003, ONCOGENE, V22, P983, DOI 10.1038/sj.onc.1206195; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	33	16	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5792	5798		10.1038/sj.onc.1207739	http://dx.doi.org/10.1038/sj.onc.1207739			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15122325				2022-12-25	WOS:000222629800008
J	Klenotic, PA; Munier, FL; Marmorstein, LY; Anand-Apte, B				Klenotic, PA; Munier, FL; Marmorstein, LY; Anand-Apte, B			Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) - Implications for macular degenerations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SORSBYS-FUNDUS-DYSTROPHY; MUTATION; EXPRESSION; LOCALIZATION; ANGIOGENESIS; ACCUMULATION; PHENOTYPE; GENE	Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a matrix-bound inhibitor of matrix metalloproteinases. Mutations in the Timp-3 gene cause Sorsby fundus dystrophy (SFD), a hereditary macular degenerative disease. The pathogenic mechanisms responsible for the disease phenotype are unknown. In an in vivo quest for binding partners of the TIMP-3 protein in the subretina, we identified epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1, also known as fibulin 3) as a strong interacting protein. The COOH-terminal end of TIMP-3 was involved in the interaction. Interestingly, a missense mutation in EFEMP1 is responsible for another hereditary macular degenerative disease, Malattia Leventinese (ML). Both SFD and ML have strong similarities to age-related macular degeneration (AMD), a major cause of blindness in the elderly population of the Western hemisphere. Our results were supported by significant accumulation and expression overlap of both TIMP-3 and EFEMP1 between the retinal pigment epithelia and Bruch membrane in the eyes of ML and AMD patients. These results provide the first link between two different macular degenerative disease genes and imply the possibility of a common pathogenic mechanism behind different forms of macular degeneration.	Univ Arizona, Dept Ophthalmol & Cell Biol, Tucson, AZ 85711 USA; Cleveland Clin Fdn, Dept Ophthalm Res, Cole Eye Inst, Cleveland, OH 44195 USA; Jules Gonin Eye Hosp, Oculognet Unit, CH-1004 Lausanne, Switzerland; Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA	University of Arizona; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Marmorstein, LY (corresponding author), Univ Arizona, Dept Ophthalmol & Cell Biol, Tucson, AZ 85711 USA.	lmarmorstein@oacs01.eyes.arizona.edu; anandab@ccf.org			NATIONAL EYE INSTITUTE [R29EY012109, R01EY016490, R01EY013847] Funding Source: NIH RePORTER; NEI NIH HHS [R29 EY012109, R01 EY016490, R01EY13847, 1 R29 EY12109-01] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Bergers G, 2000, CURR OPIN GENET DEV, V10, P120, DOI 10.1016/S0959-437X(99)00043-X; Blackburn J, 2003, INVEST OPHTH VIS SCI, V44, P4613, DOI 10.1167/iovs.03-0112; BLENIS J, 1983, P NATL ACAD SCI-BIOL, V80, P770, DOI 10.1073/pnas.80.3.770; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5; CAPON MRC, 1989, OPHTHALMOLOGY, V96, P1769; Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899; Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921; Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x; Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367; Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778; Langton KP, 2000, J BIOL CHEM, V275, P27027; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Qi JH, 2002, J BIOL CHEM, V277, P13394, DOI 10.1074/jbc.M110870200; Soboleva G, 2003, J CELL PHYSIOL, V197, P149, DOI 10.1002/jcp.10361; Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285; Tabata Y, 1998, HUM GENET, V103, P179, DOI 10.1007/PL00008707; Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130; Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; Woessner JF, 2001, J CLIN INVEST, V108, P799, DOI 10.1172/JCI13709; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200	30	125	131	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30469	30473		10.1074/jbc.M403026200	http://dx.doi.org/10.1074/jbc.M403026200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123717	hybrid			2022-12-25	WOS:000222531900074
J	Kock, MA; Hew, BE; Bammert, H; Fritzinger, DC; Vogel, CW				Kock, MA; Hew, BE; Bammert, H; Fritzinger, DC; Vogel, CW			Structure and function of recombinant cobra venom factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT-ACTIVATING PROTEIN; N-LINKED OLIGOSACCHARIDES; ALTERNATIVE PATHWAY; 3RD COMPONENT; FACTOR-B; BIOCHEMICAL-CHARACTERIZATION; BETA-1H GLOBULIN; C3-C5 CONVERTASE; C3B INACTIVATOR; EXPRESSION	Cobra venom factor (CVF) is the complement-activating protein from cobra venom. It is a structural and functional analog of complement component C3. CVF functionally resembles C3b, the activated form of C3. Like C3b, CVF binds factor B, which is subsequently cleaved by factor D to form the bimolecular complex CVF, Bb. CVF, Bb is a C3/C5 convertase that cleaves both complement components C3 and C5. CVF is a three-chain protein that structurally resembles the C3b degradation product C3c, which is unable to form a C3/C5 convertase. Both C3 and CVF are synthesized as single-chain prepro-proteins. This study reports the recombinant expression of pro-CVF in two insect cell expression systems (baculovirus-infected Sf9 Spodoptera frugiperda cells and stably transfected S2 Drosophila melanogaster cells). In both expression systems pro-CVF is synthesized initially as a single-chain pro-CVF molecule that is subsequently proteolytically processed into a two-chain form of pro-CVF that structurally resembles C3. The C3-like form of pro-CVF can be further proteolytically processed into another two-chain form of pro-CVF that structurally resembles C3b. Unexpectedly, all three forms of pro-CVF exhibit functional activity of mature, natural CVF. Recombinant pro-CVF supports the activation of factor B in the presence of factor D and Mg2+ and depletes serum complement activity like natural CVF. The bimolecular convertase pro-CVF, Bb exhibits both C3 cleaving and C5 cleaving activity. The activity of pro-CVF and the resulting C3/C5 convertase is indistinguishable from CVF and the CVF, Bb convertase. The ability to produce active forms of pro-CVF recombinantly ensures the continued availability of an important research reagent for complement depletion because cobra venom as the source for natural CVF will be increasingly difficult to obtain as the Indian cobra is on the list of endangered species. Experimental systems to express pro-CVF recombinantly will also be invaluable for studies to delineate the structure and function relationship of CVF and its differences from C3 as well as to generate human C3 derivatives with CVF-like function for therapeutic complement depletion ("humanized CVF").	Univ Hawaii Manoa, Canc Res Ctr Hawaii, Honolulu, HI 96813 USA; Univ Hamburg, Dept Biochem & Mol Biol, D-20146 Hamburg, Germany	Cancer Research Center of Hawaii; University of Hawaii System; University of Hawaii Manoa; University of Hamburg	Vogel, CW (corresponding author), Univ Hawaii Manoa, Canc Res Ctr Hawaii, 1236 Lauhala St, Honolulu, HI 96813 USA.	cvogel@crch.hawaii.edu	Fritzinger, David C/E-5259-2012					ALPER CA, 1976, SCIENCE, V191, P1275, DOI 10.1126/science.56780; Bambai B, 1998, MOL IMMUNOL, V35, P408, DOI 10.1016/S0161-5890(98)90843-4; BROWN TL, 1981, J BIOL CHEM, V256, P743; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COCHRANE CG, 1970, J IMMUNOL, V105, P55; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P5584, DOI 10.1021/bi00475a024; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DISCIPIO RG, 1983, J BIOL CHEM, V258, P629; DUNCKER BP, 1994, BIOCHEM BIOPH RES CO, V203, P1851, DOI 10.1006/bbrc.1994.2403; EGGERTSEN G, 1981, MOL IMMUNOL, V18, P125, DOI 10.1016/0161-5890(81)90078-X; FRITZINGER DC, 1994, P NATL ACAD SCI USA, V91, P12775, DOI 10.1073/pnas.91.26.12775; Fritzinger DC, 2003, MOL IMMUNOL, V40, P199; FRITZINGER DC, 1992, J IMMUNOL, V149, P3554; GOWDA DC, 1992, MOL IMMUNOL, V29, P335, DOI 10.1016/0161-5890(92)90020-X; Gowda DC, 2001, GLYCOBIOLOGY, V11, P195, DOI 10.1093/glycob/11.3.195; GOWDA DC, 1994, J IMMUNOL, V152, P2977; GRIER AH, 1987, J IMMUNOL, V139, P1245; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; HAUGEN TH, 1979, P NATL ACAD SCI USA, V76, P2689, DOI 10.1073/pnas.76.6.2689; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HENSLEY P, 1986, J BIOL CHEM, V261, P1038; Hew BE, 2004, MOL IMMUNOL, V41, P244; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; ISAAC L, 1992, J BIOL CHEM, V267, P10062; Iwanaga S., 1979, SNAKE VENOMS, P61; KIRKPATRICK RB, 1995, J BIOL CHEM, V270, P19800, DOI 10.1074/jbc.270.34.19800; KRESS LF, 1983, BIOCHIM BIOPHYS ACTA, V745, P113, DOI 10.1016/0167-4838(83)90039-0; LACHMANN PJ, 1975, CLIN EXP IMMUNOL, V21, P109; LAO ZG, 1994, J IMMUNOL METHODS, V176, P127; LESAVRE PH, 1979, J IMMUNOL, V123, P529; MATSUOKA K, 1991, P NATL ACAD SCI USA, V88, P834, DOI 10.1073/pnas.88.3.834; MEDICUS RG, 1976, J EXP MED, V144, P1076, DOI 10.1084/jem.144.4.1076; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MOGUILEVSKY N, 1991, EUR J BIOCHEM, V197, P605, DOI 10.1111/j.1432-1033.1991.tb15950.x; Morgan BP, 2003, MOL IMMUNOL, V40, P159, DOI 10.1016/S0161-5890(03)00111-1; NAGAKI K, 1978, INT ARCH ALLER A IMM, V57, P221, DOI 10.1159/000232106; OKEEFE MC, 1988, J BIOL CHEM, V263, P12690; PANGBURN MK, 1992, J BIOL CHEM, V267, P8584; PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257; PAUL JI, 1990, J BIOL CHEM, V265, P13074; PETRELLA EC, 1987, J IMMUNOL METHODS, V104, P159, DOI 10.1016/0022-1759(87)90500-X; Petrella EC, 1991, COMPLEMENT INFLAMM, V9, P210; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SMITH CA, 1984, J EXP MED, V159, P324, DOI 10.1084/jem.159.1.324; SMITH CA, 1982, J BIOL CHEM, V257, P9879; Vogel C.-W., 1991, HDB NATURAL TOXINS, P147; VOGEL CW, 1984, J IMMUNOL METHODS, V73, P203, DOI 10.1016/0022-1759(84)90045-0; Vogel CW, 1996, ADV EXP MED BIOL, V391, P97; VOGEL CW, 1982, J BIOL CHEM, V257, P8292; VOGEL CW, 1984, J IMMUNOL, V133, P3235; VOGT W, 1974, H-S Z PHYSIOL CHEM, V355, P171, DOI 10.1515/bchm2.1974.355.1.171; Wehrhahn Daniel, 2000, Immunopharmacology, V49, P94, DOI 10.1016/S0162-3109(00)80281-7; WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147; Wuster W, 1996, TOXICON, V34, P399, DOI 10.1016/0041-0101(95)00139-5	55	47	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30836	30843		10.1074/jbc.M403196200	http://dx.doi.org/10.1074/jbc.M403196200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131128	hybrid			2022-12-25	WOS:000222531900116
J	Xu, YH; Liu, YW; Lou, ZY; Qin, L; Li, X; Bai, ZH; Pang, H; Tien, P; Gao, GF; Rao, Z				Xu, YH; Liu, YW; Lou, ZY; Qin, L; Li, X; Bai, ZH; Pang, H; Tien, P; Gao, GF; Rao, Z			Structural basis for coronavirus-mediated membrane fusion - Crystal structure of mouse hepatitis virus spike protein fusion core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TO-CELL FUSION; ENVELOPE GLYCOPROTEIN; INFLUENZA HEMAGGLUTININ; EBOLA-VIRUS; CONFORMATIONAL-CHANGE; HIV-1 ENTRY; COILED-COIL; HYDROPHOBIC REGIONS; POTENT INHIBITORS; ATOMIC-STRUCTURE	The surface transmembrane glycoprotein is responsible for mediating virion attachment to cell and subsequent virus-cell membrane fusion. However, the molecular mechanisms for the viral entry of coronaviruses remain poorly understood. The crystal structure of the fusion core of mouse hepatitis virus S protein, which represents the first fusion core structure of any coronavirus, reveals a central hydrophobic coiled coil trimer surrounded by three helices in an oblique, antiparallel manner. This structure shares significant similarity with both the low pH-induced conformation of influenza hemagglutinin and fusion core of HIV gp41, indicating that the structure represents a fusion-active state formed after several conformational changes. Our results also indicate that the mechanisms for the viral fusion of coronaviruses are similar to those of influenza virus and HIV. The coiled coil structure has unique features, which are different from other viral fusion cores. Highly conserved heptad repeat 1 (HR1) and HR2 regions in coronavirus spike proteins indicate a similar three-dimensional structure among these fusion cores and common mechanisms for the viral fusion. We have proposed the binding regions of HR1 and HR2 of other coronaviruses and a structure model of their fusion core based on our mouse hepatitis virus fusion core structure and sequence alignment. Drug discovery strategies aimed at inhibiting viral entry by blocking hairpin formation may be applied to the inhibition of a number of emerging infectious diseases, including severe acute respiratory syndrome.	Tsing Hua Univ, Struct Biol Lab, Sch Life Sci & Engn, Beijing 100084, Peoples R China; Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Chinese Acad Sci, Inst Microbiol, Beijing 100080, Peoples R China; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England	Tsinghua University; Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of Microbiology, CAS; University of Oxford	Rao, Z (corresponding author), Tsing Hua Univ, Struct Biol Lab, Sch Life Sci & Engn, Beijing 100084, Peoples R China.	raozh@xtal.tsinghua.edu.cn	Bai, Zhihui/O-5303-2019; Rao, Zihe/HCH-6944-2022; Gao, George Fu/ABD-5229-2021; Li, Xu/A-7108-2013	Bai, Zhihui/0000-0002-3818-527X; 				Baker KA, 1999, MOL CELL, V3, P309, DOI 10.1016/S1097-2765(00)80458-X; BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001; Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHAMBERS P, 1990, J GEN VIROL, V71, P3075, DOI 10.1099/0022-1317-71-12-3075; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Damico RL, 1998, P NATL ACAD SCI USA, V95, P2580, DOI 10.1073/pnas.95.5.2580; DAVIES HA, 1979, ARCH VIROL, V59, P25, DOI 10.1007/BF01317891; Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898; Fass D, 1995, CURR BIOL, V5, P1377, DOI 10.1016/S0960-9822(95)00275-2; Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757; Gibbons DL, 2004, NATURE, V427, P320, DOI 10.1038/nature02239; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; Hernandez LD, 1997, J CELL BIOL, V139, P1455, DOI 10.1083/jcb.139.6.1455; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Luo ZL, 1999, J VIROL, V73, P8152, DOI 10.1128/JVI.73.10.8152-8159.1999; Luo ZL, 1998, VIROLOGY, V244, P483, DOI 10.1006/viro.1998.9121; Malashkevich VN, 1999, P NATL ACAD SCI USA, V96, P2662, DOI 10.1073/pnas.96.6.2662; Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; SIDDELL S, 1983, J GEN VIROL, V64, P761, DOI 10.1099/0022-1317-64-4-761; Singh M, 1999, J MOL BIOL, V290, P1031, DOI 10.1006/jmbi.1999.2796; SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Weissenhorn W, 1998, P NATL ACAD SCI USA, V95, P6032, DOI 10.1073/pnas.95.11.6032; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Wool-Lewis RJ, 1999, J VIROL, V73, P1419, DOI 10.1128/JVI.73.2.1419-1426.1999; Yamada YK, 1997, VIROLOGY, V227, P215, DOI 10.1006/viro.1996.8313; Zhao X, 2000, P NATL ACAD SCI USA, V97, P14172, DOI 10.1073/pnas.260499197	51	104	113	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30514	30522		10.1074/jbc.M403760200	http://dx.doi.org/10.1074/jbc.M403760200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123674	hybrid, Green Published			2022-12-25	WOS:000222531900080
J	Bjerkan, TM; Bender, CL; Ertesvag, H; Drablos, F; Fakhr, MK; Preston, LA; Skjak-Braek, G; Valla, S				Bjerkan, TM; Bender, CL; Ertesvag, H; Drablos, F; Fakhr, MK; Preston, LA; Skjak-Braek, G; Valla, S			The pseudomonas syringae genome encodes a combined mannuronan C-5-epimerase and O-acetylhydrolase, which strongly enhances the predicted gel-forming properties of alginates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL GROUPS; GENE-CLUSTER; ALGINIC ACID; SEQUENCE; SECRETION; PROTEIN; EXPRESSION; FLUORESCENS; FAMILY; ALGG	Alginates are industrially important, linear copolymers of beta-D-mannuronic acid (M) and its C-5-epimer alpha-L-guluronic acid ( G). The G residues originate from a post-polymerization reaction catalyzed by mannuronan C-5-epimerases (MEs), leading to extensive variability in M/G ratios and distribution patterns. Alginates containing long continuous stretches of G residues ( G blocks) can form strong gels, a polymer type not found in alginate-producing bacteria belonging to the genus Pseudomonas. Here we show that the Pseudomonas syringae genome encodes a Ca2+-dependent ME (PsmE) that efficiently forms such G blocks in vitro. The deduced PsmE protein consists of 1610 amino acids and is a modular enzyme related to the previously characterized family of Azotobacter vinelandii ME (AlgE1-7). A- and R-like modules with sequence similarity to those in the AlgE enzymes are found in PsmE, and the A module of PsmE (PsmEA) was found to be sufficient for epimerization. Interestingly, an R module from AlgE4 stimulated PsmEA activity. PsmE contains two regions designated M and RTX, both presumably involved in the binding of Ca2+. Bacterial alginates are partly acetylated, and such modified residues cannot be epimerized. Based on a detailed computer-assisted analysis and experimental studies another PsmE region, designated N, was found to encode an acetylhydrolase. By the combined action of N and A PsmE was capable of redesigning an extensively acetylated alginate low in G from a non gel-forming to a gel-forming state. Such a property has to our knowledge not been previously reported for an enzyme acting on a polysaccharide.	Norwegian Univ Sci & Technol, Dept Biotechnol, N-7491 Trondheim, Norway; Oklahoma State Univ, Dept Entomol & Plant Pathol, Stillwater, OK 74078 USA; Norwegian Univ Sci & Technol, Fac Med, Dept Canc Res & Mol Med, N-7489 Trondheim, Norway	Norwegian University of Science & Technology (NTNU); Oklahoma State University System; Oklahoma State University - Stillwater; Norwegian University of Science & Technology (NTNU)	Valla, S (corresponding author), Norwegian Univ Sci & Technol, Dept Biotechnol, N-7491 Trondheim, Norway.	Svein.Valla@biotech.ntnu.no	Heggeset, Tonje Marita Bjerkan/I-9077-2019; Drablos, Finn/L-4970-2019	Drablos, Finn/0000-0001-5794-828X; Heggeset, Tonje/0000-0002-1221-8598; Ertesvag, helga/0000-0001-9437-9469	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043311] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BARTA TM, 1992, J BACTERIOL, V174, P3021, DOI 10.1128/JB.174.9.3021-3029.1992; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BJERKAN TM, 2004, IN PRESS BIOCH J; Buchanan SK, 2001, TRENDS BIOCHEM SCI, V26, P3, DOI 10.1016/S0968-0004(00)01733-3; Budde IP, 2000, MOL PLANT MICROBE IN, V13, P951, DOI 10.1094/MPMI.2000.13.9.951; Buell CR, 2003, P NATL ACAD SCI USA, V100, P10181, DOI 10.1073/pnas.1731982100; COTE GL, 1988, CARBOHYD RES, V181, P143, DOI 10.1016/0008-6215(88)84030-8; DAVIDSON IW, 1977, J GEN MICROBIOL, V98, P603, DOI 10.1099/00221287-98-2-603; Dickens NJ, 2002, CURR BIOL, V12, pR197, DOI 10.1016/S0960-9822(02)00748-0; DUONG F, 1992, GENE, V121, P47, DOI 10.1016/0378-1119(92)90160-Q; ERTESVAG H, 1995, MOL MICROBIOL, V16, P719, DOI 10.1111/j.1365-2958.1995.tb02433.x; ERTESVAG H, 1994, J BACTERIOL, V176, P2846; Ertesvag H, 1999, J BACTERIOL, V181, P3033; Ertesvag H, 1999, METH BIOTEC, V10, P71; Ertesvag H, 1999, METAB ENG, V1, P262, DOI 10.1006/mben.1999.0130; FRANKLIN MJ, 1994, J BACTERIOL, V176, P1821, DOI 10.1128/JB.176.7.1821-1830.1994; GACESA P, 1987, FEBS LETT, V212, P199, DOI 10.1016/0014-5793(87)81344-3; Gimmestad M, 2003, J BACTERIOL, V185, P3515, DOI 10.1128/JB.185.12.3515-3523.2003; Ginalski K, 2003, BIOINFORMATICS, V19, P1015, DOI 10.1093/bioinformatics/btg124; GORIN PAJ, 1966, CAN J CHEMISTRY, V44, P993, DOI 10.1139/v66-147; GOVAN JRW, 1981, J GEN MICROBIOL, V125, P217; GRASDALEN H, 1981, CARBOHYD RES, V89, P179, DOI 10.1016/S0008-6215(00)85243-X; GRASDALEN H, 1983, CARBOHYD RES, V118, P255, DOI 10.1016/0008-6215(83)88053-7; Hartmann M, 2002, BBA-GEN SUBJECTS, V1570, P104, DOI 10.1016/S0304-4165(02)00195-2; HAUG A, 1967, ACTA CHEM SCAND, V21, P768, DOI 10.3891/acta.chem.scand.21-0768; HAUG A, 1974, CARBOHYD RES, V32, P217, DOI 10.1016/S0008-6215(00)82100-X; Ho YS, 1999, PROTEIN ENG, V12, P693, DOI 10.1093/protein/12.8.693; Hoidal HK, 1999, J BIOL CHEM, V274, P12316, DOI 10.1074/jbc.274.18.12316; Jaroszewski L, 2000, PROTEIN SCI, V9, P1487, DOI 10.1110/ps.9.8.1487; JONES JDG, 1987, GENE, V61, P299, DOI 10.1016/0378-1119(87)90193-4; Kaneko T, 2001, DNA RES, V8, P205, DOI 10.1093/dnares/8.5.205; Keith RC, 2003, MICROBIOL-SGM, V149, P1127, DOI 10.1099/mic.0.26109-0; KEITH RC, 2002, EXPRESSION ALGINATE; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Lally ET, 1999, TRENDS MICROBIOL, V7, P356, DOI 10.1016/S0966-842X(99)01530-9; LETOFFE S, 1992, J BACTERIOL, V174, P4920; LETOFFE S, 1994, J BACTERIOL, V176, P5372; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; LINKER A, 1984, J BACTERIOL, V159, P958, DOI 10.1128/JB.159.3.958-964.1984; LINKER A, 1964, NATURE, V204, P187, DOI 10.1038/204187a0; Lo Conte L, 2002, NUCLEIC ACIDS RES, V30, P264; McMullen TWP, 2000, PROTEIN ENG, V13, P865, DOI 10.1093/protein/13.12.865; MICHELL RE, 1982, PHYSL PLANT PATHOL, V20, P83; Molgaard A, 2000, STRUCTURE, V8, P373, DOI 10.1016/S0969-2126(00)00118-0; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nelson KE, 2002, ENVIRON MICROBIOL, V4, P799, DOI 10.1046/j.1462-2920.2002.00366.x; OSMAN SF, 1986, J BACTERIOL, V166, P66, DOI 10.1128/jb.166.1.66-71.1986; PALMER DA, 1993, APPL ENVIRON MICROB, V59, P1619, DOI 10.1128/AEM.59.5.1619-1626.1993; PenalozaVazquez A, 1997, J BACTERIOL, V179, P4464, DOI 10.1128/jb.179.14.4464-4472.1997; Ramstad MV, 1999, ENZYME MICROB TECH, V24, P636, DOI 10.1016/S0141-0229(98)00148-3; Rehm BH, 1996, J BACTERIOL, V178, P5884, DOI 10.1128/jb.178.20.5884-5889.1996; Rychlewski L, 2000, PROTEIN SCI, V9, P232, DOI 10.1110/ps.9.2.232; Sambrook J., 2001, MOL CLONING LAB MANU; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sheffield PJ, 2001, PROTEIN ENG, V14, P513, DOI 10.1093/protein/14.7.513; Skjak-Braek G, 1996, CARBOHYDR EUR, V14, P19; SKJAKBRAEK G, 1986, CARBOHYD RES, V154, P239; SKJAKBRAEK G, 1985, CARBOHYD RES, V145, P169; Smidsrod O., 1996, CARBOHYDR EUR, V14, P6; STASKAWICZ BJ, 1984, P NATL ACAD SCI-BIOL, V81, P6024, DOI 10.1073/pnas.81.19.6024; Sutton JM, 1996, MOL PLANT MICROBE IN, V9, P671, DOI 10.1094/MPMI-9-0671; Svanem BIG, 2001, J BIOL CHEM, V276, P31542, DOI 10.1074/jbc.M102562200; Svanem BIG, 1999, J BACTERIOL, V181, P68, DOI 10.1128/JB.181.1.68-77.1999; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Ullrich MS, 2000, MICROBIOL-SGM, V146, P2457, DOI 10.1099/00221287-146-10-2457; Valla S, 2001, BIOCHIMIE, V83, P819, DOI 10.1016/S0300-9084(01)01313-X; WASSIF C, 1995, J BACTERIOL, V177, P5790, DOI 10.1128/jb.177.20.5790-5798.1995; Welch RA, 2001, CURR TOP MICROBIOL, V257, P85; YOUNG JM, 1988, INT COLLECTION MICRO; Yu J, 1999, MOL MICROBIOL, V33, P712, DOI 10.1046/j.1365-2958.1999.01516.x	72	15	16	0	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28920	28929		10.1074/jbc.M313293200	http://dx.doi.org/10.1074/jbc.M313293200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123694	hybrid			2022-12-25	WOS:000222445300013
J	Fischer, OM; Giordano, S; Comoglio, PM; Ullrich, A				Fischer, OM; Giordano, S; Comoglio, PM; Ullrich, A			Reactive oxygen species mediate met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF RECEPTOR; C-MET; BETA-CATENIN; HYDROGEN-PEROXIDE; ANGIOTENSIN-II; CROSS-TALK; TYROSINE PHOSPHORYLATION; SCATTER-FACTOR; ACTIVATION; GENERATION	Cross-communication between the Met receptor tyrosine kinase and the epidermal growth factor receptor ( EGFR) has been proposed to involve direct association of both receptors and EGFR kinase-dependent phosphorylation. Here, we demonstrate that in human hepatocellular and pancreatic carcinoma cells the Met receptor becomes tyrosine phosphorylated not only upon EGF stimulation but also in response to G protein-coupled receptor ( GPCR) agonists. Whereas specific inhibition of the EGFR kinase activity blocked EGF- but not GPCR agonist-induced Met receptor transactivation, it was abrogated in the presence of a reducing agent or treatment of cells with a NADPH oxidase inhibitor. Both GPCR ligands and EGF are further shown to increase the level of reactive oxygen species within the cell. Interestingly, stimulation of the Met receptor by either GPCR agonists, EGF or its cognate ligand HGF, resulted in release of Met-associated beta-catenin and in its Met-dependent translocation into the nucleus, as analyzed by small interfering RNA-mediated knockdown of the Met receptor. Our results provide a new molecular explanation for cell surface receptor cross-talk involving the Met receptor and thereby link the wide diversity of GPCRs and the EGFR to the oncogenic potential of Met signaling in human carcinoma cells.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany; Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10060 Turin, Italy	Max Planck Society; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Ullrich, A (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.	ullrich@biochem.mpg.de	Giordano, Silvia/J-9858-2018; Fischer, Oliver/V-7641-2019	Giordano, Silvia/0000-0003-1854-1086; Comoglio, Paolo/0000-0002-7056-5328				Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Bergstrom JD, 2000, EXP CELL RES, V259, P293, DOI 10.1006/excr.2000.4967; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daveau M, 2003, MOL CARCINOGEN, V36, P130, DOI 10.1002/mc.10103; De Palma M, 2002, METHOD ENZYMOL, V346, P514; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Gschwind A, 2002, CANCER RES, V62, P6329; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Herynk MH, 2003, CLIN EXP METASTAS, V20, P291, DOI 10.1023/A:1024024218529; Hiscox S, 1999, ANTICANCER RES, V19, P509; Hiscox S, 1999, BIOCHEM BIOPH RES CO, V261, P406, DOI 10.1006/bbrc.1999.1002; Holland JA, 1998, ENDOTHELIUM-NEW YORK, V6, P113, DOI 10.3109/10623329809072198; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Kikuchi H, 2000, GENE, V254, P237, DOI 10.1016/S0378-1119(00)00258-4; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lee FS, 2001, P NATL ACAD SCI USA, V98, P3555, DOI 10.1073/pnas.061020198; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; Miura Y, 2003, BIOCHEM BIOPH RES CO, V305, P160, DOI 10.1016/S0006-291X(03)00725-3; Monga SPS, 2002, CANCER RES, V62, P2064; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; Nath D, 2001, J CELL SCI, V114, P1213; Pai R, 2003, FASEB J, V17, P1640, DOI 10.1096/fj.02-1011com; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; Peghini PL, 2002, CLIN CANCER RES, V8, P2273; Perner A, 2003, GUT, V52, P231, DOI 10.1136/gut.52.2.231; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAMSBY ML, 1994, ELECTROPHORESIS, V15, P265, DOI 10.1002/elps.1150150146; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Rhee S G, 2000, Sci STKE, V2000, ppe1; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; Saito Y, 2001, J MOL CELL CARDIOL, V33, P3, DOI 10.1006/jmcc.2000.1272; Scheving LA, 2002, BIOCHEM BIOPH RES CO, V290, P197, DOI 10.1006/bbrc.2001.6157; Schiavo G, 2001, NAT REV MOL CELL BIO, V2, P530, DOI 10.1038/35080089; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Thuringer D, 2002, J BIOL CHEM, V277, P2028, DOI 10.1074/jbc.M109493200; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358	61	93	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28970	28978		10.1074/jbc.M402508200	http://dx.doi.org/10.1074/jbc.M402508200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123705	hybrid			2022-12-25	WOS:000222445300019
J	Li, AM; Dong, JX; Harris, DA				Li, AM; Dong, JX; Harris, DA			Cell surface expression of the prion protein in yeast does not alter copper utilization phenotypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE-DISMUTASE; SIGNAL SEQUENCES; ALPHA-SYNUCLEIN; PLASMA-MEMBRANE; CULTURED-CELLS; METAL-IONS; IN-VIVO; PRP	Prion diseases are fatal neurodegenerative disorders that result from conversion of a normal, cell surface glycoprotein (PrPC) into a conformationally altered isoform (PrPSc) that is thought to be infectious. Although a great deal is known about the role of PrPSc in the disease process, the physiological function of PrPC has remained enigmatic. In this report, we have used the yeast Saccharomyces cerevisiae to test one hypothesized function of PrPC, as a receptor for the uptake or efflux of copper ions. We first modified the PrP signal peptide by replacing its hydrophobic core with the signal sequence from the yeast protein dipeptidyl aminopeptidase B, so that the resulting protein was targeted cotranslationally to the secretory pathway when synthesized in yeast. PrP molecules with the modified signal peptide were efficiently glycosylated, glycolipid-anchored, and localized to the plasma membrane. We then tested whether PrP expression altered the growth deficiency phenotypes of yeast strains harboring deletions in genes that encode key components of copper utilization pathways, including transporters, chaperones, pumps, reductases, and cuproenzymes. We found that PrP did not rescue any of these mutant phenotypes, arguing against a direct role for the protein in copper utilization. Our results provide further clarification of the physiological function of PrPC, and lay the groundwork for using PrP-expressing yeast to study other aspects of prion biology.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Harris, DA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	dharris@cellbio.wustl.edu		Harris, David/0000-0002-6985-5790	NINDS NIH HHS [NS40061] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040061] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], 2004, CURRENT PROTOCOLS MO; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; BOLTON DC, 1991, J VIROL, V65, P3667, DOI 10.1128/JVI.65.7.3667-3675.1991; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; Brown DR, 2002, J NEUROSCI RES, V67, P211, DOI 10.1002/jnr.10118; Brown Lesley R., 2002, P103; Brown LR, 2003, J NEUROCHEM, V87, P353, DOI 10.1046/j.1471-4159.2003.01996.x; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Burns CS, 2003, BIOCHEMISTRY-US, V42, P6794, DOI 10.1021/bi027138+; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; Doering TL, 1997, BIOCHEM J, V328, P669; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Eide DJ, 2000, ADV MICROB PHYSIOL, V43, P1, DOI 10.1016/S0065-2911(00)43001-8; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Gemmill TR, 1999, BBA-GEN SUBJECTS, V1426, P227, DOI 10.1016/S0304-4165(98)00126-3; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; Glick BS, 1996, CURR BIOL, V6, P1570, DOI 10.1016/S0960-9822(02)70774-4; HARRIS DA, 1991, P NATL ACAD SCI USA, V88, P7664, DOI 10.1073/pnas.88.17.7664; Hasnain SS, 2001, J MOL BIOL, V311, P467, DOI 10.1006/jmbi.2001.4795; Heller U, 2003, J BIOL CHEM, V278, P36139, DOI 10.1074/jbc.M304002200; Holscher C, 2001, J BIOL CHEM, V276, P13388, DOI 10.1074/jbc.M007331200; Hutter G, 2003, BIOL CHEM, V384, P1279, DOI 10.1515/BC.2003.142; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Labbe S, 1999, TRENDS MICROBIOL, V7, P500, DOI 10.1016/S0966-842X(99)01638-8; Lehmann S, 2002, CURR OPIN CHEM BIOL, V6, P187, DOI 10.1016/S1367-5931(02)00295-8; Lehmann S, 1997, J BIOL CHEM, V272, P21479, DOI 10.1074/jbc.272.34.21479; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; Lledo PM, 1996, P NATL ACAD SCI USA, V93, P2403, DOI 10.1073/pnas.93.6.2403; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; Mange A, 2002, FEBS LETT, V514, P159, DOI 10.1016/S0014-5793(02)02338-4; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Oidtmann B, 2003, FEBS LETT, V538, P96, DOI 10.1016/S0014-5793(03)00149-2; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Prusiner SB, 2004, PRION BIOL DIS; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Qin KF, 2002, J BIOL CHEM, V277, P1981, DOI 10.1074/jbc.M108744200; Quaglio E, 2001, J BIOL CHEM, V276, P11432, DOI 10.1074/jbc.M009666200; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Riley ML, 2002, PROTEIN ENG, V15, P529, DOI 10.1093/protein/15.6.529; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; Simonic T, 2000, FEBS LETT, V469, P33, DOI 10.1016/S0014-5793(00)01232-1; Solforosi L, 2004, SCIENCE, V303, P1514, DOI 10.1126/science.1094273; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; Stewart RS, 2001, J BIOL CHEM, V276, P2212, DOI 10.1074/jbc.M006763200; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Strumbo B, 2001, FEBS LETT, V508, P170, DOI 10.1016/S0014-5793(01)03027-7; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; Uptain SM, 2002, ANNU REV MICROBIOL, V56, P703, DOI 10.1146/annurev.micro.56.013002.100603; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Waggoner DJ, 2000, J BIOL CHEM, V275, P7455, DOI 10.1074/jbc.275.11.7455; Willingham S, 2003, SCIENCE, V302, P1769, DOI 10.1126/science.1090389; Wong BS, 2000, BIOCHEM BIOPH RES CO, V275, P249, DOI 10.1006/bbrc.2000.3158; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454; Zheng N, 1996, CELL, V86, P849, DOI 10.1016/S0092-8674(00)80159-2	75	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29469	29477		10.1074/jbc.M402517200	http://dx.doi.org/10.1074/jbc.M402517200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15090539	hybrid			2022-12-25	WOS:000222445300079
J	Osborne, AR; Zhang, HQ; Fejer, G; Palubin, KM; Niesen, MI; Blanck, G				Osborne, AR; Zhang, HQ; Fejer, G; Palubin, KM; Niesen, MI; Blanck, G			Oct-1 maintains an intermediate, stable state of HLA-DRA promoter repression in Rb-defective cells - An Oct-1-containing repressosome that prevents NF-Y binding to the HLA-DRA promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX CLASS-II; BARE LYMPHOCYTE SYNDROME; DEFICIENT COMBINED IMMUNODEFICIENCY; RETINOBLASTOMA PROTEIN EXPRESSION; CD4(+) T-CELLS; IN-VIVO; COOPERATIVE BINDING; GAMMA-INDUCTION; CARCINOMA CELLS; GENE-EXPRESSION	The cell surface HLA-DR molecule binds foreign peptide antigen and forms an intercellular complex with the T cell receptor in the course of the development of an immune response against or immune tolerance to the antigen represented by the bound peptide. The HLA-DR molecule also functions as a receptor that mediates cell signaling pathways, including as yet poorly characterized pathway(s) leading to apoptosis. Expression of HLA-DR mRNA and protein is ordinarily inducible by interferon-gamma but is not inducible in tumor cells defective for the retinoblastoma tumor suppressor protein (Rb). In the case of the HLA-DRA gene, which encodes the HLA-DR heavy chain, previous work has indicated that this loss of inducibility is attributable to Oct-1 binding to the HLA-DRA promoter. In this report, we used Oct-1 antisense transformants to determine that Oct-1 represses the interferon-gamma response of the endogenous HLA-DRA gene. This determination is consistent with results from a chromatin immunoprecipitation assay, indicating that Oct-1 occupies the endogenous HLA-DRA promoter when the HLA-DRA promoter is inactive in Rb-defective cells but not when the promoter is converted to a previously defined, transcriptionally competent state, induced by treatment of the Rb-defective cells with the HDAC inhibitor, trichostatin A. In vitro DNA-protein binding analyses indicated that Oct-1 prevents HLA-DRA promoter activation by mediating the formation of a complex of proteins, termed DRAN (DRA negative), that blocks NF-Y access to the promoter.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol & Lab Med, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Blanck, G (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, MDC Box 7,12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	gblanck@hsc.usf.edu	Fejer, Gyorgy/D-5080-2011; Blanck, George/A-5365-2012; Niesen, Melissa I/J-5453-2013; Fejer, Gyorgy/F-8515-2019	Niesen, Melissa I/0000-0001-8020-0958; Fejer, Gyorgy/0000-0001-6761-0506	NATIONAL CANCER INSTITUTE [R01CA081497] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA81497] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armstrong TD, 1998, J IMMUNOTHER, V21, P218, DOI 10.1097/00002371-199805000-00008; BLANCK G, 1990, HUM IMMUNOL, V29, P150, DOI 10.1016/0198-8859(90)90078-4; Caretti G, 2000, J MOL BIOL, V302, P539, DOI 10.1006/jmbi.2000.4028; DeSandro AM, 2000, MOL CELL BIOL, V20, P6587, DOI 10.1128/MCB.20.17.6587-6599.2000; Eason DD, 2001, J IMMUNOL, V166, P1041, DOI 10.4049/jimmunol.166.2.1041; Fontes JD, 1999, MOL CELL BIOL, V19, P941; GONCZY P, 1989, MOL CELL BIOL, V9, P296; Huang X, 1999, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V21, P252; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KARA CJ, 1993, IMMUNOGENETICS, V37, P227; KARA CJ, 1993, J IMMUNOL, V150, P4934; KARA CJ, 1993, EMBO J, V12, P187, DOI 10.1002/j.1460-2075.1993.tb05644.x; Liberati C, 1998, J BIOL CHEM, V273, P16880, DOI 10.1074/jbc.273.27.16880; LU YM, 1994, ONCOGENE, V9, P1015; Lu YM, 1996, J IMMUNOL, V156, P2495; Masternak K, 2000, GENE DEV, V14, P1156; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; MUNCASTER MM, 1992, CANCER RES, V52, P654; Osborne A, 1997, NUCLEIC ACIDS RES, V25, P5095, DOI 10.1093/nar/25.24.5095; Osborne A, 2001, MOL CELL BIOL, V21, P6495, DOI 10.1128/MCB.21.19.6495-6506.2001; OSTRANDROSENBERG S, 1990, J IMMUNOL, V144, P4068; Otten LA, 1998, EUR J IMMUNOL, V28, P473, DOI 10.1002/(SICI)1521-4141(199802)28:02<473::AID-IMMU473>3.0.CO;2-E; Pieper R, 1999, J EXP MED, V189, P757, DOI 10.1084/jem.189.5.757; Pulaski BA, 1998, CANCER RES, V58, P1486; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; Scholl T, 1997, P NATL ACAD SCI USA, V94, P6330, DOI 10.1073/pnas.94.12.6330; SHERMAN PA, 1989, MOL CELL BIOL, V9, P50, DOI 10.1128/MCB.9.1.50; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Villard J, 1999, INT IMMUNOL, V11, P461, DOI 10.1093/intimm/11.3.461; Villard J, 2000, MOL CELL BIOL, V20, P3364, DOI 10.1128/MCB.20.10.3364-3376.2000; Wang RF, 1999, SCIENCE, V284, P1351, DOI 10.1126/science.284.5418.1351; Wright KL, 1998, P NATL ACAD SCI USA, V95, P6267, DOI 10.1073/pnas.95.11.6267; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; Wu GD, 1997, J BIOL CHEM, V272, P2396; Xu XXS, 2000, GENE, V242, P219, DOI 10.1016/S0378-1119(99)00522-3; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang HQ, 1999, CELL GROWTH DIFFER, V10, P457; Zhu X, 1999, ONCOGENE, V18, P4940, DOI 10.1038/sj.onc.1202876; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000; Zika E, 2003, MOL CELL BIOL, V23, P3091, DOI 10.1128/MCB.23.9.3091-3102.2003	43	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28911	28919		10.1074/jbc.M403118200	http://dx.doi.org/10.1074/jbc.M403118200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15105429	hybrid			2022-12-25	WOS:000222445300012
J	Zhou, DJ; Chen, B; Ye, JJ; Chen, SA				Zhou, DJ; Chen, B; Ye, JJ; Chen, SA			A novel crosstalk mechanism between nuclear receptor-mediated and growth factor/Ras-mediated pathways through PNRC-Grb2 interaction	ONCOGENE			English	Article						PNRC; nuclear receptor coactivator; Grb2; growth factor/Ras; signal transduction	ACTIVATED PROTEIN-KINASE; ESTROGEN-RECEPTOR; COACTIVATORS; CELLS; COREPRESSORS; ALPHA-1; BINDING; MOTIF; SH2	It has been demonstrated that proline-rich nuclear receptor coregulatory protein (PNRC) is a nuclear receptor coactivator that interacts with nuclear receptors through an SH3-binding motif located in its C-terminus. In the present report, a physical interaction between PNRC and Grb2 (an adapter protein involved in growth factor/Ras-mediated pathways) has been demonstrated using the GST pull-down assay, the yeast two-hybrid assay, as well as by coimmunoprecipitation. Cotransfection and fluorescence imaging have also confirmed the colocalization of PNRC and Grb2 in mammalian cells. Transient transfection experiments have demonstrated that, by interacting with each other, Grb2 decreases the coactivator activity of PNRC for nuclear receptors, and that PNRC suppresses Grb2-mediated Ras/MAP-kinase activation. Furthermore, it was discovered that HeLa cells overexpressing PNRC grew more slowly when compared to matched controls. Additionally, using a RT-PCR analysis of mRNA on six pairs of cancer/noncancer tissues, PNRC expression was found to be significantly lower in breast cancer tissue than in noncancer tissue. Based on these findings, we believe that PNRC and Grb2, by interacting with each other, can suppress nuclear receptor-mediated regulation and growth factor-mediated regulation in human breast tissue. This is a newly identified crosstalk mechanism for modulating these two important types of regulatory pathways.	Beckman Res Inst City Hope, Dept Surg Res, Duarte, CA 91010 USA; Third Mil Med Univ, Dept Biochem, Chongqing, Peoples R China	City of Hope; Beckman Research Institute of City of Hope; Army Medical University	Chen, SA (corresponding author), Beckman Res Inst City Hope, Dept Surg Res, Duarte, CA 91010 USA.	schen@coh.org			NCI NIH HHS [CA44735] Funding Source: Medline; NIDDK NIH HHS [DK60560] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060560] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chen S, 2001, J BIOL CHEM, V276, P28465, DOI 10.1074/jbc.M102638200; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Cussac D, 1999, FASEB J, V13, P31, DOI 10.1096/fasebj.13.1.31; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Gay B, 1999, INT J CANCER, V83, P235, DOI 10.1002/(SICI)1097-0215(19991008)83:2<235::AID-IJC15>3.0.CO;2-B; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Harris RA, 1999, INT J CANCER, V80, P477, DOI 10.1002/(SICI)1097-0215(19990129)80:3<477::AID-IJC23>3.0.CO;2-W; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NICHOLSON RI, 1996, HORMONES CANC, P227; Ordentlich P, 2001, CURR TOP MICROBIOL, V254, P101; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rauh MJ, 1999, MOL CELL BIOL, V19, P8169; Rooij J, 1997, ONCOGENE, V14, P623; RUSSELL KS, 1992, CANCER RES, V52, P6624; Tari AM, 1999, ONCOGENE, V18, P1325, DOI 10.1038/sj.onc.1202422; Verbeek BS, 1997, J PATHOL, V183, P195; Zhou DJ, 2001, NUCLEIC ACIDS RES, V29, P3939, DOI 10.1093/nar/29.19.3939; Zhou DJ, 2000, MOL ENDOCRINOL, V14, P986, DOI 10.1210/me.14.7.986	22	22	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	2004	23	31					5394	5404		10.1038/sj.onc.1207695	http://dx.doi.org/10.1038/sj.onc.1207695			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15122321				2022-12-25	WOS:000222491600015
J	Kasiviswanathan, R; Shin, JH; Melamud, E; Kelman, Z				Kasiviswanathan, R; Shin, JH; Melamud, E; Kelman, Z			Biochemical characterization of the Methanothermobacter thermautotrophicus minichromosome maintenance (MCM) helicase N-terminal domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRENARCHAEON SULFOLOBUS-SOLFATARICUS; DNA-BINDING-PROTEIN; 3RD DOMAIN; REPLICATION; COMPLEX; THERMOAUTOTROPHICUM; DUPLEX; EUKARYAL; LIFE	Minichromosome maintenance helicases are ring-shaped complexes that play an essential role in archaeal and eukaryal DNA replication by separating the two strands of chromosomal DNA to provide the single-stranded substrate for the replicative polymerases. For the archaeal protein it was shown that the N-terminal portion of the protein, which is composed of domains A, B, and C, is involved in multimer formation and single-stranded DNA binding and may also play a role in regulating the helicase activity. Here, a detailed biochemical characterization of the N-terminal region of the Methanothermobacter thermautotrophicus minichromosome maintenance helicase is described. Using biochemical and biophysical analyses it is shown that domain C of the N-terminal portion, located adjacent to the helicase catalytic domains, is required for protein multimerization and that domain B is the main contact region with single-stranded DNA. It is also shown that although oligomerization is not essential for single-stranded DNA binding and ATPase activity, the presence of domain C is essential for helicase activity.	Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA		Kelman, Z (corresponding author), Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	kelman@umbi.umd.edu	Kasiviswanathan, Rajesh/D-2744-2012					Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Carpentieri F, 2002, J BIOL CHEM, V277, P12118, DOI 10.1074/jbc.M200091200; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; De Felice M, 2003, J BIOL CHEM, V278, P46424, DOI 10.1074/jbc.M306075200; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Grabowski B, 2003, ANNU REV MICROBIOL, V57, P487, DOI 10.1146/annurev.micro.57.030502.090709; Grainge I, 2003, NUCLEIC ACIDS RES, V31, P4888, DOI 10.1093/nar/gkg662; Hardy CFJ, 1997, P NATL ACAD SCI USA, V94, P3151, DOI 10.1073/pnas.94.7.3151; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Kaplan DL, 2000, J MOL BIOL, V301, P285, DOI 10.1006/jmbi.2000.3965; Kaplan DL, 2003, J BIOL CHEM, V278, P49171, DOI 10.1074/jbc.M308074200; Kelman Z, 2003, NAT STRUCT BIOL, V10, P148, DOI 10.1038/nsb0303-148; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Laskey RA, 2003, EMBO REP, V4, P26, DOI 10.1038/sj.embor.embor706; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; Pape T, 2003, EMBO REP, V4, P1079, DOI 10.1038/sj.embor.7400010; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Poplawski A, 2001, J BIOL CHEM, V276, P49371, DOI 10.1074/jbc.M108519200; Sato M, 2000, J MOL BIOL, V300, P421, DOI 10.1006/jmbi.2000.3865; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Shechter DF, 2000, J BIOL CHEM, V275, P15049, DOI 10.1074/jbc.M000398200; Shin JH, 2003, J BIOL CHEM, V278, P49053, DOI 10.1074/jbc.M308599200; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Smelkova NV, 1997, J VIROL, V71, P8766, DOI 10.1128/JVI.71.11.8766-8773.1997; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; Tye BK, 2000, P NATL ACAD SCI USA, V97, P2399, DOI 10.1073/pnas.97.6.2399; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; You ZY, 2002, J BIOL CHEM, V277, P42471, DOI 10.1074/jbc.M205769200; Yu X, 2002, EMBO REP, V3, P792, DOI 10.1093/embo-reports/kvf160	34	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28358	28366		10.1074/jbc.M403202200	http://dx.doi.org/10.1074/jbc.M403202200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15100218	hybrid			2022-12-25	WOS:000222265400068
J	Kim, BC; van Gelder, H; Kim, TA; Lee, HJ; Baik, KG; Chun, HH; Lee, DA; Choi, KS; Kim, SJ				Kim, BC; van Gelder, H; Kim, TA; Lee, HJ; Baik, KG; Chun, HH; Lee, DA; Choi, KS; Kim, SJ			Activin receptor-like kinase-7 induces apoptosis through activation of MAPKs in a Smad3-dependent mechanism in hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; SERINE/THREONINE KINASE; ALK7; PROTEIN; PHOSPHORYLATION; PROTEASES; CLEAVAGE; CLONING	Activin receptor-like kinase (ALK)7 is a type I serine/threonine kinase receptor of the transforming growth factor (TGF)-beta family of proteins that has similar properties to other type I receptors when activated. To see whether ALK7 can induce apoptosis as can some of the other ALK proteins, we infected the FaO rat hepatoma cell line with adenovirus expressing a constitutively active form of the ALK7. Cells infected with active ALK7 adenovirus showed an apoptotic-positive phenotype, as opposed to those that were infected with a control protein. DNA fragmentation assays and fluorescence-activated cell sorter analysis also indicated that ALK7 infection induced apoptosis in FaO cells. We also confirmed this finding in Hep3B human hepatoma cells by transiently transfecting the constitutively active form of ALK7, ALK7(T194D). Investigation into the downstream targets and mechanisms involved in ALK7-induced apoptosis revealed that the TGF-beta signaling intermediates, Smad2 and -3, were activated, as well as the MAPKs JNK and p38. In addition, caspase-3 and -9 were also activated, and cytochrome c release from the mitochondria was observed. Short interfering RNA-mediated inhibition of Smad3 markedly suppressed ALK7-induced caspase-3 activation. Treatment with protein synthesis inhibitors or the expression of the dominant-negative form of the stress-activated protein/extracellular signal-regulated kinase 1 abolished not only JNK activation but apoptosis as well. Taken together, these results suggest that ALK7 induces apoptosis through activation of the traditional TGF-beta pathway components, thus resulting in new gene transcription and JNK and p38 activation that initiates cross-talk with the cellular stress death pathway and ultimately leads to apoptosis.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; Kangwon Natl Univ, Coll Nat Sci, Chunchon 200701, South Korea; Ajou Univ, Sch Med, Inst Med Sci, Lab Endocrinol, Suwon 441749, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kangwon National University; Ajou University	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA.	kims@mail.nih.gov		Choi, Kyeong Sook/0000-0003-2331-0856	NATIONAL CANCER INSTITUTE [Z01BC005617] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bondestam J, 2001, CYTOGENET CELL GENET, V95, P157, DOI 10.1159/000059339; Cain K, 1996, BIOCHEM J, V314, P27, DOI 10.1042/bj3140027; Choi KS, 1998, HEPATOLOGY, V27, P415, DOI 10.1002/hep.510270215; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; Coyle B, 2003, J BIOL CHEM, V278, P5920, DOI 10.1074/jbc.M211300200; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Hsing AY, 1996, CANCER RES, V56, P5146; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; Jornvall H, 2001, J BIOL CHEM, V276, P5140, DOI 10.1074/jbc.M005200200; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; Kishimoto H, 2003, J BIOL CHEM, V278, P16595, DOI 10.1074/jbc.M213182200; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; Reissmann E, 2001, GENE DEV, V15, P2010, DOI 10.1101/gad.201801; Roberts HJ, 2003, BIOL REPROD, V68, P1719, DOI 10.1095/biolreprod.102.013045; Tsuchida K, 1996, MOL CELL NEUROSCI, V7, P467, DOI 10.1006/mcne.1996.0034; Watanabe R, 1999, BIOCHEM BIOPH RES CO, V254, P707, DOI 10.1006/bbrc.1998.0118	22	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28458	28465		10.1074/jbc.M313277200	http://dx.doi.org/10.1074/jbc.M313277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15107418	Green Published, hybrid			2022-12-25	WOS:000222265400080
J	Werner, AB; Tait, SWG; de Vries, E; Eldering, E; Borst, J				Werner, AB; Tait, SWG; de Vries, E; Eldering, E; Borst, J			Requirement for aspartate-cleaved bid in apoptosis signaling by DNA-damaging anti-cancer regimens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; GRANZYME-B; THYMOCYTE APOPTOSIS; BH3-ONLY PROTEINS; DEATH RECEPTORS; FLOW-CYTOMETRY; LEUKEMIC-CELLS; P53; GENE; MITOCHONDRIA	Lymphoid malignancies can escape from DNA-damaging anti-cancer drugs and gamma-radiation by blocking apoptosis-signaling pathways. How these regimens induce apoptosis is incompletely defined, especially in cells with nonfunctional p53. We report here that the BH3-only Bcl-2 family member Bid is required for mitochondrial permeabilization and apoptosis induction by etoposide and gamma-radiation in p53 mutant T leukemic cells. Bid is not transcriptionally up-regulated in response to these stimuli but is activated by cleavage on aspartate residues 60 and/or 75, which are the targets of caspase-8 and granzyme B. Bid activity is not inhibitable by c-Flip(L), CrmA, or dominant negative caspase-9 and therefore is independent of inducer caspase activation by death receptors or the mitochondria. Caspase-2, which has been implicated as inducer caspase in DNA damage pathways, appeared to be processed in response to etoposide and gamma-radiation but downstream of caspase-9. Knock down of caspase-2 by short interfering RNA further excluded its role in Bid activation by DNA damage. Caspase-2 was implicated in the death receptor pathway however, where it contributed to effector caspase processing downstream of inducer caspases. Granzyme B-specific serpins could not block DNA damage-induced apoptosis, excluding a role for granzyme B in the generation of active Bid. We conclude that Bid, cleaved by an undefined aspartate-specific protease, can be a key mediator of the apoptotic response to DNA-damaging anticancer regimens.	Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1100 DD Amsterdam, Netherlands	Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam	Borst, J (corresponding author), Netherlands Canc Inst, Div Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.borst@nki.nl		Tait, Stephen/0000-0001-7697-132X; Borst, Jannie/0000-0002-8043-5009				Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; BORST J, 1987, J IMMUNOL, V139, P1952; Brown JM, 1999, CANCER RES, V59, P1391; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bruno AP, 2000, BLOOD, V96, P1914, DOI 10.1182/blood.V96.5.1914.h8001914_1914_1920; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Droin N, 2001, BLOOD, V97, P1835, DOI 10.1182/blood.V97.6.1835; Eldering E, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng153; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jin SK, 2003, GENE DEV, V17, P359, DOI 10.1101/gad.1047003; Kataoka T, 1998, J IMMUNOL, V161, P3936; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; LAUMANN R, 1992, LEUKEMIA, V6, P227; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Medema JP, 2001, J EXP MED, V194, P657, DOI 10.1084/jem.194.5.657; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Mori N, 1997, BLOOD, V90, P4924, DOI 10.1182/blood.V90.12.4924.4924_4924_4932; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Renatus M, 2000, STRUCT FOLD DES, V8, P789, DOI 10.1016/S0969-2126(00)00165-9; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitt CA, 2000, COLD SPRING HARB SYM, V65, P499, DOI 10.1101/sqb.2000.65.499; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; Squier MKT, 1997, J IMMUNOL, V158, P3690; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Sutton VR, 2003, IMMUNITY, V18, P319, DOI 10.1016/S1074-7613(03)00050-5; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Waterhouse NJ, 2003, CELL DEATH DIFFER, V10, P853, DOI 10.1038/sj.cdd.4401263; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Werner AB, 2002, J BIOL CHEM, V277, P40760, DOI 10.1074/jbc.M204351200; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zinkel SS, 2003, GENE DEV, V17, P229, DOI 10.1101/gad.1045603	63	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28771	28780		10.1074/jbc.M400268200	http://dx.doi.org/10.1074/jbc.M400268200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117953	hybrid			2022-12-25	WOS:000222265400115
J	Banhegyi, G; Benedetti, A; Fulceri, R; Senesi, S				Banhegyi, G; Benedetti, A; Fulceri, R; Senesi, S			Cooperativity between 11 beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase in the lumen of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; CORTISONE REDUCTASE DEFICIENCY; PENTOSE-PHOSPHATE PATHWAY; FUNCTIONAL-RELATIONSHIP; GLUCOCORTICOID ACTION; VESICLES; MICE; 6-PHOSPHOGLUCONOLACTONASE; GLUCOSE-6-PHOSPHATE; METYRAPONE	The functional coupling of 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase was investigated in rat liver microsomal vesicles. The activity of both enzymes was latent in intact vesicles, indicating the intraluminal localization of their active sites. Glucose-6-phosphate, a substrate for hexose-6-phosphate dehydrogenase, stimulated the cortisone reductase activity of 11B-hydroxysteroid dehydrogenase type 1. Inhibition of glucose-6-phosphate uptake by S3483, a specific inhibitor of the microsomal glucose-6-phosphate transporter, decreased this effect. Similarly, cortisone increased the intravesicular accumulation of radioactivity upon the addition of radiolabeled glucose-6-phosphate, indicating the stimulation of hexose-6-phosphate dehydrogenase activity. A correlation was shown between glucose-6-phosphate-dependent cortisone reduction and cortisone-dependent glucose-6-phosphate oxidation. The results demonstrate a close cooperation of the enzymes based on co-localization and the mutual generation of cofactors for each other.	Univ Siena, Dept Pathophysiol Expt Med & Publ Hlth, I-53100 Siena, Italy; Hungarian Acad Sci, Endoplasm Reticulum Res Grp, H-1444 Budapest, Hungary; Semmelweis Univ, H-1444 Budapest, Hungary	University of Siena; Hungarian Academy of Sciences; Semmelweis University	Benedetti, A (corresponding author), Univ Siena, Dept Pathophysiol Expt Med & Publ Hlth, Viale Aldo Moro, I-53100 Siena, Italy.	benedetti@unisi.it	Bánhegyi, Gábor/A-1476-2014					Alberts P, 2003, ENDOCRINOLOGY, V144, P4755, DOI 10.1210/en.2003-0344; Banhegyi G, 1997, J BIOL CHEM, V272, P13584, DOI 10.1074/jbc.272.21.13584; Bannenberg G, 2003, CHEM-BIOL INTERACT, V143, P449, DOI 10.1016/S0009-2797(02)00183-7; BUBLITZ C, 1988, J BIOL CHEM, V263, P12849; BUBLITZ C, 1988, BIOCHIM BIOPHYS ACTA, V965, P90, DOI 10.1016/0304-4165(88)90155-9; BUBLITZ C, 1987, BIOCHEM J, V245, P263, DOI 10.1042/bj2450263; Chou Janice Yang, 2002, Current Molecular Medicine (Hilversum), V2, P121, DOI 10.2174/1566524024605798; Clarke JL, 2003, ARCH BIOCHEM BIOPHYS, V415, P229, DOI 10.1016/S0003-9861(03)00229-7; Collard F, 1999, FEBS LETT, V459, P223, DOI 10.1016/S0014-5793(99)01247-8; Draper N, 2003, NAT GENET, V34, P434, DOI 10.1038/ng1214; FULCERI R, 1994, ARCH BIOCHEM BIOPHYS, V309, P43, DOI 10.1006/abbi.1994.1081; Gerin I, 2002, FEBS LETT, V517, P257, DOI 10.1016/S0014-5793(02)02640-6; Herling AW, 1998, AM J PHYSIOL-GASTR L, V274, pG1087, DOI 10.1152/ajpgi.1998.274.6.G1087; HINO Y, 1982, J BIOCHEM, V92, P547, DOI 10.1093/oxfordjournals.jbchem.a133963; HINO Y, 1983, J BIOL CHEM, V258, P1415; HORI SH, 1977, BIOCHIM BIOPHYS ACTA, V496, P1, DOI 10.1016/0304-4165(77)90109-X; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jamieson A, 1999, J CLIN ENDOCR METAB, V84, P3570, DOI 10.1210/jc.84.10.3570; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; KULKARNI AP, 1982, BIOCHEM PHARMACOL, V31, P1131, DOI 10.1016/0006-2952(82)90353-7; MASER E, 1994, BIOCHEM PHARMACOL, V47, P1805, DOI 10.1016/0006-2952(94)90309-3; Masuzaki H, 2003, J CLIN INVEST, V112, P83, DOI 10.1172/JCI17845; OZOLS J, 1995, J BIOL CHEM, V270, P2305, DOI 10.1074/jbc.270.5.2305; OZOLS J, 1993, P NATL ACAD SCI USA, V90, P5302, DOI 10.1073/pnas.90.11.5302; SampathKumar R, 1997, J STEROID BIOCHEM, V62, P195, DOI 10.1016/S0960-0760(97)00027-7; SAWADA H, 1981, J BIOCHEM-TOKYO, V90, P1077, DOI 10.1093/oxfordjournals.jbchem.a133559; SAWADA H, 1980, J BIOCHEM-TOKYO, V87, P985, DOI 10.1093/oxfordjournals.jbchem.a132829; Seckl JR, 2001, ENDOCRINOLOGY, V142, P1371, DOI 10.1210/en.142.4.1371; TAKAHASHI T, 1981, BIOCHIM BIOPHYS ACTA, V672, P165, DOI 10.1016/0304-4165(81)90390-1; TAKAHASHI T, 1978, BIOCHIM BIOPHYS ACTA, V524, P262, DOI 10.1016/0005-2744(78)90163-8; Varsanyi M, 2004, J BIOL CHEM, V279, P3370, DOI 10.1074/jbc.M307783200	31	149	152	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27017	27021		10.1074/jbc.M404159200	http://dx.doi.org/10.1074/jbc.M404159200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15090536	hybrid			2022-12-25	WOS:000222120400027
J	Brown, GE; Stewart, MQ; Bissonnette, SA; Elia, AEH; Wilker, E; Yaffe, MB				Brown, GE; Stewart, MQ; Bissonnette, SA; Elia, AEH; Wilker, E; Yaffe, MB			Distinct ligand-dependent roles for p38 MAPK in priming and activation of the neutrophil NADPH oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TUMOR-NECROSIS-FACTOR; RESPIRATORY-DISTRESS SYNDROME; SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE-C; COLONY-STIMULATING FACTOR; LIPOPOLYSACCHARIDE-BINDING-PROTEIN; ADHERENT HUMAN-NEUTROPHILS; SRC HOMOLOGY-3 DOMAINS; MULTIPLE ORGAN FAILURE; ACUTE LUNG INJURY	In response to certain cytokines and inflammatory mediators, the activity of the neutrophil NADPH oxidase enzyme is primed for enhanced superoxide production when the cells receive a subsequent oxidase-activating stimulus. The relative role of p38 MAPK in the priming and activation processes is incompletely understood. We have developed a 2-step assay that allows the relative contributions of p38 MAPK activity in priming to be distinguished from those involved in oxidase activation. Using this assay, together with in vitro kinase assays and immunochemical studies, we report that p38 MAPK plays a critical role in TNFalpha priming of the human and porcine NADPH oxidase for superoxide production in response to complement-opsonized zymosan (OpZ), but little, if any, role in neutrophil priming by platelet-activating factor (PAF) for OpZ-dependent responses. The OpZ-mediated activation process per se is independent of p38 MAPK activity, in contrast to oxidase activation by fMLP, where 70% of the response is eliminated by p38 MAPK inhibitors regardless of the priming agent. We further report that incubation of neutrophils with TNFalpha results in the p38 MAPK-dependent phosphorylation of a subpopulation of p47(phox) and p67(phox) molecules, whereas PAF priming results in phosphorylation only of p67(phox). Despite these phosphorylations, TNFalpha priming does not result in significant association of either of these oxidase subunits with neutrophil membranes, demonstrating that the molecular basis for priming does not appear to involve preassembly of the NADPH oxidase holoenzyme/cytochrome complex prior to oxidase activation.	Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02120 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Div Biol Engn, Cambridge, MA 02139 USA	Harvard University; Beth Israel Deaconess Medical Center; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Yaffe, MB (corresponding author), Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02120 USA.	myaffe@mit.edu		Stewart, Mary Q/0000-0001-6924-0123	NIGMS NIH HHS [GM98059] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8; Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; ALLEN RC, 1986, METHOD ENZYMOL, V133, P449; AMARI T, 1993, J APPL PHYSIOL, V74, P2641, DOI 10.1152/jappl.1993.74.6.2641; Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; BASS DA, 1986, J IMMUNOL, V136, P860; BENDER JG, 1983, J IMMUNOL, V130, P2316; Botha AJ, 1996, BRIT J SURG, V83, P1407, DOI 10.1002/bjs.1800831027; BROWN GE, 1991, J IMMUNOL, V147, P965; Brown GE, 2003, MOL CELL, V11, P35, DOI 10.1016/S1097-2765(03)00005-4; Cadwallader KA, 2002, J IMMUNOL, V169, P3336, DOI 10.4049/jimmunol.169.6.3336; Camhi S L, 1995, New Horiz, V3, P170; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CHOLLETMARTIN S, 1992, AM REV RESPIR DIS, V146, P990, DOI 10.1164/ajrccm/146.4.990; Clark RA, 1999, J INFECT DIS, V179, pS309, DOI 10.1086/513849; Condliffe AM, 1998, FEBS LETT, V439, P147, DOI 10.1016/S0014-5793(98)01358-1; Condliffe AM, 1998, CLIN SCI, V94, P461, DOI 10.1042/cs0940461; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dang PMC, 1999, J BIOL CHEM, V274, P20704, DOI 10.1074/jbc.274.29.20704; Dang PMC, 2003, BIOCHEMISTRY-US, V42, P4520, DOI 10.1021/bi0205754; DeLeo FR, 1999, J IMMUNOL, V163, P6732; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; Dewas C, 2000, J IMMUNOL, V165, P5238, DOI 10.4049/jimmunol.165.9.5238; Dewas C, 2003, J IMMUNOL, V171, P4392, DOI 10.4049/jimmunol.171.8.4392; Duilio C, 2001, AM J PHYSIOL-HEART C, V280, pH2649, DOI 10.1152/ajpheart.2001.280.6.H2649; Dusi S, 1996, J IMMUNOL, V157, P4615; DUSI S, 1993, BIOCHEM J, V290, P173, DOI 10.1042/bj2900173; ELAWAR FY, 1990, AM J VET RES, V51, P1561; ElBenna J, 1995, BLOOD CELL MOL DIS, V21, P201, DOI 10.1006/bcmd.1995.0023; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ElBenna J, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; EXLEY AR, 1992, GUT, V33, P1126, DOI 10.1136/gut.33.8.1126; Fink Mitchell P, 2002, Curr Opin Crit Care, V8, P6, DOI 10.1097/00075198-200202000-00002; FLETCHER MP, 1990, J LEUKOCYTE BIOL, V47, P355, DOI 10.1002/jlb.47.4.355; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; Forsberg M, 2001, IMMUNOLOGY, V103, P465, DOI 10.1046/j.1365-2567.2001.01270.x; Fuortes M, 1999, J CLIN INVEST, V104, P327, DOI 10.1172/JCI6018; Gao XP, 2002, J IMMUNOL, V168, P3974, DOI 10.4049/jimmunol.168.8.3974; GONZALEZ PK, 1995, J PHARMACOL EXP THER, V275, P798; GUICE KS, 1991, J SURG RES, V51, P495, DOI 10.1016/0022-4804(91)90171-H; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; HILL ME, 1994, J IMMUNOL, V153, P3673; Johnson JL, 1998, J BIOL CHEM, V273, P35147, DOI 10.1074/jbc.273.52.35147; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Karlsson A, 2000, J LEUKOCYTE BIOL, V67, P396, DOI 10.1002/jlb.67.3.396; Kobayashi T, 1998, J CELL SCI, V111, P81; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lal AS, 1999, BIOCHEM BIOPH RES CO, V259, P465, DOI 10.1006/bbrc.1999.0759; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; Lian JP, 1999, J IMMUNOL, V163, P4527; LINAS SL, 1992, KIDNEY INT, V42, P610, DOI 10.1038/ki.1992.325; Livingston D H, 1995, New Horiz, V3, P257; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; Lundqvist H, 1996, J LEUKOCYTE BIOL, V59, P270, DOI 10.1002/jlb.59.2.270; Lundqvist H, 1996, FREE RADICAL BIO MED, V20, P785, DOI 10.1016/0891-5849(95)02189-2; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P537, DOI 10.1002/jlb.64.4.537; MEAKINS JL, 1990, J TRAUMA, V30, pS165; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NATHAN CF, 1989, BLOOD, V73, P301; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; Nick JA, 1996, J IMMUNOL, V156, P4867; PARK JW, 1995, BIOCHEM BIOPH RES CO, V211, P410, DOI 10.1006/bbrc.1995.1829; Park JW, 1997, BIOCHEMISTRY-US, V36, P7474, DOI 10.1021/bi9700936; PARSONS PE, 1989, AM REV RESPIR DIS, V140, P294, DOI 10.1164/ajrccm/140.2.294; Partrick D A, 1996, New Horiz, V4, P194; Partrick DA, 2000, ARCH SURG-CHICAGO, V135, P219, DOI 10.1001/archsurg.135.2.219; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1995, METHOD ENZYMOL, V256, P256; RAFIEE P, 1995, J IMMUNOL, V154, P4785; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; RIVKIND AI, 1991, CIRC SHOCK, V33, P48; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SHAKED G, 1994, J TRAUMA, V37, P22, DOI 10.1097/00005373-199407000-00006; SULLIVAN R, 1987, J IMMUNOL, V139, P3422; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; TANAKA H, 1991, ANN SURG, V214, P187, DOI 10.1097/00000658-199108000-00014; Vaissiere C, 1999, J LEUKOCYTE BIOL, V65, P629, DOI 10.1002/jlb.65.5.629; VERCELLOTTI GM, 1988, BLOOD, V71, P1100; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; VOSBECK K, 1990, J LEUKOCYTE BIOL, V47, P97, DOI 10.1002/jlb.47.2.97; Walder CE, 1997, STROKE, V28, P2252, DOI 10.1161/01.STR.28.11.2252; WATERMAN WH, 1995, BIOCHEM J, V307, P39, DOI 10.1042/bj3070039; WEISBART RH, 1987, BLOOD, V69, P18; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEWERS MD, 1990, AM J PHYSIOL, V259, pL276, DOI 10.1152/ajplung.1990.259.4.L276; WOLLERT PS, 1994, SHOCK, V2, P362, DOI 10.1097/00024382-199411000-00011; WORTHEN GS, 1987, AM REV RESPIR DIS, V136, P19, DOI 10.1164/ajrccm/136.1.19; Yaffe MB, 1999, SURGERY, V126, P248, DOI 10.1016/S0039-6060(99)70162-5; Yan SR, 2002, INFECT IMMUN, V70, P4068, DOI 10.1128/IAI.70.8.4068-4074.2002; ZIMMERMAN GA, 1983, AM REV RESPIR DIS, V127, P290; Zu YL, 1996, BLOOD, V87, P5287, DOI 10.1182/blood.V87.12.5287.bloodjournal87125287; Zu YL, 1998, J IMMUNOL, V160, P1982	102	70	75	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27059	27068		10.1074/jbc.M314258200	http://dx.doi.org/10.1074/jbc.M314258200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102856	hybrid			2022-12-25	WOS:000222120400032
J	Klucky, B; Koch, B; Radolf, M; Steinlein, P; Wintersberger, E				Klucky, B; Koch, B; Radolf, M; Steinlein, P; Wintersberger, E			Polyomavirus tumorantigens have a profound effect on gene expression in mouse fibroblasts	ONCOGENE			English	Article						T antigens; microarray; gene expression	LARGE T-ANTIGEN; SIMIAN-VIRUS-40 SMALL-T; HUMAN CELL-TRANSFORMATION; CYCLIN-A; TRANS-ACTIVATION; MIDDLE-T; S-PHASE; PROTEIN; GROWTH; TRANSACTIVATION	Polyomavirus (Pv) large and small tumorantigens together are competent to induce S phase in growth-arrested mouse fibroblasts. The capacity of the large tumorantigen to bind the pocket proteins, pRB, p130 and p107, is important for the transactivation of DNA synthesis enzymes and the cyclins E and A, while the interference of small tumorantigen with protein phosphatase PP2A causes a destabilization of the cdk2 inhibitor p27, and thus leads to strong cyclin E- and cyclin A-dependent cdk2 activity. Py small tumorantigen, in addition, is able to transactivate cyclin A. Hence, this protein might have a much wider effect on gene expression in arrested mouse fibroblasts than hitherto suspected. This may have a profound part in the known capacity of Py to form tumors in mice. Therefore, it was interesting to gain an insight into the spectrum of transcriptional deregulation by Py tumorantigens. Accordingly, we performed microarray analysis of quiescent mouse fibroblasts in the absence and presence of small or large tumorantigen. We found that the viral proteins can induce or repress a great variety of genes beyond those involved in the S phase induction and DNA synthesis. The results of the microarray analysis were confirmed for selected genes by several methods, including real-time PCR. Interestingly, a mutation of the binding site for pocket proteins in case of LT and for PP2A in case of ST has a variable effect on the deregulation of genes by the viral proteins depending on the gene in question. In fact, some genes are transactivated by LT as well as ST completely independent of an interaction with their major cellular targets, pocket proteins and PP2A, respectively.	Med Univ Vienna, Div Mol Biol, Inst Med Biochem, A-1030 Vienna, Austria; Inst Mol Pathol, A-1030 Vienna, Austria	Medical University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Wintersberger, E (corresponding author), Med Univ Vienna, Div Mol Biol, Inst Med Biochem, Dr Bohrgasse 9, A-1030 Vienna, Austria.	Erhard.Wintersberger@univie.ac.at		Koch, Birgit/0000-0003-4683-3115				ADAMCZEWSKI JP, 1993, J VIROL, V67, P6551, DOI 10.1128/JVI.67.11.6551-6557.1993; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Benjamin TL, 2001, VIROLOGY, V289, P167, DOI 10.1006/viro.2001.1124; BIKEL I, 1992, J VIROL, V66, P1489, DOI 10.1128/JVI.66.3.1489-1494.1992; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Damania B, 1998, MOL CELL BIOL, V18, P3926, DOI 10.1128/MCB.18.7.3926; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Felton-Edkins ZA, 2002, J BIOL CHEM, V277, P48182, DOI 10.1074/jbc.M201333200; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; Gottlieb KA, 2001, MICROBIOL MOL BIOL R, V65, P288, DOI 10.1128/MMBR.65.2.288-318.2001; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Kino T, 2001, GENES CELLS, V6, P441, DOI 10.1046/j.1365-2443.2001.00432.x; Kresse H, 2001, J CELL PHYSIOL, V189, P266, DOI 10.1002/jcp.10030; Lecanda F, 2000, J CELL BIOCHEM, V77, P499, DOI 10.1002/(SICI)1097-4644(20000601)77:3<499::AID-JCB14>3.0.CO;2-0; LOEKEN M, 1988, CELL, V55, P1171, DOI 10.1016/0092-8674(88)90261-9; LOEKEN MR, 1992, J VIROL, V66, P2551, DOI 10.1128/JVI.66.4.2551-2555.1992; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUTCHMAN M, 1995, CANCER RES, V55, P2270; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MUDRAK I, 1994, MOL CELL BIOL, V14, P1886, DOI 10.1128/MCB.14.3.1886; Nemethova M, 1999, J VIROL, V73, P1734, DOI 10.1128/JVI.73.2.1734-1739.1999; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; OGRIS E, 1993, ONCOGENE, V8, P1277; OGRIS E, 1992, J VIROL, V66, P53, DOI 10.1128/JVI.66.1.53-61.1992; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Porras A, 1996, J VIROL, V70, P6902; Porras A, 1999, J VIROL, V73, P3102; Sambrook J., 2002, MOL CLONING LAB MANU; Schuchner S, 2001, J VIROL, V75, P6498, DOI 10.1128/JVI.75.14.6498-6507.2001; Schuchner S, 1999, J VIROL, V73, P9266; Shin CS, 2000, J CELL BIOCHEM, V78, P566, DOI 10.1002/1097-4644(20000915)78:4<566::AID-JCB6>3.0.CO;2-K; SONNTAG E, 1993, CELL, V75, P887; Stander M, 1999, CELL TISSUE RES, V296, P221, DOI 10.1007/s004410051283; Tsuruga H, 1997, GENES CELLS, V2, P381, DOI 10.1046/j.1365-2443.1997.1290327.x; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204	41	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4707	4721		10.1038/sj.onc.1207640	http://dx.doi.org/10.1038/sj.onc.1207640			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122341				2022-12-25	WOS:000221799200006
J	Sun, LX; Vitolo, MI; Qiao, M; Anglin, IE; Passaniti, A				Sun, LX; Vitolo, MI; Qiao, M; Anglin, IE; Passaniti, A			Regulation of TGF beta(1)-mediated growth inhibition and apoptosis by RUNX2 isoforms in endothelial cells	ONCOGENE			English	Article						transcription factors; endothelial cells; proliferation; apoptosis	TRANSCRIPTION FACTOR PEBP2/CBF; ANGIOGENESIS IN-VITRO; FACTOR-BETA; EXTRACELLULAR-MATRIX; TGF-BETA; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; TUMOR ANGIOGENESIS; DEPENDENT KINASE; BONE-DEVELOPMENT	Runx transcription factors regulate viral growth, hematopoiesis, bone formation, angiogenesis, and gastric epithelial development through specific DNA-binding motifs on target gene promoters. Vascular endothelial cells (ECs) express RUNX genes that are activated by angiogenic factors. The RUNX2 gene also activates the vascular endothelial growth factor promoter. Alternatively spliced forms of RUNX genes have been described, but their functions in angiogenesis have not been elucidated. In this study, expression of a novel alternatively spliced variant of RUNX2 (RUNX2Delta8), lacking the region encoded by exon 8, was detected in aortic tissue undergoing angiogenesis in vitro and in ECs. Expression of RUNX2 and RUNX2Delta8 increased in vascular sprouts concomitant with expression of cellular proteases and cytokines known to mediate angiogenesis. RUNX2 DNA-binding activity was expressed in proliferating but not quiescent ECs. Ectopic expression of RUNX2 in ECs increased cell sprouting, cell proliferation, DNA synthesis, and phosphorylation of phosphorylated retinoblastoma relative to control transfectants while RUNX2, but not RUNX2Delta8 transfectants, acquired resistance to growth inhibition by transforming growth factor (TGFbeta(1)). Furthermore, RUNX2Delta8-transfected cells were more sensitive to TGFbeta(1)-induced apoptosis than RUNX2 transfectants. Consistent with these data, the RUNX2 gene was a strong repressor of the promoter of the cyclin-dependent kinase inhibitor, p21(CIP1), while RUNX2Delta8 was a competitive inhibitor of RUNX2 and exhibited weak repression activity. These results support the hypothesis that ECs regulate growth and apoptosis, in part, by alternative splicing events in the RUNX2 transcription factor to affect the TGFbeta(1) signaling pathway. The exon 8 domain of RUNX2 may contribute to the strong repression activity of RUNX2 for some target gene promoters.	Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Passaniti, A (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, 655 W Baltimore St, Baltimore, MD 21201 USA.	apass001@umaryland.edu		Vitolo, Michele/0000-0001-8055-9645	NCI NIH HHS [CA95350-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA095350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; ASAHARA T, 1995, CIRCULATION, V92, P365, DOI 10.1161/01.CIR.92.9.365; Baltzinger M, 1999, DEV DYNAM, V216, P420, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<420::AID-DVDY10>3.0.CO;2-C; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Blyth K, 2001, ONCOGENE, V20, P295, DOI 10.1038/sj.onc.1204090; Bravo J, 2001, NAT STRUCT BIOL, V8, P371, DOI 10.1038/86264; Burchardt M, 1999, BIOL REPROD, V60, P398, DOI 10.1095/biolreprod60.2.398; Carmeliet P, 2000, J PATHOL, V190, P387; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferrara N, 2000, RECENT PROG HORM RES, V55, P15; FLAUMENHAFT R, 1992, J CELL BIOL, V118, P901, DOI 10.1083/jcb.118.4.901; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Geoffroy V, 1998, MAMM GENOME, V9, P54, DOI 10.1007/s003359900679; Gothie E, 2000, J BIOL CHEM, V275, P6922, DOI 10.1074/jbc.275.10.6922; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hata-Sugi N, 2002, BIOL PHARM BULL, V25, P446, DOI 10.1248/bpb.25.446; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Huang YQ, 2000, BLOOD, V95, P1993, DOI 10.1182/blood.V95.6.1993; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Kalluri R, 2000, CURR OPIN NEPHROL HY, V9, P413, DOI 10.1097/00041552-200007000-00013; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kriventseva EV, 2003, TRENDS GENET, V19, P124, DOI 10.1016/S0168-9525(03)00023-4; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lehr JE, 1998, J NATL CANCER I, V90, P118, DOI 10.1093/jnci/90.2.118; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li WW, 2000, ACAD RADIOL, V7, P800, DOI 10.1016/S1076-6332(00)80629-7; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257; NEWTON LK, 1990, EXP CELL RES, V190, P127, DOI 10.1016/0014-4827(90)90153-2; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; NICOSIA RF, 1990, LAB INVEST, V63, P115; NICOSIA RF, 1994, J CELL BIOL, V124, P183, DOI 10.1083/jcb.124.1.183; NICOSIA RF, 1994, AM J PATHOL, V145, P1023; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; Perry C, 2002, ONCOGENE, V21, P8428, DOI 10.1038/sj.onc.1205945; Pollman MJ, 1999, J CELL PHYSIOL, V178, P359, DOI 10.1002/(SICI)1097-4652(199903)178:3<359::AID-JCP10>3.3.CO;2-F; Rabbani SA, 1998, IN VIVO, V12, P135; Riccioni T, 1998, GENE THER, V5, P747, DOI 10.1038/sj.gt.3300681; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Sato Y, 2000, PHARMACOL THERAPEUT, V87, P51, DOI 10.1016/S0163-7258(00)00067-X; Selvamurugan N, 2000, J BIOL CHEM, V275, P5037, DOI 10.1074/jbc.275.7.5037; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Smith JS, 2002, TRENDS CELL BIOL, V12, P404, DOI 10.1016/S0962-8924(02)02342-5; Sorek R, 2001, NAT BIOTECHNOL, V19, P196, DOI 10.1038/85613; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Sun LX, 2001, CANCER RES, V61, P4994; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; TAKECHI H, 1994, MOL CELL BIOL, V14, P567, DOI 10.1128/MCB.14.1.567; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Wang WG, 1999, J CELL BIOCHEM, V73, P321; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378-1119(98)00227-3; Yang CL, 1996, CELL GROWTH DIFFER, V7, P161; Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925-4773(01)00428-2; Zhang YW, 1997, ONCOGENE, V15, P367, DOI 10.1038/sj.onc.1201352	77	41	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4722	4734		10.1038/sj.onc.1207589	http://dx.doi.org/10.1038/sj.onc.1207589			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15107836				2022-12-25	WOS:000221799200007
J	Chen, G; Bower, KA; Ma, CL; Fang, SY; Thiele, CJ; Luo, J				Chen, G; Bower, KA; Ma, CL; Fang, SY; Thiele, CJ; Luo, J			Glycogen synthase kinase 3 beta (GSK3 beta) mediates 6-hydroxydopamine-induced neuronal death	FASEB JOURNAL			English	Article						apoptosis; caspases; endoplasmic reticulum stress; neurodegeneration; neurotrophins	ENDOPLASMIC-RETICULUM STRESS; CEREBELLAR GRANULE NEURONS; UNFOLDED PROTEIN RESPONSE; NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; INDUCED APOPTOSIS; CELL-DEATH; PARKINSONIAN-PATIENTS; NEUROBLASTOMA-CELLS; TAU PHOSPHORYLATION	The causes of sporadic Parkinson's disease (PD) are poorly understood. 6-Hydroxydopamine (6-OHDA), a PD mimetic, is widely used to model this neurodegenerative disorder in vitro and in vivo; however, the underlying mechanisms remain incompletely elucidated. We demonstrate here that 6-OHDA evoked endoplasmic reticulum ( ER) stress, which was characterized by an up-regulation in the expression of GRP78 and GADD153 (Chop), cleavage of procaspase-12, and phosphorylation of eukaryotic initiation factor-2 alpha in a human dopaminergic neuronal cell line (SH-SY5Y) and cultured rat cerebellar granule neurons (CGNs). Glycogen synthase kinase-3 beta (GSK3beta) responds to ER stress, and its activity is regulated by phosphorylation. 6-OHDA significantly inhibited phosphorylation of GSK3beta at Ser9, whereas it induced hyperphosphorylation of Tyr216 with little effect on GSK3beta expression in SH-SY5Y cells and PC12 cells (a rat dopamine cell line), as well as CGNs. Furthermore, 6-OHDA decreased the expression of cyclin D1, a substrate of GSK3beta, and dephosphorylated Akt, the upstream signaling component of GSK3beta. Protein phosphatase 2A (PP2A), an ER stress-responsive phosphatase, was involved in 6-OHDA-induced GSK3beta dephosphorylation (Ser9). Blocking GSK3beta activity by selective inhibitors ( lithium, TDZD-8, and L803-mts) prevented 6-OHDA-induced cleavage of caspase-3 and poly(ADP-ribose) polymerase (PARP), DNA fragmentations and cell death. With a tetracycline (Tet)-controlled TrkB inducible system, we demonstrated that activation of TrkB in SH-SY5Y cells alleviated 6-OHDA-induced GSK3beta dephosphorylation (Ser9) and ameliorated 6-OHDA neurotoxicity. TrkB activation also protected CGNs against 6-OHDA-induced damage. Although antioxidants also offered neuroprotection, they had little effect on 6-OHDA-induced GSK3beta activation. These results suggest that GSK3beta is a critical intermediate in pro-apoptotic signaling cascades that are associated with neurodegenerative diseases, thus providing a potential target site amenable to pharmacological intervention.	W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, Baltimore, MD 21201 USA; NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA; Chinese Acad Sci, SIBS, Inst Nutr Sci, Shanghai, Peoples R China	West Virginia University; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Luo, J (corresponding author), W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA.	jluo@hsc.wvu.edu	Fang, Shengyun/H-3802-2011; Luo, Jia/E-4674-2012	Luo, Jia/0000-0002-6968-3618; Fang, Shengyun/0000-0001-7280-5463	NCI NIH HHS [CA90385] Funding Source: Medline; NIAAA NIH HHS [AA12968] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R03AA012968] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ANDREW R, 1993, NEUROCHEM RES, V18, P1175, DOI 10.1007/BF00978370; Benisty S, 1998, NEUROSCIENCE, V86, P813, DOI 10.1016/S0306-4522(98)00126-2; Betarbet R, 2002, BRAIN PATHOL, V12, P499; Bhat RV, 2002, NEUROSIGNALS, V11, P251, DOI 10.1159/000067423; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.0.CO;2-E; COHEN G, 1974, J BIOL CHEM, V249, P2447; Courtney MJ, 1997, J NEUROSCI, V17, P4201; Crowder RJ, 2000, J BIOL CHEM, V275, P34266, DOI 10.1074/jbc.M006160200; CURTIUS HC, 1974, J CHROMATOGR, V99, P529, DOI 10.1016/S0021-9673(00)90882-3; Daily D, 2001, J BIOL CHEM, V276, P21618, DOI 10.1074/jbc.M101400200; Dechant G, 2001, CELL TISSUE RES, V305, P229, DOI 10.1007/s004410100378; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DIMATTEO Y, 2003, CURR DRUG TARGET CNS, V2, P95; Dodel RC, 1999, MOL BRAIN RES, V64, P141, DOI 10.1016/S0169-328X(98)00318-0; Elkon H, 2001, CELL MOL NEUROBIOL, V21, P771, DOI 10.1023/A:1015160323009; Foulstone EJ, 1999, NEUROSCI LETT, V264, P125, DOI 10.1016/S0304-3940(99)00166-4; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; FREI B, 1986, FEBS LETT, V198, P99, DOI 10.1016/0014-5793(86)81192-9; Glazner GW, 1998, J COMP NEUROL, V391, P42, DOI 10.1002/(SICI)1096-9861(19980202)391:1<42::AID-CNE4>3.0.CO;2-R; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hara H, 2003, MOL BRAIN RES, V119, P125, DOI 10.1016/j.molbrainres.2003.08.021; Hartigan JA, 1999, J BIOL CHEM, V274, P21395, DOI 10.1074/jbc.274.30.21395; Hetman M, 2000, J NEUROSCI, V20, P2567; Ho R, 2002, CANCER RES, V62, P6462; Holtz WA, 2003, J BIOL CHEM, V278, P19367, DOI 10.1074/jbc.M211821200; Hou ST, 2001, J NEUROCHEM, V78, P287, DOI 10.1046/j.1471-4159.2001.00402.x; HYNES MA, 1994, J NEUROSCI RES, V37, P144, DOI 10.1002/jnr.490370118; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Jaboin J, 2002, CANCER RES, V62, P6756; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaytor MD, 2002, CURR OPIN NEUROBIOL, V12, P275, DOI 10.1016/S0959-4388(02)00320-3; Kim CJ, 1999, AM J PATHOL, V155, P1661, DOI 10.1016/S0002-9440(10)65481-8; Leroy K, 1999, J CHEM NEUROANAT, V16, P279, DOI 10.1016/S0891-0618(99)00012-5; Lesort M, 1999, J NEUROCHEM, V72, P576, DOI 10.1046/j.1471-4159.1999.0720576.x; Levites Y, 2002, J BIOL CHEM, V277, P30574, DOI 10.1074/jbc.M202832200; Li Z, 2001, DEV BRAIN RES, V132, P47, DOI 10.1016/S0165-3806(01)00294-2; Lin SZ, 2003, LIFE SCI, V72, P1635, DOI 10.1016/S0024-3205(02)02442-6; Linert W, 1996, BBA-MOL BASIS DIS, V1316, P160, DOI 10.1016/0925-4439(96)00020-8; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Luo J, 1999, J NEUROSCI, V19, P10014, DOI 10.1523/jneurosci.19-22-10014.1999; Luo J, 2003, J BIOL CHEM, V278, P4542, DOI 10.1074/jbc.M208295200; Luo J, 1997, ALCOHOL CLIN EXP RES, V21, P1108; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Martinez A, 2002, J MED CHEM, V45, P1292, DOI 10.1021/jm011020u; Mattson MP, 1998, J NEUROCHEM, V70, P1; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Miller FD, 2001, CELL MOL LIFE SCI, V58, P1045, DOI 10.1007/PL00000919; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Neff F, 2002, ANN NY ACAD SCI, V973, P70, DOI 10.1111/j.1749-6632.2002.tb04608.x; Nishio T, 1998, NEUROREPORT, V9, P2847, DOI 10.1097/00001756-199808240-00030; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Plotkin B, 2003, J PHARMACOL EXP THER, V305, P974, DOI 10.1124/jpet.102.047381; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Ryu EJ, 2002, J NEUROSCI, V22, P10690; Sarabi A, 2000, EXP NEUROL, V170, P283, DOI 10.1006/exnr.2001.7714; Shastry BS, 2002, DRUG TODAY, V38, P445, DOI 10.1358/dot.2002.38.6.678351; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Song L, 2002, J BIOL CHEM, V277, P44701, DOI 10.1074/jbc.M206047200; Soto-Otero R, 2000, J NEUROCHEM, V74, P1605, DOI 10.1046/j.1471-4159.2000.0741605.x; Spencer JPE, 1998, J NEUROCHEM, V71, P2112; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; Storch A, 2000, J NEUROCHEM, V75, P2259, DOI 10.1046/j.1471-4159.2000.0752259.x; Sun YB, 2002, J CELL PHYSIOL, V192, P225, DOI 10.1002/jcp.10132; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TAKAHASHI T, 1994, J NEURAL TRANSM-GEN, V98, P107, DOI 10.1007/BF01277014; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; Tsuboi K, 2000, BRAIN RES, V866, P55, DOI 10.1016/S0006-8993(00)02219-8; Ugarte SD, 2003, J NEUROSCI RES, V73, P105, DOI 10.1002/jnr.10632; Volpe BT, 1998, NEUROSCIENCE, V83, P741, DOI 10.1016/S0306-4522(97)00424-7; von Coelln R, 2001, J NEUROCHEM, V77, P263, DOI 10.1046/j.1471-4159.2001.t01-1-00236.x; Warner TT, 2003, ANN NEUROL, V53, pS16, DOI 10.1002/ana.10487; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; YOUDIM MBH, 1993, J NEURAL TRANSM-GEN, P57	85	257	274	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1162	+		10.1096/fj.04-1551fje	http://dx.doi.org/10.1096/fj.04-1551fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132987				2022-12-25	WOS:000221883200022
J	Roosterman, D; Cottrell, GS; Schmidlin, F; Steinhoff, M; Bunnett, NW				Roosterman, D; Cottrell, GS; Schmidlin, F; Steinhoff, M; Bunnett, NW			Recycling and resensitization of the neurokinin 1 receptor - Influence of agonist concentration and Rab GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SUBSTANCE-P RECEPTOR; BETA-ARRESTIN; ENDOCYTIC PATHWAY; BETA(2)-ADRENERGIC RECEPTOR; DEPENDENT PHOSPHORYLATION; INDUCED TRAFFICKING; EPITHELIAL-CELLS; PLASMA-MEMBRANE; EARLY ENDOSOMES	Substance P (SP) induces endocytosis and recycling of the neurokinin 1 receptor (NK1R) in endothelial cells and spinal neurons at sites of inflammation and pain, and it is thus important to understand the mechanism and function of receptor trafficking. We investigated how the SP concentration affects NK1R trafficking and determined the role of Rab GTPases in trafficking. NK1R trafficking was markedly influenced by the SP concentration. High SP (10 nM) induced translocation of the NK1R and beta-arrestin 1 to perinuclear sorting endosomes containing Rab5a, where NK1R remained for >60 min. Low SP (1 nM) induced translocation of the NK1R to early endosomes located immediately beneath the plasma membrane that also contained Rab5a and beta-arrestin 1, followed by rapid recycling of the NK1R. Overexpression of Rab5a promoted NK1R translocation to perinuclear sorting endosomes, whereas the GTP binding-deficient mutant Rab5aS34N caused retention of the NK1R in superficial early endosomes. NK1R translocated from superficial early endosomes to recycling endosomes containing Rab4a and Rab11a, and Rab11aS25N inhibited NK1R recycling. Rapid NK1R recycling coincided with resensitization of SP-induced Ca2+ mobilization and with the return of surface SP binding sites. Resensitization was minimally affected by inhibition of vacuolar H+-ATPase and phosphatases but was markedly suppressed by disruption of Rab4a and Rab11a. Thus, whereas beta-arrestins mediate NK1R endocytosis, Rab5a regulates translocation between early and sorting endosomes, and Rab4a and Rab11a regulate trafficking through recycling endosomes. We have thus identified a new function of Rab5a as a control protein for directing concentration-dependent trafficking of the NK1R into different intracellular compartments and obtained evidence that Rab4a and Rab11a contribute to G-protein-coupled receptor recycling from early endosomes.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bunnett, NW (corresponding author), Univ Calif San Francisco, Dept Surg, 521 Parnassus Ave, San Francisco, CA 94143 USA.	nigelb@itsa.ucsf.edu	Steinhoff, Martin/F-6312-2013	Steinhoff, Martin/0000-0002-7090-2187; Cottrell, Graeme/0000-0001-9098-7627; Bunnett, Nigel W./0000-0003-3367-0644	NIDDK NIH HHS [DK39957, DK43207] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039957, R01DK043207, R56DK043207, R37DK039957] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barak LS, 1999, J BIOL CHEM, V274, P7565, DOI 10.1074/jbc.274.11.7565; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Bohm SK, 1997, J BIOL CHEM, V272, P2363; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BUNNETT NW, 1995, PEPTIDES, V16, P733, DOI 10.1016/0196-9781(95)00042-I; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Dale LB, 2004, J BIOL CHEM, V279, P13110, DOI 10.1074/jbc.M313333200; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Dery O, 2001, AM J PHYSIOL-CELL PH, V280, pC1097, DOI 10.1152/ajpcell.2001.280.5.C1097; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Garland AM, 1996, MOL PHARMACOL, V49, P438; GARLAND AM, 1994, BIOCHEM J, V303, P177, DOI 10.1042/bj3030177; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; Iwata K, 1999, EUR J BIOCHEM, V263, P596, DOI 10.1046/j.1432-1327.1999.00549.x; Kim YM, 2002, J BIOL CHEM, V277, P30760, DOI 10.1074/jbc.M204528200; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; Mohrmann K, 1999, MOL MEMBR BIOL, V16, P81, DOI 10.1080/096876899294797; MOORE RH, 1995, J CELL SCI, V108, P2983; Nishimura K, 1998, BIOCHEMISTRY-US, V37, P1192, DOI 10.1021/bi972302s; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Roosterman D, 2003, AM J PHYSIOL-CELL PH, V284, pC1319, DOI 10.1152/ajpcell.00540.2002; Roush ED, 1999, MOL PHARMACOL, V55, P855; Schmidlin F, 2002, P NATL ACAD SCI USA, V99, P3324, DOI 10.1073/pnas.052161299; Schmidlin F, 2003, AM J PHYSIOL-CELL PH, V285, pC945, DOI 10.1152/ajpcell.00541.2002; Schmidlin F, 2001, J BIOL CHEM, V276, P25427, DOI 10.1074/jbc.M101688200; Seachrist JL, 2000, J BIOL CHEM, V275, P27221; Seachrist JL, 2002, J BIOL CHEM, V277, P679, DOI 10.1074/jbc.M109022200; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; VIGNA SR, 1994, J NEUROSCI, V14, P834; Vigna SR, 1999, J NEUROCHEM, V73, P1925; Volpicelli LA, 2001, J BIOL CHEM, V276, P47590, DOI 10.1074/jbc.M106535200; VON ZM, 1992, J BIOL CHEM, V267, P3530; Warabi K, 2002, FEBS LETT, V521, P140, DOI 10.1016/S0014-5793(02)02858-2	46	70	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30670	30679		10.1074/jbc.M402479200	http://dx.doi.org/10.1074/jbc.M402479200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15128739	hybrid			2022-12-25	WOS:000222531900097
J	Fischer, AM; Mercer, JC; Iyer, A; Ragin, MJ; August, A				Fischer, AM; Mercer, JC; Iyer, A; Ragin, MJ; August, A			Regulation of CXC chemokine receptor 4-mediated migration by the tec family tyrosine kinase ITK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; LYMPHOCYTE CHEMOATTRACTANT; HOMOLOGY DOMAIN; CUTTING EDGE; MICE LACKING; HIV-1 ENTRY; ACTIVATION; SDF-1; CHEMOTAXIS	Chemokines are critical in controlling lymphocyte traffic and migration. The CXC chemokine CXCL12/ SDF-1alpha interacts with its receptor CXCR4 to induce the migration of a number of different cell types. Although an understanding of the physiological functions of this chemokine is emerging, the mechanism by which it regulates T cell migration is still unclear. We show here that the Tec family kinase ITK is activated rapidly following CXCL12/SDF-1alpha stimulation, and this requires Src and phosphatidylinositol 3-kinase activities. ITK regulates the ability of CXCL12/SDF-1alpha to induce T cell migration as overexpression of wild-type ITK-enhanced migration, and T cells lacking ITK exhibit reduced migration as well as adhesion in response to CXCL12/SDF-1alpha. Further analysis suggests that ITK may regulate CXCR4-mediated migration and adhesion by altering the actin cytoskeleton, as ITK null T cells were significantly defective in CXCL12/SDF-1a-mediated actin polymerization. Our data suggest that ITK may regulate the ability of CXCR4 to induce T cell migration.	Penn State Univ, Dept Vet Sci, Immunol Res Labs, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, Pathobiol Grad Program, University Pk, PA 16802 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Immunobiol Opt Integrated Biosci Grad Program, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	August, A (corresponding author), Penn State Univ, Dept Vet Sci, Immunol Res Labs, 115 Henning Bldg, University Pk, PA 16802 USA.	axa45@psu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051626] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI51626] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; DApuzzo M, 1997, EUR J IMMUNOL, V27, P1788, DOI 10.1002/eji.1830270729; Dutt P, 1998, J IMMUNOL, V161, P3652; Gibson S, 1996, J IMMUNOL, V156, P2716; GIBSON S, 1993, BLOOD, V82, P1561; Grasis JA, 2003, J IMMUNOL, V170, P3971, DOI 10.4049/jimmunol.170.8.3971; Hao SL, 2002, FEBS LETT, V525, P53, DOI 10.1016/S0014-5793(02)03066-1; Hunter AJ, 2000, J IMMUNOL, V164, P1143, DOI 10.4049/jimmunol.164.3.1143; Johnston B, 2002, SEMIN IMMUNOL, V14, P83, DOI 10.1006/smim.2001.0345; LANO CM, 2003, CURR BIOL, V13, P1619; Liao XC, 1995, IMMUNITY, V3, P757, DOI 10.1016/1074-7613(95)90065-9; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Lu YL, 1998, J IMMUNOL, V161, P5404; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; Mueller C, 2003, J IMMUNOL, V170, P5056, DOI 10.4049/jimmunol.170.10.5056; Nishita M, 2002, MOL CELL BIOL, V22, P774, DOI 10.1128/MCB.22.3.774-783.2002; Ottoson NC, 2001, J IMMUNOL, V167, P1857, DOI 10.4049/jimmunol.167.4.1857; Shan XC, 1999, J BIOL CHEM, V274, P29323, DOI 10.1074/jbc.274.41.29323; Sotsios Y, 1999, J IMMUNOL, V163, P5954; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; Vicente-Manzanares M, 1999, J IMMUNOL, V163, P4001; Woods ML, 2001, J LEUKOCYTE BIOL, V69, P874; Woods ML, 2001, EMBO J, V20, P1232, DOI 10.1093/emboj/20.6.1232	27	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29816	29820		10.1074/jbc.M312848200	http://dx.doi.org/10.1074/jbc.M312848200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123627	hybrid			2022-12-25	WOS:000222445300118
J	Liu, HB; Holm, M; Xie, XQ; Wolf-Watz, M; Grundstrom, T				Liu, HB; Holm, M; Xie, XQ; Wolf-Watz, M; Grundstrom, T			AML1/Runx1 recruits calcineurin to regulate granulocyte macrophage colony-stimulating factor by Ets1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE-BINDING-FACTOR; T-CELL-RECEPTOR; GM-CSF PROMOTER; NF-KAPPA-B; DNA-BINDING; TRANSCRIPTION FACTOR; PHOSPHATASE CALCINEURIN; NEGATIVE REGULATION; PROTEIN INTERFERES; SIGNALING PATHWAYS	Acute myeloid leukemia 1 (AML1), also denoted Runx1, is a transcription factor essential for hematopoiesis, and the AML1 gene is the most common target of chromosomal translocations in human leukemias. AML1 binds to sequences present in the regulatory regions of a number of hematopoiesis-specific genes, including certain cytokines such as granulocyte macrophage colony-stimulating factor (GM-CSF) up-regulated after T cell receptor stimulation. Here we show that both subunits of the Ca2+/calmodulin-dependent protein phosphatase calcineurin (CN), which is activated upon T cell receptor stimulation, interact directly with the N-terminal runt homology domain-containing part of AML1. The regulatory CN subunit binds AML1 with a higher affinity and in addition also interacts with the isolated runt homology domain. The related Runx2 transcription factor, which is essential for bone formation, also interacts with CN. A constitutively active derivative of CN is shown to activate synergistically the GM-CSF promoter/enhancer together with AML1 or Runx2. We also provide evidence that relief of the negative effect of the AML1 sites is important for Ca2+ activation of the GM-CSF promoter/enhancer and that AML1 overexpression increases this Ca2+ activation. Both subunits of CN interact with AML1 in coimmunoprecipitation analyses, and confocal microscopy analysis of cells expressing fluorescence-tagged protein derivatives shows that CN can be recruited to the nucleus by AML1 in vivo. Mutant analysis of the GM-CSF promoter shows that the Ets1 binding site of the promoter is essential for the synergy between AML1 and CN in Jurkat T cells. Analysis of the effects of inhibitors of the protein kinase glycogen synthase kinase-beta and in vitro phosphorylation/dephosphorylation analysis of Ets1 suggest that glycogen synthase kinase-3beta-phosphorylated Ets1 is a target of AML1-recruited CN phosphatase at the GM-CSF promoter.	Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden	Umea University	Grundstrom, T (corresponding author), Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden.	thomas.grundstrom@molbiol.umu.se	Holm, Magnus/B-8932-2008					Backstrom S, 2002, J MOL BIOL, V322, P259, DOI 10.1016/S0022-2836(02)00702-7; BAE SC, 1993, ONCOGENE, V8, P809; Balmain A, 2002, NATURE, V417, P235, DOI 10.1038/417235a; Benschop RJ, 2001, J IMMUNOL, V167, P4172, DOI 10.4049/jimmunol.167.8.4172; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Chen G, 1999, J NEUROCHEM, V72, P1327, DOI 10.1046/j.1471-4159.2000.0721327.x; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Diehn M, 2002, P NATL ACAD SCI USA, V99, P11796, DOI 10.1073/pnas.092284399; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; FRASER JK, 1994, MOL CELL BIOL, V14, P2213, DOI 10.1128/MCB.14.3.2213; GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110; GAJEWSKI TF, 1994, J EXP MED, V179, P481, DOI 10.1084/jem.179.2.481; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; Garvie CW, 2001, MOL CELL, V8, P1267, DOI 10.1016/S1097-2765(01)00410-5; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; HALLBERG B, 1992, NUCLEIC ACIDS RES, V20, P6495, DOI 10.1093/nar/20.24.6495; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; Hughes K, 1998, FEBS LETT, V441, P132, DOI 10.1016/S0014-5793(98)01537-3; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050; LARS N, 1993, INT IMMUNOL, V5, P271, DOI 10.1093/intimm/5.3.271; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Liles W C, 2001, Semin Respir Infect, V16, P11; Liu H, 2002, MOL BIOL CELL, V13, P4497, DOI 10.1091/mbc.E02-03-0149; LU J, 1995, MOL CELL BIOL, V15, P1651; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; McKinlay LH, 1998, J IMMUNOL, V161, P4098; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Murphy LLS, 2002, J IMMUNOL, V169, P3717, DOI 10.4049/jimmunol.169.7.3717; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Ohteki T, 2000, J EXP MED, V192, P99, DOI 10.1084/jem.192.1.99; Okuda T, 2001, INT J HEMATOL, V74, P252, DOI 10.1007/BF02982057; Perry C, 2002, LEUKEMIA RES, V26, P221, DOI 10.1016/S0145-2126(01)00128-X; PISTOIA V, 1995, STEM CELLS, V13, P487, DOI 10.1002/stem.5530130506; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; REDONDO JM, 1991, MOL CELL BIOL, V11, P5671, DOI 10.1128/MCB.11.11.5671; Shang C, 1999, INT IMMUNOL, V11, P1945, DOI 10.1093/intimm/11.12.1945; Shannon MF, 1997, CRIT REV IMMUNOL, V17, P301, DOI 10.1615/CritRevImmunol.v17.i3-4.30; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SloanLancaster J, 1996, J EXP MED, V184, P1525, DOI 10.1084/jem.184.4.1525; Speck NA, 2001, CURR OPIN HEMATOL, V8, P192, DOI 10.1097/00062752-200107000-00002; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; THOMAS RS, 1995, ONCOGENE, V11, P2135; THORNELL A, 1993, J BIOL CHEM, V268, P21946; THORNELL A, 1991, J VIROL, V65, P42, DOI 10.1128/JVI.65.1.42-50.1991; Tian JM, 1999, J BIOL CHEM, V274, P15173, DOI 10.1074/jbc.274.21.15173; TRUNEH A, 1985, J IMMUNOL, V135, P2262; UEKI K, 1992, BIOCHEM BIOPH RES CO, V187, P537, DOI 10.1016/S0006-291X(05)81527-X; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Xie XQ, 1999, EUR J IMMUNOL, V29, P488, DOI 10.1002/(SICI)1521-4141(199902)29:02<488::AID-IMMU488>3.0.CO;2-N; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015; Zhang YW, 1997, MOL CELL BIOL, V17, P4133, DOI 10.1128/MCB.17.7.4133; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	78	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29398	29408		10.1074/jbc.M403173200	http://dx.doi.org/10.1074/jbc.M403173200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123671	hybrid			2022-12-25	WOS:000222445300072
J	Marlowe, JL; Knudsen, ES; Schwemberger, S; Puga, A				Marlowe, JL; Knudsen, ES; Schwemberger, S; Puga, A			The aryl hydrocarbon receptor displaces p300 from E2F-dependent promoters and represses S phase-specific gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSLOCATOR PROTEIN; RAT HEPATOMA-CELLS; AH DIOXIN RECEPTOR; RETINOBLASTOMA PROTEIN; HUMAN KERATINOCYTES; LACTATIONAL EXPOSURE; FUNCTIONAL DOMAINS; CANCER MORTALITY; CYCLE ARREST; E2F FAMILY	The environmental contaminant 2,3,7,8-tetrachlorodibenzop- dioxin ( TCDD) causes a wide range of toxic, teratogenic, and carcinogenic effects. TCDD is a ligand for the aromatic hydrocarbon receptor (AHR), a ligand-activated transcription factor believed to be the primary mediator of these effects. Activation of the AHR by TCDD also elicits a variety of effects on cell cycle progression, ranging from proliferation to arrest. In this report, we have characterized further the role of the activated AHR in cell cycle regulation. In human mammary carcinoma MCF-7 and mouse hepatoma Hepa-1 cells, TCDD treatment decreased the number of cells in S phase and caused the accumulation of cells in G(1). In Hepa-1 cells, this effect correlated with the transcriptional repression of several E2F-regulated genes required for S phase progression. AHR-mediated gene repression was dependent on its interaction with retinoblastoma protein but was independent of its transactivation function because AHR mutants lacking DNA binding or transactivation domains repressed E2F-dependent expression as effectively as wild type AHR. Overexpression of p300 suppressed retinoblastoma protein-dependent gene repression, and this effect was reversed by TCDD. Chromatin immunoprecipitation assays showed that TCDD treatment caused the recruitment of AHR to E2F-dependent promoters and the concurrent displacement of p300. These results delineate a novel mechanism whereby the AHR, a known transcriptional activator, also mediates gene repression by pathways involving combinatorial interactions at E2F-responsive promoters, leading to the repression of E2F-dependent, S phase-specific genes. The AHR seems to act as an environmental checkpoint that senses exposure to environmental toxicants and responds by signaling cell cycle inhibition.	Univ Cincinnati, Med Ctr, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Ctr Environm Genet, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Shriners Hosp Children, Cincinnati, OH 45229 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Puga, A (corresponding author), Univ Cincinnati, Med Ctr, Dept Environm Hlth, POB 670056, Cincinnati, OH 45267 USA.	Alvaro.Puga@UC.edu	Puga, Alvaro/B-7676-2008		NIEHS NIH HHS [ES06273, P30 ES06096] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006273, P30ES006096, R56ES006273] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abdelrahim M, 2003, MOL PHARMACOL, V63, P1373, DOI 10.1124/mol.63.6.1373; Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; BERNHARD HP, 1973, DEV BIOL, V35, P83, DOI 10.1016/0012-1606(73)90008-0; Bertazzi PA, 2001, AM J EPIDEMIOL, V153, P1031, DOI 10.1093/aje/153.11.1031; BERTAZZI PA, 1993, EPIDEMIOLOGY, V4, P398, DOI 10.1097/00001648-199309000-00004; BIRNBAUM LS, 1995, ENVIRON HEALTH PERSP, V103, P89, DOI 10.2307/3432515; BJERKE DL, 1994, TOXICOL APPL PHARM, V127, P241, DOI 10.1006/taap.1994.1158; BROOKS SC, 1973, J BIOL CHEM, V248, P6251; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; CHOI EJ, 1991, J BIOL CHEM, V266, P9591; Cummings AM, 1996, TOXICOL APPL PHARM, V138, P131, DOI 10.1006/taap.1996.0106; Dragan YP, 2000, FOOD ADDIT CONTAM A, V17, P289, DOI 10.1080/026520300283360; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Elferink CJ, 2001, MOL PHARMACOL, V59, P664, DOI 10.1124/mol.59.4.664; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; FINGERHUT MA, 1991, NEW ENGL J MED, V324, P212, DOI 10.1056/NEJM199101243240402; FLESCHJANYS D, 1995, AM J EPIDEMIOL, V142, P1165, DOI 10.1093/oxfordjournals.aje.a117575; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; GAIDO KW, 1992, J BIOL CHEM, V267, P24591; GAIDO KW, 1994, TOXICOL APPL PHARM, V127, P199, DOI 10.1006/taap.1994.1154; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; GOTTLICHER M, 1990, CARCINOGENESIS, V11, P2205, DOI 10.1093/carcin/11.12.2205; GOTTLICHER M, 1991, TOXICOL APPL PHARM, V111, P496, DOI 10.1016/0041-008X(91)90253-B; Guo JH, 2004, TOXICOL APPL PHARM, V194, P79, DOI 10.1016/j.taap.2003.09.002; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hestermann EV, 2002, AQUAT TOXICOL, V58, P201, DOI 10.1016/S0166-445X(01)00229-6; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Kamath AB, 1997, TOXICOL APPL PHARM, V142, P367, DOI 10.1006/taap.1996.8049; Kerkvliet NI, 1995, ENVIRON HEALTH PERSP, V103, P47, DOI 10.2307/3432722; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Kobayashi A, 1997, J BIOCHEM, V122, P703; Koliopanos A, 2002, ONCOGENE, V21, P6059, DOI 10.1038/sj.onc.1205633; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Levine-Fridman A, 2004, MOL PHARMACOL, V65, P461, DOI 10.1124/mol.65.2.461; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; Ma Q, 1996, MOL CELL BIOL, V16, P2144; MABLY TA, 1992, TOXICOL APPL PHARM, V114, P118, DOI 10.1016/0041-008X(92)90103-Y; Mann PC, 1997, TOXICOL PATHOL, V25, P72, DOI 10.1177/019262339702500114; MANZ A, 1991, LANCET, V338, P959, DOI 10.1016/0140-6736(91)91835-I; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; MCCONKEY DJ, 1989, BIOCHEM BIOPH RES CO, V160, P1003, DOI 10.1016/S0006-291X(89)80101-9; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MILSTONE LM, 1984, J INVEST DERMATOL, V82, P532, DOI 10.1111/1523-1747.ep12261149; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; Moolgavkar SH, 1996, TOXICOL APPL PHARM, V138, P31, DOI 10.1006/taap.1996.0094; Nguyen TA, 1999, ARCH BIOCHEM BIOPHYS, V367, P250, DOI 10.1006/abbi.1999.1282; OUGHTON JA, 1995, FUND APPL TOXICOL, V25, P60, DOI 10.1006/faat.1995.1040; PIRKLE JL, 1989, J TOXICOL ENV HEALTH, V27, P165, DOI 10.1080/15287398909531288; PROBST MR, 1993, MOL PHARMACOL, V44, P511; Puga A, 2000, J BIOL CHEM, V275, P2943, DOI 10.1074/jbc.275.4.2943; Puga A, 2000, BIOCHEM PHARMACOL, V60, P1129, DOI 10.1016/S0006-2952(00)00403-2; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; RIER SE, 1993, FUND APPL TOXICOL, V21, P433, DOI 10.1006/faat.1993.1119; Safe S, 1998, TOXICOL LETT, V103, P343; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Steenland K, 1999, J NATL CANCER I, V91, P779, DOI 10.1093/jnci/91.9.779; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Sun WM, 1997, J BIOL CHEM, V272, P31845, DOI 10.1074/jbc.272.50.31845; SUSKIND RR, 1985, SCAND J WORK ENV HEA, V11, P165, DOI 10.5271/sjweh.2240; SUTTER TR, 1992, CHEMOSPHERE, V25, P223, DOI 10.1016/0045-6535(92)90519-W; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Wang F, 1999, BIOCHEMISTRY-US, V38, P11490, DOI 10.1021/bi982578f; Wang S, 2002, J BIOL CHEM, V277, P11821, DOI 10.1074/jbc.M110122200; Wang WL, 1998, ARCH BIOCHEM BIOPHYS, V356, P239, DOI 10.1006/abbi.1998.0782; Wang XH, 1996, BIOCHEM BIOPH RES CO, V220, P784, DOI 10.1006/bbrc.1996.0481; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; WIEBEL FJ, 1991, TOXICOL LETT, V55, P161, DOI 10.1016/0378-4274(91)90130-X; WOLFLE D, 1988, CARCINOGENESIS, V9, P919, DOI 10.1093/carcin/9.6.919; Worner W, 1996, CANCER RES, V56, P1272; 1997, IARC MONOGRAPH EVALU	78	114	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29013	29022		10.1074/jbc.M404315200	http://dx.doi.org/10.1074/jbc.M404315200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123621	hybrid			2022-12-25	WOS:000222445300024
J	Mortl, M; Diederichs, K; Welte, W; Molla, G; Motteran, L; Andriolo, G; Pilone, MS; Pollegioni, L				Mortl, M; Diederichs, K; Welte, W; Molla, G; Motteran, L; Andriolo, G; Pilone, MS; Pollegioni, L			Structure-function correlation in glycine oxidase from Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID OXIDASE; MONOMERIC SARCOSINE OXIDASE; PARA-HYDROXYBENZOATE HYDROXYLASE; CATABOLITE REPRESSION; CRYSTAL-STRUCTURE; DIFFRACTION DATA; PROTEIN; SUBSTRATE; MECHANISM; RESOLUTION	Structure-function relationships of the flavoprotein glycine oxidase ( GO), which was recently proposed as the first enzyme in the biosynthesis of thiamine in Bacillus subtilis, has been investigated by a combination of structural and functional studies. The structure of the GO-glycolate complex was determined at 1.8 Angstrom, a resolution at which a sketch of the residues involved in FAD binding and in substrate interaction can be depicted. GO can be considered a member of the "amine oxidase" class of flavoproteins, such as D-amino acid oxidase and monomeric sarcosine oxidase. With the obtained model of GO the monomer-monomer interactions can be analyzed in detail, thus explaining the structural basis of the stable tetrameric oligomerization state of GO, which is unique for the GR(2) subfamily of flavooxidases. On the other hand, the three-dimensional structure of GO and the functional experiments do not provide the functional significance of such an oligomerization state; GO does not show an allosteric behavior. The results do not clarify the metabolic role of this enzyme in B. subtilis; the broad substrate specificity of GO cannot be correlated with the inferred function in thiamine biosynthesis, and the structure does not show how GO could interact with ThiS, the following enzyme in thiamine biosynthesis. However, they do let a general catabolic role of this enzyme on primary or secondary amines to be excluded because the expression of GO is not inducible by glycine, sarcosine, or D-alanine as carbon or nitrogen sources.	Univ Insubria, Dept Struct & Funct Biol, I-21100 Varese, Italy; Univ Konstanz, Biol Sect, D-7750 Constance, Germany	University of Insubria; University of Konstanz	Pollegioni, L (corresponding author), Univ Insubria, Dept Struct & Funct Biol, Via JH Dunant 3, I-21100 Varese, Italy.	loredano.pollegioni@uninsubria.it		Molla, Gianluca/0000-0003-3688-3397; POLLEGIONI, LOREDANO/0000-0003-1733-7243				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; DIEDERICHS K, 1995, PROTEINS, V23, P187, DOI 10.1002/prot.340230208; Dym O, 2001, PROTEIN SCI, V10, P1712, DOI 10.1110/ps.12801; ENTSCH B, 1995, FASEB J, V9, P476, DOI 10.1096/fasebj.9.7.7737455; Fisher SH, 1999, MOL MICROBIOL, V32, P223, DOI 10.1046/j.1365-2958.1999.01333.x; Fisher Susan H., 1993, P221; HUECK CJ, 1995, MOL MICROBIOL, V15, P395, DOI 10.1111/j.1365-2958.1995.tb02252.x; Job V, 2002, J BIOL CHEM, V277, P6985, DOI 10.1074/jbc.M111095200; Job V, 2002, EUR J BIOCHEM, V269, P1456, DOI 10.1046/j.1432-1033.2002.02790.x; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; Kleywegt G. J., 2001, INT TABLES CRYSTALLO, VF, P353, DOI DOI 10.1107/97809553602060000111; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mattevi A, 1996, P NATL ACAD SCI USA, V93, P7496, DOI 10.1073/pnas.93.15.7496; Mattevi A, 1999, STRUCTURE, V7, P745, DOI 10.1016/S0969-2126(99)80099-9; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MirandaRios J, 1997, J BACTERIOL, V179, P6887, DOI 10.1128/jb.179.22.6887-6893.1997; Molla G, 2003, EUR J BIOCHEM, V270, P1474, DOI 10.1046/j.1432-1033.2003.03513.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Pawelek PD, 2000, EMBO J, V19, P4204, DOI 10.1093/emboj/19.16.4204; PHILIPPSEN A, 2003, DINO VISUALIZING STR; Pilone MS, 2000, CELL MOL LIFE SCI, V57, P1732, DOI 10.1007/PL00000655; POLLEGIONI L, 1995, BIOCHEM J, V310, P577, DOI 10.1042/bj3100577; PORTER DJT, 1977, J BIOL CHEM, V252, P4464; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Sacchi S, 2002, J BIOL CHEM, V277, P27510, DOI 10.1074/jbc.M203946200; Saier MH, 1996, J BACTERIOL, V178, P3411, DOI 10.1128/jb.178.12.3411-3417.1996; Saier MH, 1996, MICROBIOL-UK, V142, P217, DOI 10.1099/13500872-142-2-217; Sambrook J, 2001, MOL CLONING LAB MANU; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHREIER HJ, 1983, BACILLUS SUBTILIS OT, P281; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; Settembre EC, 2003, BIOCHEMISTRY-US, V42, P2971, DOI 10.1021/bi026916v; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Trickey P, 1999, STRUCTURE, V7, P331, DOI 10.1016/S0969-2126(99)80043-4; Umhau S, 2000, P NATL ACAD SCI USA, V97, P12463, DOI 10.1073/pnas.97.23.12463; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VANDERHORN PB, 1993, J BACTERIOL, V175, P982, DOI 10.1128/JB.175.4.982-992.1993; Wagner MA, 2000, BIOCHEMISTRY-US, V39, P8825, DOI 10.1021/bi000350y; Wagner MA, 1997, ARCH BIOCHEM BIOPHYS, V342, P176, DOI 10.1006/abbi.1997.0106; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; Zhao GH, 2002, BIOCHEMISTRY-US, V41, P9747, DOI 10.1021/bi020285n	48	55	57	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29718	29727		10.1074/jbc.M401224200	http://dx.doi.org/10.1074/jbc.M401224200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15105420	hybrid, Green Published			2022-12-25	WOS:000222445300108
J	Nouet, S; Amzallag, N; Li, JM; Louis, S; Seitz, I; Cui, TX; Alleaume, AM; Di Benedetto, M; Boden, C; Masson, M; Strosberg, AD; Horiuchi, M; Couraud, PO; Nahmias, C				Nouet, S; Amzallag, N; Li, JM; Louis, S; Seitz, I; Cui, TX; Alleaume, AM; Di Benedetto, M; Boden, C; Masson, M; Strosberg, AD; Horiuchi, M; Couraud, PO; Nahmias, C			Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; TYPE-2 RECEPTOR; COUPLED RECEPTORS; INDEPENDENT ACTIVATION; SHP-1; AT(2); TRANSACTIVATION; LOCALIZATION; ASSOCIATION; INHIBITION	Negative regulation of mitogenic pathways is a fundamental process that remains poorly characterized. The angiotensin II AT2 receptor is a rare example of a 7-transmembrane domain receptor that negatively cross-talks with receptor tyrosine kinases to inhibit cell growth. In the present study, we report the molecular cloning of a novel protein, ATIP1 (AT2-interacting protein), which interacts with the C-terminal tail of the AT2 receptor, but not with those of other receptors such as angiotensin AT1, bradykinin BK2, and adrenergic beta(2) receptor. ATIP1 defines a family of at least four members that possess the same domain of interaction with the AT2 receptor, contain a large coiled-coil region, and are able to dimerize. Ectopic expression of ATIP1 in eukaryotic cells leads to inhibition of insulin, basic fibroblast growth factor, and epidermal growth factor-induced ERK2 activation and DNA synthesis, and attenuates insulin receptor autophosphorylation, in the same way as the AT2 receptor. The inhibitory effect of ATIP1 requires expression, but not ligand activation, of the AT2 receptor and is further increased in the presence of Ang II, indicating that ATIP1 cooperates with AT2 to transinactivate receptor tyrosine kinases. Our findings therefore identify ATIP1 as a novel early component of growth inhibitory signaling cascade.	Inst Cochin Genet Mol, Dept Cell Biol, CNRS, UMR8104,INSERM,U567, F-75014 Paris, France; Univ Melbourne, Clin Pharmacol Unit, Austin Hlth, Heidelberg, Vic 3084, Australia; Ehime Univ, Sch Med, Dept Med Biochem, Shigenobu, Ehime 7910295, Japan; Mol Engines Labs, F-75011 Paris, France; Deutsch Herzzentrum Munich, D-80636 Munich, Germany; Hybrigenics SA, F-75014 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Ehime University; German Heart Centre Munich	Nahmias, C (corresponding author), Inst Cochin Genet Mol, Dept Cell Biol, CNRS, UMR8104,INSERM,U567, 22 Rue Mechain, F-75014 Paris, France.	nahmias@cochin.inserm.fr	Di Benedetto, Melanie MD/C-1512-2018	Di Benedetto, Melanie MD/0000-0003-1119-3752; Alleaume, Anne-Marie/0000-0001-7881-1880; Cui, Taixing/0000-0002-9528-7299				AbdAlla S, 2001, J BIOL CHEM, V276, P39721, DOI 10.1074/jbc.M105253200; Akishita M, 1999, J CLIN INVEST, V103, P63, DOI 10.1172/JCI5182; Ango F, 2001, NATURE, V411, P962, DOI 10.1038/35082096; Bedecs K, 1997, BIOCHEM J, V325, P449, DOI 10.1042/bj3250449; Bockaert J, 2003, FEBS LETT, V546, P65, DOI 10.1016/S0014-5793(03)00453-8; Brady AE, 2002, CELL SIGNAL, V14, P297, DOI 10.1016/S0898-6568(01)00239-X; Cui TX, 2002, MOL ENDOCRINOL, V16, P2113, DOI 10.1210/me.2001-0284; Cui TX, 2001, CARDIOVASC RES, V49, P863, DOI 10.1016/S0008-6363(00)00299-6; Cui TX, 2000, BIOCHEM BIOPH RES CO, V279, P938, DOI 10.1006/bbrc.2000.4055; Daviet L, 1999, J BIOL CHEM, V274, P17058, DOI 10.1074/jbc.274.24.17058; De Paolis P, 2002, J HYPERTENS, V20, P693, DOI 10.1097/00004872-200204000-00027; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; Di Liberto G, 2003, AM J PHYSIOL-CELL PH, V285, pC599, DOI 10.1152/ajpcell.00040.2003; Elbaz N, 2000, MOL ENDOCRINOL, V14, P795, DOI 10.1210/me.14.6.795; Feng YH, 2002, P NATL ACAD SCI USA, V99, P12049, DOI 10.1073/pnas.192404199; Gallinat S, 2000, AM J PHYSIOL-ENDOC M, V278, pE357, DOI 10.1152/ajpendo.2000.278.3.E357; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hall RA, 2002, CIRC RES, V91, P672, DOI 10.1161/01.RES.0000037000.74258.03; Horiuchi M, 1999, TRENDS ENDOCRIN MET, V10, P391, DOI 10.1016/S1043-2760(99)00191-5; Knowle D, 2000, REGUL PEPTIDES, V87, P73, DOI 10.1016/S0167-0115(99)00111-1; LAZARD D, 1994, RECEPTOR CHANNEL, V2, P271; Lehtonen JYA, 1999, MOL ENDOCRINOL, V13, P1051, DOI 10.1210/me.13.7.1051; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Marrero MB, 1998, AM J PHYSIOL-CELL PH, V275, pC1216, DOI 10.1152/ajpcell.1998.275.5.C1216; Matsubara H, 2001, BIOCHEM BIOPH RES CO, V282, P1085, DOI 10.1006/bbrc.2001.4695; Miura SI, 2000, EMBO J, V19, P4026, DOI 10.1093/emboj/19.15.4026; NAHMIAS C, 1995, BIOCHEM J, V306, P87, DOI 10.1042/bj3060087; Nouet S, 2000, TRENDS ENDOCRIN MET, V11, P1, DOI 10.1016/S1043-2760(99)00205-2; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pulakat L, 2002, FEBS LETT, V524, P73, DOI 10.1016/S0014-5793(02)03005-3; Salahpour A, 2000, TRENDS ENDOCRIN MET, V11, P163, DOI 10.1016/S1043-2760(00)00260-5; Senbonmatsu T, 2003, EMBO J, V22, P6471, DOI 10.1093/emboj/cdg637; Shibasaki Y, 2001, HYPERTENSION, V38, P367, DOI 10.1161/01.HYP.38.3.367; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; Stoll M, 2001, REGUL PEPTIDES, V99, P175, DOI 10.1016/S0167-0115(01)00246-4; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Volpe M, 2003, J HYPERTENS, V21, P1429, DOI 10.1097/00004872-200308000-00001; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8	41	135	140	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28989	28997		10.1074/jbc.M403880200	http://dx.doi.org/10.1074/jbc.M403880200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123706	hybrid			2022-12-25	WOS:000222445300021
J	Phan, J; Peterfy, M; Reue, K				Phan, J; Peterfy, M; Reue, K			Lipin expression preceding peroxisome proliferator-activated receptor-gamma is critical for adipogenesis in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL GENERALIZED LIPODYSTROPHY; FAMILIAL PARTIAL LIPODYSTROPHY; ADIPOCYTE DIFFERENTIATION; ADIPOSE-TISSUE; MICE LACKING; INSULIN-RESISTANCE; METABOLIC SYNDROME; LAMIN A/C; WHITE FAT; OBESITY	We recently identified mutations in the lipin gene, Lpin1, as the cause of lipodystrophy in the fatty liver dystrophy (fld) mouse. Here we identify impaired adipocyte differentiation as the basis for lipodystrophy in lipin-deficient mice and demonstrate that lipin is required for normal induction of the adipogenic gene transcription program. We found that the reduced adiposity in chow fed fld mice and resistance to obesity in fld mice fed a high-fat diet is associated with reduced adipogenic gene expression. Using primary mouse embryonic fibroblasts isolated from fld mice, we confirmed that lipin deficiency prevents normal lipid accumulation and induction of key adipogenic genes, including peroxisome proliferator-activated receptor (PPAR)gamma and CCAAT enhancer-binding protein (C/EBP)alpha. However, our previous studies of daily gene expression in differentiating 3T3-L1 preadipocytes indicated that lipin expression is undetectable until about day 3 of differentiation, at a point after PPARgamma and C/EBPalpha gene expression is established. This paradox was resolved by examining gene expression at 10-h intervals during 3T3-L1 cell differentiation, leading to detection of transient lipin expression at 10 h into the differentiation program, prior to the induction of PPARgamma and C/EBPalpha. Consistent with a requirement for lipin expression upstream of PPARgamma, differentiation of lipin-deficient mouse embryonic fibroblasts could be rescued by ectopic expression of PPARgamma. Thus, we conclude that lipin expression is required prior to PPARgamma during adipocyte differentiation.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA; Vet Afffairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Reue, K (corresponding author), 11301 Wilshire Blvd,Bldg 113,Room 312, Los Angeles, CA 90073 USA.	reuek@ucla.edu		Phan, Jack/0000-0001-5977-6004	NHLBI NIH HHS [HL28481] Funding Source: Medline; NIGMS NIH HHS [GM08042] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Agarwal AK, 2003, TRENDS ENDOCRIN MET, V14, P214, DOI 10.1016/S1043-2760(03)00078-X; Agarwal AK, 2002, J CLIN ENDOCR METAB, V87, P408, DOI 10.1210/jc.87.1.408; Agarwal AK, 2002, NAT GENET, V31, P21, DOI 10.1038/ng880; Alexander DL, 1998, J CELL SCI, V111, P3311; Anand A, 2000, NAT GENET, V24, P377, DOI 10.1038/74207; Bhayana S, 2002, CLIN BIOCHEM, V35, P171, DOI 10.1016/S0009-9120(02)00297-7; Cao H, 2000, HUM MOL GENET, V9, P109, DOI 10.1093/hmg/9.1.109; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; Circolo A, 1999, IMMUNOPHARMACOLOGY, V42, P135, DOI 10.1016/S0162-3109(99)00021-1; Garg A, 2004, NEW ENGL J MED, V350, P1220, DOI 10.1056/NEJMra025261; Goudriaan JR, 2001, ARTERIOSCL THROM VAS, V21, P1488, DOI 10.1161/hq0901.095147; Hegele RA, 2003, TRENDS ENDOCRIN MET, V14, P371, DOI 10.1016/S1043-2760(03)00142-5; Hegele RA, 2002, DIABETES, V51, P3586, DOI 10.2337/diabetes.51.12.3586; Huffman TA, 2002, P NATL ACAD SCI USA, V99, P1047, DOI 10.1073/pnas.022634399; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Koutnikova H, 2001, ANN MED, V33, P556, DOI 10.3109/07853890108995966; KOZAK LP, 1991, GENE DEV, V5, P2256, DOI 10.1101/gad.5.12a.2256; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Le Lay S, 2002, J BIOL CHEM, V277, P35625, DOI 10.1074/jbc.M203913200; Lloyd DJ, 2002, HUM MOL GENET, V11, P769, DOI 10.1093/hmg/11.7.769; Magre J, 2001, NAT GENET, V28, P365, DOI 10.1038/ng585; Miki H, 2001, MOL CELL BIOL, V21, P2521, DOI 10.1128/MCB.21.7.2521-2532.2001; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Morrison RF, 2000, J NUTR, V130, p3116S, DOI 10.1093/jn/130.12.3116S; Mounkes L, 2003, CURR OPIN GENET DEV, V13, P223, DOI 10.1016/S0959-437X(03)00058-3; Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523; Oral EA, 2003, REV ENDOCR METAB DIS, V4, P61, DOI 10.1023/A:1021827520301; Peterfy M, 2001, NAT GENET, V27, P121, DOI 10.1038/83685; Reitman ML, 2000, TRENDS ENDOCRIN MET, V11, P410, DOI 10.1016/S1043-2760(00)00309-X; Reue K, 2000, Curr Atheroscler Rep, V2, P390, DOI 10.1007/s11883-000-0077-1; Reue K, 2000, J LIPID RES, V41, P1067; Robinson SW, 2000, ANNU REV GENET, V34, P687, DOI 10.1146/annurev.genet.34.1.687; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Scott CL, 2003, AM J CARDIOL, V92, p35I, DOI 10.1016/S0002-9149(03)00507-1; Shackleton S, 2000, NAT GENET, V24, P153, DOI 10.1038/72807; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tange Y, 2002, J CELL SCI, V115, P4375, DOI 10.1242/jcs.00135; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Valet P, 2002, J LIPID RES, V43, P835; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Worman HJ, 2002, TRENDS CELL BIOL, V12, P591, DOI 10.1016/S0962-8924(02)02401-7	49	176	188	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29558	29564		10.1074/jbc.M403506200	http://dx.doi.org/10.1074/jbc.M403506200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123608	hybrid			2022-12-25	WOS:000222445300090
J	Sato, O; White, HD; Inoue, A; Belknap, B; Ikebe, R; Ikebe, M				Sato, O; White, HD; Inoue, A; Belknap, B; Ikebe, R; Ikebe, M			Human deafness mutation of myosin VI (C442Y) accelerates the ADP dissociation rate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; PHOSPHORYLATION-DEPENDENT REGULATION; MOTOR DOMAIN DETERMINES; LIGHT-CHAIN KINASE; ACTIN-BASED MOTOR; UNCONVENTIONAL MYOSIN; KINETIC MECHANISM; SNELLS-WALTZER; INNER-EAR; 2-HEADED STRUCTURE	The missense mutation of Cys(442) to Tyr of myosin VI causes progressive postlingual sensorineural deafness. Here we report the affects of the C442Y mutation on the kinetics of the actomyosin ATP hydrolysis mechanism and motor function of myosin VI. The largest changes in the kinetic mechanism of ATP hydrolysis produced by the C442Y mutation are about 10-fold increases in the rate of ADP dissociation from both myosin VI and actomyosin VI. The rates of ADP dissociation from acto-C442Y myosin VI-ADP and C442Y myosin VI-ADP are 20 - 40 times more rapid than the steady state rates and cannot be the rate-limiting steps of the hydrolysis mechanism in the presence or absence of actin. The 2-fold increase in the actin gliding velocity of C442Y compared with wild type (WT) may be explained at least in part by the more rapid rate of ADP dissociation. The C442Y myosin VI has a significant increase (similar to 10-fold) in the steady state ATPase rate in the absence of actin relative to WT myosin VI. The steady state rate of actin-activated ATP hydrolysis is unchanged by the C442Y mutation at low (< 10(-7) M) calcium but is calcium-sensitive with a 1.6-fold increase at high ( similar to 10(-4) M) calcium that does not occur with WT. The actin gliding velocity of the C442Y mutant decreases significantly at low surface density of myosin VI, suggesting that the mutation hampers the processive movement of myosin VI.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA; Eastern Virginia Med Sch, Dept Physiol Sci, Norfolk, VA 23507 USA	University of Massachusetts System; University of Massachusetts Worcester; Eastern Virginia Medical School	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.	Mitsuo.Ikebe@umassmed.edu			NIAMS NIH HHS [AR 48526, AR41653] Funding Source: Medline; NIBIB NIH HHS [EB00209] Funding Source: Medline; NIGMS NIH HHS [GM 55834] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048526, R01AR041653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000209] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; Bohrmann J, 1997, CELL MOL LIFE SCI, V53, P652, DOI 10.1007/s000180050084; Buss F, 2001, FEBS LETT, V508, P295, DOI 10.1016/S0014-5793(01)03065-4; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; COLUCCIO LM, 1994, J CELL SCI, V107, P2279; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; DEOL MS, 1966, GENET RES, V8, P339, DOI 10.1017/S0016672300010193; El Mezgueldi M, 2002, J BIOL CHEM, V277, P21514, DOI 10.1074/jbc.M200713200; Friedman TB, 1999, AM J MED GENET, V89, P147, DOI 10.1002/(SICI)1096-8628(19990924)89:3<147::AID-AJMG5>3.0.CO;2-6; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; HEINTZELMAN MB, 1994, J CELL SCI, V107, P3535; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Hodge T, 2000, J CELL SCI, V113, P3353; Homma K, 2000, J BIOL CHEM, V275, P34766, DOI 10.1074/jbc.M003132200; Homma K, 2001, NATURE, V412, P831, DOI 10.1038/35090597; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1987, J BIOL CHEM, V262, P13828; KAMM KE, 1987, AM REV RESPIR DIS, V136, pS12, DOI 10.1164/ajrccm/136.4_Pt_2.S12; Kovacs M, 2003, J BIOL CHEM, V278, P38132, DOI 10.1074/jbc.M305453200; Kovacs M, 2002, J BIOL CHEM, V277, P28459, DOI 10.1074/jbc.M202180200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XD, 2000, BIOCHEMISTRY-US, V39, P2254, DOI 10.1021/bi9924617; Li XD, 2003, J BIOL CHEM, V278, P29435, DOI 10.1074/jbc.M301784200; Li XD, 1998, J BIOL CHEM, V273, P27404, DOI 10.1074/jbc.273.42.27404; Malnasi-Csizmadia A, 2000, BIOCHEMISTRY-US, V39, P16135, DOI 10.1021/bi001125j; MATSUURA M, 1995, FEBS LETT, V363, P246, DOI 10.1016/0014-5793(95)00326-5; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Melchionda S, 2001, AM J HUM GENET, V69, P635, DOI 10.1086/323156; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Nishikawa S, 2002, BIOCHEM BIOPH RES CO, V290, P311, DOI 10.1006/bbrc.2001.6142; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REYNARD AM, 1961, J BIOL CHEM, V236, P2277; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; Rosenfeld SS, 2003, J BIOL CHEM, V278, P27449, DOI 10.1074/jbc.M302555200; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; Self T, 1999, DEV BIOL, V214, P331, DOI 10.1006/dbio.1999.9424; Sellers J. R., 1999, MYOSINS; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Tanaka H, 2002, NATURE, V415, P192, DOI 10.1038/415192a; TAYLOR EW, 1977, BIOCHEMISTRY-US, V16, P732, DOI 10.1021/bi00623a027; Titus MA, 1997, TRENDS CELL BIOL, V7, P119, DOI 10.1016/S0962-8924(97)01019-2; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; Wendt T, 1999, J CELL BIOL, V147, P1385, DOI 10.1083/jcb.147.7.1385; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020; WHITE HD, 1993, J BIOL CHEM, V268, P10039; YANO K, 1993, BIOCHEMISTRY-US, V32, P12054, DOI 10.1021/bi00096a016; Yoshimura M, 2001, J BIOL CHEM, V276, P39600, DOI 10.1074/jbc.M105080200; Zhu T, 1998, J BIOL CHEM, V273, P20481, DOI 10.1074/jbc.273.32.20481; Zhu T, 1996, BIOCHEMISTRY-US, V35, P513, DOI 10.1021/bi952053c	59	18	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28844	28854		10.1074/jbc.M314332200	http://dx.doi.org/10.1074/jbc.M314332200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123708	hybrid			2022-12-25	WOS:000222445300004
J	Ding, ZH; Gillespie, LL; Mercer, FC; Paterno, GD				Ding, ZH; Gillespie, LL; Mercer, FC; Paterno, GD			The SANT domain of human MI-ER1 interacts with Sp1 to interfere with GC box recognition and repress transcription from its own promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; FUNCTIONAL INTERACTION; INDEPENDENT MECHANISMS; NUCLEAR RECEPTOR; GROWTH-FACTOR; N-COR; PROTEIN; COMPLEX; GENE; ELEMENT	ld;&. 2qTo gain insight into the regulation of hmi-er1 expression, we cloned a human genomic DNA fragment containing one of the two hmi-er1 promoters and consisting of 1460 bp upstream of the translation initiation codon of hMI-ER1. Computer-assisted sequence analysis revealed that the hmi-er1 promoter region contains a CpG island but lacks an identifiable TATA element, initiator sequence and downstream promoter element. This genomic DNA was able to direct transcription of a luciferase reporter gene in a variety of human cell lines, and the minimal promoter was shown to be located within - 68/+144 bp. Several putative Sp1 binding sites were identified, and we show that Sp1 can bind to the hmi-er1 minimal promoter and increase transcription, suggesting that the level of hmi-er1 expression may depend on the availability of Sp1 protein. Functional analysis revealed that hMI-ER1 represses Sp1-activated transcription from the minimal promoter by a histone deacetylase-independent mechanism. Chromatin immunoprecipitation analysis demonstrated that both Sp1 and hMI-ER1 are associated with the chromatin of the hmi-er1 promoter and that overexpression of hMI-ER1 in cell lines that allow Tet-On-inducible expression resulted in loss of detectable Sp1 from the endogenous hmi-er1 promoter. The mechanism by which this occurs does not involve binding of hMI-ER1 to cis-acting elements. Instead, we show that hMI-ER1 physically associates with Sp1 and that endogenous complexes containing the two proteins could be detected in vivo. Furthermore, hMI-ER1 specifically interferes with binding of Sp1 to the hmi-er1 minimal promoter as well as to an Sp1 consensus oligonucleotide. Deletion analysis revealed that this interaction occurs through a region containing the SANT domain of hMI-ER1. Together, these data reveal a functional role for the SANT domain in the action of co-repressor regulatory factors and suggest that the association of hMI-ER1 with Sp1 represents a novel mechanism for the negative regulation of Sp1 target promoters.	Mem Univ Newfoundland, Fac Med, Div Basic Med Sci, Terry Fox Canc Res Labs, St John, NF A1B 3V6, Canada	Memorial University Newfoundland	Paterno, GD (corresponding author), Mem Univ Newfoundland, Fac Med, Div Basic Med Sci, Terry Fox Canc Res Labs, 300 Prince Phillip Dr, St John, NF A1B 3V6, Canada.	gpaterno@mun.ca						Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; Ding ZH, 2003, MOL CELL BIOL, V23, P250, DOI 10.1128/MCB.23.1.250-258.2003; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Fernandes I, 2003, MOL CELL, V11, P139, DOI 10.1016/S1097-2765(03)00014-5; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Johnson-Pais T, 2001, P NATL ACAD SCI USA, V98, P2211, DOI 10.1073/pnas.051415898; Kaczynski J, 2001, J BIOL CHEM, V276, P36749, DOI 10.1074/jbc.M105831200; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Laj A, 1999, MOL CELL BIOL, V19, P6632; Lee DK, 2002, J BIOL CHEM, V277, P26761, DOI 10.1074/jbc.M202078200; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Paterno GD, 1997, J BIOL CHEM, V272, P25591, DOI 10.1074/jbc.272.41.25591; Paterno GD, 1998, GENE, V222, P77, DOI 10.1016/S0378-1119(98)00473-9; Paterno GD, 2002, GENE, V295, P79, DOI 10.1016/S0378-1119(02)00823-5; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Post JN, 2001, FEBS LETT, V502, P41, DOI 10.1016/S0014-5793(01)02653-9; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Solari F, 1999, DEVELOPMENT, V126, P2483; Sterner DE, 2002, J BIOL CHEM, V277, P8178, DOI 10.1074/jbc.M108601200; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Suzuki T, 2003, J BIOL CHEM, V278, P28758, DOI 10.1074/jbc.M302228200; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; Weinmann AS, 2001, NAT IMMUNOL, V2, P51, DOI 10.1038/83168; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	38	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28009	28016		10.1074/jbc.M403793200	http://dx.doi.org/10.1074/jbc.M403793200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117948	hybrid			2022-12-25	WOS:000222265400024
J	Divinski, I; Mittelman, L; Gozes, I				Divinski, I; Mittelman, L; Gozes, I			A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; DEPENDENT NEUROTROPHIC FACTOR; NEUROPROTECTIVE PEPTIDE; HEAD-INJURY; DIPHTHERIA-TOXIN; NAP; VIP; TOXICITY; CELLS; BRAIN	An octapeptide was previously described that protects neurons against a wide variety of insults directly and indirectly as a result of interactions (at femtomolar concentrations) with supporting glial cells. The current study set out to identify the octapeptide binding molecules so as to understand the high affinity mechanisms of cellular protection. Studies utilizing affinity chromatography of brain extracts identified tubulin, the brain major protein, as the octapeptide-binding ligand. Dot blot analysis with pure tubulin and the biotinylated octapeptide verified this finding. When added to cerebral cortical astrocytes, the octapeptide (10(-15)-10(-10) M) induced a rapid microtubule reorganization into distinct microtubular structures that were stained by monoclonal tubulin antibodies and visualized by confocal microscopy. Fluorescein-labeled octapeptide induced a similar change and was detected in the intracellular milieu, even when cells were incubated at 4 degreesC or at low pH. In a cell-free system, the octapeptide stimulated tubulin assembly into microtubules. Furthermore, treatment of astrocytes with zinc chloride resulted in microtubule disassembly and cell death that was protected by the octapeptide. In conclusion, the results suggest that the octapeptide crosses the plasma membrane and interacts directly with tubulin, the microtubule subunit, to induce microtubule reorganization and improved survival. Because microtubules are the key component of the neuronal and glial cytoskeleton that regulates cell division, differentiation, and efficiency of the cellular protective capacities of the octapeptide.	Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Interdepartmental Core Facil, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Gozes, I (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel.	igozes@post.tau.ac.il						Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; Ashur-Fabian O, 2003, PEPTIDES, V24, P1413, DOI 10.1016/j.peptides.2003.08.005; Ashur-Fabian O, 2001, NEUROSCI LETT, V307, P167, DOI 10.1016/S0304-3940(01)01954-1; Bassan M, 1999, J NEUROCHEM, V72, P1283, DOI 10.1046/j.1471-4159.1999.0721283.x; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Brenneman DE, 2004, J PHARMACOL EXP THER, V309, P1190, DOI 10.1124/jpet.103.063891; Brenneman DE, 1996, J CLIN INVEST, V97, P2299, DOI 10.1172/JCI118672; Brenneman DE, 1998, J PHARMACOL EXP THER, V285, P619; Brenneman DE, 2000, BIOCHEM SOC T, V28, P452, DOI 10.1042/0300-5127:0280452; Brion JP, 2001, BIOCHEM SOC SYMP, V67, P81; Chen CJ, 2003, J NEUROCHEM, V85, P443, DOI 10.1046/j.1471-4159.2003.01691.x; Cribbs DH, 1997, J BIOL CHEM, V272, P7431, DOI 10.1074/jbc.272.11.7431; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; GOTTLIEB P, 1982, EUR J BIOCHEM, V125, P631, DOI 10.1111/j.1432-1033.1982.tb06729.x; Gozes I, 2000, J PHARMACOL EXP THER, V293, P1091; GOZES I, 1982, NEUROCHEM INT, V4, P101, DOI 10.1016/0197-0186(82)90003-1; Gozes I, 2003, J MOL NEUROSCI, V20, P315, DOI 10.1385/JMN:20:3:315; GOZES I, 1981, NATURE, V294, P477, DOI 10.1038/294477a0; Gozes I, 2002, J MOL NEUROSCI, V19, P167, DOI 10.1007/s12031-002-0028-0; GOZES I, 1978, NATURE, V276, P411, DOI 10.1038/276411a0; GOZES I, 1982, P NATL ACAD SCI-BIOL, V79, P2579, DOI 10.1073/pnas.79.8.2579; Gozes I, 2001, TRENDS NEUROSCI, V24, P700, DOI 10.1016/S0166-2236(00)01931-7; Gozes I, 2000, J MOL NEUROSCI, V14, P61, DOI 10.1385/JMN:14:1-2:061; Hamel E, 2002, BIOPOLYMERS, V66, P142, DOI 10.1002/bip.10255; Islam K, 1997, AM J PATHOL, V151, P265; Leker RR, 2002, STROKE, V33, P1085, DOI 10.1161/01.STR.0000014207.05597.D7; Li GB, 2003, J NEUROCHEM, V84, P347, DOI 10.1046/j.1471-4159.2003.01526.x; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Loring JF, 2001, DNA CELL BIOL, V20, P683, DOI 10.1089/10445490152717541; Martin A, 2002, J VIROL, V76, P4961, DOI 10.1128/JVI.76.10.4961-4970.2002; MAXWELL IH, 1992, LEUKEMIA LYMPHOMA, V7, P457, DOI 10.3109/10428199209049802; Moscarello MA, 2002, MULT SCLER J, V8, P130, DOI 10.1191/1352458502ms776oa; Offen D, 2000, BRAIN RES, V854, P257, DOI 10.1016/S0006-8993(99)02375-6; Petrova PS, 2004, PROG BRAIN RES, V146, P167, DOI 10.1016/S0079-6123(03)46012-3; PIZZA M, 1990, J BIOL CHEM, V265, P17759; Plassart-Schiess E, 2001, BRAIN RES REV, V37, P133, DOI 10.1016/S0165-0173(01)00113-8; Romano J, 2002, J MOL NEUROSCI, V18, P37, DOI 10.1385/JMN:18:1-2:37; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; SARIS P, 1990, FEMS MICROBIOL LETT, V68, P143; SEBO P, 1995, INFECT IMMUN, V63, P3851, DOI 10.1128/IAI.63.10.3851-3857.1995; Sigalov E, 2000, J MOL NEUROSCI, V15, P147, DOI 10.1385/JMN:15:3:147; Spong CY, 2001, J PHARMACOL EXP THER, V297, P774; Steingart RA, 2000, J MOL NEUROSCI, V15, P137, DOI 10.1385/JMN:15:3:137; STENMARK H, 1991, J CELL BIOL, V113, P1025, DOI 10.1083/jcb.113.5.1025; Terry RD, 1998, J NEURAL TRANSM-SUPP, P141; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; Yoshiyama Y, 2003, J NEUROSCI, V23, P10662; Zaltzman R, 2003, NEUROREPORT, V14, P481, DOI 10.1097/01.wnr.0000058036.29600.ff; Zamostiano R, 2001, J BIOL CHEM, V276, P708, DOI 10.1074/jbc.M007416200; Zemlyak I, 2000, REGUL PEPTIDES, V96, P39, DOI 10.1016/S0167-0115(00)00198-1	51	124	130	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28531	28538		10.1074/jbc.M403197200	http://dx.doi.org/10.1074/jbc.M403197200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123709	hybrid			2022-12-25	WOS:000222265400089
J	Miranda, E; Romisch, K; Lomas, DA				Miranda, E; Romisch, K; Lomas, DA			Mutants of neuroserpin that cause dementia accumulate as polymers within the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE INHIBITOR; PLASMINOGEN-ACTIVATOR; INCLUSION-BODIES; ALPHA(1)-ANTITRYPSIN DEFICIENCY; CONFORMATIONAL DISEASE; PROTEINASE-INHIBITOR; REACTIVE LOOP; LIVER-INJURY; IN-VITRO; DEGRADATION	The dementia familial encephalopathy with neuroserpin inclusion bodies (FENIB) is caused by the accumulation of mutant neuroserpin within neurons (Davis, R. L., Shrimpton, A. E., Holohan, P. D., Bradshaw, C., Feiglin, D., Sonderegger, P., Kinter, J., Becker, L. M., Lacbawan, F., Krasnewich, D., Muenke, M., Lawrence, D. A., Yerby, M. S., Shaw, C.-M., Gooptu, B., Elliott, P. R., Finch, J. T., Carrell, R. W., and Lomas, D. A. ( 1999) Nature 401, 376-379), but little is known about the trafficking of wild type and mutant neuroserpins. We have established a cell model to study the processing of wild type neuroserpin and the Syracuse (S49P) and Portland (S52R) mutants that cause FENIB. Here we show that Syracuse and Portland neuroserpin are retained soon after their synthesis in the endoplasmic reticulum and that the limiting step in their processing is the transport to the Golgi complex. This is in contrast to the wild type protein, which is secreted into the culture medium. Mutant neuroserpin is retained within the endoplasmic reticulum as polymers, similar to those isolated from the intraneuronal inclusions in the brains of individuals with FENIB. Remarkably, the Portland mutant showed faster accumulation and slower secretion compared with the Syracuse mutant, in keeping with the more severe clinical phenotype found in patients with the Portland variant of neuroserpin. Both mutant and wild type neuroserpin were partially degraded by proteasomes. Taken together, our results provide further understanding of how cells handle defective but ordered mutant proteins and provide strong support for a common mechanism of disease caused by mutants of the serine protease inhibitor superfamily.	Univ Cambridge, Cambridge Inst Med Res, Dept Med, Cambridge CB2 2XY, England; Univ Cambridge, Cambridge Inst Med Res, Dept Clin Biochem, Cambridge CB2 2XY, England	University of Cambridge; University of Cambridge	Miranda, E (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Dept Med, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	em285@cam.ac.uk	Miranda, Elena/J-4999-2012; Römisch, Karin/AAO-1210-2021	Miranda, Elena/0000-0002-0586-8795; Römisch, Karin/0000-0003-0415-6558				Barker-Carlson K, 2002, J BIOL CHEM, V277, P46852, DOI 10.1074/jbc.M207740200; Belorgey D, 2002, J BIOL CHEM, V277, P17367, DOI 10.1074/jbc.M200680200; BRANTLY M, 1988, SCIENCE, V242, P1700, DOI 10.1126/science.2904702; Burrows JAJ, 2000, P NATL ACAD SCI USA, V97, P1796, DOI 10.1073/pnas.97.4.1796; Cabral CM, 2000, J BIOL CHEM, V275, P25015, DOI 10.1074/jbc.M910172199; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Davis RL, 1999, AM J PATHOL, V155, P1901, DOI 10.1016/S0002-9440(10)65510-1; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; Davis RL, 2002, LANCET, V359, P2242, DOI 10.1016/S0140-6736(02)09293-0; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; Hastings GA, 1997, J BIOL CHEM, V272, P33062, DOI 10.1074/jbc.272.52.33062; Hill RM, 2002, ANN NY ACAD SCI, V971, P406, DOI 10.1111/j.1749-6632.2002.tb04503.x; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE A, 1990, J BIOL CHEM, V265, P14001; LE AQ, 1992, J BIOL CHEM, V267, P1072; LIBBY P, 1978, SCIENCE, V199, P534, DOI 10.1126/science.622552; Lomas DA, 2002, NAT REV GENET, V3, P759, DOI 10.1038/nrg907; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; Lomas DA, 2002, J CLIN INVEST, V110, P1585, DOI 10.1172/JCI200216782; Madani R, 2003, MOL CELL NEUROSCI, V23, P473, DOI 10.1016/S1044-7431(03)00077-0; Mahadeva R, 2002, J BIOL CHEM, V277, P6771, DOI 10.1074/jbc.C100722200; Mahadeva R, 1999, J CLIN INVEST, V103, P999, DOI 10.1172/JCI4874; Osterwalder T, 1998, J BIOL CHEM, V273, P2312, DOI 10.1074/jbc.273.4.2312; Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x; Parfrey H, 2003, J BIOL CHEM, V278, P33060, DOI 10.1074/jbc.M302646200; Parmar PK, 2002, J NEUROCHEM, V82, P1406, DOI 10.1046/j.1471-4159.2002.01100.x; Perlmutter DH, 2002, J CLIN INVEST, V110, P1579, DOI 10.1172/JCI200216787; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Rutishauser J, 2002, SWISS MED WKLY, V132, P211; Schrimpf SP, 1997, GENOMICS, V40, P55, DOI 10.1006/geno.1996.4514; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; Sivasothy P, 2000, J BIOL CHEM, V275, P33663, DOI 10.1074/jbc.M004054200; Tanaka Y, 2002, J BIOL CHEM, V277, P51058, DOI 10.1074/jbc.M210231200; Teckman JH, 2000, AM J PHYSIOL-GASTR L, V279, pG961, DOI 10.1152/ajpgi.2000.279.5.G961; Teckman JH, 1996, J BIOL CHEM, V271, P13215, DOI 10.1074/jbc.271.22.13215; Teckman JH, 2001, J BIOL CHEM, V276, P44865, DOI 10.1074/jbc.M103703200; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100; Yazaki M, 2001, AM J PATHOL, V158, P227, DOI 10.1016/S0002-9440(10)63961-2; Yepes M, 2002, J CLIN INVEST, V109, P1571, DOI 10.1172/JCI200214308; Yepes M, 2000, BLOOD, V96, P569; Zhou AW, 2003, J BIOL CHEM, V278, P15116, DOI 10.1074/jbc.M211663200	50	97	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28283	28291		10.1074/jbc.M313166200	http://dx.doi.org/10.1074/jbc.M313166200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15090543	Green Published, hybrid			2022-12-25	WOS:000222265400059
J	Uccelletti, D; O'Callaghan, C; Berninsone, P; Zemtseva, I; Abeijon, C; Hirschberg, CB				Uccelletti, D; O'Callaghan, C; Berninsone, P; Zemtseva, I; Abeijon, C; Hirschberg, CB			ire-1-dependent transcriptional up-regulation of a lumenal uridine diphosphatase from Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE SUGAR TRANSPORTERS; VACUOLAR H+-ATPASE; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; NUCLEOSIDE DIPHOSPHATASE; MESSENGER-RNA; ALPHA-3-D-MANNOSIDE BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE-I; SCHIZOSACCHAROMYCES-POMBE; GUANOSINE DIPHOSPHATASE; EPITHELIAL INVAGINATION	Lumenal ecto-nucleoside tri- and di-phosphohydrolases (ENTPDases) of the secretory pathway of eukaryotes hydrolyze nucleoside diphosphates resulting from glycosyltransferase-mediated reactions, yielding nucleoside monophosphates. The latter are weaker inhibitors of glycosyltransferases than the former and are also antiporters for the transport of nucleotide sugars from the cytosol to the endoplasmic reticulum ( ER) and Golgi apparatus (GA) lumen. Here we describe the presence of two cation-dependent nucleotide phosphohydrolase activities in membranes of Caenorhabditis elegans: one, UDA-1, is a UDP/GDPase encoded by the gene uda-1, whereas the other is an apyrase encoded by the gene ntp-1. UDA-1 shares significant amino acid sequence similarity to yeast GA Gda1p and mammalian UDP/GDPases and has a lumenal active site in vesicles displaying an intermediate density between those of the ER and GA when expressed in S. cerevisiae. NTP-1 expressed in COS-7 cells appeared to localize to the GA. The transcript of uda-1 but not those of two other C. elegans ENTPDase mRNAs (ntp-1 and mig-23) was induced up to 3.5-fold by high temperature, tunicamycin, and ethanol. The same effectors triggered the unfolded protein response as shown by the induction of expression of green fluorescent protein under the control of the BiP chaperone promoter and the UDP-glucose: glycoprotein glucosyltransferase. Up-regulation of uda-1 did not occur in ire-1-deficient mutants, demonstrating the role of this ER stress sensor in this event. We hypothesize that up-regulation of uda-1 favors hydrolysis of the glucosyltransferase inhibitory product UDP to UMP, and that the latter product then exits the lumen of the ER or pre-GA compartment in a coupled exchange with the entry of UDP-glucose, thereby further relieving ER stress by favoring protein re-glycosylation.	Boston Univ, Dept Mol & Cell Biol, Goldman Sch Dent Med, Boston, MA 02118 USA	Boston University	Hirschberg, CB (corresponding author), Boston Univ, Dept Mol & Cell Biol, Goldman Sch Dent Med, Boston, MA 02118 USA.	chirschb@bu.edu		Hirschberg, Carlos/0000-0003-2299-7721; Uccelletti, Daniela/0000-0001-6841-8129	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030365, R01GM030365] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; Arnold SM, 2000, BIOCHEMISTRY-US, V39, P2149, DOI 10.1021/bi9916473; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; Biederbick A, 1999, J CELL SCI, V112, P2473; BRENNER S, 1974, GENETICS, V77, P71; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; CAREY DJ, 1981, J BIOL CHEM, V256, P989; CAREY DJ, 1980, J BIOL CHEM, V255, P4348; Chen SH, 2003, BIOCHIMIE, V85, P391, DOI 10.1016/S0300-9084(03)00009-9; Chen SH, 2002, BBA-GEN SUBJECTS, V1573, P271, DOI 10.1016/S0304-4165(02)00393-8; Coppi MV, 1997, FEBS LETT, V405, P281, DOI 10.1016/S0014-5793(97)00182-8; D'Alessio C, 2003, J BIOL CHEM, V278, P22379, DOI 10.1074/jbc.M300892200; Dejgaard S, 2004, CURR ISSUES MOL BIOL, V6, P29; Failer BU, 2002, J BIOL CHEM, V277, P36978, DOI 10.1074/jbc.M201656200; Fernandez F, 1996, EMBO J, V15, P705, DOI 10.1002/j.1460-2075.1996.tb00406.x; Gao XD, 1999, J BIOL CHEM, V274, P21450, DOI 10.1074/jbc.274.30.21450; Gerardy-Schahn R, 2001, BIOCHIMIE, V83, P775, DOI 10.1016/S0300-9084(01)01322-0; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Herman T, 1999, P NATL ACAD SCI USA, V96, P968, DOI 10.1073/pnas.96.3.968; Herrero AB, 2002, EUKARYOT CELL, V1, P420, DOI 10.1128/EC.1.3.420-431.2002; Hirschberg CB, 2001, J CLIN INVEST, V108, P3; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Hwang HY, 2003, J BIOL CHEM, V278, P11735, DOI 10.1074/jbc.C200518200; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Kawar ZS, 2002, J BIOL CHEM, V277, P34924, DOI 10.1074/jbc.M206112200; Kegel B, 1997, NEUROPHARMACOLOGY, V36, P1189, DOI 10.1016/S0028-3908(97)00115-9; Krause M, 1995, METHOD CELL BIOL, V48, P483; KUBOTA S, 1977, J BIOCHEM-TOKYO, V81, P197, DOI 10.1093/oxfordjournals.jbchem.a131436; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lopez-Avalos MD, 2001, GLYCOBIOLOGY, V11, P413, DOI 10.1093/glycob/11.5.413; Mezzacasa A, 2002, TRAFFIC, V3, P833, DOI 10.1034/j.1600-0854.2002.31108.x; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; NAKAJIMA T, 1975, P NATL ACAD SCI USA, V72, P3912, DOI 10.1073/pnas.72.10.3912; Nishiwaki K, 2004, NAT CELL BIOL, V6, P31, DOI 10.1038/ncb1079; Park BJ, 2001, MOL BIOL CELL, V12, P2835, DOI 10.1091/mbc.12.9.2835; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; PEREZ M, 1986, J BIOL CHEM, V261, P6822; SHERMAN F, 1986, METHODS YEAST GENETI, P121; Trombetta ES, 1999, EMBO J, V18, P3282, DOI 10.1093/emboj/18.12.3282; Wang TF, 1998, J BIOL CHEM, V273, P11392, DOI 10.1074/jbc.273.18.11392; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351; Zheng QL, 2002, J BIOL CHEM, V277, P39823, DOI 10.1074/jbc.M207487200; Zhong XT, 1999, J BIOL CHEM, V274, P32704, DOI 10.1074/jbc.274.46.32704; Zhong XT, 2003, J BIOL CHEM, V278, P33436, DOI 10.1074/jbc.M305785200; Zhong XT, 2000, J BIOL CHEM, V275, P35592, DOI 10.1074/jbc.M006932200; Zimmermann H, 2001, DRUG DEVELOP RES, V52, P44, DOI 10.1002/ddr.1097; ZIMMERMANN H, 1994, TRENDS NEUROSCI, V17, P420, DOI 10.1016/0166-2236(94)90016-7; Zuber C, 2001, P NATL ACAD SCI USA, V98, P10710, DOI 10.1073/pnas.191359198	50	13	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27390	27398		10.1074/jbc.M402624200	http://dx.doi.org/10.1074/jbc.M402624200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102851	hybrid			2022-12-25	WOS:000222120400070
J	Wang, JF; Zhang, XF; Groopman, JE				Wang, JF; Zhang, XF; Groopman, JE			Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; HYDROGEN-PEROXIDE; VEGF-C; MEDIATED ACTIVATION; BREAST-CANCER; EGF RECEPTORS; KAPPA-B; SRC; GENE	Reactive oxygen species (ROS) mediate cell damage and have been implicated in the pathogenesis of diseases that involve endothelial injury. Cells possess antioxidant systems, including intracellular antioxidants and ROS scavenging enzymes, that control the redox state and prevent cell damage. In addition to intracellular antioxidants, certain growth factor receptors can be activated under oxidative stress and trigger downstream cell survival signaling cascades. Vascular endothelial growth factor receptor-3 (VEGFR-3) is a primary modulator of lymphatic endothelial proliferation and survival. Here, we provide evidence that activation of VEGFR-3 signaling in response to hydrogen peroxide (H2O2) promotes endothelial cell survival. Treatment with H2O2 induced the tyrosine phosphorylation of VEGFR-3 and its association with the signaling adaptor proteins Shc, growth factor receptor binding protein 2, Sos, p85, SHP-2, and phospholipase C-gamma. Of note, a hereditary lymphoedema-linked mutant of VEGFR-3 was not phosphorylated by H2O2 treatment. Isoforms of protein kinase C (PKC), alpha and delta, were also tyrosine-phosphorylated after H2O2 stimulation. However, only the delta isoform of PKC was required for H2O2-induced phosphorylation of VEGFR-3. The tyrosine phosphorylation of VEGFR-3 or isoforms of PKC was completely inhibited by treatment with 4-amino-5-(4-chlorophenyl)-7-(t- butyl) pyrazolo[ 3,4-d] pyrimidine, a specific inhibitor for Src family kinases, indicating that Src family kinases are upstream of PKC and VEGFR-3. Furthermore, expression of the wild-type but not the lymphoedema-linked mutant form of VEGFR-3 in porcine artery endothelial cells significantly enhanced the activation of Akt after H2O2 stimulation. Consistent with these biochemical changes, we observed that expression and activation of the wild-type but not the mutant form of VEGFR-3 inhibited H2O2-induced apoptosis. These studies suggest that VEGFR-3 protects against oxidative damage in endothelial cells, and that patients with hereditary lymphoedema may be susceptible to ROS-induced cell damage.	Harvard Univ, Sch Med,Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Groopman, JE (corresponding author), Harvard Univ, Sch Med,Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	jgroopma@bidmc.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061940] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL61940] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Bouis Diane, 2001, Angiogenesis, V4, P91, DOI 10.1023/A:1012259529167; Brown NS, 2001, BREAST CANCER RES, V3, P323, DOI 10.1186/bcr315; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; Danilkovitch-Miagkova A, 2000, J BIOL CHEM, V275, P14783, DOI 10.1074/jbc.C000028200; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Frank GD, 2001, BIOCHEM BIOPH RES CO, V280, P1116, DOI 10.1006/bbrc.2001.4251; GALLAND F, 1993, ONCOGENE, V8, P1233; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; GonzalezRubio M, 1996, KIDNEY INT, V50, P164, DOI 10.1038/ki.1996.299; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; Hooshmand-Rad R, 1998, J CELL SCI, V111, P607; Huang RP, 2001, MOL CARCINOGEN, V30, P209, DOI 10.1002/mc.1030; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Irrthum A, 2000, AM J HUM GENET, V67, P295, DOI 10.1086/303019; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kamata H, 2000, EUR J BIOCHEM, V267, P1933, DOI 10.1046/j.1432-1327.2000.01194.x; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Kevil CG, 2001, AM J PHYSIOL-CELL PH, V281, pC1940, DOI 10.1152/ajpcell.2001.281.6.C1940; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kirkin V, 2001, EUR J BIOCHEM, V268, P5530, DOI 10.1046/j.1432-1033.2001.02476.x; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; KOSHIO O, 1988, BIOCHEM J, V250, P95, DOI 10.1042/bj2500095; LU D, 1993, AM J PHYSIOL, V264, pC715, DOI 10.1152/ajpcell.1993.264.3.C715; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Min DS, 1998, J BIOL CHEM, V273, P29986, DOI 10.1074/jbc.273.45.29986; Nair VD, 2003, BIOCHEM J, V373, P25, DOI 10.1042/BJ20030017; Ng CKD, 2002, AM J PHYSIOL-CELL PH, V283, pC93, DOI 10.1152/ajpcell.00301.2001; Niwa K, 2001, FREE RADICAL RES, V35, P519, DOI 10.1080/10715760100301531; OHKUMA M, 1993, LYMPHOLOGY, V26, P38; Padera TP, 2002, SCIENCE, V296, P1883, DOI 10.1126/science.1071420; Qin SF, 2003, BIOCHEMISTRY-US, V42, P2995, DOI 10.1021/bi0205911; ROEBUCK KA, 1995, J BIOL CHEM, V270, P18966, DOI 10.1074/jbc.270.32.18966; Saaristo A, 2002, ANN NY ACAD SCI, V979, P94, DOI 10.1111/j.1749-6632.2002.tb04871.x; Saito S, 2002, J BIOL CHEM, V277, P44695, DOI 10.1074/jbc.M208332200; Shono T, 1996, MOL CELL BIOL, V16, P4231; Siems WG, 2002, QJM-INT J MED, V95, P803, DOI 10.1093/qjmed/95.12.803; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Sorescu Dan, 2002, Congest Heart Fail, V8, P132, DOI 10.1111/j.1527-5299.2002.00717.x; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Tapia JA, 2003, J BIOL CHEM, V278, P35220, DOI 10.1074/jbc.M303119200; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Wan YS, 2001, INT J ONCOL, V18, P461; Wang JF, 2001, J BIOL CHEM, V276, P41950, DOI 10.1074/jbc.M101370200; Wang XT, 2001, J BIOL CHEM, V276, P28364, DOI 10.1074/jbc.M102693200; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367	65	63	75	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27088	27097		10.1074/jbc.M314015200	http://dx.doi.org/10.1074/jbc.M314015200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102829	hybrid			2022-12-25	WOS:000222120400035
J	Yoon, T; Cowan, JA				Yoon, T; Cowan, JA			Frataxin-mediated iron delivery to ferrochelatase in the final step of heme biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLUSTER BIOSYNTHESIS; FRIEDREICH ATAXIA; ENZYME; DEFICIENT; HOMODIMER; PROTEINS; BINDING; FORMS	Human ferrochelatase, a mitochondrial membrane-associated protein, catalyzes the terminal step of heme biosynthesis by insertion of ferrous iron into protoporphyrin IX. The recently solved x-ray structure of human ferrochelatase identifies a potential binding site for an iron donor protein on the matrix side of the homodimer. Herein we demonstrate Hs holofrataxin to be a high affinity iron binding partner for Hs ferrochelatase that is capable of both delivering iron to ferrochelatase and mediating the terminal step in mitochondrial heme biosynthesis. A general regulatory mechanism for mitochondrial iron metabolism is described that defines frataxin involvement in both heme and iron-sulfur cluster biosyntheses. In essence, the distinct binding affinities of holofrataxin to the target proteins, ferrochelatase ( heme synthesis) and ISU (iron-sulfur cluster synthesis), allows discrimination between the two major iron-dependent pathways and facilitates targeted heme biosynthesis following down-regulation of frataxin.	Ohio State Univ, Evans Lab Chem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Cowan, JA (corresponding author), Ohio State Univ, Evans Lab Chem, 100 W 18th Ave, Columbus, OH 43210 USA.	cowan@chemistry.ohio-state.edu						Becker EM, 2002, BLOOD, V99, P3813, DOI 10.1182/blood.V99.10.3813; Burden AE, 1999, BBA-PROTEIN STRUCT M, V1435, P191, DOI 10.1016/S0167-4838(99)00196-X; Cavadini P, 2002, HUM MOL GENET, V11, P217, DOI 10.1093/hmg/11.3.217; Cavadini P, 2000, J BIOL CHEM, V275, P41469, DOI 10.1074/jbc.M006539200; Chen OS, 2002, P NATL ACAD SCI USA, V99, P12321, DOI 10.1073/pnas.192449599; Dhe-Paganon S, 2000, J BIOL CHEM, V275, P30753, DOI 10.1074/jbc.C000407200; Foury F, 2002, J BIOL CHEM, V277, P24475, DOI 10.1074/jbc.M111789200; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Grzybowska E, 2002, ARCH BIOCHEM BIOPHYS, V398, P170, DOI 10.1006/abbi.2001.2730; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Lesuisse E, 2003, HUM MOL GENET, V12, P879, DOI 10.1093/hmg/ddg096; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; Musco G, 2000, STRUCTURE, V8, P695, DOI 10.1016/S0969-2126(00)00158-1; Park S, 2003, J BIOL CHEM, V278, P31340, DOI 10.1074/jbc.M303158200; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Sellers VM, 2001, BIOCHEMISTRY-US, V40, P9821, DOI 10.1021/bi010012c; Wu CK, 2001, NAT STRUCT BIOL, V8, P156, DOI 10.1038/84152; Yoon T, 2003, J AM CHEM SOC, V125, P6078, DOI 10.1021/ja027967i	18	226	237	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					25943	25946		10.1074/jbc.C400107200	http://dx.doi.org/10.1074/jbc.C400107200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15123683	hybrid			2022-12-25	WOS:000222003000003
J	Kask, L; Trouw, LA; Dahlback, B; Blom, AM				Kask, L; Trouw, LA; Dahlback, B; Blom, AM			The C4b-binding protein-protein S complex inhibits the phagocytosis of apoptotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; BINDING LECTIN ENGAGEMENT; SHBG-LIKE REGION; STRUCTURAL REQUIREMENTS; CLASSICAL PATHWAY; PLASMA-PROTEINS; ALPHA-CHAIN; C1Q; SURFACE; PURIFICATION	The phagocytosis of apoptotic cells is a complex process involving numerous interactions between the target cell and the macrophage. We have examined a role of the major soluble inhibitor of the classic and lectin complement pathways, C4b-binding protein (C4BP), in the clearance of apoptotic cells. The major form of C4BP present in blood is composed of seven alpha-chains and one beta-chain, which binds protein S ( PS). Approximately 70% of all PS in human plasma is trapped in such a complex and is able to localize C4BP to the surface of apoptotic cells due to the high affinity to phosphatidylserine. Free PS has recently been shown to enhance phagocytosis of apoptotic cells by macrophages. We observed a stimulatory effect of free PS on the engulfment of apoptotic cells (BL-41 and Jurkat) by primary human macrophages or THP-1 cells and a decrease of activity in serum depleted of PS in agreement with previous results. However, we also show that the process is strongly inhibited in the presence of the C4BP-PS complex. Addition of the C4BP-PS complex to serum deficient in both molecules abolished the enhancing effect of serum on phagocytosis. The effect of both free PS and the C4BP-PS complex could be inhibited with monoclonal antibody directed against the Gla domain of PS. Although the presence of the C4BP-PS complex on apoptotic cells may lead to decreased phagocytosis, it may still be beneficial to the host, since it could prevent secondary necrosis because it inhibits further complement attack.	Lund Univ, Malmo Univ Hosp, Dept Clin Chem, Wallenberg Lab, S-20502 Malmo, Sweden	Lund University; Skane University Hospital	Blom, AM (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Clin Chem, Wallenberg Lab, S-20502 Malmo, Sweden.	Anna.Blom@klkemi.mas.lu.se	Trouw, Leendert/AGK-5202-2022; Blom, Anna/B-9607-2009; Blom, Anna/AFS-7369-2022	Trouw, Leendert/0000-0001-5186-2290; Blom, Anna/0000-0002-1348-1734; Kask, Lena/0000-0002-4380-4354; Dahlback, Bjorn/0000-0003-1546-0328				Anderson HA, 2003, NAT IMMUNOL, V4, P87, DOI 10.1038/ni871; BARNUM SR, 1990, COMPLEMENT INFLAMMAT, V7, P71, DOI 10.1159/000463131; Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4; Botto M, 1998, EXP CLIN IMMUNOGENET, V15, P231, DOI 10.1159/000019076; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Carlsson F, 2003, J EXP MED, V198, P1057, DOI 10.1084/jem.20030543; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DE FRUTOS PG, 1994, BLOOD, V84, P815; Evenas P, 2000, BIOL CHEM, V381, P199, DOI 10.1515/BC.2000.027; Evenas P, 1999, EUR J BIOCHEM, V266, P935, DOI 10.1046/j.1432-1327.1999.00928.x; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; Giri TK, 2002, J BIOL CHEM, V277, P15099, DOI 10.1074/jbc.M103036200; HILLARP A, 1989, FEBS LETT, V259, P53, DOI 10.1016/0014-5793(89)81492-9; Kalafatis M, 1997, CRIT REV EUKAR GENE, V7, P241, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.40; MALM J, 1990, EUR J BIOCHEM, V187, P737, DOI 10.1111/j.1432-1033.1990.tb15361.x; Mevorach D, 1998, J EXP MED, V188, P2313, DOI 10.1084/jem.188.12.2313; Moffatt OD, 1999, J IMMUNOL, V162, P6800; Nauta AJ, 2003, EUR J IMMUNOL, V33, P2853, DOI 10.1002/eji.200323888; Nauta AJ, 2003, TRENDS IMMUNOL, V24, P148, DOI 10.1016/S1471-4906(03)00030-9; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; Nyberg P, 1998, FEBS LETT, V433, P28, DOI 10.1016/S0014-5793(98)00877-1; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; TENNER AJ, 1981, J IMMUNOL, V127, P648; Webb JH, 2003, BLOOD COAGUL FIBRIN, V14, P355, DOI 10.1097/00001721-200306000-00006; Webb JH, 2002, J IMMUNOL, V169, P2580, DOI 10.4049/jimmunol.169.5.2580	29	64	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23869	23873		10.1074/jbc.C400159200	http://dx.doi.org/10.1074/jbc.C400159200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15096498	hybrid			2022-12-25	WOS:000221702500006
J	Clarkson, AN; Liu, HZ; Pearson, L; Kapoor, M; Harrison, JC; Sammut, IA; Jackson, DM; Appleton, I				Clarkson, AN; Liu, HZ; Pearson, L; Kapoor, M; Harrison, JC; Sammut, IA; Jackson, DM; Appleton, I			Neuroprotective effects of spermine following hypoxia-ischemia-induced brain damage: A mechanistic study	FASEB JOURNAL			English	Article						polyamines; arginase activity; nitric oxide synthase	NITRIC-OXIDE SYNTHASE; FOCAL CEREBRAL-ISCHEMIA; METHYL-D-ASPARTATE; ORNITHINE-DECARBOXYLASE ACTIVITY; MITOCHONDRIAL RESPIRATORY-CHAIN; RAT-BRAIN; HIPPOCAMPAL SLICES; CELL-DEATH; ELECTRICAL RECOVERY; NADH FLUORESCENCE	The polyamines (spermine, putrescine, and spermidine) can have neurotoxic or neuroprotective properties in models of neurodegeneration. However, assessment in a model of hypoxia ischemia (HI) has not been defined. Furthermore, the putative mechanisms of neuroprotection have not been elucidated. Therefore, the present study examined the effects of the polyamines in a rat pup model of HI and determined effects on key enzymes involved in inflammation, namely, nitric oxide synthase (NOS) and arginase. In addition, effects on mitochondrial function were investigated. The polyamines or saline were administered i.p. at 10mg/kg/day for 6 days post-HI. Histological assessment 7 days post-HI revealed that only spermine significantly ( P<0.01) reduced infarct size from 46.14 +/- 10.4mm(3) ( HI + saline) to 4.9 +/- 2.7 mm(3). NOS activity was significantly increased following spermine treatment in the left (ligated) hemisphere compared with nonintervention controls (P< 0.01) and HI + saline (P< 0.05). In contrast, spermine decreased arginase activity compared with HI + saline but was still significantly elevated in comparison to nonintervention controls ( P< 0.01). Assessment of mitochondrial function in the HI + saline group, revealed significant and extensive damage to complex-I ( P< 0.01) and IV (P< 0.001) and loss of citrate synthase activity (P< 0.05). No effect on complex II-III was observed. Spermine treatment significantly prevented all these effects. This study has therefore confirmed the neuroprotective effects of spermine in vivo. However, for the first time, we have shown that this effect may, in part, be due to increased NOS activity and preservation of mitochondrial function.	Univ Otago, Dept Pharmacol & Toxicol, Dunedin, New Zealand	University of Otago	Appleton, I (corresponding author), Univ Otago, Dept Pharmacol & Toxicol, POB 913, Dunedin, New Zealand.	ian.appleton@stonebow.otago.ac.nz		Clarkson, Andrew/0000-0003-3804-3834; Sammut, Ivan/0000-0002-9217-9452; Harrison, Joanne/0000-0002-2431-4480				ABE K, 1993, BRAIN RES, V605, P322, DOI 10.1016/0006-8993(93)91759-L; ALMEIDA A, 1995, J NEUROCHEM, V65, P1698; Baskaya MK, 1997, BRAIN RES, V744, P302; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Brown GC, 2002, FREE RADICAL BIO MED, V33, P1440, DOI 10.1016/S0891-5849(02)01112-7; Coert BA, 2000, NEUROSCI LETT, V282, P5, DOI 10.1016/S0304-3940(00)00856-9; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Dogan A, 1999, J NEUROCHEM, V72, P765, DOI 10.1046/j.1471-4159.1999.0720765.x; Escott KJ, 1998, J CEREBR BLOOD F MET, V18, P281, DOI 10.1097/00004647-199803000-00006; FARBISZEWSKI R, 1995, ACTA NEUROBIOL EXP, V55, P254; Ferchmin PA, 2000, BRAIN RES, V859, P273, DOI 10.1016/S0006-8993(00)01973-9; Ferriero DM, 1996, NEUROBIOL DIS, V3, P64, DOI 10.1006/nbdi.1996.0006; GILAD GM, 1991, EXP NEUROL, V111, P349, DOI 10.1016/0014-4886(91)90102-I; GUTTERIDGE JMC, 1990, ARCH BIOCHEM BIOPHYS, V283, P223, DOI 10.1016/0003-9861(90)90635-C; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; Ha HC, 1998, P NATL ACAD SCI USA, V95, P11140, DOI 10.1073/pnas.95.19.11140; Henley CM, 1997, J NEUROCHEM, V69, P259; HU JG, 1994, NEUROSCI LETT, V175, P41, DOI 10.1016/0304-3940(94)91073-1; HUANG Z, 1996, J CEREB BLOOD FLOW M, V15, P378; Iadecola C, 1997, J NEUROSCI, V17, P9157; JENSEN JR, 1987, J NEUROCHEM, V48, P765, DOI 10.1111/j.1471-4159.1987.tb05583.x; KLEIHUES P, 1975, BRAIN RES, V95, P61, DOI 10.1016/0006-8993(75)90207-3; KOENIG H, 1990, STROKE, V21, P98; LAPIDUS RG, 1992, FEBS LETT, V313, P314, DOI 10.1016/0014-5793(92)81217-A; LEE JA, 1992, CIRC RES, V71, P58, DOI 10.1161/01.RES.71.1.58; LENZEN S, 1992, BIOCHEM J, V286, P597, DOI 10.1042/bj2860597; Maccarrone M, 2001, FEBS LETT, V507, P30, DOI 10.1016/S0014-5793(01)02949-0; Mateo J, 2003, BIOCHEM J, V376, P537, DOI 10.1042/BJ20031155; MUNIR M, 1993, BRAIN RES, V616, P163, DOI 10.1016/0006-8993(93)90205-2; NEGARDT C, 2003, CELL BIOL INT, V27, P115; OHMORI S, 1988, RES COMMUN CHEM PATH, V62, P235; PASCHEN W, 1991, BRAIN RES, V566, P354, DOI 10.1016/0006-8993(91)91726-H; PASCHEN W, 1992, NEUROSCI LETT, V135, P121, DOI 10.1016/0304-3940(92)90150-6; PASCHEN W, 1991, J CEREB BLOOD FLO S2, V11, P59; PEGG AE, 1982, AM J PHYSIOL, V243, P212; Perez-Pinzon MA, 1998, BRAIN RES, V786, P165, DOI 10.1016/S0006-8993(97)01438-8; PerezPinzon MA, 1997, BRAIN RES, V754, P163, DOI 10.1016/S0006-8993(97)00066-8; PHILLIPS JE, 1982, BIOCHEM BIOPH RES CO, V108, P174, DOI 10.1016/0006-291X(82)91847-2; RADI R, 1991, J BIOL CHEM, V266, P4244; Rao AM, 2000, J NEUROCHEM, V74, P1106; RAO AM, 1995, J NEUROCHEM, V65, P2639; Rao VLR, 1998, BRAIN RES, V783, P163, DOI 10.1016/S0006-8993(97)01301-2; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; ROSENTHAL M, 1995, J CEREBR BLOOD F MET, V15, P655, DOI 10.1038/jcbfm.1995.81; Rossignol F, 2003, J CELL BIOCHEM, V89, P67, DOI 10.1002/jcb.10484; Sammut IA, 2001, AM J PATHOL, V158, P1821, DOI 10.1016/S0002-9440(10)64138-7; SCIAMANNA MA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P223, DOI 10.1016/0167-4889(92)90180-J; SILVERSTEIN FS, 1986, J NEUROCHEM, V47, P1614, DOI 10.1111/j.1471-4159.1986.tb00803.x; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SOUSSI B, 1990, ACTA PHYSIOL SCAND, V138, P107, DOI 10.1111/j.1748-1716.1990.tb08822.x; Stefanelli C, 1999, FEBS LETT, V451, P95, DOI 10.1016/S0014-5793(99)00549-9; Stefanelli C, 1998, FEBS LETT, V437, P233, DOI 10.1016/S0014-5793(98)01239-3; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TADOLINI B, 1988, BIOCHEM J, V249, P33, DOI 10.1042/bj2490033; WANG WW, 1995, BIOCHEM BIOPH RES CO, V210, P1009, DOI 10.1006/bbrc.1995.1757; WELSH FA, 1991, J CEREBR BLOOD F MET, V11, P459, DOI 10.1038/jcbfm.1991.88; WELSH FA, 1982, J CEREBR BLOOD F MET, V2, P221, DOI 10.1038/jcbfm.1982.22	61	58	61	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2004	18	7					1114	+		10.1096/fj.03-1203fje	http://dx.doi.org/10.1096/fj.03-1203fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132986				2022-12-25	WOS:000221883200021
J	Koziczak, M; Holbro, T; Hynes, NE				Koziczak, M; Holbro, T; Hynes, NE			Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins	ONCOGENE			English	Article						FGFR; cyclin D; breast cancer; tyrosine kinase inhibitor	FIBROBLAST-GROWTH-FACTOR; TRANSCRIPTIONAL REGULATION; PHOSPHOINOSITIDE 3-KINASE; RECEPTOR GENES; PROTEIN-KINASE; EXPRESSION; AMPLIFICATION; ERBB2; OVEREXPRESSION; ANGIOGENESIS	Overexpression of fibroblast growth factor receptor ( FGFR) tyrosine kinases has been found in many human breast cancers and has been associated with poor patient prognosis. In order to understand the mechanism by which FGFR mediates breast cancer cell proliferation, we used a low molecular weight compound, PD173074, that selectively inhibits FGFR tyrosine kinase activity and autophosphorylation. This potential anticancer agent caused a G1 growth arrest of MDA-MB-415, MDA-MB-453 and SUM 52 breast cancer cells. Our analyses revealed that FGFR signaling links to the cell cycle machinery via D-type cyclins. PD173074-mediated inhibition of FGFR activity caused downregulation of cyclin D1 and cyclin D2 expression, inhibition of cyclin D/cdk4 activity and, as a consequence, reduction of pRB phosphorylation. Retroviral-mediated ectopic expression of cyclin D1 prevented pRB hypophosphorylation and the cell cycle G1 block in PD173074-treated cells, suggesting a central role for D cyclins in proliferation of FGFR-driven breast cancer cells. The repression of FGFR activity caused downregulation of MAPK in MDA-MB-415 and MDA-MB453 cells. In SUM 52 cells, both MAPK and PI3K signaling pathways were suppressed. In conclusion, results shown here describe a mechanism by which FGFR promotes proliferation of breast cancer cells.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hynes, NE (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	nancy.hynes@fmi.ch						ADNANE J, 1991, ONCOGENE, V6, P659; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Chodosh LA, 2000, DEV BIOL, V219, P259, DOI 10.1006/dbio.2000.9614; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Cross MJ, 2000, J CELL SCI, V113, P643; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Cuny M, 2000, CANCER RES, V60, P1077; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; ETHIER SP, 1993, CANCER RES, V53, P627; Gerwins P, 2000, CRIT REV ONCOL HEMAT, V34, P185, DOI 10.1016/S1040-8428(00)00062-7; Giri D, 1999, CLIN CANCER RES, V5, P1063; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hosokawa Y, 1998, GENE CHROMOSOME CANC, V22, P66, DOI 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; Jang JH, 2001, CANCER RES, V61, P3541; Kim I, 2001, BBA-GENE STRUCT EXPR, V1518, P152, DOI 10.1016/S0167-4781(00)00282-7; KLINT P, 1999, FRONT BIOSCI, V4, P165; Kornmann M, 1997, ONCOGENE, V15, P1417, DOI 10.1038/sj.onc.1201307; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Koziczak M, 2000, MOL CELL BIOL, V20, P2014, DOI 10.1128/MCB.20.6.2014-2022.2000; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lavia P, 1999, BIOESSAYS, V21, P221; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Ornitz DM, 2001, GENOME BIOL, V2; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; RIMOKH R, 1994, BLOOD, V83, P3689; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Valve E, 2000, INT J CANCER, V88, P718, DOI 10.1002/1097-0215(20001201)88:5<718::AID-IJC6>3.0.CO;2-F; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159	51	137	165	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3501	3508		10.1038/sj.onc.1207331	http://dx.doi.org/10.1038/sj.onc.1207331			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116089				2022-12-25	WOS:000221101700001
J	Sasaki, H; Hirai, K; Yamamoto, H; Tanooka, H; Sakamoto, H; Iwamoto, T; Takahashi, T; Terada, M; Ochiya, T				Sasaki, H; Hirai, K; Yamamoto, H; Tanooka, H; Sakamoto, H; Iwamoto, T; Takahashi, T; Terada, M; Ochiya, T			HST-1/FGF-4 plays a critical role in crypt cell survival and facilitates epithelial cell restitution and proliferation	ONCOGENE			English	Article						HST-1/FGF-4; intestinal damage; crypt survival; apoptosis; radiation	ADENOVIRUS-MEDIATED TRANSFER; KERATINOCYTE GROWTH-FACTOR; INTESTINAL STEM-CELLS; IN-VIVO; RADIATION-DAMAGE; PROTECTS MICE; SMALL-BOWEL; FACTOR-BETA; IRRADIATION; MIGRATION	The fibroblast growth factor-4 (HST-1/FGF-4) is a heparin-binding growth factor that influences on epithelial and many other cells through interaction with FGF receptors. It has been demonstrated that the HST-1/FGF-4 gene protects mice from lethal irradiation by preventing bone marrow damage and intestinal tract damage. However, the radioprotective mechanism is unknown. In this study, we have investigated the expression of Hst-1/Fgf-4 in mouse small intestine after irradiation, and determined the role of HST-1/FGF-4 in mouse intestinal crypt cell survival and epithelial cell proliferation and restitution. We found the induction of endogenous Hst-1/Fgf-4 expression in intestine when mice are exposed to 9.0 Gy irradiation. Laser-captured microdissection (LCM) coupled with RT-PCR analysis revealed that expression of Hst-1/Fgf-4 was found in epithelial cell of the villi and crypt cells. Pretreatment of HST-1/FGF-4 caused an increase in the number of surviving crypt cells, and clearly suppresses the radiation-induced apoptosis of the crypt cells. Moreover, exogenous HST-1/FGF-4 enhances epithelial cell restitution and proliferation in an in vitro model. These data suggest that HST-1/FGF-4 is induced by irradiation injury, and that HST-1/FGF-4 will find a therapeutic role in the prevention of intestinal cell toxicity following intensive chemotherapy and radiation therapy protocols, and in allogenic cell transplantation.	Natl Canc Ctr, Res Inst, Sect Studies Metastasis, Chuo Ku, Tokyo 1040045, Japan; Natl Inst Radiol Sci, Inage Ku, Chiba 2638555, Japan; Natl Inst Canc Res, Div Genet, Chuo Ku, Tokyo 1040045, Japan; St Marianna Univ, Sch Med, Dept Urol, Miyamae Ku, Kanagawa 2168511, Japan	National Cancer Center - Japan; National Institutes for Quantum Science & Technology; National Cancer Center - Japan; Saint Marianna University	Ochiya, T (corresponding author), Natl Canc Ctr, Res Inst, Sect Studies Metastasis, Chuo Ku, 1-1 Tsukiji,5 Chome, Tokyo 1040045, Japan.	tochiya@ncc.go.jp	Ochiya, Takahiro/AAH-7585-2019					Arman E, 1998, P NATL ACAD SCI USA, V95, P5082, DOI 10.1073/pnas.95.9.5082; Aviezer D, 1999, BIOCHEM BIOPH RES CO, V263, P621, DOI 10.1006/bbrc.1999.1434; Bach SP, 2000, CARCINOGENESIS, V21, P469, DOI 10.1093/carcin/21.3.469; CIACCI C, 1993, GASTROENTEROLOGY, V105, P93, DOI 10.1016/0016-5085(93)90014-4; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; Cohn SM, 1997, J CLIN INVEST, V99, P1367, DOI 10.1172/JCI119296; Cutler NS, 2003, CANCER RES, V63, P1748; Deroanne CF, 1997, CANCER RES, V57, P5590; DIGNASS AU, 1993, GASTROENTEROLOGY, V105, P1323, DOI 10.1016/0016-5085(93)90136-Z; DIGNASS AU, 1994, GASTROENTEROLOGY, V106, P1254, DOI 10.1016/0016-5085(94)90017-5; Farrell CL, 1998, CANCER RES, V58, P933; FEIL W, 1987, GASTROENTEROLOGY, V92, P1973, DOI 10.1016/0016-5085(87)90632-9; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; Houchen CW, 1999, AM J PHYSIOL-GASTR L, V276, pG249, DOI 10.1152/ajpgi.1999.276.1.G249; HUGHES SE, 1993, LAB INVEST, V69, P173; Khan WB, 1997, RADIAT RES, V148, P248, DOI 10.2307/3579609; LACY ER, 1988, J CLIN GASTROENTEROL, V10, P72; LEIGH BR, 1995, RADIAT RES, V142, P12, DOI 10.2307/3578961; LI YQ, 1992, CARCINOGENESIS, V13, P361, DOI 10.1093/carcin/13.3.361; MCCORMACK SA, 1992, AM J PHYSIOL-GASTR L, V263, P426; NUSRAT A, 1992, J CLIN INVEST, V89, P1501, DOI 10.1172/JCI115741; OCHIYA T, 1997, J TOXICOL PATHOL, V10, P129; Okunieff P, 1998, RADIAT RES, V150, P204, DOI 10.2307/3579856; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Potten CS, 1997, BRIT J CANCER, V75, P1454, DOI 10.1038/bjc.1997.249; POTTEN CS, 1981, INT J RADIAT BIOL, V40, P321, DOI 10.1080/09553008114551251; POTTEN CS, 1992, CARCINOGENESIS, V13, P2305, DOI 10.1093/carcin/13.12.2305; ROBERTS DB, 1993, RADIAT RES, V135, P56, DOI 10.2307/3578396; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P12368, DOI 10.1073/pnas.91.26.12368; Santos MF, 1997, J CLIN INVEST, V100, P216, DOI 10.1172/JCI119515; Takahama Y, 1999, ONCOGENE, V18, P5943, DOI 10.1038/sj.onc.1203171; Wambersie A, 1996, Rev Med Brux, V17, P75; WINTON DJ, 1990, P ROY SOC B-BIOL SCI, V241, P13, DOI 10.1098/rspb.1990.0059; WITHERS HR, 1970, INT J RADIAT BIOL RE, V17, P261, DOI 10.1080/09553007014550291; Wright JA, 1996, HISTOL HISTOPATHOL, V11, P521; YOSHIDA T, 1994, CANCER LETT, V83, P261, DOI 10.1016/0304-3835(94)90328-X	38	17	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3681	3688		10.1038/sj.onc.1207348	http://dx.doi.org/10.1038/sj.onc.1207348			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116099				2022-12-25	WOS:000221101700020
J	Behrmann, I; Smyczek, T; Heinrich, PC; Schmitz-Van de Leur, H; Komyod, W; Giese, B; Muller-Newen, G; Haan, S; Haan, C				Behrmann, I; Smyczek, T; Heinrich, PC; Schmitz-Van de Leur, H; Komyod, W; Giese, B; Muller-Newen, G; Haan, S; Haan, C			Janus kinase (Jak) subcellular localization revisited - The exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak center dot receptor complex to be equivalent to a receptor tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; SIGNAL TRANSDUCER GP130; PROTEIN-KINASE; FERM DOMAIN; ENDOPLASMIC-RETICULUM; NUCLEAR-LOCALIZATION; INTERFERON RESPONSES; N-TERMINUS; TYK2; INTERLEUKIN-6	The Janus kinases are considered to be cytoplasmic kinases that constitutively associate with the cytoplasmic region of cytokine receptors, and the Janus kinases (Jaks) are crucial for cytokine signal transduction. We investigated Jak1 localization using subcellular fractionation techniques and fluorescence microscopy (immunofluorescence and yellow fluorescent protein-tagged Jaks). In the different experimental approaches we found Jak1 (as well as Jak2 and Tyk2) predominantly located at membranes. In contrast to previous reports we did not observe Jak proteins in significant amounts within the nucleus or in the cytoplasm. The cytoplasmic localization observed for the Jak1 mutant L80A/Y81A, which is unable to associate with cytokine receptors, indicates that Jak1 does not have a strong intrinsic membrane binding potential and that only receptor binding is crucial for the membrane recruitment. Finally we show that Jak1 remains a membrane-localized protein after cytokine stimulation. These data strongly support the hypothesis that cytokine receptor Janus kinase complexes can be regarded as receptor tyrosine kinases.	Univ Luxembourg, Fac Sci Technol & Commun, Lab Biol & Physiol Integree, L-1511 Luxembourg, Luxembourg; Univ Klinikum Aachen, Inst Biochem, D-52074 Aachen, Germany	University of Luxembourg; RWTH Aachen University; RWTH Aachen University Hospital	Haan, C (corresponding author), Univ Luxembourg, Fac Sci Technol & Commun, Lab Biol & Physiol Integree, 162A Ave Faiencerie, L-1511 Luxembourg, Luxembourg.	claude.haan@rwth-aachen.de	Komyod, Waraporn/CAG-9665-2022	Komyod, Waraporn/0000-0001-8020-0026; Behrmann, Iris/0000-0003-3688-3645				ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; BERNARDS A, 1991, ONCOGENE, V6, P1185; Bork P, 1996, METHOD ENZYMOL, V266, P162; BUCKLEY AR, 1988, P NATL ACAD SCI USA, V85, P8649, DOI 10.1073/pnas.85.22.8649; Cacalano NA, 1999, EMBO J, V18, P1549, DOI 10.1093/emboj/18.6.1549; Candotti F, 1997, BLOOD, V90, P3996, DOI 10.1182/blood.V90.10.3996; Cohen J, 1997, BIOCHEM J, V327, P391, DOI 10.1042/bj3270391; Dondi E, 2001, J BIOL CHEM, V276, P47004, DOI 10.1074/jbc.M104316200; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Giese B, 2003, J BIOL CHEM, V278, P39205, DOI 10.1074/jbc.M303347200; Girault JA, 1998, MOL MED, V4, P751, DOI 10.1007/BF03401769; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Haan C, 2000, BIOCHEM J, V349, P261, DOI 10.1042/0264-6021:3490261; Haan C, 2002, BIOCHEM J, V361, P105, DOI 10.1042/0264-6021:3610105; Haan C, 2001, J BIOL CHEM, V276, P37451, DOI 10.1074/jbc.M106135200; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Han BG, 2000, NAT STRUCT BIOL, V7, P871; Hilkens CMU, 2001, FEBS LETT, V505, P87, DOI 10.1016/S0014-5793(01)02783-1; Hoffner G, 2002, J CELL SCI, V115, P941; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Ihle J N, 1995, Semin Immunol, V7, P247, DOI 10.1006/smim.1995.0029; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Kampa D, 2000, BIOCHEM BIOPH RES CO, V278, P175, DOI 10.1006/bbrc.2000.3757; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Lavoie C, 2000, P NATL ACAD SCI USA, V97, P13637, DOI 10.1073/pnas.240278097; Lobie PE, 1996, ENDOCRINOLOGY, V137, P4037, DOI 10.1210/en.137.9.4037; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Ragimbeau J, 2001, J BIOL CHEM, V276, P30812, DOI 10.1074/jbc.M103559200; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; Shimoda K, 2000, IMMUNITY, V13, P561, DOI 10.1016/S1074-7613(00)00055-8; Siewert E, 1999, EUR J BIOCHEM, V265, P251, DOI 10.1046/j.1432-1327.1999.00719.x; SORENSON RL, 1995, ENDOCRINOLOGY, V136, P4092, DOI 10.1210/en.136.9.4092; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; Vigouroux C, 2001, J CELL SCI, V114, P4459; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; Yeh TC, 2000, P NATL ACAD SCI USA, V97, P8991, DOI 10.1073/pnas.160130297; Yeh TC, 1999, CELL MOL LIFE SCI, V55, P1523, DOI 10.1007/s000180050392	48	78	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35486	35493		10.1074/jbc.M404202200	http://dx.doi.org/10.1074/jbc.M404202200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15123646	hybrid			2022-12-25	WOS:000223303400042
J	Tasiemski, A; Vandenbulcke, F; Mitta, G; Lemoine, J; Lefebvre, C; Sautiere, PE; Salzet, M				Tasiemski, A; Vandenbulcke, F; Mitta, G; Lemoine, J; Lefebvre, C; Sautiere, PE; Salzet, M			Molecular characterization of two novel antibacterial peptides inducible upon bacterial challenge in an annelid, the leech Theromyzon tessulatum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH ANTIMICROBIAL PEPTIDE; NEMATODE ASCARIS-SUUM; INNATE IMMUNITY; INSECT IMMUNITY; HOST-DEFENSE; FROG-SKIN; DROSOPHILA; EXPRESSION; INDUCTION; MUSSEL	Two novel antimicrobial peptides named theromacin and theromyzin were isolated and characterized from the coelomic liquid of the leech Theromyzon tessulatum. Theromacin is a 75-amino acid cationic peptide containing 10 cysteine residues arranged in a disulfide array showing no similarities with other known antimicrobial peptides. Theromyzin is an 86-amino acid linear peptide and constitutes the first anionic antimicrobial peptide observed in invertebrates. Both peptides exhibit activity directed against Gram-positive bacteria. Theromacin and theromyzin cDNAs code precursor molecules containing a putative signal sequence directly followed by the mature peptide. The enhancement of theromacin and theromyzin mRNA levels has been observed after blood meal ingestion and upon bacterial challenge. In situ hybridization revealed that both genes are expressed in large fat cells in contact with coelomic cavities. Gene products were immunodetected in large fat cells, in intestinal epithelia, and at the epidermis level. In addition, a rapid release of the peptides into the coelomic liquid was observed after bacterial challenge. The presence of antimicrobial peptide genes in leeches and their expression in a specific tissue functionally resembling the insect fat body provide evidence for the first time of an antibacterial response in a lophotrochozoan comparable to that of holometabola insects.	Univ Sci & Technol Lille, CNRS, UMR 8017, Lab Neuroimmunol, F-59655 Villeneuve Dascq, France; Univ Sci & Technol Lille, CNRS, UMR 8576, Lab Glycobiol Struct & Fonct, F-59655 Villeneuve Dascq, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Salzet, M (corresponding author), Univ Sci & Technol Lille, CNRS, UMR 8017, Lab Neuroimmunol, SN3, F-59655 Villeneuve Dascq, France.	michel.salzet@univ-lille1.fr	Lefebvre, christophe/J-7396-2013; MITTA, Guillaume/A-6489-2010; lemoine, jerome/C-4272-2014; Salzet, Michel/A-7675-2011; Tasiemski, Aurelie/S-2537-2016	Lefebvre, christophe/0000-0002-2690-373X; lemoine, jerome/0000-0002-5497-6880; Salzet, Michel/0000-0003-4318-0817; SAUTIERE, Pierre-Eric/0000-0003-4974-7116; mitta, guillaume/0000-0003-1188-1467; Tasiemski, Aurelie/0000-0003-3559-5115; Vandenbulcke, Franck/0000-0002-9735-1784				Adoutte A, 2000, P NATL ACAD SCI USA, V97, P4453, DOI 10.1073/pnas.97.9.4453; Bevins CL, 1999, GUT, V45, P911, DOI 10.1136/gut.45.6.911; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Brewer D, 2000, RAPID COMMUN MASS SP, V14, P1736, DOI 10.1002/1097-0231(20001015)14:19<1736::AID-RCM86>3.0.CO;2-2; Brewer D, 2002, BIOCHEMISTRY-US, V41, P5526, DOI 10.1021/bi015926d; Brogden KA, 1996, P NATL ACAD SCI USA, V93, P412, DOI 10.1073/pnas.93.1.412; BULET P, 1991, J BIOL CHEM, V266, P24520; Bulet P, 1999, DEV COMP IMMUNOL, V23, P329, DOI 10.1016/S0145-305X(99)00015-4; Cho JH, 1998, BBA-MOL BASIS DIS, V1408, P67, DOI 10.1016/S0925-4439(98)00058-1; Engstrom Y, 1999, DEV COMP IMMUNOL, V23, P345, DOI 10.1016/S0145-305X(99)00016-6; Faure-Virelizier C, 1998, ENDOCRINOLOGY, V139, P4127, DOI 10.1210/en.139.10.4127; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; Garcia-Olmedo F, 1998, BIOPOLYMERS, V47, P479, DOI 10.1002/(SICI)1097-0282(1998)47:6<479::AID-BIP6>3.0.CO;2-K; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; Kato Y, 1996, J BIOL CHEM, V271, P30493, DOI 10.1074/jbc.271.48.30493; Kato Y, 2002, BIOCHEM J, V361, P221, DOI 10.1042/0264-6021:3610221; Lamberty M, 1999, J BIOL CHEM, V274, P9320, DOI 10.1074/jbc.274.14.9320; Lamberty M, 2001, J BIOL CHEM, V276, P4085, DOI 10.1074/jbc.M002998200; LEFEBVRE C, 2004, IN PRESS BIOCH J; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Mallo GV, 2002, CURR BIOL, V12, P1209, DOI 10.1016/S0960-9822(02)00928-4; Meister M, 1996, INSECT BIOCHEM MOLEC, V26, P155, DOI 10.1016/0965-1748(95)00076-3; Mitta G, 2000, J CELL SCI, V113, P2759; Mitta G, 1999, EUR J BIOCHEM, V265, P71, DOI 10.1046/j.1432-1327.1999.00654.x; Mitta G, 2000, FEBS LETT, V486, P185, DOI 10.1016/S0014-5793(00)02192-X; Pillai A, 2003, BIOCHEM J, V371, P663, DOI 10.1042/BJ20021948; Salzet M, 2001, TRENDS IMMUNOL, V22, P285, DOI 10.1016/S1471-4906(01)01895-6; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Tzou P, 2000, IMMUNITY, V13, P737, DOI 10.1016/S1074-7613(00)00072-8; Tzou P, 2002, CURR OPIN MICROBIOL, V5, P102, DOI 10.1016/S1369-5274(02)00294-1; Vizioli J, 2001, INSECT BIOCHEM MOLEC, V31, P241, DOI 10.1016/S0965-1748(00)00143-0; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	33	77	98	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30973	30982		10.1074/jbc.M312156200	http://dx.doi.org/10.1074/jbc.M312156200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15102860	hybrid			2022-12-25	WOS:000222726800010
J	Bourguignon, LYW; Singleton, PA; Diedrich, F				Bourguignon, LYW; Singleton, PA; Diedrich, F			Hyaluronan-CD44 interaction with Rac1-dependent protein kinase N-gamma promotes phospholipase C gamma 1 activation, Ca2+ signaling, and cortactin-cytoskeleton function leading to keratinocyte adhesion and differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-CELL-MIGRATION; HUMAN EPIDERMAL-KERATINOCYTES; FYN TYROSINE KINASE; CD44 INTERACTION; MOUSE KERATINOCYTES; POTENTIAL EFFECTOR; IP3 RECEPTOR; E-CADHERIN; HUMAN SKIN; IN-VIVO	In this study we have investigated hyaluronan (HA)-CD44 interaction with protein kinase N-gamma (PKNgamma), a small GTPase (Rac1)-activated serine/threonine kinase in human keratinocytes. By using a variety of biochemical and molecular biological techniques, we have determined that CD44 and PKNgamma kinase ( molecular mass similar to 120 kDa) are physically linked in vivo. The binding of HA to keratinocytes promotes PKNgamma kinase recruitment into a complex with CD44 and subsequently stimulates Rac1-mediated PKNgamma kinase activity. The Rac1-activated PKNgamma in turn increases threonine ( but not serine) phosphorylation of phospholipase C ( PLC) gamma1 and upregulates PLCgamma1 activity leading to the onset of intracellular Ca2+ mobilization. HA/CD44-activated Rac1-PKNgamma also phosphorylates the cytoskeletal protein, cortactin, at serine/threonine residues. The phosphorylation of cortactin by Rac1-PKNgamma attenuates its ability to cross-link filamentous actin in vitro. Further analyses indicate that the N-terminal antiparallel coiled-coil (ACC) domains of PKNgamma interact directly with Rac1 in a GTP-dependent manner. The binding of HA to CD44 induces PKNgamma association with endogenous Rac1 and its activity in keratinocytes. Transfection of keratinocytes with PKNgamma-ACCcDNA reduces HA-mediated recruitment of endogenous Rac1 to PKNgamma and blocks PKNgamma activity. These findings suggest that the PKNgamma-ACC fragment acts as a potent competitive inhibitor of endogenous Rac1 binding to PKNgamma in vivo. Most important, the PKNgamma-ACC fragment functions as a strong dominant-negative mutant that effectively inhibits HA/CD44-mediated PKNgamma phosphorylation of PLCgamma1 and cortactin as well as keratinocyte signaling ( e g. Ca2+ mobilization and cortactin-actin binding) and cellular functioning (e.g. cell-cell adhesion and differentiation). Taken together, these findings strongly suggest that hyaluronan-CD44 interaction with Rac1-PKNgamma plays a pivotal role in PLCgamma1-regulated Ca2+ signaling and cortactin-cytoskeleton function required for keratinocyte cell-cell adhesion and differentiation.	Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, 4150 Clement St, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Bourguignon, LYW (corresponding author), Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, 4150 Clement St, San Francisco, CA 94121 USA.	lillyb@itsa.ucsf.edu			NATIONAL CANCER INSTITUTE [R01CA066163, R01CA078633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039448] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA66163, R01 CA 78633] Funding Source: Medline; NIAMS NIH HHS [P01 AR39448] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U; Akhtar N, 2000, CELL ADHES COMMUN, V7, P465, DOI 10.3109/15419060009040304; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bolz SS, 2000, CIRCULATION, V102, P2402, DOI 10.1161/01.CIR.102.19.2402; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Bourguignon LYW, 1996, CURR TOP MEMBR, V43, P293; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Bourguignon LYW, 2001, J MAMMARY GLAND BIOL, V6, P287, DOI 10.1023/A:1011371523994; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; BOURGUIGNON LYW, 1998, FRONT BIOSCI, V3, P637; Bruno S, 2000, CARCINOGENESIS, V21, P893, DOI 10.1093/carcin/21.5.893; Calautti E, 2002, J CELL BIOL, V156, P137, DOI 10.1083/jcb.200105140; CALAUTTI E, 1995, GENE DEV, V9, P2279, DOI 10.1101/gad.9.18.2279; Dingemans KP, 1999, BRIT J DERMATOL, V140, P17; DLUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286, DOI 10.1002/mc.2940050409; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; DRIMME HU, 1999, BRIT J DERMATOL, V141, P824; Haase I, 1997, J INVEST DERMATOL, V108, P748, DOI 10.1111/1523-1747.ep12292135; HAGGERTY JG, 1992, J INVEST DERMATOL, V99, P374, DOI 10.1111/1523-1747.ep12616087; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Heider KH, 1996, CANCER IMMUNOL IMMUN, V43, P245, DOI 10.1007/s002620050329; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HENNINGS H, 1983, J CELL PHYSIOL, V116, P265, DOI 10.1002/jcp.1041160303; Hong-Geller E, 2000, J CELL BIOL, V148, P481, DOI 10.1083/jcb.148.3.481; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Kaya G, 1997, GENE DEV, V11, P996, DOI 10.1101/gad.11.8.996; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Koivisto L, 2004, EXP CELL RES, V293, P68, DOI 10.1016/j.yexcr.2003.09.026; Lee YS, 1998, J INVEST DERMATOL, V111, P762, DOI 10.1046/j.1523-1747.1998.00365.x; Lesley J, 2000, J BIOL CHEM, V275, P26967; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LI LW, 1995, J CELL PHYSIOL, V163, P105, DOI 10.1002/jcp.1041630112; LOKESHWAR VB, 1991, J BIOL CHEM, V266, P17983; Lokeshwar VB, 1996, J BIOL CHEM, V271, P23853, DOI 10.1074/jbc.271.39.23853; MATSUI MS, 1992, J INVEST DERMATOL, V99, P565, DOI 10.1111/1523-1747.ep12667411; Mukai H, 2003, J BIOCHEM, V133, P17, DOI 10.1093/jb/mvg019; Oliferenko S, 2000, J CELL BIOL, V148, P1159, DOI 10.1083/jcb.148.6.1159; PILLAI S, 1988, J CELL PHYSIOL, V134, P229, DOI 10.1002/jcp.1041340208; PILLAI S, 1988, J BIOL CHEM, V263, P5390; PILLAI S, 1990, J CELL PHYSIOL, V143, P294, DOI 10.1002/jcp.1041430213; PUNNONEN K, 1993, J INVEST DERMATOL, V101, P719, DOI 10.1111/1523-1747.ep12371682; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Seiter S, 1996, VIRCHOWS ARCH, V428, P141; Shen S, 2001, DIABETES, V50, P255, DOI 10.2337/diabetes.50.2.255; Simon JC, 1996, EUR J CANCER, V32A, P1394, DOI 10.1016/0959-8049(96)00196-7; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Singleton PA, 2004, EXP CELL RES, V295, P102, DOI 10.1016/j.yexcr.2003.12.025; Singleton PA, 2002, CELL MOTIL CYTOSKEL, V53, P293, DOI 10.1002/cm.10078; Sun HQ, 1997, J CELL BIOL, V138, P811, DOI 10.1083/jcb.138.4.811; Takeda H, 1999, NAT STRUCT BIOL, V6, P310, DOI 10.1038/7542; Tammi R, 1998, J BIOL CHEM, V273, P28878, DOI 10.1074/jbc.273.44.28878; TAMMI R, 1994, PROG HISTOCHEM CYTOC, V29, P1; TAMMI R, 1988, J INVEST DERMATOL, V90, P412, DOI 10.1111/1523-1747.ep12456530; TANG W, 1988, J INVEST DERMATOL, V90, P37, DOI 10.1111/1523-1747.ep12462536; Thorne RF, 2004, J CELL SCI, V117, P373, DOI 10.1242/jcs.00954; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Wang HQ, 2001, MOL PHARMACOL, V59, P860, DOI 10.1124/mol.59.4.860; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Xie ZJ, 1999, J BIOL CHEM, V274, P20421, DOI 10.1074/jbc.274.29.20421; Yeo TK, 1996, AM J PATHOL, V148, P1733; Yoshinaga C, 1999, J BIOCHEM, V126, P475, DOI 10.1093/oxfordjournals.jbchem.a022476	70	61	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29654	29669		10.1074/jbc.M403608200	http://dx.doi.org/10.1074/jbc.M403608200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123640	hybrid			2022-12-25	WOS:000222445300102
J	Gong, XM; Choi, JY; Franzin, CM; Zhai, DY; Reed, JC; Marassi, FM				Gong, XM; Choi, JY; Franzin, CM; Zhai, DY; Reed, JC; Marassi, FM			Conformation of membrane-associated proapoptotic tBid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; SECONDARY STRUCTURE; STRUCTURAL BASIS; BCL-W; NMR; PROTEIN; BAX; MITOCHONDRIA; FAMILY; DEATH	The proapoptotic Bcl-2 family protein Bid is cleaved by caspase-8 to release the C-terminal fragment tBid, which translocates to the outer mitochondrial membrane and induces massive cytochrome c release and cell death. In this study, we have characterized the conformation of tBid in lipid membrane environments, using NMR and CD spectroscopy with lipid micelle and lipid bilayer samples. In micelles, tBid adopts a unique helical conformation, and the solution NMR H-1/N-15 HSQC spectra have a single well resolved resonance for each of the protein amide sites. In lipid bilayers, tBid associates with the membrane with its helices parallel to the membrane surface and without trans-membrane helix insertion, and the solid-state NMR H-1/N-15 polarization inversion with spin exchange at the magic angle spectrum has all of the amide resonances centered at N-15 chemical shift ( 70 - 90 ppm) and H-1-N-15 dipolar coupling (0 - 5 kHz) frequencies associated with NH bonds parallel to the bilayer surface, with no intensity at frequencies associated with NH bonds in trans-membrane helices. Thus, the cytotoxic activity of tBid at mitochondria may be similar to that observed for antibiotic polypeptides, which bind to the surface of bacterial membranes as amphipathic helices and destabilize the bilayer structure, promoting the leakage of cell contents.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Marassi, FM (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	fmarassi@burnham.org			NATIONAL CANCER INSTITUTE [P30CA030199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI063563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065374, R01GM060554] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA30199, P30 CA030199] Funding Source: Medline; NIAID NIH HHS [R21 AI063563, R21 AI063563-02] Funding Source: Medline; NIBIB NIH HHS [P41 EB002031, P41EB002031] Funding Source: Medline; NIGMS NIH HHS [R01 GM065374-04, R01GM60554, R01 GM065374, R01 GM060554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.biophys.24.1.611; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Denault JB, 2002, CHEM REV, V102, P4489, DOI 10.1021/cr010183n; Denisov AY, 2003, J BIOL CHEM, V278, P21124, DOI 10.1074/jbc.M301798200; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2003, CELL DEATH DIFFER, V10, P1300, DOI 10.1038/sj.cdd.4401306; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Franzin CM, 2004, MAGN RESON CHEM, V42, P172, DOI 10.1002/mrc.1322; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; GROSS E, 1961, J AM CHEM SOC, V83, P1510, DOI 10.1021/ja01467a052; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; Hinds MG, 2003, EMBO J, V22, P1497, DOI 10.1093/emboj/cdg144; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Krueger-Koplin RD, 2004, J BIOMOL NMR, V28, P43, DOI 10.1023/B:JNMR.0000012875.80898.8f; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; LEVITT MH, 1986, J CHEM PHYS, V84, P4243, DOI 10.1063/1.450046; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Losonczi JA, 2000, BIOCHEMISTRY-US, V39, P11024, DOI 10.1021/bi000919v; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Marassi FM, 2000, J MAGN RESON, V144, P156, DOI 10.1006/jmre.2000.2036; Marassi FM, 2000, J MAGN RESON, V144, P150, DOI 10.1006/jmre.2000.2035; Marassi FM, 2001, BIOPHYS J, V80, P994, DOI 10.1016/S0006-3495(01)76078-X; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; OH KJ, 2004, 5 BIENN STRUCT BIOL; Opella SJ, 2001, METHOD ENZYMOL, V339, P285, DOI 10.1016/S0076-6879(01)39319-9; Ostrander DB, 2001, J BIOL CHEM, V276, P38061; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; STALEY JP, 1994, PROTEIN SCI, V3, P1822, DOI 10.1002/pro.5560031021; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tian CL, 2003, PROTEIN SCI, V12, P2597, DOI 10.1110/ps.03168503; Wang J, 2000, J MAGN RESON, V144, P162, DOI 10.1006/jmre.2000.2037; Wang JJ, 2002, P NATL ACAD SCI USA, V99, P1188, DOI 10.1073/pnas.032565999; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; WU CH, 1994, J MAGN RESON SER A, V109, P270, DOI 10.1006/jmra.1994.1169; Xie ZH, 1998, BIOCHEMISTRY-US, V37, P6410, DOI 10.1021/bi973052i; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	49	51	52	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28954	28960		10.1074/jbc.M403490200	http://dx.doi.org/10.1074/jbc.M403490200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123718	Green Accepted, hybrid			2022-12-25	WOS:000222445300017
J	Saitoh, F; Tian, QB; Okano, A; Sakagami, H; Kondo, H; Suzuki, T				Saitoh, F; Tian, QB; Okano, A; Sakagami, H; Kondo, H; Suzuki, T			NIDD, a novel DHHC-containing protein, targets neuronal nitric-oxide synthase (nNOS) to the synaptic membrane through a PDZ-dependent interaction and regulates nNOS activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; ASPARTATE RECEPTOR ANTAGONIST; POSTSYNAPTIC DENSITY; MESSENGER-RNAS; SELECTIVE IMPAIRMENT; HIPPOCAMPAL-NEURONS; TERNARY COMPLEX; RAT-BRAIN; LOCALIZATION; DOMAIN	Targeting of neuronal nitric-oxide synthase (nNOS) to appropriate sites in a cell is mediated by interactions with its PDZ domain and plays an important role in specifying the sites of reaction of nitric oxide (NO) in the central nervous system. Here we report the identification and characterization of a novel nNOS-interacting DHHC domain-containing protein with dendritic mRNA (NIDD) (GenBank(TM) accession number AB098078), which increases nNOS enzyme activity by targeting the nNOS to the synaptic plasma membrane in a PDZ domain-dependent manner. The deduced NIDD protein consisted of 392 amino acid residues and possessed five transmembrane segments, a zinc finger DHHC domain, and a PDZ-binding motif (-EDIV) at its C-terminal tail. In vitro pull-down assays suggested that the C-terminal tail region of NIDD specifically interacted with the PDZ domain of nNOS. The PDZ dependence was confirmed by an experiment using a deletion mutant, and the interaction was further confirmed by co-sedimentation assays using COS-7 cells transfected with NIDD and nNOS. Both NIDD and nNOS were enriched in synaptosome and synaptic plasma membrane fractions and were present in the lipid raft and postsynaptic density fractions in the rat brain. Co-localization of these proteins was also observed by double staining of the proteins in cultured cortical neurons. Thus, NIDD and nNOS were co-localized in the brain, although the co-localizing regions were restricted, as indicated by the distribution of their mRNA expression. Most important, co-transfection of NIDD and nNOS increased NO-producing nNOS activity. These results suggested that NIDD plays an important role in the regulation of the NO signaling pathway at postsynaptic sites through targeting of nNOS to the postsynaptic membrane.	Shinshu Univ, Grad Sch Med, Inst Aging & Adaptat, Dept Neuroplast, Matsumoto, Nagano 3908621, Japan; Tohoku Univ, Grad Sch Med, Dept Cell Biol, Div Histol, Sendai, Miyagi 9808575, Japan	Shinshu University; Tohoku University	Suzuki, T (corresponding author), Shinshu Univ, Grad Sch Med, Inst Aging & Adaptat, Dept Neuroplast, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	suzukit@sch.md.shinshu-u.ac.jp						Arancio O, 1996, J PHYSIOLOGY-PARIS, V90, P321, DOI 10.1016/S0928-4257(97)87907-7; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Christopherson KS, 1999, J BIOL CHEM, V274, P27467, DOI 10.1074/jbc.274.39.27467; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; Das UN, 2003, BRAIN DEV-JPN, V25, P251, DOI 10.1016/S0387-7604(02)00221-8; Fang M, 2000, NEURON, V28, P183, DOI 10.1016/S0896-6273(00)00095-7; Firestein BL, 1999, J BIOL CHEM, V274, P10545, DOI 10.1074/jbc.274.15.10545; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Govers R, 2002, BIOCHEM J, V361, P193, DOI 10.1042/0264-6021:3610193; Hawkins RD, 1996, NEURON, V16, P465, DOI 10.1016/S0896-6273(00)80064-1; HECKER M, 1994, J NEUROCHEM, V62, P1524; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Jaffrey SR, 2002, P NATL ACAD SCI USA, V99, P3199, DOI 10.1073/pnas.261705799; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Kendrick KM, 1997, NATURE, V388, P670, DOI 10.1038/41765; Kou RQ, 2002, J BIOL CHEM, V277, P29669, DOI 10.1074/jbc.M204519200; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Li BJ, 2002, J BIOL CHEM, V277, P28870, DOI 10.1074/jbc.M202388200; Li WD, 2001, J BIOL CHEM, V276, P21417, DOI 10.1074/jbc.M010744200; Li XJ, 1996, P NATL ACAD SCI USA, V93, P4839, DOI 10.1073/pnas.93.10.4839; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Murata S, 2000, MOL BRAIN RES, V78, P80, DOI 10.1016/S0169-328X(00)00077-2; Putilina T, 1999, MOL CELL BIOCHEM, V195, P219, DOI 10.1023/A:1006932522197; Riefler GM, 2001, J BIOL CHEM, V276, P48262, DOI 10.1074/jbc.M106503200; Sakagami H, 1998, MOL BRAIN RES, V54, P311, DOI 10.1016/S0169-328X(97)00362-8; Schepens J, 1997, FEBS LETT, V409, P53, DOI 10.1016/S0014-5793(97)00481-X; Son H, 1996, CELL, V87, P1015, DOI 10.1016/S0092-8674(00)81796-1; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Sun JX, 2002, P NATL ACAD SCI USA, V99, P13108, DOI 10.1073/pnas.202260999; Suzuki T, 2002, NEUROSCI RES, V44, P1, DOI 10.1016/S0168-0102(02)00080-9; Suzuki T, 2001, MOL BRAIN RES, V89, P20, DOI 10.1016/S0169-328X(01)00051-1; Tian QB, 2003, J NEUROCHEM, V87, P665, DOI 10.1046/j.1471-4159.2003.02024.x; Tian QB, 1999, MOL BRAIN RES, V72, P147, DOI 10.1016/S0169-328X(99)00214-4; Yun HY, 1999, DIABETES RES CLIN PR, V45, P113, DOI 10.1016/S0168-8227(99)00039-X	41	35	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29461	29468		10.1074/jbc.M401471200	http://dx.doi.org/10.1074/jbc.M401471200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15105416	hybrid			2022-12-25	WOS:000222445300078
J	Stewart, SA; Kothapalli, D; Yung, YV; Assoian, RK				Stewart, SA; Kothapalli, D; Yung, YV; Assoian, RK			Antimitogenesis linked to regulation of Skp2 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; BOX PROTEIN SKP2; UBIQUITIN LIGASE; PROSTACYCLIN RECEPTOR; CYCLE PROGRESSION; BINDING-PROTEIN; SHEAR-STRESS; G1 PHASE; S-PHASE; P27(KIP1)	Prostacyclin has many effects in the vasculature; one of the less well understood is the ability to block cell cycle progression through G(1) phase. We previously reported that the prostacyclin mimetic, cicaprost, selectively inhibits cyclin E-cyclin-dependent kinase-2 (Cdk2), and now we show that it acts by regulating the expression of Skp2, the F-box protein that targets p27(Kip1) for ubiquitin-mediated proteolysis. First, we show that cicaprost prevents the late G(1) phase down-regulation of p27(Kip1) and that the inhibitory effect of cicaprost on cyclin E-Cdk2 activity and S phase entry is eliminated by deleting p27(Kip1). Levels of the closely related Cdk2 inhibitor, p21(Cip1), are unaffected by cicaprost. Moreover, we show that cicaprost blocks the induction of Skp2 mRNA and that ectopic expression of a Skp2 cDNA overrides the effect of cicaprost on p27(Kip1) levels and S phase entry. Our data show that inhibition of F-box protein gene expression can underlie the effect of a potent antimitogen.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Assoian, RK (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 167 Johnson pavil,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	rka@pharm.med.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL062250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051878] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62250] Funding Source: Medline; NIGMS NIH HHS [GM51878] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bashir T, 2003, ADV CANCER RES, V88, P101, DOI 10.1016/S0065-230X(03)88305-7; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; COLEMAN RA, 1994, PROSTAGLANDINS, V47, P151, DOI 10.1016/0090-6980(94)90084-1; Doroudi R, 2000, BIOCHEM BIOPH RES CO, V269, P257, DOI 10.1006/bbrc.2000.2279; EGAN K, 2000, CIRCULATION, V102, P234; Fink A N, 1999, Heart Dis, V1, P29; Ii M, 2001, CARDIOVASC RES, V52, P500, DOI 10.1016/S0008-6363(01)00411-4; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kothapalli D, 2003, MOL PHARMACOL, V64, P249, DOI 10.1124/mol.64.2.249; Kramer A, 1996, J BIOL CHEM, V271, P6579; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NAMBA T, 1994, J BIOL CHEM, V269, P9986; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Takahashi Y, 2000, GENE DEV, V14, P804; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Vidal A, 2002, J BIOL CHEM, V277, P16433, DOI 10.1074/jbc.M112090200; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Weber AA, 1998, BASIC RES CARDIOL, V93, P54; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	36	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29109	29113		10.1074/jbc.M404271200	http://dx.doi.org/10.1074/jbc.M404271200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15126498	hybrid			2022-12-25	WOS:000222445300035
J	Breit, A; Lagace, M; Bouvier, M				Breit, A; Lagace, M; Bouvier, M			Hetero-oligomerization between beta 2-and beta 3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; RESONANCE ENERGY-TRANSFER; BETA(2)-ADRENERGIC RECEPTOR; OPIOID RECEPTORS; LIVING CELLS; BETA(3)-ADRENERGIC RECEPTOR; TRANSFER BRET; KINASE; HETERODIMERIZATION; SUBTYPES	The ability of the closely related beta(2)- and beta(3)-adrenergic receptors (AR) to form hetero-oligomers was assessed by bioluminescence resonance energy transfer. Quantitative bioluminescence resonance energy transfer titration curves revealed that the beta(2)AR has identical propensity to hetero-oligomerize with the beta(3)AR than to form homo-oligomers. To determine the influence of hetero-oligomerization, a HEK293 cell line stably expressing an excess of beta(3)AR over beta(2)AR was generated so that all beta(2)AR are engaged in hetero-oligomerization with beta(3)AR, providing a tool to study the effect of hetero- oligomerization on beta(2)AR function in the absence of any beta(2)AR homo-oligomer. The hetero- oligomerization had no effect on the ligand binding properties of various beta(2)AR ligands and did not affect the potency of isoproterenol to stimulate adenylyl cyclase. Despite the unaltered ligand binding properties of the beta(2/3)AR hetero-oligomer, the stable association of the beta(2)AR with the beta(3)AR completely blocked agonist-stimulated internalization of the beta(2)AR. Given that the beta(3)AR is resistant to agonist-promoted endocytosis, the results indicate that the beta(3)AR acted as a dominant negative of the beta(2)AR endocytosis process. Consistent with this notion, the beta(2/3)AR hetero-oligomer displayed a lower propensity to recruit beta-arrestin-2 than the beta(2)AR. The hetero-oligomerization also led to a change in G protein coupling selectivity. Indeed, in contrast to beta(2)AR and beta(3)AR, which regulate adenylyl cyclase and extracellular signal-regulated kinase activity through a coupling to G(s) and G(i/o), no G(i/o) coupling was observed for the beta(2/3)AR hetero-oligomer. Together, these results demonstrate that hetero- oligomerization between beta(2)AR and beta(3)AR forms a beta-adrenergic signaling unit that possesses unique functional properties.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Grp Rech Syst Nerveux Autonome, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal	Bouvier, M (corresponding author), Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada.	michel.bouvier@umontreal.ca	Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100				AbdAlla S, 2001, J BIOL CHEM, V276, P39721, DOI 10.1074/jbc.M105253200; AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Ayoub MA, 2002, J BIOL CHEM, V277, P21522, DOI 10.1074/jbc.M200729200; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Carrillo JJ, 2003, J BIOL CHEM, V278, P42578, DOI 10.1074/jbc.M306165200; Charest PG, 2003, J BIOL CHEM, V278, P41541, DOI 10.1074/jbc.M306589200; Chesley A, 2000, CIRC RES, V87, P1172, DOI 10.1161/01.RES.87.12.1172; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; CHUANG DM, 1982, BIOCHEM BIOPH RES CO, V105, P1466, DOI 10.1016/0006-291X(82)90953-6; Chung S, 1999, PFLUG ARCH EUR J PHY, V437, P508, DOI 10.1007/s004240050810; Collins S, 2001, EXP BIOL MED, V226, P982, DOI 10.1177/153537020122601104; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gerhardt CC, 1999, MOL PHARMACOL, V55, P255, DOI 10.1124/mol.55.2.255; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; Gong HB, 2000, BRIT J PHARMACOL, V131, P594, DOI 10.1038/sj.bjp.0703591; Gouldson PR, 1998, PROTEIN ENG, V11, P1181, DOI 10.1093/protein/11.12.1181; Gouldson PR, 2000, NEUROPSYCHOPHARMACOL, V23, pS60, DOI 10.1016/S0893-133X(00)00153-6; Grimm M, 1998, J MOL CELL CARDIOL, V30, P1917, DOI 10.1006/jmcc.1998.0769; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hanyaloglu AC, 2002, J BIOL CHEM, V277, P50422, DOI 10.1074/jbc.M209340200; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HERTEL C, 1985, J BIOL CHEM, V260, P2547; Jockers R, 1998, ENDOCRINOLOGY, V139, P2676, DOI 10.1210/en.139.6.2676; Jockers R, 1996, J BIOL CHEM, V271, P9355, DOI 10.1074/jbc.271.16.9355; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; KENT RS, 1980, MOL PHARMACOL, V17, P14; Klein U, 2001, J BIOL CHEM, V276, P17442, DOI 10.1074/jbc.M009214200; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lafontan M., 1997, Human Reproduction (Oxford), V12, P6; LANGIN D, 1991, EUR J PHARMACOL, V199, P291, DOI 10.1016/0014-2999(91)90492-9; Lavoie C, 2003, CAN J PHYSIOL PHARM, V81, P186, DOI 10.1139/Y02-167; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Lee CW, 2002, J BIOL CHEM, V277, P15795, DOI 10.1074/jbc.M111818200; Lefkowitz RJ, 2002, MOL PHARMACOL, V62, P971, DOI 10.1124/mol.62.5.971; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; Lindquist JM, 2000, J BIOL CHEM, V275, P22670, DOI 10.1074/jbc.M909093199; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Milligan G, 2001, J CELL SCI, V114, P1265; NANTEL F, 1993, MOL PHARMACOL, V43, P548; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; PIETRIROUXEL F, 1995, FUNDAM CLIN PHARM, V9, P211, DOI 10.1111/j.1472-8206.1995.tb00288.x; Ramsay D, 2002, BIOCHEM J, V365, P429, DOI 10.1042/BJ20020251; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Salahpour A, 2000, TRENDS ENDOCRIN MET, V11, P163, DOI 10.1016/S1043-2760(00)00260-5; Soeder KJ, 1999, J BIOL CHEM, V274, P12017, DOI 10.1074/jbc.274.17.12017; STAEHELIN M, 1982, EMBO J, V1, P187, DOI 10.1002/j.1460-2075.1982.tb01145.x; STAEHELIN M, 1983, J BIOL CHEM, V258, P3496; Stanasila L, 2003, J BIOL CHEM, V278, P40239, DOI 10.1074/jbc.M306085200; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; THILLET J, 1990, FEBS LETT, V269, P450, DOI 10.1016/0014-5793(90)81213-8; VON ZM, 1992, J BIOL CHEM, V267, P3530; XIAO RP, 1995, MOL PHARMACOL, V47, P322; Xu JG, 2003, J BIOL CHEM, V278, P10770, DOI 10.1074/jbc.M207968200; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151; Ye CI, 2000, BIOPHYS J, V79, P2547, DOI 10.1016/S0006-3495(00)76495-2; Zamah AM, 2002, J BIOL CHEM, V277, P31249, DOI 10.1074/jbc.M202753200; Zilberfarb V, 1997, J CELL SCI, V110, P801; Zou YZ, 1999, J BIOL CHEM, V274, P9760, DOI 10.1074/jbc.274.14.9760	80	131	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28756	28765		10.1074/jbc.M313310200	http://dx.doi.org/10.1074/jbc.M313310200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123695	hybrid			2022-12-25	WOS:000222265400113
J	Hartman, ME; O'Connor, JC; Godbout, JP; Minor, KD; Mazzocco, VR; Freund, GG				Hartman, ME; O'Connor, JC; Godbout, JP; Minor, KD; Mazzocco, VR; Freund, GG			Insulin receptor substrate-2-dependent interleukin-4 signaling in macrophages is impaired in two models of type 2 diabetes mellitus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SUBSTRATE-1 TYROSINE PHOSPHORYLATION; GROWTH-FACTOR-I; MURINE PERITONEAL-MACROPHAGES; PROTEIN-KINASE; SERINE/THREONINE PHOSPHORYLATION; MAMMALIAN TARGET; HIGH GLUCOSE; TNF-ALPHA; PHOSPHATIDYLINOSITOL 3'-KINASE	We have shown previously that hyperinsulinemia inhibits interferon-alpha-dependent activation of phosphatidylinositol 3-kinase (PI3-kinase) through mammalian target of rapamycin (mTOR)-induced serine phosphorylation of insulin receptor substrate (IRS)-1. Here we report that chronic insulin and high glucose synergistically inhibit interleukin (IL)-4-dependent activation of PI3-kinase in macrophages via the mTOR pathway. Resident peritoneal macrophages (PerMPhis) from diabetic (db/db) mice showed a 44% reduction in IRS-2-associated PI3-kinase activity stimulated by IL-4 compared with PerMPhis from heterozygote (db/+) control mice. IRS-2 from db/db mouse PerMPhis also showed a 78% increase in Ser/Thr-Pro motif phosphorylation without a difference in IRS-2 mass. To investigate the mechanism of this PI3-kinase inhibition, 12-O-tetradecanoylphorbol-13-acetate-matured U937 cells were treated chronically with insulin ( 1 nM, 18 h) and high glucose (4.5 g/liter, 48 h). In these cells, IL-4-stimulated IRS-2-associated PI3-kinase activity was reduced by 37.5%. Importantly, chronic insulin or high glucose alone did not impact IL-4-activated IRS-2-associated PI3-kinase. Chronic insulin + high glucose did reduce IL-4-dependent IRS-2 tyrosine phosphorylation and p85 association by 54 and 37%, respectively, but did not effect IL-4-activated JAK/STAT signaling. When IRS-2 Ser/Thr-Pro motif phosphorylation was examined, chronic insulin + high glucose resulted in a 92% increase in IRS-2 Ser/Thr-Pro motif phosphorylation without a change in IRS-2 mass. Pretreatment of matured U937 cells with rapamycin blocked chronic insulin + high glucose-dependent IRS-2 Ser/Thr-Pro motif phosphorylation and restored IL-4-dependent IRS-2-associated PI3-kinase activity. Taken together these results indicate that IRS-2-dependent IL-4 signaling in macrophages is impaired in models of type 2 diabetes mellitus through a mechanism that relies on insulin/ glucose-dependent Ser/Thr-Pro motif serine phosphorylation mediated by the mTOR pathway.	Univ Illinois, Coll Med, Dept Pathol, Urbana, IL 61801 USA; Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Freund, GG (corresponding author), Univ Illinois, Coll Med, Dept Pathol, 506 S Mathews, Urbana, IL 61801 USA.	freun@uiuc.edu		Hartman, Matt/0000-0002-6238-1887	NIDDK NIH HHS [DK 064862] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064862] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; Bonder CS, 2001, GROWTH FACTORS, V19, P207, DOI 10.3109/08977190109001087; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Buren J, 2003, EUR J ENDOCRINOL, V148, P157, DOI 10.1530/eje.0.1480157; Ceddia MA, 1999, J APPL PHYSIOL, V87, P2253, DOI 10.1152/jappl.1999.87.6.2253; Cengel KA, 1999, J BIOL CHEM, V274, P27969, DOI 10.1074/jbc.274.39.27969; Cengel KA, 1998, BIOCHEM J, V335, P397, DOI 10.1042/bj3350397; Chen J, 2002, BIOCHEM PHARMACOL, V64, P1071, DOI 10.1016/S0006-2952(02)01263-7; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Deszo EL, 2004, CELL SIGNAL, V16, P271, DOI 10.1016/S0898-6568(03)00137-2; Deszo EL, 2001, J BIOL CHEM, V276, P10212, DOI 10.1074/jbc.M010589200; Egawa K, 2000, ENDOCRINOLOGY, V141, P1930, DOI 10.1210/en.141.6.1930; Fasshauer M, 2000, J BIOL CHEM, V275, P25494, DOI 10.1074/jbc.M004046200; GAUTAM S, 1992, J IMMUNOL, V148, P1725; Godbout JP, 1999, CELL SIGNAL, V11, P15, DOI 10.1016/S0898-6568(98)00024-2; Greaves David R., 2001, Trends in Immunology, V22, P180, DOI 10.1016/S1471-4906(00)01848-2; Greene MW, 2002, BIOCHEMISTRY-US, V41, P7082, DOI 10.1021/bi015992f; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Haddad TC, 1997, J BIOL CHEM, V272, P19525, DOI 10.1074/jbc.272.31.19525; Hartman ME, 2001, BIOCHEM BIOPH RES CO, V280, P776, DOI 10.1006/bbrc.2000.4214; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Huang SL, 2003, CANCER BIOL THER, V2, P222, DOI 10.4161/cbt.2.3.360; Johnston JA, 1996, J LEUKOCYTE BIOL, V60, P441, DOI 10.1002/jlb.60.4.441; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; Kubota T, 2003, CIRCULATION, V107, P3073, DOI 10.1161/01.CIR.0000070937.52035.25; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Liu BF, 1999, DIABETES, V48, P2074, DOI 10.2337/diabetes.48.10.2074; MARCINKIEWICZ J, 1991, CYTOKINE, V3, P327, DOI 10.1016/1043-4666(91)90501-4; McMahon LP, 2002, MOL CELL BIOL, V22, P7428, DOI 10.1128/MCB.22.21.7428-7438.2002; Minshall C, 1997, J IMMUNOL, V159, P1225; Minshall C, 1999, J IMMUNOL, V162, P4542; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Muller S, 2002, DIABETOLOGIA, V45, P805, DOI 10.1007/s00125-002-0829-2; Nakajima K, 2000, J BIOL CHEM, V275, P20880, DOI 10.1074/jbc.M905410199; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; O'Connor JC, 2003, METABOLISM, V52, P666, DOI 10.1016/S0026-0495(03)00026-X; OHARA J, 1987, NATURE, V325, P537, DOI 10.1038/325537a0; Orchansky PL, 1997, J BIOL CHEM, V272, P22940, DOI 10.1074/jbc.272.36.22940; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pirola L, 2003, J BIOL CHEM, V278, P15641, DOI 10.1074/jbc.M208984200; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; Plutzky J, 2002, J DIABETES COMPLICAT, V16, P401, DOI 10.1016/S1056-8727(02)00202-7; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Previs SF, 2000, J BIOL CHEM, V275, P38990, DOI 10.1074/jbc.M006490200; Qiao LY, 1999, J BIOL CHEM, V274, P10625, DOI 10.1074/jbc.274.15.10625; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Salt IP, 2003, J BIOL CHEM, V278, P18791, DOI 10.1074/jbc.M210618200; Sartippour MR, 2000, DIABETES, V49, P597, DOI 10.2337/diabetes.49.4.597; Strle K, 2001, CRIT REV IMMUNOL, V21, P427; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Vollenweider P, 2002, DIABETES, V51, P1052, DOI 10.2337/diabetes.51.4.1052; WAGTEVELD AJ, 1991, LEUKEMIA, V5, P782; Warne JP, 2003, J ENDOCRINOL, V177, P351, DOI 10.1677/joe.0.1770351; Welham MJ, 1997, J BIOL CHEM, V272, P1377, DOI 10.1074/jbc.272.2.1377; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; Winkler G, 1998, DIABETES RES CLIN PR, V42, P169, DOI 10.1016/S0168-8227(98)00109-0; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Withers DJ, 2001, BIOCHEM SOC T, V29, P525, DOI 10.1042/BST0290525; Wurster AL, 2002, MOL CELL BIOL, V22, P117, DOI 10.1128/MCB.22.1.117-126.2002; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; YIN TG, 1994, J BIOL CHEM, V269, P26614	76	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28045	28050		10.1074/jbc.M404368200	http://dx.doi.org/10.1074/jbc.M404368200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123681	hybrid			2022-12-25	WOS:000222265400028
J	O'Connor, MS; Safari, A; Liu, D; Qin, J; Zhou, SY				O'Connor, MS; Safari, A; Liu, D; Qin, J; Zhou, SY			The human Rap1 protein complex and modulation of telomere length	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPEAT-BINDING FACTOR-1; STRAND BREAK REPAIR; POLY(ADP-RIBOSE) POLYMERASE; RNA INTERFERENCE; YEAST RAP1; TRF1; END; TANKYRASE-1; DEREGULATION; MAINTENANCE	Proper maintenance of telomere length and structure is necessary for normal proliferation of mammalian cells. Mammalian telomere length is regulated by a number of proteins including human repressor activator protein (hRap1), a known association factor of TRF2. To further delineate hRap1 function and its associated proteins, we affinity-purified and identified the hRap1 protein complex through mass spectrometry analysis. In addition to TRF2, we found DNA repair proteins Rad50, Mre11, PARP1 (poly(ADP-ribose) polymerase), and Ku86/Ku70 to be in this telomeric complex. We demonstrated by deletional analysis that Rad-50/Mre-11 and Ku86 were recruited to hRap1 independent of TRF2. PARP1, however, most likely interacted with hRap1 through TRF2. Interestingly, knockdown of endogenous hRap1 expression by small hairpin interference RNA resulted in longer telomeres. In addition, overexpression of full-length and mutant hRap1 that lacked the BRCA1 C-terminal domain functioned as dominant negatives and extended telomeres. Deletion of a novel linker domain of hRap1 (residues 199-223), however, abolished the dominant negative effect of hRap1 overexpression. These results indicate that hRap1 negatively regulates telomere length in vivo and suggest that the linker region of hRap1 may modulate the recruitment of negative regulators of telomere length.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine	Zhou, SY (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	songyang@bcm.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA084208] Funding Source: NIH RePORTER; NCI NIH HHS [CA 84208] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Bundock P, 2002, NUCLEIC ACIDS RES, V30, P3395, DOI 10.1093/nar/gkf445; Chai WH, 2002, J BIOL CHEM, V277, P47242, DOI 10.1074/jbc.M208542200; Connelly JC, 2002, TRENDS BIOCHEM SCI, V27, P410, DOI 10.1016/S0968-0004(02)02144-8; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Diede SJ, 2001, CURR BIOL, V11, P1336, DOI 10.1016/S0960-9822(01)00400-6; Driller L, 2000, J BIOL CHEM, V275, P24921, DOI 10.1074/jbc.M002588200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Featherstone C, 1999, CURR BIOL, V9, pR759, DOI 10.1016/S0960-9822(00)80005-6; Gallego ME, 2003, PLANT CELL, V15, P782, DOI 10.1105/tpc.008623; Gotta M, 1997, BIOESSAYS, V19, P367, DOI 10.1002/bies.950190503; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; Hanaoka S, 2001, J MOL BIOL, V312, P167, DOI 10.1006/jmbi.2001.4924; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hopfner KP, 2002, CURR OPIN STRUC BIOL, V12, P115, DOI 10.1016/S0959-440X(02)00297-X; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Kanoh J, 2001, CURR BIOL, V11, P1624, DOI 10.1016/S0960-9822(01)00503-6; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Li BB, 2003, MOL BIOL CELL, V14, P5060, DOI 10.1091/mbc.e03-06-0403; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Morse RH, 2000, TRENDS GENET, V16, P51, DOI 10.1016/S0168-9525(99)01936-8; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Okabe J, 2000, HUM MOL GENET, V9, P2639, DOI 10.1093/hmg/9.18.2639; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Park MJ, 2002, MOL CELLS, V13, P327; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Riha K, 2002, EMBO J, V21, P2819, DOI 10.1093/emboj/21.11.2819; Rippmann JF, 2002, J MOL BIOL, V323, P217, DOI 10.1016/S0022-2836(02)00946-4; Rodriguez M, 2003, J BIOL CHEM, V278, P52914, DOI 10.1074/jbc.C300407200; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Sbodio JI, 2002, BIOCHEM J, V361, P451, DOI 10.1042/0264-6021:3610451; Seimiya H, 2002, J BIOL CHEM, V277, P14116, DOI 10.1074/jbc.M112266200; Shore D, 1997, BIOL CHEM, V378, P591; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Trujillo KM, 2001, J BIOL CHEM, V276, P35458, DOI 10.1074/jbc.M105482200; Tsukamoto Y, 2001, CURR BIOL, V11, P1328, DOI 10.1016/S0960-9822(01)00372-4; Tuschl T, 2001, CHEMBIOCHEM, V2, P239, DOI 10.1002/1439-7633(20010401)2:4<239::AID-CBIC239>3.0.CO;2-R; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139; Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074	56	136	143	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28585	28591		10.1074/jbc.M312913200	http://dx.doi.org/10.1074/jbc.M312913200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15100233	hybrid			2022-12-25	WOS:000222265400094
J	Song, BL; DeBose-Boyd, RA				Song, BL; DeBose-Boyd, RA			Ubiquitination of 3-hydroxy-3-methylglutaryl-CoA reductase in permeabilized cells mediated by cytosolic E1 and a putative membrane-bound ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; HMG COA REDUCTASE; STEROL-REGULATED DEGRADATION; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; IN-VIVO; PROTEIN; DOMAIN; PROTEOLYSIS; RECEPTOR	The endoplasmic reticulum ( ER) enzyme, 3-hydroxy-3-methylglutaryl-CoA reductase, catalyzes the production of mevalonate, a rate-controlling step in cholesterol biosynthesis. Excess sterols promote ubiquitination and subsequent degradation of reductase as part of a negative feedback regulatory mechanism. To characterize the process in more detail, we here report the development of a permeabilized cell system that supports reductase ubiquitination stimulated by the addition of sterols in vitro. Sterol-dependent ubiquitination of reductase in permeabilized cells is dependent upon exogenous cytosol, ATP, and either Insig-1 or Insig-2, two membrane-bound ER proteins shown previously to mediate sterol regulation of reductase degradation in intact cells. Oxysterols, but not cholesterol, promote reductase ubiquitination under our conditions. Finally, we show that ubiquitin-activating enzyme (E1) can efficiently replace cytosol to ubiquitinate reductase in response to sterol treatment, suggesting that other molecules required for ubiquitination of reductase, such as the ubiquitin-conjugating and -ligating enzymes (E2 and E3), are localized to ER membranes.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	DeBose-Boyd, RA (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA.	Russell.DeBose-Boyd@utsouthwestern.edu		Song, Bao-Liang/0000-0002-6397-5935	NHLBI NIH HHS [HL 20948, HL 70441] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, K01HL070441] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; BROWN MS, 1980, J LIPID RES, V21, P505; CORRELL CC, 1994, J BIOL CHEM, V269, P633; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hampton RY, 2002, ANNU REV CELL DEV BI, V18, P345, DOI 10.1146/annurev.cellbio.18.032002.131219; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; INOUE S, 1991, J BIOL CHEM, V266, P13311; Kikkert M, 2004, J BIOL CHEM, V279, P3525, DOI 10.1074/jbc.M307453200; LISCUM L, 1985, J BIOL CHEM, V260, P522; LISCUM L, 1983, J BIOL CHEM, V258, P8450; LUSKEY KL, 1985, J BIOL CHEM, V260, P271; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; Sever N, 2003, J BIOL CHEM, V278, P52479, DOI 10.1074/jbc.M310053200; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Shamu CE, 2001, MOL BIOL CELL, V12, P2546, DOI 10.1091/mbc.12.8.2546; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; Tiwari S, 2001, J BIOL CHEM, V276, P16193, DOI 10.1074/jbc.M007640200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	36	61	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28798	28806		10.1074/jbc.M402442200	http://dx.doi.org/10.1074/jbc.M402442200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15090540	hybrid			2022-12-25	WOS:000222265400118
J	Thomas, X; Destoumieux-Garzon, D; Peduzzi, J; Afonso, C; Blond, A; Birlirakis, N; Goulard, C; Dubost, L; Thai, R; Tabet, JC; Rebuffat, S				Thomas, X; Destoumieux-Garzon, D; Peduzzi, J; Afonso, C; Blond, A; Birlirakis, N; Goulard, C; Dubost, L; Thai, R; Tabet, JC; Rebuffat, S			Siderophore peptide, a new type of post-translationally modified antibacterial peptide with potent activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MICROCIN E492; KLEBSIELLA-PNEUMONIAE; OUTER-MEMBRANE; CATECHOLATE SIDEROPHORE; STRUCTURAL ELUCIDATION; MASS-SPECTROMETRY; IRON; ENTEROBACTIN; PROTEIN	Microcin E492 (MccE492, 7886 Da), the 84-amino acid antimicrobial peptide from Klebsiella pneumoniae, was purified in a post-translationally modified form, MccE492m ( 8717 Da), from culture supernatants of either the recombinant Escherichia coli VCS257 strain harboring the pJAM229 plasmid or the K. pneumoniae RYC492 strain. Chymotrypsin digestion of MccE492m led to the MccE492m-( 74 - 84) C-terminal fragment that carries the modification and that was analyzed by mass spectrometry and nuclear magnetic resonance at natural abundance. The 831-Da post-translational modification consists of a trimer of N-(2,3- dihydroxybenzoyl)-L-serine linked via a C-glycosidic linkage to a beta-D-glucose moiety, itself linked to the MccE492m Ser-84-carboxyl through an O-glycosidic bond. This modification, which mimics a catechol-type siderophore, was shown to bind ferric ions by analysis of the collision-induced dissociation pattern obtained for MccE492m-( 74 - 84) by electrospray ion trap mass spectrometry experiments in the presence of FeCl3. By using a series of wild-type and mutant isogenic strains, the three catechol-type siderophore receptors Fiu, Cir, and FepA were shown to be responsible for the recognition of MccE492m at the outer membrane of sensitive bacteria. Because MccE492m shows a broader spectrum of antibacterial activity and is more potent than MccE492, we propose that by increasing the microcin/receptor affinity, the modification leads to a better recognition and subsequently to a higher antimicrobial activity of the microcin. Therefore, MccE492m is the first member of a new class of antimicrobial peptides carrying a siderophore-like post-translational modification and showing potent activity, which we term siderophore-peptides.	Museum Natl Hist Nat, Lab Chim & Biochim Subst Nat, CNRS,UMR 5154,USM 502, Dept REgulat Dev & Divers Mol, F-75005 Paris, France; Univ Paris 06, CNRS, UMR 7613, Lab Chim Struct Organ & Biol, F-75252 Paris 5, France; CNRS, Inst Chim Subst Nat, Lab RMN Haut Champ, F-91190 Gif Sur Yvette, France; CEA Saclay, Dept Etud & Ingn Prot, F-91190 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay	Rebuffat, S (corresponding author), Museum Natl Hist Nat, Lab Chim & Biochim Subst Nat, CNRS,UMR 5154,USM 502, Dept REgulat Dev & Divers Mol, 63 Rue Buffon, F-75005 Paris, France.	rebuffat@mnhn.fr	Rebuffat, Sylvie/AAE-4194-2021; Rebuffat, Sylvie/AAO-2072-2020; Destoumieux-Garzón, Delphine/O-3328-2014; Afonso, Carlos/E-9736-2011	Destoumieux-Garzón, Delphine/0000-0002-8793-9138; Afonso, Carlos/0000-0002-2406-5664; Rebuffat, Sylvie/0000-0002-5257-5039; Thai, Robert/0000-0001-9438-4225				Afonso C, 2002, J MASS SPECTROM, V37, P755, DOI 10.1002/jms.341; ARMSTRONG SK, 1990, J BIOL CHEM, V265, P14536; BAQUERO F, 1984, FEMS MICROBIOL LETT, V23, P117; BERNER I, 1991, BIOL MET, V4, P113, DOI 10.1007/BF01135388; Braun V, 2002, BIOCHIMIE, V84, P365, DOI 10.1016/S0300-9084(02)01427-X; BRICKMAN TJ, 1992, J BIOL CHEM, V267, P12350; Carlesso V, 2002, INT J MASS SPECTROM, V219, P559, DOI 10.1016/S1387-3806(02)00742-X; Corsini G, 2002, BIOCHIMIE, V84, P539, DOI 10.1016/S0300-9084(02)01415-3; DELORENZO V, 1985, ANTIMICROB AGENTS CH, V27, P666, DOI 10.1128/AAC.27.4.666; DELORENZO V, 1984, ARCH MICROBIOL, V139, P72, DOI 10.1007/BF00692715; Destoumieux-Garzon D, 2003, MOL MICROBIOL, V49, P1031, DOI 10.1046/j.1365-2958.2003.03610.x; Destoumieux-Garzon D, 2002, BIOCHIMIE, V84, P511, DOI 10.1016/S0300-9084(02)01411-6; DRAUTZ H, 1986, J ANTIBIOT, V39, P1657, DOI 10.7164/antibiotics.39.1657; Fiedler HP, 2001, FEMS MICROBIOL LETT, V196, P147, DOI 10.1016/S0378-1097(01)00053-2; Guy PA, 1999, J AM SOC MASS SPECTR, V10, P969, DOI 10.1016/S1044-0305(99)00069-0; Hantke K, 2003, P NATL ACAD SCI USA, V100, P3677, DOI 10.1073/pnas.0737682100; HANTKE K, 1990, FEMS MICROBIOL LETT, V67, P5, DOI 10.1111/j.1574-6968.1990.tb13826.x; HILL CW, 1981, P NATL ACAD SCI-BIOL, V78, P7069, DOI 10.1073/pnas.78.11.7069; HOFSTEENGE J, 1994, BIOCHEMISTRY-US, V33, P13524, DOI 10.1021/bi00250a003; Kunzel E, 1999, J AM CHEM SOC, V121, P11058, DOI 10.1021/ja9915347; Lagos R, 1999, J BACTERIOL, V181, P212, DOI 10.1128/JB.181.1.212-217.1999; Lagos R, 2001, MOL MICROBIOL, V42, P229, DOI 10.1046/j.1365-2958.2001.02630.x; LAGOS R, 1993, FEBS LETT, V321, P145, DOI 10.1016/0014-5793(93)80096-D; Larsen RA, 1999, MOL MICROBIOL, V31, P1809, DOI 10.1046/j.1365-2958.1999.01317.x; Leo PM, 2002, ORG LETT, V4, P2711, DOI 10.1021/ol026222e; Moeck GS, 2001, J BACTERIOL, V183, P2755, DOI 10.1128/JB.183.9.2755-2764.2001; Nemirovskiy OV, 1998, J AM SOC MASS SPECTR, V9, P1020, DOI 10.1016/S1044-0305(98)00071-3; NIKAIDO H, 1990, J BACTERIOL, V172, P1361, DOI 10.1128/jb.172.3.1361-1367.1990; OBRIEN IG, 1971, BIOCHIM BIOPHYS ACTA, V237, P537, DOI 10.1016/0304-4165(71)90274-1; OBRIEN IG, 1970, BIOCHIM BIOPHYS ACTA, V215, P393, DOI 10.1016/0304-4165(70)90038-3; Orellana C, 1996, FEMS MICROBIOL LETT, V136, P297; Patzer SI, 2003, MICROBIOL-SGM, V149, P2557, DOI 10.1099/mic.0.26396-0; PAYNE SM, 1988, CRC CR REV MICROBIOL, V16, P81, DOI 10.3109/10408418809104468; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POLLACK JR, 1970, BIOCHEM BIOPH RES CO, V38, P989, DOI 10.1016/0006-291X(70)90819-3; Pons AM, 2002, BIOCHIMIE, V84, P531, DOI 10.1016/S0300-9084(02)01416-5; Pons AM, 2002, ANTIMICROB AGENTS CH, V46, P229, DOI 10.1128/AAC.46.1.229-230.2002; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SCARROW RC, 1991, INORG CHEM, V30, P900, DOI 10.1021/ic00005a007; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TAKAHASHI K, 1981, J ANTIBIOT, V34, P271, DOI 10.7164/antibiotics.34.271; Wilkens M, 1997, J BACTERIOL, V179, P4789, DOI 10.1128/jb.179.15.4789-4794.1997; Wuthrich K, 1986, NMR PROTEINS NUCL AC	43	122	127	4	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28233	28242		10.1074/jbc.M400228200	http://dx.doi.org/10.1074/jbc.M400228200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102848	hybrid			2022-12-25	WOS:000222265400053
J	Kondo, T; Kobayashi, M; Tanaka, J; Yokoyama, A; Suzuki, S; Kato, N; Onozawa, M; Chiba, K; Hashino, S; Imamura, M; Minami, Y; Minamino, N; Asaka, M				Kondo, T; Kobayashi, M; Tanaka, J; Yokoyama, A; Suzuki, S; Kato, N; Onozawa, M; Chiba, K; Hashino, S; Imamura, M; Minami, Y; Minamino, N; Asaka, M			Rapid degradation of Cdt1 upon UV-induced DNA damage is mediated by SCFSkp2 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-DEPENDENT DEGRADATION; RADIOSENSITIZING AGENT; S-PHASE; LICENSING FACTOR; PROTEIN-KINASE; CYCLIN-E; REPLICATION; GEMININ; INHIBITION; LIGASE	Cdt1 is a licensing factor for DNA replication, the function of which is tightly controlled to maintain genome integrity. Previous studies have indicated that the cell cycle-dependent degradation of Cdt1 is triggered at S phase to prevent re-replication. In this study, we found that Cdt1 is degraded upon DNA damage induced by either UV treatment or gamma-irradiation (IR). Although the IR-triggered degradation of Cdt1 was caffeine-insensitive, the UV-triggered degradation of Cdt1 was caffeine-sensitive. This indicates that the cells treated with UV utilize the checkpoint pathway, which differs from that triggered by IR. A recent study has suggested that Cdt1 is phosphorylated, ubiquitylated, and degraded at the G(1)/S boundary in the normal cell cycle. Treatment with MG132, a proteasome inhibitor, inhibited the degradation of Cdt1 and resulted in the accumulation of the phosphorylated form of Cdt1 after UV treatment. In the case of UV treatment, phosphorylation of Cdt1 induced the recruitment of Cdt1 to a SCFSkp2 complex. Moreover, ectopic overexpression of Cdt1 after UV treatment interfered the inhibition of DNA synthesis. These results indicate that Cdt1 is a target molecule of the cell cycle checkpoint in UV-induced DNA damage.	Hokkaido Univ, Dept Gastroenterol & Hematol, Grad Sch Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Div Canc Pathobiol, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Natl Cardiovasc Ctr, Res Inst, Osaka 5658565, Japan; Hokkaido Univ, Dept Hematol & Oncol, Grad Sch Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Kobe Univ, Dept Genome Sci, Grad Sch Med, Chuo Ku, Kobe, Hyogo 6500017, Japan	Hokkaido University; Hokkaido University; National Cerebral & Cardiovascular Center - Japan; Hokkaido University; Kobe University	Kondo, T (corresponding author), Hokkaido Univ, Dept Gastroenterol & Hematol, Grad Sch Med, Kita Ku, Nishi 7, Sapporo, Hokkaido 0608638, Japan.	t-kondoh@med.hokudai.ac.jp	Hashino, Satoshi/A-4815-2012; Asaka, Masahiro/A-5948-2012; Kondo, Takeshi/G-2103-2012; Onozawa, Masahiro/A-4136-2012	Kondo, Takeshi/0000-0001-7455-5824; Kobayashi, Masanobu/0000-0002-7445-9741				Arentson E, 2002, ONCOGENE, V21, P1150, DOI 10.1038/sj.onc.1205175; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Bhattacharya S, 2003, ONCOGENE, V22, P2443, DOI 10.1038/sj.onc.1206339; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Busby EC, 2000, CANCER RES, V60, P2108; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Higa LAA, 2003, NAT CELL BIOL, V5, P1008, DOI 10.1038/ncb1061; Hodgson B, 2002, CURR BIOL, V12, P678, DOI 10.1016/S0960-9822(02)00778-9; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yanow SK, 2001, EMBO J, V20, P4648, DOI 10.1093/emboj/20.17.4648; Yeh KH, 2001, BIOCHEM BIOPH RES CO, V281, P884, DOI 10.1006/bbrc.2001.4442; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	36	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27315	27319		10.1074/jbc.M314023200	http://dx.doi.org/10.1074/jbc.M314023200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102855	hybrid			2022-12-25	WOS:000222120400061
J	Sevilla, A; Santos, CR; Vega, FM; Lazo, PA				Sevilla, A; Santos, CR; Vega, FM; Lazo, PA			Human vaccinia-related kinase 1 (VRK1) activates the ATF2 transcriptional activity by novel phosphorylation on Thr-73 and Ser-62 and cooperates with JNK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; C-JUN PROMOTER; RESPONSE ELEMENT; BINDING PROTEIN; MDM-2 BINDING; CREB-BINDING; FACTOR-2; EXPRESSION; FAMILY; IDENTIFICATION	In the human kinome, vaccinia-related kinase-1 (VRK1) is a new Ser-Thr kinase associated with proliferating tissues. VRK1 colocalizes with ATF2 in the nucleus and can form a stable complex. We have studied the phosphorylation of the transcription factor ATF2, which regulates gene expression by forming dimers with proteins with basic region-leucine zipper domains and recognizing cAMP-response element or AP1 sequences implicated in cellular responses to stress. VRK1 phosphorylates ATF2 mainly on Thr-73, stabilizing the ATF2 protein and increasing its intracellular level. Mutagenesis studies showed that Thr-73 and Ser-62 are implicated in ATF2 transcriptional activation by VRK1 detected in a functional assay based on ATF2 dimerization. VRK1 can activate the collagenase gene promoter that is regulated by ATF2 in a dose-dependent manner. Loss of kinase activity (K179E mutant) or the T73A substitution in ATF2 prevents both its accumulation and activation of transcription. VRK1 and JNK, which phosphorylates ATF2 in Thr-69 and Thr-71, have an additive effect on ATF2-dependent transcription at suboptimal doses. Therefore, two groups of amino acids in the ATF2 aminoterminal region can integrate different cellular signals mediated by at least five different kinases. VRK1 is an element of a novel signaling pathway that regulates gene transcription.	Univ Salamanca, Ctr Invest Canc, CSIC, Inst Biol Mol & Celular Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Lazo, PA (corresponding author), Univ Salamanca, Ctr Invest Canc, CSIC, Inst Biol Mol & Celular Canc, Campus Miguel Unamuno, E-37007 Salamanca, Spain.	plazozbi@usal.es	Vega, Francisco M./C-4678-2008; Sevilla, Ana/N-8579-2017; Lazo, Pedro A./M-6435-2014	Vega, Francisco M./0000-0002-9015-864X; Sevilla, Ana/0000-0002-9251-4759; Lazo, Pedro A./0000-0001-8997-3025				Ban N, 2000, DIABETES, V49, P1142, DOI 10.2337/diabetes.49.7.1142; BANHAM AH, 1992, VIROLOGY, V191, P803, DOI 10.1016/0042-6822(92)90256-O; Barcia R, 2002, ARCH BIOCHEM BIOPHYS, V399, P1, DOI 10.1006/abbi.2001.2746; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Clerk A, 1997, BIOCHEM J, V325, P801, DOI 10.1042/bj3250801; Clerk A, 1999, J MOL CELL CARDIOL, V31, P2087, DOI 10.1006/jmcc.1999.1040; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; Duyndam MCA, 1999, ONCOGENE, V18, P2311, DOI 10.1038/sj.onc.1202584; Firestein R, 1998, J BIOL CHEM, V273, P5892, DOI 10.1074/jbc.273.10.5892; Fuchs SY, 1999, MOL CELL BIOL, V19, P3289; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAGMEYER BM, 1995, BIOESSAYS, V17, P621, DOI 10.1002/bies.950170708; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Jabbur JR, 2002, ONCOGENE, V21, P7100, DOI 10.1038/sj.onc.1205856; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIN SQ, 1992, J VIROL, V66, P2717, DOI 10.1128/JVI.66.5.2717-2723.1992; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Lopez-Borges S, 2000, ONCOGENE, V19, P3656, DOI 10.1038/sj.onc.1203709; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mayr BM, 2001, P NATL ACAD SCI USA, V98, P10936, DOI 10.1073/pnas.191152098; Nezu J, 1997, GENOMICS, V45, P327, DOI 10.1006/geno.1997.4938; Nichols RJ, 2004, J BIOL CHEM, V279, P7934, DOI 10.1074/jbc.M310813200; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; REMPEL RE, 1992, J VIROL, V66, P4413, DOI 10.1128/JVI.66.7.4413-4426.1992; SAKURAI A, 1991, BIOCHEM BIOPH RES CO, V181, P629, DOI 10.1016/0006-291X(91)91237-7; Schon O, 2002, J MOL BIOL, V323, P491, DOI 10.1016/S0022-2836(02)00852-5; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; Steinmuller L, 2001, BIOCHEM J, V360, P599, DOI 10.1042/0264-6021:3600599; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Vega FM, 2003, FEBS LETT, V544, P176, DOI 10.1016/S0014-5793(03)00501-5; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; Xu X, 1996, VIROLOGY, V218, P362, DOI 10.1006/viro.1996.0205; ZU YL, 1992, J BIOL CHEM, V267, P20181	48	94	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27458	27465		10.1074/jbc.M401009200	http://dx.doi.org/10.1074/jbc.M401009200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15105425	hybrid			2022-12-25	WOS:000222120400077
J	Zhu, HB; Zhang, LD; Wu, SH; Teraishi, F; Davis, JJ; Jacob, D; Fang, BL				Zhu, HB; Zhang, LD; Wu, SH; Teraishi, F; Davis, JJ; Jacob, D; Fang, BL			Induction of S-phase arrest and p21 overexpression by a small molecule 2[[3-(2,3-dichlorophenoxy)propyl] amino]ethanol in correlation with activation of ERK	ONCOGENE			English	Article						S-phase arrest; p21; ATM; p53; ERK; small molecule	CYCLIN-DEPENDENT KINASES; TAXOL-INDUCED APOPTOSIS; CELL-CYCLE; CANCER-CELLS; DNA-DAMAGE; PROTEIN-KINASES; INHIBITOR P21; GENE-THERAPY; ADENOVIRUS; P53	We recently found that a small molecule 2[[3-(2,3-dichlorophenoxy)propyl]amino]ethanol (2,3-DCPE) could induce apoptosis and downregulate Bcl-XL expression in various cancer cells. Here, we found that 2,3- DCPE suppressed the proliferation of Bcl-XL-overexpressing cancer cells without inducing apoptosis. Subsequently, we found that 2,3-DCPE could induce S-phase arrest and upregulate p21 but not p27 at a time- and dose-dependent but p53-dispensable manner in DLD-1 human colon cancer cells. Activation of ERK was also detected after treatment with 2,3-DCPE. Moreover, p21 induction was dramatically attenuated by ERK inhibitors PD98059 and U0126. Induction of p21 and S-phase arrest and corresponding activation of ERK were also observed in ATM-defective cells, suggesting that 2,3-DCPE-induced these events were ATM-dispensable. Furthermore, ERK inhibitors dramatically attenuated 2,3-DCPE-induced S-phase arrest. Together, our data indicate that ERK activation correlated with the 2,3-DCPE-mediated induction of p21 expression and S-phase arrest. This finding may have implication for cancer therapy.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Unit 445, Houston, TX 77030 USA; Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Surg Oncol, Hangzhou 310016, Peoples R China; Univ Texas, Grad Sch Biomed Sci, Program Gene Therapy & Virol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Zhejiang University; University of Texas System	Fang, BL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Unit 445, 1515 Holcombe Blvd, Houston, TX 77030 USA.	Bfang@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA098582, R01CA092487, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, R01 CA 098582-01A1, R01 CA 092487-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Borel F, 2002, J CELL SCI, V115, P2829; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EASTHAM JA, 1995, CANCER RES, V55, P5151; EL DW, 1993, CELL, V75, P817; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Hall MC, 2000, J UROLOGY, V163, P1033, DOI 10.1016/S0022-5347(05)67877-9; HARPER JW, 1993, CELL, V75, P805; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kagawa S, 2001, CANCER RES, V61, P3330; Katayose Y, 1997, CANCER RES, V57, P5441; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; Lodygin D, 2002, J CLIN INVEST, V110, P1717, DOI 10.1172/JCI200216588; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Park KS, 2002, BRIT J PHARMACOL, V137, P597, DOI 10.1038/sj.bjp.0704909; Pedeux R, 1998, J INVEST DERMATOL, V111, P472, DOI 10.1046/j.1523-1747.1998.00324.x; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; Seidman R, 2001, EXP CELL RES, V268, P84, DOI 10.1006/excr.2001.5262; Senderowicz AM, 2000, ONCOGENE, V19, P6600, DOI 10.1038/sj.onc.1204085; Shapiro GI, 1999, J CLIN INVEST, V104, P1645, DOI 10.1172/JCI9054; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Toogood PL, 2002, CURR OPIN CHEM BIOL, V6, P472, DOI 10.1016/S1367-5931(02)00342-3; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wu SH, 2004, CANCER RES, V64, P1110, DOI 10.1158/0008-5472.CAN-03-2790; Zhang L, 2002, GENE THER, V9, P1262, DOI 10.1038/sj.gt.3301797; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	38	70	76	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					4984	4992		10.1038/sj.onc.1207645	http://dx.doi.org/10.1038/sj.onc.1207645			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15122344				2022-12-25	WOS:000222237300004
J	Levin, MK; Wang, YH; Patel, SS				Levin, MK; Wang, YH; Patel, SS			The functional interaction of the hepatitis C virus helicase molecules is responsible for unwinding processivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-UVRD; SINGLE-STRANDED-DNA; NS3 PROTEIN; HEXAMERIC HELICASES; CRYSTAL-STRUCTURE; STEADY-STATE; STEP-SIZE; IN-VITRO; RNA; DOMAIN	Although helicases participate in virtually every cellular process involving nucleic acids, the details of their mechanism including the role of interaction between the subunits remains unclear. Here we study the unwinding kinetics of the helicase from hepatitis C virus using DNA substrates with a range of tail and duplex lengths. The binding of the helicase to the substrates was characterized by electron microscopy and fluorimetric titrations. Depending on the length of the ssDNA tail, one or more helicase molecules can be loaded on the DNA. Unwinding was measured under single-turnover conditions, and the results show that a monomer is active on short duplexes yet multiple molecules are needed to unwind long duplexes. Thus, increasing the ssDNA tail length increases the unwinding efficiency. The unwinding kinetics was modeled as a stepwise process performed by single or multiple helicase molecules. The model programmed in MATLAB was used for global fitting of the kinetics, yielding values for the rate of unwinding, processivity, cooperativity, step size, and occlusion site. The results indicate that a single hepatitis C virus helicase molecule unwinds DNA with a low processivity. The multiple helicase molecules present on the DNA substrate show functional cooperativity and unwind with greater efficiency, although they bind and release the substrate non-cooperatively, and the ATPase cycle of the helicase molecules is not coordinated. The functional interaction model explains the efficient unwinding by multiple helicases and is generally applicable.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Patel, SS (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	patelss@umdnj.edu			NIGMS NIH HHS [GM55310] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ail JA, 1999, J MOL BIOL, V293, P815, DOI 10.1006/jmbi.1999.3185; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; Cheng W, 2001, J MOL BIOL, V310, P327, DOI 10.1006/jmbi.2001.4758; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; Epshtein V, 2003, EMBO J, V22, P4719, DOI 10.1093/emboj/cdg452; Epshtein V, 2003, SCIENCE, V300, P801, DOI 10.1126/science.1083219; Frick DN, 2004, J BIOL CHEM, V279, P1269, DOI 10.1074/jbc.M310630200; Gallinari P, 1999, BIOCHEMISTRY-US, V38, P5620, DOI 10.1021/bi982892+; Gallinari P, 1998, J VIROL, V72, P6758, DOI 10.1128/JVI.72.8.6758-6769.1998; Gwack Y, 1996, BIOCHEM BIOPH RES CO, V225, P654, DOI 10.1006/bbrc.1996.1225; HAN DS, 1995, J GEN VIROL, V76, P985, DOI 10.1099/0022-1317-76-4-985; Howe AYM, 1999, PROTEIN SCI, V8, P1332, DOI 10.1110/ps.8.6.1332; Jankowsky E, 2000, NATURE, V403, P447, DOI 10.1038/35000239; Kato M, 2001, J BIOL CHEM, V276, P21809, DOI 10.1074/jbc.M101470200; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; KOLYKHALOV AA, 1994, J VIROL, V68, P7525, DOI 10.1128/JVI.68.11.7525-7533.1994; Kuang WF, 2004, BIOCHEM BIOPH RES CO, V317, P211, DOI 10.1016/j.bbrc.2004.03.032; Levin M.K., 2003, MOL MOTORS, P179; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; Levin MK, 2002, J BIOL CHEM, V277, P29377, DOI 10.1074/jbc.M112315200; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Lucius AL, 2003, BIOPHYS J, V85, P2224, DOI 10.1016/S0006-3495(03)74648-7; Lucius AL, 2002, J MOL BIOL, V324, P409, DOI 10.1016/S0022-2836(02)01067-7; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Morris PD, 1999, BIOCHEMISTRY-US, V38, P5164, DOI 10.1021/bi9822269; Nanduri B, 2002, P NATL ACAD SCI USA, V99, P14722, DOI 10.1073/pnas.232401899; Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Porter DJT, 1998, J BIOL CHEM, V273, P18906, DOI 10.1074/jbc.273.30.18906; Preugschat F, 1996, J BIOL CHEM, V271, P24449, DOI 10.1074/jbc.271.40.24449; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; Tackett AJ, 2001, NUCLEIC ACIDS RES, V29, P565, DOI 10.1093/nar/29.2.565; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Xu HQ, 2003, J BIOL CHEM, V278, P34925, DOI 10.1074/jbc.M303581200; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8	40	109	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26005	26012		10.1074/jbc.M403257200	http://dx.doi.org/10.1074/jbc.M403257200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087464	hybrid			2022-12-25	WOS:000222003000011
J	Pedraza, LG; Stewart, RA; Li, DM; Xu, T				Pedraza, LG; Stewart, RA; Li, DM; Xu, T			Drosophila Src-family kinases function with Csk to regulate cell proliferation and apoptosis	ONCOGENE			English	Article						Src; Csk; oncogene; proliferation; apoptosis	C-SRC; TYROSINE KINASES; TRANSGENIC MICE; DEATH; GENE; EYE; EXPRESSION; ACTIVATION; CANCER; MATTER	Elevated Src protein levels and activity are associated with the development and progression of a variety of cancers. The consequences of deregulated Src activity have been studied extensively in cell culture; however, the effects of this deregulation in vivo, as well as the mechanisms of Src-induced tumorigenesis, remain poorly understood. In this study, the effect of expressing wildtype and constitutively active Drosophila Src-family kinases (SFKs) in the developing eye was examined. Overexpression of either wild-type Drosophila SFK (Src64 and Src42) is sufficient to induce ectopic proliferation in G(1)/G(0)-arrested, uncommitted cells in eye imaginal discs. In addition, both kinases trigger apoptosis in vivo, in a dosage-dependent manner. Constitutively active mutants are hypermorphic as they trigger proliferation and death more potently than their wild-type counterparts. Moreover, SFK-induced proliferation and apoptosis are largely independent events, as blocking ectopic proliferation does not block cell death. Further, DCsk (the Drosophila homolog of the C-terminal Src kinase) phosphorylates and interacts genetically with the wild-type SFKs, but not with the constitutively active mutants in which a conserved C-terminal tyrosine was mutated to phenylalanine, providing the first in vivo evidence that Csk regulates SFKs during development through phosphorylation of their C-terminal tyrosine.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst,Dept Genet, New Haven, CT 06536 USA	Howard Hughes Medical Institute; Yale University	Xu, T (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst,Dept Genet, 295 Congress Ave,POB 9812, New Haven, CT 06536 USA.	tian.xu@yale.edu	Stewart, Rodney/ABA-6757-2020	Stewart, Rodney/0000-0003-1220-1830	NATIONAL CANCER INSTITUTE [R01CA069408] Funding Source: NIH RePORTER; NCI NIH HHS [CA69408] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aouacheria A, 2002, BIOCHEM PHARMACOL, V64, P1605, DOI 10.1016/S0006-2952(02)01385-0; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Boudny V, 2002, BRIT J CANCER, V86, P463, DOI 10.1038/sj.bjc.6600080; BOUGERET C, 1993, ONCOGENE, V8, P1241; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; DENOOIJ JC, 1995, SCIENCE, V270, P983, DOI 10.1126/science.270.5238.983; Dodson GS, 1998, DEVELOPMENT, V125, P2883; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; Duffy JB, 2002, GENESIS, V34, P1, DOI 10.1002/gene.10150; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Evan G, 1997, INT J CANCER, V71, P709, DOI 10.1002/(SICI)1097-0215(19970529)71:5<709::AID-IJC2>3.0.CO;2-V; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; Igaki T, 2000, P NATL ACAD SCI USA, V97, P662, DOI 10.1073/pnas.97.2.662; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Johnson D, 2000, CELL DEATH DIFFER, V7, P685, DOI 10.1038/sj.cdd.4400700; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KUSSICK SJ, 1993, ONCOGENE, V8, P2791; KUSSICK SJ, 1992, ONCOGENE, V7, P2461; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; Stewart RA, 2003, ONCOGENE, V22, P6436, DOI 10.1038/sj.onc.1206820; Takahashi F, 1996, GENE DEV, V10, P1645, DOI 10.1101/gad.10.13.1645; Tateno M, 2000, SCIENCE, V287, P324, DOI 10.1126/science.287.5451.324; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Webb BL, 2000, MOL CELL BIOL, V20, P9271, DOI 10.1128/MCB.20.24.9271-9280.2000; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; Weissenberger J, 1997, ONCOGENE, V14, P2005, DOI 10.1038/sj.onc.1201168; WOLFF T, 1991, DEVELOPMENT, V113, P841	36	43	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4754	4762		10.1038/sj.onc.1207635	http://dx.doi.org/10.1038/sj.onc.1207635			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15107833				2022-12-25	WOS:000221799200010
J	Hanissian, SH; Akbar, U; Teng, B; Janjetovic, Z; Hoffmann, A; Hitzler, JK; Iscove, N; Hamre, K; Du, XP; Tong, Y; Mukatira, S; Robertson, JH; Morris, SW				Hanissian, SH; Akbar, U; Teng, B; Janjetovic, Z; Hoffmann, A; Hitzler, JK; Iscove, N; Hamre, K; Du, XP; Tong, Y; Mukatira, S; Robertson, JH; Morris, SW			CDNA cloning and characterization of a novel gene encoding the MLF1-interacting protein MLF1IP	ONCOGENE			English	Article						MLF1; NPM-MLF1; MLF1IP; acute myeloid leukemia	CHROMOSOMAL LOCALIZATION; MYELOID-LEUKEMIA; BINDING; PHOSPHORYLATION; NUCLEOPHOSMIN; TRANSPORT; RECEPTOR; ADAPTER; DOMAIN; SITE	Myelodysplasia/acute myeloid leukemia (MDS/AML) is characterized by a t(3;5)(q25.1;q34) chromosomal translocation that forms a fusion gene between nucleophosmin (NPM) and MDS/myeloid leukemia factor 1 (MLF1). We identified a novel protein, MLF1-interacting protein (MLF1IP), that specifically associates with MLF1 by yeast two-hybrid analysis and in pulldown assays, and colocalizes with it in both the nuclei and cytoplasm of cells. The MLF1IP gene locus is at chromosome 4q35.1 and is composed of 14 exons spanning 75.8 kb of genomic DNA. The MLF1IP cDNA encodes a 46-kDa protein that contains two bipartite and two classical nuclear localization signals, two nuclear receptor-binding motifs (LXXLL), two leucine zippers, two PEST residues and several potential phosphorylation sites. MLF1IP transcripts are expressed in a variety of tissues (e.g. fetal liver, bone marrow, thymus and testis). MLF1IP appears to be a lineage-specific gene whose expression is confined exclusively to the CFU-E erythroid precursor cells, but not in mature erythrocytes. These observations, together with previous data demonstrating a role for MLF1 in suppressing red cell maturation, suggest a possible role for MLF1IP and MLF1 deregulation in the genesis of erythroleukemias.	Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, Memphis, TN 38163 USA; Univ Kiel, Ctr Biochem & Mol Biol, D-24118 Kiel, Germany; Univ Toronto, Hosp Sick Children, Dept Pediat, Div Hematol Oncol Canc & Blood, Toronto, ON, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Kiel; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital	Hanissian, SH (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, 847 Monroe,Room 427, Memphis, TN 38163 USA.	shanissi@utmem.edu		Akbar, Umair/0000-0001-5423-0002	NATIONAL CANCER INSTITUTE [R01CA076301] Funding Source: NIH RePORTER; NCI NIH HHS [CA76301, CA27165] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1992, IN SITU HYBRIDIZATIO; Billia F, 2001, BLOOD, V97, P2257, DOI 10.1182/blood.V97.8.2257; Bornberg-Bauer E, 1998, NUCLEIC ACIDS RES, V26, P2740, DOI 10.1093/nar/26.11.2740; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Cope MJTV, 1996, STRUCTURE, V4, P969, DOI 10.1016/S0969-2126(96)00103-7; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Gregson HC, 2002, CHROMOSOME RES, V10, P267, DOI 10.1023/A:1016563523208; Gregson HC, 2001, J BIOL CHEM, V276, P47575, DOI 10.1074/jbc.M103364200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hitzler JK, 1999, AM J PATHOL, V155, P53, DOI 10.1016/S0002-9440(10)65098-5; ISCOVE NN, 1977, CELL TISSUE KINET, V10, P323, DOI 10.1111/j.1365-2184.1977.tb00300.x; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Kozak M, 2000, GENOMICS, V70, P396, DOI 10.1006/geno.2000.6412; Kuefer MU, 1996, GENOMICS, V35, P392, DOI 10.1006/geno.1996.0376; Lim R, 2002, J BIOL CHEM, V277, P40997, DOI 10.1074/jbc.M206041200; Matsumoto N, 2000, LEUKEMIA, V14, P1757, DOI 10.1038/sj.leu.2401897; OLSON MOJ, 1986, BIOCHEMISTRY-US, V25, P484, DOI 10.1021/bi00350a031; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; RAIMONDI SC, 1989, LEUKEMIA, V3, P42; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Schmiesing JA, 1998, P NATL ACAD SCI USA, V95, P12906, DOI 10.1073/pnas.95.22.12906; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Speck O, 2003, NATURE, V421, P83, DOI 10.1038/nature01295; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Williams JH, 1999, EMBO J, V18, P5559, DOI 10.1093/emboj/18.20.5559; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	30	55	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3700	3707		10.1038/sj.onc.1207448	http://dx.doi.org/10.1038/sj.onc.1207448			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116101				2022-12-25	WOS:000221101700022
J	Rosenblatt-Velin, N; Lerch, R; Papageorgiou, I; Montessuit, C				Rosenblatt-Velin, N; Lerch, R; Papageorgiou, I; Montessuit, C			Insulin resistance in adult cardiomyocytes undergoing dedifferentiation: role of GLUT4 expression and translocation	FASEB JOURNAL			English	Article						hypertrophy; myocytes; metabolism; signal transduction	GLUCOSE TRANSPORTER GLUT4; HEART-MUSCLE-CELLS; SKELETAL-MUSCLE; RAT-HEART; 3T3-L1 ADIPOCYTES; IN-VIVO; CARDIAC-HYPERTROPHY; VENTRICULAR CELLS; GENE-EXPRESSION; ISCHEMIA	Myocardium undergoing remodeling in vivo exhibits insulin resistance that has been attributed to a shift from the insulin-sensitive glucose transporter GLUT4 to the fetal, less insulin-sensitive, isoform GLUT1. To elucidate the role of altered GLUT4 expression in myocardial insulin resistance, glucose uptake and the expression of the glucose transporter isoforms GLUT4 and GLUT1 were measured in adult rat cardiomyocytes (ARC). ARC in culture spontaneously undergo dedifferentiation, hypertrophy-like spreading, and return to a fetal-like gene expression pattern. Insulin stimulation of 2-deoxy-D-glucose uptake was completely abolished on day 2 and 3 of culture and recovered thereafter. Although GLUT4 protein level was reduced, the time-course of unresponsiveness to insulin did not correlate with altered expression of GLUT1 and GLUT4. However, translocation of GLUT4 to the sarcolemma in response to insulin was completely abolished during transient insulin resistance. Insulin-mediated phosphorylation of Akt was not reduced, indicating that activation of phosphatidylinositol 3-kinase (PI3K) was preserved. On the other hand, total and phosphorylated Cbl was reduced during insulin resistance, suggesting that activation of Cbl/CAP is essential for insulin-mediated GLUT4 translocation, in addition to activation of PI3K. Pharmacological inhibition of contraction in insulin-sensitive ARC reduced insulin sensitivity and lowered phosphorylated Cbl. The results suggest that transient insulin resistance in ARC is related to impairment of GLUT4 translocation. A defect in the PI3K-independent insulin signaling pathway involving Cbl seems to contribute to reduced insulin responsiveness and may be related to contractile arrest.	Univ Hosp Geneva, Div Cardiol, CH-1211 Geneva 14, Switzerland	University of Geneva	Montessuit, C (corresponding author), Univ Hosp Geneva, Div Cardiol, 24 Micheli Crest, CH-1211 Geneva 14, Switzerland.	christophe.montessuit@hcuge.ch		Montessuit, Christophe/0000-0002-2580-7711; Rosenblatt, Nathalie/0000-0003-2011-2862				BARNARD RJ, 1992, FASEB J, V6, P3238, DOI 10.1096/fasebj.6.14.1426762; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; Doenst T, 2001, METABOLISM, V50, P1083, DOI 10.1053/meta.2001.25605; Egert S, 1999, CIRC RES, V84, P1407; EPPENBERGEREBERHARDT M, 1990, DEV BIOL, V139, P269, DOI 10.1016/0012-1606(90)90296-U; Fares N, 1998, J PHYSIOL-LONDON, V506, P73, DOI 10.1111/j.1469-7793.1998.073bx.x; FISCHER Y, 1991, LIFE SCI, V49, P1679, DOI 10.1016/0024-3205(91)90310-8; FISCHER Y, 1995, ENDOCRINOLOGY, V136, P412, DOI 10.1210/en.136.2.412; Garvey WT, 1998, J CLIN INVEST, V101, P2377, DOI 10.1172/JCI1557; GWATHMEY JK, 1991, CIRC RES, V69, P1280, DOI 10.1161/01.RES.69.5.1280; HARIHARAN R, 1995, CIRCULATION, V91, P2435, DOI 10.1161/01.CIR.91.9.2435; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; LORELL BH, 1984, J AM COLL CARDIOL, V3, P341, DOI 10.1016/S0735-1097(84)80018-2; MESSERLI JM, 1995, MICROSC RES TECHNIQ, V30, P521, DOI 10.1002/jemt.1070300609; Olson AL, 2001, J BIOL CHEM, V276, P10706, DOI 10.1074/jbc.M007610200; Paternostro G, 1999, CARDIOVASC RES, V42, P246, DOI 10.1016/S0008-6363(98)00233-8; Paternostro G, 1996, J CLIN INVEST, V98, P2094, DOI 10.1172/JCI119015; PATERNOSTRO G, 1995, CARDIOVASC RES, V30, P205, DOI 10.1016/0008-6363(95)00019-4; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SALTIS J, 1991, J BIOL CHEM, V266, P261; SANTALUCIA T, 1992, ENDOCRINOLOGY, V130, P837, DOI 10.1210/en.130.2.837; SARGEANT RJ, 1993, BIOCHEM J, V290, P913, DOI 10.1042/bj2900913; SIVITZ WI, 1991, ENDOCRINOLOGY, V128, P2387, DOI 10.1210/endo-128-5-2387; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; Tardy-Cantalupi I, 1999, J MOL CELL CARDIOL, V31, P1143, DOI 10.1006/jmcc.1999.0952; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WALLBERGHENRIKSSON H, 1988, J APPL PHYSIOL, V65, P909, DOI 10.1152/jappl.1988.65.2.909; WEINBERG EO, 1995, CIRCULATION, V92, P385; Young LH, 1997, CIRCULATION, V95, P415	32	30	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					872	+		10.1096/fj.03-1095fje	http://dx.doi.org/10.1096/fj.03-1095fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15117888				2022-12-25	WOS:000220522800002
J	Fiermonte, G; De Leonardis, F; Todisco, S; Palmieri, L; Lasorsa, FM; Palmieri, F				Fiermonte, G; De Leonardis, F; Todisco, S; Palmieri, L; Lasorsa, FM; Palmieri, F			Identification of the mitochondrial ATP-Mg/P-i transporter - Bacterial expression, reconstitution, functional characterization, and tissue distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ADENINE-NUCLEOTIDE TRANSPORT; ADP/ATP CARRIER; BOVINE MITOCHONDRIA; GLUCAGON TREATMENT; MOLECULAR-CLONING; PHOSPHATE CARRIER; YEAST; PROTEIN; ACCUMULATION	The mitochondrial carriers are a family of transport proteins that, with a few exceptions, are found in the inner membranes of mitochondria. They shuttle metabolites, nucleotides, and cofactors through this membrane and thereby connect and/or regulate cytoplasm and matrix functions. ATP-Mg is transported in exchange for phosphate, but no protein has ever been associated with this activity. We have isolated three human cDNAs that encode proteins of 458, 468, and 489 amino acids with 66-75% similarity and with the characteristic features of the mitochondrial carrier family in their C-terminal domains and three EF-hand Ca2+-binding motifs in their N-terminal domains. These proteins have been overexpressed in Escherichia coli and reconstituted into phospholipid vesicles. Their transport properties and their targeting to mitochondria demonstrate that they are isoforms of the ATP-Mg/P-i carrier described in the past in whole mitochondria. The tissue specificity of the three isoforms shows that at least one isoform was present in all of the tissues investigated. Because phosphate recycles via the phosphate carrier in mitochondria, the three isoforms of the ATP-Mg/P-i carrier are most likely responsible for the net uptake or efflux of adenine nucleotides into or from the mitochondria and hence for the variation in the matrix adenine nucleotide content, which has been found to change in many physiopathological situations.	Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, I-70125 Bari, Italy; CNR, Inst Biomembranes & Bioenerget, I-70125 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR)	Palmieri, F (corresponding author), Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, Via Orabona 4, I-70125 Bari, Italy.	fpalm@farmbiol.uniba.it	Fiermonte, Giuseppe/D-3680-2018; lasorsa, francesco massimo m/B-7931-2008; Todisco, Simona/AAU-2091-2021	Fiermonte, Giuseppe/0000-0002-6764-9395; lasorsa, francesco massimo m/0000-0001-8418-5222; 				APRILLE JR, 1982, BIOCHEM BIOPH RES CO, V108, P834, DOI 10.1016/0006-291X(82)90905-6; APRILLE JR, 1981, ARCH BIOCHEM BIOPHYS, V207, P157, DOI 10.1016/0003-9861(81)90021-7; APRILLE JR, 1980, ARCH BIOCHEM BIOPHYS, V201, P564, DOI 10.1016/0003-9861(80)90546-9; APRILLE JR, 1988, FASEB J, V2, P2547, DOI 10.1096/fasebj.2.10.3290024; APRILLE JR, 1993, J BIOENERG BIOMEMBR, V25, P473, DOI 10.1007/BF01108404; APRILLE JR, 1988, INTEGRATION MITOCHON, P393; AUSTIN J, 1983, ARCH BIOCHEM BIOPHYS, V222, P321, DOI 10.1016/0003-9861(83)90529-5; AUSTIN J, 1984, J BIOL CHEM, V259, P154; BARBOUR RL, 1983, CANCER RES, V43, P1511; BATTINI R, 1987, J BIOL CHEM, V262, P4355; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; DAVIES NT, 1986, BIOCHIM BIOPHYS ACTA, V848, P294, DOI 10.1016/0005-2728(86)90203-3; Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998; Dyall SD, 2000, MOL CELL BIOL, V20, P2488, DOI 10.1128/MCB.20.7.2488-2497.2000; Fiermonte G, 2002, J BIOL CHEM, V277, P19289, DOI 10.1074/jbc.M201572200; Fiermonte G, 1998, J BIOL CHEM, V273, P22782, DOI 10.1074/jbc.273.35.22782; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; Fiore C, 1998, BIOCHIMIE, V80, P137, DOI 10.1016/S0300-9084(98)80020-5; GEHNRICH SC, 1988, COMP BIOCHEM PHYS B, V91, P11, DOI 10.1016/0305-0491(88)90107-1; Gonzalez-Barroso MM, 1999, J MOL BIOL, V292, P137, DOI 10.1006/jmbi.1999.3049; HAGEN T, 1993, ARCH BIOCHEM BIOPHYS, V303, P195, DOI 10.1006/abbi.1993.1273; Hagen T, 2003, AM J PHYSIOL-GASTR L, V285, pG274, DOI 10.1152/ajpgi.00052.2003; HAYNES RC, 1986, J BIOL CHEM, V261, P6121; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; JOYAL JL, 1992, J BIOL CHEM, V267, P19198; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; LANOUE KF, 1974, ARCH BIOCHEM BIOPHYS, V161, P544, DOI 10.1016/0003-9861(74)90337-3; LANOUE KF, 1984, BIOENERGETICS, P221; Lasorsa FM, 2003, J BIOL CHEM, V278, P38686, DOI 10.1074/jbc.M304988200; Marobbio CMT, 2003, EMBO J, V22, P5975, DOI 10.1093/emboj/cdg574; Marobbio CMT, 2002, EMBO J, V21, P5653, DOI 10.1093/emboj/cdf583; Mashima H, 2003, J BIOL CHEM, V278, P9520, DOI 10.1074/jbc.M208398200; Muller V, 1996, BIOCHEMISTRY-US, V35, P16132, DOI 10.1021/bi960667r; NAKAZAWA T, 1977, J BIOCHEM-TOKYO, V82, P1575, DOI 10.1093/oxfordjournals.jbchem.a131852; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; NOSEK MT, 1990, J BIOL CHEM, V265, P8444; NOSEK MT, 1992, ARCH BIOCHEM BIOPHYS, V296, P691, DOI 10.1016/0003-9861(92)90628-A; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3; Palmieri L, 2000, BBA-BIOENERGETICS, V1459, P363, DOI 10.1016/S0005-2728(00)00173-0; Palmieri L, 2001, EMBO J, V20, P5049, DOI 10.1093/emboj/20.18.5049; Palmieri L, 2001, EMBO J, V20, P5060, DOI 10.1093/emboj/20.18.5060; Picault N, 2004, TRENDS PLANT SCI, V9, P138, DOI 10.1016/j.tplants.2004.01.007; POLLAK JK, 1980, BIOCHEM J, V192, P75, DOI 10.1042/bj1920075; Prohl C, 2001, MOL CELL BIOL, V21, P1089, DOI 10.1128/MCB.21.4.1089-1097.2001; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SEITZ HJ, 1985, BIOCHEM J, V227, P149, DOI 10.1042/bj2270149; SOBOLL S, 1986, FEBS LETT, V205, P109, DOI 10.1016/0014-5793(86)80875-4; SULLIVAN TD, 1995, PLANTA, V196, P477, DOI 10.1007/BF00203647; WALKER JE, 1987, CHEM SCRIPTA, V27B, P97; WATANABE F, 1983, J BIOCHEM-TOKYO, V94, P493, DOI 10.1093/oxfordjournals.jbchem.a134380; Weber FE, 1997, P NATL ACAD SCI USA, V94, P8509, DOI 10.1073/pnas.94.16.8509; WOJTCZAK AB, 1987, INT J BIOCHEM, V19, P479, DOI 10.1016/0020-711X(87)90072-3; ZARA V, 1992, J BIOL CHEM, V267, P12077; [No title captured]	58	158	163	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30722	30730		10.1074/jbc.M400445200	http://dx.doi.org/10.1074/jbc.M400445200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123600	hybrid			2022-12-25	WOS:000222531900103
J	Sze, CI; Su, M; Pugazhenthi, S; Jambal, P; Hsu, LJ; Heath, J; Schultz, L; Chang, NS				Sze, CI; Su, M; Pugazhenthi, S; Jambal, P; Hsu, LJ; Heath, J; Schultz, L; Chang, NS			Down-regulation of WW domain-containing oxidoreductase induces Tau phosphorylation in vitro - A potential role in Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PAIRED HELICAL FILAMENTS; NEUROBLASTOMA CELL-LINE; TUMOR-SUPPRESSOR GENE; PROLYL ISOMERASE PIN1; N-TERMINAL KINASE; NEUROFIBRILLARY TANGLES; BINDING-PROTEIN; ESTROGEN; APOPTOSIS	Numerous enzymes hyperphosphorylate Tau in vivo, leading to the formation of neurofibrillary tangles (NFTs) in the neurons of Alzheimer's disease ( AD). Compared with age-matched normal controls, we demonstrated here that the protein levels of WW domain-containing oxidoreductase WOX1 ( also known as WWOX or FOR), its Tyr(33)-phosphorylated form, and WOX2 were significantly down-regulated in the neurons of AD hippocampi. Remarkably knock-down of WOX1 expression by small interfering RNA in neuroblastoma SK-N-SH cells spontaneously induced Tau phosphorylation at Thr(212)/Thr(231) and Ser(515)/Ser(516), enhanced phosphorylation of glycogen synthase kinase 3beta (GSK-3beta) and ERK, and enhanced NFT formation. Also an increased binding of phospho-GSK-3beta with phospho-Tau was observed in these WOX1 knock-down cells. In comparison, increased phosphorylation of Tau, GSK-3beta, and ERK, as well as NFT formation, was observed in the AD hippocampi. Activation of JNK1 by anisomycin further increased Tau phosphorylation, and SP600125 (a JNK inhibitor) and PD-98059 (an MEK1/2 inhibitor) blocked Tau phosphorylation and NFT formation in these WOX1 knock-down cells. Ectopic or endogenous WOX1 colocalized with Tau, JNK1, and GSK-3beta in neurons and cultured cells. 17beta-Estradiol, a neuronal protective hormone, increased the binding of WOX1 and GSK-3beta with Tau. Mapping analysis showed that WOX1 bound Tau via its COOH-terminal short-chain alcohol dehydrogenase/reductase domain. Together WOX1 binds Tau via its short-chain alcohol dehydrogenase/reductase domain and is likely to play a critical role in regulating Tau hyper-phosphorylation and NFT formation in vivo.	Guthrie Res Inst, Lab Mol Immunol, Sayre, PA 18840 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Chang, NS (corresponding author), Guthrie Res Inst, Lab Mol Immunol, Sayre, PA 18840 USA.	chang_nanshan@guthrie.org	Hsu, Li-Jin/G-7822-2011					Allen B, 2002, J NEUROSCI, V22, P9340; Ba F, 2004, NEUROCHEM INT, V44, P401, DOI 10.1016/j.neuint.2003.08.004; Bednarek AK, 2001, CANCER RES, V61, P8068; Belcredito S, 2001, BRAIN RES REV, V37, P335, DOI 10.1016/S0165-0173(01)00138-2; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bonnefort AB, 1998, FEBS LETT, V441, P220, DOI 10.1016/S0014-5793(98)01552-X; CASANOVA MF, 1993, PSYCHIAT RES, V49, P41, DOI 10.1016/0165-1781(93)90029-G; Chang NS, 2003, BIOCHEM PHARMACOL, V66, P1347, DOI 10.1016/S0006-2952(03)00484-2; Chang NS, 2003, J BIOL CHEM, V278, P9195, DOI 10.1074/jbc.M208373200; Chang NS, 2002, INT J MOL MED, V9, P19; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; Chen ST, 2004, NEUROSCIENCE, V124, P831, DOI 10.1016/j.neuroscience.2003.12.036; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7; Dou F, 2003, P NATL ACAD SCI USA, V100, P721, DOI 10.1073/pnas.242720499; Driouch K, 2002, ONCOGENE, V21, P1832, DOI 10.1038/sj.onc.1205273; Ferrer I, 2001, J NEURAL TRANSM, V108, P1397, DOI 10.1007/s007020100016; Fukutani Y, 2000, PSYCHIAT CLIN NEUROS, V54, P523, DOI 10.1046/j.1440-1819.2000.00747.x; Gamblin TC, 2003, BIOCHEMISTRY-US, V42, P2252, DOI 10.1021/bi0272510; Giannakopoulos P, 2003, NEUROLOGY, V60, P1495, DOI 10.1212/01.WNL.0000063311.58879.01; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; Greenfield JP, 2002, J BIOL CHEM, V277, P12128, DOI 10.1074/jbc.M110009200; Holzer M, 2002, ACTA NEUROPATHOL, V104, P471, DOI 10.1007/s00401-002-0581-1; Jellinger KA, 2001, J CELL MOL MED, V5, P1, DOI 10.1111/j.1582-4934.2001.tb00134.x; Kaytor MD, 2002, CURR OPIN NEUROBIOL, V12, P275, DOI 10.1016/S0959-4388(02)00320-3; Kitamura Y, 1997, BIOCHEM BIOPH RES CO, V232, P418, DOI 10.1006/bbrc.1997.6301; Ksiezak-Reding H, 2003, BBA-MOL BASIS DIS, V1639, P159, DOI 10.1016/j.bbadis.2003.09.001; LEW GM, 1993, GEN PHARMACOL, V24, P1383, DOI 10.1016/0306-3623(93)90423-U; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Liou YC, 2003, NATURE, V424, P556, DOI 10.1038/nature01832; Liu F, 2002, FEBS LETT, V530, P209, DOI 10.1016/S0014-5793(02)03487-7; Lu PJ, 1999, NATURE, V399, P784; MA ZQ, 1993, P NATL ACAD SCI USA, V90, P3740, DOI 10.1073/pnas.90.8.3740; Mailliot C, 2000, ANN NY ACAD SCI, V920, P107; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Morishima-Kawashima M, 2002, J NEUROSCI RES, V70, P392, DOI 10.1002/jnr.10355; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; Okazawa Hitohi, 2002, Am J Alzheimers Dis Other Demen, V17, P79, DOI 10.1177/153331750201700209; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; Pei JJ, 2001, J ALZHEIMERS DIS, V3, P41, DOI 10.3233/JAD-2001-3107; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Ramakrishnan P, 2003, NEUROBIOL DIS, V14, P251, DOI 10.1016/S0969-9961(03)00109-8; Reyna-Neyra A, 2002, BRAIN RES BULL, V58, P607, DOI 10.1016/S0361-9230(02)00829-8; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; Rohn TT, 2001, NEUROBIOL DIS, V8, P1006, DOI 10.1006/nbdi.2001.0449; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Shimura H, 2004, J BIOL CHEM, V279, P17957, DOI 10.1074/jbc.M400351200; Takayama N, 2002, NEUROPATHOLOGY, V22, P147, DOI 10.1046/j.1440-1789.2002.00433.x; Tandon A, 2003, J NEUROCHEM, V86, P572, DOI 10.1046/j.1471-4159.2003.01865.x; Tanemura K, 2001, NEUROBIOL DIS, V8, P1036, DOI 10.1006/nbdi.2001.0439; Tatebayashi Y, 2002, P NATL ACAD SCI USA, V99, P13896, DOI 10.1073/pnas.202205599; Watanabe A, 2003, CANCER RES, V63, P8629; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x	59	93	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30498	30506		10.1074/jbc.M401399200	http://dx.doi.org/10.1074/jbc.M401399200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15126504	hybrid			2022-12-25	WOS:000222531900078
J	Baxter, TK; Gagnon, SJ; Davis-Harrison, RL; Beck, JC; Binz, AK; Turner, RV; Biddison, WE; Baker, BM				Baxter, TK; Gagnon, SJ; Davis-Harrison, RL; Beck, JC; Binz, AK; Turner, RV; Biddison, WE; Baker, BM			Strategic mutations in the class I major histocompatibility complex HLA-A2 independently affect both peptide binding and T cell receptor recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ANTIGEN (HLA)-A2; CRYSTAL-STRUCTURES; STRUCTURAL BASIS; VIRAL PEPTIDES; VIRUS TYPE-1; TAX PEPTIDE; HTLV-1 TAX; ALPHA-BETA; IMMUNOGENICITY; MOLECULES	Mutational studies of T cell receptor (TCR) contact residues on the surface of the human class I major histocompatibility complex (MHC) molecule HLA-A2 have identified a "functional hot spot" that comprises Arg(65) and Lys(66) and is involved in recognition by most peptide-specific HLA-A2-restricted TCRs. Although there is a significant amount of functional data on the effects of mutations at these positions, there is comparatively little biochemical information that could illuminate their mode of action. Here, we have used a combination of fluorescence anisotropy, functional assays, and Biacore binding experiments to examine the effects of mutations at these positions on the peptide-MHC interaction and TCR recognition. The results indicate that mutations at both position 65 and position 66 influence peptide binding by HLA-A2 to various extents. In particular, mutations at position 66 result in significantly increased peptide dissociation rates. However, these effects are independent of their effects on TCR recognition, and the Arg(65)-Lys(66) region thus represents a true "hot spot" for TCR recognition. We also made the observation that in vitro T cell reactivity does not scale with the half-life of the peptide-MHC complex, as is often assumed. Finally, position 66 is implicated in the "dual recognition" of both peptide and TCR, emphasizing the multiple roles of the class I MHC peptide-binding domain.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Univ Notre Dame, Walther Canc Res Ctr, Notre Dame, IN 46556 USA; NINDS, Mol Immunol Sect, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA	University of Notre Dame; University of Notre Dame; Walther Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Baker, BM (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	bbaker2@nd.edu	Baker, Brian/B-4584-2009	Baker, Brian/0000-0002-0864-0964	NIGMS NIH HHS [GM067079] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002603] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson MW, 2003, J IMMUNOL, V171, P5683, DOI 10.4049/jimmunol.171.11.5683; Arden Bernhard, 1995, Immunogenetics, V42, P455; Baker BM, 2000, IMMUNITY, V13, P475, DOI 10.1016/S1074-7613(00)00047-9; Baker BM, 2001, J EXP MED, V193, P551, DOI 10.1084/jem.193.5.551; Bevington PR, 1992, DATA REDUCTION ERROR; Binz AK, 2003, BIOCHEMISTRY-US, V42, P4954, DOI 10.1021/bi034077m; Bouvier M, 1998, PROTEINS, V33, P97, DOI 10.1002/(SICI)1097-0134(19981001)33:1<97::AID-PROT9>3.0.CO;2-I; Bouvier M, 2003, MOL IMMUNOL, V39, P697, DOI 10.1016/S0161-5890(02)00261-4; Bouvier M, 1998, NAT STRUCT BIOL, V5, P377, DOI 10.1038/nsb0598-377; Buslepp J, 2003, IMMUNITY, V19, P595, DOI 10.1016/S1074-7613(03)00269-3; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; Eyring H, 1935, CHEM REV, V17, P65, DOI 10.1021/cr60056a006; FAHNESTOCK ML, 1992, SCIENCE, V258, P1658, DOI 10.1126/science.1360705; Gabdoulline RR, 2002, CURR OPIN STRUC BIOL, V12, P204, DOI 10.1016/S0959-440X(02)00311-1; Gagnon SJ, 2003, J IMMUNOL, V171, P2233, DOI 10.4049/jimmunol.171.5.2233; Gakamsky DM, 2000, BIOCHEMISTRY-US, V39, P11163, DOI 10.1021/bi000763z; Gakamsky DM, 1999, BIOCHEMISTRY-US, V38, P12165, DOI 10.1021/bi9905821; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Garboczi DN, 1996, J IMMUNOL, V157, P5403; Hausmann S, 1999, J IMMUNOL, V162, P5389; Hennecke J, 2001, CELL, V104, P1, DOI 10.1016/S0092-8674(01)00185-4; Hillig RC, 2001, J MOL BIOL, V310, P1167, DOI 10.1006/jmbi.2001.4816; Holler PD, 2001, J EXP MED, V194, P1043, DOI 10.1084/jem.194.8.1043; Hornell TMC, 1999, J IMMUNOL, V163, P3217; Huard R, 1997, INT IMMUNOL, V9, P1701, DOI 10.1093/intimm/9.11.1701; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; Khan AR, 2000, J IMMUNOL, V164, P6398, DOI 10.4049/jimmunol.164.12.6398; Kirksey TJ, 1999, J BIOL CHEM, V274, P37259, DOI 10.1074/jbc.274.52.37259; Krogsgaard M, 2003, MOL CELL, V12, P1367, DOI 10.1016/S1097-2765(03)00474-X; Kuhns JJ, 1999, J BIOL CHEM, V274, P36422, DOI 10.1074/jbc.274.51.36422; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Manning TC, 1998, IMMUNITY, V8, P413, DOI 10.1016/S1074-7613(00)80547-6; MATSUI M, 1994, HUM IMMUNOL, V41, P160, DOI 10.1016/0198-8859(94)90010-8; Morgan CS, 1997, PROTEIN SCI, V6, P1771, DOI 10.1002/pro.5560060819; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Robinson J, 2003, NUCLEIC ACIDS RES, V31, P311, DOI [10.1093/nar/gkg070, 10.1093/nar/GKG070]; Schlueter CJ, 1996, J IMMUNOL, V157, P4478; SETTE A, 1994, J IMMUNOL, V153, P5586; Sharma AK, 2001, J BIOL CHEM, V276, P21443, DOI 10.1074/jbc.M010791200; Sliz P, 2001, J IMMUNOL, V167, P3276, DOI 10.4049/jimmunol.167.6.3276; Springer S, 1998, BIOCHEMISTRY-US, V37, P3001, DOI 10.1021/bi9717441; Stewart-Jones GBE, 2003, NAT IMMUNOL, V4, P657, DOI 10.1038/ni942; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; Sykulev Y, 1995, P NATL ACAD SCI USA, V92, P11990, DOI 10.1073/pnas.92.26.11990; UTZ U, 1992, J IMMUNOL, V149, P214; Utz U, 1996, J VIROL, V70, P843, DOI 10.1128/JVI.70.2.843-851.1996; van der Merwe PA, 2001, IMMUNITY, V14, P665, DOI 10.1016/S1074-7613(01)00155-8; vanderBurg SH, 1996, J IMMUNOL, V156, P3308; Wang ZC, 2002, J IMMUNOL, V169, P3146, DOI 10.4049/jimmunol.169.6.3146; Wu LC, 2002, NATURE, V418, P552, DOI 10.1038/nature00920; Zhao R, 1999, J EXP MED, V189, P359, DOI 10.1084/jem.189.2.359	55	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29175	29184		10.1074/jbc.M403372200	http://dx.doi.org/10.1074/jbc.M403372200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15131131	hybrid			2022-12-25	WOS:000222445300044
J	Doering, CJ; Kisilevsky, AE; Feng, ZP; Arnot, MI; Peloquin, J; Hamid, J; Barr, W; Nirdosh, A; Simms, B; Winkfein, RJ; Zamponi, GW				Doering, CJ; Kisilevsky, AE; Feng, ZP; Arnot, MI; Peloquin, J; Hamid, J; Barr, W; Nirdosh, A; Simms, B; Winkfein, RJ; Zamponi, GW			A single G beta subunit locus controls cross-talk between protein kinase C and G protein regulation of N-type calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; GAMMA-SUBUNITS; SYNAPTIC-TRANSMISSION; DEPENDENT MODULATION; CRYSTAL-STRUCTURE; BINDING DOMAIN; INHIBITION; DETERMINANTS; NEURONS; SITES	The modulation of N-type calcium channels is a key factor in the control of neurotransmitter release. Whereas N-type channels are inhibited by Gbetagamma subunits in a G protein beta-isoform-dependent manner, channel activity is typically stimulated by activation of protein kinase C (PKC). In addition, there is cross-talk among these pathways, such that PKC-dependent phosphorylation of the Gbetagamma target site on the N-type channel antagonizes subsequent G protein inhibition, albeit only for Gbeta(1)-mediated responses. The molecular mechanisms that control this G protein beta subunit subtype-specific regulation have not been described. Here, we show that G protein inhibition of N-type calcium channels is critically dependent on two separate but adjacent similar to20-amino acid regions of the Gbeta subunit, plus a highly conserved Asn-Tyr-Val motif. These regions are distinct from those implicated previously in Gbetagamma signaling to other effectors such as G protein-coupled inward rectifier potassium channels, phospholipase beta(2), and adenylyl cyclase, thus raising the possibility that the specificity for G protein signaling to calcium channels might rely on unique G protein structural determinants. In addition, we identify a highly specific locus on the Gbeta(1) subunit that serves as a molecular detector of PKC-dependent phosphorylation of the G protein target site on the N-type channel alpha(1) subunit, thus providing for a molecular basis for G protein-PKC cross-talk. Overall, our results significantly advance our understanding of the molecular details underlying the integration of G protein and PKC signaling pathways at the level of the N-type calcium channel alpha(1) subunit.	Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary	Zamponi, GW (corresponding author), Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	Zamponi@ucalgary.ca		Zamponi, Gerald W./0000-0002-0644-9066				Agler HL, 2003, J GEN PHYSIOL, V121, P495, DOI 10.1085/jgp.200208770; Albsoul-Younes AM, 2001, J BIOL CHEM, V276, P12712, DOI 10.1074/jbc.M011231200; Arnot MI, 2000, J PHYSIOL-LONDON, V527, P203, DOI 10.1111/j.1469-7793.2000.00203.x; Barrett CF, 2000, J GEN PHYSIOL, V115, P277, DOI 10.1085/jgp.115.3.277; Buck E, 1999, SCIENCE, V283, P1332, DOI 10.1126/science.283.5406.1332; Chen YB, 1997, P NATL ACAD SCI USA, V94, P2711, DOI 10.1073/pnas.94.6.2711; Cooper CB, 2000, J BIOL CHEM, V275, P40777, DOI 10.1074/jbc.C000673200; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Feng ZP, 2001, J BIOL CHEM, V276, P45051, DOI 10.1074/jbc.M107784200; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Garcia DE, 1998, J NEUROSCI, V18, P9163; Hamid J, 1999, J BIOL CHEM, V274, P6195, DOI 10.1074/jbc.274.10.6195; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Mirshahi T, 2002, J BIOL CHEM, V277, P36345, DOI 10.1074/jbc.M205359200; Mirshahi T, 2002, J BIOL CHEM, V277, P7348, DOI 10.1074/jbc.M109999200; Page KM, 1997, J NEUROSCI, V17, P1330; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Ruiz-Velasco V, 2000, J NEUROSCI, V20, P2183; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; SWARTZ KJ, 1993, NEURON, V11, P305, DOI 10.1016/0896-6273(93)90186-U; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; Yan K, 1997, J BIOL CHEM, V272, P2056; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597; Zamponi GW, 2001, CELL BIOCHEM BIOPHYS, V34, P79, DOI 10.1385/CBB:34:1:79; ZAMPONI GW, 1997, NATURE, V385, P242	32	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29709	29717		10.1074/jbc.M308693200	http://dx.doi.org/10.1074/jbc.M308693200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15105422	hybrid			2022-12-25	WOS:000222445300107
J	Lopez-Rubio, JJ; Padmanabhan, S; Lazaro, JM; Salas, M; Murillo, FJ; Elias-Arnanz, M				Lopez-Rubio, JJ; Padmanabhan, S; Lazaro, JM; Salas, M; Murillo, FJ; Elias-Arnanz, M			Operator design and mechanism for CarA repressor-mediated down-regulation of the photoinducible carB operon in Myxococcus xanthus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-INDUCED CAROTENOGENESIS; OPEN-COMPLEX-FORMATION; MAJOR SIGMA-FACTOR; LAC UV5 PROMOTER; RNA-POLYMERASE; TRANSCRIPTION INITIATION; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; BLUE-LIGHT; CAROTENOID SYNTHESIS	The carB operon encodes all except one of the enzymes involved in light-induced carotenogenesis in Myxococcus xanthus. Expression of its promoter (P-B) is repressed in the dark by sequence-specific DNA binding of CarA to a palindrome (pI) located between positions - 47 and - 64 relative to the transcription start site. This promotes subsequent binding of CarA to additional sites that remain to be defined. CarS, produced in the light, interacts physically with CarA, abrogates CarA-DNA binding, and thereby derepresses P-B. In this study, we delineate the operator design that exists for CarA by precisely mapping out the second operator element. For this, we examined how stepwise deletions and site-directed mutagenesis in the region between the palindrome and the transcription start site affect CarA binding around P-B in vitro and expression of P-B in vivo. These revealed the second operator element to be an imperfect interrupted palindrome (pII) spanning positions - 26 to -40. In vitro assays using purified M. xanthus RNA polymerase showed that CarA abolishes P-B-RNA polymerase binding and runoff transcription and that both were restored by CarS, thus rationalizing the observations in vivo. CarA binding to pII ( after association with pI) effectively occludes RNA polymerase from P-B and so provides the operative mechanism for the repression of the carB operon by CarA. The bipartite operator design, whereby transcription is blocked by the low affinity CarA-pII binding and is readily restored by CarS, may have evolved to match the needs for a rapid and an effective response to light.	Univ Murcia, Fac Biol, Dept Genet & Microbiol, E-30071 Murcia, Spain; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	University of Murcia; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Murillo, FJ (corresponding author), Univ Murcia, Fac Biol, Dept Genet & Microbiol, E-30071 Murcia, Spain.	araujo@um.es; melias@um.es	Salas, Margarita/J-9873-2014; Padmanabhan, S./E-8943-2017; Elías-Arnanz, Montserrat/H-4707-2015; lopez-rubio, jose juan/A-4509-2014	Salas, Margarita/0000-0001-5939-3441; Elías-Arnanz, Montserrat/0000-0003-1980-3092; Padmanabhan, S./0000-0002-8772-0152; lopez-rubio, jose juan/0000-0002-0555-1122				BALSALOBRE JM, 1987, P NATL ACAD SCI USA, V84, P2359, DOI 10.1073/pnas.84.8.2359; BERTRANDBURGGRAF E, 1987, J MOL BIOL, V193, P293, DOI 10.1016/0022-2836(87)90220-8; Biran D, 1997, MOL MICROBIOL, V25, P463, DOI 10.1046/j.1365-2958.1997.4751843.x; BOTELLA JA, 1995, EUR J BIOCHEM, V233, P238, DOI 10.1111/j.1432-1033.1995.238_1.x; BRETSCHER AP, 1978, J BACTERIOL, V133, P763, DOI 10.1128/JB.133.2.763-768.1978; Browning DF, 2003, MOL MICROBIOL, V48, P237, DOI 10.1046/j.1365-2958.2003.03431.x; Camacho A, 2001, J BIOL CHEM, V276, P28927, DOI 10.1074/jbc.M103738200; Cayuela ML, 2003, J BACTERIOL, V185, P3527, DOI 10.1128/JB.185.12.3527-3537.2003; CHOY H, 1996, ESCHERICHIA COLI SAL, V1, P1287; CHOY HE, 1992, P NATL ACAD SCI USA, V89, P11264, DOI 10.1073/pnas.89.23.11264; Ciubotaru M, 2003, BIOCHEMISTRY-US, V42, P4253, DOI 10.1021/bi027318j; Courey AJ, 2001, CURR BIOL, V11, pR250, DOI 10.1016/S0960-9822(01)00130-0; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; Elias-Arnanz M, 1999, GENE DEV, V13, P2502, DOI 10.1101/gad.13.19.2502; Fontes M, 2003, MOL MICROBIOL, V47, P561, DOI 10.1046/j.1365-2958.2003.03319.x; FONTES M, 1993, EMBO J, V12, P1265, DOI 10.1002/j.1460-2075.1993.tb05771.x; Gorham HC, 1996, MOL MICROBIOL, V19, P171, DOI 10.1046/j.1365-2958.1996.360888.x; HAWLEY DK, 1985, J BIOL CHEM, V260, P8618; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hodgson D, 1993, MYXOBACTERIA, VII, P157; Huffman JL, 2002, CURR OPIN STRUC BIOL, V12, P98, DOI 10.1016/S0959-440X(02)00295-6; INOUYE S, 1990, J BACTERIOL, V172, P80, DOI 10.1128/JB.172.1.80-85.1990; Lee YS, 1997, J BIOL CHEM, V272, P83; Lloyd G, 2001, ESSAYS BIOCHEM, V37, P17, DOI 10.1042/bse0370017; Lopez-Rubio JJ, 2002, J BIOL CHEM, V277, P7262, DOI 10.1074/jbc.M110351200; Martinez-Argudo I, 1998, MOL MICROBIOL, V30, P883, DOI 10.1046/j.1365-2958.1998.01129.x; MARTINEZLABORDA A, 1989, GENETICS, V122, P801; MCGOWAN SJ, 1993, MOL MICROBIOL, V10, P713, DOI 10.1111/j.1365-2958.1993.tb00943.x; MECSAS J, 1991, J MOL BIOL, V220, P585, DOI 10.1016/0022-2836(91)90102-C; Monsalve M, 1996, EMBO J, V15, P383, DOI 10.1002/j.1460-2075.1996.tb00368.x; Moreno AJ, 2001, J BACTERIOL, V183, P557, DOI 10.1128/JB.183.2.557-569.2001; Muller-Hill B, 1998, MOL MICROBIOL, V29, P13, DOI 10.1046/j.1365-2958.1998.00870.x; NICOLAS FJ, 1994, GENE DEV, V8, P2375, DOI 10.1101/gad.8.19.2375; Nicolas FJ, 1996, P NATL ACAD SCI USA, V93, P6881, DOI 10.1073/pnas.93.14.6881; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; Padmanabhan S, 2001, J BIOL CHEM, V276, P41566, DOI 10.1074/jbc.M106352200; PEREZMARIN MC, 2004, J BIOL CHEM     0525; Ptashne M., 1986, A GENETIC SWITCH; ROJO F, 1991, EMBO J, V10, P3429, DOI 10.1002/j.1460-2075.1991.tb04907.x; Rojo F, 1999, J BACTERIOL, V181, P2987, DOI 10.1128/JB.181.10.2987-2991.1999; RUDD KE, 1982, J BACTERIOL, V151, P89, DOI 10.1128/JB.151.1.89-105.1982; RUIZVAZQUEZ R, 1993, MOL MICROBIOL, V10, P25, DOI 10.1111/j.1365-2958.1993.tb00900.x; RUIZVAZQUEZ R, 1984, J BACTERIOL, V160, P818; SAMBROOK J, 2000, MOL CLONING LAB MANU; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; SCHLAX PJ, 1995, J MOL BIOL, V245, P331, DOI 10.1006/jmbi.1994.0028; Smith TL, 1996, P NATL ACAD SCI USA, V93, P8868, DOI 10.1073/pnas.93.17.8868; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P2723, DOI 10.1021/bi00332a019; STRANEY SB, 1987, BIOCHEMISTRY-US, V26, P5063, DOI 10.1021/bi00390a027; SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992; WHIPPLE FW, 1992, J MOL BIOL, V223, P399, DOI 10.1016/0022-2836(92)90660-C; Whitworth DE, 2001, MOL MICROBIOL, V42, P809, DOI 10.1046/j.1365-2958.2001.02679.x; WILLIAMS DR, 1993, NUCLEIC ACIDS RES, V21, P1141, DOI 10.1093/nar/21.5.1141; Zeng XM, 1999, J BACTERIOL, V181, P1719, DOI 10.1128/JB.181.6.1719-1727.1999; Zeng XM, 2000, J BACTERIOL, V182, P1916, DOI 10.1128/JB.182.7.1916-1922.2000	55	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28945	28953		10.1074/jbc.M403459200	http://dx.doi.org/10.1074/jbc.M403459200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123730	hybrid			2022-12-25	WOS:000222445300016
J	Tani, M; Okino, N; Sueyoshi, N; Ito, M				Tani, M; Okino, N; Sueyoshi, N; Ito, M			Conserved amino acid residues in the COOH-terminal tail are indispensable for the correct folding and localization and enzyme activity of neutral ceramidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; PSEUDOMONAS-AERUGINOSA; MEDIATED DEGRADATION; ALKALINE CERAMIDASE; PROTEIN; GENE; PURIFICATION; SECRETION; SPHINGOSINE; APOPTOSIS	Several lines of evidence suggest that neutral ceramidase is involved in the regulation of ceramide-mediated signaling. Recently, the enzymes from mouse and rat were found to be localized at plasma membranes as a type II integral membrane protein, occasionally being detached from the cells after proteolytic processing of the NH2-terminal anchoring region (Tani, M., Iida, H., and Ito, M. (2003) J. Biol. Chem. 278, 10523-10530). We report here that conserved hydrophobic amino acid residues in the COOH-terminal tail are indispensable for the correct folding and localization, and enzyme activity of neutral ceramidase. Truncation of four, but not three, amino acid residues from the COOH terminus of rat neutral ceramidase resulted in a complete loss of enzyme activity as well as cell surface expression in HEK293 cells. Point mutation analysis revealed that Ile(758), the 4th amino acid residue from the COOH terminus, and Phe(756) are essential for the enzyme to function. The truncated and mutated enzymes were found to be retained in the endoplasmic reticulum (ER) and rapidly degraded without transportation to the Golgi apparatus. Treatment of the cells expressing the aberrant COOH-terminal enzyme with MG-132, a specific inhibitor for the proteasome, increased the accumulation of the enzyme in the ER, indicating that the misfolded enzyme was degraded by the proteasome. It was also found that the COOH-terminal tail was indispensable for the enzyme activity and correct folding of the prokaryote ceramidase from Pseudomonas aeruginosa, indicating that the importance of the COOH-terminal tail of the enzyme has been preserved through evolution.	Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, Fukuoka 8128581, Japan	Kyushu University	Ito, M (corresponding author), Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	makotoi@agr.kyushu-u.ac.jp	Okino, Nozomu/AAY-2635-2021; Ito, Makoto/Q-6164-2019	Tani, Motohiro/0000-0003-4316-8260; ito, Makoto/0000-0003-3159-7818				Acharya U, 2003, SCIENCE, V299, P1740, DOI 10.1126/science.1080549; BRODBECK RM, 1992, J BIOL CHEM, V267, P294; CRYSTAL RG, 1989, TRENDS GENET, V5, P411, DOI 10.1016/0168-9525(89)90200-X; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; Domowicz MS, 2000, J BIOL CHEM, V275, P35098, DOI 10.1074/jbc.275.45.35098; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Franzen R, 2002, J BIOL CHEM, V277, P46184, DOI 10.1074/jbc.M204034200; Franzen R, 2001, J BIOL CHEM, V276, P35382, DOI 10.1074/jbc.M102153200; GATT S, 1963, J BIOL CHEM, V238, P3131; ITO M, 2003, CERAMIDE SIGNALING, P41; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lydakis-Simantiris N, 1999, BIOCHEMISTRY-US, V38, P15528, DOI 10.1021/bi991599m; Maki CG, 1996, CANCER RES, V56, P2649; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; Okino N, 1998, J BIOL CHEM, V273, P14368, DOI 10.1074/jbc.273.23.14368; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Shimada Y, 1999, J BIOL CHEM, V274, P18536, DOI 10.1074/jbc.274.26.18536; Spiegel S, 2002, LEUKEMIA, V16, P1596, DOI 10.1038/sj.leu.2402611; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Tani M, 2003, J BIOL CHEM, V278, P10523, DOI 10.1074/jbc.M207932200; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462; Tani M, 1998, ANAL BIOCHEM, V263, P183, DOI 10.1006/abio.1998.2781; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; Yoshimura Y, 2002, J BIOCHEM, V132, P229, DOI 10.1093/oxfordjournals.jbchem.a003215; Zhang ZJ, 2000, MOL GENET METAB, V70, P301, DOI 10.1006/mgme.2000.3029	30	8	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29351	29358		10.1074/jbc.M404012200	http://dx.doi.org/10.1074/jbc.M404012200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123644	hybrid			2022-12-25	WOS:000222445300066
J	Chan, SL; Fu, WM; Zhang, PS; Cheng, AW; Lee, JW; Kokame, K; Mattson, MP				Chan, SL; Fu, WM; Zhang, PS; Cheng, AW; Lee, JW; Kokame, K; Mattson, MP			Herp stabilizes neuronal Ca2+ homeostasis and mitochondrial function during endoplasmic reticulum stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; AMYLOID PRECURSOR PROTEIN; N-TERMINAL KINASE; INDUCED APOPTOSIS; CELL-DEATH; CALCIUM; ACTIVATION; CASPASE-12; ER; MODULATION	In response to endoplasmic reticulum ( ER) stress, cells launch homeostatic and protective responses, but can also activate cell death cascades. A 54 kDa integral ER membrane protein called Herp was identified as a stress-responsive protein in non-neuronal cells. We report that Herp is present in neurons in the developing and adult brain, and that it is regulated in neurons by ER stress; sublethal levels of ER stress increase Herp levels, whereas higher doses decrease Herp levels and induce apoptosis. The decrease in Herp protein levels following a lethal ER stress occurs prior to mitochondrial dysfunction and cell death, and is mediated by caspases which generate a 30-kDa proteolytic Herp fragment. Mutagenesis of the caspase cleavage site in Herp enhances its neuroprotective function during ER stress. While suppression of Herp induction by RNA interference sensitizes neural cells to apoptosis induced by ER stress, overexpression of Herp promotes survival by a mechanism involving stabilization of ER Ca2+ levels, preservation of mitochondrial function and suppression of caspase 3 activation. ER stress-induced activation of JNK/c-Jun and caspase 12 are reduced by Herp, whereas induction of major ER chaperones is unaffected. Herp prevents ER Ca2+ overload under conditions of ER stress and agonist-induced ER Ca2+ release is attenuated by Herp suggesting a role for Herp in regulating neuronal Ca2+ signaling. By stabilizing ER Ca2+ homeostasis and mitochondrial functions, Herp serves a neuroprotective function under conditions of ER stress.	NIA, Neurosci Lab, Gerontol Res Ctr, Intramural Res Program, Baltimore, MD 21224 USA; Natl Cardiovasc Res Inst, Osaka 5658565, Japan; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Cerebral & Cardiovascular Center - Japan; Johns Hopkins University	Chan, SL (corresponding author), NIA, Neurosci Lab, Gerontol Res Ctr, Intramural Res Program, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	chanst@grc.nia.nih.gov	Mattson, Mark P/F-6038-2012; Lee, Jaewon/N-9064-2013	Lee, Jaewon/0000-0003-3203-2130; Kokame, Koichi/0000-0002-9654-6299	NATIONAL INSTITUTE ON AGING [Z01AG000312, ZIAAG000313, ZIAAG000314, Z01AG000313, Z01AG000314, ZIAAG000312] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahn W, 2003, J BIOL CHEM, V278, P20795, DOI 10.1074/jbc.M301638200; Arnaudeau S, 2002, J BIOL CHEM, V277, P46696, DOI 10.1074/jbc.M202395200; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Berridge MJ, 2001, NOVART FDN SYMP, V239, P52; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Chan SL, 2000, J BIOL CHEM, V275, P18195, DOI 10.1074/jbc.M000040200; Duchen MR, 2000, CELL CALCIUM, V28, P339, DOI 10.1054/ceca.2000.0170; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Guo Q, 1997, J NEUROSCI, V17, P4212; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Inanami O, 1999, ANTIOXID REDOX SIGN, V1, P501, DOI 10.1089/ars.1999.1.4-501; Kahns S, 2002, J BIOL CHEM, V277, P15303, DOI 10.1074/jbc.M111534200; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kitao Y, 2004, J NEUROSCI, V24, P1486, DOI 10.1523/JNEUROSCI.4029-03.2004; Kokame K, 2000, J BIOL CHEM, V275, P32846, DOI 10.1074/jbc.M002063200; Kouroku Y, 2002, HUM MOL GENET, V11, P1505, DOI 10.1093/hmg/11.13.1505; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Larsen AH, 2001, BMC BIOCHEM, V2; Lee B, 2001, ENDOCRINOLOGY, V142, P1744, DOI 10.1210/en.142.5.1744; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; Ma TS, 1999, CELL CALCIUM, V26, P25, DOI 10.1054/ceca.1999.0049; Mackrill JJ, 1998, BIOCHEM BIOPH RES CO, V245, P428, DOI 10.1006/bbrc.1998.8450; MATTSON MP, 1995, METHOD CELL BIOL, V46, P187; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Putney JW, 2001, J CELL SCI, V114, P2223; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Roth W, 2003, CELL DEATH DIFFER, V10, P1178, DOI 10.1038/sj.cdd.4401287; Ryu EJ, 2002, J NEUROSCI, V22, P10690; Sai X, 2002, J BIOL CHEM, V277, P12915, DOI 10.1074/jbc.M112372200; Sakata E, 2003, EMBO REP, V4, P301, DOI 10.1038/sj.embor.embor764; Savage MJ, 2002, J NEUROSCI, V22, P3376; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Troy CM, 2001, J NEUROCHEM, V77, P157, DOI 10.1046/j.1471-4159.2001.00218.x; Upadhya SC, 2003, TRENDS BIOCHEM SCI, V28, P280, DOI 10.1016/S0968-0004(03)00092-6; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Vanden Abeele F, 2002, CANCER CELL, V1, P169; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	59	102	107	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28733	28743		10.1074/jbc.M404272200	http://dx.doi.org/10.1074/jbc.M404272200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102845	hybrid			2022-12-25	WOS:000222265400111
J	Gruber, A; Mancek, M; Wagner, H; Kirschning, CJ; Jerala, R				Gruber, A; Mancek, M; Wagner, H; Kirschning, CJ; Jerala, R			Structural model of MD-2 and functional role of its basic amino acid clusters involved in cellular lipopolysaccharide recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; DUST-MITE ALLERGEN; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; GM2-ACTIVATOR PROTEIN; TERTIARY STRUCTURE; INNATE IMMUNITY; DISULFIDE BONDS; RESPONSIVENESS; COMPLEX	The receptor complex resulting from association of MD-2 and the ectodomain of Toll-like receptor 4 (TLR4) mediates lipopolysaccharide (LPS) signal transduction across the cell membrane. We prepared a tertiary structure model of MD-2, based on the known structures of homologous lipid-binding proteins. Analysis of circular dichroic spectra of purified bacterially expressed MD-2 indicates high content of beta-type secondary structure, in agreement with the structural model. Bacterially expressed MD-2 was able to confer LPS responsiveness to cells expressing TLR4 despite lacking glycosylation. We identified several clusters of basic residues on the surface of MD-2. Mutation of each of two clusters encompassing the residues Lys(89)-Arg(90)-Lys(91) and Lys(125)-Lys(125) significantly decreased the signal transduction of the respective MD-2 mutants either upon co-expression with TLR4 or upon addition as soluble protein into the supernatant of cells overexpressing TLR4. These basic clusters lie at the edge of the beta-sheet sandwich, which in cholesterol-binding protein connected to Niemann-Pick disease C2 (NPC2), dust mite allergen Der p2, and ganglioside GM2-activator protein form a hydrophobic pocket. In contrast, mutation of another basic cluster composed of Arg(69)-Lys(72), which according to the model lies further apart from the hydrophobic pocket only weakly decreased MD-2 activity. Furthermore, addition of the peptide, comprising the surface loop between Cys(95) and Cys(105), predicted by model, particularly in oxidized form, decreased LPS-induced production of tumor necrosis factor alpha and interleukin-8 upon application to monocytic cells and fibroblasts, respectively, supporting its involvement in LPS signaling. Our structural model of MD-2 is corroborated by biochemical analysis and contributes to the unraveling of molecular interactions in LPS recognition.	Natl Inst Chem, Biotechnol Lab, Ljubljana 1000, Slovenia; Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany	National Institute of Chemistry - Slovenia; Technical University of Munich	Jerala, R (corresponding author), Natl Inst Chem, Biotechnol Lab, Ljubljana 1000, Slovenia.	roman.jerala@ki.si	Jerala, Roman/H-9850-2015	Jerala, Roman/0000-0002-6337-5251				Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andreeva A, 2004, NUCLEIC ACIDS RES, V32, pD226, DOI 10.1093/nar/gkh039; DASILVA CJ, 2002, J BIOL CHEM, V277, P1845, DOI [DOI 10.1074/JBC.M109910200, 10.1074/jbc.M109910200]; Derewenda U, 2002, J MOL BIOL, V318, P189, DOI 10.1016/S0022-2836(02)00027-X; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Ferguson AD, 2000, STRUCTURE, V8, P585; Fiser A, 2003, BIOINFORMATICS, V19, P2500, DOI 10.1093/bioinformatics/btg362; Frecer V, 2000, EUR J BIOCHEM, V267, P837, DOI 10.1046/j.1432-1327.2000.01069.x; Friedland N, 2003, P NATL ACAD SCI USA, V100, P2512, DOI 10.1073/pnas.0437840100; Ginalski K, 2003, PROTEINS, V53, P410, DOI 10.1002/prot.10548; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Guyard-Dangremont V, 1999, PROTEIN SCI, V8, P2392; Inohara N, 2002, TRENDS BIOCHEM SCI, V27, P219, DOI 10.1016/S0968-0004(02)02084-4; Kawasaki K, 2003, J IMMUNOL, V170, P413, DOI 10.4049/jimmunol.170.1.413; Kawasaki K, 2000, J BIOL CHEM, V275, P2251, DOI 10.1074/jbc.275.4.2251; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; Lee HK, 2004, J BIOL CHEM, V279, P10564, DOI 10.1074/jbc.M311564200; Mancek M, 2002, BIOCHEM BIOPH RES CO, V292, P880, DOI 10.1006/bbrc.2002.6748; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Meng GX, 2003, J BIOL CHEM, V278, P39822, DOI 10.1074/jbc.M304766200; Mueller GA, 1998, BIOCHEMISTRY-US, V37, P12707, DOI 10.1021/bi980578+; Mullen GED, 2003, P NATL ACAD SCI USA, V100, P3919, DOI 10.1073/pnas.0630495100; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Ohnishi T, 2003, CLIN DIAGN LAB IMMUN, V10, P405, DOI 10.1128/CDLI.10.3.405-410.2003; Ohnishi T, 2001, J IMMUNOL, V167, P3354, DOI 10.4049/jimmunol.167.6.3354; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pristovsek P, 1999, J MED CHEM, V42, P4604, DOI 10.1021/jm991031b; Re F, 2003, J IMMUNOL, V171, P5272, DOI 10.4049/jimmunol.171.10.5272; Re F, 2002, J BIOL CHEM, V277, P23427, DOI 10.1074/jbc.M202554200; Rost B, 2003, NUCLEIC ACIDS RES, V31, P3300, DOI 10.1093/nar/gkg508; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Schubert WD, 2001, J MOL BIOL, V312, P783, DOI 10.1006/jmbi.2001.4989; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THANNHAUSER TW, 1984, ANAL BIOCHEM, V138, P181, DOI 10.1016/0003-2697(84)90786-3; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; Visintin A, 2001, P NATL ACAD SCI USA, V98, P12156, DOI 10.1073/pnas.211445098; Wright CS, 2003, J MOL BIOL, V331, P951, DOI 10.1016/S0022-2836(03)00794-0; Wright CS, 2000, J MOL BIOL, V304, P411, DOI 10.1006/jmbi.2000.4225; ZHANG KYJ, 1994, PROTEIN SCI, V3, P687	47	108	114	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28475	28482		10.1074/jbc.M400993200	http://dx.doi.org/10.1074/jbc.M400993200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15111623	hybrid			2022-12-25	WOS:000222265400082
J	Ingham, KC; Brew, SA; Erickson, HP				Ingham, KC; Brew, SA; Erickson, HP			Localization of a cryptic binding site for tenascin on fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK MYOTENDINOUS ANTIGEN; HUMAN-PLASMA FIBRONECTIN; CELL-ADHESION; EXTRACELLULAR-MATRIX; DOMAINS; PROTEIN	Fibronectin and tenascin are large extracellular matrix proteins that interact with each other and with integrin receptors to regulate cell growth and movement. They are both modular proteins composed of independently folded domains ( modules) that are arranged in linear fashion. Fibronectin is a covalent dimer and tenascin is a hexamer. The site on tenascin to which fibronectin binds has been localized to type III modules 3 - 5. In this study we use surface plasmon resonance to examine the interaction between various fragments of fibronectin and tenascin to further characterize and localize the binding sites. We found that tenascin fragments that contain type III modules 3 - 5 bind primarily to the N-terminal 29-kDa hep-1/fib-1 domain, which contains the first five type I modules of fibronectin. The dissociation constant, K-d, is approximate to 1 muM. The binding site on fibronectin appears to be cryptic in the whole molecule in solution but is exposed on the proteolytic fragments and probably when fibronectin is in the extended conformation.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Amer Red Cross, Holland Lab, Dept Biochem, Rockville, MD 20896 USA	Duke University; American Red Cross	Erickson, HP (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709, Durham, NC 27710 USA.	h.erickson@cellbio.duke.edu			NATIONAL CANCER INSTITUTE [R37CA047056, R01CA047056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021791] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47056] Funding Source: Medline; NHLBI NIH HHS [HL 21791] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHIQUET M, 1984, J CELL BIOL, V98, P1937, DOI 10.1083/jcb.98.6.1937; CHIQUET M, 1984, J CELL BIOL, V98, P1926, DOI 10.1083/jcb.98.6.1926; CHIQUETEHRISMANN R, 1988, CELL, V53, P383, DOI 10.1016/0092-8674(88)90158-4; CHUNG CY, 1995, J BIOL CHEM, V270, P29012, DOI 10.1074/jbc.270.48.29012; Chung CY, 1997, J CELL SCI, V110, P1413; Fischer D, 1997, J CELL SCI, V110, P1513; Huang WT, 2001, CANCER RES, V61, P8586; Ingham KC, 1997, J BIOL CHEM, V272, P1718, DOI 10.1074/jbc.272.3.1718; INGHAM KC, 1984, J BIOL CHEM, V259, P1901; INGHAM KC, 1990, BIOCHEM J, V272, P605, DOI 10.1042/bj2720605; Johnson KJ, 1999, J BIOL CHEM, V274, P15473, DOI 10.1074/jbc.274.22.15473; LIGHTNER VA, 1990, ANN NY ACAD SCI, V580, P260, DOI 10.1111/j.1749-6632.1990.tb17935.x; LIGHTNER VA, 1990, J CELL SCI, V95, P263; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; NARASIMHAN C, 1989, BIOCHEMISTRY-US, V28, P5041, DOI 10.1021/bi00438a021; Ohashi T, 1999, P NATL ACAD SCI USA, V96, P2153, DOI 10.1073/pnas.96.5.2153; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; RIOU JF, 1990, DEV BIOL, V137, P305, DOI 10.1016/0012-1606(90)90256-I; ROCCO M, 1983, J BIOL CHEM, V258, P4545; UGAROVA TP, 1995, BIOCHEMISTRY-US, V34, P4457, DOI 10.1021/bi00013a039; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	21	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28132	28135		10.1074/jbc.M312785200	http://dx.doi.org/10.1074/jbc.M312785200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123658	hybrid			2022-12-25	WOS:000222265400039
J	Laliberte, J; Whitson, LJ; Beaudoin, J; Holloway, SP; Hart, PJ; Labbe, S				Laliberte, J; Whitson, LJ; Beaudoin, J; Holloway, SP; Hart, PJ; Labbe, S			The Schizosaccharomyces pombe Pccs protein functions in both copper trafficking and metal detoxification pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE-DISMUTASE; IRON UPTAKE; FISSION YEAST; TRANSCRIPTION FACTOR; MUTATIONAL ANALYSIS; PHYSIOLOGICAL-ROLE; HETEROLOGOUS PROTEINS; METALLOTHIONEIN GENE	Because copper is both an essential cofactor and a toxic metal, different strategies have evolved to appropriately regulate its homeostasis as a function of changing environmental copper levels. In this report, we describe a metallochaperone-like protein from Schizosaccharomyces pombe that maintains the delicate balance between essentiality and toxicity. This protein, designated Pccs, has four distinct domains. SOD activity assays reveal that the first three domains of Pccs are necessary and sufficient to deliver copper to its target, copper-zinc superoxide dismutase (SOD1). Pccs domain IV, which is absent in Saccharomyces cerevisiae CCS1, contains seventeen cysteine residues, eight pairs of which are in a potential metal coordination arrangement, Cys-Cys. We show that S. cerevisiae ace1Delta mutant cells expressing the full-length Pccs molecule are resistant to copper toxicity. Furthermore, we demonstrate that the Pccs domain IV enhances copper resistance of the ace1Delta cells by an order of magnitude compared with that observed in the same strain expressing a pccs(+)I-II-III allele encoding Pccs domains I-III. We consistently found that S. pombe cells disrupted in the pccs(+) gene exhibit an increased sensitivity to copper and cadmium. Furthermore, we demonstrate that overexpression of pccs(+) is associated with increased copper resistance in fission yeast cells. Taken together, our findings suggest that Pccs activates apo-SOD1 under copper-limiting conditions through the use of its first three domains and protects cells against metal ion toxicity via its fourth domain.	Univ Sherbrooke, Fac Med, Dept Biochim, Sherbrooke, PQ J1H 5N4, Canada; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Xray Crystallog Core Lab, San Antonio, TX 78229 USA	University of Sherbrooke; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Labbe, S (corresponding author), Univ Sherbrooke, Fac Med, Dept Biochim, 3001 12E Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	Simon.Labbe@USherbrooke.ca		Labbe, Simon/0000-0002-4947-523X	NINDS NIH HHS [R01 NS039112] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039112] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALFA C, 1993, EXPT FISSION YEASTS; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Beaudoin J, 2003, J BIOL CHEM, V278, P14565, DOI 10.1074/jbc.M300861200; Beaudoin J, 2001, J BIOL CHEM, V276, P15472, DOI 10.1074/jbc.M011256200; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Bellemare DR, 2002, J BIOL CHEM, V277, P46676, DOI 10.1074/jbc.M206444200; Bellemare DR, 2001, GENE, V273, P191, DOI 10.1016/S0378-1119(01)00591-1; Bezanilla M, 1997, MOL BIOL CELL, V8, P2693, DOI 10.1091/mbc.8.12.2693; Borrelly GPM, 2002, J BIOL CHEM, V277, P30394, DOI 10.1074/jbc.M203145200; BUTLER G, 1991, MOL CELL BIOL, V11, P476, DOI 10.1128/MCB.11.1.476; BUTT TR, 1984, P NATL ACAD SCI-BIOL, V81, P3332, DOI 10.1073/pnas.81.11.3332; CHANG EC, 1991, J BIOL CHEM, V266, P4417; COTTAREL G, 1993, CURR GENET, V23, P547, DOI 10.1007/BF00312650; Crapo J D, 1978, Methods Enzymol, V53, P382; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; CULOTTA VC, 1994, J BIOL CHEM, V269, P25295; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; Cyrne L, 2003, FREE RADICAL BIO MED, V34, P385, DOI 10.1016/S0891-5849(02)01300-X; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Field LS, 2003, J BIOL CHEM, V278, P28052, DOI 10.1074/jbc.M304296200; Field LS, 2002, J BIOENERG BIOMEMBR, V34, P373, DOI 10.1023/A:1021202119942; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; Forsburg SL, 1997, GENETICS, V147, P1025; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; GRALLA EB, 1991, P NATL ACAD SCI USA, V88, P8558, DOI 10.1073/pnas.88.19.8558; Ha SB, 1999, PLANT CELL, V11, P1153, DOI 10.1105/tpc.11.6.1153; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HAMER DH, 1985, SCIENCE, V228, P685, DOI 10.1126/science.3887570; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Kim J, 1998, GENETICS, V149, P795; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Koch KA, 1997, CHEM BIOL, V4, P549, DOI 10.1016/S1074-5521(97)90241-6; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Labbe Simon, 2002, P571; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P14720, DOI 10.1021/bi002207a; Lee J, 2002, BIOCHEM BIOPH RES CO, V297, P854, DOI 10.1016/S0006-291X(02)02290-8; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Luk E, 2003, J BIOL INORG CHEM, V8, P803, DOI 10.1007/s00775-003-0482-3; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; Maxfield AB, 2004, J BIOL CHEM, V279, P5072, DOI 10.1074/jbc.M311772200; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Mutoh N, 2002, CURR GENET, V41, P82, DOI 10.1007/s00294-002-0288-9; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Philpott CC, 2002, BIOCHEM SOC T, V30, P698, DOI 10.1042/bst0300698; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Punter FA, 2003, J BIOL CHEM, V278, P30875, DOI 10.1074/jbc.M302358200; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rentzsch A, 1999, CURR GENET, V35, P103, DOI 10.1007/s002940050438; SAINTJACQUES E, 1993, DNA CELL BIOL, V12, P329, DOI 10.1089/dna.1993.12.329; Schmidt PJ, 2000, J BIOL CHEM, V275, P33771, DOI 10.1074/jbc.M006254200; Schmidt PJ, 1999, J BIOL CHEM, V274, P36952, DOI 10.1074/jbc.274.52.36952; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; SIKORSKI RS, 1989, GENETICS, V122, P19; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Sturtz LA, 2002, METHOD ENZYMOL, V349, P167, DOI 10.1016/S0076-6879(02)49332-9; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zhou H, 2001, J BIOL CHEM, V276, P20529, DOI 10.1074/jbc.M102004200; Zhu HN, 2000, BIOCHEMISTRY-US, V39, P5413, DOI 10.1021/bi992727+	89	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28744	28755		10.1074/jbc.M403426200	http://dx.doi.org/10.1074/jbc.M403426200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15107426	hybrid			2022-12-25	WOS:000222265400112
J	Lewitzky, M; Harkiolaki, M; Domart, MC; Jones, EY; Feller, SM				Lewitzky, M; Harkiolaki, M; Domart, MC; Jones, EY; Feller, SM			Mona/Gads SH3C binding to hematopoietic progenitor kinase 1 (HPK1) combines an atypical SH3 binding motif, R/KXXK, with a classical PXXP motif embedded in a polyproline type II (PPII) helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC PROGENITOR KINASE-1; N-TERMINAL KINASE; CASPASE-MEDIATED CLEAVAGE; SRC HOMOLOGY 3; ADAPTER PROTEINS; SIGNAL-TRANSDUCTION; STRUCTURAL BASIS; KAPPA-B; DOMAIN; ACTIVATION	Hematopoietic progenitor kinase 1 (HPK1) is implicated in signaling downstream of the T cell receptor. Its non-catalytic, C-terminal half contains several proline-rich motifs, which have been shown to interact with different SH3 domain-containing adaptor proteins in vitro. One of these, Mona/Gads, was also shown to bind HPK1 in mouse T cells in vivo. The region of HPK1 that binds to the Mona/Gads C-terminal SH3 domain has been mapped and shows only very limited similarity to a recently identified high affinity binding motif in SLP-76, another T-cell adaptor. Using isothermal titration calorimetry and x-ray crystallography, the binding of the HPK1 motif to Mona/Gads SH3C has now been characterized in molecular detail. The results indicate that although charge interactions through an RXXK motif are essential for complex formation, a PXXP motif in HPK1 strongly complements binding. This unexpected binding mode therefore differs considerably from the previously described interaction of Mona/Gads SH3C with SLP-76. The crystal structure of the complex highlights the great versatility of SH3 domains, which allows interactions with very different proteins. This currently limits our ability to categorize SH3 binding properties by simple rules.	Univ Oxford, Weatherall Inst Mol Med, Mol Oncol Lab, Canc Res UK Cell Signalling Grp, Oxford OX3 9DS, England; Univ Burgundy, UFR Sci Vie, F-21000 Dijon, France; Canc Res UK Receptor Struct Grp, Oxford OX3 7BN, England	Cancer Research UK; University of Oxford; Universite de Bourgogne; Cancer Research UK	Feller, SM (corresponding author), John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England.	stephan.feller@cancer.org.uk	Jones, Yvonne/N-8111-2019; Jones, Yvonne/J-2293-2016	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Domart, Marie-Charlotte/0000-0002-5703-2922				Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Arnold R, 2001, J BIOL CHEM, V276, P14675, DOI 10.1074/jbc.M008343200; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Chen YR, 1999, ONCOGENE, V18, P7370, DOI 10.1038/sj.onc.1203116; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Ensenat D, 1999, J BIOL CHEM, V274, P33945, DOI 10.1074/jbc.274.48.33945; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Han J, 2003, J BIOL CHEM, V278, P52195, DOI 10.1074/jbc.M305026200; Harkiolaki M, 2003, EMBO J, V22, P2571, DOI 10.1093/emboj/cdg258; Hu MCT, 1999, ONCOGENE, V18, P5514, DOI 10.1038/sj.onc.1202740; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kami K, 2002, EMBO J, V21, P4268, DOI 10.1093/emboj/cdf428; Kaneko T, 2003, J BIOL CHEM, V278, P48162, DOI 10.1074/jbc.M306677200; Kiefer F, 2002, TRANSPL IMMUNOL, V9, P69, DOI 10.1016/S0966-3274(02)00009-6; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Ling P, 1999, MOL CELL BIOL, V19, P1359; Liou J, 2000, IMMUNITY, V12, P399, DOI 10.1016/S1074-7613(00)80192-2; Liu Q, 2003, MOL CELL, V11, P471, DOI 10.1016/S1097-2765(03)00046-7; Liu SK, 2000, J IMMUNOL, V165, P1417, DOI 10.4049/jimmunol.165.3.1417; Ma WB, 2001, ONCOGENE, V20, P1703, DOI 10.1038/sj.onc.1204224; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagata Y, 1999, BLOOD, V93, P3347, DOI 10.1182/blood.V93.10.3347.410k06_3347_3354; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Sauer K, 2001, J BIOL CHEM, V276, P45207, DOI 10.1074/jbc.M106811200; Sawasdikosol S, 2003, BLOOD, V101, P3687, DOI 10.1182/blood-2002-07-2316; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Tsuji S, 2001, J EXP MED, V194, P529, DOI 10.1084/jem.194.4.529; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Zamora-Leon SP, 2001, J BIOL CHEM, V276, P39950, DOI 10.1074/jbc.M107807200; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	35	51	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28724	28732		10.1074/jbc.M402745200	http://dx.doi.org/10.1074/jbc.M402745200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15100220	hybrid			2022-12-25	WOS:000222265400110
J	Vindis, C; Teli, T; Cerretti, DP; Turner, CE; Huynh-Do, U				Vindis, C; Teli, T; Cerretti, DP; Turner, CE; Huynh-Do, U			EphB1-mediated cell migration requires the phosphorylation of paxillin at Tyr-31/Tyr-118	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPH RECEPTORS; LD4 MOTIF; ADHESION; KINASE; ACTIVATION; CRK	Interactions between Eph receptors and their membrane-bound ligands (ephrins) are of critical importance for key developmental processes such as boundary formation or vascular development. Their downstream signaling pathways are intricate and heterogeneous at several levels, the combined effect being a highly complex and flexible system. Here we demonstrate that activated EphB1 induces tyrosine phosphorylation of the focal adhesion protein paxillin at Tyr-31 and Tyr-118 and is recruited to paxillin-focal adhesion kinase (FAK) complexes. Pretreatment with the specific Src inhibitor PP2, or expression of dominant-negative, kinase-dead c-Src abrogates EphB1-induced tyrosine phosphorylation of paxillin. Cells transfected with the paxillin mutant Y31F/Y118F displayed a reduced migration in response to ephrin B2 stimulation. Furthermore, expression of an LD4 deletion mutant ( paxillin DeltaLD4) significantly reduces EphB1-paxillin association, paxillin tyrosine phosphorylation, as well as EphB1-dependent cell migration. Finally, mutation of the Nck-binding site of EphB1 (Y594F) interrupts the interaction between Nck, paxillin, and EphB1. These data suggest a model in which ligand-activated EphB1 forms a signaling complex with Nck, paxillin, and focal adhesion kinase and induces tyrosine phosphorylation of paxillin in a c-Src-dependent manner to promote cell migration.	Univ Bern, Dept Clin Res, Div Nephrol, CH-3010 Bern, Switzerland; Amgen Corp, Seattle, WA 98101 USA; SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	University of Bern; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Huynh-Do, U (corresponding author), Univ Bern, Dept Clin Res, Div Nephrol, CH-3010 Bern, Switzerland.	uyen.huynh-do@insel.ch	Vindis, Cécile/AAH-2708-2019	Vindis, Cécile/0000-0003-2421-1155	NIGMS NIH HHS [GM 47607, R01 GM047607] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047607, R29GM047607] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Carter N, 2002, NAT CELL BIOL, V4, P565, DOI 10.1038/ncb823; Contractor A, 2002, SCIENCE, V296, P1864, DOI 10.1126/science.1069081; Davy A, 2000, EMBO J, V19, P5396, DOI 10.1093/emboj/19.20.5396; Han DC, 2002, J BIOL CHEM, V277, P45655, DOI 10.1074/jbc.M203165200; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Mellitzer G, 2000, CURR OPIN NEUROBIOL, V10, P400, DOI 10.1016/S0959-4388(00)00095-7; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Vindis C, 2003, J CELL BIOL, V162, P661, DOI 10.1083/jcb.200302073; West KA, 2001, J CELL BIOL, V154, P161, DOI 10.1083/jcb.200101039; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076	18	58	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27965	27970		10.1074/jbc.M401295200	http://dx.doi.org/10.1074/jbc.M401295200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15107421	hybrid			2022-12-25	WOS:000222265400018
J	Ray, SS; Swanson, HI				Ray, SS; Swanson, HI			Dioxin-induced immortalization of normal human keratinocytes and silencing of p53 and p16(INK4a)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; AH RECEPTOR; CELLULAR SENESCENCE; DNA METHYLATION; GENE-REGULATION; CANCER; DEGRADATION; PROMOTER; CELLS; DIFFERENTIATION	Dioxin, a potent tumor promoter, activates the aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor belonging to the basic helix-loop-helix-PAS family, to enhance tumorigenesis via unknown mechanisms. We undertook this study to determine the mechanisms underlying the impact of dioxin on cell fate, in particular senescence that occurs in normal human cells and is considered to play important tumor suppressive function. We have previously shown that in primary human keratinocytes, dioxin attenuates senescence while retaining the proliferative capacity and represses expression of the tumor suppressors, p16(INK4a) and p53. Here, we show that repression of p16(INK4a) and p53 transcriptional activity by dioxin absolutely requires the AHR and is accompanied by promoter methylation. Furthermore, dioxin alone is sufficient to immortalize normal human keratinocytes. Our data introduce a previously unrecognized regulatory pathway, that of the AHR, that impacts senescence. More importantly, this is the first report of a tumor promoter capable of inhibiting senescence in a receptor mediated manner and introduces a novel mechanism by which this carcinogen may contribute to human malignancies.	Univ Kentucky, Med Ctr, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA	University of Kentucky	Swanson, HI (corresponding author), Univ Kentucky, Med Ctr, Dept Mol & Biomed Pharmacol, 800 Rose St,MS 305, Lexington, KY 40536 USA.	hswan@uky.edu		Swanson, Hollie/0000-0002-3725-5504	NIEHS NIH HHS [R01 ES011295, ES11295-01] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011295] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agirre X, 2003, ONCOGENE, V22, P1070, DOI 10.1038/sj.onc.1206236; Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Edelman P, 2003, ENVIRON HEALTH PERSP, V111, P1906, DOI 10.1289/ehp.6315; Elferink CJ, 1996, BIOTECHNIQUES, V20, P470; Elizondo G, 2000, MOL PHARMACOL, V57, P1056; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; FernandezSalguero PM, 1997, VET PATHOL, V34, P605, DOI 10.1177/030098589703400609; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Henry EC, 1999, MOL PHARMACOL, V55, P716; HERMAN JG, 1995, CANCER RES, V55, P4525; Ishikawa F, 2003, CANCER SCI, V94, P944, DOI 10.1111/j.1349-7006.2003.tb01382.x; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kaiser J, 2000, SCIENCE, V290, P1071; Kaiser J, 2000, SCIENCE, V288, P1941; Kubota T, 1997, NAT GENET, V16, P16, DOI 10.1038/ng0597-16; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ma Q, 2000, J BIOL CHEM, V275, P8432, DOI 10.1074/jbc.275.12.8432; Pelicci PG, 2004, J CLIN INVEST, V113, P4, DOI 10.1172/JCI200420750; Puga A, 2002, TOXICOLOGY, V181, P171, DOI 10.1016/S0300-483X(02)00276-7; Ray SS, 2003, TOXICOL APPL PHARM, V192, P131, DOI 10.1016/S0041-008X(03)00277-1; REISMAN D, 1988, P NATL ACAD SCI USA, V85, P5146, DOI 10.1073/pnas.85.14.5146; Schmidt CW, 2004, ENVIRON HEALTH PERSP, V112, pA40, DOI 10.1289/ehp.112-a40; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Sharpless NE, 2004, J CLIN INVEST, V113, P160, DOI 10.1172/JCI200420761; Song ZJ, 2003, MOL PHARMACOL, V63, P597, DOI 10.1124/mol.63.3.597; Song ZJ, 2002, MOL PHARMACOL, V62, P806, DOI 10.1124/mol.62.4.806; Starr TB, 2003, ENVIRON HEALTH PERSP, V111, P1443, DOI 10.1289/ehp.6219; SUSKIND RR, 1985, SCAND J WORK ENV HEA, V11, P165, DOI 10.5271/sjweh.2240; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Swanson HI, 1996, J BIOL CHEM, V271, P31657, DOI 10.1074/jbc.271.49.31657; SWANSON HI, 2004, IN PRESS MOL METHODS	38	66	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27187	27193		10.1074/jbc.M402771200	http://dx.doi.org/10.1074/jbc.M402771200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15111621	hybrid			2022-12-25	WOS:000222120400045
J	Mueller, M; Lindner, B; Kusumoto, S; Fukase, K; Schromm, AB; Seydel, U				Mueller, M; Lindner, B; Kusumoto, S; Fukase, K; Schromm, AB; Seydel, U			Aggregates are the biologically active units of endotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LPS BINDING-PROTEIN; FREE LIPID-A; ESCHERICHIA-COLI; LIPOPOLYSACCHARIDE-BINDING; RE LIPOPOLYSACCHARIDE; CHEMICAL-STRUCTURE; CD14; PRINCIPLE; ACTIVATION; COMPLEXES	For the elucidation of the very early steps of immune cell activation by endotoxins (lipopolysaccharide, LPS) leading to the production and release of proinflammatory cytokines the question concerning the biologically active unit of endotoxins has to be addressed: are monomeric endotoxin molecules able to activate cells or is the active unit represented by larger endotoxin aggregates? This question has been answered controversially in the past. Inspired by the observation that natural isolates of lipid A, the lipid moiety of LPS harboring its endotoxic principle, from Escherichia coli express a higher endotoxic activity than the same amounts of the synthetic E. coli-like hexaacylated lipid A (compound 506), we looked closer at the chemical composition of natural isolates. We found in these isolates that the largest fraction was hexaacylated, but also significant amounts of penta- and tetraacylated molecules were present that, when administered to human mononuclear cells, may antagonize the induction of cytokines by biologically active hexaacylated endotoxins. We prepared separate aggregates of either compound 506 or 406 (tetraacylated precursor IVa), mixed at different molar ratios, and mixed aggregates containing both compounds in the same ratios. Surprisingly, the latter mixtures showed higher endotoxic activity than that of the pure compound 506 up to an admixture of 20% of compound 406. Similar results were obtained when using various phospholipids instead of compound 406. These observations can only be understood by assuming that the active unit of endotoxins is the aggregate. We further confirmed this result by preparing monomeric lipid A and LPS by a dialysis procedure and found that, at the same concentrations, only the aggregates were biologically active, whereas the monomers showed no activity.	Res Ctr Borstel, Ctr Med & Biosci, Dept Immunochem & Biochem Microbiol, Div Biophys, D-23845 Borstel, Germany; Osaka Univ, Grad Sch Sci, Dept Chem, Osaka 5600043, Japan	Forschungszentrum Borstel; Osaka University	Seydel, U (corresponding author), Res Ctr Borstel, Ctr Med & Biosci, Dept Immunochem & Biochem Microbiol, Div Biophys, Parkallee 10, D-23845 Borstel, Germany.	useydel@fz-borstel.de	Schromm, Andra/O-3936-2018; Lindner, Buko/G-9731-2014					Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; BRANDENBURG K, 1993, EUR J BIOCHEM, V218, P555, DOI 10.1111/j.1432-1033.1993.tb18409.x; BUSCHNER S, 1999, THESIS CHRISTIAN ALB; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Friberger P, 1987, DETECTION BACTERIAL, P49; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; GALANOS C, 1985, EUR J BIOCHEM, V148, P1, DOI 10.1111/j.1432-1033.1985.tb08798.x; GALLATI H, 1982, J CLIN CHEM CLIN BIO, V20, P907; Gutsmann T, 2001, INFECT IMMUN, V69, P6942, DOI 10.1128/IAI.69.11.6942-6950.2001; IMOTO M, 1984, P JPN ACAD B-PHYS, V60, P285, DOI 10.2183/pjab.60.285; IMOTO M, 1987, B CHEM SOC JPN, V60, P2205, DOI 10.1246/bcsj.60.2205; Israelachvili JN, 2011, INTERMOLECULAR AND SURFACE FORCES, 3RD EDITION, P341, DOI 10.1016/B978-0-12-375182-9.10015-6; Janusch H, 2002, J ENDOTOXIN RES, V8, P343, DOI 10.1179/096805102125000678; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; Lindner B, 2000, METH MOL B, V145, P311; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; LUDERITZ O, 1978, NATURWISSENSCHAFTEN, V65, P578, DOI 10.1007/BF00364907; NOWOTNY A, 1987, REV INFECT DIS, V9, pS503; Oikawa M, 1997, B CHEM SOC JPN, V70, P1435, DOI 10.1246/bcsj.70.1435; POHLMAN TH, 1987, J EXP MED, V165, P1393, DOI 10.1084/jem.165.5.1393; Schromm AB, 2000, EUR J BIOCHEM, V267, P2008, DOI 10.1046/j.1432-1327.2000.01204.x; Seydel U, 2003, EUR J IMMUNOL, V33, P1586, DOI 10.1002/eji.200323649; SHNYRA A, 1993, INFECT IMMUN, V61, P5351, DOI 10.1128/IAI.61.12.5351-5360.1993; TAKAYAMA K, 1994, J BIOL CHEM, V269, P2241; TAKAYAMA K, 1990, J BIOL CHEM, V265, P14023; TOBIAS PS, 1994, CHEST, V105, pS48, DOI 10.1378/chest.105.3.48S; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; WOLLENWEBER HW, 1982, EUR J BIOCHEM, V124, P191, DOI 10.1111/j.1432-1033.1982.tb05924.x; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; ZAHRINGER U, 1994, ADV CARBOHYD CHEM BI, V50, P211, DOI 10.1016/S0065-2318(08)60152-3; Zahringer U, 2001, J ENDOTOXIN RES, V7, P133, DOI 10.1177/09680519010070020801	31	172	195	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26307	26313		10.1074/jbc.M401231200	http://dx.doi.org/10.1074/jbc.M401231200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15096514	hybrid			2022-12-25	WOS:000222003000049
J	Shieh, JJ; Pan, CJ; Mansfield, BC; Chou, JY				Shieh, JJ; Pan, CJ; Mansfield, BC; Chou, JY			A potential new role for muscle in blood glucose homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-STORAGE-DISEASE; PHOSPHOHISTIDINE-ENZYME INTERMEDIATE; GLUCOSE-6-PHOSPHATE TRANSPORTER; MURINE GLUCOSE-6-PHOSPHATASE; SKELETAL-MUSCLE; GENE; TYPE-1A; IDENTIFICATION; CATALYSIS; PROTEIN	The breakdown of tissue glycogen into glucose is critical for blood glucose homeostasis between meals. In the final steps of glycogenolysis, intracellular glucose 6-phosphate (Glc-6-P) is transported into the endoplasmic reticulum where it is hydrolyzed to glucose by glucose-6-phosphatase (Glc-6-Pase). Although the majority of body glycogen is stored in the muscle, the current dogma holds that Glc-6-Pase (now named Glc-6-Pase-alpha) is expressed only in the liver, kidney, and intestine, implying that muscle glycogen cannot contribute to interprandial blood glucose homeostasis. Recently we reported a second Glc-6-P hydrolase, Glc-6-Pase-beta. Glc-6-Pase-alpha shares kinetic and structural similarities to Glc-6-Pase-alpha and couples with the Glc-6-P transporter to form an active Glc-6-Pase complex (Shieh, J.-J., Pan, C.-J., Mansfield, B. C., and Chou, J. Y. (2003) J. Biol. Chem. 278, 47098-47103). Here we demonstrate that muscle expresses both Glc-6-Pase-beta and Glc-6-P transporter and that they can couple to form an active Glc-6-Pase complex. Our data suggest that muscle may have a previously unrecognized role in interprandial glucose homeostasis.	NICHD, Sect Cellular Differentat, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Chou, JY (corresponding author), NICHD, Sect Cellular Differentat, Heritable Disorders Branch, NIH, Bldg 10,Rm 9S241,9000 Rockville Pike, Bethesda, MD 20892 USA.	chouja@mail.nih.gov	Shieh, Jeng-Jer/AAX-6903-2020	Shieh, Jeng-Jer/0000-0001-8412-3603; Mansfield, Brian/0000-0002-8533-2789	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000912] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000912] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAYNES J, 1999, MED BIOCH, P139; BURCHELL A, 1988, CLIN CHIM ACTA, V173, P183, DOI 10.1016/0009-8981(88)90256-2; Chen LY, 2003, HUM MOL GENET, V12, P2547, DOI 10.1093/hmg/ddg263; Chou Janice Yang, 2002, Current Molecular Medicine (Hilversum), V2, P121, DOI 10.2174/1566524024605798; COLLINS JE, 1990, J INHERIT METAB DIS, V13, P195, DOI 10.1007/BF01799686; Gallagher D., 1999, The role of protein and amino acids in sustaining and enhancing performance., P255; Gamberucci A, 1996, MOL MEMBR BIOL, V13, P103, DOI 10.3109/09687689609160583; Gerin I, 1999, GENE, V227, P189, DOI 10.1016/S0378-1119(98)00614-3; Ghosh A, 2002, J BIOL CHEM, V277, P32837, DOI 10.1074/jbc.M201853200; Ghosh A, 2004, J BIOL CHEM, V279, P12479, DOI 10.1074/jbc.M313271200; Guionie O, 2003, FEBS LETT, V551, P159, DOI 10.1016/S0014-5793(03)00903-7; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hiraiwa H, 1999, J BIOL CHEM, V274, P5532, DOI 10.1074/jbc.274.9.5532; Janssen I, 2000, J APPL PHYSIOL, V89, P465, DOI 10.1152/jappl.2000.89.2.465; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; Lin BC, 2000, HUM GENET, V107, P526, DOI 10.1007/s004390000404; Lin BC, 1998, J BIOL CHEM, V273, P31656, DOI 10.1074/jbc.273.48.31656; Marcolongo P, 1998, FEBS LETT, V436, P247, DOI 10.1016/S0014-5793(98)01129-6; Martin CC, 2002, J MOL ENDOCRINOL, V29, P205, DOI 10.1677/jme.0.0290205; Massillon D, 2001, J BIOL CHEM, V276, P4055, DOI 10.1074/jbc.M007939200; Mitanchez D, 1997, ENDOCR REV, V18, P520, DOI 10.1210/er.18.4.520; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, P349; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; Pan CJ, 1998, ARCH BIOCHEM BIOPHYS, V358, P17, DOI 10.1006/abbi.1998.0849; POWELL RC, 1981, METABOLISM, V30, P443, DOI 10.1016/0026-0495(81)90178-5; Scriver C.R., 2001, METABOLIC MOL BASIS, VEighth; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; Shieh JJ, 2003, J BIOL CHEM, V278, P47098, DOI 10.1074/jbc.M309472200; Snyder WS, 1975, REPORT TASK GROUP RE; TSALIKIAN E, 1984, AM J PHYSIOL, V247, pE513, DOI 10.1152/ajpendo.1984.247.4.E513	31	22	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26215	26219		10.1074/jbc.M402036200	http://dx.doi.org/10.1074/jbc.M402036200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087461	hybrid			2022-12-25	WOS:000222003000037
J	Takada, Y; Khuri, FR; Aggarwal, BB				Takada, Y; Khuri, FR; Aggarwal, BB			Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappa B activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappa B-regulated gene expression and up-regulation of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FARNESYL TRANSFERASE INHIBITOR; SIGNAL-TRANSDUCTION PATHWAYS; ALPHA-INDUCED APOPTOSIS; INDUCED CELL-DEATH; KINASE C-ZETA; TRANSCRIPTIONAL ACTIVITY; P65 PHOSPHORYLATION; ENDOTHELIAL-CELLS; TNF-ALPHA	Ras farnesyltransferase inhibitor (FTI) exhibit antiproliferative and antiangiogenic effects through a mechanism that is poorly understood. Because of the known role of Ras in the activation of transcription factor NF-kappaB and because NF-kappaB-regulated genes can control cell survival and angiogenesis, we postulated that FTI mediates its effects in part by modulating NF-kappaB activation. Therefore, in the present study we investigated the effect of FTI, SCH 66336, on NF-kappaB and NF-kappaB-regulated gene expression activated by a variety of inflammatory and carcinogenic agents. We demonstrate by DNA-binding assay that NF-kappaB activation induced by tumor necrosis factor (TNF), phorbol 12-myristate 13-acetate, cigarette smoke, okadaic acid, and H2O2 was completely suppressed by SCH 66336; the suppression was not cell type-specific. This FTI suppressed the activation of IkappaBalpha kinase (IKK), thus abrogating the phosphorylation and degradation of IkappaBalpha. Additionally, TNF-activated Ras and SCH 66336 inhibited the activation. Also, overexpression of Ras (V12) enhanced TNF-induced NF-kappaB activation, and adenoviral dominant-negative Ras (N17) suppressed the activation, thus suggesting the critical role of Ras in TNF signaling. SCH 66336 also inhibited the NF-kappaB-dependent reporter gene expression activated by TNF, TNFR1, TRADD, TRAF2, NIK, and IKK but not that activated by the p65 subunit of NF-kappaB. The TNF-induced NF-kappaB-regulated gene products cyclin D1, COX-2, MMP-9, survivin, IAP1, IAP2, XIAP, Bcl-2, Bfl-1/A1, TRAF1, and FLIP were all down-regulated by SCH 66336, which potentiated apoptosis induced by TNF and doxorubicin. Overall, our results indicate that SCH 66336 inhibited activation of NF-kappaB and NF-kappaB-regulated gene expressions induced by carcinogens and inflammatory stimuli, which may provide a molecular basis for the ability of SCH 66336 to suppress proliferation and angiogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Houston, TX 77030 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA	University of Texas System; UTMD Anderson Cancer Center; Emory University	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Khuri, Fadlo R./AAU-4942-2020; Aggarwal, Bharat B/G-3388-2013	Khuri, Fadlo R./0000-0002-8638-7618; 	NCI NIH HHS [P01-CA91844] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adjei AA, 2000, CANCER RES, V60, P1871; Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Ashikawa K, 2002, J IMMUNOL, V169, P6490, DOI 10.4049/jimmunol.169.11.6490; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Caunt CJ, 2001, J BIOL CHEM, V276, P6280, DOI 10.1074/jbc.M006772200; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Chun KH, 2003, CANCER RES, V63, P4796; Cohen LH, 2000, BIOCHEM PHARMACOL, V60, P1061, DOI 10.1016/S0006-2952(00)00386-5; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Feldkamp MM, 1999, ONCOGENE, V18, P7514, DOI 10.1038/sj.onc.1203105; Feldkamp MM, 2001, CANCER RES, V61, P4425; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Folgueira L, 1996, J VIROL, V70, P2332, DOI 10.1128/JVI.70.4.2332-2338.1996; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hoover RR, 2002, BLOOD, V100, P1068, DOI 10.1182/blood.V100.3.1068; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOONG AC, 1994, CANCER RES, V54, P5273; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Liu M, 1998, CANCER RES, V58, P4947; Mansell A, 2001, J BIOL CHEM, V276, P43597, DOI 10.1074/jbc.M105202200; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Millan O, 2003, ONCOGENE, V22, P477, DOI 10.1038/sj.onc.1206179; Nakajima A, 2003, MOL CANCER THER, V2, P219; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Njoroge FG, 1998, J MED CHEM, V41, P4890, DOI 10.1021/jm980462b; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; Pomerantz JL, 2000, NATURE, V406, P26, DOI 10.1038/35017673; Prendergast GC, 2000, CURR OPIN CELL BIOL, V12, P166, DOI 10.1016/S0955-0674(99)00072-1; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Shi B, 2000, CANCER CHEMOTH PHARM, V46, P387, DOI 10.1007/s002800000170; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Smalley KSM, 2003, INT J CANCER, V105, P165, DOI 10.1002/ijc.11064; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Takada Y, 2003, J BIOL CHEM, V278, P23390, DOI 10.1074/jbc.M213237200; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; TRAVIS J, 1993, SCIENCE, V260, P1877, DOI 10.1126/science.8316828; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; VAN AD, 1996, SCIENCE, V274, P787; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zhang B, 2002, CANCER RES, V62, P450; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	73	97	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26287	26299		10.1074/jbc.M400963200	http://dx.doi.org/10.1074/jbc.M400963200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15090542	hybrid			2022-12-25	WOS:000222003000047
J	Baldanzi, G; Mitola, S; Cutrupi, S; Filigheddu, N; van Blitterswijk, WJ; Sinigaglia, F; Bussolino, F; Graziani, A				Baldanzi, G; Mitola, S; Cutrupi, S; Filigheddu, N; van Blitterswijk, WJ; Sinigaglia, F; Bussolino, F; Graziani, A			Activation of diacylglycerol kinase alpha is required for VEGF-induced angiogenic signaling in vitro	ONCOGENE			English	Article						diacylglycerol kinase; VEGF; phosphatidic acid; Src; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; FOCAL ADHESION KINASE; PHOSPHATIDIC-ACID; PROCESSIVE PHOSPHORYLATION; PHOSPHOLIPASE-D; CELL MIGRATION; C-ALPHA; PHOSPHATIDYLINOSITOL; EXPRESSION; INHIBITOR	Vascular endothelial growth factor-A (VEGF-A) promotes angiogenesis by stimulating migration, proliferation and organization of endothelium, through the activation of signaling pathways involving Src tyrosine kinase. As we had previously shown that Src-mediated activation of diacylglycerol kinase-alpha (Dgk-alpha) is required for hepatocytes growth factor-stimulated cell migration, we asked whether Dgk-alpha is involved in the transduction of angiogenic signaling. In PAE-KDR cells, an endothelial-derived cell line expressing VEGFR-2, VEGF-A(165), stimulates the enzymatic activity of Dgk-alpha: activation is inhibited by R59949, an isoform-specific Dgk inhibitor, and is dependent on Src tyrosine kinase, with which Dgk-alpha forms a complex. Conversely in HUVEC, VEGF-A(165)-induced activation of Dgk is only partially sensitive to R59949, suggesting that also other isoforms may be activated, albeit still dependent on Src tyrosine kinase. Specific inhibition of Dgk-alpha, obtained in both cells by R59949 and in PAE-KDR by expression of Dgk-alpha dominant-negative mutant, imp airs VEGF-A(165)-dependent chemotaxis, proliferation and in vitro angiogenesis. In addition, in HUVEC, specific downregulation of Dgk-alpha by siRNA impairs in vitro angiogenesis on matrigel, further suggesting the requirement for Dgk-alpha in angiogenic signaling in HUVEC. Thus, we propose that activation of Dgk-alpha generates a signal essential for both proliferative and migratory response to VEGF-A(165), suggesting that it may constitute a novel pharmacological target for angiogenesis control.	Univ Amedeo Avogadro Piemonte Orientale, Dept Med Sci, I-28100 Novara, Italy; Univ Turin, Dept Oncol Sci, I-10124 Turin, Italy; Univ Turin, Inst Canc Res & Treatment IRCC, I-10124 Turin, Italy; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	University of Eastern Piedmont Amedeo Avogadro; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Netherlands Cancer Institute	Graziani, A (corresponding author), Univ Amedeo Avogadro Piemonte Orientale, Dept Med Sci, V Solaroli 17, I-28100 Novara, Italy.	graziani@med.unipmn.it	Bussolino, Federico/AES-3951-2022; Filigheddu, Nicoletta/N-7219-2015; graziani, andrea/B-2554-2009; Baldanzi, Gianluca/AAO-7673-2021; Graziani, Andrea/AAB-6301-2022; cutrupi, santina/AAC-4479-2022; Bussolino, Federico/K-2500-2016	Filigheddu, Nicoletta/0000-0002-3848-611X; graziani, andrea/0000-0002-6302-2317; Baldanzi, Gianluca/0000-0002-1370-9903; Graziani, Andrea/0000-0002-6302-2317; Bussolino, Federico/0000-0002-5348-1341; MITOLA, Stefania/0000-0002-5557-738X; CUTRUPI, SANTINA/0000-0002-2358-5852				Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Andresen BT, 2002, FEBS LETT, V531, P65, DOI 10.1016/S0014-5793(02)03483-X; Baldanzi G, 2002, J CELL BIOL, V159, P1029, DOI 10.1083/jcb.200207165; Benelli R, 1999, INT J BIOL MARKER, V14, P243, DOI 10.1177/172460089901400408; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cipres A, 2003, J BIOL CHEM, V278, P35629, DOI 10.1074/jbc.M305635200; Cutrupi S, 2000, EMBO J, V19, P4614, DOI 10.1093/emboj/19.17.4614; DAVIDSON L, 2004, IN PRESS J BIOL CHEM; DECOURCELLES DD, 1989, J BIOL CHEM, V264, P3274; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Gomez-Cambronero J, 1998, CELL SIGNAL, V10, P387, DOI 10.1016/S0898-6568(97)00197-6; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jiang Y, 2000, BIOCHEM PHARMACOL, V59, P763, DOI 10.1016/S0006-2952(99)00395-0; Jones DR, 2002, FASEB J, V16, P595, DOI 10.1096/fj.01-0762fje; KAI M, 1994, J BIOL CHEM, V269, P18492; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; O'Luanaigh N, 2002, MOL BIOL CELL, V13, P3730, DOI 10.1091/mbc.E02-04-0213; PANETTI TS, 2002, BIOCHIM BIOPHYS ACTA, V23, P190; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; POOLE CA, 1993, J CELL SCI, V106, P685; SCHAAP D, 1993, BIOCHEM J, V289, P875, DOI 10.1042/bj2890875; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; Scott MP, 2000, BIOCHEMISTRY-US, V39, P14531, DOI 10.1021/bi001850u; Seibenhener M L, 1999, Mol Cell Biol Res Commun, V2, P28, DOI 10.1006/mcbr.1999.0140; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; SWIFT S, 1999, CURR PROTOCOLS IMMUN, DOI DOI 10.17.14-10.17.29; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; Waltenberger J, 1999, CIRC RES, V85, P12; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang AH, 2002, CIRC RES, V90, P609, DOI 10.1161/01.RES.0000012503.30315.E8; Wellner M, 1999, ARTERIOSCL THROM VAS, V19, P178, DOI 10.1161/01.ATV.19.1.178; Xie YH, 2002, J BIOL CHEM, V277, P32516, DOI 10.1074/jbc.M203864200; Zeng HY, 2002, J BIOL CHEM, V277, P46791, DOI 10.1074/jbc.M206133200; Zhong XP, 2002, J BIOL CHEM, V277, P31089, DOI 10.1074/jbc.M203818200	50	62	62	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4828	4838		10.1038/sj.onc.1207633	http://dx.doi.org/10.1038/sj.onc.1207633			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15122338	Green Published			2022-12-25	WOS:000222104200003
J	Guo, FK; Zheng, Y				Guo, FK; Zheng, Y			Rho family GTPases cooperate with p53 deletion to promote primary mouse embryonic fibroblast cell invasion	ONCOGENE			English	Article						Rho GTPases; p53; cell migration; invasion	TUMOR-SUPPRESSOR PROTEIN; GENE-EXPRESSION; BREAST-CANCER; RAS; TRANSFORMATION; MOTILITY; GROWTH; RAC1; OVEREXPRESSION; PROLIFERATION	The Rho family GTPases Rac1, RhoA and Cdc42 function as molecular switches that transduce intracellular signals regulating multiple cell functions including gene expression, adhesion, migration and invasion. p53 and its regulator p19(Arf) on the other hand, are tumor suppressors that are critical in regulating cell cycle progression and apoptosis. Previously, we have demonstrated that the Rho proteins contribute to the cell proliferation, gene transcription and migration phenotypes unleashed by p19Arf or p53 deletion in primary mouse embryo fibroblasts (MEFs). To further investigate their functional interaction in the present study, we have examined the involvement of Rho signaling pathways in p53-mediated cell invasion. We found that in primary MEFs (1) p53 or p19(Arf) deficiency led to a marked increase in the number of focal adhesion plaques and fibronectin production, and RhoA, Rac1 and Cdc42 contribute to the p53- and p19(Arf)-mediated focal adhesion regulation, but not fibronectin synthesis; (2) although endogenous Rac1 activity was required for the p19(Arf) or p53 deficiency-induced migration phenotype, hyperactive Rho GTPases could not further enhance cell migration, rather they suppressed cell-cell adhesion of p53(-/-) MEFs; (3) expression of the active mutant of RhoA, Rac1 or Cdc42, but not Ras, promoted an invasion phenotype of p53(-/-), not p19Arf(-/-), cells; (4) although ROCK activation can partially recapitulate Rho-induced invasion phenotype, multiple pathways regulated by RhoA, in addition to ROCK, are required to fully cooperate with p53 deficiency to promote cell invasion; and (5) extracellular proteases produced by the active RhoA-transduced cells are also required for the invasion phenotype of p53(-/-) cells. Combined with our previous observations, these results strongly suggest that mitogenic activation of Rho family GTPases can cooperate with p53 deficiency to promote primary cell invasion as well as transformation and that multiple signaling components regulated by the Rho proteins are involved in these processes.	Univ Cincinnati, Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Zheng, Y (corresponding author), Univ Cincinnati, Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA.	yi.zheng@chmcc.org	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NCI NIH HHS [CA105117] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA105117] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandrova A, 2000, ONCOGENE, V19, P5826, DOI 10.1038/sj.onc.1203944; Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; Gadea G, 2002, EMBO J, V21, P2373, DOI 10.1093/emboj/21.10.2373; Gloushankova N, 1997, ONCOGENE, V15, P2985, DOI 10.1038/sj.onc.1201483; Guo FK, 2004, MOL CELL BIOL, V24, P1426, DOI 10.1128/MCB.24.3.1426-1438.2004; Guo FK, 2003, J BIOL CHEM, V278, P14414, DOI 10.1074/jbc.M300341200; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Preudhomme C, 2000, ONCOGENE, V19, P2023, DOI 10.1038/sj.onc.1203521; Ridley AJ, 2001, J CELL SCI, V114, P2713; Sablina AA, 2003, J BIOL CHEM, V278, P27362, DOI 10.1074/jbc.M300547200; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; VAN AL, 1997, GENE DEV, V11, P2295; Zhao RB, 2000, GENE DEV, V14, P981; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	43	69	70	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5577	5585		10.1038/sj.onc.1207752	http://dx.doi.org/10.1038/sj.onc.1207752			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15122327				2022-12-25	WOS:000222629500002
J	Kumar, P; Rao, AGA; Hariharaputran, S; Chandra, N; Gowda, LR				Kumar, P; Rao, AGA; Hariharaputran, S; Chandra, N; Gowda, LR			Molecular mechanism of dimerization of Bowman-Birk inhibitors - Pivotal role of Asp(76) in the dimerzation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SOYBEAN TRYPSIN-INHIBITORS; GRAM DOLICHOS-BIFLORUS; EYED PEA TRYPSIN; RED KIDNEY BEANS; PROTEINASE-INHIBITOR; CHYMOTRYPSIN-INHIBITOR; PROTEASE INHIBITORS; PHASEOLUS-VULGARIS; CRYSTAL-STRUCTURE	Horsegram (Dolichos biflorus), a protein-rich leguminous pulse, is a crop native to Southeast Asia and tropical Africa. The seeds contain multiple forms of Bowman-Birk type inhibitors. The major inhibitor HGI-III, from the native seed with 76 amino acid residues exists as a dimer. The amino acid sequence of three isoforms of Bowman-Birk inhibitor from germinated horsegram, designated as HGGI-I, HGGI-II, and HGGI-III, have been obtained by sequential Edman analyses of the pyridylethylated inhibitors and peptides derived there from by enzymatic and chemical cleavage. The HGGIs are monomers, comprising of 66, 65, and 60 amino acid residues, respectively. HGGI-III from the germinated seed differs from the native seed inhibitor in the physiological deletion of a dodecapeptide at the amino terminus and a tetrapeptide, -SHDD, at the carboxyl terminus. The study of the state of association of HGI-III, by size-exclusion chromatography and SDS-PAGE in the presence of 1 mM ZnCl2, has revealed the role of charged interactions in the monomer <----> dimer equilibria. Chemical modification studies of Lys and Arg have confirmed the role of charge interactions in the above equilibria. These results support the premise that a unique interaction, which stabilizes the dimer, is the cause of self-association in the inhibitors. This interaction in HGI-III involves the epsilon-amino group of the Lys(24) (P-1 residue) at the first reactive site of one monomer and the carboxyl of an Asp(76) at the carboxyl terminus of the second monomer. Identification of the role of these individual amino acids in the structure and stability of the dimer was accomplished by chemical modifications, multiple sequence alignment of legume Bowman-Birk inhibitors, and homology modeling. The state of association may also influence the physiological and functional role of these inhibitors.	Cent Food Technol Res Inst, Dept Prot Chem & Technol, Mysore 570020, Karnataka, India; Indian Inst Sci, Bioinformat Ctr, Bangalore 560012, Karnataka, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Food Technological Research Institute (CFTRI); Indian Institute of Science (IISC) - Bangalore	Gowda, LR (corresponding author), Cent Food Technol Res Inst, Dept Prot Chem & Technol, Mysore 570020, Karnataka, India.	lrg@cftri.com	Hariharaputran, Sridhar/B-1063-2012; Gowda, Lalitha/C-7644-2009	Hariharaputran, Sridhar/0000-0002-9979-3244; Chandra, Nagasuma/0000-0002-9939-8439				AITKEN A, 1989, PROTEIN SEQUENCING P, P43; Allen G., 1981, LABORATORY TECHNIQUE, V9, P73; ASAO T, 1991, AGR BIOL CHEM TOKYO, V55, P707, DOI 10.1080/00021369.1991.10870641; BERGERON D, 1993, J AGR FOOD CHEM, V41, P1544, DOI 10.1021/jf00034a003; BIRK Y, 1985, INT J PEPT PROT RES, V25, P113, DOI 10.1111/j.1399-3011.1985.tb02155.x; BROWN WE, 1984, BIOCHEMISTRY-US, V23, P3418, DOI 10.1021/bi00310a006; Catalano M, 2003, BIOCHEMISTRY-US, V42, P2836, DOI 10.1021/bi020576w; CHEN P, 1992, J BIOL CHEM, V267, P1990; CHRISTIANSON DW, 1989, J AM CHEM SOC, V111, P6412, DOI 10.1021/ja00198a065; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; de la Sierra IL, 1999, J MOL BIOL, V285, P1195, DOI 10.1006/jmbi.1998.2351; deFreitas SM, 1997, FEBS LETT, V409, P121, DOI 10.1016/S0014-5793(97)00419-5; Deshimaru M, 2002, BIOSCI BIOTECH BIOCH, V66, P1897, DOI 10.1271/bbb.66.1897; DIXON HBF, 1968, BIOCHEM J, V109, P312, DOI 10.1042/bj1090312; FOARD D E, 1982, Plant Molecular Biology, V1, P227, DOI 10.1007/BF00021034; FUNK A, 1993, Z LEBENSM UNTERS FOR, V196, P343, DOI 10.1007/BF01197933; GENNIS LS, 1976, J BIOL CHEM, V251, P747; GODBOLE SA, 1994, J SCI FOOD AGR, V64, P87, DOI 10.1002/jsfa.2740640113; HARMSRINGDAHL M, 1979, BIOCHEM BIOPH RES CO, V86, P492, DOI 10.1016/0006-291X(79)91741-8; HARRY JB, 1970, EUR J BIOCHEM, V16, P174, DOI 10.1111/j.1432-1033.1970.tb01069.x; HAYNES R, 1967, J BIOL CHEM, V242, P5378; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HWANG DLR, 1977, BIOCHIM BIOPHYS ACTA, V495, P239; Ikenaka T, 1986, PROTEINASE INHIBITOR, P361; JOUBERT FJ, 1984, PHYTOCHEMISTRY, V23, P957, DOI 10.1016/S0031-9422(00)82591-1; JOUBERT FJ, 1979, EUR J BIOCHEM, V97, P85, DOI 10.1111/j.1432-1033.1979.tb13088.x; Kennedy AR, 1998, AM J CLIN NUTR, V68, p1406S, DOI 10.1093/ajcn/68.6.1406S; Koepke J, 2000, J MOL BIOL, V298, P477, DOI 10.1006/jmbi.2000.3677; Kumar P, 2002, PHYTOCHEMISTRY, V60, P581, DOI 10.1016/S0031-9422(02)00178-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN GD, 1993, EUR J BIOCHEM, V212, P549, DOI 10.1111/j.1432-1033.1993.tb17692.x; Luckett S, 1999, J MOL BIOL, V290, P525, DOI 10.1006/jmbi.1999.2891; Miles E W, 1977, Methods Enzymol, V47, P431; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; ODANI S, 1977, J BIOCHEM-TOKYO, V82, P1523, DOI 10.1093/oxfordjournals.jbchem.a131846; ODANI S, 1978, J BIOCHEM-TOKYO, V83, P747, DOI 10.1093/oxfordjournals.jbchem.a131968; Prakash B, 1996, J MOL EVOL, V42, P560, DOI 10.1007/BF02352286; RAMASARMA PR, 1995, BBA-PROTEIN STRUCT M, V1248, P35, DOI 10.1016/0167-4838(95)00004-E; Singh RR, 2002, BBA-PROTEIN STRUCT M, V1597, P280, DOI 10.1016/S0167-4838(02)00301-1; Smith E L, 1977, Methods Enzymol, V47, P156; Song HK, 1999, J MOL BIOL, V293, P1133, DOI 10.1006/jmbi.1999.3239; Sreerama YN, 1997, BBA-PROTEIN STRUCT M, V1343, P235, DOI 10.1016/S0167-4838(97)00117-9; Sreerama YN, 1998, J AGR FOOD CHEM, V46, P2596, DOI 10.1021/jf980075a; Sreerama YN, 1997, J FOOD BIOCHEM, V21, P461, DOI 10.1111/j.1745-4514.1997.tb00200.x; SUZUKI A, 1993, J MOL BIOL, V234, P722, DOI 10.1006/jmbi.1993.1622; Tanaka AS, 1996, J PROTEIN CHEM, V15, P553, DOI 10.1007/BF01908537; TANAKA AS, 1996, J BIOL CHEM, V378, P273; TERADA S, 1994, BIOSCI BIOTECH BIOCH, V58, P371, DOI 10.1271/bbb.58.371; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSUNOGAE Y, 1986, J BIOCHEM-TOKYO, V100, P1637, DOI 10.1093/oxfordjournals.jbchem.a121872; VENTURA MM, 1981, AN ACAD BRAS CIENC, V53, P195; Voss RH, 1996, EUR J BIOCHEM, V242, P122, DOI 10.1111/j.1432-1033.1996.0122r.x; WERNER MH, 1992, BIOCHEMISTRY-US, V31, P999, DOI 10.1021/bi00119a008; WILSON KA, 1983, PLANT PHYSIOL, V71, P341, DOI 10.1104/pp.71.2.341; WILSON KA, 1973, J BIOL CHEM, V248, P756; WU C, 1990, J AGR FOOD CHEM, V38, P1523, DOI 10.1021/jf00097a021; ZHANG Y, 1982, SCI SIN B-CHEM B A M, V25, P268	59	43	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30425	30432		10.1074/jbc.M402972200	http://dx.doi.org/10.1074/jbc.M402972200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123729	hybrid			2022-12-25	WOS:000222531900069
J	Lee, JY; Kim, H; Ryu, CH; Kim, JY; Choi, BH; Lim, Y; Huh, PW; Kim, YH; Lee, KH; Jun, TY; Rha, HK; Kang, JK; Choi, CR				Lee, JY; Kim, H; Ryu, CH; Kim, JY; Choi, BH; Lim, Y; Huh, PW; Kim, YH; Lee, KH; Jun, TY; Rha, HK; Kang, JK; Choi, CR			Merlin, a tumor suppressor, interacts with transactivation-responsive RNA-binding protein and inhibits its oncogenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-2 NEUROFIBROMATOSIS; UNITED-KINGDOM; KINASE PKR; TAR; TRBP; GENE; HIV-1; DOMAIN; MOUSE; ACTIVATION	The neurofibromatosis type 2 gene-encoded protein, merlin, is related to the ERM (ezrin, radixin, and moesin) family of membrane-cytoskeleton-associated proteins. Recent studies suggest that the loss of neurofibromatosis type 2 function contributes to tumor development and metastasis. Although the cellular functions of merlin as a tumor suppressor are relatively well characterized, the cellular mechanism whereby merlin controls cell proliferation from membrane locations is still poorly understood. During our efforts to find potential merlin modulators through protein-protein interactions, we identified transactivation-responsive RNA-binding protein (TRBP) as a merlin-binding protein in a yeast two-hybrid screen. The interaction between TRBP and merlin was confirmed by glutathione S-transferase pull-down assays, co-immunoprecipitation, and co-localization experiments. The carboxyl-terminal regions of each protein were responsible for their interaction. Cells overexpressing TRBP showed enhanced cell growth in cell proliferation assays and also exhibited transformed phenotypes, such as anchorage-independent cell growth and tumor development in mouse xenografts. Merlin efficiently inhibited these oncogenic activities of TRBP in our experiments. These results provide the first clue to the functional interaction between TRBP and merlin and suggest a novel mechanism for the tumor suppressor function of merlin both in vitro and in vivo.	Catholic Univ Korea, Catholic Neurosci Ctr, Seoul 137701, South Korea; Catholic Univ Korea, Dept Neurosurg, Seoul 137701, South Korea; Catholic Univ Korea, Dept Occupat & Environm Med, Seoul 137701, South Korea; Catholic Univ Korea, Dept Pharmacol, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Kim, YH (corresponding author), Catholic Univ Korea, Catholic Neurosci Ctr, Seoul 137701, South Korea.	pedkyh@catholic.ac.kr	Lee, Joo-Yong/AAE-3388-2019	Lee, Joo-Yong/0000-0003-1049-6006				Bannwarth S, 2001, J BIOL CHEM, V276, P48803, DOI 10.1074/jbc.M104645200; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Daher A, 2001, J BIOL CHEM, V276, P33899, DOI 10.1074/jbc.M103584200; Donzeau M, 1997, J VIROL, V71, P2628, DOI 10.1128/JVI.71.4.2628-2635.1997; Duarte M, 2000, J BIOMED SCI, V7, P494; EVANS DGR, 1992, J MED GENET, V29, P847, DOI 10.1136/jmg.29.12.847; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; Gatignol A, 1996, GENE EXPRESSION, V5, P217; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Giovannini M, 2000, GENE DEV, V14, P1617; Gusella JF, 1996, CURR OPIN GENET DEV, V6, P87, DOI 10.1016/S0959-437X(96)90016-7; Kalamarides M, 2002, GENE DEV, V16, P1060, DOI 10.1101/gad.226302; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; Kim H, 2004, J BIOL CHEM, V279, P7812, DOI 10.1074/jbc.M305526200; Kim H, 2002, MOL CELLS, V14, P108; Kim JY, 2002, BIOCHEM BIOPH RES CO, V296, P1295, DOI 10.1016/S0006-291X(02)02077-6; KOZAK CA, 1995, GENOMICS, V25, P66, DOI 10.1016/0888-7543(95)80110-8; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Lee K, 1996, MOL CELL BIOL, V16, P3023; Lim JY, 2003, BIOCHEM BIOPH RES CO, V302, P238, DOI 10.1016/S0006-291X(03)00124-4; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; Sainio M, 1997, J CELL SCI, V110, P2249; Siffroi JP, 2001, MOL HUM REPROD, V7, P219, DOI 10.1093/molehr/7.3.219; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Zhong J, 1999, NAT GENET, V22, P171, DOI 10.1038/9684; Zhong J, 1998, MAMM GENOME, V9, P413, DOI 10.1007/s003359900786	38	52	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30265	30273		10.1074/jbc.M312083200	http://dx.doi.org/10.1074/jbc.M312083200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123692	hybrid, Green Published			2022-12-25	WOS:000222531900051
J	Dubel, SJ; Altier, C; Chaumont, S; Lory, P; Bourinet, E; Nargeot, J				Dubel, SJ; Altier, C; Chaumont, S; Lory, P; Bourinet, E; Nargeot, J			Plasma membrane expression of T-type calcium channel alpha(1) subunits is modulated by high voltage-activated auxiliary subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNEL; BETA-SUBUNIT; FUNCTIONAL-PROPERTIES; MOLECULAR CHARACTERIZATION; ALPHA(2)DELTA SUBUNIT; ENDOPLASMIC-RETICULUM; SKELETAL-MUSCLE; GAMMA-SUBUNIT; CELL LINE; TRAFFICKING	It has been suggested that the auxiliary subunits of high voltage-activated (HVA) calcium channels modulate T-type, low voltage-activated (LVA) calcium channels. Such a regulation has yet to be documented, especially because there has been no biochemical characterization of T-channels. To monitor total protein levels and plasma membrane expression of T-channels in living cells, external epitopes ( hemagglutinin, FLAG) were introduced into human recombinant Ca(V)3 channels that were also N-terminally fused to green fluorescent protein. Utilizing Western blot techniques, fluorescence flow cytometry, immunofluorescence, luminometry, and electrophysiology, we describe here that beta(1b) and alpha(2)-delta(1) subunits enhance the level of Ca(V)3 proteins as well as their plasma membrane expression in various expression systems. We also report that, in both Xenopus oocytes and mammalian cells, the alpha(2)-delta(1) and beta(1b) subunits increase by at least 2-fold the current density of Ca(V)3 channels with no change in the electrophysiological properties. Altogether, these data indicate that HVA auxiliary subunits modulate Ca(V)3 channel surface expression, suggesting that the membrane targeting of HVA and LVA alpha1 subunits is regulated dynamically through the expression of a common set of regulatory subunits.	Dept Physiol, Lab Genom Fonct, CNRS, Unite Propre Rech 2580, F-34396 Montpellier 01, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Nargeot, J (corresponding author), Dept Physiol, Lab Genom Fonct, CNRS, Unite Propre Rech 2580, 141 Rue Cardonille, F-34396 Montpellier 01, France.	joel.nargeot@igh.cnrs.fr		Chaumont-Dubel, Severine/0000-0001-6860-6891; bourinet, emmanuel/0000-0001-8021-0419; LORY, philippe/0000-0002-1638-7604; Nargeot, Joel/0000-0003-2893-5636				Agueev V, 2000, BIOPHYS J, V78, p457A; Altier C, 2002, J BIOL CHEM, V277, P33598, DOI 10.1074/jbc.M202476200; Baroudi G, 2001, CIRC RES, V88, pE78, DOI 10.1161/hh1201.093270; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Chen Y, 2003, CELL, V115, P37, DOI 10.1016/S0092-8674(03)00726-8; Chen YC, 2003, ANN NEUROL, V54, P239, DOI 10.1002/ana.10607; Cornet V, 2002, EUR J NEUROSCI, V16, P883, DOI 10.1046/j.1460-9568.2002.02168.x; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; Dolphin AC, 1999, J PHYSIOL-LONDON, V519, P35, DOI 10.1111/j.1469-7793.1999.0035o.x; Gao BN, 2000, J BIOL CHEM, V275, P12237, DOI 10.1074/jbc.275.16.12237; Gao TY, 1999, J BIOL CHEM, V274, P2137, DOI 10.1074/jbc.274.4.2137; Garcia R, 2002, J PHYSIOL-LONDON, V545, P407, DOI 10.1113/jphysiol.2002.027433; Gee NS, 1996, J BIOL CHEM, V271, P5768, DOI 10.1074/jbc.271.10.5768; Green PJ, 2001, J PHYSIOL-LONDON, V533, P467, DOI 10.1111/j.1469-7793.2001.0467a.x; Hobom M, 2000, EUR J NEUROSCI, V12, P1217, DOI 10.1046/j.1460-9568.2000.01009.x; Howard M, 1995, AM J PHYSIOL-CELL PH, V269, pC1565, DOI 10.1152/ajpcell.1995.269.6.C1565; Howard M, 1996, KIDNEY INT, V49, P1642, DOI 10.1038/ki.1996.239; Jones SW, 1998, J BIOENERG BIOMEMBR, V30, P299, DOI 10.1023/A:1021977304001; Kang MG, 2003, J BIOL CHEM, V278, P21315, DOI 10.1074/jbc.R300004200; Klugbauer N, 1999, J NEUROSCI, V19, P684; Kuchenbecker M, 2001, PFLUG ARCH EUR J PHY, V443, P280, DOI 10.1007/s004240100688; Lacinova L, 1999, J PHYSIOL-LONDON, V516, P639, DOI 10.1111/j.1469-7793.1999.0639u.x; Lambert RC, 1997, J NEUROSCI, V17, P6621; Leuranguer V, 1998, NEUROPHARMACOLOGY, V37, P701, DOI 10.1016/S0028-3908(98)00060-4; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; McRory JE, 2001, J BIOL CHEM, V276, P3999, DOI 10.1074/jbc.M008215200; Monteil A, 2000, J BIOL CHEM, V275, P6090, DOI 10.1074/jbc.275.9.6090; Perez-Reyes E, 2003, PHYSIOL REV, V83, P117, DOI 10.1152/physrev.00018.2002; Perez-Reyes E, 1998, J BIOENERG BIOMEMBR, V30, P313, DOI 10.1023/A:1021981420839; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; TOMLINSON WJ, 1993, NEUROPHARMACOLOGY, V32, P1117, DOI 10.1016/0028-3908(93)90006-O; Wei S, 2000, CIRC RES, V86, P175, DOI 10.1161/01.RES.86.2.175; WELLING A, 1993, J PHYSIOL-LONDON, V471, P749, DOI 10.1113/jphysiol.1993.sp019926; Wyatt CN, 1998, J PHYSIOL-LONDON, V510, P347, DOI 10.1111/j.1469-7793.1998.347bk.x; Yamaguchi H, 1998, J BIOL CHEM, V273, P19348, DOI 10.1074/jbc.273.30.19348; Yunker AMR, 2003, NEUROSCIENCE, V117, P321, DOI 10.1016/S0306-4522(02)00936-3; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976; Zhang Y, 2002, J NEUROSCI, V22, P6362	40	92	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29263	29269		10.1074/jbc.M313450200	http://dx.doi.org/10.1074/jbc.M313450200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123697	hybrid			2022-12-25	WOS:000222445300055
J	Ketcham, C; Wang, F; Fisher, SZ; Ercan, A; van der Wel, H; Locke, RD; Sirajud-Doulah, K; Matta, KL; West, CM				Ketcham, C; Wang, F; Fisher, SZ; Ercan, A; van der Wel, H; Locke, RD; Sirajud-Doulah, K; Matta, KL; West, CM			Specificity of a soluble UDP-galactose : fucoside alpha 1,3-galactosyltransferase that modifies the cytoplasmic glycoprotein Skp1 in Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCF UBIQUITIN LIGASE; CYTOSOLIC GLYCOPROTEIN; COMPLEX GLYCOSYLATION; GLCNAC-TRANSFERASE; OLIGOSACCHARIDES; FP21; GALACTOSYLTRANSFERASES; GLYCOSYLTRANSFERASES; IDENTIFICATION; PURIFICATION	Skp1 is an adaptor-like protein in E3SCF-ubiquitin ligases and other multiprotein complexes of the cytoplasm and nucleus. In Dictyostelium, Skp1 is modified by an unusual pentasaccharide containing a Galalpha1-Fuc linkage, whose formation is examined here. A cytosolic extract from Dictyostelium was found to yield, after 2400-fold purification, an activity that could transfer Gal from UDP-Gal to both a Fuc-terminated glycoform of Skp1 and synthetic Fuc conjugates in the presence of Mn2+ and dithiothreitol. The microsomal fraction was devoid of activity. The linkage formed was Galalpha1,3Fuc based on co-chromatography with only this synthetic isomer conjugate, and sensitivity to alpha1,3/6-galactosidase. Skp1 exhibited an almost 1000-fold lower K-m and 35-fold higher V-max compared with a simple alpha-fucoside, but this advantage was abolished by denaturation or alkylation of Cys residues. A comparison of a complete series of synthetic glycosides representing the non-reducing terminal mono-, di-, and trisaccharides of Skp1 revealed, surprisingly, that the disaccharide is most active owing primarily to a V-max advantage, but still much less active than Skp1 itself because of a K-m difference. These findings indicate that alpha-GalT1 is a cytoplasmic enzyme whose modification of Skp1 requires proper presentation of the terminal acceptor disaccharide by a folded Skp1 polypeptide, which correlates with previous evidence that the Galalpha1,3Fuc linkage is deficient in expressed mutant Skp1 proteins.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biophys, Buffalo, NY 14263 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; State University System of Florida; University of Florida; Roswell Park Cancer Institute	West, CM (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, 940 Stanton L Young Blvd,BMSB 853, Oklahoma City, OK 73104 USA.	Christopher-West@ouhsc.edu	Ercan, Altan/AGO-4238-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037539] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM37539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Bekiroglu S, 2000, CARBOHYD RES, V328, P409, DOI 10.1016/S0008-6215(00)00104-X; Breton C, 1998, J BIOCHEM, V123, P1000; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Farras R, 2001, EMBO J, V20, P2742, DOI 10.1093/emboj/20.11.2742; FLOWERS HM, 1979, CARBOHYD RES, V74, P177, DOI 10.1016/S0008-6215(00)84774-6; Galan JM, 2001, MOL CELL BIOL, V21, P3105, DOI 10.1128/MCB.21.9.3105-3117.2001; GONZALEZYANES B, 1992, J BIOL CHEM, V267, P9595; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Kaplan KB, 1997, CELL, V91, P491, DOI 10.1016/S0092-8674(00)80435-3; KOZAROV E, 1995, J BIOL CHEM, V270, P3022, DOI 10.1074/jbc.270.7.3022; Martin-Pastor M, 2000, BIOCHEMISTRY-US, V39, P4674, DOI 10.1021/bi992050q; MATTA KL, 1975, CARBOHYD RES, V43, P299, DOI 10.1016/S0008-6215(00)83494-1; MATTA KL, 1984, CARBOHYD RES, V131, P247, DOI 10.1016/0008-6215(84)85246-5; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Pedersen LL, 2003, CELL MOL LIFE SCI, V60, P259, DOI 10.1007/s000180300021; RANA SS, 1981, CARBOHYD RES, V96, P231, DOI 10.1016/S0008-6215(00)81873-X; Sassi S, 2001, GLYCOBIOLOGY, V11, P283, DOI 10.1093/glycob/11.4.283; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Shao L, 2003, CELL MOL LIFE SCI, V60, P241, DOI 10.1007/s000180300019; Taylor SG, 2003, GLYCOBIOLOGY, V13, P327, DOI 10.1093/glycob/cwg030; Teng-umnuay P, 1998, J BIOL CHEM, V273, P18242, DOI 10.1074/jbc.273.29.18242; Teng-umnuay P, 1999, J BIOL CHEM, V274, P36392, DOI 10.1074/jbc.274.51.36392; TOOMRE DK, 1994, GLYCOBIOLOGY, V4, P653, DOI 10.1093/glycob/4.5.653; van der Wel H, 2002, J BIOL CHEM, V277, P46527, DOI 10.1074/jbc.M208824200; van der Wel H, 2002, J BIOL CHEM, V277, P46328, DOI 10.1074/jbc.M208024200; van der Wel H, 2001, J BIOL CHEM, V276, P33952, DOI 10.1074/jbc.M102555200; Wang F, 2003, J BIOL CHEM, V278, P51395, DOI 10.1074/jbc.M308756200; West CM, 2002, GLYCOBIOLOGY, V12, p17R, DOI 10.1093/glycob/12.2.17R; West CM, 1996, J BIOL CHEM, V271, P12024, DOI 10.1074/jbc.271.20.12024; West CM, 2003, CELL MOL LIFE SCI, V60, P229, DOI 10.1007/s000180300018; West CM, 1997, GENE, V200, P1, DOI 10.1016/S0378-1119(97)00194-7; WEST CM, 2004, BIOCH BIOPHYS ACTA; WONGMADDEN ST, 1995, GLYCOBIOLOGY, V5, P19, DOI 10.1093/glycob/5.1.19; Zhang Y, 1997, GLYCOBIOLOGY, V7, P1153, DOI 10.1093/glycob/7.8.1153; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	37	21	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29050	29059		10.1074/jbc.M313858200	http://dx.doi.org/10.1074/jbc.M313858200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123660	hybrid			2022-12-25	WOS:000222445300028
J	Liekens, S; Hernandez, AI; Ribatti, D; De Clercq, E; Camarasa, MJ; Perez-Perez, MJ; Balzarini, J				Liekens, S; Hernandez, AI; Ribatti, D; De Clercq, E; Camarasa, MJ; Perez-Perez, MJ; Balzarini, J			The nucleoside derivative 5 '-O-trityl-inosine (KIN59) suppresses thymidine phosphorylase-triggered angiogenesis via a noncompetitive mechanism of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL GROWTH-FACTOR; MULTISUBSTRATE ANALOG INHIBITORS; EMBRYO CHORIOALLANTOIC MEMBRANE; HYPOXIA-INDUCED APOPTOSIS; INTRATUMORAL MICROVESSELS; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; EXPRESSION; 2-DEOXY-D-RIBOSE	Thymidine phosphorylase (TPase) catalyzes the reversible phosphorolysis of pyrimidine deoxynucleosides to 2-deoxy-D-ribose-1-phosphate and their respective pyrimidine bases. The enzymatic activity of TPase was found to be essential for its angiogenesis-stimulating properties. All of the previously described TPase inhibitors are either pyrimidine analogues that interact with the nucleoside-binding site of the enzyme or modified purine derivatives that mimic the pyrimidine structure and either compete with thymidine or act as a multisubstrate (competitive) inhibitor. We now describe the inhibitory activity of the purine riboside derivative KIN59 (5'-O-tritylinosine) against human and bacterial recombinant TPase and TPase-induced angiogenesis. In contrast to previously described TPase inhibitors, KIN59 does not compete with the pyrimidine nucleoside or the phosphate-binding site of the enzyme but noncompetitively inhibits TPase when thymidine or phosphate is used as the variable substrate. In addition, KIN59 was far more active than other TPase inhibitors, previously tested by us, against TPase-induced angiogenesis in the chorioallantoic membrane assay. The observed anti-angiogenic effect of KIN59 was not accompanied by inflammation or any visible toxicity. Inosine did not inhibit the enzymatic or angiogenic activity of the enzyme, indicating that the 5'-O-trityl group in KIN59 is essential for the observed effects. In contrast with current concepts, our data indicate that the angiogenic activity of TPase is not solely directed through its functional nucleoside and phosphate-binding sites. Other regulatory (allosteric) site(s) in TPase may play an important role in the mechanism of TPase-triggered angiogenesis stimulation and apoptosis inhibition. Identification of these site(s) is important to obtain a better insight into the molecular role of TPase in the progression of cancer and angiogenic diseases.	Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium; Dept Human Anat & Histol, I-70124 Bari, Italy; CSIC, Inst Quim Med, E-28006 Madrid, Spain	KU Leuven; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Medica (IQM); CSIC - Instituto de Quimica Organica General (IQOG)	Liekens, S (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Minderbroedersstr 10, B-3000 Louvain, Belgium.	sandra.liekens@rega.kuleuven.ac.be	Camarasa, María-José/N-8845-2019; Higueras, Ana Isabel Hernandez/F-9372-2016; Camarasa, María-José/B-6340-2015; Perez-Perez, Maria-Jesus/O-4580-2014	Camarasa, María-José/0000-0002-4978-6468; Higueras, Ana Isabel Hernandez/0000-0003-2310-3718; Camarasa, María-José/0000-0002-4978-6468; Perez-Perez, Maria-Jesus/0000-0003-1336-7760; De Clercq, Erik/0000-0002-2985-8890				Balzarini J, 2000, FEBS LETT, V483, P181, DOI 10.1016/S0014-5793(00)02101-3; Balzarini J, 1998, FEBS LETT, V438, P91, DOI 10.1016/S0014-5793(98)01271-X; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; Brown NS, 2000, CANCER RES, V60, P6298; Brown NS, 1998, BIOCHEM J, V334, P1; CHU CK, 1989, J ORG CHEM, V54, P2217, DOI 10.1021/jo00270a036; Cole C, 2003, J MED CHEM, V46, P207, DOI 10.1021/jm020964w; DESGRANGES C, 1983, BIOCHEM PHARMACOL, V32, P3583, DOI 10.1016/0006-2952(83)90307-6; Esteban-Gamboa A, 2000, J MED CHEM, V43, P971, DOI 10.1021/jm9911377; Focher F, 2000, J MED CHEM, V43, P2601, DOI 10.1021/jm000037u; HARAGUCHI M, 1994, NATURE, V368, P198, DOI 10.1038/368198a0; Hata K, 1998, ULTRASOUND OBST GYN, V12, P201, DOI 10.1046/j.1469-0705.1998.12030201.x; Hotchkiss KA, 2003, J BIOL CHEM, V278, P19272, DOI 10.1074/jbc.M212670200; Hotchkiss KA, 2003, CANCER RES, V63, P527; Ikeda R, 2003, BIOCHEM BIOPH RES CO, V301, P358, DOI 10.1016/S0006-291X(02)03034-6; Ikeda R, 2002, BIOCHEM BIOPH RES CO, V291, P806, DOI 10.1006/bbrc.2002.6432; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; Kitazono M, 1998, BIOCHEM BIOPH RES CO, V253, P797, DOI 10.1006/bbrc.1998.9852; Klein RS, 2001, BIOCHEM PHARMACOL, V62, P1257, DOI 10.1016/S0006-2952(01)00783-3; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Liekens S, 2002, FEBS LETT, V510, P83, DOI 10.1016/S0014-5793(01)03233-1; Liekens S, 2001, CANCER RES, V61, P5057; Matsushita S, 1999, CANCER RES, V59, P1911; Matsuura T, 1999, CANCER RES, V59, P5037; Mendieta J, 2004, BIOCHEMISTRY-US, V43, P405, DOI 10.1021/bi034793o; MIYADERA K, 1995, CANCER RES, V55, P1687; MOGHADDAM A, 1995, P NATL ACAD SCI USA, V92, P998, DOI 10.1073/pnas.92.4.998; Mori S, 2002, BIOCHEM BIOPH RES CO, V295, P300, DOI 10.1016/S0006-291X(02)00662-9; Norman RA, 2004, STRUCTURE, V12, P75, DOI 10.1016/j.str.2003.11.018; Okamoto E, 2001, PATHOL INT, V51, P158, DOI 10.1046/j.1440-1827.2001.01184.x; Pugmire MJ, 1998, STRUCTURE, V6, P1467, DOI 10.1016/S0969-2126(98)00145-2; Ribatti D, 2002, J CELL MOL MED, V6, P439, DOI 10.1111/j.1582-4934.2002.tb00524.x; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; Rick SW, 1999, PROTEINS, V37, P242, DOI 10.1002/(SICI)1097-0134(19991101)37:2<242::AID-PROT9>3.0.CO;2-5; Seki N, 2000, EUR J CANCER, V36, P68, DOI 10.1016/S0959-8049(99)00201-4; Sengupta S, 2003, BRIT J PHARMACOL, V139, P219, DOI 10.1038/sj.bjp.0705216; Stevenson DP, 1998, AM J PATHOL, V152, P1641; TOI M, 1995, INT J CANCER, V64, P79, DOI 10.1002/ijc.2910640202; USUKI K, 1992, BIOCHEM BIOPH RES CO, V184, P1311, DOI 10.1016/S0006-291X(05)80025-7; WALTER MR, 1990, J BIOL CHEM, V265, P14016	40	45	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29598	29605		10.1074/jbc.M402602200	http://dx.doi.org/10.1074/jbc.M402602200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123637	Green Published, hybrid			2022-12-25	WOS:000222445300095
J	Cabart, P; Chew, HK; Murphy, S				Cabart, P; Chew, HK; Murphy, S			BRCA1 cooperates with NUFIP and P-TEFb to activate transcription by RNA polymerase II	ONCOGENE			English	Article						BRCA1; P-TEFb; NUFIP; RNA polymerase II; transcriptional activator	CARBOXYL-TERMINAL DOMAIN; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; MAJOR LATE PROMOTER; ELONGATION COMPLEXES; TATA-BOX; DEPENDENT TRANSCRIPTION; FUNCTIONAL INTERACTIONS; BINDING PROTEIN; KINASE-ACTIVITY	The tumor suppressor gene product BRCA1 is a component of the RNA polymerase II (pol II) holoenzyme that is involved, through binding to various regulatory proteins, in either activation or repression of transcription. Using a yeast two-hybrid screen, we have identified a human zinc-finger-containing protein NUFIP that interacts with BRCA1. The ubiquitous, stably expressed, nuclear protein NUFIP specifically stimulates activator-independent pol II transcription in vitro and in vivo. Immunodepletion of the endogenous NUFIP causes a marked decrease of pol II transcription, which is then shown to be restored by stable complex of ectopically produced NUFIP and associated factors. NUFIP not only interacts with BRCA1 but also associates with the positive elongation factor P-TEFb through interaction with the regulatory Cyclin T1 subunit. Cyclin T1 is required for BRCA1- and NUFIP-dependent synergistic activation of pol II transcription in 293 cells. Mutation of the zinc-finger domain abolishes the NUFIP-mediated transcriptional activation. We show that NUFIP is associated with preinitiation complexes, open transcription complexes, and elongation complexes. In addition, NUFIP facilitates ATP-dependent dissociation of hyperphosphorylated pol II from open transcription complexes in vitro.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Calif Davis, Ctr Canc, Div Hematol Oncol, Sacramento, CA 95817 USA	University of Oxford; University of California System; University of California Davis	Cabart, P (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Jack & Pearl Resnick Campus,1300 Morris Pk Ave, Bronx, NY 10461 USA.	pcabart@aecom.yu.edu		Cabart, Pavel/0000-0003-0065-367X				Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; ARIAS JA, 1989, J BIOL CHEM, V264, P3223; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Bardoni B, 1999, HUM MOL GENET, V8, P2557, DOI 10.1093/hmg/8.13.2557; Bardoni B, 2003, EXP CELL RES, V289, P95, DOI 10.1016/S0014-4827(03)00222-2; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; Cabart P, 2001, J BIOL CHEM, V276, P43056, DOI 10.1074/jbc.M108515200; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; Chen YM, 1996, CANCER RES, V56, P3168; Chiba N, 2002, CANCER RES, V62, P4222; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DAHMUS ME, 1994, PROG NUCLEIC ACID RE, V48, P143, DOI 10.1016/S0079-6603(08)60855-7; DAHMUS ME, 1981, J BIOL CHEM, V256, P3332; Deng CX, 2000, BIOESSAYS, V22, P728; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Fujinaga K, 1999, P NATL ACAD SCI USA, V96, P1285, DOI 10.1073/pnas.96.4.1285; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Ivanov D, 2000, MOL CELL BIOL, V20, P2970, DOI 10.1128/MCB.20.9.2970-2983.2000; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kim JB, 2001, J BIOL CHEM, V276, P12317, DOI 10.1074/jbc.M010908200; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; Krum SA, 2003, J BIOL CHEM, V278, P52012, DOI 10.1074/jbc.M308418200; Kugel JF, 1998, P NATL ACAD SCI USA, V95, P9232, DOI 10.1073/pnas.95.16.9232; Kugel JF, 2002, MOL CELL BIOL, V22, P762, DOI 10.1128/MCB.22.3.762-773.2002; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Monteiro ANA, 2000, TRENDS BIOCHEM SCI, V25, P469, DOI 10.1016/S0968-0004(00)01632-7; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Murphy S, 1997, NUCLEIC ACIDS RES, V25, P2068, DOI 10.1093/nar/25.11.2068; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; Narita T, 2003, MOL CELL BIOL, V23, P1863, DOI 10.1128/MCB.23.6.1863-1873.2003; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; Parvin JD, 2001, P NATL ACAD SCI USA, V98, P5952, DOI 10.1073/pnas.121184998; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Ping YH, 1999, J BIOL CHEM, V274, P7399, DOI 10.1074/jbc.274.11.7399; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; ROHAN RM, 1987, J BIOL CHEM, V262, P8500; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shore SM, 2003, GENE, V307, P175, DOI 10.1016/S0378-1119(03)00466-9; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Spangler L, 2001, P NATL ACAD SCI USA, V98, P5544, DOI 10.1073/pnas.101004498; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; SZENTIRMAY MN, 1994, NUCLEIC ACIDS RES, V22, P5341, DOI 10.1093/nar/22.24.5341; Taube R, 2002, MOL CELL BIOL, V22, P321, DOI 10.1128/MCB.22.1.321-331.2002; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Venkitaraman AR, 2001, J CELL SCI, V114, P3591; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200; Zhong Q, 2002, CANCER RES, V62, P3966; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	84	20	20	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	2004	23	31					5316	5329		10.1038/sj.onc.1207684	http://dx.doi.org/10.1038/sj.onc.1207684			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15107825				2022-12-25	WOS:000222491600007
J	Arif, A; Vasanthi, P; Hansen, IA; Scheller, K; Dutta-Gupta, A				Arif, A; Vasanthi, P; Hansen, IA; Scheller, K; Dutta-Gupta, A			The insect hemolymph protein HP19 mediates the nongenomic effect of ecdysteroids on acid phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; LARVAL FAT-BODY; MOTH CORCYRA-CEPHALONICA; STEROID-HORMONES; RICE MOTH; 3-DIMENSIONAL STRUCTURE; POLYACRYLAMIDE GELS; HEXAMERIN RECEPTOR; PIERIS-BRASSICAE; STORAGE PROTEIN	The activity of acid phosphatase (ACP) in insect fat bodies is stimulated by the steroid hormone 20-hydoxyecdysone (20E) in vivo. However, in fat bodies kept in culture, a factor from the hemolymph is required to enhance the ACP activity. We identified the factor as a protein with a molecular mass of 19 kDa (HP19) from the hemolymph of a lepidopteran insect, the rice moth, Corcyra cephalonica. Western analysis of hemolymph proteins with denaturing and non-denaturing PAGE using antibodies raised against HP19 suggest that this protein exists as a monomer. It is synthesized by the hind gut-associated lobular fat body of the larvae and is released into the hemolymph. The stimulatory effect of HP19 on the ACP activity is developmentally regulated and exhibits its maximal effect shortly before the onset of metamorphosis. We cloned the HP19 cDNA by immunoscreening a hind gut-associated lobular fat body cDNA expression library. Analysis of the amino acid sequence shows that HP19 belongs to the family of glutathione S-transferase (GST) like proteins. However, affinity-purified GST from Corcyra failed to show any mediation effect on 20E-stimulated ACP activity, and HP19 lacks GST enzymatic activity. Notably, HP19 mediates the hormone-stimulated ACP activity in intact fat body tissue and homogenates even in the presence of inhibitors of transcription and translation, suggesting a nongenomic mode of action. In addition, we show that HP19 inhibits the 20E-induced phosphorylation of the hexamerin receptor protein.	Univ Hyderabad, Sch Life Sci, Dept Anim Sci, Hyderabad 500046, Andhra Pradesh, India; Univ Wurzburg, Bioctr, Dept Cell & Dev Biol, D-97074 Wurzburg, Germany; Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA	University of Hyderabad; University of Wurzburg; University of California System; University of California Riverside	Dutta-Gupta, A (corresponding author), Univ Hyderabad, Sch Life Sci, Dept Anim Sci, Hyderabad 500046, Andhra Pradesh, India.	apdgsl@uohyd.ernet.in						Arif A, 2003, INSECT BIOCHEM MOLEC, V33, P921, DOI 10.1016/S0965-1748(03)00098-5; ASHOK M, 1991, INVERTEBR REPROD DEV, V20, P159, DOI 10.1080/07924259.1991.9672193; ASHOK M, 1988, BIOCHEM INT, V17, P1087; BEAUFAY H, 1954, B SOC CHIM BIOL, V36, P1539; BIRREN B, 1997, GENOME ANAL LAB MANU, P6; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burmester T, 1999, NATURWISSENSCHAFTEN, V86, P468, DOI 10.1007/s001140050656; Burmester T, 1997, EUR J BIOCHEM, V247, P695, DOI 10.1111/j.1432-1033.1997.00695.x; Burmester T, 1999, EUR J BIOCHEM, V262, P49, DOI 10.1046/j.1432-1327.1999.00315.x; CAGLAYAN SH, 1990, BIOCHEM INT, V20, P511; Csikos G, 1997, ARCH INSECT BIOCHEM, V34, P369, DOI 10.1002/(SICI)1520-6327(1997)34:3<369::AID-ARCH10>3.3.CO;2-U; Dutta-Gupta Aparna, 1998, Entomon, V23, P245; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Farkas R, 1998, IN VITRO CELL DEV-AN, V34, P813; Feng QL, 1999, INSECT BIOCHEM MOLEC, V29, P779, DOI 10.1016/S0965-1748(99)00048-X; Gilbert LI, 2002, ANNU REV ENTOMOL, V47, P883, DOI 10.1146/annurev.ento.47.091201.145302; GRAY R, 1987, J INSECT PHYSIOL, V33, P325, DOI 10.1016/0022-1910(87)90120-X; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hansen IA, 2002, EUR J BIOCHEM, V269, P954, DOI 10.1046/j.0014-2956.2001.02736.x; HATAYAMA I, 1986, BIOCHEM BIOPH RES CO, V140, P581, DOI 10.1016/0006-291X(86)90771-0; Haunerland NH, 1996, INSECT BIOCHEM MOLEC, V26, P755, DOI 10.1016/S0965-1748(96)00035-5; Henrich VC, 1999, VITAM HORM, V55, P73; HENRIKSON PA, 1972, J INSECT PHYSIOL, V18, P1981, DOI 10.1016/0022-1910(72)90167-9; JI XH, 1995, BIOCHEMISTRY-US, V34, P5317, DOI 10.1021/bi00016a003; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; Kirankumar N, 1997, INSECT BIOCHEM MOLEC, V27, P671, DOI 10.1016/S0965-1748(97)00047-7; KUTUZOVA N M, 1991, Ukrainskii Biokhimicheskii Zhurnal, V63, P41; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKSHMI M, 1990, BIOCHEM INT, V22, P269; Lee CY, 2001, DEVELOPMENT, V128, P1443; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARUYAMA H, 1984, J BIOL CHEM, V259, P2449; Meltzer JC, 1997, J HISTOCHEM CYTOCHEM, V45, P599, DOI 10.1177/002215549704500412; Nijhout HF, 2002, P NATL ACAD SCI USA, V99, P15446, DOI 10.1073/pnas.242548399; PRIESTER DW, 1979, CELL TISSUE RES, V200, P435; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; Riddiford LM, 2001, VITAM HORM, V60, P1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASS M, 1989, COMP BIOCHEM PHYS A, V92, P285, DOI 10.1016/0300-9629(89)90565-3; SASS M, 1980, J INSECT PHYSIOL, V26, P569, DOI 10.1016/0022-1910(80)90132-8; Scheller K, 2003, EXP PHYSIOL, V88, P129, DOI 10.1113/eph8802507; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; SHIRAISHI A, 1989, INSECT BIOCHEM, V19, P261, DOI 10.1016/0020-1790(89)90071-1; Smagghe GJ, 2003, IN VITRO CELL DEV-AN, V39, P8, DOI 10.1290/1543-706X(2003)039<0008:EOAFBE>2.0.CO;2; Staffas L, 1998, BIOCHEM J, V332, P763, DOI 10.1042/bj3320763; TELFER WH, 1991, ANNU REV ENTOMOL, V36, P205, DOI 10.1146/annurev.en.36.010191.001225; Thummel CS, 2001, BIOESSAYS, V23, P677, DOI 10.1002/bies.1096; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Truman JW, 2002, ANNU REV ENTOMOL, V47, P467, DOI 10.1146/annurev.ento.47.091201.145230; Verkuil E.V.P., 1979, J INSECT PHYSL, V25, P965; VERKUIL EVP, 1980, J INSECT PHYSL, V26, P91; VERKUIL EVP, 1979, CELL TISSUE RES, V203, P443; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATSON RD, 1987, J EXP BIOL, V128, P159; Webster SG, 1998, BIOL BULL-US, V195, P282, DOI 10.2307/1543140; White R, 1998, ENDOCR-RELAT CANCER, V5, P1, DOI 10.1677/erc.0.0050001	58	8	11	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28000	28008		10.1074/jbc.M402311200	http://dx.doi.org/10.1074/jbc.M402311200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117951	hybrid			2022-12-25	WOS:000222265400023
J	Chen, RX; Le Rouzic, E; Kearney, JA; Mansky, LM; Benichou, S				Chen, RX; Le Rouzic, E; Kearney, JA; Mansky, LM; Benichou, S			Vpr-mediated incorporation of UNG2 into HIV-1 particles is required to modulate the virus mutation rate and for replication in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; URACIL-DNA GLYCOSYLASE; VIRAL-PROTEIN-R; NUCLEAR-PORE COMPLEX; TYPE-1 VPR; CELL-CYCLE; IN-VIVO; REVERSE-TRANSCRIPTASE; REGULATORY PROTEIN; REPAIR ENZYME	Human immunodeficiency virus type 1 is able to infect nondividing cells, such as macrophages, and the viral Vpr protein has been shown to participate in this process. Here, we investigated the impact of the recruitment into virus particles of the nuclear form of uracil DNA glycosylase (UNG2), a cellular DNA repair enzyme, on the virus mutation rate and on replication in macrophages. We demonstrate that the interaction of Vpr with UNG2 led to virion incorporation of a catalytically active enzyme that is directly involved with Vpr in modulating the virus mutation rate. The lack of UNG in virions during virus replication in primary monocyte-derived macrophages further exacerbated virus mutant frequencies to an 18-fold increase compared with the 4-fold increase measured in actively dividing cells. Because the presence of UNG is also critical for efficient infection of macrophages, these observations extend the role of Vpr to another early step of the virus life cycle, e. g. viral DNA synthesis, that is essential for replication of human immunodeficiency virus type 1 in nondividing cells.	Univ Minnesota, Inst Mol Virol, Minneapolis, MN 55455 USA; Ohio State Univ, Biochem Grad Program, Columbus, OH 43210 USA; Inst Cochin, Dept Infect Dis, INSERM,U567, CNRS,UMR 8104, Paris, France	University of Minnesota System; University of Minnesota Twin Cities; University System of Ohio; Ohio State University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Benichou, S (corresponding author), Univ Minnesota, Inst Mol Virol, 18-242 Moos Tower,515 Delaware St SE, Minneapolis, MN 55455 USA.	benichou@cochin.inserm.fr		Benichou, Serge/0000-0003-3602-3530	NIGMS NIH HHS [GM 56615] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056615, R29GM056615] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agostini I, 1999, FEBS LETT, V450, P235, DOI 10.1016/S0014-5793(99)00501-3; Bachand F, 1999, J BIOL CHEM, V274, P9083, DOI 10.1074/jbc.274.13.9083; BouHamdan M, 1998, J BIOL CHEM, V273, P8009, DOI 10.1074/jbc.273.14.8009; Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; Chen RX, 2002, J GEN VIROL, V83, P2339, DOI 10.1099/0022-1317-83-10-2339; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; Cohen O J, 2001, Adv Intern Med, V46, P207; Fouchier RAM, 1998, J VIROL, V72, P6004, DOI 10.1128/JVI.72.7.6004-6013.1998; HAUG T, 1994, FEBS LETT, V353, P180, DOI 10.1016/0014-5793(94)01042-0; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Klarmann GJ, 2003, J BIOL CHEM, V278, P7902, DOI 10.1074/jbc.M207223200; KUMAR NV, 1994, NUCLEIC ACIDS RES, V22, P3737, DOI 10.1093/nar/22.18.3737; Le Rouzic E, 2002, J BIOL CHEM, V277, P45091, DOI 10.1074/jbc.M207439200; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; LERNER DL, 1995, P NATL ACAD SCI USA, V92, P7480, DOI 10.1073/pnas.92.16.7480; LICHTENSTEIN DL, 1995, J VIROL, V69, P2881, DOI 10.1128/JVI.69.5.2881-2888.1995; LU YL, 1993, J VIROL, V67, P6542, DOI 10.1128/JVI.67.11.6542-6550.1993; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; MANSKY LM, 1994, J VIROL, V68, P494, DOI 10.1128/JVI.68.1.494-499.1994; Mansky LM, 2000, J VIROL, V74, P7039, DOI 10.1128/JVI.74.15.7039-7047.2000; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; Mansky LM, 1996, VIROLOGY, V222, P391, DOI 10.1006/viro.1996.0436; Mansky LM, 2003, J VIROL, V77, P2071, DOI 10.1128/JVI.77.3.2071-2080.2003; Mansky LM, 2003, VIROLOGY, V307, P116, DOI 10.1016/S0042-6822(02)00069-7; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Miller RJ, 2000, J VIROL, V74, P7187, DOI 10.1128/JVI.74.16.7187-7195.2000; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; Morellet N, 2003, J MOL BIOL, V327, P215, DOI 10.1016/S0022-2836(03)00060-3; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Popov S, 1998, J BIOL CHEM, V273, P13347, DOI 10.1074/jbc.273.21.13347; Priet S, 2003, J BIOL CHEM, V278, P4566, DOI 10.1074/jbc.M209311200; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; Selig L, 1999, J VIROL, V73, P592, DOI 10.1128/JVI.73.1.592-600.1999; Selig L, 1997, J VIROL, V71, P4842, DOI 10.1128/JVI.71.6.4842-4846.1997; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sherman MP, 2002, MICROBES INFECT, V4, P67, DOI 10.1016/S1286-4579(01)01511-8; Turelli P, 1997, J VIROL, V71, P4522, DOI 10.1128/JVI.71.6.4522-4530.1997; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; Willetts KE, 1999, J VIROL, V73, P1682, DOI 10.1128/JVI.73.2.1682-1688.1999; Wu XY, 1997, EMBO J, V16, P5113, DOI 10.1093/emboj/16.16.5113; WU XY, 1995, J VIROL, V69, P3389, DOI 10.1128/JVI.69.6.3389-3398.1995; Yao XJ, 1999, GENE THER, V6, P1590, DOI 10.1038/sj.gt.3300988; Yao XJ, 2002, J BIOL CHEM, V277, P48816, DOI 10.1074/jbc.M207982200; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	49	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28419	28425		10.1074/jbc.M403875200	http://dx.doi.org/10.1074/jbc.M403875200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15096517	hybrid			2022-12-25	WOS:000222265400075
J	Corbett, MC; Hu, YL; Naderi, F; Ribbe, MW; Hedman, B; Hodgson, KO				Corbett, MC; Hu, YL; Naderi, F; Ribbe, MW; Hedman, B; Hodgson, KO			Comparison of iron-molybdenum cofactor-deficient nitrogenase MoFe proteins by X-ray absorption spectroscopy - Implications for P-cluster biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII NITROGENASE; FEMO-COFACTOR; KLEBSIELLA-PNEUMONIAE; CRYSTAL-STRUCTURE; 4FE-4S CLUSTERS; DINITROGENASE REDUCTASE; ANGSTROM RESOLUTION; PHOSPHINE CLUSTERS; NIFB COFACTOR; SULFUR	Nitrogenase, the enzyme system responsible for biological nitrogen fixation, is believed to utilize two unique metalloclusters in catalysis. There is considerable interest in understanding how these metalloclusters are assembled in vivo. It has been presumed that immature iron-molybdenum cofactor-deficient nitrogenase MoFe proteins contain the P-cluster, although no biosynthetic pathway for the assembly of this complex cluster has been identified as yet. Through the comparison by iron K-edge x-ray absorption edge and extended fine structure analyses of cofactor-deficient MoFe proteins resulting from nifH and nifB deletion strains of Azotobacter vinelandii, a novel [Fe-S] cluster is identified in the DeltanifH MoFe protein. The iron-iron scattering displayed by the DeltanifH MoFe protein is more similar to that of a standard [Fe4S4]-containing protein than that of the DeltanifB MoFe protein, which is shown to contain a "normal" P-cluster. The iron-sulfur scattering of the DeltanifH MoFe protein, however, indicates differences in its cluster from an [Fe4S4](Cys)(4) site that may be consistent with the presence of either oxygenic or nitrogenic ligation. Based on these results, models for the [Fe-S] center in the DeltanifH MoFe protein are constructed, the most likely of which consist of two separate [ Fe4S4] sites, each with some non-cysteinyl coordination. This type of model suggests that the P-cluster is formed by the condensation of two [ Fe4S4] fragments, possibly concomitant with Fe protein (NifH)-induced conformational change.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Stanford Univ, Stanford Synchrotron Radiat Lab, Stanford Linear Accelerator Ctr, Stanford, CA 94305 USA	Stanford University; University of California System; University of California Irvine; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Hedman, B (corresponding author), Stanford Univ, Stanford Synchrotron Radiat Lab, 2575 Sand Hill Rd,MS 69, Menlo Pk, CA 94025 USA.	hedman@ssrl.slac.stanford.edu; hodgson@ssrl.slac.stanford.edu			NCRR NIH HHS [RR 01209] Funding Source: Medline; NIGMS NIH HHS [GM 67626] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067626] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; ALLEN RM, 1993, J BIOL CHEM, V268, P23670; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; Blanchard CZ, 1996, BIOCHEMISTRY-US, V35, P472, DOI 10.1021/bi951429j; Brereton PS, 1998, BIOCHEMISTRY-US, V37, P7351, DOI 10.1021/bi972864b; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; Bursey EH, 1998, J BIOL CHEM, V273, P29678, DOI 10.1074/jbc.273.45.29678; Christiansen J, 2001, ANNU REV PLANT PHYS, V52, P269, DOI 10.1146/annurev.arplant.52.1.269; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; Dean D.R., 1992, BIOL NITROGEN FIXATI, P763; Dos Santos PC, 2004, CHEM REV, V104, P1159, DOI 10.1021/cr020608l; Einsle O, 2002, SCIENCE, V297, P1696, DOI 10.1126/science.1073877; ELLIS PJ, 1995, J SYNCHROTRON RADIAT, V2, P190, DOI 10.1107/S0909049595006789; EMPTAGE MH, 1983, J BIOL CHEM, V258, P1106; Gailer J, 2001, J AM CHEM SOC, V123, P10121, DOI 10.1021/ja0158915; Gao-Sheridan HS, 1998, J BIOL CHEM, V273, P5514, DOI 10.1074/jbc.273.10.5514; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GAVINI N, 1994, BIOCHEMISTRY-US, V33, P11842, DOI 10.1021/bi00205a021; Goh C, 1998, INORG CHIM ACTA, V270, P46, DOI 10.1016/S0020-1693(97)05822-2; Goodwin PJ, 1998, BIOCHEMISTRY-US, V37, P10420, DOI 10.1021/bi980435n; HAGEN KS, 1981, J AM CHEM SOC, V103, P4054, DOI 10.1021/ja00404a013; HAWKES TR, 1983, BIOCHEM J, V209, P43, DOI 10.1042/bj2090043; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; Igarashi RY, 2003, CRIT REV BIOCHEM MOL, V38, P351, DOI 10.1080/10409230390242380; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; KENNEDY MC, 1984, J BIOL CHEM, V259, P3145; KURTZ DM, 1979, P NATL ACAD SCI USA, V76, P4986, DOI 10.1073/pnas.76.10.4986; Lee SC, 2004, CHEM REV, V104, P1135, DOI 10.1021/cr0206216; LIU HBI, 1994, J AM CHEM SOC, V116, P2418, DOI 10.1021/ja00085a022; LUDDEN PW, 1998, BIOL NITROGEN FIXATI, P33; Magnuson JK, 1997, TETRAHEDRON, V53, P11971, DOI 10.1016/S0040-4020(97)00710-2; Mansy SS, 2002, BIOCHEMISTRY-US, V41, P1195, DOI 10.1021/bi011811y; Mayer SM, 1999, J MOL BIOL, V292, P871, DOI 10.1006/jmbi.1999.3107; Messick TE, 2002, BIOCHEMISTRY-US, V41, P3931, DOI 10.1021/bi012035x; MUCHMORE SW, 1996, MECH METALLOCLUSTER, V11, P111; Musgrave KB, 1998, J AM CHEM SOC, V120, P5325, DOI 10.1021/ja980598z; Musgrave KB, 1998, J BIOL INORG CHEM, V3, P344, DOI 10.1007/s007750050243; Ohki Y, 2003, J AM CHEM SOC, V125, P4052, DOI 10.1021/ja029383m; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; Peters JW, 1997, BIOCHEMISTRY-US, V36, P1181, DOI 10.1021/bi9626665; PICKERING IJ, 1993, J AM CHEM SOC, V115, P9498, DOI 10.1021/ja00074a014; Rangaraj P, 1999, J BIOL CHEM, V274, P19778, DOI 10.1074/jbc.274.28.19778; Rangaraj P, 1997, P NATL ACAD SCI USA, V94, P11250, DOI 10.1073/pnas.94.21.11250; Rao PV, 2004, CHEM REV, V104, P527, DOI 10.1021/cr020615+; Ribbe M, 1997, J BIOL CHEM, V272, P26627, DOI 10.1074/jbc.272.42.26627; Ribbe MW, 2002, J BIOL CHEM, V277, P23469, DOI 10.1074/jbc.M202061200; Ribbe MW, 2000, J BIOL CHEM, V275, P17631, DOI 10.1074/jbc.275.23.17631; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; Rubio L. M., 2002, Nitrogen fixation at the millennium, P101, DOI 10.1016/B978-044450965-9/50004-5; Schlessman JL, 1998, J MOL BIOL, V280, P669, DOI 10.1006/jmbi.1998.1898; Schmid B, 2002, SCIENCE, V296, P352, DOI 10.1126/science.1070010; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; SHAH VK, 1994, J BIOL CHEM, V269, P1154; Smith BE, 1999, ADV INORG CHEM, V47, P159, DOI 10.1016/S0898-8838(08)60078-1; Strop P, 2001, BIOCHEMISTRY-US, V40, P651, DOI 10.1021/bi0016467; SURERUS KK, 1992, J AM CHEM SOC, V114, P8579, DOI 10.1021/ja00048a034; TAL S, 1991, J BIOL CHEM, V266, P10654; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Westre TE, 1997, J AM CHEM SOC, V119, P6297, DOI 10.1021/ja964352a; WHITE TC, 1992, J BIOL CHEM, V267, P24007; Zhang HH, 1999, INORGANIC ELECTRONIC STRUCTURE AND SPECTROSCOPY, VOL I, P513; Zhang Y, 2004, INORG CHEM, V43, P674, DOI 10.1021/ic030259t; Zhang YG, 2002, J AM CHEM SOC, V124, P14292, DOI 10.1021/ja0279702; Zhou HC, 2003, INORG CHEM, V42, P11, DOI 10.1021/ic020464t; [No title captured]	68	49	49	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28276	28282		10.1074/jbc.M403156200	http://dx.doi.org/10.1074/jbc.M403156200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102840	hybrid			2022-12-25	WOS:000222265400058
J	Marheineke, K; Hyrien, O				Marheineke, K; Hyrien, O			Control of replication origin density and firing time in Xenopus egg extracts - Role of a caffeine-sensitive, ATR-dependent checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC DNA-REPLICATION; RECOGNITION COMPLEX; DAMAGE CHECKPOINT; EARLY EMBRYOS; INITIATION; CHROMATIN; LAEVIS; PROTEIN; PROGRESSION; INHIBITION	A strict control of replication origin density and firing time is essential to chromosomal stability. Replication origins in early frog embryos are located at apparently random sequences, are spaced at close ( similar to 10-kb) intervals, and are activated in clusters that fire at different times throughout a very brief S phase. Using molecular combing of DNA from sperm nuclei replicating in Xenopus egg extracts, we show that the temporal order of origin firing can be modulated by the nucleocytoplasmic ratio and the checkpoint-abrogating agent caffeine in the absence of external challenge. Increasing the concentration of nuclei in the extract increases S phase length. Contrary to a previous interpretation, this does not result from a change in local origin spacing but from a spreading of the time over which distinct origin clusters fire and from a decrease in replication fork velocity. Caffeine addition or ATR inhibition with a specific neutralizing antibody increases origin firing early in S phase, suggesting that a checkpoint controls the time of origin firing during unperturbed S phase. Furthermore, fork progression is impaired when excess forks are assembled after caffeine treatment. We also show that caffeine allows more early origin firing with low levels of aphidicolin treatment but not higher levels. We propose that a caffeine-sensitive, ATR-dependent checkpoint adjusts the frequency of initiation to the supply of replication factors and optimizes fork density for safe and efficient chromosomal replication during normal S phase.	Ecole Normale Super, UMR 8541, Genet Mol Lab, F-75230 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Hyrien, O (corresponding author), Ecole Normale Super, UMR 8541, Genet Mol Lab, 46 Rue Ulm, F-75230 Paris 05, France.	hyrien@wotan.ens.fr	Marheineke, Kathrin/C-1797-2008; Hyrien, Olivier/R-5108-2017	Hyrien, Olivier/0000-0001-8879-675X; Marheineke, Kathrin/0000-0002-1514-0167				Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Berezney R, 2000, CHROMOSOMA, V108, P471, DOI 10.1007/s004120050399; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; Blow JJ, 2001, J CELL BIOL, V152, P15, DOI 10.1083/jcb.152.1.15; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; CHOI OH, 1988, LIFE SCI, V43, P387, DOI 10.1016/0024-3205(88)90517-6; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Cortez D, 2003, J BIOL CHEM, V278, P37139, DOI 10.1074/jbc.M307088200; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Dimitrova DS, 1999, MOL CELL, V4, P983, DOI 10.1016/S1097-2765(00)80227-0; Donaldson AD, 1998, MOL CELL, V2, P173, DOI 10.1016/S1097-2765(00)80127-6; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; Fredholm BB, 1999, PHARMACOL REV, V51, P83; Goren A, 2003, NAT REV MOL CELL BIO, V4, P25, DOI 10.1038/nrm1008; Harvey KJ, 2003, MOL CELL BIOL, V23, P6769, DOI 10.1128/MCB.23.19.6769-6779.2003; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Herrick J, 2000, J MOL BIOL, V300, P1133, DOI 10.1006/jmbi.2000.3930; HYRIEN O, 1995, SCIENCE, V270, P994, DOI 10.1126/science.270.5238.994; Hyrien O, 2003, BIOESSAYS, V25, P116, DOI 10.1002/bies.10208; HYRIEN O, 1993, EMBO J, V12, P4511, DOI 10.1002/j.1460-2075.1993.tb06140.x; Jun S, 2004, CELL CYCLE, V3, P223; Kaufmann WK, 2003, MUTAT RES-FUND MOL M, V532, P85, DOI 10.1016/j.mrfmmm.2003.08.012; Kubota Y, 2003, GENE DEV, V17, P1141, DOI 10.1101/gad.1070003; LASKEY RA, 1985, J EMBRYOL EXP MORPH, V89, P285; Lucas I, 2000, J MOL BIOL, V296, P769, DOI 10.1006/jmbi.2000.3500; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Marheineke K, 2001, J BIOL CHEM, V276, P17092, DOI 10.1074/jbc.M100271200; Maric C, 1999, J MOL BIOL, V291, P775, DOI 10.1006/jmbi.1999.3017; McNairn AJ, 2003, BIOESSAYS, V25, P647, DOI 10.1002/bies.10305; Miao H, 2003, J BIOL CHEM, V278, P4295, DOI 10.1074/jbc.M204264200; Michalet X, 1997, SCIENCE, V277, P1518, DOI 10.1126/science.277.5331.1518; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Raghuraman MK, 1997, SCIENCE, V276, P806, DOI 10.1126/science.276.5313.806; Rippe K, 2001, TRENDS BIOCHEM SCI, V26, P733, DOI 10.1016/S0968-0004(01)01978-8; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sharma K, 2001, GENETICS, V159, P35; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; Waiter J, 1997, SCIENCE, V275, P993, DOI 10.1126/science.275.5302.993; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	47	121	125	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28071	28081		10.1074/jbc.M401574200	http://dx.doi.org/10.1074/jbc.M401574200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123715	Green Published, hybrid			2022-12-25	WOS:000222265400032
J	Matsunaga, T; Kotamraju, S; Kalivendi, SV; Dhanasekaran, A; Joseph, J; Kalyanaraman, B				Matsunaga, T; Kotamraju, S; Kalivendi, SV; Dhanasekaran, A; Joseph, J; Kalyanaraman, B			Ceramide-induced intracellular oxidant formation, iron signaling, and apoptosis in endothelial cells - Protective role of endogenous nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; OXIDATIVE STRESS; REACTIVE OXYGEN; DEPENDENT APOPTOSIS; ACTIVATION; MITOCHONDRIA; TRANSLOCATION; SUPEROXIDE; DEATH	Sphingolipid ceramide (N-acetylsphingosine), a bioactive second messenger lipid, was shown to activate reactive oxygen species (ROS), mitochondrial oxidative damage, and apoptosis in neuronal and vascular cells. The proapoptotic effects of tumor necrosis factor-alpha, hypoxia, and chemotherapeutic drugs were attributed to increased ceramide formation. Here we investigated the protective role of nitric oxide ((NO)-N-.) during hydrogen peroxide (H2O2)-mediated transferrin receptor (TfR)-dependent iron signaling and apoptosis in C-2-ceramide (C-2-cer)-treated bovine aortic endothelial cells (BAECs). Addition of C-2-cer (5-20 muM) to BAECs enhanced (NO)-N-. generation. However, at higher concentrations of C-2-cer (greater than or equal to20 muM), (NO)-N-. generation did not increase proportionately. C-2-cer (20-50 muM) also resulted in H2O2-mediated dichlorodihydrofluorescein oxidation, reduced glutathione depletion, aconitase inactivation, TfR overexpression, TfR-dependent uptake of Fe-55, release of cytochrome c from mitochondria into cytosol, caspase-3 activation, and DNA fragmentation. Nw-Nitro-L-arginine methyl ester (L-NAME), a nonspecific inhibitor of nitric-oxide synthases, augmented these effects in BAECs at much lower (i.e. nonapoptotic) concentrations of C-2-cer. The 26 S proteasomal activity in BAECs was slightly elevated at lower concentrations of C-2-cer (less than or equal to10 muM) but was greatly suppressed at higher concentrations (> 10 muM). Intracellular scavengers of H2O2, cell-permeable iron chelators, anti-TfR receptor antibody, or mitochondria-targeted antioxidant greatly abrogated C-2-cer- and/or L-NAME-induced oxidative damage, iron signaling, and apoptosis. We conclude that C-2-cer-induced H2O2 and TfR-dependent iron signaling are responsible for its prooxidant and proapoptotic effects and that (NO)-N-. exerts an antioxidative and cytoprotective role.	Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Dept Biophys, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	balarama@mcw.edu	Dhanasekaran, Anuradha/AAF-3160-2022; Dhanasekaran, Anuradha/AFH-8265-2022	Dhanasekaran, Anuradha/0000-0002-0195-9681	NHLBI NIH HHS [HL 073056-01, 1P01 HL 68769-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073056, P01HL068769] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ariga T, 1998, J LIPID RES, V39, P1; BALLA G, 1992, J BIOL CHEM, V267, P18148; Barsacchi R, 2002, CELL DEATH DIFFER, V9, P1248, DOI 10.1038/sj.cdd.4401095; Chatterjee S, 1998, ARTERIOSCL THROM VAS, V18, P1523, DOI 10.1161/01.ATV.18.10.1523; CHITAMBAR CR, 1986, J CLIN INVEST, V78, P1538, DOI 10.1172/JCI112746; Corda S, 2001, AM J RESP CELL MOL, V24, P762, DOI 10.1165/ajrcmb.24.6.4228; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Cutler RG, 2002, ANN NEUROL, V52, P448, DOI 10.1002/ana.10312; Day BJ, 1995, J PHARMACOL EXP THER, V275, P1227; Deshpande SS, 2003, ARTERIOSCL THROM VAS, V23, pE1, DOI 10.1161/01.ATV.0000047869.13737.53; Erdreich-Epstein A, 2002, J BIOL CHEM, V277, P49531, DOI 10.1074/jbc.M209962200; Escargueil-Blanc I, 1998, J BIOL CHEM, V273, P27389, DOI 10.1074/jbc.273.42.27389; FranceLanord V, 1997, J NEUROCHEM, V69, P1612; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Heinloth A, 2002, ATHEROSCLEROSIS, V162, P93, DOI 10.1016/S0021-9150(01)00687-6; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; Hui DY, 2002, J LIPID RES, V43, P2017, DOI 10.1194/jlr.R200013-JLR200; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Igarashi J, 1999, P NATL ACAD SCI USA, V96, P12583, DOI 10.1073/pnas.96.22.12583; Irizarry MC, 2003, ANN NEUROL, V54, P7, DOI 10.1002/ana.10642; Ito A, 1999, BBA-MOL CELL RES, V1452, P263, DOI 10.1016/S0167-4889(99)00131-7; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Kojima H, 1998, CHEM PHARM BULL, V46, P373; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; Kotamraju S, 2004, ARCH BIOCHEM BIOPHYS, V423, P74, DOI 10.1016/j.abb.2003.12.037; Kotamraju S, 2003, P NATL ACAD SCI USA, V100, P10653, DOI 10.1073/pnas.1933581100; Kotamraju S, 2002, J BIOL CHEM, V277, P17179, DOI 10.1074/jbc.M111604200; Lenaz G, 2002, ANN NY ACAD SCI, V959, P199, DOI 10.1111/j.1749-6632.2002.tb02094.x; Levade T, 2001, CIRC RES, V89, P957, DOI 10.1161/hh2301.100350; Li HG, 2002, CIRCULATION, V106, P2250, DOI 10.1161/01.CIR.0000035650.05921.50; McCarty MF, 1998, MED HYPOTHESES, V51, P465, DOI 10.1016/S0306-9877(98)90066-4; Nakatsubo N, 1998, FEBS LETT, V427, P263, DOI 10.1016/S0014-5793(98)00440-2; Pajonk F, 2002, FREE RADICAL BIO MED, V32, P536, DOI 10.1016/S0891-5849(02)00743-8; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Phillips DC, 2002, ARCH BIOCHEM BIOPHYS, V407, P15, DOI 10.1016/S0003-9861(02)00496-4; Puglielli L, 2003, J BIOL CHEM, V278, P19777, DOI 10.1074/jbc.M300466200; Ribeiro ACM, 2001, CARDIOVASC RES, V49, P697, DOI 10.1016/S0008-6363(00)00267-4; Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; Sawai H, 1997, J BIOL CHEM, V272, P2452; Schuler F, 2001, BBA-BIOENERGETICS, V1506, P79, DOI 10.1016/S0005-2728(01)00183-9; Sorescu D, 2002, CIRCULATION, V105, P1429, DOI 10.1161/01.CIR.0000012917.74432.66; Sparagna GC, 2000, AM J PHYSIOL-HEART C, V279, pH2124, DOI 10.1152/ajpheart.2000.279.5.H2124; Tampo Y, 2003, CIRC RES, V92, P56, DOI 10.1161/01.RES.0000048195.15637.AC; Tang CH, 2004, J BIOL CHEM, V279, P288, DOI 10.1074/jbc.M310821200; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4	51	85	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28614	28624		10.1074/jbc.M400977200	http://dx.doi.org/10.1074/jbc.M400977200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102832	hybrid			2022-12-25	WOS:000222265400097
J	Taille, C; El-Benna, J; Lanone, S; Dang, MC; Ogier-Denis, E; Aubier, M; Boczkowski, J				Taille, C; El-Benna, J; Lanone, S; Dang, MC; Ogier-Denis, E; Aubier, M; Boczkowski, J			Induction of heme oxygenase-1 inhibits NAD(P)H oxidase activity by down-regulating cytochrome b(558) expression via the reduction of heme availability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIRWAY SMOOTH-MUSCLE; GENERATING NADPH OXIDASE; KAPPA-B ACTIVATION; FLAVOCYTOCHROME B(558); ENDOTHELIAL-CELLS; BILIRUBIN; ANTIOXIDANT; SYSTEM; GP91(PHOX); PHOSPHORYLATION	Heme-oxygenase- 1 (HO-1), the rate-limiting enzyme of heme degradation, has powerful anti-oxidant properties related to the production of the reactive oxygen species scavenger bilirubin. However, some data suggest that HO-1 could also inhibit the cellular production of reactive oxygen species. Therefore, we investigated whether the anti-oxidant properties of HO-1 could be mediated by modulation of the activity and/or expression of the heme-containing NAD(P)H oxidase, the main source of the superoxide anion (O-2((sic)) in phagocytic cells. Increasing HO-1 expression in RAW 264.7 macrophages effectively decreased NAD( P) H oxidase activity and expression of gp91(phox), its heme-containing catalytic component, because of deficient protein maturation and increased degradation. Loading cells with heme reversed the decrease in O2((sic)). production and gp91(phox) expression induced by HO-1 overexpression. Similar results were obtained in vivo in rat alveolar macrophages after pharmacological modulation of HO-1 expression or activity. These results show that a decrease in heme content due to HO-1 activation limits heme availability for maturation of the gp91(phox) subunit and assembly of the functional NAD(P)H oxidase. This study provides a new mechanism to explain HO-1 anti-oxidant properties.	Univ Paris 07, Inst Federat Rech 02, INSERM, U408, F-75018 Paris, France; Univ Paris 07, Inst Federat Rech 02, INSERM, U479, F-75018 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Boczkowski, J (corresponding author), Fac Xavier Bichat, INSERM, U408, BP416, F-75870 Paris 18, France.	jbb2@bichat.inserm.fr	Taille, Camille/J-3751-2017; Boczkowski, Jorge/S-7474-2018; Ogier-Denis, Eric/E-5030-2016; Lanone, Sophie/I-4042-2016	Boczkowski, Jorge/0000-0001-6619-5785; Lanone, Sophie/0000-0003-2509-8799; Ogier-Denis, Eric/0000-0002-0057-7593				Babior B M, 1995, Curr Opin Hematol, V2, P55; BALLA G, 1992, J BIOL CHEM, V267, P18148; Brar SS, 2003, AM J PHYSIOL-CELL PH, V285, pC353, DOI 10.1152/ajpcell.00525.2002; Brar SS, 2002, AM J PHYSIOL-LUNG C, V282, pL782, DOI 10.1152/ajplung.00206.2001; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643, DOI 10.1152/ajpheart.2000.278.2.H643; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; Dore S, 2000, NEUROSCIENCE, V99, P587, DOI 10.1016/S0306-4522(00)00216-5; DRUMMOND GS, 1982, P NATL ACAD SCI-BIOL, V79, P2384, DOI 10.1073/pnas.79.7.2384; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; Exner M, 2001, J ENDOVASC THER, V8, P433, DOI 10.1583/1545-1550(2001)008<0433:HOGPMP>2.0.CO;2; Foresti R, 2001, AM J PHYSIOL-HEART C, V281, pH1976, DOI 10.1152/ajpheart.2001.281.5.H1976; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Haider A, 2002, J PHARMACOL EXP THER, V300, P188, DOI 10.1124/jpet.300.1.188; Ishikawa K, 2001, CIRC RES, V88, P506, DOI 10.1161/01.RES.88.5.506; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; Juan SH, 2001, CIRCULATION, V104, P1519, DOI 10.1161/hc3801.095663; KAPPAS A, 1986, J CLIN INVEST, V77, P335, DOI 10.1172/JCI112309; KWAK JY, 1991, BIOCHIM BIOPHYS ACTA, V1076, P369, DOI 10.1016/0167-4838(91)90478-I; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Li Volti G, 2003, HYPERTENSION, V41, P715, DOI 10.1161/01.HYP.0000049163.23426.66; MEIER B, 1991, BIOCHEM J, V275, P241, DOI 10.1042/bj2750241; Minetti M, 1998, ARCH BIOCHEM BIOPHYS, V352, P165, DOI 10.1006/abbi.1998.0584; MOTTERLINI R, 1995, AM J PHYSIOL-HEART C, V269, pH648, DOI 10.1152/ajpheart.1995.269.2.H648; Nemeth ZH, 2004, MOL PHARMACOL, V65, P342, DOI 10.1124/mol.65.2.342; Otterbein LE, 2002, ANTIOXID REDOX SIGN, V4, P309, DOI 10.1089/152308602753666361; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Samb A, 2002, AM J PHYSIOL-LUNG C, V283, pL596, DOI 10.1152/ajplung.00446.2001; Schillinger M, 2002, THROMB RES, V106, P131, DOI 10.1016/S0049-3848(02)00100-7; Segal AW, 1997, ANN NY ACAD SCI, V832, P215, DOI 10.1111/j.1749-6632.1997.tb46249.x; Serfas L, 1998, ARCH BIOCHEM BIOPHYS, V359, P8, DOI 10.1006/abbi.1998.0887; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Szocs K, 2002, ARTERIOSCL THROM VAS, V22, P21, DOI 10.1161/hq0102.102189; Taille C, 2003, J BIOL CHEM, V278, P27160, DOI 10.1074/jbc.M300364200; Taille C, 2001, AM J RESP CRIT CARE, V163, P753, DOI 10.1164/ajrccm.163.3.2004202; Thabut G, 2002, J BIOL CHEM, V277, P22814, DOI 10.1074/jbc.M200315200; Tulis DA, 2001, ATHEROSCLEROSIS, V155, P113, DOI 10.1016/S0021-9150(00)00552-9; Turcanu V, 1998, RES IMMUNOL, V149, P741, DOI 10.1016/S0923-2494(99)80050-9; Turcanu V, 1998, TRANSPL P, V30, P4184, DOI 10.1016/S0041-1345(98)01385-2; Wagener FADTG, 1999, J PHARMACOL EXP THER, V291, P416; Yu LX, 1999, J BIOL CHEM, V274, P4364, DOI 10.1074/jbc.274.7.4364; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993	43	162	174	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28681	28688		10.1074/jbc.M310661200	http://dx.doi.org/10.1074/jbc.M310661200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123630	hybrid			2022-12-25	WOS:000222265400105
J	Staruschenko, A; Medina, JL; Patel, P; Shapiro, MS; Booth, RE; Stockand, JD				Staruschenko, A; Medina, JL; Patel, P; Shapiro, MS; Booth, RE; Stockand, JD			Fluorescence resonance energy transfer analysis of subunit stoichiometry of the epithelial Na+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; ENAC; ACTIVATION; CELLS	Activity of the epithelial Na+ channel (ENaC) is rate-limiting for Na+ ( re) absorption across electrically tight epithelia. ENaC is a heteromeric channel comprised of three subunits, alpha, beta, and gamma, with each subunit contributing to the functional channel pore. The subunit stoichiometry of ENaC remains uncertain with electrophysiology and biochemical experiments supporting both a tetramer with a 2alpha: 1beta: 1gamma stoichiometry and a higher ordered channel with a 3alpha: 3beta: 3gamma stoichiometry. Here we used an independent biophysical approach based upon fluorescence resonance energy transfer ( FRET) between differentially fluorophore-tagged ENaC subunits to determine the subunit composition of mouse ENaC functionally reconstituted in Chinese hamster ovary and COS-7 cells. We found that when all three subunits were co-expressed, ENaC contained at least two of each type of subunit. Findings showing that ENaC subunits interact with similar subunits in immunoprecipitation studies are consistent with these FRET results. Upon native polyacrylamide gel electrophoresis, moreover, oligomerized ENaC runs predominantly as a single species with a molecular mass of > 600 kDa. Because single ENaC subunits have a molecular mass of similar to 90 kDa, these results also agree with the FRET results. The current results as a whole, thus, are most consistent with a higher ordered channel possibly with a 3alpha: 3beta: 3gamma stoichiometry.	SW Texas State Univ, Dept Chem & Biochem, San Marcos, TX 78666 USA; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	Texas State University System; Texas State University San Marcos; University of Texas System; University of Texas Health San Antonio	Booth, RE (corresponding author), SW Texas State Univ, Dept Chem & Biochem, 601 Univ Dr,CHEM 216, San Marcos, TX 78666 USA.	rbooth@txstate.edu		Stockand, James/0000-0002-3817-4319; Staruschenko, Alexander/0000-0002-5190-8356	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059594] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-59594] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benos DJ, 1999, J PHYSIOL-LONDON, V520, P631, DOI 10.1111/j.1469-7793.1999.00631.x; Bianchi L, 2002, NEURON, V34, P337, DOI 10.1016/S0896-6273(02)00687-6; Booth RE, 2003, J BIOL CHEM, V278, P41367, DOI 10.1074/jbc.M305400200; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CATTERALL WA, 1993, TRENDS NEUROSCI, V16, P500, DOI 10.1016/0166-2236(93)90193-P; Centonze VE, 2003, METHOD ENZYMOL, V360, P542; Dijkink L, 2002, PFLUG ARCH EUR J PHY, V444, P549, DOI 10.1007/s00424-002-0855-4; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Eskandari S, 1999, J BIOL CHEM, V274, P27281, DOI 10.1074/jbc.274.38.27281; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; FRINDT G, 1990, AM J PHYSIOL, V258, pF562, DOI 10.1152/ajprenal.1990.258.3.F562; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; HAMILTON KL, 1985, AM J PHYSIOL, V249, pC200, DOI 10.1152/ajpcell.1985.249.3.C200; Hendron E, 2002, MOL BIOL CELL, V13, P3042, DOI 10.1091/mbc.E02-05-0260; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Jovov B, 1999, J BIOL CHEM, V274, P37845, DOI 10.1074/jbc.274.53.37845; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Tong QS, 2004, J BIOL CHEM, V279, P22654, DOI 10.1074/jbc.M401004200; Tong QS, 2004, AM J PHYSIOL-RENAL, V286, pF1232, DOI 10.1152/ajprenal.00345.2003; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7; Zheng J, 2002, NEURON, V36, P891, DOI 10.1016/S0896-6273(02)01099-1	31	55	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27729	27734		10.1074/jbc.M404169200	http://dx.doi.org/10.1074/jbc.M404169200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096495	hybrid			2022-12-25	WOS:000222120400107
J	Weser, S; Gruber, C; Hafner, HM; Teichmann, M; Roeder, RG; Seifart, KH; Meissner, W				Weser, S; Gruber, C; Hafner, HM; Teichmann, M; Roeder, RG; Seifart, KH; Meissner, W			Transcription factor (TF)-like nuclear regulator, the 250-kDa form of Homo sapiens TFIIIB '', is an essential component of human TFIIIC1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; 2 FUNCTIONAL COMPONENTS; TATA-BINDING PROTEIN; IN-VITRO; GENES; PROMOTERS; COMPLEX; CELLS; DIFFERENTIATION; SEPARATION	The general human RNA polymerase III transcription factor (TF) IIIC1 has hitherto been ill defined with respect to the polypeptides required for reconstitution of its activity. Here we identify Homo sapiens TFIIIB" (HsBdp1) as an essential component of hTFIIIC1 and hT-FIIIC1-like activities. Several forms of HsBdp1 are described. The 250-kDa form of HsBdp1, also designated the "transcription factor-like nuclear regulator," strictly co-eluted with TFIIIC1 activity over multiple chromatographic purification steps as revealed by Western blot with anti-HsBdp1 antibodies and by MALDI-TOF analysis. In addition, TFIIIC1 activity could be depleted from partially purified fractions with anti-HsBdp1 antibodies but not with control antibodies. Moreover, highly purified recombinant HsBdp1 could replace TFIIIC1 activity in reconstituted transcription of the VAI gene in vitro. Furthermore, smaller proteins of similar to 90 - 150 kDa that were recognized by anti-HsBdp1 antibodies co-eluted with TFIIIC1-like activity. Finally, cytoplasmic extracts from differentiated mouse F9 fibroblast cells that lacked TFIIIC1 activity could be made competent for transcription of the VA1 gene by the addition of TFIIIC1, TFIIIC1-like, or recombinant HsBdp1. These results suggest that HsBdp1 proteins represent essential components of TFIIIC1 and TFIIIC1-like activities.	Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany; Univ Bordeaux 2, Inst Europeaen Chim & Biol, F-33607 Pessac, France; Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	Philipps University Marburg; UDICE-French Research Universities; Universite de Bordeaux; Rockefeller University	Meissner, W (corresponding author), Univ Marburg, Inst Mol Biol & Tumorforsch, Lahnstr 3, D-35037 Marburg, Germany.	meissner@imt.uni-marburg.de	Teichmann, Martin/M-7407-2014	Teichmann, Martin/0000-0002-5257-0510				Alzuherri HM, 1998, J BIOL CHEM, V273, P17166, DOI 10.1074/jbc.273.27.17166; Cabart P, 2002, J BIOL CHEM, V277, P26831, DOI 10.1074/jbc.M203119200; Cabart P, 2001, J BIOL CHEM, V276, P43056, DOI 10.1074/jbc.M108515200; DEAN N, 1987, NUCLEIC ACIDS RES, V15, P9895, DOI 10.1093/nar/15.23.9895; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Hernandez N, 2001, J BIOL CHEM, V276, P26733, DOI 10.1074/jbc.R100032200; Hu P, 2003, MOL CELL, V12, P699, DOI 10.1016/j.molcel.2003.08.011; Huang Y, 2001, NUCLEIC ACIDS RES, V29, P2675, DOI 10.1093/nar/29.13.2675; JAHN D, 1987, J MOL BIOL, V193, P303, DOI 10.1016/0022-2836(87)90221-X; Kelter AR, 2000, GENOMICS, V70, P315, DOI 10.1006/geno.2000.6396; Kober I, 1998, J MOL BIOL, V284, P7, DOI 10.1006/jmbi.1998.2165; Meissner W, 2002, J BIOL CHEM, V277, P7148, DOI 10.1074/jbc.M108721200; Oettel S, 1997, NUCLEIC ACIDS RES, V25, P2440, DOI 10.1093/nar/25.12.2440; Oettel S, 1998, NUCLEIC ACIDS RES, V26, P4324, DOI 10.1093/nar/26.19.4324; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHNEIDER HR, 1989, NUCLEIC ACIDS RES, V17, P5003, DOI 10.1093/nar/17.13.5003; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; TEICHMANN M, 1995, EMBO J, V14, P5974, DOI 10.1002/j.1460-2075.1995.tb00286.x; Teichmann M, 1997, EMBO J, V16, P4708, DOI 10.1093/emboj/16.15.4708; Teichmann M, 2000, P NATL ACAD SCI USA, V97, P14200, DOI 10.1073/pnas.97.26.14200; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; Wang ZX, 1996, MOL CELL BIOL, V16, P6841; WEIL PA, 1979, J BIOL CHEM, V254, P6163; Weser S, 2000, NUCLEIC ACIDS RES, V28, P3935, DOI 10.1093/nar/28.20.3935; Weser S, 2003, NUCLEIC ACIDS RES, V31, P2408, DOI 10.1093/nar/gkg345; Willis IM, 2002, GENE DEV, V16, P1337, DOI 10.1101/gad.998102; YOON JB, 1995, MOL CELL BIOL, V15, P2019; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585	30	16	17	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27022	27029		10.1074/jbc.M312790200	http://dx.doi.org/10.1074/jbc.M312790200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096501	hybrid			2022-12-25	WOS:000222120400028
J	Suzuki, H; Yagi, K; Kondo, M; Kato, M; Miyazono, K; Miyazawa, K				Suzuki, H; Yagi, K; Kondo, M; Kato, M; Miyazono, K; Miyazawa, K			c-Ski inhibits the TGF-beta signaling pathway through stabilization of inactive Smad complexes on Smad-binding elements	ONCOGENE			English	Article						Ski; Smad; TGF-beta; Smad-binding element	TGF-BETA-1 INHIBITION; MEDIATED REPRESSION; ONCOPROTEIN SKI; CELL-MEMBRANE; GROWTH; MYC; PROTEINS; PROMOTER; SNON; TRANSCRIPTION	c-Ski inhibits transforming growth factor-beta (TGF-beta) signaling through interaction with Smad proteins. c-Ski represses Smad-mediated transcriptional activation, probably through its action as a transcriptional co-repressor. c-Ski also inhibits TGF-beta-induced downregulation of genes such as c-myc. How ever, mechanisms for transcriptional regulation of target genes by c-Ski have not been fully determined. In this study, we examined how c-Ski inhibits both TGF-beta-induced transcriptional activation and repression. DNA-affinity precipitation analysis revealed that c-Ski enhances the binding of Smad2 and 4, and to a lesser extent Smad3, to both CAGA and TGF-beta1 inhibitory element probes. A c-Ski mutant, which is unable to interact with Smad4, failed to enhance the binding of Smad complex on these probes and to inhibit the Smad-responsive promoter. These results suggest that stabilization of inactive Smad complexes on DNA is a critical event in c-Ski-mediated inhibition of TGF-beta signaling.	Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan.	miyazono-ind@umin.ac.jp	MIYAZAWA, KEIJI/I-9713-2014					Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Mizuide M, 2003, J BIOL CHEM, V278, P531, DOI 10.1074/jbc.C200596200; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Prunier C, 2003, J BIOL CHEM, V278, P26249, DOI 10.1074/jbc.M304459200; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Suzuki H, 2001, ONCOGENE, V20, P5779, DOI 10.1038/sj.onc.1204742; Takeda M, 2004, MOL BIOL CELL, V15, P963, DOI 10.1091/mbc.E03-07-0478; Ueki N, 2003, J BIOL CHEM, V278, P32489, DOI 10.1074/jbc.C300276200; Ueki N, 2003, J BIOL CHEM, V278, P24858, DOI 10.1074/jbc.M303447200; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Yagi K, 2002, J BIOL CHEM, V277, P854, DOI 10.1074/jbc.M104170200; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703	33	95	108	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5068	5076		10.1038/sj.onc.1207690	http://dx.doi.org/10.1038/sj.onc.1207690			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15107821				2022-12-25	WOS:000222237300013
J	Cheng, HYY; Li, P; David, M; Smithgall, TE; Feng, LL; Lieberman, MW				Cheng, HYY; Li, P; David, M; Smithgall, TE; Feng, LL; Lieberman, MW			Arsenic inhibition of the JAK-STAT pathway	ONCOGENE			English	Article						arsenite; JAK; STAT3; SOCS; IL-6	ACTIVATED T-CELLS; SERINE PHOSPHORYLATION; PROLIFERATION; EXPRESSION; STRESS; SECRETION; APOPTOSIS; SIGNALS; LINES; IL-6	The Janus kinase (JAK)-signal transducer and activator of transcription ( STAT) pathway is an essential cascade for mediating normal functions of different cytokines in the development of the hematopoietic and immune systems. Chronic exposure to arsenic has been found to cause immunotoxicity and has been associated with the suppression of hematopoiesis ( anemia and leukopenia). Here, we report the novel finding of arsenic-mediated inactivation of the JAK-STAT signaling pathway by its direct interaction with JAK tyrosine kinase. Pretreatment with sodium arsenite strongly inhibited IL-6-inducible STAT3 tyrosine phosphorylation in HepG2 cells and did not affect its serine phosphorylation. As a result, sodium arsenite completely abolished STAT activity-dependent expression of suppressors of cytokine signaling ( SOCS). Both cellular and subcelluar experiments showed that the inhibition of JAK-STAT signaling resulted from JAK tyrosine kinase's direct interaction with arsenite, and that arsenic's suppression of JAK tyrosine kinase activity also occurred in the interferon gamma (IFNgamma) pathway. The ligand-independent inhibition by arsenic indicates that JAK was the direct target of arsenic action. Other inflammatory stimulants, stress agents, and metal cadmium failed to induce similar effects on the tyrosine phosphorylation of STAT3 as arsenic does. Our experiments also revealed that arsenic inactivation of the JAK-STAT pathway occurred independent of arsenic activation of MAP kinases. Taken together, our findings indicate that arsenic directly inhibits JAK tyrosine kinase activity and suggest that this direct interference in the JAK-STAT pathway may play a role in arsenic-associated pathogenesis.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Calif San Diego, UCSD Canc Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15261 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; University of California System; University of California San Diego; University of California System; University of California San Diego; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Baylor College of Medicine	Lieberman, MW (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Olazam, Houston, TX 77030 USA.	mikel@bcm.tmc.edu			NIEHS NIH HHS [ES 10389] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010389] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AHMAD S, 1995, ARCH INSECT BIOCHEM, V29, P135, DOI 10.1002/arch.940290205; Ahmed ST, 2000, J IMMUNOL, V165, P5227, DOI 10.4049/jimmunol.165.9.5227; Aringer M, 1999, LIFE SCI, V64, P2173, DOI 10.1016/S0024-3205(98)00538-4; Barchowsky A, 1999, TOXICOL APPL PHARM, V159, P65, DOI 10.1006/taap.1999.8723; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BURNS LA, 1993, J PHARMACOL EXP THER, V265, P150; BURNS LA, 1993, J PHARMACOL EXP THER, V265, P178; Bustamante J, 1997, TOXICOLOGY, V118, P129, DOI 10.1016/S0300-483X(96)03607-4; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; Galicia G, 2003, INT IMMUNOPHARMACOL, V3, P671, DOI 10.1016/S1567-5769(03)00049-3; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Haq R, 2002, J BIOL CHEM, V277, P17359, DOI 10.1074/jbc.M201842200; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Ishitsuka K, 2002, LEUKEMIA LYMPHOMA, V43, P1107, DOI 10.1080/10428190290021461; Iwamoto T, 2000, ONCOGENE, V19, P4795, DOI 10.1038/sj.onc.1203829; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; LOH JE, 1994, MOL CELL BIOL, V14, P2170, DOI 10.1128/MCB.14.3.2170; *NAT RES COUNC SUB, 2001, ARS DRINK WAT, P82; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Sengupta TK, 1996, P NATL ACAD SCI USA, V93, P9499, DOI 10.1073/pnas.93.18.9499; Vega L, 1999, IMMUNOPHARM IMMUNOT, V21, P203, DOI 10.3109/08923979909052758; WOODS JS, 1996, TOXICOLOGY METALS, P939; Yoo JY, 2002, CELL, V108, P331, DOI 10.1016/S0092-8674(02)00636-0; Yu HS, 1998, ARCH DERMATOL RES, V290, P681, DOI 10.1007/s004030050373; Zhou YJ, 2001, MOL CELL, V8, P959, DOI 10.1016/S1097-2765(01)00398-7	33	52	58	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3603	3612		10.1038/sj.onc.1207466	http://dx.doi.org/10.1038/sj.onc.1207466			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116095	Green Published			2022-12-25	WOS:000221101700012
J	Pradeep, A; Sharma, C; Sathyanarayana, P; Albanese, C; Fleming, JV; Wang, TC; Wolfe, MM; Baker, KM; Pestell, RG; Rana, B				Pradeep, A; Sharma, C; Sathyanarayana, P; Albanese, C; Fleming, JV; Wang, TC; Wolfe, MM; Baker, KM; Pestell, RG; Rana, B			Gastrin-mediated activation of cyclin D1 transcription involves beta-catenin and CREB pathways in gastric cancer cells	ONCOGENE			English	Article						cyclin D1; Wnt signaling; transcription; gastrin (G-17); CREB	ELEMENT-BINDING PROTEIN; C-MYC; COLORECTAL-CANCER; ACID-SECRETION; KINASE PATHWAY; MOUSE MODEL; AGS CELLS; EXPRESSION; HYPERGASTRINEMIA; PHOSPHORYLATION	Gastrin and its precursors promote proliferation in different gastrointestinal cells. Since mature, amidated gastrin (G-17) can induce cyclin D1, we determined whether G-17-mediated induction of cyclin D1 transcription involved Wnt signaling and CRE-binding protein (CREB) pathways. Our studies indicate that G-17 induces protein, mRNA expression and transcription of the G(1)-specific marker cyclin D1, in the gastric adenocarcinoma cell line AGSE (expressing the gastrin/cholecystokinin B receptor). This was associated with an increase in steady-state levels of total and nonphospho beta-catenin and its nuclear translocation, indicating the activation of the Wnt-signaling pathway. In addition, G-17-mediated increase in cyclin D1 transcription was significantly attenuated by axin or dominant-negative (dn) T-cell factor 4(TCF4), suggesting crosstalk of G-17 with the Wnt-signaling pathway. Mutational analysis indicated that this effect was mediated through the cyclic AMP response element (CRE) (predominantly) and the TCF sites in the cyclin D1 promoter, which was also inhibited by dnCREB. Furthermore, G-17 stimulation resulted in increased CRE-responsive reporter activity and CREB phosphorylation, indicating an activation of CREB. Chromatin immunoprecipitation studies revealed a G-17-mediated increase in the interaction of beta-catenin with cyclin D1 CRE, which was attenuated by dnTCF4 and dnCREB. These results indicate that G-17 induces cyclin D1 transcription, via the activation of beta-catenin and CREB pathways.	Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Div Mol Cardiol, Temple, TX 76504 USA; Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20057 USA; Univ Massachusetts, Sch Med, Gastrointestinal Div, Worcester, MA 01605 USA; Boston Med Ctr, Gastroenterol Sect, Boston, MA 02118 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Georgetown University; University of Massachusetts System; University of Massachusetts Worcester; Boston Medical Center	Rana, B (corresponding author), Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Div Mol Cardiol, Temple, TX 76504 USA.	brana@medicine.tamu.edu		Wang, Timothy/0000-0001-5730-3019	NCI NIH HHS [CA86072, CA70896, CA75503] Funding Source: Medline; NHLBI NIH HHS [HL44883, HL54583] Funding Source: Medline; NIA NIH HHS [AG2033] Funding Source: Medline; NIDDK NIH HHS [DK53158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070896, R29CA070896, R01CA086072, R01CA075503, R55CA075503] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arato-Ohshima T, 1999, INT J CANCER, V83, P387, DOI 10.1002/(SICI)1097-0215(19991029)83:3<387::AID-IJC15>3.0.CO;2-O; Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bierkamp C, 2002, ONCOGENE, V21, P7656, DOI 10.1038/sj.onc.1205999; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Du KY, 2000, MOL CELL BIOL, V20, P4320, DOI 10.1128/MCB.20.12.4320-4327.2000; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hirata Y, 2001, INFECT IMMUN, V69, P3965, DOI 10.1128/IAI.69.6.3965-3971.2001; Hollande F, 2001, J BIOL CHEM, V276, P40402, DOI 10.1074/jbc.M105090200; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kikuchi A, 1999, CYTOKINE GROWTH F R, V10, P255, DOI 10.1016/S1359-6101(99)00017-9; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Konturek SJ, 2000, REGUL PEPTIDES, V93, P13, DOI 10.1016/S0167-0115(00)00173-7; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LIND T, 1988, SCAND J GASTROENTERO, V23, P1259, DOI 10.3109/00365528809090202; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Miyaji M, 1997, TUMOR BIOL, V18, P311, DOI 10.1159/000218044; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Noble PJM, 2003, AM J PHYSIOL-GASTR L, V284, pG75, DOI 10.1152/ajpgi.00300.2002; Oda K, 1999, RES COMMUN MOL PATH, V105, P237; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Parker D, 1996, MOL CELL BIOL, V16, P694; PENMAN ID, 1993, GUT, V34, P1559, DOI 10.1136/gut.34.11.1559; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; PINSON DM, 1995, GASTROENTEROLOGY, V108, P1068, DOI 10.1016/0016-5085(95)90204-X; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Qvigstad G, 2002, APMIS, V110, P132, DOI 10.1034/j.1600-0463.2002.100302.x; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; Raychowdhury R, 2002, BIOCHEM BIOPH RES CO, V297, P1089, DOI 10.1016/S0006-291X(02)02345-8; ROSS SE, 2000, SCIENCE, V0289, P00950, DOI [DOI 10.1126/SCIENCE.289.5481.950, DOI 10.1126/science.289.5481.950, 10.1126/science.289.5481.950]; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; Singh P, 2000, GASTROENTEROLOGY, V119, P162, DOI 10.1053/gast.2000.8527; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; SMITH JTL, 1990, GUT, V31, P522, DOI 10.1136/gut.31.5.522; Song DH, 2003, AM J PHYSIOL-GASTR L, V285, pG217, DOI 10.1152/ajpgi.00516.2002; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thommesen L, 2001, AM J PHYSIOL-ENDOC M, V281, pE1316, DOI 10.1152/ajpendo.2001.281.6.E1316; Thorburn CM, 1998, GASTROENTEROLOGY, V115, P275, DOI 10.1016/S0016-5085(98)70193-3; Varro A, 2002, GUT, V50, P827, DOI 10.1136/gut.50.6.827; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Watson SA, 2000, CANCER RES, V60, P5902; Watson SA, 2001, CANCER RES, V61, P625; Watson SA, 2001, EXPERT OPIN BIOL TH, V1, P309, DOI 10.1517/14712598.1.2.309; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wu GY, 2001, P NATL ACAD SCI USA, V98, P2808, DOI 10.1073/pnas.051634198; Xu LF, 2000, GENE DEV, V14, P585; Zhukova E, 2001, J CELL PHYSIOL, V189, P291, DOI 10.1002/jcp.10018	62	87	91	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3689	3699		10.1038/sj.onc.1207454	http://dx.doi.org/10.1038/sj.onc.1207454			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116100				2022-12-25	WOS:000221101700021
J	Li, L; Gronning, LM; Anderson, PO; Li, SL; Edvardsen, K; Johnston, J; Kioussis, D; Shepherd, PR; Wang, P				Li, L; Gronning, LM; Anderson, PO; Li, SL; Edvardsen, K; Johnston, J; Kioussis, D; Shepherd, PR; Wang, P			Insulin induces SOCS-6 expression and its binding to the p85 monomer of phosphoinositide 3-kinase, resulting in improvement in glucose metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE KINASE-ACTIVITY; MICE LACKING; GROWTH-HORMONE; CYTOKINE SIGNALING-1; IN-VIVO; PHOSPHATIDYLINOSITOL 3-KINASE; P85-ALPHA SUBUNIT; 85-KDA SUBUNIT; BOX MOTIF; SUPPRESSOR	The suppressors of cytokine signaling ( SOCS) family is thought to act largely as a negative regulator of signaling by cytokines and some growth factors. Surprisingly, the SOCS-6 transgenics had no significant defects in the cytokine signaling and hematopoietic system but displayed significant improvements in glucose metabolism. Insulin stimulation of Akt/protein kinase B was also potentiated. Biochemical analysis showed that, after insulin stimulation, SOCS-6 interacted with the monomeric p85 subunit of class-Ia phosphoinositide ( PI) 3-kinase but not with p85/p110 dimers. Furthermore, SOCS-6 expression is transiently increased by serum and insulin in normal fibroblasts. However, both the mRNA and protein of SOCS-6 were rapidly degraded after induction by insulin. The degradation of the SOCS-6 protein was partially inhibited by a proteasome inhibitor, suggesting a proteasome-mediated degradation mechanism. In contrast, SOCS-6- associated p85 was not degraded and could be recruited to the newly synthesized SOCS-6 molecules in the presence of insulin, suggesting that SOCS-6 expression and its interaction with p85, but not the degradation, is regulated by insulin. The phenotype of SOCS-6 transgenic mice bears a striking resemblance to p85 knock-out mouse models in which glucose metabolism stimulated by insulin is significantly improved despite reduced activation of PI 3-kinase. This suggests that monomeric p85 might play a physiologically important role in attenuating signaling through PI 3-kinase-dependent pathways in unstimulated cells. Therefore, our results indicate that SOCS-6 may provide a dynamically regulated mechanism by which insulin can transiently overcome the negative effects that p85 monomers have on signaling via PI 3-kinase-dependent signaling pathways.	St Barts & Rotal London Sch Med, Inst Cell & Mol Sci, Immunol Grp, London EC1A 7ED, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Natl Inst Med Res, Div Mol Immunol, MRC, London NW7 1AA, England; Lund Univ, Dept Tumor Immunol, S-22362 Lund, Sweden; Queens Univ Belfast, Dept Immunol, Belfast BT9 7BL, Antrim, North Ireland	University of London; Queen Mary University London; University of London; University College London; MRC National Institute for Medical Research; Lund University; Queens University Belfast	Wang, P (corresponding author), Barts & London Queen Marys Sch Med & Dent, Inst Cell & Mol Sci, Immunol Grp, 59 Bartholomews Close, London EC1A 7ED, England.	p.wang@qmul.ac.uk		Wang, Ping/0000-0001-8992-1233; Anderson, Per/0000-0002-0958-7990				Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Berlato C, 2002, J IMMUNOL, V168, P6404, DOI 10.4049/jimmunol.168.12.6404; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Denson LA, 2003, AM J PHYSIOL-GASTR L, V284, pG646, DOI 10.1152/ajpgi.00178.2002; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Dogusan Z, 2000, J NEUROIMMUNOL, V109, P34, DOI 10.1016/S0165-5728(00)00300-3; Emanuelli B, 2001, J BIOL CHEM, V276, P47944, DOI 10.1074/jbc.M104602200; Foukas LC, 2004, MOL CELL BIOL, V24, P966, DOI 10.1128/MCB.24.3.966-975.2004; Fruman DA, 2000, NAT GENET, V26, P379, DOI 10.1038/81715; Greenhalgh CJ, 2002, J BIOL CHEM, V277, P40181, DOI 10.1074/jbc.C200450200; HAYASHI H, 1993, J BIOL CHEM, V268, P7107; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hortner M, 2002, J IMMUNOL, V169, P1219, DOI 10.4049/jimmunol.169.3.1219; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Krebs DL, 2000, J CELL SCI, V113, P2813; Krebs DL, 2002, MOL CELL BIOL, V22, P4567, DOI 10.1128/MCB.22.13.4567-4578.2002; Lebel E, 2000, ENDOCRINOLOGY, V141, P3749, DOI 10.1210/en.141.10.3749; Li SL, 2000, J EXP MED, V191, P985, DOI 10.1084/jem.191.6.985; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Mauvais-Jarvis F, 2002, J CLIN INVEST, V109, P141, DOI 10.1172/JCI200213305; Mooney RA, 2001, J BIOL CHEM, V276, P25889, DOI 10.1074/jbc.M010579200; Philp AJ, 2001, CANCER RES, V61, P7426; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Sadowski CL, 2001, J BIOL CHEM, V276, P20703, DOI 10.1074/jbc.M101014200; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; Ueki K, 2000, J CLIN INVEST, V105, P1437, DOI 10.1172/JCI7656; Ueki K, 2003, J BIOL CHEM, V278, P48453, DOI 10.1074/jbc.M305602200; Ueki K, 2002, MOL CELL BIOL, V22, P965, DOI 10.1128/MCB.22.3.965-977.2002; Ueki K, 2002, P NATL ACAD SCI USA, V99, P419, DOI 10.1073/pnas.012581799; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zhang JG, 2001, P NATL ACAD SCI USA, V98, P13261, DOI 10.1073/pnas.231486498; ZHANG WG, 1993, P NATL ACAD SCI USA, V90, P11317, DOI 10.1073/pnas.90.23.11317	41	52	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34107	34114		10.1074/jbc.M312672200	http://dx.doi.org/10.1074/jbc.M312672200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15123678	hybrid			2022-12-25	WOS:000223134800007
J	Aggelidou, E; Iordanidou, P; Tsantili, P; Papadopoulos, G; Hadzopoulou-Cladaras, M				Aggelidou, E; Iordanidou, P; Tsantili, P; Papadopoulos, G; Hadzopoulou-Cladaras, M			Critical role of residues defining the ligand binding pocket in hepatocyte nuclear factor-4 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; TRANSCRIPTION FACTOR; APOCIII PROMOTER; GENE-EXPRESSION; HNF-4 GENE; DOMAIN; PROTEIN; ORPHAN; LIVER; TRANSACTIVATION	Hepatocyte nuclear factor-4alpha (HNF-4alpha), a member of the nuclear receptor superfamily, is a crucial regulator of a large number of genes involved in glucose, cholesterol, and fatty acid metabolism. Unlike other members of the superfamily, HNF-4alpha activates transcription in the absence of exogenously added ligand. Recently published crystallographic data show that fatty acids are endogenous ligands for HNF-4. Transcriptional analysis of point mutations of the residues that are located in helices H3, H5, H10, and H11, which have been shown to come in contact with the ligand, resulted in a dramatic decrease in activity, without affecting DNA binding and dimerization. Our results show the importance of residues Ser-181, Met-182 in H3, Leu-219, Leu-220 and Arg-226 in H5, Ile-338 in H10, and Ile-346 in H11 that line the ligand-binding domain pocket in HNF-4alpha and impair its transactivation potential. Structural modeling reveals that the mutations do not cause any large scale structural alterations, and the observed loss in transactivation can be attributed to local changes, demonstrating that these residues play a significant role in maintaining the structural integrity of the HNF-4alpha ligand binding pocket.	Aristotle Univ Thessaloniki, Fac Sci, Sch Biol, Dept Genet Dev & Mol Biol, GR-54124 Thessaloniki, Greece; Univ Thessaly, Dept Biochem & Biotechnol, Thessaly 41221, Greece	Aristotle University of Thessaloniki; University of Thessaly	Hadzopoulou-Cladaras, M (corresponding author), Aristotle Univ Thessaloniki, Fac Sci, Sch Biol, Dept Genet Dev & Mol Biol, GR-54124 Thessaloniki, Greece.	cladaras@bio.auth.gr	Aggelidou, Eleni/GQZ-2215-2022	Papadopoulos, Georgios/0000-0002-2742-8467				[Anonymous], 2001, NUCL RECEPTORS GENET; Bogan AA, 2000, J MOL BIOL, V302, P831, DOI 10.1006/jmbi.2000.4099; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CARDOT P, 1993, BIOCHEMISTRY-US, V32, P9080, DOI 10.1021/bi00086a013; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Chou WC, 2003, MOL BIOL CELL, V14, P1279, DOI 10.1091/mbc.E02-07-0375; Dell H, 1999, J BIOL CHEM, V274, P9013, DOI 10.1074/jbc.274.13.9013; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Gronemeyer H, 2001, CELL MOL BIOL LETT, V6, P3; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Hadzopoulou-Cladaras M, 1998, BIOCHEMISTRY-US, V37, P14078, DOI 10.1021/bi9804176; HADZOPOULOUCLADARAS M, 1993, BIOCHEMISTRY-US, V32, P9657, DOI 10.1021/bi00088a018; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Kardassis D, 1998, J BIOL CHEM, V273, P17810, DOI 10.1074/jbc.273.28.17810; Kardassis D, 1997, ARTERIOSCL THROM VAS, V17, P222, DOI 10.1161/01.ATV.17.1.222; Kardassis D, 2000, J BIOL CHEM, V275, P41405, DOI 10.1074/jbc.M007896200; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Li JX, 2000, GENE DEV, V14, P464; METZGER S, 1993, J BIOL CHEM, V268, P16831; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; OGAMI K, 1990, J BIOL CHEM, V265, P9808; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; Wang JC, 1998, J BIOL CHEM, V273, P30847, DOI 10.1074/jbc.273.47.30847; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	34	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30680	30688		10.1074/jbc.M401120200	http://dx.doi.org/10.1074/jbc.M401120200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123688	hybrid			2022-12-25	WOS:000222531900098
J	Duvernay, MT; Zhou, FG; Wu, GY				Duvernay, MT; Zhou, FG; Wu, GY			A conserved motif for the transport of G protein-coupled receptors from the endoplasmic reticulum to the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-II RECEPTOR; 3RD INTRACELLULAR LOOP; ER EXPORT; ALPHA(2)-ADRENERGIC RECEPTORS; CARBOXYL-TERMINUS; SECRETORY PATHWAY; CYTOPLASMIC TAIL; C-TERMINUS; EXPRESSION; ENDOCYTOSIS	The structural determinants for the export trafficking of G protein-coupled receptors are poorly defined. In this report, we determined the role of carboxyl termini (CTs) of alpha(2B)-adrenergic receptor (AR) and angiotensin II type 1A receptor (AT1R) in their transport from the endoplasmic reticulum (ER) to the cell surface. The alpha(2B)-AR and AT1R mutants lacking the CTs were completely unable to transport to the cell surface and were trapped in the ER. Alanine-scanning mutagenesis revealed that residues Phe(436) and Ile(443)-Leu(444) in the CT were required for alpha(2B)-AR export. Insertion or deletion between Phe(436) and Ile(443)-Leu(444) as well as Ile(443)-Leu(444) mutation to FF severely disrupted alpha(2B)-AR transport, indicating there is a defined spatial requirement, which is essential for their function as a single motif regulating receptor transport from the ER. Furthermore, the carboxyl-terminally truncated as well as Phe(436) and Ile(443)-Leu(444) mutants were unable to bind ligand and the alpha(2B)-AR CT conferred its transport properties to the AT1R mutant without the CT in a Phe(436)- Ile(443)-Leu(444)-dependent manner. These data suggest that the Phe436 and Ile(443)-Leu(444) may be involved in both proper folding and export from the ER of the receptor. Similarly, residues Phe(309) and Leu(316)-Leu(317) in the CT were identified as essential for AT1R export. The sequence F(X)(6)LL (where X can be any residue, and L is leucine or isoleucine) is highly conserved in the membrane-proximal CTs of many G protein-coupled receptors and may function as a common motif mediating receptor transport from the ER to the cell surface.	Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Wu, GY (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, 1901 Perdido St, New Orleans, LA 70112 USA.	gwu@lsuhsc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018766] Funding Source: NIH RePORTER; NCRR NIH HHS [1P20RR018766] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; Conchon S, 1998, AM J PHYSIOL-ENDOC M, V274, pE336, DOI 10.1152/ajpendo.1998.274.2.E336; DeGraff JL, 2002, J BIOL CHEM, V277, P43247, DOI 10.1074/jbc.M207495200; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; HAMAMDZIC D, 1995, AM J PHYSIOL-ENDOC M, V269, pE162, DOI 10.1152/ajpendo.1995.269.1.E162; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Jayadev S, 1999, ENDOCRINOLOGY, V140, P2010, DOI 10.1210/en.140.5.2010; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Miller KC, 2002, GEOL SOC AM BULL, V114, P497, DOI 10.1130/0016-7606(2002)114<0497:GEFMEA>2.0.CO;2; Morello JP, 2001, ANNU REV PHYSIOL, V63, P607, DOI 10.1146/annurev.physiol.63.1.607; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Nufer O, 2003, J CELL SCI, V116, P4429, DOI 10.1242/jcs.00759; Nufer O, 2002, J CELL SCI, V115, P619; Oksche A, 1998, FEBS LETT, V424, P57, DOI 10.1016/S0014-5793(98)00140-9; Olkkonen VM, 2000, NEW ENGL J MED, V343, P1095, DOI 10.1056/NEJM200010123431507; Pankevych H, 2003, J BIOL CHEM, V278, P30283, DOI 10.1074/jbc.M212918200; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; Sayeski PP, 1998, REGUL PEPTIDES, V78, P19, DOI 10.1016/S0167-0115(98)00137-2; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Stojanovic A, 2002, RECEPTOR CHANNEL, V8, P33, DOI 10.1080/10606820212137; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Wang Q, 2002, J BIOL CHEM, V277, P50589, DOI 10.1074/jbc.M208503200; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026; Wu GY, 2003, J BIOL CHEM, V278, P47062, DOI 10.1074/jbc.M305707200; Wu GY, 2001, CIRC RES, V89, P1130, DOI 10.1161/hh2401.100427; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197; Yang Q, 1999, MOL PHARMACOL, V56, P651, DOI 10.1124/mol.56.3.651; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102	52	128	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30741	30750		10.1074/jbc.M313881200	http://dx.doi.org/10.1074/jbc.M313881200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123661	hybrid			2022-12-25	WOS:000222531900105
J	Sazinsky, MH; Bard, J; Di Donato, A; Lippard, SJ				Sazinsky, MH; Bard, J; Di Donato, A; Lippard, SJ			Crystal structure of the toluene/o-xylene monooxygenase hydroxylase from Pseudomonas stutzeri OX1 - Insight into the substrate specificity, substrate channeling, and active site tuning of multicomponent monooxygenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE METHANE MONOOXYGENASE; METHYLOSINUS-TRICHOSPORIUM OB3B; ACYL CARRIER PROTEIN; COLI RIBONUCLEOTIDE REDUCTASE; RAPID ELECTRON-TRANSFER; OXYGEN ACTIVATION; R2 SUBUNIT; DIOXYGEN ACTIVATION; PHENOL HYDROXYLASE; DIIRON	The four-component toluene/o-xylene monooxygenase (ToMO) from Pseudomonas stutzeri OX1 is capable of oxidizing arenes, alkenes, and haloalkanes at a carboxylate-bridged diiron center similar to that of soluble methane monooxygenase (sMMO). The remarkable variety of substrates accommodated by ToMO invites applications ranging from bioremediation to the regio- and enantiospecific oxidation of hydrocarbons on an industrial scale. We report here the crystal structures of the ToMO hydroxylase (ToMOH), azido ToMOH, and ToMOH containing the product analogue 4-bromophenol to 2.3 or greater resolution. The catalytic diiron( III) core resembles that of the sMMO hydroxylase, but aspects of the alpha(2)beta(2)gamma(2) tertiary structure are notably different. Of particular interest is a 6-10 Angstrom-wide channel of similar to35 Angstrom in length extending from the active site to the protein surface. The presence of three bromophenol molecules in this space confirms this route as a pathway for substrate entrance and product egress. An analysis of the ToMOH active site cavity offers insights into the different substrate specificities of multicomponent monooxygenases and explains the behavior of mutant forms of homologous enzymes described in the literature.	MIT, Dept Chem, Cambridge, MA 02139 USA; Wyeth Pharmaceut, Div Struct Biol, Cambridge, MA 02140 USA; Univ Naples Federico II, Dipartimento Chim Biol, I-80134 Naples, Italy	Massachusetts Institute of Technology (MIT); Pfizer; University of Naples Federico II	Lippard, SJ (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	lippard@lippard.mit.edu	Di Donato, Alberto/G-5494-2012	DI DONATO, Alberto/0000-0001-9129-9850	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032134, R01GM032134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ai JY, 1997, J BIOL INORG CHEM, V2, P37, DOI 10.1007/s007750050104; Andersson ME, 1999, J AM CHEM SOC, V121, P2346, DOI 10.1021/ja982280c; Archelas A, 1997, ANNU REV MICROBIOL, V51, P491, DOI 10.1146/annurev.micro.51.1.491; ATTA M, 1993, EUR J BIOCHEM, V217, P217, DOI 10.1111/j.1432-1033.1993.tb18236.x; Baldwin J, 2000, J AM CHEM SOC, V122, P12195, DOI 10.1021/ja001278u; Bertoni G, 1996, APPL ENVIRON MICROB, V62, P3704, DOI 10.1128/AEM.62.10.3704-3711.1996; Broadwater JA, 1998, BIOCHEMISTRY-US, V37, P14664, DOI 10.1021/bi981839i; Broadwater JA, 1999, BIOCHEMISTRY-US, V38, P12197, DOI 10.1021/bi9914199; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cadieux E, 2002, BIOCHEMISTRY-US, V41, P10680, DOI 10.1021/bi025901u; Cafaro V, 2002, EUR J BIOCHEM, V269, P5689, DOI 10.1046/j.1432-1033.2002.03281.x; Canada KA, 2002, J BACTERIOL, V184, P344, DOI 10.1128/JB.184.2.344-349.2002; Chauhan S, 1998, APPL ENVIRON MICROB, V64, P3023; Coufal DE, 2000, EUR J BIOCHEM, V267, P2174, DOI 10.1046/j.1432-1327.2000.01210.x; Divari S, 2003, EUR J BIOCHEM, V270, P2244, DOI 10.1046/j.1432-1033.2003.03592.x; Elango N, 1997, PROTEIN SCI, V6, P556; FEIG AL, 1994, CHEM REV, V94, P759, DOI 10.1021/cr00027a011; FOX BG, 1993, P NATL ACAD SCI USA, V90, P2486, DOI 10.1073/pnas.90.6.2486; Gherman BF, 2004, J AM CHEM SOC, V126, P2978, DOI 10.1021/ja036506+; GIBBS CR, 1976, ANAL CHEM, V48, P1197, DOI 10.1021/ac50002a034; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUPTA N, 1995, BIOCHEMISTRY-US, V34, P3310, DOI 10.1021/bi00010a021; Hanson RS, 1996, MICROBIOL REV, V60, P439, DOI 10.1128/MMBR.60.2.439-471.1996; Krebs C, 2000, J AM CHEM SOC, V122, P12207, DOI 10.1021/ja001279m; Krissinel E., 2003, P 5 INT C MOL STRUCT, P88; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Leahy JG, 2003, FEMS MICROBIOL REV, V27, P449, DOI 10.1016/S0168-6445(03)00023-8; LEMASTER DM, 1985, BIOCHEMISTRY-US, V24, P7263, DOI 10.1021/bi00346a036; Lloyd JS, 1999, MICROBIOL-SGM, V145, P461, DOI 10.1099/13500872-145-2-461; MacArthur R, 2002, J AM CHEM SOC, V124, P13392, DOI 10.1021/ja0279904; McClay K, 2000, APPL ENVIRON MICROB, V66, P1877, DOI 10.1128/AEM.66.5.1877-1882.2000; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merkx M, 2001, ANGEW CHEM INT EDIT, V40, P2782, DOI 10.1002/1521-3773(20010803)40:15<2782::AID-ANIE2782>3.0.CO;2-P; Mitchell KH, 2002, BIOCHEMISTRY-US, V41, P3176, DOI 10.1021/bi012036p; MITCHELL KH, 2002, THESIS U WISCONSIN M; MIURA A, 1995, BIOSCI BIOTECH BIOCH, V59, P853, DOI 10.1271/bbb.59.853; NEWMAN LM, 1995, BIOCHEMISTRY-US, V34, P14066, DOI 10.1021/bi00043a012; Notomista E, 2003, J MOL EVOL, V56, P435, DOI 10.1007/s00239-002-2414-1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pikus JD, 1997, BIOCHEMISTRY-US, V36, P9283, DOI 10.1021/bi971049t; Pikus JD, 1996, BIOCHEMISTRY-US, V35, P9106, DOI 10.1021/bi960456m; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; Rosenzweig AC, 1997, PROTEINS, V29, P141, DOI 10.1002/(SICI)1097-0134(199710)29:2<141::AID-PROT2>3.3.CO;2-W; Scognamiglio R, 2001, PROTEIN SCI, V10, P482, DOI 10.1110/ps.35701; STEFFAN RJ, 2000, Patent No. 2000073425; Studts JM, 2000, PROTEIN EXPRES PURIF, V20, P58, DOI 10.1006/prep.2000.1281; Sullivan JP, 1998, CRIT REV MICROBIOL, V24, P335, DOI 10.1080/10408419891294217; Whittington DA, 2001, BIOCHEMISTRY-US, V40, P3476, DOI 10.1021/bi0022487	48	157	157	1	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30600	30610		10.1074/jbc.M400710200	http://dx.doi.org/10.1074/jbc.M400710200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15096510	hybrid			2022-12-25	WOS:000222531900090
J	Hayashi, A; Ohnishi, H; Okazawa, H; Nakazawa, S; Ikeda, H; Motegi, S; Aoki, N; Kimura, S; Mikuni, M; Matozaki, T				Hayashi, A; Ohnishi, H; Okazawa, H; Nakazawa, S; Ikeda, H; Motegi, S; Aoki, N; Kimura, S; Mikuni, M; Matozaki, T			Positive regulation of phagocytosis by SIRP beta and its signaling mechanism in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RECEPTOR-MEDIATED PHAGOCYTOSIS; INTEGRIN-ASSOCIATED PROTEIN; NEURAL ADHESION MOLECULE; LIGHT-CHAIN KINASE; FC-GAMMA; TYROSINE-PHOSPHATASE; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSMEMBRANE GLYCOPROTEIN; PHOSPHOINOSITIDE 3-KINASE	SIRPbeta (signal-regulatory protein beta) is a transmembrane protein that is expressed in hematopoietic cells but whose functions are unknown. We have now cloned mouse SIRPbeta cDNA and have shown that the gene is expressed in various tissues in addition to cells of the macrophage lineage. Engagement of SIRPbeta by specific monoclonal antibodies promoted Fcgamma receptor-dependent or -independent phagocytosis in mouse peritoneal macrophages. It also induced marked activation of MAPK and the upstream kinase MEK but weak activation of Akt. MEK inhibitors markedly blocked the promotion of phagocytosis by SIRPbeta, whereas an inhibitor of phosphoinositide 3-kinase partly blocked such response. In addition, inhibitors of myosin light chain kinase or of myosin ATPase blocked the promotion of phagocytosis by SIRPbeta. Furthermore, SIRPbeta induced the formation of filopodia and lamellipodia in macrophages as well as the translocation of activated MAPK to these structures. It also elicited tyrosine phosphorylation of DAP12, Syk, and SLP-76, and a Syk inhibitor blocked the promotion of phagocytosis and activation of MAPK by SIRPbeta. Our results suggest that engagement of SIRPbeta promotes phagocytosis in macrophages by inducing the tyrosine phosphorylation of DAP12, Syk, and SLP-76 and the subsequent activation of a MEK-MAPK-myosin light chain kinase cascade.	Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Res Ctr, Gunma 3718512, Japan; Gunma Univ, Grad Sch Med, Dept Psychiat & Human Behav, Gunma 3718511, Japan; Asahikawa Med Coll, Dept Pathol, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Sch Nursing, Asahikawa, Hokkaido 0788510, Japan	Gunma University; Gunma University; Asahikawa Medical College; Asahikawa Medical College	Matozaki, T (corresponding author), Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Res Ctr, 3-39-15 Showa Machi, Gunma 3718512, Japan.	matozaki@showa.gunma-u.ac.jp	Okazawa, Hideki/C-3836-2011; Okazawa, Hideki/E-3055-2010					Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Allen LAH, 1996, J EXP MED, V184, P627, DOI 10.1084/jem.184.2.627; Aoki N, 2000, J IMMUNOL, V165, P3790, DOI 10.4049/jimmunol.165.7.3790; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Bhatt NY, 2002, J IMMUNOL, V169, P6427, DOI 10.4049/jimmunol.169.11.6427; Bonilla FA, 2000, P NATL ACAD SCI USA, V97, P1725, DOI 10.1073/pnas.040543597; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Cant CA, 2001, CELL MOL LIFE SCI, V58, P117, DOI 10.1007/PL00000771; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Comu S, 1997, J NEUROSCI, V17, P8702; Cox D, 2001, SEMIN IMMUNOL, V13, P339, DOI 10.1006/smim.2001.0330; Dietrich J, 2000, J IMMUNOL, V164, P9, DOI 10.4049/jimmunol.164.1.9; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; Gross BS, 1999, J BIOL CHEM, V274, P5963, DOI 10.1074/jbc.274.9.5963; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Karimi K, 1998, INFLAMMATION, V22, P67, DOI 10.1023/A:1022347808042; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lanier LL, 1998, IMMUNITY, V8, P693, DOI 10.1016/S1074-7613(00)80574-9; Liu SKW, 2001, ONCOGENE, V20, P6284, DOI 10.1038/sj.onc.1204771; Mansfield PJ, 2000, BLOOD, V95, P2407, DOI 10.1182/blood.V95.7.2407.007k02_2407_2412; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Motegi S, 2003, EMBO J, V22, P2634, DOI 10.1093/emboj/cdg278; NINOMIYA N, 1994, J BIOL CHEM, V269, P22732; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Olazabal IM, 2002, CURR BIOL, V12, P1413, DOI 10.1016/S0960-9822(02)01069-2; Oldenborg PA, 2001, J EXP MED, V193, P855, DOI 10.1084/jem.193.7.855; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Oshima K, 2002, FEBS LETT, V519, P1, DOI 10.1016/S0014-5793(02)02703-5; Paine R, 2002, AM J PHYSIOL-LUNG C, V283, pL180, DOI 10.1152/ajplung.00430.2001; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Sada K, 1997, EUR J BIOCHEM, V248, P827, DOI 10.1111/j.1432-1033.1997.00827.x; SAITOH M, 1987, J BIOL CHEM, V262, P7796; Sano S, 1999, BIOCHEM J, V344, P667, DOI 10.1042/0264-6021:3440667; Sato R, 2003, BIOCHEM BIOPH RES CO, V309, P584, DOI 10.1016/j.bbrc.2003.08.031; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Seiffert M, 2001, BLOOD, V97, P2741, DOI 10.1182/blood.V97.9.2741; Somlyo AV, 2002, CIRC RES, V91, P83, DOI 10.1161/01.RES.0000028341.63905.91; Stephens L, 2002, CURR OPIN CELL BIOL, V14, P203, DOI 10.1016/S0955-0674(02)00311-3; Strzelecka A, 1997, FEBS LETT, V400, P11, DOI 10.1016/S0014-5793(96)01359-2; Tomasello E, 2000, EUR J IMMUNOL, V30, P2147, DOI 10.1002/1521-4141(2000)30:8<2147::AID-IMMU2147>3.0.CO;2-1; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Wu J, 2000, J EXP MED, V192, P1059, DOI 10.1084/jem.192.7.1059; Yablonski D, 2001, ADV IMMUNOL, V79, P93, DOI 10.1016/S0065-2776(01)79003-7; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yamao T, 2002, J BIOL CHEM, V277, P39833, DOI 10.1074/jbc.M203287200; YANO H, 1993, J BIOL CHEM, V268, P25846	60	51	54	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29450	29460		10.1074/jbc.M400950200	http://dx.doi.org/10.1074/jbc.M400950200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123631	hybrid			2022-12-25	WOS:000222445300077
J	Lange, H; Muhlenhoff, U; Denzel, M; Kispal, G; Lill, R				Lange, H; Muhlenhoff, U; Denzel, M; Kispal, G; Lill, R			The heme synthesis defect of mutants impaired in mitochondrial iron-sulfur protein biogenesis is caused by reversible inhibition of ferrochelatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLUSTER BIOSYNTHESIS; YEAST FRATAXIN; SACCHAROMYCES-CEREVISIAE; SCAFFOLD PROTEIN; MATURATION; HOMOLOG; DEFICIENCY; FRIEDREICH; ATAXIA; FERREDOXIN	Mitochondria are responsible for the synthesis of both iron-sulfur clusters and heme, but the potential connection between the two major iron-consuming pathways is unknown. Here, we have shown that mutants in the yeast mitochondrial iron-sulfur cluster (ISC) assembly machinery displayed reduced cytochrome levels and diminished activity of the heme-containing cytochrome c oxidase, in addition to iron-sulfur protein defects. In contrast, mutants in components of the mitochondrial ISC export machinery, which are specifically required for maturation of cytosolic iron-sulfur proteins, were not decreased in heme synthesis or cytochrome levels. Heme synthesis does not involve the function of mitochondrial ISC components, because immunological depletion of various ISC proteins from mitochondrial extracts did not affect the formation and amounts of heme. The heme synthesis defects of ISC mutants were found in vivo in isolated mitochondria and in mitochondrial detergent extracts and were confined to an inhibition of ferrochelatase, the enzyme catalyzing the insertion of iron into protoporphyrin IX. In support of these findings, immunopurification of ferrochelatase from ISC mutants restored its activity to wild-type levels. We conclude that the reversible inhibition of ferrochelatase is the molecular reason for the heme deficiency in ISC assembly mutants. This inhibitory mechanism may be used for regulation of iron distribution between the two iron-consuming processes.	Univ Marburg, Inst Zytobiol & Zytopathol, D-35033 Marburg, Germany; Univ Med Sch Pecs, Inst Biochem, H-7624 Pecs, Hungary	Philipps University Marburg; University of Pecs	Lill, R (corresponding author), Univ Marburg, Inst Zytobiol & Zytopathol, Robert Koch Str 6, D-35033 Marburg, Germany.	Lill@mailer.uni-marburg.de	Denzel, Martin/C-9047-2014	Denzel, Martin/0000-0002-5691-3349; Lill, Roland/0000-0002-8345-6518; Lange, Heike/0000-0002-8222-3448				ABBAS A, 1993, J BIOL CHEM, V268, P8541; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Barros MH, 2002, J BIOL CHEM, V277, P9997, DOI 10.1074/jbc.M112025200; Barros MH, 2001, FEBS LETT, V492, P133, DOI 10.1016/S0014-5793(01)02249-9; Bekri S, 2000, BLOOD, V96, P3256; Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; Cossee M, 2000, HUM MOL GENET, V9, P1219, DOI 10.1093/hmg/9.8.1219; Craig EA, 2002, CELL MOL LIFE SCI, V59, P1658, DOI 10.1007/PL00012493; Crisp RJ, 2003, J BIOL CHEM, V278, P45499, DOI 10.1074/jbc.M307229200; Dailey HA, 2002, BIOCHEM SOC T, V30, P590, DOI 10.1042/bst0300590; Diekert K, 2001, METHOD CELL BIOL, V65, P37, DOI 10.1016/S0091-679X(01)65003-9; Dutkiewicz R, 2003, J BIOL CHEM, V278, P29719, DOI 10.1074/jbc.M303527200; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; Frazzon J, 2003, CURR OPIN CHEM BIOL, V7, P166, DOI 10.1016/S1367-5931(03)00021-8; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HARLOW E, 1998, USING ANTIBODIES LAB; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Kaut A, 2000, J BIOL CHEM, V275, P15955, DOI 10.1074/jbc.M909502199; Kim R, 2001, J BIOL CHEM, V276, P17524, DOI 10.1074/jbc.M010695200; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Knight SAB, 1998, J BIOL CHEM, V273, P18389, DOI 10.1074/jbc.273.29.18389; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; Labbe-Bois R, 1990, BIOSYNTHESIS HEME CH, P235; Labbe-Bois Rosine, 1994, V11, P413; Lange H, 1999, J BIOL CHEM, V274, P18989, DOI 10.1074/jbc.274.27.18989; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Lange H, 2001, EMBO REP, V2, P715, DOI 10.1093/embo-reports/kve161; Lesuisse E, 2003, HUM MOL GENET, V12, P879, DOI 10.1093/hmg/ddg096; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Li J, 2001, J BIOL CHEM, V276, P1503, DOI 10.1074/jbc.M007198200; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; LILL R, 2003, NORD GUIDE RARE DISO, P374; MORGAN RO, 1979, CAN J NEUROL SCI, V6, P227, DOI 10.1017/S0317167100119699; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; Muhlenhoff U, 2002, J BIOL CHEM, V277, P29810, DOI 10.1074/jbc.M204675200; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Ramazzotti A, 2004, FEBS LETT, V557, P215, DOI 10.1016/S0014-5793(03)01498-4; Robinson KM, 1995, METHOD ENZYMOL, V260, P34, DOI 10.1016/0076-6879(95)60128-7; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Sambrook J, 2001, MOL CLONING LAB MANU; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sipos K, 2002, J BIOL CHEM, V277, P26944, DOI 10.1074/jbc.M200677200; Taketani S, 2000, EUR J BIOCHEM, V267, P4685, DOI 10.1046/j.1432-1327.2000.01519.x; Wilson RB, 2003, J NEUROL SCI, V207, P103, DOI 10.1016/S0022-510X(02)00432-X; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352; Wu G, 2002, J BIOL INORG CHEM, V7, P526, DOI 10.1007/s00775-001-0330-2; Yoon T, 2003, J AM CHEM SOC, V125, P6078, DOI 10.1021/ja027967i; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754	58	46	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29101	29108		10.1074/jbc.M403721200	http://dx.doi.org/10.1074/jbc.M403721200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15128732	hybrid			2022-12-25	WOS:000222445300034
J	Sawchuk, DJ; Mansilla-Soto, J; Alarcon, C; Singha, NC; Langen, H; Bianchi, ME; Lees-Miller, SP; Nussenzweig, MC; Cortes, P				Sawchuk, DJ; Mansilla-Soto, J; Alarcon, C; Singha, NC; Langen, H; Bianchi, ME; Lees-Miller, SP; Nussenzweig, MC; Cortes, P			Ku70/Ku80 and DNA-dependent protein kinase catalytic subunit modulate RAG-mediated cleavage - Implications for the enforcement of the 12/23 rule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V(D)J RECOMBINATION; MICE DEFICIENT; IN-VIVO; GENE; REPAIR; COMPLEX; TRANSPOSITION; INSIGHTS; SIGNALS; BINDING	The 12/23 rule is a critical step for regulation of V( D) J recombination. To date, only the RAG proteins and high mobility group protein 1 or 2 have been implicated in 12/23 regulation. Through protein fractionation and biochemical experiments, we find that Ku70/Ku80 and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) modulate RAG-mediated cleavage. Modulation of cleavage by Ku70/80 and DNA-PKcs results in preferential inhibition of 12/12 and 23/23 DNA cleavage, thus increasing 12/23 rule specificity. This observation indicates that DNA repair factors, Ku70/80 and DNA-PKcs, might be present upstream of the DNA cleavage events and not recruited downstream as is currently thought, assigning new nonrepair functions to the DNA-dependent protein kinase.	CUNY Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA; Rockefeller Univ, Lab Mol Immunol, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; F Hoffmann La Roche & Co Ltd, Genet, CH-4070 Basel, Switzerland; Univ Vita Salute San Raffaele, I-20132 Milan, Italy; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Roche Holding; Vita-Salute San Raffaele University; University of Calgary	Cortes, P (corresponding author), CUNY Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA.	patricia.cortes@mssm.edu	Nussenzweig, Michel/AAE-7292-2019; Bianchi, Marco Emilio/K-3417-2018	Bianchi, Marco Emilio/0000-0002-5329-6445; Lees-Miller, Susan/0000-0001-5809-2516	NIAID NIH HHS [AI45996-05, AI38890] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045996] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aidinis V, 1999, MOL CELL BIOL, V19, P6532; Bertocci B, 2003, IMMUNITY, V19, P203, DOI 10.1016/S1074-7613(03)00203-6; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; Chan DW, 1996, BIOCHEM CELL BIOL, V74, P67, DOI 10.1139/o96-007; Cortes P, 1996, P NATL ACAD SCI USA, V93, P14008, DOI 10.1073/pnas.93.24.14008; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; Hiom K, 1998, MOL CELL, V1, P1011, DOI 10.1016/S1097-2765(00)80101-X; ISACKSON PJ, 1983, BIOCHIM BIOPHYS ACTA, V748, P436, DOI 10.1016/0167-4838(83)90190-5; Jung D, 2004, CELL, V116, P299, DOI 10.1016/S0092-8674(04)00039-X; Kim DR, 1998, MOL CELL BIOL, V18, P4679, DOI 10.1128/MCB.18.8.4679; Larijani M, 1999, NUCLEIC ACIDS RES, V27, P2304, DOI 10.1093/nar/27.11.2304; Lee KB, 2000, J MOL BIOL, V304, P135, DOI 10.1006/jmbi.2000.4206; Lees-Miller SP, 2003, BIOCHIMIE, V85, P1161, DOI 10.1016/j.biochi.2003.10.011; Lew S, 2000, MOL CELL BIOL, V20, P7170, DOI 10.1128/MCB.20.19.7170-7177.2000; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Mansilla-Soto J, 2003, J EXP MED, V197, P543, DOI 10.1084/jem.20022210; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ono M, 1996, MOL IMMUNOL, V33, P787, DOI 10.1016/0161-5890(96)00030-2; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Ronfani L, 2001, DEVELOPMENT, V128, P1265; Sawchuk DJ, 1997, J EXP MED, V185, P2025, DOI 10.1084/jem.185.11.2025; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Schlissel MS, 2003, NAT REV IMMUNOL, V3, P890, DOI 10.1038/nri1225; Steen SB, 1996, GENES CELLS, V1, P543; Swanson PC, 2002, MOL CELL BIOL, V22, P7790, DOI 10.1128/MCB.22.22.7790-7801.2002; Thai TH, 2002, NAT IMMUNOL, V3, P457, DOI 10.1038/ni788; Vanasse GJ, 1999, J CLIN INVEST, V103, P1669, DOI 10.1172/JCI6658; vanGent DC, 1997, EMBO J, V16, P2665, DOI 10.1093/emboj/16.10.2665; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; West RB, 1998, MOL CELL BIOL, V18, P6408, DOI 10.1128/MCB.18.11.6408	37	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29821	29831		10.1074/jbc.M403706200	http://dx.doi.org/10.1074/jbc.M403706200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123719	hybrid			2022-12-25	WOS:000222445300119
J	Stern, JC; Anderson, BJ; Owens, TJ; Schildbach, JF				Stern, JC; Anderson, BJ; Owens, TJ; Schildbach, JF			Energetics of the sequence-specific binding of single-stranded DNA by the F factor relaxase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNIT; HEAT-CAPACITY CHANGES; CRYSTAL-STRUCTURE; TELOMERIC DNA; KH DOMAINS; RECOGNITION; SITE; ORIGIN; SSDNA; CLEAVAGE	Transfer of conjugative plasmids between bacteria requires the activity of relaxases or mobilization proteins. These proteins nick the plasmid in a site- and strand-specific manner prior to transfer of the cut strand from donor to recipient. TraI36, the relaxase domain of TraI from plasmid F factor, binds a single-stranded DNA (ssDNA) oligonucleotide containing an F factor sequence with high affinity and sequence specificity. To better understand the energetics of this interaction, we examined the temperature, salt, and pH dependence of TraI36 recognition. Binding is entropically driven below 25 degreesC and enthalpically driven at higher temperatures. van't Hoff analysis yields an estimated DeltaC(P)(0) of binding (-3300 cal mol(-1) K-1) that is larger and more negative than that observed for most double-stranded DNA (dsDNA)-binding proteins. Based on analyses of circular dichroism data and the crystal structure of the unliganded protein, we attribute the DeltaC(P)(0) to both burial of hydrophobic surface area and coupled folding and binding of the protein. The salt dependence of the binding indicates that several ssDNA phosphates are buried in the complex, and the pH dependence of the binding suggests that some of these ssDNA phosphates form ionic interactions with basic residues of the protein. Although data are available for relatively few sequence-specific ssDNA-binding proteins, sufficient differences exist between TraI36 and other proteins to indicate that, like dsDNA-binding proteins, ssDNA-binding proteins use different motifs and combinations of forces to achieve specific recognition.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Schildbach, JF (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.	joel@jhu.edu		Anderson, Brian/0000-0002-2426-9683; Schildbach, Joel/0000-0002-3038-9745	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061017] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61017] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackroyd PC, 2001, BIOCHEMISTRY-US, V40, P2911, DOI 10.1021/bi0023854; Anderson EM, 2003, BIOCHEMISTRY-US, V42, P3751, DOI 10.1021/bi027047c; BARKLEY MD, 1981, BIOCHEMISTRY-US, V20, P3842, DOI 10.1021/bi00516a027; Braddock DT, 2002, NATURE, V415, P1051, DOI 10.1038/4151051a; Braddock DT, 2002, EMBO J, V21, P3476, DOI 10.1093/emboj/cdf352; Campos-Olivas R, 2002, P NATL ACAD SCI USA, V99, P10310, DOI 10.1073/pnas.152342699; Classen S, 2003, BIOCHEMISTRY-US, V42, P9269, DOI 10.1021/bi0273718; Classen S, 2001, J MOL BIOL, V314, P1113, DOI 10.1006/jmbi.2000.5191; Datta S, 2003, STRUCTURE, V11, P1369, DOI 10.1016/j.str.2003.10.001; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Gallagher K, 1998, BIOPHYS J, V75, P769, DOI 10.1016/S0006-3495(98)77566-6; Garvie CW, 2001, MOL CELL, V8, P937, DOI 10.1016/S1097-2765(01)00392-6; Goddard NL, 2000, PHYS REV LETT, V85, P2400, DOI 10.1103/PhysRevLett.85.2400; Guasch A, 2003, NAT STRUCT BIOL, V10, P1002, DOI 10.1038/nsb1017; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; Hard T, 1996, BIOPHYS CHEM, V62, P121, DOI 10.1016/S0301-4622(96)02197-7; Harley MJ, 2002, BIOCHEMISTRY-US, V41, P6460, DOI 10.1021/bi011969i; Hickman AB, 2002, MOL CELL, V10, P327, DOI 10.1016/S1097-2765(02)00592-0; Horvath MP, 2001, J MOL BIOL, V310, P367, DOI 10.1006/jmbi.2001.4766; Horvath MP, 1998, CELL, V95, P963, DOI 10.1016/S0092-8674(00)81720-1; Jen-Jacobson L, 2000, STRUCTURE, V8, P1015, DOI 10.1016/S0969-2126(00)00501-3; Kozlov AG, 1999, BIOCHEMISTRY-US, V38, P7388, DOI 10.1021/bi990309z; Lei M, 2003, NATURE, V426, P198, DOI 10.1038/nature02092; Lei M, 2002, BIOCHEMISTRY-US, V41, P14560, DOI 10.1021/bi026674z; Mitton-Fry RM, 2004, J MOL BIOL, V338, P241, DOI 10.1016/j.jmb.2004.01.063; Mitton-Fry RM, 2002, SCIENCE, V296, P145, DOI 10.1126/science.1068799; OLMSTED MC, 1989, P NATL ACAD SCI USA, V86, P7766, DOI 10.1073/pnas.86.20.7766; Peersen OB, 2002, NAT STRUCT BIOL, V9, P182, DOI 10.1038/nsb761; Poon GMK, 2002, BIOCHEMISTRY-US, V41, P2361, DOI 10.1021/bi015572q; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P462; SHERMAN JA, 1994, J BIOL CHEM, V269, P26220; Sidorova NY, 2001, J MOL BIOL, V310, P801, DOI 10.1006/jmbi.2001.4781; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Stern JC, 2001, BIOCHEMISTRY-US, V40, P11586, DOI 10.1021/bi010877q; Street LM, 2003, BBA-PROTEINS PROTEOM, V1646, P86, DOI 10.1016/S1570-9639(02)00553-8	35	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29155	29159		10.1074/jbc.M402965200	http://dx.doi.org/10.1074/jbc.M402965200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123728	hybrid			2022-12-25	WOS:000222445300041
J	Stok, JE; Huang, HZ; Jones, PD; Wheelock, CE; Morisseau, C; Hammock, BD				Stok, JE; Huang, HZ; Jones, PD; Wheelock, CE; Morisseau, C; Hammock, BD			Identification, expression, and purification of a pyrethroid-hydrolyzing carboxylesterase from mouse liver microsomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; RAT; ESTERASES; TOXICITY; SEQUENCE; CLONING; CDNA; METABOLISM; ENZYMES; ORGANOPHOSPHORUS	Carboxylesterases are enzymes that catalyze the hydrolysis of a wide range of ester-containing endogenous and xenobiotic compounds. Although the use of pyrethroids is increasing, the specific enzymes involved in the hydrolysis of these insecticides have yet to be identified. A pyrethroid-hydrolyzing enzyme was partially purified from mouse liver microsomes using a fluorescent reporter similar in structure to cypermethrin (Shan, G., and Hammock, B. D. ( 2001) Anal. Biochem. 299, 54 - 62 and Wheelock, C. E., Wheelock, A. M., Zhang, R., Stok, J. E., Morisseau, C., Le Valley, S. E., Green, C. E., and Hammock, B. D. ( 2003) Anal. Biochem. 315, 208 - 222) and subsequently identified as a carboxylesterase (NCBI accession number BAC36707). The expressed sequence tag was then cloned, expressed in baculovirus, and purified to homogeneity. Kinetic constants for a large number of both type I and type II pyrethroid or pyrethroid-like substrates were determined. This esterase possesses similar kinetic constants for cypermethrin and its fluorescent-surrogate (k(cat) = 0.12 +/- 0.03 versus 0.11 +/- 0.01 s(-1)). Compared with their cis-counterparts, trans-permethrin and cypermethrin were hydrolyzed 22- and 4-fold faster, respectively. Of the four fenvalerate isomers the (2R)(alphaR)-isomer was hydrolyzed at least 1 order of magnitude faster than any other isomer. However, it is unlikely that this enzyme accounts for the total pyrethroid hydrolysis in the microsomes because both isoelectrofocusing and native PAGE indicate the presence of a second region of cypermethrin-metabolizing enzymes. A second carboxylesterase gene ( NCBI accession number NM_ 133960), isolated during a cDNA mouse liver library screening, was also found to hydrolyze pyrethroids. Both these enzymes could be used as preliminary tools in establishing the relative toxicity of new pyrethroids.	Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; Univ Calif Davis, Canc Res Ctr, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Hammock, BD (corresponding author), Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA.	bdhammock@ucdavis.edu		Stok, Jeanette/0000-0002-8759-3931	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI058267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004699, R37ES002710, P30ES005707] Funding Source: NIH RePORTER; NIAID NIH HHS [AI58267] Funding Source: Medline; NIDDK NIH HHS [T32 DK07355-22] Funding Source: Medline; NIEHS NIH HHS [R37 ES02710, P30 ES 05707, P42 ES04699] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABERNATHY CO, 1973, PESTIC BIOCHEM PHYS, V3, P300, DOI 10.1016/0048-3575(73)90028-X; CANTALAMESSA F, 1993, ARCH TOXICOL, V67, P510, DOI 10.1007/BF01969923; CASIDA JE, 1983, ANNU REV PHARMACOL, V23, P413, DOI 10.1146/annurev.pa.23.040183.002213; Choi J, 2002, PESTIC BIOCHEM PHYS, V74, P117, DOI 10.1016/S0048-3575(02)00154-2; El-Tawil OS, 2001, PHARMACOL RES, V44, P33, DOI 10.1006/phrs.2001.0826; Hodgson E, 2003, J BIOCHEM MOL TOXIC, V17, P201, DOI 10.1002/jbt.10080; HUANG TL, 1993, J PHARM PHARMACOL, V45, P458, DOI 10.1111/j.2042-7158.1993.tb05576.x; Huang TL, 1996, PHARMACEUT RES, V13, P1495, DOI 10.1023/A:1016071311190; Kakko I, 2004, ENVIRON TOXICOL PHAR, V15, P95, DOI 10.1016/j.etap.2003.11.005; KANEKO H, 1988, J PESTIC SCI, V13, P535; KAO LR, 1985, PESTIC BIOCHEM PHYS, V23, P66, DOI 10.1016/0048-3575(85)90079-3; KROETZ DL, 1993, BIOCHEMISTRY-US, V32, P11606, DOI 10.1021/bi00094a018; Landrigan PJ, 1999, ENVIRON HEALTH PERSP, V107, P431, DOI 10.1289/ehp.99107s3431; LAWRENCE LJ, 1982, PESTIC BIOCHEM PHYS, V18, P9, DOI 10.1016/0048-3575(82)90082-7; LJUNGQUIST A, 1971, EUR J BIOCHEM, V23, P303, DOI 10.1111/j.1432-1033.1971.tb01622.x; Miyamoto J, 1995, TOXICOL LETT, V82-3, P933, DOI 10.1016/0378-4274(95)03604-0; MIYAMOTO J, 1976, ENVIRON HEALTH PERSP, V14, P15, DOI 10.2307/3428358; Miyata M, 2003, YAKUGAKU ZASSHI, V123, P569, DOI 10.1248/yakushi.123.569; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; OVNIC M, 1991, GENOMICS, V11, P956, DOI 10.1016/0888-7543(91)90020-F; OZOLS J, 1989, J BIOL CHEM, V264, P12533; Pindel EV, 1997, J BIOL CHEM, V272, P14769, DOI 10.1074/jbc.272.23.14769; ROBBI M, 1991, J BIOL CHEM, V266, P20498; Satoh T, 1998, ANNU REV PHARMACOL, V38, P257, DOI 10.1146/annurev.pharmtox.38.1.257; Shan GM, 2001, ANAL BIOCHEM, V299, P54, DOI 10.1006/abio.2001.5388; Shan GM, 1999, J AGR FOOD CHEM, V47, P2145, DOI 10.1021/jf981210m; SODERLUND DM, 1992, XENOBIOTICA, V22, P1185, DOI 10.3109/00498259209051872; SODERLUND DM, 1982, PESTIC BIOCHEM PHYS, V17, P162, DOI 10.1016/0048-3575(82)90021-9; Soderlund DM, 2002, TOXICOLOGY, V171, P3, DOI 10.1016/S0300-483X(01)00569-8; Sogorb MA, 2002, TOXICOL LETT, V128, P215, DOI 10.1016/S0378-4274(01)00543-4; SONE T, 1994, BBA-PROTEIN STRUCT M, V1207, P138, DOI 10.1016/0167-4838(94)90063-9; SUZUKI T, 1978, PESTIC BIOCHEM PHYS, V8, P186, DOI 10.1016/0048-3575(78)90038-X; TAKAGI Y, 1988, J BIOCHEM-TOKYO, V104, P801, DOI 10.1093/oxfordjournals.jbchem.a122553; TAKAMATSU Y, 1987, J PESTIC SCI, V12, P397; TALCOTT RE, 1979, TOXICOL APPL PHARM, V47, P145, DOI 10.1016/0041-008X(79)90081-4; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; Wheelock CE, 2003, ANAL BIOCHEM, V315, P208, DOI 10.1016/S0003-2697(03)00002-2; Wheelock CE, 2001, CHEM RES TOXICOL, V14, P1563, DOI 10.1021/tx015508+; Whyatt RM, 2002, ENVIRON HEALTH PERSP, V110, P507, DOI 10.1289/ehp.02110507	39	55	62	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29863	29869		10.1074/jbc.M403673200	http://dx.doi.org/10.1074/jbc.M403673200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123619	hybrid			2022-12-25	WOS:000222445300124
J	Matsuzaki, Y; Takaoka, Y; Hitomi, T; Nishino, H; Sakai, T				Matsuzaki, Y; Takaoka, Y; Hitomi, T; Nishino, H; Sakai, T			Activation of protein kinase C promotes human cancer cell growth through downregulation of p18(INK4c)	ONCOGENE			English	Article						p18(ink4c); TPA; PKC	CDK INHIBITORS; RETINOBLASTOMA PROTEIN; P18 GENES; P16(INK4A); EXPRESSION; P15(INK4B); MICE; PHOSPHORYLATION; PROLIFERATION; TRANSDUCTION	p18(INK4c), a member of INK4 family of cyclin-dependent kinase inhibitors, negatively regulates the cyclin D-cyclin-dependent kinase 4/6 complexes which promote G1/S transition by phosphorylating the retinoblastoma tumor-suppressor gene product. Several recent studies using p18(INK4c)-null mice revealed that the p18(INK4c) plays an important role in cell proliferation and tumor development. We report here that 12-O-tetradecanoylphorbol-13-acetate (TPA), widely used as a protein kinase C (PKC) activator, suppresses the expression of p18(INK4c) through its promoter, accompanied by the induction of human cancer cell growth. Reduction of p18(INK4c) using small interfering RNA (siRNA) also enhanced cell growth, suggesting that p18(INK4c) is a critical target of TPA. Ro 31-8425, a potent and highly specific PKC inhibitor abrogated the suppressive effect of TPA on p18(INK4c) gene expression. However, the expression of dominant-negative c-Jun (TAM-67) did not inhibit the action of TPA on p18(INK4c). These findings suggest that activation of PKC promotes human cancer cell growth through downregulation of p18(INK4c) in an AP-1 activation-independent manner. These results suggest that the accelerated cellular proliferation of some human tumors caused by enhanced PKC activity at least partially involves the suppression of p18(INK4c), which is a ubiquitously expressed cyclin-dependent kinase inhibitor.	Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Biochem & Mol Biol, Kamigyo Ku, Kyoto 6028566, Japan	Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine	Sakai, T (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan.	tsakai@koto.kpu-m.ac.jp						ALVARO V, 1992, INT J CANCER, V50, P724, DOI 10.1002/ijc.2910500510; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bai F, 2003, MOL CELL BIOL, V23, P1269, DOI 10.1128/MCB.23.4.1269-1277.2003; BIT RA, 1993, J MED CHEM, V36, P21, DOI 10.1021/jm00053a003; BROWN PH, 1994, ONCOGENE, V9, P791; da Rocha AB, 2002, ONCOLOGIST, V7, P17, DOI 10.1634/theoncologist.7-1-17; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Goekjian PG, 2001, EXPERT OPIN INV DRUG, V10, P2117; Gordge PC, 1996, EUR J CANCER, V32A, P2120, DOI 10.1016/S0959-8049(96)00255-9; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hatta Y, 1997, BRIT J HAEMATOL, V99, P665; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Miller CW, 1996, CANCER GENET CYTOGEN, V86, P136, DOI 10.1016/0165-4608(95)00216-2; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OBRIAN CA, 1989, CANCER RES, V49, P3215; Otsuki T, 1996, LEUKEMIA, V10, P356; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Rusin MR, 1996, INT J CANCER, V65, P734, DOI 10.1002/(SICI)1097-0215(19960315)65:6<734::AID-IJC4>3.0.CO;2-#; Schenk PW, 1999, BBA-MOL CELL RES, V1449, P1, DOI 10.1016/S0167-4889(98)00178-5; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Swannie Helen C, 2002, Curr Oncol Rep, V4, P37, DOI 10.1007/s11912-002-0046-7; Virchis Andres, 2002, Hematol J, V3, P131, DOI 10.1038/sj.thj.6200165; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Yamamoto H, 1999, CLIN CANCER RES, V5, P1805; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	36	20	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5409	5414		10.1038/sj.onc.1207702	http://dx.doi.org/10.1038/sj.onc.1207702			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15107819				2022-12-25	WOS:000222491600017
J	Oestergaard, VH; Knudsen, BR; Andersen, AH				Oestergaard, VH; Knudsen, BR; Andersen, AH			Dissecting the cell-killing mechanism of the topoisomerase II-targeting drug ICRF-193	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE; 2-GATE MECHANISM; PROTEIN CLAMP; YEAST; TRANSPORT; ALPHA; BISDIOXOPIPERAZINES; HYPERSENSITIVITY; INHIBITION; EXPRESSION	Topoisomerase II is an essential enzyme that is targeted by a number of clinically valuable anticancer drugs. One class referred to as topoisomerase II poisons works by increasing the cellular level of topoisomerase II-mediated DNA breaks, resulting in apoptosis. Another class of topoisomerase II-directed drugs, the bis-dioxopiperazines, stabilizes the conformation of the enzyme where it attains an inactive salt-stable closed clamp structure. Bis-dioxopiperazines, similar to topoisomerase II poisons, induce cell killing, but the underlying mechanism is presently unclear. In this study, we use three different biochemically well characterized human topoisomerase IIalpha mutant enzymes to dissect the catalytic requirements needed for the enzyme to cause dominant sensitivity in yeast to the bis-dioxopirazine ICRF193 and the topoisomerase II poison m-AMSA. We find that the clamp-closing activity, the DNA cleavage activity, and even both activities together are insufficient for topoisomerase II to cause dominant sensitivity to ICRF193 in yeast. Rather, the strand passage event per se is an absolute requirement, most probably because this involves a simultaneous interaction of the enzyme with two DNA segments. Furthermore, we show that the ability of human topoisomerase IIalpha to cause dominant sensitivity to m-AMSA in yeast does not depend on clamp closure or strand passage but is directly related to the capability of the enzyme to respond to m-AMSA with increased DNA cleavage complex formation.	Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark	Aarhus University	Andersen, AH (corresponding author), Aarhus Univ, Dept Mol Biol, CF Mollers Alle,Bldg 130, DK-8000 Aarhus C, Denmark.	aha@mb.au.dk	Oestergaard, Vibe Hallundbæk/B-7254-2015; Andersen, Anni/O-1162-2017	Oestergaard, Vibe Hallundbæk/0000-0002-1633-0560; Andersen, Anni/0000-0001-7194-3258; Knudsen, Birgitta Ruth/0000-0002-3484-3802				Adachi N, 2003, J BIOL CHEM, V278, P35897, DOI 10.1074/jbc.M306500200; Bjergbaek L, 2000, J BIOL CHEM, V275, P13041, DOI 10.1074/jbc.275.17.13041; Classen S, 2003, P NATL ACAD SCI USA, V100, P10629, DOI 10.1073/pnas.1832879100; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; Hajji N, 2003, MUTAT RES-FUND MOL M, V530, P35, DOI 10.1016/S0027-5107(03)00135-0; Hasinoff BB, 1997, BIOCHEM PHARMACOL, V53, P1843, DOI 10.1016/S0006-2952(97)00013-0; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; Huang KC, 2001, J BIOL CHEM, V276, P44488, DOI 10.1074/jbc.M104383200; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jensen LH, 2000, J BIOL CHEM, V275, P2137, DOI 10.1074/jbc.275.3.2137; Jensen S, 1996, MOL CELL BIOL, V16, P3866; Kobayashi M, 2001, CANCER LETT, V166, P71, DOI 10.1016/S0304-3835(01)00447-5; Morris SNK, 1999, J BIOL CHEM, V274, P3446, DOI 10.1074/jbc.274.6.3446; Munoz P, 1998, MOL CELL BIOL, V18, P5797, DOI 10.1128/MCB.18.10.5797; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Oestergaard VH, 2004, J BIOL CHEM, V279, P28093, DOI 10.1074/jbc.M402120200; Oestergaard VH, 2004, J BIOL CHEM, V279, P1684, DOI 10.1074/jbc.M309624200; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; van Hille B, 1999, BRIT J CANCER, V81, P800, DOI 10.1038/sj.bjc.6690767; van Hille B, 1998, CANCER CHEMOTH PHARM, V42, P345, DOI 10.1007/s002800050828; Xiao H, 2003, P NATL ACAD SCI USA, V100, P3239, DOI 10.1073/pnas.0736401100	25	19	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28100	28105		10.1074/jbc.M402119200	http://dx.doi.org/10.1074/jbc.M402119200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123716	hybrid			2022-12-25	WOS:000222265400035
J	Samson, T; Smyth, N; Janetzky, S; Wendler, O; Muller, JM; Schule, R; von der Mark, H; von der Mark, K; Wixler, V				Samson, T; Smyth, N; Janetzky, S; Wendler, O; Muller, JM; Schule, R; von der Mark, H; von der Mark, K; Wixler, V			The LIM-only proteins FHL2 and FHL3 interact with alpha- and beta-subunits of the muscle alpha(7)beta(1) integrin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; CYTOPLASMIC DOMAINS; TRANSCRIPTIONAL COACTIVATOR; ALPHA-7-BETA-1 INTEGRIN; AFFINITY-CHROMATOGRAPHY; EXPRESSION PATTERNS; MOUSE DEVELOPMENT; BINDING PROTEIN; HUMAN-PLASMA; ACTIVATION	FHL1, FHL2, and FHL3 are members of the four and one-half LIM domain protein subclass that are expressed in striated muscles. Here we show that FHL2 and FHL3 are novel alpha(7)beta(1) integrin-interacting proteins. They bind both the alpha- and the beta-subunit as well as different splice isoforms. The minimal binding sites for FHL2 and FHL3 on beta(1A)-chain overlap, whereas on alpha(7A) and alpha(7B) subunits they are situated adjacent. Determining the binding sites for integrins on FHL2 or FHL3 revealed that the suprastructure of the whole molecule is important for these associations, rather than any single LIM domain. Immunofluorescence studies with cells expressing full-length FHL proteins or their deletion mutants showed that FHL2 and FHL3 but not FHL1 colocalize with integrins at cell adhesion sites. Further, their recruitment to the membrane results from binding to either the alpha- or the beta-chain of the integrin receptor. The association of FHL2 or FHL3 with integrin receptors neither influences attachment of cells to different substrates nor changes their migration capacity. However, in cardiac and skeletal muscles, FHL2 and FHL3, respectively, are colocalized with alpha(7)beta(1) integrin receptor at the periphery of Z-discs, suggesting a role in mechanical stabilization of muscle cells.	Univ Erlangen Nurnberg, Nikolaus Fiebiger Zentrum Mol Med, Lehrstuhl Expt Med 1, D-91054 Erlangen, Germany; Univ Cologne, Fak Med, Inst Biochem, D-50931 Cologne, Germany; Univ Freiburg, Frauenklin, D-79106 Freiburg, Germany; Univ Freiburg Klinikum, Zentrum Klin Forsch, D-79106 Freiburg, Germany	University of Erlangen Nuremberg; University of Cologne; University of Freiburg; University of Freiburg	Wixler, V (corresponding author), Univ Erlangen Nurnberg, Nikolaus Fiebiger Zentrum Mol Med, Lehrstuhl Expt Med 1, Gluckstr 6, D-91054 Erlangen, Germany.	vwixler@molmed.uni-erlangen.de		Smyth, Neil/0000-0002-3734-2149; Wendler, Olaf/0000-0002-5443-4889				Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; Brown S, 1999, J BIOL CHEM, V274, P27083, DOI 10.1074/jbc.274.38.27083; Burkin DJ, 1999, CELL TISSUE RES, V296, P183, DOI 10.1007/s004410051279; Chu PH, 2000, MOL CELL BIOL, V20, P7460, DOI 10.1128/MCB.20.20.7460-7462.2000; Chu PH, 2000, MECH DEVELOP, V95, P259, DOI 10.1016/S0925-4773(00)00341-5; Coghill ID, 2003, J BIOL CHEM, V278, P24139, DOI 10.1074/jbc.M213259200; Du XJ, 2002, BBA-GENE STRUCT EXPR, V1577, P93, DOI 10.1016/S0167-4781(02)00414-1; Echtermeyer F, 1996, J BIOL CHEM, V271, P2071, DOI 10.1074/jbc.271.4.2071; El Mourabit H, 2002, MATRIX BIOL, V21, P207, DOI 10.1016/S0945-053X(01)00198-6; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kaariainen M, 2002, AM J PATHOL, V161, P1023, DOI 10.1016/S0002-9440(10)64263-0; Kong YF, 2001, CIRCULATION, V103, P2731; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; Lange S, 2002, J CELL SCI, V115, P4925, DOI 10.1242/jcs.00181; LAYROVSKII VA, 1976, TSITOLOGIYA, V18, P113; Li HY, 2001, J CELL BIOCHEM, V80, P293, DOI 10.1002/1097-4644(20010301)80:3<293::AID-JCB10>3.3.CO;2-L; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Liu SC, 2000, J CELL SCI, V113, P3563; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; McGrath MJ, 2003, AM J PHYSIOL-CELL PH, V285, pC1513, DOI 10.1152/ajpcell.00207.2003; McLoughlin P, 2002, J BIOL CHEM, V277, P37045, DOI 10.1074/jbc.M203336200; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; Mielenz D, 2001, J BIOL CHEM, V276, P13417, DOI 10.1074/jbc.M011481200; Morgan MJ, 1999, BIOCHEM BIOPH RES CO, V255, P245, DOI 10.1006/bbrc.1999.0179; Morgan MJ, 1999, BIOCHEM BIOPH RES CO, V255, P251, DOI 10.1006/bbrc.1999.0180; Morgan MJ, 1996, BIOCHEM BIOPH RES CO, V225, P632, DOI 10.1006/bbrc.1996.1222; Morlon A, 2003, P NATL ACAD SCI USA, V100, P3977, DOI 10.1073/pnas.0735923100; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Nawrotzki R, 2003, HUM MOL GENET, V12, P483, DOI 10.1093/hmg/ddg047; Paul AC, 2002, CELL TISSUE RES, V308, P255, DOI 10.1007/s00441-002-0526-y; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; Robinson PA, 2003, AM J PHYSIOL-CELL PH, V284, pC681, DOI 10.1152/ajpcell.00370.2002; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schmeichel KL, 1997, MOL BIOL CELL, V8, P219, DOI 10.1091/mbc.8.2.219; Scholl FA, 2000, J CELL BIOL, V151, P495, DOI 10.1083/jcb.151.3.495; SONG WK, 1993, J CELL SCI, V106, P1139; Stilo R, 2002, FEBS LETT, V521, P165, DOI 10.1016/S0014-5793(02)02869-7; Tanahashi H, 2000, HUM MOL GENET, V9, P2281, DOI 10.1093/oxfordjournals.hmg.a018919; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; VanderFlier A, 1997, DEV DYNAM, V210, P472, DOI 10.1002/(SICI)1097-0177(199712)210:4<472::AID-AJA10>3.0.CO;2-9; Velling T, 1996, DEV DYNAM, V207, P355, DOI 10.1002/(SICI)1097-0177(199612)207:4<355::AID-AJA1>3.0.CO;2-G; Vignier N, 1999, BIOCHEM BIOPH RES CO, V260, P357, DOI 10.1006/bbrc.1999.0916; Vinogradova O, 2000, P NATL ACAD SCI USA, V97, P1450, DOI 10.1073/pnas.040548197; von der Mark H, 2002, J BIOL CHEM, V277, P6012, DOI 10.1074/jbc.M102188200; VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; Wixler V, 1999, FEBS LETT, V445, P351, DOI 10.1016/S0014-5793(99)00151-9; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	53	84	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28641	28652		10.1074/jbc.M312894200	http://dx.doi.org/10.1074/jbc.M312894200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117962	hybrid			2022-12-25	WOS:000222265400100
J	Ding, Y; Wang, L; Su, LK; Frey, JA; Shao, RP; Hunt, KK; Yan, DH				Ding, Y; Wang, L; Su, LK; Frey, JA; Shao, RP; Hunt, KK; Yan, DH			Antitumor activity of IFIX, a novel interferon-inducible HIN-200 gene, in breast cancer	ONCOGENE			English	Article						IFIX; interferon; HIN-200; p21(CIP1); breast cancer	DEATH-DOMAIN-FOLD; CARCINOMA CELL-LINES; INDUCED APOPTOSIS; PYRIN DOMAIN; TUMOR SUPPRESSION; CDK INHIBITORS; CYCLE CONTROL; EXPRESSION; GROWTH; FAMILY	We identified IFIX as a new member of the hematopoietic interferon (IFN)-inducible nuclear protein with the 200-amino-acid repeat (HIN-200) family. Six different alternatively spliced forms of mRNA are transcribed from the IFIX gene, which are predicted to encode six different isoforms of IFIX proteins (IFIXalpha1, alpha2, beta1, beta2, gamma1, and gamma2). The IFIX proteins are primarily localized in the nucleus. They share a common N-terminal region that contains a predicted pyrin domain and a putative nuclear localization signal. Unlike IFIXalpha and IFIXbeta, IFIXgamma isoforms do not have the 200-amino-acid signature motif. Interestingly, the expression of IFIX was reduced in most human breast tumors and breast cancer cell lines. Expression of IFIXalpha1, the longest isoform of IFIX, in human breast cancer cell lines reduced their anchorage-dependent and -independent growth in vitro and tumor-igenicity in nude mice. Moreover, a liposome-mediated IFIXalpha1 gene transfer suppressed the growth of already-formed tumors in a breast cancer xenograft model. IFIXalpha1 appears to suppress the growth of breast cancer cells in a pRB- and p53-independent manner by increasing the expression of the cyclin-dependent kinase inhibitor p21(CIp1), which leads to the reduction of the kinase activity of both Cdk2 and p34(Cdc2). Together, our results show that IFIXalpha1 possesses a tumor-suppressor activity and suggest IFIXalpha1 may be used as a therapeutic agent in cancer treatment.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Yan, DH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dyan@mdanderson.org			NCI NIH HHS [CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Choubey D, 2000, FEBS LETT, V474, P38, DOI 10.1016/S0014-5793(00)01571-4; Choubey D, 2000, J BIOL REG HOMEOS AG, V14, P187; Coradini D, 1998, ANTICANCER RES, V18, P177; Cox LS, 1997, J PATHOL, V183, P134, DOI 10.1002/(SICI)1096-9896(199710)183:2<134::AID-PATH960>3.0.CO;2-D; Dawson MJ, 1996, J LEUKOCYTE BIOL, V60, P310, DOI 10.1002/jlb.60.3.310; DAWSON MJ, 1995, J CELL BIOCHEM, V57, P39, DOI 10.1002/jcb.240570106; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; Ding Y, 2002, CLIN CANCER RES, V8, P3290; Doree M, 2002, J CELL SCI, V115, P2461; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Fang M, 2000, ANTICANCER RES, V20, P103; Funk JO, 1998, TRENDS BIOCHEM SCI, V23, P337; Gariglio M, 2002, J INTERF CYTOK RES, V22, P815, DOI 10.1089/107999002320271413; Gooch JL, 2000, CELL GROWTH DIFFER, V11, P335; Gribaudo G, 1999, FEBS LETT, V456, P31, DOI 10.1016/S0014-5793(99)00916-3; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; Hingorani R, 2000, J IMMUNOL, V164, P4032, DOI 10.4049/jimmunol.164.8.4032; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; KIMCHI A, 1988, MOL CELL BIOL, V8, P2828, DOI 10.1128/MCB.8.7.2828; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; Liepinsh E, 2003, J MOL BIOL, V332, P1155, DOI 10.1016/j.jmb.2003.07.007; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; Nadal A, 1997, J PATHOL, V183, P156; Naldini A, 2002, J CELL PHYSIOL, V191, P290, DOI 10.1002/jcp.10101; PRICE JE, 1990, CANCER RES, V50, P717; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Staub E, 2001, TRENDS BIOCHEM SCI, V26, P83, DOI 10.1016/S0968-0004(00)01717-5; Wei W, 2003, HISTOCHEM CELL BIOL, V119, P45, DOI 10.1007/s00418-002-0485-0; Wen Y, 2000, CANCER RES, V60, P42; Wen Y, 2001, CANCER RES, V61, P7142; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368; Yin F, 2001, ANTICANCER RES, V21, P413; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhang JF, 1996, P NATL ACAD SCI USA, V93, P4513, DOI 10.1073/pnas.93.9.4513; ZHANG RD, 1991, INVAS METAST, V11, P204; Zhou YH, 2002, CANCER INVEST, V20, P348, DOI 10.1081/CNV-120001180; Zou YY, 2002, CANCER RES, V62, P8	39	51	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4556	4566		10.1038/sj.onc.1207592	http://dx.doi.org/10.1038/sj.onc.1207592			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15122330				2022-12-25	WOS:000221799000005
J	Park, SW; Vepachedu, R; Owens, RA; Vivanco, JM				Park, SW; Vepachedu, R; Owens, RA; Vivanco, JM			The N-glycosidase activity of the ribosome-inactivating protein ME1 targets single-stranded regions of nucleic acids independent of sequence or structural motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POKEWEED ANTIVIRAL PROTEIN; RICIN-A-CHAIN; POLYNUCLEOTIDE-ADENOSINE GLYCOSIDASE; CENTRAL CONSERVED REGION; RNA IDENTITY ELEMENTS; IN-VIVO; ALPHA-SARCIN; SYNTHETIC OLIGORIBONUCLEOTIDE; NONSPECIFIC DEADENYLATION; EUKARYOTIC RIBOSOMES	ME1, a type I ribosome-inactivating protein ( RIP), belongs to a family of enzymes long believed to possess rRNA N-glycosidase activity directed solely at the universally conserved residue A4324 in the sarcin/ricin loop of large eukaryotic and prokaryotic rRNAs. We have investigated the effect of modifying the structure of non-ribosomal RNA substrates on their interaction with ME1 and other RIPs. ME1 was shown to depurinate a variety of partially denatured nucleic acids, randomly removing adenine residues from single-stranded regions and, to a lesser extent, guanine residues from wobble base-pairs in hairpin stems. A defined sequence motif was not required for recognition of non-paired adenosines and cleavage of the N-glycosidic bond. Substrate recognition and ME1 activity appeared to depend on the physical availability of nucleotides, and denaturation of nucleic acid substrates increased their interaction with ME1. Pretreatment of mRNA at 75 degreesC rather than 60 degreesC, for example, lowered the apparent K-D from 87.1 to 73.9 nM, making it more vulnerable to depurination by RIPs. Exposure to ME1 in vitro completely abolished the infectivity of partially denatured RNA transcripts of the potato spindle tuber viroid, suggesting that RIPs may target invading nucleic acids before they reach host ribosomes in vivo. Our data suggest that the extensive folding of many potential substrates interferes with their ability to interact with RIPs, thereby blocking their inactivation by ME1 (or other RIPs).	Colorado State Univ, Dept Hort & Landscape Architecture, Ft Collins, CO 80523 USA; Colorado State Univ, Cell & Mol Biol Program, Ft Collins, CO 80523 USA; ARS, Mol Plant Pathol Lab, USDA, Beltsville, MD 20705 USA	Colorado State University; Colorado State University; United States Department of Agriculture (USDA)	Vivanco, JM (corresponding author), Colorado State Univ, Dept Hort & Landscape Architecture, Shepardson Bldg,Rm 217, Ft Collins, CO 80523 USA.	j.vivanco@colostate.edu						Antal M, 2002, NUCLEIC ACIDS RES, V30, P912, DOI 10.1093/nar/30.4.912; ARON GM, 1980, ANTIMICROB AGENTS CH, V17, P1032, DOI 10.1128/AAC.17.6.1032; Au TK, 2000, FEBS LETT, V471, P169, DOI 10.1016/S0014-5793(00)01389-2; Barbieri L, 1997, NUCLEIC ACIDS RES, V25, P518, DOI 10.1093/nar/25.3.518; Barbieri L, 1996, BIOCHEM J, V319, P507, DOI 10.1042/bj3190507; BARBIERI L, 1994, NATURE, V372, P624, DOI 10.1038/372624a0; BARBIERI L, 1992, BIOCHEM J, V286, P1; Barbieri L, 2000, J BIOCHEM-TOKYO, V128, P883, DOI 10.1093/oxfordjournals.jbchem.a022827; Batey RT, 1998, RNA, V4, P984, DOI 10.1017/S1355838298980426; BAUMSTARK T, 1995, NUCLEIC ACIDS RES, V23, P4246, DOI 10.1093/nar/23.21.4246; Bink HHJ, 2002, P NATL ACAD SCI USA, V99, P13465, DOI 10.1073/pnas.202287499; Bonin M, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf080; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen XY, 1998, BIOCHEMISTRY-US, V37, P11605, DOI 10.1021/bi980990p; COLE PE, 1972, BIOCHEMISTRY-US, V11, P4358, DOI 10.1021/bi00773a024; CRESS DE, 1983, NUCLEIC ACIDS RES, V11, P6821, DOI 10.1093/nar/11.19.6821; DOMINGO C, 1994, PLANT MOL BIOL, V24, P725, DOI 10.1007/BF00029854; Draper DE, 1996, NAT STRUCT BIOL, V3, P397, DOI 10.1038/nsb0596-397; ENDO Y, 1988, J BIOL CHEM, V263, P8735; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1987, J BIOL CHEM, V262, P5908; ENDO Y, 1988, J BIOL CHEM, V263, P7917; ENDO Y, 1991, J MOL BIOL, V254, P848; Ferre-d'Amare AR, 1999, ANNU REV BIOPH BIOM, V28, P57, DOI 10.1146/annurev.biophys.28.1.57; GLUCK A, 1994, NUCLEIC ACIDS RES, V22, P321, DOI 10.1093/nar/22.3.321; GLUCK A, 1992, J MOL BIOL, V226, P411, DOI 10.1016/0022-2836(92)90956-K; HARTLEY MR, 1991, FEBS LETT, V290, P65, DOI 10.1016/0014-5793(91)81227-Y; He WJ, 2002, ARCH BIOCHEM BIOPHYS, V399, P181, DOI 10.1006/abbi.2001.2748; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; Hudak KA, 2000, RNA, V6, P369, DOI 10.1017/S1355838200991337; Hudak KA, 2002, RNA, V8, P1148, DOI 10.1017/S1355838202026638; LODGE JK, 1993, P NATL ACAD SCI USA, V90, P7089, DOI 10.1073/pnas.90.15.7089; MARCHANT A, 1995, J MOL BIOL, V254, P848, DOI 10.1006/jmbi.1995.0660; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MCGRATH MS, 1989, P NATL ACAD SCI USA, V86, P2844, DOI 10.1073/pnas.86.8.2844; Nicolas E, 1997, FEBS LETT, V406, P162, DOI 10.1016/S0014-5793(97)00267-6; Nicolas E, 1998, J BIOL CHEM, V273, P17216, DOI 10.1074/jbc.273.27.17216; Nielsen K, 2001, ANNU REV PLANT PHYS, V52, P785, DOI 10.1146/annurev.arplant.52.1.785; Nikolcheva T, 1999, J MOL BIOL, V292, P557, DOI 10.1006/jmbi.1999.3083; Orita M, 1996, NUCLEIC ACIDS RES, V24, P611, DOI 10.1093/nar/24.4.611; ORITA M, 1993, NUCLEIC ACIDS RES, V21, P5670, DOI 10.1093/nar/21.24.5670; OSBORN RW, 1990, EUR J BIOCHEM, V193, P401, DOI 10.1111/j.1432-1033.1990.tb19353.x; Panabieres F, 1995, MOL PLANT MICROBE IN, V8, P996, DOI 10.1094/MPMI-8-0996; Park SW, 2002, PLANT PHYSIOL, V130, P164, DOI 10.1104/pp.000794; Peumans WJ, 2001, FASEB J, V15, P1493, DOI 10.1096/fj.00-0751rev; PODLECKIS EV, 1993, J VIROL METHODS, V43, P147, DOI 10.1016/0166-0934(93)90072-Y; Rajamohan F, 1999, BIOCHEM BIOPH RES CO, V263, P419, DOI 10.1006/bbrc.1999.1335; Rajamohan F, 1999, BIOCHEM BIOPH RES CO, V260, P453, DOI 10.1006/bbrc.1999.0922; READY MP, 1986, P NATL ACAD SCI USA, V83, P5053, DOI 10.1073/pnas.83.14.5053; RIESNER D, 1990, SEMIN VIROL, V1, P83; Schrader O, 2003, NUCLEIC ACIDS RES, V31, P988, DOI 10.1093/nar/gkg193; Schroeder R, 2002, CURR OPIN STRUC BIOL, V12, P296, DOI 10.1016/S0959-440X(02)00325-1; SHAW JG, 1986, VIROLOGY, V148, P326, DOI 10.1016/0042-6822(86)90329-6; Steger G., 2003, Viroids, P15; STEIN A, 1976, BIOCHEMISTRY-US, V15, P157, DOI 10.1021/bi00646a024; SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581; Tang S, 2001, BBA-GENE STRUCT EXPR, V1519, P192, DOI 10.1016/S0167-4781(01)00236-6; Tanner MA, 1996, RNA, V2, P74; TAYLOR S, 1994, PLANT J, V5, P827, DOI 10.1046/j.1365-313X.1994.5060827.x; USSERY MA, 1977, ANN NY ACAD SCI, V284, P431, DOI 10.1111/j.1749-6632.1977.tb21979.x; Vepachedu R, 2003, PLANTA, V217, P498, DOI 10.1007/s00425-003-1014-7; Vivanco JM, 1999, PLANT PHYSIOL, V119, P1447, DOI 10.1104/pp.119.4.1447; Wassenegger M, 1996, VIROLOGY, V226, P191, DOI 10.1006/viro.1996.0646; Wu XJ, 1997, VIROLOGY, V239, P426, DOI 10.1006/viro.1997.8870; ZAMBONI M, 1989, BIOCHEM J, V259, P639, DOI 10.1042/bj2590639; ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0; Zhu YL, 2002, PLANT PHYSIOL, V130, P138, DOI 10.1104/pp.006403; Zoubenko O, 2000, PLANT MOL BIOL, V44, P219, DOI 10.1023/A:1006443626864; Zuker M., 1999, V70, P11	69	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34165	34174		10.1074/jbc.M400105200	http://dx.doi.org/10.1074/jbc.M400105200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15123667	hybrid			2022-12-25	WOS:000223134800014
J	Yun, JS; Tomida, A; Andoh, T; Tsuruo, T				Yun, JS; Tomida, A; Andoh, T; Tsuruo, T			Interaction between glucose-regulated destruction domain of DNA topoisomerase II alpha and MPN domain of Jab1/CSN5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS E1A-INDUCED APOPTOSIS; NUCLEAR-LOCALIZATION SIGNALS; CANCER CELL-LINE; COP9 SIGNALOSOME; DEPENDENT REGULATION; UBIQUITIN SYSTEM; DIRECTED DRUGS; SOLID TUMORS; DEGRADATION; RESISTANCE	DNA topoisomerase (topo) IIalpha, an essential enzyme for cell proliferation, is targeted to a proteasome-dependent degradation pathway when human tumor cells are glucose-starved. Here we show that the topo IIalpha destabilization depends on the newly identified domain, GRDD (glucose-regulated destruction domain), which was mapped to the N-terminal 70 - 170 amino acid sequence. Indeed, the deletion of GRDD conferred a stable feature on topo IIalpha, whereas the fusion of GRDD rendered green fluorescent protein unstable under glucose starvation conditions. Nuclear localization was a prerequisite for GRDD function, because the inhibition of nuclear translocation resulted in the suppression of GRDD-mediated topo IIalpha degradation. Further, GRDD was identified as an interactive domain for Jab1/CSN5, which promoted the degradation of topo IIalpha in a manner dependent on the MPN (Mpr1p/ Prd1p N terminus) domain. Depleting Jab1/CSN5 by antisense oligonucleotide and treating cells with the CSN-associated kinase inhibitor, curcumin, inhibited topo IIalpha degradation induced by glucose starvation. These findings demonstrate that GRDD can act as a stress-activated degron for regulating topo IIalpha stability, possibly through interaction with the MPN domain of Jab1/CSN5.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Soka Univ, Fac Engn, Dept Bioengn, Tokyo 1920003, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	University of Tokyo; Soka University; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	ttsuruo@iam.u-tokyo.ac.jp						Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Brown JM, 1998, CANCER RES, V58, P1408; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Deng XW, 2000, TRENDS GENET, V16, P202, DOI 10.1016/S0168-9525(00)01982-X; Dingemans AMC, 1998, BBA-GENE STRUCT EXPR, V1400, P275, DOI 10.1016/S0167-4781(98)00141-9; HARKER WG, 1995, CANCER RES, V55, P1707; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Horie K, 2002, ONCOGENE, V21, P7913, DOI 10.1038/sj.onc.1205917; HSIANG YH, 1988, CANCER RES, V48, P3230; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kim HD, 1999, J CELL PHYSIOL, V180, P97, DOI 10.1002/(SICI)1097-4652(199907)180:1<97::AID-JCP11>3.0.CO;2-Y; KROLL DJ, 1991, J BIOL CHEM, V266, P7957; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Lim MS, 2002, BLOOD, V100, P2950, DOI 10.1182/blood.V100.8.2950; Mao Y, 2001, J BIOL CHEM, V276, P40652, DOI 10.1074/jbc.M104009200; Mashima T, 1999, ONCOGENE, V18, P2423, DOI 10.1038/sj.onc.1202558; Mirski SEL, 1997, EXP CELL RES, V237, P452, DOI 10.1006/excr.1997.3805; MIRSKI SEL, 1995, CANCER RES, V55, P2129; Nakajima T, 1996, J BIOL CHEM, V271, P24842, DOI 10.1074/jbc.271.40.24842; NAKAJIMA T, 1995, ONCOGENE, V10, P651; Ogiso Y, 2000, CANCER RES, V60, P2429; Ogiso Y, 2002, CANCER RES, V62, P5008; Salmena L, 2001, BIOCHEM PHARMACOL, V61, P795, DOI 10.1016/S0006-2952(01)00580-9; Schwechheimer C, 2001, TRENDS CELL BIOL, V11, P420, DOI 10.1016/S0962-8924(01)02091-8; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; SHEN J, 1987, P NATL ACAD SCI USA, V84, P3278, DOI 10.1073/pnas.84.10.3278; SULLIVAN DM, 1987, CANCER RES, V47, P3973; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; Tomida A, 1999, ANTI-CANCER DRUG DES, V14, P169; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; Uhle S, 2003, EMBO J, V22, P1302, DOI 10.1093/emboj/cdg127; VASSETZKY YS, 1995, BIOESSAYS, V17, P767, DOI 10.1002/bies.950170906; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; WELLS NJ, 1995, J BIOL CHEM, V270, P28357; Yang XM, 2002, CURR BIOL, V12, P667, DOI 10.1016/S0960-9822(02)00791-1; Yu Q, 1997, BIOCHEMISTRY-US, V36, P5868, DOI 10.1021/bi962400y; Yun J, 1995, ONCOL RES, V7, P583	44	27	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31296	31303		10.1074/jbc.M401411200	http://dx.doi.org/10.1074/jbc.M401411200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15126503	hybrid			2022-12-25	WOS:000222726800049
J	Gu, Y; Lin, Q; Childress, C; Yang, WN				Gu, Y; Lin, Q; Childress, C; Yang, WN			Identification of the region in Cdc42 that confers the binding specificity to activated Cdc42-associated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONRECEPTOR TYROSINE KINASE; ALDRICH SYNDROME PROTEIN; ACTIN CYTOSKELETON; C-ELEGANS; GTPASE; COMPLEX; DOMAIN; TARGET; EFFECTOR; FAMILY	The Rho family small G-protein Cdc42 has been implicated in a diversity of biological functions. Multiple downstream effectors have been identified. How Cdc42 discriminates the interaction with its multiple downstream effectors is not known. Activated Cdc42-associated tyrosine kinase (ACK) is a very specific effector of Cdc42. To delineate the Cdc42 signaling pathway mediated by ACK, we set about to identify the specific ACK-binding region in Cdc42. We utilized TC10, another member of the Rho family of G-proteins that is 66.7% identical to Cdc42, to construct TC10/Cdc42 chimeras for screening the specific ACK-binding region in Cdc42. A region between switch I and switch II has been identified as the specific ACK-binding ( AB) region. The replacement of the AB region with the corresponding region in TC10 resulted in the complete loss of ACK-binding ability but did not affect the binding to WASP, suggesting that the AB region confers the binding specificity to ACK. On the other hand, replacement of the corresponding region of TC10 with the AB region enabled TC10 to acquire ACK-binding ability. Eight residues are different between the AB region and the corresponding region of TC10. The mutational analysis indicated that all eight residues contribute to the binding to ACK2. The assays for the Cdc42-mediated activation of ACK2 indicated that the AB region is essential for Cdc42 to activate ACK2 in cells. Thus, our studies have defined a specific ACK-binding region in Cdc42 and have provided a molecular basis for generating ACK binding-defective mutants of Cdc42 to delineate ACK-mediated signaling pathway.	Weis Ctr Res, Geisinger Clin, Danville, PA 17822 USA; Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA	Cornell University	Yang, WN (corresponding author), Weis Ctr Res, Geisinger Clin, 100 N Acad Ave, Danville, PA 17822 USA.	wyang1@geisinge.edu						Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Coon M, 2002, J CELL BIOCHEM, V84, P655, DOI 10.1002/jcb.10078; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; Erickson JW, 2001, CURR OPIN CELL BIOL, V13, P153, DOI 10.1016/S0955-0674(00)00192-7; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; Garrard SM, 2003, EMBO J, V22, P1125, DOI 10.1093/emboj/cdg110; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hopper NA, 2000, MOL CELL, V6, P65, DOI 10.1016/S1097-2765(00)00008-3; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; Owen D, 2000, BIOCHEMISTRY-US, V39, P1243, DOI 10.1021/bi991567z; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Teo M, 2001, J BIOL CHEM, V276, P18392, DOI 10.1074/jbc.M008795200; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Yang WN, 1999, J BIOL CHEM, V274, P8524, DOI 10.1074/jbc.274.13.8524; Yang WN, 2001, J BIOL CHEM, V276, P17468, DOI 10.1074/jbc.M010893200; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	31	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30507	30513		10.1074/jbc.M313518200	http://dx.doi.org/10.1074/jbc.M313518200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123659	hybrid			2022-12-25	WOS:000222531900079
J	Hartman, HL; Bowers, KE; Fierke, CA				Hartman, HL; Bowers, KE; Fierke, CA			Lysine beta 311 of protein geranylgeranyltransferase type I partially replaces magnesium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYROPHOSPHATE BINDING; FARNESYL-TRANSFERASE; FLUORESCENCE ASSAY; METAL REQUIREMENTS; KINETIC MECHANISM; MAMMALIAN-CELLS; FARNESYLTRANSFERASE; RAT; PRENYLTRANSFERASES; PRENYLATION	Protein geranylgeranyltransferase type I (GGTase I) catalyzes the attachment of a geranylgeranyl lipid group near the carboxyl terminus of protein substrates. Unlike protein farnesyltransferase (FTase) and protein geranylgeranyltransferase type II, which require both Zn(II) and Mg(II) for maximal turnover, GGTase I turnover is dependent only on Zn(II). In FTase, the magnesium ion is coordinated by aspartate beta352 and the diphosphate of farnesyl diphosphate to stabilize the developing charge in the transition state (Pickett, J. S., Bowers, K. E., and Fierke, C. A. (2003) J. Biol. Chem. 278, 51243-51250). In GGTase I, lysine beta311 is substituted for this aspartate and is proposed to replace the catalytic function of Mg(II) (Taylor, J. S., Reid, T. S., Terry, K. L., Casey, P. J., and Beese, L. S. (2003) EMBO J. 22, 5963-5974). Here we demonstrate that the prenylation rate constant catalyzed by wild type GGTase I (k(chem) = 0.18 +/- 0.02 s(-1)) is not dependent on Mg(II), is similar to20-fold slower than the maximal rate constant catalyzed by FTase, and has a single pK(a) of 6.4 +/- 0.1, likely reflecting deprotonation of the peptide thiol. Mutation of lysine beta311 in GGTase I to alanine (Kbeta311A) or aspartate (Kbeta311D) decreases the k(chem) in the absence of magnesium 9-41fold without significantly affecting the binding affinity of either substrate. Furthermore, the geranylgeranylation rate constant is enhanced by the addition of Mg(II) for Kbeta311A and Kbeta311D GGTase I 2-5- fold compared with wild type GGTase I with K-Mg of 140 +/- 10 mM and 6.4 +/- 0.8 mM, respectively. These results demonstrate that lysine beta311 of GGTase I partially replaces the catalytic function of Mg(II) observed in FTase.	Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Fierke, CA (corresponding author), Univ Michigan, Dept Chem, 930 N Univ Ave, Ann Arbor, MI 48109 USA.	fierke@umich.edu			NCI NIH HHS [F32CA84757] Funding Source: Medline; NIGMS NIH HHS [GM07767, GM40602] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA084757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040602, R29GM040602] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bowers KE, 2004, BIOCHEMISTRY-US, V43, P5256, DOI 10.1021/bi049822p; CAPLIN BE, 1994, BBA-PROTEIN STRUCT M, V1205, P39, DOI 10.1016/0167-4838(94)90089-2; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CASSIDY PB, 1995, METHOD ENZYMOL, V250, P30; Chehade KAH, 2002, J AM CHEM SOC, V124, P8206, DOI 10.1021/ja0124717; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FURFINE ES, 1995, BIOCHEMISTRY-US, V34, P6857, DOI 10.1021/bi00020a032; Grubbs RD, 2002, BIOMETALS, V15, P251, DOI 10.1023/A:1016026831789; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hightower KE, 1998, BIOCHEMISTRY-US, V37, P15555, DOI 10.1021/bi981525v; Huang CC, 2000, BIOCHEMISTRY-US, V39, P2593, DOI 10.1021/bi992356x; Huang CC, 1997, J BIOL CHEM, V272, P20; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; Liang PH, 2002, EUR J BIOCHEM, V269, P3339, DOI 10.1046/j.1432-1033.2002.03014.x; Long SB, 2000, STRUCTURE, V8, P209, DOI 10.1016/S0969-2126(00)00096-4; Long SB, 2002, NATURE, V419, P645, DOI 10.1038/nature00986; Long SB, 2001, P NATL ACAD SCI USA, V98, P12948, DOI 10.1073/pnas.241407898; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; Pickett JS, 2003, J BIOL CHEM, V278, P51243, DOI 10.1074/jbc.M309226200; Pickett JS, 2003, BIOCHEMISTRY-US, V42, P9741, DOI 10.1021/bi0346852; PICKETT WC, 1995, ANAL BIOCHEM, V225, P60, DOI 10.1006/abio.1995.1108; POMPLIANO DL, 1992, J AM CHEM SOC, V114, P7945, DOI 10.1021/ja00046a070; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, J BIOL CHEM, V266, P10672; Rellick LM, 1997, BIOPOLYMERS, V42, P191, DOI 10.1002/(SICI)1097-0282(199708)42:2<191::AID-BIP8>3.0.CO;2-I; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; Saderholm MJ, 2000, BIOCHEMISTRY-US, V39, P12398, DOI 10.1021/bi0011781; SAGAMI H, 1992, ARCH BIOCHEM BIOPHYS, V297, P314, DOI 10.1016/0003-9861(92)90678-P; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEBTI SM, 2001, FARNESYLTRANSFERASE, P21; Tamanoi F, 2001, CELL MOL LIFE SCI, V58, P1636, DOI 10.1007/PL00000802; Taylor JS, 2003, EMBO J, V22, P5963, DOI 10.1093/emboj/cdg571; Wolf Federica I., 2003, Molecular Aspects of Medicine, V24, P11, DOI 10.1016/S0098-2997(02)00088-2; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; YOKOYAMA K, 1992, BIOCHEM SOC T, V20, P489, DOI 10.1042/bst0200489; Yokoyama K, 1997, J BIOL CHEM, V272, P3944, DOI 10.1074/jbc.272.7.3944; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; ZHANG FL, 1994, J BIOL CHEM, V269, P3175; Zhang FL, 1996, BIOCHEM J, V320, P925, DOI 10.1042/bj3200925; ZHANG FL, 1994, J BIOL CHEM, V269, P23465; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zimmerman KK, 1998, PROTEIN EXPRES PURIF, V14, P395, DOI 10.1006/prep.1998.0979	55	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30546	30553		10.1074/jbc.M403469200	http://dx.doi.org/10.1074/jbc.M403469200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131129	hybrid			2022-12-25	WOS:000222531900084
J	Ropers, D; Ayadi, L; Gattoni, R; Jacquenet, S; Damier, L; Branlant, C; Stevenin, J				Ropers, D; Ayadi, L; Gattoni, R; Jacquenet, S; Damier, L; Branlant, C; Stevenin, J			Differential effects of the SR proteins 9G8, SC35, ASF/SF2, and SRp40 on the utilization of the A1 to A5 splicing sites of HIV-1 RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HNRNP A/B PROTEINS; MESSENGER-RNA; TAT EXON-2; IN-VITRO; REGULATORY ELEMENTS; SILENCER ELEMENT/; ALTERNATIVE EXON; INFECTED CELLS; BRANCH SITE	Splicing is a crucial step for human immunodeficiency virus, type 1 (HIV-1) multiplication; eight acceptor sites are used in competition to produce the vif, vpu, vpr, nef, env, tat, and rev mRNAs. The effects of SR proteins have only been investigated on a limited number of HIV-1 splicing sites by using small HIV-1 RNA pieces. To understand how SR proteins influence the use of HIV-1 splicing sites, we tested the effects of overproduction of individual SR proteins in HeLa cells on the splicing pattern of an HIV-1 RNA that contained all the splicing sites. The steady state levels of the HIV-1 mRNAs produced were quantified by reverse transcriptase-PCR. For interpretation of the data, transcripts containing one or several of the HIV-1 acceptor sites were spliced in vitro in the presence or the absence of one of the tested SR proteins. Both in vivo and in vitro, acceptor sites A2 and A3 were found to be strongly and specifically regulated by SR proteins. ASF/SF2 strongly activates site A2 and to a lesser extent site A1. As a result, upon ASF/SF2 overexpression, the vpr mRNA steady state level is specifically increased. SC35 and SRp40, but not 9G8, strongly activate site A3, and their overexpression ex vivo induces a dramatic accumulation of the tat mRNA, to the detriment of most of the other viral mRNAs. Here we showed by Western blot analysis that the Nef protein synthesis is strongly decreased by overexpression of SC35, SRp40, and ASF/SF2. Finally, activation by ASF/SF2 and 9G8 was found to be independent of the RS domain. This is the first investigation of the effects of variations of individual SR protein concentrations that is performed ex vivo on an RNA containing a complex set of splicing sites.	Univ Henri Poincare, Lab Maturat ARN & Enzymol Mol, UMAR 7567, CNRS,Fac Sci, F-54506 Vandoeuvre Les Nancy, France; IGBMC, CNRS, INSERM, ULP 7104, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Branlant, C (corresponding author), Univ Henri Poincare, Lab Maturat ARN & Enzymol Mol, UMAR 7567, CNRS,Fac Sci, Blvd Aiguillettes,BP 239, F-54506 Vandoeuvre Les Nancy, France.	Christiane.Branlant@maem.uhp-nancy.fr		Ropers, Delphine/0000-0003-2659-3003; Branlant, Christiane/0000-0003-4728-5499				AMENDT BA, 1994, MOL CELL BIOL, V14, P3960, DOI 10.1128/MCB.14.6.3960; AMENDT BA, 1995, MOL CELL BIOL, V15, P4606; Arora VK, 2002, MICROBES INFECT, V4, P189, DOI 10.1016/S1286-4579(01)01527-1; Azad AA, 2000, BIOCHEM BIOPH RES CO, V267, P677, DOI 10.1006/bbrc.1999.1708; BENKO DM, 1990, J VIROL, V64, P2505, DOI 10.1128/JVI.64.6.2505-2518.1990; Bertsch C, 2002, ARCH VIROL, V147, P1963, DOI 10.1007/s00705-002-0857-8; Bilodeau PS, 2001, J VIROL, V75, P8487, DOI 10.1128/JVI.75.18.8487-8497.2001; Bilodeau PS, 1999, J VIROL, V73, P9764, DOI 10.1128/JVI.73.12.9764-9772.1999; Boris-Lawrie K, 2001, LIFE SCI, V69, P2697, DOI 10.1016/S0024-3205(01)01360-1; Bourgeois CF, 1999, MOL CELL BIOL, V19, P7347; Bres V, 2003, NAT CELL BIOL, V5, P754, DOI 10.1038/ncb1023; Bres V, 2002, EMBO J, V21, P6811, DOI 10.1093/emboj/cdf669; Bukrinsky M, 1999, REV MED VIROL, V9, P39, DOI 10.1002/(SICI)1099-1654(199901/03)9:1<39::AID-RMV235>3.0.CO;2-3; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Caputi M, 2002, EMBO J, V21, P845, DOI 10.1093/emboj/21.4.845; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Damier L, 1997, BIOCHEM BIOPH RES CO, V237, P182, DOI 10.1006/bbrc.1997.7091; DAMIER L, 1997, THESIS U H POINCARE; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DYHRMIKKELSEN H, 1995, J BIOL CHEM, V270, P24060, DOI 10.1074/jbc.270.41.24060; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; HIMMELSPACH M, 1995, RNA, V1, P794; Jacquenet S, 2001, J BIOL CHEM, V276, P40464, DOI 10.1074/jbc.M104070200; Jacquenet S, 2001, NUCLEIC ACIDS RES, V29, P464, DOI 10.1093/nar/29.2.464; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; Lejeune F, 2001, J BIOL CHEM, V276, P7850, DOI 10.1074/jbc.M009510200; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Maldarelli F, 1998, VIRUS RES, V53, P39, DOI 10.1016/S0168-1702(97)00130-5; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Marchand V, 2002, J MOL BIOL, V323, P629, DOI 10.1016/S0022-2836(02)00967-1; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; Molin M, 2000, J VIROL, V74, P9002, DOI 10.1128/JVI.74.19.9002-9009.2000; OREILLY MM, 1995, VIROLOGY, V213, P373, DOI 10.1006/viro.1995.0010; Pongoski J, 2002, J VIROL, V76, P5108, DOI 10.1128/JVI.76.10.5108-5120.2002; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Ryo A, 2000, AIDS RES HUM RETROV, V16, P995, DOI 10.1089/08892220050058416; Schaal TD, 1999, MOL CELL BIOL, V19, P1705; Si ZH, 1997, NUCLEIC ACIDS RES, V25, P861, DOI 10.1093/nar/25.4.861; Si ZH, 1998, MOL CELL BIOL, V18, P5404, DOI 10.1128/MCB.18.9.5404; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; STAFFA A, 1994, J VIROL, V68, P3071, DOI 10.1128/JVI.68.5.3071-3079.1994; STAFFA A, 1995, MOL CELL BIOL, V15, P4597; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; Tang HL, 1999, ANNU REV GENET, V33, P133, DOI 10.1146/annurev.genet.33.1.133; Tange TO, 2001, J MOL BIOL, V312, P649, DOI 10.1006/jmbi.2001.4971; Tange TO, 2001, EMBO J, V20, P5748; Xu XN, 1997, J EXP MED, V186, P7, DOI 10.1084/jem.186.1.7; Zahler AM, 2004, J BIOL CHEM, V279, P10077, DOI 10.1074/jbc.M312743200; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; Zauli G, 1999, BLOOD, V93, P1000, DOI 10.1182/blood.V93.3.1000.403a12_1000_1010; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9	65	59	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29963	29973		10.1074/jbc.M404452200	http://dx.doi.org/10.1074/jbc.M404452200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123677	hybrid			2022-12-25	WOS:000222531900013
J	Sattlegger, E; Swanson, MJ; Ashcraft, EA; Jennings, JL; Fekete, RA; Link, AJ; Hinnebusch, AG				Sattlegger, E; Swanson, MJ; Ashcraft, EA; Jennings, JL; Fekete, RA; Link, AJ; Hinnebusch, AG			YIH1 is an actin-binding protein that inhibits protein kinase GCN2 and impairs general amino acid control when overexpressed	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCHARGED TRANSFER-RNA; INITIATION FACTOR-II; TRANSLATIONAL ACTIVATOR; SHUTTLE VECTORS; BUDDING YEAST; GI DOMAIN; ASSOCIATION; PHOSPHORYLATION; CYTOSKELETON; EXPRESSION	The general amino acid control (GAAC) enables yeast cells to overcome amino acid deprivation by activation of the alpha subunit of translation initiation factor 2 (eIF2alpha) kinase GCN2 and consequent induction of GCN4, a transcriptional activator of amino acid biosynthetic genes. Binding of GCN2 to GCN1 is required for stimulation of GCN2 kinase activity by uncharged tRNA in starved cells. Here we show that YIH1, when overexpressed, dampens the GAAC response (Gcn(-) phenotype) by suppressing eIF2alpha phosphorylation by GCN2. The overexpressed YIH1 binds GCN1 and reduces GCN1-GCN2 complex formation, and, consistent with this, the Gcn(-) phenotype produced by YIH1 overexpression is suppressed by GCN2 overexpression. YIH1 interacts with the same GCN1 fragment that binds GCN2, and this YIH1-GCN1 interaction requires Arg-2259 in GCN1 in vitro and in full-length GCN1 in vivo, as found for GCN2-GCN1 interaction. However, deletion of YIH1 does not increase eIF2alpha phosphorylation or derepress the GAAC, suggesting that YIH1 at native levels is not a general inhibitor of GCN2 activity. We discovered that YIH1 normally resides in a complex with monomeric actin, rather than GCN1, and that a genetic reduction in actin levels decreases the GAAC response. This Gcn(-) phenotype was partially suppressed by deletion of YIH1, consistent with YIH1-mediated inhibition of GCN2 in actin-deficient cells. We suggest that YIH1 resides in a YIH1-actin complex and may be released for inhibition of GCN2 and stimulation of protein synthesis under specialized conditions or in a restricted cellular compartment in which YIH1 is displaced from monomeric actin.	NICHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA; Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37232 USA; NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hinnebusch, AG (corresponding author), NICHD, Lab Gene Regulat & Dev, NIH, Bldg 6A,Rm B1A-13, Bethesda, MD 20892 USA.	ahinnebusch@nih.gov			NCI NIH HHS [CA098131] Funding Source: Medline; NHLBI NIH HHS [HL68744] Funding Source: Medline; NIEHS NIH HHS [ES11993] Funding Source: Medline; NIGMS NIH HHS [GM64779] Funding Source: Medline; NINDS NIH HHS [NS43952] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001004] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001004] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA098131] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064779] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043952] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; Adams Alison, 1997, P143; Amberg DC, 1998, MOL BIOL CELL, V9, P3259, DOI 10.1091/mbc.9.12.3259; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Ben-Asouli Y, 2002, CELL, V108, P221, DOI 10.1016/S0092-8674(02)00616-5; Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; Cesareni G, 1987, GENETIC ENG PRINCIPL, V9, P135, DOI DOI 10.1007/978-1-4684-5377-5_9; Chen JJ, 2000, COLD SPRING HARBOR M, V39, P529; DEALDANA CRV, 1995, EMBO J, V14, P3184, DOI 10.1002/j.1460-2075.1995.tb07321.x; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Dong JS, 2000, MOL CELL, V6, P269, DOI 10.1016/S1097-2765(00)00028-9; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; Garcia-Barrio M, 2000, EMBO J, V19, P1887, DOI 10.1093/emboj/19.8.1887; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOLDMAN E, 1990, MOL MICROBIOL, V4, P2035, DOI 10.1111/j.1365-2958.1990.tb00563.x; GUELMAN R, 2002, BONE, V30, P23; HANNIG EM, 1990, GENETICS, V126, P549; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hinnebusch A. G., 1992, MOL CELLULAR BIOL YE, P319, DOI DOI 10.1016/J.ACA.2008.01.060; HINNEBUSCH AG, 1983, P NATL ACAD SCI-BIOL, V80, P5374, DOI 10.1073/pnas.80.17.5374; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; Kubota H, 2001, J BIOL CHEM, V276, P17591, DOI 10.1074/jbc.M011793200; Kubota H, 2000, J BIOL CHEM, V275, P20243, DOI 10.1074/jbc.C000262200; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Maniatis T., 1982, MOL CLONING LAB MANU; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; Olave IA, 2002, ANNU REV BIOCHEM, V71, P755, DOI 10.1146/annurev.biochem.71.110601.135507; Qiu HF, 2002, GENE DEV, V16, P1271, DOI 10.1101/gad.979402; RAMIREZ M, 1992, MOL CELL BIOL, V12, P5801, DOI 10.1128/MCB.12.12.5801; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Ron D, 2000, COLD SPRING HARBOR M, V39, P547; Sattlegger E, 2000, EMBO J, V19, P6622, DOI 10.1093/emboj/19.23.6622; Schott D, 2002, CURR OPIN MICROBIOL, V5, P564, DOI 10.1016/S1369-5274(02)00369-7; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIKORSKI RS, 1989, GENETICS, V122, P19; WEK SA, 1995, MOL CELL BIOL, V15, P4497; WERTMAN KF, 1992, GENETICS, V132, P337; Zhu SH, 1998, J BIOL CHEM, V273, P1808, DOI 10.1074/jbc.273.3.1808	45	43	46	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29952	29962		10.1074/jbc.M404009200	http://dx.doi.org/10.1074/jbc.M404009200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15126500	hybrid			2022-12-25	WOS:000222531900012
J	Shim, KS; Schmutte, C; Tombline, G; Heinen, CD; Fishel, R				Shim, KS; Schmutte, C; Tombline, G; Heinen, CD; Fishel, R			hXRCC2 enhances ADP/ATP processing and strand exchange by hRAD51	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RAD51 PROTEIN; ESCHERICHIA-COLI RECA; HUMAN EXONUCLEASE-I; NUCLEOTIDE EXCHANGE; MISMATCH REPAIR; DNA-REPAIR; BIOCHEMICAL-CHARACTERIZATION; HOMOLOGOUS RECOMBINATION; MOLECULAR SWITCH; ATP HYDROLYSIS	The assembly of bacterial RecA, and its human homolog hRAD51, into an operational ADP/ATP-regulated DNA-protein ( nucleoprotein) filament is essential for homologous recombination repair (HRR). Yet hRAD51 lacks the coordinated ADP/ATP processing exhibited by RecA and is less efficient in HRR reactions in vitro. In this study, we demonstrate that hXRCC2, one of five other poorly understood non-redundant human mitotic RecA homologs (hRAD51B, hRAD51C, hRAD51D, hXRCC2, and hXRCC3), stimulates hRAD51 ATP processing. hXRCC2 also increases hRAD51-mediated DNA unwinding and strand exchange activities that are integral for HRR. Although there does not seem to be a long-lived interaction between hXRCC2 and hRAD51, we detail a strong adenosine nucleotide-regulated interaction between the hXRCC2-hRAD51D heterodimer and hRAD51. These observations begin to elucidate the separate and specialized functions of the human mitotic RecA homologs that enable an efficient nucleoprotein filament required for HRR.	Thomas Jefferson Univ, Kimmel Canc Ctr, Genet & Mol Biol Program, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Fishel, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Genet & Mol Biol Program, Dept Microbiol & Immunol, BLSB933,233 S 10th St, Philadelphia, PA 19107 USA.	rfishel@lac.jci.tju.edu			NATIONAL CANCER INSTITUTE [R01CA056542] Funding Source: NIH RePORTER; NCI NIH HHS [CA56542] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; COX MM, 1995, J BIOL CHEM, V270, P26021, DOI 10.1074/jbc.270.44.26021; De Zutter SK, 1999, J MOL BIOL, V293, P769, DOI 10.1006/jmbi.1999.3200; Deans B, 2000, EMBO J, V19, P6675, DOI 10.1093/emboj/19.24.6675; Easter J, 2002, MOL CELL, V10, P427, DOI 10.1016/S1097-2765(02)00594-4; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; Fishel R, 2000, COLD SPRING HARB SYM, V65, P217, DOI 10.1101/sqb.2000.65.217; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; Guerrette S, 1998, MOL CELL BIOL, V18, P6616, DOI 10.1128/MCB.18.11.6616; Gupta RC, 1999, MOL CELL, V4, P705, DOI 10.1016/S1097-2765(00)80381-0; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Holmes VF, 2001, NUCLEIC ACIDS RES, V29, P5052, DOI 10.1093/nar/29.24.5052; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; JONES NJ, 1995, GENOMICS, V26, P619, DOI 10.1016/0888-7543(95)80187-Q; Kabani M, 2000, MOL CELL BIOL, V20, P6923, DOI 10.1128/MCB.20.18.6923-6934.2000; Kabani M, 2002, MOL CELL BIOL, V22, P4677, DOI 10.1128/MCB.22.13.4677-4689.2002; KOWALCZYKOWSKI SC, 1995, P NATL ACAD SCI USA, V92, P3478, DOI 10.1073/pnas.92.8.3478; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kurumizaka H, 2002, J BIOL CHEM, V277, P14315, DOI 10.1074/jbc.M105719200; Kurumizaka H, 2001, P NATL ACAD SCI USA, V98, P5538, DOI 10.1073/pnas.091603098; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Masson JY, 2001, P NATL ACAD SCI USA, V98, P8440, DOI 10.1073/pnas.111005698; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Morrison C, 1999, MOL CELL BIOL, V19, P6891; Namsaraev EA, 2000, J BIOL CHEM, V275, P3970, DOI 10.1074/jbc.275.6.3970; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; O'Regan P, 2001, J BIOL CHEM, V276, P22148, DOI 10.1074/jbc.M102396200; Renault L, 2001, CELL, V105, P245, DOI 10.1016/S0092-8674(01)00315-4; Rice KP, 2001, J BIOL CHEM, V276, P38570, DOI 10.1074/jbc.M105678200; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; SABLIN EP, 2001, CURR OPIN STRUC BIOL, V11, P617; Schild D, 2000, J BIOL CHEM, V275, P16443, DOI 10.1074/jbc.M001473200; Schlichting I, 1999, NAT STRUCT BIOL, V6, P721, DOI 10.1038/11485; Schmutte C, 1998, CANCER RES, V58, P4537; Schmutte C, 2001, J BIOL CHEM, V276, P33011, DOI 10.1074/jbc.M102670200; Shinohara A, 1999, MUTAT RES-DNA REPAIR, V435, P13, DOI 10.1016/S0921-8777(99)00033-6; Sigurdsson S, 2001, GENE DEV, V15, P3308, DOI 10.1101/gad.935501; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; THACKER J, 1995, HUM MOL GENET, V4, P113, DOI 10.1093/hmg/4.1.113; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; Tombline G, 2002, J BIOL CHEM, V277, P14426, DOI 10.1074/jbc.M109916200; Tombline G, 2002, J BIOL CHEM, V277, P14417, DOI 10.1074/jbc.M109915200; Tombline G, 2002, J BIOL CHEM, V277, P14434, DOI 10.1074/jbc.M109917200; Tsuzuki T, 1996, CARCINOGENESIS, V17, P1215, DOI 10.1093/carcin/17.6.1215; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398	62	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30385	30394		10.1074/jbc.M306066200	http://dx.doi.org/10.1074/jbc.M306066200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123651	hybrid			2022-12-25	WOS:000222531900064
J	Binet, V; Brajon, C; Le Corre, L; Acher, F; Pin, JP; Prezeau, L				Binet, V; Brajon, C; Le Corre, L; Acher, F; Pin, JP; Prezeau, L			The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; PROTEIN-COUPLED RECEPTOR; B-RECEPTOR; BINDING-SITE; PHARMACOLOGICAL CHARACTERIZATION; MUTATIONAL ANALYSIS; ACID(B) RECEPTORS; GB2 SUBUNITS; C-TERMINI; RHODOPSIN	The gamma-aminobutyric acid, type B (GABA(B)) receptor is well recognized as being composed of two subunits, GABA(B1) and GABA(B2). Both subunits share structural homology with other class-III G-protein-coupled receptors. They are composed of two main domains: a heptahelical domain (HD) typical of all G-protein-coupled receptors and a large extracellular domain (ECD). Although GABA(B1) binds GABA, GABA(B2) is required for GABAB1 to reach the cell surface. However, it is still not demonstrated whether the association of these two subunits is always required for function in the brain. Indeed, GABA(B2) plays a major role in the coupling of the heteromer to G-proteins, such that it is possible that GABA(B2) can transmit a signal in the absence of GABA(B1). Today only ligands interacting with GABA(B1) ECD have been identified. Thus, the compounds acting exclusively on the GABA(B2) subunit will be helpful in analyzing the specific role of this subunit in the brain. Here, we explored the mechanism of action of CGP7930, a compound described as a positive allosteric regulator of the GABA(B) receptor. We showed that it activates the wild type GABA(B) receptor but with a low efficacy. The GABA(B2) HD is necessary for this effect, although one cannot exclude that CGP7930 could also bind to GABA(B1). Of interest, CGP7930 could activate GABA(B2) expressed alone and is the first described agonist of GABA(B2). Finally, we show that CGP7930 retains its agonist activity on a GABA(B2) subunit deleted of its ECD. This demonstrates that the HD of GABA(B2) behaves similar to a rhodopsin-like receptor, because it can reach the cell surface alone, can couple to G-protein, and be activated by agonists. These data open new strategies for studying the mechanism of activation of GABA(B) receptor and examine any possible role of homomeric GABA(B2) receptors.	CNRS, INSERM, Ctr Pharmacol Endocrinol, Lab Funct Genom,Dept Mol Pharmacol,UPR 2580, F-34094 Montpellier 5, France; Univ Paris 05, CNRS, UMR 8601, Lab Pharmacol & Toxicol Chem & Biochem, F-75270 Paris 6, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Prezeau, L (corresponding author), CNRS, INSERM, Ctr Pharmacol Endocrinol, Lab Funct Genom,Dept Mol Pharmacol,UPR 2580, F-34094 Montpellier 5, France.	lprezeau@ccipe.cnrs.fr	Pin, Jean-Philippe/Y-6668-2019	Pin, Jean-Philippe/0000-0002-1423-345X				Billinton A, 2001, TRENDS NEUROSCI, V24, P277, DOI 10.1016/S0166-2236(00)01815-4; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Brabet I, 1998, NEUROPHARMACOLOGY, V37, P1043, DOI 10.1016/S0028-3908(98)00091-4; Calver AR, 2000, NEUROSCIENCE, V100, P155, DOI 10.1016/S0306-4522(00)00262-1; Calver AR, 2001, J NEUROSCI, V21, P1203; Carroll FY, 2001, MOL PHARMACOL, V59, P965, DOI 10.1124/mol.59.5.965; Chabre M, 2003, NATURE, V426, P30, DOI 10.1038/426030b; Couve A, 2000, MOL CELL NEUROSCI, V16, P296, DOI 10.1006/mcne.2000.0908; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Duthey B, 2002, J BIOL CHEM, V277, P3236, DOI 10.1074/jbc.M108900200; Franek M, 1999, NEUROPHARMACOLOGY, V38, P1657, DOI 10.1016/S0028-3908(99)00135-5; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; Galvez T, 2000, MOL PHARMACOL, V57, P419, DOI 10.1124/mol.57.3.419; Gasparini F, 2002, CURR OPIN PHARMACOL, V2, P43, DOI 10.1016/S1471-4892(01)00119-9; Goudet C, 2004, P NATL ACAD SCI USA, V101, P378, DOI 10.1073/pnas.0304699101; Grunewald S, 2002, MOL PHARMACOL, V61, P1070, DOI 10.1124/mol.61.5.1070; Havlickova M, 2002, MOL PHARMACOL, V62, P343, DOI 10.1124/mol.62.2.343; Hu JX, 2003, TRENDS ENDOCRIN MET, V14, P282, DOI 10.1016/S1043-2760(03)00104-8; Johnson MP, 2003, J MED CHEM, V46, P3189, DOI 10.1021/jm034015u; JOLY C, 1995, J NEUROSCI, V15, P3970; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Joubert L, 2002, J BIOL CHEM, V277, P25502, DOI 10.1074/jbc.M202539200; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kniazeff J, 2004, J NEUROSCI, V24, P370, DOI 10.1523/JNEUROSCI.3141-03.2004; Kniazeff J, 2002, J NEUROSCI, V22, P7352; Knoflach F, 2001, P NATL ACAD SCI USA, V98, P13402, DOI 10.1073/pnas.231358298; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lavreysen H, 2003, MOL PHARMACOL, V63, P1082, DOI 10.1124/mol.63.5.1082; Litschig S, 1999, MOL PHARMACOL, V55, P453; Liu JF, 2004, J BIOL CHEM, V279, P15824, DOI 10.1074/jbc.M313639200; Malherbe P, 2003, MOL PHARMACOL, V64, P823, DOI 10.1124/mol.64.4.823; Malherbe P, 2003, J BIOL CHEM, V278, P8340, DOI 10.1074/jbc.M211759200; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14649, DOI 10.1073/pnas.251554498; Marino MJ, 2003, P NATL ACAD SCI USA, V100, P13668, DOI 10.1073/pnas.1835724100; Martin SC, 1999, MOL CELL NEUROSCI, V13, P180, DOI 10.1006/mcne.1999.0741; Mathiesen JM, 2003, BRIT J PHARMACOL, V138, P1026, DOI 10.1038/sj.bjp.0705159; Maurel D, 2004, ANAL BIOCHEM, V329, P253, DOI 10.1016/j.ab.2004.02.013; Nehring RB, 2000, J BIOL CHEM, V275, P35185, DOI 10.1074/jbc.M002727200; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; O'Brien JA, 2003, MOL PHARMACOL, V64, P731, DOI 10.1124/mol.64.3.731; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Pagano A, 2000, J BIOL CHEM, V275, P33750, DOI 10.1074/jbc.M006230200; Pagano A, 2001, J NEUROSCI, V21, P1189; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parmentier ML, 2002, TRENDS PHARMACOL SCI, V23, P268, DOI 10.1016/S0165-6147(02)02016-3; Pin JP, 2002, CNS NEUROL DISORD-DR, V1, P297, DOI 10.2174/1568007023339328; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; Pin JP, 2001, MOL PHARMACOL, V60, P881, DOI 10.1124/mol.60.5.881; Robbins MJ, 2001, J NEUROSCI, V21, P8043, DOI 10.1523/JNEUROSCI.21-20-08043.2001; Schaffhauser H, 2003, MOL PHARMACOL, V64, P798, DOI 10.1124/mol.64.4.798; Urwyler S, 2003, J PHARMACOL EXP THER, V307, P322, DOI 10.1124/jpet.103.053074; Urwyler S, 2001, MOL PHARMACOL, V60, P963, DOI 10.1124/mol.60.5.963; Vernon E, 2001, MOL CELL NEUROSCI, V17, P637, DOI 10.1006/mcne.2000.0960; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; White JH, 2000, P NATL ACAD SCI USA, V97, P13967, DOI 10.1073/pnas.240452197	58	164	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29085	29091		10.1074/jbc.M400930200	http://dx.doi.org/10.1074/jbc.M400930200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15126507	hybrid, Green Submitted, Green Accepted			2022-12-25	WOS:000222445300032
J	Fotia, AB; Ekberg, J; Adams, DJ; Cook, DI; Poronnik, P; Kumar, S				Fotia, AB; Ekberg, J; Adams, DJ; Cook, DI; Poronnik, P; Kumar, S			Regulation of neuronal voltage-gated sodium channels by the ubiquitin-protein ligases Nedd4 and Nedd4-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; WW DOMAINS; INTERNALIZATION; IDENTIFICATION; SPECIFICITY; EXPRESSION	Nedd4 and Nedd4-2 are ubiquitin-protein ligases known to regulate a number of membrane proteins including receptors and ion transporters. Regulation of the epithelial Na+ channel by Nedd4 and Nedd4-2 is mediated via interactions between the PY motifs of the epithelial sodium channel subunits and the Nedd4/Nedd4-2 WW domains. This example serves as a model for the regulation of other PY motif-containing ion channels by Nedd4 and Nedd4-2. We found that the carboxyl termini of the six voltage-gated Na+ (Na-v) channels contain typical PY motifs (PPXY), and a further Na-v contains a PY motif variant (LPXY). Not only did we demonstrate by Far-Western analysis that Nedd4 and Nedd4-2 interact with the PY motif-containing Na-v channels, but we also showed that these channels have conserved WW domain binding specificity. We further showed that the carboxyl termini fusion proteins of one central nervous system and one peripheral nervous system-derived Na+ channel (Na(v)1.2 and Na(v)1.7, respectively) are readily ubiquitinated by Nedd4-2. In Xenopus oocytes, Nedd4-2 strongly inhibited the activities of all three Na(v)s (Na(v)1.2, Na(v)1.7, and Na(v)1.8) tested. Interestingly, Nedd4 suppressed the activity of Na(v)1.2 and Na(v)1.7 but was a poor inhibitor of Na(v)1.8. Our results provide evidence that Nedd4 and Nedd4-2 are likely to be key regulators of specific neuronal Na-v channels in vivo.	Inst Med & Vet Sci, Hanson Inst, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Med, Adelaide, SA 5005, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Univ Sydney, Dept Physiol, Sydney, NSW 2006, Australia	Hanson Institute; Institute Medical & Veterinary Science Australia; University of Adelaide; University of Queensland; University of Sydney	Kumar, S (corresponding author), Inst Med & Vet Sci, Hanson Inst, POB 14,Rundle Mall,Frome Rd, Adelaide, SA 5000, Australia.	sharad.kumar@imvs.sa.gov.au	Ekberg, Jenny/AAV-2006-2020; Adams, David John/K-3578-2019; Kumar, Sharad/AAX-7787-2020	Adams, David John/0000-0002-7030-2288; Kumar, Sharad/0000-0001-7126-9814; Poronnik, Philip/0000-0002-6246-528X; Ekberg, Jenny/0000-0001-5151-4966				Abriel H, 2000, FEBS LETT, V466, P377, DOI 10.1016/S0014-5793(00)01098-X; Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; DARGENT B, 1994, NEURON, V13, P683, DOI 10.1016/0896-6273(94)90035-3; DARGENT B, 1995, J NEUROCHEM, V65, P407; DARGENT B, 1990, P NATL ACAD SCI USA, V87, P5907, DOI 10.1073/pnas.87.15.5907; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Fotia AB, 2002, FASEB J, V16, P70, DOI 10.1096/fj.02-0497fje; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Harvey KF, 2001, J BIOL CHEM, V276, P8597, DOI 10.1074/jbc.C000906200; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; Henry PC, 2003, J BIOL CHEM, V278, P20019, DOI 10.1074/jbc.M211153200; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Kasanov J, 2001, CHEM BIOL, V8, P231, DOI 10.1016/S1074-5521(01)00005-9; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Yu FH, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-207	20	122	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28930	28935		10.1074/jbc.M402820200	http://dx.doi.org/10.1074/jbc.M402820200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123669	hybrid			2022-12-25	WOS:000222445300014
J	Hanssen, E; Hew, FH; Moore, E; Gibson, MA				Hanssen, E; Hew, FH; Moore, E; Gibson, MA			MAGP-2 has multiple binding regions on fibrillins and has covalent periodic association with fibrillin-containing microfibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELASTIN-ASSOCIATED MICROFIBRILS; MARFAN-SYNDROME; EXTRACELLULAR MICROFIBRILS; MOLECULAR-CLONING; DEVELOPMENTAL EXPRESSION; GLYCOPROTEIN-1 MAGP-1; TISSUE MICROFIBRILS; RICH MICROFIBRILS; TERNARY COMPLEX; COLLAGEN-VI	The interactions of microfibril-associated glycoprotein (MAGP)-2 have been investigated with fibrillins and fibrillin-containing microfibrils. Solid phase binding assays were conducted with recombinant fragments covering fibrillin-1 and most of fibrillin-2. MAGP-2, and its structure relative MAGP-1, were found to bind two fragments spanning the N-terminal half of fibrillin-1 and an N-terminal fragment of fibrillin-2. Blocking experiments indicated that MAGP-2 had a binding site(s) close to the N terminus of the fibrillin-1 molecule that was distinct from that for MAGP-1 and an additional, more central binding site( s) that may be shared by the two MAGPs. Immunogold labeling of developing nuchal ligament tissue showed that MAGP-2 had regular covalent and periodic (about 56 nm) association with fibrillin-containing microfibrils of elastic fibers in this tissue. Further analysis of isolated microfibrils indicated that MAGP-2 was attached at two points along the microfibril substructure, "site 1" on the "beads" and "site 2" at the "shoulder" of the interbead region close to where the two "arms" fuse. In contrast, MAGP-1 was located only on the beads. Comparison of the MAGP-2 binding data with known fibrillin epitope maps of the microfibrils showed that site 1 correlated with the N-terminal MAGP-2 binding region, and site 2 correlated with the second, more central, MAGP-2 binding region on the fibrillin-1 molecule. Of particular note, immunolabeling at site 2 was markedly decreased, relative to that at site 1, on extended microfibrils with bead-to-bead periods over 90 nm, suggesting that site 2 may move toward the beads when the microfibril is stretched. The study points to MAGP-2 being an integral component of some populations of fibrillin-containing microfibrils. Moreover, the identification of multiple MAGP-binding sequences on fibrillins supports the concept that MAGPs may function as molecular cross-linkers, stabilizing fibrillin monomers in folded conformation within or between the microfibrils, and thus MAGPs may be implicated in the modulation of the elasticity of these structures.	Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia	University of Adelaide	Gibson, MA (corresponding author), Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia.	mark.gibson@adelaide.edu.au	Hanssen, Eric/A-7217-2013	Hanssen, Eric/0000-0002-4064-1844				ABRAMS WR, 1995, GENOMICS, V26, P47, DOI 10.1016/0888-7543(95)80081-V; Ashworth JL, 1999, J CELL SCI, V112, P4163; Baldock C, 2001, J CELL BIOL, V152, P1045, DOI 10.1083/jcb.152.5.1045; BROWNAUGSBURGER P, 1994, J BIOL CHEM, V269, P28443; Charbonneau NL, 2003, J BIOL CHEM, V278, P2740, DOI 10.1074/jbc.M209201200; Cleary E. G., 1996, EXTRACELLULAR MATRIX, V2, P95; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; Colombatti A, 2000, MATRIX BIOL, V19, P289, DOI 10.1016/S0945-053X(00)00074-3; Corson GM, 2004, GENOMICS, V83, P461, DOI 10.1016/j.ygeno.2003.08.023; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Finnis ML, 1997, J BIOL CHEM, V272, P22817, DOI 10.1074/jbc.272.36.22817; Gibson MA, 1998, J HISTOCHEM CYTOCHEM, V46, P871, DOI 10.1177/002215549804600802; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; Gibson MA, 1999, J BIOL CHEM, V274, P13060, DOI 10.1074/jbc.274.19.13060; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; GIBSON MA, 2004, IN PRESS MARFAN SYND; GIBSON MA, 1986, J BIOL CHEM, V26, P11436; Handford PA, 2000, MATRIX BIOL, V19, P457, DOI 10.1016/S0945-053X(00)00100-1; Hanssen E, 2003, J BIOL CHEM, V278, P24334, DOI 10.1074/jbc.M303455200; Hanssen E, 2001, MATRIX BIOL, V20, P77, DOI 10.1016/S0945-053X(01)00122-6; Haston JL, 2003, J BIOL CHEM, V278, P41189, DOI 10.1074/jbc.M212854200; Henderson M, 1996, J HISTOCHEM CYTOCHEM, V44, P1389, DOI 10.1177/44.12.8985131; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Isogai Z, 2002, J BIOL CHEM, V277, P4565, DOI 10.1074/jbc.M110583200; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; Kielty CM, 1998, ANAL BIOCHEM, V255, P108, DOI 10.1006/abio.1997.2442; Kielty CM, 2002, J MUSCLE RES CELL M, V23, P581, DOI 10.1023/A:1023479010889; KUMARATILAKE JS, 1989, EUR J CELL BIOL, V50, P117; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Oklu R, 2000, BIOCHEM J, V352, P601, DOI 10.1042/0264-6021:3520601; Penner AS, 2002, J BIOL CHEM, V277, P35044, DOI 10.1074/jbc.M206363200; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Ramirez F, 1996, CURR OPIN GENET DEV, V6, P309, DOI 10.1016/S0959-437X(96)80007-4; Reinboth B, 2002, J BIOL CHEM, V277, P3950, DOI 10.1074/jbc.M109540200; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; Saharinen J, 1999, CYTOKINE GROWTH F R, V10, P99, DOI 10.1016/S1359-6101(99)00010-6; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sasaki T, 1999, FEBS LETT, V460, P280, DOI 10.1016/S0014-5793(99)01362-9; Segade F, 2002, J BIOL CHEM, V277, P11050, DOI 10.1074/jbc.M110347200; Sherratt MJ, 2003, J MOL BIOL, V332, P183, DOI 10.1016/S0022-2836(03)00829-5; Sinha S, 1998, MATRIX BIOL, V17, P529, DOI 10.1016/S0945-053X(98)90106-8; Trask BC, 2000, MOL BIOL CELL, V11, P1499, DOI 10.1091/mbc.11.5.1499; Werneck CC, 2004, J BIOL CHEM, V279, P23045, DOI 10.1074/jbc.M402656200; Whiteman P, 2003, HUM MOL GENET, V12, P727, DOI 10.1093/hmg/ddg081; YEH H, 1994, GENOMICS, V23, P443, DOI 10.1006/geno.1994.1521; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855; ZHAO ZY, 1995, HUM MOL GENET, V4, P589, DOI 10.1093/hmg/4.4.589	55	38	42	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29185	29194		10.1074/jbc.M313672200	http://dx.doi.org/10.1074/jbc.M313672200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15131124	hybrid			2022-12-25	WOS:000222445300045
J	Huang, ZH; Gu, DS; Mazzone, T				Huang, ZH; Gu, DS; Mazzone, T			Oleic acid modulates the post-translational glycosylation of macrophage ApoE to increase its secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; RESISTANCE SYNDROME PREDICTS; CORONARY-HEART-DISEASE; HUMAN APOLIPOPROTEIN-E; INSULIN-RESISTANCE; LIPOPROTEIN-LIPASE; CHOLESTEROL EFFLUX; PLASMA-MEMBRANE; CELLULAR UPTAKE; EXPRESSION	There has been increasing interest in a potential role for fatty acids in adversely affecting organismal substrate utilization and contributing to the cardiovascular complications in insulin resistance. Fatty acids have already been implicated in regulating the expression of a number of genes in resident cells of the vessel wall. In the current studies, we evaluated a potential role for fatty acids in the regulation of macrophage apoE expression. Incubation in oleic acid increased the synthesis and secretion of apoE by human monocyte-derived macrophages. Part of this stimulation was mediated at a post-translational locus. Oleic acid increased the secretion of apoE from macrophages that constitutively expressed a human apoE3 cDNA. Incubation in palmitic acid decreased apoE secretion from these cells. The effect of oleic acid on apoE secretion could not be accounted for by the known effect of fatty acid on cellular sterol, because incubation in oleic acid did not suppress the degradation of nascent apoE. Incubation in oleic acid for at least 6 h was required to observe an effect on apoE secretion. Oleic acid altered the glycosylation pattern of cellular and secreted apoE, with a loss of the most heavily sialylated isoform. Oleic acid had no effect on the glycosylation of interleukin 6 secreted from macrophages. Elimination of apoE glycosylation, by substitution of threonine 194 with alanine, eliminated oleic acid-mediated stimulation of apoE secretion. These results indicate that oleic acid increases apoE secretion from macrophages at a locus involving post-translational glycosylation.	Univ Illinois, Dept Med, Sect Diabet & Metab, Chicago, IL 60612 USA; Univ Illinois, Dept Pharmacol, Sect Diabet & Metab, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Mazzone, T (corresponding author), Univ Illinois, Dept Med & Pharmacol, Sect Diabet & Metab, M-C 797,1819 W Polk St, Chicago, IL 60612 USA.	tmazzone@uic.edu			NHLBI NIH HHS [HL 39653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039653] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASHEERUDDIN K, 1992, J BIOL CHEM, V267, P1219; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; Choukroun GJ, 2000, J CLIN INVEST, V106, P983, DOI 10.1172/JCI8914; CORR PB, 1984, CIRC RES, V55, P135, DOI 10.1161/01.RES.55.2.135; Cullis P.R., 1996, NEW COMPREHENSIVE BI, V31, P1; Curtiss LK, 2000, CURR OPIN LIPIDOL, V11, P243, DOI 10.1097/00041433-200006000-00004; DORY L, 1993, BIOCHEM J, V292, P105, DOI 10.1042/bj2920105; Du XN, 2001, BIOCHEM J, V357, P275, DOI 10.1042/0264-6021:3570275; Duan HW, 2000, BBA-MOL CELL BIOL L, V1484, P142, DOI 10.1016/S1388-1981(00)00005-6; Duan HW, 1997, J BIOL CHEM, V272, P31156, DOI 10.1074/jbc.272.49.31156; Duplus E, 2000, J BIOL CHEM, V275, P30749, DOI 10.1074/jbc.R000015200; Galbete JL, 2000, BIOCHEM J, V348, P307, DOI 10.1042/0264-6021:3480307; Ghosh P, 2000, AM J CLIN NUTR, V72, P190; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Huang ZH, 2003, BIOCHEMISTRY-US, V42, P3949, DOI 10.1021/bi0269207; Johnson RA, 2003, BIOCHEMISTRY-US, V42, P1637, DOI 10.1021/bi0264465; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; KOTLOFF RM, 1990, AM J RESP CELL MOL, V3, P497, DOI 10.1165/ajrcmb/3.5.497; Lagace TK, 2000, J BIOL CHEM, V275, P14367, DOI 10.1074/jbc.275.19.14367; Lee JY, 2001, J BIOL CHEM, V276, P16683, DOI 10.1074/jbc.M011695200; Lempiainen P, 1999, CIRCULATION, V100, P123, DOI 10.1161/01.CIR.100.2.123; Lin CY, 1999, J LIPID RES, V40, P1618; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Lucas M, 1996, J BIOL CHEM, V271, P13454, DOI 10.1074/jbc.271.23.13454; MAZZONE T, 1992, J BIOL CHEM, V267, P1081; Mazzone T, 1996, CURR OPIN LIPIDOL, V7, P303, DOI 10.1097/00041433-199610000-00008; MAZZONE T, 1994, J LIPID RES, V35, P1345; MAZZONE T, 1986, BIOCHIM BIOPHYS ACTA, V875, P393, DOI 10.1016/0005-2760(86)90190-6; McArthur MJ, 1999, J LIPID RES, V40, P1371; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; Michaud SE, 2001, DIABETES, V50, P660, DOI 10.2337/diabetes.50.3.660; Nilsson L, 1998, ARTERIOSCL THROM VAS, V18, P1679, DOI 10.1161/01.ATV.18.11.1679; Olsson U, 1999, DIABETES, V48, P616, DOI 10.2337/diabetes.48.3.616; ORITA T, 1994, J BIOCHEM-TOKYO, V115, P345, DOI 10.1093/oxfordjournals.jbchem.a124340; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; POTTER BJ, 1989, ANNU REV NUTR, V9, P253, DOI 10.1146/annurev.nu.09.070189.001345; Prescott J, 1999, BBA-MOL CELL BIOL L, V1439, P110, DOI 10.1016/S1388-1981(99)00082-7; Pyorala M, 2000, ARTERIOSCL THROM VAS, V20, P538, DOI 10.1161/01.ATV.20.2.538; REDDY TS, 1987, J NEUROSCI RES, V18, P449, DOI 10.1002/jnr.490180311; Seo T, 2002, BIOCHEMISTRY-US, V41, P7885, DOI 10.1021/bi011949g; WERNETTEHAMMOND ME, 1989, J BIOL CHEM, V264, P9094; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Worgall TS, 2002, J BIOL CHEM, V277, P3878, DOI 10.1074/jbc.M102393200; YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G; ZANNIS VI, 1986, J BIOL CHEM, V261, P3415; Zhao YW, 2000, J BIOL CHEM, V275, P4759, DOI 10.1074/jbc.275.7.4759	46	19	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29195	29201		10.1074/jbc.M402631200	http://dx.doi.org/10.1074/jbc.M402631200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15131109	hybrid			2022-12-25	WOS:000222445300046
J	Beis, K; Collins, RF; Ford, RC; Kamis, AB; Whitfield, C; Naismith, JH				Beis, K; Collins, RF; Ford, RC; Kamis, AB; Whitfield, C; Naismith, JH			Three-dimensional structure of Wza, the protein required for translocation of group 1 capsular polysaccharide across the outer membrane of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AUTOKINASE; ELECTRON-MICROSCOPY; MULTIDRUG EFFLUX; SECRETIN PULD; CHANNEL; EXPORT; EXPRESSION; PHOSPHORYLATION; RECONSTRUCTION; TRANSPORT	Wza is a highly conserved multimeric outer membrane protein complex required for the surface expression of the serotype K30 group 1 capsular polysaccharide in Escherichia coli. Here we present the first three-dimensional structure of this type of polysaccharide exporter at a 15.5-Angstrom resolution obtained using single particle averaging on a dataset of cryo-negatively stained protein. Previous structural studies on purified Wza have revealed a homo-oligomeric ring structure that is most probably composed of eight subunits. Symmetry analysis of the three-dimensional structure combined with biochemical two-and three-dimensional crystallographic data strongly suggest that Wza is an octameric complex with a C4 quasi-rotational symmetry and is organized as a tetramer of dimeric subunits. Wza is best described as a stack of two 4-Angstrom high rings with differing diameters providing a mushroom-like aspect from the side. The larger ring has a distinctive square shape with a diameter of 115 Angstrom, whereas the smaller is almost circular with a diameter of 90 Angstrom. In the center of the complex and enclosed by the four symmetrical arms is a small elliptical cagelike cavity of similar to 40 Angstrom in diameter. The central cavity is effectively sealed at the top and bottom of the complex but has small inter-arm holes when viewed from the side. We discuss the structure of this complex and implications in the surface translocation of cell-surface polysaccharide.	Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada	University of St Andrews; University of Manchester; University of Guelph	Naismith, JH (corresponding author), Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland.	naismith@st-andrews.ac.uk	Naismith, James Henderson/H-3408-2012; Naismith, James Henderson/AAB-8614-2020	Naismith, James Henderson/0000-0001-6744-5061; Naismith, James Henderson/0000-0001-6744-5061; Beis, Konstantinos/0000-0001-5727-4721; Ford, Robert/0000-0002-0958-1505	Biotechnology and Biological Sciences Research Council [B19490] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Adrian M, 1998, MICRON, V29, P145, DOI 10.1016/S0968-4328(97)00068-1; ALLAOUI A, 1993, MOL MICROBIOL, V7, P59, DOI 10.1111/j.1365-2958.1993.tb01097.x; Alm RA, 1997, GENE, V192, P89, DOI 10.1016/S0378-1119(96)00805-0; AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; Andersen C, 2000, EMBO REP, V1, P313, DOI 10.1093/embo-reports/kvd075; Andersen C, 2001, CURR OPIN CELL BIOL, V13, P412, DOI 10.1016/S0955-0674(00)00229-5; BAILEY AE, 1994, PHYS REV E, V50, P4853, DOI 10.1103/PhysRevE.50.4853; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beis K, 2004, ACTA CRYSTALLOGR D, V60, P558, DOI 10.1107/S0907444903029494; Bitter W, 1998, MOL MICROBIOL, V27, P209, DOI 10.1046/j.1365-2958.1998.00677.x; Bliss JM, 1997, J BACTERIOL, V179, P1400, DOI 10.1128/jb.179.4.1400-1403.1997; Blocker A, 2001, MOL MICROBIOL, V39, P652, DOI 10.1046/j.1365-2958.2001.02200.x; Collins RF, 2001, J BACTERIOL, V183, P3825, DOI 10.1128/JB.183.13.3825-3832.2001; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; da Fonseca PCA, 2003, P NATL ACAD SCI USA, V100, P3936, DOI 10.1073/pnas.0536251100; Drummelsmith J, 1999, MOL MICROBIOL, V31, P1321, DOI 10.1046/j.1365-2958.1999.01277.x; Drummelsmith J, 2000, EMBO J, V19, P57, DOI 10.1093/emboj/19.1.57; FINKE A, 1991, J BACTERIOL, V173, P4088, DOI 10.1128/jb.173.13.4088-4094.1991; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Frank J., 1996, 3 DIMENSIONAL ELECT, Ved, ppp 54; GOTSCHLICH EC, 1981, J BIOL CHEM, V256, P8915; Hankamer BD, 2004, J BIOL CHEM, V279, P8862, DOI 10.1074/jbc.M307889200; HARPAZ Y, 1994, STRUCTURE, V2, P641, DOI 10.1016/S0969-2126(00)00065-4; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; HOVMOLLER S, 1992, ULTRAMICROSCOPY, V41, P121, DOI 10.1016/0304-3991(92)90102-P; JANN K, 1987, REV INFECT DIS, V9, pS517; JANN K, 1992, CAN J MICROBIOL, V38, P705, DOI 10.1139/m92-116; Jann K., 1997, P113; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Koronakis V, 2003, FEBS LETT, V555, P66, DOI 10.1016/S0014-5793(03)01125-6; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; MACLACHLAN PR, 1993, J BACTERIOL, V175, P7515, DOI 10.1128/JB.175.23.7515-7522.1993; Nesper J, 2003, J BIOL CHEM, V278, P49763, DOI 10.1074/jbc.M308775200; Nikaido H, 2001, J MOL MICROB BIOTECH, V3, P215; Nouwen N, 2000, EMBO J, V19, P2229, DOI 10.1093/emboj/19.10.2229; Nouwen N, 1999, P NATL ACAD SCI USA, V96, P8173, DOI 10.1073/pnas.96.14.8173; Opalka N, 2003, J MOL BIOL, V325, P461, DOI 10.1016/S0022-2836(02)01246-9; Paiment A, 2002, J BACTERIOL, V184, P6437, DOI 10.1128/JB.184.23.6437-6447.2002; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Rosenthal PB, 2003, J MOL BIOL, V333, P721, DOI 10.1016/j.jmb.2003.07.013; SAXTON WO, 1984, ULTRAMICROSCOPY, V13, P57, DOI 10.1016/0304-3991(84)90057-3; SCHMIDT MA, 1982, FEMS MICROBIOL LETT, V14, P69, DOI 10.1016/0378-1097(82)90045-3; Silver RP, 2001, RES MICROBIOL, V152, P357, DOI 10.1016/S0923-2508(01)01207-4; Sokolova O, 2001, STRUCTURE, V9, P215, DOI 10.1016/S0969-2126(01)00578-0; Thanabalu T, 1998, EMBO J, V17, P6487, DOI 10.1093/emboj/17.22.6487; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; Wugeditsch T, 2001, J BIOL CHEM, V276, P2361, DOI 10.1074/jbc.M009092200	50	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28227	28232		10.1074/jbc.M402913200	http://dx.doi.org/10.1074/jbc.M402913200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15090537	hybrid			2022-12-25	WOS:000222265400052
J	Fortin, A; MacLaurin, JG; Arbour, N; Cregan, SP; Kushwaha, N; Callaghan, SM; Park, DS; Albert, PR; Slack, RS				Fortin, A; MacLaurin, JG; Arbour, N; Cregan, SP; Kushwaha, N; Callaghan, SM; Park, DS; Albert, PR; Slack, RS			The proapoptotic gene SIVA is a direct transcriptional target for the tumor suppressors p53 and E2F1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; NEURONAL CELL-DEATH; FACTOR RECEPTOR FAMILY; INDUCED APOPTOSIS; DNA-DAMAGE; P53-INDUCED APOPTOSIS; CORTICAL-NEURONS; PROTECTS NEURONS; GLOBAL-ISCHEMIA; MICE LACKING	The p53 tumor suppressor gene is believed to play an important role in neuronal cell death in acute neurological disease and in neurodegeneration. The p53 signaling cascade is complex, and the mechanism by which p53 induces apoptosis is cell type-dependent. Using DNA microarray analysis, we have found a striking induction of the proapoptotic gene, SIVA. SIVA is a proapoptotic protein containing a death domain and interacts with members of the tumor necrosis factor receptor family as well as anti-apoptotic Bcl-2 family proteins. SIVA is induced following direct p53 gene delivery, treatment with a DNA-damaging agent camptothecin, and stroke injury in vivo. SIVA up-regulation is sufficient to initiate the apoptotic cascade in neurons. Through isolation and analysis of the SIVA promoter, we have identified response elements for both p53 and E2F1. Like p53, E2F1 is another tumor suppressor gene involved in the regulation of apoptosis, including neuronal injury models. We have identified E2F consensus sites in the promoter region, whereas p53 recognition sequences were found in intron1. Sequence analysis has shown that these consensus sites are also conserved between mouse and human SIVA genes. Electrophoretic mobility shift assays reveal that both transcription factors are capable of binding to putative consensus sites, and luciferase reporter assays reveal that E2F1 and p53 can activate transcription from the SIVA promoter. Here, we report that the proapoptotic gene, SIVA, which functions in a broad spectrum of cell types, is a direct transcriptional target for both tumor suppressors, p53 and E2F1.	Univ Ottawa, Ottawa Hlth Res Inst, Ctr Neurosci, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Slack, RS (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst, Ctr Neurosci, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	rslack@uottawa.ca	Albert, Paul/E-4804-2010; Cregan, Sean/M-3205-2013	Albert, Paul/0000-0002-1809-3554; Park, David/0000-0002-4490-3784; Slack, Ruth/0000-0002-1552-2835				AGEMATSU K, 1994, J IMMUNOL, V153, P1421; Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; Banasiak KJ, 1998, BRAIN RES, V797, P295, DOI 10.1016/S0006-8993(98)00286-8; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; CAMERINI D, 1991, J IMMUNOL, V147, P3165; Cao C, 2001, J BIOL CHEM, V276, P11465, DOI 10.1074/jbc.C100050200; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Cregan SP, 2000, GENE THER, V7, P1200, DOI 10.1038/sj.gt.3301208; Cregan SP, 1999, J NEUROSCI, V19, P7860; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; Daoud SS, 2003, CANCER RES, V63, P2782; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; Gendron TF, 2001, J NEUROCHEM, V78, P316, DOI 10.1046/j.1471-4159.2001.00423.x; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Giovanni A, 1999, J BIOL CHEM, V274, P19011, DOI 10.1074/jbc.274.27.19011; GRAVESTEIN LA, 1993, EUR J IMMUNOL, V23, P943, DOI 10.1002/eji.1830230427; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; HINTZEN RQ, 1995, J IMMUNOL, V154, P2612; Hou ST, 2000, J NEUROCHEM, V75, P91, DOI 10.1046/j.1471-4159.2000.0750091.x; Hsieh JK, 2002, MOL CELL BIOL, V22, P78, DOI 10.1128/MCB.22.1.78-93.2002; Ihrie RA, 2003, CURR BIOL, V13, P1985, DOI 10.1016/j.cub.2003.10.055; Jacquot S, 1997, J IMMUNOL, V159, P2652; Johnson MD, 1998, J NEUROSCI RES, V54, P721, DOI 10.1002/(SICI)1097-4547(19981215)54:6<721::AID-JNR1>3.0.CO;2-1; Johnson MD, 1999, J NEUROSCI, V19, P2996; Keramaris E, 2000, MOL CELL NEUROSCI, V15, P368, DOI 10.1006/mcne.2000.0838; KOBATA T, 1994, J IMMUNOL, V153, P5422; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI Y, 1994, STROKE, V25, P849, DOI 10.1161/01.STR.25.4.849; MacManus JP, 1999, NEUROREPORT, V10, P2711, DOI 10.1097/00001756-199909090-00004; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; McGahan L, 1998, MOL BRAIN RES, V56, P133, DOI 10.1016/S0169-328X(98)00038-2; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Miller FD, 2000, CELL DEATH DIFFER, V7, P880, DOI 10.1038/sj.cdd.4400736; MIYASHITA T, 1995, CELL, V80, P293; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morrison RS, 1996, J NEUROSCI, V16, P1337; NEVINS JR, 1992, SCIENCE, V258, P424; O'Hare MJ, 2000, J BIOL CHEM, V275, P25358, DOI 10.1074/jbc.M001725200; Okuno K, 2001, DIS COLON RECTUM, V44, P295, DOI 10.1007/BF02234309; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; Prasad KVS, 1997, P NATL ACAD SCI USA, V94, P6346, DOI 10.1073/pnas.94.12.6346; Prives C, 1999, J PATHOL, V187, P112; Py B, 2004, J IMMUNOL, V172, P4008, DOI 10.4049/jimmunol.172.7.4008; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; Slack RS, 1996, J CELL BIOL, V135, P1085, DOI 10.1083/jcb.135.4.1085; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Spinicelli S, 2002, CELL DEATH DIFFER, V9, P1382, DOI 10.1038/sj.cdd.4401140; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Wang FH, 2002, J CEREBR BLOOD F MET, V22, P171, DOI 10.1097/00004647-200202000-00005; Watanabe H, 1999, BRAIN RES, V837, P38, DOI 10.1016/S0006-8993(99)01652-2; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Xiang H, 1996, J NEUROSCI, V16, P6753; Xiang H, 1998, J NEUROSCI, V18, P1363; Xue L, 2002, P NATL ACAD SCI USA, V99, P6925, DOI 10.1073/pnas.102182299; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yoon Y, 1999, ONCOGENE, V18, P7174, DOI 10.1038/sj.onc.1203144; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200	72	70	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28706	28714		10.1074/jbc.M400376200	http://dx.doi.org/10.1074/jbc.M400376200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15105421	hybrid			2022-12-25	WOS:000222265400108
J	Marson, A; Lawn, RM; Mikita, T				Marson, A; Lawn, RM; Mikita, T			Oxidized low density lipoprotein blocks lipopolysaccharide-induced interferon beta synthesis in human macrophages by interfering with IRF3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN/P300; TOLL-LIKE RECEPTOR-4; GENE-EXPRESSION; IFN-BETA; REGULATORY FACTOR-3; TRANSCRIPTION FACTORS; ALPHA; GAMMA; ATHEROSCLEROSIS; INDUCTION	In response to lipopolysaccharide (LPS) exposure, macrophages activate the transcription of a large number of pro-inflammatory genes by way of signaling pathways downstream of the LPS receptor, Toll-Like Receptor 4. Many of these genes are expressed sequentially in time, with early synthesis events resulting in the secretion of soluble factors that drive the transcription of genes expressed later in the activation cycle. In this study we show that human blood-derived macrophages pretreated with oxidized low density lipoprotein ( OxLDL) fail to transcribe and secrete interferon beta (IFNbeta) immediately following LPS stimulation. As such, the normal downstream activation of Stat1 is blocked, and numerous IFNbeta/Stat1-activated genes, including the chemokines IP10 and ITAC, are weakly expressed or not expressed at all in these cells. Inspection of the LPS-induced activation state of several transcription factors known to play a prominent role in IFNbeta transcription reveals that, although NFkappaB, c-Jun, and ATF-2 activation appears normal, the LPS-induced activation of IFNbeta regulatory factor 3 (IRF3), as measured by DNA-binding activity and association with the coactivator CBP, is inhibited in the OxLDL pre-treated cells. These IRF3 activities have been shown to be essential for the initiation of transcription of the IFNbeta gene, and the loss of these activities presumably accounts for the lack of LPS-induced IFNbeta transcription seen in the OxLDL pre-treated cells.	CV Therapeut Inc, Palo Alto, CA 94304 USA	CV Therapeutics, Inc.	Mikita, T (corresponding author), CV Therapeut Inc, 3172 Porter Dr, Palo Alto, CA 94304 USA.	tom.mikita@cvt.com						Abbas A. K., 2000, CELLULAR MOL IMMUNOL, P270; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; BARTHOLOME EJ, 2000, J INTERFERON CYTOKIN, V21, P495; Blake GJ, 2002, J INTERN MED, V252, P283, DOI 10.1046/j.1365-2796.2002.01019.x; Bogdan C, 2000, CURR OPIN IMMUNOL, V12, P419, DOI 10.1016/S0952-7915(00)00111-4; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Cascieri MA, 2002, NAT REV DRUG DISCOV, V1, P122, DOI 10.1038/nrd723; Castrillo A, 2003, MOL CELL, V12, P805, DOI 10.1016/S1097-2765(03)00384-8; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Cremer I, 2002, FEBS LETT, V511, P41, DOI 10.1016/S0014-5793(01)03276-8; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Edfeldt K, 2002, CIRCULATION, V105, P1158, DOI 10.1161/circ.105.10.1158; Espinola-Klein C, 2002, CIRCULATION, V105, P15, DOI 10.1161/hc0102.101362; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Hansson GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/hq1201.100220; Hida S, 2000, IMMUNITY, V13, P643, DOI 10.1016/S1074-7613(00)00064-9; Ito Takayuki, 2003, Current Drug Targets - Inflammation and Allergy, V2, P257, DOI 10.2174/1568010033484106; Jungo F, 2001, CYTOKINE, V14, P272, DOI 10.1006/cyto.2001.0884; Kalayoglu MV, 2002, JAMA-J AM MED ASSOC, V288, P2724, DOI 10.1001/jama.288.21.2724; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Kopp E, 2003, CURR OPIN IMMUNOL, V15, P396, DOI 10.1016/S0952-7915(03)00080-3; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; Mackman N, 2003, ARTERIOSCL THROM VAS, V23, P1133, DOI 10.1161/01.ATV.0000080641.10662.4C; Makowski L, 2001, NAT MED, V7, P699, DOI 10.1038/89076; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Mikita T, 2001, J BIOL CHEM, V276, P45729, DOI 10.1074/jbc.M106114200; Mintzer RJ, 1998, J INTERF CYTOK RES, V18, P939, DOI 10.1089/jir.1998.18.939; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nakaya T, 2001, BIOCHEM BIOPH RES CO, V283, P1150, DOI 10.1006/bbrc.2001.4913; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Ricote M, 2004, ARTERIOSCL THROM VAS, V24, P230, DOI 10.1161/01.ATV.0000103951.67680.B1; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Robinson CM, 2003, J INTERF CYTOK RES, V23, P413, DOI 10.1089/107999003322277829; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sgarbanti M, 2002, J EXP MED, V195, P1359, DOI 10.1084/jem.20010753; Shiffman D, 2000, J BIOL CHEM, V275, P37324, DOI 10.1074/jbc.M004732200; SOUTAR AK, 1982, BIOCHEM J, V204, P549, DOI 10.1042/bj2040549; Struyf S, 1998, J LEUKOCYTE BIOL, V63, P364; Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Suzuki T, 2000, BLOOD, V96, P2584; Taniguchi T, 2002, CURR OPIN IMMUNOL, V14, P111, DOI 10.1016/S0952-7915(01)00305-3; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Walton KA, 2003, J BIOL CHEM, V278, P29661, DOI 10.1074/jbc.M300738200; Walton KA, 2003, ARTERIOSCL THROM VAS, V23, P1197, DOI 10.1161/01.ATV.0000079340.80744.B8; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Widney DP, 2000, J IMMUNOL, V164, P6322, DOI 10.4049/jimmunol.164.12.6322; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Yang HM, 2002, EUR J BIOCHEM, V269, P6142, DOI 10.1046/j.1432-1033.2002.03330.x	66	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28781	28788		10.1074/jbc.M313207200	http://dx.doi.org/10.1074/jbc.M313207200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15107417	hybrid			2022-12-25	WOS:000222265400116
J	Frontelo, P; Leader, JE; Yoo, N; Potocki, AC; Crawford, M; Kulik, M; Lechleider, RJ				Frontelo, P; Leader, JE; Yoo, N; Potocki, AC; Crawford, M; Kulik, M; Lechleider, RJ			Suv39h histone methyltransferases interact with Smads and cooperate in BMP-induced repression	ONCOGENE			English	Article						Smad; BMP; histone methyltransferase; transcription; repression	TRANSCRIPTIONAL ACTIVATION; BREAST-CANCER; I RECEPTORS; LYSINE 9; PROTEINS; METHYLATION; H3; HETEROCHROMATIN; SIGNALS; BINDING	Smad proteins transduce signals from transforming growth factor-beta (TGF-beta) superfamily ligands to regulate the expression of target genes. In order to identify novel partners of Smad proteins in transcriptional regulation, we performed a two-hybrid screen using Smad5, a protein that is activated predominantly by bone morphogenetic protein (BMP) signaling. We identified an interaction between Smad5 and suppressor of variegation 3-9 homolog 2 (Suv39h2), a chromatin modifier enzyme. Suv39h proteins are histone methyltransferases that methylate histone H3 on lysine 9, resulting in transcriptional repression or silencing of target genes. Biochemical studies in mammalian cells demonstrated that Smad5 binds to both known mammalian isoforms of Suv39h proteins, and that Smad proteins activated by the TGF-beta signaling pathway, Smad2 and Smad3, do not bind with significant affinity. Functional studies using the muscle creatine kinase (MCK) promoter, which is suppressed by BMP signaling, demonstrate that Suv39h proteins and Smads cooperate to repress promoter activity. These data suggest a model where association of Smad proteins with Suv39h methyltransferases can repress or silence genes involved in developmental processes, and argues that inefficient gene repression may result in the alteration of the differentiated phenotype. Thus, examination of the Smad - Suv interaction may provide insight into the mechanism of phenotypic determination mediated by BMP signaling.	Georgetown Univ, Sch Med, Dept Cell Biol, Washington, DC 20057 USA; Georgetown Univ, Sch Med, Tumor Biol Program, Washington, DC 20057 USA; Uniformed Serv Univ Hlth Sci, Mol & Cell Biol Program, Bethesda, MD 20814 USA	Georgetown University; Georgetown University; Uniformed Services University of the Health Sciences - USA	Lechleider, RJ (corresponding author), Georgetown Univ, Sch Med, Dept Cell Biol, Box 571436, Washington, DC 20057 USA.	rjl24@georgetown.edu	Yoo, Nam Jin/GNM-9060-2022		NATIONAL CANCER INSTITUTE [R21CA102660] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065681] Funding Source: NIH RePORTER; NCI NIH HHS [CA102660] Funding Source: Medline; NHLBI NIH HHS [HL65681] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; Akiyama S, 1997, EXP CELL RES, V235, P362, DOI 10.1006/excr.1997.3680; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Brubaker KD, 2004, J CELL BIOCHEM, V91, P151, DOI 10.1002/jcb.10679; CAESTECKER MD, 2001, RESP RES, V2, P193; Chakraborty S, 2003, ONCOGENE, V22, P5229, DOI 10.1038/sj.onc.1206600; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Davey C, 2003, J MOL BIOL, V325, P873, DOI 10.1016/S0022-2836(02)01340-2; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Firestein R, 2000, MOL CELL BIOL, V20, P4900, DOI 10.1128/MCB.20.13.4900-4909.2000; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Keeton EK, 2002, J BIOL CHEM, V277, P28247, DOI 10.1074/jbc.M203898200; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Li JW, 2002, MOL CELL BIOL, V22, P5688, DOI 10.1128/MCB.22.16.5688-5697.2002; Liberati NT, 2001, J BIOL CHEM, V276, P22595, DOI 10.1074/jbc.M010778200; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Melcher M, 2000, MOL CELL BIOL, V20, P3728, DOI 10.1128/MCB.20.10.3728-3741.2000; Melhuish TA, 2000, J BIOL CHEM, V275, P39762, DOI 10.1074/jbc.C000416200; Moustakas A, 2001, J CELL SCI, V114, P4359; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Pouliot F, 2002, J ENDOCRINOL, V172, P187, DOI 10.1677/joe.0.1720187; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; Snowden AW, 2002, CURR BIOL, V12, P2159, DOI 10.1016/S0960-9822(02)01391-X; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445	43	20	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5242	5251		10.1038/sj.onc.1207660	http://dx.doi.org/10.1038/sj.onc.1207660			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15107829				2022-12-25	WOS:000222382500013
J	Kent, NA; Eibert, SM; Mellor, J				Kent, NA; Eibert, SM; Mellor, J			Cbf1p is required for chromatin remodeling at promoter-proximal CACGTG motifs in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTROMERE-BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; LEFT ARM; GENE; REGION; MET4; PURIFICATION; KINETOCHORE	Cbf1p is a basic-helix-loop-helix-zipper protein of Saccharomyces cerevisiae required for the function of centromeres and MET gene promoters, where it binds DNA via the consensus core motif CACRTG ( R = A or G). At MET genes Cbf1p appears to function in both activator recruitment and chromatin-remodeling. Cbf1p has been implicated in the regulation of other genes, and CACRTG motifs are common in potential gene regulatory DNA. A recent genome-wide location analysis showed that the majority of intergenic CACGTG palindromes are bound by Cbf1p. Here we tested whether all potential Cbf1p binding motifs in the yeast genome are likely to be bound by Cbf1p using chromatin immunoprecipitation. We also tested which of the motifs are actually functional by assaying for Cbf1p-dependent chromatin remodeling. We show that Cbf1p binding and activity is restricted to palindromic CACGTG motifs in promoter-proximal regions. Cbf1p does not function through CACGTG motifs that occur in promoter-distal locations within coding regions nor where CACATG motifs occur alone except at centromeres. Cbf1p can be made to function at promoter-distal CACGTG motifs by overexpression, suggesting that the concentration of Cbf1p is normally limiting for binding and is biased to gene regulatory DNA by interactions with other factors. We conclude that Cbf1p is required for normal nucleosome positioning wherever the CACGTG motif occurs in gene regulatory DNA. Cbf1p has been shown to interact with the chromatin-remodeling ATPase Isw1p. Here we show that recruitment of Isw1p by Cbf1p is likely to be general but that Isw1p is only partially required for Cbf1p-dependent chromatin structures.	Univ Oxford, Dept Biochem, Genet Unit, Oxford OX1 3QU, England; Univ Oxford, Dept Biochem, Microbiol Unit, Oxford OX1 3QU, England	University of Oxford; University of Oxford	Kent, NA (corresponding author), Univ Oxford, Dept Biochem, Genet Unit, S Parks Rd, Oxford OX1 3QU, England.	nicholas.kent@bioch.ox.ac.uk	Kent, Nicholas/A-4503-2010	Kent, Nicholas/0000-0002-4114-1307				AVEDANO A, 1997, J BACTERIOL, V179, P5594; BAKER RE, 1989, J BIOL CHEM, V264, P10843; BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; Baker RE, 1998, GENETICS, V149, P73; Blaiseau PL, 1998, EMBO J, V17, P6327, DOI 10.1093/emboj/17.21.6327; Blaiseau PL, 1997, MOL CELL BIOL, V17, P3640, DOI 10.1128/MCB.17.7.3640; BLOOM KS, 1982, CELL, V29, P305, DOI 10.1016/0092-8674(82)90147-7; BRAM RJ, 1987, MOL CELL BIOL, V7, P403, DOI 10.1128/MCB.7.1.403; CAI MJ, 1989, MOL CELL BIOL, V9, P2544, DOI 10.1128/MCB.9.6.2544; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; Chen CY, 1999, J CELL BIOL, V147, P1223, DOI 10.1083/jcb.147.6.1223; CLARK MW, 1992, YEAST, V8, P133, DOI 10.1002/yea.320080208; CLARK MW, 1993, YEAST, V9, P543, DOI 10.1002/yea.320090511; DEWINDE JH, 1993, YEAST, V9, P847, DOI 10.1002/yea.320090805; DEWINDE JH, 1995, EUR J BIOCHEM, V233, P200; Dormer UH, 2000, J BIOL CHEM, V275, P32611, DOI 10.1074/jbc.M004167200; FUNK M, 1989, MOL GEN GENET, V219, P153, DOI 10.1007/BF00261171; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Hemmerich P, 2000, P NATL ACAD SCI USA, V97, P12583, DOI 10.1073/pnas.97.23.12583; JIANG WD, 1989, MOL CELL BIOL, V9, P5585, DOI 10.1128/MCB.9.12.5585; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; KENT NA, 1994, MOL CELL BIOL, V14, P5229, DOI 10.1128/MCB.14.8.5229; KENT NA, 1993, NUCLEIC ACIDS RES, V21, P4653, DOI 10.1093/nar/21.19.4653; Kent NA, 2001, GENE DEV, V15, P619, DOI 10.1101/gad.190301; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; KRAAKMAN LS, 1991, BIOCHIM BIOPHYS ACTA, V1090, P204, DOI 10.1016/0167-4781(91)90102-R; Kuras L, 2002, MOL CELL, V10, P69, DOI 10.1016/S1097-2765(02)00561-0; KURAS L, 1995, FEBS LETT, V367, P15, DOI 10.1016/0014-5793(95)00528-H; Kuras L, 1997, EMBO J, V16, P2441, DOI 10.1093/emboj/16.9.2441; Kuras L, 1996, EMBO J, V15, P2519, DOI 10.1002/j.1460-2075.1996.tb00609.x; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MASISON DC, 1992, GENETICS, V131, P43; McAinsh AD, 2003, ANNU REV CELL DEV BI, V19, P519, DOI 10.1146/annurev.cellbio.19.111301.155607; MELLOR J, 1991, NUCLEIC ACIDS RES, V19, P2961, DOI 10.1093/nar/19.11.2961; MELLOR J, 1990, EMBO J, V9, P4017, DOI 10.1002/j.1460-2075.1990.tb07623.x; Meluh PB, 1999, METHOD ENZYMOL, V304, P414; Meluh PB, 1997, GENE DEV, V11, P3401, DOI 10.1101/gad.11.24.3401; Moreau JL, 2003, MOL CELL, V11, P1609, DOI 10.1016/S1097-2765(03)00184-9; Morillon A, 2003, CELL, V115, P425, DOI 10.1016/S0092-8674(03)00880-8; NIEDENTHAL R, 1991, MOL CELL BIOL, V11, P3545, DOI 10.1128/MCB.11.7.3545; NUTTEN PR, 2000, THESIS U OXFORD; OCONNELL KF, 1995, MOL CELL BIOL, V15, P1879; Oechsner U, 1996, NUCLEIC ACIDS RES, V24, P2395, DOI 10.1093/nar/24.12.2395; Oechsner U, 1998, MOL GEN GENET, V260, P417, DOI 10.1007/s004380050912; Ortiz J, 2000, PROTOPLASMA, V211, P12, DOI 10.1007/BF01279895; Otte S, 2001, J CELL BIOL, V152, P503, DOI 10.1083/jcb.152.3.503; Packham EA, 1996, MOL GEN GENET, V250, P348; Patton EE, 2000, EMBO J, V19, P1613, DOI 10.1093/emboj/19.7.1613; Robinson KA, 2000, NUCLEIC ACIDS RES, V28, P1499, DOI 10.1093/nar/28.7.1499; SAUNDERS M, 1988, P NATL ACAD SCI USA, V85, P175, DOI 10.1073/pnas.85.1.175; SINCLAIR DA, 1994, MOL CELL BIOL, V14, P214, DOI 10.1128/MCB.14.1.214; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; THOMAS D, 1989, MOL CELL BIOL, V9, P3292, DOI 10.1128/MCB.9.8.3292; Wieland G, 2001, NUCLEIC ACIDS RES, V29, P1054, DOI 10.1093/nar/29.5.1054; WILMEN A, 1994, NUCLEIC ACIDS RES, V22, P2791, DOI 10.1093/nar/22.14.2791; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; Wu L, 1997, NUCLEIC ACIDS RES, V25, P4230, DOI 10.1093/nar/25.21.4230; Yano KI, 1997, P NATL ACAD SCI USA, V94, P1721, DOI 10.1073/pnas.94.5.1721	60	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27116	27123		10.1074/jbc.M403818200	http://dx.doi.org/10.1074/jbc.M403818200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15111622	hybrid			2022-12-25	WOS:000222120400038
J	Noti, JD; Johnson, AK; Dillon, JD				Noti, JD; Johnson, AK; Dillon, JD			The zinc finger transcription factor transforming growth factor beta-inducible early gene-1 confers myeloid-specific activation of the leukocyte integrin CD11d promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; CELL-DIFFERENTIATION; RB PROTEIN; ALPHA-D; EXPRESSION; SP1; IDENTIFICATION; BINDS; LEUKOINTEGRIN; ADHESION	CD11d encodes the alpha(D) subunit for a leukocyte integrin that is expressed on myeloid cells. In this study we show that the -100 to -20 region of the CD11d promoter confers myeloid-specific activation of the CD11d promoter. Transforming growth factor beta-inducible early gene-1 (TIEG1) was isolated in a yeast one-hybrid screen using the -100 to -20 region of the CD11d promoter as bait. Purified GST.TIEG1 protein was able to bind within the -61 to -45 region that overlaps a shorter binding site for Sp1. Transient overexpression of TIEG1 activated the CD11d promoter specifically in myeloid cells, whereas, down-regulation of TIEG1 with small interfering TIEG1 RNA also down-regulated expression of CD11d. In vivo, TIEG1 does not physically interact with Sp1. Cotransfection and electrophoretic mobility shift analyses of TIEG1, Sp1, and Sp3 revealed that TIEG1 competes with these Sp proteins for binding to overlapping sites in the CD11d promoter. Although TIEG1 and Sp1 are ubiquitously expressed in myeloid and non-myeloid cells, chromatin immunoprecipitation assays revealed differential occupancy of the CD11d promoter by these factors. In undifferentiated myeloid and non-myeloid cells, occupancy of the CD11d promoter by TIEG1 is similar. Upon differentiation of myeloid cells and subsequent up-regulation of CD11d expression, TIEG1 occupancy increases. In contrast, occupancy by TIEG1 remains low in non-myeloid cells exposed to phorbol ester. We propose that up-regulation of CD11d expression following differentiation of myeloid cells is mediated through increased binding of TIEG1 binding to the CD11d promoter.	Guthrie Res Inst, Sayre, PA 18840 USA		Noti, JD (corresponding author), Guthrie Res Inst, 1 Guthrie Sq, Sayre, PA 18840 USA.	noti_john@guthrie.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063891] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL63891] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Banerjee SS, 2003, J BIOL CHEM, V278, P2581, DOI 10.1074/jbc.M210859200; BLOK LJ, 1995, MOL ENDOCRINOL, V9, P1610, DOI 10.1210/me.9.11.1610; Chalaux E, 1999, FEBS LETT, V457, P478, DOI 10.1016/S0014-5793(99)01051-0; CHEN HM, 1993, J BIOL CHEM, V268, P8230; Chrisman HR, 2003, DNA CELL BIOL, V22, P187, DOI 10.1089/104454903321655819; Cook T, 1999, J BIOL CHEM, V274, P29500, DOI 10.1074/jbc.274.41.29500; DANILENKO DM, 1995, J IMMUNOL, V155, P35; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; ElGabalawy H, 1996, ARTHRITIS RHEUM-US, V39, P1913, DOI 10.1002/art.1780391119; Ellenrieder V, 2002, EMBO J, V21, P2451, DOI 10.1093/emboj/21.10.2451; Gunther M, 2000, MOL CELL BIOCHEM, V210, P131, DOI 10.1023/A:1007177623283; Harris ES, 2000, J BIOL CHEM, V275, P23409, DOI 10.1074/jbc.R000004200; Hefferan TE, 2000, J BIOL CHEM, V275, P20255, DOI 10.1074/jbc.C000135200; IMHOF BA, 1995, ADV IMMUNOL, V58, P345, DOI 10.1016/S0065-2776(08)60623-9; Johnsen SA, 2002, ONCOGENE, V21, P5783, DOI 10.1038/sj.onc.1205681; Johnsen SA, 2002, J CELL BIOCHEM, V87, P233, DOI 10.1002/jcb.10299; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KURZINGER K, 1981, J IMMUNOL, V127, P596; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LAW SKA, 1987, EMBO J, V6, P915, DOI 10.1002/j.1460-2075.1987.tb04838.x; LopezRodriguez C, 1995, EUR J IMMUNOL, V25, P3496, DOI 10.1002/eji.1830251243; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; Noti JD, 1996, MOL IMMUNOL, V33, P115, DOI 10.1016/0161-5890(95)00140-9; Noti JD, 2000, J BIOL CHEM, V275, P8959, DOI 10.1074/jbc.275.12.8959; Noti JD, 2002, INT J MOL MED, V10, P721; Noti JD, 1996, MOL CELL BIOL, V16, P2940; Noti John D., 2003, Current Genomics, V4, P527, DOI 10.2174/1389202033490240; Ribeiro A, 1999, HEPATOLOGY, V30, P1490, DOI 10.1002/hep.510300620; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; Sanchez-Madrid F, 1992, Semin Cell Biol, V3, P199; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; Shanley TP, 1998, J IMMUNOL, V160, P1014; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SPRINGER TA, 1986, J IMMUNOL, V136, P240; Subramaniam M, 1998, J CELL BIOCHEM, V68, P226, DOI 10.1002/(SICI)1097-4644(19980201)68:2<226::AID-JCB9>3.0.CO;2-X; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; Tachibana I, 1997, J CLIN INVEST, V99, P2365, DOI 10.1172/JCI119418; Tanabe A, 2002, BIOL PHARM BULL, V25, P970, DOI 10.1248/bpb.25.970; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; Wei Z, 1999, MOL CELL BIOL, V19, P1271; Zhang JS, 2001, MOL CELL BIOL, V21, P5041, DOI 10.1128/MCB.21.15.5041-5049.2001; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	46	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26948	26958		10.1074/jbc.M310634200	http://dx.doi.org/10.1074/jbc.M310634200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15087465	hybrid			2022-12-25	WOS:000222120400020
J	Suetake, I; Shinozaki, F; Miyagawa, J; Takeshima, H; Tajima, S				Suetake, I; Shinozaki, F; Miyagawa, J; Takeshima, H; Tajima, S			DNMT3L stimulates the DNA methylation activity of Dnmt3a and Dnmt3b through a direct interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO METHYLATION; CYTOSINE-5 METHYLTRANSFERASES; TRANSCRIPTIONAL REPRESSOR; ENZYMATIC-PROPERTIES; HISTONE DEACETYLASE; CONTROL REGION; FAMILY; GENE; RESTRICTION; LYSINE-9	In mammals, the resetting of DNA methylation patterns in early embryos and germ cells is crucial for development. Two DNA methyltransferases, Dnmt3a and Dnmt3b, are responsible for the creation of DNA methylation patterns. Dnmt3L, a member of the Dnmt3 family, has been reported to be necessary for maternal methylation imprinting, possibly by interacting with Dnmt3a and/or Dnmt3b (Hata, K., Okano, M., Lei, H., and Li, E. ( 2002) Development 129, 1983 - 1993). In the present study, the effect of DNMT3L, a human homologue of Dnmt3L, on the DNA methylation activity of mouse Dnmt3a and Dnmt3b was examined in vitro. DNMT3L enhanced the DNA methylation activity of Dnmt3a and Dnmt3b about 1.5-3-fold in a dose-dependent manner but did not enhance the DNA methylation activity of Dnmt1. Although the extents of stimulation were different, a stimulatory effect on the DNA methylation activity was observed for all of the substrate DNA sequences examined, such as those of the maternally methylated SNRPN and Lit-1 imprinting genes, the paternally methylated H19 imprinting gene, the CpG island of the myoD gene, the 5 S ribosomal RNA gene, an artificial 28-bp DNA, poly(dG-dC)- poly(dG-dC), and poly(dI-dC)- poly(dI-dC). DNMT3L could not bind to DNA but could bind to Dnmt3a and Dnmt3b, indicating that the stimulatory effect of DNMT3L on the DNA methylation activity may not be due to the guiding of Dnmt3a and Dnmt3b to the targeting DNA sequence but may comprise a direct effect on their catalytic activity. The carboxyl-terminal half of DNMT3L was found to be responsible for the enhancement of the enzyme activity.	Osaka Univ, Inst Prot Res, Div Physiol, Suita, Osaka 5650871, Japan	Osaka University	Tajima, S (corresponding author), Osaka Univ, Inst Prot Res, Div Physiol, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tajima@protein.osaka-u.ac.jp	Suetake, Isao/G-3144-2013; Suetake, Isao/D-4326-2009	Suetake, Isao/0000-0002-1246-8474; Takeshima, Hideyuki/0000-0002-8552-2427				Aapola U, 2000, GENOMICS, V65, P293, DOI 10.1006/geno.2000.6168; Aapola U, 2002, NUCLEIC ACIDS RES, V30, P3602, DOI 10.1093/nar/gkf474; ANTEQUERA F, 1993, DNA METHYLATION MOL, P169; Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chedin F, 2002, P NATL ACAD SCI USA, V99, P16916, DOI 10.1073/pnas.262443999; Deplus R, 2002, NUCLEIC ACIDS RES, V30, P3831, DOI 10.1093/nar/gkf509; Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Hata K, 2002, DEVELOPMENT, V129, P1983; Iida T, 2002, GENES CELLS, V7, P997, DOI 10.1046/j.1365-2443.2002.00584.x; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Margot JB, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-7; MONK M, 1990, PHILOS T R SOC B, V326, P299, DOI 10.1098/rstb.1990.0013; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Reik W, 2001, NAT GENET, V27, P255, DOI 10.1038/85804; Riggs A.D., 1996, EPIGENETIC MECH GENE, P231; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shi LH, 2001, J BIOCHEM, V130, P359, DOI 10.1093/oxfordjournals.jbchem.a002994; Suetake I, 2003, J BIOCHEM, V133, P737, DOI 10.1093/jb/mvg095; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; Tajima S, 1998, J BIOCHEM-TOKYO, V123, P993, DOI 10.1093/oxfordjournals.jbchem.a022066; Tamaru H, 2003, NAT GENET, V34, P75, DOI 10.1038/ng1143; Tremblay KD, 1997, MOL CELL BIOL, V17, P4322, DOI 10.1128/MCB.17.8.4322; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; Watanabe D, 2002, MECH DEVELOP, V118, P187, DOI 10.1016/S0925-4773(02)00242-3; Yatsuki H, 2002, GENOME RES, V12, P1860, DOI 10.1101/gr.110702	34	320	336	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27816	27823		10.1074/jbc.M400181200	http://dx.doi.org/10.1074/jbc.M400181200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15105426	hybrid			2022-12-25	WOS:000222120400117
J	Winteringham, LN; Kobelke, S; Williams, JH; Ingley, E; Klinken, SP				Winteringham, LN; Kobelke, S; Williams, JH; Ingley, E; Klinken, SP			Myeloid Leukemia Factor 1 inhibits erythropoietin-induced differentiation, cell cycle exit and p27(Kip1) accumulation	ONCOGENE			English	Article						Mlf1; erythroleukemia; p27(Kip1)	TERMINAL ERYTHROID-DIFFERENTIATION; MYELODYSPLASTIC SYNDROME; DEPENDENT KINASES; PROGENITOR CELLS; UP-REGULATION; IN-VITRO; LINE M1; EXPRESSION; GENE; PROTEIN	Myeloid leukemia factor 1 (MLF1) is a novel oncoprotein involved in translocations associated with acute myeloid leukemia (AML), especially erythroleukemias. In this study, we demonstrate that ectopic expression of Mlf1 prevented J2E erythroleukemic cells from undergoing biological and morphological maturation in response to erythropoietin (Epo). We show that Mlf1 inhibited Epo-induced cell cycle exit and suppressed a rise in the cell cycle inhibitor p27(Kip1). Unlike differentiating J2E cells, Mlf1-expressing cells did not downregulate Cul1 and Skp2, components of the ubiquitin E3 ligase complex SCFSkp2 involved in the proteasomal degradation of p27(Kip1). In contrast, Mlf1 did not interfere with increases in p27(Kip1) and terminal differentiation initiated by thyroid hormone withdrawal from erythroid cells, or cytokine-stimulated maturation of myeloid cells. These data demonstrate that Mlf1 interferes with an Epo-responsive pathway involving p27(Kip1) accumulation, which inhibits cell cycle arrest essential for erythroid terminal differentiation.	Western Australian Inst Med Res, Lab Canc Med, Perth, WA 6000, Australia; Univ Western Australia, Med Res Ctr, Perth, WA 6000, Australia	University of Western Australia; University of Western Australia	Klinken, SP (corresponding author), Western Australian Inst Med Res, Lab Canc Med, Level 6,MRF Bldg,50 Murray St, Perth, WA 6000, Australia.	pklinken@waimr.uwa.edu.au	Ingley, Evan/C-2401-2013; Winteringham, Louise/H-6105-2014	Ingley, Evan/0000-0002-8112-9134; Williams, James/0000-0002-0950-1958; Winteringham, Louise/0000-0002-8117-5069				Bouscary D, 2003, BLOOD, V101, P3436, DOI 10.1182/blood-2002-07-2332; BUSFIELD SJ, 1992, BLOOD, V80, P412; Caslini C, 2000, P NATL ACAD SCI USA, V97, P2797, DOI 10.1073/pnas.040574897; Dai MS, 2000, BLOOD, V96, P3985, DOI 10.1182/blood.V96.12.3985.h8003985_3985_3987; Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Hitzler JK, 1999, AM J PATHOL, V155, P53, DOI 10.1016/S0002-9440(10)65098-5; Hochheimer A, 2002, NATURE, V420, P439, DOI 10.1038/nature01167; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; Ingley E, 2001, J BIOL CHEM, V276, P43428, DOI 10.1074/jbc.M106645200; Jacobs-Helber SM, 2002, J BIOL CHEM, V277, P4859, DOI 10.1074/jbc.M107243200; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Lim R, 2002, J BIOL CHEM, V277, P40997, DOI 10.1074/jbc.M206041200; Matsumoto N, 2000, LEUKEMIA, V14, P1757, DOI 10.1038/sj.leu.2401897; Matushansky I, 2000, BLOOD, V96, P2755, DOI 10.1182/blood.V96.8.2755.h8002755_2755_2764; Matushansky I, 2000, P NATL ACAD SCI USA, V97, P14317, DOI 10.1073/pnas.250488697; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Ohno K, 2000, GENE, V260, P133, DOI 10.1016/S0378-1119(00)00447-9; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Panzenbock B, 1998, BLOOD, V92, P3658, DOI 10.1182/blood.V92.10.3658.422k18_3658_3668; RAIMONDI SC, 1989, LEUKEMIA, V3, P42; Rylski M, 2003, MOL CELL BIOL, V23, P5031, DOI 10.1128/MCB.23.14.5031-5042.2003; Tamir A, 2000, CELL GROWTH DIFFER, V11, P269; Tanaka H, 2000, BLOOD, V95, P1264, DOI 10.1182/blood.V95.4.1264.004k09_1264_1273; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; Whyatt David J., 1997, Genes and Function, V1, P11; Williams JH, 1999, EMBO J, V18, P5559, DOI 10.1093/emboj/18.20.5559; Yamaguchi Y, 1998, BLOOD, V91, P450, DOI 10.1182/blood.V91.2.450.450_450_457; Yoneda-Kato N, 1999, BLOOD, V94, p484A; YonedaKato N, 1996, ONCOGENE, V12, P265	32	39	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5105	5109		10.1038/sj.onc.1207661	http://dx.doi.org/10.1038/sj.onc.1207661			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15122318				2022-12-25	WOS:000222237300019
J	Horisberger, JD; Kharoubi-Hess, S; Guennoun, S; Michielin, O				Horisberger, JD; Kharoubi-Hess, S; Guennoun, S; Michielin, O			The fourth transmembrane segment of the Na,K-ATPase alpha subunit - A systematic mutagenesis study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY NA+,K+-ATPASE; CYSTEINE-SCANNING MUTAGENESIS; SARCOPLASMIC-RETICULUM; FUNCTIONAL CONSEQUENCES; BETA-SUBUNIT; GASTRIC H+,K+-ATPASE; STRUCTURAL-CHANGES; CATION-BINDING; CALCIUM-PUMP; CA2+-ATPASE	The Na,K-ATPase is a major ion-motive ATPase of the P-type family responsible for many aspects of cellular homeostasis. To determine the structure of the pathway for cations across the transmembrane portion of the Na, K-ATPase, we mutated 24 residues of the fourth transmembrane segment into cysteine and studied their function and accessibility by exposure to the sulfhydryl reagent 2-aminoethyl-methanethiosulfonate. Accessibility was also examined after treatment with palytoxin, which transforms the Na, K-pump into a cation channel. Of the 24 tested cysteine mutants, seven had no or a much reduced transport function. In particular cysteine mutants of the highly conserved "PEG" motif had a strongly reduced activity. However, most of the non-functional mutants could still be transformed by palytoxin as well as all of the functional mutants. Accessibility, determined as a 2-aminoethylmethanethiosulfonate- induced reduction of the transport activity or as inhibition of the membrane conductance after palytoxin treatment, was observed for the following positions: Phe(323), Ile(322), Gly(326), Ala(330), Pro(333), Glu(334), and Gly(335). In accordance with a structural model of the Na,K-ATPase obtained by homology modeling with the two published structures of sarcoplasmic and endoplasmic reticulum calcium ATPase ( Protein Data Bank codes 1EUL and 1IWO), the results suggest the presence of a cation pathway along the side of the fourth transmembrane segment that faces the space between transmembrane segments 5 and 6. The phenylalanine residue in position 323 has a critical position at the outer mouth of the cation pathway. The residues thought to form the cation binding site II ((333)PEGL) are also part of the accessible wall of the cation pathway opened by palytoxin through the Na, K-pump.	Univ Lausanne, Inst Pharmacol & Toxicol, Dept Pharmacol & Toxicol, Sch Med, CH-1005 Lausanne, Switzerland; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pharmacol Physiol, Newark, NJ 07103 USA; Swiss Inst Bioinformat, CH-1066 Epalinges, Switzerland; Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland; CHU Vaudois, Ctr Pluridsiciplinaire Oncol, CH-1011 Lausanne, Switzerland	University of Lausanne; Rutgers State University New Brunswick; Rutgers State University Medical Center; Swiss Institute of Bioinformatics; Ludwig Institute for Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Horisberger, JD (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, Dept Pharmacol & Toxicol, Sch Med, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	Jean-Daniel.Horisberger@ipharm.unil.ch	Horisberger, Jean-Daniel/A-2538-2009; Michielin, Olivier/ABE-7924-2020					ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; Artigas P, 2004, J GEN PHYSIOL, V123, P357, DOI 10.1085/jgp.200308964; Artigas P, 2003, P NATL ACAD SCI USA, V100, P501, DOI 10.1073/pnas.0135849100; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1993, J BIOL CHEM, V268, P18359; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; GIRARDET M, 1981, BIOCHEMISTRY-US, V20, P6684, DOI 10.1021/bi00526a025; Guennoun S, 2000, FEBS LETT, V482, P144, DOI 10.1016/S0014-5793(00)02050-0; Guennoun S, 2002, FEBS LETT, V513, P277, DOI 10.1016/S0014-5793(02)02323-2; Hermsen HPH, 2001, BIOCHEMISTRY-US, V40, P6527, DOI 10.1021/bi002456z; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAUNIN P, 1992, J BIOL CHEM, V267, P577; Jorgensen PL, 2003, ANNU REV PHYSIOL, V65, P817, DOI 10.1146/annurev.physiol.65.092101.142558; Jorgensen PL, 2003, ANN NY ACAD SCI, V986, P22, DOI 10.1111/j.1749-6632.2003.tb07135.x; Koenderink JB, 2001, J BIOL CHEM, V276, P11705, DOI 10.1074/jbc.M010804200; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAUGER P, 1979, BIOCHIM BIOPHYS ACTA, V552, P143, DOI 10.1016/0005-2736(79)90253-0; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Mense M, 2000, J BIOL CHEM, V275, P1749, DOI 10.1074/jbc.275.3.1749; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; Qiu LY, 2003, J BIOL CHEM, V278, P47240, DOI 10.1074/jbc.M308833200; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Swarts HGP, 1998, EMBO J, V17, P3029, DOI 10.1093/emboj/17.11.3029; Swarts HGP, 2001, J BIOL CHEM, V276, P36909, DOI 10.1074/jbc.M103945200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1992, FEBS LETT, V314, P301, DOI 10.1016/0014-5793(92)81494-7; VILSEN B, 1995, FEBS LETT, V363, P179, DOI 10.1016/0014-5793(95)00313-X; VILSEN B, 1989, J BIOL CHEM, V264, P21024; Wang XY, 1996, MOL PHARMACOL, V50, P687	39	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29542	29550		10.1074/jbc.M400585200	http://dx.doi.org/10.1074/jbc.M400585200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123699	hybrid			2022-12-25	WOS:000222445300088
J	Lambers, TT; Weidema, AF; Nilius, B; Hoenderop, JGJ; Bindels, RJM				Lambers, TT; Weidema, AF; Nilius, B; Hoenderop, JGJ; Bindels, RJM			Regulation of the mouse epithelial Ca2+ channel TRPV6 by the Ca2+-sensor calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-CHANNEL; BINDING-SITES; EXPRESSION; IDENTIFICATION; INACTIVATION; INHIBITION; MECHANISM; TERMINUS; SUBUNIT; PROTEIN	TRPV5 and TRPV6 are members of the superfamily of transient receptor potential (TRP) channels and facilitate Ca2+ influx in a variety of epithelial cells. The activity of these Ca2+ channels is tightly controlled by the intracellular Ca2+ concentration in close vicinity to the channel mouth. The molecular mechanism underlying the Ca2+-dependent activity of TRPV5/TRPV6 is, however, still unknown. Here, the putative role of calmodulin (CaM) as the Ca2+ sensor mediating the regulation of channel activity was investigated. Overexpression of Ca2+-insensitive CaM mutants (CaM1234 and CaM34) significantly reduced the Ca2+ as well as the Na+ current of TRPV6- but not that of TRPV5-expressing HEK293 cells. By combining pull-down assays and co-immunoprecipitations, we demonstrated that CaM binds to both TRPV5 and TRPV6 in a Ca2+-dependent fashion. The binding of CaM to TRPV6 was localized to the transmembrane domain (TRPV6(327-577)) and consensus CaM-binding motifs located in the N (1-5-10 motif, TRPV6(88-97)) and C termini ( 1 - 8- 14 motif, TRPV6(643-656)), suggesting a mechanism of regulation involving multiple interaction sites. Subsequently, chimeric TRPV6/TRPV5 proteins, in which the N and/or C termini of TRPV6 were substituted by that of TRPV5, were co-expressed with CaM34 in HEK293 cells. Exchanging, the N and/or the C termini of TRPV6 by that of TRPV5 did not affect the CaM34- induced reduction of the Ca2+ and Na+ currents. These results suggest that CaM positively affects TRPV6 activity upon Ca2+ binding to EF-hands 3 and 4, located in the high Ca2+ affinity CaM C terminus, which involves the N and C termini and the transmembrane domain of TRPV6.	Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Physiol, NL-6500 HB Nijmegen, Netherlands; Katholieke Univ Leuven, Dept Physiol, B-3000 Louvain, Belgium	Radboud University Nijmegen; KU Leuven	Bindels, RJM (corresponding author), Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Physiol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	r.bindels@ncmls.kun.nl	Bindels, René JM/B-9824-2013; Hoenderop, Joost G.J./H-8047-2014	Bindels, René JM/0000-0003-1167-1339; Hoenderop, Joost G.J./0000-0002-1816-8544				Boulay G, 2002, CELL CALCIUM, V32, P201, DOI 10.1016/S0143416002001550; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Hirnet D, 2003, CELL CALCIUM, V33, P509, DOI 10.1016/S0143-4160(03)00066-6; Hoenderop JGJ, 2003, J CLIN INVEST, V112, P1906, DOI 10.1172/JCI200319826; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hoenderop JGJ, 2002, ANNU REV PHYSIOL, V64, P529, DOI 10.1146/annurev.physiol.64.081501.155921; Hoenderop JGJ, 1999, BIOCHEM BIOPH RES CO, V261, P488, DOI 10.1006/bbrc.1999.1059; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Liang HY, 2003, NEURON, V39, P951, DOI 10.1016/S0896-6273(03)00560-9; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Nilius B, 2002, J BIOL CHEM, V277, P30852, DOI 10.1074/jbc.M202418200; Nilius B, 2001, CELL CALCIUM, V29, P417, DOI 10.1054/ceca.2001.0201; Numazaki M, 2003, P NATL ACAD SCI USA, V100, P8002, DOI 10.1073/pnas.1337252100; Peng CH, 2003, J BIOL CHEM, V278, P24617, DOI 10.1074/jbc.M301699200; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Van de Graaf SFJ, 2003, EMBO J, V22, P1478, DOI 10.1093/emboj/cdg162; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; WANG CLA, 1985, BIOCHEM BIOPH RES CO, V130, P426, DOI 10.1016/0006-291X(85)90434-6; Wei X, 1996, RECEPTOR CHANNEL, V4, P205; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	28	101	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28855	28861		10.1074/jbc.M313637200	http://dx.doi.org/10.1074/jbc.M313637200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123711	Green Published, hybrid			2022-12-25	WOS:000222445300005
J	Belouzard, S; Delcroix, D; Rouille, Y				Belouzard, S; Delcroix, D; Rouille, Y			Low levels of expression of leptin receptor at the cell surface result from constitutive endocytosis and intracellular retention in the biosynthetic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEGRADATION; LONG; TRAFFICKING; ACTIVATION; GENERATION; INTERNALIZATION; LOCALIZATION; PROTEINS; CLEAVAGE; ISOFORMS	The leptin receptor is mainly localized in intracellular compartments in target tissues. To study the mechanisms leading to this intracellular localization, two main isoforms of leptin receptors, OB-Ra and OB-Rb, were expressed in HeLa cells. Both isoforms were localized at steady state in the trans-Golgi network, in endosomes, and to a lesser extent, at the cell surface. They turned over with a half-life of less than 2 h. Both isoforms of leptin receptors were constitutively endocytosed in a ligand-independent manner and degraded in lysosomes with no evidence of recycling to the cell surface or to the trans-Golgi network. The endocytosis was inhibited by the deletion of the cytoplasmic domain. Newly synthesized leptin receptors were partially retained in the Golgi complex or in a post-Golgi intracellular compartment. The transmembrane domain was found to be important for this intracellular retention in the biosynthetic pathway, whereas the cytoplasmic domain was not involved. The data suggest that the low levels of expression of leptin receptors at the cell surface results from partial retention in the biosynthetic pathway, coupled to constitutive removal from the plasma membrane via ligand-independent, constitutive endocytosis.	Inst Biol Lille, CNRS, Unite Propre Rech 2511, F-59021 Lille, France; Inst Biol Lille, CNRS, Equipe Postulante 525, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Rouille, Y (corresponding author), Inst Biol Lille, CNRS, Unite Propre Rech 2511, F-59021 Lille, France.	yves.rouille@ibl.fr	Belouzard, Sandrine/AAX-1584-2021; Rouillé, Yves/P-2405-2016; Belouzard, Sandrine/O-8527-2016	Belouzard, Sandrine/0000-0002-9972-4054; Belouzard, Sandrine/0000-0002-9972-4054; Rouille, Yves/0000-0003-0788-9271				Barr VA, 1999, J BIOL CHEM, V274, P21416, DOI 10.1074/jbc.274.30.21416; Baskin DG, 1999, J HISTOCHEM CYTOCHEM, V47, P353, DOI 10.1177/002215549904700309; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Benharouga M, 2001, J CELL BIOL, V153, P957, DOI 10.1083/jcb.153.5.957; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 2001, J BIOL CHEM, V276, P4747, DOI 10.1074/jbc.M007439200; Blondel MO, 2004, MOL BIOL CELL, V15, P883, DOI 10.1091/mbc.E03-04-0202; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Couturier C, 2003, J BIOL CHEM, V278, P26604, DOI 10.1074/jbc.M302002200; De Matteis R, 1998, NEUROENDOCRINOLOGY, V68, P412, DOI 10.1159/000054391; Devos R, 1997, J BIOL CHEM, V272, P18304, DOI 10.1074/jbc.272.29.18304; Diano S, 1998, J NEUROENDOCRINOL, V10, P647, DOI 10.1046/j.1365-2826.1998.00261.x; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Fayadat L, 2003, MOL BIOL CELL, V14, P1268, DOI 10.1091/mbc.E02-06-0363; Fourgeaud L, 2003, J BIOL CHEM, V278, P12222, DOI 10.1074/jbc.M205663200; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gavrilova O, 1997, J BIOL CHEM, V272, P30546, DOI 10.1074/jbc.272.48.30546; Ge HF, 2002, J BIOL CHEM, V277, P45898, DOI 10.1074/jbc.M205825200; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Haniu M, 1998, J BIOL CHEM, V273, P28691, DOI 10.1074/jbc.273.44.28691; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Keller SH, 2001, J BIOL CHEM, V276, P18384, DOI 10.1074/jbc.M100691200; KOPITO RR, 1999, PHYSIOL REV, V79, P167; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lundin A, 2000, BBA-MOL CELL RES, V1499, P130, DOI 10.1016/S0167-4889(00)00114-2; Maamra M, 2001, ENDOCRINOLOGY, V142, P4389, DOI 10.1210/en.142.10.4389; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Niswender KD, 2001, NATURE, V413, P794, DOI 10.1038/35101657; O'Rahilly S, 2003, ENDOCRINOLOGY, V144, P3757, DOI 10.1210/en.2003-0373; Reggiori F, 2002, NAT CELL BIOL, V4, P117, DOI 10.1038/ncb743; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; STROUS GJAM, 1983, J CELL BIOL, V97, P1815, DOI 10.1083/jcb.97.6.1815; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Uotani S, 1999, DIABETES, V48, P279, DOI 10.2337/diabetes.48.2.279; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; van Kerkhof P, 2003, MOL CELL ENDOCRINOL, V201, P57, DOI 10.1016/S0303-7207(02)00434-3; Waguri S, 2003, MOL BIOL CELL, V14, P142, DOI 10.1091/mbc.E02-06-0338; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	43	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28499	28508		10.1074/jbc.M400508200	http://dx.doi.org/10.1074/jbc.M400508200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123629	hybrid			2022-12-25	WOS:000222265400085
J	Brewer, BY; Malicka, J; Blackshear, PJ; Wilson, GM				Brewer, BY; Malicka, J; Blackshear, PJ; Wilson, GM			RNA sequence elements required for high affinity binding by the zinc finger domain of tristetraprolin - Conformational changes coupled to the bipartite nature of AU-rich mRNA-destabilizing motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DNA; FLUORESCENCE ANISOTROPY; STABILITY; ALPHA; THERMODYNAMICS; DISTINCT; HUR	Tristetraprolin (TTP) binds AU-rich elements (AREs) encoded within selected labile mRNAs and targets these transcripts for rapid cytoplasmic decay. RNA binding by TTP is mediated by an similar to70-amino acid domain containing two tandemly arrayed CCCH zinc fingers. Here we show that a 73-amino acid peptide spanning the TTP zinc finger domain, denoted TTP73, forms a dynamic, equimolar RNA . peptide complex with a 13-nucleotide fragment of the ARE from tumor necrosis factor alpha mRNA, which includes small but significant contributions from ionic interactions. Association of TTP73 with high affinity RNA substrates is accompanied by a large negative change in heat capacity without substantial modification of RNA structure, consistent with conformational changes in the peptide moiety during RNA binding. Analyses using mutant ARE substrates indicate that two adenylate residues located 3 - 6 bases apart within a uridylate-rich sequence are sufficient for high affinity recognition by TTP73 (K-d < 20 nM), with optimal affinity observed for RNA substrates containing AUUUA or AUUUUA. Linkage of conformational changes and binding affinity to the presence and spacing of these adenylate residues provides a thermodynamic basis for the RNA substrate specificity of TTP.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Ctr Fluorescence Spect, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; NIEHS, Lab Signal Transduct, NIH, US Dept HHS, Res Triangle Pk, NC 27709 USA; NIEHS, Off Clin Res, NIH, US Dept HHS, Res Triangle Pk, NC 27709 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilson, GM (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Ctr Fluorescence Spect, 108 N Greene St, Baltimore, MD 21201 USA.	gwils001@umaryland.edu	Wilson, Gerald/AAF-3874-2019; Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529; Wilson, Gerald/0000-0002-1273-7507	NCI NIH HHS [R01 CA 10242 8] Funding Source: Medline; NCRR NIH HHS [P41 RR 08119] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR008119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090080] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baumann C, 1996, J BIOL CHEM, V271, P12269, DOI 10.1074/jbc.271.21.12269; Bergqvist S, 2004, J MOL BIOL, V336, P829, DOI 10.1016/j.jmb.2003.12.061; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Blackshear PJ, 2003, J BIOL CHEM, V278, P19947, DOI 10.1074/jbc.M301290200; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fisher BM, 1998, BIOCHEMISTRY-US, V37, P12121, DOI 10.1021/bi980743l; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; Gryczynski Ignacy, 1997, J Fluoresc, V7, P167, DOI 10.1007/bf02758217; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; Hall KB, 1995, METHOD ENZYMOL, V259, P261; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; Hudson BP, 2004, NAT STRUCT MOL BIOL, V11, P257, DOI 10.1038/nsmb738; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; Katsamba PS, 2001, J BIOL CHEM, V276, P21476, DOI 10.1074/jbc.M101624200; Klostermeier D, 2001, METHODS, V23, P240, DOI 10.1006/meth.2000.1135; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, P368; Lapucci A, 2002, J BIOL CHEM, V277, P16139, DOI 10.1074/jbc.M201377200; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Michel SLJ, 2003, BIOCHEMISTRY-US, V42, P4626, DOI 10.1021/bi034073h; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; Park-Lee S, 2003, J BIOL CHEM, V278, P39801, DOI 10.1074/jbc.M307105200; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sarkar B, 2003, MOL CELL BIOL, V23, P6685, DOI 10.1128/MCB.23.18.6685-6693.2003; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; WEBER G, 1952, BIOCHEM J, V51, P155, DOI 10.1042/bj0510155; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Wilson GM, 2001, J BIOL CHEM, V276, P44450, DOI 10.1074/jbc.M108521200; Wilson GM, 2001, J BIOL CHEM, V276, P8695, DOI 10.1074/jbc.M009848200; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Worthington MT, 2002, J BIOL CHEM, V277, P48558, DOI 10.1074/jbc.M206505200	43	115	117	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27870	27877		10.1074/jbc.M402551200	http://dx.doi.org/10.1074/jbc.M402551200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117938	hybrid			2022-12-25	WOS:000222265400008
J	Kassenbrock, CK; Anderson, SM				Kassenbrock, CK; Anderson, SM			Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; V-CBL; PROTOONCOGENE; RING; DOMAIN; ONCOGENE; COMPLEX	c-Cbl down-regulates receptor tyrosine kinases by conjugating ubiquitin to them, leading to receptor internalization and degradation. The ubiquitin protein ligase activity of c-Cbl ( abbreviated as E3 activity) is mediated by its RING finger domain. We show here that the E3 activity of c-Cbl is negatively regulated by other domains present in the amino-terminal half of the protein ( the TKB and linker helix domains) and that this negative regulation is removed when the protein is phosphorylated on tyrosine residues. Protease digestion studies indicate that tyrosine phosphorylation alters the conformation of c-Cbl. We also show that mutation of certain conserved tyrosine residues to glutamate can constitutively activate the E3 activity of c-Cbl. In particular, a Y371E mutant shows constitutive E3 activity while retaining the ability to bind epidermal growth factor receptor ( EGFR). The Y371E mutant also has altered protease sensitivity from wild type, instead resembling the proteolytic pattern seen with tyrosine-phosphorylated c-Cbl. Mutation of the homologous tyrosine residue in Cbl-b to glutamate also leads to E3 activation while retaining EGFR-binding ability. These studies argue that Tyr-371 plays a key role in activating the E3 activity of c-Cbl and that the Y371E mutant may partially mimic phosphorylation at that site. However, Tyr-371 point mutants of c-Cbl are still able to undergo phosphorylation-induced E3 activation, and we show that Tyr-368 can also be phosphorylated in addition to Tyr-371, and contributes to activation.	Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Anderson, SM (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pathol, Box B-216,4200 E 9th Ave, Denver, CO 80262 USA.	steve.anderson@uchsc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055754] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 53858] Funding Source: Medline; NIGMS NIH HHS [GM 55754] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Bisson SA, 2002, ONCOGENE, V21, P3677, DOI 10.1038/sj.onc.1205510; BLAKE TJ, 1991, ONCOGENE, V6, P653; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Tongaonkar P, 1998, ANAL BIOCHEM, V260, P135, DOI 10.1006/abio.1998.2697; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	29	106	106	4	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28017	28027		10.1074/jbc.M404114200	http://dx.doi.org/10.1074/jbc.M404114200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117950	hybrid			2022-12-25	WOS:000222265400025
J	Bourguignon, LYW; Singleton, PA; Diedrich, F; Stern, R; Gilad, E				Bourguignon, LYW; Singleton, PA; Diedrich, F; Stern, R; Gilad, E			CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ANKYRIN-BINDING DOMAIN; INTRACELLULAR PH; TRANSMEMBRANE GLYCOPROTEIN; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; CHROMOSOME 3P21.3; GENE-EXPRESSION; HYALURONAN; CANCER; RECEPTOR	We have explored CD44 (a hyaluronan (HA) receptor) interaction with a Na+-H+ exchanger (NHE1) and hyaluronidase-2 (Hyal-2) during HA-induced cellular signaling in human breast tumor cells (MDA-MB-231 cell line). Immunological analyses demonstrate that CD44s (standard form) and two signaling molecules (NHE1 and Hyal-2) are closely associated in a complex in MDA-MB-231 cells. These three proteins are also significantly enriched in cholesterol and ganglioside-containing lipid rafts, characterized as caveolin and flotillin-rich plasma membrane microdomains. The binding of HA to CD44 activates Na+-H+ exchange activity which, in turn, promotes intracellular acidification and creates an acidic extracellular matrix environment. This leads to Hyal-2-mediated HA catabolism, HA modification, and cysteine proteinase (cathepsin B) activation resulting in breast tumor cell invasion. In addition, we have observed the following: (i) HA/CD44-activated Rho kinase (ROK) mediates NHE1 phosphorylation and activity, and (ii) inhibition of ROK or NHE1 activity (by treating cells with a ROK inhibitor, Y27632, or NHE1 blocker, S-(N-ethyl-N- isopropyl) amiloride, respectively) blocks NHE1 phosphorylation/Na+-H+ exchange activity, reduces intracellular acidification, eliminates the acidic environment in the extracellular matrix, and suppresses breast tumor-specific behaviors (e.g. Hyal-2-mediated HA modification, cathepsin B activation, and tumor cell invasion). Finally, down-regulation of CD44 or Hyal-2 expression (by treating cells with CD44 or Hyal-2-specific small interfering RNAs) not only inhibits HA-mediated CD44 signaling (e.g. ROK-mediated Na+-H+ exchanger reaction and cellular pH changes) but also impairs oncogenic events (e.g. Hyal-2 activity, hyaluronan modification, cathepsin B activation, and tumor cell invasion). Taken together, our results suggest that CD44 interaction with a ROK-activated NHE1 (a Na+-H+ exchanger) in cholesterol/ganglioside-containing lipid rafts plays a pivotal role in promoting intracellular/extracellular acidification required for Hyal-2 and cysteine proteinase-mediated matrix degradation and breast cancer progression.	Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, Endocrine Unit, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Bourguignon, LYW (corresponding author), Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, 4150 Clement St, San Francisco, CA 94121 USA.	lillyb@itsa.ucsf.edu			NATIONAL CANCER INSTITUTE [R01CA078633, R01CA066163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039448] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA78633, R01 CA66163] Funding Source: Medline; NIAMS NIH HHS [P01 AR39448] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Beech DJ, 2002, J SURG RES, V103, P203, DOI 10.1006/jsre.2002.6351; Bertrand P, 1997, INT J CANCER, V73, P327, DOI 10.1002/(SICI)1097-0215(19971104)73:3<327::AID-IJC4>3.0.CO;2-1; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Bourguignon LYW, 2002, J BIOL CHEM, V277, P39703, DOI 10.1074/jbc.M204320200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; Bourguignon LYW, 2001, J MAMMARY GLAND BIOL, V6, P287, DOI 10.1023/A:1011371523994; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; BOURGUIGNON LYW, 1998, FRONT BIOSCI, V3, P637; BOYER MJ, 1992, CANCER RES, V52, P4441; Bullis BL, 2002, EUR J BIOCHEM, V269, P4887, DOI 10.1046/j.1432-1033.2002.03202.x; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Cherr GN, 2001, MATRIX BIOL, V20, P515, DOI 10.1016/S0945-053X(01)00171-8; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; Csoka AB, 1999, GENOMICS, V60, P356, DOI 10.1006/geno.1999.5876; Csoka TB, 1998, GENOMICS, V48, P63, DOI 10.1006/geno.1997.5158; DALL P, 1995, INT J CANCER, V60, P471, DOI 10.1002/ijc.2910600408; DANILKOVITCHMIA.A, P NATL ACAD SCI US, V100, P4580; DEFIGUEIREDO CEP, 1991, AM J PHYSIOL, V261, pC1138, DOI 10.1152/ajpcell.1991.261.6.C1138; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Diwu ZJ, 1999, CHEM BIOL, V6, P411, DOI 10.1016/S1074-5521(99)80059-3; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P145, DOI 10.1007/BF00132746; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fielding CJ, 2001, ADV DRUG DELIVER REV, V49, P251, DOI 10.1016/S0169-409X(01)00140-5; Flannery CR, 1998, BIOCHEM BIOPH RES CO, V251, P824, DOI 10.1006/bbrc.1998.9561; Frost GI, 2000, ONCOGENE, V19, P870, DOI 10.1038/sj.onc.1203317; Ge LS, 1995, J NEURO-ONCOL, V26, P251, DOI 10.1007/BF01052628; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; GOTTESMAN MM, 1990, SEMIN CANCER BIOL, V1, P127; GUNTHERT U, 1999, J CELL BIOL, V146, P843; HOPKINS DM, 1992, J PATHOL, V166, P317, DOI 10.1002/path.1711660316; IIDA N, 1995, J CELL PHYSIOL, V162, P127, DOI 10.1002/jcp.1041620115; Ilangumaran S, 1998, BLOOD, V91, P3901; Isacke CM, 2002, INT J BIOCHEM CELL B, V34, P718, DOI 10.1016/S1357-2725(01)00166-2; Isshiki M, 1999, CELL CALCIUM, V26, P201, DOI 10.1054/ceca.1999.0073; KALISH ED, 1999, FRONT BIOSCI, V4, P1; KALLINOWSKI F, 1988, CANCER RES, V48, P7264; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; Kasahara K, 2000, GLYCOCONJUGATE J, V17, P153, DOI 10.1023/A:1026576804247; KAUFMANN M, 1995, LANCET, V345, P615, DOI 10.1016/S0140-6736(95)90521-9; Kaya G, 1997, GENE DEV, V11, P996, DOI 10.1101/gad.11.8.996; Knudson W, 2002, MATRIX BIOL, V21, P15, DOI 10.1016/S0945-053X(01)00186-X; KRAYERPAWLOWSKA D, 1991, J MEMBRANE BIOL, V120, P173, DOI 10.1007/BF01872400; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Lepperdinger G, 1998, J BIOL CHEM, V273, P22466, DOI 10.1074/jbc.273.35.22466; Lepperdinger G, 2001, MATRIX BIOL, V20, P509, DOI 10.1016/S0945-053X(01)00170-6; Lerman MI, 2000, CANCER RES, V60, P6116; Li YJ, 2000, AM J RESP CELL MOL, V23, P411, DOI 10.1165/ajrcmb.23.3.4102; LIAO HX, 1995, J IMMUNOL, V155, P3938; Linebaugh BE, 1999, EUR J BIOCHEM, V264, P100, DOI 10.1046/j.1432-1327.1999.00582.x; LIOTTA LA, 1993, CANC PRINCIPLES PRAC, P134; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; MARTIN GR, 1994, CANCER RES, V54, P5670; McCabe JB, 2001, MOL BIOL CELL, V12, P3601, DOI 10.1091/mbc.12.11.3601; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MIN H, 1986, ANAL BIOCHEM, V155, P275, DOI 10.1016/0003-2697(86)90437-9; Montcourrier P, 1997, CLIN EXP METASTAS, V15, P382, DOI 10.1023/A:1018446104071; Nicoll SB, 2002, BIOCHEM BIOPH RES CO, V292, P819, DOI 10.1006/bbrc.2002.6697; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; Novak U, 1999, CANCER RES, V59, P6246; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Rai SK, 2001, P NATL ACAD SCI USA, V98, P4443, DOI 10.1073/pnas.071572898; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Reshkin SJ, 2000, J BIOL CHEM, V275, P5361, DOI 10.1074/jbc.275.8.5361; Scott JE, 2002, BIOMACROMOLECULES, V3, P547, DOI 10.1021/bm010170j; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Sharma P, 2002, SEMIN CELL DEV BIOL, V13, P205, DOI 10.1016/S1084-9521(02)00049-6; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Singleton PA, 2002, CELL MOTIL CYTOSKEL, V53, P293, DOI 10.1002/cm.10078; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Strobl B, 1998, GENOMICS, V53, P214, DOI 10.1006/geno.1998.5472; STUBBS M, 1995, ADV ENZYME REGUL, V35, P101, DOI 10.1016/0065-2571(94)00016-V; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; Sy Man-Sun, 1997, Current Opinion in Oncology, V9, P108; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Tammi R, 2001, J BIOL CHEM, V276, P35111, DOI 10.1074/jbc.M103481200; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; VanNoorden CJF, 1997, ANAL BIOCHEM, V252, P71, DOI 10.1006/abio.1997.2312; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Webb SD, 1999, J THEOR BIOL, V196, P237, DOI 10.1006/jtbi.1998.0836; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WINKEL GK, 1993, J BIOL CHEM, V268, P3396; Yamagata M, 1998, BRIT J CANCER, V77, P1726, DOI 10.1038/bjc.1998.289; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; Zhu D, 2000, J CELL PHYSIOL, V183, P182, DOI 10.1002/(SICI)1097-4652(200005)183:2<182::AID-JCP5>3.0.CO;2-O; Zhu D, 1998, CELL MOTIL CYTOSKEL, V39, P209, DOI 10.1002/(SICI)1097-0169(1998)39:3<209::AID-CM4>3.0.CO;2-#	103	340	349	3	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26991	27007		10.1074/jbc.M311838200	http://dx.doi.org/10.1074/jbc.M311838200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15090545	hybrid			2022-12-25	WOS:000222120400025
J	Gandlur, SM; Wei, L; Levine, J; Russell, J; Kaur, P				Gandlur, SM; Wei, L; Levine, J; Russell, J; Kaur, P			Membrane topology of the DrrB protein of the doxorubicin transporter of Streptomyces peucetius	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ABC TRANSPORTERS; P-GLYCOPROTEIN; LACZ FUSIONS; GENE; RESISTANCE; IDENTIFICATION; EXPRESSION; COMPONENT; BACTERIA	Daunorubicin and doxorubicin, two commonly used anticancer agents, are produced by the soil bacterium Streptomyces peucetius. Self-resistance to these antibiotics in S. peucetius is conferred by the drrAB locus that codes for two proteins, DrrA and DrrB. DrrA is an ATP-binding protein. It belongs to the ABC family of transporters and shares sequence and functional similarities with P-glycoprotein of cancer cells. DrrB is an integral membrane protein that might function as a transporter for the efflux of daunorubicin and doxorubicin. Together, DrrA and DrrB are believed to form an ATP-driven pump for the efflux of these drugs. The drrAB locus has been cloned, and the two proteins have been expressed in a functional form in Escherichia coli. A topological analysis of the DrrB protein was performed using gene fusion methodology. Random and site-directed fusions of the drrB gene to lacZ, phoA, or gfp reporter genes were created. Based on the fusion data, a topological model of the DrrB protein is proposed in which the protein has eight membrane-spanning domains with both the N terminus and the C terminus in the cytoplasm.	Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA	University System of Georgia; Georgia State University	Kaur, P (corresponding author), Georgia State Univ, Dept Biol, POB 4010, Atlanta, GA 30303 USA.	pkaur@gsu.edu						BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; DiGiuseppe PA, 2004, ASM NEWS, V70, P71; Drew D, 2002, P NATL ACAD SCI USA, V99, P2690, DOI 10.1073/pnas.052018199; EVANS IJ, 1986, GENE, V43, P95, DOI 10.1016/0378-1119(86)90012-0; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; FROSCH M, 1991, MOL MICROBIOL, V5, P1251, DOI 10.1111/j.1365-2958.1991.tb01899.x; Fulkerson JF, 2000, J BACTERIOL, V182, P1722, DOI 10.1128/JB.182.6.1722-1730.2000; GENTSCHEV I, 1992, MOL GEN GENET, V232, P40, DOI 10.1007/BF00299135; Gileadi U, 1997, J BIOL CHEM, V272, P11103; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GUILFOILE PG, 1991, P NATL ACAD SCI USA, V88, P8553, DOI 10.1073/pnas.88.19.8553; Haardt M, 1996, J BACTERIOL, V178, P5370, DOI 10.1128/jb.178.18.5370-5381.1996; Kaur P, 1997, J BACTERIOL, V179, P569, DOI 10.1128/jb.179.3.569-575.1997; Kaur P, 1998, J BIOL CHEM, V273, P17933, DOI 10.1074/jbc.273.28.17933; KROLL JS, 1990, J BACTERIOL, V172, P1374, DOI 10.1128/jb.172.3.1374-1379.1990; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MARULLO S, 1988, P NATL ACAD SCI USA, V85, P7551, DOI 10.1073/pnas.85.20.7551; MILLER RL, 1972, ANAL BIOCHEM, V45, P202, DOI 10.1016/0003-2697(72)90020-6; Olano C, 1996, FEMS MICROBIOL LETT, V143, P133; PAVELKA MS, 1991, J BACTERIOL, V173, P4603, DOI 10.1128/jb.173.15.4603-4610.1991; PEARCE SR, 1992, MOL MICROBIOL, V6, P47, DOI 10.1111/j.1365-2958.1992.tb00836.x; REIZER J, 1992, PROTEIN SCI, V1, P1326, DOI 10.1002/pro.5560011012; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; SMITH AN, 1990, MOL MICROBIOL, V4, P1863, DOI 10.1111/j.1365-2958.1990.tb02035.x; SNYDER WB, 1995, J BACTERIOL, V177, P953, DOI 10.1128/jb.177.4.953-963.1995; SOLOMON KA, 1989, J BACTERIOL, V171, P3039, DOI 10.1128/jb.171.6.3039-3045.1989; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509	33	30	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27799	27806		10.1074/jbc.M402898200	http://dx.doi.org/10.1074/jbc.M402898200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15090538	hybrid			2022-12-25	WOS:000222120400115
J	Li, Z; Chan, C				Li, Z; Chan, C			Integrating gene expression and metabolic profiles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEAST-SQUARES REGRESSION; FATTY-ACID SYNTHASE; CULTURED-HEPATOCYTES; FLUX ANALYSIS; PLASMA; PROMOTER; ENZYMES; INSULIN; CYCLE; UREA	Recent advances in high throughput technologies have generated an abundance of biological information, such as gene expression, protein-protein interaction, and metabolic data. These various types of data capture different aspects of the cellular response to environmental factors. Integrating data from different measurements enhances the ability of modeling frameworks to predict cellular function more accurately and can lead to a more coherent reconstruction of the underlying regulatory network structure. Different techniques, newly developed and borrowed, have been applied for the purpose of extracting this information from experimental data. In this study, we developed a framework to integrate metabolic and gene expression profiles for a hepatocellular system. Specifically, we applied genetic algorithm and partial least square analysis to identify important genes relevant to a specific cellular function. We identified genes 1) whose expression levels quantitatively predict a metabolic function and 2) that play a part in regulating a hepatocellular function and reconstructed their role in the metabolic network. The framework 1) preprocesses the gene expression data using statistical techniques, 2) selects genes using a genetic algorithm and couples them to a partial least squares analysis to predict cellular function, and 3) reconstructs, with the assistance of a literature search, the pathways that regulate cellular function, namely intracellular triglyceride and urea synthesis. This provides a framework for identifying cellular pathways that are active as a function of the environment and in turn helps to uncover the interplay between gene and metabolic networks.	Michigan State Univ, Dept Clin Engn & Mat Sci, E Lansing, MI 48824 USA	Michigan State University	Chan, C (corresponding author), Michigan State Univ, Dept Clin Engn & Mat Sci, 1257 EB, E Lansing, MI 48824 USA.	krischan@egr.msu.edu						Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; Bangalore AS, 1996, ANAL CHEM, V68, P4200, DOI 10.1021/ac9607121; Chan C, 2003, BIOTECHNOL BIOENG, V81, P33, DOI 10.1002/bit.10453; Chan C, 2003, METAB ENG, V5, P1, DOI 10.1016/S1096-7176(02)00011-3; Chan C, 2003, BIOTECHNOL PROGR, V19, P580, DOI 10.1021/bp025660h; Chan C, 2002, BIOTECHNOL BIOENG, V78, P753, DOI 10.1002/bit.10275; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fellenberg K, 2001, P NATL ACAD SCI USA, V98, P10781, DOI 10.1073/pnas.181597298; GELADI P, 1986, ANAL CHIM ACTA, V185, P1, DOI 10.1016/0003-2670(86)80028-9; Goldberg D. E., 1989, GENETIC ALGORITHMS S; Holland J.H., 1992, ADAPTATION NATURAL A; HOUCK C, 1995, 9509 N CAR STAT U; Idris I, 2001, DIABETOLOGIA, V44, P659, DOI 10.1007/s001250051675; IZPISUA JC, 1989, INT J OBESITY, V13, P531; Leardi R, 2000, J CHEMOMETR, V14, P643, DOI 10.1002/1099-128X(200009/12)14:5/6<643::AID-CEM621>3.0.CO;2-E; Li Z, 2004, FASEB J, V18, P746, DOI 10.1096/fj.03-0475fje; LI Z, 2004, IN PRESS TRENDS BIOT; Liang S, 1998, Pac Symp Biocomput, P18; Loew LM, 2001, TRENDS BIOTECHNOL, V19, P401, DOI 10.1016/S0167-7799(01)01740-1; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; MARTINREQUERO A, 1992, AM J PHYSIOL, V263, pE493, DOI 10.1152/ajpendo.1992.263.3.E493; MEIJER AJ, 1990, PHYSIOL REV, V70, P701, DOI 10.1152/physrev.1990.70.3.701; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; Morris SM, 2002, ANNU REV NUTR, V22, P87, DOI 10.1146/annurev.nutr.22.110801.140547; Nakao, 1999, Genome Inform Ser Workshop Genome Inform, V10, P94; Roder K, 1999, EUR J BIOCHEM, V260, P743, DOI 10.1046/j.1432-1327.1999.00216.x; Smith SA, 2002, BIOCHEM SOC T, V30, P1086, DOI 10.1042/BST0301086; van Helden J, 2000, BIOL CHEM, V381, P921; Xie ZJ, 2002, EUR J BIOCHEM, V269, P2434, DOI 10.1046/j.1432-1033.2002.02910.x	29	24	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27124	27137		10.1074/jbc.M403494200	http://dx.doi.org/10.1074/jbc.M403494200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15107427	hybrid			2022-12-25	WOS:000222120400039
J	Kim, J; Lee, J; Yadav, N; Wu, Q; Carter, C; Richard, S; Richie, E; Bedford, MT				Kim, J; Lee, J; Yadav, N; Wu, Q; Carter, C; Richard, S; Richie, E; Bedford, MT			Loss of CARM1 results in hypomethylation of thymocyte cyclic AMP-regulated phosphoprotein and deregulated early T cell development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE N-METHYLTRANSFERASE; PROTEIN METHYLTRANSFERASE; SUBSTRATE-SPECIFICITY; IN-VIVO; METHYLATION; EXPRESSION; BINDING; GENE; RNA; SELECTION	The coactivator-associated arginine methyltransferase, CARM1, is a positive regulator of transcription. Using high density protein arrays, we have previously identified in vitro substrates for CARM1. One of these substrates, TARPP (thymocyte cyclic AMP-regulated phosphoprotein), is expressed specifically in immature thymocytes. Here, we have demonstrated that TARPP is arginine-methylated at a single residue, Arg(650), both in vitro and in vivo. In addition, recombinant TARPP is not methylated by extracts from Carm1(-/-) cells, indicating that there is no redundancy in this pathway. We show that thymi from Carm1(-/-) embryos (E18.5) have a 5-10-fold reduction in cellularity compared with wild type littermates. Flow cytometric analysis of thymocytes revealed a decrease in the relative proportion of double negative thymocytes in Carm1(-/-) embryos because of a partial developmental arrest in the earliest thymocyte progenitor subset. These results demonstrate that CARM1 plays a significant role in promoting the differentiation of early thymocyte progenitors, possibly through its direct action on TARPP.	Univ Texas, MD Anderson Hosp & Tumor Inst, Ctr Canc, Sci Pk Res Div, Smithville, TX 78957 USA; McGill Univ, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	University of Texas System; UTMD Anderson Cancer Center; Lady Davis Institute; McGill University	Bedford, MT (corresponding author), Univ Texas, MD Anderson Hosp & Tumor Inst, Ctr Canc, Sci Pk Res Div, Smithville, TX 78957 USA.	mtbedford@mdanderson.org	Bedford, Mark T/E-7856-2011	Richie, Ellen/0000-0003-0786-973X	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK062248, R01DK062248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline; NIDDK NIH HHS [DK62248-01] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anderson G, 2001, NAT REV IMMUNOL, V1, P31, DOI 10.1038/35095500; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Bussow K, 1998, NUCLEIC ACIDS RES, V26, P5007, DOI 10.1093/nar/26.21.5007; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chevillard-Briet M, 2002, EMBO J, V21, P5457, DOI 10.1093/emboj/cdf548; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; Frankel A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/jbc.M108786200; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; Gill J, 2003, IMMUNOL REV, V195, P28, DOI 10.1034/j.1600-065X.2003.00077.x; GODFREY DI, 1993, J IMMUNOL, V150, P4244; Grishin NV, 1998, TRENDS BIOCHEM SCI, V23, P329, DOI 10.1016/S0968-0004(98)01258-4; Henry MF, 1996, MOL CELL BIOL, V16, P3668; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; Kisielow J, 2001, EUR J IMMUNOL, V31, P1141, DOI 10.1002/1521-4141(200104)31:4<1141::AID-IMMU1141>3.0.CO;2-R; Lee J, 2002, EMBO REP, V3, P268, DOI 10.1093/embo-reports/kvf052; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; Li HW, 2002, J BIOL CHEM, V277, P44623, DOI 10.1074/jbc.M206187200; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LIU Q, 1995, MOL CELL BIOL, V15, P2800; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; McMurry MT, 2000, SCIENCE, V287, P495, DOI 10.1126/science.287.5452.495; Michie AM, 2002, SEMIN IMMUNOL, V14, P311, DOI 10.1016/S1044-5323(02)00064-7; PENIT C, 1995, J IMMUNOL, V154, P5103; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; Reizis B, 1999, J EXP MED, V189, P1669, DOI 10.1084/jem.189.10.1669; Rodewald HR, 1998, ADV IMMUNOL, V69, P1, DOI 10.1016/S0065-2776(08)60606-9; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; Shortman K, 1996, ANNU REV IMMUNOL, V14, P29, DOI 10.1146/annurev.immunol.14.1.29; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Yadav N, 2003, P NATL ACAD SCI USA, V100, P6464, DOI 10.1073/pnas.1232272100; ZunigaPflucker JC, 1996, CURR OPIN IMMUNOL, V8, P215, DOI 10.1016/S0952-7915(96)80060-4	37	84	86	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25339	25344		10.1074/jbc.M402544200	http://dx.doi.org/10.1074/jbc.M402544200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15096520	hybrid			2022-12-25	WOS:000221827900055
J	Sierra, OL; Cheng, SL; Loewy, AP; Charlton-Kachigian, N; Towler, DA				Sierra, OL; Cheng, SL; Loewy, AP; Charlton-Kachigian, N; Towler, DA			MINT, the Msx2 interacting nuclear matrix target, enhances Runx2-dependent activation of the osteocalcin fibroblast growth factor response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; BONE MORPHOGENETIC PROTEINS; TRANSCRIPTION FACTOR; OSTEOBLAST DIFFERENTIATION; GENE-EXPRESSION; SIGNALING PATHWAY; VASCULAR CALCIFICATION; HOMEODOMAIN PROTEINS; BINDING-PROTEIN; TERMINAL DOMAIN	Msx2 promotes osteogenic lineage allocation from mesenchymal progenitors but inhibits terminal differentiation demarcated by osteocalcin (OC) gene expression. Msx2 inhibits OC expression by targeting the fibroblast growth factor responsive element (OCFRE), a 42-bp DNA domain in the OC gene bound by the Msx2 interacting nuclear target protein (MINT) and Runx2/Cbfa1. To better understand Msx2 regulation of the OCFRE, we have studied functional interactions between MINT and Runx2, a master regulator of osteoblast differentiation. In MC3T3E1 osteoblasts ( with endogenous Runx2 and FGFR2), MINT augments transcription driven by the OCFRE that is further enhanced by FGF2 treatment. OCFRE regulation can be reconstituted in the naive CV1 fibroblast cell background. In CV1 cells, MINT synergizes with Runx2 to enhance OCFRE activity in the presence of activated FGFR2. The RNA recognition motif domain of MINT ( which binds the OCFRE) is required. Runx2 structural studies reveal that synergy with MINT uniquely requires Runx2 activation domain 3. In confocal immunofluorescence microscopy, MINT adopts a reticular nuclear matrix distribution that overlaps transcriptionally active osteoblast chromatin, extensively co-localizing with the phosphorylated RNA polymerase II meshwork. MINT only partially co-localizes with Runx2; however, co-localization is enhanced 2.5-fold by FGF2 stimulation. Msx2 abrogates Runx2-MINT OCFRE activation, and MINT-directed RNA interference reduces endogenous OC expression. In chromatin immunoprecipitation assays, Msx2 selectively inhibits Runx2 binding to OC chromatin. Thus, MINT enhances Runx2 activation of multiprotein complexes assembled by the OCFRE. Msx2 targets this complex as a mechanism of transcriptional inhibition. In osteoblasts, MINT may serve as a nuclear matrix platform that organizes and integrates osteogenic transcriptional responses.	Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Internal Med,Div Bone & Mineral Dis, St Louis, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL)	Towler, DA (corresponding author), Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Internal Med,Div Bone & Mineral Dis, North Campus Box 8301,660 S Euclid Ave, St Louis, MO 63110 USA.	dtowler@im.wustl.edu		Towler, Dwight/0000-0003-2107-7923	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043731] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43731] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bidder M, 1998, J BONE MINER RES, V13, P609, DOI 10.1359/jbmr.1998.13.4.609; Bidwell JP, 1998, J BONE MINER RES, V13, P155, DOI 10.1359/jbmr.1998.13.2.155; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200; Cohen MM, 2000, J CRAN GENET DEV BIO, V20, P19; Demer LL, 2003, ARTERIOSCL THROM VAS, V23, P1739, DOI 10.1161/01.ATV.0000093547.63630.0F; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Franceschi RT, 2003, CALCIFIED TISSUE INT, V72, P638, DOI 10.1007/s00223-002-1053-2; Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Garcia-Minaur S, 2003, EUR J HUM GENET, V11, P892, DOI 10.1038/sj.ejhg.5201062; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; Goodman RH, 2000, GENE DEV, V14, P1553; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; Hawkins SM, 2001, J BIOL CHEM, V276, P44472, DOI 10.1074/jbc.M104193200; HOFFMANN HM, 1994, P NATL ACAD SCI USA, V91, P12887, DOI 10.1073/pnas.91.26.12887; Karsenty G, 2001, ENDOCRINOLOGY, V142, P2731, DOI 10.1210/en.142.7.2731; Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654; Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050; Kuroda K, 2003, IMMUNITY, V18, P301, DOI 10.1016/S1074-7613(03)00029-3; Lin PS, 2002, J BIOL CHEM, V277, P45949, DOI 10.1074/jbc.M208588200; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; Miller J, 2002, NAT GENET, V32, P645, DOI 10.1038/ng1049; Mo XM, 2002, MOL CELL BIOL, V22, P8088, DOI 10.1128/MCB.22.22.8088-8099.2002; Newberry EP, 1997, BIOCHEMISTRY-US, V36, P10451, DOI 10.1021/bi971008x; Newberry EP, 1999, BIOCHEMISTRY-US, V38, P10678, DOI 10.1021/bi990967j; Newberry EP, 1997, J BIOL CHEM, V272, P29607, DOI 10.1074/jbc.272.47.29607; Newberry EP, 1996, MOL ENDOCRINOL, V10, P1029, DOI 10.1210/me.10.8.1029; Newberry EP, 1998, BIOCHEMISTRY-US, V37, P16360, DOI 10.1021/bi981878u; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; ONATE SA, 1995, SCIENCE, V270, P1354; Oswald F, 2002, EMBO J, V21, P5417, DOI 10.1093/emboj/cdf549; Rebay I, 2000, GENETICS, V154, P695; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Shannon MF, 2003, NAT GENET, V34, P4, DOI 10.1038/ng0503-4; Shao JS, 2003, J BIOL CHEM, V278, P50195, DOI 10.1074/jbc.M308825200; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Shirakabe K, 2001, GENES CELLS, V6, P851, DOI 10.1046/j.1365-2443.2001.00466.x; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Verschure PJ, 1999, J CELL BIOL, V147, P13, DOI 10.1083/jcb.147.1.13; Wee HJ, 2002, EMBO REP, V3, P967, DOI 10.1093/embo-reports/kvf193; Wiellette EL, 1999, DEVELOPMENT, V126, P5373; Wilkie AOM, 2000, NAT GENET, V24, P387, DOI 10.1038/74224; Willis DM, 2002, J BIOL CHEM, V277, P37280, DOI 10.1074/jbc.M206482200; Woodard RL, 1999, J BIOL CHEM, V274, P478, DOI 10.1074/jbc.274.1.478; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200; Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084; Yu K, 2000, P NATL ACAD SCI USA, V97, P14536, DOI 10.1073/pnas.97.26.14536; Zaidi SK, 2001, J CELL SCI, V114, P3093; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585	57	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32913	32923		10.1074/jbc.M314098200	http://dx.doi.org/10.1074/jbc.M314098200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15131132	hybrid			2022-12-25	WOS:000222849700111
J	Pal, S; Nemeth, MJ; Bodine, D; Miller, JL; Svaren, J; Thein, SL; Lowry, PJ; Bresnick, EH				Pal, S; Nemeth, MJ; Bodine, D; Miller, JL; Svaren, J; Thein, SL; Lowry, PJ; Bresnick, EH			Neurokinin-B transcription in erythroid cells - Direct activation by the hematopoietic transcription factor GATA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-K RECEPTOR; DNA-BINDING; EXPRESSION; GENE; DIFFERENTIATION; IDENTIFICATION; SPECIFICITY; PROMOTER; DOMAIN; FETAL	The GATA family of transcription factors establishes genetic networks that control developmental processes including hematopoiesis, vasculogenesis, and cardiogenesis. We found that GATA-1 strongly activates transcription of the Tac-2 gene, which encodes proneurokinin-B, a precursor of neurokinin-B (NK-B). Neurokinins function through G protein-coupled transmembrane receptors to mediate diverse physiological responses including pain perception and the control of vascular tone. Whereas an elevated level of NK-B was implicated in pregnancy-associated pre-eclampsia ( Page, N. M., Woods, R. J., Gardiner, S. M., Lomthaisong, K., Gladwell, R. T., Butlin, D. J., Manyonda, I. T., and Lowry, P. J. ( 2000) Nature 405, 797 - 800), the regulation of NK-B synthesis and function are poorly understood. Tac-2 was expressed in normal murine erythroid cells and was induced upon ex vivo erythropoiesis. An estrogen receptor fusion to GATA-1 (ER-GATA-1) and endogenous GATA-1 both occupied a region of Tac-2 intron-7, which contains two conserved GATA motifs. Genetic complementation analysis in GATA-1-null G1E cells revealed that endogenous GATA-2 occupied the same region of intron-7, and expression of ER-GATA-1 displaced GATA-2 and activated Tac-2 transcription. Erythroid cells did not express neurokinin receptors, whereas aortic and yolk sac endothelial cells differentially expressed neurokinin receptor subtypes. Since NK-B induced cAMP accumulation in yolk sac endothelial cells, these results suggest a new mode of vascular regulation in which GATA-1 controls NK-B synthesis in erythroid cells.	Univ Wisconsin, Sch Med, Dept Pharmacol, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA; NHGI, NIH, Bethesda, MD 20892 USA; NIDDK, NIH, Bethesda, MD 20892 USA; Hematol Med, London SE5 9PJ, England; Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA; Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England	University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of London; King's College London; University of Wisconsin System; University of Wisconsin Madison; University of Reading	Bresnick, EH (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, Mol & Cellular Pharmacol Program, 1300 Univ Ave,383 Med Sci Ctr, Madison, WI 53706 USA.	ehbresni@wisc.edu	Svaren, John/A-1605-2010	Svaren, John/0000-0003-2963-7921	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000197, Z01HG000083, ZIAHG000083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK025089, R01DK055700, R01DK050107] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55700, DK50107] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; Brownbill P, 2003, J CLIN ENDOCR METAB, V88, P2164, DOI 10.1210/jc.2002-021727; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Cantor AB, 2002, MOL CELL BIOL, V22, P4268, DOI 10.1128/MCB.22.12.4268-4279.2002; Chi JT, 2003, P NATL ACAD SCI USA, V100, P10623, DOI 10.1073/pnas.1434429100; Cintado CG, 2001, J PHARMACOL EXP THER, V299, P934; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; CROSSLEY M, 1994, J BIOL CHEM, V269, P15440; DORLEANSJUSTE P, 1991, EUR J PHARMACOL, V204, P329, DOI 10.1016/0014-2999(91)90860-S; Eszterhas SK, 2002, MOL CELL BIOL, V22, P469, DOI 10.1128/MCB.22.2.469-479.2002; Fujiwara Y, 2004, BLOOD, V103, P583, DOI 10.1182/blood-2003-08-2870; GERARD NP, 1990, J BIOL CHEM, V265, P20455; Grass JA, 2003, P NATL ACAD SCI USA, V100, P8811, DOI 10.1073/pnas.1432147100; GREENO EW, 1993, J EXP MED, V177, P1269, DOI 10.1084/jem.177.5.1269; GUMKOWSKI F, 1987, BLOOD VESSELS, V24, P11; Hirasawa R, 2002, J EXP MED, V195, P1379, DOI 10.1084/jem.20020170; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; Ho M, 2003, PHYSIOL GENOMICS, V13, P249, DOI 10.1152/physiolgenomics.00186.2002; Im Hogune, 2004, Methods Mol Biol, V284, P129; INGI T, 2001, J PHARMACOL EXP THER, V259, P968; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Joshi DD, 2001, BLOOD, V98, P2697, DOI 10.1182/blood.V98.9.2697; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KOTANI H, 1986, P NATL ACAD SCI USA, V83, P7074, DOI 10.1073/pnas.83.18.7074; Letting DL, 2004, P NATL ACAD SCI USA, V101, P476, DOI 10.1073/pnas.0306315101; Letting DL, 2003, MOL CELL BIOL, V23, P1334, DOI 10.1128/MCB.23.4.1334-1340.2003; Lu LS, 1996, P NATL ACAD SCI USA, V93, P14782, DOI 10.1073/pnas.93.25.14782; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P7976, DOI 10.1073/pnas.94.15.7976; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; Minami T, 2004, ARTERIOSCL THROM VAS, V24, P41, DOI 10.1161/01.ATV.0000099880.09014.7D; Minegishi N, 2003, BLOOD, V102, P896, DOI 10.1182/blood-2002-12-3809; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; Nardelli J, 1999, DEV BIOL, V210, P305, DOI 10.1006/dbio.1999.9278; NUDEL U, 1977, P NATL ACAD SCI USA, V74, P1100, DOI 10.1073/pnas.74.3.1100; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; Page NM, 2000, NATURE, V405, P797, DOI 10.1038/35015579; Page NM, 2001, REGUL PEPTIDES, V98, P97, DOI 10.1016/S0167-0115(00)00239-1; Pai SY, 2004, P NATL ACAD SCI USA, V101, P1993, DOI 10.1073/pnas.0308697100; Pal S, 2004, P NATL ACAD SCI USA, V101, P980, DOI 10.1073/pnas.0307612100; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Pedersen KE, 2000, J PHARMACOL EXP THER, V292, P319; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Rylski M, 2003, MOL CELL BIOL, V23, P5031, DOI 10.1128/MCB.23.14.5031-5042.2003; Severini C, 2002, PHARMACOL REV, V54, P285, DOI 10.1124/pr.54.2.285; Shirahase H, 2000, BRIT J PHARMACOL, V129, P937, DOI 10.1038/sj.bjp.0703140; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Surinya KH, 1998, J BIOL CHEM, V273, P16798, DOI 10.1074/jbc.273.27.16798; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Svaren J, 1998, EMBO J, V17, P6010, DOI 10.1093/emboj/17.20.6010; Svaren J, 1997, GENOMICS, V41, P33, DOI 10.1006/geno.1997.4609; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tufarelli C, 2003, NAT GENET, V34, P157, DOI 10.1038/ng1157; Vyas P, 1999, DEVELOPMENT, V126, P2799; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; Wojda U, 2002, BLOOD, V99, P3005, DOI 10.1182/blood.V99.8.3005.h8003005_3005_3013; Yu CN, 2002, J EXP MED, V195, P1387, DOI 10.1084/jem.20020656; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	68	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31348	31356		10.1074/jbc.M403475200	http://dx.doi.org/10.1074/jbc.M403475200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15123623	hybrid			2022-12-25	WOS:000222726800055
J	Kanzaki, M; Furukawa, M; Raab, W; Pessin, JE				Kanzaki, M; Furukawa, M; Raab, W; Pessin, JE			Phosphatidylinositol 4,5-bisphosphate regulates adipocyte actin dynamics and GLUT4 vesicle recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							RECEPTOR-MEDIATED ENDOCYTOSIS; GLUCOSE-TRANSPORTER GLUT4; CLATHRIN-COATED PITS; PLECKSTRIN HOMOLOGY DOMAINS; ISOLATED RAT ADIPOCYTES; LIPID KINASE FAMILY; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; N-WASP; GOLGI-COMPLEX	To investigate the potential role of phosphatidylinositol 4, 5-bisphosphate (PI(4,5)P-2) in the regulation of actin polymerization and GLUT4 translocation, the type I phosphatidylinositol 4-phosphate 5-kinases (PIP5Ks) were expressed in 3T3L1 adipocytes. In preadipocytes (fibroblasts) PIP5K expression promoted actin polymerization on membrane-bound vesicles to form motile actin comets. In contrast, expression of PIP5K in differentiated 3T3L1 adipocytes resulted in the formation of enlarged vacuole-like structures coated with F-actin, cortactin, dynamin, and N-WASP. Treatment with either latrunculin B (an inhibitor for actin polymerization) or Clostridium difficile toxin B (a general Rho family inhibitor) resulted in a relatively slower disappearance of coated F-actin from these vacuoles, but the vacuoles themselves remained unaffected. Functionally, the increased PI(4,5) P2 levels resulted in an inhibition of transferrin receptor and GLUT4 endocytosis and a slow accumulation of these proteins in the PI(4,5)P-2-enriched vacuoles along with the non-clathrin-derived endosome marker (caveolin) and the AP-2 adaptor complex. However, these structures were devoid of early endosome markers (EEA1, clathrin) and the biosynthetic membrane secretory machinery markers p115 (Golgi) and syntaxin 6 (trans-Golgi Network). Taken together, these data demonstrate that PI(4,5) P2 has distinct morphologic and functional properties depending upon specific cell context. In adipocytes, altered PI(4,5) P2 metabolism has marked effects on GLUT4 endocytosis and intracellular vesicle trafficking due to the derangement of actin dynamics.	SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kanzaki, M (corresponding author), Tohoku Univ, Biomed Engn Res Org, Grad Sch Med, Aoba Ku, Bldg 1,2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	kanzaki@tubero.tohoku.ac.jp	Kanzaki, Makoto/H-6680-2017	Kanzaki, Makoto/0000-0002-6884-2955	NIDDK NIH HHS [DK59291, DK33823] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033823, R01DK059291, R01DK033823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aikawa Y, 2003, J CELL BIOL, V162, P647, DOI 10.1083/jcb.200212142; Barbieri MA, 2001, J BIOL CHEM, V276, P47212, DOI 10.1074/jbc.C100490200; Benesch S, 2002, J BIOL CHEM, V277, P37771, DOI 10.1074/jbc.M204145200; Bogan JS, 1999, J CELL BIOL, V146, P609, DOI 10.1083/jcb.146.3.609; Bose A, 2001, MOL CELL BIOL, V21, P5262, DOI 10.1128/MCB.21.15.5262-5275.2001; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Cremona O, 2001, J CELL SCI, V114, P1041; CZECH MP, 1993, J BIOL CHEM, V268, P9187; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; di Campli A, 1999, CELL MOTIL CYTOSKEL, V43, P334, DOI 10.1002/(SICI)1097-0169(1999)43:4<334::AID-CM6>3.0.CO;2-3; Doughman RL, 2003, J MEMBRANE BIOL, V194, P77, DOI 10.1007/s00232-003-2027-7; Eitzen G, 2002, J CELL BIOL, V158, P669, DOI 10.1083/jcb.200204089; Emoto M, 2001, J BIOL CHEM, V276, P10677, DOI 10.1074/jbc.M010785200; Fletcher LM, 2000, BIOCHEM J, V352, P267, DOI 10.1042/0264-6021:3520267; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Galiano FJ, 2002, J CELL BIOCHEM, V85, P131, DOI 10.1002/jcb.10100; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Hellsten E, 2002, BIOL REPROD, V66, P1522, DOI 10.1095/biolreprod66.5.1522; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Imamura T, 1999, J BIOL CHEM, V274, P33691, DOI 10.1074/jbc.274.47.33691; Imamura T, 1999, MOL CELL BIOL, V19, P6765; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Jahraus A, 2001, MOL BIOL CELL, V12, P155, DOI 10.1091/mbc.12.1.155; James DJ, 2004, J BIOL CHEM, V279, P20567, DOI 10.1074/jbc.C400096200; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; JOUNEAUX C, 1994, J BIOL CHEM, V269, P1845; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kanzaki M, 2002, MOL BIOL CELL, V13, P2334, DOI 10.1091/mbc.01-10-0490; Kanzaki M, 2002, J BIOL CHEM, V277, P25867, DOI 10.1074/jbc.C200292200; Kanzaki M, 2000, J BIOL CHEM, V275, P7167, DOI 10.1074/jbc.275.10.7167; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Kanzaki M, 2001, J BIOL CHEM, V276, P49331, DOI 10.1074/jbc.M109657200; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kessels MM, 2002, EMBO J, V21, P6083, DOI 10.1093/emboj/cdf604; Khayat ZA, 2000, J CELL SCI, V113, P279; Krauss M, 2003, J CELL BIOL, V162, P113, DOI 10.1083/jcb.200301006; Krueger EW, 2003, MOL BIOL CELL, V14, P1085, DOI 10.1091/mbc.E02-08-0466; Kwik J, 2003, P NATL ACAD SCI USA, V100, P13964, DOI 10.1073/pnas.2336102100; Lampson MA, 2001, MOL BIOL CELL, V12, P3489, DOI 10.1091/mbc.12.11.3489; Lawrence JTR, 2003, P NATL ACAD SCI USA, V100, P13320, DOI 10.1073/pnas.2232129100; Lawrence JTR, 2001, MOL CELL BIOL, V21, P5276, DOI 10.1128/MCB.21.15.5276-5285.2001; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; Lin HC, 1997, J BIOL CHEM, V272, P25999, DOI 10.1074/jbc.272.41.25999; Liu LB, 2003, J BIOL CHEM, V278, P30157, DOI 10.1074/jbc.M301511200; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Luna A, 2002, MOL BIOL CELL, V13, P866, DOI 10.1091/mbc.01-12-0579; Mao YX, 2001, CELL, V104, P433, DOI 10.1016/S0092-8674(01)00230-6; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Mizutani K, 2004, BIOCHEM BIOPH RES CO, V313, P468, DOI 10.1016/j.bbrc.2003.11.139; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; Musch A, 2001, EMBO J, V20, P2171, DOI 10.1093/emboj/20.9.2171; Naslavsky N, 2003, MOL BIOL CELL, V14, P417, DOI 10.1091/mbc.02-04-0053; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; OKADA T, 1994, J BIOL CHEM, V269, P3568; Olson AL, 2001, J BIOL CHEM, V276, P10706, DOI 10.1074/jbc.M007610200; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Padron D, 2003, J CELL BIOL, V162, P693, DOI 10.1083/jcb.200302051; Patki V, 2001, MOL BIOL CELL, V12, P129, DOI 10.1091/mbc.12.1.129; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Powelka AM, 2004, TRAFFIC, V5, P20, DOI 10.1111/j.1600-0854.2004.00150.x; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Qualmann B, 2002, INT REV CYTOL, V220, P93; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rohde G, 2002, J CELL BIOL, V158, P209, DOI 10.1083/jcb.200203103; Ros-Baro A, 2001, P NATL ACAD SCI USA, V98, P12050, DOI 10.1073/pnas.211341698; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Rudich A, 2003, ACTA PHYSIOL SCAND, V178, P297, DOI 10.1046/j.1365-201X.2003.01163.x; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; Schafer DA, 2002, CURR BIOL, V12, P1852, DOI 10.1016/S0960-9822(02)01228-9; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Shigematsu S, 2003, J BIOL CHEM, V278, P10683, DOI 10.1074/jbc.M208563200; Shigematsu S, 2002, MOL ENDOCRINOL, V16, P1060, DOI 10.1210/me.16.5.1060; Singh RD, 2003, MOL BIOL CELL, V14, P3254, DOI 10.1091/mbc.E02-12-0809; Stamnes M, 2002, CURR OPIN CELL BIOL, V14, P428, DOI 10.1016/S0955-0674(02)00349-6; Suetsugu S, 2003, J BIOL CHEM, V278, P42515, DOI 10.1074/jbc.M302177200; Takenawa T, 2001, BBA-MOL CELL BIOL L, V1533, P190, DOI 10.1016/S1388-1981(01)00165-2; Tebar F, 1999, MOL BIOL CELL, V10, P2687, DOI 10.1091/mbc.10.8.2687; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; Valderrama F, 2001, TRAFFIC, V2, P717, DOI 10.1034/j.1600-0854.2001.21006.x; Valderrama F, 1998, EUR J CELL BIOL, V76, P9, DOI 10.1016/S0171-9335(98)80012-5; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; Watson RT, 2003, MOL CELL BIOL, V23, P961, DOI 10.1128/MCB.23.3.961-974.2003; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; Watson RT, 2004, EMBO J, V23, P2059, DOI 10.1038/sj.emboj.7600159; Weaver AM, 2002, CURR BIOL, V12, P1270, DOI 10.1016/S0960-9822(02)01035-7; Weernink PAO, 2004, J BIOL CHEM, V279, P7840, DOI 10.1074/jbc.M312737200; Welch MD, 2002, ANNU REV CELL DEV BI, V18, P247, DOI 10.1146/annurev.cellbio.18.040202.112133; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1; Wong KW, 2003, J EXP MED, V198, P603, DOI 10.1084/jem.20021363; Wu-Wong JSR, 1999, J BIOL CHEM, V274, P8103, DOI 10.1074/jbc.274.12.8103; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; YANG J, 1993, J BIOL CHEM, V268, P4600; Ying M, 2003, TRAFFIC, V4, P772, DOI 10.1034/j.1600-0854.2003.00134.x; Yorek M, 1999, ARCH BIOCHEM BIOPHYS, V361, P241, DOI 10.1006/abbi.1998.0982	123	48	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30622	30633		10.1074/jbc.M401443200	http://dx.doi.org/10.1074/jbc.M401443200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123724	hybrid			2022-12-25	WOS:000222531900092
J	Ivanov, AV; Gable, ME; Askari, A				Ivanov, AV; Gable, ME; Askari, A			Interaction of SDS with Na+/K+-ATPase - SDS-solubilized enzyme retains partial structure and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSICALLY UNSTRUCTURED PROTEINS; ACTIVATED ADENOSINE-TRIPHOSPHATASE; SODIUM DODECYL-SULFATE; KIDNEY OUTER MEDULLA; MAMMALIAN KIDNEY; GAMMA-SUBUNIT; FXYD PROTEINS; PIG-KIDNEY; OLIGOMERIC STRUCTURE; MEMBRANE-PROTEINS	Because nearly all structure/function studies on Na+/ K+-ATPase have been done on enzymes prepared in the presence of SDS, we have studied previously unrecognized consequences of SDS interaction with the enzyme. When the purified membrane-bound kidney enzyme was solubilized with SDS or TDS concentrations just sufficient to cause complete solubilization, but not at concentrations severalfold higher, the enzyme retained quaternary structure, exhibiting alpha,alpha-, alpha,beta-, beta,beta-, and alpha,gamma- associations as detected by chemical cross-linking. The presence of solubilized oligomers was confirmed by sucrose density gradient centrifugation. This solubilized enzyme had no ATPase activity and was not phosphorylated by ATP, but it retained the ability to occlude Rb+ and Na+. This, and comparison of cross-linking patterns obtained with different reagents, suggested that the transmembrane domains of the enzyme are more resistant to SDS-induced unfolding than its other domains. These findings ( a) indicate that the partially unfolded oligomer(s) retaining partial function is the intermediate in the SDS-induced denaturation of the native membrane enzyme having the minimum oligomeric structure of (alpha, beta, gamma)(2) and (b) suggest potential functions for Na+/K+-ATPase with intrinsically unfolded domains. Mixtures of solubilized/ partially unfolded enzyme and membrane-bound enzyme exhibited cross-linking patterns and Na+ occlusion capacities different from those of either enzyme species, suggesting that the two interact. Formation of the partially unfolded enzyme during standard purification procedure for the preparation of the membrane-bound enzyme was shown, indicating that it is necessary to ensure the separation of the partially unfolded enzyme from the membrane-bound enzyme to avoid the distortion of the properties of the latter.	Med Coll Ohio, Dept Pharmacol, Toledo, OH 43614 USA		Askari, A (corresponding author), Med Coll Ohio, Dept Pharmacol, 3035 Arlington Ave, Toledo, OH 43614 USA.	mheck@mco.edu			NHLBI NIH HHS [HL-36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; Arystarkhova E, 2002, AM J PHYSIOL-RENAL, V282, pF393, DOI 10.1152/ajprenal.00146.2001; Askari A, 2000, INT CONGR SER, V1207, P17; Askari A, 1988, Prog Clin Biol Res, V268A, P149; ASKARI A, 1987, J BIOENERG BIOMEMBR, V19, P359, DOI 10.1007/BF00768539; BLACKBURN MN, 1981, ARCH BIOCHEM BIOPHYS, V212, P162, DOI 10.1016/0003-9861(81)90355-6; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; CRAIG WS, 1980, J BIOL CHEM, V255, P6262; Crambert G, 2004, MOL PHARMACOL, V65, P335, DOI 10.1124/mol.65.2.335; Das TK, 1998, EUR J BIOCHEM, V254, P662, DOI 10.1046/j.1432-1327.1998.2540662.x; Donnet C, 2001, J BIOL CHEM, V276, P7357, DOI 10.1074/jbc.M009131200; DUNHAM PB, 1970, P NATL ACAD SCI USA, V66, P936, DOI 10.1073/pnas.66.3.936; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; DZHANDZHUGAZYAN KN, 1981, BIOORG KHIM+, V7, P847; ESMANN M, 1985, BIOCHEM BIOPH RES CO, V127, P857, DOI 10.1016/S0006-291X(85)80022-X; ESMANN M, 1992, BIOCHIM BIOPHYS ACTA, V1106, P1, DOI 10.1016/0005-2736(92)90214-7; FORBUSH B, 1982, J BIOL CHEM, V257, P2678; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; Geering K, 2003, ANN NY ACAD SCI, V986, P388, DOI 10.1111/j.1749-6632.2003.tb07219.x; Grimsley JK, 1997, BIOCHEMISTRY-US, V36, P14366, DOI 10.1021/bi971596e; Grinberg AV, 2001, EUR J BIOCHEM, V268, P5027, DOI 10.1046/j.0014-2956.2001.02436.x; HANSEN O, 1979, NATURE, V280, P410, DOI 10.1038/280410a0; HASENAUER J, 1993, J BIOL CHEM, V268, P3289; Hasler U, 2001, J BIOL CHEM, V276, P16356, DOI 10.1074/jbc.M008778200; Hebert H, 2001, J MOL BIOL, V314, P479, DOI 10.1006/jmbi.2001.5137; Ivanov AV, 2002, BIOCHEM J, V364, P293, DOI 10.1042/bj3640293; JENSEN J, 1984, J PHYSIOL-LONDON, V346, P219, DOI 10.1113/jphysiol.1984.sp015018; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P53, DOI 10.1016/0005-2736(74)90293-4; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; JORGENSEN PL, 1971, BIOCHIM BIOPHYS ACTA, V233, P366, DOI 10.1016/0005-2736(71)90334-8; JORGENSEN PL, 1971, BIOCHIM BIOPHYS ACTA, V233, P381, DOI 10.1016/0005-2736(71)90335-X; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Klodos I, 2002, KIDNEY INT, V62, P2097, DOI 10.1046/j.1523-1755.2002.00654.x; KOSTER JC, 1995, J BIOL CHEM, V270, P14332, DOI 10.1074/jbc.270.24.14332; le Maire M, 2000, BBA-BIOMEMBRANES, V1508, P86, DOI 10.1016/S0304-4157(00)00010-1; LIANG SM, 1977, J BIOL CHEM, V252, P8278; Liu LJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1550, DOI 10.1152/ajpcell.00555.2002; Martin DW, 1999, BIOCHEMISTRY-US, V38, P7485, DOI 10.1021/bi983019b; MIMURA K, 1993, BIOCHIM BIOPHYS ACTA, V1145, P63, DOI 10.1016/0005-2736(93)90382-A; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; Ohnishi S, 2001, BBA-BIOMEMBRANES, V1515, P159, DOI 10.1016/S0005-2736(01)00410-2; PARKER W, 1992, BIOPHYS J, V61, P1435, DOI 10.1016/S0006-3495(92)81949-5; PERIYASAMY SM, 1983, J BIOL CHEM, V258, P9878; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Reynolds J A, 1988, Prog Clin Biol Res, V268A, P137; Rice WJ, 2001, BIOPHYS J, V80, P2187, DOI 10.1016/S0006-3495(01)76191-7; ROBINSON JD, 1980, BIOCHIM BIOPHYS ACTA, V598, P543, DOI 10.1016/0005-2736(80)90034-6; SACHS JR, 1994, BBA-BIOMEMBRANES, V1193, P199, DOI 10.1016/0005-2736(94)90349-2; SHANISEKLER M, 1988, J BIOL CHEM, V263, P19331; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; Sweadner KJ, 2003, ANN NY ACAD SCI, V986, P382, DOI 10.1111/j.1749-6632.2003.tb07218.x; TANFORD C, 1976, BIOCHIM BIOPHYS ACTA, V457, P133, DOI 10.1016/0304-4157(76)90009-5; Taniguchi K, 2001, J BIOCHEM, V129, P335, DOI 10.1093/oxfordjournals.jbchem.a002862; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Tsuda T, 1998, J BIOL CHEM, V273, P24339, DOI 10.1074/jbc.273.38.24339; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Xie ZJ, 2002, EUR J BIOCHEM, V269, P2434, DOI 10.1046/j.1432-1033.2002.02910.x; Yokoyama T, 1999, J BIOL CHEM, V274, P31792, DOI 10.1074/jbc.274.45.31792; ZOLOTARJOVA N, 1995, J BIOL CHEM, V270, P3989, DOI 10.1074/jbc.270.8.3989	60	10	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29832	29840		10.1074/jbc.M401986200	http://dx.doi.org/10.1074/jbc.M401986200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123703	hybrid			2022-12-25	WOS:000222445300120
J	Lewis, DE; Merched-Sauvage, M; Goronzy, JJ; Weyand, CM; Vallejo, AN				Lewis, DE; Merched-Sauvage, M; Goronzy, JJ; Weyand, CM; Vallejo, AN			Tumor necrosis factor-alpha and CD80 modulate CD28 expression through a similar mechanism of T-cell receptor-independent inhibition of transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOWN-REGULATION; NUCLEAR FACTOR; GENE; B7-1; REQUIREMENTS; REPERTOIRE; ACTIVATION; INITIATOR; PATHWAYS; DISTINCT	Replicative senescence of human T cells is characterized by the loss of CD28 expression, exemplified by the clonal expansion of CD28(null) T cells during repeated stimulation in vitro as well as in chronic inflammatory and infectious diseases and in the normal course of aging. Because CD28 is the major costimulatory receptor for the induction of T cell-mediated immunity, the mechanism(s) underlying CD28 loss is of paramount interest. Current models of replicative senescence involve protracted procedures to generate CD28(null) cells from CD28(+) precursors; hence, a T-cell line model was used to examine the dynamics of CD28 expression. Here, we show the versatility of the JT and Jtag cell lines in tracking CD28(null) <----> CD28(hi) phenotypic transitions. JT and Jtag cells were CD28(null) and CD28(lo), respectively, but expressed high levels of CD28 when exposed to phorbol 12-myristate 13-acetate. This was a result of the reconstitution of the CD28 gene transcriptional initiator (INR). Tumor necrosis factor-alpha reduced CD28 expression because of the inhibition of INR-driven transcription. Ligation of CD28 by an antibody or by CD80 also down-regulated CD28 transcription through the same mechanism, providing evidence that CD28 can generate a T cell receptor-independent signal with a unique biological outcome. Collectively, these data unequivocally demonstrate the critical role of the INR in the regulation of CD28 expression. T cell lines with transient expression of CD28 are invaluable in the dissection of the biochemical processes involved in the transactivation of the CD28 INR, the silencing of which is a key event in the ontogenesis of senescent T cells.	Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Emory Univ, Sch Med, Lowance Ctr Human Immunol, Atlanta, GA 30322 USA; Mayo Clin, Dept Med, Div Rheumatol, Rochester, MN 55905 USA	Baylor College of Medicine; Emory University; Mayo Clinic	Vallejo, AN (corresponding author), Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Rangos Res Ctr 2122, 3705 5th Ave, Pittsburgh, PA 15213 USA.	abbe.vallejo@chp.edu	Weyand, Cornelia/AAH-3343-2021	Goronzy, Jorg/0000-0001-7670-1856	NIAID NIH HHS [R37-AI36682, R21 AI054251] Funding Source: Medline; NIA NIH HHS [R01 AG022379-02, R01-AG15043, R01-AG22379, R01 AG022379] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI054251, R37AI036682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022379, R01AG015043] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; AZUMA M, 1992, J EXP MED, V175, P353, DOI 10.1084/jem.175.2.353; Bruunsgaard H, 2002, EUR CYTOKINE NETW, V13, P389; Bryl E, 2001, J IMMUNOL, V167, P3231, DOI 10.4049/jimmunol.167.6.3231; Burastero SE, 1999, J ALLERGY CLIN IMMUN, V103, P1136, DOI 10.1016/S0091-6749(99)70189-2; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chambers CA, 1999, CURR OPIN CELL BIOL, V11, P203, DOI 10.1016/S0955-0674(99)80027-1; Chen HX, 1998, J IMMUNOL, V160, P5045; Cortesini R, 2001, IMMUNOL REV, V182, P201, DOI 10.1034/j.1600-065X.2001.1820116.x; Dutra WO, 1996, SCAND J IMMUNOL, V43, P88, DOI 10.1046/j.1365-3083.1996.d01-9.x; Eck SC, 1997, TRANSPLANTATION, V64, P1497, DOI 10.1097/00007890-199711270-00025; Effros RB, 1997, DEV COMP IMMUNOL, V21, P471, DOI 10.1016/S0145-305X(97)00027-X; Erbe DV, 2002, J BIOL CHEM, V277, P7363, DOI 10.1074/jbc.M110162200; FREEMAN GJ, 1995, IMMUNITY, V2, P523, DOI 10.1016/1074-7613(95)90032-2; Garraway IP, 1996, P NATL ACAD SCI USA, V93, P4336, DOI 10.1073/pnas.93.9.4336; Goronzy JJ, 2001, J VIROL, V75, P12182, DOI 10.1128/JVI.75.24.12182-12187.2001; Honda M, 2001, CLIN IMMUNOL, V99, P211, DOI 10.1006/clim.2001.5023; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Kariv I, 1996, J IMMUNOL, V157, P29; Kaufmann J, 1998, MOL CELL BIOL, V18, P233, DOI 10.1128/MCB.18.1.233; Khan N, 2002, J IMMUNOL, V169, P1984, DOI 10.4049/jimmunol.169.4.1984; Kollias G, 2002, CYTOKINE GROWTH F R, V13, P315, DOI 10.1016/S1359-6101(02)00019-9; Lamprecht P, 2001, THORAX, V56, P751, DOI 10.1136/thorax.56.10.751; LEE KP, 1990, J IMMUNOL, V145, P344; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Lewis DE, 1999, AIDS, V13, P1029, DOI 10.1097/00002030-199906180-00005; Lewis DE, 1999, CLIN IMMUNOL, V90, P302, DOI 10.1006/clim.1998.4663; Lin CJ, 2001, J IMMUNOL, V166, P6134, DOI 10.4049/jimmunol.166.10.6134; Lloyd TE, 1997, J IMMUNOL, V158, P1551; Luhder F, 2003, J EXP MED, V197, P955, DOI 10.1084/jem.20021024; Martens PB, 1997, ARTHRITIS RHEUM, V40, P1106, DOI 10.1002/art.1780400615; Monteiro J, 1996, J IMMUNOL, V156, P3587; Moosig F, 1998, CLIN EXP IMMUNOL, V114, P113; Nakajima T, 2002, CIRCULATION, V105, P570, DOI 10.1161/hc0502.103348; Namekawa T, 1998, ARTHRITIS RHEUM, V41, P2108; NEIL GA, 1994, DIGEST DIS SCI, V39, P1900, DOI 10.1007/BF02088123; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; NUNES J, 1993, INT IMMUNOL, V5, P311, DOI 10.1093/intimm/5.3.311; Park W, 1997, EUR J IMMUNOL, V27, P1082, DOI 10.1002/eji.1830270507; Paul ME, 2001, J ALLERGY CLIN IMMUN, V108, P258, DOI 10.1067/mai.2001.117179; PELLATDECEUNYNCK C, 1994, BLOOD, V84, P2597, DOI 10.1182/blood.V84.8.2597.bloodjournal8482597; POSNETT DN, 1994, J EXP MED, V179, P609, DOI 10.1084/jem.179.2.609; Posnett DN, 1999, INT IMMUNOL, V11, P229, DOI 10.1093/intimm/11.2.229; RUGVEIT J, 1997, CLIN EXP IMMUNOL, V110, P104; Saurwein-Teissl M, 2002, J IMMUNOL, V168, P5893, DOI 10.4049/jimmunol.168.11.5893; Schirmer M, 2002, ARTHRITIS RES, V4, P71, DOI 10.1186/ar386; Schlienger K, 1998, J IMMUNOL, V161, P2407; Schmidt D, 1996, MOL MED, V2, P608, DOI 10.1007/BF03401644; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; Slavik JM, 1999, J BIOL CHEM, V274, P3116, DOI 10.1074/jbc.274.5.3116; Snyder MR, 2002, J IMMUNOL, V168, P3839, DOI 10.4049/jimmunol.168.8.3839; Spaulding C, 1999, EXP GERONTOL, V34, P633, DOI 10.1016/S0531-5565(99)00033-9; Tarazona R, 2000, MECH AGEING DEV, V121, P77; Vallejo AN, 2000, J IMMUNOL, V165, P6301, DOI 10.4049/jimmunol.165.11.6301; Vallejo AN, 1998, J BIOL CHEM, V273, P8119, DOI 10.1074/jbc.273.14.8119; Vallejo AN, 1999, J IMMUNOL, V162, P6572; Vallejo AN, 2004, TRENDS MOL MED, V10, P119, DOI 10.1016/j.molmed.2004.01.002; Vallejo AN, 2002, J BIOL CHEM, V277, P46940, DOI 10.1074/jbc.M207352200; Vallejo AN, 2001, J BIOL CHEM, V276, P2565, DOI 10.1074/jbc.M005503200; Warrington KJ, 2003, BLOOD, V101, P3543, DOI 10.1182/blood-2002-08-2574; Warrington KJ, 2001, ARTHRITIS RHEUM, V44, P13, DOI 10.1002/1529-0131(200101)44:1<13::AID-ANR3>3.0.CO;2-6; Weyand CM, 1998, MECH AGEING DEV, V102, P131, DOI 10.1016/S0047-6374(97)00161-9; ZUPO S, 1993, J CLIN IMMUNOL, V13, P228, DOI 10.1007/BF00919976	64	33	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29130	29138		10.1074/jbc.M402194200	http://dx.doi.org/10.1074/jbc.M402194200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15128741	hybrid			2022-12-25	WOS:000222445300038
J	Liu, W; Rogge, CE; Bambai, B; Palmer, G; Tsai, AL; Kulmacz, RJ				Liu, W; Rogge, CE; Bambai, B; Palmer, G; Tsai, AL; Kulmacz, RJ			Characterization of the heme environment in Arabidopsis thaliana fatty acid alpha-dioxygenase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-H SYNTHASE; SHEEP VESICULAR GLAND; RAY CRYSTAL-STRUCTURE; ENDOPEROXIDE SYNTHETASE; CANINE MYELOPEROXIDASE; SELECTIVE-INHIBITION; ANGSTROM RESOLUTION; CYANIDE BINDING; NSAID BINDING; H-2 SYNTHASE	Plant alpha-dioxygenases (PADOX) are hemoproteins in the myeloperoxidase family. We have used a variety of spectroscopic, mutagenic, and kinetic approaches to characterize the heme environment in Arabidopsis thaliana PADOX-1. Recombinant PADOX-1 purified to homogeneity contained 1 mol of heme bound tightly but noncovalently per protein monomer. Electronic absorbance, electron paramagnetic resonance, and magnetic circular dichroism spectra showed a high spin ferric heme that could be reduced to the ferrous state by dithionite. Cyanide bound relatively weakly in the ferric PADOX-1 heme vicinity (K-d similar to 10 mM) but did not shift the heme to the low spin state. Cyanide was a very strong inhibitor of the fatty acid oxygenase activity (K-i similar to5 muM) and increased the K-m value for oxygen but not that for fatty acid. Spectroscopic analyses indicated that carbon monoxide, azide, imidazole, and a variety of substituted imidazoles did not bind appreciably in the ferric PADOX-1 heme vicinity. Substitution of His-163 and His-389 with cysteine, glutamine, tyrosine, or methionine resulted in variable degrees of perturbation of the heme absorbance spectrum and oxygenase activity, consistent with His-389 serving as the proximal heme ligand and indicating that the heme has a functional role in catalysis. Overall, A. thaliana PADOX-1 resembles a b-type cytochrome, although with much more restricted access to the distal face of the heme than seen in most other myeloperoxidase family members, explaining the previously puzzling lack of peroxidase activity in the plant protein. PADOX-1 is unusual in that it has a high affinity, inhibitory cyanide-binding site distinct from the distal heme face and the fatty acid site.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Houston, TX 77030 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA	University of Texas System; University of Texas Health Science Center Houston; Rice University	Kulmacz, RJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, MSB 5-284,6431 Fannin St, Houston, TX 77030 USA.	richard.j.kulmacz@uth.tmc.edu		Bambai, Bijan/0000-0002-9947-1691	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK061929] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044911, R01GM052170] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK061929, DK61929] Funding Source: Medline; NIGMS NIH HHS [R01 GM052170, R01 GM044911, R01 GM044911-15, GM44911, GM52170] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1988, CURRENT PROTOCOLS MO; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; Daiyasu H, 2000, J MOL EVOL, V51, P433, DOI 10.1007/s002390010106; DePillis GD, 1997, J BIOL CHEM, V272, P8857; DONG JG, 1992, P NATL ACAD SCI USA, V89, P9789, DOI 10.1073/pnas.89.20.9789; Fayadat L, 1999, J BIOL CHEM, V274, P10533, DOI 10.1074/jbc.274.15.10533; Fei MJ, 2000, ACTA CRYSTALLOGR D, V56, P529, DOI 10.1107/S0907444900002213; FENNA R, 1995, ARCH BIOCHEM BIOPHYS, V316, P653, DOI 10.1006/abbi.1995.1086; FOUST GP, 1969, ANAL BIOCHEM, V27, P530, DOI 10.1016/0003-2697(69)90066-9; Grossmann K, 1996, PHYSIOL PLANTARUM, V97, P772, DOI 10.1111/j.1399-3054.1996.tb00543.x; HAINING JL, 1958, J BIOL CHEM, V232, P193; Hamberg M, 1999, J BIOL CHEM, V274, P24503, DOI 10.1074/jbc.274.35.24503; Hamberg M, 2002, PROSTAG OTH LIPID M, V68-9, P363, DOI 10.1016/S0090-6980(02)00040-0; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HEMLER ME, 1978, BIOCHEM BIOPH RES CO, V85, P1325, DOI 10.1016/0006-291X(78)91148-8; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Koeduka T, 2002, J BIOL CHEM, V277, P22648, DOI 10.1074/jbc.M110420200; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KULMACZ RJ, 1985, PROSTAGLANDINS, V29, P175, DOI 10.1016/0090-6980(85)90200-X; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1987, J BIOL CHEM, V262, P10524; KULMACZ RJ, 1989, PROSTAGLANDINS, V38, P277, DOI 10.1016/0090-6980(89)90133-0; KULMACZ RJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P502, DOI 10.1016/0003-9861(89)90317-2; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; Lu GQ, 1999, J BIOL CHEM, V274, P16162, DOI 10.1074/jbc.274.23.16162; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MACDONALD ID, 1989, J INORG BIOCHEM, V37, P35, DOI 10.1016/0162-0134(89)80027-3; MACDONALD ID, 1989, BIOCHEM CELL BIOL, V67, P301; MARQUEZ LA, 1989, BIOCHEM CELL BIOL, V67, P187, DOI 10.1139/o89-029; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; NIMURA N, 1988, ANAL CHEM, V60, P2067, DOI 10.1021/ac00170a017; OHTAKI S, 1985, J BIOL CHEM, V260, P441; Oxvig C, 1999, J BIOL CHEM, V274, P16953, DOI 10.1074/jbc.274.24.16953; Perera R, 2003, P NATL ACAD SCI USA, V100, P3641, DOI 10.1073/pnas.0737142100; PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; ROTH GJ, 1981, J BIOL CHEM, V256, P18; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanz A, 1998, PLANT CELL, V10, P1523, DOI 10.1105/tpc.10.9.1523; Selinsky BS, 2001, BIOCHEMISTRY-US, V40, P5172, DOI 10.1021/bi010045s; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; SMITH WL, 1972, J BIOL CHEM, V247, P1038; SOMERS CE, 1989, J BIOL CHEM, V264, P17231; Su C, 1998, J BIOL CHEM, V273, P20744, DOI 10.1074/jbc.273.33.20744; Su C, 1996, J BIOL CHEM, V271, P14112, DOI 10.1074/jbc.271.24.14112; Tang MS, 1997, BIOCHEMISTRY-US, V36, P7527, DOI 10.1021/bi962750k; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; TITUS BG, 1982, ARCH BIOCHEM BIOPHYS, V214, P824, DOI 10.1016/0003-9861(82)90089-3; TSAI AL, 1993, J BIOL CHEM, V268, P8554; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; VANDEROUDERAA FJ, 1979, BIOCHIM BIOPHYS ACTA, V572, P29, DOI 10.1016/0005-2760(79)90197-8; Vickery L E, 1978, Methods Enzymol, V54, P284; Williams C H Jr, 1979, Methods Enzymol, V62, P185; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	60	19	21	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29805	29815		10.1074/jbc.M401779200	http://dx.doi.org/10.1074/jbc.M401779200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15100225	hybrid, Green Accepted			2022-12-25	WOS:000222445300117
J	Brehmer, D; Gassler, C; Rist, W; Mayer, MP; Bukau, B				Brehmer, D; Gassler, C; Rist, W; Mayer, MP; Bukau, B			Influence of GrpE on DnaK-substrate interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; HSP70 MOLECULAR CHAPERONE; ESCHERICHIA-COLI; PEPTIDE BINDING; ATPASE DOMAIN; PROTEIN; SIGMA(32); RELEASE; PURIFICATION; THERMOSENSOR	The DnaK chaperone of Escherichia coli assists protein folding by an ATP-dependent interaction with short peptide stretches within substrate polypeptides. This interaction is regulated by the DnaJ and GrpE co-chaperones, which stimulate ATP hydrolysis and nucleotide exchange by DnaK, respectively. Furthermore, GrpE has been claimed to trigger substrate release independent of its role as a nucleotide exchange factor. However, we show here that GrpE can accelerate substrate release from DnaK exclusively in the presence of ATP. In addition, GrpE prevented the association of peptide substrates with DnaK through an activity of its N-terminal 33 amino acids. A ternary complex of GrpE, DnaK, and a peptide substrate could be observed only when the peptide binding to DnaK precedes GrpE binding. Furthermore, we demonstrate that GrpE slows down the release of a protein substrate, sigma(32), from DnaK in the absence of ATP. These findings suggest that the ATP-triggered dissociation of GrpE and substrates from DnaK occurs in a concerted fashion.	Heidelberg Univ, Zentrum Mol Biol Heidelberg, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Bukau, B (corresponding author), Heidelberg Univ, Zentrum Mol Biol Heidelberg, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	Bukau@zmbh.uni-heidelberg.de	Mayer, Matthias P./B-9340-2013	Mayer, Matthias P./0000-0002-7859-3112; Rist, Wolfgang/0000-0002-0626-3544; Bukau, Bernd/0000-0003-0521-7199				Brehmer D, 2001, NAT STRUCT BIOL, V8, P427, DOI 10.1038/87588; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BURKHOLDER WF, 1999, MOL CHAPERONES FOLDI, P105; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Chesnokova LS, 2003, BIOCHEMISTRY-US, V42, P9028, DOI 10.1021/bi0346493; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; Gassler CS, 1998, P NATL ACAD SCI USA, V95, P15229, DOI 10.1073/pnas.95.26.15229; Gassler CS, 2001, J BIOL CHEM, V276, P32538, DOI 10.1074/jbc.M105328200; Gelinas AD, 2003, BIOCHEMISTRY-US, V42, P9050, DOI 10.1021/bi034416b; Gelinas AD, 2002, J MOL BIOL, V323, P131, DOI 10.1016/S0022-2836(02)00915-4; GRAGEROV A, 1994, J MOL BIOL, V241, P133, DOI 10.1006/jmbi.1994.1482; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Grimshaw JPA, 2003, J BIOL CHEM, V278, P19048, DOI 10.1074/jbc.M300924200; Grimshaw JPA, 2001, J BIOL CHEM, V276, P6098, DOI 10.1074/jbc.M009290200; Groemping Y, 2001, J MOL BIOL, V314, P167, DOI 10.1006/jmbi.2001.5116; Han WJ, 2003, BIOCHEM J, V369, P627, DOI 10.1042/BJ20020943; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; Landry SJ, 2003, BIOCHEMISTRY-US, V42, P4926, DOI 10.1021/bi027070y; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Laufen T., 1998, MOL CHAPERONES PROTE, P241; Mally A, 2001, NAT STRUCT BIOL, V8, P254, DOI 10.1038/85002; Mayer MP, 2000, BIOL CHEM, V381, P877, DOI 10.1515/BC.2000.109; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mayer MP, 2002, ADV PROTEIN CHEM, V59, P1; Mayer MP, 1999, J MOL BIOL, V289, P1131, DOI 10.1006/jmbi.1999.2844; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; McCarty JS, 1996, J MOL BIOL, V256, P829, DOI 10.1006/jmbi.1996.0129; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Russell R, 1998, BIOCHEMISTRY-US, V37, P596, DOI 10.1021/bi972025p; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; Schonfeld HJ, 1995, PROG COLL POL SCI S, V99, P7; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Suh WC, 1999, J BIOL CHEM, V274, P30534, DOI 10.1074/jbc.274.43.30534; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; Tatsuta T, 1998, MOL MICROBIOL, V30, P583, DOI 10.1046/j.1365-2958.1998.01091.x; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Tomoyasu T, 2001, J BACTERIOL, V183, P5911, DOI 10.1128/JB.183.20.5911-5917.2001; Wittung-Stafshede P, 2003, BIOCHEMISTRY-US, V42, P4937, DOI 10.1021/bi027333o; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591; [No title captured]	47	51	54	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27957	27964		10.1074/jbc.M403558200	http://dx.doi.org/10.1074/jbc.M403558200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102842	hybrid			2022-12-25	WOS:000222265400017
J	Giannone, G; Ronde, P; Gaire, M; Beaudouin, J; Haiech, J; Ellenberg, J; Takeda, K				Giannone, G; Ronde, P; Gaire, M; Beaudouin, J; Haiech, J; Ellenberg, J; Takeda, K			Calcium rises locally trigger focal adhesion disassembly and enhance residency of focal adhesion kinase at focal adhesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SMOOTH-MUSCLE-CELLS; C-TERMINAL DOMAIN; DIFFERENTIAL REGULATION; MIGRATING NEUTROPHILS; INTRACELLULAR CALCIUM; ASTROCYTOMA-CELLS; GENE-EXPRESSION; STRESS FIBERS; NULL CELLS	Focal adhesion kinase (FAK) activity and Ca2+ signaling led to a turnover of focal adhesions (FAs) required for cell spreading and migration. We used yellow Cameleon-2 (Ycam), a fluorescent protein-based Ca2+ sensor fused to FAK or to a FAK-related non-kinase domain, to measure simultaneously local Ca2+ variations at FA sites and FA dynamics. Discrete subcellular Ca2+ oscillators initiate both propagating and abortive Ca2+ waves in migrating U87 astrocytoma cells. Ca2+-dependent FA disassembly occurs when the Ca2+ wave reaches individual FAs, indicating that local but not global Ca2+ increases trigger FA disassembly. An unexpectedly rapid flux of FAK between cytosolic and FA compartments was revealed by fluorescence recovery after photobleaching studies. The FAK-Ycam recovery half-time (17 s) at FAs was slowed (to 29 s) by Ca2+ elevation. FAK-related non-kinase domain-Ycam had a faster, Ca2+-insensitive recovery half-time (11 s), which is consistent with the effect of Ca2+ on FAK-Ycam dynamics not being due to a general modification of the dynamics of FA components. Because FAK association at FAs was prolonged by Ca2+ and FAK autophosphorylation was correlated to intracellular Ca2+ levels, we propose that local Ca2+ elevations increase the residency of FAK at FAs, possibly by means of tyrosine phosphorylation of FAK, thereby leading to increased activation of its effectors involved in FA disassembly.	Univ Louis Pasteur Strasbourg 1, Lab Pharmacol & Physicochim Interact Cellulaires, CNRS, UMR 7034, F-67401 Illkirch Graffenstaden, France; European Mol Biol Lab, Gene Express & Cell Biol Programme, D-69117 Heidelberg, Germany; European Mol Biol Lab, Biophys Programme, D-69117 Heidelberg, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL)	Takeda, K (corresponding author), Univ Louis Pasteur Strasbourg 1, Lab Pharmacol & Physicochim Interact Cellulaires, CNRS, UMR 7034, BP 60024, F-67401 Illkirch Graffenstaden, France.	kt@pharma.u-strasbg.fr	Ellenberg, Jan/I-4688-2014; haiech, jacques J/F-2890-2010	Ellenberg, Jan/0000-0001-5909-701X; Giannone, Gregory/0000-0002-0932-1690; haiech, jacques/0000-0003-2908-8053				Achison M, 2001, J BIOL CHEM, V276, P3167, DOI 10.1074/jbc.M007186200; Alessandro R, 1998, BIOCHEM BIOPH RES CO, V248, P635, DOI 10.1006/bbrc.1998.8705; Ballestrem C, 2001, J CELL BIOL, V155, P1319, DOI 10.1083/jcb.200107107; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cattelino A, 1999, MOL BIOL CELL, V10, P373, DOI 10.1091/mbc.10.2.373; CHAN PY, 1994, J BIOL CHEM, V269, P20567; Cooley MA, 2000, MOL BIOL CELL, V11, P3247, DOI 10.1091/mbc.11.9.3247; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; Daigle N, 2001, J CELL BIOL, V154, P71, DOI 10.1083/jcb.200101089; Dewitt S, 2002, J CELL BIOL, V159, P181, DOI 10.1083/jcb.200206089; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Eddy RJ, 2000, J CELL SCI, V113, P1287; Edlund M, 2001, CELL MOTIL CYTOSKEL, V48, P190, DOI 10.1002/1097-0169(200103)48:3<190::AID-CM1008>3.0.CO;2-C; Fadel MP, 1999, J BIOL CHEM, V274, P15085, DOI 10.1074/jbc.274.21.15085; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Giannone G, 2002, J BIOL CHEM, V277, P26364, DOI 10.1074/jbc.M203952200; Goicoechea S, 2000, J BIOL CHEM, V275, P36358, DOI 10.1074/jbc.M005951200; Goldmann WH, 2000, BIOCHEM BIOPH RES CO, V271, P553, DOI 10.1006/bbrc.2000.2653; GOUGH AH, 1993, J CELL BIOL, V121, P1095, DOI 10.1083/jcb.121.5.1095; HAHN K, 1992, NATURE, V359, P736, DOI 10.1038/359736a0; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Klingbeil CK, 2001, J CELL BIOL, V152, P97, DOI 10.1083/jcb.152.1.97; Komuro H, 1996, NEURON, V17, P275, DOI 10.1016/S0896-6273(00)80159-2; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Lee J, 1999, NATURE, V400, P382, DOI 10.1038/22578; Leitinger B, 2000, BBA-MOL CELL RES, V1498, P91, DOI 10.1016/S0167-4889(00)00086-0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; MANDEVILLE JTH, 1995, BIOPHYS J, V68, P1207, DOI 10.1016/S0006-3495(95)80336-X; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Rajfur Z, 2002, NAT CELL BIOL, V4, P286, DOI 10.1038/ncb772; Ren XD, 2000, J CELL SCI, V113, P3673; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Ronde P, 2000, BBA-MOL CELL RES, V1498, P273, DOI 10.1016/S0167-4889(00)00102-6; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Scherberich A, 2000, J CELL SCI, V113, P653; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Simpson PB, 1998, J NEUROSCI RES, V52, P672; Sjaastad MD, 1997, BIOESSAYS, V19, P47, DOI 10.1002/bies.950190109; Smilenov LB, 1999, SCIENCE, V286, P1172, DOI 10.1126/science.286.5442.1172; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Tahiliani PD, 1997, J BIOL CHEM, V272, P7892, DOI 10.1074/jbc.272.12.7892; Taylor JM, 2001, MOL CELL BIOL, V21, P1565, DOI 10.1128/MCB.21.5.1565-1572.2001; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Toutant M, 2002, MOL CELL BIOL, V22, P7731, DOI 10.1128/MCB.22.22.7731-7743.2002; Tsuruta D, 2002, FASEB J, V16, P866, DOI 10.1096/fj.01-0878fje; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Yao L, 2002, J LEUKOCYTE BIOL, V71, P47; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	70	108	111	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28715	28723		10.1074/jbc.M404054200	http://dx.doi.org/10.1074/jbc.M404054200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102844	hybrid			2022-12-25	WOS:000222265400109
J	Li, J; O'Connor, KL; Hellmich, MR; Greeley, GH; Townsend, CM; Evers, BM				Li, J; O'Connor, KL; Hellmich, MR; Greeley, GH; Townsend, CM; Evers, BM			The role of protein kinase D in neurotensin secretion mediated by protein kinase C-alpha/-delta and Rho/Rho kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GASTROINTESTINAL HORMONES; INSULIN-SECRETION; PHORBOL ESTERS; PKC-ALPHA; CELL; ACTIVATION; RHO; MU; PHOSPHORYLATION	Neurotensin (NT) is a gut peptide that plays an important role in gastrointestinal (GI) secretion, motility, and growth as well as the proliferation of NT receptor positive cancers. Secretion of NT is regulated by phorbol ester-sensitive protein kinase C (PKC) isoforms-alpha and -delta and may involve protein kinase D (PKD). The purpose of our present study was: (i) to define the role of PKD in NT release from BON endocrine cells and (ii) to delineate the upstream signaling mechanisms mediating this effect. Here, we demonstrate that small interfering RNA ( siRNA) targeted against PKD dramatically inhibited both basal and PMA-stimulated NT secretion; NT release is significantly increased by overexpression of PKD. PKC-alpha and -delta siRNA attenuated PKD activity, whereas overexpression of PKC-alpha and -delta enhanced PKD activity. Rho kinase (ROK) siRNA significantly inhibited NT secretion, whereas overexpression of ROKalpha effectively increased NT release. Rho protein inhibitor C3 dramatically inhibited both NT secretion and PKD activity. In conclusion, our results demonstrate that PKD activation plays a central role in NT peptide secretion; upstream regulators of PKD include PKC-alpha and -delta and Rho/ROK. Importantly, our results identify novel signaling pathways, which culminate in gut peptide release.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Evers, BM (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	mevers@utmb.edu	O'Connor, Kathleen L/H-2569-2013; Li, Jing/B-7206-2011	O'Connor, Kathleen L/0000-0002-1088-9734; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058119, P01DK035608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG010885] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA 10212] Funding Source: Medline; NIA NIH HHS [2R37 AG 10885] Funding Source: Medline; NIDDK NIH HHS [P01 DK 35608, R01 DK 48489, R01 DK 58119] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amin RH, 2003, ENDOCRINOLOGY, V144, P4508, DOI 10.1210/en.2003-0106; ARMSTRONG MJ, 1986, AM J PHYSIOL, V251, pG823, DOI 10.1152/ajpgi.1986.251.6.G823; Barandier C, 2003, BIOCHEM BIOPH RES CO, V304, P714, DOI 10.1016/S0006-291X(03)00668-5; Brandlin I, 2002, J BIOL CHEM, V277, P45451, DOI 10.1074/jbc.M205299200; Brandlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200; Buyukafsar K, 2003, BIOCHEM BIOPH RES CO, V303, P777, DOI 10.1016/S0006-291X(03)00422-4; CARRAWAY RE, 1994, REGUL PEPTIDES, V53, P17, DOI 10.1016/0167-0115(94)90155-4; Chen XQ, 2002, J BIOL CHEM, V277, P12680, DOI 10.1074/jbc.M109839200; CHUNG DH, 1992, GASTROENTEROLOGY, V103, P1254, DOI 10.1016/0016-5085(92)91512-3; Daniel S, 2002, BIOCHEMISTRY-US, V41, P9663, DOI 10.1021/bi025604p; Evers BM, 2002, WORLD J SURG, V26, P799, DOI 10.1007/s00268-002-4055-3; EVERS BM, 1994, ANN NY ACAD SCI, V733, P393, DOI 10.1111/j.1749-6632.1994.tb17289.x; EVERS BM, 1992, GASTROENTEROLOGY, V103, P86, DOI 10.1016/0016-5085(92)91099-P; EVERS BM, 1995, MOL CELL BIOL, V15, P3870; Frantz C, 2002, EXP CELL RES, V273, P119, DOI 10.1006/excr.2001.5432; GASMAN S, 2003, MOL BIOL CELL; Gomez DE, 1999, ONCOL REP, V6, P1363; Goodge KA, 2000, SEMIN CELL DEV BIOL, V11, P235, DOI 10.1006/scdb.2000.0172; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Guo YS, 1999, CONT ENDOCRINOL, V8, P189; Hausser A, 2002, J CELL BIOL, V156, P65, DOI 10.1083/jcb.200110047; Hellmich MR, 1999, J BIOL CHEM, V274, P23901, DOI 10.1074/jbc.274.34.23901; Hippenstiel S, 1998, BIOCHEM BIOPH RES CO, V245, P830, DOI 10.1006/bbrc.1998.8525; Holinstat M, 2003, J BIOL CHEM, V278, P28793, DOI 10.1074/jbc.M303900200; Hong-Geller E, 2000, J CELL BIOL, V148, P481, DOI 10.1083/jcb.148.3.481; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; JONES PM, 1989, BIOCHEM SOC T, V17, P61, DOI 10.1042/bst0170061; Just I, 2001, INT J MED MICROBIOL, V291, P243, DOI 10.1078/1438-4221-00127; Kowluru A, 2003, AM J PHYSIOL-ENDOC M, V285, pE669, DOI 10.1152/ajpendo.00196.2003; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Li J, 2002, AM J PHYSIOL-GASTR L, V283, pG1197, DOI 10.1152/ajpgi.00177.2002; Li XY, 2003, ONCOL RES, V13, P323; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Moore EDW, 1999, J BIOL CHEM, V274, P22493, DOI 10.1074/jbc.274.32.22493; Nevins AK, 2003, AM J PHYSIOL-CELL PH, V285, pC698, DOI 10.1152/ajpcell.00093.2003; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Nozu F, 1999, AM J PHYSIOL-GASTR L, V276, pG915, DOI 10.1152/ajpgi.1999.276.4.G915; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; PAREKH D, 1994, PANCREAS, V9, P83, DOI 10.1097/00006676-199401000-00013; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Sakabe K, 2002, FEBS LETT, V511, P15, DOI 10.1016/S0014-5793(01)03264-1; Sasaki Y, 2003, J PHARMACOL SCI, V93, P35, DOI 10.1254/jphs.93.35; SHIMODA I, 1994, AM J PHYSIOL, V266, pG706, DOI 10.1152/ajpgi.1994.266.4.G706; Shirai Y, 2002, J BIOCHEM, V132, P663, DOI 10.1093/oxfordjournals.jbchem.a003271; Slater SJ, 2001, BIOCHEMISTRY-US, V40, P4437, DOI 10.1021/bi001654n; Slater SJ, 2003, BIOCHEMISTRY-US, V42, P12105, DOI 10.1021/bi034860e; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Sturany S, 2002, J BIOL CHEM, V277, P29431, DOI 10.1074/jbc.M200934200; Sullivan R, 1999, J BIOL CHEM, V274, P38140, DOI 10.1074/jbc.274.53.38140; Tan MQ, 2003, J BIOL CHEM, V278, P2824, DOI 10.1074/jbc.M211523200; Thomas RP, 2003, ENDOCR REV, V24, P571, DOI 10.1210/er.2002-0028; THOR K, 1986, GASTROENTEROLOGY, V90, P27, DOI 10.1016/0016-5085(86)90070-3; Tian YM, 1996, MOL CELL ENDOCRINOL, V119, P185, DOI 10.1016/0303-7207(96)03811-7; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; TOWNSEND CM, 1994, SURG TODAY, V24, P772, DOI 10.1007/BF01636304; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; VITALE ML, 1992, NEUROSCIENCE, V51, P463, DOI 10.1016/0306-4522(92)90330-5; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Yaney GC, 2002, AM J PHYSIOL-ENDOC M, V283, pE880, DOI 10.1152/ajpendo.00474.2001; Yuan JZ, 2002, BIOCHEM BIOPH RES CO, V291, P444, DOI 10.1006/bbrc.2002.6469; Yuan JZ, 2001, J BIOL CHEM, V276, P38619, DOI 10.1074/jbc.M105530200; ZHANG T, 1995, ENDOCRINOLOGY, V136, P2252, DOI 10.1210/en.136.5.2252	70	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28466	28474		10.1074/jbc.M314307200	http://dx.doi.org/10.1074/jbc.M314307200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123666	hybrid			2022-12-25	WOS:000222265400081
J	Tsushima, S; Kai, M; Yamada, K; Imai, S; Houkin, K; Kanoh, H; Sakane, F				Tsushima, S; Kai, M; Yamada, K; Imai, S; Houkin, K; Kanoh, H; Sakane, F			Diacylglycerol kinase gamma serves as an upstream suppressor of Rac1 and lamellipodium formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTORS; EF-HAND MOTIFS; PHOSPHATIDIC-ACID; MOLECULAR-CLONING; LYSOPHOSPHATIDIC ACID; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; REGULATORY ROLE; CELL MOTILITY; ACTIVATION	Nine diacylglycerol kinase (DGK) isozymes have been identified. However, our knowledge of their individual functions is still limited. Here, we demonstrate the role of DGKgamma in regulating Rac1-governed cell morphology. We found that the expression of kinase-dead DGKgamma, which acts as a dominant-negative mutant, and inhibition of endogenous DGKgamma activity with R59949 induced lamellipodium and membrane ruffle formation in NIH3T3 fibroblasts in the absence of growth factor stimulation. Reciprocally, lamellipodium formation induced by platelet-derived growth factor was significantly inhibited upon expression of constitutively active DGKgamma. Moreover, the constitutively active DGKgamma mutant suppressed integrin-mediated cell spreading. These effects are isoform-specific because, in the same experiments, none of the corresponding mutants of DGKalpha and DGKbeta, closely related isoforms, affected cell morphology. These results suggest that DGKgamma specifically participates in the Rac1-mediated signaling pathway leading to cytoskeletal reorganization. In support of this, DGKgamma co-localized with dominant-active Rac1 especially in lamellipodia. Moreover, we found that endogenous DGKgamma was physically associated with cellular Rac1. Dominant-negative Rac1 expression blocked the lamellipodium formation induced by kinase-dead DGKgamma, indicating that DGKgamma acts upstream of Rac1. This model is supported by studies demonstrating that kinase-dead DGKgamma selectively activated Rac1, but not Cdc42. Taken together, these results strongly suggest that DGKgamma functions through its catalytic action as an upstream suppressor of Rac1 and, consequently, lamellipodium/ruffle formation.	Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Neurosurg, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Hlth Sci, Dept Liberal Arts & Sci, Chuo Ku, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University	Sakane, F (corresponding author), Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, South 1,West 17, Sapporo, Hokkaido 0608556, Japan.	sakane@sapmed.ac.jp	Sakane, Fumio/H-2693-2017; Houkin, Kiyohiro/G-5364-2012	Sakane, Fumio/0000-0003-0857-0377; 				Abramovici H, 2003, MOL BIOL CELL, V14, P4499, DOI 10.1091/mbc.E03-03-0190; AHMED S, 1993, J BIOL CHEM, V268, P10709; Aragones J, 2001, J BIOL CHEM, V276, P10548, DOI 10.1074/jbc.M006180200; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Caloca MJ, 2003, BIOCHEM J, V375, P313, DOI 10.1042/BJ20030727; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Cutrupi S, 2000, EMBO J, V19, P4614, DOI 10.1093/emboj/19.17.4614; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HASS R, 1989, EUR J CELL BIOL, V48, P282; Houssa B, 1999, J BIOL CHEM, V274, P6820, DOI 10.1074/jbc.274.11.6820; Hurley JH, 1997, PROTEIN SCI, V6, P477; Imai S, 2002, J BIOL CHEM, V277, P35323, DOI 10.1074/jbc.M202035200; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jiang Y, 2000, J BIOL CHEM, V275, P34092, DOI 10.1074/jbc.M004914200; Jiang Y, 2000, BIOCHEM PHARMACOL, V59, P763, DOI 10.1016/S0006-2952(99)00395-0; Jones DR, 2002, FASEB J, V16, P595, DOI 10.1096/fj.01-0762fje; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; Kanoh H, 2002, J BIOCHEM, V131, P629, DOI 10.1093/oxfordjournals.jbchem.a003144; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Rosner H, 1999, EUR J CELL BIOL, V78, P698; SAKANE F, 1991, J BIOL CHEM, V266, P7096; Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X; SAKANE F, 1991, BIOCHEM BIOPH RES CO, V181, P1015, DOI 10.1016/0006-291X(91)92038-L; Sakane F, 2002, J BIOL CHEM, V277, P43519, DOI 10.1074/jbc.M206895200; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; Sun XG, 1999, CELL GROWTH DIFFER, V10, P343; Tolias KF, 1998, MOL CELL BIOL, V18, P762, DOI 10.1128/MCB.18.2.762; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; VAN AL, 1997, GENE DEV, V11, P2295; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; YAMADA K, 1989, FEBS LETT, V244, P402, DOI 10.1016/0014-5793(89)80572-1; Yamada K, 1997, BIOCHEM J, V321, P59, DOI 10.1042/bj3210059; Yamada K, 2003, BIOCHEM BIOPH RES CO, V305, P101, DOI 10.1016/S0006-291X(03)00713-7	58	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28603	28613		10.1074/jbc.M314031200	http://dx.doi.org/10.1074/jbc.M314031200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102830	hybrid			2022-12-25	WOS:000222265400096
J	Krauss, SW; Lee, G; Chasis, JA; Mohandas, N; Heald, R				Krauss, SW; Lee, G; Chasis, JA; Mohandas, N; Heald, R			Two protein 4.1 domains essential for mitotic spindle and aster microtubule dynamics and organization in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; BINDING DOMAIN; 4.1 FAMILY; ACTIN; NUMA; DYNACTIN; ISOFORMS; IDENTIFICATION; INTERACTS; COMPONENT	Multifunctional structural proteins belonging to the 4.1 family are components of nuclei, spindles, and centrosomes in vertebrate cells. Here we report that 4.1 is critical for spindle assembly and the formation of centrosome-nucleated and motor-dependent self-organized microtubule asters in metaphase-arrested Xenopus egg extracts. Immunodepletion of 4.1 disrupted microtubule arrays and mislocalized the spindle pole protein NuMA. Remarkably, assembly was completely rescued by supplementation with a recombinant 4.1R isoform. We identified two 4.1 domains critical for its function in microtubule polymerization and organization utilizing dominant negative peptides. The 4.1 spectrin-actin binding domain or NuMA binding C-terminal domain peptides caused morphologically disorganized structures. Control peptides with low homology or variant spectrin-actin binding domain peptides that were incapable of binding actin had no deleterious effects. Unexpectedly, the addition of C-terminal domain peptides with reduced NuMA binding caused severe microtubule destabilization in extracts, dramatically inhibiting aster and spindle assembly and also depolymerizing preformed structures. However, the mutant C-terminal peptides did not directly inhibit or destabilize microtubule polymerization from pure tubulin in a microtubule pelleting assay. Our data showing that 4.1 is a crucial factor for assembly and maintenance of mitotic spindles and self-organized and centrosome-nucleated microtubule asters indicates that 4.1 is involved in regulating both microtubule dynamics and organization. These investigations underscore an important functional context for protein 4.1 in microtubule morphogenesis and highlight a previously unappreciated role for 4.1 in cell division.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; New York Blood Ctr, New York, NY 10021 USA; Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; New York Blood Center; University of California System; University of California Berkeley	Krauss, SW (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 1 Cyclotron Rd,MS 74-157, Berkeley, CA 94720 USA.	sakrauss@lbl.gov		Heald, Rebecca/0000-0001-6671-6528	NIDDK NIH HHS [DK59079, DK32094] Funding Source: Medline; NIGMS NIH HHS [GM057839] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094, R01DK059079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057839] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHFORD A, 1998, CELL BIOL LAB HDB, V2, P206; CHASIS JA, 1993, J CLIN INVEST, V91, P329, DOI 10.1172/JCI116189; Clark IB, 1999, J CELL SCI, V112, P3507; CLARK SW, 1992, NATURE, V359, P246, DOI 10.1038/359246a0; COMPTON DA, 1992, J CELL BIOL, V116, P1395, DOI 10.1083/jcb.116.6.1395; CONBOY JG, 1988, P NATL ACAD SCI USA, V85, P9062, DOI 10.1073/pnas.85.23.9062; Dammermann A, 2003, CURR BIOL, V13, pR614, DOI 10.1016/S0960-9822(03)00530-X; DeCarcer G, 1995, BIOCHEM J, V312, P871, DOI 10.1042/bj3120871; Delhommeau F, 2002, BLOOD, V100, P2629, DOI 10.1182/blood.V100.7.2629; Du QS, 2002, CURR BIOL, V12, P1928, DOI 10.1016/S0960-9822(02)01298-8; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; Gascard P, 1998, BLOOD, V92, P4404, DOI 10.1182/blood.V92.11.4404.423k50_4404_4414; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Haren L, 2002, J CELL SCI, V115, P1815; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; HORNE WC, 1990, BIOCHIM BIOPHYS ACTA, V1055, P87, DOI 10.1016/0167-4889(90)90095-U; HUANG JP, 1993, J BIOL CHEM, V268, P3758; Hung LY, 2000, MOL CELL BIOL, V20, P7813, DOI 10.1128/MCB.20.20.7813-7825.2000; KISELEVA E, 2004, IN PRESS J CELL SCI; Krauss SW, 1997, J CELL BIOL, V137, P275, DOI 10.1083/jcb.137.2.275; Krauss SW, 1997, P NATL ACAD SCI USA, V94, P7297, DOI 10.1073/pnas.94.14.7297; Krauss SW, 2002, J BIOL CHEM, V277, P44339, DOI 10.1074/jbc.M204135200; Krauss SW, 2003, P NATL ACAD SCI USA, V100, P10752, DOI 10.1073/pnas.1934680100; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; Merdes A, 1997, J CELL BIOL, V138, P953, DOI 10.1083/jcb.138.5.953; Moudjou M, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P111; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Parra M, 2000, J BIOL CHEM, V275, P3247, DOI 10.1074/jbc.275.5.3247; Parra M, 1998, GENOMICS, V49, P298, DOI 10.1006/geno.1998.5265; PARRA M, 1998, CELL, V9, pA265; Pederson T, 2002, J STRUCT BIOL, V140, P3, DOI 10.1016/S1047-8477(02)00528-2; Perez-Ferreiro CM, 2001, J BIOL CHEM, V276, P44785, DOI 10.1074/jbc.M107369200; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Quintyne NJ, 2002, J CELL BIOL, V159, P245, DOI 10.1083/jcb.200203089; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SAWIN KE, 1994, MOL BIOL CELL, V5, P217, DOI 10.1091/mbc.5.2.217; SCHAFER DA, 1994, J CELL BIOL, V126, P403, DOI 10.1083/jcb.126.2.403; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SUBRAHMANYAM G, 1991, P NATL ACAD SCI USA, V88, P5222, DOI 10.1073/pnas.88.12.5222; Sun DM, 2001, J CELL SCI, V114, P161; Walensky LD, 1998, J CELL BIOL, V141, P143, DOI 10.1083/jcb.141.1.143; Walensky LD, 1999, J NEUROSCI, V19, P6457; Wignall SM, 2004, CHEM BIOL, V11, P135, DOI 10.1016/j.chembiol.2003.12.019; WINARDI R, 1995, BLOOD, V86, P4315, DOI 10.1182/blood.V86.11.4315.bloodjournal86114315; YANG CH, 1992, J CELL BIOL, V116, P1303, DOI 10.1083/jcb.116.6.1303	50	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27591	27598		10.1074/jbc.M402813200	http://dx.doi.org/10.1074/jbc.M402813200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102852	Green Submitted, hybrid			2022-12-25	WOS:000222120400093
J	Moore, JMR; Galicia, SJ; McReynolds, AC; Nguyen, NH; Scanlan, TS; Guy, RK				Moore, JMR; Galicia, SJ; McReynolds, AC; Nguyen, NH; Scanlan, TS; Guy, RK			Quantitative proteomics of the thyroid hormone receptor-coregulator interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LXXLL-RELATED MOTIFS; GENES IN-VIVO; NUCLEAR RECEPTOR; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL COACTIVATORS; POSTNATAL-DEVELOPMENT; PEPTIDE LIBRARIES; PROTEIN RIP140; LIGAND; SPECIFICITY	The thyroid hormone receptor regulates a diverse set of genes that control processes from embryonic development to adult homeostasis. Upon binding of thyroid hormone, the thyroid receptor releases corepressor proteins and undergoes a conformational change that allows for the interaction of coactivating proteins necessary for gene transcription. This interaction is mediated by a conserved motif, termed the NR box, found in many coregulators. Recent work has demonstrated that differentially assembled coregulator complexes can elicit specific biological responses. However, the mechanism for the selective assembly of these coregulator complexes has yet to be elucidated. To further understand the principles underlying thyroid receptor-coregulator selectivity, we designed a high-throughput in vitro binding assay to measure the equilibrium affinity of thyroid receptor to a library of potential coregulators in the presence of different ligands including the endogenous thyroid hormone T3, synthetic thyroid receptor beta-selective agonist GC-1, and antagonist NH-3. Using this homogenous method several coregulator NR boxes capable of associating with thyroid receptor at physiologically relevant concentrations were identified including ones found in traditional coactivating proteins such as SRC1, SRC2, TRAP220, TRBP, p300, and ARA70; and those in coregulators known to repress gene activation including RIP140 and DAX-1. In addition, it was discovered that the thyroid receptor-coregulator binding patterns vary with ligand and that this differential binding can be used to predict biological responses. Finally, it is demonstrated that this is a general method that can be applied to other nuclear receptors and can be used to establish rules for nuclear receptor-coregulator selectivity.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Guy, RK (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	rguy@cgl.ucsf.edu	Guy, Rodney/J-7107-2013	Guy, Rodney/0000-0002-9638-2060	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK052798, P01DK058390, R01DK052798] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-52798, DK-58390] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bramlett KS, 2001, MOL ENDOCRINOL, V15, P909, DOI 10.1210/me.15.6.909; Braverman L.E., 1991, THYROID FUNDAMENTAL; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Cheskis BJ, 2003, J BIOL CHEM, V278, P13271, DOI 10.1074/jbc.M211031200; Chiellini G, 1998, CHEM BIOL, V5, P299, DOI 10.1016/S1074-5521(98)90168-5; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Coulthard VH, 2003, J BIOL CHEM, V278, P10942, DOI 10.1074/jbc.M212950200; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; ECKNER R, 1994, COLD SPRING HARB SYM, V59, P85, DOI 10.1101/SQB.1994.059.01.012; Esterbauer H, 1999, GENOMICS, V62, P98, DOI 10.1006/geno.1999.5977; Feng X, 2000, MOL ENDOCRINOL, V14, P947, DOI 10.1210/me.14.7.947; Flamant F, 2003, TRENDS ENDOCRIN MET, V14, P85, DOI 10.1016/S1043-2760(02)00043-7; Forrest D, 1996, RECENT PROG HORM RES, V51, P1; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; Fraichard A, 1997, EMBO J, V16, P4412, DOI 10.1093/emboj/16.14.4412; Gauthier K, 1999, EMBO J, V18, P623, DOI 10.1093/emboj/18.3.623; Geistlinger TR, 2004, CHEM BIOL, V11, P273, DOI 10.1016/j.chembiol.2004.01.016; Greenspan FS., 1997, THYROID GLAND BASIC; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Kodera Y, 2000, J BIOL CHEM, V275, P33201, DOI 10.1074/jbc.C000517200; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li XT, 2003, MOL CELL BIOL, V23, P3763, DOI 10.1128/MCB.23.11.3763-3773.2003; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Mellgren G, 2003, MOL CELL ENDOCRINOL, V203, P91, DOI 10.1016/S0303-7207(03)00097-2; Miyata KS, 1998, MOL CELL ENDOCRINOL, V146, P69; Ng L, 2001, NAT GENET, V27, P94, DOI 10.1038/83829; Nguyen NH, 2002, J MED CHEM, V45, P3310, DOI 10.1021/jm0201013; Northrop JP, 2000, MOL ENDOCRINOL, V14, P605, DOI 10.1210/me.14.5.605; Ren YS, 2000, MOL CELL BIOL, V20, P5433, DOI 10.1128/MCB.20.15.5433-5446.2000; Sadow PM, 2003, MOL CELL ENDOCRINOL, V203, P65, DOI 10.1016/S0303-7207(03)00122-9; Sadow PM, 2003, MOL ENDOCRINOL, V17, P882, DOI 10.1210/me.2002-0174; Sadow PM, 2003, AM J PHYSIOL-ENDOC M, V284, pE36, DOI 10.1152/ajpendo.00226.2002; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; Suzuki T, 2003, MOL CELL BIOL, V23, P238, DOI 10.1128/MCB.23.1.238-249.2003; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Takeuchi Y, 2002, ENDOCRINOLOGY, V143, P1346, DOI 10.1210/en.143.4.1346; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Trost SU, 2000, ENDOCRINOLOGY, V141, P3057, DOI 10.1210/en.141.9.3057; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wagner RL, 2001, MOL ENDOCRINOL, V15, P398, DOI 10.1210/me.15.3.398; Weiss RE, 2002, ENDOCRINOLOGY, V143, P1554, DOI 10.1210/en.143.4.1554; Weiss RE, 1999, EMBO J, V18, P1900, DOI 10.1093/emboj/18.7.1900; Wellings DA, 1997, METHOD ENZYMOL, V289, P44; Wu YF, 2002, J BIOL CHEM, V277, P8898, DOI 10.1074/jbc.M110761200; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yeh S, 2000, J FORMOS MED ASSOC, V99, P885; Yoshihara HAI, 2003, J MED CHEM, V46, P3152, DOI 10.1021/jm0301181; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhang JC, 1999, MOL ENDOCRINOL, V13, P1130, DOI 10.1210/me.13.7.1130; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510	60	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27584	27590		10.1074/jbc.M403453200	http://dx.doi.org/10.1074/jbc.M403453200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15100213	Green Published, hybrid			2022-12-25	WOS:000222120400092
J	Zhu, M; Rajamani, S; Kaylor, J; Han, S; Zhou, FM; Fink, AL				Zhu, M; Rajamani, S; Kaylor, J; Han, S; Zhou, FM; Fink, AL			The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; OXIDATIVE STRESS; MAJOR COMPONENT; CELL-DEATH; IN-VITRO; L-DOPA; MECHANISM; PATHOGENESIS; MODEL; NEUROTOXICITY	The aggregation of alpha-synuclein has been implicated as a critical step in the development of Parkinson's disease. Parkinson's disease is a progressive neurodegenerative disorder caused by the loss of dopaminergic neurons from the substantia nigra; currently, no cure exists. Baicalein is a flavonoid with antioxidant properties; upon oxidation, it forms several products including quinones. We show here that low micromolar concentrations of baicalein, and especially its oxidized forms, inhibit the formation of alpha-synuclein fibrils. In addition, existing fibrils of alpha-synuclein are disaggregated by baicalein. The product of the inhibition reaction is predominantly a soluble oligomer of alpha-synuclein, in which the protein molecules have been covalently modified by baicalein quinone to form a Schiff base with a lysine side chain in alpha-synuclein. The binding of baicalein was abolished by conversion of the Tyr residues into Phe, demonstrating that Tyr is involved in the interaction of alpha-synuclein with baicalein. In disaggregation baicalein causes fragmentation throughout the length of the fibril. These observations suggest that baicalein and similar compounds may have potential as therapeutic leads in combating Parkinson's disease and that diets rich in flavonoids may be effective in preventing the disorder.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Calif State Univ Los Angeles, Los Angeles, CA 90032 USA	University of California System; University of California Santa Cruz; California State University System; California State University Los Angeles	Fink, AL (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.	enzyme@cats.ucsc.edu	Kaylor, Joanna/Y-5184-2019		NINDS NIH HHS [NS43778] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS043778] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABBOTT RA, 1992, EUR J CLIN NUTR, V46, P879; Anguiano M, 2002, BIOCHEMISTRY-US, V41, P11338, DOI 10.1021/bi020314u; Asanuma M, 2003, NEUROTOX RES, V5, P165, DOI 10.1007/BF03033137; BENESI HA, 1949, J AM CHEM SOC, V71, P2703, DOI 10.1021/ja01176a030; Braak H, 2000, J NEUROL, V247, P3; Butterfield DA, 2001, MECH AGEING DEV, V122, P945, DOI 10.1016/S0047-6374(01)00249-4; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Commenges D, 2000, EUR J EPIDEMIOL, V16, P357, DOI 10.1023/A:1007614613771; da Costa CA, 2003, CURR MOL MED, V3, P17, DOI 10.2174/1566524033361690; Datla KP, 2001, NEUROREPORT, V12, P3871, DOI 10.1097/00001756-200112040-00053; El-Agnaf OMA, 2001, J MOL BIOL, V310, P157, DOI 10.1006/jmbi.2001.4743; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Gao ZH, 2001, PHARMACOL RES, V43, P173, DOI 10.1006/phrs.2000.0761; Giasson BI, 2002, FREE RADICAL BIO MED, V32, P1264, DOI 10.1016/S0891-5849(02)00804-3; GOEDERT M, 2001, PARKINSONS DIS METHO; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; Ikezoe T, 2001, PROSTATE, V49, P285, DOI 10.1002/pros.10024; Joseph JA, 1999, J NEUROSCI, V19, P8114; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Khurana R, 2003, BIOPHYS J, V85, P1135, DOI 10.1016/S0006-3495(03)74550-0; LANGE KW, 1994, J NEURAL TRANSM-SUPP, P183; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Lebeau A, 2001, NEUROREPORT, V12, P2199, DOI 10.1097/00001756-200107200-00031; Li BQ, 2000, IMMUNOPHARMACOLOGY, V49, P295, DOI 10.1016/S0162-3109(00)00244-7; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Nie GJ, 2002, REDOX REP, V7, P171, DOI 10.1179/135100002125000424; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Perry EK, 1999, J PHARM PHARMACOL, V51, P527, DOI 10.1211/0022357991772808; Prasad KN, 1999, J AM COLL NUTR, V18, P413, DOI 10.1080/07315724.1999.10718878; Schroeter H, 2000, FREE RADICAL BIO MED, V29, P1222, DOI 10.1016/S0891-5849(00)00415-9; Shieh DE, 2000, ANTICANCER RES, V20, P2861; Spencer JPE, 1996, FREE RADICAL RES, V24, P95, DOI 10.3109/10715769609088005; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Watanabe CMH, 2001, P NATL ACAD SCI USA, V98, P6577, DOI 10.1073/pnas.111126298; Wu JA, 2001, AM J CHINESE MED, V29, P69, DOI 10.1142/S0192415X01000083; Yamin G, 2003, FEBS LETT, V542, P147, DOI 10.1016/S0014-5793(03)00367-3; Zhang Y, 2000, NEUROBIOL DIS, V7, P240, DOI 10.1006/nbdi.2000.0319	41	360	371	7	58	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26846	26857		10.1074/jbc.M403129200	http://dx.doi.org/10.1074/jbc.M403129200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096521	hybrid			2022-12-25	WOS:000222120400008
J	Park, HU; Jeong, JH; Chung, JH; Brady, JN				Park, HU; Jeong, JH; Chung, JH; Brady, JN			Human T-cell leukemia virus type 1 Tax interacts with Chk1 and attenuates DNA-damage induced G(2) arrest mediated by Chk1	ONCOGENE			English	Article						HTLV-1 Tax; Chk1; interaction; attenuation; G(2) checkpoint	TELANGIECTASIA-MUTATED ATM; PRIMARY HUMAN-LYMPHOCYTES; S-PHASE CHECKPOINT; HTLV-I; IONIZING-RADIATION; TRANSACTIVATION FUNCTION; TUMOR-SUPPRESSOR; GENE-EXPRESSION; PROTEIN-KINASE; CANCER-CELLS	Checkpoint kinase 1 (Chk1) mediates diverse cellular responses to genotoxic stress, regulating the network of genome-surveillance pathways that coordinate cell cycle progression with DNA repair. Chk1 is essential for mammalian development and viability, and has been shown to be important for both S and G(2) checkpoints. We now present evidence that the HTLV-1 Tax protein interacts directly with Chk1 and impairs its kinase activities in vitro and in vivo. The direct and physical interaction of Chk1 and Tax was observed in HTLV-1-infected T cells (C81, HuT 102 and MT-2) and transfected fibroblasts (293 T) by coimmunoprecipitation and by in vitro GST pull-down assays. Interestingly, Tax inhibited the kinase activity of Chk1 protein in in vitro and in vivo kinase assays. Consistent with these results, Tax inhibited the phosphorylation-dependent degradation of Cdc25A and G(2) arrest in response to gamma-irradiation (IR) in a dose-dependent manner in vivo. The G(2) arrest did not require Chk2 or p53. These studies provide the first example of a viral transforming protein targeting Chk1 and provide important insights into checkpoint pathway regulation.	NCI, Virus Tumor Biol Sect, Cellular Oncol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Brady, JN (corresponding author), NCI, Virus Tumor Biol Sect, Cellular Oncol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA.	bradyj@exchange.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC005691, Z01BC005691] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002243, Z01HL002243] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Anderson CW, 1998, J PROTEIN CHEM, V17, P527; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Ariumi Y, 2003, ONCOGENE, V22, P1611, DOI 10.1038/sj.onc.1206244; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Chen ZH, 2003, MOL CANCER THER, V2, P543; Clifford B, 2003, CANCER RES, V63, P4074; Coscoy L, 1998, VIROLOGY, V248, P332, DOI 10.1006/viro.1998.9298; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Guerra B, 2003, ONCOGENE, V22, P4933, DOI 10.1038/sj.onc.1206721; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Haoudi A, 2003, VIROLOGY, V305, P229, DOI 10.1006/viro.2002.1642; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jeang KT, 1997, J VIROL, V71, P6277, DOI 10.1128/JVI.71.9.6277-6278.1997; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Johnson JM, 2001, INT J EXP PATHOL, V82, P135, DOI 10.1046/j.1365-2613.2001.00191.x; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; Lemoine FJ, 2000, AIDS RES HUM RETROV, V16, P1623, DOI 10.1089/08892220050193056; Liu QH, 2000, GENE DEV, V14, P1448; Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1159/000064998; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McGowan CH, 2002, BIOESSAYS, V24, P502, DOI 10.1002/bies.10101; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; MIWA M, 1984, GANN, V75, P752; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Pise-Masison CA, 2001, J BIOL CHEM, V276, P200, DOI 10.1074/jbc.M005601200; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Shieh SY, 2000, GENE DEV, V14, P289; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Sugiyama K, 2000, INT J CANCER, V85, P703, DOI 10.1002/(SICI)1097-0215(20000301)85:5<703::AID-IJC17>3.0.CO;2-7; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yu Q, 2002, CANCER RES, V62, P5743; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao B, 2002, J BIOL CHEM, V277, P46609, DOI 10.1074/jbc.M201233200; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	73	46	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					4966	4974		10.1038/sj.onc.1207644	http://dx.doi.org/10.1038/sj.onc.1207644			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15107832				2022-12-25	WOS:000222237300002
J	Akama, H; Matsuura, T; Kashiwagi, S; Yoneyama, H; Narita, SI; Tsukihara, T; Nakagawa, A; Nakae, T				Akama, H; Matsuura, T; Kashiwagi, S; Yoneyama, H; Narita, SI; Tsukihara, T; Nakagawa, A; Nakae, T			Crystal structure of the membrane fusion protein, MexA, of the multidrug transporter in Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPRM EFFLUX PUMP; ANTIBIOTIC EXTRUSION; RESISTANCE; EXPRESSION; FAMILY; ACRA; INVOLVEMENT; REFINEMENT; SUBUNIT; GENE	The MexAB-OprM efflux pump of Pseudomonas aeruginosa is central to multidrug resistance of this organism, which infects immunocompromised hospital patients. The MexA, MexB, and OprM subunits were assumed to function as the membrane fusion protein, the body of the transporter, and the outer membrane channel protein, respectively. For better understanding of this important xenobiotic transporter, we show the x-ray crystallographic structure of MexA at a resolution of 2.40 Angstrom. The global MexA structure showed unforeseen new features with a spiral assembly of six and seven protomers that were joined together at one end by a pseudo 2-fold image. The protomer showed a new protein structure with a tandem arrangement consisting of at least three domains and presumably one more. The rod domain had a long hairpin of twisted coiled-coil that extended to one end. The second domain adjacent to the rod alpha-helical domain was globular and constructed by a cluster of eight short beta-sheets. The third domain located distal to the alpha-helical rod was globular and composed of seven short beta-sheets and one short alpha-helix. The 13-mer was shaped like a woven rattan cylinder with a large internal tubular space and widely opened flared ends. The 6-mer and 7-mer had a funnel-like structure consisting of a tubular rod at one side and a widely opened flared funnel top at the other side. Based on these results, we constructed a model of the MexAB-OprM pump assembly. The three pairs of MexA dimers interacted with the periplasmic alpha-barrel domain of OprM via the alpha-helical hairpin, the second domain interacted with both MexB and OprM at their contact site, and the third and disordered domains probably interacted with the distal domain of MexB. In this fashion, the MexA subunit connected MexB and OprM, indicating that MexA is the membrane bridge protein.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 2591193, Japan	Osaka University; Tokai University	Nakagawa, A (corresponding author), Osaka Univ, Inst Prot Res, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	atsushi@protein.osaka-u.ac.jp	Nakagawa, Atsushi/M-5731-2019; Nakagawa, Atsushi/D-4329-2009; Matsuura, Takanori/J-1413-2012	Nakagawa, Atsushi/0000-0002-1700-7861; Nakagawa, Atsushi/0000-0002-1700-7861; Matsuura, Takanori/0000-0003-2001-9537; Narita, Shin-ichiro/0000-0001-9425-2943				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Avila-Sakar AJ, 2001, J STRUCT BIOL, V136, P81, DOI 10.1006/jsbi.2001.4418; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P41; BRUNGER AT, 1998, ACTA CRYSTALLGOR D, V54, P240; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DINH T, 1994, J BACTERIOL, V176, P3825, DOI 10.1128/JB.176.13.3825-3831.1994; DONG QH, 1994, MOL MICROBIOL, V14, P185, DOI 10.1111/j.1365-2958.1994.tb01278.x; Eda S, 2003, J BIOL CHEM, V278, P2085, DOI 10.1074/jbc.C200661200; Elkins CA, 2003, J BACTERIOL, V185, P5349, DOI 10.1128/JB.185.18.5349-5356.2003; GRAHAM LL, 1991, TRENDS BIOCHEM SCI, V16, P328, DOI 10.1016/0968-0004(91)90135-I; Guan L, 1999, J BIOL CHEM, V274, P10517, DOI 10.1074/jbc.274.15.10517; Guan L, 2001, J BACTERIOL, V183, P1734, DOI 10.1128/JB.183.5.1734-1739.2001; Johnson JM, 1999, J MOL BIOL, V287, P695, DOI 10.1006/jmbi.1999.2630; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LI XZ, 1995, ANTIMICROB AGENTS CH, V39, P1948, DOI 10.1128/AAC.39.9.1948; Ma Dzwokai, 1994, Trends in Microbiology, V2, P489, DOI 10.1016/0966-842X(94)90654-8; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORSHED SRM, 1995, BIOCHEM BIOPH RES CO, V210, P356, DOI 10.1006/bbrc.1995.1669; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nakajima A, 2000, J BIOL CHEM, V275, P30064, DOI 10.1074/jbc.M005742200; Narita S, 2003, BIOCHEM BIOPH RES CO, V308, P922, DOI 10.1016/S0006-291X(03)01512-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Paulsen IT, 1997, FEMS MICROBIOL LETT, V156, P1, DOI 10.1111/j.1574-6968.1997.tb12697.x; POOLE K, 1993, J BACTERIOL, V175, P7363, DOI 10.1128/JB.175.22.7363-7372.1993; POOLE K, 1993, MOL MICROBIOL, V10, P529, DOI 10.1111/j.1365-2958.1993.tb00925.x; Poole K, 2001, J MOL MICROB BIOTECH, V3, P255; RELLA M, 1982, ANTIMICROB AGENTS CH, V22, P242, DOI 10.1128/AAC.22.2.242; Saito K, 2001, FEMS MICROBIOL LETT, V195, P23, DOI 10.1016/S0378-1097(00)00539-5; Sheldrick GM, 1997, METHOD ENZYMOL, V276, P628, DOI 10.1016/S0076-6879(97)76083-X; Srikumar R, 2000, J BACTERIOL, V182, P1410, DOI 10.1128/JB.182.5.1410-1414.2000; Tseng Tsai-Tien, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P107; Yoneyama H, 1997, BIOCHEM BIOPH RES CO, V233, P611, DOI 10.1006/bbrc.1997.6506; Yoneyama H, 2000, J BIOL CHEM, V275, P4628, DOI 10.1074/jbc.275.7.4628; Zgurskaya HI, 2000, J BACTERIOL, V182, P4264, DOI 10.1128/JB.182.15.4264-4267.2000	42	213	225	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					25939	25942		10.1074/jbc.C400164200	http://dx.doi.org/10.1074/jbc.C400164200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15117957	Green Published, hybrid			2022-12-25	WOS:000222003000002
J	Tian, MY; Huitema, E; da Cunha, L; Torto-Alalibo, T; Kamoun, S				Tian, MY; Huitema, E; da Cunha, L; Torto-Alalibo, T; Kamoun, S			A Kazal-like extracellular serine protease inhibitor from Phytophthora infestans targets the tomato pathogenesis-related protease P69B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXOPLASMA-GONDII; CLADOSPORIUM-FULVUM; PROTEINASE-INHIBITOR; MOLECULAR-CLONING; RESISTANCE; DATABASE; SEQUENCE; FAMILIES; ELICITORS; PLANTS	The oomycetes form one of several lineages within the eukaryotes that independently evolved a parasitic lifestyle and consequently are thought to have developed alternative mechanisms of pathogenicity. The oomycete Phytophthora infestans causes late blight, a ravaging disease of potato and tomato. Little is known about processes associated with P. infestans pathogenesis, particularly the suppression of host defense responses. We describe and functionally characterize an extracellular protease inhibitor, EPI1, from P. infestans. EPI1 contains two domains with significant similarity to the Kazal family of serine protease inhibitors. Database searches suggested that Kazal-like proteins are mainly restricted to animals and apicomplexan parasites but appear to be widespread and diverse in the oomycetes. Recombinant EPI1 specifically inhibited subtilisin A among major serine proteases and inhibited and interacted with the pathogenesis-related P69B subtilisin-like serine protease of tomato in intercellular fluids. The epi1 and P69B genes were coordinately expressed and up-regulated during infection of tomato by P. infestans. Inhibition of tomato proteases by EPI1 could form a novel type of defense-counterdefense mechanism between plants and microbial pathogens. In addition, this study points to a common virulence strategy between the oomycete plant pathogen P. infestans and several mammalian parasites, such as the apicomplexan Toxoplasma gondii.	Ohio State Univ, Ohio Agr Res & Dev Ctr, Dept Plant Pathol, Wooster, OH 44691 USA	University System of Ohio; Ohio State University	Kamoun, S (corresponding author), Ohio State Univ, Ohio Agr Res & Dev Ctr, Dept Plant Pathol, 1680 Madison Ave, Wooster, OH 44691 USA.	kamoun.1@osu.edu	Kamoun, Sophien/B-3529-2009; Huitema, Edgar/G-3760-2011	Kamoun, Sophien/0000-0002-0290-0315; Huitema, Edgar/0000-0002-5766-0830; Tian, Miaoying/0000-0001-8900-6414				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andreu A, 1998, EUR J PLANT PATHOL, V104, P777, DOI 10.1023/A:1008602910733; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Birch PRJ, 2001, MOL PLANT PATHOL, V2, P257, DOI 10.1046/j.1464-6722.2001.00073.x; Bouarab K, 2002, NATURE, V418, P889, DOI 10.1038/nature00950; CATEN CE, 1968, CAN J BOTANY, V46, P329, DOI 10.1139/b68-055; Chain P, 2003, J BACTERIOL, V185, P2759, DOI 10.1128/JB.185.9.2759-2773.2003; Coffeen WC, 2004, PLANT CELL, V16, P857, DOI 10.1105/tpc.017947; Delaria KA, 1997, J BIOL CHEM, V272, P12209, DOI 10.1074/jbc.272.18.12209; DEWIT PJGM, 1982, PHYSIOL PLANT PATHOL, V21, P1, DOI 10.1016/0048-4059(82)90002-9; Dubey JP, 1998, PARASITOLOGY, V116, P43, DOI 10.1017/S0031182097001935; Hanna SL, 2000, MICROBIOL-UK, V146, P2495, DOI 10.1099/00221287-146-10-2495; HEATH MC, 1995, CAN J BOT, V73, pS616, DOI 10.1139/b95-303; Heath MC, 2000, PLANT MOL BIOL, V44, P321, DOI 10.1023/A:1026592509060; Henikoff JG, 2000, NUCLEIC ACIDS RES, V28, P228, DOI 10.1093/nar/28.1.228; HUITEMA E, 2003, FUNCTIONAL GENOMICS, P79; Joosten MHAJ, 1997, PLANT CELL, V9, P367; Jorda L, 1999, J BIOL CHEM, V274, P2360, DOI 10.1074/jbc.274.4.2360; Kamoun S, 1998, PLANT CELL, V10, P1413, DOI 10.1105/tpc.10.9.1413; KAMOUN S, 1993, MOL PLANT MICROBE IN, V6, P15, DOI 10.1094/MPMI-6-015; Kamoun S, 2003, EUKARYOT CELL, V2, P191, DOI 10.1128/EC.2.2.191-199.2003; Kamoun S, 1997, MOL PLANT MICROBE IN, V10, P13, DOI 10.1094/MPMI.1997.10.1.13; Karsch-Mizrachi I, 2001, Methods Biochem Anal, V43, P45; Kruger J, 2002, SCIENCE, V296, P744, DOI 10.1126/science.1069288; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Lindh JG, 2001, MOL BIOCHEM PARASIT, V116, P137, DOI 10.1016/S0166-6851(01)00314-0; Lu SM, 2001, P NATL ACAD SCI USA, V98, P1410, DOI 10.1073/pnas.031581398; Lu WY, 1997, J MOL BIOL, V266, P441, DOI 10.1006/jmbi.1996.0781; MARGULIS L, 2000, 5 KINGDOMS ILLUSTRAT, P168; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; Milstone AM, 2000, J BIOL CHEM, V275, P29391, DOI 10.1074/jbc.M002715200; Morris MT, 2003, MOL BIOCHEM PARASIT, V128, P119, DOI 10.1016/S0166-6851(03)00051-3; Morris MT, 2002, J BIOL CHEM, V277, P45259, DOI 10.1074/jbc.M205517200; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; NIELSEN H, 1998, P 6 INT C INT SYST M, P122; Pszenny V, 2000, MOL BIOCHEM PARASIT, V107, P241, DOI 10.1016/S0166-6851(00)00202-4; Pszenny V, 2002, MOL BIOCHEM PARASIT, V121, P283, DOI 10.1016/S0166-6851(02)00045-2; Ristaino JB, 2002, MICROBES INFECT, V4, P1369, DOI 10.1016/S1286-4579(02)00010-2; Rose JKC, 2002, PLANT CELL, V14, P1329, DOI 10.1105/tpc.002253; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanchez Leandro M., 1992, Annals of the Phytopathological Society of Japan, V58, P664, DOI 10.3186/jjphytopath.58.664; Shattock RC, 2002, PEST MANAG SCI, V58, P944, DOI 10.1002/ps.527; SHEWMAKER CK, 1990, NUCLEIC ACIDS RES, V18, P4276, DOI 10.1093/nar/18.14.4276; Smart C. D., 2001, Biological Invasions, V3, P235, DOI 10.1023/A:1015200920772; Sogin ML, 1998, INT J PARASITOL, V28, P11, DOI 10.1016/S0020-7519(97)00181-1; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tornero P, 1997, J BIOL CHEM, V272, P14412, DOI 10.1074/jbc.272.22.14412; Torto TA, 2002, CURR GENET, V40, P385, DOI 10.1007/s00294-002-0272-4; Torto TA, 2003, GENOME RES, V13, P1675, DOI 10.1101/gr.910003; UNKLES SE, 1991, GENE, V100, P105, DOI 10.1016/0378-1119(91)90355-F; Van Loon LC, 1999, PHYSIOL MOL PLANT P, V55, P85, DOI 10.1006/pmpp.1999.0213; VANDENACKERVEKEN GFJM, 1993, PLANT PHYSIOL, V103, P91, DOI 10.1104/pp.103.1.91; Waugh M, 2000, NUCLEIC ACIDS RES, V28, P87, DOI 10.1093/nar/28.1.87; Woltering EJ, 2002, PLANT PHYSIOL, V130, P1764, DOI 10.1104/pp.006338; Yoshioka Hirofumi, 1995, Annals of the Phytopathological Society of Japan, V61, P7, DOI 10.3186/jjphytopath.61.7	56	216	234	2	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26370	26377		10.1074/jbc.M400941200	http://dx.doi.org/10.1074/jbc.M400941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15096512	hybrid			2022-12-25	WOS:000222003000057
J	Wu, KL; Khan, S; Lakhe-Reddy, S; Jarad, G; Mukherjee, A; Obejero-Paz, CA; Konieczkowski, M; Sedor, JR; Schelling, JR				Wu, KL; Khan, S; Lakhe-Reddy, S; Jarad, G; Mukherjee, A; Obejero-Paz, CA; Konieczkowski, M; Sedor, JR; Schelling, JR			The NHE1 Na+/H+ exchanger recruits ezrin/radixin/moesin proteins to regulate Akt-dependent cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOTIC VOLUME DECREASE; INTRACELLULAR PH; ERM PROTEINS; CASPASE ACTIVATION; OSMOTIC-STRESS; PATHWAY; MECHANISMS; GROWTH; EXPRESSION; TRANSLOCATION	Apoptosis results in cell shrinkage and intracellular acidification, processes opposed by the ubiquitously expressed NHE1 Na+/H+ exchanger. In addition to mediating Na+/H+ transport, NHE1 interacts with ezrin/radixin/moesin (ERM), which tethers NHE1 to cortical actin cytoskeleton to regulate cell shape, adhesion, motility, and resistance to apoptosis. We hypothesize that apoptotic stress activates NHE1-dependent Na+/H+ exchange, and NHE1-ERM interaction is required for cell survival signaling. Apoptotic stimuli induced NHE1-regulated Na+/H+ transport, as demonstrated by ethyl-N-isopropyl-amiloride-inhibitable, intracellular alkalinization. Ectopic NHE1, but not NHE3, expression rescued NHE1-null cells from apoptosis induced by staurosporine or N-ethylmaleimide-stimulated KCl efflux. When cells were subjected to apoptotic stress, NHE1 and phosphorylated ERM physically associated within the cytoskeleton-enriched fraction, resulting in activation of the pro-survival kinase, Akt. NHE1-associated Akt activity and cell survival were inhibited in cells expressing ERM binding-deficient NHE1, dominant negative ezrin constructs, or ezrin mutants with defective binding to phosphoinositide 3-kinase, an upstream regulator of Akt. We conclude that NHE1 promotes cell survival by dual mechanisms: by defending cell volume and pH(i) through Na+/H+ exchange and by functioning as a scaffold for recruitment of a signalplex that includes ERM, phosphoinositide 3-kinase, and Akt.	Case Western Reserve Univ, Rammelkamp Ctr Res, Dept Med, Cleveland, OH 44109 USA; Case Western Reserve Univ, Rammelkamp Ctr Res, Dept Physiol & Biophys, Cleveland, OH 44109 USA	Case Western Reserve University; MetroHealth System; Case Western Reserve University; MetroHealth System	Schelling, JR (corresponding author), 2500 MetroHlth Dr,G531, Cleveland, OH 44109 USA.	jeffrey.schelling@case.edu	Mukherjee, Amitava/AAK-4002-2020	Mukherjee, Amitava/0000-0001-5603-5147	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK054178, R01DK064719, R01DK038558] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK054178, DK64719, DK38558] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aharonovitz O, 2000, J CELL BIOL, V150, P213, DOI 10.1083/jcb.150.1.213; Barriere H, 2001, AM J PHYSIOL-CELL PH, V281, pC810, DOI 10.1152/ajpcell.2001.281.3.C810; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BIANCHINI L, 1995, AM J PHYSIOL-CELL PH, V269, pC998, DOI 10.1152/ajpcell.1995.269.4.C998; Bortner CD, 2003, J BIOL CHEM, V278, P39176, DOI 10.1074/jbc.M303516200; Bortner CD, 2002, CELL DEATH DIFFER, V9, P1307, DOI 10.1038/sj.cdd.4401126; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chambrey R, 1997, AM J PHYSIOL-CELL PH, V273, pC1064, DOI 10.1152/ajpcell.1997.273.3.C1064; Denker SP, 2002, J CELL BIOL, V159, P1087, DOI 10.1083/jcb.200208050; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; Ingber DE, 2003, J CELL SCI, V116, P1397, DOI 10.1242/jcs.00360; Jarad G, 2002, J BIOL CHEM, V277, P47826, DOI 10.1074/jbc.M204901200; Khan S, 2001, KIDNEY INT, V60, P65, DOI 10.1046/j.1523-1755.2001.00771.x; Khan S, 1999, LAB INVEST, V79, P1089; KITAMURA K, 1995, AM J PHYSIOL, V268, P101; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lang F, 2000, PFLUG ARCH EUR J PHY, V440, P902, DOI 10.1007/s004240000358; Lauf PK, 2000, CELL PHYSIOL BIOCHEM, V10, P341, DOI 10.1159/000016357; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; Nath SK, 1996, AM J PHYSIOL-GASTR L, V270, pG431, DOI 10.1152/ajpgi.1996.270.3.G431; Okada Y, 2001, J PHYSIOL-LONDON, V532, P3, DOI 10.1111/j.1469-7793.2001.0003g.x; Orlov SN, 1996, BIOCHEM BIOPH RES CO, V221, P708, DOI 10.1006/bbrc.1996.0661; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Perez OD, 2002, IMMUNITY, V16, P51, DOI 10.1016/S1074-7613(02)00266-2; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scanga SE, 2000, ONCOGENE, V19, P3971, DOI 10.1038/sj.onc.1203739; Schelling JR, 1996, AM J PHYSIOL-RENAL, V270, pF682, DOI 10.1152/ajprenal.1996.270.4.F682; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; Segal MS, 2001, AM J PHYSIOL-CELL PH, V281, pC1196, DOI 10.1152/ajpcell.2001.281.4.C1196; Soleimani M, 1998, KIDNEY INT, V53, P423, DOI 10.1046/j.1523-1755.1998.00771.x; Tafani M, 2002, J BIOL CHEM, V277, P49569, DOI 10.1074/jbc.M208915200; Takeda T, 2001, J CLIN INVEST, V108, P289, DOI 10.1172/JCI12539; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Weinman EJ, 2000, AM J PHYSIOL-RENAL, V279, pF393, DOI 10.1152/ajprenal.2000.279.3.F393; Wu KL, 2003, AM J PHYSIOL-RENAL, V284, pF829, DOI 10.1152/ajprenal.00314.2002	47	138	142	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26280	26286		10.1074/jbc.M400814200	http://dx.doi.org/10.1074/jbc.M400814200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15096511	hybrid			2022-12-25	WOS:000222003000046
J	Chung, TW; Lee, YC; Kim, CH				Chung, TW; Lee, YC; Kim, CH			Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERKs and PI-3K/AKT pathways: Involvement of invasive potential	FASEB JOURNAL			English	Article						hepatitis B virus X protein; extracellular signal-regulated kinase 1/2; phosphatidylinositol 3-kinase; activating protein-1; nuclear factor-kappa B	VIRUS-X-PROTEIN; NF-KAPPA-B; IV COLLAGENASE EXPRESSION; MATRIX METALLOPROTEINASES; PHOSPHATIDYLINOSITOL 3-KINASE; METASTATIC PHENOTYPE; GELATINASE-B; TRANSCRIPTIONAL ACTIVITY; GROWTH-FACTORS; DNA-BINDING	Hepatitis B virus (HBV) X protein (HBx) has been shown to be essential for the development of hepatocellular carcinoma (HCC). Recently, we have found that HBx causes the progression of liver cancer through down-expression of PTEN, known as a tumor suppressor gene ( 1). The prognosis for HCC depends mainly on the clinicopathological characteristic regarding invasion and metastasis. The expression of matrix metalloproteinase (MMP)-9 has been implicated as playing an important role in HCC invasion and metastasis. We previously reported that HBV infection increased the invasiveness of hepatocytes and HCC cells through the transcriptional activation of MMP-9 (2). The HBx was shown to activate the mitogen-activated protein (MAP) kinase and phosphatidylinositol 3-kinase (PI-3K) signal cascade, which is essential for activation of transcription factors such as activating protein (AP)-1 and nuclear factor (NF)-kappaB. In this study, we show that the HBx protein stimulates the activities of the PI-3K-Akt/protein kinase B (PKB) as well as extracellular signal-regulated kinase 1/2 (ERK 1/2) in HBx-transfected cells. Furthermore, we have shown that enhanced expression of MMP-9 in HBx-transfected cells mediated by not only activation of AP-1 transcriptional activity through ERKs pathway but also activation of NF-kappaB transcriptional activity through PI-3K-AKT/PKB pathway, and was associated with the invasive potential. However, treatment with U0126 ( known as the ERKs inhibitor) or wortmannin ( known as the PI-3K inhibitor), but not SB203580 ( known as the p38 MAPK inhibitor), markedly inhibited the expression of MMP-9 induced by HBx in HBx-transfected cells. Seemingly, the invasiveness of HBx-transfected cells was decreased by treating with U0126 or wortmannin, but not SB203580. These results clearly suggest that the HBx contributed to the transcriptional regulation of MMP-9 through the ERKs and PI-3K-AKT/PKB pathway, and increased an invasive potential of cells.	Dongguk Univ, Coll Oriental Med, Natl Res Labs Glycobiol, MOST, Kyungju 780714, Kyungbuk, South Korea; Dongguk Univ, Coll Oriental Med, Dept Biochem & Mol Biol, Kyungju 780714, Kyungbuk, South Korea; Dong A Univ, Fac Biotechnol, Pusan 604714, South Korea	Dongguk University; Dongguk University; Dong A University	Kim, CH (corresponding author), Dongguk Univ, Coll Oriental Med, Natl Res Labs Glycobiol, MOST, Sukjang Dong 707, Kyungju 780714, Kyungbuk, South Korea.	chkimbio@dongguk.ac.kr		Kim, Cheorl-Ho/0000-0002-6323-0714; Chung, Tae-Wook/0000-0001-5243-5020				Abiru S, 2002, HEPATOLOGY, V35, P1117, DOI 10.1053/jhep.2002.32676; Arii S, 1996, HEPATOLOGY, V24, P316; Basset P, 1997, MATRIX BIOL, V15, P535, DOI 10.1016/S0945-053X(97)90028-7; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; Chung TW, 2002, ARCH BIOCHEM BIOPHYS, V408, P147, DOI 10.1016/S0003-9861(02)00522-2; Chung TW, 2003, CANCER RES, V63, P3453; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FINI ME, 1994, J BIOL CHEM, V269, P28620; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; GARBISA S, 1987, CANCER RES, V47, P1523; Genersch E, 2000, J CELL SCI, V113, P4319; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Hayasaka A, 1996, HEPATOLOGY, V24, P1058; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; Jiang BB, 2002, ARTERIOSCL THROM VAS, V22, P1811, DOI 10.1161/01.ATV.0000037679.60584.3F; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; KOHN EC, 1995, CANCER RES, V55, P1856; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; Lee YI, 2001, J BIOL CHEM, V276, P16969, DOI 10.1074/jbc.M011263200; LENGYEL E, 1995, CANCER RES, V55, P963; LEVY AT, 1991, CANCER RES, V51, P439; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; Lochter A, 1999, APMIS, V107, P128, DOI 10.1111/j.1699-0463.1999.tb01535.x; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MASURE S, 1993, EUR J BIOCHEM, V218, P129, DOI 10.1111/j.1432-1033.1993.tb18359.x; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MENZO S, 1993, VIROLOGY, V196, P878, DOI 10.1006/viro.1993.1550; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MONTGOMERY AMP, 1993, CANCER RES, V53, P693; NATOLI G, 1994, ONCOGENE, V9, P2837; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Prost S, 1998, J BIOL CHEM, V273, P33327, DOI 10.1074/jbc.273.50.33327; Rao JS, 1996, CLIN EXP METASTAS, V14, P12, DOI 10.1007/BF00157681; RAO JS, 1993, CANCER RES, V53, P2208; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Sakamoto Y, 2000, INT J ONCOL, V17, P237; SATO H, 1993, ONCOGENE, V8, P395; Sato T, 2002, CANCER RES, V62, P1025; Scorilas A, 2001, BRIT J CANCER, V84, P1488, DOI 10.1054/bjoc.2001.1810; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; TIOLLAIS P, 1981, SCIENCE, V213, P406, DOI 10.1126/science.6264599; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WATANABE H, 1993, J CELL SCI, V104, P991; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427	68	276	303	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1123	+		10.1096/fj.03-1429fje	http://dx.doi.org/10.1096/fj.03-1429fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132991				2022-12-25	WOS:000221883200023
J	Nemes, Z; Devreese, B; Steinert, PM; Van Beeumen, J; Fesus, L				Nemes, Z; Devreese, B; Steinert, PM; Van Beeumen, J; Fesus, L			Cross-linking of ubiquitin, HSP27, parkin and alpha-synuclein by gamma-glutamyl-epsilon-lysine bonds in Alzheimer's neurofibrillary tangles	FASEB JOURNAL			English	Article						transglutaminase; neurodegeneration; proteasome; neurofibrillary tangles	PAIRED HELICAL FILAMENTS; SODIUM DODECYL-SULFATE; HEAT-SHOCK-PROTEIN; LEWY BODIES; HUNTINGTONS-DISEASE; NEURODEGENERATIVE DISORDERS; PROTEASOME INHIBITION; CEREBROSPINAL-FLUID; TAU-PROTEIN; CELL-DEATH	The accumulation of misfolded proteins in intracellular inclusions is a generic feature of neurodegenerative disorders. Although heavily ubiquitylated, the aggregated proteins are not degraded by the proteasomes. A possible reason for this phenomenon may be a modification of deposited proteins by transglutaminases forming gamma-glutamyl-epsilon-lysine (GGEL) cross-links between distinct proteins. Here, we show that the frequency of GGEL cross-links is an order of magnitude higher in Alzheimer's brain cortex than in age-matched or younger controls. This difference is due to the accumulation of GGEL cross-links in ubiquitin-immunopositive protein particles present in both Alzheimer's brains and those from aged individuals. The highly crosslinked protein aggregates show immunoreactivity to antibodies against tau and neurofilament proteins, and partially also to alpha-synuclein, indicating that these structures are inherent in Alzheimer's neurofibrillary tangles and Lewy bodies. Using mass sequence analysis, we identified the same six pairs of peptide sequences cross-linked in both senile and Alzheimer's specimens: Gln(31) and Gln(190) of HSP27 protein are cross-linked with Lys(29) and Lys(48) of ubiquitin and HSP27 therefore may cross-link two (poly) ubiquitin chains. One lysine residue of parkin and one of alpha-synuclein were also found to be cross-linked. The data suggest that cross-linking of (poly) ubiquitin moieties via HSP27 may have a role in the stabilization of the intraneuronal protein aggregates by interference with the proteasomal elimination of unfolded proteins.	Univ Debrecen, Res Ctr Mol Med, Hungarian Acad Sci, Dept Psychiat, H-4012 Debrecen, Hungary; Univ Debrecen, Res Ctr Mol Med, Hungarian Acad Sci, Dept Biochem & Mol Biol, H-4012 Debrecen, Hungary; Univ Debrecen, Res Ctr Mol Med, Hungarian Acad Sci, Signaling & Apoptosis Res Grp, H-4012 Debrecen, Hungary; Univ Ghent, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium; NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA	Hungarian Academy of Sciences; University of Debrecen; Hungarian Academy of Sciences; University of Debrecen; Hungarian Academy of Sciences; University of Debrecen; Ghent University; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Nemes, Z (corresponding author), Univ Debrecen, Med & Hlth Sci Ctr, Dept Psychiat, Nagyerdei Krt 98, H-4012 Debrecen, Hungary.	znemes@dote.hu	Devreese, Bart/B-2011-2009; Devreese, Bart/K-2841-2019	Devreese, Bart/0000-0002-9764-2581; Devreese, Bart/0000-0002-9764-2581	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041084] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Choi P, 2001, NEUROREPORT, V12, P2839, DOI 10.1097/00001756-200109170-00017; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu CT, 2000, MODERN PATHOL, V13, P420, DOI 10.1038/modpathol.3880072; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Citron BA, 2001, J BIOL CHEM, V276, P3295, DOI 10.1074/jbc.M004776200; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Dedeoglu A, 2002, J NEUROSCI, V22, P8942; Der-Sarkissian A, 2003, J BIOL CHEM, V278, P37530, DOI 10.1074/jbc.M305266200; DUDEK SM, 1993, J NEUROCHEM, V61, P1159, DOI 10.1111/j.1471-4159.1993.tb03636.x; Fornai F, 2003, J NEUROSCI, V23, P8955; Franzblau C, 1977, Adv Exp Med Biol, V79, P313; Garcia-Sierra F, 2003, J ALZHEIMERS DIS, V5, P65, DOI 10.3233/JAD-2003-5201; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; Grenard P, 2001, J BIOL CHEM, V276, P33066, DOI 10.1074/jbc.M102553200; Grierson AJ, 2001, NEUROSCI LETT, V298, P9, DOI 10.1016/S0304-3940(00)01714-6; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; Iseki E, 2002, J NEUROL SCI, V195, P85, DOI 10.1016/S0022-510X(01)00689-X; Ishizawa T, 2003, J NEUROPATH EXP NEUR, V62, P389, DOI 10.1093/jnen/62.4.389; Itoh Y, 1998, J NEUROL SCI, V157, P73, DOI 10.1016/S0022-510X(98)00050-1; Jeitner TM, 2001, J NEUROCHEM, V79, P1109, DOI 10.1046/j.1471-4159.2001.00673.x; Kim SY, 1999, J BIOL CHEM, V274, P30715, DOI 10.1074/jbc.274.43.30715; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNOX G, 1988, NEUROSCI LETT, V94, P211, DOI 10.1016/0304-3940(88)90297-2; Li L, 2002, J BIOL CHEM, V277, P41390, DOI 10.1074/jbc.M206334200; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; Martin-Aparicio E, 2001, J NEUROSCI, V21, P8772, DOI 10.1523/JNEUROSCI.21-22-08772.2001; Mattson MP, 2002, PHYSIOL REV, V82, P637, DOI 10.1152/physrev.00004.2002; McNaught KS, 2002, NEUROREPORT, V13, P1437, DOI 10.1097/00001756-200208070-00018; McNaught KSP, 2002, EUR J NEUROSCI, V16, P2136, DOI 10.1046/j.1460-9568.2002.02301.x; Miller RJ, 2003, TRENDS PHARMACOL SCI, V24, P18, DOI 10.1016/S0165-6147(02)00011-1; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; Murthy SNP, 1998, J NEUROCHEM, V71, P2607; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; Nemes Z, 2001, NEUROBIOL AGING, V22, P403, DOI 10.1016/S0197-4580(01)00224-X; Norlund MA, 1999, BRAIN RES, V851, P154, DOI 10.1016/S0006-8993(99)02179-4; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P511; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Sarvari M, 2002, ANAL BIOCHEM, V311, P187, DOI 10.1016/S0003-2697(02)00422-0; Sarvari M, 2002, DRUG DEVELOP RES, V56, P458, DOI 10.1002/ddr.10098; SELKOE DJ, 1982, SCIENCE, V215, P1243, DOI 10.1126/science.6120571; Seshadri S, 1997, NEUROLOGY, V49, P1498, DOI 10.1212/WNL.49.6.1498; Singer SM, 2002, NEUROCHEM INT, V40, P17, DOI 10.1016/S0197-0186(01)00061-4; Takeda A, 1998, AM J PATHOL, V152, P367; Tanzi RE, 1999, J CLIN INVEST, V104, P1175, DOI 10.1172/JCI8593; Terry Robert D., 1994, P179; Tsuboi Y, 2001, NEUROLOGY, V57, P1675, DOI 10.1212/WNL.57.9.1675; Tucholski J, 1999, J NEUROCHEM, V73, P1871; van de Warrenburg BPC, 2001, NEUROLOGY, V56, P555, DOI 10.1212/WNL.56.4.555; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; VATH JE, 1990, INT J MASS SPECTROM, V100, P287, DOI 10.1016/0168-1176(90)85079-H; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573	63	88	105	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1135	+		10.1096/fj.04-1493fje	http://dx.doi.org/10.1096/fj.04-1493fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132984				2022-12-25	WOS:000221883200019
J	Halawani, D; Mondeh, R; Stanton, LA; Beier, F				Halawani, D; Mondeh, R; Stanton, LA; Beier, F			p38 MAP kinase signaling is necessary for rat chondrosarcoma cell proliferation	ONCOGENE			English	Article						chondrosarcoma; p38 MAPK; cell cycle; cyclins; p21(waf1/cip1)	ACTIVATED PROTEIN-KINASE; CYCLIN-A PROMOTER; TRANSCRIPTION FACTOR-2; RETINOBLASTOMA PROTEIN; MELANOMA-CELLS; D1; DIFFERENTIATION; INDUCTION; EXPRESSION; CHONDROCYTES	Chondrosarcomas represent the second most frequent class of primary skeletal malignancies. This tumor type is highly resistant to radiation therapy and currently available chemotherapies, thereby limiting treatment choice to surgical resection. Identifying the mechanisms responsible for chondrosarcoma cell proliferation is therefore crucial for the development of new treatment strategies. Here, we demonstrate a significant reduction in rat chondrosarcoma cell proliferation following treatment with pharmacological inhibitors (SB202190 and PD169316) of p38 mitogen-activated protein (MAP) kinases. In an attempt to dissect possible mechanisms, we investigated the effect of p38 inhibition on promoter activity of cell-cycle genes. Surprisingly, p38 inhibition resulted in upregulation of the activities of all three D-type cyclin promoters. In addition, p38 inhibitors induced increased transcription of the cell-cycle inhibitor p21(waf1/cip1). As expected, promoter activity of the cyclin A gene, which lies downstream of D-type cyclins and p21 in cell-cycle progression, was strongly reduced by p38 inhibitors. These effects were independent of a cyclic AMP response element and conferred by the proximal 150 nucleotides of the cyclin A promoter. Decreased transcription was accompanied by greatly reduced cyclin A protein levels upon p38 inhibition. These observations indicate complex regulation of chondrosarcoma cell-cycle progression by p38 signaling, and suggest that components of p38 MAP kinase pathways may be effective targets in the treatment of these tumors.	Univ Western Ontario, Dept Physiol & Pharmacol, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Beier, F (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, London, ON N6A 5C1, Canada.	fbeier@uwo.ca	Beier, Frank/T-4734-2019; Beier, Frank/G-4595-2013; Halawani, Dalia/AAN-3261-2021	Beier, Frank/0000-0002-8505-7537; Beier, Frank/0000-0002-8505-7537; Halawani, Dalia/0000-0003-4738-0656				Aigner T, 2002, VIRCHOWS ARCH, V441, P219, DOI 10.1007/s00428-002-0641-X; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alderton F, 2001, MOL PHARMACOL, V59, P1119, DOI 10.1124/mol.59.5.1119; Ambrosino C, 2001, BIOL CELL, V93, P47, DOI 10.1016/S0248-4900(01)01124-8; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Beier F, 2000, J BIOL CHEM, V275, P12948, DOI 10.1074/jbc.275.17.12948; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Beier F, 2002, MOL ENDOCRINOL, V16, P2163, DOI 10.1210/me.2001-0103; Beier F, 2001, MOL BIOL CELL, V12, P3852, DOI 10.1091/mbc.12.12.3852; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; Carnero A, 2002, BRIT J CANCER, V87, P129, DOI 10.1038/sj.bjc.6600458; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Diehl NL, 2000, J EXP MED, V191, P321, DOI 10.1084/jem.191.2.321; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; Greenberg AK, 2002, AM J RESP CELL MOL, V26, P558, DOI 10.1165/ajrcmb.26.5.4689; Juretic N, 2001, J CELL BIOCHEM, V83, P92, DOI 10.1002/jcb.1211; Kakonen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200; KIESS M, 1995, ONCOGENE, V10, P159; Maher P, 1999, J BIOL CHEM, V274, P17491, DOI 10.1074/jbc.274.25.17491; Meyyappan M, 1998, MOL CELL BIOL, V18, P3163, DOI 10.1128/MCB.18.6.3163; Mollano Anthony V, 2002, Iowa Orthop J, V22, P1; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; PETERS G, 1994, J CELL SCI, P89; Pring ME, 2001, J BONE JOINT SURG AM, V83A, P1630, DOI 10.2106/00004623-200111000-00003; Puri PL, 2000, GENE DEV, V14, P574; Recio JA, 2002, ONCOGENE, V21, P1000, DOI 10.1038/sj.onc.1205150; Royuela M, 2002, HUM PATHOL, V33, P299, DOI 10.1053/hupa.2002.32227; Shemirani B, 2002, ORAL ONCOL, V38, P251, DOI 10.1016/S1368-8375(01)00052-5; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; Smalley KSM, 2002, MELANOMA RES, V12, P187, DOI 10.1097/00008390-200206000-00001; Sylvester AM, 1998, J CLIN INVEST, V101, P940, DOI 10.1172/JCI1630; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YAN GZ, 1995, J NEUROSCI, V15, P6200; Yosimichi G, 2001, EUR J BIOCHEM, V268, P6058, DOI 10.1046/j.0014-2956.2001.02553.x; Zhao M, 2002, ARCH BIOCHEM BIOPHYS, V400, P199, DOI 10.1016/S0003-9861(02)00028-0; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103	40	43	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3726	3731		10.1038/sj.onc.1207422	http://dx.doi.org/10.1038/sj.onc.1207422			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116104				2022-12-25	WOS:000221101700026
J	Landon, C; Thouzeau, C; Labbe, H; Bulet, P; Vovelle, F				Landon, C; Thouzeau, C; Labbe, H; Bulet, P; Vovelle, F			Solution structure of spheniscin, a beta-defensin from the penguin stomach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDES; ANTIBACTERIAL ACTIVITIES; PROGRAM; SYSTEM; IDENTIFICATION; INFECTION; REVEALS; CHICKEN; FOOD	Recently two beta-defensins, named spheniscins, have been isolated from the stomach content of the king penguin (Aptenodytes patagonicus), which is capable of preserving food for several weeks during egg incubation (Thouzeau, C., Le Maho, Y., Froget, G., Sabatier, L., Le Bohec, C., Hoffmann, J.A., and Bulet, P. (2003) J. Biol. Chem. 278, 51053-51058). It has been proposed that, in combination with other antimicrobial peptides, spheniscins may be involved in this long term preservation of food in the bird's stomach. To draw some structure/function features, the three-dimensional structure in aqueous solution of the most abundant spheniscin (Sphe-2) was determined by two-dimensional NMR and molecular modeling techniques. The overall fold of Sphe-2 includes a three-stranded antiparallel beta-sheet stabilized by three disulfide bridges with a pairing typical of beta-defensins. In addition, the N-terminal segment shows helical features on most structures. Sphe-2 is highly cationic, and its surface displays a hydrophobic patch. Comparative modeling revealed that this patch is preserved in avian defensins. The activity of Sphe-2 against a pathogenic Gram-positive strain was retained in vitro in the conditions of osmolarity found in penguin stomach content and also in different salt concentrations and compositions up to those reported for seawater. Comparison with structurally related mammalian beta-defensins showed that the hydrophobic patch is not preserved in mammalian beta-defensins and that the high cationicity of Sphe-2 is presumably the critical factor for its retained activity in high salt concentrations. Such peculiarities, in addition to a broad activity spectrum, suggest that penguin defensins may represent interesting probes for the design of highly efficient antibiotics to fight off pathogens that develop in relatively salt-rich body fluids.	Univ Orleans, Ctr Biophys Mol, CNRS, UPR 4301, F-45071 Orleans 2, France; CNRS, UPR 9010, Ctr Ecol & Physiol Energet, F-67087 Strasbourg 02, France; Atheris Labs, CH-1233 Geneva, Switzerland	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Universite de Orleans; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Vovelle, F (corresponding author), Univ Orleans, Ctr Biophys Mol, CNRS, UPR 4301, Rue Charles Sadron, F-45071 Orleans 2, France.	vovelle@cnrs-orleans.fr	BULET, Philippe/C-8557-2014	BULET, Philippe/0000-0001-9016-265X				Bateman A, 1996, J BIOL CHEM, V271, P10654, DOI 10.1074/jbc.271.18.10654; Bauer F, 2001, PROTEIN SCI, V10, P2470, DOI 10.1110/ps.ps.24401; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bulet P, 2003, INFEC DIS S, P89; CASTEELS P, 1994, BIOCHEM BIOPH RES CO, V199, P339, DOI 10.1006/bbrc.1994.1234; Cole AM, 2002, P NATL ACAD SCI USA, V99, P1813, DOI 10.1073/pnas.052706399; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dinulos JGH, 2003, CLIN DIAGN LAB IMMUN, V10, P161, DOI 10.1128/CDLI.10.1.161-166.2003; ECKERT R, 1988, ANIMAL PHYSL MECH AD, P389; Evans EW, 1995, VET MICROBIOL, V47, P295, DOI 10.1016/0378-1135(95)00126-3; EVANS EW, 1994, J LEUKOCYTE BIOL, V56, P661, DOI 10.1002/jlb.56.5.661; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Garcia JRC, 2001, CELL TISSUE RES, V306, P257, DOI 10.1007/s004410100433; Garcia-Olmedo F, 1998, BIOPOLYMERS, V47, P479, DOI 10.1002/(SICI)1097-0282(1998)47:6<479::AID-BIP6>3.0.CO;2-K; Gauthier-Clerc M, 2000, NATURE, V408, P928, DOI 10.1038/35050163; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; HARWIG SSL, 1994, FEBS LETT, V342, P281, DOI 10.1016/0014-5793(94)80517-2; Hetru C, 1997, Methods Mol Biol, V78, P35; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hoover DM, 2000, J BIOL CHEM, V275, P32911, DOI 10.1074/jbc.M006098200; Hoover DM, 2001, J BIOL CHEM, V276, P39021, DOI 10.1074/jbc.M103830200; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; Mandal M, 2002, PEPTIDES, V23, P413, DOI 10.1016/S0196-9781(01)00628-3; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sawai MV, 2001, BIOCHEMISTRY-US, V40, P3810, DOI 10.1021/bi002519d; Schibli DJ, 2002, J BIOL CHEM, V277, P8279, DOI 10.1074/jbc.M108830200; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498; Thouzeau C, 2003, POLAR BIOL, V26, P115, DOI 10.1007/s00300-002-0451-2; Thouzeau C, 2003, J BIOL CHEM, V278, P51053, DOI 10.1074/jbc.M306839200; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhao CQ, 2001, INFECT IMMUN, V69, P2684, DOI 10.1128/IAI.69.4.2684-2691.2001	43	36	41	1	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30433	30439		10.1074/jbc.M401338200	http://dx.doi.org/10.1074/jbc.M401338200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123713	hybrid			2022-12-25	WOS:000222531900070
J	Frew, IJ; Sims, NA; Quinn, JMW; Walkley, CR; Purton, LE; Bowtell, DDL; Gillespie, MT				Frew, IJ; Sims, NA; Quinn, JMW; Walkley, CR; Purton, LE; Bowtell, DDL; Gillespie, MT			Osteopenia in Siah1a mutant mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-FORMATION; TRANSCRIPTIONAL RESPONSES; UBIQUITIN LIGASE; DEGRADATION; P53; GENERATION; DEFICIENT; DECREASE; PATHWAY; CELLS	Siah1a has been implicated in numerous signaling pathways because of its ability to induce ubiquitin-mediated degradation of many protein substrates. Siah1a knockout mice are growth-retarded, exhibit early lethality, and display spermatogenic defects. In this study we identified a striking low bone volume phenotype in these mice (trabecular bone volume was halved compared with wild type mice), linking Siah1a to bone metabolism for the first time. Markers of bone formation, including osteoblast numbers and osteoid volume, were decreased by up to 40%, whereas the number of osteoclasts was more than doubled in Siah1a mutant mice. However, ex vivo osteoclast formation occurs normally and hematopoietic osteoclast progenitor cell types were present in normal numbers in Siah1a mutant mice. Moreover, adoptive transfer of Siah1a mutant bone marrow into wild type mice failed to reproduce the osteopenia or increased osteoclast numbers observed in mutant mice. Although ex vivo osteoblast colony formation was normal in Siah1a mutant mice, mineralization from these cells was elevated in cultures from Siah1a mutant mice, which may explain the reduction in osteoid volume seen in vivo. These findings suggest that although Siah1a is clearly essential for normal bone metabolism, the bone defect in Siah1a mutant mice is not due to cell-autonomous requirements for Siah1a in osteoblast or osteoclast formation. We propose that bone metabolism defects in Siah1a mutant mice are secondary to an alteration in an unidentified systemic, paracrine, or metabolic factor in these mice.	St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 3002, Australia; St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia; Univ Melbourne, Dept Med, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Biochem, Parkville, Vic 3010, Australia	St. Vincent's Institute of Medical Research; Peter Maccallum Cancer Center; St Vincent's Hospital Melbourne; University of Melbourne; University of Melbourne	Sims, NA (corresponding author), St Vincents Inst Med Res, 9 Princes St, Fitzroy, Vic 3065, Australia.	nsims@unimelb.edu.au	Bowtell, David/H-1007-2016; Walkley, Carl/AAO-6021-2020; Purton, Louise/AAI-8956-2021; Sims, Natalie Ann/A-7192-2012	Bowtell, David/0000-0001-9089-7525; Walkley, Carl/0000-0002-4784-9031; Purton, Louise/0000-0001-6593-3168; Sims, Natalie Ann/0000-0003-1421-8468; Frew, Ian/0000-0003-2735-5509; Gillespie, Matthew/0000-0001-6543-8909				Blair HC, 2002, BIOCHEM J, V364, P329, DOI 10.1042/BJ20020165; Borton AJ, 2001, J BONE MINER RES, V16, P1754, DOI 10.1359/jbmr.2001.16.10.1754; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; DELLA NG, 1993, DEVELOPMENT, V117, P1333; Dickins RA, 2002, MOL CELL BIOL, V22, P2294, DOI 10.1128/MCB.22.7.2294-2303.2002; Frew IJ, 2003, MOL CELL BIOL, V23, P9150, DOI 10.1128/MCB.23.24.9150-9161.2003; Frew IJ, 2002, MOL CELL BIOL, V22, P8155, DOI 10.1128/MCB.22.23.8155-8164.2002; Gravallese EM, 2001, ARTHRITIS RES, V3, P6, DOI 10.1186/ar134; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Johnsen SA, 2002, ONCOGENE, V21, P5783, DOI 10.1038/sj.onc.1205681; Johnsen SA, 2002, J BIOL CHEM, V277, P30754, DOI 10.1074/jbc.M204812200; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Quinn JMW, 2002, BONE, V30, P164, DOI 10.1016/S8756-3282(01)00654-8; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Sims NA, 2000, J CLIN INVEST, V106, P1095, DOI 10.1172/JCI10753; Sims Natalie, 2000, P1; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Yamazaki H, 2001, EXP HEMATOL, V29, P68, DOI 10.1016/S0301-472X(00)00626-3	25	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29583	29588		10.1074/jbc.M312755200	http://dx.doi.org/10.1074/jbc.M312755200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123657	hybrid			2022-12-25	WOS:000222445300093
J	Lum, R; Tkach, JM; Vierling, E; Glover, JR				Lum, R; Tkach, JM; Vierling, E; Glover, JR			Evidence for an unfolding/threading mechanism for protein disaggregation by Saccharomyces cerevisiae Hsp104	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL ATPASE DOMAIN; DEPENDENT CLP PROTEASE; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE; PURIFICATION; TRANSLOCATION; YEAST; HSP70	Saccharomyces cerevisiae Hsp104, a hexameric member of the Hsp100/Clp subfamily of AAA+ ATPases with two nucleotide binding domains (NBD1 and 2), refolds aggregated proteins in conjunction with Hsp70 molecular chaperones. Hsp104 may act as a "molecular crowbar" to pry aggregates apart and/or may extract proteins from aggregates by unfolding and threading them through the axial channel of the Hsp104 hexamer. Targeting Tyr-662, located in a Gly-Tyr-Val-Gly motif that forms part of the axial channel loop in NBD2, we created conservative (Phe and Trp) and non-conservative (Ala and Lys) amino acid substitutions. Each of these Hsp104 derivatives was comparable to the wild type protein in their ability to hydrolyze ATP, assemble into hexamers, and associate with heat-shock-induced aggregates in living cells. However, only those with conservative substitutions complemented the thermotolerance defect of a Deltahsp104 yeast strain and promoted refolding of aggregated protein in vitro. Monitoring fluorescence from Trp-662 showed that titration of fully assembled molecules with either ATP or ADP progressively quenches fluorescence, suggesting that nucleotide binding determines the position of the loop within the axial channel. A Glu to Lys substitution at residue 645 in the NBD2 axial channel strongly alters the nucleotide-induced change in fluorescence of Trp-662 and specifically impairs in protein refolding. These data establish that the structural integrity of the axial channel through NBD2 is required for Hsp104 function and support the proposal that Hsp104 and ClpB use analogous unfolding/threading mechanisms to promote disaggregation and refolding that other Hsp100s use to promote protein degradation.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA	University of Toronto; University of Arizona	Glover, JR (corresponding author), Univ Toronto, Dept Biochem, Rm 5302,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	john.glover@utoronto.ca		Vierling, Elizabeth/0000-0002-0066-4881				Abbas-Terki T, 2001, MOL CELL BIOL, V21, P7569, DOI 10.1128/MCB.21.22.7569-7575.2001; Ben-Zvi AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/jsbi.2001.4352; Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Fujita K, 1998, BIOCHEM BIOPH RES CO, V248, P542, DOI 10.1006/bbrc.1998.9008; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Glover JR, 2001, BIOCHEM CELL BIOL, V79, P557, DOI 10.1139/bcb-79-5-557; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Hattendorf DA, 2002, P NATL ACAD SCI USA, V99, P2732, DOI 10.1073/pnas.261693199; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; Hong SW, 2000, P NATL ACAD SCI USA, V97, P4392, DOI 10.1073/pnas.97.8.4392; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Ishikawa T, 2001, P NATL ACAD SCI USA, V98, P4328, DOI 10.1073/pnas.081543698; Kim DY, 2003, J BIOL CHEM, V278, P50664, DOI 10.1074/jbc.M305882200; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Ortega J, 2000, MOL CELL, V6, P1515, DOI 10.1016/S1097-2765(00)00148-9; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; Reid BG, 2001, P NATL ACAD SCI USA, V98, P3768, DOI 10.1073/pnas.071043698; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Schirmer EC, 1998, METHOD ENZYMOL, V290, P430, DOI 10.1016/S0076-6879(98)90036-2; Schirmer EC, 2001, P NATL ACAD SCI USA, V98, P914, DOI 10.1073/pnas.031568098; Schlee S, 2004, J MOL BIOL, V336, P275, DOI 10.1016/j.jmb.2003.12.013; Siddiqui SM, 2004, GENE DEV, V18, P369, DOI 10.1101/gad.1170304; SIKORSKI RS, 1989, GENETICS, V122, P19; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; Song HK, 2000, P NATL ACAD SCI USA, V97, P14103, DOI 10.1073/pnas.250491797; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Strub C, 2003, FEBS LETT, V553, P125, DOI 10.1016/S0014-5793(03)00985-2; Wang J, 2001, STRUCTURE, V9, P177, DOI 10.1016/S0969-2126(01)00570-6; Wang J, 2001, STRUCTURE, V9, P1107, DOI 10.1016/S0969-2126(01)00670-0; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Wegele H, 2003, J BIOL CHEM, V278, P25970, DOI 10.1074/jbc.M301548200; Weibezahn J, 2004, MICROB CELL FACT, V3, DOI 10.1186/1475-2859-3-1; Yoo SJ, 1996, J BIOL CHEM, V271, P14035, DOI 10.1074/jbc.271.24.14035	40	178	179	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29139	29146		10.1074/jbc.M403777200	http://dx.doi.org/10.1074/jbc.M403777200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15128736	hybrid			2022-12-25	WOS:000222445300039
J	Massa, A; Barbieri, F; Aiello, C; Arena, S; Pattarozzi, A; Pirani, P; Corsaro, A; Iuliano, R; Fusco, A; Zona, G; Spaziante, R; Florio, T; Schettini, G				Massa, A; Barbieri, F; Aiello, C; Arena, S; Pattarozzi, A; Pirani, P; Corsaro, A; Iuliano, R; Fusco, A; Zona, G; Spaziante, R; Florio, T; Schettini, G			The expression of the phosphotyrosine phosphatase DEP-1/PTP eta dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; EPIDERMAL-GROWTH-FACTOR; HORMONE-RELEASING HORMONE; IN-VITRO; RECEPTOR SUBTYPES; ETA SUPPRESSES; THYROID-CELLS; COLON-CANCER; TUMOR-CELLS; ACTIVATION	Here we characterize the intracellular effectors of the antiproliferative activity of somatostatin in glioma cell lines and post-surgical specimens. The responsiveness to somatostatin correlated with the expression of the phosphotyrosine phosphatase DEP-1/PTPeta, identified in C6 and U87MG cells, in which somatostatin inhibited cell growth. The expression of a dominant negative mutant of DEP-1/PTPeta in C6 cells abolished somatostatin effects, confirming the involvement of this phosphotyrosine phosphatase in such effects. Somatostatin treatment increased the activity of DEP-1/PTPeta and inhibited ERK1/2 activation. Conversely, basic fibroblast growth factor-dependent MEK phosphorylation was not affected, suggesting a direct effect on ERK1/2. In vitro experiments showed that PTPeta was able to interact and dephosphorylate ERK1/2 activated by basic fibroblast growth factor. Furthermore, by transfecting PTPeta in the somatostatin-unresponsive, DEP-1/PTPeta-deficient U373MG cells, the somatostatin-dependent control of cell proliferation was recovered. Finally we evaluated the requirement for DEP-1/PTPeta in somatostatin inhibition of cell proliferation in post-surgical specimens derived from different grade human gliomas. Although all of the glioma analyzed expressed somatostatin receptor mRNA, DEP-1/PTPeta expression was limited to 8 of 22 of the tumors. Culturing seven gliomas, a correlation between the expression of DEP-1/PTPeta and the somatostatin antiproliferative effects was identified. In conclusion we propose that the expression and activation of DEP-1/PTPeta is required for somatostatin inhibition of glioma proliferation.	Univ Genoa, Dept Oncol Biol & Genet, Pharmacol Sect, I-16132 Genoa, Italy; Ist Nazl Ric Canc, I-16132 Genoa, Italy; Univ Catanzaro, Dept Clin & Expt Med, I-88100 Catanzaro, Italy; Univ Naples Federico II, Natl Res Council, Endocrinol & Expt Oncol Ctr, I-80131 Naples, Italy; Univ Naples Federico II, Dept Mol & Cellular Pathol, I-80131 Naples, Italy; Univ Genoa, Dept Neurosci Ophthalmol & Genet, Div Neurosurg, I-16132 Genoa, Italy	University of Genoa; University of Genoa; IRCCS AOU San Martino IST; Magna Graecia University of Catanzaro; University of Naples Federico II; University of Naples Federico II; University of Genoa	Florio, T (corresponding author), Univ Genoa, Dept Oncol Biol & Genet, Pharmacol Sect, Largo R Benzi 10, I-16132 Genoa, Italy.	florio@cba.unige.it	Barbieri, Federica/L-8753-2015; zona, gianluigi/AAF-8235-2021; FLORIO, TULLIO/ABG-3182-2020; Florio, Tullio/A-2211-2012	Barbieri, Federica/0000-0001-8988-6896; Florio, Tullio/0000-0002-2394-996X; Fusco, Alfredo/0000-0003-3332-5197; ZONA, GIANLUIGI/0000-0002-3577-7894; Corsaro, Alessandro/0000-0003-4565-7914				Albini A, 1999, FASEB J, V13, P647, DOI 10.1096/fasebj.13.6.647; Baker JE, 2001, MOL CELL BIOL, V21, P2393, DOI 10.1128/MCB.21.7.2393-2403.2001; Bedecs K, 1997, BIOCHEM J, V325, P449, DOI 10.1042/bj3250449; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Borges LG, 1996, CIRC RES, V79, P570, DOI 10.1161/01.RES.79.3.570; Bousquet C, 1998, J BIOL CHEM, V273, P7099, DOI 10.1074/jbc.273.12.7099; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; CHEUNG NW, 1995, ENDOCRINOLOGY, V136, P4174, DOI 10.1210/en.136.10.4174; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corsaro A, 2002, NEUROCHEM INT, V41, P55, DOI 10.1016/S0197-0186(01)00137-1; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Dutour A, 1998, INT J CANCER, V76, P620, DOI 10.1002/(SICI)1097-0215(19980529)76:5<620::AID-IJC2>3.3.CO;2-X; DY DY, 1992, CANCER RES, V52, P917; FEINDT J, 1995, J NEUROCHEM, V65, P1997; Florio T, 1999, EUR J ENDOCRINOL, V141, P396, DOI 10.1530/eje.0.1410396; Florio T, 1996, J BIOL CHEM, V271, P6129, DOI 10.1074/jbc.271.11.6129; Florio T, 1999, MOL ENDOCRINOL, V13, P24, DOI 10.1210/me.13.1.24; Florio T, 2003, ENDOCRINOLOGY, V144, P1574, DOI 10.1210/en.2002-220949; Florio T, 1997, ENDOCRINOLOGY, V138, P3756, DOI 10.1210/en.138.9.3756; Florio T, 2001, MOL ENDOCRINOL, V15, P1838, DOI 10.1210/me.15.10.1838; FLORIO T, 1992, J BIOL CHEM, V267, P24169; FLORIO T, 1994, MOL ENDOCRINOL, V8, P1289, DOI 10.1210/me.8.10.1289; Florio T, 1996, J MOL ENDOCRINOL, V17, P89, DOI 10.1677/jme.0.0170089; Grobben B, 2002, CELL TISSUE RES, V310, P257, DOI 10.1007/s00441-002-0651-7; HIEROWSKI MT, 1985, FEBS LETT, V179, P252, DOI 10.1016/0014-5793(85)80529-9; Iuliano R, 2003, CANCER RES, V63, P882; Keane MM, 1996, CANCER RES, V56, P4236; Klingler-Hoffmann M, 2001, J BIOL CHEM, V276, P46313, DOI 10.1074/jbc.M106571200; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Lamszus K, 1997, J NEURO-ONCOL, V35, P353, DOI 10.1023/A:1005893223090; LEE MT, 1991, P NATL ACAD SCI USA, V88, P1656, DOI 10.1073/pnas.88.5.1656; Lopez F, 1996, METABOLISM, V45, P14, DOI 10.1016/S0026-0495(96)90071-2; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Martelli ML, 1998, EXP CELL RES, V245, P195, DOI 10.1006/excr.1998.4257; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Osborne JM, 1998, J LEUKOCYTE BIOL, V64, P692, DOI 10.1002/jlb.64.5.692; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; PINSKI J, 1994, CANCER RES, V54, P5895; Plonowski A, 2002, PROSTATE, V52, P173, DOI 10.1002/pros.10105; Porcile C, 2003, NEUROCHEM INT, V43, P31, DOI 10.1016/S0197-0186(02)00197-3; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Reardon DB, 1997, MOL ENDOCRINOL, V11, P1062, DOI 10.1210/me.11.8.1062; REUBI JC, 1995, TRENDS PHARMACOL SCI, V16, P110, DOI 10.1016/S0165-6147(00)88992-0; REUBI JC, 1987, CANCER RES, V47, P551; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; SCHETTINI G, 1989, BRAIN RES, V492, P65, DOI 10.1016/0006-8993(89)90889-5; Srikant CB, 1996, ENDOCRINOLOGY, V137, P3461, DOI 10.1210/en.137.8.3461; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Zhang L, 1997, EXP CELL RES, V235, P62, DOI 10.1006/excr.1997.3659	54	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29004	29012		10.1074/jbc.M403573200	http://dx.doi.org/10.1074/jbc.M403573200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123617	hybrid			2022-12-25	WOS:000222445300023
J	Akagi, T; Inoue, T; Miyoshi, G; Bessho, Y; Takahashi, M; Lee, JE; Guillemot, F; Kageyama, R				Akagi, T; Inoue, T; Miyoshi, G; Bessho, Y; Takahashi, M; Lee, JE; Guillemot, F; Kageyama, R			Requirement of multiple basic helix-loop-helix genes for retinal neuronal subtype specification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FATE DETERMINATION; DEVELOPING NERVOUS-SYSTEM; MAMMALIAN ACHAETE-SCUTE; DEVELOPING RAT RETINA; HOMEOBOX GENE; VERTEBRATE RETINA; GANGLION-CELL; BHLH PROTEIN; DIFFERENTIATION; PHOTORECEPTOR	Retinal precursor cells give rise to six types of neurons and one type of glial cell during development, and this process is controlled by multiple basic helix-loop-helix ( bHLH) genes. However, the precise mechanism for specification of retinal neuronal subtypes, particularly horizontal neurons and photoreceptors, remains to be determined. Here, we examined retinas with three different combinations of triple bHLH gene mutations. In retinas lacking the bHLH genes Ngn2, Math3, and NeuroD, horizontal neurons as well as other neurons such as bipolar cells were severely decreased in number. In the retina lacking the bHLH genes Mash1, Ngn2, and Math3, horizontal and other neurons were severely decreased, whereas ganglion cells were increased. In the retina lacking the bHLH genes Mash1, Math3, and NeuroD, photoreceptors were severely decreased, whereas ganglion cells were increased. In all cases, glial cells were increased. The increase and decrease of these cells were the result of cell fate changes and cell death and seem to be partly attributable to the remaining bHLH gene expression, which also changes because of triple bHLH gene mutations. These results indicate that multiple bHLH genes cross-regulate each other, cooperatively specify neuronal subtypes, and regulate neuronal survival in the developing retina.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068507, Japan; Kyoto Univ Hosp, Translat Res Ctr, Dept Expt Therapeut, Kyoto 6068507, Japan; Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; Natl Inst Med Res, London NW7 1AA, England	Kyoto University; Kyoto University; Kyoto University; University of Colorado System; University of Colorado Boulder; MRC National Institute for Medical Research	Kageyama, R (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.	rkageyam@virus.kyoto-u.ac.jp	Miyoshi, Goichi/H-4759-2012; Miyoshi, Goichi/O-2029-2019; Guillemot, Francois/AAV-1482-2021					AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; Brown NL, 1998, DEVELOPMENT, V125, P4821; Brown NL, 2001, DEVELOPMENT, V128, P2497; Cayouette M, 2003, NEURON, V40, P897, DOI 10.1016/S0896-6273(03)00756-6; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Cepko CL, 1999, CURR OPIN NEUROBIOL, V9, P37, DOI 10.1016/S0959-4388(99)80005-1; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Dyer MA, 2003, NAT GENET, V34, P53, DOI 10.1038/ng1144; Fode C, 1998, NEURON, V20, P483, DOI 10.1016/S0896-6273(00)80989-7; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; Gradwohl G, 1996, DEV BIOL, V180, P227, DOI 10.1006/dbio.1996.0297; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; Harris WA, 1997, CURR OPIN GENET DEV, V7, P651, DOI 10.1016/S0959-437X(97)80013-5; Haruta M, 2001, NAT NEUROSCI, V4, P1163, DOI 10.1038/nn762; Hatakeyama J, 2004, SEMIN CELL DEV BIOL, V15, P83, DOI 10.1016/j.semcdb.2003.09.005; Hatakeyama J, 2002, METHODS, V28, P387, DOI 10.1016/S1046-2023(02)00257-8; Hatakeyama J, 2001, DEVELOPMENT, V128, P1313; Hojo M, 2000, DEVELOPMENT, V127, P2515; Inoue T, 2002, DEVELOPMENT, V129, P831; Jasoni CL, 1996, J COMP NEUROL, V369, P319; Kay JN, 2001, NEURON, V30, P725, DOI 10.1016/S0896-6273(01)00312-9; Kill IR, 1996, J CELL SCI, V109, P1253; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Liu M, 2000, P NATL ACAD SCI USA, V97, P865, DOI 10.1073/pnas.97.2.865; Livesey FJ, 2001, NAT REV NEUROSCI, V2, P109, DOI 10.1038/35053522; Marquardt T, 2002, TRENDS NEUROSCI, V25, P32, DOI 10.1016/S0166-2236(00)02028-2; McGinnis JF, 1999, J NEUROSCI RES, V55, P252, DOI 10.1002/(SICI)1097-4547(19990115)55:2<252::AID-JNR13>3.0.CO;2-N; Miyata T, 1999, GENE DEV, V13, P1647, DOI 10.1101/gad.13.13.1647; Morrow EM, 1999, DEVELOPMENT, V126, P23; Nishida A, 2003, NAT NEUROSCI, V6, P1255, DOI 10.1038/nn1155; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; Takebayashi K, 1997, EMBO J, V16, P384, DOI 10.1093/emboj/16.2.384; Tomita K, 2000, EMBO J, V19, P5460, DOI 10.1093/emboj/19.20.5460; Tomita K, 1996, GENES CELLS, V1, P765, DOI 10.1111/j.1365-2443.1996.tb00016.x; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; Vetter ML, 2001, SEMIN CELL DEV BIOL, V12, P491, DOI 10.1006/scdb.2001.0273; Wang SW, 2001, GENE DEV, V15, P24, DOI 10.1101/gad.855301; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215	44	110	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28492	28498		10.1074/jbc.M400871200	http://dx.doi.org/10.1074/jbc.M400871200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15105417	hybrid			2022-12-25	WOS:000222265400084
J	Austermuhle, MI; Hall, JA; Klug, CS; Davidson, AL				Austermuhle, MI; Hall, JA; Klug, CS; Davidson, AL			Maltose-binding protein is open in the catalytic transition state for ATP hydrolysis during maltose transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASSETTE ABC TRANSPORTER; INDUCED CONFORMATIONAL-CHANGES; RECONSTITUTED P-GLYCOPROTEIN; TERTIARY STRUCTURE CHANGES; ESCHERICHIA-COLI; NUCLEOTIDE-BINDING; ACTIVE-TRANSPORT; LIGAND-BINDING; PERIPLASMIC PERMEASES; 2 MODES	The maltose transport complex of Escherichia coli, a member of the ATP-binding cassette superfamily, mediates the high affinity uptake of maltose at the expense of ATP. The membrane-associated transporter consists of two transmembrane subunits, MalF and MalG, and two copies of the cytoplasmic ATP-binding cassette subunit, MalK. Maltose-binding protein (MBP), a soluble periplasmic protein, delivers maltose to the MalFGK(2) transporter and stimulates hydrolysis by the transporter. Site-directed spin labeling electron paramagnetic resonance spectroscopy is used to monitor binding of MBP to MalFGK(2) and conformational changes in MBP as it interacts with MalFGK(2). Cysteine residues and spin labels have been introduced into the two lobes of MBP so that spin-spin interaction will report on ligand-induced closure of the protein (Hall, J.A., Thorgeirsson, T. E., Liu, J., Shin, Y. K., and Nikaido, H. (1997) J. Biol. Chem. 272, 17610-17614). At least two different modes of interaction between MBP and MalFGK(2) were detected. Binding of MBP to MalFGK(2) in the absence of ATP resulted in a decrease in motion of spin label at position 41 in the C-terminal domain of MBP. In a vanadate-trapped transition state intermediate, all free MBP became tightly bound to MalFGK(2), spin label in both lobes became completely immobilized, and spin-spin interactions were lost, suggesting that MBP was in an open conformation. Binding of non-hydrolyzable MgATP analogs or ATP in the absence of Mg is sufficient to stabilize a complex of open MBP and MalFGK(2). Taken together, these data suggest that closure of the MalK dimer interface coincides with opening of MBP and maltose release to the transporter.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Interdepartmental Program Cell & Mol Biol, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston; Medical College of Wisconsin	Davidson, AL (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, MS BCM 280,1 Baylor Plaza, Houston, TX 77030 USA.	davidson@bcm.tmc.edu			NIGMS NIH HHS [GM 49261] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049261, R29GM049261] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aleksandrov AA, 2000, J PHYSIOL-LONDON, V528, P259, DOI 10.1111/j.1469-7793.2000.00259.x; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15471, DOI 10.1021/bi011544w; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; Ames GFL, 1996, J BIOL CHEM, V271, P14264, DOI 10.1074/jbc.271.24.14264; BOOS W, 1996, ESCHERICHIA COLI SAL, V1, P1175; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; COVITZ KMY, 1994, EMBO J, V13, P1752, DOI 10.1002/j.1460-2075.1994.tb06439.x; DASSA E, 1993, MOL MICROBIOL, V7, P29, DOI 10.1111/j.1365-2958.1993.tb01094.x; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; Davidson AL, 1996, J BIOL CHEM, V271, P4858; DEAN DA, 1992, MOL MICROBIOL, V6, P2033, DOI 10.1111/j.1365-2958.1992.tb01376.x; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; DUPLAY P, 1987, J MOL BIOL, V194, P675, DOI 10.1016/0022-2836(87)90244-0; DUPLAY P, 1987, J MOL BIOL, V194, P663, DOI 10.1016/0022-2836(87)90243-9; FERENCI T, 1986, BIOCHIM BIOPHYS ACTA, V860, P44, DOI 10.1016/0005-2736(86)90496-7; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; FIKES JD, 1987, J BACTERIOL, V169, P2352, DOI 10.1128/jb.169.6.2352-2359.1987; FROSHAUER S, 1988, J MOL BIOL, V200, P501, DOI 10.1016/0022-2836(88)90539-6; GEHRING K, 1991, BIOCHEMISTRY-US, V30, P5524, DOI 10.1021/bi00236a027; Hall JA, 1997, J BIOL CHEM, V272, P17615, DOI 10.1074/jbc.272.28.17615; Hall JA, 1997, J BIOL CHEM, V272, P17610, DOI 10.1074/jbc.272.28.17610; Hall JA, 1997, J BIOL CHEM, V272, P17605, DOI 10.1074/jbc.272.28.17605; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; HOR LI, 1993, J MOL BIOL, V233, P659, DOI 10.1006/jmbi.1993.1543; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Julien M, 2000, BIOCHEMISTRY-US, V39, P4559, DOI 10.1021/bi992744z; KELLERMANN O, 1974, EUR J BIOCHEM, V47, P139, DOI 10.1111/j.1432-1033.1974.tb03677.x; Klug Candice S., 2004, V24, P269; Klug CS, 1997, BIOCHEMISTRY-US, V36, P13027, DOI 10.1021/bi971232m; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Liu RH, 2000, BIOCHEMISTRY-US, V39, P14927, DOI 10.1021/bi0018786; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; MANSON MD, 1985, J BIOL CHEM, V260, P9727; Martin C, 2000, BIOCHEMISTRY-US, V39, P11901, DOI 10.1021/bi000559b; MARTINEAU P, 1990, BIOCHIMIE, V72, P397, DOI 10.1016/0300-9084(90)90063-M; MERINO G, 1995, J THEOR BIOL, V177, P171, DOI 10.1006/jtbi.1995.0236; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Mourez M, 1997, EMBO J, V16, P3066, DOI 10.1093/emboj/16.11.3066; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; Sharma S, 2000, J BACTERIOL, V182, P6570, DOI 10.1128/JB.182.23.6570-6576.2000; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; Sonveaux N, 1999, J BIOL CHEM, V274, P17649, DOI 10.1074/jbc.274.25.17649; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; SZMELCMAN S, 1975, J BACTERIOL, V124, P112, DOI 10.1128/JB.124.1.112-118.1975; TREPTOW NA, 1988, J MOL BIOL, V202, P809, DOI 10.1016/0022-2836(88)90560-8; Vergani P, 2003, J GEN PHYSIOL, V121, P17, DOI 10.1085/jgp.20028673; Vigano C, 2002, J BIOL CHEM, V277, P5008, DOI 10.1074/jbc.M107928200; Wang GC, 1997, BIOCHEM J, V328, P897, DOI 10.1042/bj3280897; Wang GC, 1998, EUR J BIOCHEM, V255, P383, DOI 10.1046/j.1432-1327.1998.2550383.x; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200; ZHANG YH, 1992, J BIOL CHEM, V267, P22813	63	65	70	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28243	28250		10.1074/jbc.M403508200	http://dx.doi.org/10.1074/jbc.M403508200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117946	hybrid			2022-12-25	WOS:000222265400054
J	Caldinelli, L; Iametti, S; Barbiroli, A; Bonomi, F; Piubelli, L; Ferranti, P; Picariello, G; Pilone, MS; Pollegioni, L				Caldinelli, L; Iametti, S; Barbiroli, A; Bonomi, F; Piubelli, L; Ferranti, P; Picariello, G; Pilone, MS; Pollegioni, L			Unfolding intermediate in the peroxisomal flavoprotein D-amino acid oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOTORULA-GRACILIS; BETA-LACTOGLOBULIN; PROTEIN; IMPORT; PROTEOLYSIS; STABILITY; HEAT; FORM	The flavoenzyme D-amino acid oxidase ( DAAO) from Rhodotorula gracilis is a peroxisomal enzyme and a prototypical member of the glutathione reductase family of flavoproteins. DAAO is a stable homodimer with a FAD molecule tightly bound to each 40-kDa subunit. In this work, the urea-induced unfolding of dimeric DAAO was compared with that of a monomeric form of the same protein, a deleted dimerization loop mutant. By using circular dichroism spectroscopy, protein and flavin fluorescence, 1,8-anilinonaphtalene sulfonic acid binding and activity assays, we demonstrated that the urea-induced unfolding of DAAO is a three-state process, yielding an intermediate, and that this process is reversible. The intermediate species lacks the catalytic activity and the characteristic tertiary structure of native DAAO but has significant secondary structure and retains flavin binding. Unfolding of DAAO proceeds through formation of an expanded, partially unfolded inactive intermediate, characterized by low solubility, by increased exposure of hydrophobic surfaces, and by increased sensitivity to trypsin of the beta-strand F5 belonging to the FAD binding domain. The oligomeric state does not modify the inferred folding process. The strand F5 is in contact with the C-terminal alpha-helix containing the Ser-Lys-Leu sequence corresponding to the type 1 peroxisomal targeting signal, and this structural element interacts with the N-terminal betaalphabeta flavin binding motif (Rossmann fold). The expanded conformation of the folding intermediate (and in particular the higher disorder of the mentioned secondary structure elements) could match the structure of the inactive holoenzyme required for in vivo trafficking of DAAO through the peroxisomal membrane.	Univ Insubria, Dept Struct & Funct Biol, I-21100 Varese, Italy; Univ Milan, Dipartimento Sci Mol Agroaliment, I-20133 Milan, Italy; Univ Naples Federico II, Dipartimento Sci Alimenti, I-80055 Portici, Italy; CNR, Inst Food Sci, I-83100 Avellino, Italy	University of Insubria; University of Milan; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze dell' Alimentazione (ISA-CNR)	Pollegioni, L (corresponding author), Univ Insubria, Dept Struct & Funct Biol, Via JH Dunant 3, I-21100 Varese, Italy.	loredano.pollegioni@uninsubria.it	Iametti, Stefania/AGY-9694-2022; Ferranti, Pasquale/ABF-8111-2021	POLLEGIONI, LOREDANO/0000-0003-1733-7243; PIUBELLI, LUCIANO/0000-0003-0805-5121; Iametti, Stefania/0000-0002-4159-3768; Bonomi, Francesco/0000-0003-4556-2640; PICARIELLO, Gianluca/0000-0003-1290-1239; BARBIROLI, ALBERTO GIUSEPPE/0000-0003-1678-5431; FERRANTI, Pasquale/0000-0002-6250-6512				Ayed A, 1999, PROTEIN SCI, V8, P1116, DOI 10.1110/ps.8.5.1116; Brocard CB, 2003, TRAFFIC, V4, P74, DOI 10.1034/j.1600-0854.2003.40203.x; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CAIROLI S, 1994, J PROTEIN CHEM, V13, P347, DOI 10.1007/BF01901568; Campaner S, 1998, BIOCHEM J, V330, P615, DOI 10.1042/bj3300615; Curti B., 1991, CHEM BIOCH FLAVOENZY, V3, P69; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; Englander SW, 2000, ANNU REV BIOPH BIOM, V29, P213, DOI 10.1146/annurev.biophys.29.1.213; Iametti S, 2002, EUR J BIOCHEM, V269, P1362, DOI 10.1046/j.1432-1033.2002.02769.x; Iametti S, 1996, EUR J BIOCHEM, V237, P106, DOI 10.1111/j.1432-1033.1996.0106n.x; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; Molla G, 1998, PROTEIN EXPRES PURIF, V14, P289, DOI 10.1006/prep.1998.0956; Neuberger G, 2003, J MOL BIOL, V328, P567, DOI 10.1016/S0022-2836(03)00318-8; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; Pilone MS, 2000, CELL MOL LIFE SCI, V57, P1732, DOI 10.1007/PL00000655; Piubelli L, 2003, PROTEIN ENG, V16, P1063, DOI 10.1093/protein/gzg125; Piubelli L, 2002, FEBS LETT, V526, P43, DOI 10.1016/S0014-5793(02)03111-3; Pollegioni L, 2002, J MOL BIOL, V324, P535, DOI 10.1016/S0022-2836(02)01062-8; Pollegioni L, 2003, PROTEIN SCI, V12, P1018, DOI 10.1110/ps.0234603; POLLEGIONI L, 1995, BIOCHEM J, V310, P577, DOI 10.1042/bj3100577; Prakash K, 2002, PROTEIN SCI, V11, P46, DOI 10.1110/ps.ps.20102; PTISTYN OB, 1992, PROTEIN FOLDING, P243; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Samuel D, 2001, J BIOL CHEM, V276, P4134, DOI 10.1074/jbc.M005921200; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; Terlecky SR, 2000, TRAFFIC, V1, P465, DOI 10.1034/j.1600-0854.2000.010604.x; Umhau S, 2000, P NATL ACAD SCI USA, V97, P12463, DOI 10.1073/pnas.97.23.12463; Van Mierlo CPM, 1998, PROTEIN SCI, V7, P2331, DOI 10.1002/pro.5560071110; WALTON PA, 1995, MOL BIOL CELL, V6, P675, DOI 10.1091/mbc.6.6.675	31	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28426	28434		10.1074/jbc.M403489200	http://dx.doi.org/10.1074/jbc.M403489200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102841	hybrid			2022-12-25	WOS:000222265400076
J	Cordell, PA; Futers, TS; Grant, PJ; Pease, RJ				Cordell, PA; Futers, TS; Grant, PJ; Pease, RJ			The human hydroxyacylglutathione hydrolase (HAGH) gene encodes both cytosolic and mitochondrial forms of glyoxalase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE; PROTEIN; TRANSLATION; PATHWAY; CLONING; SYSTEM; IDENTIFICATION; METHYLGLYOXAL; PURIFICATION	In yeast and higher plants, separate genes encode the cytosolic and mitochondrial forms of glyoxalase II. In contrast, although glyoxalase II activity has been detected both in the cytosol and mitochondria of mammals, only a single gene encoding glyoxalase II has been identified. Previously it was thought that this gene ( the hydroxyacylglutathione hydrolase gene), comprised 8 exons that are transcribed into mRNA and that the resulting mRNA species encoded a single cytosolic form of glyoxalase II. Here we show that this gene gives rise to two distinct mRNA species transcribed from 9 and 10 exons, respectively. The 9-exon-derived transcript encodes two protein species: mitochondrially targeted glyoxylase II, which is initiated from an AUG codon in a previously uncharacterized part of the mRNA sequence, and cytosolic glyoxalase II, which is initiated by internal ribosome entry at a downstream AUG codon. The transcript deriving from 10 exons has an in-frame termination codon between the two initiating AUG codons and hence only encodes the cytosolic form of the protein. Confocal fluorescence microscopy indicates that the mitochondrially targeted form of glyoxalase II is directed to the mitochondrial matrix. Analysis of glyoxalase II mRNA sequences from a number of species indicates that dual initiation from alternative AUG codons is conserved throughout vertebrates.	Univ Leeds, Fac Med & Hlth, Leeds Inst Genet Hlth & Therapeut, Acad Unit Mol Vasc Med, Leeds LS1 3EX, W Yorkshire, England	University of Leeds	Grant, PJ (corresponding author), Gen Infirm, Martin Wing, Leeds LS1 3EX, W Yorkshire, England.	p.j.grant@leeds.ac.uk						Bito A, 1997, J BIOL CHEM, V272, P21509, DOI 10.1074/jbc.272.34.21509; Broadway NM, 2003, BIOCHEM J, V370, P223, DOI 10.1042/BJ20021269; Cho MY, 1998, EXP MOL MED, V30, P53, DOI 10.1038/emm.1998.8; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Daiyasu H, 2001, FEBS LETT, V503, P1, DOI 10.1016/S0014-5793(01)02686-2; Higashitsuji H, 2002, CANCER CELL, V2, P335, DOI 10.1016/S1535-6108(02)00152-6; HUANG XQ, 1992, GENOMICS, V14, P18, DOI 10.1016/S0888-7543(05)80277-0; Ji XH, 1997, BIOCHEM BIOPH RES CO, V241, P714, DOI 10.1006/bbrc.1997.7880; Koehler CM, 2000, FEBS LETT, V476, P27, DOI 10.1016/S0014-5793(00)01664-1; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Kozak M, 2000, GENOMICS, V70, P396, DOI 10.1006/geno.2000.6412; Kozak M, 2001, MOL CELL BIOL, V21, P1899, DOI 10.1128/MCB.21.6.1899-1907.2001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauring AS, 2000, MOL CELL, V6, P939, DOI 10.1016/S1097-2765(05)00084-5; MacLean MJ, 1998, MOL MICROBIOL, V27, P563, DOI 10.1046/j.1365-2958.1998.00701.x; Maiti MK, 1997, PLANT MOL BIOL, V35, P471, DOI 10.1023/A:1005891123344; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; Mihara K, 2000, BIOESSAYS, V22, P364, DOI 10.1002/(SICI)1521-1878(200004)22:4<364::AID-BIES6>3.0.CO;2-N; PENNINCKX MJ, 1983, J BIOL CHEM, V258, P6030; Pesole G, 1999, TRENDS GENET, V15, P378, DOI 10.1016/S0168-9525(99)01795-3; Ridderstrom M, 1996, J BIOL CHEM, V271, P319, DOI 10.1074/jbc.271.1.319; Satoh M, 2003, BIOCHEM BIOPH RES CO, V300, P482, DOI 10.1016/S0006-291X(02)02874-7; Scire A, 2000, PROTEINS, V41, P33, DOI 10.1002/1097-0134(20001001)41:1<33::AID-PROT60>3.0.CO;2-N; Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885; Singla-Pareek SL, 2003, P NATL ACAD SCI USA, V100, P14672, DOI 10.1073/pnas.2034667100; TALESA V, 1988, BIOCHIM BIOPHYS ACTA, V955, P103, DOI 10.1016/0167-4838(88)90183-5; TALESA V, 1989, BIOCHIM BIOPHYS ACTA, V993, P7, DOI 10.1016/0304-4165(89)90135-9; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thornalley PJ, 1998, CHEM-BIOL INTERACT, V112, P137, DOI 10.1016/S0009-2797(97)00157-9; THORNALLEY PJ, 1990, BIOCHEM J, V269, P1; UOTILA L, 1989, COENZYMES COFACTORS, V3, P767; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Vander Jagt D.L., 1989, GLUTATHIONE CHEM, P597; Zang TM, 2001, J BIOL CHEM, V276, P4788, DOI 10.1074/jbc.M005090200; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	36	44	50	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28653	28661		10.1074/jbc.M403470200	http://dx.doi.org/10.1074/jbc.M403470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117945	hybrid			2022-12-25	WOS:000222265400101
J	Terui, Y; Saad, N; Jia, S; McKeon, F; Yuan, JY				Terui, Y; Saad, N; Jia, S; McKeon, F; Yuan, JY			Dual role of sumoylation in the nuclear localization and transcriptional activation of NFAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEINS; KAPPA-B-ALPHA; NF-AT; SUMO-1 MODIFICATION; COVALENT MODIFICATION; PORE COMPLEX; FAMILY; CALCINEURIN; RANGAP1; ENZYME	The nuclear import of nuclear factor of activated T cells ( NFAT) transcription factors is critical for regulating NFAT activity. Here we demonstrate that the sumoylation of NFAT1 defines a novel mechanism of the nuclear anchorage and transcriptional activation downstream from the known mechanism of calcineurin-mediated dephosphorylation and nuclear import. We show that Lys(684) and Lys(897) of NFAT1 can be sumoylated. The sumoylation at Lys(684) is required for NFAT1 transcriptional activity and subsequent sumoylation of Lys(897), whereas the sumoylation of Lys(897) is only required for nuclear anchorage. Because Lys(897) of NFAT1 is not conserved among other members of the NFAT family, we propose that sumoylation of Lys(897) may provide a mechanism for NFAT1 isotype-specific regulation of nuclear anchorage and transcriptional activation. Furthermore, we found that treatment with both ionomycin and phorbol 12-myristate 13-acetate ensured efficient nuclear anchorage with the recruitment of NFAT1 into the SUMO-1 bodies, whereas treatment with ionomycin alone induced nuclear translocation of NFAT1 but not recruitment into the SUMO-1 bodies. Our results suggest that the recruitment of NFAT1 into SUMO-1 bodies may be required for the progressive transcriptional activity of NFAT1 upon co-stimulation with ionomycin and phorbol 12-myristate 13-acetate, whereas anergic transcription stimulated by ionomycin alone may occur without recruitment into the SUMO-1 bodies.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Japanese Fdn Canc Res, Canc Inst Hosp, Dept Med Oncol, Tokyo 1708455, Japan; Japanese Fdn Canc Res, Div Clin Chemotherapy, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	Harvard University; Harvard Medical School; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research	Yuan, JY (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	jyuan@hms.harvard.edu	Terui, Yasuhito/GWC-4824-2022					Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Duprez E, 1999, J CELL SCI, V112, P381; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Hay RT, 1999, PHILOS T R SOC B, V354, P1601, DOI 10.1098/rstb.1999.0504; Hodge MR, 1996, SCIENCE, V274, P1903, DOI 10.1126/science.274.5294.1903; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; Macian F, 2002, CELL, V109, P719, DOI 10.1016/S0092-8674(02)00767-5; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; Matsui K, 1998, J IMMUNOL, V161, P3469; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892	37	81	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28257	28265		10.1074/jbc.M403153200	http://dx.doi.org/10.1074/jbc.M403153200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117942	hybrid			2022-12-25	WOS:000222265400056
J	Salatino, M; Schillaci, R; Proietti, CJ; Carnevale, R; Frahm, I; Molinolo, AA; Iribarren, A; Charreau, EH; Elizalde, PV				Salatino, M; Schillaci, R; Proietti, CJ; Carnevale, R; Frahm, I; Molinolo, AA; Iribarren, A; Charreau, EH; Elizalde, PV			Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity	ONCOGENE			English	Article						breast cancer; IGF-IR; antisense strategies	ACTIVATED PROTEIN-KINASE; MOUSE MAMMARY ADENOCARCINOMAS; ESTROGEN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; DEPENDENT PHOSPHORYLATION; GLIOBLASTOMA CELLS; DOWN-REGULATION; GENE-TRANSFER; TUMOR-GROWTH; MCF-7 CELLS	The present study addresses the effect of targeting type I insulin-like growth factor receptor (IGF-IR) with antisense strategies in in vivo growth of breast cancer cells. Our research was carried out on C4HD tumors from an experimental model of hormonal carcinogenesis in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in Balb/c mice. We employed two different experimental strategies. With the first one we demonstrated that direct intratumor injection of phosphorothioate antisense oligodeoxynucleotides (AS[S] ODNs) to IGF-IR mRNA resulted in a significant inhibition of C4HD tumor growth. In the second experimental strategy, we assessed the effect of intravenous ( i. v.) injection of AS [S] ODN on C4HD tumor growth. This systemic treatment also resulted in significant reduction in tumor growth. The antitumor effect of IGF-IR AS[S] ODNs in both experimental protocols was due to a specific antisense mechanism, since growth inhibition was dose-dependent and no abrogation of tumor proliferation was observed in mice treated with phosphorothioate sense ODNs ( S[ S] ODNs). In addition, IGF-IR expression was inhibited in tumors from mice receiving AS[ S] ODNs, as compared to tumors from control groups. We then investigated signal transduction pathways modulated in vivo by AS[ S] ODNs treatment. Tumors from AS[ S] ODN-treated mice of both intratumoral and intravenous protocols showed a significant decrease in the degree of insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation. Activation of two of the main IGF-IR signaling pathways, phosphatidylinositol 3-kinase (PI-3K)/Akt and p42/p44 mitogen-activated protein kinases ( MAPK) was abolished in tumors growing in AS[ S] ODN-treated animals. Moreover, ErbB-2 tyrosine phosphorylation was blocked by in vivo administration of AS[ S] ODNs. On the other hand, we found no regulation of either progesterone receptor expression or activity by in vivo AS[S] ODNs administration. Our results for the first time demonstrated that breast cancer growth can be inhibited by direct in vivo administration of IGF-IR AS[S] ODNs.	Consejo Nacl Invest Cient & Tecn, IBYME, Lab Mol Mech Carcinogenesis, RA-1428 Buenos Aires, DF, Argentina; Sanatorio Mater Dei, Serv Pathol, Buenos Aires, DF, Argentina; Inst Invest Ingn Genet & Biol Mol, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine	Elizalde, PV (corresponding author), Consejo Nacl Invest Cient & Tecn, IBYME, Lab Mol Mech Carcinogenesis, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	elizalde@dna.uba.ar		Elizalde, Patricia V./0000-0002-5923-9898				Adeyinka A, 2002, CLIN CANCER RES, V8, P1747; ARTEAGA CL, 1989, CANCER RES, V49, P6237; BACKER JM, 1993, J BIOL CHEM, V268, P8204; Balana ME, 2001, ONCOGENE, V20, P34, DOI 10.1038/sj.onc.1204050; Balana ME, 1999, ONCOGENE, V18, P6370, DOI 10.1038/sj.onc.1203028; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Chakravarti A, 2002, CANCER RES, V62, P200; Chernicky CL, 2000, CANCER GENE THER, V7, P384, DOI 10.1038/sj.cgt.7700126; Chernicky CL, 2002, J CLIN PATHOL-MOL PA, V55, P102, DOI 10.1136/mp.55.2.102; CHO HS, 1994, ENDOCRINOLOGY, V134, P658, DOI 10.1210/en.134.2.658; Clemm DL, 2000, MOL ENDOCRINOL, V14, P52, DOI 10.1210/me.14.1.52; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; Cui XJ, 2003, MOL ENDOCRINOL, V17, P575, DOI 10.1210/me.2002-0318; Dunn SE, 1998, CANCER RES, V58, P3353; Elizalde PV, 1998, J STEROID BIOCHEM, V67, P305, DOI 10.1016/S0960-0760(98)00123-X; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; KATZENELLENBOGEN BS, 1990, ENDOCRINOLOGY, V126, P891, DOI 10.1210/endo-126-2-891; Labriola L, 2003, MOL CELL BIOL, V23, P1095, DOI 10.1128/MCB.23.3.1095-1111.2003; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Lee CT, 1996, CANCER RES, V56, P3038; Lee CT, 2003, CANCER GENE THER, V10, P57, DOI 10.1038/sj.cgt.7700524; Li WQ, 2000, CANCER RES, V60, P3909; Liu XD, 1998, CANCER RES, V58, P5432; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; Nakamura K, 2000, CANCER RES, V60, P760; Navarro M, 2001, ENDOCRINOLOGY, V142, P1073, DOI 10.1210/en.142.3.1073; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; Oesterreich S, 2001, CANCER RES, V61, P5771; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PLAUTZ GE, 1993, P NATL ACAD SCI USA, V90, P4645, DOI 10.1073/pnas.90.10.4645; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Qiu M, 2003, MOL ENDOCRINOL, V17, P628, DOI 10.1210/me.2002-0378; Ram TG, 1996, MOL CARCINOGEN, V15, P227, DOI 10.1002/(SICI)1098-2744(199603)15:3<227::AID-MC8>3.0.CO;2-E; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; ROHLIK QT, 1987, BIOCHEM BIOPH RES CO, V149, P276, DOI 10.1016/0006-291X(87)91635-4; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Scrimgeour AG, 1997, ENDOCRINOLOGY, V138, P2552, DOI 10.1210/en.138.6.2552; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; Shen TJ, 2001, MOL CELL BIOL, V21, P6122, DOI 10.1128/MCB.21.18.6122-6131.2001; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; Swantek JL, 1999, ENDOCRINOLOGY, V140, P3163, DOI 10.1210/en.140.7.3163; Tamm I, 2001, LANCET, V358, P489, DOI 10.1016/S0140-6736(01)05629-X; Werner H, 2000, CELL MOL LIFE SCI, V57, P932, DOI 10.1007/PL00000735; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472	54	60	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5161	5174		10.1038/sj.onc.1207659	http://dx.doi.org/10.1038/sj.onc.1207659			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122317	Green Published			2022-12-25	WOS:000222382500006
J	Ishida, J; Hashimoto, T; Hashimoto, Y; Nishiwaki, S; Iguchi, T; Harada, S; Sugaya, T; Matsuzaki, H; Yamamoto, R; Shiota, N; Okunishi, H; Kihara, M; Umemura, S; Sugiyama, F; Yagami, K; Kasuya, Y; Mochizuki, N; Fukamizu, A				Ishida, J; Hashimoto, T; Hashimoto, Y; Nishiwaki, S; Iguchi, T; Harada, S; Sugaya, T; Matsuzaki, H; Yamamoto, R; Shiota, N; Okunishi, H; Kihara, M; Umemura, S; Sugiyama, F; Yagami, K; Kasuya, Y; Mochizuki, N; Fukamizu, A			Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS PEPTIDE LIGAND; NITRIC-OXIDE SYNTHASE; II TYPE-2 RECEPTOR; ORPHAN RECEPTOR; TISSUE DISTRIBUTION; APELIN; MICE; GENE; AKT; PROTEIN	APJ is a G-protein-coupled receptor with seven transmembrane domains, and its endogenous ligand, apelin, was identified recently. They are highly expressed in the cardiovascular system, suggesting that APJ is important in the regulation of blood pressure. To investigate the physiological functions of APJ, we have generated mice lacking the gene encoding APJ. The base-line blood pressure of APJ-deficient mice is equivalent to that of wild-type mice in the steady state. The administration of apelin transiently decreased the blood pressure of wild-type mice and a hypertensive model animal, a spontaneously hypertensive rat. On the other hand, this hypotensive response to apelin was abolished in APJ-deficient mice. This apelin-induced response was inhibited by pretreatment with a nitric-oxide synthase inhibitor, and apelin-induced phosphorylation of endothelial nitric-oxide synthase in lung endothelial cells from APJ-deficient mice disappeared. In addition, APJ-deficient mice showed an increased vasopressor response to the most potent vasoconstrictor angiotensin II, and the base-line blood pressure of double mutant mice homozygous for both APJ and angiotensin-type 1a receptor was significantly elevated compared with that of angiotensin-type 1a receptor-deficient mice. These results demonstrate that APJ exerts the hypotensive effect in vivo and plays a counterregulatory role against the pressor action of angiotensin II.	Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Lab Anim Resource Ctr, Tsukuba, Ibaraki 3058577, Japan; Yokohama City Univ, Sch Med, Dept Internal Med 2, Kanagawa 2360004, Japan; Shimane Univ, Sch Med, Dept Pharmacol, Izumo, Shimane 6938501, Japan; Chiba Univ, Grad Sch Med, Dept Mol Pharmacol & Biochem, Chuo Ku, Chiba 2608670, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Struct Anal, Osaka 5658565, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba; Yokohama City University; Shimane University; Chiba University; National Cerebral & Cardiovascular Center - Japan	Fukamizu, A (corresponding author), Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan.	akif@tara.tsukuba.ac.jp	fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020; Kasuya, Yoshitoshi/0000-0003-0614-5836; Matsuzaki, Hitomi/0000-0002-8890-5933				Chen MM, 2003, CIRCULATION, V108, P1432, DOI 10.1161/01.CIR.0000091235.94914.75; Cheng X, 2003, EUR J PHARMACOL, V470, P171, DOI 10.1016/S0014-2999(03)01821-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Foldes G, 2003, BIOCHEM BIOPH RES CO, V308, P480, DOI 10.1016/S0006-291X(03)01424-4; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GOTO Y, 1995, LAB ANIM SCI, V45, P601; HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0; Hosoya M, 2000, J BIOL CHEM, V275, P21061, DOI 10.1074/jbc.M908417199; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; Katugampola SD, 2001, BRIT J PHARMACOL, V132, P1255, DOI 10.1038/sj.bjp.0703939; Kawamata Y, 2001, BBA-MOL CELL RES, V1538, P162, DOI 10.1016/S0167-4889(00)00143-9; Lee DK, 2000, J NEUROCHEM, V74, P34, DOI 10.1046/j.1471-4159.2000.0740034.x; Medhurst AD, 2003, J NEUROCHEM, V84, P1162, DOI 10.1046/j.1471-4159.2003.01587.x; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Miyagishi M, 2000, INT J MOL MED, V5, P27; ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O; Reaux A, 2001, J NEUROCHEM, V77, P1085, DOI 10.1046/j.1471-4159.2001.00320.x; SUGAYA T, 1995, J BIOL CHEM, V270, P18719, DOI 10.1074/jbc.270.32.18719; Szokodi I, 2002, CIRC RES, V91, P434, DOI 10.1161/01.RES.0000033522.37861.69; Taheri S, 2002, BIOCHEM BIOPH RES CO, V291, P1208, DOI 10.1006/bbrc.2002.6575; Tatemoto K, 2001, REGUL PEPTIDES, V99, P87, DOI 10.1016/S0167-0115(01)00236-1; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Vickers C, 2002, J BIOL CHEM, V277, P14838, DOI 10.1074/jbc.M200581200; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458	27	324	371	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26274	26279		10.1074/jbc.M404149200	http://dx.doi.org/10.1074/jbc.M404149200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087458	hybrid			2022-12-25	WOS:000222003000045
J	Feshchenko, EA; Smirnova, EV; Swaminathan, G; Teckchandani, AM; Agrawal, R; Band, H; Zhang, XL; Annan, RS; Carr, SA; Tsygankov, AY				Feshchenko, EA; Smirnova, EV; Swaminathan, G; Teckchandani, AM; Agrawal, R; Band, H; Zhang, XL; Annan, RS; Carr, SA; Tsygankov, AY			TULA: an SH3- and UBA-containing protein that binds to c-Cbl and ubiquitin	ONCOGENE			English	Article						TULA; c-Cbl; UBA; SH3; ubiquitin; protein tyrosine kinase	GROWTH-FACTOR RECEPTOR; T-CELL-RECEPTOR; DAMAGE-INDUCIBLE PROTEINS; TYROSINE KINASE; RING FINGER; EGF-RECEPTOR; NEGATIVE REGULATION; PHOSPHORYLATION SITES; HERPESVIRUS-SAIMIRI; MASS-SPECTROMETRY	Downregulation of protein tyrosine kinases is a major function of the multidomain protein c-Cbl. This effect of c-Cbl is critical for both negative regulation of normal physiological stimuli and suppression of cellular transformation. In spite of the apparent importance of these effects of c-Cbl, their own regulation is poorly understood. To search for possible novel regulators of c-Cbl, we purified a number of c-Cbl-associated proteins by affinity chromatography and identified them by mass spectrometry. Among them, we identified the UBA- and SH3-containing protein T-cell Ubiquitin LigAnd (TULA), which can also bind to ubiquitin. Functional studies in a model system based on co-expression of TULA, c-Cbl, and EGF receptor in 293T cells demonstrate that TULA is capable of inhibiting c-Cbl-mediated downregulation of EGF receptor. Furthermore, modulation of TULA concentration in Jurkat T-lymphoblastoid cells demonstrates that TULA upregulates the activity of both Zap kinase and NF-AT transcription factor. Therefore, our study indicates that TULA counters the inhibitory effect of c-Cbl on protein tyrosine kinases and, thus, may be involved in the regulation of biological effects of c-Cbl. Finally, our results suggest that TULA-mediated inhibition of the effects of c-Cbl on protein tyrosine kinases is caused by TULA-induced ubiquitylation and degradation of c-Cbl.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; GlaxoSmithKline, King Of Prussia, PA USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; GlaxoSmithKline; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Tsygankov, AY (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.	alexander.tsygankov@temple.edu	Tsygankov, Alexander Y/K-6205-2017; Carr, Steven A./AAH-8366-2019		NCI NIH HHS [CA78499] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078499] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Bertolaet BL, 2001, J MOL BIOL, V313, P955, DOI 10.1006/jmbi.2001.5105; Broome MA, 1999, ONCOGENE, V18, P2908, DOI 10.1038/sj.onc.1202873; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; de Melker AA, 2001, J CELL SCI, V114, P2167; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; Hasham MG, 2004, VIROLOGY, V320, P313, DOI 10.1016/j.virol.2003.11.032; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Klapper LN, 2000, CANCER RES, V60, P3384; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Merlo JJ, 2001, VIROLOGY, V279, P325, DOI 10.1006/viro.2000.0714; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Oksvold MP, 2001, EUR J CELL BIOL, V80, P285, DOI 10.1078/0171-9335-00160; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Rao N, 2000, J IMMUNOL, V164, P4616, DOI 10.4049/jimmunol.164.9.4616; Rao NV, 2002, P NATL ACAD SCI USA, V99, P3794, DOI 10.1073/pnas.062055999; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; SANJAY A, 2001, SCI STKE, pE40; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Teckchandani AM, 2001, ONCOGENE, V20, P1739, DOI 10.1038/sj.onc.1204246; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; TSYGANKOV AY, 1994, J LEUKOCYTE BIOL, V55, P289, DOI 10.1002/jlb.55.3.289; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; Wang HY, 2001, J BIOL CHEM, V276, P26004, DOI 10.1074/jbc.M010738200; Wang J, 2001, BIOTECHNIQUES, V31, P722, DOI 10.2144/01314bm01; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Wattenhofer M, 2001, HUM GENET, V108, P140, DOI 10.1007/s004390000453; Wilhelmsen K, 2002, ONCOGENE, V21, P1079, DOI 10.1038/sj.onc.1205166; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	72	64	65	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4690	4706		10.1038/sj.onc.1207627	http://dx.doi.org/10.1038/sj.onc.1207627			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15107835				2022-12-25	WOS:000221799200005
J	Zong, YN; Bice, TW; Ton-That, H; Schneewind, O; Narayana, SVL				Zong, YN; Bice, TW; Ton-That, H; Schneewind, O; Narayana, SVL			Crystal structures of Staphylococcus aureus sortase A and its substrate complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; IMIDAZOLIUM ION-PAIR; SURFACE-PROTEINS; CELL-WALL; ANCHOR STRUCTURE; SRTA GENE; IN-VITRO; STREPTOCOCCUS-PNEUMONIAE; LISTERIA-MONOCYTOGENES; CATALYTIC MECHANISM	The cell wall envelope of staphylococci and other Gram-positive pathogens is coated with surface proteins that interact with human host tissues. Surface proteins of Staphylococcus aureus are covalently linked to the cell wall envelope by a mechanism requiring C-terminal sorting signals with an LPXTG motif. Sortase (SrtA) cleaves surface proteins between the threonine ( T) and the glycine ( G) of the LPXTG motif and catalyzes the formation of an amide bond between threonine at the C-terminal end of polypeptides and cell wall crossbridges. The active site architecture and catalytic mechanism of sortase A has hitherto not been revealed. Here we present the crystal structures of native SrtA, of an active site mutant of SrtA, and of the mutant SrtA complexed with its substrate LPETG peptide and describe the substrate binding pocket of the enzyme. Highly conserved proline ( P) and threonine ( T) residues of the LPXTG motif are held in position by hydrophobic contacts, whereas the glutamic acid residue ( E) at the X position points out into the solvent. The scissile T-G peptide bond is positioned between the active site Cys(184) and Arg(197) residues and at a greater distance from the imidazolium side chain of His(120). All three residues, His(120), Cys(184), and Arg(197), are conserved in sortase enzymes from Gram-positive bacteria. Comparison of the active sites of S. aureus sortase A and sortase B provides insight into substrate specificity and suggests a universal sortase-catalyzed mechanism of bacterial surface protein anchoring in Gram-positive bacteria.	Univ Alabama, Sch Optometry, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA; Univ Chicago, Comm Microbiol, Chicago, IL 60637 USA	University of Alabama System; University of Alabama Birmingham; University of Chicago	Narayana, SVL (corresponding author), Univ Alabama, Sch Optometry, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA.	narayana@uab.edu	Ton-That, Hung/AAB-6155-2020	Ton-That, Hung/0000-0003-1611-0469	NIAID NIH HHS [AI38897, AI52765] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038897, R01AI052765] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Antosiewicz J, 1996, J COMPUT CHEM, V17, P1633, DOI 10.1002/(SICI)1096-987X(19961115)17:14<1633::AID-JCC5>3.0.CO;2-M; Barnett TC, 2002, J BACTERIOL, V184, P2181, DOI 10.1128/JB.184.8.2181-2191.2002; Bierne H, 2002, MOL MICROBIOL, V43, P869, DOI 10.1046/j.1365-2958.2002.02798.x; Bolken TC, 2001, INFECT IMMUN, V69, P75, DOI 10.1128/IAI.69.1.75-80.2001; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burton NA, 1998, FARADAY DISCUSS, V110, P463, DOI 10.1039/a801719k; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Connolly KM, 2003, J BIOL CHEM, V278, P34061, DOI 10.1074/jbc.M305245200; Cossart P, 2000, P NATL ACAD SCI USA, V97, P5013, DOI 10.1073/pnas.97.10.5013; Dardenne LE, 2003, PROTEINS, V52, P236, DOI 10.1002/prot.10368; Dessen A, 2004, STRUCTURE, V12, P6, DOI 10.1016/j.str.2003.12.009; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Garandeau C, 2002, INFECT IMMUN, V70, P1382, DOI 10.1128/IAI.70.3.1382-1390.2002; Harrison MJ, 1997, J AM CHEM SOC, V119, P12285, DOI 10.1021/ja9711472; Hava DL, 2003, J BACTERIOL, V185, P413, DOI 10.1128/JB.185.2.413-421.2003; Huang XY, 2003, BIOCHEMISTRY-US, V42, P11307, DOI 10.1021/bi034391g; Ilangovan U, 2001, P NATL ACAD SCI USA, V98, P6056, DOI 10.1073/pnas.101064198; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; Jonsson IM, 2002, J INFECT DIS, V185, P1417, DOI 10.1086/340503; Jonsson IM, 2003, MICROBES INFECT, V5, P775, DOI 10.1016/S1286-4579(03)00143-6; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; Kharat AS, 2003, INFECT IMMUN, V71, P2758, DOI 10.1128/IAI.71.5.2758-2765.2003; Kruger RG, 2004, BIOCHEMISTRY-US, V43, P1541, DOI 10.1021/bi035920j; Lee SF, 2003, INFECT IMMUN, V71, P676, DOI 10.1128/IAI.71.2.676-681.2003; Mazmanian SK, 2002, P NATL ACAD SCI USA, V99, P2293, DOI 10.1073/pnas.032523999; Mazmanian SK, 1999, SCIENCE, V285, P760, DOI 10.1126/science.285.5428.760; Mazmanian SK, 2000, P NATL ACAD SCI USA, V97, P5510, DOI 10.1073/pnas.080520697; Mazmanian SK, 2001, MOL MICROBIOL, V40, P1049, DOI 10.1046/j.1365-2958.2001.02411.x; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Pallen MJ, 2001, TRENDS MICROBIOL, V9, P97, DOI 10.1016/S0966-842X(01)01956-4; Perry AM, 2002, J BIOL CHEM, V277, P16241, DOI 10.1074/jbc.M109194200; Pinitglang S, 1997, BIOCHEMISTRY-US, V36, P9968, DOI 10.1021/bi9705974; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Ruzin A, 2002, J BACTERIOL, V184, P2141, DOI 10.1128/JB.184.8.2141-2147.2002; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; Silvaggi NR, 2003, BIOCHEMISTRY-US, V42, P1199, DOI 10.1021/bi0268955; STORER AC, 1994, METHOD ENZYMOL, V244, P486; Ton-That H, 2003, MOL MICROBIOL, V50, P1429, DOI 10.1046/j.1365-2958.2003.03782.x; Ton-That H, 1998, J BIOL CHEM, V273, P29143, DOI 10.1074/jbc.273.44.29143; Ton-That H, 1999, J BIOL CHEM, V274, P24316, DOI 10.1074/jbc.274.34.24316; Ton-That H, 2000, J BIOL CHEM, V275, P9876, DOI 10.1074/jbc.275.13.9876; Ton-That H, 2002, J BIOL CHEM, V277, P7447, DOI 10.1074/jbc.M109945200; Ton-That H, 1999, P NATL ACAD SCI USA, V96, P12424, DOI 10.1073/pnas.96.22.12424; TonThat H, 1997, J BIOL CHEM, V272, P22285, DOI 10.1074/jbc.272.35.22285; Zong YN, 2004, STRUCTURE, V12, P105, DOI 10.1016/j.str.2003.11.021	52	187	207	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31383	31389		10.1074/jbc.M401374200	http://dx.doi.org/10.1074/jbc.M401374200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15117963	hybrid			2022-12-25	WOS:000222726800059
J	Oeggerli, M; Tomovska, S; Schraml, P; Calvano-Forte, D; Schafroth, S; Simon, R; Gasser, T; Mihatsch, MJ; Sauter, G				Oeggerli, M; Tomovska, S; Schraml, P; Calvano-Forte, D; Schafroth, S; Simon, R; Gasser, T; Mihatsch, MJ; Sauter, G			E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer	ONCOGENE			English	Article						bladder cancer; 6p22; E2F3; amplification; FISH; IHC	COMPARATIVE GENOMIC HYBRIDIZATION; TISSUE MICROARRAY ANALYSIS; CHROMOSOMAL IMBALANCES; TRANSCRIPTION FACTORS; GENE AMPLIFICATION; COPY NUMBER; S-PHASE; CARCINOMA; P53; EXPRESSION	E2F3 is located in the 6p22 bladder amplicon and encodes a transcription factor important for cell cycle regulation and DNA replication. To further investigate the role of E2F3 in bladder cancer, a tissue microarray containing samples from 2317 bladder tumors was used for gene copy number and expression analysis by means of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). E2F3 amplification was strongly associated with invasive tumor phenotype and high tumor grade (P<0.0001 each). None of 272 pTaG1/G2 tumors, but 35 of 311 pT1-4 carcinomas (11.3%), had E2F3 amplification. A high E2F3 expression level was associated with high grade, advanced stage, and E2F3 gene amplification (P<0.0001 each). To evaluate whether E2F3 expression correlates with tumor proliferation, the Ki67 labeling index (LI) was analysed for each tumor. There was a strong association between a high Ki67 LI and E2F3 expression (P < 0.0001), which was independent of grade and stage. We conclude that E2F3 is frequently amplified and overexpressed in invasively growing bladder cancer (stage pT1-4). E2F3 expression appears to provide a growth advantage to tumor cells by activating cell proliferation in a subset of bladder tumors.	Univ Basel, Inst Pathol, CH-4031 Basel, Switzerland; Inst Pathol, CH-4031 Basel, Switzerland; Urol Clin, CH-4410 Liestal, Switzerland	University of Basel	Sauter, G (corresponding author), Univ Basel, Inst Pathol, Schoenbeinstr 40, CH-4031 Basel, Switzerland.			Simon, Ronald/0000-0003-0158-4258				Anantharaman V, 2001, FEMS MICROBIOL LETT, V197, P215, DOI 10.1111/j.1574-6968.2001.tb10606.x; Bruch J, 2000, CANCER RES, V60, P4526; Bubendorf L, 2001, AM J CLIN PATHOL, V116, P79; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DIMATTIA GE, 1990, J BIOL CHEM, V265, P16412; FARR CJ, 1993, MAMM GENOME, V4, P577, DOI 10.1007/BF00361388; Halling KC, 2000, J UROLOGY, V164, P1768, DOI 10.1016/S0022-5347(05)67104-2; Hui R, 1997, ONCOGENE, V15, P1617, DOI 10.1038/sj.onc.1201311; Humbert PO, 2000, GENE DEV, V14, P690; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; KONDO I, 1983, CYTOGENET CELL GENET, V35, P9, DOI 10.1159/000131829; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; LIPPONEN PK, 1993, BRIT J UROL, V72, P451, DOI 10.1111/j.1464-410X.1993.tb16176.x; Liukkonen T, 1999, EUR UROL, V36, P393, DOI 10.1159/000020039; MITELMAN F, 1994, CATALOG CHROMOSOME A; Moch H, 1997, UROL RES, V25, pS25, DOI 10.1007/BF00942044; Mostofi FK, 1973, HISTOLOGICAL TYPING; Nakopoulou L, 1998, HUM PATHOL, V29, P146, DOI 10.1016/S0046-8177(98)90225-8; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nocito A, 2001, J PATHOL, V194, P349, DOI 10.1002/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D; Pfister C, 1998, EUR UROL, V33, P278, DOI 10.1159/000019580; Polanowska J, 2000, GENE CHROMOSOME CANC, V28, P126, DOI 10.1002/(SICI)1098-2264(200005)28:1<126::AID-GCC15>3.0.CO;2-G; POPESCU NC, 1989, GENOMICS, V4, P362, DOI 10.1016/0888-7543(89)90343-1; Rabbani F, 1999, J NATL CANCER I, V91, P874, DOI 10.1093/jnci/91.10.874; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Richter J, 1999, CANCER RES, V59, P5687; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Richter J, 1998, AM J PATHOL, V153, P1615, DOI 10.1016/S0002-9440(10)65750-1; Richter J, 1997, CANCER RES, V57, P2860; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; Sauter G., 1994, Pathology Research and Practice, V190, P281; Simon R, 2000, INT J ONCOL, V17, P1025; Simon R, 2003, INT J CANCER, V107, P764, DOI 10.1002/ijc.11477; Simon R, 2002, ONCOGENE, V21, P2476, DOI 10.1038/sj.onc.1205304; Simon R, 1998, J PATHOL, V185, P345; Simon R, 2001, CANCER RES, V61, P4514; Terracciano L, 1999, J PATHOL, V189, P230, DOI 10.1002/(SICI)1096-9896(199910)189:2<230::AID-PATH407>3.0.CO;2-8; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Union for International Cancer Control (UICC), 1992, TNM CLASS MAL TUM; Veltman JA, 2003, CANCER RES, V63, P2872; VOORTER C, 1995, AM J PATHOL, V146, P1341; Wagner U, 1997, AM J PATHOL, V151, P753; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; Zaharieva BM, 2003, J PATHOL, V201, P603, DOI 10.1002/path.1481; Zhao JM, 1999, CANCER RES, V59, P4658	50	127	138	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	2004	23	33					5616	5623		10.1038/sj.onc.1207749	http://dx.doi.org/10.1038/sj.onc.1207749			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15122326				2022-12-25	WOS:000222629500006
J	Khan, H; Barna, T; Harris, RJ; Bruce, NC; Barsukov, I; Munro, AW; Moody, PCE; Scrutton, NS				Khan, H; Barna, T; Harris, RJ; Bruce, NC; Barsukov, I; Munro, AW; Moody, PCE; Scrutton, NS			Atomic resolution structures and solution Behavior of enzyme-substrate complexes of Enterobacter cloacae PB2 pentaerythritol tetranitrate reductase - Multiple conformational states and implications for the mechanism of nitroaromatic explosive degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL MORPHINONE REDUCTASE; CRYSTAL-STRUCTURE; 2,4,6-TRINITROTOLUENE; SEQUENCE; CRYSTALLOGRAPHY; BINDING	The structure of pentaerythritol tetranitrate (PETN) reductase in complex with the nitroaromatic substrate picric acid determined previously at 1.55 Angstrom resolution indicated additional electron density between the indole ring of residue Trp-102 and the nitro group at C-6 of picrate. The data suggested the presence of an unusual bond between substrate and the tryptophan side chain. Herein, we have extended the resolution of the PETN reductase-picric acid complex to 0.9 Angstrom. This high-resolution analysis indicates that the active site is partially occupied with picric acid and that the anomalous density seen in the original study is attributed to the population of multiple conformational states of Trp-102 and not a formal covalent bond between the indole ring of Trp-102 and picric acid. The significance of any interaction between Trp-102 and nitroaromatic substrates was probed further in solution and crystal complexes with wild-type and mutant (W102Y and W102F) enzymes. Unlike with wild-type enzyme, in the crystalline form picric acid was bound at full occupancy in the mutant enzymes, and there was no evidence for multiple conformations of active site residues. Solution studies indicate tighter binding of picric acid in the active sites of the W102Y and W102F enzymes. Mutation of Trp-102 does not impair significantly enzyme reduction by NADPH, but the kinetics of decay of the hydride-Meisenheimer complex are accelerated in the mutant enzymes. The data reveal that decay of the hydride-Meisenheimer complex is enzyme catalyzed and that the final distribution of reaction products for the mutant enzymes is substantially different from wild-type enzyme. Implications for the mechanism of high explosive degradation by PETN reductase are discussed.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ York, Ctr Novel Agr Prod, Dept Biol, York YO10 5YW, N Yorkshire, England	University of Leicester; University of York - UK	Scrutton, NS (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	nss4@le.ac.uk	barna, terez/R-1357-2018; Moody, Peter/A-6832-2008; Munro, Andrew/G-5639-2019	Moody, Peter/0000-0003-1762-9238; Munro, Andrew/0000-0002-4642-180X; Bruce, Neil Charles/0000-0003-0398-2997				Barna T, 2002, J BIOL CHEM, V277, P30976, DOI 10.1074/jbc.M202846200; Barna TM, 2001, J MOL BIOL, V310, P433, DOI 10.1006/jmbi.2001.4779; Basran J, 2003, J BIOL CHEM, V278, P43973, DOI 10.1074/jbc.M305983200; Binks PR, 1996, APPL ENVIRON MICROB, V62, P1214, DOI 10.1128/AEM.62.4.1214-1219.1996; Blehert DS, 1999, J BACTERIOL, V181, P6254, DOI 10.1128/JB.181.20.6254-6263.1999; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; French CE, 1995, BIOCHEM J, V312, P671, DOI 10.1042/bj3120671; French CE, 1998, APPL ENVIRON MICROB, V64, P2864; French CE, 1996, J BACTERIOL, V178, P6623, DOI 10.1128/jb.178.22.6623-6627.1996; Khan H, 2002, J BIOL CHEM, V277, P21906, DOI 10.1074/jbc.M200637200; Lario PI, 2003, J MOL BIOL, V326, P1635, DOI 10.1016/S0022-2836(03)00054-8; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pak JW, 2000, APPL ENVIRON MICROB, V66, P4742, DOI 10.1128/AEM.66.11.4742-4750.2000; Ravelli RBG, 2000, STRUCTURE, V8, P315, DOI 10.1016/S0969-2126(00)00109-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Snape JR, 1997, J BACTERIOL, V179, P7796, DOI 10.1128/jb.179.24.7796-7802.1997; Wang CY, 2003, ENVIRON SCI TECHNOL, V37, P3595, DOI 10.1021/es030010a; Wang CY, 2000, BIOTECHNOL LETT, V22, P15, DOI 10.1023/A:1005663104888; Williams RE, 2001, BIOCHEM SOC SYMP, V68, P143; WILLIAMS RE, 1999, FLAVINS FLAVOPROTEIN, P663; WILLIAMS RE, 2004, IN PRESS APPL ENV MI	25	36	38	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30563	30572		10.1074/jbc.M403541200	http://dx.doi.org/10.1074/jbc.M403541200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15128738	hybrid			2022-12-25	WOS:000222531900086
J	Rugles, SW; Fletterick, RJ; Craik, CS				Rugles, SW; Fletterick, RJ; Craik, CS			Characterization of structural determinants of granzyme B reveals potent mediators of extended substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM CRYSTAL-STRUCTURE; SERINE-PROTEASE GENES; CONVERTING TRYPSIN; CASPASE FAMILY; KEY MEDIATORS; HUMAN CHYMASE; ACTIVE-SITE; FACTOR XA; PROTEINASE; CLEAVAGE	Granzymes are trypsin-like serine proteases mediating apoptotic cell death that are composed of two genetically distinct subfamilies: granzyme A-like proteases resemble trypsin in their active site architecture, while granzyme B-like proteases are quite distinct. Granzyme B prefers substrates containing P4 to P1 amino acids Ile/Val, Glu/Met/Gln, Pro/Xaa, and aspartic acid N-terminal to the proteolytic cleavage. By investigating the narrow extended specificity of the granzyme B-like proteases the mediators of their unique specificity are being defined. The foci of this study were the structural determinants Ile(99), Tyr(174), Arg(192), and Asn(218). Even modest mutations of these residues resulted in unique extended specificity profiles as determined using combinatorial substrate libraries and individual fluorogenic substrates. As with other serine proteases, Ile(99) completely defines and predicts P2 specificity, primarily through the binding constant K-m. Asn(218) variants have minor effects alone but in combination with mutations at Arg(192) and Ile(99) alter P2 through P4 extended specificity. For each variant, the activity on its cognate substrate was equal to that of granzyme B for the same substrate. Thus, mutations at these determinants change extended selectivity preferentially over catalytic power. Additionally Asn(218) variants result in increased activity on the wild type substrate, while the N218A/I99A variant disrupts the additivity between P2 and P4 specificity. This defines Asn(218) not only as a determinant of specificity but also as a structural component required for P2 and P4 independence. This study confirms four determinants of granzyme B extended substrate specificity that constitute a canon applicable to the study of the remaining family members.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Craik, CS (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 600 16th St,Box 2280, San Francisco, CA 94143 USA.	craik@cgl.ucsf.edu			NATIONAL CANCER INSTITUTE [P01CA072006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039304] Funding Source: NIH RePORTER; NCI NIH HHS [CA72006] Funding Source: Medline; NIDDK NIH HHS [DK39304] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bell JK, 2003, NAT STRUCT BIOL, V10, P527, DOI 10.1038/nsb944; BLOW DM, 1976, ACCOUNTS CHEM RES, V9, P145, DOI 10.1021/ar50100a004; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; Caputo A, 1999, PROTEINS, V35, P415, DOI 10.1002/(SICI)1097-0134(19990601)35:4<415::AID-PROT5>3.0.CO;2-7; CAPUTO A, 1994, NAT STRUCT BIOL, V1, P364, DOI 10.1038/nsb0694-364; Case A, 2003, BIOCHEMISTRY-US, V42, P3335, DOI 10.1021/bi020668l; CHAN C, 2000, FMOC SOLID PHASE SYN; Estebanez-Perpina E, 2000, BIOL CHEM, V381, P1203, DOI 10.1515/BC.2000.148; Friedrich R, 2002, J BIOL CHEM, V277, P2160, DOI 10.1074/jbc.M109830200; HANSON RD, 1990, P NATL ACAD SCI USA, V87, P960, DOI 10.1073/pnas.87.3.960; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Harris JL, 1998, J BIOL CHEM, V273, P27364, DOI 10.1074/jbc.273.42.27364; HEDSTROM L, 1994, BIOCHEMISTRY-US, V33, P8757, DOI 10.1021/bi00195a017; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HEUSEL JW, 1991, J BIOL CHEM, V266, P6152; Hof P, 1996, EMBO J, V15, P5481, DOI 10.1002/j.1460-2075.1996.tb00933.x; Hopfner KP, 1999, STRUCTURE, V7, P989, DOI 10.1016/S0969-2126(99)80125-7; HUDIG D, 1987, BIOCHEM BIOPH RES CO, V149, P882, DOI 10.1016/0006-291X(87)90490-6; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; Kam CM, 2000, BBA-PROTEIN STRUCT M, V1477, P307, DOI 10.1016/S0167-4838(99)00282-4; McGrath ME, 1997, BIOCHEMISTRY-US, V36, P14318, DOI 10.1021/bi971403n; Pereira PJB, 1999, J MOL BIOL, V286, P163, DOI 10.1006/jmbi.1998.2462; PERONA JJ, 1995, BIOCHEMISTRY-US, V34, P1489, DOI 10.1021/bi00005a004; Perona JJ, 1997, BIOCHEMISTRY-US, V36, P5381, DOI 10.1021/bi9617522; Pham CTN, 1999, P NATL ACAD SCI USA, V96, P8627, DOI 10.1073/pnas.96.15.8627; POE M, 1991, J BIOL CHEM, V266, P98; REMINGTON SJ, 1988, BIOCHEMISTRY-US, V27, P8097, DOI 10.1021/bi00421a019; Rezaie AR, 1996, EUR J BIOCHEM, V242, P477, DOI 10.1111/j.1432-1033.1996.477rr.x; REZAIE AR, 1993, J BIOL CHEM, V268, P19943; Rezaie AR, 1996, J BIOL CHEM, V271, P23807, DOI 10.1074/jbc.271.39.23807; Rose T, 2002, J BIOL CHEM, V277, P19243, DOI 10.1074/jbc.C200132200; Rotonda J, 2001, CHEM BIOL, V8, P357, DOI 10.1016/S1074-5521(01)00018-7; RYPNIEWSKI WR, 1994, PROTEIN ENG, V7, P57, DOI 10.1093/protein/7.1.57; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHECHTER I, 1968, BIOCHEM BIOPH RES CO, V32, P898, DOI 10.1016/0006-291X(68)90326-4; Sharif-Askari E, 2001, EMBO J, V20, P3101, DOI 10.1093/emboj/20.12.3101; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Trapani JA, 2001, GENOME BIOL, V2; VandeCraen M, 1997, EUR J IMMUNOL, V27, P1296, DOI 10.1002/eji.1830270535; Waugh SM, 2000, NAT STRUCT BIOL, V7, P762, DOI 10.1038/78992	42	25	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30751	30759		10.1074/jbc.M400949200	http://dx.doi.org/10.1074/jbc.M400949200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123647	hybrid			2022-12-25	WOS:000222531900106
J	Adachi, T; Pimentel, DR; Heibeck, T; Hou, XY; Lee, YJ; Jiang, BB; Ido, Y; Cohen, RA				Adachi, T; Pimentel, DR; Heibeck, T; Hou, XY; Lee, YJ; Jiang, BB; Ido, Y; Cohen, RA			S-glutathiolation of Ras mediates redox-sensitive signaling by angiotensin II in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; OXYGEN SPECIES MEDIATE; PROTEIN-KINASE; OXIDATIVE STRESS; REGULATED KINASE; FACTOR RECEPTOR; NADPH OXIDASE; ACTIVATION; PHOSPHORYLATION; IDENTIFICATION	Angiotensin II (AII) increases production of reactive oxygen species from NAD(P) H oxidase, a response that contributes to vascular hypertrophy. Here we show in cultured vascular smooth muscle cells that S-glutathiolation of the redox-sensitive Cys(118) on the small GTPase, Ras, plays a critical role in AII-induced hypertrophic signaling. AII simultaneously increased the Ras activity and the S-glutathiolation of Ras (GSS-Ras) detected by biotin-labeled GSH or mass spectrometry. Both the increase in activity and GSS-Ras was labile under reducing conditions, suggesting the essential nature of this thiol modification to Ras activation. Overexpression of catalase, a dominant-negative p47(phox), or glutaredoxin-1 decreased GSS-Ras, Ras activation, p38, and Akt phosphorylation and the induction of protein synthesis by AII. Furthermore, expression of a Cys(118) mutant Ras decreased AII-mediated p38 and Akt phosphorylation as well as protein synthesis. These results show that H2O2 from NAD( P) H oxidase forms GSS-Ras on Cys(118) and increases its activity leading to p38 and Akt phosphorylation, which contributes to the induction of protein synthesis. This study suggests that GSS-Ras is a redox-sensitive signaling switch that participates in the cellular response to AII.	Boston Univ, Med Ctr X707, Whitaker Cardiovasc Inst, Vasc Biol Unit, Boston, MA 02118 USA; Boston Univ, Med Ctr, Whitaker Cardiovasc Inst, Myocardial Biol Unit, Boston, MA 02118 USA; Boston Univ, Med Ctr, Whitaker Cardiovasc Inst, Diabet & Metab Unit, Boston, MA 02118 USA; Univ Pittsburgh, Hillman Canc Ctr, Dept Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Hillman Canc Ctr, Inst Canc, Pittsburgh, PA 15260 USA	Boston University; Boston University; Boston University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Adachi, T (corresponding author), Boston Univ, Med Ctr X707, Whitaker Cardiovasc Inst, Vasc Biol Unit, 650 Albany St, Boston, MA 02118 USA.	tadachi@bumc.bu.edu		/0000-0002-1070-6408; Pimentel, David/0000-0002-0537-7195; Ido, Yasuo/0000-0002-3036-9971	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055620] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL55620] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barry-Lane PA, 2001, J CLIN INVEST, V108, P1513, DOI 10.1172/JCI11927; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; Dodds E, 1999, J NEUROCHEM, V72, P2105, DOI 10.1046/j.1471-4159.1999.0722105.x; Eaton P, 2002, J BIOL CHEM, V277, P9806, DOI 10.1074/jbc.M111454200; Eguchi S, 1999, J BIOL CHEM, V274, P36843, DOI 10.1074/jbc.274.52.36843; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Frank GD, 2000, ENDOCRINOLOGY, V141, P3120, DOI 10.1210/en.141.9.3120; Griendling KK, 2000, ARTERIOSCL THROM VAS, V20, P2175, DOI 10.1161/01.ATV.20.10.2175; Hojo Y, 2002, CIRC RES, V91, P712, DOI 10.1161/01.RES.0000037981.97541.25; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; Landmesser U, 2002, HYPERTENSION, V40, P511, DOI 10.1161/01.HYP.0000032100.23772.98; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Mallis RJ, 2001, BIOCHEM J, V355, P145, DOI 10.1042/bj3550145; Pimentel DR, 2001, CIRC RES, V89, P453, DOI 10.1161/hh1701.096615; Song JJ, 2003, BIOCHEM J, V373, P845, DOI 10.1042/BJ20030275; Sullivan DM, 2000, BIOCHEMISTRY-US, V39, P11121, DOI 10.1021/bi0007674; Takahashi T, 1997, J BIOL CHEM, V272, P16018, DOI 10.1074/jbc.272.25.16018; Teng KK, 1999, J BIOL CHEM, V274, P37315, DOI 10.1074/jbc.274.52.37315; Touyz RM, 2003, ARTERIOSCL THROM VAS, V23, P981, DOI 10.1161/01.ATV.0000069236.27911.68; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Wang HD, 2001, CIRC RES, V88, P947, DOI 10.1161/hh0901.089987; Ward NE, 2000, BIOCHEMISTRY-US, V39, P10319, DOI 10.1021/bi000781g; Williams JG, 2003, P NATL ACAD SCI USA, V100, P6376, DOI 10.1073/pnas.1037299100; Wolin MS, 2000, ARTERIOSCL THROM VAS, V20, P1430, DOI 10.1161/01.ATV.20.6.1430	29	238	244	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29857	29862		10.1074/jbc.M313320200	http://dx.doi.org/10.1074/jbc.M313320200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123696	hybrid			2022-12-25	WOS:000222445300123
J	Chen, OS; Crisp, RJ; Valachovic, M; Bard, M; Winge, DR; Kaplan, J				Chen, OS; Crisp, RJ; Valachovic, M; Bard, M; Winge, DR; Kaplan, J			Transcription of the yeast iron regulon does not respond directly to iron but rather to iron-sulfur cluster biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRATAXIN; MITOCHONDRIAL; PROTEINS; BIOGENESIS; EXPRESSION; TRANSPORT; GENES; NFS1P; CCC1; AFT1	Saccharomyces cerevisiae responds to iron deprivation by increased transcription of the iron regulon, including the high affinity cell-surface transport system encoded by FET3 and FTR1. Here we demonstrate that transcription of these genes does not respond directly to cytosolic iron but rather to the mitochondrial utilization of iron for the synthesis of iron-sulfur (Fe-S) clusters. We took advantage of a mutant form of an iron-dependent enzyme in the sterol pathway (Erg25-2p) to assess cytosolic iron levels. We showed that disruption of mitochondrial Fe-S biosynthesis, which results in excessive mitochondrial iron accumulation, leads to transcription of the iron transport system independent of the cytosolic iron level. There is an inverse correlation between the activity of the mitochondrial Fe-S-containing enzyme aconitase and the induction of FET3. Regulation of transcription by Fe-S biosynthesis represents a mechanism by which cellular iron acquisition is integrated with mitochondrial iron metabolism.	Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA; Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46202 USA; Univ Utah, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Indiana University System; Indiana University-Purdue University Indianapolis; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Kaplan, J (corresponding author), Univ Utah, Sch Med, Dept Pathol, 50 North 1900 East, Salt Lake City, UT 84132 USA.	jerry.kaplan@path.utah.edu	Winge, Dennis/G-3611-2010; Valachovic, Martin/O-5962-2017	Valachovic, Martin/0000-0001-7096-9325	NATIONAL CANCER INSTITUTE [R01CA061286, P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052380] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062104] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA42014, CA 61286] Funding Source: Medline; NIDDK NIH HHS [DK52380] Funding Source: Medline; NIGMS NIH HHS [GM62104] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; BREUER W, 1995, AM J PHYSIOL-CELL PH, V268, pC1354, DOI 10.1152/ajpcell.1995.268.6.C1354; Chen OS, 2000, J BIOL CHEM, V275, P7626, DOI 10.1074/jbc.275.11.7626; Chen OS, 2002, P NATL ACAD SCI USA, V99, P16922, DOI 10.1073/pnas.232392299; Crisp RJ, 2003, J BIOL CHEM, V278, P45499, DOI 10.1074/jbc.M307229200; Duby G, 2002, HUM MOL GENET, V11, P2635, DOI 10.1093/hmg/11.21.2635; Foury F, 1999, FEBS LETT, V456, P281, DOI 10.1016/S0014-5793(99)00961-8; Kennedy MA, 2001, BBA-GENE STRUCT EXPR, V1517, P177, DOI 10.1016/S0167-4781(00)00246-3; Kiley PJ, 2003, CURR OPIN MICROBIOL, V6, P181, DOI 10.1016/S1369-5274(03)00039-0; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Lesuisse E, 2003, HUM MOL GENET, V12, P879, DOI 10.1093/hmg/ddg096; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Li LT, 1996, J BIOL CHEM, V271, P16927, DOI 10.1074/jbc.271.28.16927; Li LT, 2001, J BIOL CHEM, V276, P29515, DOI 10.1074/jbc.M103944200; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schwartz CJ, 2001, P NATL ACAD SCI USA, V98, P14895, DOI 10.1073/pnas.251550898; Stearman R, 1998, GENE, V212, P197, DOI 10.1016/S0378-1119(98)00179-6; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x	24	162	163	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29513	29518		10.1074/jbc.M403209200	http://dx.doi.org/10.1074/jbc.M403209200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123701	hybrid			2022-12-25	WOS:000222445300084
J	Connors, NC; Adams, ME; Froehner, SC; Kofuji, P				Connors, NC; Adams, ME; Froehner, SC; Kofuji, P			The potassium channel Kir4.1 associates with the dystrophin-glycoprotein complex via alpha-syntrophin in glia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; RECTIFYING K+ CHANNEL; PHENOTYPIC IMPACT; BRAIN ASTROCYTES; WATER TRANSPORT; MULLER CELL; RAT-BRAIN; PROTEIN; AQUAPORIN-4; DYSTROGLYCAN	One of the major physiological roles of potassium channels in glial cells is to promote "potassium spatial buffering" in the central nervous system, a process necessary to maintain an optimal potassium concentration in the extracellular environment. This process requires the precise distribution of potassium channels accumulated at high density in discrete subdomains of glial cell membranes. To obtain a better understanding of how glial cells selectively target potassium channels to discrete membrane subdomains, we addressed the question of whether the glial inwardly rectifying potassium channel Kir4.1 associates with the dystrophin-glycoprotein complex (DGC). Immunoprecipitation experiments revealed that Kir4.1 is associated with the DGC in mouse brain and cultured cortical astrocytes. In vitro immunoprecipitation and pull-down assays demonstrated that Kir4.1 can bind directly to alpha-syntrophin, requiring the presence of the last three amino acids of the channel (SNV), a consensus PDZ domain-binding motif. Furthermore, Kir4.1 failed to associate with the DGC in brains from alpha-syntrophin knockout mice. These results suggest that Kir4.1 is localized in glial cells by its association with the DGC through a PDZ domain-mediated interaction with alpha-syntrophin and suggest an important role for the DGC in central nervous system physiology.	Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA; Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Washington; University of Washington Seattle	Kofuji, P (corresponding author), Univ Minnesota, Dept Neurosci, 6-145 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	kofuj001@tc.umn.edu	Kofuji, Paulo/AAR-7835-2021	Kofuji, Paulo/0000-0002-4840-9986	NEI NIH HHS [EY 07133, EY 12949-01] Funding Source: Medline; NINDS NIH HHS [NS 33145] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033145] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams ME, 2000, J CELL BIOL, V150, P1385, DOI 10.1083/jcb.150.6.1385; ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; Aleman V, 2001, HISTOCHEM CELL BIOL, V115, P243; Amedee T, 1997, GLIA, V21, P46, DOI 10.1002/(SICI)1098-1136(199709)21:1<46::AID-GLIA5>3.0.CO;2-#; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P13615, DOI 10.1073/pnas.2336064100; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Anderson JL, 2002, BRAIN, V125, P4, DOI 10.1093/brain/awf012; Blake DJ, 1999, J CELL BIOL, V147, P645, DOI 10.1083/jcb.147.3.645; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; Cavaldesi M, 1999, J NEUROCHEM, V72, P1648, DOI 10.1046/j.1471-4159.1999.721648.x; Claudepierre T, 2000, J CELL SCI, V113, P3409; Connors NC, 2002, J NEUROSCI, V22, P4321, DOI 10.1523/JNEUROSCI.22-11-04321.2002; Dalloz C, 2003, HUM MOL GENET, V12, P1543, DOI 10.1093/hmg/ddg170; DIETZEL I, 1980, EXP BRAIN RES, V40, P432; DWYER TM, 1995, FEBS LETT, V375, P91, DOI 10.1016/0014-5793(95)01176-F; Gee SH, 1998, J NEUROSCI, V18, P128; Grewal PK, 2003, HUM MOL GENET, V12, pR259, DOI 10.1093/hmg/ddg272; Gu F, 2003, J NEUROSCI RES, V72, P709, DOI 10.1002/jnr.10603; Han ZQ, 1998, J BIOL CHEM, V273, P6001, DOI 10.1074/jbc.273.11.6001; Hashida-Okumura A, 1999, J BIOL CHEM, V274, P11736, DOI 10.1074/jbc.274.17.11736; Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1; Higashi K, 2001, AM J PHYSIOL-CELL PH, V281, pC922, DOI 10.1152/ajpcell.2001.281.3.C922; HILGEMANN DW, 2001, SCI STKE; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Holthoff K, 2000, GLIA, V29, P288, DOI 10.1002/(SICI)1098-1136(20000201)29:3<288::AID-GLIA10>3.0.CO;2-8; Horio Y, 1997, J BIOL CHEM, V272, P12885, DOI 10.1074/jbc.272.20.12885; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Imamura M, 1998, P NATL ACAD SCI USA, V95, P6139, DOI 10.1073/pnas.95.11.6139; Inoue M, 2002, TOHOKU J EXP MED, V197, P87, DOI 10.1620/tjem.197.87; Ishii M, 1997, J NEUROSCI, V17, P7725; Kofuji P, 2003, MOL NEUROBIOL, V28, P195, DOI 10.1385/MN:28:2:195; Kofuji P, 2000, J NEUROSCI, V20, P5733, DOI 10.1523/JNEUROSCI.20-15-05733.2000; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; Leonoudakis D, 2001, J CELL SCI, V114, P987; Martin-Rendon E, 2003, TRENDS PHARMACOL SCI, V24, P178, DOI 10.1016/S0165-6147(03)00050-6; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Michele DE, 2003, J BIOL CHEM, V278, P15457, DOI 10.1074/jbc.R200031200; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; Newman E, 1996, TRENDS NEUROSCI, V19, P307, DOI 10.1016/0166-2236(96)10040-0; Oak SA, 2001, BIOCHEMISTRY-US, V40, P11270, DOI 10.1021/bi010490n; ODETTE LL, 1988, GLIA, V1, P198, DOI 10.1002/glia.440010305; Poopalasundaram S, 2000, GLIA, V30, P362, DOI 10.1002/(SICI)1098-1136(200006)30:4<362::AID-GLIA50>3.0.CO;2-4; Rosa G, 1996, BIOCHEM BIOPH RES CO, V223, P272, DOI 10.1006/bbrc.1996.0883; Saadoun S, 2003, J CLIN PATHOL, V56, P972, DOI 10.1136/jcp.56.12.972; Ueda H, 2000, NEUROSCI LETT, V283, P121, DOI 10.1016/S0304-3940(00)00925-3; YANG B, 1995, J BIOL CHEM, V270, P4975, DOI 10.1074/jbc.270.10.4975; Zaccaria ML, 2001, NEUROSCIENCE, V104, P311, DOI 10.1016/S0306-4522(01)00092-6; Zelenina M, 2002, AM J PHYSIOL-RENAL, V283, pF309, DOI 10.1152/ajprenal.00260.2001; Zhu T, 1999, J BIOL CHEM, V274, P29102, DOI 10.1074/jbc.274.41.29102	52	150	164	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28387	28392		10.1074/jbc.M402604200	http://dx.doi.org/10.1074/jbc.M402604200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102837	hybrid, Green Submitted			2022-12-25	WOS:000222265400071
J	Hosszu, LLP; Jackson, GS; Trevitt, CR; Jones, S; Batchelor, M; Bhelt, D; Prodromidou, K; Clarke, AR; Waltho, JP; Collinge, J				Hosszu, LLP; Jackson, GS; Trevitt, CR; Jones, S; Batchelor, M; Bhelt, D; Prodromidou, K; Clarke, AR; Waltho, JP; Collinge, J			The residue 129 polymorphism in human prion protein does not confer susceptibility to Creutzfeldt-Jakob disease by altering the structure or global stability of PrP(C)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIR GENE INSERTION; NMR STRUCTURE; VARIANT CJD; HYDROGEN-EXCHANGE; CRYSTAL-STRUCTURE; CHEMICAL-SHIFT; SCRAPIE; SENSITIVITY; MICE; BSE	There are two common forms of prion protein (PrP) in humans, with either methionine or valine at position 129. This polymorphism is a powerful determinant of the genetic susceptibility of humans toward both sporadic and acquired forms of prion disease and restricts propagation of particular prion strains. Despite its key role, we have no information on the effect of this mutation on the structure, stability, folding, and dynamics of the cellular form of PrP (PrP(C)). Here, we show that the mutation has no measurable effect on the folding, dynamics, and stability of PrP(C). Our data indicate that the 129M/V polymorphism does not affect prion propagation through its effect on PrP(C); rather, its influence is likely to be downstream in the disease mechanism. We infer that the M/V effect is mediated through the conformation or stability of disease-related PrP (PrP(Sc)) or intermediates or on the kinetics of their formation.	UCL, Inst Neurol, Dept Neurodegenerat Dis, MRC,Prion Unit, London WC1N 3BG, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst Biomol Res, Sheffield S10 2TN, S Yorkshire, England	University of London; University College London; University of Sheffield	Collinge, J (corresponding author), UCL, Inst Neurol, Dept Neurodegenerat Dis, MRC,Prion Unit, Queen Sq, London WC1N 3BG, England.	j.collinge@prion.ucl.ac.uk		Prodromidou, Kanella/0000-0001-5721-9124; Waltho, Jonathan/0000-0002-7402-5492; Jackson, Graham/0000-0002-3125-2011				Asante EA, 2002, EMBO J, V21, P6358, DOI 10.1093/emboj/cdf653; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; BAX A, 1991, Journal of Biomolecular NMR, V1, P99, DOI 10.1007/BF01874573; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COLLINGE J, 1992, BRAIN, V115, P687, DOI 10.1093/brain/115.3.687; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; COLLINGE J, 1995, NATURE, V378, P779, DOI 10.1038/378779a0; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Collinge J, 1996, LANCET, V348, P56, DOI 10.1016/S0140-6736(05)64378-4; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DLOUHY SR, 1992, NAT GENET, V1, P64, DOI 10.1038/ng0492-64; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; FERRIN TE, 1991, J MOL GRAPHICS, V9, P27, DOI 10.1016/0263-7855(91)80030-4; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Garcia FL, 2000, P NATL ACAD SCI USA, V97, P8334, DOI 10.1073/pnas.97.15.8334; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Haire LF, 2004, J MOL BIOL, V336, P1175, DOI 10.1016/j.jmb.2003.12.059; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hill AF, 2003, BRAIN, V126, P1333, DOI 10.1093/brain/awg125; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Hosszu LLP, 1999, NAT STRUCT BIOL, V6, P740, DOI 10.1038/11507; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; Jackson GS, 1999, BBA-PROTEIN STRUCT M, V1431, P1, DOI 10.1016/S0167-4838(99)00038-2; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Mead S, 2003, SCIENCE, V300, P640, DOI 10.1126/science.1083320; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PARCHI P, 1996, ANN NEUROL, V39, P669; PARKER MJ, 1995, J MOL BIOL, V253, P771, DOI 10.1006/jmbi.1995.0590; Peti W, 2001, J BIOMOL NMR, V19, P153, DOI 10.1023/A:1008307323283; POULTER M, 1992, BRAIN, V115, P675, DOI 10.1093/brain/115.3.675; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riek R, 1998, P NATL ACAD SCI USA, V95, P11667, DOI 10.1073/pnas.95.20.11667; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; Whitehead B, 1997, J BIOMOL NMR, V9, P313, DOI 10.1023/A:1018687127330; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zhang YB, 2000, J BIOL CHEM, V275, P33650, DOI 10.1074/jbc.C000483200	61	65	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28515	28521		10.1074/jbc.M313762200	http://dx.doi.org/10.1074/jbc.M313762200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123682	hybrid			2022-12-25	WOS:000222265400087
J	Meyer, AN; Gastwirt, RF; Schlaepfer, DD; Donoghue, DJ				Meyer, AN; Gastwirt, RF; Schlaepfer, DD; Donoghue, DJ			The cytoplasmic tyrosine kinase Pyk2 as a novel effector of fibroblast growth factor receptor 3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; MULTIPLE-MYELOMA CELLS; SERINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT ACTIVATION; PROTEIN; MUTATIONS; EXPRESSION; APOPTOSIS; TRANSFORMATION	Activating mutations within fibroblast growth factor receptor 3 (FGFR3), a receptor tyrosine kinase, are responsible for human skeletal dysplasias including achondroplasia and the neonatal lethal syndromes thanatophoric dysplasia types I and II. Several of these same FGFR3 mutations have also been identified somatically in human cancers, including multiple myeloma, bladder carcinoma, and cervical cancer. The molecular pathways exploited by FGFR3 to stimulate abnormal proliferation during neoplasia are unclear. The nonreceptor protein-tyrosine kinase Pyk2 (proline-rich tyrosine kinase 2) has been shown previously to regulate apoptosis in multiple myeloma cells. Here we describe a novel interaction between FGFR3 and Pyk2, mediated by the juxtamembrane domain of FGFR3 and the kinase domain of Pyk2. Within the FGFR family, Pyk2 also interacted significantly with FGFR2. Overexpression of Pyk2 alone led to its spontaneous activation and tyrosine phosphorylation, resulting in activation of Stat5B, indicated by the reporter GFP-Stat5B. These effects were completely dependent upon Tyr(402), the autophosphorylation site of Pyk2, which allows recruitment of Src family members for further activating phosphorylations at other sites on Pyk2. In the presence of activated FGFR3, the activation of Pyk2 itself became independent of Tyr(402), indicating that FGFR3 activation circumvents the requirement for c-Src recruitment at Tyr(402) of Pyk2. We also examined the role of the tyrosine phosphatase Shp2 in antagonizing Pyk2 activation. Taken together, these results suggest that signaling pathways regulated by FGFR3 may converge with Pyk2-dependent pathways to provide maximal activation of Stat5B.	Univ Calif San Diego, Ctr Mol Genet, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Program Biomed Sci, La Jolla, CA 92093 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute	Donoghue, DJ (corresponding author), Univ Calif San Diego, Ctr Mol Genet, Dept Chem & Biochem, La Jolla, CA 92093 USA.	ddonoghue@ucsd.edu			NATIONAL CANCER INSTITUTE [R01CA090900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065490] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 90900] Funding Source: Medline; NIGMS NIH HHS [R01 GM 65490] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; Buettner R, 2002, CLIN CANCER RES, V8, P945; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chauhan D, 2000, J BIOL CHEM, V275, P27845; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chesi M, 2000, ANN ONCOL, V11, P131, DOI 10.1023/A:1008300325610; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Constantino S, 2001, ONCOGENE, V20, P2080, DOI 10.1038/sj.onc.1204308; Demoulin JB, 1999, J BIOL CHEM, V274, P25855, DOI 10.1074/jbc.274.36.25855; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; Galvin BD, 1996, P NATL ACAD SCI USA, V93, P7894, DOI 10.1073/pnas.93.15.7894; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; Hart KC, 2001, MOL BIOL CELL, V12, P931, DOI 10.1091/mbc.12.4.931; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; Jang JH, 2001, CANCER RES, V61, P3541; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kirken RA, 1997, J BIOL CHEM, V272, P14098, DOI 10.1074/jbc.272.22.14098; Kong M, 2002, J BIOL CHEM, V277, P15962, DOI 10.1074/jbc.M102777200; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Nagy ZS, 2002, J LEUKOCYTE BIOL, V72, P819; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; OZAKI S, 1994, LEUKEMIA, V8, P2207; Park SH, 2001, MOL ENDOCRINOL, V15, P2157, DOI 10.1210/me.15.12.2157; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; Ronchetti D, 2001, ONCOGENE, V20, P3553, DOI 10.1038/sj.onc.1204465; Rousseau F, 1996, HUM MOL GENET, V5, P509, DOI 10.1093/hmg/5.4.509; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Tang H, 2000, J BIOL CHEM, V275, P8389, DOI 10.1074/jbc.275.12.8389; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Thompson LM, 1997, MOL CELL BIOL, V17, P4169, DOI 10.1128/MCB.17.7.4169; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Webster MK, 1997, MOL CELL BIOL, V17, P5739, DOI 10.1128/MCB.17.10.5739; Webster MK, 1996, MOL CELL BIOL, V16, P4081; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xiong WC, 1998, J CELL SCI, V111, P1981; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	60	24	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28450	28457		10.1074/jbc.M403335200	http://dx.doi.org/10.1074/jbc.M403335200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15105428	hybrid			2022-12-25	WOS:000222265400079
J	Ohnishi, H; Kobayashi, H; Okazawa, H; Ohe, Y; Tomizawa, K; Sato, R; Matozaki, T				Ohnishi, H; Kobayashi, H; Okazawa, H; Ohe, Y; Tomizawa, K; Sato, R; Matozaki, T			Ectodomain shedding of SHPS-1 and its role in regulation of cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHP-2; INTEGRIN-ASSOCIATED PROTEIN; NEURAL ADHESION MOLECULE; GROWTH-FACTOR; FOCAL ADHESION; BINDING; SURFACE; KINASE; CD47; GLYCOPROTEIN	SHPS-1 is a transmembrane protein whose cytoplasmic region undergoes tyrosine phosphorylation and then binds the protein-tyrosine phosphatase SHP-2. Formation of the SHPS-1-SHP-2 complex is implicated in regulation of cell migration. In addition, SHPS-1 and its ligand CD47 constitute an intercellular recognition system that contributes to inhibition of cell migration by cell-cell contact. The ectodomain of SHPS-1 has now been shown to be shed from cells in a reaction likely mediated by a metalloproteinase. This process was promoted by activation of protein kinase C or of Ras, and the released ectodomain exhibited minimal CD47-binding activity. Metalloproteinases catalyzed the cleavage of a recombinant SHPS-1-Fc fusion protein in vitro, and the primary cleavage site was localized to the juxtamembrane region of SHPS-1. Forced expression of an SHPS-1 mutant resistant to ectodomain shedding impaired cell migration, cell spreading, and reorganization of the actin cytoskeleton. It also increased the tyrosine phosphorylation of paxillin and FAK triggered by cell adhesion. These results suggest that shedding of the ectodomain of SHPS-1 plays an important role in regulation of cell migration and spreading by this protein.	Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Res Ctr, Gunma 3718512, Japan	Gunma University	Matozaki, T (corresponding author), Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Res Ctr, 3-39-15 Showa Machi, Gunma 3718512, Japan.	matozaki@showa.gunma-u.ac.jp	Okazawa, Hideki/C-3836-2011; Okazawa, Hideki/E-3055-2010					Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; CHUANG W, 1990, DEV BIOL, V137, P219, DOI 10.1016/0012-1606(90)90249-I; Comu S, 1997, J NEUROSCI, V17, P8702; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Galko MJ, 2000, SCIENCE, V289, P1365, DOI 10.1126/science.289.5483.1365; Guo L, 2002, MOL CELL PROTEOMICS, V1, P30, DOI 10.1074/mcp.M100020-MCP200; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; Inagaki K, 2000, EMBO J, V19, P6721, DOI 10.1093/emboj/19.24.6721; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Lacalle RA, 2002, J CELL BIOL, V157, P277, DOI 10.1083/jcb.200109031; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; Liu Y, 2001, J BIOL CHEM, V276, P40156, DOI 10.1074/jbc.M104138200; Manes S, 1999, MOL CELL BIOL, V19, P3125; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; Motegi S, 2003, EMBO J, V22, P2634, DOI 10.1093/emboj/cdg278; Ohe Y, 2003, BIOCHEM BIOPH RES CO, V308, P719, DOI 10.1016/S0006-291X(03)01454-2; Ohnishi H, 1999, J NEUROCHEM, V72, P1402, DOI 10.1046/j.1471-4159.1999.721402.x; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Sato R, 2003, BIOCHEM BIOPH RES CO, V309, P584, DOI 10.1016/j.bbrc.2003.08.031; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Takayama Y, 1999, J BIOL CHEM, V274, P2291, DOI 10.1074/jbc.274.4.2291; Tanaka Y, 2002, BIOCHEM BIOPH RES CO, V299, P472, DOI 10.1016/S0006-291X(02)02681-5; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; Umata T, 2001, J BIOL CHEM, V276, P30475, DOI 10.1074/jbc.M103673200; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Yamao T, 1997, BIOCHEM BIOPH RES CO, V231, P61, DOI 10.1006/bbrc.1996.6047; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	48	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27878	27887		10.1074/jbc.M313085200	http://dx.doi.org/10.1074/jbc.M313085200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123722	hybrid			2022-12-25	WOS:000222265400009
J	Scassa, ME; Guberman, AS; Ceruti, JM; Canepa, ET				Scassa, ME; Guberman, AS; Ceruti, JM; Canepa, ET			Hepatic nuclear factor 3 and nuclear factor 1 regulate 5-aminolevulinate synthase gene expression and are involved in insulin repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-AMINOLEVULINATE SYNTHASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; BINDING-SITES; FACTOR-I; TRANSCRIPTIONAL REGULATION; GLUCOCORTICOID RESPONSE; AMINOTRANSFERASE GENE; MEDIATES REPRESSION; GLUT4 PROMOTER; FACTOR 3-BETA	Although the negative regulation of gene expression by insulin has been widely studied, the transcription factors responsible for the insulin effect are still unknown. The purpose of this work was to explore the molecular mechanisms involved in the insulin repression of the 5-aminolevulinate synthase ( ALAS) gene. Deletion analysis of the 5'-regulatory region allowed us to identify an insulin-responsive region located at -459 to -354 bp. This fragment contains a highly homologous insulin-responsive (IRE) sequence. By transient transfection assays, we determined that hepatic nuclear factor 3 (HNF3) and nuclear factor 1 (NF1) are necessary for an appropriate expression of the ALAS gene. Insulin overrides the HNF3beta or HNF3beta plus NF1-mediated stimulation of ALAS transcriptional activity. Electrophoretic mobility shift assay and Southwestern blotting indicate that HNF3 binds to the ALAS promoter. Mutational analysis of this region revealed that IRE disruption abrogates insulin action, whereas mutation of the HNF3 element maintains hormone responsiveness. This dissociation between HNF3 binding and insulin action suggests that HNF3beta is not the sole physiologic mediator of insulin-induced transcriptional repression. Furthermore, Southwestern blotting assay shows that at least two polypeptides other than HNF3beta can bind to ALAS promoter and that this binding is dependent on the integrity of the IRE. We propose a model in which insulin exerts its negative effect through the disturbance of HNF3beta binding or transactivation potential, probably due to specific phosphorylation of this transcription factor by Akt. In this regard, results obtained from transfection experiments using kinase inhibitors support this hypothesis. Due to this event, NF1 would lose accessibility to the promoter. The posttranslational modification of HNF3 would allow the binding of a protein complex that recognizes the core IRE. These results provide a potential mechanism for the insulin-mediated repression of IRE-containing promoters.	Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, Mol Biol Lab, RA-1428 Buenos Aires, DF, Argentina	University of Buenos Aires	Canepa, ET (corresponding author), Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, Mol Biol Lab, Pabellon 2 Piso 4,Ciudad Univ, RA-1428 Buenos Aires, DF, Argentina.	ecanepa@qb.fcen.uba.ar		Canepa, Eduardo T./0000-0002-4322-1650				Andersson C, 1999, J INTERN MED, V245, P193, DOI 10.1046/j.1365-2796.1999.0448e.x; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Beurton F, 1999, BIOCHEM J, V343, P687, DOI 10.1042/0264-6021:3430687; BISHOP DF, 1990, NUCLEIC ACIDS RES, V18, P7187, DOI 10.1093/nar/18.23.7187; BRODIE MJ, 1977, CLIN SCI MOL MED, V53, P365, DOI 10.1042/cs0530365; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; Cha JY, 2001, EXP MOL MED, V33, P59, DOI 10.1038/emm.2001.11; Chaya D, 2001, J BIOL CHEM, V276, P44385, DOI 10.1074/jbc.M108214200; CHOMCZYNSKY P, 1987, ANAL BIOCHEM, V71, P341; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; COCKELL M, 1995, MOL CELL BIOL, V15, P1933; Cooke DW, 1999, J BIOL CHEM, V274, P12917, DOI 10.1074/jbc.274.18.12917; Cooke DW, 1999, BIOCHEM BIOPH RES CO, V260, P600, DOI 10.1006/bbrc.1999.0959; Czech MP, 2003, P NATL ACAD SCI USA, V100, P11198, DOI 10.1073/pnas.2135308100; Delesque-Touchard N, 2000, J BIOL CHEM, V275, P34173, DOI 10.1074/jbc.M004027200; Dong Y, 2002, EXP CELL RES, V276, P328, DOI 10.1006/excr.2002.5534; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; Giono LE, 2001, BIOCHEM J, V353, P307, DOI 10.1042/0264-6021:3530307; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Guberman AS, 2003, J BIOL CHEM, V278, P2317, DOI 10.1074/jbc.M205057200; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; Hall Robert K., 1999, Journal of Basic and Clinical Physiology and Pharmacology, V10, P119; Hoodless PA, 2001, GENE DEV, V15, P1257, DOI 10.1101/gad.881501; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; Kappas A, 1995, METABOLIC MOL BASES, P2103; Li B, 1999, J BIOL CHEM, V274, P17534, DOI 10.1074/jbc.274.25.17534; Li WW, 1995, J CLIN INVEST, V96, P2601, DOI 10.1172/JCI118324; MAY BK, 1995, PROG NUCLEIC ACID RE, V51, P1, DOI 10.1016/S0079-6603(08)60875-2; Navas MA, 2000, HUM HERED, V50, P370, DOI 10.1159/000022943; O'Brien RM, 2001, BIOCHEM SOC T, V29, P552, DOI 10.1042/BST0290552; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Ortiz L, 1999, J BIOL CHEM, V274, P15213, DOI 10.1074/jbc.274.21.15213; Park SH, 2001, J BIOL CHEM, V276, P43031, DOI 10.1074/jbc.M107597200; Patel S, 2001, BIOCHEM J, V359, P611, DOI 10.1042/0264-6021:3590611; Ponka P, 1999, AM J MED SCI, V318, P241, DOI 10.1097/00000441-199910000-00004; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rausa FM, 2000, MOL CELL BIOL, V20, P8264, DOI 10.1128/MCB.20.21.8264-8282.2000; ROUX J, 1995, DNA CELL BIOL, V14, P385, DOI 10.1089/dna.1995.14.385; Sadlon TJ, 1999, INT J BIOCHEM CELL B, V31, P1153, DOI 10.1016/S1357-2725(99)00073-4; Sambrook J, 2001, MOL CLONING LAB MANU; Scassa ME, 2001, EXP CELL RES, V271, P201, DOI 10.1006/excr.2001.5386; Scassa ME, 1998, EXP CELL RES, V244, P460, DOI 10.1006/excr.1998.4206; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Shim EY, 1998, GENE DEV, V12, P5, DOI 10.1101/gad.12.1.5; Shimizu S, 2002, BBA-GENE STRUCT EXPR, V1574, P337, DOI 10.1016/S0167-4781(02)00232-4; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; Sumner C, 1996, J NEUROVIROL, V2, P87, DOI 10.3109/13550289609146542; Sund NJ, 2000, MOL CELL BIOL, V20, P5175, DOI 10.1128/MCB.20.14.5175-5183.2000; Sund NJ, 2001, GENE DEV, V15, P1706, DOI 10.1101/gad.901601; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; Varone CL, 1996, BIOCHEM CELL BIOL, V74, P271, DOI 10.1139/o96-029; Varone CL, 1999, ARCH BIOCHEM BIOPHYS, V372, P261, DOI 10.1006/abbi.1999.1470; Wang DP, 1996, J LIPID RES, V37, P1831; WANG J, 2002, J BIOL CHEM, V275, P14717; Wang JC, 1999, MOL ENDOCRINOL, V13, P604, DOI 10.1210/me.13.4.604; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Waxman David J., 1995, P391; Wolfrum C, 2003, P NATL ACAD SCI USA, V100, P11624, DOI 10.1073/pnas.1931483100; Yeagley D, 2000, J BIOL CHEM, V275, P17814, DOI 10.1074/jbc.M909842199; Yeagley D, 1998, J BIOL CHEM, V273, P18743, DOI 10.1074/jbc.273.30.18743	63	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28082	28092		10.1074/jbc.M401792200	http://dx.doi.org/10.1074/jbc.M401792200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123725	Green Published, hybrid			2022-12-25	WOS:000222265400033
J	Tapley, TL; Vickery, LE				Tapley, TL; Vickery, LE			Preferential substrate binding orientation by the molecular chaperone HscA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFUR CLUSTER BIOSYNTHESIS; THERMOTOGA-MARITIMA ISCU; ASSEMBLY PROTEIN ISCU; ESCHERICHIA-COLI; DNAK CHAPERONE; EXTINCTION COEFFICIENTS; BIMANE FLUORESCENCE; PEPTIDE BINDING; GENE-CLUSTER; SYSTEM	HscA, a specialized bacterial hsp70-class chaperone, interacts with the iron-sulfur cluster assembly protein IscU by recognizing a conserved LPPVK sequence motif at positions 99-103. We have used a site-directed fluorescence labeling and quenching strategy to determine whether HscA binds to IscU in a preferred orientation. HscA was selectively labeled on opposite sides of the substrate binding domain with the fluorescent probe bimane, and the ability of LPPVK-containing peptides having tryptophan at the N or C terminus to quench bimane fluorescence was measured. Quenching was highly dependent on the position of tryptophan in the peptide and the location of bimane on HscA implying a strong directional preference for peptide binding. Similar experiments showed that full-length IscU binds in the same orientation as IscU-derived peptides and that binding orientation is unaffected by the co-chaperone HscB. The preferred orientation of the HscA-IscU complex is the reverse of that previously described for peptide complexes of Escherichia coli DnaK and rat Hsc70 substrate binding domain fragments establishing that hsp70 isoforms can bind peptide/polypeptide substrates in different orientations.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Vickery, LE (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.	lvickery@uci.edu			NCI NIH HHS [5T32 CA 09054] Funding Source: Medline; NIGMS NIH HHS [GM 54264] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Bertini I, 2003, J MOL BIOL, V331, P907, DOI 10.1016/S0022-2836(03)00768-X; Foster MW, 2000, J AM CHEM SOC, V122, P6805, DOI 10.1021/ja000800+; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; Hoff KG, 2003, J BIOL CHEM, V278, P37582, DOI 10.1074/jbc.M305292200; Hoff KG, 2002, J BIOL CHEM, V277, P27353, DOI 10.1074/jbc.M202814200; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kasper P, 2000, PROTEINS, V40, P185, DOI 10.1002/(SICI)1097-0134(20000801)40:2<185::AID-PROT20>3.0.CO;2-X; KAWULA TH, 1994, J BACTERIOL, V176, P610, DOI 10.1128/jb.176.3.610-619.1994; KOSOWER EM, 1986, J PHYS CHEM-US, V90, P5552, DOI 10.1021/j100280a014; KOSOWER EM, 1995, METHOD ENZYMOL, V251, P133, DOI 10.1016/0076-6879(95)51117-2; Liu W, 2003, J PHYS CHEM B, V107, P11563, DOI 10.1021/jp035872c; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Mansoor SE, 2002, BIOCHEMISTRY-US, V41, P2475, DOI 10.1021/bi011198i; Mansoor SE, 1999, BIOCHEMISTRY-US, V38, P16383, DOI 10.1021/bi991331v; Mansy SS, 2004, J BIOL CHEM, V279, P10469, DOI 10.1074/jbc.M312051200; Mansy SS, 2002, J BIOL CHEM, V277, P21397, DOI 10.1074/jbc.M201439200; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; SATO E, 1988, BIOORG CHEM, V16, P298, DOI 10.1016/0045-2068(88)90017-X; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SEATON BL, 1994, P NATL ACAD SCI USA, V91, P2066, DOI 10.1073/pnas.91.6.2066; Silberg JJ, 1998, J BACTERIOL, V180, P6617, DOI 10.1128/JB.180.24.6617-6624.1998; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Silberg JJ, 2000, J BIOL CHEM, V275, P7779, DOI 10.1074/jbc.275.11.7779; Stevens SY, 2003, PROTEIN SCI, V12, P2588, DOI 10.1110/ps.03269103; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Takeda S, 1996, BIOCHEMISTRY-US, V35, P4636, DOI 10.1021/bi952903o; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Vickery LE, 1997, PROTEIN SCI, V6, P1047, DOI 10.1002/pro.5560060511; Wang H, 1998, BIOCHEMISTRY-US, V37, P7929, DOI 10.1021/bi9800855; Wu G, 2002, BIOCHEMISTRY-US, V41, P5024, DOI 10.1021/bi016073s; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	47	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28435	28442		10.1074/jbc.M400803200	http://dx.doi.org/10.1074/jbc.M400803200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15100228	hybrid			2022-12-25	WOS:000222265400077
J	Li, T; Lu, ZY; Lu, L				Li, T; Lu, ZY; Lu, L			Regulation of eye development by transcription control of CCCTC binding factor (CTCF)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BLOCKING ACTIVITY; HUMAN PAX6 GENE; PROTEIN CTCF; XENOPUS-LAEVIS; DNA-SEQUENCE; METHYLATION; PROMOTER; EXPRESSION; ACTIVATION; MUTATIONS	CCCTC binding factor ( CTCF), a transcriptional regulator, plays important roles in epigenetics and development. In the present study, we report that overexpression of CTCF in transgenic mice during embryonic development suppresses Pax6 gene expression. This effect causes defects in ocular development that result in microophthalmia. In eye-derived cells transfected with a tetracycline turn-on CTCF system, up-regulation of CTCF expression significantly suppressed Pax6 expression. In contrast, the knockdown of CTCF mRNA resulted in the down-regulation of CTCF protein expression, which in turn enhanced the Pax6 expression. CTCF controls Pax6 transcription by interacting with a repressor element located in the 5'-flanking region upstream of the Pax6 P0 promoter. This interaction suppressed Pax6 gene transcription by blocking the effect of an ectoderm enhancer located 3.5 kb upstream from the P0 promoter. We also found an 80-bp sequence in a region -1.2 kbp upstream from the P0 promoter that contained multiple CTCF binding sites and interacted with nuclear proteins obtained from eye-derived cells forming electrophoretic mobility shift assay complexes with CTCF. We conclude that a novel function of CTCF is to regulate Pax6 transcription by binding to the repressor element, which in turn blocks the effect of the ectoderm enhancer resulting in the inhibition of P0 promoter activity.	Univ Calif Los Angeles, Harbor UCLA Med Ctr, David Geffen Sch Med, Div Mol Med, Torrance, CA 90502 USA; Shanghai Med Univ 2, Dept Med Genet, Shanghai 200025, Peoples R China	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Shanghai Jiao Tong University	Lu, L (corresponding author), Univ Calif Los Angeles, Harbor UCLA Med Ctr, David Geffen Sch Med, Div Mol Med, 1124 W Carson St,C-2, Torrance, CA 90502 USA.	lluou@ucla.edu			NEI NIH HHS [R01 EY015281, EY12953, EY15281] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY015281, R01EY012953] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Altmann CR, 1997, DEV BIOL, V185, P119, DOI 10.1006/dbio.1997.8573; Awad TA, 1999, J BIOL CHEM, V274, P27092, DOI 10.1074/jbc.274.38.27092; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Burcin M, 1997, MOL CELL BIOL, V17, P1281, DOI 10.1128/MCB.17.3.1281; Burke LJ, 2002, MECH DEVELOP, V113, P95, DOI 10.1016/S0925-4773(02)00005-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Davis JA, 1996, J NEUROSCI, V16, P5082; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9; Gehring WJ, 1996, GENES CELLS, V1, P11, DOI 10.1046/j.1365-2443.1996.11011.x; Gehring WJ, 1999, TRENDS GENET, V15, P371, DOI 10.1016/S0168-9525(99)01776-X; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; HANSON IM, 1994, NAT GENET, V6, P168, DOI 10.1038/ng0294-168; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Kang SS, 2001, CURR EYE RES, V23, P397, DOI 10.1076/ceyr.23.6.397.6965; Klenova EM, 1997, NUCLEIC ACIDS RES, V25, P466, DOI 10.1093/nar/25.3.466; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; Koroma BM, 1997, INVEST OPHTH VIS SCI, V38, P108; Li T, 2002, J BIOL CHEM, V277, P32668, DOI 10.1074/jbc.M203519200; Marquardt T, 2001, CELL, V105, P43, DOI 10.1016/S0092-8674(01)00295-1; MARTIN P, 1992, ONCOGENE, V7, P1721; MCFALL RC, 1977, CANCER RES, V37, P1003; Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; Onuma Y, 2002, P NATL ACAD SCI USA, V99, P2020, DOI 10.1073/pnas.022626999; Percec I, 2002, SCIENCE, V295, P287, DOI 10.1126/science.1068663; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; PLAZA S, 1995, MOL CELL BIOL, V15, P3344; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; Reik W, 2000, NATURE, V405, P408, DOI 10.1038/35013178; Shiraishi A, 1998, INVEST OPHTH VIS SCI, V39, P2554; Song SY, 1999, GASTROENTEROLOGY, V117, P1416, DOI 10.1016/S0016-5085(99)70292-1; Underhill DA, 2000, BIOCHEM CELL BIOL, V78, P629, DOI 10.1139/bcb-78-5-629; Vostrov AA, 1997, J BIOL CHEM, V272, P33353, DOI 10.1074/jbc.272.52.33353; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Wang L, 1999, J BIOL CHEM, V274, P3678, DOI 10.1074/jbc.274.6.3678; Williams SC, 1998, MECH DEVELOP, V73, P225, DOI 10.1016/S0925-4773(98)00057-4; Xu PX, 1999, DEVELOPMENT, V126, P383; Zieske JD, 2001, INVEST OPHTH VIS SCI, V42, P1465	44	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27575	27583		10.1074/jbc.M313942200	http://dx.doi.org/10.1074/jbc.M313942200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096508	hybrid			2022-12-25	WOS:000222120400091
J	Wines, BD; Trist, HM; Monteiro, RC; van Kooten, C; Hogarth, PM				Wines, BD; Trist, HM; Monteiro, RC; van Kooten, C; Hogarth, PM			Fc receptor gamma chain residues at the interface of the cytoplasmic and transmembrane domains affect association with Fc alpha RI, surface expression, and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; T-CELLS; EPSILON-RI; ZETA-CHAIN; IMMUNOGLOBULIN; IGA; SUBUNIT; BETA; CD89; IDENTIFICATION	The assembly of multiple subunit immunoreceptors is dependent on transmembrane interactions. The Fc receptor gamma (FcR-gamma) chain is a ubiquitous immune receptor tyrosine-based activation motif-containing dimeric subunit, gamma(2), which in humans associates with both the activating members of the leukocyte receptor cluster, including the IgA receptor FcalphaRI, and the classical Fc receptors, including the IgE receptor FcepsilonRI. This study identifies a new site in the transmembrane region of FcR-gamma that affects receptor assembly and surface expression with FcalphaRI but not with FcepsilonRI. The wild type complex, FcalphaRI-gamma(2) WT, remains robustly associated in both Brij-96 and Thesit detergent conditions. However, mutation of either Tyr(25) or Cys(26) of FcR-gamma, near the interface of the transmembrane and cytoplasmic regions, resulted in impaired FcR-gamma association with FcalphaRI. This association was disrupted in the presence of the detergent Brij-96 but was preserved in milder conditions using the detergent Thesit. Ligand-mediated cross-linking of the FcalphaRI-gamma(2)Y25F mutant receptor resulted in diminished signal transduction, including an abnormal calcium response, compared with the FcalphaRI-gamma(2)WT receptor. Furthermore, the FcalphaRI-gamma(2)Y25F mutant receptor was expressed at the cell surface at similar to10% of that of the wild type, whereas the surface expression of FcepsilonRI-gamma(2)Y25F was not significantly different from the wild type. In contrast, although the FcalphaRI-gamma(2)C26S mutant was also less stably associated, it was not reduced in surface expression or function. Thus, these TM residues of FcR-gamma are important for association with FcalphaRI and probably other activating LRC members but not with the classical FcR, FcepsilonRI.	Austin Repatriat Med Ctr, Austin Res Inst, Helen Macpherson Smith Trust Inflammatory Dis Lab, Heidelberg, Vic 3084, Australia; Bichat Med Sch, INSERM, E0225, F-75870 Paris, France; Leiden Univ, Med Ctr, Dept Nephrol, NL-2333 ZA Leiden, Netherlands	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Wines, BD (corresponding author), Austin Repatriat Med Ctr, Austin Res Inst, Helen Macpherson Smith Trust Inflammatory Dis Lab, Studley Rd, Heidelberg, Vic 3084, Australia.	b.wines@ari.unimelb.edu.au	Monteiro, Renato C/U-8633-2017; van Kooten, Cees/E-5694-2018	Monteiro, Renato C/0000-0001-5202-5646; van Kooten, Cees/0000-0002-6257-0899; Hogarth, Mark/0000-0002-0360-7890				Alarcon B, 2003, IMMUNOL REV, V191, P38, DOI 10.1034/j.1600-065X.2003.00017.x; AUSUBEL FM, 1993, CURRENT PROTOCOLS MO, V2; Benschop RJ, 2001, J IMMUNOL, V167, P4172, DOI 10.4049/jimmunol.167.8.4172; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; Bolliger L, 1999, J IMMUNOL, V163, P3867; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; Borges L, 2000, CYTOKINE GROWTH F R, V11, P209, DOI 10.1016/S1359-6101(00)00007-1; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Colonna M, 2000, SEMIN IMMUNOL, V12, P121, DOI 10.1006/smim.2000.0214; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; Cronin FE, 1998, J IMMUNOL, V161, P252; Daeron M, 1997, Int Rev Immunol, V16, P1, DOI 10.3109/08830189709045701; Dietrich J, 1999, EUR J IMMUNOL, V29, P1719, DOI 10.1002/(SICI)1521-4141(199905)29:05<1719::AID-IMMU1719>3.3.CO;2-D; Enyedy EJ, 2001, ARTHRITIS RHEUM, V44, P1114, DOI 10.1002/1529-0131(200105)44:5<1114::AID-ANR192>3.0.CO;2-B; EVANS MJ, 1995, J IMMUNOL METHODS, V184, P123, DOI 10.1016/0022-1759(95)00093-P; Fong DC, 2000, J IMMUNOL, V165, P4453, DOI 10.4049/jimmunol.165.8.4453; GEISLER C, 1989, J IMMUNOL, V143, P4069; GRUPP SA, 1993, J BIOL CHEM, V268, P25776; GRUPP SA, 1995, J EXP MED, V181, P161, DOI 10.1084/jem.181.1.161; Honorio-Fransa AC, 2001, J LEUKOCYTE BIOL, V69, P289; HULETT MD, 1993, EUR J IMMUNOL, V23, P640, DOI 10.1002/eji.1830230310; JONES B, 1986, J IMMUNOL, V136, P348; Kim MK, 2003, BLOOD, V101, P4479, DOI 10.1182/blood.V101.11.4479; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; Launay P, 1999, J BIOL CHEM, V274, P7216, DOI 10.1074/jbc.274.11.7216; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; Maeda A, 1998, J EXP MED, V188, P991, DOI 10.1084/jem.188.5.991; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; Martin AM, 2002, TRENDS IMMUNOL, V23, P81, DOI 10.1016/S1471-4906(01)02155-X; MITCHELL RN, 1995, J EXP MED, V181, P1705, DOI 10.1084/jem.181.5.1705; MONTEIRO RC, 1992, J IMMUNOL, V148, P1764; Monteiro RC, 2003, ANNU REV IMMUNOL, V21, P177, DOI 10.1146/annurev.immunol.21.120601.141011; Moonga BS, 2002, AM J PHYSIOL-RENAL, V282, pF921, DOI 10.1152/ajprenal.00045.2000; Morton HC, 2001, ARCH IMMUNOL THER EX, V49, P217; MORTON HC, 1995, J BIOL CHEM, V270, P29781; Nakajima H, 1999, J IMMUNOL, V162, P5; Nolan GP, 1998, CURR OPIN BIOTECH, V9, P447, DOI 10.1016/S0958-1669(98)80027-X; PFEFFERKORN LC, 1994, J IMMUNOL, V153, P3228; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; RodriguezTarduchy G, 1996, J BIOL CHEM, V271, P30417, DOI 10.1074/jbc.271.48.30417; Sahuquillo AG, 1998, J EXP MED, V187, P1179, DOI 10.1084/jem.187.8.1179; Schamel WWA, 2000, MOL IMMUNOL, V37, P253, DOI 10.1016/S0161-5890(00)00025-0; Schamel WWA, 2000, IMMUNITY, V13, P5, DOI 10.1016/S1074-7613(00)00003-0; SHAW AC, 1990, CELL, V63, P381, DOI 10.1016/0092-8674(90)90171-A; Shen L, 2001, BLOOD, V97, P205, DOI 10.1182/blood.V97.1.205; Spain LM, 2002, J IMMUNOL, V168, P127, DOI 10.4049/jimmunol.168.1.127; Takai T, 2001, IMMUNOL REV, V181, P215, DOI 10.1034/j.1600-065X.2001.1810118.x; Takai T, 2002, NAT REV IMMUNOL, V2, P580, DOI 10.1038/nri856; van der Boog PJM, 2002, J IMMUNOL, V168, P1252, DOI 10.4049/jimmunol.168.3.1252; van Egmond M, 2001, TRENDS IMMUNOL, V22, P205, DOI 10.1016/S1471-4906(01)01873-7; van Zandbergen G, 1999, J IMMUNOL, V163, P5806; VARINBLANK N, 1990, J BIOL CHEM, V265, P15685; VIVIER E, 1991, J IMMUNOL, V147, P4263; Wines BD, 1999, J IMMUNOL, V162, P2146; Wines BD, 2001, J IMMUNOL, V166, P1781, DOI 10.4049/jimmunol.166.3.1781; Wu J, 2000, J EXP MED, V192, P1059, DOI 10.1084/jem.192.7.1059; Zheng YM, 2001, J BIOL CHEM, V276, P12999, DOI 10.1074/jbc.M009344200	59	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26339	26345		10.1074/jbc.M403684200	http://dx.doi.org/10.1074/jbc.M403684200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15096494	hybrid			2022-12-25	WOS:000222003000053
J	Gu, YJ; Sanjo, N; Chen, FS; Hasegawa, H; Petit, A; Ruan, XY; Li, WP; Shier, C; Kawarai, T; Schmitt-Ulms, G; Westaway, D; St George-Hyslop, P; Fraser, PE				Gu, YJ; Sanjo, N; Chen, FS; Hasegawa, H; Petit, A; Ruan, XY; Li, WP; Shier, C; Kawarai, T; Schmitt-Ulms, G; Westaway, D; St George-Hyslop, P; Fraser, PE			The presenilin proteins are components of multiple membrane-bound complexes that have different biological activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; GAMMA-SECRETASE ACTIVITY; MISSENSE MUTATIONS; BETA-CATENIN; NICASTRIN; NOTCH; APH-1; PATHWAY; APP	Several lines of evidence have indicated that the presenilin proteins function within macromolecular complexes and are necessary for the regulated intramembranous proteolysis of certain type 1 transmembrane proteins, including the amyloid precursor protein, Notch, and p75. Data from multiple complementary experiments now suggest that there may be several distinct presenilin complexes. We show here that presenilin mutations and certain detergents affect the abundance and componentry of the presenilin complexes, and these structural effects correlate with their effects on gamma-secretase activity. Our data suggest that there are at least three complexes, including a similar to150-kDa nicastrin-aph-1 complex ( which is likely to be a precursor complex). There is a stable and abundant intermediate complex of similar to 440 kDa, which contains aph-1, pen-2, nicastrin, and PS1. However, it is the very low abundance, high mass (greater than or equal to 670 kDa) heteromeric complexes that are associated with the highest gamma-secretase-specific activity.	Univ Toronto, Dept Med, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; Toronto Western Hosp, Dept Med, Div Neurol, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	St George-Hyslop, P (corresponding author), Univ Toronto, Dept Med, Ctr Res Neurodegenerat Dis, Tanz Neurosci Bldg,6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	p.hyslop@utoronto.ca	Kawarai, Toshitaka/C-2822-2013	Kawarai, Toshitaka/0000-0003-4547-8131; Sanjo, Nobuo/0000-0002-1226-2425; Petit-Paitel, Agnes/0000-0003-1138-9966; St George-Hyslop, Peter/0000-0003-0796-7209				Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; Chen FS, 2000, J BIOL CHEM, V275, P36794, DOI 10.1074/jbc.M006986200; Culvenor JG, 2004, EUR J BIOCHEM, V271, P375, DOI 10.1046/j.1432-1033.2003.03936.x; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P323, DOI 10.1021/bi035748j; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hayashi H, 2000, BBA-MOL CELL BIOL L, V1483, P81, DOI 10.1016/S1388-1981(99)00174-2; KOO EH, 1994, J BIOL CHEM, V269, P17386; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; Nixon RA, 2001, J ALZHEIMERS DIS, V3, P97, DOI 10.3233/JAD-2001-3114; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Tian GC, 2003, J BIOL CHEM, V278, P28968, DOI 10.1074/jbc.M300905200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, J BIOL CHEM, V275, P27348; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	29	64	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31329	31336		10.1074/jbc.M401548200	http://dx.doi.org/10.1074/jbc.M401548200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15123598	hybrid			2022-12-25	WOS:000222726800053
J	Chaumont, S; Jiang, LH; Penna, A; North, RA; Rassendren, F				Chaumont, S; Jiang, LH; Penna, A; North, RA; Rassendren, F			Identification of a trafficking motif involved in the stabilization and polarization of P2X receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED GLYCOSYLATION; CELL-SURFACE; ION-CHANNEL; MOLECULAR PHYSIOLOGY; ACTIN CYTOSKELETON; POTASSIUM CHANNEL; AMINO-ACIDS; C-TERMINUS; FILAMIN-A; SUBUNIT	Extracellular ATP-gated channels (P2X receptors) define the third major family of ionotropic receptors, and they are expressed widely in nerve cells, muscles, and endocrine and exocrine glands. P2X subunits have two membrane-spanning domains, and a receptor is thought to be formed by oligomerization of three subunits. We have identified a conserved motif in the cytoplasmic C termini of P2X subunits that is necessary for their surface expression; mutations in this motif result in a marked reduction of the receptors at the plasma membrane because of a rapid internalization. Transfer of the motif to a reporter protein (CD4) enhances the surface expression of the chimera, indicating that this motif is likely involved in the stabilization of P2X receptor at the cell surface. In neurons, mutated P2X(2) subunits showed reduced membrane expression and an altered axodendritic distribution. This motif is also present in intracellular regions of other membrane proteins, such as in the third intracellular loop of some G protein-coupled receptors, suggesting that it might be involve in their cellular stabilization and polarization.	CNRS, UPR2580, Lab Gen Fonct, Dept Pharmacol, F-34396 Montpellier, France; Univ Sheffield, Inst Mol Physiol, Sheffield S10 2TN, S Yorkshire, England	Centre National de la Recherche Scientifique (CNRS); University of Sheffield	Rassendren, F (corresponding author), CNRS, UPR2580, Lab Gen Fonct, Dept Pharmacol, 141 Rue Cardonille, F-34396 Montpellier, France.	far@igh.cnrs.fr	Rassendren, Francois/AAA-6190-2021; North, Richard/GQA-6156-2022; Jiang, Lin-Hua/D-2030-2010; penna, aubin/AAD-2550-2019; PENNA, aubin/E-2208-2018; Jiang, Lin-Hua/AAU-1078-2020	Jiang, Lin-Hua/0000-0001-6398-0411; penna, aubin/0000-0002-1070-5990; PENNA, aubin/0000-0002-1070-5990; Jiang, Lin-Hua/0000-0001-6398-0411; Chaumont-Dubel, Severine/0000-0001-6860-6891; Rassendren, Francois/0000-0003-3320-2461				Bedford FK, 2001, NAT NEUROSCI, V4, P908, DOI 10.1038/nn0901-908; Bo XN, 2003, MOL PHARMACOL, V63, P1407, DOI 10.1124/mol.63.6.1407; Bobanovic LK, 2002, J NEUROSCI, V22, P4814, DOI 10.1523/JNEUROSCI.22-12-04814.2002; Brady AE, 2003, J BIOL CHEM, V278, P32405, DOI 10.1074/jbc.M304195200; Brandle U, 1997, FEBS LETT, V404, P294, DOI 10.1016/S0014-5793(97)00128-2; Buell G, 1996, EUR J NEUROSCI, V8, P2221, DOI 10.1111/j.1460-9568.1996.tb00745.x; Denlinger LC, 2003, J IMMUNOL, V171, P1304, DOI 10.4049/jimmunol.171.3.1304; Egan TM, 1998, J NEUROSCI, V18, P2350; Ennion S, 2000, J BIOL CHEM, V275, P29361, DOI 10.1074/jbc.M003637200; Ennion SJ, 2002, MOL PHARMACOL, V61, P303, DOI 10.1124/mol.61.2.303; Jiang LH, 2000, J BIOL CHEM, V275, P34190, DOI 10.1074/jbc.M005481200; Jiang LH, 2001, J BIOL CHEM, V276, P14902, DOI 10.1074/jbc.M011327200; Jiang LH, 2003, J NEUROSCI, V23, P8903; Jones CA, 2004, MOL PHARMACOL, V65, P979, DOI 10.1124/mol.65.4.979; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; Khakh BS, 2001, NAT REV NEUROSCI, V2, P165, DOI 10.1038/35058521; Koshimizu T, 1999, J BIOL CHEM, V274, P37651, DOI 10.1074/jbc.274.53.37651; Kucenas S, 2003, NEUROSCIENCE, V121, P935, DOI 10.1016/S0306-4522(03)00566-9; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; Newbolt A, 1998, J BIOL CHEM, V273, P15177, DOI 10.1074/jbc.273.24.15177; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Parker KE, 1998, J PHYSIOL-LONDON, V510, P19, DOI 10.1111/j.1469-7793.1998.019bz.x; Radford KM, 1997, J NEUROSCI, V17, P6529; Rassendren F, 1997, EMBO J, V16, P3446, DOI 10.1093/emboj/16.12.3446; Royle SJ, 2002, J BIOL CHEM, V277, P35378, DOI 10.1074/jbc.M204844200; Sampson LJ, 2003, J BIOL CHEM, V278, P41988, DOI 10.1074/jbc.M307479200; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; Smith FM, 1999, J PHYSIOL-LONDON, V520, P91, DOI 10.1111/j.1469-7793.1999.00091.x; Stoop R, 1999, MOL PHARMACOL, V56, P973, DOI 10.1124/mol.56.5.973; Torres GE, 1998, FEBS LETT, V425, P19, DOI 10.1016/S0014-5793(98)00179-3; Torres GE, 1998, BIOCHEMISTRY-US, V37, P14845, DOI 10.1021/bi981209g; Toth-Zsamboki E, 2002, FEBS LETT, V524, P15, DOI 10.1016/S0014-5793(02)02987-3; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485; Wiley JS, 2003, J BIOL CHEM, V278, P17108, DOI 10.1074/jbc.M212759200; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	39	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29628	29638		10.1074/jbc.M403940200	http://dx.doi.org/10.1074/jbc.M403940200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15126501	Green Submitted, hybrid			2022-12-25	WOS:000222445300099
J	Cao, XQ; Cismowski, MJ; Sato, M; Blumer, JB; Lanier, SM				Cao, XQ; Cismowski, MJ; Sato, M; Blumer, JB; Lanier, SM			Identification and characterization of AGS4 - A protein containing three G-protein regulatory motifs that regulate the activation state of G(i)alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; GOLGI MEMBRANES; ALPHA-SUBUNITS; CELL POLARITY; GOLOCO MOTIF; BETA-GAMMA; LOCALIZATION; PHOSPHORYLATION; DISSOCIATION; TRAFFICKING	Activators of G-protein signaling 1-3 (AGS1-3) were identified in a functional screen of mammalian cDNAs that activated G-protein signaling in the absence of a receptor. We report the isolation and characterization of an additional AGS protein (AGS4) from a human prostate leiomyosarcoma cDNA library. AGS4 is identical to G18.1b, which is encoded by a gene within the major histocompatibility class III region of chromosome 6. The activity of AGS4 in the yeast-based functional screen was selective for G(i2)/G(i3) and independent of guanine-nucleotide exchange by G(i)alpha. RNA blots indicated enrichment of AGS4/G18.1b mRNA in heart, placenta, lung, and liver. Immunocytochemistry with AGS4/G18.1b-specific antisera indicated a predominant nonhomogeneous, extranuclear distribution within the cell following expression in COS7 or Chinese hamster ovary cells. AGS4/G18.1b contains three G-protein regulatory motifs downstream of an amino terminus domain with multiple prolines. Glutathione S-transferase (GST)-AGS4/G18.1b fusion proteins interacted with purified G(i)alpha, and peptides derived from each of the G-protein regulatory motifs inhibited guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) binding to purified G(i)alpha(1). AGS4/G18.1b was also complexed with G(i)alpha(3) in COS7 cell lysates following cell transfection. However, AGS4/G18.1b did not alter the generation of inositol phosphates in COS7 cells cotransfected with the Gbetagamma-regulated effector phospholipase C-beta2. These data suggest either that an additional signal is required to position AGS4/G18.1b in the proper cellular location where it can access heterotrimer and promote subunit dissociation or that AGS4 serves as an alternative binding partner for G(i)alpha independent of Gbetagamma participating in G-protein signaling events that are independent of classical G-protein-coupled receptors at the cell surface.	Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA; Guthrie Res Inst, Sayre, PA 18840 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Lanier, SM (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol, 1901 Perdido St, New Orleans, LA 70112 USA.	slanie@lsuhsc.edu	Cismowski, Mary/E-2897-2011	Lanier, Stephen/0000-0002-2740-7607; Blumer, Joe/0000-0002-0020-3815	NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH065092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024821, R01NS024821] Funding Source: NIH RePORTER; NIMH NIH HHS [MH90531, F32MH65092, F32 MH065092] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adhikari A, 2003, J BIOL CHEM, V278, P51825, DOI 10.1074/jbc.M306300200; Ahringer J, 2003, CURR OPIN CELL BIOL, V15, P73, DOI 10.1016/S0955-0674(02)00018-2; Bernard ML, 2001, J BIOL CHEM, V276, P1585, DOI 10.1074/jbc.M005291200; Blumer JB, 2003, RECEPTOR CHANNEL, V9, P195, DOI 10.1080/10606820390203839; Blumer JB, 2003, J BIOL CHEM, V278, P23217, DOI 10.1074/jbc.C200686200; Blumer JB, 2002, J BIOL CHEM, V277, P15897, DOI 10.1074/jbc.M112185200; Chatterjee TK, 2003, J BIOL CHEM, V278, P30272, DOI 10.1074/jbc.M212688200; Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; Colombo K, 2003, SCIENCE, V300, P1957, DOI 10.1126/science.1084146; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; Du QS, 2001, NAT CELL BIOL, V3, P1069, DOI 10.1038/ncb1201-1069; Ghosh M, 2003, J BIOL CHEM, V278, P34747, DOI 10.1074/jbc.C300271200; Gotta M, 2003, CURR BIOL, V13, P1029, DOI 10.1016/S0960-9822(03)00371-3; Hollinger S, 2003, BIOCHEMISTRY-US, V42, P811, DOI 10.1021/bi026664y; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Kaushik R, 2003, MOL BIOL CELL, V14, P3144, DOI 10.1091/mbc.E03-04-0212; Kimple RJ, 2004, BIOCHEM J, V378, P801, DOI 10.1042/BJ20031686; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; Natochin M, 2000, J BIOL CHEM, V275, P40981, DOI 10.1074/jbc.M006478200; Nebl T, 2002, J BIOL CHEM, V277, P43399, DOI 10.1074/jbc.M205386200; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; Peterson YK, 2002, J BIOL CHEM, V277, P6767, DOI 10.1074/jbc.C100699200; Pizzinat N, 2001, J BIOL CHEM, V276, P16601, DOI 10.1074/jbc.M007573200; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Srinivasan DG, 2003, GENE DEV, V17, P1225, DOI 10.1101/gad.1081203; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Wu GY, 2003, J BIOL CHEM, V278, P47062, DOI 10.1074/jbc.M305707200; Yu FW, 2002, MOL CELL BIOL, V22, P4230, DOI 10.1128/MCB.22.12.4230-4240.2002; Zarling AL, 2000, J EXP MED, V192, P1755, DOI 10.1084/jem.192.12.1755	33	39	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27567	27574		10.1074/jbc.M312786200	http://dx.doi.org/10.1074/jbc.M312786200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096500	hybrid			2022-12-25	WOS:000222120400090
J	Maggiolini, M; Vivacqua, A; Fasanella, G; Recchia, AG; Sisci, D; Pezzi, V; Montanaro, D; Musti, AM; Picard, D; Ando, S				Maggiolini, M; Vivacqua, A; Fasanella, G; Recchia, AG; Sisci, D; Pezzi, V; Montanaro, D; Musti, AM; Picard, D; Ando, S			The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17 beta-estradiol and phytoestrogens in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; EPIDERMAL-GROWTH-FACTOR; TERNARY COMPLEX FACTORS; MEMBRANE ESTROGEN-RECEPTORS; TRANSCRIPTIONAL ACTIVATION; PROTOONCOGENE EXPRESSION; SIGNAL-TRANSDUCTION; STEROID-HORMONES; PROSTATE-CANCER; GENE-EXPRESSION	A growing body of evidence concerning estrogen effects cannot be explained by the classic model of hormone action, which involves the binding to estrogen receptors (ERs) alpha and ERbeta and the interaction of the steroid-receptor complex with specific DNA sequences associated with target genes. Using c-fos proto-oncogene expression as an early molecular sensor of estrogen action in ERalpha-positive MCF7 and ER-negative SKBR3 breast cancer cells, we have discovered that 17beta-estradiol (E2), and the two major phytoestrogens, genistein and quercetin, stimulate c-fos expression through ERalpha as well as through an ER-independent manner via the G protein-coupled receptor homologue GPR30. The c-fos response is repressed in GPR30-expressing SKBR3 cells transfected with an antisense oligonucleotide against GPR30 and reconstituted in GPR30-deficient MDA-MB 231 and BT-20 breast cancer cells transfected with a GPR30 expression vector. GPR30-dependent activation of ERK1/2 by E2 and phytoestrogens occurs via a Gbetagamma-associated pertussis toxin-sensitive pathway that requires both Src-related and EGF receptor tyrosine kinase activities. The ability of E2 and phytoestrogens to regulate the expression of growth-related genes such as c-fos even in the absence of ER has interesting implications for understanding breast cancer progression.	Univ Calabria, Dipartimento Biol Cellulare, I-87030 Arcavacata Di Rende, CS, Italy; Univ Calabria, Dept Pharmacobiol, I-87030 Arcavacata Di Rende, CS, Italy; Univ Geneva, Dept Biol Cellulaire, CH-1211 Geneva 4, Switzerland	University of Calabria; University of Calabria; University of Geneva	Ando, S (corresponding author), Univ Calabria, Dipartimento Biol Cellulare, I-87030 Arcavacata Di Rende, CS, Italy.	sebastiano.ando@unical.it	Musti, Anna Maria/M-2520-2019; Pezzi, Vincenzo/AAL-4017-2020; Maggiolini, Marcello/Z-4729-2019; Recchia, Anna Grazia/ABA-5228-2020; /AAD-9701-2019; vivacqua, adele/I-2771-2015	/0000-0001-6577-1541; vivacqua, adele/0000-0001-5333-8396; Recchia, Anna Grazia/0000-0001-5748-2002; Maggiolini, Marcello/0000-0002-7485-854X; MUSTI, Anna Maria/0000-0003-1443-2739; pezzi, Vincenzo/0000-0003-2311-2286				BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Bonapace IM, 1996, ONCOGENE, V12, P753; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; CANDELIERE GA, 1991, MOL ENDOCRINOL, V5, P1780, DOI 10.1210/mend-5-12-1780; Carmeci C, 1997, GENOMICS, V45, P607, DOI 10.1006/geno.1997.4972; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; Curran T, 1988, ONCOGENE HDB, P307; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; Duan RQ, 2002, BIOCHEM BIOPH RES CO, V294, P384, DOI 10.1016/S0006-291X(02)00499-0; Duan RQ, 2001, J BIOL CHEM, V276, P11590, DOI 10.1074/jbc.M005492200; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; Gallo A, 2002, ONCOGENE, V21, P6434, DOI 10.1038/sj.onc.1205822; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; HERBER B, 1994, ONCOGENE, V9, P1295; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; JENSEN EV, 1995, ANN NY ACAD SCI, V761, P1, DOI 10.1111/j.1749-6632.1995.tb31364.x; Kanda N, 2003, J INVEST DERMATOL, V121, P771, DOI 10.1046/j.1523-1747.2003.12487.x; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Kim-Kaneyama J, 2002, BIOCHEM BIOPH RES CO, V299, P360, DOI 10.1016/S0006-291X(02)02644-X; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kroeze WK, 2003, J CELL SCI, V116, P4867, DOI 10.1242/jcs.00902; Lau KM, 2000, CANCER RES, V60, P3175; LEE K, 1994, ENDOCRINOLOGY, V134, P441, DOI 10.1210/en.134.1.441; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; Lopez-Otin C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; Maggiolini M, 1999, BIOL CHEM, V380, P695, DOI 10.1515/BC.1999.086; Maggiolini M, 2002, J STEROID BIOCHEM, V82, P315, DOI 10.1016/S0960-0760(02)00230-3; Maggiolini M, 2001, MOL PHARMACOL, V60, P595; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; Mcewen BS, 1999, ENDOCR REV, V20, P279, DOI 10.1210/er.20.3.279; MEYER DJ, 1993, P NATL ACAD SCI USA, V90, P6721, DOI 10.1073/pnas.90.14.6721; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Morey AK, 1997, ENDOCRINOLOGY, V138, P3330, DOI 10.1210/en.138.8.3330; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; O'Dowd BF, 1998, GENOMICS, V47, P310, DOI 10.1006/geno.1998.5095; Picard D, 1997, BIOCHEM SOC T, V25, P597, DOI 10.1042/bst0250597; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Recchia AG, 2004, FOOD ADDIT CONTAM A, V21, P134, DOI [10.1080/02646830020032300, 10.1080/02652030310001641177]; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197; Singer CA, 1999, J NEUROSCI, V19, P2455; Singh M, 1999, J NEUROSCI, V19, P1179; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Taylor AH, 2001, ANTISENSE NUCLEIC A, V11, P219, DOI 10.1089/108729001317022223; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; VANDERBURG B, 1991, J STEROID BIOCHEM, V40, P215, DOI 10.1016/0960-0760(91)90185-8; VANDERBURG B, 1990, MOL ENDOCRINOL, V4, P1720, DOI 10.1210/mend-4-11-1720; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; Vivacqua A, 2003, ENDOCRINE, V22, P275, DOI 10.1385/ENDO:22:3:275; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513; Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WEISZ A, 1993, CRIT REV ONCOGENESIS, V4, P361; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; WILDING G, 1988, CANCER RES, V48, P802; Wyckoff MH, 2001, J BIOL CHEM, V276, P27071, DOI 10.1074/jbc.M100312200; Zhu Y, 2002, SCIENCE, V295, P505, DOI 10.1126/science.1065250	86	371	392	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27008	27016		10.1074/jbc.M403588200	http://dx.doi.org/10.1074/jbc.M403588200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15090535	hybrid			2022-12-25	WOS:000222120400026
J	Subramaniam, K; Chen, K; Joseph, K; Raymond, JR; Tholanikunnel, BG				Subramaniam, K; Chen, K; Joseph, K; Raymond, JR; Tholanikunnel, BG			The 3 '-untranslated region of the beta(2)-adrenergic receptor mRNA regulates receptor synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; AU-RICH ELEMENTS; BETA-ADRENERGIC-RECEPTOR; TRANSLATIONAL CONTROL; BETA-2-ADRENERGIC RECEPTOR; POLY(A)-BINDING PROTEIN; 3-UNTRANSLATED REGION; GAMMA-INTERFERON; CREATINE-KINASE; LEADER CISTRON	beta(2)-Adrenergic receptors (beta(2)-ARs) are low abundance integral membrane proteins that mediate the effects of catecholamines at the cell surface. Post-transcriptional regulation of beta(2)-AR is dependent, in part, on sequences within the 5'- and 3'-untranslated regions ( UTRs) of the receptor mRNA. In this work, we demonstrate that 3'-UTR sequences regulate the translation of the receptor mRNA. Deletion of the 3'-UTR sequences resulted in 2-2.5-fold increases in receptor expression. The steadystate levels of beta(2)-AR mRNA did not change significantly in the presence or absence of the 3'-UTR, suggesting that the translation of the receptor mRNA is suppressed by 3'-UTR sequences. Introduction of the receptor 3'-UTR sequences into the 3'-UTR of a heterologous reporter gene ( luciferase) resulted in a 70% decrease in reporter gene expression without significant changes in luciferase mRNA levels. Sucrose density gradient fractionation of cytoplasmic extracts from Chinese hamster ovary cells transfected with full-length receptor cDNA demonstrated that the receptor transcripts were distributed between polysomal and non-polysomal fractions. Deletion of 3'-UTR sequences from the receptor cDNA resulted in a clear shift in the distribution of receptor mRNA toward the polysomal fractions, favoring increased translation. The 3'-UTR sequences of the receptor mRNA were sufficient to shift the distribution of luciferase mRNA from predominantly polysomal fractions toward non-polysomal fractions in cells transfected with the chimeric luciferase construct. Taken together, our results provide the first evidence for translational control of beta(2\)-AR expression by 3'-UTR sequences. Presumably, this occurs by affecting the receptor mRNA localization.	Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA; Med Univ S Carolina, Div Pulm Crit Care Med Allergy & Clin Immunol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Tholanikunnel, BG (corresponding author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,829 CSB, Charleston, SC 29425 USA.	tholanik@musc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058740, R01GM063909] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM63909, 1R01 GM58740] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JM, 1988, EMBO J, V7, P133, DOI 10.1002/j.1460-2075.1988.tb02792.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHNG JLC, 1989, P NATL ACAD SCI USA, V86, P10006, DOI 10.1073/pnas.86.24.10006; CHNG JLC, 1990, SCIENCE, V248, P1003, DOI 10.1126/science.2343304; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; Dalgleish G, 2001, J BIOL CHEM, V276, P13593, DOI 10.1074/jbc.M001141200; Danner S, 1998, J BIOL CHEM, V273, P3223, DOI 10.1074/jbc.273.6.3223; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Di Noia JM, 2000, J BIOL CHEM, V275, P10218, DOI 10.1074/jbc.275.14.10218; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2003, J EXP MED, V198, P475, DOI 10.1084/jem.20030616; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; Duquette M, 2002, J BIOL CHEM, V277, P44631, DOI 10.1074/jbc.M207007200; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Gray NK, 2000, EMBO J, V19, P4723, DOI 10.1093/emboj/19.17.4723; GRENS A, 1990, J BIOL CHEM, V265, P11810; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Izquierdo JM, 1997, MOL CELL BIOL, V17, P5255, DOI 10.1128/MCB.17.9.5255; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; Jacobs GH, 2002, NUCLEIC ACIDS RES, V30, P310, DOI 10.1093/nar/30.1.310; Kloc M, 2002, CELL, V108, P533, DOI 10.1016/S0092-8674(02)00651-7; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LECUYER TJ, 1995, P NATL ACAD SCI USA, V92, P7520, DOI 10.1073/pnas.92.16.7520; Mazumder B, 1999, MOL CELL BIOL, V19, P6898; Mazumder B, 2003, CELL, V115, P187, DOI 10.1016/S0092-8674(03)00773-6; Mazumder B, 2001, MOL CELL BIOL, V21, P6440, DOI 10.1128/MCB.21.19.6440-6449.2001; Mazumder B, 2003, TRENDS BIOCHEM SCI, V28, P91, DOI 10.1016/S0968-0004(03)00002-1; Mbella EGM, 2000, MOL CELL BIOL, V20, P4572, DOI 10.1128/MCB.20.13.4572-4579.2000; McGraw DW, 1998, J CLIN INVEST, V102, P1927, DOI 10.1172/JCI4862; Mikulits W, 2000, FASEB J, V14, P1641, DOI 10.1096/fj.14.11.1641; Millard SS, 2000, MOL CELL BIOL, V20, P5947, DOI 10.1128/MCB.20.16.5947-5959.2000; NAKADA MT, 1989, BIOCHEM J, V260, P53, DOI 10.1042/bj2600053; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; PAROLA AL, 1994, J BIOL CHEM, V269, P4497; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Ranganathan G, 2000, J BIOL CHEM, V275, P40986, DOI 10.1074/jbc.M008775200; Reimann I, 2002, J MOL BIOL, V315, P965, DOI 10.1006/jmbi.2001.5315; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sampath P, 2003, MOL CELL BIOL, V23, P1509, DOI 10.1128/MCB.23.5.1509-1519.2003; Seydoux G, 1996, CURR OPIN GENET DEV, V6, P555, DOI 10.1016/S0959-437X(96)80083-9; Spicher A, 1998, MOL CELL BIOL, V18, P7371, DOI 10.1128/MCB.18.12.7371; Tholanikunnel BG, 1999, BIOCHEMISTRY-US, V38, P15564, DOI 10.1021/bi9913348; Tholanikunnel BG, 1997, J BIOL CHEM, V272, P11471; THOLANIKUNNEL BG, 2000, REGULATION G PROTEIN, P273; Wiklund L, 2002, J BIOL CHEM, V277, P40462, DOI 10.1074/jbc.M205929200; Yang Q, 1997, J BIOL CHEM, V272, P15466, DOI 10.1074/jbc.272.24.15466; Yu Q, 2003, J BIOL CHEM, V278, P1579, DOI 10.1074/jbc.M203526200; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952	54	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27108	27115		10.1074/jbc.M401352200	http://dx.doi.org/10.1074/jbc.M401352200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15107422	hybrid			2022-12-25	WOS:000222120400037
J	Michels, J; O'Neill, JW; Dallman, CL; Mouzakiti, A; Habens, F; Brimmell, M; Zhang, KYJ; Craig, RW; Marcusson, EG; Johnson, PWM; Packham, G				Michels, J; O'Neill, JW; Dallman, CL; Mouzakiti, A; Habens, F; Brimmell, M; Zhang, KYJ; Craig, RW; Marcusson, EG; Johnson, PWM; Packham, G			Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage	ONCOGENE			English	Article						apoptosis; Mcl-1; antisense; non-Hodgkin's lymphoma; Bcl-2; caspase	CHRONIC LYMPHOCYTIC-LEUKEMIA; APOPTOSIS-REGULATING PROTEINS; BCL-2 FAMILY; IN-VIVO; EXPRESSION; HOMOLOG; DIFFERENTIATION; ACTIVATION; PROTECTS; MYELOMA	Enforced expression of the antiapoptotic Bcl-2 family protein Mcl-1 promotes lymphomagenesis in the mouse; however, the functional role of Mcl-1 in human B-cell lymphoma remains unclear. We demonstrate that Mcl-1 is widely expressed in malignant B-cells, and high-level expression of Mcl-1 is required for B-lymphoma cell survival, since transfection of Mcl-1-specific antisense oligodeoxynucleotides was sufficient to promote apoptosis in Akata6 lymphoma cells. Mcl-1 was efficiently cleaved by caspases at evolutionarily conserved aspartic acid residues in vitro, and during cisplatin-induced apoptosis in B-lymphoma cell lines and spontaneous apoptosis of primary malignant B-cells. Overexpression of the Mcl-1 cleavage product that accumulated during apoptosis was sufficient to kill cells. Therefore, Mcl-1 is an essential survival molecule for B-lymphoma cells and is cleaved by caspases to a death-promoting molecule during apoptosis. In contrast to Mcl-1, Bcl-2 and Bcl-X-L were relatively resistant to caspase cleavage in vitro and in intact cells. Interfering with Mcl-1 function appears to be an effective means of inducing apoptosis in Mcl-1-positive B-cell lymphoma, and the unique sensitivity of Mcl-1 to caspase-mediated cleavage suggests an attractive strategy for converting it to a proapoptotic molecule.	Univ Southampton, Sch Med, Canc Sci Div, Canc Res UK Oncol Unit, Southampton, Hants, England; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA; Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH USA; ISIS Pharmaceut, Dept Mol Pharmacol, Carlsbad, CA 92008 USA	University of Southampton; Fred Hutchinson Cancer Center; Dartmouth College; Isis Pharmaceuticals Inc	Packham, G (corresponding author), Southampton Gen Hosp, Canc Res UK Oncol Unit, Somers Canc Res Bldg MP824,Tremona Rd, Southampton SO16 6YD, Hants, England.	G.K.Packham@soton.ac.uk	Zhang, Kam Y. J./B-3552-2012; Johnson, Peter/O-3529-2019; Johnson, Peter/L-2403-2018	Zhang, Kam Y. J./0000-0002-9282-8045; Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974; Marcusson, Eric/0000-0002-0504-8674; Packham, Graham/0000-0002-9232-5691	NATIONAL CANCER INSTITUTE [R01CA057359] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA57359] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Agarwal B, 2002, AM J HEMATOL, V70, P278, DOI 10.1002/ajh.10139; Akgul C, 2000, FEBS LETT, V478, P72, DOI 10.1016/S0014-5793(00)01809-3; Altmeyer A, 1997, IMMUNITY, V7, P667, DOI 10.1016/S1074-7613(00)80387-8; Bannerman DD, 2001, J BIOL CHEM, V276, P14924, DOI 10.1074/jbc.M100819200; Bellosillo B, 1999, BLOOD, V94, P2836, DOI 10.1182/blood.V94.8.2836.420k35_2836_2843; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Byrd JC, 2002, BLOOD, V99, P1038, DOI 10.1182/blood.V99.3.1038; CAZALSHATEM DL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P109, DOI 10.1016/0167-4781(92)90064-7; Chen MC, 2001, BBA-GENE STRUCT EXPR, V1519, P127, DOI 10.1016/S0167-4781(01)00209-3; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CRAIG RW, 1984, CANCER RES, V44, P2421; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; DALLMAN CL, 2004, IN PRESS MOL METHODS; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Drexler HG., 2001, LEUKEMIA LYMPHOMA CE, P2, DOI [10.1016/B978-012221970-2/50002-4, DOI 10.1016/B978-012221970-2/50002-4]; Ghia P, 1998, BLOOD, V91, P244, DOI 10.1182/blood.V91.1.244.244_244_251; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Iglesias-Serret D, 2003, ARCH BIOCHEM BIOPHYS, V417, P141, DOI 10.1016/S0003-9861(03)00345-X; Inman GJ, 2001, J VIROL, V75, P2400, DOI 10.1128/JVI.75.5.2400-2410.2001; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Khoury JD, 2003, J PATHOL, V199, P90, DOI 10.1002/path.1254; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Lenoir G M, 1985, IARC Sci Publ, P309; Lomo J, 1996, CANCER RES, V56, P40; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; NIHAWAN D, 2003, GENE DEV, V17, P1475; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; OXFORD SME, 2004, IN PRESS CURRENT MED; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Packham G, 1998, APOPTOSIS, V3, P75, DOI 10.1023/A:1009688706783; Pagnano KBB, 2002, ACTA HAEMATOL-BASEL, V107, P29, DOI 10.1159/000046626; Pedersen IM, 2002, BLOOD, V100, P1795, DOI 10.1182/blood.V100.5.1795.h81702001795_1795_1801; Pepper C, 2002, EUR J HAEMATOL, V69, P227, DOI 10.1034/j.1600-0609.2002.02799.x; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; Snowden RT, 2003, LEUKEMIA, V17, P1981, DOI 10.1038/sj.leu.2403088; Soini Y, 1998, TUMOR BIOL, V19, P176, DOI 10.1159/000030005; Spender LC, 1999, J VIROL, V73, P4678, DOI 10.1128/JVI.73.6.4678-4688.1999; Spets H, 2002, EUR J HAEMATOL, V69, P76, DOI 10.1034/j.1600-0609.2002.01549.x; TAKADA K, 1991, VIRUS GENES, V5, P147, DOI 10.1007/BF00571929; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vrana JA, 2002, CANCER RES, V62, P892; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902	51	121	130	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4818	4827		10.1038/sj.onc.1207648	http://dx.doi.org/10.1038/sj.onc.1207648			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15122313				2022-12-25	WOS:000222104200002
J	Unno, M; Kumauchi, M; Hamada, N; Tokunaga, F; Yamauchi, S				Unno, M; Kumauchi, M; Hamada, N; Tokunaga, F; Yamauchi, S			Resonance Raman evidence for two conformations involved in the L intermediate of photoactive yellow protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOPHILIC PHOTOTROPHIC BACTERIUM; ECTOTHIORHODOSPIRA-HALOPHILA; ACTIVE-SITE; PHOTOCYCLE; SPECTROSCOPY; CHROMOPHORE; PHOTORECEPTOR; MUTANTS; COLOR; FOLD	The blue light receptor photoactive yellow protein (PYP) displays a photocycle that involves several intermediate states. Here we report resonance Raman spectroscopic investigations of the short-lived red-shifted intermediate denoted PYPL. We have found that the Raman bands of the carbonyl C = O stretching mode nu(11) as well as the C = C stretching mode nu(13) for the chromophore can be resolved into two peaks, and the ratio of the two components varies as a function of pH with pK(a) similar to6. The isotope effects on the resonance Raman spectra have confirmed a deprotonated cis-chromophore for the two components. The results indicate the presence of two conformations in the active site of PYPL. The normal coordinate calculations based on the density functional theory provide a structural model for the two conformations, where the low pH form is possibly an active structure for the protonation reaction generating a following intermediate in the photocycle.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Sendai, Miyagi 9808577, Japan; Osaka Univ, Grad Sch Sci, Dept Earth & Space Sci, Osaka 5600043, Japan; Osaka Univ, JST, CREST, Suita, Osaka 5650871, Japan	Tohoku University; Osaka University; Japan Science & Technology Agency (JST); Osaka University	Unno, M (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Sendai, Miyagi 9808577, Japan.	unno@tagen.tohoku.ac.jp		Unno, Masashi/0000-0002-5016-6274				BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Brudler R, 2001, NAT STRUCT BIOL, V8, P265, DOI 10.1038/85021; Chosrowjan H, 2004, J PHYS CHEM B, V108, P2686, DOI 10.1021/jp031126w; Devanathan S, 1999, BIOCHEMISTRY-US, V38, P13766, DOI 10.1021/bi991634p; El-Mashtoly SF, 2004, BIOCHEMISTRY-US, V43, P2279, DOI 10.1021/bi035638c; Frisch G.W., 2016, GAUSSIAN 16 REVISION; Genick UK, 1997, BIOCHEMISTRY-US, V36, P8, DOI 10.1021/bi9622884; Genick UK, 1998, NATURE, V392, P206, DOI 10.1038/32462; Hendriks J, 2003, BIOPHYS J, V84, P1180, DOI 10.1016/S0006-3495(03)74932-7; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; Imamoto Y, 1997, J BIOL CHEM, V272, P12905, DOI 10.1074/jbc.272.20.12905; KIM M, 1995, BIOCHEMISTRY-US, V34, P12669, DOI 10.1021/bi00039a024; Kroon AR, 1996, J BIOL CHEM, V271, P31949, DOI 10.1074/jbc.271.50.31949; MEYER TE, 1987, BIOCHEMISTRY-US, V26, P418, DOI 10.1021/bi00376a012; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; Mihara K, 1997, J BIOCHEM, V121, P876; Onsager L, 1936, J AM CHEM SOC, V58, P1486, DOI 10.1021/ja01299a050; Pan DH, 2004, BIOPHYS J, V86, P2374, DOI 10.1016/S0006-3495(04)74294-0; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Takeuchi H., 1981, SPECTROSCOPY BIOL SY, V13, P113; Ujj L, 1998, BIOPHYS J, V75, P406, DOI 10.1016/S0006-3495(98)77525-3; Unno M, 2000, J AM CHEM SOC, V122, P4233, DOI 10.1021/ja000032m; Unno M, 2003, J PHYS CHEM B, V107, P2837, DOI 10.1021/jp026448z; Unno M, 2002, BIOCHEMISTRY-US, V41, P5668, DOI 10.1021/bi025508o; Voet D VJ, 1990, BIOCHEMISTRY; Xie AH, 2001, BIOCHEMISTRY-US, V40, P1510, DOI 10.1021/bi002449a	26	32	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23855	23858		10.1074/jbc.C400137200	http://dx.doi.org/10.1074/jbc.C400137200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15096497	hybrid			2022-12-25	WOS:000221702500003
J	Marriott, HM; Ali, F; Read, RC; Mitchell, TJ; Whyte, MKB; Dockrell, DH				Marriott, HM; Ali, F; Read, RC; Mitchell, TJ; Whyte, MKB; Dockrell, DH			Nitric oxide levels regulate macrophage commitment to apoptosis or necrosis during pneumococcal infection	FASEB JOURNAL			English	Article						programmed cell death; human; monocytes	PERMEABILITY TRANSITION PORE; NADPH PHAGOCYTE OXIDASE; MYCOBACTERIUM-TUBERCULOSIS; STREPTOCOCCUS-PNEUMONIAE; MURINE MACROPHAGES; IN-VITRO; EXPERIMENTAL SALMONELLOSIS; PERITONEAL-MACROPHAGES; ANTIMICROBIAL ACTIONS; ALVEOLAR MACROPHAGES	Macrophages are resistant to constitutive apoptosis, but infectious stimuli can induce either microbial or host-mediated macrophage apoptosis. Phagocytosis and killing of opsonized pneumococci by macrophages are potent stimuli for host-mediated apoptosis, but the link between pneumococcal killing and apoptosis induction remains undefined. We now show phagocytosis of pneumococci by differentiated human monocyte-derived macrophages (MDM) results in up-regulation of inducible nitric oxide synthase ( iNOS) and increased production of NO and reactive nitrogen species. NO accumulation in macrophages initiates an apoptotic program that involves NO-dependent mitochondrial membrane permeabilization, Mcl-1 downregulation, and caspase activation and results in nuclear condensation and fragmentation. An inhibitor of mitochondrial permeability transition, bongkrekic acid, decreases pneumococcal-associated macrophage apoptosis. Conversely, inhibition of NO production using iNOS inhibitors decreases bacterial killing and shifts the cell death program from apoptosis to necrosis. Pneumolysin contributes to both NO production and apoptosis induction. After initial microbial killing, NO accumulation switches the macrophage phenotype from an activated cell to a cell susceptible to apoptosis. These results illustrate important roles for NO in the integration of host defense and regulation of inflammation in human macrophages.	Univ Sheffield, Sch Med & Biomed Sci, Div Genom Med, Sheffield, S Yorkshire, England; Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow, Lanark, Scotland	University of Sheffield; University of Glasgow	Dockrell, DH (corresponding author), Univ Sheffield, Sch Med, Div Genom Med, F Floor,Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	d.h.dockrell@sheffield.ac.uk	Whyte, Moira/E-6210-2010	Marriott, Helen/0000-0003-1070-0054; Read, Robert/0000-0002-4297-6728; Dockrell, David/0000-0002-2718-4861; Mitchell, Timothy/0000-0002-8309-5556				Ali F, 2003, J INFECT DIS, V188, P1119, DOI 10.1086/378675; Banick PD, 1997, J CELL PHYSIOL, V172, P12, DOI 10.1002/(SICI)1097-4652(199707)172:1<12::AID-JCP2>3.0.CO;2-G; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Bergeron Y, 1999, ANTIMICROB AGENTS CH, V43, P2283, DOI 10.1128/AAC.43.9.2283; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Braun JS, 1999, INFECT IMMUN, V67, P3750, DOI 10.1128/IAI.67.8.3750-3756.1999; Braun JS, 2002, J CLIN INVEST, V109, P19; Broillet MC, 2001, FEBS LETT, V491, P227, DOI 10.1016/S0014-5793(01)02206-2; Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582; Coakley RJ, 2002, BLOOD, V100, P3383, DOI 10.1182/blood.V100.9.3383; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Darwin KH, 2003, SCIENCE, V302, P1963, DOI 10.1126/science.1091176; Dockrell DH, 2003, J IMMUNOL, V171, P5380, DOI 10.4049/jimmunol.171.10.5380; Dockrell DH, 2001, J INFECT DIS, V184, P713, DOI 10.1086/323084; DUMAREY CH, 1994, J LEUKOCYTE BIOL, V56, P36, DOI 10.1002/jlb.56.1.36; Ehrt S, 2001, J EXP MED, V194, P1123, DOI 10.1084/jem.194.8.1123; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; Gantt KR, 2001, J IMMUNOL, V167, P893, DOI 10.4049/jimmunol.167.2.893; Gao LY, 2000, TRENDS MICROBIOL, V8, P306, DOI 10.1016/S0966-842X(00)01784-4; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Gordon SB, 2000, INFECT IMMUN, V68, P2286, DOI 10.1128/IAI.68.4.2286-2293.2000; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Heinloth A, 2002, ATHEROSCLEROSIS, V162, P93, DOI 10.1016/S0021-9150(01)00687-6; Hortelano S, 2003, J IMMUNOL, V171, P6059, DOI 10.4049/jimmunol.171.11.6059; Hortelano S, 1999, FASEB J, V13, P2311, DOI 10.1096/fasebj.13.15.2311; Keane J, 1997, INFECT IMMUN, V65, P298, DOI 10.1128/IAI.65.1.298-304.1997; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Kolb H, 1998, IMMUNOL TODAY, V19, P556, DOI 10.1016/S0167-5699(98)01366-8; Lacza Z, 2003, FREE RADICAL BIO MED, V35, P1217, DOI 10.1016/S0891-5849(03)00510-0; Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7; Liu HT, 2001, J EXP MED, V194, P113, DOI 10.1084/jem.194.2.113; Liu LM, 1999, CELL DEATH DIFFER, V6, P937, DOI 10.1038/sj.cdd.4400578; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Mastroeni P, 2000, J EXP MED, V192, P237, DOI 10.1084/jem.192.2.237; MOLLOY A, 1994, J EXP MED, V180, P1499, DOI 10.1084/jem.180.4.1499; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; NATHAN C, 1995, CELL, V82, P873, DOI 10.1016/0092-8674(95)90019-5; Nicholson S, 1996, J EXP MED, V183, P2293, DOI 10.1084/jem.183.5.2293; Oddo M, 1998, J IMMUNOL, V160, P5448; Orman KL, 1998, J INFECT DIS, V178, P1649, DOI 10.1086/314526; REILING N, 1994, EUR J IMMUNOL, V24, P1941, DOI 10.1002/eji.1830240836; Rijneveld AW, 2002, J INFECT DIS, V185, P91, DOI 10.1086/338122; Rojas M, 1997, J IMMUNOL, V159, P1352; Sato E, 2000, J BIOL CHEM, V275, P10826, DOI 10.1074/jbc.275.15.10826; Schaible UE, 2003, NAT MED, V9, P1039, DOI 10.1038/nm906; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471, DOI 10.1164/ajrccm/141.2.471; Sly LM, 2003, J IMMUNOL, V170, P430, DOI 10.4049/jimmunol.170.1.430; Stevanin TM, 2002, INFECT IMMUN, V70, P4399, DOI 10.1128/IAI.70.8.4399-4405.2002; Suzuki N, 2002, J BIOL CHEM, V277, P47, DOI 10.1074/jbc.M108195200; TUOMANEN EI, 1995, NEW ENGL J MED, V332, P1280, DOI 10.1056/NEJM199505113321907; Ulett GC, 2003, J INFECT DIS, V188, P1049, DOI 10.1086/378202; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; Vazquez-Torres A, 2000, J EXP MED, V192, P227, DOI 10.1084/jem.192.2.227; VODOVOTZ Y, 1995, J IMMUNOL, V154, P2914; Webb JL, 2001, INFECT IMMUN, V69, P6391, DOI 10.1128/IAI.69.10.6391-6400.2001; WEINBERG JB, 1995, BLOOD, V86, P1184; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zanella B, 2002, BIOCHEM BIOPH RES CO, V290, P1010, DOI 10.1006/bbrc.2001.6284; Zhang X, 2002, J BIOL CHEM, V277, P48472, DOI 10.1074/jbc.M209130200; Zychlinsky A, 1997, J CLIN INVEST, V100, P493, DOI 10.1172/JCI119557	63	96	101	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2004	18	7					1126	+		10.1096/fj.03-1450fje	http://dx.doi.org/10.1096/fj.03-1450fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132983				2022-12-25	WOS:000221883200018
J	Bluher, M; Patti, ME; Gesta, S; Kahn, BB; Kahn, CR				Bluher, M; Patti, ME; Gesta, S; Kahn, BB; Kahn, CR			Intrinsic heterogeneity in adipose tissue of fat-specific insulin receptor knock-out mice is associated with differences in patterns of gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; NECROSIS-FACTOR-ALPHA; SKELETAL-MUSCLE; DIABETIC MICE; TNF-ALPHA; OBESITY; METABOLISM; ADIPOGENESIS; RAT; DIFFERENTIATION	Mice with a fat-specific insulin receptor knock-out (FIRKO) have reduced adipose tissue mass, are protected against obesity, and have an extended life span. White adipose tissue of FIRKO mice is also characterized by a polarization into two major populations of adipocytes, one small (< 50 mu m) and one large (> 100 mum), which differ with regard to basal triglyceride synthesis and lipolysis, as well as in the expression of fatty acid synthase, sterol regulatory element-binding protein 1c, and CCAAT/enhancer-binding protein alpha (C/EBP-alpha). Gene expression analysis using RNA isolated from large and small adipocytes of FIRKO and control (IR lox/lox) mice was performed on oligonucleotide microarrays. Of the 12,488 genes/expressed sequence tags represented, 111 genes were expressed differentially in the four populations of adipocytes at the p < 0.001 level. These alterations exhibited 10 defined patterns and occurred in response to two distinct regulatory effects. 63 genes were identified as changed in expression depending primarily upon adipocyte size, including C/EBP-alpha, C/EBP-delta, superoxide dismutase 3, and the platelet-derived growth factor receptor. 48 genes were regulated primarily by impairment of insulin signaling, including transforming growth factor beta, interferon gamma, insulin-like growth factor I receptor, activating transcription factor 3, aldehyde dehydrogenase 2, and protein kinase C delta. These data suggest an intrinsic heterogeneity of adipocytes with differences in gene expression related to adipocyte size and insulin signaling.	Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrine, Diabet Unit, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Kahn, CR (corresponding author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.	c.ronald.kahn@joslin.harvard.edu	Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060837] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 60837, R01 DK043051, DK30136] Funding Source: Medline; PHS HHS [45935] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Alessi MC, 2000, DIABETES, V49, P1374, DOI 10.2337/diabetes.49.8.1374; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Braiman L, 1999, MOL ENDOCRINOL, V13, P2002, DOI 10.1210/me.13.12.2002; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; CUSHMAN SW, 1978, J LIPID RES, V19, P269; ETHERTON TD, 1977, J LIPID RES, V18, P552; FRIEDMAN SL, 1989, J CLIN INVEST, V84, P1780, DOI 10.1172/JCI114362; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Joffe BI, 2001, LANCET, V357, P1379, DOI 10.1016/S0140-6736(00)04616-X; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; REBUFFESCRIVE M, 1989, METABOLISM, V38, P453, DOI 10.1016/0026-0495(89)90198-4; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; Samad F, 1999, P NATL ACAD SCI USA, V96, P6902, DOI 10.1073/pnas.96.12.6902; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; SPIEGELMAN BM, 1993, J BIOL CHEM, V268, P6823; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Suzawa M, 2003, NAT CELL BIOL, V5, P224, DOI 10.1038/ncb942; Tomlinson JW, 2001, ENDOCRINOLOGY, V142, P1982, DOI 10.1210/en.142.5.1982; TOZZO E, 1995, AM J PHYSIOL-ENDOC M, V268, pE956, DOI 10.1152/ajpendo.1995.268.5.E956; Tozzo E, 1997, ENDOCRINOLOGY, V138, P1604, DOI 10.1210/en.138.4.1604; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Vaziri C, 1996, J BIOL CHEM, V271, P13642, DOI 10.1074/jbc.271.23.13642; Waite KJ, 2001, J BIOL CHEM, V276, P7062, DOI 10.1074/jbc.M007894200; Wang SP, 2001, OBES RES, V9, P119, DOI 10.1038/oby.2001.15; Xu HY, 2002, DIABETES, V51, P1876, DOI 10.2337/diabetes.51.6.1876; Yechoor VK, 2002, P NATL ACAD SCI USA, V99, P10587, DOI 10.1073/pnas.142301999	31	71	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31891	31901		10.1074/jbc.M404569200	http://dx.doi.org/10.1074/jbc.M404569200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15131119	hybrid			2022-12-25	WOS:000222726800116
J	Kato, Y; Nagata, K; Takahashi, M; Lian, LB; Herrero, JJ; Sudol, M; Tanokura, M				Kato, Y; Nagata, K; Takahashi, M; Lian, LB; Herrero, JJ; Sudol, M; Tanokura, M			Common mechanism of ligand recognition by group II/III WW domains - Redefining their functional classification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH LIGANDS; AMYLOID PRECURSOR PROTEIN; SURFACE-PLASMON RESONANCE; SH3 DOMAINS; STRUCTURAL BASIS; PEPTIDE LIGANDS; BINDING; SPECIFICITY; PROFILIN; COMPLEX	WW domain is a well known protein module that mediates protein to protein interactions by binding to proline-containing ligands. Based on the ligand predilections, the WW domains have been classified into four major groups. Group II and III WW domains have been reported to bind the proline-leucine and proline-arginine motifs, respectively. In the present study, using surface plasmon resonance technique we have shown that these WW domains have almost indistinguishable ligand preferences and kinetic properties. Hence, we propose that Group II and III WW domains should be joined together as one group ( Group II/III). Unlike Group I and IV WW domains, Group II/III WW domains can bind simple polyprolines as well as the proline-leucine and proline-arginine motifs, and they possess two Xaa-proline (where Xaa is any amino acid) binding grooves similar to SH3 domains. Our work assigns Group II and III WW domains to a larger family of polyproline-binding modules and proteins, which includes SH3 domains and profilin. Because polyprolines belong to the most frequently found peptide motifs in several genomes, our study implies the versatile importance of Group II/III WW domains in signaling.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan; AxCell Biosci, Newtown, PA 18940 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	University of Tokyo; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Tanokura, M (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	amtanok@mail.ecc.u-tokyo.ac.jp		Tanokura, Masaru/0000-0001-5072-2480; Nagata, Koji/0000-0002-4704-0603	NIDDK NIH HHS [DK62345] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK062345] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aasland R, 2002, FEBS LETT, V513, P141, DOI 10.1016/S0014-5793(01)03295-1; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Creamer TP, 1998, PROTEINS, V33, P218, DOI 10.1002/(SICI)1097-0134(19981101)33:2<218::AID-PROT6>3.0.CO;2-E; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Espanel X, 1999, J BIOL CHEM, V274, P17284, DOI 10.1074/jbc.274.24.17284; Faber PW, 1998, HUM MOL GENET, V7, P1463, DOI 10.1093/hmg/7.9.1463; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hu H, 2004, PROTEOMICS, V4, P643, DOI 10.1002/pmic.200300632; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Kato Y, 2002, J BIOL CHEM, V277, P10173, DOI 10.1074/jbc.M110490200; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Komuro A, 1999, J BIOL CHEM, V274, P36513, DOI 10.1074/jbc.274.51.36513; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LEMMON MA, 1994, J BIOL CHEM, V269, P31653; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Linn H, 1997, BIOL CHEM, V378, P531, DOI 10.1515/bchm.1997.378.6.531; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Mahoney NM, 1999, NAT STRUCT BIOL, V6, P666, DOI 10.1038/10722; Mahoney NM, 1997, NAT STRUCT BIOL, V4, P953, DOI 10.1038/nsb1197-953; Marinaro JA, 1999, FEBS LETT, V450, P240, DOI 10.1016/S0014-5793(99)00499-8; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Oda M, 1999, FEBS LETT, V454, P288, DOI 10.1016/S0014-5793(99)00833-9; Petrella EC, 1996, BIOCHEMISTRY-US, V35, P16535, DOI 10.1021/bi961498d; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Sudol M, 2001, FEBS LETT, V490, P190, DOI 10.1016/S0014-5793(01)02122-6; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Tanahashi H, 1999, BIOCHEM BIOPH RES CO, V258, P385, DOI 10.1006/bbrc.1999.0639; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Xu GM, 2002, GENOMICS, V79, P87, DOI 10.1006/geno.2001.6684; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zarrinpar A, 2000, NAT STRUCT BIOL, V7, P611, DOI 10.1038/77891; ZARRINPAR A, 2003, SCI STKE, V179, P1	47	58	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31833	31841		10.1074/jbc.M404719200	http://dx.doi.org/10.1074/jbc.M404719200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15133021	hybrid			2022-12-25	WOS:000222726800110
J	Chang, WC; Parekh, AB				Chang, WC; Parekh, AB			Close functional coupling between Ca2+ release-activated Ca2+ channels, arachidonic acid release, and leukotriene C-4 secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; CURRENT I-CRAC; PHOSPHOLIPASE A(2); CALCIUM CURRENT; ADENYLYL CYCLASES; ENTRY; 5-LIPOXYGENASE; DEPLETION; TRANSLOCATION; INACTIVATION	In non-excitable cells, one major route for Ca2+ influx is through store-operated Ca2+ channels in the plasma membrane. These channels are activated by the emptying of intracellular Ca2+ stores, and in some cell types, particularly of hemopoietic origin, store-operated influx occurs through Ca2+ release-activated Ca2+ (CRAC) channels. However, little is known about the downstream consequences of CRAC channel activation. Here, we report that Ca2+ entry through CRAC channels stimulates arachidonic acid production, whereas Ca2+ release from the stores is ineffective even though the latter evokes a robust intracellular Ca2+ signal. We find that arachidonic acid released by Ca2+ entering through CRAC channels is used to synthesize the potent paracrine pro-inflammatory signal leukotriene C-4 (LTC4). Both pharmacological inhibitors of CRAC channels and mitochondrial depolarization, which impairs CRAC channel activity, suppress arachidonic acid release and LTC4 secretion. Thus, arachidonic acid release is preferentially stimulated by elevated subplasmalemmal Ca2+ levels due to open CRAC channels, suggesting that the enzyme is located close to the CRAC channels. Our results also identify a novel role for CRAC channels, namely the activation of a downstream signal transduction pathway resulting in the secretion of LTC4. Finally, mitochondria are key determinants of the generation of both intracellular ( arachidonic acid) and paracrine ( LTC4) signals through their effects on CRAC channel activity.	Univ Oxford, Lab Cellular & Mol Signalling, Dept Physiol, Oxford OX1 3PT, England	University of Oxford	Parekh, AB (corresponding author), Univ Oxford, Lab Cellular & Mol Signalling, Dept Physiol, Parks Rd, Oxford OX1 3PT, England.	anant.parekh@physiol.ox.ac.uk		Chang, Wei-Chiao/0000-0002-8573-5924	Medical Research Council [G0200218] Funding Source: Medline; MRC [G0200218] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Artalejo AR, 1998, PFLUG ARCH EUR J PHY, V436, P934, DOI 10.1007/PL00008088; Bakowski D, 2001, J PHYSIOL-LONDON, V532, P55, DOI 10.1111/j.1469-7793.2001.0055g.x; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Cooper DMF, 2003, BIOCHEM J, V375, P517, DOI 10.1042/BJ20031061; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Hammarberg T, 1999, BIOCHEMISTRY-US, V38, P4441, DOI 10.1021/bi9824700; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Hart PH, 2001, IMMUNOL CELL BIOL, V79, P149, DOI 10.1046/j.1440-1711.2001.00983.x; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Hoth M, 2000, P NATL ACAD SCI USA, V97, P10607, DOI 10.1073/pnas.180143997; KHAN WA, 1995, CELL SIGNAL, V7, P171, DOI 10.1016/0898-6568(94)00089-T; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; LUO D, 2001, J BIOL CHEM, V274, P31174; Mignen O, 2003, J BIOL CHEM, V278, P40088, DOI 10.1074/jbc.M306365200; Mignen O, 2003, J BIOL CHEM, V278, P10174, DOI 10.1074/jbc.M212536200; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; Parekh AB, 2003, J PHYSIOL-LONDON, V547, P333, DOI 10.1113/jphysiol.2002.034140; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Smani T, 2003, J BIOL CHEM, V278, P11909, DOI 10.1074/jbc.M210878200; UEDA N, 1986, J BIOL CHEM, V261, P7982; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Werz Oliver, 2002, Current Drug Targets - Inflammation and Allergy, V1, P23, DOI 10.2174/1568010023344959; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	35	76	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29994	29999		10.1074/jbc.M403969200	http://dx.doi.org/10.1074/jbc.M403969200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15133023	hybrid			2022-12-25	WOS:000222531900017
J	Kulkarni, S; Jackson, SP				Kulkarni, S; Jackson, SP			Platelet factor XIII and calpain negatively regulate integrin alpha(IIb)beta(3) adhesive function and thrombus growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN IIB-IIIA; CYTOPLASMIC DOMAIN; BINDING PROTEIN; CALCIUM SIGNALS; PROCOAGULANT ACTIVITY; STIMULATED PLATELETS; BETA(3) SUBUNIT; CLEAVAGE; AGGREGATION; ACTIVATION	Excessive accumulation of platelets at sites of atherosclerotic plaque rupture leads to the development of arterial thrombi, precipitating clinical events such as the acute coronary syndromes and ischemic stroke. The major platelet adhesion receptor glycoprotein (GP) IIb-IIIa (integrin alpha(IIb)beta(3)) plays a central role in this process by promoting platelet aggregation and thrombus formation. We demonstrate here a novel mechanism down-regulating integrin alpha(IIb)beta(3) adhesive function, involving platelet factor XIII (FXIII) and calpain, which serves to limit platelet aggregate formation and thrombus growth. This mechanism principally occurs in collagen-adherent platelets and is induced by prolonged elevations in cytosolic calcium, leading to dramatic changes in platelet morphology (membrane contraction, fragmentation, and microvesiculation) and a specific reduction in integrin alpha(IIb)beta(3) adhesive function. Adhesion receptor signal transduction plays a major role in the process by sustaining cytosolic calcium flux necessary for calpain and FXIII activation. Analysis of thrombus formation on a type I fibrillar collagen substrate revealed an important role for FXIII and calpain in limiting platelet recruitment into developing aggregates, thereby leading to reduced thrombus formation. These studies define a previously unidentified role for platelet FXIII and calpain in regulating integrin alpha(IIb)beta(3) adhesive function. Moreover, they demonstrate the existence of an autoregulatory feedback mechanism that serves to limit excessive platelet accumulation on highly reactive thrombogenic surfaces.	Box Hill Hosp, Monash Med Sch, Dept Med, Australian Ctr Blood Dis, Box Hill, Vic 3128, Australia	Box Hill Hospital; Monash University	Jackson, SP (corresponding author), Monash Univ, Dept Med, Australian Ctr Blood Dis, Level 5 Clive Ward Bldg,Arnold St, Box Hill, Vic 3128, Australia.	shaun.jackson@med.monash.edu.au		Jackson, Shaun/0000-0002-4750-1991				ARFORS KE, 1968, BRIT MED J, V4, P430, DOI 10.1136/bmj.4.5628.430; ARFORS KE, 1968, BRIT J SURG, V55, P858; Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001; BAUMGARTNER HR, 1973, MICROVASC RES, V5, P167, DOI 10.1016/0026-2862(73)90069-1; Bhatt DL, 2003, NAT REV DRUG DISCOV, V2, P15, DOI 10.1038/nrd985; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; COHEN I, 1981, BIOCHIM BIOPHYS ACTA, V676, P137, DOI 10.1016/0304-4165(81)90181-1; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; COX AD, 1994, BLOOD, V83, P1006, DOI 10.1182/blood.V83.4.1006.bloodjournal8341006; Cranmer SL, 1999, J BIOL CHEM, V274, P6097, DOI 10.1074/jbc.274.10.6097; Dale GL, 2002, NATURE, V415, P175, DOI 10.1038/415175a; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; FOX JEB, 1990, BLOOD, V76, P2510; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1991, J BIOL CHEM, V266, P13289; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Goncalves I, 2003, J BIOL CHEM, V278, P34812, DOI 10.1074/jbc.M306504200; Heemskerk JWM, 1997, BLOOD, V90, P2615, DOI 10.1182/blood.V90.7.2615.2615_2615_2625; Huang C, 1997, J BIOL CHEM, V272, P19248, DOI 10.1074/jbc.272.31.19248; Jackson SP, 2003, J THROMB HAEMOST, V1, P1602, DOI 10.1046/j.1538-7836.2003.00267.x; Kulkarni S, 2000, J CLIN INVEST, V105, P783, DOI 10.1172/JCI7569; Mazzucato M, 2002, BLOOD, V100, P2793, DOI 10.1182/blood-2002-02-0514; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; Meredith J, 1998, J BIOL CHEM, V273, P19525, DOI 10.1074/jbc.273.31.19525; Muszbek L, 1996, CRIT REV CL LAB SCI, V33, P357, DOI 10.3109/10408369609084691; Nesbitt WS, 2003, J CELL BIOL, V160, P1151, DOI 10.1083/jcb.200207119; Nesbitt WS, 2002, J BIOL CHEM, V277, P2965, DOI 10.1074/jbc.M110070200; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; ODA A, 1993, J BIOL CHEM, V268, P12603; OLLGAARD E, 1961, THROMB DIATH HAEMOST, V6, P86; Pfaff M, 1999, FEBS LETT, V460, P17, DOI 10.1016/S0014-5793(99)01250-8; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Ruggeri ZM, 1999, BLOOD, V94, P172, DOI 10.1182/blood.V94.1.172.413k17_172_178; Ruggeri ZM, 1997, THROMB HAEMOSTASIS, V78, P611; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; SAKARIASSEN KS, 1986, BRIT J HAEMATOL, V63, P681, DOI 10.1111/j.1365-2141.1986.tb07552.x; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P1694, DOI 10.1074/jbc.272.3.1694; Schoenwaelder SM, 2000, PLATELETS, V11, P189; TRANZER JP, 1968, EXP BIOL MED, V3, P80; WALKER JH, 1992, BIOCHEM SOC T, V20, P828, DOI 10.1042/bst0200828; WESTER J, 1978, LAB INVEST, V39, P298; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200; Yap CL, 2000, J BIOL CHEM, V275, P41377, DOI 10.1074/jbc.M005590200; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847	45	80	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30697	30706		10.1074/jbc.M403559200	http://dx.doi.org/10.1074/jbc.M403559200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131115	hybrid			2022-12-25	WOS:000222531900100
J	O'Hagan, HM; Ljungman, M				O'Hagan, HM; Ljungman, M			Nuclear accumulation of p53 following inhibition of transcription is not due to diminished levels of MDM2	ONCOGENE			English	Article						DRB; nuclear export; ubiquitylation; nucleolus	PROTEASOME-MEDIATED DEGRADATION; DAMAGE-INDUCED PHOSPHORYLATION; ATM-DEPENDENT PHOSPHORYLATION; AUTOREGULATORY FEEDBACK LOOP; RING-FINGER DOMAIN; RNA-POLYMERASE-II; DNA-DAMAGE; TUMOR-SUPPRESSOR; DOWN-REGULATION; UV-RADIATION	A common mechanism by which the tumor suppressor p53 accumulates in the nucleus following cellular stress is through the attenuation of its interaction with MDM2, a protein involved in the nuclear export and degradation of p53. This is accomplished by induced modifications of p53, MDM2 or both. We have previously found that the kinase and mRNA synthesis inhibitor DRB (5,6-dichloro-1-b-D-ribofuranosylbenzimidazole) induces the nuclear accumulation of p53 without concomitant phosphorylation of the ser15 site of p53, which is thought to be a modification important for the attenuation of p53-MDM2 interaction. It has been proposed that the mechanism by which p53 accumulates following blockage of transcription involves the downregulation of MDM2 expression. In this study, we tested this hypothesis and found that after DRB treatment, p53 accumulated despite the fact that MDM2 levels remained high in human cells. Furthermore, over expression of MDM2 did not prevent the accumulation of p53 following DRB treatment. In, addition, p53 accumulating in the nucleus after DRB treatment was able to interact with MDM2 and was ubiquitylated. These findings suggest that blockage of transcription induce the nuclear accumulation of p53 without breaking the p53-MDM2 regulation loop.	Univ Michigan, Sch Med,Div Radiat & Canc Biol, Dept Radiat Oncol, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Environm Hlth Sci, Sch Publ Hlth, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ljungman, M (corresponding author), Univ Michigan, Sch Med,Div Radiat & Canc Biol, Dept Radiat Oncol, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA.	ljungman@umich.edu		O'Hagan, Heather/0000-0001-9750-5088	NATIONAL CANCER INSTITUTE [R01CA082376] Funding Source: NIH RePORTER; NCI NIH HHS [CA 82376] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arriola EL, 1999, ONCOGENE, V18, P1081, DOI 10.1038/sj.onc.1202391; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen LH, 1999, MOL MED, V5, P21, DOI 10.1007/BF03402136; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; David-Pfeuty T, 2001, ONCOGENE, V20, P5951, DOI 10.1038/sj.onc.1204741; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Inoue T, 2001, FEBS LETT, V490, P196, DOI 10.1016/S0014-5793(01)02123-8; Joseph TW, 2003, FASEB J, V17, P1622, DOI 10.1096/fj.02-0931com; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; KASTAN MB, 1991, CANCER RES, V51, P6304; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Klibanov SA, 2001, J CELL SCI, V114, P1867; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Latonen L, 2003, CELL SIGNAL, V15, P95, DOI 10.1016/S0898-6568(02)00044-X; LEACH FS, 1993, CANCER RES, V53, P2231; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Ljungman M, 2001, ONCOGENE, V20, P5964, DOI 10.1038/sj.onc.1204734; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; O'Hagan HM, 2004, MUTAT RES-FUND MOL M, V546, P7, DOI 10.1016/j.mrfmmm.2003.10.003; OHAGAN HM, IN PRESS EXP CELL RE; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; SCHEER U, 1984, J CELL BIOL, V99, P672, DOI 10.1083/jcb.99.2.672; SCHEER U, 1990, BIOESSAYS, V12, P14, DOI 10.1002/bies.950120104; Schneiderhan N, 2003, ONCOGENE, V22, P2857, DOI 10.1038/sj.onc.1206431; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shinozaki T, 2003, ONCOGENE, V22, P8870, DOI 10.1038/sj.onc.1207176; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Yu ZK, 2000, ONCOGENE, V19, P5892, DOI 10.1038/sj.onc.1203980; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	64	34	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5505	5512		10.1038/sj.onc.1207709	http://dx.doi.org/10.1038/sj.onc.1207709			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15094782				2022-12-25	WOS:000222588400010
J	Bae, E; Phillips, GN				Bae, E; Phillips, GN			Structures and analysis of highly homologous psychrophilic, mesophilic, and thermophilic adenylate kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD ADAPTATION; EXTREME ENVIRONMENTS; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURES; STABILITY; ENZYMES; PROTEIN; ZINC; THERMOSTABILITY; DEHYDROGENASE	The crystal structures of adenylate kinases from the psychrophile Bacillus globisporus and the mesophile Bacillus subtilis have been solved and compared with that from the thermophile Bacillus stearothermophilus. This is the first example we know of where a trio of protein structures has been solved that have the same number of amino acids and a high level of identity (66 - 74%) and yet come from organisms with different operating temperatures. The enzymes were characterized for their own thermal denaturation and inactivation, and they exhibited the same temperature preferences as their source organisms. The structures of the three highly homologous, dynamic proteins with different temperature-activity profiles provide an opportunity to explore a molecular mechanism of cold and heat adaptation. Their analysis suggests that the maintenance of the balance between stability and flexibility is crucial for proteins to function at their environmental temperatures, and it is achieved by the modification of intramolecular interactions in the process of temperature adaptation.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Phillips, GN (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	phillips@biochem.wisc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013790] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR 13790, RR 07707] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aghajari N, 1998, STRUCTURE, V6, P1503, DOI 10.1016/S0969-2126(98)00149-X; Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; Berry MB, 1998, PROTEIN-STRUCT FUNCT, V32, P275; Boyer P.D, 1973, ENZYMES, P279; Bruins ME, 2001, APPL BIOCHEM BIOTECH, V90, P155, DOI 10.1385/ABAB:90:2:155; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruns CM, 1999, J MOL BIOL, V288, P427, DOI 10.1006/jmbi.1999.2697; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Claus D., 1986, BERGEYS MANUAL SYSTE, P1105, DOI DOI 10.1016/0922-338X(92)90270-5; Criswell AR, 2003, J MOL BIOL, V330, P1087, DOI 10.1016/S0022-2836(03)00655-7; D'Amico S, 2003, J BIOL CHEM, V278, P7891, DOI 10.1074/jbc.M212508200; D'Amico S, 2002, PHILOS T R SOC B, V357, P917, DOI 10.1098/rstb.2002.1105; Deming JW, 2002, CURR OPIN MICROBIOL, V5, P301, DOI 10.1016/S1369-5274(02)00329-6; Demirjian DC, 2001, CURR OPIN CHEM BIOL, V5, P144, DOI 10.1016/S1367-5931(00)00183-6; Elcock AH, 1998, J MOL BIOL, V284, P489, DOI 10.1006/jmbi.1998.2159; Fields PA, 2001, COMP BIOCHEM PHYS A, V129, P417, DOI 10.1016/S1095-6433(00)00359-7; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; Gianese G, 2002, PROTEINS, V47, P236, DOI 10.1002/prot.10084; GILLES AM, 1994, J BACTERIOL, V176, P520, DOI 10.1128/JB.176.2.520-523.1994; GLASER P, 1992, BIOCHEMISTRY-US, V31, P3038, DOI 10.1021/bi00127a002; HENSEL R, 1988, FEMS MICROBIOL LETT, V49, P75, DOI 10.1111/j.1574-6968.1988.tb02685.x; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; Jamrog DC, 2003, ACTA CRYSTALLOGR D, V59, P304, DOI 10.1107/S0907444902021935; Kim SY, 1999, J BIOL CHEM, V274, P11761, DOI 10.1074/jbc.274.17.11761; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lonhienne T, 2000, BBA-PROTEIN STRUCT M, V1543, P1, DOI 10.1016/S0167-4838(00)00210-7; Martins LO, 1996, J BACTERIOL, V178, P5644, DOI 10.1128/jb.178.19.5644-5651.1996; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; Muller CW, 1996, STRUCTURE, V4, P147, DOI 10.1016/S0969-2126(96)00018-4; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perl D, 2000, NAT STRUCT BIOL, V7, P380; PERRIER V, 1994, BIOCHEMISTRY-US, V33, P9960, DOI 10.1021/bi00199a019; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612; Rayment I, 2002, STRUCTURE, V10, P147, DOI 10.1016/S0969-2126(02)00711-6; Rothschild LJ, 2001, NATURE, V409, P1092, DOI 10.1038/35059215; Russell NJ, 2000, EXTREMOPHILES, V4, P83, DOI 10.1007/s007920050141; SCHULZ GE, 1987, COLD SPRING HARB SYM, V52, P429, DOI 10.1101/SQB.1987.052.01.050; Sheridan PP, 2000, BBA-PROTEIN STRUCT M, V1543, P417, DOI 10.1016/S0167-4838(00)00237-5; Shi ZS, 2002, BIOCHEMISTRY-US, V41, P2120, DOI 10.1021/bi011307t; SMALAS AO, 1994, PROTEINS, V20, P149, DOI 10.1002/prot.340200205; Szilagyi A, 2000, STRUCTURE, V8, P493, DOI 10.1016/S0969-2126(00)00133-7; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P2597, DOI 10.1021/bi951988q; Thomas T, 2000, J BACTERIOL, V182, P1328, DOI 10.1128/JB.182.5.1328-1332.2000; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsai CJ, 2002, CRIT REV BIOCHEM MOL, V37, P55, DOI 10.1080/10409230290771456; Van Petegem F, 2003, J BIOL CHEM, V278, P7531, DOI 10.1074/jbc.M206862200; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; VONRHEIN C, 1995, STRUCTURE, V3, P483, DOI 10.1016/S0969-2126(01)00181-2; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V	50	166	169	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28202	28208		10.1074/jbc.M401865200	http://dx.doi.org/10.1074/jbc.M401865200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15100224	hybrid			2022-12-25	WOS:000222265400049
J	Betz, C; Schlenstedt, G; Bailer, SM				Betz, C; Schlenstedt, G; Bailer, SM			Asr1p, a novel yeast ring/PHD finger protein, signals alcohol stress to the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; SACCHAROMYCES-CEREVISIAE; NUCLEOCYTOPLASMIC TRANSPORT; TRANSCRIPTION FACTORS; ETHANOL STRESS; BUDDING YEAST; ENVIRONMENTAL-CHANGES; OXIDATIVE STRESS; LOCALIZATION; KINASE	During fermentation, yeast cells are exposed to increasing amounts of alcohol, which is stressful and affects both growth and viability. On the molecular level, numerous aspects of alcohol stress signaling remain unresolved. We have identified a novel yeast Ring/PHD finger protein that constitutively shuttles between nucleus and cytoplasm but accumulates in the nucleus upon exposure to ethanol, 2-propanol, or 1-butanol. Subcellular localization of this protein is not altered by osmotic, oxidative, or heat stress or during nitrogen or glucose starvation. Because of its exclusive sensitivity to environmental alcohol, the protein was called Asr1p for Alcohol Sensitive Ring/PHD finger 1 protein. Nuclear accumulation of Asr1p is rapid, reversible, and requires a functional Ran/Gsp1p gradient. Asr1p contains two N terminally located leucine-rich nuclear export sequences (NES) required for nuclear export. Consistently, it accumulates in the nucleus of xpo1-1 cells at restrictive temperature and forms a trimeric complex with the exportin Xpo1p and Ran-GTP. Deletion of ASR1 leads to sensitivity in growth on medium containing alcohol or detergent, consistent with a function of Asr1p in alcohol-related signaling. Asr1p is the first reported protein that changes its subcellular localization specifically upon exposure to alcohol and therefore represents a key element in the analysis of alcohol-responsive signaling.	Univ Saarland, D-66421 Homburg, Germany	Saarland University	Bailer, SM (corresponding author), Univ Saarland, Gebaude 44, D-66421 Homburg, Germany.	dr.susanne.bailer@med-rz.uni-saarland.de						Alepuz PM, 2001, MOL CELL, V7, P767, DOI 10.1016/S1097-2765(01)00221-0; ALEXANDRE H, 1994, FEMS MICROBIOL LETT, V124, P17, DOI 10.1016/0378-1097(94)90326-3; Alexandre H, 2001, FEBS LETT, V498, P98, DOI 10.1016/S0014-5793(01)02503-0; AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; Aranda A, 2002, ARCH MICROBIOL, V177, P304, DOI 10.1007/s00203-001-0391-1; Aravind L, 2003, CELL CYCLE, V2, P123, DOI 10.4161/cc.2.2.335; Bailer SM, 2001, MOL CELL BIOL, V21, P7944, DOI 10.1128/MCB.21.23.7944-7955.2001; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Carroll AS, 2002, TRENDS BIOCHEM SCI, V27, P87, DOI 10.1016/S0968-0004(01)02040-0; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; Damelin M, 2002, METHOD ENZYMOL, V351, P587; de Nadal E, 2002, EMBO REP, V3, P735, DOI 10.1093/embo-reports/kvf158; Elion EA, 2001, J CELL SCI, V114, P3967; Estruch F, 2000, FEMS MICROBIOL REV, V24, P469, DOI 10.1016/S0168-6445(00)00035-8; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorner M, 1999, BIOL CHEM, V380, P147; Gorner W, 2002, EMBO J, V21, P135, DOI 10.1093/emboj/21.1.135; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; James TC, 2003, J APPL MICROBIOL, V94, P432, DOI 10.1046/j.1365-2672.2003.01849.x; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1111/j.1574-6976.2002.tb00613.x; Komeili A, 2000, J CELL BIOL, V151, P863, DOI 10.1083/jcb.151.4.863; Komeili A, 2000, CURR OPIN CELL BIOL, V12, P355, DOI 10.1016/S0955-0674(00)00100-9; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Kunzler M, 2000, MOL CELL BIOL, V20, P4295, DOI 10.1128/MCB.20.12.4295-4308.2000; Lorenz MC, 2000, MOL BIOL CELL, V11, P183, DOI 10.1091/mbc.11.1.183; Maurer P, 2001, MOL BIOL CELL, V12, P539, DOI 10.1091/mbc.12.3.539; Mayordomo I, 2002, J BIOL CHEM, V277, P35650, DOI 10.1074/jbc.M204198200; O'Rourke SM, 2002, TRENDS GENET, V18, P405, DOI 10.1016/S0168-9525(02)02723-3; PIPER PW, 1995, FEMS MICROBIOL LETT, V134, P121, DOI 10.1016/0378-1097(95)00431-9; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; ROSE AH, 1993, J APPL BACTERIOL, V74, pS110, DOI 10.1111/j.1365-2672.1993.tb04347.x; Schuller Christoph, 2002, Results Probl Cell Differ, V35, P169; Schuller HJ, 2003, CURR GENET, V43, P139, DOI 10.1007/s00294-003-0381-8; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Solsbacher J, 1998, MOL CELL BIOL, V18, P6805, DOI 10.1128/MCB.18.11.6805; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Takahashi T, 2001, MOL GENET GENOMICS, V265, P1112, DOI 10.1007/s004380100510; Tamas MJ, 2000, FEBS LETT, V472, P159, DOI 10.1016/S0014-5793(00)01445-9; van Drogen F, 2002, CURR BIOL, V12, pR53, DOI 10.1016/S0960-9822(01)00672-8; Weis K, 2002, CURR OPIN CELL BIOL, V14, P328, DOI 10.1016/S0955-0674(02)00337-X; Yamaga M, 1999, J BIOL CHEM, V274, P28537, DOI 10.1074/jbc.274.40.28537	49	24	28	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28174	28181		10.1074/jbc.M401595200	http://dx.doi.org/10.1074/jbc.M401595200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117954	hybrid			2022-12-25	WOS:000222265400045
J	Guzman, M; Lo Verme, J; Fu, J; Oveisi, F; Blazquez, C; Piomelli, D				Guzman, M; Lo Verme, J; Fu, J; Oveisi, F; Blazquez, C; Piomelli, D			Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID AMIDES; CARNITINE PALMITOYLTRANSFERASE; MESSENGER-RNA; RAT; LIPOGENESIS; HEPATOCYTES; MODULATION; METABOLISM; MECHANISMS; ASTROCYTES	Amides of fatty acids with ethanolamine (FAE) are biologically active lipids that participate in a variety of biological functions, including the regulation of feeding. The polyunsaturated FAE anandamide ( arachidonoylethanolamide) increases food intake by activating G protein-coupled cannabinoid receptors. On the other hand, the monounsaturated FAE oleoylethanolamide (OEA) reduces feeding and body weight gain by activating the nuclear receptor PPAR-alpha ( peroxisome proliferator-activated receptor alpha). In the present report, we examined whether OEA can also influence energy utilization. OEA ( 1 - 20 muM) stimulated glycerol and fatty acid release from freshly dissociated rat adipocytes in a concentration-dependent and structurally selective manner. Under the same conditions, OEA had no effect on glucose uptake or oxidation. OEA enhanced fatty acid oxidation in skeletal muscle strips, dissociated hepatocytes, and primary cardiomyocyte cultures. Administration of OEA in vivo ( 5 mg kg(-1), intraperitoneally) produced lipolysis in both rats and wild-type mice, but not in mice in which PPAR-alpha had been deleted by homologous recombination (PPAR-alpha(-/-)). Likewise, OEA was unable to enhance lipolysis in adipocytes or stimulate fatty acid oxidation in skeletal muscle strips isolated from PPAR-alpha mice. The synthetic PPAR-alpha agonist Wy-14643 produced similar effects, which also were dependent on the presence of PPAR-alpha. Subchronic treatment with OEA reduced body weight gain and triacylglycerol content in liver and adipose tissue of diet-induced obese rats and wild-type mice, but not in obese PPAR-alpha(-/-) mice. The results suggest that OEA stimulates fat utilization through activation of PPAR-alpha and that this effect may contribute to its anti-obesity actions.	Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Univ Complutense, Dept Bioquim & Biol Mol 1, E-28040 Madrid, Spain	University of California System; University of California Irvine; Complutense University of Madrid	Piomelli, D (corresponding author), Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA.	piomelli@uci.edu	Fu, Jin/A-3510-2012	Guzman, Manuel/0000-0001-7475-118X				Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Berry EM, 2002, PHARMACOL THERAPEUT, V95, P185, DOI 10.1016/S0163-7258(02)00257-7; BEYNEN AC, 1979, DIABETES, V28, P828, DOI 10.2337/diabetes.28.9.828; Blazquez C, 1998, J NEUROCHEM, V71, P1597; Blazquez C, 2000, FASEB J, V14, P2315, DOI 10.1096/fj.00-0122com; Bocher Virginie, 2002, Journal de la Societe de Biologie, V196, P47; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; COLODZIN M, 1963, BIOCHEM BIOPH RES CO, V10, P165, DOI 10.1016/0006-291X(63)90044-5; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; FLINK IL, 1992, J BIOL CHEM, V267, P9917; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Fu J, 2003, NATURE, V425, P90, DOI 10.1038/nature01921; Gaetani S, 2003, NEUROPSYCHOPHARMACOL, V28, P1311, DOI 10.1038/sj.npp.1300166; Giuffrida A, 2000, ANAL BIOCHEM, V280, P87, DOI 10.1006/abio.2000.4509; GUZMAN M, 1992, BIOCHEM J, V287, P487, DOI 10.1042/bj2870487; Kersten S, 2001, EMBO REP, V2, P282, DOI 10.1093/embo-reports/kve071; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Mazzari S, 1996, EUR J PHARMACOL, V300, P227, DOI 10.1016/0014-2999(96)00015-5; Muoio DM, 1997, DIABETES, V46, P1360, DOI 10.2337/diabetes.46.8.1360; Nakatani T, 2002, J BIOL CHEM, V277, P9562, DOI 10.1074/jbc.M110132200; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; RODBELL M, 1964, J BIOL CHEM, V239, P375; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Schmid HHO, 1996, CHEM PHYS LIPIDS, V80, P133, DOI 10.1016/0009-3084(96)02554-6; SCHMID PC, 1985, J BIOL CHEM, V260, P4145; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; STRALFORS P, 1987, J BIOL CHEM, V262, P11486; Stremmel W, 2001, LIPIDS, V36, P981, DOI 10.1007/s11745-001-0809-2; SUN YX, 2004, IN PRESS BIOCH J; Ueda Hiroshi, 2002, Nihon Yakurigaku Zasshi, V119, P79; Unger RH, 2003, ANNU REV PHYSIOL, V65, P333, DOI 10.1146/annurev.physiol.65.092101.142622; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Winegar DA, 2001, J LIPID RES, V42, P1543	37	259	273	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27849	27854		10.1074/jbc.M404087200	http://dx.doi.org/10.1074/jbc.M404087200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123613	hybrid			2022-12-25	WOS:000222265400005
J	Prommeenate, P; Lennon, AM; Markert, C; Hippler, M; Nixon, PJ				Prommeenate, P; Lennon, AM; Markert, C; Hippler, M; Nixon, PJ			Subunit composition of NDH-1 complexes of Synechocystis sp PCC 6803 - Identification of two new ndh gene products with nuclear-encoded homologues in the chloroplast Ndh complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; PYRIDINE-NUCLEOTIDE DEHYDROGENASE; INORGANIC CARBON TRANSPORT; MEMBRANE-PROTEIN COMPLEXES; CYCLIC ELECTRON-TRANSPORT; SP STRAIN PCC-6803; NAD(P)H DEHYDROGENASE; RESPIRATORY COMPLEX; CO2 UPTAKE; POLYACRYLAMIDE GELS	Cyanobacteria contain several genes, annotated ndh, whose products show sequence similarities to subunits found in complex I ( NADH: ubiquinone oxidoreductase) of eubacteria and mitochondria. However, it is still unclear whether the cyanobacterial ndh gene products actually form a single large protein complex or exist as smaller independent complexes. To address this, we have constructed a strain of Synechocystis sp. PCC 6803 in which the C terminus of the NdhJ subunit was fused to an His(6) tag to aid isolation. Three major NdhJ-containing complexes were resolved by blue native polyacrylamide gel electrophoresis, with approximate apparent molecular masses of 460, 330, and 110 kDa. N-terminal sequencing and mass spectrometry revealed that the 460-kDa complex contained ten annotated ndh gene products. Detergent-induced fragmentation experiments indicated that the 460-kDa complex was composed of hydrophobic ( 150 kDa) and hydrophilic ( 110 130 kDa) modules similar to that found in the minimal form of complex I found in Escherichia coli, except that the electron input module was not conserved. The difference in size between the 460- and 330-kDa complexes is attributed to differences in the stoichiometry of the hydrophilic and hydrophobic modules in the complex, either 2: 1 or 1: 1, respectively. We have also detected the presence of two new Ndh subunits (slr1623 and sll1262) that are unrelated to subunits in the eubacterial complex I but which have homologues in the closely related chloroplast Ndh complex of maize ( Funk, E., Schafer, E., and Steinmuller, K. ( 1999) J. Plant Physiol. 154, 16 - 23). The presence of these additional subunits might reflect the use by the NDH-1 and Ndh complexes of a different, so far unidentified, electron input module.	Univ London Imperial Coll Sci Technol & Med, Wolfson Labs, Dept Biol Sci, London SW7 2AZ, England; Univ Jena, Lehrstuhl Pflanzenphysiol, D-07743 Jena, Germany	Imperial College London; Friedrich Schiller University of Jena	Nixon, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Wolfson Labs, Dept Biol Sci, S Kensington Campus, London SW7 2AZ, England.	p.nixon@imperial.ac.uk		Michael, Hippler/0000-0001-9670-6101; Nixon, Peter/0000-0003-1952-6937				Albracht SPJ, 2003, BBA-BIOENERGETICS, V1557, P41, DOI 10.1016/S0005-2728(02)00393-6; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Appel J, 1996, BBA-PROTEIN STRUCT M, V1298, P141, DOI 10.1016/S0167-4838(96)00176-8; Badger MR, 2003, J EXP BOT, V54, P609, DOI 10.1093/jxb/erg076; Baumer S, 2000, J BIOL CHEM, V275, P17968, DOI 10.1074/jbc.M000650200; BERGER S, 1991, FEBS LETT, V286, P129, DOI 10.1016/0014-5793(91)80957-5; BERGER S, 1993, FEBS LETT, V326, P246, DOI 10.1016/0014-5793(93)81800-F; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Brandt U, 2003, FEBS LETT, V545, P9, DOI 10.1016/S0014-5793(03)00387-9; Bruggemann H, 2000, EUR J BIOCHEM, V267, P5810, DOI 10.1046/j.1432-1327.2000.01657.x; Burrows PA, 1998, EMBO J, V17, P868, DOI 10.1093/emboj/17.4.868; Cooley JW, 2001, J BACTERIOL, V183, P4251, DOI 10.1128/JB.183.14.4251-4258.2001; Deng Y, 2003, PLANT CELL PHYSIOL, V44, P534, DOI 10.1093/pcp/pcg067; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Friedrich T, 1997, J THEOR BIOL, V187, P529, DOI 10.1006/jtbi.1996.0387; FRIEDRICH T, 1995, FEBS LETT, V367, P107, DOI 10.1016/0014-5793(95)00548-N; Friedrich T, 2000, FEBS LETT, V479, P1, DOI 10.1016/S0014-5793(00)01867-6; Funk E, 1999, J PLANT PHYSIOL, V154, P16, DOI 10.1016/S0176-1617(99)80312-5; GALANTE YM, 1979, ARCH BIOCHEM BIOPHYS, V192, P559, DOI 10.1016/0003-9861(79)90126-7; Guedeney G, 1996, FEBS LETT, V378, P277, DOI 10.1016/0014-5793(95)01473-X; Heazlewood JL, 2003, BBA-BIOENERGETICS, V1604, P159, DOI 10.1016/S0005-2728(03)00045-8; Herranen M, 2004, PLANT PHYSIOL, V134, P470, DOI 10.1104/pp.103.032326; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holt PJ, 2003, J BIOL CHEM, V278, P43114, DOI 10.1074/jbc.M308247200; Ito M, 1999, J BACTERIOL, V181, P2394, DOI 10.1128/JB.181.8.2394-2402.1999; Kaneko T, 1996, DNA Res, V3, P109; Kashani-Poor N, 2001, BBA-BIOENERGETICS, V1504, P363, DOI 10.1016/S0005-2728(00)00266-8; Klughammer B, 1999, MOL MICROBIOL, V32, P1305, DOI 10.1046/j.1365-2958.1999.01457.x; Mathiesen C, 2002, BBA-BIOENERGETICS, V1556, P121, DOI 10.1016/S0005-2728(02)00343-2; Matsuo M, 1998, PLANT CELL PHYSIOL, V39, P263, DOI 10.1093/oxfordjournals.pcp.a029366; MI HL, 1992, PLANT CELL PHYSIOL, V33, P1233; MI HL, 1995, PLANT CELL PHYSIOL, V36, P661; MORTZ E, 1994, BIOL MASS SPECTROM, V23, P249, DOI 10.1002/bms.1200230503; Nakamura Y, 1998, NUCLEIC ACIDS RES, V26, P63, DOI 10.1093/nar/26.1.63; Nixon PJ, 2000, PHILOS T R SOC B, V355, P1541, DOI 10.1098/rstb.2000.0714; OGAWA T, 1992, PLANT PHYSIOL, V99, P1604, DOI 10.1104/pp.99.4.1604; OGAWA T, 1991, P NATL ACAD SCI USA, V88, P4275, DOI 10.1073/pnas.88.10.4275; Ohkawa H, 2000, J BIOL CHEM, V275, P31630, DOI 10.1074/jbc.M003706200; Ohkawa H, 2000, J BACTERIOL, V182, P2591, DOI 10.1128/JB.182.9.2591-2596.2000; Ohkawa H, 2001, J BACTERIOL, V183, P4938, DOI 10.1128/JB.183.16.4938-4939.2001; Pieulle L, 2000, FEBS LETT, V487, P272, DOI 10.1016/S0014-5793(00)02369-3; Quiles MJ, 2003, PLANT SCI, V164, P541, DOI 10.1016/S0168-9452(03)00003-7; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmitz O, 1996, NATURWISSENSCHAFTEN, V83, P525; Shibata M, 2001, P NATL ACAD SCI USA, V98, P11789, DOI 10.1073/pnas.191258298; Stauber EJ, 2003, EUKARYOT CELL, V2, P978, DOI 10.1128/EC.2.5.978-994.2003; Tichy M, 2003, BBA-BIOENERGETICS, V1605, P55, DOI 10.1016/S0005-2728(03)00064-1; Wellburn A. R., 1984, Advances in photosynthesis research. Vol.II., P9; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766	54	98	112	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28165	28173		10.1074/jbc.M401107200	http://dx.doi.org/10.1074/jbc.M401107200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102833	hybrid			2022-12-25	WOS:000222265400044
J	Bierl, C; Voetsch, B; Jin, RC; Handy, DE; Loscalzo, J				Bierl, C; Voetsch, B; Jin, RC; Handy, DE; Loscalzo, J			Determinants of human plasma glutathione peroxidase (GPx-3) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL LINING FLUID; MESSENGER-RNA; NITRIC-OXIDE; SELENIUM DEFICIENCY; OXIDATIVE STRESS; HUMAN LUNG; GENE; HYDROPEROXIDE; SEQUENCE; CELLS	Plasma glutathione peroxidase (GPx-3) is a selenocysteine-containing protein with antioxidant properties. GPx-3 deficiency has been associated with cardiovascular disease and stroke. The regulation of GPx-3 expression remains largely uncharacterized, however, and we studied its transcriptional and translational determinants in a cultured cell system. In transient transfections of a renal cell line (Caki-2), the published sequence cloned upstream of a luciferase reporter gene produced minimal activity (relative luminescence (RL) = 0.6 +/- 0.4). Rapid amplification of cDNA ends was used to identify a novel transcription start site that is located 233 bp downstream (3') of the published site and that produced a >25-fold increase in transcriptional activity (RL = 16.8 +/- 1.9; p < 0.0001). Analysis of the novel GPx-3 promoter identified Sp-1- and hypoxia-inducible factor-1-binding sites, as well as the redox-sensitive metal response element and antioxidant response element. Hypoxia was identified as a strong transcriptional regulator of GPx-3 expression, in part through the presence of the hypoxia-inducible factor-1-binding site, leading to an almost 3-fold increase in expression levels after 24 h compared with normoxic conditions (normalized RL = 3.5 +/- 0.3 versus 1.2 +/- 0.1; p < 0.001). We also investigated the role of the translational cofactors tRNA(Sec), SECIS-binding protein-2, and SelD (selenophosphate synthetase D) in GPx-3 protein expression. tRNA(Sec) and SelD significantly enhanced GPx-3 expression, whereas SECIS-binding protein-2 showed a trend toward increased expression. These results demonstrate the presence of a novel functional transcription start site for the human GPx-3 gene with a promoter regulated by hypoxia, and identify unique translational determinants of GPx-3 expression.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Evans Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA	Boston University; Boston University; Boston University	Loscalzo, J (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,W507, Boston, MA 02118 USA.	jloscalz@bu.edu	Loscalzo, Joseph/ABD-8980-2021	Handy, Diane/0000-0002-4310-8527	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058976, P50HL055993, R37HL061795, R01HL061795] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58976, HL55993, HL61795] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arrigo AP, 1999, FREE RADICAL BIO MED, V27, P936, DOI 10.1016/S0891-5849(99)00175-6; Arthur JR, 2000, CELL MOL LIFE SCI, V57, P1825; Avissar N, 1996, AM J PHYSIOL-LUNG C, V270, pL173, DOI 10.1152/ajplung.1996.270.2.L173; AVISSAR N, 1991, J NUTR, V121, P1243, DOI 10.1093/jn/121.8.1243; AVISSAR N, 1994, AM J PHYSIOL, V266, pC367, DOI 10.1152/ajpcell.1994.266.2.C367; AVISSAR N, 1994, ARCH BIOCHEM BIOPHYS, V309, P239, DOI 10.1006/abbi.1994.1108; Avissar NE, 2000, AM J RESP CRIT CARE, V162, P1342, DOI 10.1164/ajrccm.162.4.9912041; Barkats M, 2000, J NEUROCHEM, V75, P1438, DOI 10.1046/j.1471-4159.2000.0751438.x; Becker LB, 1999, AM J PHYSIOL-HEART C, V277, pH2240, DOI 10.1152/ajpheart.1999.277.6.H2240; Behne D, 2001, ANNU REV NUTR, V21, P453, DOI 10.1146/annurev.nutr.21.1.453; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; BrigeliusFlohe R, 1997, BIOMED ENVIRON SCI, V10, P163; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; CHU FF, 1992, BLOOD, V79, P3233; Comhair SAA, 2000, AM J RESP CELL MOL, V23, P350, DOI 10.1165/ajrcmb.23.3.4076; Comhair SAA, 2001, FASEB J, V15, P70, DOI 10.1096/fj.00-0085com; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; Dogru-Abbasoglu S, 1999, CLIN BIOCHEM, V32, P671, DOI 10.1016/S0009-9120(99)00076-4; Flohe L, 2000, IUBMB LIFE, V49, P411; Flohe Leopold, 1997, P415; Freedman JE, 1996, J CLIN INVEST, V97, P979, DOI 10.1172/JCI118522; Holtzman Jordan L, 2002, Clin Lab, V48, P129; Kenet G, 1999, ARTERIOSCL THROM VAS, V19, P2017, DOI 10.1161/01.ATV.19.8.2017; Kim KK, 1999, PEDIATR RES, V46, P715, DOI 10.1203/00006450-199912000-00013; Kingsley PD, 1998, MOL REPROD DEV, V49, P343, DOI 10.1002/(SICI)1098-2795(199804)49:4<343::AID-MRD1>3.3.CO;2-T; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Lando D, 2003, EUR J BIOCHEM, V270, P781, DOI 10.1046/j.1432-1033.2003.03445.x; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; Lesnefsky EJ, 2003, ARCH BIOCHEM BIOPHYS, V420, P287, DOI 10.1016/j.abb.2003.09.046; Low SC, 2000, EMBO J, V19, P6882, DOI 10.1093/emboj/19.24.6882; LOW SC, 1995, J BIOL CHEM, V270, P21659, DOI 10.1074/jbc.270.37.21659; MADDIPATI KR, 1987, J BIOL CHEM, V262, P17398; Maiorino M, 2003, J BIOL CHEM, V278, P34286, DOI 10.1074/jbc.M305327200; Merante F, 2002, MOL CELL BIOCHEM, V229, P73, DOI 10.1023/A:1017921110363; Moreno SG, 2003, BIOL CHEM, V384, P635, DOI 10.1515/BC.2003.070; Moriarty PM, 1998, MOL CELL BIOL, V18, P2932, DOI 10.1128/MCB.18.5.2932; Muzakova V, 2000, PHYSIOL RES, V49, P315; Nakane T, 1998, FREE RADICAL BIO MED, V25, P504, DOI 10.1016/S0891-5849(98)00078-1; PORTER M, 1992, CLIN SCI, V83, P343, DOI 10.1042/cs0830343; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RIEDER MJ, 2003, ES15478 NIEHSSNPS DE; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Sugawara T, 2003, ANTIOXID REDOX SIGN, V5, P597, DOI 10.1089/152308603770310266; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; Takebe G, 2002, J BIOL CHEM, V277, P41254, DOI 10.1074/jbc.M202773200; Whitin JC, 2002, AM J PHYSIOL-RENAL, V283, pF20, DOI 10.1152/ajprenal.00014.2001; YOSHIMURA S, 1994, GENE, V145, P293; Yoshimura S, 1996, NEPHRON, V73, P207	49	108	116	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26839	26845		10.1074/jbc.M401907200	http://dx.doi.org/10.1074/jbc.M401907200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096516	hybrid			2022-12-25	WOS:000222120400007
J	Hughes, WE; Elgundi, Z; Huang, P; Frohman, MA; Biden, TJ				Hughes, WE; Elgundi, Z; Huang, P; Frohman, MA; Biden, TJ			Phospholipase D1 regulates secretagogue-stimulated insulin release in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; KINASE-C ACTIVATION; LYSOPHOSPHATIDIC ACID; SECRETORY GRANULES; PHOSPHATIDIC-ACID; PLASMA-MEMBRANE; ISLET CELLS; BREFELDIN-A; MAST-CELLS; D1	Phospholipase D (PLD) has been strongly implicated in the regulation of Golgi trafficking as well as endocytosis and exocytosis. Our aim was to investigate the role of PLD in regulating the biphasic exocytosis of insulin from pancreatic beta-cells that is essential for mammalian glucose homeostasis. We observed that PLD activity in MIN6 pancreatic beta-cells is closely coupled to secretion. Cellular PLD activity was increased in response to a variety of secretagogues including the nutrient glucose and the cholinergic receptor agonist carbamoylcholine. Conversely, pharmacological or hormonal inhibition of stimulated secretion reduced PLD activity. Most importantly, blockade of PLD-catalyzed phosphatidic acid formation using butan-1-ol inhibited insulin secretion in both MIN6 cells and isolated pancreatic islets. It was further established that PLD activity was required for both the first and the second phase of glucose-stimulated insulin release, suggesting a role in the very distal steps of exocytosis, beyond granule recruitment into a readily releasable pool. Visualization of granules using green fluorescent protein-phogrin confirmed a requirement for PLD prior to granule fusion with the plasma membrane. PLD1 was shown to be the predominant isoform in MIN6 cells, and it was located at least partially on insulin granules. Overexpression of wild-type or a dominant negative catalytically inactive mutant of PLD1 augmented or inhibited secretagogue-stimulated secretion, respectively. The results suggest that phosphatidic acid formation on the granule membrane by PLD1 is essential for the regulated secretion of insulin from pancreatic beta-cells.	Garvan Inst Med Res, Cell Signalling Grp, Sydney, NSW 2010, Australia; SUNY Stony Brook, Med Ctr, Dept Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Med Ctr, Ctr Dev Genet, Stony Brook, NY 11794 USA	Garvan Institute of Medical Research; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hughes, WE (corresponding author), Garvan Inst Med Res, Cell Signalling Grp, 384 Victoria St, Sydney, NSW 2010, Australia.	w.hughes@garvan.org.au	Biden, Trevor/AAW-2829-2021	Biden, Trevor/0000-0001-5211-0234; Hughes, William/0000-0002-7149-3987				Aizawa T, 2002, DIABETES, V51, pS96, DOI 10.2337/diabetes.51.2007.S96; ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; Biden TJ, 2004, DIABETES, V53, pS159, DOI 10.2337/diabetes.53.2007.S159; Brown FD, 1998, CURR BIOL, V8, P835, DOI 10.1016/S0960-9822(98)70326-4; Busch AK, 2002, DIABETES, V51, P977, DOI 10.2337/diabetes.51.4.977; Capito K, 1996, J MOL ENDOCRINOL, V17, P101, DOI 10.1677/jme.0.0170101; Chen MC, 2000, ENDOCRINOLOGY, V141, P2822, DOI 10.1210/en.141.8.2822; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Choi WS, 2002, J IMMUNOL, V168, P5682, DOI 10.4049/jimmunol.168.11.5682; Cockcroft S, 2002, MOL IMMUNOL, V38, P1277, DOI 10.1016/S0161-5890(02)00075-5; Dohke Y, 2002, BIOCHEM BIOPH RES CO, V299, P663, DOI 10.1016/S0006-291X(02)02713-4; DU G, 2004, MOL BIOL CELL; DUNLOP M, 1989, BIOCHEM BIOPH RES CO, V163, P922, DOI 10.1016/0006-291X(89)92310-3; DUNLOP M, 1992, ENDOCRINOLOGY, V130, P93, DOI 10.1210/en.130.1.93; Emoto M, 2000, J BIOL CHEM, V275, P7144, DOI 10.1074/jbc.275.10.7144; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Freyberg Z, 2001, MOL BIOL CELL, V12, P943, DOI 10.1091/mbc.12.4.943; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; GERICH JE, 1976, ANNU REV PHYSIOL, V38, P353, DOI 10.1146/annurev.ph.38.030176.002033; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; Hughes WE, 2002, J BIOL CHEM, V277, P22974, DOI 10.1074/jbc.M201391200; Hughes WE, 2001, BIOCHEM J, V356, P727, DOI 10.1042/0264-6021:3560727; Humeau Y, 2001, P NATL ACAD SCI USA, V98, P15300, DOI 10.1073/pnas.261358698; Kaldi K, 2002, J LEUKOCYTE BIOL, V71, P695; Kooijman EE, 2003, TRAFFIC, V4, P162, DOI 10.1034/j.1600-0854.2003.00086.x; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; Liscovitch M, 1999, BBA-MOL CELL BIOL L, V1439, P245, DOI 10.1016/S1388-1981(99)00098-0; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; METZ SA, 1990, BIOCHEM J, V270, P427, DOI 10.1042/bj2700427; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Morris AJ, 1997, ANAL BIOCHEM, V252, P1, DOI 10.1006/abio.1997.2299; Nie ZZ, 2003, CURR OPIN CELL BIOL, V15, P396, DOI 10.1016/S0955-0674(03)00071-1; Ohara-Imaizumi M, 2002, J BIOL CHEM, V277, P3805, DOI 10.1074/jbc.C100712200; Powner DJ, 2002, FEBS LETT, V531, P62, DOI 10.1016/S0014-5793(02)03410-5; RASMUSSEN H, 1995, ENDOCR REV, V16, P649, DOI 10.1210/er.16.5.649; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; Sarri E, 2003, BIOCHEM J, V369, P319, DOI 10.1042/BJ20021347; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Sharp GWG, 1996, AM J PHYSIOL-CELL PH, V271, pC1781, DOI 10.1152/ajpcell.1996.271.6.C1781; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Straub SG, 2002, DIABETES-METAB RES, V18, P451, DOI 10.1002/dmrr.329; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; Takenawa T, 2001, BBA-MOL CELL BIOL L, V1533, P190, DOI 10.1016/S1388-1981(01)00165-2; Tsuboi T, 2000, CURR BIOL, V10, P1307, DOI 10.1016/S0960-9822(00)00756-9; Vitale N, 2002, ANN NY ACAD SCI, V971, P193, DOI 10.1111/j.1749-6632.2002.tb04463.x; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; Wang LX, 2002, BIOCHEM J, V367, P751, DOI 10.1042/BJ20020586; Wollheim CB, 2000, DIABETOLOGIA, V43, P265, DOI 10.1007/s001250050044; WOLLHEIM CB, 1986, ANN NY ACAD SCI, V488, P317	54	71	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27534	27541		10.1074/jbc.M403012200	http://dx.doi.org/10.1074/jbc.M403012200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15087463	hybrid			2022-12-25	WOS:000222120400086
J	Le, NH; van der Bent, P; Huls, G; van de Wetering, M; Loghman-Adham, M; Ong, ACM; Calvet, JP; Clevers, H; Breuning, MH; van Dam, H; Peters, DJM				Le, NH; van der Bent, P; Huls, G; van de Wetering, M; Loghman-Adham, M; Ong, ACM; Calvet, JP; Clevers, H; Breuning, MH; van Dam, H; Peters, DJM			Aberrant polycystin-1 expression results in modification of activator protein-1 activity, whereas Wnt signaling remains unaffected	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; KIDNEY-DISEASE; C-JUN; BETA-CATENIN; GENE-PRODUCT; FUNCTIONAL POLYCYSTIN-1; E-CADHERIN; 2ND GENE; LOCALIZATION; MUTATIONS	Polycystin-1, the polycystic kidney disease 1 gene product, has been implicated in several signaling complexes that are known to regulate essential cellular functions. We investigated the role of polycystin-1 in Wnt signaling and activator protein-1 (AP-1) activation. To this aim, a membrane-targeted construct encoding the conserved C-terminal region of mouse polycystin-1 reported to mediate signal transduction activity was expressed in human embryonic and renal epithelial cells. To ensure specificity and minimal co-transfection effects, we focused our study on the endogenous proteins that actually transduce the signals, beta-catenin and T-cell factor/lymphoid-enhancing factor for Wnt signaling and (phosphorylated) c-Jun, ATF2, and c-Fos for AP-1. Our data indicate that the C-terminal region of polycystin-1 activates AP-1 by inducing phosphorylation and expression of at least c-Jun and ATF2, whereas c-Fos was not affected. Under our experimental conditions, polycystin-1 did not modulate Wnt signaling. AP-1 activity was aberrant in human autosomal dominant polycystic kidney disease (ADPKD) renal cystic epithelial cells and in renal epithelial cells expressing transgenic full-length polycystin-1, resulting in decreased Jun-ATF and increased Jun-Fos activity, whereas Wnt signaling remained unaffected. Since our data indicate that aberrant polycystin-1 expression results in altered AP-1 activity, polycystin-1 may be required for adequate AP-1 activity.	Leiden Univ, Med Ctr, Dept Human Genet, Sylvius Labs, NL-2333 AL Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2333 AL Leiden, Netherlands; Univ Utrecht, Med Ctr, Dept Immunol, NL-3508 AB Utrecht, Netherlands; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Sheffield, Sheffield Kidney Inst, Sheffield S5 7AU, S Yorkshire, England; St Louis Univ, Dept Pediat, St Louis, MO 63104 USA; St Louis Univ, Pediat Res Inst, St Louis, MO 63104 USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Utrecht University; University of Kansas; University of Kansas Medical Center; University of Sheffield; Saint Louis University; Saint Louis University	Peters, DJM (corresponding author), Leiden Univ, Med Ctr, Dept Human Genet, Sylvius Labs, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.	D.J.M.Peters@lumc.nl	Peters, Dorien/AFH-8507-2022; Ong, Albert/AAN-9430-2021; Huls, G.A./L-4398-2015; Breuning, Martijn H/E-3429-2010	Peters, Dorien/0000-0001-6974-7143; Ong, Albert/0000-0002-7211-5400; van Dam, Hans/0000-0002-8307-4325				Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Bhunia AK, 2002, CELL, V109, P157, DOI 10.1016/S0092-8674(02)00716-X; Duyndam MCA, 1999, ONCOGENE, V18, P2311, DOI 10.1038/sj.onc.1202584; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966; Huan YH, 1999, J CLIN INVEST, V104, P1459, DOI 10.1172/JCI5111; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; Kugoh H, 2002, MOL CARCINOGEN, V33, P131, DOI 10.1002/mc.10034; Loghman-Adham M, 2003, AM J PHYSIOL-RENAL, V285, pF397, DOI 10.1152/ajprenal.00310.2002; Lohning C, 1997, MAMM GENOME, V8, P307, DOI 10.1007/s003359900429; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Moser M, 2003, LAB INVEST, V83, P571, DOI 10.1097/01.LAB.0000064703.92382.50; Muto S, 2002, HUM MOL GENET, V11, P1731, DOI 10.1093/hmg/11.15.1731; Newby LJ, 2002, J BIOL CHEM, V277, P20763, DOI 10.1074/jbc.M107788200; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Parnell SC, 2002, J BIOL CHEM, V277, P19566, DOI 10.1074/jbc.M201875200; PETERS DJM, 1993, NAT GENET, V5, P359, DOI 10.1038/ng1293-359; Pritchard L, 2000, HUM MOL GENET, V9, P2617, DOI 10.1093/hmg/9.18.2617; Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03-0132fje; Rodova M, 2002, J BIOL CHEM, V277, P29577, DOI 10.1074/jbc.M203570200; Saadi-Kheddouci S, 2001, ONCOGENE, V20, P5972, DOI 10.1038/sj.onc.1204825; Scheffers MS, 2002, HUM MOL GENET, V11, P59, DOI 10.1093/hmg/11.1.59; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Smits R, 2000, GENE CHROMOSOME CANC, V29, P229, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1033>3.0.CO;2-R; Sorenson CM, 1996, AM J PHYSIOL-RENAL, V271, pF184, DOI 10.1152/ajprenal.1996.271.1.F184; Spaargaren M, 1999, MOL BIOL CELL, V10, P3239, DOI 10.1091/mbc.10.10.3239; Streets AJ, 2003, J AM SOC NEPHROL, V14, P1804, DOI 10.1097/01.ASN.0000076075.49819.9B; Sutters M, 2001, KIDNEY INT, V60, P484, DOI 10.1046/j.1523-1755.2001.060002484.x; TRUDEL M, 1992, CONTRIB NEPHROL, V97, P47; Upadhya P, 2000, P NATL ACAD SCI USA, V97, P217, DOI 10.1073/pnas.97.1.217; van Adelsberg J, 2000, NEPHROL DIAL TRANSPL, V15, P1, DOI 10.1093/ndt/15.1.1; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; WARD CJ, 1994, CELL, V77, P881	40	29	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27472	27481		10.1074/jbc.M312183200	http://dx.doi.org/10.1074/jbc.M312183200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15087466	Green Accepted, hybrid			2022-12-25	WOS:000222120400079
J	Pan, Y; Oprysko, PR; Asham, AM; Koch, CJ; Simon, MC				Pan, Y; Oprysko, PR; Asham, AM; Koch, CJ; Simon, MC			p53 cannot be induced by hypoxia alone but responds to the hypoxic microenvironment	ONCOGENE			English	Article						hypoxia; anoxia; p53; HIF; tumor cells	INDUCIBLE FACTOR 1-ALPHA; LOW-OXYGEN CONDITIONS; TRANSCRIPTION FACTOR; TUMOR ANGIOGENESIS; PROTEIN; CELLS; MDM2; GENE; DEGRADATION; ACTIVATION	Solid tumors frequently contain hypoxic subregions due to insufficient blood supply. In these domains, cells can undergo p53-dependent apoptosis. Therefore, hypoxia has been implicated as a physiological stimulus for p53 accumulation and activation. In such an environment, p53 mutant cells exhibit a selective growth advantage. Hypoxic regulation of p53 has been proposed to be hypoxia inducible factor (HIF) dependent; however, controversy remains over whether and to what extent low oxygen (O-2) tension by itself enhances p53 protein stability. Here, we examined the p53 response to hypoxia and hypoxia mimetics in several cell lines expressing different HIF-alpha proteins. Most cells exhibited elevated levels of p53 in response to hypoxia mimetics such as deferoxamine mesylate and CoCl2, regardless of their HIF-alpha protein expression profile. However, over a range of O-2 levels, from 1.5% to less than 0.02%, we failed to observe p53 accumulation or p53 nuclear translocation in any cell lines tested. Only after treatment with a combination of hypoxia and acidosis/nutrient deprivation did some cells exhibit p53 induction. Our results suggest that, although hypoxia induces p53 accumulation in vivo, secondary effects such as acidosis caused by a hypoxic Pasteur effect ( instead of low O-2 by itself) are necessary for p53 accumulation. Therefore, the expression of HIF-1alpha and p53 proteins is not coupled during the cellular hypoxia response.	Univ Penn, Howard Hughes Med Inst, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Simon, MC (corresponding author), Univ Penn, Howard Hughes Med Inst, Abramson Family Canc Res Inst, BRB 2-3 Rm 456,421 Curie Blvd, Philadelphia, PA 19104 USA.	celeste2@mail.med.upenn.edu	Simon, Celeste/AAG-3941-2021		NATIONAL CANCER INSTITUTE [P01CA079862] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA79862] Funding Source: Medline; PHS HHS [66310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434; Alarcon R, 1999, CANCER RES, V59, P6046; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Denko NC, 2000, EXP CELL RES, V258, P82, DOI 10.1006/excr.2000.4928; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Gardner LB, 2001, J BIOL CHEM, V276, P7919, DOI 10.1074/jbc.M010189200; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Keith B, 2001, P NATL ACAD SCI USA, V98, P6692, DOI 10.1073/pnas.121494298; Kim CY, 1997, CANCER RES, V57, P4200; Koch CJ, 2002, METHOD ENZYMOL, V352, P3; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Makino Y, 2002, J BIOL CHEM, V277, P32405, DOI 10.1074/jbc.C200328200; Maltepe E, 2000, BIOCHEM BIOPH RES CO, V273, P231, DOI 10.1006/bbrc.2000.2928; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maya R, 2000, ONCOGENE, V19, P3213, DOI 10.1038/sj.onc.1203658; Ohtsubo T, 1997, CANCER RES, V57, P3910; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Ravi R, 2000, GENE DEV, V14, P34; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; Sax JK, 2002, CELL CYCLE, V1, P90, DOI 10.4161/cc.1.1.105; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 2002, INTERNAL MED, V41, P79, DOI 10.2169/internalmedicine.41.79; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Stempien-Otero A, 1999, J BIOL CHEM, V274, P8039, DOI 10.1074/jbc.274.12.8039; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wenger RH, 1998, CANCER RES, V58, P5678; Wenger RH, 1996, NATURE, V380, P100, DOI 10.1038/380100d0; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhong H, 1999, CANCER RES, V59, P5830; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	58	76	86	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					4975	4983		10.1038/sj.onc.1207657	http://dx.doi.org/10.1038/sj.onc.1207657			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15107830				2022-12-25	WOS:000222237300003
J	Mao, H; Zhao, QS; Daigle, M; Ghahremani, MH; Chidiac, P; Albert, PR				Mao, H; Zhao, QS; Daigle, M; Ghahremani, MH; Chidiac, P; Albert, PR			RGS17/RGSZ2, a novel regulator of G(i/o), G(z), and G(q) signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; RGS PROTEINS; ADENYLYL-CYCLASE; ALPHA-SUBUNITS; RECEPTOR; INHIBITION; FAMILY; INTERACTS; DOMAIN; GAIP	To identify novel regulators of Galpha(o), the most abundant G-protein in brain, we used yeast two-hybrid screening with constitutively active Galpha(o) as bait and identified a new regulator of G-protein signaling (RGS) protein, RGS17 (RGSZ2), as a novel human member of the RZ (or A) subfamily of RGS proteins. RGS17 contains an amino-terminal cysteine-rich motif and a carboxyl-terminal RGS domain with highest homology to hRGSZ1- and hRGS-Galpha-interacting protein. RGS17 RNA was strongly expressed as multiple species in cerebellum and other brain regions. The interactions between hRGS17 and active forms of Galpha(i1-3), Galpha(o), Galpha(z), or Galpha(q) but not Galpha(s) were detected by yeast two-hybrid assay, in vitro pull-down assay, and co-immunoprecipitation studies. Recombinant RGS17 acted as a GTPase-activating protein (GAP) on free Galpha(i2) and Galpha(o) under pre-steady-state conditions, and on M2-muscarinic receptor-activated Galpha(i1), Galpha(i2), Galpha(i3), Galpha(z), and Galpha(o) in steady-state GTPase assays in vitro. Unlike RGSZ1, which is highly selective for G(z), RGS17 exhibited limited selectivity for G(o) among G(i)/G(o) proteins. All RZ family members reduced dopamine-D2/Galpha(i)-mediated inhibition of cAMP formation and abolished thyrotropin-releasing hormone receptor/Galpha(q)-mediated calcium mobilization. RGS17 is a new RZ member that preferentially inhibits receptor signaling via G(i/o), G(z), and G(q) over G(s) to enhance cAMP-dependent signaling and inhibit calcium signaling. Differences observed between in vitro GAP assays and whole-cell signaling suggest additional determinants of the G-protein specificity of RGS GAP effects that could include receptors and effectors.	Univ Ottawa, Ottawa Hlth Res Inst, Dept Neurosci, Ottawa, ON K1H 8M5, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada	University of Ottawa; Ottawa Hospital Research Institute; Western University (University of Western Ontario)	Chidiac, P (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst, Dept Neurosci, Ottawa, ON K1H 8M5, Canada.	peter.chidiac@fmd.uwo.ca; palbert@uottawa.ca	Albert, Paul/E-4804-2010; Chidiac, Peter/L-5906-2015; Zhao, Qingshi/H-9839-2013; Ghahremani, Mohammad H/F-1615-2013	Albert, Paul/0000-0002-1809-3554; Chidiac, Peter/0000-0001-8365-6109; Ghahremani, Mohammad H/0000-0001-5051-6214				Albert PR, 1999, J BIOL CHEM, V274, P35469, DOI 10.1074/jbc.274.50.35469; ALBERT PR, 1994, VITAM HORM, V48, P59, DOI 10.1016/S0083-6729(08)60496-3; Albert PR, 2002, ENDOCRINOLOGY, V143, P744, DOI 10.1210/en.143.3.744; ALBERT PR, 1990, J BIOL CHEM, V265, P2098; Anger T, 2004, J BIOL CHEM, V279, P3906, DOI 10.1074/jbc.M309496200; Barker SA, 2001, GENOMICS, V78, P223, DOI 10.1006/geno.2001.6659; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Bernstein LS, 2004, J BIOL CHEM, V279, P21248, DOI 10.1074/jbc.M312407200; Burchett SA, 2003, J NEUROCHEM, V87, P551, DOI 10.1046/j.1471-4159.2003.02047.x; Burchett SA, 2000, J NEUROCHEM, V75, P1335, DOI 10.1046/j.1471-4159.2000.0751335.x; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Cladman W, 2002, MOL PHARMACOL, V62, P654, DOI 10.1124/mol.62.3.654; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Fischer T, 2003, P NATL ACAD SCI USA, V100, P8270, DOI 10.1073/pnas.1432965100; Ghahremani MH, 1999, J BIOL CHEM, V274, P9238, DOI 10.1074/jbc.274.14.9238; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Hooks SB, 2003, J BIOL CHEM, V278, P10087, DOI 10.1074/jbc.M211382200; ITO M, 1993, FEBS LETT, V320, P125, DOI 10.1016/0014-5793(93)80076-7; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; Lembo PMC, 1997, MOL PHARMACOL, V52, P164, DOI 10.1124/mol.52.1.164; Liu YT, 2002, INT J ELEC POWER, V24, P271, DOI 10.1016/S0142-0615(01)00032-1; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; Nixon AB, 2002, J BIOL CHEM, V277, P18127, DOI 10.1074/jbc.M201065200; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; Posner BA, 1999, BIOCHEMISTRY-US, V38, P7773, DOI 10.1021/bi9906367; Poyry TAA, 2004, GENE DEV, V18, P62, DOI 10.1101/gad.276504; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Schneider S, 1996, BIOTECHNIQUES, V20, P960; Sierra DA, 2002, GENOMICS, V79, P177, DOI 10.1006/geno.2002.6693; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Tu YP, 2003, J BIOL CHEM, V278, P52273, DOI 10.1074/jbc.M309626200; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Wang YR, 2002, J BIOL CHEM, V277, P48325, DOI 10.1074/jbc.M206116200; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wylie F, 1999, AM J PHYSIOL-CELL PH, V276, pC497, DOI 10.1152/ajpcell.1999.276.2.C497; Zaworski PG, 1999, BRIT J PHARMACOL, V128, P1181, DOI 10.1038/sj.bjp.0702905; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; ZHAO D, 1993, ENDOCRINOLOGY, V130, P3529; Zmijewski JW, 2001, BBA-MOL CELL RES, V1541, P201, DOI 10.1016/S0167-4889(01)00144-6	44	71	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26314	26322		10.1074/jbc.M401800200	http://dx.doi.org/10.1074/jbc.M401800200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15096504	hybrid			2022-12-25	WOS:000222003000050
J	Miyaoka, Y; Kadowaki, Y; Ishihara, S; Ose, T; Fukuhara, H; Kazumori, H; Takasawa, S; Okamoto, H; Chiba, T; Kinoshita, Y				Miyaoka, Y; Kadowaki, Y; Ishihara, S; Ose, T; Fukuhara, H; Kazumori, H; Takasawa, S; Okamoto, H; Chiba, T; Kinoshita, Y			Transgenic overexpression of Reg protein caused gastric cell proliferation and differentiation along parietal cell and chief cell lineages	ONCOGENE			English	Article						Reg; gastric cells; transgenic mice; growth factor	GROWTH-FACTOR-ALPHA; REGENERATING GENE PROTEIN; PANCREATIC THREAD PROTEIN; MUCOUS EPITHELIAL-CELLS; MENETRIERS DISEASE; PRIMARY CULTURES; MOUSE STOMACH; EXPRESSION; INSULIN; MICE	Reg (regenerating gene product) was originally identified as a growth factor involved in pancreatic regeneration. During the healing course of gastric erosion, Reg expression is highly increased in the enterochromaffin-like (ECL) cells surrounding the ulcer crater, suggesting its role as a regulator of gastric mucosal regeneration. However, there has been no direct in vivo evidence of a growth-promoting role of Reg for the gastric mucosal cells. In the current study, Reg-transgenic mice were created and gastric mucosa were analysed for histological changes. Transgenic mice showed a marked increase in the thickness of the fundic mucosa. Anti-proliferating cell nuclear antigen ( PCNA) staining of the fundic mucosa demonstrated the enlargement of the proliferating neck zone and the lower PCNA-negative zone. Histological analysis employing antibodies against cell-type markers revealed expansion of the chief cell and parietal cell populations and no change in the number of surface mucus-producing cells, ECL cells, or G cells. In conclusion, Reg has a growth-promoting effect on gastric progenitor cells and an activity to direct the differentiation of the cells into chief cell and parietal cell lineages. This was in contrast to other factors, all of which had been shown to drive differentiation towards mucus producing cells in vivo. In the injured gastric mucosa, Reg may play a unique and important part in the reconstruction of the properly organized mucosal architecture.	Tohoku Univ, Grad Sch Med, Dept Biochem, Sendai, Miyagi 980, Japan; Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Kyoto, Japan	Tohoku University; Kyoto University	Kadowaki, Y (corresponding author), Shimane Med Univ, Dept Internal Med 2, Izumo, Shimane 6938501, Japan.	y-kado@momo.so-net.ne.jp						Asahara M, 1996, GASTROENTEROLOGY, V111, P45, DOI 10.1053/gast.1996.v111.pm8698224; BEAUCHAMP RD, 1989, J CLIN INVEST, V84, P1017, DOI 10.1172/JCI114223; BORDI C, 1995, ENDOCR PATHOL, V6, P103, DOI 10.1007/BF02739873; CHEN MC, 1991, J CLIN INVEST, V87, P1716, DOI 10.1172/JCI115189; DEMPSEY PJ, 1992, GASTROENTEROLOGY, V103, P1950, DOI 10.1016/0016-5085(92)91455-D; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Fukui H, 1998, GASTROENTEROLOGY, V115, P1483, DOI 10.1016/S0016-5085(98)70027-7; HATTORI T, 1976, CELL TISSUE RES, V172, P171; Higham AD, 1999, GASTROENTEROLOGY, V116, P1310, DOI 10.1016/S0016-5085(99)70495-6; Kadowaki Y, 2002, FEBS LETT, V530, P59, DOI 10.1016/S0014-5793(02)03398-7; KARAM SM, 1993, ANAT REC, V236, P333, DOI 10.1002/ar.1092360206; KARAM SM, 1992, ANAT RECORD, V232, P231, DOI 10.1002/ar.1092320208; Kazumori H, 2000, GASTROENTEROLOGY, V119, P1610, DOI 10.1053/gast.2000.20262; Kobayashi S, 2000, J BIOL CHEM, V275, P10723, DOI 10.1074/jbc.275.15.10723; POLK WH, 1992, GASTROENTEROLOGY, V102, P1467, DOI 10.1016/0016-5085(92)91703-7; RUTTEN MJ, 1993, AM J PHYSIOL, V265, pG361, DOI 10.1152/ajpgi.1993.265.2.G361; RUTTEN MJ, 1991, SCAND J GASTROENTERO, V26, P965, DOI 10.3109/00365529108996250; SHARP R, 1995, DEVELOPMENT, V121, P149; TAKAGI H, 1992, J CLIN INVEST, V90, P1161, DOI 10.1172/JCI115936; TAKAHASHI M, 1995, J CLIN INVEST, V95, P1994, DOI 10.1172/JCI117884; TERAZONO K, 1988, J BIOL CHEM, V263, P2111; TERAZONO K, 1990, DIABETOLOGIA, V33, P250, DOI 10.1007/BF00404804; UNNO M, 1993, J BIOL CHEM, V268, P15974; WATANABE T, 1990, J BIOL CHEM, V265, P7432; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; YOSHIURA K, 1994, DIGEST DIS SCI, V39, P1454, DOI 10.1007/BF02088048; Zenilman ME, 1996, GASTROENTEROLOGY, V110, P1208, DOI 10.1053/gast.1996.v110.pm8613011	27	55	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3572	3579		10.1038/sj.onc.1207333	http://dx.doi.org/10.1038/sj.onc.1207333			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116092				2022-12-25	WOS:000221101700008
J	Nordlund, HR; Laitinen, OH; Hytonen, VP; Uotila, STH; Porkka, E; Kulomaa, MS				Nordlund, HR; Laitinen, OH; Hytonen, VP; Uotila, STH; Porkka, E; Kulomaa, MS			Construction of a dual chain pseudotetrameric chicken avidin by combining two circularly permuted avidins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG-WHITE AVIDIN; BIOTIN BINDING; HIGH-AFFINITY; STRUCTURAL CONSEQUENCES; MONOMERIC STREPTAVIDIN; SUBUNIT ASSOCIATION; PROTEINS; COMPLEX; GENE; PERMUTATION	Two distinct circularly permuted forms of chicken avidin were designed with the aim of constructing a fusion avidin containing two biotin-binding sites in one polypeptide. The old N and C termini of wild-type avidin were connected to each other via a glycine/serine-rich linker, and the new termini were introduced into two different loops. This enabled the creation of the desired fusion construct using a short linker peptide between the two different circularly permuted subunits. The circularly permuted avidins (circularly permuted avidin 5 --> 4 and circularly permuted avidin 6 --> 5) and their fusion, pseudotetrameric dual chain avidin, were biologically active, i.e. showed biotin binding, and also displayed structural characteristics similar to those of wild-type avidin. Dual chain avidin facilitates the development of dual affinity avidins by allowing adjustment of the ligand-binding properties in half of the binding sites independent of the other half. In addition, the subunit fusion strategy described in this study can be used, where applicable, to modify oligomeric proteins in general.	Univ Jyvaskyla, Dept Biol & Environm Sci, NanoSci Ctr, FIN-40014 Jyvaskyla, Finland; Univ Kuopio, Dept Mol Med, AI Virtanen Inst, FIN-70211 Kuopio, Finland	University of Jyvaskyla; Finland National Institute for Health & Welfare; University of Eastern Finland	Kulomaa, MS (corresponding author), Univ Jyvaskyla, Dept Biol & Environm Sci, NanoSci Ctr, POB 35, FIN-40014 Jyvaskyla, Finland.	kulomaa@csc.fi	Hytonen, Vesa P./E-8855-2013; Laitinen, Olli H/A-6618-2016; Kulomaa, Markku S/C-9063-2014	Hytonen, Vesa P./0000-0002-9357-1480; Laitinen, Olli H/0000-0002-3751-9952; 				Ahlroth MK, 2000, ANIM GENET, V31, P367, DOI 10.1046/j.1365-2052.2000.00681.x; Airenne KJ, 1997, PROTEIN EXPRES PURIF, V9, P100, DOI 10.1006/prep.1996.0660; ARGARANA CE, 1986, NUCLEIC ACIDS RES, V14, P1871, DOI 10.1093/nar/14.4.1871; Bayer EA, 1996, ELECTROPHORESIS, V17, P1319, DOI 10.1002/elps.1150170808; CHILKOTI A, 1995, P NATL ACAD SCI USA, V92, P1754, DOI 10.1073/pnas.92.5.1754; CHILKOTI A, 1995, BIO-TECHNOL, V13, P1198, DOI 10.1038/nbt1195-1198; Chu V, 1998, PROTEIN SCI, V7, P848; Ding ZL, 2001, NATURE, V411, P59, DOI 10.1038/35075028; ELLISON D, 1995, PROTEIN SCI, V4, P1337, DOI 10.1002/pro.5560040709; Freitag S, 1999, P NATL ACAD SCI USA, V96, P8384, DOI 10.1073/pnas.96.15.8384; GREEN N. M., 1970, Methods in Enzymology, V18A, P418, DOI 10.1016/0076-6879(71)18342-5; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; Laitinen OH, 2003, J BIOL CHEM, V278, P4010, DOI 10.1074/jbc.M205844200; Laitinen OH, 1999, FEBS LETT, V461, P52, DOI 10.1016/S0014-5793(99)01423-4; Laitinen OH, 2001, J BIOL CHEM, V276, P8219, DOI 10.1074/jbc.M007930200; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; Marttila AT, 2003, BIOCHEM J, V369, P249, DOI 10.1042/BJ20020886; Marttila AT, 1998, FEBS LETT, V441, P313, DOI 10.1016/S0014-5793(98)01570-1; Marttila AT, 2000, FEBS LETT, V467, P31, DOI 10.1016/S0014-5793(00)01119-4; McDevitt TC, 1999, BIOTECHNOL PROGR, V15, P391, DOI 10.1021/bp990043n; Nordlund HR, 2003, J BIOL CHEM, V278, P2479, DOI 10.1074/jbc.M210721200; PUGLIESE L, 1993, J MOL BIOL, V231, P698, DOI 10.1006/jmbi.1993.1321; Qureshi MH, 2002, PROTEIN EXPRES PURIF, V25, P409, DOI 10.1016/S1046-5928(02)00021-9; Qureshi MH, 2001, J BIOL CHEM, V276, P46422, DOI 10.1074/jbc.M107398200; Reznik GO, 1996, NAT BIOTECHNOL, V14, P1007, DOI 10.1038/nbt0896-1007; Reznik GO, 1998, P NATL ACAD SCI USA, V95, P13525, DOI 10.1073/pnas.95.23.13525; Sanders KE, 2002, BLOOD, V100, P299, DOI 10.1182/blood.V100.1.299; Sano T, 1997, P NATL ACAD SCI USA, V94, P6153, DOI 10.1073/pnas.94.12.6153; SANO T, 1995, P NATL ACAD SCI USA, V92, P3180, DOI 10.1073/pnas.92.8.3180; Shimoboji T, 2001, BIOCONJUGATE CHEM, V12, P314, DOI 10.1021/bc000107b; Uliel S, 2001, PROTEIN ENG, V14, P533, DOI 10.1093/protein/14.8.533; WALLEN MJ, 1995, GENE, V161, P205, DOI 10.1016/0378-1119(95)00187-B; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; Wilchek M, 1999, BIOMOL ENG, V16, P1	35	34	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36715	36719		10.1074/jbc.M403496200	http://dx.doi.org/10.1074/jbc.M403496200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15131113	hybrid			2022-12-25	WOS:000223453600071
J	Cameron, A; Read, J; Tranter, R; Winter, VJ; Sessions, RB; Brady, RL; Vivas, L; Easton, A; Kendrick, H; Croft, SL; Barros, D; Lavandera, JL; Martin, JJ; Risco, F; Garcia-Ochoa, S; Gamo, FJ; Sanz, L; Leon, L; Ruiz, JR; Gabarro, R; Mallo, A; de las Heras, FG				Cameron, A; Read, J; Tranter, R; Winter, VJ; Sessions, RB; Brady, RL; Vivas, L; Easton, A; Kendrick, H; Croft, SL; Barros, D; Lavandera, JL; Martin, JJ; Risco, F; Garcia-Ochoa, S; Gamo, FJ; Sanz, L; Leon, L; Ruiz, JR; Gabarro, R; Mallo, A; de las Heras, FG			Identification and activity of a series of azole-based compounds with lactate dehydrogenase-directed anti-malarial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA PARASITE; SUBSTRATE-INHIBITION; MALATE-DEHYDROGENASE; STRUCTURAL BASIS; DRUG; SPECIFICITY; INVITRO; CHLOROQUINE; ASSAY	Plasmodium falciparum, the causative agent of malaria, relies extensively on glycolysis coupled with homolactic fermentation during its blood-borne stages for energy production. Selective inhibitors of the parasite lactate dehydrogenase (LDH), central to NAD(+) regeneration, therefore potentially provide a route to new antimalarial drugs directed against a novel molecular target. A series of heterocyclic, azole-based compounds are described that preferentially inhibit P. falciparum LDH at sub-micromolar concentrations, typically at concentrations about 100-fold lower than required for human lactate dehydrogenase inhibition. Crystal structures show these competitive inhibitors form a network of interactions with amino acids within the active site of the enzyme, stacking alongside the nicotinamide ring of the NAD(+) cofactor. These compounds display modest activity against parasitized erythrocytes, including parasite strains with known resistance to existing anti-malarials and against Plasmodium berghei in BALB/c mice. Initial toxicity data suggest the azole derivatives have generally low cytotoxicity, and preliminary pharmocokinetic data show favorable bioavailability and circulation times. These encouraging results suggest that further enhancement of these structures may yield candidates suitable for consideration as new therapeutics for the treatment of malaria. In combination these studies also provide strong support for the validity of targeting the Plasmodium glycolytic pathway and, in particular, LDH in the search for novel anti-malarials.	Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Bristol, Mol Recognit Ctr, Bristol BS8 1TD, Avon, England; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; GlaxoSmithKline, Madrid 28760, Spain	University of Bristol; University of Bristol; University of London; London School of Hygiene & Tropical Medicine; GlaxoSmithKline	Brady, RL (corresponding author), Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England.	L.Brady@bris.ac.uk	Mallo, Araceli/P-3345-2014; Lavandera, Jose Luis L/K-3690-2014; Lavandera, José Luis/J-6913-2019; Conners, Rebecca/C-2608-2013	Mallo, Araceli/0000-0002-5411-0382; Lavandera, Jose Luis L/0000-0003-0730-6865; Lavandera, José Luis/0000-0003-0730-6865; Sessions, Richard/0000-0003-0320-0895; Conners, Rebecca/0000-0002-8653-1771				ALLAIN CC, 1973, CLIN CHEM, V19, P223; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARSTOW DA, 1990, BIOCHIM BIOPHYS ACTA, V1087, P73, DOI 10.1016/0167-4781(90)90123-J; Chapman ADM, 1999, J MOL BIOL, V285, P703, DOI 10.1006/jmbi.1998.2357; Dando C, 2001, MOL BIOCHEM PARASIT, V118, P23, DOI 10.1016/S0166-6851(01)00360-7; Deck LM, 1998, J MED CHEM, V41, P3879, DOI 10.1021/jm980334n; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; Dunn CR, 1996, NAT STRUCT BIOL, V3, P912, DOI 10.1038/nsb1196-912; Eszes CM, 1996, FEBS LETT, V399, P193, DOI 10.1016/S0014-5793(96)01317-8; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gomez MS, 1997, MOL BIOCHEM PARASIT, V90, P235, DOI 10.1016/S0166-6851(97)00140-0; Hewitt CO, 1999, PROTEIN ENG, V12, P491, DOI 10.1093/protein/12.6.491; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lang-Unnasch N, 1998, ANNU REV MICROBIOL, V52, P561, DOI 10.1146/annurev.micro.52.1.561; MAKLER MT, 1993, AM J TROP MED HYG, V48, P739, DOI 10.4269/ajtmh.1993.48.739; Menting JG, 1997, MOL BIOCHEM PARASIT, V88, P215, DOI 10.1016/S0166-6851(97)00095-9; NOVOA WB, 1959, J BIOL CHEM, V234, P1143; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palomino JC, 1999, EUR J CLIN MICROBIOL, V18, P380, DOI 10.1007/PL00015025; Perozzo R, 2002, J BIOL CHEM, V277, P13106, DOI 10.1074/jbc.M112000200; PETERS W, 1975, ANN TROP MED PARASIT, V69, P155, DOI 10.1080/00034983.1975.11686997; PONNUDURAI T, 1981, TROP GEOGR MED, V33, P50; Read JA, 2001, PROTEINS, V43, P175, DOI 10.1002/1097-0134(20010501)43:2<175::AID-PROT1029>3.0.CO;2-#; Ridley RG, 1997, EXP PARASITOL, V87, P293, DOI 10.1006/expr.1997.4230; ROTH EF, 1982, BIOCHEM BIOPH RES CO, V109, P355, DOI 10.1016/0006-291X(82)91728-4; ROYER RE, 1986, J MED CHEM, V29, P1799, DOI 10.1021/jm00159a043; SCHEIBEL LW, 1979, P NATL ACAD SCI USA, V76, P5303, DOI 10.1073/pnas.76.10.5303; Sessions RB, 1997, PROTEIN ENG, V10, P301, DOI 10.1093/protein/10.4.301; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Vander Jagt D.L., 1989, Progress in Clinical and Biological Research, V313, P105; Wieland H, 1930, LIEBIGS ANN CHEM, V478, P43; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; Winter VJ, 2003, MOL BIOCHEM PARASIT, V131, P1, DOI 10.1016/S0166-6851(03)00170-1; Yu Y, 2001, BIOCHEM PHARMACOL, V62, P81, DOI 10.1016/S0006-2952(01)00636-0; Yuvaniyama J, 2003, NAT STRUCT BIOL, V10, P357, DOI 10.1038/nsb921	35	110	118	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31429	31439		10.1074/jbc.M402433200	http://dx.doi.org/10.1074/jbc.M402433200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15117937	hybrid, Green Published			2022-12-25	WOS:000222726800064
J	Mishra, RK; Jatiani, SS; Kumar, A; Simhadri, VR; Hosur, RV; Mittal, R				Mishra, RK; Jatiani, SS; Kumar, A; Simhadri, VR; Hosur, RV; Mittal, R			Dynamin interacts with members of the sumoylation machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; NUCLEOCAPSID PROTEIN; LARGER PROTEINS; UBIQUITIN; NUCLEAR; SUMO-1; BINDING; ASSIGNMENT; MODIFIER-1; GTPASE	Dynamin is a GTP-binding protein whose oligomerization-dependent assembly around the necks of lipid vesicles mediates their scission from parent membranes. Dynamin is thus directly involved in the regulation of endocytosis. Sumoylation is a post-translational protein modification whereby the ubiquitin-like modifier Sumo is covalently attached to lysine residues on target proteins by a process requiring the concerted action of an activating enzyme (ubiquitin-activating enzyme), a conjugating enzyme ( ubiquitin carrier protein), and a ligating enzyme (ubiquitin-protein isopeptide ligase). Here, we show that dynamin interacts with Sumo-1, Ubc9, and PIAS-1, all of which are members of the sumoylation machinery. Ubc9 and PIAS-1 are known ubiquitin carrier protein and ubiquitin-protein isopeptide ligase enzymes, respectively, for the process of sumoylation. We have identified the coiled-coil GTPase effector domain (GED) of dynamin as the site on dynamin that interacts with Sumo-1, Ubc9, and PIAS-1. Although we saw no evidence of covalent Sumo-1 attachment to dynamin, Sumo-1 and Ubc9 are shown here to inhibit the lipid-dependent oligomerization of dynamin. Expression of Sumo-1 and Ubc9 in mammalian cells down-regulated the dynamin-mediated endocytosis of transferrin, whereas dynamin-independent fluid-phase uptake was not affected. Furthermore, using high resolution NMR spectroscopy, we have identified amino acid residues on Sumo-1 that directly interact with the GED of dynamin. The results suggest that the GED of dynamin may serve as a scaffold that concentrates the sumoylation machinery in the vicinity of potential acceptor proteins.	Tata Inst Fundamental Res, Dept Biol Sci, Bombay 400005, Maharashtra, India; Tata Inst Fundamental Res, Dept Chem Sci, Bombay 400005, Maharashtra, India	Tata Institute of Fundamental Research (TIFR); Tata Institute of Fundamental Research (TIFR)	Mittal, R (corresponding author), Tata Inst Fundamental Res, Dept Biol Sci, Homi Bhabha Rd, Bombay 400005, Maharashtra, India.	mittal@tifr.res.in	Mishra, Ram/AAJ-1538-2020; Mishra, Ram/ABA-6071-2020	Mishra, Ram/0000-0002-9528-0476				Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Baillat G, 2002, J BIOL CHEM, V277, P18961, DOI 10.1074/jbc.M108818200; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Bhavesh NS, 2001, BIOCHEMISTRY-US, V40, P14727, DOI 10.1021/bi015683p; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Engelhardt OG, 2001, EXP CELL RES, V271, P286, DOI 10.1006/excr.2001.5380; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GRZESIEK S, 1992, J MAGN RESON, V99, P201, DOI 10.1016/0022-2364(92)90169-8; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Haigis MC, 2003, J CELL SCI, V116, P313, DOI 10.1242/jcs.00214; Haller O, 2002, TRAFFIC, V3, P710, DOI 10.1034/j.1600-0854.2002.31003.x; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Jin CW, 2001, INT J BIOL MACROMOL, V28, P227, DOI 10.1016/S0141-8130(00)00169-0; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kaukinen P, 2003, VIRUS RES, V92, P37, DOI 10.1016/S0168-1702(02)00312-X; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Li WH, 2000, NUCLEIC ACIDS RES, V28, P1145, DOI 10.1093/nar/28.5.1145; Lin DH, 2002, J BIOL CHEM, V277, P21740, DOI 10.1074/jbc.M108418200; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; Liu Q, 1999, J BIOL CHEM, V274, P16979, DOI 10.1074/jbc.274.24.16979; Longtine MS, 2003, TRENDS CELL BIOL, V13, P403, DOI 10.1016/S0962-8924(03)00151-X; Maeda A, 2003, VIROLOGY, V305, P288, DOI 10.1006/viro.2002.1767; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Newmyer SL, 2003, DEV CELL, V4, P929, DOI 10.1016/S1534-5807(03)00157-6; Okamoto PM, 1999, J BIOL CHEM, V274, P10277, DOI 10.1074/jbc.274.15.10277; Panchal SC, 2001, J BIOMOL NMR, V20, P135, DOI 10.1023/A:1011239023422; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; PYPAERT M, 1991, J CELL BIOL, V114, P1159, DOI 10.1083/jcb.114.6.1159; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; Smirnova E, 1999, J BIOL CHEM, V274, P14942, DOI 10.1074/jbc.274.21.14942; Sobko A, 2002, DEV CELL, V2, P745, DOI 10.1016/S1534-5807(02)00186-7; Song BD, 2003, BIOCHEMISTRY-US, V42, P1369, DOI 10.1021/bi027062h; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Tan TC, 2003, NAT CELL BIOL, V5, P701, DOI 10.1038/ncb1020; TUMA PL, 1993, J BIOL CHEM, V268, P17240; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; Vorobjev I A, 2000, Membr Cell Biol, V14, P219; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; Wojcikiewicz RJH, 2004, TRENDS PHARMACOL SCI, V25, P35, DOI 10.1016/j.tips.2003.11.008	67	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31445	31454		10.1074/jbc.M402911200	http://dx.doi.org/10.1074/jbc.M402911200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15123615	hybrid			2022-12-25	WOS:000222726800066
J	Buglino, J; Onwueme, KC; Ferreras, JA; Quadri, LEN; Lima, CD				Buglino, J; Onwueme, KC; Ferreras, JA; Quadri, LEN; Lima, CD			Crystal structure of PapA5, a phthiocerol dimycocerosyl transferase from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE SYNTHETASE CONDENSATION; CELL-WALL; VIBRIO-CHOLERAE; GENE-CLUSTER; SYNTHASE; BIOSYNTHESIS; ACETYLTRANSFERASE; GENOME; RECONSTITUTION; ATTENUATION	Polyketide-associated protein A5 (PapA5) is an acyltransferase that is involved in production of phthiocerol and phthiodiolone dimycocerosate esters, a class of virulence-enhancing lipids produced by Mycobacterium tuberculosis. Structural analysis of PapA5 at 2.75-resolution reveals a two-domain structure that shares unexpected similarity to structures of chloramphenicol acetyltransferase, dihydrolipoyl transacetylase, carnitine acetyltransferase, and VibH, a non-ribosomal peptide synthesis condensation enzyme. The PapA5 active site includes conserved histidine and aspartic acid residues that are critical to PapA5 acyltransferase activity. PapA5 catalyzes acyl transfer reactions on model substrates that contain long aliphatic carbon chains, and two hydrophobic channels were observed linking the PapA5 surface to the active site with properties consistent with these biochemical activities and substrate preferences. An additional alpha helix not observed in other acyltransferase structures blocks the putative entrance into the PapA5 active site, indicating that conformational changes may be associated with PapA5 activity. PapA5 represents the first structure solved for a protein involved in polyketide synthesis in Mycobacteria.	Sloan Kettering Inst, Struct Biol Program, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Lima, CD (corresponding author), Sloan Kettering Inst, Struct Biol Program, Box 414,1275 York Ave, New York, NY 10021 USA.	lima@limalab.org	Ferreras, Julian/U-5032-2019	Ferreras, Julian/0000-0003-4189-2917; Lima, Christopher/0000-0002-9163-6092	NIAID NIH HHS [1 F31 AI054326-01] Funding Source: Medline; NIGMS NIH HHS [GM62529] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F31AI054326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062529] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azad AK, 1997, J BIOL CHEM, V272, P16741, DOI 10.1074/jbc.272.27.16741; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bentley R, 1999, ANNU REV MICROBIOL, V53, P411, DOI 10.1146/annurev.micro.53.1.411; Brennan PJ, 2001, LEPROSY REV, V72, P415; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Camacho LR, 1999, MOL MICROBIOL, V34, P257, DOI 10.1046/j.1365-2958.1999.01593.x; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Constant P, 2002, J BIOL CHEM, V277, P38148, DOI 10.1074/jbc.M206538200; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; DECRECYLAGARD V, 1999, COMPREHENSIVE NATURA, V4, P221; DeLano W.L., 2002, PYMOL OPEN SOURCE MO; Dubey VS, 2003, J BACTERIOL, V185, P4620, DOI 10.1128/JB.185.15.4620-4625.2003; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Floss HG, 1999, CURR OPIN CHEM BIOL, V3, P592, DOI 10.1016/S1367-5931(99)00014-9; Garnier T, 2003, P NATL ACAD SCI USA, V100, P7877, DOI 10.1073/pnas.1130426100; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hubbard TJP, 1997, NUCLEIC ACIDS RES, V25, P236, DOI 10.1093/nar/25.1.236; Jogl G, 2003, CELL, V112, P113, DOI 10.1016/S0092-8674(02)01228-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keating TA, 2002, NAT STRUCT BIOL, V9, P522, DOI 10.1038/nsb810; Keating TA, 2000, BIOCHEMISTRY-US, V39, P15513, DOI 10.1021/bi001651a; Keating TA, 2000, BIOCHEMISTRY-US, V39, P15522, DOI 10.1021/bi0016523; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; LESLIE AGW, 1988, P NATL ACAD SCI USA, V85, P4133, DOI 10.1073/pnas.85.12.4133; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; MATHUR M, 1992, J BIOL CHEM, V267, P19388; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Ng V, 2000, CELL, V103, P511, DOI 10.1016/S0092-8674(00)00142-2; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIU XD, 1990, BIOCHEMISTRY-US, V29, P8614, DOI 10.1021/bi00489a017; Onwueme KC, 2004, P NATL ACAD SCI USA, V101, P4608, DOI 10.1073/pnas.0306928101; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Quadri LEN, 1999, BIOCHEMISTRY-US, V38, P14941, DOI 10.1021/bi991787c; Quadri LEN, 2000, MOL MICROBIOL, V37, P1, DOI 10.1046/j.1365-2958.2000.01941.x; Rambukkana A, 2002, SCIENCE, V296, P927, DOI 10.1126/science.1067631; Rousseau C, 2003, MICROBIOL-SGM, V149, P1837, DOI 10.1099/mic.0.26278-0; Sirakova TD, 2003, INFECT IMMUN, V71, P3794, DOI 10.1128/IAI.71.7.3794-3801.2003; Sirakova TD, 2003, J BACTERIOL, V185, P2999, DOI 10.1128/JB.185.10.2999-3008.2003; Sirakova TD, 2001, J BIOL CHEM, V276, P16833, DOI 10.1074/jbc.M011468200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839	42	53	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30634	30642		10.1074/jbc.M404011200	http://dx.doi.org/10.1074/jbc.M404011200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123643	hybrid			2022-12-25	WOS:000222531900093
J	Klampfer, L; Huang, J; Swaby, LA; Augenlicht, L				Klampfer, L; Huang, J; Swaby, LA; Augenlicht, L			Requirement of histone deacetylase activity for signaling by STAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-GAMMA; INTERFERON-GAMMA; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTORS; ULCERATIVE-COLITIS; COLON-CANCER; PPAR-GAMMA; TYROSINE PHOSPHORYLATION; INDEPENDENT PATHWAYS; INDUCED APOPTOSIS	STAT1 is a transcription factor that plays a crucial role in signaling by interferons (IFNs). In this study we demonstrated that inhibitors of histone deacetylase ( HDAC) activity, butyrate, trichostatin A, and suberoylanilide hydroxamic acid, prevented IFNgamma-induced JAK1 activation, STAT1 phosphorylation, its nuclear translocation, and STAT1-dependent gene activation. Furthermore, we showed that silencing of HDAC1, HDAC2, and HDAC3 through RNA interference markedly decreased IFNgamma-driven gene activation and that overexpression of HDAC1, HDAC2, and HDAC3 enhanced STAT1-dependent transcriptional activity. Our data therefore established the essential role of deacetylase activity in STAT1 signaling. Induction of IRF-1 by IFNgamma requires functional STAT1 signaling and was abrogated by butyrate, trichostatin A, suberoylanilide hydroxamic acid, and STAT1 small interfering RNA. In contrast, silencing of STAT1 did not interfere with IFNgamma-induced expression of STAT2 and caspase-7, and HDAC inhibitors did not preclude IFNgamma-induced expression of STAT1, STAT2, and caspase-7, suggesting that HDAC inhibitors impede the expression of IFNgamma target genes whose expression depends on STAT1 but do not interfere with STAT1-independent signaling by IFNgamma. Finally, we showed that inhibitors of deacetylase activity sensitized colon cancer cells to IFNgamma-induced apoptosis through cooperative negative regulation of Bcl-x expression, demonstrating that interruption of the balance between STAT1-dependent and STAT1-independent signaling significantly alters the biological activity of IFNgamma.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Klampfer, L (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.	lklampf@aecom.yu.edu			NCI NIH HHS [UO1 CA88104] Funding Source: Medline; PHS HHS [P30-13330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA088104] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Azuma T, 2000, J BIOL CHEM, V275, P3761, DOI 10.1074/jbc.275.6.3761; Biasco G, 2002, DIGEST LIVER DIS, V34, P339, DOI 10.1016/S1590-8658(02)80127-X; Bousquet C, 1999, J CLIN INVEST, V104, P1277, DOI 10.1172/JCI7924; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BREESE E, 1993, IMMUNOLOGY, V78, P127; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Chen GX, 2001, J BIOL CHEM, V276, P766, DOI 10.1074/jbc.M008330200; Clifford JL, 2002, CLIN CANCER RES, V8, P2067; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FAIS S, 1991, GUT, V32, P403, DOI 10.1136/gut.32.4.403; Frank DA, 1996, LEUKEMIA, V10, P1724; Fuss IJ, 1996, J IMMUNOL, V157, P1261; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Jove R, 2000, ONCOGENE, V19, P2466, DOI 10.1038/sj.onc.1203549; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kim HY, 2003, J IMMUNOL, V171, P6072, DOI 10.4049/jimmunol.171.11.6072; Klampfer L, 2003, J BIOL CHEM, V278, P46278, DOI 10.1074/jbc.M304721200; Klampfer L, 2003, MOL CANCER RES, V1, P855; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Kuhbacher T, 2001, CLIN EXP IMMUNOL, V123, P395, DOI 10.1046/j.1365-2249.2001.01455.x; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; LEE TH, 1993, J BIOL CHEM, V268, P6154; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lewis JD, 2001, AM J GASTROENTEROL, V96, P3323; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Magrassi L, 1999, J NEUROSURG, V91, P440, DOI 10.3171/jns.1999.91.3.0440; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; Mariadason JM, 2000, CANCER RES, V60, P4561; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; MARX JL, 1979, SCIENCE, V204, P1183, DOI 10.1126/science.451564; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Meyer T, 2002, EXP CELL RES, V272, P45, DOI 10.1006/excr.2001.5405; Navarro A, 2003, J LEUKOCYTE BIOL, V73, P540, DOI 10.1189/jlb.1002508; Nikitakis NG, 2002, CANCER RES, V62, P1004; Nusinzon I, 2003, P NATL ACAD SCI USA, V100, P14742, DOI 10.1073/pnas.2433987100; Park EJ, 2003, J BIOL CHEM, V278, P14747, DOI 10.1074/jbc.M210819200; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Schreiber S, 2002, GUT, V51, P379, DOI 10.1136/gut.51.3.379; Sen GC, 2000, SEMIN CANCER BIOL, V10, P93, DOI 10.1006/scbi.2000.0312; Shao JY, 2002, CANCER RES, V62, P3282; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Stallmach A, 1998, GUT, V43, P499, DOI 10.1136/gut.43.4.499; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Stephanou A, 1999, GENE EXPRESSION, V7, P311; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; SUN M, 1981, SCIENCE, V212, P141, DOI 10.1126/science.6163213; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Uddin S, 1997, BIOCHEM BIOPH RES CO, V235, P83, DOI 10.1006/bbrc.1997.6741; Ullman Thomas A., 2002, Curr Treat Options Gastroenterol, V5, P163, DOI 10.1007/s11938-002-0038-6; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; VILCEK J, 1970, SCIENCE, V168, P398, DOI 10.1126/science.168.3929.398; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wang JP, 2002, P NATL ACAD SCI USA, V99, P16209, DOI 10.1073/pnas.252454799; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; Welch JS, 2003, P NATL ACAD SCI USA, V100, P6712, DOI 10.1073/pnas.1031789100; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; You M, 1997, J BIOL CHEM, V272, P23376, DOI 10.1074/jbc.272.37.23376; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Zamai L, 1996, CYTOMETRY, V23, P303, DOI 10.1002/(SICI)1097-0320(19960401)23:4<303::AID-CYTO6>3.3.CO;2-B	83	144	148	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30358	30368		10.1074/jbc.M401359200	http://dx.doi.org/10.1074/jbc.M401359200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123634	hybrid			2022-12-25	WOS:000222531900061
J	Pan, YP; Ma, BY; Keskin, O; Nussinov, R				Pan, YP; Ma, BY; Keskin, O; Nussinov, R			Characterization of the conformational state and flexibility of HIV-1 glycoprotein gp120 core domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CD4 RECEPTOR-BINDING; ENVELOPE GLYCOPROTEIN; CRYSTAL-STRUCTURE; VARIABLE REGIONS; ATOMIC-STRUCTURE; NEUTRALIZATION; IDENTIFICATION; ANTIBODY; RETROVIRUS	gp120 is key to the human immunodeficiency virus type 1 viral cell entry. Knowledge of the detailed conformational states of gp120 is crucial to intervention, yet the unbound form is still resistant to structural characterization probably because of its flexibility. Toward this goal, we performed molecular dynamics simulations on the wild type gp120 core domain extracted from its ternary crystal structure and on a modeled mutant, S375W, that experimentally has a significantly different phenotype from the wild type. Although the mutant retained a bound-like conformation, the wild type drifted to a different conformational state. The wild type beta strands 2 and 3 of the bridging sheet were very mobile and partially unfolded, and the organization among the inner and outer domains and beta strands 20 and 21 of the bridging sheet, near the mutation site, was more open than in the bound form, although the overall structure was maintained. These differences were apparently a result of the strengthening of the hydrophobic core in the mutant. This stabilization further explains the experimentally significantly different thermodynamic properties between the wild type and the mutant. Taken together, our results suggest that the free form, although different from the bound state, shares many of the bound structural features. The observed loss of freedom near the binding site, rather than the previously hypothesized more dramatic conformational transition from the unbound to the bound state, appears to be the major contributor to the large entropy cost for the CD4 binding to the wild type.	NCI, Basic Res Program, Sci Applicat Int Corp Frederick Inc, Lab Expt & Computat Biol, Frederick, MD 21702 USA; Koc Univ, Ctr Computat Biol & Bioinformat, TR-34450 Istanbul, Turkey; Koc Univ, Coll Engn, TR-34450 Istanbul, Turkey; Tel Aviv Univ, Sackler Sch Med, Sackler Inst Mol Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); Koc University; Koc University; Tel Aviv University; Sackler Faculty of Medicine	Nussinov, R (corresponding author), NCI, Basic Res Program, Sci Applicat Int Corp Frederick Inc, Lab Expt & Computat Biol, Bldg 469,Rm 151, Frederick, MD 21702 USA.	ruthn@ncifcrf.gov	Ma, Buyong/F-9491-2011	Ma, Buyong/0000-0002-7383-719X; Nussinov, Ruth/0000-0002-8115-6415	NATIONAL CANCER INSTITUTE [Z01BC010441] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ARENDRUP M, 1992, J ACQ IMMUN DEF SYND, V5, P303; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; Biorn AC, 2004, BIOCHEMISTRY-US, V43, P1928, DOI 10.1021/bi035088i; Boussard C, 2002, EUR J MED CHEM, V37, P883, DOI 10.1016/S0223-5234(02)01412-5; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CORDONNIER A, 1989, NATURE, V340, P571, DOI 10.1038/340571a0; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Keskin O, 2002, BIOPHYS J, V83, P663, DOI 10.1016/S0006-3495(02)75199-0; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000; Kwong PD, 2000, STRUCTURE, V8, P1329, DOI 10.1016/S0969-2126(00)00547-5; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; Lin PF, 2003, P NATL ACAD SCI USA, V100, P11013, DOI 10.1073/pnas.1832214100; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; McKnight D, 2003, P NATL ACAD SCI USA, V100, P10581, DOI 10.1073/pnas.2035071100; MODROW S, 1987, J VIROL, V61, P570, DOI 10.1128/JVI.61.2.570-578.1987; MOEBIUS U, 1992, J EXP MED, V176, P507, DOI 10.1084/jem.176.2.507; Morikita T, 1997, AIDS RES HUM RETROV, V13, P1291, DOI 10.1089/aid.1997.13.1291; Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; PETERSON A, 1988, CELL, V54, P65, DOI 10.1016/0092-8674(88)90180-8; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; THALI M, 1992, J VIROL, V66, P5635, DOI 10.1128/JVI.66.9.5635-5641.1992; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; WEISS CD, 1990, J VIROL, V64, P5674, DOI 10.1128/JVI.64.11.5674-5677.1990; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Xiang SH, 2002, J VIROL, V76, P9888, DOI 10.1128/JVI.76.19.9888-9899.2002	42	29	30	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30523	30530		10.1074/jbc.M404364200	http://dx.doi.org/10.1074/jbc.M404364200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131118	hybrid, Green Submitted			2022-12-25	WOS:000222531900081
J	Stefansson, S; Yepes, M; Gorlatova, N; Day, DE; Moore, EG; Zabaleta, A; McMahon, GA; Lawrence, DA				Stefansson, S; Yepes, M; Gorlatova, N; Day, DE; Moore, EG; Zabaleta, A; McMahon, GA; Lawrence, DA			Mutants of plasminogen activator inhibitor-1 designed to inhibit neutrophil elastase and cathepsin g are more effective in vivo than their endogenous inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; REACTIVE-CENTER; ALPHA(1)-PROTEINASE INHIBITOR; ALPHA-1-PROTEINASE INHIBITOR; PHYSIOLOGICAL RELEVANCE; ESCHERICHIA-COLI; GROWTH-FACTOR; TISSUE-TYPE; LIPOPROTEIN; HEPARIN	Neutrophil elastase and cathepsin G are abundant intracellular neutrophil proteinases that have an important role in destroying ingested particles. However, when neutrophils degranulate, these proteinases are released and can cause irreparable damage by degrading host connective tissue proteins. Despite abundant endogenous inhibitors, these proteinases are protected from inhibition because of their ability to bind to anionic surfaces. Plasminogen activator inhibitor type-1 (PAI-1), which is not an inhibitor of these proteinases, possesses properties that could make it an effective inhibitor of neutrophil proteinases if its specificity could be redirected. PAI-1 efficiently inhibits surface-sequestered proteinases, and it efficiently mediates rapid cellular clearance of PAI-1-proteinase complexes. Therefore, we examined whether PAI-1 could be engineered to inhibit and clear neutrophil elastase and cathepsin G. By introducing specific mutations in the reactive center loop of wild-type PAI-1, we generated PAI-1 mutants that are effective inhibitors of both proteinases. Kinetic analysis shows that the inhibition of neutrophil proteinases by these PAI-1 mutants is not affected by the sequestration of neutrophil elastase and cathepsin G onto surfaces. In addition, complexes of these proteinases and PAI-1 mutants are endocytosed and degraded by lung epithelial cells more efficiently than either the neutrophil proteinases alone or in complex with their physiological inhibitors, alpha(1)-proteinase inhibitor and alpha(1)-anti-chymotrypsin. Finally, the PAI-1 mutants were more effective in reducing the neutrophil elastase and cathepsin G activities in an in vivo model of lung inflammation than were their physiological inhibitors.	JH Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA; Mol Innovat Inc, Southfield, MI 48034 USA		Stefansson, S (corresponding author), JH Holland Lab, Dept Vasc Biol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	StefansS@usa.redcross.org	Yepes, Manuel/C-3576-2011	Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055374, P01HL054710, R01HL055747, R43HL069624] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55374, HL55747, HL54710, 1 R43 HL69624-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; Belorgey D, 1998, BIOCHEMISTRY-US, V37, P16416, DOI 10.1021/bi981536o; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BIRRER P, 1995, RESPIRATION, V62, P25; BULLEN JJ, 1979, IMMUNOLOGY, V36, P781; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Coakley RJ, 2001, AM J MED SCI, V321, P33, DOI 10.1097/00000441-200101000-00006; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; Duranton J, 2000, J BIOL CHEM, V275, P3787, DOI 10.1074/jbc.275.6.3787; Duranton J, 2000, FEBS LETT, V473, P154, DOI 10.1016/S0014-5793(00)01512-X; EDELBERG JM, 1991, J BIOL CHEM, V266, P7488; ERMOLIEFF J, 1994, J BIOL CHEM, V269, P29502; Eyles JE, 1999, INT J PHARM, V189, P75, DOI 10.1016/S0378-5173(99)00239-2; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; Forsyth S, 2003, GENOMICS, V81, P336, DOI 10.1016/S0888-7543(02)00041-1; FROMMHERZ KJ, 1991, J BIOL CHEM, V266, P15356; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hastings GA, 1997, J BIOL CHEM, V272, P33062, DOI 10.1074/jbc.272.52.33062; HEKMAN CM, 1988, ARCH BIOCHEM BIOPHYS, V262, P199, DOI 10.1016/0003-9861(88)90182-8; Huntington JA, 1999, J MOL BIOL, V293, P449, DOI 10.1006/jmbi.1999.3184; IACOVIELLO L, 1995, ARTERIOSCL THROM VAS, V15, P2037, DOI 10.1161/01.ATV.15.11.2037; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KEIJER J, 1991, BLOOD, V78, P401; KEIJER J, 1991, BLOOD, V78, P1254; KISS I, 1989, J BIOL CHEM, V264, P8126; KITZ R, 1962, J BIOL CHEM, V237, P3245; Koehl C, 2003, J BIOL CHEM, V278, P12609, DOI 10.1074/jbc.M210074200; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; LAURENT P, 1989, BIOCHIM BIOPHYS ACTA, V994, P285, DOI 10.1016/0167-4838(89)90306-3; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; Lawrence DA, 1997, NAT STRUCT BIOL, V4, P339, DOI 10.1038/nsb0597-339; Le YY, 2002, TRENDS IMMUNOL, V23, P541, DOI 10.1016/S1471-4906(02)02316-5; LINZMEIER R, 1993, FEBS LETT, V321, P267, DOI 10.1016/0014-5793(93)80122-B; MALLAMPALLI RK, 1992, IN VITRO CELL DEV-AN, V28A, P181; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; ROSS R, 1989, LANCET, V1, P1179; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SHUBEITA HE, 1990, J BIOL CHEM, V265, P18379; Si-Tahar M, 1997, J BIOL CHEM, V272, P11636; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 1996, J BIOL CHEM, V271, P8215, DOI 10.1074/jbc.271.14.8215; STEFANSSON S, 1995, J CELL SCI, V108, P2361; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; TAKAHARA H, 1980, J BIOCHEM, V88, P417, DOI 10.1093/oxfordjournals.jbchem.a132988; Tucker HM, 1996, EUR J BIOCHEM, V237, P180, DOI 10.1111/j.1432-1033.1996.0180n.x; Wells MJ, 1999, THROMB HAEMOSTASIS, V81, P325, DOI 10.1055/s-0037-1614472; Welty-Wolf KE, 2001, SEMIN HEMATOL, V38, P35, DOI 10.1016/S0037-1963(01)90145-3; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WU K, 1995, BLOOD, V86, P1056, DOI 10.1182/blood.V86.3.1056.bloodjournal8631056	53	24	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29981	29987		10.1074/jbc.M401913200	http://dx.doi.org/10.1074/jbc.M401913200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131125	hybrid			2022-12-25	WOS:000222531900015
J	Wondrak, GT; Roberts, MJ; Jacobson, MK; Jacobson, EL				Wondrak, GT; Roberts, MJ; Jacobson, MK; Jacobson, EL			3-hydroxypyridine chromophores are endogenous sensitizers of photooxidative stress in human skin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAILLARD REACTION-PRODUCTS; SINGLET OXYGEN; CROSS-LINKS; ADVANCED GLYCATION; UVA; COLLAGEN; PYRIDOXINE; DAMAGE; IRRADIATION; PROTEINS	Photocarcinogenesis and photoaging are established consequences of chronic exposure of human skin to solar irradiation. Accumulating evidence supports a causative involvement of UVA irradiation in skin photodamage. UVA photodamage has been attributed to photosensitization by endogenous skin chromophores leading to the formation of reactive oxygen species and organic free radicals as key mediators of cellular photooxidative stress. In this study, 3-hydroxypyridine derivatives contained in human skin have been identified as a novel class of potential endogenous photosensitizers. A structure-activity relationship study of skin cell photosensitization by endogenous pyridinium derivatives ( pyridinoline, desmosine, pyridoxine, pyridoxamine, pyridoxal, pyridoxal-5'-phosphate) and various synthetic hydroxypyridine isomers identified 3-hydroxypyridine and N-alkyl-3-hydroxypyridinium cation as minimum phototoxic chromophores sufficient to effect skin cell sensitization toward UVB and UVA, respectively. Photosensitization of cultured human skin keratinocytes ( HaCaT) and fibroblasts (CF3) by endogenous and synthetic 3-hydroxypyridine derivatives led to a dose-dependent inhibition of proliferation, cell cycle arrest in G(2)/M, and induction of apoptosis, all of which were reversible by thiol antioxidant intervention. Enhancement of UVA-induced intracellular peroxide formation and p38 mitogen-activated protein kinase-dependent stress signaling suggest a photooxidative mechanism of skin cell photosensitization by 3-hydroxypyridine derivatives. 3-Hydroxypyridine derivatives were potent photosensitizers of macromolecular damage, effecting protein ( RNase A) photocross-linking and peptide (melittin) photooxidation with incorporation of molecular oxygen. Based on these results, we conclude that 3-hydroxypyridine derivatives comprising a wide range of skin biomolecules, such as enzymatic collagen cross-links, B-6 vitamers, and probably advanced glycation end products in chronologically aged skin constitute a novel class of UVA photosensitizers, capable of skin photooxidative damage.	Univ Arizona, Arizona Canc Ctr, Dept Pharmacol & Toxicol, Coll Pharm, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona	Jacobson, EL (corresponding author), Univ Arizona, Arizona Canc Ctr, Dept Pharmacol & Toxicol, Coll Pharm, 1515 N Campbell Ave, Tucson, AZ 85724 USA.	elaine.jacobson@pharmacy.arizona.edu			NATIONAL CANCER INSTITUTE [R41CA099469, R01CA043894] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038496] Funding Source: NIH RePORTER; NCI NIH HHS [CA099469-01A1, CA43894] Funding Source: Medline; NINDS NIH HHS [NS38496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agar NS, 2004, P NATL ACAD SCI USA, V101, P4954, DOI 10.1073/pnas.0401141101; Aveline BM, 1998, PHOTOCHEM PHOTOBIOL, V68, P266, DOI 10.1562/0031-8655(1998)068<0266:EFRMOC>2.3.CO;2; Bachelor MA, 2004, SEMIN CANCER BIOL, V14, P131, DOI 10.1016/j.semcancer.2003.09.017; Bachelor MA, 2002, ONCOGENE, V21, P7092, DOI 10.1038/sj.onc.1205855; Balakrishnan G, 2000, J PHYS CHEM A, V104, P1834, DOI 10.1021/jp993052n; Bilski P, 2000, PHOTOCHEM PHOTOBIOL, V71, P129, DOI 10.1562/0031-8655(2000)071&lt;0129:SIPVBP&gt;2.0.CO;2; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Buchczyk DP, 2001, CARCINOGENESIS, V22, P879, DOI 10.1093/carcin/22.6.879; CARBONARE MD, 1992, J PHOTOCH PHOTOBIO B, V14, P105, DOI 10.1016/1011-1344(92)85086-A; Coburn SP, 2003, J INVEST DERMATOL, V120, P292, DOI 10.1046/j.1523-1747.2003.12034.x; Daumer KM, 2000, J BIOL CHEM, V275, P34681, DOI 10.1074/jbc.M002003200; de Gruijl FR, 2000, METHOD ENZYMOL, V319, P359; deLaat JMT, 1997, EXP DERMATOL, V6, P292; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; FEITELSON J, 1973, J PHYS CHEM-US, V77, P10, DOI 10.1021/j100620a003; FOOTE CS, 1991, PHOTOCHEM PHOTOBIOL, V54, P659, DOI 10.1111/j.1751-1097.1991.tb02071.x; FUJIMOTO D, 1978, BIOCHEM BIOPH RES CO, V84, P52, DOI 10.1016/0006-291X(78)90261-9; Gasparro FP, 2000, ENVIRON HEALTH PERSP, V108, P71, DOI 10.2307/3454633; Gineyts E, 2000, BIOCHEM J, V345, P481, DOI 10.1042/0264-6021:3450481; Gortz V, 2002, MACROMOLECULES, V35, P4258, DOI 10.1021/ma011750b; GUPTASARMA P, 1992, BIOCHEMISTRY-US, V31, P4296, DOI 10.1021/bi00132a021; Harrison GI, 2004, J INVEST DERMATOL, V122, P183, DOI 10.1046/j.0022-202X.2003.22119.x; Heck DE, 2003, J BIOL CHEM, V278, P22432, DOI 10.1074/jbc.C300048200; Jeanmaire C, 2001, BRIT J DERMATOL, V145, P10, DOI 10.1046/j.1365-2133.2001.04275.x; Kipp C, 1999, PHOTOCHEM PHOTOBIOL, V70, P191, DOI 10.1562/0031-8655(1999)070<0191:TSEPDC>2.3.CO;2; Klotz LO, 2000, METHOD ENZYMOL, V319, P130; Kvam E, 1997, CARCINOGENESIS, V18, P2379, DOI 10.1093/carcin/18.12.2379; LEVY SB, 1992, J AM ACAD DERMATOL, V27, P989, DOI 10.1016/0190-9622(92)70300-5; Liu ZF, 2003, CHEM RES TOXICOL, V16, P232, DOI 10.1021/tx020095d; Luxford C, 1999, BIOCHEM J, V344, P125, DOI 10.1042/0264-6021:3440125; Maeda T, 2000, ARCH DERMATOL RES, V292, P562, DOI 10.1007/s004030000174; Menon EL, 2002, PHOTOCHEM PHOTOBIOL, V75, P565, DOI 10.1562/0031-8655(2002)075<0565:FOSOBU>2.0.CO;2; Metz TO, 2003, ARCH BIOCHEM BIOPHYS, V419, P41, DOI 10.1016/j.abb.2003.08.021; MORTHY PN, 1975, J AM CHEM SOC, V97; Murata Y, 1998, J AM ACAD DERMATOL, V39, P314, DOI 10.1016/S0190-9622(98)70379-2; Nagai R, 2002, J BIOL CHEM, V277, P48905, DOI 10.1074/jbc.M205688200; Ohta BK, 2002, J AM CHEM SOC, V124, P12064, DOI 10.1021/ja0205481; Okano Y, 2001, J DERMATOL SCI, V27, pS11; Ortwerth BJ, 1997, PHOTOCHEM PHOTOBIOL, V65, P666, DOI 10.1111/j.1751-1097.1997.tb01909.x; Pasquali M, 1997, P ASSOC AM PHYSICIAN, V109, P33; Peus D, 1998, J INVEST DERMATOL, V110, P966, DOI 10.1046/j.1523-1747.1998.00210.x; REIBER H, 1972, BIOCHIM BIOPHYS ACTA, V279, P310, DOI 10.1016/0304-4165(72)90148-1; REISER KM, 1987, BIOCHIM BIOPHYS ACTA, V926, P339, DOI 10.1016/0304-4165(87)90220-0; ROBINS SP, 1983, BIOCHEM J, V215, P167, DOI 10.1042/bj2150167; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SATO K, 1995, J INVEST DERMATOL, V105, P608, DOI 10.1111/1523-1747.ep12323724; SATO K, 1993, J INVEST DERMATOL, V100, P266, DOI 10.1111/1523-1747.ep12469648; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; SCHIRCH V, 1985, J BACTERIOL, V163, P1; SHWARTZMAN G, 1947, J BIOL CHEM, V167, P345; Tessier FJ, 2003, BIOCHEM J, V369, P705, DOI 10.1042/BJ20020668; Tyrrell RM, 1995, BIOCHEM SOC SYMP, P47, DOI 10.1042/bss0610047; Wang JH, 1996, J PHYS CHEM-US, V100, P16141, DOI 10.1021/jp961295z; Wolken JK, 1999, J AM CHEM SOC, V121, P6010, DOI 10.1021/ja983789a; Wondrak GT, 2003, J INVEST DERMATOL, V121, P578, DOI 10.1046/j.1523-1747.2003.12414.x; Wondrak GT, 2002, J INVEST DERMATOL, V119, P489, DOI 10.1046/j.1523-1747.2002.01788.x; Wondrak GT, 2002, PHOTOCH PHOTOBIO SCI, V1, P355, DOI 10.1039/b202732c; Wondrak GT, 2002, BIOCHEM PHARMACOL, V63, P361, DOI 10.1016/S0006-2952(01)00915-7; Wright A, 2003, FREE RADICAL BIO MED, V34, P637, DOI 10.1016/S0891-5849(02)01361-8; Young AR, 1997, PHYS MED BIOL, V42, P789, DOI 10.1088/0031-9155/42/5/004	61	56	57	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30009	30020		10.1074/jbc.M404379200	http://dx.doi.org/10.1074/jbc.M404379200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15133022	hybrid			2022-12-25	WOS:000222531900019
J	Lund, G; Andersson, L; Lauria, M; Lindholm, M; Fraga, MF; Villar-Garea, A; Ballestar, E; Esteller, M; Zaina, S				Lund, G; Andersson, L; Lauria, M; Lindholm, M; Fraga, MF; Villar-Garea, A; Ballestar, E; Esteller, M; Zaina, S			DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLHOMOCYSTEINE; HISTONE H4; HYPOMETHYLATION; HOMOCYSTEINE; EXPRESSION; DISEASE; CANCER; HYPERCHOLESTEROLEMIA; METHYLTRANSFERASE; TRANSCRIPTION	The present work investigates the occurrence and significance of aberrant DNA methylation patterns during early stages of atherosclerosis. To this end, we asked whether the genetically atherosclerosis-prone APOEnull mice show any changes in DNA methylation patterns before the appearance of histologically detectable vascular lesion. We exploited a combination of various techniques: DNA fingerprinting, in vitro methyl-accepting assay, 5-methylcytosine quantitation, histone post-translational modification analysis, Southern blotting, and PCR. Our results show that alterations in DNA methylation profiles, including both hyper- and hypomethylation, were present in aortas and PBMC of 4-week-old mutant mice with no detectable atherosclerotic lesion. Sequencing and expression analysis of 60 leukocytic polymorphisms revealed that epigenetic changes involve transcribed genic sequences, as well as repeated interspersed elements. Furthermore, we showed for the first time that atherogenic lipoproteins promote global DNA hypermethylation in a human monocyte cell line. Taken together, our results unequivocally show that alterations in DNA methylation profiles are early markers of atherosclerosis in a mouse model and may play a causative role in atherogenesis.	Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark; Royal Vet & Agr Coll, Dept Plant Biochem, Inst Plant Biol, DK-1871 Frederiksberg, Denmark; Lund Univ, Dept Med, S-20502 Malmo, Sweden; Spanish Natl Canc Ctr, Canc Epigenet Lab, Madrid 28029, Spain	Rigshospitalet; University of Copenhagen; University of Copenhagen; Lund University; Centro Nacional de Investigaciones Oncologicas (CNIO)	Zaina, S (corresponding author), Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark.	silvio.zaina@rh.dk	Fraga, Mario F/H-7824-2017; Ballestar, Esteban/ABG-8561-2020; Zaina, Silvio/C-5255-2017; Lindholm, Marie W/B-8736-2015; Lund, Gertrud/M-3612-2014; Esteller, Manel/L-5956-2014	Fraga, Mario F/0000-0001-8450-2603; Zaina, Silvio/0000-0001-6589-076X; Lindholm, Marie W/0000-0003-4309-3203; Lund, Gertrud/0000-0003-3556-8520; Esteller, Manel/0000-0003-4490-6093; Wikstrom Lindholm, Marie/0000-0002-0975-2394; Ballestar, Esteban/0000-0002-1400-2440; Villar Garea, Ana/0000-0001-8960-1635				AUVERX J, 1991, EXPERIENTIA, V47, P22; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Brattstrom L, 2000, AM J CLIN NUTR, V72, P315; Castro R, 2003, CLIN CHEM, V49, P1292, DOI 10.1373/49.8.1292; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Chen ZT, 2001, HUM MOL GENET, V10, P433, DOI 10.1093/hmg/10.5.433; Dong CM, 2002, J NUTR, V132, p2406S, DOI 10.1093/jn/132.8.2406S; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fraga MF, 2002, ELECTROPHORESIS, V23, P1677, DOI 10.1002/1522-2683(200206)23:11&lt;1677::AID-ELPS1677&gt;3.0.CO;2-Z; Friso S, 2002, J NUTR, V132, p2382S, DOI 10.1093/jn/132.8.2382S; Furano AV, 2000, PROG NUCLEIC ACID RE, V64, P255, DOI 10.1016/S0079-6603(00)64007-2; GOODWIN GH, 1977, BIOCHEM J, V167, P485, DOI 10.1042/bj1670485; GURLEY LR, 1983, ANAL BIOCHEM, V131, P465, DOI 10.1016/0003-2697(83)90200-2; Hansson GK, 2002, CIRC RES, V91, P281, DOI 10.1161/01.RES.0000029784.15893.10; Hashimshony T, 2003, NAT GENET, V34, P187, DOI 10.1038/ng1158; Hiltunen M, 2002, VASC MED, V7, P5, DOI 10.1191/1358863x02vm418oa; Hiltunen MO, 2003, ARTERIOSCL THROM VAS, V23, P1750, DOI 10.1161/01.ATV.0000092871.30563.41; Ingrosso D, 2003, LANCET, V361, P1693, DOI 10.1016/S0140-6736(03)13372-7; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; Issa JP, 2002, J NUTR, V132, p2388S, DOI 10.1093/jn/132.8.2388S; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Laukkanen MO, 1999, ARTERIOSCL THROM VAS, V19, P2171, DOI 10.1161/01.ATV.19.9.2171; Lauria M, 2004, PLANT CELL, V16, P510, DOI 10.1105/tpc.017780; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; LINDHOLM M, 1993, ANN NUTR METAB, V37, P302, DOI 10.1159/000177781; LINDNER H, 1992, J CHROMATOGR, V608, P211, DOI 10.1016/0021-9673(92)87126-S; MCCLELLAND M, 1994, NUCLEIC ACIDS RES, V22, P3640, DOI 10.1093/nar/22.17.3640; Moghadasian MH, 2001, FASEB J, V15, P2623, DOI 10.1096/fj.01-0463com; Muller K, 2001, J BIOL CHEM, V276, P14271; Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013; Newman PE, 1999, MED HYPOTHESES, V53, P421, DOI 10.1054/mehy.1998.0794; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Panin L. E., 1995, Ukrainskii Biokhimicheskii Zhurnal, V67, P64; Panin L E, 1998, Membr Cell Biol, V11, P631; Panin LE, 2003, J STEROID BIOCHEM, V87, P309, DOI 10.1016/j.jsbmb.2003.09.004; POPESKO P, 1992, COLOUR ATLAS ANATOMY, V2, P105; ReynaLopez GE, 1997, MOL GEN GENET, V253, P703, DOI 10.1007/s004380050374; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Santourlidis S, 1999, PROSTATE, V39, P166; Sarg B, 2002, J BIOL CHEM, V277, P39195, DOI 10.1074/jbc.M205166200; Schmitt F, 1997, J BIOL CHEM, V272, P1534, DOI 10.1074/jbc.272.3.1534; Schulz WA, 2002, GENE CHROMOSOME CANC, V35, P58, DOI 10.1002/gcc.10092; Steinberg D, 2002, NAT MED, V8, P1211, DOI 10.1038/nm1102-1211; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407; Yatabe Y, 2001, P NATL ACAD SCI USA, V98, P10839, DOI 10.1073/pnas.191225998; Yi P, 2000, J BIOL CHEM, V275, P29318, DOI 10.1074/jbc.M002725200; Zaina S, 2002, J BIOL CHEM, V277, P4505, DOI 10.1074/jbc.M108061200; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	53	240	288	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29147	29154		10.1074/jbc.M403618200	http://dx.doi.org/10.1074/jbc.M403618200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15131116	Green Published, hybrid			2022-12-25	WOS:000222445300040
J	Pozzi, A; Yan, XX; Macias-Perez, I; Wei, SZ; Hata, AN; Breyer, RM; Morrow, JD; Capdevila, JH				Pozzi, A; Yan, XX; Macias-Perez, I; Wei, SZ; Hata, AN; Breyer, RM; Morrow, JD; Capdevila, JH			Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FAMILIAL ADENOMATOUS POLYPOSIS; CYCLOOXYGENASE-2 OVEREXPRESSION; PROSTANOID RECEPTORS; TRANSGENIC MICE; KNOCKOUT MICE; CANCER CELLS; APC GENE; FACTOR-I; INHIBITION	Cyclooxygenase (COX) and its prostanoid metabolites have been implicated in the control of cell survival; however, their role as mitogens remains undefined. To better understand the role of prostanoids on cell growth, we used mouse colon adenocarcinoma (CT26) cells to investigate the role of prostaglandin E-2 (PGE(2)) in cell proliferation. CT26 cells express both COX1 and COX2 and metabolize arachidonic acid to PGE(2). Treatment with indomethacin, or COX-selective inhibitors, prevents PGE(2) biosynthesis and CT26 cell proliferation. The anti-proliferative effects of COX inhibition are rescued specifically by treatment with PGE(2) or the EP4 receptor-selective agonist PGE(1)-OH via phosphatidylinositol 3-kinase/extracellular signal-regulated kinase (ERK) activation, thus providing a functional link between PGE(2)-induced cell proliferation and EP4-mediated ERK signaling. Indomethacin or COX2 inhibitors, but not COX1 inhibitors, reduced the size and number of CT26-derived tumors in vivo. These inhibitory effects are paralleled by marked declines in the levels of tumor PGE(2), suggesting that their anti-tumor effects are directly associated with the inhibition of COX2 enzymatic activity. The described anti-tumor effects of indomethacin are evident whether it is administered at the time of, or 7 days after, tumor cell injection, suggesting that it has tumor preventive and therapeutic actions. Furthermore, the observation that indomethacin increases the survival rates of tumor-bearing mice, even after withdrawal of the drug, indicates that its effects are long lasting and that it may be potentially useful for the prevention and the clinical management of human cancers.	Vanderbilt Univ, Med Ctr, Dept Med, Div Nephrol,Med Ctr N, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN 37232 USA; Vet Affairs Hosp, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Pozzi, A (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Nephrol,Med Ctr N, B3109, Nashville, TN 37232 USA.	ambra.pozzi@vanderbilt.edu			NATIONAL CANCER INSTITUTE [R01CA094849, P01CA077839, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039261, R01DK048831, R01DK046205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER; NCI NIH HHS [CA94849-01, CA-68485, CA77839] Funding Source: Medline; NIDDK NIH HHS [DK48831, DK46205, P50-DK39261-16] Funding Source: Medline; NIGMS NIH HHS [GM 37922, GM15431] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baek SJ, 2002, J PHARMACOL EXP THER, V301, P1126, DOI 10.1124/jpet.301.3.1126; Bol DK, 2002, CANCER RES, V62, P2516; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P341, DOI 10.1016/0005-2760(94)00197-7; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; Fischer S M, 1980, Adv Prostaglandin Thromboxane Res, V6, P517; Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200; Giardiello FM, 1998, DIGEST DIS SCI, V43, P311; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Hansen-Petrik MB, 2002, CANCER RES, V62, P403; Hata AN, 2003, J PHARMACOL EXP THER, V306, P463, DOI 10.1124/jpet.103.050955; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hoshino T, 2003, J BIOL CHEM, V278, P12752, DOI 10.1074/jbc.M212097200; Leahy KM, 2002, CANCER RES, V62, P625; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Mahmoud NN, 1998, CARCINOGENESIS, V19, P87, DOI 10.1093/carcin/19.1.87; Marnett LJ, 2002, ANNU REV PHARMACOL, V42, P55, DOI 10.1146/annurev.pharmtox.42.082301.164620; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Mutoh M, 2002, CANCER RES, V62, P28; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Piazza GA, 1997, CANCER RES, V57, P2909; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Pozzi A, 2002, ONCOGENE, V21, P272, DOI 10.1038/sj.onc.1205045; Raz A, 2002, BIOCHEM PHARMACOL, V63, P343, DOI 10.1016/S0006-2952(01)00857-7; Reese J, 2000, P NATL ACAD SCI USA, V97, P9759, DOI 10.1073/pnas.97.17.9759; Rigas B, 2000, MED HYPOTHESES, V54, P210, DOI 10.1054/mehy.1999.0023; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Turini ME, 2002, ANNU REV MED, V53, P35, DOI 10.1146/annurev.med.53.082901.103952; Wilson JW, 2000, CANCER RES, V60, P4645; Yasumaru M, 2003, CANCER RES, V63, P6726	37	130	132	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29797	29804		10.1074/jbc.M313989200	http://dx.doi.org/10.1074/jbc.M313989200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123663	hybrid			2022-12-25	WOS:000222445300116
J	Aquilina, JA; Benesch, JLP; Ding, LL; Yaron, O; Horwitz, J; Robinson, CV				Aquilina, JA; Benesch, JLP; Ding, LL; Yaron, O; Horwitz, J; Robinson, CV			Phosphorylation of alpha B-crystallin alters chaperone function through loss of dimeric substructure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; HUMAN LENS CRYSTALLINS; AGE-RELATED-CHANGES; MASS-SPECTROMETRY; COMPLEXES; ELECTROSPRAY; SUBUNIT; DISEASE	Phosphorylation is the most common posttranslational modification of the alpha-crystallins in the human lens. These phosphorylated forms are not only important because of their abundance in aging lenses and the implications for cataract but also because they have been identified in patients with degenerative brain disease. By using mimics corresponding to the reported in vivo phosphorylation sites in the human lens, we have examined the effects of phosphorylation upon the chaperone-like properties and structure of alphaB-crystallin. Here we show that phosphorylation of alphaB-crystallin at Ser-45 results in uncontrolled aggregation. By using an innovative tandem mass spectrometry approach, we demonstrate how this alteration in behavior stems from disruption of dimeric substructure within the polydisperse alphaB-crystallin assembly. This structural perturbation appears to disturb the housekeeping role of alphaB-crystallin and consequently has important implications for the disease states caused by protein aggregation in the lens and deposition in non-lenticular tissue.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA	University of Cambridge; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Robinson, CV (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	cvr24@cam.ac.uk	Aquilina, John Andrew/AGF-4013-2022; Aquilina, J. Andrew/A-5366-2013; Benesch, Justin/A-4250-2008	Benesch, Justin/0000-0002-1507-3742; robinson, carol/0000-0001-7829-5505	NEI NIH HHS [EY 3897] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY003897, R37EY003897] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aquilina JA, 2003, P NATL ACAD SCI USA, V100, P10611, DOI 10.1073/pnas.1932958100; Benesch JLP, 2003, ANAL CHEM, V75, P2208, DOI 10.1021/ac034132x; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Carver JA, 1996, EXP EYE RES, V63, P639, DOI 10.1006/exer.1996.0158; Clark JI, 2000, CURR OPIN STRUC BIOL, V10, P52, DOI 10.1016/S0959-440X(99)00048-2; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; Friedrich KL, 2004, J BIOL CHEM, V279, P1080, DOI 10.1074/jbc.M311104200; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Haslbeck M, 2004, EMBO J, V23, P638, DOI 10.1038/sj.emboj.7600080; Haslbeck Martin, 2002, Prog Mol Subcell Biol, V28, P37; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200; Kamei A, 2001, BIOL PHARM BULL, V24, P96, DOI 10.1248/bpb.24.96; Kantorow M, 1998, INT J BIOL MACROMOL, V22, P307, DOI 10.1016/S0141-8130(98)00028-2; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Lampi KJ, 1998, EXP EYE RES, V67, P31, DOI 10.1006/exer.1998.0481; Ma ZX, 1998, EXP EYE RES, V67, P21, DOI 10.1006/exer.1998.0482; MANN E, 1991, FEBS LETT, V294, P133, DOI 10.1016/0014-5793(91)81359-G; MIESBAUER LR, 1994, J BIOL CHEM, V269, P12494; Moroni M, 2001, BBA-PROTEIN STRUCT M, V1546, P282, DOI 10.1016/S0167-4838(01)00154-6; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Sobott F, 2002, ANAL CHEM, V74, P1402, DOI 10.1021/ac0110552; Sobott F, 2002, J BIOL CHEM, V277, P38921, DOI 10.1074/jbc.M206060200; Stromer T, 2003, J BIOL CHEM, V278, P18015, DOI 10.1074/jbc.M301640200; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; VANKLEEF FSM, 1975, NATURE, V258, P264, DOI 10.1038/258264a0; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; Wieske M, 2001, EUR J BIOCHEM, V268, P2083, DOI 10.1046/j.1432-1327.2001.02082.x; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9	33	140	144	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28675	28680		10.1074/jbc.M403348200	http://dx.doi.org/10.1074/jbc.M403348200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117944	hybrid			2022-12-25	WOS:000222265400104
J	Beom, SR; Cheong, D; Torres, G; Caron, MG; Kim, KM				Beom, SR; Cheong, D; Torres, G; Caron, MG; Kim, KM			Comparative studies of molecular mechanisms of dopamine D-2 and D-3 receptors for the activation of extracellular signal-regulated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; GROWTH-FACTOR RECEPTOR; G-BETA-GAMMA; C-DEPENDENT MECHANISM; MAP KINASE; BETA(2)-ADRENERGIC RECEPTOR; DIFFERENTIAL REGULATION; INOSITOL TRISPHOSPHATE; MEDIATED ENDOCYTOSIS; DISTINCT PATHWAYS	Dopamine D-2 and D-3 receptors (D2R/D3R), which have similar structural architecture as well as functional similarities, are expressed in the same brain dopaminergic neurons. It is intriguing that two receptor proteins with virtually the same functional roles are expressed in the same neuron. Recently we have shown that D2R and D3R possess different regulatory processes including intracellular trafficking properties, which implies that they might employ different signaling mechanisms for regulation of the same cellular processes. Here we studied the signaling pathways of ERK activation mediated by D2R and D3R in HEK-293 cells and corroborated them with concomitant studies in COS-7 cells and C6 cells. Our results show that Src, phosphatidylinositol 3-kinase, and atypical protein kinase C were commonly involved in D2R-/D3R-mediated ERK activation. However, beta-arrestin and sequestration of D2R/D3R were found not to be involved. ERK activations mediated by D3R, but not D2R, were blocked by betaARK-CT, AG1478 epidermal growth factor receptor ( EGFR) inhibitor, and by dominant negative mutants of Ras and Raf, suggesting the involvement of the Gbeta(gammai) pathway. The alpha-subunit of G(o) (Galpha(o)) was able to couple with D3R to mediate ERK activation. We conclude that D3R mainly utilizes the betagamma pathway of G(i) protein, which involves the transactivation of EGFR in HEK-293 cells. In contrast, the alpha-subunit of the G(i) protein plays a main role in D2R-mediated ERK activation. Our study suggests one example of intricate cellular regulations in the brain, that is, dopaminergic neurons could regulate ERK activity more flexibly through alternative usage of either the D2R or D3R pathway depending on the cellular situation.	Chonnam Natl Univ, Coll Pharm, Dept Pharmacol, Kwangju 500757, South Korea; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Chonnam National University; Duke University	Kim, KM (corresponding author), Chonnam Natl Univ, Coll Pharm, Dept Pharmacol, Kwangju 500757, South Korea.	kmkim@chonnam.ac.kr	Kim, Kyeong-Man/AAA-9847-2020					AHN S, 2004, J BIOL CHEM; Banihashemi B, 2002, MOL ENDOCRINOL, V16, P2393, DOI 10.1210/me.2001-0220; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Casabona G, 1997, PROG NEURO-PSYCHOPH, V21, P407, DOI 10.1016/S0278-5846(97)00011-0; Chen W, 2001, P NATL ACAD SCI USA, V98, P14889, DOI 10.1073/pnas.211572798; Choi EY, 1999, BIOCHEM BIOPH RES CO, V256, P33, DOI 10.1006/bbrc.1999.0286; Cussac D, 1999, MOL PHARMACOL, V56, P1025, DOI 10.1124/mol.56.5.1025; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Diaz J, 2000, J NEUROSCI, V20, P8677; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; Diverse-Pierluissi MA, 1999, J BIOL CHEM, V274, P14490, DOI 10.1074/jbc.274.20.14490; Downward J, 1996, CANCER SURV, V27, P87; Ghahremani MH, 2000, MOL CELL BIOL, V20, P1497, DOI 10.1128/MCB.20.5.1497-1506.2000; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GIROS B, 1990, CR ACAD SCI III-VIE, V311, P501; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Gurevich EV, 1999, NEUROPSYCHOPHARMACOL, V20, P60, DOI 10.1016/S0893-133X(98)00066-9; Gutkind J. S., 2000, SCI STKE, pre1, DOI DOI 10.1126/STKE.2000.40.RE1; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; KAWAGOE KT, 1992, NEUROSCIENCE, V51, P55, DOI 10.1016/0306-4522(92)90470-M; Kim KM, 2001, J BIOL CHEM, V276, P37409, DOI 10.1074/jbc.M106728200; KIM SJ, 2003, MOL ENDOCRINOL; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Lefkowitz RJ, 2002, MOL PHARMACOL, V62, P971, DOI 10.1124/mol.62.5.971; Leof EB, 2000, TRENDS CELL BIOL, V10, P343, DOI 10.1016/S0962-8924(00)01795-5; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Liu JC, 2002, J BIOL CHEM, V277, P35819, DOI 10.1074/jbc.M202920200; Luo YQ, 1998, J NEUROCHEM, V71, P980; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Oak JN, 2001, MOL PHARMACOL, V60, P92, DOI 10.1124/mol.60.1.92; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; PIZZI M, 1987, EUR J PHARMACOL, V136, P263, DOI 10.1016/0014-2999(87)90724-2; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rasolonjanahary R, 2002, ENDOCRINOLOGY, V143, P747, DOI 10.1210/en.143.3.747; ROBINSON SW, 1994, MOL PHARMACOL, V46, P352; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; VAN BT, 1995, NATURE, V376, P781; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Welsh GI, 1998, J NEUROCHEM, V70, P2139; Xue LZ, 1998, CELL SIGNAL, V10, P339, DOI 10.1016/S0898-6568(98)00011-4; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	65	95	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28304	28314		10.1074/jbc.M403899200	http://dx.doi.org/10.1074/jbc.M403899200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102843	hybrid			2022-12-25	WOS:000222265400062
J	Chen, C; Dudenhausen, EE; Pan, YX; Zhong, C; Kilberg, MS				Chen, C; Dudenhausen, EE; Pan, YX; Zhong, C; Kilberg, MS			Human CCAAT/enhancer-binding protein beta gene expression is activated by endoplasmic reticulum stress through an unfolded protein response element downstream of the protein coding sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE SYNTHETASE GENE; TRANSCRIPTION FACTORS; MESSENGER-RNA; C/EBP FAMILY; ER STRESS; NF-Y; ATF6; CELLS; PROMOTER; PATHWAYS	CCAAT/enhancer-binding protein beta (C/EBPbeta) is a member of the bZIP family of transcription factors that contribute to the regulation of a wide range of important cellular processes. The data in the present study document that transcription from the human C/EBPbeta gene is induced in response to endoplasmic reticulum stress, such as glucose deprivation, or treatment of cells with tunicamycin or thapsigargin. Transient transfection of C/EBPbeta genomic fragments linked to a luciferase reporter gene demonstrated that the C/EBPbeta promoter plays no major regulatory role. Instead, by deletion analysis it was discovered that a 46-bp region, located at a genomic site that corresponds to the 3'-untranslated region of the C/EBPbeta mRNA, harbored an element that was required for the stress response. Mutagenesis demonstrated that a cis-regulatory element located at nt + 1614 - 1621 (5'-TGACGCAA-3') is responsible for activation of the C/EBPbeta gene. Electrophoresis mobility shift analysis revealed that proteins are bound to this element and that the amount of binding is increased following glucose deprivation. This element is homologous to a previously reported mammalian unfolded protein response element that binds XBP-1. Consistent with those data, overexpression of XBP-1 caused an increase in transcription that was mediated by the C/EBPbeta mammalian unfolded protein response element.	Univ Florida, Coll Med, Ctr Mammalian Genet, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Ctr Nutr Sci, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Kilberg, MS (corresponding author), Univ Florida, Coll Med, Ctr Mammalian Genet, Dept Biochem & Mol Biol, Box 100245, Gainesville, FL 32610 USA.	mkilberg@ufl.edu	Pan, Yuan-Xiang/C-6576-2019	Pan, Yuan-Xiang/0000-0003-3219-4367	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059315, R01DK052064] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 59315, DK 52064] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Aslanian AM, 2001, BIOCHEM J, V357, P321, DOI 10.1042/0264-6021:3570321; Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; KILBERG MS, 1989, METHOD ENZYMOL, V173, P564; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Leung-Pineda V, 2002, J BIOL CHEM, V277, P16585, DOI 10.1074/jbc.M110972200; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; MARTEN NW, 1994, FASEB J, V8, P538, DOI 10.1096/fasebj.8.8.8181673; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Newman JRS, 2003, SCIENCE, V300, P2097, DOI 10.1126/science.1084648; Niehof M, 2001, J MOL BIOL, V309, P855, DOI 10.1006/jmbi.2001.4708; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Pan YX, 2003, J BIOL CHEM, V278, P38402, DOI 10.1074/jbc.M304574200; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Takiguchi M, 1998, INT J EXP PATHOL, V79, P369, DOI 10.1046/j.1365-2613.1998.00082.x; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang Y, 2000, J BIOL CHEM, V275, P27013; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhong C, 2003, BIOCHEM J, V372, P603, DOI 10.1042/BJ20030076; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	39	56	56	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27948	27956		10.1074/jbc.M313920200	http://dx.doi.org/10.1074/jbc.M313920200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102854	hybrid			2022-12-25	WOS:000222265400016
J	Kim, HJ; Kim, JY; Kim, JY; Park, SK; Seo, JH; Kim, JB; Lee, IK; Kim, KS; Choi, HS				Kim, HJ; Kim, JY; Kim, JY; Park, SK; Seo, JH; Kim, JB; Lee, IK; Kim, KS; Choi, HS			Differential regulation of human and mouse orphan nuclear receptor small heterodimer partner promoter by sterol regulatory element binding protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE FEEDBACK-REGULATION; RETINOID-X-RECEPTOR; BILE-ACID SYNTHESIS; SHP GENE PROMOTER; TRANSGENIC MICE; LXR-ALPHA; TRANSCRIPTIONAL REGULATION; SYNERGISTIC ACTIVATION; ESTROGEN-RECEPTORS; SYNTHASE PROMOTER	Small heterodimer partner (SHP; NR0B2) is an unusual orphan nuclear receptor that lacks a conventional DNA-binding domain and acts as a modulator of transcriptional activities of a number of nuclear receptors. Herein, we report that the human SHP promoter (hSHP) is activated by sterol regulatory element-binding protein-1 (SREBP-1), which regulates the expression of various genes involved in cholesterol and fatty acid synthesis. Overexpression of SREBP-1 activated the human but not mouse SHP promoter, although SREBP-2 had little effect on the SHP promoter in CV-1 cells. Serial deletion reporter assays revealed that SREBP-1-responsive region is located within the sequences from - 243 to - 120 bp in the hSHP promoter. DNase I footprinting, gel shift assays, and chromatin immunoprecipitation assays demonstrated that SREBP-1 binds directly to the hSHP promoter. Site-directed mutagenesis made it clear that the hSHP promoter activation by SREBP-1 is mostly mediated by the SRE1 ( - 186 to - 195 bp) in the hSHP promoter, which is not conserved in the mouse SHP promoter. Moreover, adenovirus- mediated overexpression of SREBP-1c/ADD-1induced SHP mRNA expression and repressed CYP7A1 expression in HepG2 cells. Finally, we found that a four-nucleotide deletion ( - 195CT-GAdel) in the hSHP promoter, which is reported to be associated with altered body weight and insulin secretion in human, coincides with the SRE1. This mutation strongly decreased both basal and SREBP-1 dependent activities of the hSHP promoter, because of the reduced binding of SREBP-1 to the mutated SRE1. Overall, our results demonstrate a differential regulation of human and mouse SHP promoters by SREBP-1. We propose a possible role of SREBP-1 in the species differential regulation of cholesterol and bile acid homeostasis via a novel mechanism of up-regulation of the hSHP gene expression.	Chonnam Natl Univ, Sch Biol Sci & Technol, Hormone Res Ctr, Kwangju 500757, South Korea; Yonsei Univ, Coll Med, Inst Genet Sci, Dept Biochem & Mol Biol, Seoul 120752, South Korea; Keimyung Univ, Sch Med, Dept Internal Med, Taegu 700712, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea	Chonnam National University; Yonsei University; Yonsei University Health System; Keimyung University; Seoul National University (SNU)	Choi, HS (corresponding author), Chonnam Natl Univ, Sch Biol Sci & Technol, Hormone Res Ctr, Kwangju 500757, South Korea.	hsc@chonnam.ac.kr	Song, Minsun/I-5701-2015	KIM, Jae Bum/0000-0003-2337-6935; Kim, Kyung-sup/0000-0001-8483-8537				Borgius LJ, 2002, J BIOL CHEM, V277, P49761, DOI 10.1074/jbc.M205641200; Brendel C, 2002, MOL ENDOCRINOL, V16, P2065, DOI 10.1210/me.2001-0194; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Chakravarty K, 2004, J BIOL CHEM, V279, P15385, DOI 10.1074/jbc.M309905200; Chen J, 1999, BIOCHEM BIOPH RES CO, V260, P829, DOI 10.1006/bbrc.1999.0980; Choi YK, 2003, GENE THER, V10, P559, DOI 10.1038/sj.gt.3301926; Dooley KA, 1999, J BIOL CHEM, V274, P5285, DOI 10.1074/jbc.274.9.5285; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Gobinet J, 2001, BIOCHEMISTRY-US, V40, P15369, DOI 10.1021/bi011384o; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Goodwin B, 2003, MOL ENDOCRINOL, V17, P386, DOI 10.1210/me.2002-0246; Guan GM, 1997, J BIOL CHEM, V272, P10295; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Hung CCC, 2003, DIABETES, V52, P1288, DOI 10.2337/diabetes.52.5.1288; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Kim HJ, 2003, NUCLEIC ACIDS RES, V31, P6860, DOI 10.1093/nar/gkg906; Lee HK, 1998, J BIOL CHEM, V273, P14398, DOI 10.1074/jbc.273.23.14398; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lee YK, 1999, J BIOL CHEM, V274, P20869, DOI 10.1074/jbc.274.30.20869; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Menke JG, 2002, ENDOCRINOLOGY, V143, P2548, DOI 10.1210/en.143.7.2548; Mitchell SMS, 2003, DIABETES, V52, P1276, DOI 10.2337/diabetes.52.5.1276; Moon YA, 2000, J BIOL CHEM, V275, P30280, DOI 10.1074/jbc.M001066200; Nishigori H, 2001, P NATL ACAD SCI USA, V98, P575, DOI 10.1073/pnas.98.2.575; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sanyal S, 2002, J BIOL CHEM, V277, P1739, DOI 10.1074/jbc.M106140200; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Seo JB, 2003, MOL ENDOCRINOL, V17, P1522, DOI 10.1210/me.2003-0028; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shih DQ, 2001, DIABETES, V50, P2472, DOI 10.2337/diabetes.50.11.2472; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; Wang DP, 1996, J LIPID RES, V37, P1831; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; WANG XD, 1993, J BIOL CHEM, V268, P14497; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001	53	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28122	28131		10.1074/jbc.M313302200	http://dx.doi.org/10.1074/jbc.M313302200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123650	hybrid			2022-12-25	WOS:000222265400038
J	Kofler, M; Heuer, K; Zech, T; Freund, C				Kofler, M; Heuer, K; Zech, T; Freund, C			Recognition sequences for the GYF domain reveal a possible spliceosomal function of CD2BP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH PEPTIDE; PHOSPHOLIPASE-C; SPOT-SYNTHESIS; SH3 DOMAIN; WW DOMAIN; PROTEIN; MOTIF; IDENTIFICATION; SIMILARITY; ACTIVATION	Protein-protein interactions are often mediated by small domains that recognize solvent-exposed peptide sequences. Deciphering the recognition code for these adapter domains is an important step in the understanding of multi-protein assemblies. Here, we investigate the sequence requirements for the CD2BP2-GYF domain, a proline-rich sequence binding module previously shown to be involved in T cell signaling. We show that the signature (R/K/G)XXPPGX(R/K) defines a preferred peptide-binding motif that is present in several proteins of the splicing machinery. Specifically, the core small nuclear ribonucleoprotein, SmB/B', contains several PPP-PGMR motifs that interact with the CD2BP2-GYF domain in vitro and in vivo. The colocalization of CD2BP2 and SmB proteins in the nucleus of Jurkat T cells and HeLa cells suggests a function of the GYF domain of CD2BP2 in mediating protein-protein interactions within the spliceosome.	Forschungsinst Mol Pharmakol, Prot Engn Grp, D-13125 Berlin, Germany; Free Univ Berlin, D-13125 Berlin, Germany	Free University of Berlin	Freund, C (corresponding author), Forschungsinst Mol Pharmakol, Prot Engn Grp, Robert Rossle Str 10, D-13125 Berlin, Germany.	freund@fmp-berlin.de		Zech, Tobias/0000-0001-8394-088X				Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CHANG HC, 1990, J EXP MED, V172, P351, DOI 10.1084/jem.172.1.351; ECCLES C, 1991, Journal of Biomolecular NMR, V1, P111, DOI 10.1007/BF01877224; Espejo A, 2002, BIOCHEM J, V367, P697, DOI 10.1042/BJ20020860; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; FREUND C, 1993, FEBS LETT, V320, P97, DOI 10.1016/0014-5793(93)80070-B; Freund C, 2003, J BIOMOL NMR, V27, P143, DOI 10.1023/A:1024983029700; Freund C, 2002, EMBO J, V21, P5985, DOI 10.1093/emboj/cdf602; Freund C, 1999, NAT STRUCT BIOL, V6, P656, DOI 10.1038/10712; Goddard T.D., 2004, SPARKY 3; Hartmuth K, 2002, P NATL ACAD SCI USA, V99, P16719, DOI 10.1073/pnas.262483899; Heuer K, 2004, STRUCTURE, V12, P603, DOI 10.1016/j.str.2004.02.021; Kramer A, 1998, METH MOL B, V87, P25; Kramer A, 1999, J PEPT RES, V54, P319, DOI 10.1034/j.1399-3011.1999.00108.x; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Nishizawa K, 1998, P NATL ACAD SCI USA, V95, P14897, DOI 10.1073/pnas.95.25.14897; Pornillos O, 2002, NAT STRUCT BIOL, V9, P812, DOI 10.1038/nsb856; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0	23	30	31	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28292	28297		10.1074/jbc.M402008200	http://dx.doi.org/10.1074/jbc.M402008200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15105431	hybrid			2022-12-25	WOS:000222265400060
J	Ling, GY; Hauer, CR; Gronostajski, RM; Pentecost, BT; Ding, XX				Ling, GY; Hauer, CR; Gronostajski, RM; Pentecost, BT; Ding, XX			Transcriptional regulation of rat CYP2A3 by nuclear factor 1 - Identification of a novel NFI-A isoform, and evidence for tissue-selective interaction of NFI with the CYP2A3 promoter in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE LOCUS; DNA METHYLATION; GENE-TRANSCRIPTION; OLFACTORY MUCOSA; BINDING SITES; PROTEIN GENE; ACTIVATION; EXPRESSION; ELEMENT; FAMILY	Rat CYP2A3 and its mouse and human orthologs are expressed preferentially in the olfactory mucosa. We found previously that an element in the proximal promoter region of CYP2A3 ( the nasal predominant transcriptional activating (NPTA) element), which is similar to a nuclear factor 1 (NFI)-binding site, is critical for transcriptional activation of CYP2A3 in vitro. We proposed that this element might be important for tissue-selective CYP2A3 expression. The goals of the present study were to characterize NPTA-binding proteins and to obtain more definitive evidence for the role of NFI in the transcriptional activation of CYP2A3. The NPTA-binding proteins were isolated by DNA-affinity purification from rat olfactory mucosa. Mass spectral analysis indicated that isoforms corresponding to all four NFI genes were present in the purified NPTA-binding fraction. Further analysis of NPTA-binding proteins led to the identification of a novel NFI-A isoform, NFI-A-short, which was derived from alternative splicing of the NFI-A transcript. Transient transfection assay showed that NFI-A2, an NFI isoform previously identified in the olfactory mucosa, transactivated the CYP2A3 promoter, whereas NFI-A-short, which lacks the transactivation domain, counteracted the activation. Chromatin immunoprecipitation assays indicated that NFI proteins are associated with the CYP2A3 promoter in vivo, in rat olfactory mucosa, but essentially not in the liver where the CYP2A3 promoter is hypermethylated and CYP2A3 is not expressed. These data strongly support a role for NFI transcription factors in the transcriptional activation of CYP2A3.	New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Albany, NY 12201 USA; SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Ding, XX (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Empire State Plaza,Box 509, Albany, NY 12201 USA.	dingx@wadsworth.org		Hauer, Christoph/0000-0001-8704-2198; Gronostajski, Richard/0000-0003-4264-208X	NICHD NIH HHS [HD 34908] Funding Source: Medline; NIDDK NIH HHS [DK 58401] Funding Source: Medline; NIEHS NIH HHS [ES 07462] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058401] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007462] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baumeister H, 1999, MOL BRAIN RES, V72, P65, DOI 10.1016/S0169-328X(99)00210-7; Behrens M, 2000, EUR J NEUROSCI, V12, P1372, DOI 10.1046/j.1460-9568.2000.00032.x; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Blomquist P, 1996, J BIOL CHEM, V271, P153, DOI 10.1074/jbc.271.1.153; Carr BA, 2003, J BIOL CHEM, V278, P15473, DOI 10.1074/jbc.M300319200; Chaudhry AZ, 1999, J BIOL CHEM, V274, P7072, DOI 10.1074/jbc.274.11.7072; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; das Neves L, 1999, P NATL ACAD SCI USA, V96, P11946, DOI 10.1073/pnas.96.21.11946; DING X, 2003, HDB OLFACTION GUSTAT, P51; Ding XX, 2003, ANNU REV PHARMACOL, V43, P149, DOI 10.1146/annurev.pharmtox.43.100901.140251; El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002; FERNANDEZSALGUE.P, 1995, PHARMACOGENETICS, V5, P123; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Grunder A, 2003, GENE, V304, P171, DOI 10.1016/S0378-1119(02)01204-0; Grunder A, 2002, MECH DEVELOP, V112, P69, DOI 10.1016/S0925-4773(01)00640-2; Honkakoski P, 1997, DRUG METAB REV, V29, P977, DOI 10.3109/03602539709002240; Kannius-Janson M, 2002, J BIOL CHEM, V277, P17589, DOI 10.1074/jbc.M105979200; Kim J, 2001, J BIOL CHEM, V276, P7559, DOI 10.1074/jbc.M008090200; KUDRYCKI K, 1993, MOL CELL BIOL, V13, P3002, DOI 10.1128/MCB.13.5.3002; Leahy P, 1999, J BIOL CHEM, V274, P8813, DOI 10.1074/jbc.274.13.8813; Lin XH, 2003, CANCER RES, V63, P498; Liu YC, 1997, J BIOL CHEM, V272, P10739; Morel Y, 1998, J BIOL CHEM, V273, P26969, DOI 10.1074/jbc.273.41.26969; Nakajima M, 2003, TOXICOL LETT, V144, P247, DOI 10.1016/S0378-4274(03)00216-9; Norquay LD, 2003, MOL ENDOCRINOL, V17, P1027, DOI 10.1210/me.2003-0025; Ortiz L, 1999, J BIOL CHEM, V274, P15213, DOI 10.1074/jbc.274.21.15213; Osada S, 1997, J BIOCHEM, V121, P355; Osano K, 2003, EUR J BIOCHEM, V270, P2532, DOI 10.1046/j.1432-1033.2003.03628.x; Steele-Perkins G, 2003, MOL CELL BIOL, V23, P1075, DOI 10.1128/MCB.23.3.1075-1084.2003; Su T, 2002, DRUG METAB DISPOS, V30, P548, DOI 10.1124/dmd.30.5.548; Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599; Wang HJ, 2003, CANCER RES, V63, P8057; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Xie YQ, 2001, BIOCHEM BIOPH RES CO, V289, P1225, DOI 10.1006/bbrc.2001.6084; Zhang JH, 1998, J BIOL CHEM, V273, P23454, DOI 10.1074/jbc.273.36.23454; Zhang JH, 2000, J BIOL CHEM, V275, P8895, DOI 10.1074/jbc.275.12.8895	38	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27888	27895		10.1074/jbc.M403705200	http://dx.doi.org/10.1074/jbc.M403705200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123731	hybrid			2022-12-25	WOS:000222265400010
J	Yokoyama, T; Chong, KT; Miyazaki, G; Morimoto, H; Shih, DTB; Unzai, S; Tame, JRH; Park, SY				Yokoyama, T; Chong, KT; Miyazaki, G; Morimoto, H; Shih, DTB; Unzai, S; Tame, JRH; Park, SY			Novel mechanisms of pH sensitivity in tuna hemoglobin - A structural explanation of the root effect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL ADULT HEMOGLOBIN; FISH PAGOTHENIA-BERNACCHII; BETA-146 HISTIDYL RESIDUE; X-RAY-DIFFRACTION; CRYSTAL-STRUCTURE; T-STATE; ALLOSTERIC MECHANISM; THUNNUS-THYNNUS; MOLECULAR-BASIS; BLUEFIN TUNA	The crystal structure of hemoglobin has been known for several decades, yet various features of the molecule remain unexplained or controversial. Several animal hemoglobins have properties that cannot be readily explained in terms of their amino acid sequence and known atomic models of hemoglobin. Among these, fish hemoglobins are well known for their widely varying interactions with heterotropic effector molecules and pH sensitivity. Some fish hemoglobins are almost completely insensitive to pH (within physiological limits), whereas others show extremely low oxygen affinity under acid conditions, a phenomenon called the Root effect. X-ray crystal structures of Root effect hemoglobins have not, to date, provided convincing explanations of this effect. Sequence alignments have signally failed to pinpoint the residues involved, and site-directed mutagenesis has not yielded a human hemoglobin variant with this property. We have solved the crystal structure of tuna hemoglobin in the deoxy form at low and moderate pH and in the presence of carbon monoxide at high pH. A comparison of these models shows clear evidence for novel mechanisms of pH-dependent control of ligand affinity.	Yokohama City Univ, Prot Design Lab, Yokohama, Kanagawa 2300045, Japan; Osaka Univ, Grad Sch Engn Sci, Dept Bioengn, Osaka 5608531, Japan; Taipei Med Univ, Grad Inst Cell & Mol Biol, Taipei 100, Taiwan; Taipei Med Univ, Ctr Stem Cell Res, Taipei 100, Taiwan	Yokohama City University; Osaka University; Taipei Medical University; Taipei Medical University	Tame, JRH (corresponding author), Yokohama City Univ, Prot Design Lab, Suehiro Cho 1-7-29, Yokohama, Kanagawa 2300045, Japan.	jtame@tsurumi.yokohama-cu.ac.jp; park@tsurumi.yokohama-cu.ac.jp		Yokoyama, Takeshi/0000-0002-5362-8606				ARNONE A, 1972, NATURE, V237, P146, DOI 10.1038/237146a0; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; Bettati S, 1996, PROTEINS, V25, P425, DOI 10.1002/(SICI)1097-0134(199608)25:4<425::AID-PROT3>3.3.CO;2-A; Bohr C, 1904, SKAND ARCH PHYSIOL, V16, P402, DOI 10.1111/j.1748-1716.1904.tb01382.x; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BRUNGER AT, 1996, X PLOR SYSTEM CRYSTA; BRUNORI M, 1966, ARCH BIOCHEM BIOPHYS, V114, P195, DOI 10.1016/0003-9861(66)90321-3; BUSCH MR, 1991, BIOCHEMISTRY-US, V30, P1865, DOI 10.1021/bi00221a020; BUSCH MR, 1990, BIOPHYS CHEM, V37, P313, DOI 10.1016/0301-4622(90)88031-M; CAMARDELLA L, 1992, J MOL BIOL, V224, P449, DOI 10.1016/0022-2836(92)91007-C; CAREY FG, 1973, COMP BIOCHEM PHYSIOL, V44, P375, DOI 10.1016/0300-9629(73)90490-8; FERMI G, 1984, HAEMOGLOBIN MYOGLOBI; HO C, 1987, BIOCHEMISTRY-US, V26, P6299, DOI 10.1021/bi00394a001; IKEDASAITO M, 1983, J MOL BIOL, V168, P673, DOI 10.1016/S0022-2836(83)80308-8; IMAI K, 1970, Biochimica et Biophysica Acta, V200, P189, DOI 10.1016/0005-2795(70)90163-7; IMAI K, 1989, Protein Sequences and Data Analysis, V2, P81; Imai K, 1981, Methods Enzymol, V76, P438; Imai K., 1982, ALLOSTERIC EFFECTS H; ITO N, 1995, J MOL BIOL, V250, P648, DOI 10.1006/jmbi.1995.0405; JESSEN TH, 1991, P NATL ACAD SCI USA, V88, P6519, DOI 10.1073/pnas.88.15.6519; KILMARTIN JV, 1973, P NATL ACAD SCI USA, V70, P1246, DOI 10.1073/pnas.70.4.1246; Kimura MA, 1985, NEUTRAL THEORY MOL E; KOMIYAMA NH, 1995, NATURE, V373, P244, DOI 10.1038/373244a0; LUISI BF, 1986, NATURE, V320, P555, DOI 10.1038/320555a0; Mazzarella L, 1999, J MOL BIOL, V287, P897, DOI 10.1006/jmbi.1999.2632; MORRIS RJ, 1981, J BIOL CHEM, V256, P4598; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Mylvaganam SE, 1996, NAT STRUCT BIOL, V3, P275, DOI 10.1038/nsb0396-275; OLSON JS, 1988, NATURE, V336, P265, DOI 10.1038/336265a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paoli M, 1997, J MOL BIOL, V271, P161, DOI 10.1006/jmbi.1997.1180; Paoli M, 1996, J MOL BIOL, V256, P775, DOI 10.1006/jmbi.1996.0124; PARKHURST LJ, 1983, BIOCHEMISTRY-US, V22, P5401, DOI 10.1021/bi00292a023; PERUTZ MF, 1972, NATURE, V237, P495, DOI 10.1038/237495a0; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1984, P NATL ACAD SCI-BIOL, V81, P4781, DOI 10.1073/pnas.81.15.4781; PERUTZ MF, 1994, J MOL BIOL, V239, P555, DOI 10.1006/jmbi.1994.1394; PERUTZ MF, 1985, J MOL BIOL, V183, P491, DOI 10.1016/0022-2836(85)90016-6; PERUTZ MF, 1982, NATURE, V299, P421, DOI 10.1038/299421a0; PERUTZ MF, 1983, MOL BIOL EVOL, V1, P1; Perutz MF, 1998, ANNU REV BIOPH BIOM, V27, P1, DOI 10.1146/annurev.biophys.27.1.1; PERUTZ MF, 1993, J MOL BIOL, V233, P536, DOI 10.1006/jmbi.1993.1530; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; RUSSU IM, 1989, BIOCHEMISTRY-US, V28, P5298, DOI 10.1021/bi00438a057; RUSSU IM, 1982, BIOCHEMISTRY-US, V21, P5031, DOI 10.1021/bi00263a029; RUSSU IM, 1980, BIOCHEMISTRY-US, V19, P1043, DOI 10.1021/bi00546a033; RUSSU IM, 1986, BIOCHEMISTRY-US, V25, P1706, DOI 10.1021/bi00355a040; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P195, DOI 10.1107/S0907444901019291; Shibayama N, 2002, J BIOL CHEM, V277, P38791, DOI 10.1074/jbc.M205461200; SHIH DTB, 1993, J MOL BIOL, V230, P1291; SHIH DTB, 1987, J MOL BIOL, V195, P419, DOI 10.1016/0022-2836(87)90660-7; Sorensen SPL, 1909, BIOCHEM Z, V21, P131; Suzuki T, 1996, J PROTEIN CHEM, V15, P389, DOI 10.1007/BF01886865; Tame JRH, 2000, ACTA CRYSTALLOGR D, V56, P805, DOI 10.1107/S0907444900006387; Tame JRH, 1996, J MOL BIOL, V259, P749, DOI 10.1006/jmbi.1996.0355; Tsuneshige A, 2002, BIOPHYS CHEM, V98, P49, DOI 10.1016/S0301-4622(02)00084-4; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Vagin AA, 2001, ACTA CRYSTALLOGR D, V57, P1451, DOI 10.1107/S0907444901012409; WEBER RE, 1993, J APPL PHYSIOL, V75, P2646, DOI 10.1152/jappl.1993.75.6.2646; Weber RE, 2002, AM J PHYSIOL-REG I, V283, pR1052, DOI 10.1152/ajpregu.00292.2002; Yonetani T, 2002, J BIOL CHEM, V277, P34508, DOI 10.1074/jbc.M203135200; Zhang J, 1996, J MOL BIOL, V255, P484, DOI 10.1006/jmbi.1996.0040	62	61	64	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28632	28640		10.1074/jbc.M401740200	http://dx.doi.org/10.1074/jbc.M401740200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117955	hybrid			2022-12-25	WOS:000222265400099
J	Lee, CC; Putnam, AJ; Miranti, CK; Gustafson, M; Wang, LM; Woude, GFV; Gao, CF				Lee, CC; Putnam, AJ; Miranti, CK; Gustafson, M; Wang, LM; Woude, GFV; Gao, CF			Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis	ONCOGENE			English	Article						sprouty; hepatocyte growth factor/scatter factor; met; signaling; invasion; migration	DROSOPHILA-SPROUTY; DOWN-REGULATION; MET; RECEPTOR; EXPRESSION; PATHWAY; FGF; METASTASIS; ANTAGONIST; ACTIVATION	A strict regulation of hepatocyte growth factor/scatter factor (HGF/SF)-Met signaling is essential for its appropriate function. Several negative regulators of Met signaling have been identified. Here we report that human Spry2 is induced by HGF/SF and negatively regulates HGF/SF-Met signaling. We show that overexpression of Spry2 inhibits cell proliferation, anchorage-independent cell growth, and migration in wound-healing and in vitro invasion assays. Measured in an electric cell-substrate impedance sensing biosensor, cell movement is restricted, because Spry2 dramatically facilitates cell attachment and spreading by enhancing focal adhesions and increasing stress fibers. An analysis of cell cycle distribution shows, unexpectedly, that Spry2-GFP cells are polyploid. Thus, as with FGF and EGF receptors, Spry2-GFP tempers downstream Met signaling in addition to its pronounced effect on cell adhesion, and it has properties suitable to be considered a tumor-suppressor protein.	Van Andel Res Inst, Grand Rapids, MI 49503 USA	Van Andel Institute	Woude, GFV (corresponding author), Van Andel Res Inst, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.	george.vandewoude@vai.org	Miranti, Cindy/AAJ-3783-2020; Putnam, Andrew J./E-8643-2010	Putnam, Andrew J./0000-0002-1262-4377				Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Fong CW, 2003, J BIOL CHEM, V278, P33456, DOI 10.1074/jbc.M301317200; GIAEVER I, 1991, P NATL ACAD SCI USA, V88, P7896, DOI 10.1073/pnas.88.17.7896; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Guy GR, 2003, J CELL SCI, V116, P3061, DOI 10.1242/jcs.00652; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Hammond DE, 2003, MOL BIOL CELL, V14, P1346, DOI 10.1091/mbc.E02-09-0578; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Keese CR, 2004, P NATL ACAD SCI USA, V101, P1554, DOI 10.1073/pnas.0307588100; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Kramer S, 1999, DEVELOPMENT, V126, P2515; Lee SH, 2001, J BIOL CHEM, V276, P4128, DOI 10.1074/jbc.M006922200; Mailleux AA, 2001, MECH DEVELOP, V102, P81, DOI 10.1016/S0925-4773(01)00286-6; Minowada G, 1999, DEVELOPMENT, V126, P4465; Miranti CK, 2002, METHOD CELL BIOL, V69, P359, DOI 10.1016/S0091-679X(02)69023-5; Ozaki K, 2001, BIOCHEM BIOPH RES CO, V285, P1084, DOI 10.1006/bbrc.2001.5295; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Reich A, 1999, DEVELOPMENT, V126, P4139; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Yigzaw Y, 2003, J BIOL CHEM, V278, P284, DOI 10.1074/jbc.M210359200; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200; Zhang SB, 2001, MECH DEVELOP, V109, P367, DOI 10.1016/S0925-4773(01)00526-3	35	111	117	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5193	5202		10.1038/sj.onc.1207646	http://dx.doi.org/10.1038/sj.onc.1207646			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122328				2022-12-25	WOS:000222382500009
J	Isono, E; Saeki, Y; Yokosawa, H; Toh-e, A				Isono, E; Saeki, Y; Yokosawa, H; Toh-e, A			Rpn7 is required for the structural integrity of the 26 S proteasome of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-DEPENDENT PROTEOLYSIS; YEAST 26S PROTEASOME; COP9 SIGNALOSOME; REGULATORY PARTICLE; FUNCTIONAL-CHARACTERIZATION; DEGRADATION SIGNAL; PCI DOMAIN; SUBUNIT; PROTEINS; COMPLEX	Rpn7 is one of the lid subunits of the 26 S proteasome regulatory particle. The RPN7 gene is known to be essential, but its function remains to be elucidated. To explore the function of Rpn7, we isolated and characterized temperature-sensitive rpn7 mutants. All of the rpn7 mutants obtained accumulated poly-ubiquitinated proteins when grown at the restrictive temperature. The N-end rule substrate (Ub-Arg-beta-galactosidase), the UFD pathway substrate ( Ub-Pro-beta-galactosidase), and cell cycle regulators (Pds1 and Clb2) were found to be stabilized in experiments using one of the rpn7 mutants termed rpn7-3 at the restrictive temperature, indicating its defect in the ubiquitin-proteasome pathway. Subsequent analysis of the structure of the 26 S proteasome in rpn7-3 cells suggested that the defect was in the assembly of the 26 S holoenzyme. The most striking characteristic of the proteasome of the rpn7-3 mutant was that a lid subcomplex affinity-purified from the rpn7-3 cells grown at the restrictive temperature contained only 5 of the 8 lid components, a phenomenon that has not been reported in the previously isolated lid mutants. From these results, we concluded that Rpn7 is required for the integrity of the 26 S complex by establishing a correct lid structure.	Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 1130033, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biochem, Sapporo, Hokkaido 0600812, Japan	University of Tokyo; Hokkaido University	Toh-e, A (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 1130033, Japan.	toh-e@biol.s.u-tokyo.ac.jp						Asakawa K, 2001, GENETICS, V157, P1437; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Bailly E, 1999, MOL CELL BIOL, V19, P6872; BURK D, 2000, METHODS YEAST GENETI; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Davy A, 2001, EMBO REP, V2, P821, DOI 10.1093/embo-reports/kve184; DEVERAUX Q, 1995, J BIOL CHEM, V270, P23726, DOI 10.1074/jbc.270.40.23726; Finley D, 1998, TRENDS BIOCHEM SCI, V23, P244, DOI 10.1016/S0968-0004(98)01222-5; Fu HY, 2001, EMBO J, V20, P7096, DOI 10.1093/emboj/20.24.7096; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Gorbea C, 1999, MOL BIOL REP, V26, P15, DOI 10.1023/A:1006957802028; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; James P, 1996, GENETICS, V144, P1425; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; KOMINAMI K, 1995, EMBO J, V14, P3105, DOI 10.1002/j.1460-2075.1995.tb07313.x; Kominami K, 1997, MOL BIOL CELL, V8, P171, DOI 10.1091/mbc.8.1.171; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Li ZY, 2002, J BIOL CHEM, V277, P42686, DOI 10.1074/jbc.M207183200; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; NISOGI H, 1992, EXP CELL RES, V200, P48, DOI 10.1016/S0014-4827(05)80070-9; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V293, P986, DOI 10.1016/S0006-291X(02)00340-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Santamaria PG, 2003, J BIOL CHEM, V278, P6687, DOI 10.1074/jbc.M209420200; Schwartz AL, 1999, ANNU REV MED, V50, P57; Schwechheimer C, 2001, TRENDS CELL BIOL, V11, P420, DOI 10.1016/S0962-8924(01)02091-8; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Smalle J, 2003, PLANT CELL, V15, P965, DOI 10.1105/tpc.009217; Takeuchi J, 1999, MOL CELL BIOL, V19, P6575; Takeuchi J, 2001, BIOCHIMIE, V83, P333, DOI 10.1016/S0300-9084(01)01238-X; TANAKA K, 1988, J BIOL CHEM, V263, P16209; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Toh-e A, 2000, GENES GENET SYST, V75, P33, DOI 10.1266/ggs.75.33; Tsuge T, 2001, J MOL BIOL, V305, P1, DOI 10.1006/jmbi.2000.4288; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449; Wilkinson CRM, 2000, J BIOL CHEM, V275, P15182, DOI 10.1074/jbc.275.20.15182; Yen HCS, 2003, J BIOL CHEM, V278, P30669, DOI 10.1074/jbc.M302093200	49	39	40	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27168	27176		10.1074/jbc.M314231200	http://dx.doi.org/10.1074/jbc.M314231200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102831	hybrid			2022-12-25	WOS:000222120400043
J	Kumar, MB; Potter, DW; Hormann, RE; Edwards, A; Tice, CM; Smith, HC; Dipietro, MA; Polley, M; Lawless, M; Wolohan, PRN; Kethidi, DR; Palli, SR				Kumar, MB; Potter, DW; Hormann, RE; Edwards, A; Tice, CM; Smith, HC; Dipietro, MA; Polley, M; Lawless, M; Wolohan, PRN; Kethidi, DR; Palli, SR			Highly flexible ligand binding pocket of ecdysone receptor - Nonsteroidal ecdysone agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; GENE-EXPRESSION; ECDYSTEROID RECEPTOR; MAMMALIAN-CELLS; DEVELOPMENTAL EXPRESSION; SELECTIVE REGULATION; MESSENGER-RNA; CLONING; ULTRASPIRACLE; HOMOLOG	The insect steroid hormone 20-hydroxyecdysone works through a ligand-activated nuclear receptor, the ecdysone receptor (EcR), which plays critical roles in insect development and reproduction. The EcR has been exploited to develop insecticides to control pests and gene switches for gene regulation. Recently reported crystal structures of the EcR protein show different but partially overlapping binding cavities for ecdysteroid (ECD) and diacylhydrazine (DAH) ligands, providing an explanation for the differential activity of DAH ligands in insects. 1-Aroyl-4- (arylamino)-1,2,3,4-tetrahydroquinoline (THQ) ligands were recently discovered as ecdysone agonists. Mutagenesis of the EcR ( from Choristoneura fumiferana, CfEcR) ligand binding domain followed by screening in a reporter assay led to the identification of CfEcR mutants, which responded well to THQ ligands but poorly to both ECD and DAH ligands. These mutants were further improved by introducing a second mutation, A110P, which was previously reported to cause ECD insensitivity. Testing of these V128F/ A110P and V128Y/A110P mutants in a C57BL/6 mouse model coactivator interaction assay and in insect cells showed that this mutant EcR is activated by THQ ligands but not by ECD or DAH ligands. The CfEcR and its V128F/ A110P mutant were used to demonstrate simultaneous regulation of two reporter genes using THQ and DAH ligands.	Univ Kentucky, Coll Agr, Dept Entomol, Lexington, KY 40546 USA; Tripos Inc, St Louis, MO 63144 USA; RheoGene Inc, Norristown, PA 19403 USA	University of Kentucky	Palli, SR (corresponding author), Univ Kentucky, Coll Agr, Dept Entomol, Lexington, KY 40546 USA.	rpalli@uky.edu	PALLI, SUBBA REDDY/AAU-8289-2020; Winkler, David A/A-3774-2008	PALLI, SUBBA REDDY/0000-0002-0873-3247; Winkler, David A/0000-0002-7301-6076; Tice, Colin/0000-0002-9918-7383				Bai JW, 2000, CELL, V103, P1047, DOI 10.1016/S0092-8674(00)00208-7; Billas IML, 2003, NATURE, V426, P91, DOI 10.1038/nature02112; Billas IML, 2001, J BIOL CHEM, V276, P7465, DOI 10.1074/jbc.M008926200; Carlson GR, 2001, PEST MANAG SCI, V57, P115, DOI 10.1002/1526-4998(200102)57:2<115::AID-PS245>3.0.CO;2-A; CHAKRABORTI PK, 1992, J BIOL CHEM, V267, P11366; Cherbas L, 1997, GENETICS, V145, P349; CHO WL, 1995, INSECT BIOCHEM MOLEC, V25, P19, DOI 10.1016/0965-1748(94)00045-J; CHRISTOPHERSON KS, 1992, P NATL ACAD SCI USA, V89, P6314, DOI 10.1073/pnas.89.14.6314; Chung ACK, 1998, MOL CELL ENDOCRINOL, V139, P209, DOI 10.1016/S0303-7207(98)00056-2; Clayton GM, 2001, P NATL ACAD SCI USA, V98, P1549, DOI 10.1073/pnas.041611298; Dhadialla TS, 1998, ANNU REV ENTOMOL, V43, P545, DOI 10.1146/annurev.ento.43.1.545; DIXSON JA, 2000, AM CHEM SOC MID REG; FUJIWARA H, 1995, INSECT BIOCHEM MOLEC, V25, P845, DOI 10.1016/0965-1748(95)00023-O; Fussenegger M, 2001, BIOTECHNOL PROGR, V17, P1, DOI 10.1021/bp000129c; Guo XP, 1997, INSECT BIOCHEM MOLEC, V27, P945, DOI 10.1016/S0965-1748(97)00075-1; Hu X, 2003, MOL ENDOCRINOL, V17, P716, DOI 10.1210/me.2002-0287; IMHOF MO, 1993, INSECT BIOCHEM MOLEC, V23, P115, DOI 10.1016/0965-1748(93)90089-B; Kasuya A, 2003, J MOL MODEL, V9, P58, DOI 10.1007/s00894-002-0113-x; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOELLE MR, 1992, P NATL ACAD SCI USA, V89, P6167, DOI 10.1073/pnas.89.13.6167; Kothapalli R, 1995, DEV GENET, V17, P319, DOI 10.1002/dvg.1020170405; Kramer BP, 2003, BIOTECHNOL BIOENG, V83, P810, DOI 10.1002/bit.10731; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Kumar MB, 2002, P NATL ACAD SCI USA, V99, P14710, DOI 10.1073/pnas.222278999; Martinez A, 1999, INSECT BIOCHEM MOLEC, V29, P915, DOI 10.1016/S0965-1748(99)00067-3; Mouillet JF, 1997, EUR J BIOCHEM, V248, P856, DOI 10.1111/j.1432-1033.1997.00856.x; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Palli SR, 2003, EUR J BIOCHEM, V270, P1308, DOI 10.1046/j.1432-1033.2003.03501.x; Riddiford L M, 2000, Vitam Horm, V60, P1, DOI 10.1016/S0083-6729(00)60016-X; RISSTALPERS C, 1993, BIOCHEM BIOPH RES CO, V196, P173, DOI 10.1006/bbrc.1993.2231; Roux S, 1996, MOL ENDOCRINOL, V10, P1214, DOI 10.1210/me.10.10.1214; Shi YH, 2002, J AM CHEM SOC, V124, P6921, DOI 10.1021/ja016897x; Shi YH, 2001, CHEM BIOL, V8, P501, DOI 10.1016/S1074-5521(01)00028-X; Smith HC, 2003, BIOORG MED CHEM LETT, V13, P1943, DOI 10.1016/S0960-894X(03)00317-2; Suhr ST, 1998, P NATL ACAD SCI USA, V95, P7999, DOI 10.1073/pnas.95.14.7999; Sundaram M, 1998, INSECT BIOCHEM MOLEC, V28, P693, DOI 10.1016/S0965-1748(98)00035-6; SWEVERS L, 1995, INSECT BIOCHEM MOLEC, V25, P857, DOI 10.1016/0965-1748(95)00024-P; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; Tice CM, 2003, BIOORG MED CHEM LETT, V13, P1883, DOI 10.1016/S0960-894X(03)00315-9; Tice CM, 2003, BIOORG MED CHEM LETT, V13, P475, DOI 10.1016/S0960-894X(02)00980-0; Tsai CC, 1999, MOL CELL, V4, P175, DOI 10.1016/S1097-2765(00)80365-2; Wang SF, 2000, MOL CELL BIOL, V20, P3870, DOI 10.1128/MCB.20.11.3870-3879.2000; Wurtz JM, 2000, PROTEIN SCI, V9, P1073, DOI 10.1110/ps.9.6.1073; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F	47	41	49	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27211	27218		10.1074/jbc.M403839200	http://dx.doi.org/10.1074/jbc.M403839200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15107428	hybrid			2022-12-25	WOS:000222120400048
J	Pitsi, D; Octave, JN				Pitsi, D; Octave, JN			Presenilin 1 stabilizes the C-terminal fragment of the amyloid precursor protein independently of gamma-secretase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; BETA-APP; NICASTRIN; COMPLEX; CELLS; TRAFFICKING; INHIBITORS; CLEAVAGE; DISTINCT; SITES	The cleavage of the transmembrane amyloid precursor protein (APP) by beta-secretase leaves the C-terminal fragment of APP, C99, anchored in the plasma membrane. C99 is subsequently processed by gamma-secretase, an unusual aspartyl protease activity largely dependent on presenilin ( PS), generating the amyloid beta-peptide (Abeta) that accumulates in the brain of patients with Alzheimer's disease. It has been suggested that PS proteins are the catalytic core of this proteolytic activity, but a number of other proteins mandatory for gamma-secretase cleavage have also been discovered. The exact role of PS in the gamma-secretase activity remains a matter of debate, because cells devoid of PS still produce some forms of Abeta. Here, we used insect cells expressing C99 to demonstrate that the expression of presenilin 1 (PS1), which binds C99, not only increases the production of Abeta by these cells but also increases the intracellular levels of C99 to the same extent. Using pulse-chase experiments, we established that this results from an increased half-life of C99 in cells expressing PS1. In Chinese hamster ovary cells producing C99 from full-length human APP, similar results were observed. Finally, we show that a functional inhibitor of gamma-secretase does not alter the ability of PS1 to increase the intracellular levels of C99. This finding suggests that the binding of PS1 to C99 does not necessarily lead to its immediate cleavage by gamma-secretase, which could be a spatio-temporally regulated or an induced event, and provides biochemical evidence for the existence of a substrate-docking site on PS1.	Univ Catholique Louvain, Lab Pharmacol Expt, B-1200 Brussels, Belgium	Universite Catholique Louvain	Octave, JN (corresponding author), Univ Catholique Louvain, Lab Pharmacol Expt, UCL 54-10,54 Ave Hippocrate, B-1200 Brussels, Belgium.	octave@nchm.ucl.ac.be						Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Arawaka S, 2002, J NEUROCHEM, V83, P1065, DOI 10.1046/j.1471-4159.2002.01207.x; Armogida M, 2001, NAT CELL BIOL, V3, P1030, DOI 10.1038/ncb1101-1030; Beher D, 2003, BIOCHEMISTRY-US, V42, P8133, DOI 10.1021/bi034045z; Berezovska O, 2003, J NEUROSCI, V23, P4560; Cai DM, 2003, J BIOL CHEM, V278, P3446, DOI 10.1074/jbc.M209065200; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hattori C, 2002, BIOCHEM BIOPH RES CO, V293, P1228, DOI 10.1016/S0006-291X(02)00351-0; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Ikeuchi T, 2003, J BIOL CHEM, V278, P7010, DOI 10.1074/jbc.M209252200; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kornilova AY, 2003, J BIOL CHEM, V278, P16470, DOI 10.1074/jbc.C300019200; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Meredith JE, 2002, BIOCHEM BIOPH RES CO, V299, P744, DOI 10.1016/S0006-291X(02)02747-X; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Nunan J, 2001, EUR J BIOCHEM, V268, P5329, DOI 10.1046/j.0014-2956.2001.02465.x; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; Octave JN, 2000, J BIOL CHEM, V275, P1525, DOI 10.1074/jbc.275.3.1525; Pitsi D, 2002, J NEUROCHEM, V83, P390, DOI 10.1046/j.1471-4159.2002.01138.x; Qi Y, 2003, BIOCHEMISTRY-US, V42, P1042, DOI 10.1021/bi0267590; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tian GC, 2003, J BIOL CHEM, V278, P28968, DOI 10.1074/jbc.M300905200; Uemura K, 2003, J NEUROSCI RES, V74, P184, DOI 10.1002/jnr.10753; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wilson CA, 2002, NAT NEUROSCI, V5, P849, DOI 10.1038/nn898; Wiltfang J, 2001, J BIOL CHEM, V276, P42645, DOI 10.1074/jbc.M102790200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	36	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25333	25338		10.1074/jbc.M312710200	http://dx.doi.org/10.1074/jbc.M312710200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15087467	hybrid			2022-12-25	WOS:000221827900054
J	Alcorn, JF; Wright, JR				Alcorn, JF; Wright, JR			Degradation of pulmonary surfactant protein D by Pseudomonas aeruginosa elastase abrogates innate immune function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAIN; BRONCHOALVEOLAR LAVAGE FLUID; CYSTIC-FIBROSIS; ALVEOLAR MACROPHAGES; BINDING-PROTEIN; STIMULATES PHAGOCYTOSIS; ALKALINE PROTEASE; LUNG; INFECTION; CALCIUM	The alveolar epithelium is lined by surfactant, a lipoprotein complex that both reduces surface tension and mediates several innate immune functions including bacterial aggregation, alteration of alveolar macrophage function, and regulation of bacterial clearance. Surfactant protein-D (SP-D) participates in several of these immune functions, and specifically it enhances the clearance of the pulmonary pathogen Pseudomonas aeruginosa, a common cause of morbidity and mortality in cystic fibrosis (CF) patients. P. aeruginosa secretes a variety of virulence factors including elastase, a zinc-metalloprotease, which degrades both SP-A and SP-D. Here we show that SP-D is cleaved by elastase to produce a stable 35-kDa fragment in a time-, temperature-, and dose-dependent manner. Degradation is inhibited by divalent metal cations, a metal chelator, and the elastase inhibitor, phosphoramidon. Sequencing the SP-D degradation products localized the major cleavage sites to the C-terminal lectin domain. The SP-D fragment fails to bind or aggregate bacteria that are aggregated by intact SP-D. SP-D fragment is observed when normal rat bronchoalveolar lavage (BAL) is treated with Pseudomonas aeruginosa elastase, and SP-D fragments are present in the BAL of CF lung allograft patients. These data show that degradation of SP-D occurs in the BAL environment and that degradation eliminates many normal immune functions of SP-D.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Wright, JR (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709, Durham, NC 27710 USA.	j.wright@cellbio.duke.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051134] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-51134] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Azghani AO, 2000, LUNG, V178, P181; BRUCE MC, 1985, AM REV RESPIR DIS, V132, P529; Coin D, 1997, FEMS IMMUNOL MED MIC, V18, P175, DOI 10.1016/S0928-8244(97)00037-0; COLLINS JF, 1991, LUNG, V169, P165, DOI 10.1007/BF02714152; CROUCH E, 1994, J BIOL CHEM, V269, P17311; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; Dong Q, 1998, AM J PHYSIOL-LUNG C, V274, pL97, DOI 10.1152/ajplung.1998.274.1.L97; DORING G, 1983, J INFECT DIS, V147, P744, DOI 10.1093/infdis/147.4.744; Dosanjh AK, 1998, J INTERF CYTOK RES, V18, P851, DOI 10.1089/jir.1998.18.851; Engel LS, 1998, J BIOL CHEM, V273, P16792, DOI 10.1074/jbc.273.27.16792; FICK RB, 1985, J INFECT DIS, V151, P589, DOI 10.1093/infdis/151.4.589; Griese M, 2003, BBA-MOL BASIS DIS, V1638, P157, DOI 10.1016/S0925-4439(03)00063-2; Griese M, 1997, EUR RESPIR J, V10, P1983, DOI 10.1183/09031936.97.10091983; GUYTON AC, 1991, TXB MED PHYSL, P870; HAAGSMAN HP, 1990, BIOCHEMISTRY-US, V29, P8894, DOI 10.1021/bi00490a003; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; HECK LW, 1990, J IMMUNOL, V144, P2253; Hickling TP, 1999, EUR J IMMUNOL, V29, P3478, DOI 10.1002/(SICI)1521-4141(199911)29:11<3478::AID-IMMU3478>3.0.CO;2-W; Hull J, 1997, AM J RESP CRIT CARE, V156, P161, DOI 10.1164/ajrccm.156.1.9609090; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; KUROKI Y, 1992, BIOCHEM BIOPH RES CO, V187, P963, DOI 10.1016/0006-291X(92)91291-W; LAZDUNSKI A, 1990, BIOCHIMIE, V72, P147, DOI 10.1016/0300-9084(90)90140-C; LeVine AM, 2001, J IMMUNOL, V167, P5868, DOI 10.4049/jimmunol.167.10.5868; LeVine AM, 2000, J IMMUNOL, V165, P3934, DOI 10.4049/jimmunol.165.7.3934; LIM BL, 1994, BIOCHEM BIOPH RES CO, V202, P1674, DOI 10.1006/bbrc.1994.2127; LIU PV, 1974, J INFECT DIS, V130, P94; Lyczak JB, 2000, MICROBES INFECT, V2, P1051, DOI 10.1016/S1286-4579(00)01259-4; Mariencheck WI, 2003, AM J RESP CELL MOL, V28, P528, DOI 10.1165/rcmb.2002-0141OC; McIntosh JC, 1996, AM J RESP CELL MOL, V15, P509, DOI 10.1165/ajrcmb.15.4.8879185; Meyer KC, 2000, CHEST, V118, P164, DOI 10.1378/chest.118.1.164; MORIHARA K, 1965, J BIOL CHEM, V240, P3295; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; OGASAWARA Y, 1995, J BIOL CHEM, V270, P19052, DOI 10.1074/jbc.270.32.19052; ORIORDAN DM, 1995, J CLIN INVEST, V95, P2699, DOI 10.1172/JCI117972; Palaniyar N, 1998, J STRUCT BIOL, V122, P297, DOI 10.1006/jsbi.1998.4004; PERSSON A, 1990, J BIOL CHEM, V265, P5755; Postle AD, 1999, AM J RESP CELL MOL, V20, P90, DOI 10.1165/ajrcmb.20.1.3253; Restrepo CI, 1999, AM J RESP CELL MOL, V21, P576, DOI 10.1165/ajrcmb.21.5.3334; Sano H, 1998, J BIOL CHEM, V273, P4783, DOI 10.1074/jbc.273.8.4783; SCHULTZ DR, 1974, INFECT IMMUN, V10, P128, DOI 10.1128/IAI.10.1.128-135.1974; STOREY DG, 1992, INFECT IMMUN, V60, P4687, DOI 10.1128/IAI.60.11.4687-4694.1992; Tino MJ, 1996, AM J PHYSIOL-LUNG C, V270, pL677, DOI 10.1152/ajplung.1996.270.4.L677; Vanderzwan J, 1998, EUR RESPIR J, V12, P1388, DOI 10.1183/09031936.98.12061388; Yagci A, 2002, MICROBIOLOGICA, V25, P223; Yanagihara K, 2003, J MED MICROBIOL, V52, P531, DOI 10.1099/jmm.0.05154-0	47	92	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30871	30879		10.1074/jbc.M400796200	http://dx.doi.org/10.1074/jbc.M400796200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123664	hybrid			2022-12-25	WOS:000222531900121
J	He, B; Bai, SX; Hnat, AT; Kalman, RI; Minges, JT; Patterson, C; Wilson, EM				He, B; Bai, SX; Hnat, AT; Kalman, RI; Minges, JT; Patterson, C; Wilson, EM			An androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; E3 UBIQUITIN LIGASE; HUMAN GLUCOCORTICOID-RECEPTOR; TRANSCRIPTION FACTOR TFIIF; RECURRENT PROSTATE-CANCER; HUMAN ESTROGEN-RECEPTOR; ACTIVATION FUNCTION 2; NUCLEAR-RECEPTOR; BINDING DOMAIN; PHOSPHORYLATION SITES	The NH2-terminal sequence of steroid receptors is highly variable between different receptors and in the same receptor from different species. In this study, a primary sequence homology comparison identified a 14-amino acid NH2-terminal motif of the human androgen receptor (AR) that is common to AR from all species reported, including the lower vertebrates. The evolutionarily conserved motif is unique to AR, with the exception of a partial sequence in the glucocorticoid receptor of higher species. The presence of the conserved motif in AR and the glucocorticoid receptor and its absence in other steroid receptors suggests convergent evolution. The function of the AR NH2-terminal conserved motif was suggested from a yeast two-hybrid screen that identified the COOH terminus of the Hsp70-interacting protein (CHIP) as a binding partner. We found that CHIP functions as a negative regulator of AR transcriptional activity by promoting AR degradation. In support of this, two mutations in the AR NH2-terminal conserved motif previously identified in the transgenic adenocarcinoma of mouse prostate model reduced the interaction between CHIP and AR. Our results suggest that the AR NH2-terminal domain contains an evolutionarily conserved motif that functions to limit AR transcriptional activity. Moreover, we demonstrate that the combination of comparative sequence alignment and yeast two-hybrid screening using short conserved peptides as bait provides an effective strategy to probe the structure-function relationships of steroid receptor NH2-terminal domains and other intrinsically unstructured transcriptional regulatory proteins.	Univ N Carolina, Labs Reprod Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Wilson, EM (corresponding author), Univ N Carolina, Labs Reprod Biol, CB 7500,Med Biomol Res Bldg,Rm 3340,103 Mason Far, Chapel Hill, NC 27599 USA.	emw@med.unc.edu			FIC NIH HHS [R30TW001234] Funding Source: Medline; NCI NIH HHS [P01-CA77739] Funding Source: Medline; NICHD NIH HHS [HD16910, U54-HD35041] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016910, U54HD035041, R37HD016910] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [R03TW001234] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA077739] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ARBOUR NC, 1993, MOL ENDOCRINOL, V7, P1307, DOI 10.1210/me.7.10.1307; Bain DL, 2000, J BIOL CHEM, V275, P7313, DOI 10.1074/jbc.275.10.7313; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Baskakov IV, 1999, J BIOL CHEM, V274, P10693, DOI 10.1074/jbc.274.16.10693; Beitel LK, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290041; Betney R, 2003, J MOL ENDOCRINOL, V31, P427, DOI 10.1677/jme.0.0310427; Brinker A, 2002, J BIOL CHEM, V277, P19265, DOI 10.1074/jbc.M109002200; Cardozo CP, 2003, ARCH BIOCHEM BIOPHYS, V410, P134, DOI 10.1016/S0003-9861(02)00680-X; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Citri A, 2002, EMBO J, V21, P2407, DOI 10.1093/emboj/21.10.2407; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; Fang YF, 1996, J BIOL CHEM, V271, P28697, DOI 10.1074/jbc.271.45.28697; Feng Q, 2002, MOL CELL BIOL, V22, P536, DOI 10.1128/MCB.22.2.536-546.2002; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Gregory CW, 1998, CANCER RES, V58, P5718; Gregory CW, 2001, CANCER RES, V61, P2892; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Han GZ, 2001, J BIOL CHEM, V276, P11204, DOI 10.1074/jbc.M008207200; He B, 2002, J BIOL CHEM, V277, P25631, DOI 10.1074/jbc.M202809200; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 2003, MOL CELL BIOL, V23, P2135, DOI 10.1128/MCB.23.6.2135-2150.2003; He B, 2002, J BIOL CHEM, V277, P10226, DOI 10.1074/jbc.M111975200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; He B, 2001, J BIOL CHEM, V276, P42293, DOI 10.1074/jbc.M107492200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HOHFELD J, 1995, CELL, V83, P589; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; Hsu CL, 2003, J BIOL CHEM, V278, P23691, DOI 10.1074/jbc.M211908200; Jiang JH, 2003, J BIOL CHEM, V278, P49332, DOI 10.1074/jbc.M304738200; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kampinga HH, 2003, MOL CELL BIOL, V23, P4948, DOI 10.1128/MCB.23.14.4948-4958.2003; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; McClellan AJ, 2001, NAT CELL BIOL, V3, pE51, DOI 10.1038/35055162; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Nikolay R, 2004, J BIOL CHEM, V279, P2673, DOI 10.1074/jbc.M311112200; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Prapapanich V, 1996, MOL CELL BIOL, V16, P6200; Reid J, 2002, J BIOL CHEM, V277, P41247, DOI 10.1074/jbc.M205220200; Reid J, 2002, J BIOL CHEM, V277, P20079, DOI 10.1074/jbc.M201003200; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Segnitz B, 1997, J BIOL CHEM, V272, P18694, DOI 10.1074/jbc.272.30.18694; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Thornton JW, 2003, SCIENCE, V301, P1714, DOI 10.1126/science.1086185; Thornton JW, 2001, P NATL ACAD SCI USA, V98, P5671, DOI 10.1073/pnas.091553298; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; Vanaja DK, 2002, CELL STRESS CHAPERON, V7, P55, DOI 10.1379/1466-1268(2002)007<0055:EOGOAR>2.0.CO;2; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605; Zhou ZX, 2002, MOL ENDOCRINOL, V16, P287, DOI 10.1210/me.16.2.287; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208; ZHOU ZX, 1993, STEROID HORMONE RECE, P407	72	101	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30643	30653		10.1074/jbc.M403117200	http://dx.doi.org/10.1074/jbc.M403117200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15107424	hybrid, Green Published			2022-12-25	WOS:000222531900094
J	Kong, KY; Kedes, L				Kong, KY; Kedes, L			Cytoplasmic nuclear transfer of the actin-capping protein tropomodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPOMYOSIN-BINDING PROTEIN; INTRANUCLEAR ROD MYOPATHY; CHICK CARDIAC MYOCYTES; POINTED ENDS; NUCLEOCYTOPLASMIC TRANSPORT; SUBCELLULAR-LOCALIZATION; CYTOSKELETAL PROTEIN; SKELETAL-MUSCLE; MESSENGER-RNA; LEPTOMYCIN-B	Tropomodulin (Tmod) is a cytoskeletal actin-capping protein that interacts with tropomyosin at the pointed end of actin filaments. E-Tmod is an isoform that expresses predominantly in cardiac cells and slow skeletal muscle fibers. We unexpectedly discovered significant levels of Tmod in nuclei and then defined peptide domains in Tmod responsible for nuclear import and export. These domains resemble, and function as, a nuclear export signal (NES) and a pattern 4 nuclear localization signal (NLS). Both motifs are conserved in other Tmod isoforms and across species. Comparisons of wild-type Tmod and Tmod carrying mutations in these peptide domains revealed that Tmod normally traffics through the nucleus. These observations logically presuppose that Tmod functions may include a nuclear role. Indeed, increasing Tmod in the nucleus severely hampered myogenic differentiation and selectively suppressed muscle-specific gene expression (endogenous p21, myosin heavy chain, myogenin, and Tmod) but did not affect endogenous glyceraldehyde-3-phosphate dehydrogenase or expression from a transfected E-GFP vector. These results suggest that, at least in myogenic cells, nuclear Tmod may be involved in the differentiation process.	Univ So Calif, Keck Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Kedes, L (corresponding author), Univ So Calif, Keck Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA.	kedes@hsc.usc.edu						Almenar-Queralt A, 1999, J BIOL CHEM, V274, P28466, DOI 10.1074/jbc.274.40.28466; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BURGLIN TR, 1987, EMBO J, V6, P2617, DOI 10.1002/j.1460-2075.1987.tb02552.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; Conley CA, 2001, GENOMICS, V73, P127, DOI 10.1006/geno.2000.6501; CORREAS I, 1991, BIOCHEM J, V279, P581, DOI 10.1042/bj2790581; Cox PR, 2000, GENOMICS, V63, P97, DOI 10.1006/geno.1999.6061; Dye CA, 1998, DEVELOPMENT, V125, P1845; FOWLER VM, 1993, J CELL BIOL, V120, P411, DOI 10.1083/jcb.120.2.411; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; FOWLER VM, 1987, J BIOL CHEM, V262, P12792; Goebel HH, 1997, NEUROMUSCULAR DISORD, V7, P13, DOI 10.1016/S0960-8966(96)00404-X; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GREGORIO CC, 1995, J CELL BIOL, V129, P683, DOI 10.1083/jcb.129.3.683; GREGORIO CC, 1995, NATURE, V377, P83, DOI 10.1038/377083a0; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; ITO M, 1995, DEV BIOL, V167, P317, DOI 10.1006/dbio.1995.1026; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Park M, 1998, MECH DEVELOP, V75, P117, DOI 10.1016/S0925-4773(98)00098-7; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; Sakoda T, 1999, J MOL CELL CARDIOL, V31, P2037, DOI 10.1006/jmcc.1999.1035; Skeath JB, 1998, DEVELOPMENT, V125, P1857; SUNG LA, 1994, BIOCHEM BIOPH RES CO, V201, P627, DOI 10.1006/bbrc.1994.1747; SUNG LA, 1992, J BIOL CHEM, V267, P2616; Sussman MA, 1998, CIRC RES, V82, P94; SUSSMAN MA, 1994, CIRC RES, V75, P221, DOI 10.1161/01.RES.75.2.221; SUSSMAN MA, 1994, DEV BRAIN RES, V80, P45, DOI 10.1016/0165-3806(94)90088-4; Sussman MA, 1998, J CLIN INVEST, V101, P51, DOI 10.1172/JCI1167; SUSSMAN MA, 1992, EUR J BIOCHEM, V205, P355, DOI 10.1111/j.1432-1033.1992.tb16787.x; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; TemmGrove CJ, 1996, CELL MOTIL CYTOSKEL, V33, P223, DOI 10.1002/(SICI)1097-0169(1996)33:3<223::AID-CM6>3.0.CO;2-B; Turpin P, 1999, FEBS LETT, V452, P82, DOI 10.1016/S0014-5793(99)00533-5; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; Watakabe A, 1996, J CELL SCI, V109, P2299; WEBER A, 1994, J CELL BIOL, V127, P1627, DOI 10.1083/jcb.127.6.1627; Weeks DA, 2003, ULTRASTRUCT PATHOL, V27, P151, DOI 10.1080/01913120309933; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X; Zeng XL, 1999, CELL RES, V9, P61, DOI 10.1038/sj.cr.7290006; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	45	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30856	30864		10.1074/jbc.M302845200	http://dx.doi.org/10.1074/jbc.M302845200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123707	hybrid			2022-12-25	WOS:000222531900119
J	Sheppard, DC; Yeaman, MR; Welch, WH; Phan, QT; Fu, Y; Ibrahim, AS; Filler, SG; Zhang, M; Waring, AJ; Edwards, JE				Sheppard, DC; Yeaman, MR; Welch, WH; Phan, QT; Fu, Y; Ibrahim, AS; Filler, SG; Zhang, M; Waring, AJ; Edwards, JE			Functional and structural diversity in the Als protein family of Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEINS; CELL-ADHESION MOLECULE-1; SACCHAROMYCES-CEREVISIAE; SECONDARY STRUCTURE; ENDOTHELIAL-CELLS; CIRCULAR-DICHROISM; 3-DIMENSIONAL PROFILES; ADHERENCE PROPERTIES; EPITHELIAL-CELLS; GENE FAMILY	The human fungal pathogen Candida albicans colonizes and invades a wide range of host tissues. Adherence to host constituents plays an important role in this process. Two members of the C. albicans Als protein family (Als1p and Als5p) have been found to mediate adherence; however, the functions of other members of this family are unknown. In this study, members of the ALS gene family were cloned and expressed in Saccharomyces cerevisiae to characterize their individual functions. Distinct Als proteins conferred distinct adherence profiles to diverse host substrates. Using chimeric Als5p-Als6p constructs, the regions mediating substrate-specific adherence were localized to the N-terminal domains in Als proteins. Interestingly, a subset of Als proteins also mediated endothelial cell invasion, a previously unknown function of this family. Consistent with these results, homology modeling revealed that Als members contain anti-parallel beta-sheet motifs interposed by extended regions, homologous to adhesins or invasins of the immunoglobulin superfamily. This finding was confirmed using circular dichroism and Fourier transform infrared spectrometric analysis of the N-terminal domain of Als1p. Specific regions of amino acid hypervariability were found among the N-terminal domains of Als proteins, and energy-based models predicted similarities and differences in the N-terminal domains that probably govern the diverse function of Als family members. Collectively, these results indicate that the structural and functional diversity within the Als family provides C. albicans with an array of cell wall proteins capable of recognizing and interacting with a wide range of host constituents during infection.	Univ Calif Los Angeles, Harbor Res & Educ Inst, St Johns Cardiovasc Res Ctr, Div Infect Dis,Dept Med, Torrance, CA 90502 USA; Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA; Univ Nevada, Dept Biochem, Reno, NV 89507 USA; Calif State Univ Long Beach, Dept Biol Sci, Long Beach, CA 90840 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Nevada System of Higher Education (NSHE); University of Nevada Reno; California State University System; California State University Long Beach	Sheppard, DC (corresponding author), Univ Calif Los Angeles, Harbor Res & Educ Inst, St Johns Cardiovasc Res Ctr, Div Infect Dis,Dept Med, Torrance, CA 90502 USA.	dsheppard@rei.edu	Sheppard, Donald/B-4637-2008; Filler, Scott G/A-2779-2009	Sheppard, Donald/0000-0001-8877-880X; Filler, Scott G/0000-0001-7278-3700	NCRR NIH HHS [M01 RR00425] Funding Source: Medline; NIAID NIH HHS [1R01 AI054928, R03 AI054531, R01AI-48031, R01 AI19990, P01 AI37194] Funding Source: Medline; NIDCR NIH HHS [5R01 DE13974] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019990, R03AI054531, R01AI048031, R01AI054928, P01AI037194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013974] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bailey DA, 1996, J BACTERIOL, V178, P5353, DOI 10.1128/jb.178.18.5353-5360.1996; Belanger PH, 2002, CELL MICROBIOL, V4, P805, DOI 10.1046/j.1462-5822.2002.00232.x; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349; Edmond MB, 1999, CLIN INFECT DIS, V29, P239, DOI 10.1086/520192; EDWARDS JE, 2000, MANDELL DOUGLAS BENN, P2656; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FILLER SG, 1995, INFECT IMMUN, V63, P976, DOI 10.1128/IAI.63.3.976-983.1995; Fischer D, 1996, FASEB J, V10, P126, DOI 10.1096/fasebj.10.1.8566533; Fu Y, 1998, INFECT IMMUN, V66, P2078, DOI 10.1128/IAI.66.5.2078-2084.1998; Fu Y, 1998, INFECT IMMUN, V66, P1783, DOI 10.1128/IAI.66.4.1783-1786.1998; Fu Y, 2002, MOL MICROBIOL, V44, P61, DOI 10.1046/j.1365-2958.2002.02873.x; Gale CA, 1998, SCIENCE, V279, P1355, DOI 10.1126/science.279.5355.1355; Gaur NK, 2002, CELL COMMUN ADHES, V9, P45, DOI 10.1080/15419060212187; Gaur NK, 1997, INFECT IMMUN, V65, P5289, DOI 10.1128/IAI.65.12.5289-5294.1997; Gaur NK, 1999, INFECT IMMUN, V67, P6040, DOI 10.1128/IAI.67.11.6040-6047.1999; GODZIK A, 1995, PROTEIN ENG, V8, P409, DOI 10.1093/protein/8.5.409; GODZIK A, 1993, J COMPUT AID MOL DES, V7, P397, DOI 10.1007/BF02337559; GODZIK A, 1992, P NATL ACAD SCI USA, V89, P12098, DOI 10.1073/pnas.89.24.12098; GODZIK A, 1992, J MOL BIOL, V227, P227, DOI 10.1016/0022-2836(92)90693-E; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HALVERSON KJ, 1991, J AM CHEM SOC, V113, P6701, DOI 10.1021/ja00017a068; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; HEIDEN W, 1993, J COMPUT CHEM, V14, P246, DOI 10.1002/jcc.540140212; Hoyer LL, 1999, INFECT IMMUN, V67, P4251, DOI 10.1128/IAI.67.8.4251-4255.1999; Hoyer LL, 2001, GENETICS, V157, P1555; Hoyer LL, 2001, YEAST, V18, P49, DOI 10.1002/1097-0061(200101)18:1&lt;49::AID-YEA646&gt;3.0.CO;2-M; Hoyer LL, 2001, TRENDS MICROBIOL, V9, P176, DOI 10.1016/S0966-842X(01)01984-9; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jaroszewski L, 1998, PROTEIN SCI, V7, P1431; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; Kamai Y, 2002, INFECT IMMUN, V70, P5256, DOI 10.1128/IAI.70.9.5256-5258.2002; KELLOGG GE, 1991, J COMPUT AID MOL DES, V5, P545, DOI 10.1007/BF00135313; KLOTZ SA, 1992, CLIN INFECT DIS, V14, P340, DOI 10.1093/clinids/14.1.340; Li F, 2003, EUKARYOT CELL, V2, P1266, DOI 10.1128/EC.2.6.1266-1273.2003; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; LUCINDO NV, 2002, P 102 ANN M AM SOC M, P204; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Phan QT, 2000, INFECT IMMUN, V68, P3485, DOI 10.1128/IAI.68.6.3485-3490.2000; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; ROTROSEN D, 1986, REV INFECT DIS, V8, P73; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Sreerama N, 1999, PROTEIN SCI, V8, P370; Staab JF, 1999, SCIENCE, V283, P1535, DOI 10.1126/science.283.5407.1535; Sundstrom P, 2002, INFECT IMMUN, V70, P3281, DOI 10.1128/IAI.70.6.3281-3283.2002; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; Topham C M, 1990, Biochem Soc Symp, V57, P1; Tsuchimori N, 2000, INFECT IMMUN, V68, P1997, DOI 10.1128/IAI.68.4.1997-2002.2000; Viney JL, 1996, J IMMUNOL, V157, P2488; Waring AJ, 1996, PROTEIN PEPTIDE LETT, V3, P177; WELCH W, 1994, BIOCHEMISTRY-US, V33, P6074, DOI 10.1021/bi00186a006; Welch W, 1996, BIOCHEMISTRY-US, V35, P7165, DOI 10.1021/bi9527294; WOJCIECHOWICZ D, 1993, MOL CELL BIOL, V13, P2554, DOI 10.1128/MCB.13.4.2554; Zhang NX, 2003, GENOME RES, V13, P2005, DOI 10.1101/gr.1024903; Zhao H, 2002, HYBRIDOMA HYBRIDOM, V21, P25, DOI 10.1089/15368590252917610; Zhao XM, 2003, MICROBIOL-SGM, V149, P2947, DOI 10.1099/mic.0.26495-0	64	208	235	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30480	30489		10.1074/jbc.M401929200	http://dx.doi.org/10.1074/jbc.M401929200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15128742	hybrid			2022-12-25	WOS:000222531900076
J	Wang, WQ; Bembenek, J; Gee, KR; Yu, HT; Charbonneau, H; Zhang, ZY				Wang, WQ; Bembenek, J; Gee, KR; Yu, HT; Charbonneau, H; Zhang, ZY			Kinetic and mechanistic studies of a cell cycle protein phosphatase Cdc14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-STEADY-STATE; TYROSINE-PHOSPHATASE; CRYSTAL-STRUCTURE; TRANSITION-STATE; CATALYTIC MECHANISM; PHOSPHOINOSITIDE PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; INORGANIC-PHOSPHATE; TUMOR-SUPPRESSOR; SPECIFICITY	The Cdc14 family of protein phosphatases is conserved within eukaryotes and antagonizes the action of cyclin-dependent kinases, thereby promoting mitotic exit and cytokinesis. We performed a detailed kinetic and mechanistic study of the Cdc14 phosphatases with both small molecule aryl phosphates and a physiological protein substrate hCdh1. We found that Cdc14 displays a strong preference for two-ringed aryl phosphates over smaller one-ringed or larger, multi-ringed substrates, a finding that may have important implications for inhibitor design. Results from both leaving group and pH dependence of the Cdc14-catalyzed reaction are consistent with a general acid-independent mechanism for substrates with leaving group pK(a) < 7 and a general acid-dependent mechanism for substrates with leaving group pK(a) > 7. The use of both low and high leaving group pKa substrates, in combination with steady-state and pre-steady-state kinetic techniques enabled the isolation and analysis of both the phosphoenzyme (E-P) formation and hydrolysis step. We established the requirement of general acid catalysis for E-P formation in reactions with high leaving group pKa substrates, and the presence of general base catalysis in E-P hydrolysis. Mutational study of invariant acidic residues in Cdc14 identified Asp(253) as the general acid during E-P formation and the general base in E-P hydrolysis. We also identified several residues including Asp(50), Asp(129), Glu(168), Glu(171), and Asp(177) in the Cdc14 active site cleft that are required for efficient dephosphorylation of hCdh1.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Mol Probes Inc, Eugene, OR 97402 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	Yeshiva University; Albert Einstein College of Medicine; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Zhang, ZY (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	zyzhang@aecom.yu.edu		Bembenek, Joshua/0000-0002-0966-2268; Yu, Hongtao/0000-0002-8861-049X	NCI NIH HHS [CA69202] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Begley MJ, 2003, MOL CELL, V12, P1391, DOI 10.1016/S1097-2765(03)00486-6; Bembenek J, 2001, J BIOL CHEM, V276, P48237, DOI 10.1074/jbc.M108126200; BENDER ML, 1967, J CHEM EDUC, V44, P84, DOI 10.1021/ed044p84; BLACK MJ, 1983, ANAL BIOCHEM, V135, P233, DOI 10.1016/0003-2697(83)90756-X; Cerutti L, 2000, CURR OPIN GENET DEV, V10, P65, DOI 10.1016/S0959-437X(99)00044-1; Changela A, 2001, EMBO J, V20, P2575, DOI 10.1093/emboj/20.10.2575; Chen L, 1996, BIOCHEMISTRY-US, V35, P9349, DOI 10.1021/bi960700+; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; Cueille N, 2001, J CELL SCI, V114, P2649; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Fjeld CC, 2000, J BIOL CHEM, V275, P6749, DOI 10.1074/jbc.275.10.6749; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Furstenthal L, 2001, J CELL BIOL, V152, P1267, DOI 10.1083/jcb.152.6.1267; Gee KR, 1999, ANAL BIOCHEM, V273, P41, DOI 10.1006/abio.1999.4202; Gottlin EB, 1996, J BIOL CHEM, V271, P27445, DOI 10.1074/jbc.271.44.27445; Gray CH, 2003, EMBO J, V22, P3524, DOI 10.1093/emboj/cdg348; Gruneberg U, 2002, J CELL BIOL, V158, P901, DOI 10.1083/jcb.200202054; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; Hengge AC, 1996, BIOCHEMISTRY-US, V35, P7084, DOI 10.1021/bi960255i; Hengge AC, 1997, BIOCHEMISTRY-US, V36, P7928, DOI 10.1021/bi970364c; Keng YF, 1999, EUR J BIOCHEM, V259, P809, DOI 10.1046/j.1432-1327.1999.00090.x; KIRBY AJ, 1967, J AM CHEM SOC, V89, P415, DOI 10.1021/ja00978a044; KNOWLES JR, 1976, CRC CR REV BIOCH MOL, V4, P165, DOI 10.3109/10409237609105457; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; McCain DF, 2002, J BIOL CHEM, V277, P11190, DOI 10.1074/jbc.M109636200; Montserat J, 1996, J BIOL CHEM, V271, P7868, DOI 10.1074/jbc.271.13.7868; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; Rigas JD, 2001, BIOCHEMISTRY-US, V40, P4398, DOI 10.1021/bi002951v; Rudolph J, 2001, ANAL BIOCHEM, V289, P43, DOI 10.1006/abio.2000.4906; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Shen K, 2001, J BIOL CHEM, V276, P47311, DOI 10.1074/jbc.M106568200; Song HW, 2001, MOL CELL, V7, P615, DOI 10.1016/S1097-2765(01)00208-8; Sun JP, 2003, J BIOL CHEM, V278, P12406, DOI 10.1074/jbc.M212491200; TADDEI N, 1994, FEBS LETT, V350, P328, DOI 10.1016/0014-5793(94)00805-1; Taylor GS, 1997, J BIOL CHEM, V272, P24054, DOI 10.1074/jbc.272.38.24054; Trautmann S, 2002, CURR BIOL, V12, pR733, DOI 10.1016/S0960-9822(02)01250-2; Trautmann S, 2001, CURR BIOL, V11, P931, DOI 10.1016/S0960-9822(01)00268-8; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wang WQ, 2003, CURR TOP MED CHEM, V3, P739, DOI 10.2174/1568026033452302; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Wu L, 1996, BIOCHEMISTRY-US, V35, P5426, DOI 10.1021/bi952885a; Xie LP, 2002, BIOCHEMISTRY-US, V41, P4032, DOI 10.1021/bi015904r; Zachariae W, 1999, CURR OPIN CELL BIOL, V11, P708, DOI 10.1016/S0955-0674(99)00041-1; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; ZHANG ZT, 1994, J BIOL CHEM, V269, P25947; Zhang ZY, 2003, PROG NUCLEIC ACID RE, V73, P171, DOI 10.1016/S0079-6603(03)01006-7; ZHANG ZY, 1995, J BIOL CHEM, V270, P11199, DOI 10.1074/jbc.270.19.11199; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516; Zhao Y, 1998, J BIOL CHEM, V273, P5484, DOI 10.1074/jbc.273.10.5484; Zhou B, 1999, J BIOL CHEM, V274, P35526, DOI 10.1074/jbc.274.50.35526; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200	60	19	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30459	30468		10.1074/jbc.M402217200	http://dx.doi.org/10.1074/jbc.M402217200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15128740	hybrid			2022-12-25	WOS:000222531900073
J	Zhao, Y; Qin, SF; Atangan, LI; Molina, Y; Okawa, Y; Arpawong, HT; Ghosn, C; Xiao, JH; Vuligonda, V; Brown, G; Chandraratna, RAS				Zhao, Y; Qin, SF; Atangan, LI; Molina, Y; Okawa, Y; Arpawong, HT; Ghosn, C; Xiao, JH; Vuligonda, V; Brown, G; Chandraratna, RAS			Casein kinase 1 alpha interacts with retinoid x receptor and interferes with agonist-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID RECEPTOR; KINASE-I; ALPHA; ACTIVATION; PHOSPHORYLATION; BINDING; CANCER; CELLS; RXR; CHEMOPREVENTION	Agonists of retinoid X receptors (RXRs), which include the natural 9-cis-retinoic acid and synthetic analogs, are potent inducers of growth arrest and apoptosis in some cancer cells. As such, they are being used in clinical trials for the treatment and prevention of solid tumors and are used to treat cutaneous T cell lymphoma. However, the molecular mechanisms that underlie the anticancer effects of RXR agonists remain unclear. Here, we show that a novel pro-apoptotic pathway that is induced by RXR agonist is negatively regulated by casein kinase 1alpha (CK1alpha). CK1alpha associates with RXR in an agonist-dependent manner and phosphorylates RXR. The ability of an RXR agonist to recruit CK1alpha to a complex with RXR in cells correlates inversely with its ability to inhibit growth. Remarkably, depletion of CK1alpha in resistant cells renders them susceptible to RXR agonist-induced growth inhibition and apoptosis. Our study shows that CK1alpha can promote cell survival by interfering with RXR agonist-induced apoptosis. Inhibition of CK1alpha may enhance the anti-cancer effects of RXR agonists.	Allergan Pharmaceut Inc, Retinoid Res, Dept Biol, Irvine, CA 92612 USA; Allergan Pharmaceut Inc, Retinoid Res, Dept Chem, Irvine, CA 92612 USA; Univ Birmingham, Sch Med, Div Immun & Infect, Birmingham B15 2TT, W Midlands, England	AbbVie; Allergan; AbbVie; Allergan; University of Birmingham	Chandraratna, RAS (corresponding author), Allergan Pharmaceut Inc, Retinoid Res, Dept Biol, 2525 Dupont Dr, Irvine, CA 92612 USA.	chandraratna_rosh@allergan.com		Qin, Suofu/0000-0002-3323-8846				Adam-Stitah S, 1999, J BIOL CHEM, V274, P18932, DOI 10.1074/jbc.274.27.18932; Altucci L, 2001, TRENDS ENDOCRIN MET, V12, P460, DOI 10.1016/S1043-2760(01)00502-1; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; DeGrendele Heather, 2003, Clin Lung Cancer, V4, P210; Duvic M, 2001, J CLIN ONCOL, V19, P2456, DOI 10.1200/JCO.2001.19.9.2456; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gianni M, 2000, CELL DEATH DIFFER, V7, P447, DOI 10.1038/sj.cdd.4400673; Gottardis MM, 1996, CANCER RES, V56, P5566; Gross SD, 1999, J CELL SCI, V112, P2647; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Klein ES, 1996, J BIOL CHEM, V271, P22692, DOI 10.1074/jbc.271.37.22692; Klein ES, 2000, J BIOL CHEM, V275, P19401, DOI 10.1074/jbc.M002472200; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lowe M N, 2000, Am J Clin Dermatol, V1, P245, DOI 10.2165/00128071-200001040-00006; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; NAGY L, 1995, MOL CELL BIOL, V15, P3540; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Smith CM, 1997, TRENDS BIOCHEM SCI, V22, P444, DOI 10.1016/S0968-0004(97)01131-6; Solomon C, 1999, J CLIN INVEST, V103, P1729, DOI 10.1172/JCI6871; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Tanaka T, 2004, MOL CELL BIOL, V24, P3972, DOI 10.1128/MCB.24.9.3972-3982.2004; WANG R, 2002, BIOTECHNIQUES, V33, pS88; Wilkinson MG, 1998, GENE DEV, V12, P1391, DOI 10.1101/gad.12.10.1391; Wu KD, 2002, CANCER RES, V62, P6376; Xiao JH, 2003, J BIOL CHEM, V278, P29954, DOI 10.1074/jbc.M304761200	37	30	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30844	30849		10.1074/jbc.M404651200	http://dx.doi.org/10.1074/jbc.M404651200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131121	hybrid			2022-12-25	WOS:000222531900117
J	Leal, S; Acosta-Serrano, A; Morris, J; Cross, GAM				Leal, S; Acosta-Serrano, A; Morris, J; Cross, GAM			Transposon mutagenesis of Trypanosoma brucei identifies glycosylation mutants resistant to concanavalin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLPHOSPHATIDYLINOSITOL MEMBRANE ANCHORS; DROSOPHILA ELEMENT MARINER; SURFACE GLYCOPROTEIN; IN-VITRO; AFRICAN TRYPANOSOMES; STRUCTURAL-CHARACTERIZATION; DEVELOPMENTAL VARIATION; CONGENITAL DISORDERS; PROCYCLIC STAGE; TSETSE-FLY	We have engineered Trypanosoma brucei with a novel mariner transposition system that allows large populations of mutant cells to be generated and screened. As a proof of principle, we isolated and characterized two independent clones that were resistant to the cytotoxic action of concanavalin A. In both clones, the transposon had integrated into the locus encoding a homologue of human ALG12, which encodes a dolichyl-P-Man: Man(7)GlcNAc(2)-PP-dolichyl-alpha6-mannosyltransferase. Conventional knock-out of ALG12 in a wild-type background gave an identical phenotype to the mariner mutants, and biochemical analysis confirmed that they have the same defect in the N-linked oligosaccharide synthesis pathway. To our surprise, both mariner mutants were homozygous; the second allele appeared to have undergone gene conversion by the mariner-targeted allele. Subsequent experiments showed that the frequency of gene conversion at the ALG12 locus, in the absence of selection, was 0.25%. As we approach the completion of the trypanosome genome project, transposon mutagenesis provides an important addition to the repertoire of genetic tools for T. brucei.	Rockefeller Univ, Mol Parasitol Lab, New York, NY 10021 USA; Univ Dundee, Wellcome Trust Bioctr, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Rockefeller University; University of Dundee; Johns Hopkins University	Cross, GAM (corresponding author), Rockefeller Univ, Mol Parasitol Lab, 1230 York Ave, New York, NY 10021 USA.	george.cross@rockefeller.edu	Cross, George A M/B-7444-2011; Acosta-Serrano, Alvaro/L-5503-2015	Cross, George A M/0000-0003-1374-6955; Acosta-Serrano, Alvaro/0000-0002-2576-7959; Morris, James/0000-0003-2515-5714	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI021729, R01AI021334, R01AI021729] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21334, AI21729] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Acosta-Serrano A, 2000, J MOL BIOL, V304, P633, DOI 10.1006/jmbi.2000.4246; Acosta-Serrano A, 2004, EUKARYOT CELL, V3, P255, DOI 10.1128/EC.3.2.255-263.2004; Acosta-Serrano A, 1999, J BIOL CHEM, V274, P29763, DOI 10.1074/jbc.274.42.29763; Acosta-Serrano A, 2001, P NATL ACAD SCI USA, V98, P1513, DOI 10.1073/pnas.041611698; Aebi M, 2001, TRENDS CELL BIOL, V11, P136, DOI 10.1016/S0962-8924(01)01925-0; Bessereau JL, 2001, NATURE, V413, P70, DOI 10.1038/35092567; Beverley SM, 2003, NAT REV GENET, V4, P11, DOI 10.1038/nrg980; Borst P, 2002, CELL, V109, P5, DOI 10.1016/S0092-8674(02)00711-0; Chantret I, 2002, J BIOL CHEM, V277, P25815, DOI 10.1074/jbc.M203285200; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; Clayton CE, 1999, PARASITOL TODAY, V15, P372, DOI 10.1016/S0169-4758(99)01498-2; Cross GAM, 2001, INT J PARASITOL, V31, P427, DOI 10.1016/S0020-7519(01)00141-2; Dawson A, 2003, MOL CELL, V11, P225, DOI 10.1016/S1097-2765(02)00798-0; Drew ME, 2003, J BIOL CHEM, V278, P46596, DOI 10.1074/jbc.M309320200; Fadool JM, 1998, P NATL ACAD SCI USA, V95, P5182, DOI 10.1073/pnas.95.9.5182; FIELD MC, 1991, J BIOL CHEM, V266, P8392; FIELD MC, 1992, J BIOL CHEM, V267, P5324; Gueiros FJ, 1997, SCIENCE, V276, P1716, DOI 10.1126/science.276.5319.1716; GueirosFilho FJ, 1996, MOL CELL BIOL, V16, P5655; Hart DL, 1997, ANNU REV GENET, V31, P337, DOI 10.1146/annurev.genet.31.1.337; Hartl DL, 2001, GENETICS, V157, P471; Hwa KY, 1999, GLYCOBIOLOGY, V9, P181, DOI 10.1093/glycob/9.2.181; Hwa KY, 2000, MOL BIOCHEM PARASIT, V111, P173, DOI 10.1016/S0166-6851(00)00310-8; Lampe DJ, 1996, EMBO J, V15, P5470, DOI 10.1002/j.1460-2075.1996.tb00930.x; Lozovsky ER, 2002, GENETICS, V160, P527; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MEDHORA M, 1991, GENETICS, V128, P311; Morris JC, 2002, EMBO J, V21, P4429, DOI 10.1093/emboj/cdf474; Nagamune K, 2000, P NATL ACAD SCI USA, V97, P10336, DOI 10.1073/pnas.180230697; Oriol R, 2002, MOL BIOL EVOL, V19, P1451, DOI 10.1093/oxfordjournals.molbev.a004208; PATNAIK PK, 1993, EMBO J, V12, P2529, DOI 10.1002/j.1460-2075.1993.tb05908.x; Pearson TW, 2000, MOL BIOCHEM PARASIT, V111, P333, DOI 10.1016/S0166-6851(00)00327-3; RICHARDSON JP, 1988, MOL BIOCHEM PARASIT, V31, P203, DOI 10.1016/0166-6851(88)90150-8; RODITI I, 1987, NATURE, V325, P272, DOI 10.1038/325272a0; Roditi I, 1999, MOL BIOCHEM PARASIT, V103, P99, DOI 10.1016/S0166-6851(99)00124-3; Roditi I, 1998, MOL BIOCHEM PARASIT, V91, P117, DOI 10.1016/S0166-6851(97)00195-3; Ruepp S, 1997, J CELL BIOL, V137, P1369, DOI 10.1083/jcb.137.6.1369; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sherman A, 1998, NAT BIOTECHNOL, V16, P1050, DOI 10.1038/3497; Shi HF, 2002, MOL BIOCHEM PARASIT, V121, P141, DOI 10.1016/S0166-6851(02)00020-8; Tait A, 2002, PHILOS T ROY SOC B, V357, P89, DOI 10.1098/rstb.2001.1050; Treumann A, 1997, J MOL BIOL, V269, P529, DOI 10.1006/jmbi.1997.1066; Valdes J, 1996, NUCLEIC ACIDS RES, V24, P1809, DOI 10.1093/nar/24.10.1809; Vassella E, 2003, MOL BIOL CELL, V14, P1308, DOI 10.1091/mbc.E02-10-0694; Welburn SC, 1996, CELL DEATH DIFFER, V3, P229; Wirtz E, 1998, NUCLEIC ACIDS RES, V26, P4626, DOI 10.1093/nar/26.20.4626; WIRTZ E, 1994, NUCLEIC ACIDS RES, V22, P3887, DOI 10.1093/nar/22.19.3887; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X	48	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28979	28988		10.1074/jbc.M403479200	http://dx.doi.org/10.1074/jbc.M403479200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123607	Green Submitted, hybrid			2022-12-25	WOS:000222445300020
J	Lim, YM; Han, I; Jeon, J; Park, H; Bahk, YY; Oh, ES				Lim, YM; Han, I; Jeon, J; Park, H; Bahk, YY; Oh, ES			Phosphorylation of focal adhesion kinase at tyrosine 861 is crucial for ras transformation of fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MOTILITY; IN-VIVO; V-SRC; BINDING; CRK; PATHWAY; FIBRONECTIN; ASSOCIATION; INVASION; DOMAIN	Although elevated expression and increased tyrosine phosphorylation of focal adhesion kinase (FAK) are crucial for tumor progression, the mechanism by which FAK promotes oncogenic transformation is unclear. We have therefore determined the role of FAK phosphorylation at tyrosine 861 in the oncogenic transformation of NIH3T3 fibroblasts. FAK phosphorylation at tyrosine 861 was increased in both constitutively H-Ras-transformed and H-Ras-inducible NIH3T3 cells, in parallel with cell transformation. However, H-Ras-inducible cells transfected with the nonphosphorylatable mutant FAK Y861F showed decreased migration/invasion, focus forming activity and anchorage-independent growth, compared with either wild-type or kinase-defective FAK. In contrast to unaltered FAK/Src activity, the association of FAK and p130(CAS) was decreased in FAK Y861F-transfected cells, and FAK phosphorylation at tyrosine 861 enhanced this association in vitro. Consistently, FAK Y861F-transfected cells were defective in activation of c-Jun NH2-terminal kinase and in expression of matrix metalloproteinase-9 during transformation. Taken together, these results strongly suggest that FAK phosphorylation at tyrosine 861 is crucial for H-Ras-induced transformation through regulation of the association of FAK with p130CAS.	Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Ewha Womans Univ, Dept Life Sci, Div Mol Life Sci, Seoul 120750, South Korea; Natl Canc Ctr, Res Inst, Gyeonggi Goyang 411764, South Korea; Yonsei Univ, Prot Network Res Ctr, Seoul 120749, South Korea	Ewha Womans University; Ewha Womans University; National Cancer Center - Korea (NCC); Yonsei University	Oh, ES (corresponding author), Ewha Womans Univ, Ctr Cell Signaling Res, Daehyun Dong, Seoul 120750, South Korea.	OhES@mm.ewha.ac.kr						Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; Burnham MR, 1996, ONCOGENE, V12, P2467; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Hauck CR, 2001, CANCER RES, V61, P7079; Hecker TP, 2002, CANCER RES, V62, P2699; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Lim YM, 2002, J BIOL CHEM, V277, P12735, DOI 10.1074/jbc.M111011200; Nievers MG, 1997, J CELL SCI, V110, P389; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schaller MD, 1996, J ENDOCRINOL, V150, P1, DOI 10.1677/joe.0.1500001; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; Shibata K, 1998, CANCER RES, V58, P900; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Vadlamudi RK, 2003, FEBS LETT, V543, P76, DOI 10.1016/S0014-5793(03)00404-6; Wang DY, 2000, J CELL SCI, V113, P4221; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; Wei L, 2002, J CELL BIOCHEM, V87, P439, DOI 10.1002/jcb.10322; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999	34	83	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29060	29065		10.1074/jbc.M401183200	http://dx.doi.org/10.1074/jbc.M401183200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123632	hybrid			2022-12-25	WOS:000222445300029
J	Starcevic, M; Dell'Angelica, EC				Starcevic, M; Dell'Angelica, EC			Identification of snapin and three novel proteins (BLOS1, BLOS2, and BLOS3/reduced pigmentation) as subunits of biogenesis of lysosome-related organelles complex-1 (BLOC-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERMANSKY-PUDLAK-SYNDROME; MOUSE; GENE; DYSBINDIN; MODEL; YEAST; HPS1; MUTATIONS; PALLIDIN; HOMOLOG	Biogenesis of lysosome-related organelles complex-1 (BLOC-1) is a ubiquitously expressed multisubunit protein complex required for the normal biogenesis of specialized organelles of the endosomal-lysosomal system, such as melanosomes and platelet dense granules. The complex is known to contain the coiled-coil-forming proteins, Pallidin, Muted, Cappuccino, and Dysbindin. The genes encoding these proteins are defective in inbred mouse strains that serve as models of Hermansky-Pudlak syndrome (HPS), a genetic disorder characterized by hypopigmentation and platelet storage pool deficiency. In addition, mutation of human Dysbindin causes HPS type 7. Here, we report the identification of another four subunits of the complex. One is Snapin, a coiled-coil-forming protein previously characterized as a binding partner of synaptosomal-associated proteins 25 and 23 and implicated in the regulation of membrane fusion events. The other three are previously uncharacterized proteins, which we named BLOC subunits 1, 2, and 3 (BLOS1, -2, and -3). Using specific antibodies to detect endogenous proteins from human and mouse cells, we found that Snapin, BLOS1, BLOS2, and BLOS3 co-immunoprecipitate, and co-fractionate upon size exclusion chromatography, with previously known BLOC-1 subunits. Furthermore, steady-state levels of the four proteins are significantly reduced in cells from pallid mice, which carry a mutation in Pallidin and display secondary loss of other BLOC-1 subunits. Yeast two-hybrid analyses suggest a network of binary interactions involving all of the previously known and newly identified subunits. Interestingly, the HPS mouse model strain, reduced pigmentation, carries a nonsense mutation in the gene encoding BLOS3. As judged from size exclusion chromatographic analyses, the reduced pigmentation mutation affects BLOC-1 assembly less severely than the pallid mutation. Mutations in the human genes encoding Snapin and the BLOS proteins could underlie novel forms of HPS.	Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Dell'Angelica, EC (corresponding author), Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA.	Edellangelica@mednet.ucla.edu			NHLBI NIH HHS [HL 68117] Funding Source: Medline; NIGMS NIH HHS [GM 07104] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068117] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguilar RC, 1997, J BIOL CHEM, V272, P27160, DOI 10.1074/jbc.272.43.27160; Anikster Y, 2001, NAT GENET, V28, P376, DOI 10.1038/ng576; BANTA LM, 1990, MOL CELL BIOL, V10, P4638, DOI 10.1128/MCB.10.9.4638; Benson MA, 2001, J BIOL CHEM, V276, P24232, DOI 10.1074/jbc.M010418200; Benson MA, 2004, J BIOL CHEM, V279, P10450, DOI 10.1074/jbc.M312664200; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BURTON P, 2003, BIOCHEM J, V375, P433; Chiang PW, 2003, J BIOL CHEM, V278, P20332, DOI 10.1074/jbc.M300090200; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; Ciciotte SL, 2003, BLOOD, V101, P4402, DOI 10.1182/blood-2003-01-0020; Clark RH, 2003, NAT IMMUNOL, V4, P1111, DOI 10.1038/ni1000; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Di Pietro SM, 2004, TRAFFIC, V5, P276, DOI 10.1111/j.1600-0854.2004.0171.x; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Falcon-Perez JM, 2002, J BIOL CHEM, V277, P28191, DOI 10.1074/jbc.M204011200; Gautam R, 2004, J BIOL CHEM, V279, P12935, DOI 10.1074/jbc.M311311200; GIBB S, 1981, GENET RES, V37, P95, DOI 10.1017/S0016672300020048; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Huang LP, 1999, NAT GENET, V23, P329, DOI 10.1038/15507; Huizing M, 2002, PIGM CELL RES, V15, P405, DOI 10.1034/j.1600-0749.2002.02074.x; Ilardi JM, 1999, NAT NEUROSCI, V2, P119, DOI 10.1038/5673; Inoue M, 1996, CYTOGENET CELL GENET, V73, P134; King SM, 2002, SEMIN CELL DEV BIOL, V13, P293, DOI 10.1016/S1084952102000599; Li W, 2003, NAT GENET, V35, P84, DOI 10.1038/ng1229; LUNDIN LG, 1980, MOUSE NEWS LETT, V62, P77; Lyerla TA, 2003, AM J PHYSIOL-LUNG C, V285, pL643, DOI 10.1152/ajplung.00024.2003; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Martina JA, 2003, J BIOL CHEM, V278, P29376, DOI 10.1074/jbc.M301294200; Moriyama K, 2002, TRAFFIC, V3, P666, DOI 10.1034/j.1600-0854.2002.30908.x; Nakatani Y, 2000, VIRCHOWS ARCH, V437, P304, DOI 10.1007/s004280000241; Nazarian R, 2003, P NATL ACAD SCI USA, V100, P8770, DOI 10.1073/pnas.1532040100; Oh J, 1996, NAT GENET, V14, P300, DOI 10.1038/ng1196-300; Richardson SCW, 2004, MOL BIOL CELL, V15, P1197, DOI 10.1091/mbc.E03-06-0358; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Spritz RA, 2003, CURR OPIN GENET DEV, V13, P284, DOI 10.1016/S0959-437X(03)00059-5; Starcevic M, 2002, SEMIN CELL DEV BIOL, V13, P271, DOI 10.1016/S1084952102000563; Sun W, 2003, J CELL BIOL, V162, P125, DOI 10.1083/jcb.200302083; Suzuki T, 2002, NAT GENET, V30, P321, DOI 10.1038/ng835; Swank RT, 1998, PIGM CELL RES, V11, P60, DOI 10.1111/j.1600-0749.1998.tb00713.x; Vites O, 2004, J BIOL CHEM, V279, P26251, DOI 10.1074/jbc.M404079200; Watanabe T K, 1995, DNA Res, V2, P235, DOI 10.1093/dnares/2.5.235; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Zhang Q, 2003, NAT GENET, V33, P145, DOI 10.1038/ng1087; Zhang Q, 2002, HUM MOL GENET, V11, P697, DOI 10.1093/hmg/11.6.697; Zhu YX, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-r16	48	189	200	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28393	28401		10.1074/jbc.M402513200	http://dx.doi.org/10.1074/jbc.M402513200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102850	hybrid			2022-12-25	WOS:000222265400072
J	Fernandes, R; Girao, H; Pereira, P				Fernandes, R; Girao, H; Pereira, P			High glucose down-regulates intercellular communication in retinal endothelial cells by enhancing degradation of connexin 43 by a proteasome-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PIGMENT EPITHELIAL-CELLS; GAP JUNCTIONAL COMMUNICATION; DIABETIC-RATS; PHORBOL-ESTER; PHOSPHORYLATION; EXPRESSION; BETA; COMPLICATIONS; INHIBITION	Intercellular communication through gap junctions (GJIC) is most likely relevant to maintaining the integrity of the blood-retinal barrier. In this study, we investigated the mechanism whereby high glucose enhances degradation of connexin 43 (Cx43), thus contributing to a decrease in GJIC. The levels of Cx43 in bovine retinal endothelial cells exposed to high glucose (25 mM) decreased about 50% as compared with controls (5.5 mM glucose). Consistently, the half-life of the protein decreased from 2.3 to 1.9 h. The proteasome inhibitors MG132 and lactacystin prevented the loss of Cx43 induced by high glucose and extended Cx43 half-life. The amount of phosphorylated Cx43 increased in high glucose and after proteasome inhibition. Scrape-loading dye transfer experiments show that high glucose is associated to a decrease of 40% in GJIC. Significantly, this reduction can be reversed by proteasome inhibitors. The decrease in GJIC in cells exposed to high glucose is associated with a loss of Cx43 from the plasma membrane, as demonstrated by immunofluorescence and biotinylation of cell-surface proteins. Results indicate that increased phosphorylation of Cx43 under high glucose is the mechanism targeting Cx43 for degradation by a proteasome-dependent mechanism. Increased degradation of Cx43 and reduction of GJIC in high glucose may be of physiological importance by contributing to endothelial cell dysfunction associated with the breakdown of the blood-retinal barrier in diabetic retinopathy.	Univ Coimbra, Fac Med, Ctr Ophthalmol, Biomed Inst Res Light & Image, P-3000354 Coimbra, Portugal	Universidade de Coimbra	Pereira, P (corresponding author), Univ Coimbra, Fac Med, Ctr Ophthalmol, Biomed Inst Res Light & Image, P-3000354 Coimbra, Portugal.	ppereira@ibili.uc.pt	Pereira, Paulo/AAD-8375-2022; Girao, H/I-7591-2012; Fernandes, Rosa/P-1102-2014	Pereira, Paulo/0000-0002-9908-2290; Girao, H/0000-0002-5786-8447; Fernandes, Rosa/0000-0001-7828-2296				Babazono T, 1998, DIABETES, V47, P668, DOI 10.2337/diabetes.47.4.668; Beardslee MA, 2000, CIRC RES, V87, P656, DOI 10.1161/01.RES.87.8.656; Bowling N, 2001, J MOL CELL CARDIOL, V33, P789, DOI 10.1006/jmcc.2000.1349; Cottrell GT, 2003, AM J PHYSIOL-CELL PH, V284, pC511, DOI 10.1152/ajpcell.00214.2002; FALLON RF, 1981, J CELL BIOL, V90, P521, DOI 10.1083/jcb.90.2.521; Fuertes G, 2003, BIOCHEM J, V375, P75, DOI 10.1042/BJ20030282; Girao H, 2003, MOL VIS, V9, P24; Himpens B, 1999, FASEB J, V13, pS63; Husoy T, 2001, CARCINOGENESIS, V22, P221, DOI 10.1093/carcin/22.2.221; INOGUCHI T, 1995, BIOCHEM BIOPH RES CO, V208, P492, DOI 10.1006/bbrc.1995.1365; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; Inoguchi Toyoshi, 2001, Medical Electron Microscopy, V34, P86, DOI 10.1007/s007950170002; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; King GL, 1996, DIABETES, V45, pS105, DOI 10.2337/diab.45.3.S105; Koya D, 1997, J CLIN INVEST, V100, P115, DOI 10.1172/JCI119503; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Kuroki T, 1998, DIABETES, V47, P931, DOI 10.2337/diabetes.47.6.931; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; Larson DM, 1997, AM J PHYSIOL-CELL PH, V272, pC405, DOI 10.1152/ajpcell.1997.272.2.C405; Lin R, 2001, J CELL BIOL, V154, P815, DOI 10.1083/jcb.200102027; LITTLE TL, 1995, AM J PHYSIOL, V268, P729; Malfait M, 2001, J MEMBRANE BIOL, V181, P31, DOI 10.1007/s0023200100082; MATESIC DF, 1994, MOL CARCINOGEN, V10, P226, DOI 10.1002/mc.2940100407; Musil LS, 2000, J BIOL CHEM, V275, P25207, DOI 10.1074/jbc.275.33.25207; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Obrosova IG, 2003, DIABETES, V52, P864, DOI 10.2337/diabetes.52.3.864; Park JY, 2000, DIABETES, V49, P1239, DOI 10.2337/diabetes.49.7.1239; Qin H, 2003, J BIOL CHEM, V278, P30005, DOI 10.1074/jbc.M300614200; Rivedal E, 2001, CARCINOGENESIS, V22, P1543, DOI 10.1093/carcin/22.9.1543; Sato T, 2002, DIABETES, V51, P1565, DOI 10.2337/diabetes.51.5.1565; Schulz R, 2003, FASEB J, V17, P1355, DOI 10.1096/fj.02-0975fje; SHIBA T, 1993, AM J PHYSIOL, V265, pE783, DOI 10.1152/ajpendo.1993.265.5.E783; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; Stalmans P, 1997, INVEST OPHTH VIS SCI, V38, P1598; TenBroek EM, 1997, DEV BIOL, V191, P88, DOI 10.1006/dbio.1997.8703; Ward Walter F, 2002, Prog Mol Subcell Biol, V29, P35; WINEGRAD AI, 1987, DIABETES, V36, P396, DOI 10.2337/diab.36.3.396; Yeh HI, 1998, CIRC RES, V83, P1248, DOI 10.1161/01.RES.83.12.1248	41	72	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27219	27224		10.1074/jbc.M400446200	http://dx.doi.org/10.1074/jbc.M400446200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15123628	Green Published, hybrid			2022-12-25	WOS:000222120400049
J	Spierings, DCJ; de Vries, EGE; Stel, AJ; Rietstap, NT; Vellenga, E; de Jong, S				Spierings, DCJ; de Vries, EGE; Stel, AJ; Rietstap, NT; Vellenga, E; de Jong, S			Low p21(Waf1/Cip1) protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis	ONCOGENE			English	Article						TGCT; p21; Fas; cisplatin; irradiation	BCL-X-L; CISPLATIN-INDUCED APOPTOSIS; 3/P21 COMPLEX-FORMATION; WILD-TYPE P53; GAMMA-IRRADIATION; DNA-DAMAGE; C-ABL; TRANSCRIPTION FACTOR; RNA INTERFERENCE; SUPPRESSOR GENE	In the present study, we investigated the relation between p21 expression and the sensitivity of testicular germ cell tumor (TGCT) cells to apoptotic stimuli. Despite similar cisplatin-induced wild-type p53 accumulation, the TGCT cell lines Tera and Scha expressed low p21 protein and mRNA levels in comparison to A2780 ovarian cancer cells. Inhibition of the proteasome complex with MG-132 increased p21 protein levels in TGCT cells but much more in A2780 cells, whereas cisplatin had no additional effect on p21 protein levels. Inhibition of caspase-3 activity in TGCT cells with the broad-spectrum caspase inhibitor zVAD-fmk had no effect on p21 levels and also not upon cisplatin treatment. A similar induction of p53 irradiation, in contrast to cisplatin, substantially increased both p21 mRNA and protein expression in Tera cells. Cisplatin-treated Tera cells expressing low p21 protein levels were Fas-sensitive, while irradiation-induced p21, which was mainly localized in the cytosol, rendered irradiated Tera cells resistant to Fas-induced apoptosis. Sensitivity of irradiated Tera cells to Fas-induced apoptosis was restored by short interfering RNA-specific suppression of p21 expression. These results strongly indicate that the low p21 protein levels are caused by reduced p21 gene transcription and sensitize cisplatin-treated TGCT cells to the Fas death pathway.	Univ Groningen Hosp, Dept Med Oncol, NL-9713 GZ Groningen, Netherlands; Univ Groningen Hosp, Dept Hematol, NL-9713 GZ Groningen, Netherlands	University of Groningen; University of Groningen	de Jong, S (corresponding author), Univ Groningen Hosp, Dept Med Oncol, NL-9713 GZ Groningen, Netherlands.	s.de.jong@int.azg.nl		Spierings, Diana/0000-0001-8403-474X; de Vries, Elisabeth/0000-0002-8949-7425				Agami R, 1999, NATURE, V399, P809; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Arriola EL, 1999, ONCOGENE, V18, P1457, DOI 10.1038/sj.onc.1202420; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bartkova J, 2000, INT J CANCER, V85, P370, DOI 10.1002/(SICI)1097-0215(20000201)85:3<370::AID-IJC13>3.0.CO;2-A; Burger H, 1999, INT J CANCER, V81, P620, DOI 10.1002/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.3.CO;2-J; Burger H, 1997, INT J CANCER, V73, P592, DOI 10.1002/(SICI)1097-0215(19971114)73:4<592::AID-IJC22>3.0.CO;2-A; Burger H, 1998, BRIT J CANCER, V77, P1562, DOI 10.1038/bjc.1998.257; Burger H, 1998, INT J RADIAT ONCOL, V41, P415, DOI 10.1016/S0360-3016(98)00065-0; Butz K, 1998, ONCOGENE, V17, P781, DOI 10.1038/sj.onc.1201995; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Chresta CM, 1996, CANCER RES, V56, P1834; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; Datta MW, 2001, MODERN PATHOL, V14, P437, DOI 10.1038/modpathol.3880331; DEJONG S, 1993, INT J CANCER, V53, P110, DOI 10.1002/ijc.2910530121; DEJONG S, 1999, P AM ASSOC CANC RES, V40, P4588; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Dijkhuizen T, 1996, INT J CANCER, V68, P47, DOI 10.1002/(SICI)1097-0215(19960927)68:1<47::AID-IJC9>3.0.CO;2-X; Einhorn LH, 2002, P NATL ACAD SCI USA, V99, P4592, DOI 10.1073/pnas.072067999; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Glaser T, 2001, ONCOGENE, V20, P4757, DOI 10.1038/sj.onc.1204498; Gong JG, 1999, NATURE, V399, P806; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Guillou L, 1996, AM J PATHOL, V149, P1221; Hara S, 2001, UROLOGY, V58, P471, DOI 10.1016/S0090-4295(01)01172-4; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; HUDDART RA, 1995, EUR J CANCER, V31A, P739, DOI 10.1016/0959-8049(95)00047-M; Johnstone RW, 2002, MOL CELL, V10, P695, DOI 10.1016/S1097-2765(02)00693-7; Kersemaekers AMF, 2002, J PATHOL, V196, P423, DOI 10.1002/path.1058; Kersemaekers AMF, 2002, J CLIN ONCOL, V20, P1551, DOI 10.1200/JCO.20.6.1551; Kimura K, 2000, J BIOL CHEM, V275, P8610, DOI 10.1074/jbc.275.12.8610; Ko YG, 2001, J BIOL CHEM, V276, P39103, DOI 10.1074/jbc.M105928200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Levrero M, 2000, J CELL SCI, V113, P1661; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; Lutzker SG, 1998, APMIS, V106, P85, DOI 10.1111/j.1699-0463.1998.tb01323.x; Lutzker SG, 2001, ONCOGENE, V20, P2982, DOI 10.1038/sj.onc.1204394; Malashicheva AB, 2000, ONCOGENE, V19, P3858, DOI 10.1038/sj.onc.1203736; MASTERS JRW, 1993, INT J CANCER, V53, P340, DOI 10.1002/ijc.2910530228; MICHIELI P, 1994, CANCER RES, V54, P3391; Naujokat C, 2002, LAB INVEST, V82, P965, DOI 10.1097/01.LAB.0000022226.23741.37; Ogawa Y, 1998, INT J MOL MED, V2, P435; Prives C, 1999, J PATHOL, V187, P112; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303; SARK MWJ, 1995, BRIT J CANCER, V71, P684, DOI 10.1038/bjc.1995.135; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Schepers H, 2003, LEUKEMIA, V17, P2113, DOI 10.1038/sj.leu.2403106; Sheard MA, 1999, BRIT J CANCER, V80, P1689, DOI 10.1038/sj.bjc.6690585; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Skilling JS, 1996, GYNECOL ONCOL, V60, P72, DOI 10.1006/gyno.1996.0014; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Spierings DCJ, 2003, CELL DEATH DIFFER, V10, P808, DOI 10.1038/sj.cdd.4401248; Spierings DCJ, 2003, J PATHOL, V200, P137, DOI 10.1002/path.1373; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Sugihara A, 1997, ANTICANCER RES, V17, P3861; Suzuki A, 2000, CELL DEATH DIFFER, V7, P721, DOI 10.1038/sj.cdd.4400706; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Tsai KKC, 2003, CANCER RES, V63, P3418; Vikhanskaya F, 2000, NUCLEIC ACIDS RES, V28, P513, DOI 10.1093/nar/28.2.513; Xiang H, 2002, ONCOGENE, V21, P3611, DOI 10.1038/sj.onc.1205449; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	78	35	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4862	4872		10.1038/sj.onc.1207617	http://dx.doi.org/10.1038/sj.onc.1207617			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15122333				2022-12-25	WOS:000222104200007
J	Schneider, R; Bannister, AJ; Weise, C; Kouzarides, T				Schneider, R; Bannister, AJ; Weise, C; Kouzarides, T			Direct binding of INHAT to H3 tails disrupted by modifications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H3; PROTEIN SET; LYSINE 9; TRANSCRIPTION; METHYLATION; NUCLEOSOME; ACETYLATION; INHIBITOR	The N-terminal tails of histones are central to the regulation of chromatin structure. They form a binding platform for multiple protein complexes, which in turn regulate DNA processes such as transcription. Using peptide mass fingerprinting we identified INHAT ( inhibitor of acetyltransferases) as a specific histone H3 N-terminal tail-binding complex. INHAT comprises two essential subunits, SET and pp32. We demonstrate that both SET and pp32 bind directly to the N terminus of H3. The binding is differentially affected by various modifications within the H3 N terminus. In particular, single phosphorylations within the H3 tail abrogates binding of INHAT, as does the simultaneous acetylation of multiple lysine residues. The histone modifications that affect INHAT binding are therefore compatible with its known role in transcriptional repression. We suggest that the charge of the histone tail is a major determinant in allowing INHAT to bind chromatin and coordinate the activity of multiple histone acetyltransferases.	Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QR, England; Free Univ Berlin, Inst Chem Biochem, D-14195 Berlin, Germany	University of Cambridge; University of Cambridge; Free University of Berlin	Kouzarides, T (corresponding author), Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Tennis Court Rd, Cambridge CB2 1QR, England.	tk106@mole.bio.cam.ac.uk		Bannister, Andrew/0000-0002-6312-4436; Kouzarides, Tony/0000-0002-8918-4162				Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Daujat S, 2002, CURR BIOL, V12, P2090, DOI 10.1016/S0960-9822(02)01387-8; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Santos-Rosa H, 2003, MOL CELL, V12, P1325, DOI 10.1016/S1097-2765(03)00438-6; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Seo SB, 2002, J BIOL CHEM, V277, P14005, DOI 10.1074/jbc.M112455200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200	24	67	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23859	23862		10.1074/jbc.C400151200	http://dx.doi.org/10.1074/jbc.C400151200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15100215	hybrid			2022-12-25	WOS:000221702500004
J	Bai, R; Covell, DG; Taylor, GF; Kepler, JA; Copeland, TD; Nguyen, NY; Pettit, GR; Hamel, E				Bai, R; Covell, DG; Taylor, GF; Kepler, JA; Copeland, TD; Nguyen, NY; Pettit, GR; Hamel, E			Direct photoaffinity labeling by dolastatin 10 of the amino-terminal peptide of beta-tubulin containing cysteine 12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITE; ANTINEOPLASTIC AGENTS; VINCA DOMAIN; ACID-SEQUENCE; ALPHA-TUBULIN; CROSS-LINKING; IDENTIFICATION; MAYTANSINE; NUCLEOTIDE; INHIBITOR	Tubulin with bound [5-H-3] dolastatin 10 was exposed to ultraviolet light, and 8-10% of the bound drug crosslinked to the protein, most of it specifically. The primary cross-link was to the peptide spanning amino acid residues 2-31 of beta-tubulin, but the specific amino acid could not be identified. Indirect studies indicated that cross-link formation occurred between cysteine 12 and the thiazole moiety of dolastatin 10. An equipotent analog of dolastatin 10, lacking the thiazole ring, did not form an ultraviolet light-induced cross-link to beta-tubulin. Preillumination of tubulin with ultraviolet light, known to induce cross-link formation between cysteine 12 and exchangeable site nucleotide, inhibited the binding of [5-H-3] dolastatin 10 and cross-link formation more potently than it inhibited the binding of colchicine or vinblastine to tubulin. Conversely, binding of dolastatin 10 to tubulin inhibited formation of the cross-link between cysteine 12 and the exchangeable site nucleotide. Dithiothreitol inhibited formation of the beta-tubulin/dolastatin 10 cross-link but not the beta-tubulin/exchangeable site nucleotide cross-link. Modeling studies revealed a highly favored binding site for dolastatin 10 at the + end of beta-tubulin in proximity to the exchangeable site GDP. Computational docking of an energy-minimized dolastatin 10 conformation at this site placed the thiazole ring of dolastatin 10 8-9 Angstrom from the sulfur atom of cysteine 12. Dolastatin 15 and cryptophycin 1 could also be docked into positions that overlapped more extensively with the docked dolastatin 10 than with each other. This result was consistent with the observed binding properties of these peptides.	NCI, Screening Technol Branch, Dev Therapeut Program, Div Canc Treatment & Diag,NIH, Frederick, MD 21702 USA; Res Triangle Inst, Res Triangle Pk, NC 27709 USA; NCI, Lab Prot Dynam & Signaling, Ctr Canc Res, NIH, Frederick, MD 21702 USA; US FDA, Facil Biotechnol Resources, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; Arizona State Univ, Canc Res Inst, Tempe, AZ 85287 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Research Triangle Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Hamel, E (corresponding author), NCI, Screening Technol Branch, Dev Therapeut Program, Div Canc Treatment & Diag,NIH, Bldg 469,Rm 104,POB B, Frederick, MD 21702 USA.	hamele@mail.nih.gov						BAI R, 1993, BIOCHEM PHARMACOL, V45, P1503, DOI 10.1016/0006-2952(93)90051-W; BAI R, 1990, BIOCHEM PHARMACOL, V40, P1859, DOI 10.1016/0006-2952(90)90367-T; BAI R, 1991, J BIOL CHEM, V266, P15882; BAI R, 1990, J BIOL CHEM, V265, P17141; Bai RL, 1999, BIOCHEMISTRY-US, V38, P14302, DOI 10.1021/bi991323e; Bai RL, 1999, J BIOL CHEM, V274, P12710, DOI 10.1074/jbc.274.18.12710; Bai RL, 1998, J BIOL CHEM, V273, P9894, DOI 10.1074/jbc.273.16.9894; Bai RL, 1996, J BIOL CHEM, V271, P12639, DOI 10.1074/jbc.271.21.12639; BAI RL, 1989, BIOCHEMISTRY-US, V28, P5606, DOI 10.1021/bi00439a040; BAI RL, 1995, MOL PHARMACOL, V47, P965; Bai RL, 2000, J BIOL CHEM, V275, P40443, DOI 10.1074/jbc.M005299200; Bai RL, 1996, CANCER RES, V56, P4398; BAI RL, 1995, BIOCHEMISTRY-US, V34, P9714, DOI 10.1021/bi00030a009; Barbier P, 2001, BIOCHEMISTRY-US, V40, P13510, DOI 10.1021/bi010926z; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828; COVELL DG, 1994, PROTEIN SCI, V3, P2064, DOI 10.1002/pro.5560031119; Cruz-Monserrate Z, 2003, EUR J BIOCHEM, V270, P3822, DOI 10.1046/j.1432-1033.2003.03776.x; FLOYD LJ, 1989, BIOCHEMISTRY-US, V28, P8515, DOI 10.1021/bi00447a037; Gamble WR, 1999, BIOORGAN MED CHEM, V7, P1611, DOI 10.1016/S0968-0896(99)00089-9; GROVER S, 1994, EUR J BIOCHEM, V222, P163, DOI 10.1111/j.1432-1033.1994.tb18854.x; HAMEL E, 1984, J BIOL CHEM, V259, P1060; HAMEL E, 1984, BIOCHEMISTRY-US, V23, P4173, DOI 10.1021/bi00313a026; HUANG AB, 1985, BIOCHEM BIOPH RES CO, V128, P1239, DOI 10.1016/0006-291X(85)91073-3; KRAUHS E, 1981, P NATL ACAD SCI-BIOL, V78, P4156, DOI 10.1073/pnas.78.7.4156; Landon, 1977, Methods Enzymol, V47, P145; LITTLE M, 1987, BIOCHIM BIOPHYS ACTA, V912, P28, DOI 10.1016/0167-4838(87)90243-3; LUDUENA RF, 1991, PHARMACOL THERAPEUT, V49, P133, DOI 10.1016/0163-7258(91)90027-J; MANDELBAUMSHAVIT F, 1976, BIOCHEM BIOPH RES CO, V72, P47, DOI 10.1016/0006-291X(76)90958-X; MIYAZAKI K, 1995, CHEM PHARM BULL, V43, P1706; Miyazawa S, 1999, PROTEINS, V36, P357, DOI 10.1002/(SICI)1097-0134(19990815)36:3<357::AID-PROT10>3.3.CO;2-L; NASIOULAS G, 1990, EUR J BIOCHEM, V192, P69, DOI 10.1111/j.1432-1033.1990.tb19196.x; Natsume T, 2000, JPN J CANCER RES, V91, P737, DOI 10.1111/j.1349-7006.2000.tb01007.x; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Panda D, 2000, BIOCHEMISTRY-US, V39, P14121, DOI 10.1021/bi0010827; Pettit GR, 1995, ANTI-CANCER DRUG DES, V10, P529; PETTIT GR, 1989, J AM CHEM SOC, V111, P5463, DOI 10.1021/ja00196a061; Pettit GR, 1998, ANTI-CANCER DRUG DES, V13, P243; PETTIT GR, 1990, J MED CHEM, V33, P3132, DOI 10.1021/jm00174a006; PONSTINGL H, 1981, P NATL ACAD SCI-BIOL, V78, P2757, DOI 10.1073/pnas.78.5.2757; Rai SS, 1996, J BIOL CHEM, V271, P14707, DOI 10.1074/jbc.271.25.14707; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1992, J NATL CANCER I, V84, P785, DOI 10.1093/jnci/84.10.785; ROACH MC, 1984, J BIOL CHEM, V259, P2063; SAFA AR, 1987, BIOCHEMISTRY-US, V26, P97, DOI 10.1021/bi00375a014; SAWADA T, 1993, BIOCHEM PHARMACOL, V45, P1387; SAWADA T, 1993, BIOCONJUGATE CHEM, V4, P284, DOI 10.1021/bc00022a006; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; Wallqvist A, 1996, PROTEINS, V25, P403, DOI 10.1002/(SICI)1097-0134(199608)25:4<403::AID-PROT1>3.0.CO;2-E; WALLQVIST A, 1995, PROTEIN SCI, V4, P1881, DOI 10.1002/pro.5560040923; WILLIAMS RF, 1985, J BIOL CHEM, V260, P3794; WOLFF J, 1991, P NATL ACAD SCI USA, V88, P2820, DOI 10.1073/pnas.88.7.2820; YOUNG L, 1994, PROTEIN SCI, V3, P717	54	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30731	30740		10.1074/jbc.M402110200	http://dx.doi.org/10.1074/jbc.M402110200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123603	hybrid			2022-12-25	WOS:000222531900104
J	Boutahar, N; Guignandon, A; Vico, L; Lafage-Proust, MH				Boutahar, N; Guignandon, A; Vico, L; Lafage-Proust, MH			Mechanical strain on osteoblasts activates autophosphorylation of focal adhesion kinase and proline-rich tyrosine kinase 2 tyrosine sites involved in ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; SMOOTH-MUSCLE-CELLS; SRC FAMILY KINASES; PROTEIN-KINASE; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; GROWTH-FACTOR; SHEAR-STRESS; FLUID-FLOW; MC3T3-E1 OSTEOBLASTS	The mechanisms involved in the mechanical loading-induced increase in bone formation remain unclear. In this study, we showed that cyclic strain (CS) (10 min, 1% stretch at 0.25 Hz) stimulated the proliferation of overnight serum-starved ROS 17/2.8 osteoblast-like cells plated on type I collagen-coated silicone membranes. This increase was blocked by MEK inhibitor PD-98059. Signaling events were then assessed 0 min, 30 min, and 4 h after one CS period with Western blotting and co-immunoprecipitation. CS rapidly and time-dependently promoted phosphorylation of both ERK2 at Tyr-187 and focal adhesion kinase (FAK) at Tyr-397 and Tyr-925, leading to the activation of the Ras/Raf/MEK pathway. Cell transfection with FAK mutated at Tyr-397 completely blocked ERK2 Tyr-187 phosphorylation. Quantitative immunofluorescence analysis of phosphotyrosine residues showed an increase in focal adhesion plaque number and size in strained cells. CS also induced both Src-Tyr-418 phosphorylation and Src to FAK association. Treatment with the selective Src family kinase inhibitor pyrazolopyrimidine 2 did not prevent CS-induced FAK-Tyr-397 phosphorylation suggesting a Src-independent activation of FAK. CS also activated proline-rich tyrosine kinase 2 (PYK2), a tyrosine kinase highly homologous to FAK, at the 402 phosphorylation site and promoted its association to FAK in a time-dependent manner. Mutation of PYK2 at the Tyr-402 site prevented the ERK2 phosphorylation only at 4 h. Intra and extracellular calcium chelators prevented PYK2 activation only at 4 h. In summary, our data showed that osteoblast response to mitogenic CS was mediated by MEK pathway activation. The latter was induced by ERK2 phosphorylation under the control of FAK and PYK2 phosphorylation orchestrated in a time-dependent manner.	INSERM, E366, Lab Biol Tissu Osseux, F-42023 St Etienne 02, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Lafage-Proust, MH (corresponding author), INSERM, E366, Lab Biol Tissu Osseux, 15 Rue Ambroise Pare, F-42023 St Etienne 02, France.	lafagemh@univ-st-etienne.fr	Boutahar, Nadia/O-5196-2017; Vico, Laurence/ABG-7239-2020; Vico, Laurence/O-1927-2018	Boutahar, Nadia/0000-0003-2630-5366; Vico, Laurence/0000-0002-2110-287X; Vico, Laurence/0000-0002-2110-287X; Lafage-Proust, Marie-Helene/0000-0002-2091-3961; GUIGNANDON, Alain/0000-0002-0745-5417				Ajizian SJ, 1999, J INFECT DIS, V179, P939, DOI 10.1086/314659; Alahari SK, 2002, INT REV CYTOL, V220, P145; Astier A, 1997, J BIOL CHEM, V272, P228; Avraham HK, 2003, J BIOL CHEM, V278, P36661, DOI 10.1074/jbc.M301253200; BANES AJ, 1995, CYTOMECHANICS BIOCH, V73, P349; Barani AE, 2003, EXP CELL RES, V283, P196, DOI 10.1016/S0014-4827(02)00030-7; Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; Basso N, 2002, BONE, V30, P347, DOI 10.1016/S8756-3282(01)00678-0; BENES AJ, 1985, J CELL SCI, V75, P35; BOURRIN S, 1995, J BONE MINER RES, V10, P820; Boutonnat J, 1998, ANTICANCER RES, V18, P4243; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Damien E, 2000, J BONE MINER RES, V15, P2169, DOI 10.1359/jbmr.2000.15.11.2169; DAVIES PF, 1993, CIRC RES, V72, P239, DOI 10.1161/01.RES.72.2.239; Dieudonne MN, 2002, BIOCHEM BIOPH RES CO, V293, P622, DOI 10.1016/S0006-291X(02)00205-X; Fanning PJ, 2003, J BIOL CHEM, V278, P50940, DOI 10.1074/jbc.M305107200; Freitas F, 2002, BONE, V30, P99, DOI 10.1016/S8756-3282(01)00625-1; Geiger B, 2001, CURR OPIN CELL BIOL, V13, P584, DOI 10.1016/S0955-0674(00)00255-6; Guignandon A, 2003, CELL COMMUN ADHES, V10, P69, DOI 10.1080/cac.10.2.69.83; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hatton JP, 2003, J BONE MINER RES, V18, P58, DOI 10.1359/jbmr.2003.18.1.58; HUNG CT, 1995, CLIN ORTHOP RELAT R, P256; IKEDA M, 1999, AM J PHYSIOL, V276, P14; Ingram AJ, 2000, J BIOL CHEM, V275, P40301, DOI 10.1074/jbc.M007018200; Ingram AJ, 1999, KIDNEY INT, V56, P1721, DOI 10.1046/j.1523-1755.1999.00743.x; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; Iwasaki H, 2003, ENDOCRINOLOGY, V144, P2304, DOI 10.1210/en.2002-220939; Jeschke M, 1998, J BIOL CHEM, V273, P11354, DOI 10.1074/jbc.273.18.11354; Jessop HL, 2002, BONE, V31, P186, DOI 10.1016/S8756-3282(02)00797-4; Kapur S, 2003, BONE, V32, P241, DOI 10.1016/S8756-3282(02)00979-1; KASSEM M, 1993, J BONE MINER RES, V8, P1453; Kawakami K, 2001, J CELL SCI, V114, P3125; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; Matsuda K, 1998, BIOPHARM DRUG DISPOS, V19, P465, DOI 10.1002/(SICI)1099-081X(199810)19:7<465::AID-BDD126>3.0.CO;2-E; Matsuda N, 1998, BIOCHEM BIOPH RES CO, V249, P350, DOI 10.1006/bbrc.1998.9151; Milgrom C, 2000, J BONE JOINT SURG BR, V82B, P591, DOI 10.1302/0301-620X.82B4.9677; Miyauchi A, 2000, J BIOL CHEM, V275, P3335, DOI 10.1074/jbc.275.5.3335; Numaguchi K, 1999, CIRC RES, V85, P5; Ogata T, 2000, J CELL BIOCHEM, V76, P529, DOI 10.1002/(SICI)1097-4644(20000315)76:4<529::AID-JCB1>3.3.CO;2-X; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Oxlund H, 1998, ENDOCRINOLOGY, V139, P1899, DOI 10.1210/en.139.4.1899; Peake MA, 2000, J APPL PHYSIOL, V89, P2498, DOI 10.1152/jappl.2000.89.6.2498; Pommerenke H, 2002, J BONE MINER RES, V17, P603, DOI 10.1359/jbmr.2002.17.4.603; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schmidt C, 1998, J BIOL CHEM, V273, P5081, DOI 10.1074/jbc.273.9.5081; Seko Y, 1999, BIOCHEM BIOPH RES CO, V259, P8, DOI 10.1006/bbrc.1999.0720; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Smalt R, 1997, AM J PHYSIOL-ENDOC M, V273, pE751, DOI 10.1152/ajpendo.1997.273.4.E751; Takahashi M, 1997, J VASC RES, V34, P212, DOI 10.1159/000159225; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Torsoni AS, 2003, CIRC RES, V93, P140, DOI 10.1161/01.RES.0000081595.25297.1B; Usson Y, 1997, CYTOMETRY, V28, P298, DOI 10.1002/(SICI)1097-0320(19970801)28:4<298::AID-CYTO4>3.0.CO;2-8; Valk P, 2000, Hematol J, V1, P254, DOI 10.1038/sj.thj.6200036; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; Weyts FAA, 2002, J CELL BIOCHEM, V87, P85, DOI 10.1002/jcb.10278; Wozniak M, 2000, J BONE MINER RES, V15, P1731, DOI 10.1359/jbmr.2000.15.9.1731; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; YAMAMOTO H, 1995, MOKUZAI GAKKAISHI, V41, P1; You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zhang JH, 2003, FASEB J, V17, P926, DOI 10.1096/fj.02-0663fje; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021	82	145	155	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30588	30599		10.1074/jbc.M313244200	http://dx.doi.org/10.1074/jbc.M313244200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15096502	Green Submitted, hybrid			2022-12-25	WOS:000222531900089
J	Hoflich, J; Berninsone, P; Gobel, C; Gravato-Nobre, MJ; Libby, BJ; Darby, C; Politz, SM; Hodgkin, J; Hirschberg, CB; Baumeister, R				Hoflich, J; Berninsone, P; Gobel, C; Gravato-Nobre, MJ; Libby, BJ; Darby, C; Politz, SM; Hodgkin, J; Hirschberg, CB; Baumeister, R			Loss of srf-3-encoded nucleotide sugar transporter activity in Caenorhabditis elegans alters surface antigenicity and prevents bacterial adherence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE TRANSPORTER; ADHESION DEFICIENCY-II; UDP-GLUCURONIC ACID; GOLGI-APPARATUS; C-ELEGANS; INNATE IMMUNITY; ENDOPLASMIC-RETICULUM; KLUYVEROMYCES-LACTIS; BIOCHEMICAL-ANALYSIS; PARASITIC NEMATODES	During the establishment of a bacterial infection, the surface molecules of the host organism are of particular importance, since they mediate the first contact with the pathogen. In Caenorhabditis elegans, mutations in the srf-3 locus confer resistance to infection by Microbacterium nematophilum, and they also prevent biofilm formation by Yersinia pseudotuberculosis, a close relative of the bubonic plague agent Yersinia pestis. We cloned srf-3 and found that it encodes a multitransmembrane hydrophobic protein resembling nucleotide sugar transporters of the Golgi apparatus membrane. srf-3 is exclusively expressed in secretory cells, consistent with its proposed function in cuticle/surface modification. We demonstrate that SRF-3 can function as a nucleotide sugar transporter in heterologous in vitro and in vivo systems. UDP-galactose and UDP-N-acetylglucosamine are substrates for SRF-3. We propose that the inability of Yersinia biofilms and M. nematophilum to adhere to the nematode cuticle is due to an altered glycoconjugate surface composition of the srf-3 mutant.	Univ Munich, ABI Mol Neuogenet, D-80336 Munich, Germany; Inst Biol 3, D-79104 Freiburg, Germany; Boston Univ, Dept Mol & Cell Biol, Sch Dent Med, Boston, MA 02118 USA; Univ Oxford, Dept Biochem, Genet Unit, Oxford OX1 3QU, England; Worcester Polytech Inst, Dept Biol & Biotechnol, Worcester, MA 01609 USA; Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA	University of Munich; Boston University; University of Oxford; Worcester Polytechnic Institute; University of Alabama System; University of Alabama Birmingham	Baumeister, R (corresponding author), Bio Bioinformat & Mol Genet 3, Schaenzlestr 1, D-79104 Freiburg, Germany.	baumeister@celegans.de		Hirschberg, Carlos/0000-0003-2299-7721; Gravato-Nobre, Maria Joao/0000-0002-8032-2565	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI037768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030365] Funding Source: NIH RePORTER; NIAID NIH HHS [R15 AI 37768] Funding Source: Medline; NIGMS NIH HHS [R01 GM 30365] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeijon C, 1996, J BIOL CHEM, V271, P8851, DOI 10.1074/jbc.271.15.8851; Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; Alegado RA, 2003, CELL MICROBIOL, V5, P435, DOI 10.1046/j.1462-5822.2003.00287.x; Aoki K, 2003, J BIOL CHEM, V278, P22887, DOI 10.1074/jbc.M302620200; BACIC A, 1990, EXP PARASITOL, V71, P483, DOI 10.1016/0014-4894(90)90074-M; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; BLAXTER ML, 1992, PARASITOL TODAY, V8, P243, DOI 10.1016/0169-4758(92)90126-M; BLAXTER ML, 1993, J BIOL CHEM, V268, P6600; BLUMENTHAL T, 1997, C ELEGANS, V2, P117; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; Buechner M, 1999, DEV BIOL, V214, P227, DOI 10.1006/dbio.1999.9398; CLARK DV, 1988, GENETICS, V119, P345; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; Darby C, 2002, NATURE, V417, P243, DOI 10.1038/417243a; de Gives PM, 1999, PARASITOLOGY, V119, P95, DOI 10.1017/S0031182099004424; Dell A, 1999, BBA-MOL BASIS DIS, V1455, P353, DOI 10.1016/S0925-4439(99)00064-2; Descoteaux A, 1999, BBA-MOL BASIS DIS, V1455, P341, DOI 10.1016/S0925-4439(99)00065-4; EDWARDS MK, 1983, DEV BIOL, V97, P375, DOI 10.1016/0012-1606(83)90094-5; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GERARDYSCHAHN R, 2000, OLIGOSACCHARIDES CHE, V2, P19; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; Hinnebusch BJ, 1996, SCIENCE, V273, P367, DOI 10.1126/science.273.5273.367; Hirschberg CB, 2001, J CLIN INVEST, V108, P3; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Hodgkin J, 2000, CURR BIOL, V10, P1615, DOI 10.1016/S0960-9822(00)00867-8; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hwang HY, 2002, P NATL ACAD SCI USA, V99, P14218, DOI 10.1073/pnas.172522199; Joshua GWP, 2003, MICROBIOL-SGM, V149, P3221, DOI 10.1099/mic.0.26475-0; Kim DH, 2002, SCIENCE, V297, P623, DOI 10.1126/science.1073759; LIBBY BJ, 1998, THESIS WORCESTER POL; LINK CD, 1992, GENETICS, V131, P867; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/ng0501-69; MADURO M, 1995, GENETICS, V141, P977; Mahajan-Miklos S, 1999, CELL, V96, P47, DOI 10.1016/S0092-8674(00)80958-7; MEISS HK, 1982, MOL CELL BIOL, V2, P1287, DOI 10.1128/MCB.2.10.1287; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; Mohler WA, 1998, CURR BIOL, V8, P1087, DOI 10.1016/S0960-9822(98)70447-6; MOUNSEY A, 1999, C ELEGANS PRACTICAL, P181; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Oelmann S, 2001, J BIOL CHEM, V276, P26291, DOI 10.1074/jbc.M011124200; PAGE AP, 1992, EXP PARASITOL, V75, P56, DOI 10.1016/0014-4894(92)90122-Q; PEREZ M, 1987, METHOD ENZYMOL, V138, P709; POLITZ SM, 1990, P NATL ACAD SCI USA, V87, P2901, DOI 10.1073/pnas.87.8.2901; POLITZ SM, 1992, PARASITOL TODAY, V8, P6, DOI 10.1016/0169-4758(92)90302-I; POLITZ SM, 1987, GENETICS, V117, P467; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHINKMANN K, 1992, J COMP NEUROL, V316, P251, DOI 10.1002/cne.903160209; Segawa H, 2002, EUR J BIOCHEM, V269, P128, DOI 10.1046/j.0014-2956.2001.02632.x; Silverman MA, 1997, J NEMATOL, V29, P296; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; SINGH RN, 1978, NEMATOLOGICA, V24, P63, DOI 10.1163/187529278X00074; SMITH WL, 1975, J BIOL CHEM, V250, P3426; Tan MW, 1999, P NATL ACAD SCI USA, V96, P715, DOI 10.1073/pnas.96.2.715; Thein MC, 2003, DEV DYNAM, V226, P523, DOI 10.1002/dvdy.10259; Wittenburg N, 2000, NATURE, V406, P306, DOI 10.1038/35018575; Wood WB, 1988, NEMATODE CAENORHABDI	60	68	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30440	30448		10.1074/jbc.M402429200	http://dx.doi.org/10.1074/jbc.M402429200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123614	hybrid			2022-12-25	WOS:000222531900071
J	Rummel, A; Karnath, T; Henke, T; Bigalke, H; Binz, T				Rummel, A; Karnath, T; Henke, T; Bigalke, H; Binz, T			Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-CC-DOMAIN; TETANUS TOXIN; B NEUROTOXIN; CLOSTRIDIAL NEUROTOXINS; PROTEIN-RECEPTOR; BINDING-SITES; NEURONS; INTERNALIZATION; GANGLIOSIDES; ENDOCYTOSIS	Botulinum neurotoxins (BoNTs) induce muscle paralysis by selectively entering cholinergic motoneurons and subsequent specific cleavage of core components of the vesicular fusion machinery. Complex gangliosides are requisite for efficient binding to neuronal cells, but protein receptors are critical for internalization. Recent work evidenced that synaptotagmins I and II can function as protein receptors for BoNT/B (Dong, M., Richards, D. A., Goodnough, M. C., Tepp, W. H., Johnson, E. A., and Chapman, E. R. ( 003) J. Cell Biol. 162, 1293-1303). Here, we report the protein receptor for a second BoNT serotype. Like BoNT/B, BoNT/G employs synaptotagmins I and II to enter phrenic nerve cells. Using pull-down assays we show that only BoNT/G, but neither the five remaining BoNTs nor tetanus neurotoxin, interacts with synaptotagmins I and II. In contrast to BoNT/B, interactions with both isoforms are independent of the presence of gangliosides. Peptides derived from the luminal domain of synaptotagmin I and II are capable of blocking the neurotoxicity of BoNT/G in phrenic nerve preparations. Pull-down and neutralization assays further established the membrane-juxtaposed 10 luminal amino acids of synaptotagmins I and II as the critical segment for neurotoxin binding. In addition, we show that the carboxyl-terminal domain of the cell binding fragment of BoNT/B and BoNT/G mediates the interaction with their protein receptor.	Hannover Med Sch, Inst Biochem, D-30625 Hannover, Germany; Hannover Med Sch, Inst Toxicol, D-30625 Hannover, Germany	Hannover Medical School; Hannover Medical School	Binz, T (corresponding author), Hannover Med Sch, Inst Biochem, D-30625 Hannover, Germany.	Binz.Thomas@mh-hannover.de	Rummel, Andreas/I-7449-2013; Taylor, Graham/A-4027-2012	Rummel, Andreas/0000-0002-0645-1641				Bigalke H, 2000, HANDB EXP PHARM, V145, P407; BLACK JD, 1986, J CELL BIOL, V103, P535, DOI 10.1083/jcb.103.2.535; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; Dong M, 2003, J CELL BIOL, V162, P1293, DOI 10.1083/jcb.200305098; Eswaramoorthy S, 2001, ACTA CRYSTALLOGR D, V57, P1743, DOI 10.1107/S0907444901013531; Fotinou C, 2001, J BIOL CHEM, V276, P32274, DOI 10.1074/jbc.M103285200; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; HABERMANN E, 1980, N-S ARCH PHARMACOL, V311, P33, DOI 10.1007/BF00500299; HALPERN JL, 1993, J BIOL CHEM, V268, P11188; Halpern JL, 1995, CURR TOP MICROBIOL, V195, P221; Herreros J, 2000, BIOCHEM J, V347, P199, DOI 10.1042/0264-6021:3470199; Herreros J, 2001, MOL BIOL CELL, V12, P2947, DOI 10.1091/mbc.12.10.2947; Li L, 1998, J NAT TOXINS, V7, P215; Matteoli M, 1996, P NATL ACAD SCI USA, V93, P13310, DOI 10.1073/pnas.93.23.13310; MONTECUCCO C, 1986, TRENDS BIOCHEM SCI, V11, P314, DOI 10.1016/0968-0004(86)90282-3; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; Nishiki T, 1996, NEUROSCI LETT, V208, P105, DOI 10.1016/0304-3940(96)12557-X; Nishiki T, 1996, FEBS LETT, V378, P253, DOI 10.1016/0014-5793(95)01471-3; NISHIKI T, 1994, J BIOL CHEM, V269, P10498; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Rummel A, 2004, MOL MICROBIOL, V51, P631, DOI 10.1046/j.1365-2958.2003.03872.x; Rummel A, 2003, J MOL BIOL, V326, P835, DOI 10.1016/S0022-2836(02)01403-1; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; Sutton JM, 2001, FEBS LETT, V493, P45, DOI 10.1016/S0014-5793(01)02273-6; Swaminathan S, 2000, NAT STRUCT BIOL, V7, P693, DOI 10.1038/78005; YAMASAKI S, 1994, BIOCHEM BIOPH RES CO, V200, P829, DOI 10.1006/bbrc.1994.1526	27	191	213	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30865	30870		10.1074/jbc.M403945200	http://dx.doi.org/10.1074/jbc.M403945200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123599	hybrid			2022-12-25	WOS:000222531900120
J	Tsuchida, A; Yamauchi, T; Ito, Y; Hada, Y; Maki, T; Takekawa, S; Kamon, J; Kobayashi, M; Suzuki, R; Hara, K; Kubota, N; Terauchi, Y; Froguel, P; Nakae, J; Kasuga, M; Accili, D; Tobe, K; Ueki, K; Nagai, R; Kadowaki, T				Tsuchida, A; Yamauchi, T; Ito, Y; Hada, Y; Maki, T; Takekawa, S; Kamon, J; Kobayashi, M; Suzuki, R; Hara, K; Kubota, N; Terauchi, Y; Froguel, P; Nakae, J; Kasuga, M; Accili, D; Tobe, K; Ueki, K; Nagai, R; Kadowaki, T			Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; ACTIVATED PROTEIN-KINASE; FATTY-ACID OXIDATION; MOLECULAR-MECHANISMS; RESISTANCE; MICE; PHOSPHORYLATION; FKHR; INHIBITION; CLONING	Adiponectin/Acrp30 is a hormone secreted by adipocytes, which acts as an antidiabetic and antiatherogenic adipokine. We reported previously that AdipoR1 and -R2 serve as receptors for adiponectin and mediate increased fatty acid oxidation and glucose uptake by adiponectin. In the present study, we examined the expression levels and roles of AdipoR1/R2 in several physiological and pathophysiological states such as fasting/refeeding, obesity, and insulin resistance. Here we show that the expression of AdipoR1/R2 in insulin target organs, such as skeletal muscle and liver, is significantly increased in fasted mice and decreased in refed mice. Insulin deficiency induced by streptozotocin increased and insulin replenishment reduced the expression of AdipoR1/R2 in vivo. Thus, the expression of AdipoR1/R2 appears to be inversely correlated with plasma insulin levels in vivo. Interestingly, the incubation of hepatocytes or myocytes with insulin reduced the expression of AdipoR1/R2 via the phosphoinositide 3-kinase/Foxo1-dependent pathway in vitro. Moreover, the expressions of AdipoR1/R2 in ob/ob mice were significantly decreased in skeletal muscle and adipose tissue, which was correlated with decreased adiponectin binding to membrane fractions of skeletal muscle and decreased AMP kinase activation by adiponectin. This adiponectin resistance in turn may play a role in worsening insulin resistance in ob/ob mice. In conclusion, the expression of AdipoR1/R2 appears to be inversely regulated by insulin in physiological and pathophysiological states such as fasting/refeeding, insulin deficiency, and hyperinsulinemia models via the insulin/phosphoinositide 3-kinase/Foxo1 pathway and is correlated with adiponectin sensitivity.	Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, Tokyo 1138655, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi 3320012, Japan; Inst Pasteur, CNRS 8090, Inst Biol, F-59000 Lille, France; Kobe Univ, Grad Sch Med, Div Diabet Digest & Kidney Dis, Dept Clin Mol Med, Kobe, Hyogo 6500017, Japan; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Natl Inst Hlth & Nutr, Tokyo 1628636, Japan	University of Tokyo; Japan Science & Technology Agency (JST); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Kobe University; Columbia University; National Institute of Health & Nutrition - Japan	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kadowaki-3im@h.u-tokyo.ac.jp	Nakae, Jun/Q-6141-2019; Terauchi, Yasuo/AAO-4347-2020; Suzuki, Ryo/AAA-2736-2019; FROGUEL, Philippe/O-6799-2017; Kubota, Naoto/N-7892-2015	Suzuki, Ryo/0000-0002-2965-6906; FROGUEL, Philippe/0000-0003-2972-0784; 	MRC [G0000477] Funding Source: UKRI; Medical Research Council [G0000477] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Friedman JE, 1997, J BIOL CHEM, V272, P31475, DOI 10.1074/jbc.272.50.31475; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Kadowaki T, 2000, J CLIN INVEST, V106, P459, DOI 10.1172/JCI10830; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; LEVINE BS, 1980, DRUG CHEM TOXICOL, V3, P201, DOI 10.3109/01480548009108283; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P802; Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057; RAKIETEN N, 1963, CANCER CHEMOTH REP, P91; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yamauchi T, 2001, J CLIN INVEST, V108, P1001, DOI 10.1172/JCI12864; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	32	426	462	1	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30817	30822		10.1074/jbc.M402367200	http://dx.doi.org/10.1074/jbc.M402367200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123605	hybrid			2022-12-25	WOS:000222531900113
J	Cam, JA; Zerbinatti, CV; Knisely, JM; Hecimovic, S; Li, YH; Bu, GJ				Cam, JA; Zerbinatti, CV; Knisely, JM; Hecimovic, S; Li, YH; Bu, GJ			The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E RECEPTOR; ALZHEIMERS-DISEASE; GENETIC ASSOCIATION; LRP; ENDOCYTOSIS; BINDING; ALPHA-2-MACROGLOBULIN; POLYMORPHISM; TRAFFICKING; EXPRESSION	The low density lipoprotein (LDL) receptor-related protein 1B (LRP1B) is a newly identified member of the LDL receptor family that shares high homology with the LDL receptor-related protein (LRP). LRP1B was originally described as a putative tumor suppressor in lung cancer cells; however, its expression profile in several regions of adult human brain suggests it may have additional functions in the central nervous system. Since LRP1B has overlapping ligand binding properties with LRP, we investigated whether LRP1B, like LRP, could interact with the beta-amyloid precursor protein (APP) and modulate its processing to amyloid-beta peptides (Abetas). Using an LRP1B minireceptor (mLRP1B4) generated to study the trafficking of LRP1B, we found that mLRP1B4 and APP form an immunoprecipitable complex. Furthermore mLRP1B4 bound and facilitated the degradation of a soluble isoform of APP containing a Kunitz proteinase inhibitor domain but not soluble APP lacking a Kunitz proteinase inhibitor domain. A functional consequence of mLRP1B4 expression was a significant accumulation of APP at the cell surface, which is likely related to the slow endocytosis rate of LRP1B. More importantly, mLRP1B4-expressing cells that accumulated cell surface APP produced less Abeta and secreted more soluble APP. These findings reveal that LRP1B is a novel binding partner of APP that functions to decrease APP processing to Abeta. Consequently LRP1B expression could function to protect against the pathogenesis of Alzheimer's disease.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Bu, GJ (corresponding author), Washington Univ, Sch Med, Dept Pediat, Campus Box 8208,660 S Euclid Ave, St Louis, MO 63110 USA.	bu@kids.wustl.edu	Hecimovic, Silva/T-8091-2017	Hecimovic, Silva/0000-0001-6077-433X	NIA NIH HHS [P50 AG05681] Funding Source: Medline; NINDS NIH HHS [NS41872] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS041872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005681] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; BU GJ, 1994, J BIOL CHEM, V269, P18521; Bu GJ, 2001, INT REV CYTOL, V209, P79; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gylys KH, 2003, J NEUROCHEM, V84, P1442, DOI 10.1046/j.1471-4159.2003.01643.x; HECIMOVIC S, 2004, IN PRESS NEUROBIOL D; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; JIN LW, 1994, J NEUROSCI, V14, P5461; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kang DE, 1997, NEUROLOGY, V49, P56, DOI 10.1212/WNL.49.1.56; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1994, J BIOL CHEM, V269, P17386; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; LADU MJ, 1994, J BIOL CHEM, V269, P23403; Li YH, 2002, J BIOL CHEM, V277, P42366, DOI 10.1074/jbc.M207705200; Li YH, 2001, MOL NEUROBIOL, V23, P53; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Liao A, 1998, HUM MOL GENET, V7, P1953, DOI 10.1093/hmg/7.12.1953; Liu CX, 2000, CANCER RES, V60, P1961; Liu CX, 2001, J BIOL CHEM, V276, P28889, DOI 10.1074/jbc.M102727200; Marzolo MP, 2000, J NEUROSCI RES, V60, P401, DOI 10.1002/(SICI)1097-4547(20000501)60:3<401::AID-JNR15>3.3.CO;2-C; Narita M, 1997, J NEUROCHEM, V69, P1904; Obermoeller-McCormick LM, 2001, J CELL SCI, V114, P899; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Qiu ZH, 2001, J NEUROPATH EXP NEUR, V60, P430, DOI 10.1093/jnen/60.5.430; Rebeck GW, 2001, MOL BRAIN RES, V87, P238, DOI 10.1016/S0169-328X(01)00006-7; Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WavrantDeVrieze F, 1997, NEUROSCI LETT, V227, P68, DOI 10.1016/S0304-3940(97)00304-2; Yamazaki T, 1996, J CELL SCI, V109, P999; ZAGURSKY RJ, 1995, BIOTECHNIQUES, V18, P504; Zerbinatti CV, 2004, P NATL ACAD SCI USA, V101, P1075, DOI 10.1073/pnas.0305803101	41	88	94	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29639	29646		10.1074/jbc.M313893200	http://dx.doi.org/10.1074/jbc.M313893200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15126508	hybrid			2022-12-25	WOS:000222445300100
J	Chen, CF; Goyette, P; Lohnes, D				Chen, CF; Goyette, P; Lohnes, D			RAR gamma acts as a tumor suppressor in mouse keratinocytes	ONCOGENE			English	Article						retinoic acid receptors; Ras; skin tumorigenesis; keratinocytes; squamous cell carcinoma; tumor suppressor	RETINOIC ACID RECEPTOR; TARGETED DISRUPTION; NUCLEAR RECEPTORS; DOWN-REGULATION; CYCLIN D1; BETA 2; SKIN; CELLS; ACTIVATION; EXPRESSION	All-trans retinoic acid (RA), the principal biologically active form of vitamin A, is essential for many developmental process as well as homeostasis in the adult. Many lines of evidence also suggest that RA, acting through the RA receptors (RARs), can also suppress growth of tumors of diverse origin. To assess directly the role of the RARs in a model of epidermal tumorigenesis, we investigated the incidence of tumor formation using keratinocytes lacking specific RAR types. Our data suggest that loss of RARgamma, but not RARalpha, predisposed keratinocytes to v-Ha-Ras-induced squamous cell carcinoma. We also found that ablation of RARgamma, but not RARalpha, abolished RA-induced cell cycle arrest and apoptosis in these keratinocytes. Reconstitution of receptor expression into RAR-null cells restored sensitivity to RA, and reversed the tumorigenic potential of receptor-deficient keratinocytes. These data strongly support a tumor suppressor effect for the RARs, in particular endogenous RARgamma, in murine keratinocytes.	Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada; McGill Univ, Div Expt Med, Montreal, PQ H3A 2T5, Canada; Univ Montreal, Dept Mol Biol, Montreal, PQ H3C 3J7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; Universite de Montreal	Lohnes, D (corresponding author), Clin Res Inst Montreal, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	lohnesd@ircm.qc.ca						Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Angel P, 1992, Matrix Suppl, V1, P156; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Borriello A, 2000, ONCOGENE, V19, P51, DOI 10.1038/sj.onc.1203231; Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264-6021:3610621; Boudjelal M, 2000, CANCER RES, V60, P2247; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; Boyle JO, 1999, J NATL CANCER I, V91, P373, DOI 10.1093/jnci/91.4.373; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chapellier B, 2002, EMBO J, V21, P3402, DOI 10.1093/emboj/cdf331; CHEN LC, 1995, CANCER LETT, V95, P113, DOI 10.1016/0304-3835(95)03868-W; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Chiba H, 1997, J CELL BIOL, V139, P735, DOI 10.1083/jcb.139.3.735; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Darwiche N, 1996, CANCER RES, V56, P4942; DARWICHE N, 1995, CANCER RES, V55, P2774; De Luca LM, 1996, NUTR CANCER, V25, P249, DOI 10.1080/01635589609514449; Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; Fisher GJ, 1996, FASEB J, V10, P1002, DOI 10.1096/fasebj.10.9.8801161; Fontana JA, 2002, LEUKEMIA, V16, P463, DOI 10.1038/sj.leu.2402414; Ghyselinck NB, 1997, INT J DEV BIOL, V41, P425; Gianni M, 2002, J BIOL CHEM, V277, P24859, DOI 10.1074/jbc.C200230200; GIMENEZCONTI I, 1990, CARCINOGENESIS, V11, P1995, DOI 10.1093/carcin/11.11.1995; Goyette P, 2000, J BIOL CHEM, V275, P16497, DOI 10.1074/jbc.M909382199; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hansen LA, 2003, CANCER RES, V63, P5257; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Houle M, 2000, MOL CELL BIOL, V20, P6579, DOI 10.1128/MCB.20.17.6579-6586.2000; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Klaassen I, 2001, INT J CANCER, V92, P661, DOI 10.1002/1097-0215(20010601)92:5<661::AID-IJC1251>3.0.CO;2-O; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; KUMAR R, 1994, CARCINOGENESIS, V15, P701, DOI 10.1093/carcin/15.4.701; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; LARCHER F, 1992, MOL CARCINOGEN, V6, P112, DOI 10.1002/mc.2940060206; Le Q, 2000, ONCOGENE, V19, P1457, DOI 10.1038/sj.onc.1203436; Lee HY, 1999, MOL CELL BIOL, V19, P1973; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; MARKS R, 1995, CANCER-AM CANCER SOC, V75, P607, DOI 10.1002/1097-0142(19950115)75:2+<607::AID-CNCR2820751402>3.0.CO;2-8; Mehta K, 2003, J BIOL REG HOMEOS AG, V17, P1; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Moller MB, 2000, LEUKEMIA LYMPHOMA, V39, P19, DOI 10.3109/10428190009053535; Naderi S, 1999, BLOOD, V94, P1348, DOI 10.1182/blood.V94.4.1348.416k29_1348_1358; NELSON KG, 1982, CANCER RES, V42, P4176; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Oridate N, 1996, ONCOGENE, V12, P2019; Pepper C, 2002, EUR J HAEMATOL, V69, P227, DOI 10.1034/j.1600-0609.2002.02799.x; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rommel C, 1998, CURR OPIN GENET DEV, V8, P412, DOI 10.1016/S0959-437X(98)80111-1; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Wang ZQ, 1999, NAT MED, V5, P418, DOI 10.1038/7417; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Wei LN, 2003, ANNU REV PHARMACOL, V43, P47, DOI 10.1146/annurev.pharmtox.43.100901.140301; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Xu XC, 2001, CANCER RES, V61, P4306; Yen A, 1999, IN VITRO CELL DEV-AN, V35, P527; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Yuspa SH, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P147; Zhang DM, 2001, ONCOGENE, V20, P7935, DOI 10.1038/sj.onc.1204971; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022	86	32	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5350	5359		10.1038/sj.onc.1207682	http://dx.doi.org/10.1038/sj.onc.1207682			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15094780				2022-12-25	WOS:000222491600010
J	McGarry, LC; Winnie, JN; Ozanne, BW				McGarry, LC; Winnie, JN; Ozanne, BW			Invasion of v-Fos(FBR)-transformed cells is dependent upon histone deacetylase activity and suppression of histone deacetylase regulated genes	ONCOGENE			English	Article						Fos; invasion; deacetylase; STAT6; protocadherin; RYBP	TRANSCRIPTION FACTOR; TRANSFORMED FIBROBLASTS; MULTIGENIC INVASION; POLYCOMB COMPLEX; FLAT PHENOTYPE; UP-REGULATION; RAS-ONCOGENE; AP-1; DIFFERENTIATION; ACETYLATION	Transformation of fibroblasts with the v-fos oncogene produces a highly invasive phenotype that is mediated by changes in gene expression. Inhibition of histone deacetylase (HDAC) activity with trichostatin A (TSA) or valproic acid (VPA) at concentrations that do not affect morphology, motility, chemotaxis or proliferation, strongly inhibits invasion and results in the re-expression of a significant proportion of those genes that are downregulated in the v-Fos-transformed cells. Independent expression of three of these re-expressed genes, (Ring1 and YY1 binding protein (RYBP); protocadherin gamma subfamily C, 3 (PCDHGC3); and signal transducer and activator of transcription 6 (STAT6)) in Fos-transformed cells, has no effect on morphology, motility, chemotaxis or proliferation, but strongly inhibits invasion. Therefore, we conclude that the ability of v-Fos-transformed cells to invade is dependent upon repression of gene expression through either direct or indirect HDAC activity.	Beatson Inst Canc Res, Canc Res UK, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; Cancer Research UK	Ozanne, BW (corresponding author), Beatson Inst Canc Res, Canc Res UK, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	b.ozanne@beatson.gla.ac.uk						Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Buttner C, 2004, J CELL PHYSIOL, V198, P248, DOI 10.1002/jcp.10395; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Garcia E, 1999, EMBO J, V18, P3404, DOI 10.1093/emboj/18.12.3404; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Imai T, 2003, ONCOGENE, V22, P9231, DOI 10.1038/sj.onc.1207184; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; Kelly WK, 2002, EXPERT OPIN INV DRUG, V11, P1695, DOI 10.1517/13543784.11.12.1695; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Lehrmann H, 2002, ADV CANCER RES, V86, P41, DOI 10.1016/S0065-230X(02)86002-X; Liu LT, 2003, CANCER RES, V63, P3069; Marks PA, 2003, CURR OPIN PHARMACOL, V3, P344, DOI 10.1016/S1471-4892(03)00084-5; Masui T, 2003, CLIN CANCER RES, V9, P1779; MATSUMOTO M, 1992, J ANTIBIOT, V45, P879, DOI 10.7164/antibiotics.45.879; McGaha TL, 2003, ARTHRITIS RHEUM-US, V48, P2275, DOI 10.1002/art.11089; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; Rosato RR, 2003, CANCER RES, V63, P3637; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; Scott LA, 2004, MOL CELL BIOL, V24, P1540, DOI 10.1128/MCB.24.4.1540-1559.2004; Spence HJ, 2000, ONCOGENE, V19, P1266, DOI 10.1038/sj.onc.1203433; Stapleton G, 2002, J CELL SCI, V115, P2713; SUGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P379, DOI 10.1016/S0006-291X(05)80156-1; Suzuki ST, 2000, EXP CELL RES, V261, P13, DOI 10.1006/excr.2000.5039; Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Yamashita Y, 2003, INT J CANCER, V103, P572, DOI 10.1002/ijc.10699; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	38	36	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5284	5292		10.1038/sj.onc.1207687	http://dx.doi.org/10.1038/sj.onc.1207687			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15107823				2022-12-25	WOS:000222491600004
J	Denissova, NG; Liu, F				Denissova, NG; Liu, F			Repression of endogenous Smad7 by Ski	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; ANAPHASE-PROMOTING COMPLEX; TGF-BETA RECEPTOR; C-SKI; TRANSCRIPTIONAL REPRESSION; MEDIATED REPRESSION; ONCOPROTEIN SKI; ACTIVATED STAT; SNON; ANTAGONIST	The Ski protein has been proposed to serve as a corepressor for Smad4 to maintain a transforming growth factor-beta (TGF-beta)-responsive promoter at a repressed, basal level. However, there have been no reports so far that it indeed acts on a natural promoter. We have previously cloned the human Smad7 promoter and shown that it contains the 8-base pair palindromic Smad-binding element (SBE) necessary for TGF-beta induction. In this report, we have characterized the negative regulation of Smad7 promoter basal activity by Ski. We show that Ski inhibits the Smad7 promoter basal activity in a SBE-dependent manner. Mutation of the SBE abrogates the inhibitory effect of Ski on the Smad7 promoter. Moreover, mutation of the SBE increases the Smad7 promoter basal activity. Using the chromatin immunoprecipitation assay, we further show that Ski together with Smad4 binds to the endogenous Smad7 promoter. Finally, we show that RNAi knockdown of Ski increases Smad7 reporter gene activity in transient transfection assays as well as elevating the endogenous level of Smad7 mRNA. Taken together, our results provide the first evidence that Ski is indeed a corepressor for Smad4, which can inhibit a natural TGF-beta responsive gene at the basal state.	Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Ernest Mario Sch Pharm, Dept Biol Chem, Susan Lehman Cullman Lab Canc Res, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Grad Program Mol & Cellular Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center	Liu, F (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, 679 Hoes Ln, Piscataway, NJ 08854 USA.	fangliu@cabm.rutgers.edu						Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Dai P, 2002, GENE DEV, V16, P2843, DOI 10.1101/gad.1017302; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Dong CM, 2002, P NATL ACAD SCI USA, V99, P3908, DOI 10.1073/pnas.062010399; Frederick JP, 2002, STRUCTURE, V10, P1607, DOI 10.1016/S0969-2126(02)00914-0; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; He J, 2003, J BIOL CHEM, V278, P30540, DOI 10.1074/jbc.M304016200; He W, 2002, EMBO J, V21, P2580, DOI 10.1093/emboj/21.11.2580; Hua XX, 2000, J BIOL CHEM, V275, P33205, DOI 10.1074/jbc.C000568200; Imoto S, 2003, J BIOL CHEM, V278, P34253, DOI 10.1074/jbc.M304961200; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mizuide M, 2003, J BIOL CHEM, V278, P531, DOI 10.1074/jbc.C200596200; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nicol R, 1998, J BIOL CHEM, V273, P3588, DOI 10.1074/jbc.273.6.3588; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Prunier C, 2003, J BIOL CHEM, V278, P26249, DOI 10.1074/jbc.M304459200; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Saunders A, 2003, SCIENCE, V301, P1094, DOI 10.1126/science.1085712; Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Ueki N, 2003, J BIOL CHEM, V278, P32489, DOI 10.1074/jbc.C300276200; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wang BQ, 2002, AM J PHYSIOL-HEART C, V282, pH1685, DOI 10.1152/ajpheart.00266.2001; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	40	33	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28143	28148		10.1074/jbc.M404961200	http://dx.doi.org/10.1074/jbc.M404961200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15128733	hybrid			2022-12-25	WOS:000222265400041
J	Konishi, A; Aizawa, T; Mohan, A; Korshunov, VA; Berk, BC				Konishi, A; Aizawa, T; Mohan, A; Korshunov, VA; Berk, BC			Hydrogen peroxide activates the Gas6-Axl pathway in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; ARREST-SPECIFIC GENE-6; AXL TYROSINE KINASE; ANGIOTENSIN-II; SPLICE VARIANT; IN-VIVO; PROTEIN; INJURY; EXPRESSION; TRANSACTIVATION	Axl, a receptor tyrosine kinase, is involved in cell survival, proliferation, and migration. We have shown that Axl expression increases in the neointima of balloon-injured rat carotids. Because oxidative stress is known to play a major role in remodeling of injured vessels, we hypothesized that H2O2 might activate Axl by promoting autophosphorylation. H2O2 rapidly stimulated Axl tyrosine phosphorylation in rat vascular smooth muscle cells within 1 min that was maximal at 5 min (6-fold). The response to H2O2 was concentration-dependent with EC50 of similar to500 muM. Axl phosphorylation was partly dependent on production of its endogenous ligand, growth arrest gene 6 (Gas6), because Axl-Fc, a fragment of Axl extracellular domain that neutralizes Gas6, inhibited H2O2-induced Axl phosphorylation by 50%. Axl phosphorylation by H2O2 was also attenuated by warfarin, which inhibits Gas6 activity by preventing post-translational modification. In intact vessels Axl was phosphorylated by H2O2, and Axl phosphorylation was inhibited by warfarin treatment in balloon-injured carotids. Akt, a downstream target of Axl, was phosphorylated by H(2)O(2)in Axl(+/+) mouse aorta but significantly inhibited in Axl(-/-) aorta. Intimal proliferation was decreased significantly in a cuff injury model in Axl(-/-) mice compared with Axl(+/+) mice. In summary, Axl is an important signaling mediator for oxidative stress in cultured vascular smooth muscle cells and intact vessels and may represent an important therapeutic target for vascular remodeling and response to injury.	Univ Rochester, Cardiovasc Res Ctr, Rochester, NY 14642 USA	University of Rochester	Berk, BC (corresponding author), Univ Rochester, Cardiovasc Res Ctr, 601 Elmwood Ave,Box 679, Rochester, NY 14642 USA.	bradford_berk@urmc.rochester.edu		Berk, Bradford/0000-0002-2767-4115	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049192, R01HL063462] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 49192, HL 63462] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1997, CIRCULATION, V96, P1906, DOI 10.1161/01.CIR.96.6.1906; Berk BC, 1999, J AM SOC NEPHROL, V10, pS62; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Fiebeler A, 2004, AM J KIDNEY DIS, V43, P286, DOI 10.1053/j.ajkd.2003.10.016; Frank GD, 2003, MOL CELL BIOL, V23, P1581, DOI 10.1128/MCB.23.5.1581-1589.2003; Fridell YWC, 1998, J BIOL CHEM, V273, P7123, DOI 10.1074/jbc.273.12.7123; Goruppi S, 1999, ONCOGENE, V18, P4224, DOI 10.1038/sj.onc.1202788; Goruppi S, 1997, FEBS LETT, V415, P59, DOI 10.1016/S0014-5793(97)01093-4; Hafizi S, 2002, BIOCHEM BIOPH RES CO, V299, P793, DOI 10.1016/S0006-291X(02)02718-3; Hatton MWC, 1998, ARTERIOSCL THROM VAS, V18, P816, DOI 10.1161/01.ATV.18.5.816; Ishida T, 1999, J CLIN INVEST, V103, P789, DOI 10.1172/JCI4189; Kalmes A., 2001, ANN NY ACAD SCI, V947, P54; Konishi A, 2003, J BIOL CHEM, V278, P35049, DOI 10.1074/jbc.M304913200; Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554; Lu QX, 2001, SCIENCE, V293, P306, DOI 10.1126/science.1061663; Marcandalli P, 1997, FEBS LETT, V415, P56, DOI 10.1016/S0014-5793(97)01094-6; Melaragno MG, 1998, CIRC RES, V83, P697, DOI 10.1161/01.RES.83.7.697; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Moroi M, 1998, J CLIN INVEST, V101, P1225, DOI 10.1172/JCI1293; Nagai K, 2003, J BIOL CHEM, V278, P18229, DOI 10.1074/jbc.M213266200; Nakano T, 1997, J BIOL CHEM, V272, P29411, DOI 10.1074/jbc.272.47.29411; Nakano T, 1997, BIOCHEM J, V323, P387, DOI 10.1042/bj3230387; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; PASTORE CJ, 1995, CIRC RES, V77, P519, DOI 10.1161/01.RES.77.3.519; Pollman MJ, 1999, CIRC RES, V84, P113; Rao GN, 1997, CELL SIGNAL, V9, P181, DOI 10.1016/S0898-6568(96)00139-8; Reynolds AR, 2003, NAT CELL BIOL, V5, P447, DOI 10.1038/ncb981; Saito S, 2002, J BIOL CHEM, V277, P44695, DOI 10.1074/jbc.M208332200; Sata M, 2003, TRENDS CARDIOVAS MED, V13, P249, DOI 10.1016/S1050-1738(03)00106-3; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Uchiyama-Tanaka Y, 2001, KIDNEY INT, V60, P2153, DOI 10.1046/j.1523-1755.2001.00067.x; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Yanagita M, 2001, AM J PATHOL, V158, P1423, DOI 10.1016/S0002-9440(10)64093-X; Yin JL, 2002, TRANSPLANTATION, V73, P657, DOI 10.1097/00007890-200202270-00032	35	71	74	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28766	28770		10.1074/jbc.M401977200	http://dx.doi.org/10.1074/jbc.M401977200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123721	hybrid			2022-12-25	WOS:000222265400114
J	Martik, D; Baitinger, C; Modrich, P				Martik, D; Baitinger, C; Modrich, P			Differential specificities and simultaneous occupancy of human MutS alpha nucleotide binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH REPAIR; HMUTS-ALPHA; TRANSLOCATION MECHANISM; MOLECULAR SWITCH; MISPAIR-BINDING; ENERGY-TRANSFER; ATPASE ACTIVITY; SLIDING CLAMP; PROTEIN MUTS; HUMAN-CELLS	We have examined the permissible nucleotide occupancy states of human MutSalpha. The MSH2.MSH6 heterodimer binds 1 mol of ADP and 1 mol of adenosine 5'-O-(thiotriphosphate) (ATPgammaS), with a K-d for each nucleotide of about 1 muM. Anisotropy measurements using BODIPY TR and BODIPY FL fluorescent derivatives of ADP and 5'-adenylyl-beta, gamma-imidodiphosphate (AMPPNP) also indicate an interaction stoichiometry of 1 mol of ADP and 1 mol of triphosphate analogue per MutSalpha heterodimer. Di- and triphosphate sites can be simultaneously occupied as judged by sequential filling of the two binding site classes with differentially radiolabeled ADP and ATPgammaS and by fluorescence resonance energy transfer between BODIPY TR- and BODIPY FL-labeled ADP and AMPPNP. ATP hydrolysis by MutSalpha is accompanied by a pre-steady-state burst of ADP formation, and analysis of MutSalpha-bound nucleotide during the first turnover has demonstrated the presence of both ADP and ATP. Simultaneous presence of ADP and a nonhydrolyzable ATP analogue modulates MutSalpha.heteroduplex interaction in a manner that is distinct from that observed in the presence of ADP or nonhydrolyzable triphosphate alone, and it is unlikely that this effect is due to the presence of a mixed population of binary complexes between MutSalpha and ADP or a triphosphate analogue. These findings imply that MutSalpha has two nucleotide binding sites with differential specificities for ADP and ATP and suggest that the ADP.MutSalpha.ATP ternary complex has an important role in mismatch repair.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Howard Hughes Medical Institute	Modrich, P (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.	modrich@biochem.duke.edu		Modrich, Paul/0000-0001-8708-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 45190] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 2003, MOL CELL, V12, P233, DOI 10.1016/S1097-2765(03)00219-3; Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Alani E, 1996, MOL CELL BIOL, V16, P5604; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Antony E, 2003, BIOCHEMISTRY-US, V42, P7682, DOI 10.1021/bi034602h; AU KG, 1992, J BIOL CHEM, V267, P12142; Baitinger C, 2003, J BIOL CHEM, V278, P49505, DOI 10.1074/jbc.M308738200; Bjornson KP, 2003, J BIOL CHEM, V278, P34667, DOI 10.1074/jbc.M305513200; Bjornson KP, 2003, J BIOL CHEM, V278, P18557, DOI 10.1074/jbc.M301101200; Bjornson KP, 2000, BIOCHEMISTRY-US, V39, P3176, DOI 10.1021/bi992286u; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; Blackwell LJ, 2001, J BIOL CHEM, V276, P34339, DOI 10.1074/jbc.M104256200; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; CLEGG RM, 1992, BIOCHEMISTRY-US, V31, P4846, DOI 10.1021/bi00135a016; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Galio L, 1999, NUCLEIC ACIDS RES, V27, P2325, DOI 10.1093/nar/27.11.2325; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; HABER LT, 1988, J BACTERIOL, V170, P197, DOI 10.1128/jb.170.1.197-202.1988; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Hess MT, 2002, J BIOL CHEM, V277, P25545, DOI 10.1074/jbc.M202282200; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; Iaccarino I, 2000, J BIOL CHEM, V275, P2080, DOI 10.1074/jbc.275.3.2080; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; MESELSON M, 1988, RECOMBINATION GENETI, P91; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; Sixma TK, 2001, CURR OPIN STRUC BIOL, V11, P47, DOI 10.1016/S0959-440X(00)00169-X; Smith BT, 2001, MOL CELL, V8, P1197, DOI 10.1016/S1097-2765(01)00402-6; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; Umar A, 1998, GENETICS, V148, P1637; Wang HX, 2002, J BIOL CHEM, V277, P26136, DOI 10.1074/jbc.M200357200; Worth L, 1998, J BIOL CHEM, V273, P23176, DOI 10.1074/jbc.273.36.23176	57	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28402	28410		10.1074/jbc.M312108200	http://dx.doi.org/10.1074/jbc.M312108200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15105434	hybrid			2022-12-25	WOS:000222265400073
J	Elsasser, S; Chandler-Militello, D; Muller, B; Hanna, J; Finley, D				Elsasser, S; Chandler-Militello, D; Muller, B; Hanna, J; Finley, D			Rad23 and Rpn10 serve as alternative ubiquitin receptors for the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIUBIQUITIN-CHAIN-BINDING; REPAIR PROTEIN HHR23A; 26 S PROTEASOME; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; REGULATORY PARTICLE; ATPASE SUBUNIT; DOMAINS; DEGRADATION; GENE	The selective recognition of ubiquitin conjugates by proteasomes is a key step in protein degradation. The receptors that mediate this step have yet to be clearly defined although specific candidates exist. Here we show that the proteasome directly recognizes ubiquitin chains through a specific subunit, Rpn10, and also recognizes chains indirectly through Rad23, a reversibly bound proteasome cofactor. Both binding events can be observed in purified biochemical systems. A block substitution in the chain-binding ubiquitin interacting motif of RPN10 when combined with a null mutation in RAD23 results in a synthetic defect in protein degradation consistent with the view that the direct and indirect recognition modes function to some extent redundantly in vivo. Rad23 and the deubiquitinating enzyme Ubp6 both bind proteasome subunit Rpn1 through N-terminal ubiquitin-like domains. Surprisingly, Rad23 and Ubp6 do not compete with each other for proteasome binding. Thus, Rpn1 may act as a scaffold to assemble on the proteasome multiple proteins that act to either bind or hydrolyze multiubiquitin chains.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Finley, D (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Bldg C1,Rm 404,240 Longwood Ave, Boston, MA 02115 USA.	daniel_finley@hms.harvard.edu			NIGMS NIH HHS [GM43601] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043601, R01GM043601] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; Clarke DJ, 2001, MOL CELL BIOL, V21, P1997, DOI 10.1128/MCB.21.6.1997-2007.2001; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Finley D, 2002, NAT CELL BIOL, V4, pE121, DOI 10.1038/ncb0502-e121; Fu HY, 2001, EMBO J, V20, P7096, DOI 10.1093/emboj/20.24.7096; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Goldstein AL, 1999, YEAST, V15, P507, DOI 10.1002/(SICI)1097-0061(199904)15:6<507::AID-YEA369>3.0.CO;2-P; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; HARACSKA L, 1995, EUR J BIOCHEM, V231, P720, DOI 10.1111/j.1432-1033.1995.0720d.x; Hartmann-Petersen R, 2003, TRENDS BIOCHEM SCI, V28, P26, DOI 10.1016/S0968-0004(02)00002-6; Hartmann-Petersen R, 2003, FEBS LETT, V535, P77, DOI 10.1016/S0014-5793(02)03874-7; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; HOUGH R, 1986, J BIOL CHEM, V261, P2400; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lambertson D, 1999, GENETICS, V153, P69; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Lommel L, 2002, CURR GENET, V42, P9, DOI 10.1007/s00294-002-0332-9; Madura K, 2002, CELL CYCLE, V1, P233, DOI 10.4161/cc.1.4.130; Mueller TD, 2003, EMBO J, V22, P4634, DOI 10.1093/emboj/cdg467; Mueller TD, 2004, J BIOL CHEM, V279, P11926, DOI 10.1074/jbc.M312865200; Ng JMY, 2003, GENE DEV, V17, P1630, DOI 10.1101/gad.260003; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; Ryu KS, 2003, J BIOL CHEM, V278, P36621, DOI 10.1074/jbc.M304628200; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V296, P813, DOI 10.1016/S0006-291X(02)02002-8; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V293, P986, DOI 10.1016/S0006-291X(02)00340-6; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Seeger M, 2003, J BIOL CHEM, V278, P16791, DOI 10.1074/jbc.M208281200; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Walters KJ, 2003, P NATL ACAD SCI USA, V100, P12694, DOI 10.1073/pnas.1634989100; Wang QH, 2003, BIOCHEMISTRY-US, V42, P13529, DOI 10.1021/bi035391j; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Wilkinson CRM, 2000, J BIOL CHEM, V275, P15182, DOI 10.1074/jbc.275.20.15182; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	48	245	251	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26817	26822		10.1074/jbc.M404020200	http://dx.doi.org/10.1074/jbc.M404020200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15117949	hybrid, Green Published			2022-12-25	WOS:000222120400004
J	Gong, XQ; Nedialkov, YA; Burton, ZF				Gong, XQ; Nedialkov, YA; Burton, ZF			alpha-amanitin blocks translocation by human RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; TRANSCRIPT CLEAVAGE; MICROCIN J25; ELONGATION; INHIBITION; COMPLEXES; ROLES	Our laboratory has developed methods for transient state kinetic analysis of human RNA polymerase II elongation. In these studies, multiple conformations of the RNA polymerase II elongation complex were revealed by their distinct elongation potential and differing dependence on nucleoside triphosphate substrate. Among these are conformations that appear to correspond to different translocation states of the DNA template and RNA-DNA hybrid. Using alpha-amanitin as a dynamic probe of the RNA polymerase II mechanism, we show that the most highly poised conformation of the elongation complex, which we interpreted previously as the posttranslocated state, is selectively resistant to inhibition with alpha-amanitin. Because initially resistant elongation complexes form only a single phosphodiester bond before being rendered inactive in the following bond addition cycle, alpha-amanitin inhibits elongation at each translocation step.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Burton, ZF (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	burton@msu.edu	gong, xue/GYQ-8649-2022		NIGMS NIH HHS [GM57461] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artsimovitch I, 2003, SCIENCE, V302, P650, DOI 10.1126/science.1087526; Bayro MJ, 2003, J AM CHEM SOC, V125, P12382, DOI 10.1021/ja036677e; Bushnell DA, 2002, P NATL ACAD SCI USA, V99, P1218, DOI 10.1073/pnas.251664698; CHAFIN DR, 1995, J BIOL CHEM, V270, P19114, DOI 10.1074/jbc.270.32.19114; COCHETME.M, 1974, BIOCHIM BIOPHYS ACTA, V353, P160, DOI 10.1016/0005-2787(74)90182-8; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Erie DA, 2002, BBA-GENE STRUCT EXPR, V1577, P224, DOI 10.1016/S0167-4781(02)00454-2; Funk JD, 2002, J BIOL CHEM, V277, P46998, DOI 10.1074/jbc.M206249200; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Holmes SF, 2003, J BIOL CHEM, V278, P35597, DOI 10.1074/jbc.M304496200; Kettenberger H, 2003, CELL, V114, P347, DOI 10.1016/S0092-8674(03)00598-1; LAI MMC, 1995, ANNU REV BIOCHEM, V64, P259, DOI 10.1146/annurev.bi.64.070195.001355; Laptenko O, 2003, EMBO J, V22, P6322, DOI 10.1093/emboj/cdg610; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; Nedialkov YA, 2003, METHOD ENZYMOL, V371, P252; Nedialkov YA, 2003, J BIOL CHEM, V278, P18303, DOI 10.1074/jbc.M301103200; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Palangat M, 2001, J MOL BIOL, V311, P265, DOI 10.1006/jmbi.2001.4842; Rosengren KJ, 2003, J AM CHEM SOC, V125, P12464, DOI 10.1021/JA0367703; Rudd MD, 1996, J BIOL CHEM, V271, P21549, DOI 10.1074/jbc.271.35.21549; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Sosunova E, 2003, P NATL ACAD SCI USA, V100, P15469, DOI 10.1073/pnas.2536698100; Taylor JM, 2003, TRENDS MICROBIOL, V11, P185, DOI 10.1016/S0966-842X(03)00045-3; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; WIELAND T, 1981, EUR J BIOCHEM, V117, P161, DOI 10.1111/j.1432-1033.1981.tb06315.x; WIELAND T, 1968, SCIENCE, V159, P946, DOI 10.1126/science.159.3818.946; Wilson KA, 2003, J AM CHEM SOC, V125, P12475, DOI 10.1021/JA036756q; Yamaguchi Y, 2001, SCIENCE, V293, P124, DOI 10.1126/science.1057925; Yuzenkova J, 2002, J BIOL CHEM, V277, P50867, DOI 10.1074/jbc.M209425200; Zhang CF, 2003, J BIOL CHEM, V278, P50101, DOI 10.1074/jbc.M307590200	30	55	60	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27422	27427		10.1074/jbc.M402163200	http://dx.doi.org/10.1074/jbc.M402163200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096519	hybrid			2022-12-25	WOS:000222120400073
J	Lan, CG; Lee, HC; Tang, S; Zhang, L				Lan, CG; Lee, HC; Tang, S; Zhang, L			A novel mode of chaperone action - Heme activation of Hap1 by enhanced association of Hsp90 with the repressed Hsp70-Hap1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK TRANSCRIPTION FACTOR; NITRIC-OXIDE SYNTHASE; MOLECULAR CHAPERONE; BINDING PROTEINS; YEAST; RECEPTOR; MECHANISM; ABSENCE; SEQUENCE; MUTANTS	Molecular chaperones Hsp90 and Hsp70 control many signal transducers, including cyclin-dependent kinases and steroid receptors. The yeast heme-responsive transcriptional activator Hap1 is a native substrate of both Hsp90 and Hsp70. Hsp90 and Hsp70 are critical for the precise regulation of Hap1 activity by heme. Here, to decipher the molecular events underlying the actions of Hsp90 and Hsp70 in heme regulation, we purified various multichaperone-Hap1 complexes and characterized the complexes linked to Hap1 repression and activation by two-dimensional electrophoresis analysis. Notably, we found that in vitro Hap1 is associated continuously with Ssa and its co-chaperones, and this association is not weakened by heme. Heme enhances the interaction between Hap1 and Hsp90. In vivo, defective Ssa, Ydj1, or Sro9 function causes Hap1 derepression in the absence of heme, whereas defective Hsp90 function causes reduced Hap1 activity at high heme concentrations. These results show that continuous association of Hap1 with Ssa, Ydj1, and Sro9 confers Hap1 repression, whereas enhanced association of Hsp90 with the repressed Hap1-Ssa-Ydj1-Sro9 complex by heme causes Hap1 activation. This novel mechanism of chaperone action may operate to control the activity of other important signal transducers.	Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA	Columbia University	Zhang, L (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA.	lz2115@columbia.edu	Zhang, Li/L-5206-2013	Zhang, Li/0000-0001-9242-0763	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062246] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62246] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Becker J, 1996, MOL CELL BIOL, V16, P4378; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; CREUSOT F, 1988, J MOL BIOL, V204, P263, DOI 10.1016/0022-2836(88)90574-8; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Hach A, 1999, MOL CELL BIOL, V19, P4324; HALDI ML, 1995, MOL GEN GENET, V248, P229, DOI 10.1007/BF02190805; HALLADAY JT, 1995, MOL CELL BIOL, V15, P4890; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hen T, 2000, BIOCHEM BIOPH RES CO, V273, P584, DOI 10.1006/bbrc.2000.2995; Hernandez MP, 2002, J BIOL CHEM, V277, P38294, DOI 10.1074/jbc.M206566200; Hon T, 2001, MOL CELL BIOL, V21, P7923, DOI 10.1128/MCB.21.23.7923-7932.2001; Hon T, 1999, J BIOL CHEM, V274, P22770, DOI 10.1074/jbc.274.32.22770; Johnson JL, 2000, MOL CELL BIOL, V20, P3027, DOI 10.1128/MCB.20.9.3027-3036.2000; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; Kang KI, 1999, P NATL ACAD SCI USA, V96, P1439, DOI 10.1073/pnas.96.4.1439; Lee HC, 2003, MOL CELL BIOL, V23, P5857, DOI 10.1128/MCB.23.16.5857-5866.2003; Lee HC, 2002, J BIOL CHEM, V277, P7430, DOI 10.1074/jbc.M106951200; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; Murphy PJM, 2003, J BIOL CHEM, V278, P34764, DOI 10.1074/jbc.M304469200; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Picard Didier, 1998, P1; Platt A, 1998, EMBO J, V17, P4086, DOI 10.1093/emboj/17.14.4086; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Rafie-Kolpin M, 2000, J BIOL CHEM, V275, P5171, DOI 10.1074/jbc.275.7.5171; Reddy SV, 1998, BLOOD, V91, P1793, DOI 10.1182/blood.V91.5.1793.1793_1793_1801; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Sabbah M, 1996, BIOCHEM J, V314, P205, DOI 10.1042/bj3140205; Shah V, 1999, AM J PHYSIOL-GASTR L, V277, pG463, DOI 10.1152/ajpgi.1999.277.2.G463; Shao J, 2001, J BIOL CHEM, V276, P206, DOI 10.1074/jbc.M007583200; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; Sobel SG, 1999, MOL BIOL CELL, V10, P3849, DOI 10.1091/mbc.10.11.3849; Song Y, 2001, AM J PHYSIOL-CELL PH, V281, pC1819, DOI 10.1152/ajpcell.2001.281.6.C1819; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; TURCOTTE B, 1992, GENE DEV, V6, P2001, DOI 10.1101/gad.6.10.2001; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Zhang L, 1999, CELL MOL LIFE SCI, V56, P415, DOI 10.1007/s000180050442; ZHANG L, 1994, J BIOL CHEM, V269, P14643; ZHANG L, 1994, GENE DEV, V8, P2110, DOI 10.1101/gad.8.17.2110; Zhang L, 1998, MOL CELL BIOL, V18, P3819, DOI 10.1128/MCB.18.7.3819; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	48	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27607	27612		10.1074/jbc.M402777200	http://dx.doi.org/10.1074/jbc.M402777200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102838	hybrid			2022-12-25	WOS:000222120400095
J	Shimaoka, T; Nakayama, T; Hieshima, K; Kume, N; Fukumoto, N; Minami, M; Hayashida, K; Kita, T; Yoshie, O; Yonehara, S				Shimaoka, T; Nakayama, T; Hieshima, K; Kume, N; Fukumoto, N; Minami, M; Hayashida, K; Kita, T; Yoshie, O; Yonehara, S			Chemokines generally exhibit scavenger receptor activity through their receptor-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; ANTIMICROBIAL ACTIVITY; CXC CHEMOKINES; MICE REVEALS; CUTTING EDGE; ATHEROSCLEROSIS; FRACTALKINE; GALECTIN-3; ADHESION; IMMUNITY	Chemokines are a family of cytokines that induce directed migration of various types of leukocytes through specific interactions with a group of seven transmembrane receptors. Scavenger receptors are a heterogenous family of transmembrane molecules that commonly bind and uptake oxidized low density lipoprotein and bacteria. Here, we show that not only CXC chemokine 16 (CXCL16)/SR-PSOX, a transmembrane chemokine with scavenger receptor activity, but also 12 out of 15 chemokines examined efficiently bound scavenger receptor ligands in competition with cells expressing their specific chemokine receptors. Furthermore both the chemotactic and scavenger receptor activities of SR-PSOX/CXCL16 were similarly impaired in a series of mutants altered in the chemokine domain, indicating that SR-PSOX/CXCL16 binds scavenger receptor ligands as well as CXCR6 using highly overlapping binding motifs. Taken together, chemokines generally have scavenger receptor-like activity through their receptor-binding domain, suggesting a close evolutionary relationship between chemokines and scavenger receptors.	Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Kinki Univ, Sch Med, Dept Microbiol, Osaka 5898511, Japan; Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kindai University (Kinki University); Kyoto University	Yonehara, S (corresponding author), Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Shogoin Kawahara Cho 53, Kyoto 6068507, Japan.	syonehar@virus.kyoto-u.ac.jp	Hieshima, Kunio/AAF-7040-2019	Hieshima, Kunio/0000-0002-7786-4646; Yoshie, Osamu/0000-0003-4353-5809				Alcouffe J, 1999, J LIPID RES, V40, P1200; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Cole AM, 2001, J IMMUNOL, V167, P623, DOI 10.4049/jimmunol.167.2.623; Durr M, 2002, INFECT IMMUN, V70, P6515, DOI 10.1128/IAI.70.12.6515-6517.2002; Gotoh O, 1999, ADV BIOPHYS, V36, P159, DOI 10.1016/S0065-227X(99)80007-0; Gough PJ, 2000, MICROBES INFECT, V2, P305, DOI 10.1016/S1286-4579(00)00297-5; Harrison JK, 2001, J BIOL CHEM, V276, P21632, DOI 10.1074/jbc.M010261200; Hieshima K, 2003, J IMMUNOL, V170, P1452, DOI 10.4049/jimmunol.170.3.1452; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Krijgsveld J, 2000, J BIOL CHEM, V275, P20374, DOI 10.1074/jbc.275.27.20374; Lazarini F, 2003, GLIA, V42, P139, DOI 10.1002/glia.10139; Lesnik P, 2003, J CLIN INVEST, V111, P333, DOI 10.1172/JCI200315555; Matloubian M, 2000, NAT IMMUNOL, V1, P298, DOI 10.1038/79738; Mey A, 1996, J IMMUNOL, V156, P1572; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sano H, 2000, J IMMUNOL, V165, P2156, DOI 10.4049/jimmunol.165.4.2156; Shimaoka T, 2003, J IMMUNOL, V171, P1647, DOI 10.4049/jimmunol.171.4.1647; Shimaoka T, 2000, J BIOL CHEM, V275, P40663, DOI 10.1074/jbc.C000761200; Shimaoka T, 2004, J LEUKOCYTE BIOL, V75, P267, DOI 10.1189/jlb.1003465; Steinbrecher UP, 1999, BBA-MOL CELL BIOL L, V1436, P279, DOI 10.1016/S0005-2760(98)00127-1; STRIETER RM, 1995, SHOCK, V4, P155, DOI 10.1097/00024382-199509000-00001; Wilbanks A, 2001, J IMMUNOL, V166, P5145, DOI 10.4049/jimmunol.166.8.5145; Yang D, 2003, J LEUKOCYTE BIOL, V74, P448, DOI 10.1189/jlb.0103024; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Zhu WQ, 2001, BIOCHEM BIOPH RES CO, V280, P1183, DOI 10.1006/bbrc.2001.4256; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	28	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26807	26810		10.1074/jbc.C400163200	http://dx.doi.org/10.1074/jbc.C400163200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15128749	hybrid			2022-12-25	WOS:000222120400002
J	Apostolou, S; Klein, JO; Mitsuuchi, Y; Shetler, JN; Poulikakos, PI; Jhanwar, SC; Kruger, WD; Testa, JR				Apostolou, S; Klein, JO; Mitsuuchi, Y; Shetler, JN; Poulikakos, PI; Jhanwar, SC; Kruger, WD; Testa, JR			Growth inhibition and induction of apoptosis in mesothelioma cells by selenium and dependence on selenoprotein SEP15 genotype	ONCOGENE			English	Article						mesothelioma; selenium; chemoprevention; apoptosis; SEP15 genotype	SUPPRESSION SUBTRACTIVE HYBRIDIZATION; HUMAN-MALIGNANT MESOTHELIOMA; CANCER PREVENTION; EXPRESSION; GENE; SELENOCYSTEINE; PROTEIN; REGION; RISK	Malignant mesotheliomas (MMs) are aggressive tumors derived from mesothelial cells lining the lungs, pericardium and peritoneum, and are often associated with occupational asbestos exposure. Suppression subtractive hybridization was used to identify genes differentially expressed in MM cells compared to normal mesothelial cells. A gene, SEP15, encoding a 15-kDa selenium-containing protein was isolated using this approach and was subsequently shown to be downregulated in similar to60% of MM cell lines and tumor specimens. A SEP15 polymorphic variant, 1125A, resides in the SECIS recognition element in the 3'-UTR and may influence the efficiency of Sec incorporation into the protein during translation. Since previous studies have implicated a potential role of the trace element selenium as a chemopreventive agent in animal models and in several types of human cancer, we investigated the effect of selenium on MM cells and its dependence on SEP15 genotype. Selenium was shown to inhibit cell growth and induce apoptosis in a dose-dependent manner in MM cells but had minimal effect on normal mesothelial cells. However, MM cells with downregulated SEP15 or the 1125A variant were somewhat less responsive to the growth inhibitory and apoptotic effects of selenium than MM cells expressing wild-type protein. RNAi-based knockdown studies demonstrated that SEP15 inhibition makes sensitive MM cells more resistant to selenium. These data imply that selenium may be useful as a chemopreventive agent in individuals at high risk of MM due to asbestos exposure, although those with the 1125A polymorphism may be less responsive to the protective benefits of dietary selenium supplementation.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	JR_Testa@fccc.edu	Kruger, Warren/Y-2541-2018; kruger, warren/A-6407-2008	kruger, warren/0000-0002-4990-3695	NATIONAL CANCER INSTITUTE [R01CA045745, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927, CA-45745] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apostolou S, 1999, CELL, V97, P684, DOI 10.1016/S0092-8674(02)09765-9; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DIPLOCK AT, 1993, AM J CLIN NUTR, V57, P256, DOI 10.1093/ajcn/57.2.256S; ELBAYOUMY K, 1991, CANCER PRINCIPLES PR, P1; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; Gray JW, 2000, CARCINOGENESIS, V21, P443, DOI 10.1093/carcin/21.3.443; Hu YJ, 2001, CANCER RES, V61, P2307; Hufton SE, 1999, FEBS LETT, V463, P77, DOI 10.1016/S0014-5793(99)01578-1; HUNTER DJ, 1990, JAMA-J AM MED ASSOC, V264, P1128, DOI 10.1001/jama.264.9.1128; Ip C, 1998, J NUTR, V128, P1845, DOI 10.1093/jn/128.11.1845; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kumaraswamy E, 2000, J BIOL CHEM, V275, P35540, DOI 10.1074/jbc.M004014200; Lee WC, 1996, CANCER RES, V56, P4297; Menter DG, 2000, CANCER EPIDEM BIOMAR, V9, P1171; Roberts D, 2002, DNA CELL BIOL, V21, P11, DOI 10.1089/10445490252810276; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Van Lieshout EMM, 1998, ONCOL REP, V5, P959; VANDENBRANDT PA, 1993, CANCER RES, V53, P4860; Zhang ZH, 1997, BIOL TRACE ELEM RES, V57, P147, DOI 10.1007/BF02778198	21	71	72	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5032	5040		10.1038/sj.onc.1207683	http://dx.doi.org/10.1038/sj.onc.1207683			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15107826				2022-12-25	WOS:000222237300009
J	Hashida, S; Yuzawa, S; Suzuki, NN; Fujioka, Y; Takikawa, T; Sumimoto, H; Inagaki, F; Fujii, H				Hashida, S; Yuzawa, S; Suzuki, NN; Fujioka, Y; Takikawa, T; Sumimoto, H; Inagaki, F; Fujii, H			Binding of FAD to cytochrome b(558) is facilitated during activation of the phagocyte NADPH oxidase, leading to superoxide production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CELL-FREE SYSTEM; ELECTRON-SPIN-RESONANCE; SRC HOMOLOGY-3 DOMAINS; FLAVOCYTOCHROME B(558); HUMAN-NEUTROPHILS; HEME IRON; FLAVIN; P67(PHOX); P40(PHOX)	The superoxide-producing phagocyte NADPH oxidase can be reconstituted in a cell-free system. The activity of NADPH oxidase is dependent on FAD, but the physiological status of FAD in the oxidase is not fully elucidated. To clarify the role of FAD in NADPH oxidase, FAD-free full-length recombinant p47(phox), p67(phox), p40(phox), and Rac were prepared, and the activity was reconstituted with these proteins and purified cytochrome b(558) (cyt b(558)) with different amounts of FAD. A remarkably high activity, over 100 mumol/s/mumol heme, was obtained in the oxidase with purified cyt b558, ternary complex (p47-p67-p40(phox)), and Rac. From titration with FAD of the activity of NADPH oxidase reconstituted with purified FAD-devoid cyt b(558), the dissociation constant K-d of FAD in cyt b(558) of reconstituted oxidase was estimated as nearly 1 nM. We also examined addition of FAD on the assembly process in reconstituted oxidase. The activity was remarkably enhanced when FAD was present during assembly process, and the efficacy of incorporating FAD into the vacant FAD site in purified cyt b(558) increased, compared when FAD was added after assembly processes. The absorption spectra of reconstituted oxidase under anaerobiosis showed that incorporation of FAD into cyt b(558) recovered electron flow from NADPH to heme. From both K-d values of FAD and the amount of incorporated FAD in cyt b(558) of reconstituted oxidase, in combination with spectra, we propose the model in which the K-d values of FAD in cyt b(558) is changeable after activation and FAD binding works as a switch to regulate electron transfer in NADPH oxidase.	Sapporo Med Univ, Sch Hlth Sci, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Sapporo, Hokkaido 0600812, Japan; Kyushu Univ, Med Inst Bioregulat, Fukuoka 8128582, Japan; Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan	Sapporo Medical University; Hokkaido University; Kyushu University; Japan Science & Technology Agency (JST)	Fujii, H (corresponding author), Sapporo Med Univ, Sch Hlth Sci, Chuo Ku, South 1,West 17, Sapporo, Hokkaido 0608556, Japan.	hfujii@sapmed.ac.jp	Noda, Nobuo/P-1397-2015	Noda, Nobuo/0000-0002-6940-8069; Yuzawa, Satoru/0000-0002-1031-5781; Fujioka, Yuko/0000-0002-6905-0669				Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; CROSS AR, 1995, J BIOL CHEM, V270, P6543, DOI 10.1074/jbc.270.12.6543; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; Cross AR, 2000, BIOCHEM J, V349, P113, DOI 10.1042/0264-6021:3490113; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; Doussiere J, 1996, BIOCHEMISTRY-US, V35, P13400, DOI 10.1021/bi960916b; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; FOROOZAN R, 1992, J BIOL CHEM, V267, P24400; Fujii H, 1999, J BIOCHEM-TOKYO, V126, P708, DOI 10.1093/oxfordjournals.jbchem.a022507; FUJII H, 1995, J BIOL CHEM, V270, P12685, DOI 10.1074/jbc.270.21.12685; FUJII H, 1991, BIOCHIM BIOPHYS ACTA, V1095, P201, DOI 10.1016/0167-4889(91)90100-C; GABIG TG, 1982, J BIOL CHEM, V257, P4114; ISOGAI Y, 1993, J BIOL CHEM, V268, P4025; KAKINUMA K, 1974, BIOCHIM BIOPHYS ACTA, V348, P76; KAKINUMA K, 1986, J BIOL CHEM, V261, P9426; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; Kuribayashi F, 2002, EMBO J, V21, P6312, DOI 10.1093/emboj/cdf642; Lambeth JD, 2000, J BIOCHEM MOL BIOL, V33, P427; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Lapouge K, 2002, J BIOL CHEM, V277, P10121, DOI 10.1074/jbc.M112065200; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; MIKI T, 1992, J BIOL CHEM, V267, P18695; Nakamura R, 1998, EUR J BIOCHEM, V251, P583, DOI 10.1046/j.1432-1327.1998.2510583.x; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; NISIMOTO Y, 1995, J BIOL CHEM, V270, P16428, DOI 10.1074/jbc.270.27.16428; PARK JW, 1994, BIOCHEMISTRY-US, V33, P2907, DOI 10.1021/bi00176a021; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; TAMURA M, 1992, J BIOL CHEM, V267, P7529; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Yoshida LS, 1998, J BIOL CHEM, V273, P27879, DOI 10.1074/jbc.273.43.27879; YOSHIDA LS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P245; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993	38	29	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26378	26386		10.1074/jbc.M309724200	http://dx.doi.org/10.1074/jbc.M309724200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15102859	hybrid			2022-12-25	WOS:000222003000058
J	Ju, DH; Xie, YM				Ju, DH; Xie, YM			Proteasomal degradation of RPN4 via two distinct mechanisms, ubiquitin-dependent and -independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST MUTANT; SYSTEM; PROTEIN; TURNOVER; PATHWAY; SIGNAL	Substrates of the ubiquitin system are degraded by the 26 S proteasome, a complex protease consisting of at least 32 different subunits. Recent studies showed that RPN4 (also named SON1 and UFD5) is a transcriptional activator required for normal expression of the Saccharomyces cerevisiae proteasome genes. Interestingly, RPN4 is extremely short-lived and degraded by the 26 S proteasome, establishing a feedback circuit that controls the homeostatic abundance of the 26 S proteasome. The mechanism underlying the degradation of RPN4, however, remains unclear. Here we demonstrate that the proteasomal degradation of RPN4 is mediated by two independent degradation signals (degron). One degron leads to ubiquitylation on internal lysine(s), whereas the other is independent of ubiquitylation. Stabilization of RPN4 requires inhibition of internal ubiquitylation and inactivation of the ubiquitin-independent degron. RPN4 represents the first proteasomal substrate in S. cerevisiae that can be degraded through ubiquitylation or without prior ubiquitylation. This finding makes it possible to use both yeast genetics and biochemical analysis to investigate the mechanism of ubiquitin-independent proteolysis.	Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Xie, YM (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, 110 Warren Ave, Detroit, MI 48201 USA.	xiey@karmanos.org						Asher G, 2002, P NATL ACAD SCI USA, V99, P13125, DOI 10.1073/pnas.202480499; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Bossis G, 2003, MOL CELL BIOL, V23, P7425, DOI 10.1128/MCB.23.20.7425-7436.2003; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; James P, 1996, GENETICS, V144, P1425; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Mannhaupt G, 1999, FEBS LETT, V450, P27, DOI 10.1016/S0014-5793(99)00467-6; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Sasaki T, 2000, MOL GEN GENET, V262, P940, DOI 10.1007/PL00008662; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; SIKORSKI RS, 1989, GENETICS, V122, P19; Swanson R, 2000, FEBS LETT, V477, P193, DOI 10.1016/S0014-5793(00)01802-0; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; Wang GL, 1999, MOL CELL BIOL, V19, P342; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298	24	64	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23851	23854		10.1074/jbc.C400111200	http://dx.doi.org/10.1074/jbc.C400111200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15090546	hybrid			2022-12-25	WOS:000221702500002
J	Huang, Y; Hickey, RP; Yeh, JL; Liu, DG; Dadak, A; Young, LH; Johnson, RS; Giordano, FJ				Huang, Y; Hickey, RP; Yeh, JL; Liu, DG; Dadak, A; Young, LH; Johnson, RS; Giordano, FJ			Cardiac myocyte-specific HIF-1 alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart	FASEB JOURNAL			English	Article						hypoxia; cardiac muscle; contraction; gene expression	SERCA2 GENE-EXPRESSION; HYPOXIA; ANGIOGENESIS; HYPERTROPHY; ISCHEMIA; MYOCARDIUM; ACTIVATION; PATHWAY; VEGF	At a resting pulse rate the heart consumes almost twice-as much oxygen per gram tissue as the brain and more than 43 times more than resting skeletal muscle ( 1). Unlike skeletal muscle, cardiac muscle cannot sustain anaerobic metabolism. Balancing oxygen demand with availability is crucial to cardiac function and survival, and regulated gene expression is a critical element of maintaining this balance. We investigated the role of the hypoxia-inducible transcription factor HIF-1alpha in maintaining this balance under normoxic conditions. Cardiac myocyte-specific HIF-1alpha gene deletion in the hearts of genetically engineered mice caused reductions in contractility, vascularization, high-energy phosphate content, and lactate production. This was accompanied by altered calcium flux and altered expression of genes involved in calcium handling, angiogenesis, and glucose metabolism. These findings support a central role for HIF-1alpha in coordinating energy availability and utilization in the heart and have implications for disease states in which cardiac oxygen delivery is impaired. Heart muscle requires a constant supply of oxygen. When oxygen supply does not match myocardial demand cardiac contractile dysfunction occurs, and prolongation of this mismatch leads to apoptosis and necrosis. Coordination of oxygen supply and myocardial demand involves immediate adaptations, such as coronary vasodilatation, and longer-term adaptations that include altered patterns of gene expression ( 2 - 4). How the expression of multiple genes is coordinated with oxygen availability in the heart and the impact of oxygen-dependent gene expression on cardiac function are insufficiently understood. Further elucidating these relationships may help clarify the molecular pathology of various cardiovascular disease states, including ischemic cardiomyopathy and myocardial hibernation ( 5, 6).	Yale Univ, Dept Med, New Haven, CT 06520 USA; Univ Calif San Diego, Dept Biol, San Diego, CA 92103 USA	Yale University; University of California System; University of California San Diego	Giordano, FJ (corresponding author), BCMM 436C,295 Congress Ave, New Haven, CT 06510 USA.	Frank.Giordano@yale.edu	Johnson, Randall/AAM-1189-2021	Johnson, Randall/0000-0002-4084-6639; Dadak, Agnes/0000-0002-0948-4764	NHLBI NIH HHS [R01 HL64001] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064001] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abel ED, 1999, J CLIN INVEST, V104, P1703, DOI 10.1172/JCI7605; ANVERSA P, 1990, PROG CARDIOVASC DIS, V33, P49, DOI 10.1016/0033-0620(90)90039-5; ARAI M, 1994, CIRC RES, V74, P555, DOI 10.1161/01.RES.74.4.555; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chen J, 1998, DEVELOPMENT, V125, P1943; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Cramer T, 2003, CELL CYCLE, V2, P192, DOI 10.4161/cc.2.3.402; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; *GENZ, HIF 1A GEN THER BYP; GIORDANO F, 1996, CIRCULATION; Giordano FJ, 2001, P NATL ACAD SCI USA, V98, P5780, DOI 10.1073/pnas.091415198; Giordano FJ, 2001, CURR OPIN GENET DEV, V11, P35, DOI 10.1016/S0959-437X(00)00153-2; Hartong R, 1996, J MOL CELL CARDIOL, V28, P2467, DOI 10.1006/jmcc.1996.0239; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B; Kloner RA, 1998, CIRCULATION, V97, P1848, DOI 10.1161/01.CIR.97.18.1848; Lee SH, 2000, NEW ENGL J MED, V342, P626, DOI 10.1056/NEJM200003023420904; Lyn D, 2000, PHYSIOL GENOMICS, V2, P93, DOI 10.1152/physiolgenomics.2000.2.3.93; MEYER M, 1995, CIRCULATION, V92, P778, DOI 10.1161/01.CIR.92.4.778; Minchenko A, 2000, MOL CELL BIOCHEM, V208, P53, DOI 10.1023/A:1007042729486; Nielsen JN, 2003, J APPL PHYSIOL, V94, P631, DOI 10.1152/japplphysiol.00642.2002; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; Pfander D, 2003, J CELL SCI, V116, P1819, DOI 10.1242/jcs.00385; Porter MJ, 2003, AM J PHYSIOL-CELL PH, V285, pC39, DOI 10.1152/ajpcell.00461.2002; Russell RR, 1999, AM J PHYSIOL-HEART C, V277, pH643, DOI 10.1152/ajpheart.1999.277.2.H643; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sakai S, 1996, NATURE, V384, P353, DOI 10.1038/384353a0; Sakai S, 2000, CIRCULATION, V101, P2849, DOI 10.1161/01.CIR.101.24.2849; Schipani E, 2001, GENE DEV, V15, P2865; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Seagroves TN, 2003, DEVELOPMENT, V130, P1713, DOI 10.1242/dev.00403; Semenza CL, 2001, PEDIATR RES, V49, P614, DOI 10.1203/00006450-200105000-00002; Simkhovich BZ, 2003, CARDIOVASC RES, V59, P450, DOI 10.1016/S0008-6363(03)00399-7; Simkhovich BZ, 2003, CARDIOVASC PATHOL, V12, P180, DOI 10.1016/S1054-8807(03)00038-3; Tian R, 2001, CIRCULATION, V103, P2961, DOI 10.1161/01.CIR.103.24.2961; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; West, 1991, PHYSL BASIS MED PRAC	38	164	173	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1138	+		10.1096/fj.04-1510fje	http://dx.doi.org/10.1096/fj.04-1510fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132980				2022-12-25	WOS:000221883200015
J	Wegener, JW; Schulla, V; Lee, TS; Koller, A; Feil, S; Feil, R; Kleppisch, T; Klugbauer, N; Moosmang, S; Welling, A; Hofmann, F				Wegener, JW; Schulla, V; Lee, TS; Koller, A; Feil, S; Feil, R; Kleppisch, T; Klugbauer, N; Moosmang, S; Welling, A; Hofmann, F			An essential role of Ca(v)1.2 L-type calcium channel for urinary bladder function	FASEB JOURNAL			English	Article						contraction; detrusor muscle; smooth muscle; protein kinase C; tamoxifendependent cre recombinase	DETRUSOR SMOOTH-MUSCLE; GUINEA-PIG DETRUSOR; PROTEIN-KINASE-C; MUSCARINIC RECEPTOR STIMULATION; CA2+ CHANNEL; INDUCED CONTRACTION; MICE LACKING; RHO-KINASE; BAY K-8644; ACETYLCHOLINE	Mice deficient in the smooth muscle Ca(v)1.2 calcium channel (SMACKO, smooth muscle alpha(1c)-subunit calcium channel knockout) have a severely reduced micturition and an increased bladder mass. L-type calcium current, protein, and spontaneous contractile activity were absent in the bladder of SMACKO mice. K+ and carbachol (CCh)-induced contractions were reduced to 10-fold in detrusor muscles from SMACKO mice. The dihydropyridine isradipine inhibited K+- and CCh-induced contractions of muscles from CTR but had no effect in muscles from SMACKO mice. CCh-induced contraction was blocked by removing extracellular Ca2+ but was unaffected by the PLC inhibitor U73122 or depletion of intracellular Ca2+ stores by thapsigargin. In muscles from CTR and SMACKO mice, CCh-induced contraction was partially inhibited by the Rho-kinase inhibitor Y27632. These results show that the Ca(v)1.2 Ca2+ channel is essential for normal bladder function. The Rho-kinase and Ca2+-release pathways cannot compensate the lack of the L-type Ca2+ channel.	Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany	Technical University of Munich	Wegener, JW (corresponding author), Tech Univ Munich, Inst Pharmakol & Toxikol, Biedersteiner Str 29, D-80802 Munich, Germany.	Wegener@ipt.med.tu-muenchen.de	Feil, Robert/B-8918-2014; Welling, Andrea/K-6674-2017; Feil, Susanne/AAF-7032-2019	Feil, Robert/0000-0002-7335-4841; Welling, Andrea/0000-0002-5364-4980; Wegener, Jorg/0000-0002-8129-1537				An JY, 2002, BRIT J PHARMACOL, V137, P1001, DOI 10.1038/sj.bjp.0704954; ANDERSSON KE, 1991, J UROLOGY, V146, P1156, DOI 10.1016/S0022-5347(17)38030-8; Birder LA, 2002, NAT NEUROSCI, V5, P856, DOI 10.1038/nn902; BO X, 1990, BRIT J PHARMACOL, V101, P494, DOI 10.1111/j.1476-5381.1990.tb12736.x; Bolton TB, 1999, ANNU REV PHYSIOL, V61, P85, DOI 10.1146/annurev.physiol.61.1.85; Callaghan B, 2004, CIRC RES, V94, P626, DOI 10.1161/01.RES.0000118248.17466.B7; Chambers P, 1996, EXP PHYSIOL, V81, P553, DOI 10.1113/expphysiol.1996.sp003958; Choppin A, 2001, BRIT J PHARMACOL, V133, P1035, DOI 10.1038/sj.bjp.0704165; Chow KY, 2003, NEUROUROL URODYNAM, V22, P77, DOI 10.1002/nau.10081; Curtis TM, 2001, J PHYSIOL-LONDON, V532, P609, DOI 10.1111/j.1469-7793.2001.0609e.x; Davare MA, 1999, J BIOL CHEM, V274, P30280, DOI 10.1074/jbc.274.42.30280; Eglen RM, 1996, PHARMACOL REV, V48, P531; ETO M, 1995, J BIOCHEM, V118, P1104, DOI 10.1093/oxfordjournals.jbchem.a124993; Fetscher C, 2002, BRIT J PHARMACOL, V136, P641, DOI 10.1038/sj.bjp.0704781; FOVAEUS M, 1987, J UROLOGY, V137, P798, DOI 10.1016/S0022-5347(17)44214-5; Hirasawa M, 2003, P NATL ACAD SCI USA, V100, P6139, DOI 10.1073/pnas.0936131100; IACOVOU JW, 1990, J UROLOGY, V144, P775, DOI 10.1016/S0022-5347(17)39590-3; Jezior JR, 2001, BRIT J PHARMACOL, V134, P78, DOI 10.1038/sj.bjp.0704241; Jin XC, 2002, GASTROENTEROLOGY, V123, P827, DOI 10.1053/gast.2002.35388; KAMISHIMA T, 1992, AM J PHYSIOL, V263, pC69, DOI 10.1152/ajpcell.1992.263.1.C69; King JA, 1998, GEN PHARMACOL, V30, P131, DOI 10.1016/S0306-3623(97)00032-3; Klugbauer N, 2002, EUR J PHARMACOL, V447, P279, DOI 10.1016/S0014-2999(02)01850-2; Kuhbandner S, 2000, GENESIS, V28, P15, DOI 10.1002/1526-968X(200009)28:1<15::AID-GENE20>3.0.CO;2-C; MAGGI CA, 1989, BRIT J PHARMACOL, V98, P1021, DOI 10.1111/j.1476-5381.1989.tb14634.x; Masters JG, 1999, BRIT J PHARMACOL, V127, P996, DOI 10.1038/sj.bjp.0702640; Matsui M, 2000, P NATL ACAD SCI USA, V97, P9579, DOI 10.1073/pnas.97.17.9579; Matsui M, 2002, J NEUROSCI, V22, P10627; Mimata H, 1997, Int J Urol, V4, P591, DOI 10.1111/j.1442-2042.1997.tb00315.x; Moosmang S, 2003, EMBO J, V22, P6027, DOI 10.1093/emboj/cdg583; RUTH P, 1993, P NATL ACAD SCI USA, V90, P2623, DOI 10.1073/pnas.90.7.2623; Sakurada S, 2003, CIRC RES, V93, P548, DOI 10.1161/01.RES.0000090998.08629.60; Schneider T, 2004, J PHARMACOL EXP THER, V308, P47, DOI 10.1124/jpet.103.058248; Schulla V, 2003, EMBO J, V22, P3844, DOI 10.1093/emboj/cdg389; Seisenberger C, 2000, J BIOL CHEM, V275, P39193, DOI 10.1074/jbc.M006467200; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; SIBLEY GNA, 1984, J PHYSIOL-LONDON, V354, P431, DOI 10.1113/jphysiol.1984.sp015386; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; UCHIDA W, 1994, N-S ARCH PHARMACOL, V350, P398; Wellman GC, 2003, CELL CALCIUM, V34, P211, DOI 10.1016/S0143-4160(03)00124-6; Wess J, 2003, TRENDS PHARMACOL SCI, V24, P414, DOI 10.1016/S0165-6147(03)00195-0; Wibberley A, 2003, BRIT J PHARMACOL, V138, P757, DOI 10.1038/sj.bjp.0705109; Wu C, 2002, J PHYSIOL-LONDON, V538, P357, DOI 10.1113/jphysiol.2001.013191; Wu C, 1999, J UROLOGY, V162, P1840, DOI 10.1016/S0022-5347(05)68248-1	44	91	97	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2004	18	7					1159	+		10.1096/fj.04-1516fje	http://dx.doi.org/10.1096/fj.04-1516fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132976				2022-12-25	WOS:000221883200011
